-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OuwUzkAxnPcJO24fFk21os++uKQt8Ku5X/e25qj5Lox6jd8AKT/H6FKsrDP1bpm/
 e19/6myziwxtdOpgBD9d1w==

<SEC-DOCUMENT>0001213809-07-000022.txt : 20070402
<SEC-HEADER>0001213809-07-000022.hdr.sgml : 20070402
<ACCEPTANCE-DATETIME>20070402162702
ACCESSION NUMBER:		0001213809-07-000022
CONFORMED SUBMISSION TYPE:	10KSB
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20061231
FILED AS OF DATE:		20070402
DATE AS OF CHANGE:		20070402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10KSB
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		07739397

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10KSB
<SEQUENCE>1
<FILENAME>form0_ksb123106.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. FORM 10-KSB 12.31.06
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Form 10-KSB 12.31.06
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <div>
            <hr style="COLOR: black" align="left" noshade size="3" width="100%">
          </div>UNITED STATES</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
          AND EXCHANGE COMMISSION</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
          D.C. 20549</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>FORM
          10-KSB</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Mark
          one)</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">{x}</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ANNUAL
          REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
          1934</font></strong></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>For
          the fiscal year ended </u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>December
          31, 2006</u></font></strong></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">{
          }</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TRANSITION
          REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
          1934</font></strong></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font size="2">&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          For the
          transition period from_______ to _______</font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;
          Commission file number </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>333-102629</u></font></strong></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="dyadiclogo2.jpg" alt="Dyadic Logo"></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <div align="left">
              <table cellpadding="0" cellspacing="0" width="100%">

                  <tr>
                    <td valign="top" width="20%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                    <td colspan="2" valign="top" width="47%" style="border-bottom: #ffffff thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
                        International, Inc.</strong></font></div>
                    </td>
                    <td valign="top" width="24%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  </tr>
                  <tr>
                    <td valign="top" width="20%">&#160;</td>
                    <td colspan="2" valign="top" width="47%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Name
                        of small business issuer in its charter)</font></div>
                    </td>
                    <td valign="top" width="24%">&#160;</td>
                  </tr>
                  <tr>
                    <td valign="top" width="20%">&#160;</td>
                    <td colspan="2" valign="top" width="47%">&#160;</td>
                    <td valign="top" width="24%">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="2" valign="top" width="48%" style="border-bottom: #ffffff thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Delaware</strong></font></div>
                    </td>
                    <td colspan="2" valign="top" width="19%" style="border-bottom: #ffffff thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>45-0486747</strong></font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" colspan="2" valign="top" width="48%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                        or other jurisdiction of incorporation or organization)</font></div>
                    </td>
                    <td colspan="2" valign="top" width="19%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(I.R.S.
                        Employer Identification No.)</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="2" valign="top" width="48%">&#160;</td>
                    <td valign="top" width="19%">&#160;</td>
                    <td valign="top" width="24%">&#160;</td>
                  </tr>
                  <tr>
                    <td colspan="2" valign="top" width="48%" style="border-bottom: #ffffff thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>140
                        Intracoastal Pointe Drive, Suite 404 Jupiter,
                        Florida</strong></font></div>
                    </td>
                    <td colspan="2" valign="top" width="19%" style="border-bottom: #ffffff thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>33477</strong></font></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="2" valign="top" width="48%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
                        of principal executive offices)</font></div>
                    </td>
                    <td colspan="2" valign="top" width="19%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Zip
                        Code) </font></div>
                    </td>
                  </tr>
                  <tr>
                    <td colspan="2" valign="top" width="48%">&#160;</td>
                    <td colspan="2" valign="top" width="19%">&#160;</td>
                  </tr>
                  <tr>
                    <td align="left" colspan="4" valign="top" width="67%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuer&#8217;s
                        telephone number </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(561)
                        743-8333</strong></font></div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
              registered under Section 12(b) of the Exchange Act: </font></div>
            <div>&#160;</div>
            <div>
              <table cellpadding="0" cellspacing="0" width="100%">

                  <tr>
                    <td valign="top" width="41%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title
                        of each class</font></div>
                    </td>
                    <td valign="top" width="41%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name
                        of each exchange on which registered</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="41%">&#160;</td>
                    <td align="left" valign="top" width="41%">&#160;</td>
                  </tr>
                  <tr>
                    <td valign="top" width="41%" style="border-bottom: #ffffff thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Common
                        Stock, $.001 par value per share</strong></font></div>
                    </td>
                    <td valign="top" width="41%" style="border-bottom: #ffffff thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>American
                        Stock Exchange</strong></font></div>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" width="41%">&#160;</td>
                    <td align="left" valign="top" width="41%">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
              registered under Section 12(g) of the Exchange Act: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>None</strong></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
              whether the issuer is not required to file reports pursuant to Section
              13 or
              15(d) of the Exchange Act. { }</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
              whether the issuer (1) filed all reports required to be filed by Section
              13 or
              15(d) of the Exchange Act during the past 12 months (or for such shorter
              period
              that the registrant was required to file such reports), and (2) has
              been subject
              to such filing requirements for the past 90 days. Yes {X} No { }</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
              if
              there is no disclosure of delinquent filers in response to Item 405
              of
              Regulation S-B contained in this form, and no disclosure will be contained,
              to
              the best of the registrant&#8217;s knowledge, in definitive proxy or information
              statements incorporated by reference in Part III of this Form 10-KSB
              or any
              amendment to this Form 10-KSB. { } </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
              by check mark whether the registrant is a shell company (as defined
              in Rule
              12b-2 of the Exchange Act). </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
              { }
              No { X}</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">State
              issuer&#8217;s revenues for its most recent fiscal year: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>$15,383,754</u></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">State
              the
              aggregate market value of the voting and non-voting common equity held
              by
              non-affiliates computed by reference to the price at which the common
              equity was
              sold, or the average bid and asked price of such common equity, as
              of a
              specified date within the past 60 days. (See definition of affiliate
              in Rule
              12b-2 of the Exchange Act.) As of March 28, 2007 the aggregate market
              value held
              by non-affiliates was approximately $<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">120,398,355</font>.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
              of
              March 28, 2007, there were <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29,939,375
              </font>shares of registrant&#8217;s common stock outstanding, par value $.001
              (including&#160;19,698 shares held in escrow). </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Transitional
                Small Business Disclosure Format (Check One): Yes { }; No {X}
</font></div>
            </div><br>
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%" align="center">
                </div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                </div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
                  of Contents</a></em></font></div>
              </div>
            </div><br>
            <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
              <div align="left">
                <table border="0" cellpadding="0" cellspacing="0" width="80%">

                    <tr>
                      <td valign="top" width="14%">&#160;</td>
                      <td valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="TOC">TAB</a>LE
                          OF CONTENTS</strong></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%" style="border-bottom: #ffffff thin solid;">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
                          I</strong></font></div>
                      </td>
                      <td align="left" valign="top" width="60%" style="border-bottom: #ffffff solid;">&#160;</td>
                      <td valign="top" width="10%" style="border-bottom: #ffffff thin solid;">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PAGE</strong></font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          1. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Descofbus">DESCRIPTION
                          OF BUSINESS</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#theco">The
                          Company</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Strategy">Dyadic&#8217;s
                              Strategy&#160;and
                              Markets</a></font></div>
                          </div>
                        </div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#RD">Research
                        and Development</a></font></td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#PS">Dyadic&#8217;s
                          Products and Services</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Manu">Manufacturing</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Competition">Competition</a></font></td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#GovREg">Government
                        Regulation</a></font></td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Inelprop">Intellectual
                        Property</a></font></td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Emp">Employees</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                        <a href="#Abengoa">Abengoa R&amp;D Agreement</a></font></td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#II">Investor
                          Information</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Risk">Risk
                          Factors that May Affect Future
                          Results</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          2. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item2">DESCRIPTION
                          OF PROPERTY</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          3. </font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a href="#Item_3_Legal"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LEGAL
                          PROCEEDINGS</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></a></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          4. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item4">SUBMISSION
                          OF MATTERS TO A VOTE OF SECURITY
                          HOLDERS</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%" style="border-bottom: #ffffff thin solid;">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
                          II</strong></font></div>
                      </td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          5. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item5">MARKET
                          FOR COMMON EQUITY AND RELATED STOCKHOLDER
                          MATTERS</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          6. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item_6_MDA">MANAGEMENT&#8217;S
                          DISCUSSION AND ANALYSIS OF FINANCIAL
                          CONDITION AND RESULTS OF OPERATIONS</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Critical_Acct_Policies">General</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Results_of_Operations">Results
                          of Operations</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#noncash">Non-cash
                        Share-Based Compensation Charges</a></font></td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Liquidity_and_Capital_Resources">Liquidity
                          and Capital
                          Resources</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#off">Off
                          Balance Sheet Arrangements</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#critical">Critical
                          Accounting Policies and
                          Estimates</a></font></div>
                      </td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          7. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item_7_Financial_Stmts">FINANCIAL
                          STATEMENTS</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">41</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          8. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item8">CHANGES
                          IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
                          AND FINANCIAL DISCLOSURES</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">41</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          8A. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item8A">CONTROLS
                          AND PROCEDURES</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">41</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          8B. </font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item8B">OTHER
                          INFORMATION</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">42</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%" style="border-bottom: #ffffff thin solid;">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
                          III</strong></font></div>
                      </td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          9. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a href="#Item9"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DIRECTORS
                          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXECUTIVE
                          OFFICERS PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH
                          SECTION 16(a) OF
                          THE EXCHANGE ACT</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></a></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">42</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          10. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item10">EXECUTIVE
                          COMPENSATION</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">45</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          11. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item11">SECURITY
                          OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
                          MANAGEMENT</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">49</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          12. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item12">CERTAIN
                          RELATIONSHIPS AND RELATED
                          TRANSACTIONS</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          13. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item13">EXHIBITS</a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">52</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                          14. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                      </td>
                      <td align="left" valign="top" width="60%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item14">PRINCIPAL
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ACCOUNTANT
                          FEES AND SERVICES</font></a></font></div>
                      </td>
                      <td valign="top" width="10%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">56</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="14%">&#160;</td>
                      <td align="left" valign="top" width="60%">&#160;</td>
                      <td valign="top" width="10%">&#160;</td>
                    </tr>

                </table>
              </div>
            </div>
            <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
              <div id="FTR">
                <div id="GLFTR" style="WIDTH: 100%" align="center">
                </div>
              </div>
              <div id="PN" style="PAGE-BREAK-AFTER: always">
                <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">2</font></div>
                <div style="WIDTH: 100%; TEXT-ALIGN: center">
                  <hr style="COLOR: black" noshade size="2">
                </div>
              </div>
              <div id="HDR">
                <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
                  of
                  Contents</a></em></font></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Forward
      Looking Statements</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Annual Report on Form 10-KSB</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">contains
      forward-looking statements within the meaning of Section 27A of the Securities
      Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve
      substantial risks and uncertainties. Forward-looking statements can be
      identified by the fact that they do not relate strictly to historical or current
      facts. They use words such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;anticipate&#8221;,
&#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;continue&#8221;, &#8220;project&#8221;, &#8220;plan&#8221;, &#8220;shall&#8221;, &#8220;should&#8221;, and
      other similar words. You should read statements that contain these words
      carefully because they discuss our future expectations, making projections
      of
      our future results of operations or our financial condition or state other
      "forward-looking" information. Forward-looking statements involve known and
      unknown risks and uncertainties that may cause the actual results, performance
      or achievements of the Company to be materially different from those that may
      be
      expressed or implied by such statements. Important factors that could cause
      the
      actual results, performance or achievement of the Company to differ materially
      from the Company&#8217;s forward-looking statements include (i) assumptions or
      cautionary factors discussed in connection with a particular forward-looking
      statement or elsewhere in this Form 10-KSB, including the section titled
&#8220;Description of Business - Risk Factors That May Affect Future Results&#8221;, or (ii)
      cautionary factors set forth in subsequent filings of the Company made from
      time
      to time with the Securities and Exchange Commission. All forward-looking
      statements attributable to the Company are expressly qualified in their entirety
      by these and other factors. Except as required by law or regulation, we do
      not
      undertake any obligation to publicly update forward-looking statements to
      reflect events or circumstances after the date on which the statement is made
      or
      to reflect the occurrence of unanticipated events.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
      I</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      term
&#8220;the Company&#8221;, &#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221; refers to Dyadic International,
      Inc. and its consolidated subsidiaries, unless the context indicates
      otherwise.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      obtained statistical data, market data and certain other industry data and
      forecasts used throughout this Annual Report on 10-KSB from market research,
      publicly available information and industry publications. Industry publications
      generally state that they obtain their information from sources that they
      believe to be reliable, but they do not guarantee the accuracy and completeness
      of the information. Similarly, while we believe that the statistical data,
      industry data and forecasts and market research are reliable, we have not
      independently verified the data, and we do not make any representation as to
      the
      accuracy of the information. We have not sought the consent of the sources
      to
      refer to their reports in this Annual Report. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
      1. <a name="Descofbus">DESC</a>RIPTION OF BUSINESS </u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="theco">The
      Company</a></u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>General</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      International, Inc., based in Jupiter, Florida, with operations in the United
      States, Hong Kong and mainland China, Poland and The Netherlands, is a global
      biotechnology company that uses its patented and proprietary technologies (the
      &#8220;Dyadic Platform Technology&#8221;) to conduct research and development activities for
      the discovery, development, and manufacture of products and enabling solutions
      to the bioenergy, industrial enzyme and pharmaceutical industries. These
      enabling solutions primarily include:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novel,
                cost efficient production strains, enzyme mixes and related processes
                and
                manufacturing technologies currently in the research and development
                stage
                for producing abundant low cost fermentable sugars from agricultural
                residues and energy crops which may be used in the manufacturing
                of
                cellulosic ethanol, butanol, chemicals, chemical intermediates, polymers
                and other biomolecules of commercial interest, obviating the need
                for
                petroleum as a feedstock, and refer to our activities in this market
                as
                our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioEnergy
                Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Enzymes
                and other biological products for a variety of industrial and commercial
                applications. We currently sell more than 55 liquid and dry enzyme
                products to more then 200 industrial customers in approximately 50
                countries and we generated net sales of approximately $15.3 million
                in
                2006,&#160;and refer to our activities in this market as our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Enzyme
                Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
                and </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Low-cost
                production hosts for therapeutic protein production for the
                biopharmaceutical industry, and refer to our activities in this market
                as
                our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioPharma
                Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      more
      and more industries come to appreciate the financial, process efficiency,
      environmental and other advantages of applying biological solutions such as
      enzymes to their manufacturing processes in lieu of chemicals and other legacy
      technologies, we expect a variety of new market opportunities to emerge for
      which we anticipate we will be able to apply the Dyadic Platform
      Technology.</font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      1994 we have been engaged in the development and application of a number of
      fungal strains and large-scale industrial fermentation processes. We utilize
      both classical and recombinant biotechnology methods to discover, develop and
      manufacture our enzyme products. For our recombinant strain development, we
      have
      principally focused on our system for protein production, which we now call
      our
      patented and proprietary C1 Production Technology. We have spent more than
      a
      decade developing our recombinant patented and proprietary C1 Fungus, also
      referred to throughout this report as C1 (see Figure 1.), on which our C1
      Production Technology is based, to manufacture large volumes of low cost
      proteins and enzymes for diverse market opportunities.</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table border="2" bordercolor="#000000" cellpadding="15" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="20%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><img src="propagule4x31.jpg" alt="Dyadic C1 Fungus"></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Figure
                1. </em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C1
                Fungus</font></div>
            </td>
            <td align="left" valign="top" width="80%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>C1
                Features and Competitive Advantages</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C1
                is a soil-derived filamentous fungal microorganism that has a variety
                of
                unique research and commercial capabilities including its ability
                to be
                grown in microtiter dishes and in large industrial fermentors under
                very
                low viscosity due to its novel morphology. Leveraging these unique
                C1
                traits, we have also been working to develop our patented and proprietary
                C1 High Throughput Screening (HTS) Technology to rapidly screen for
                the
                discovery of genes and the proteins they produce, as well as to identify
                improved protein variants resulting from modifications to their genes.
                The
                Dyadic Platform Technology (see Figure 2.) which is based on C1,
                provides
                us with a complete set of capabilities and competencies to up regulate
                (over produce) and/or down regulate (shut off the production of)
                the gene
                encoding for enzymes of commercial interest. </font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="20%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>C1
                Attributes Summary:</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stable
                morphological mutant</strong></font></div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3-4X
                protein/gram biomass </strong></font></div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Capable
                of &gt; 100 g/l total protein</strong></font></div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Versatile
                fermentation conditions:</strong></font></div>
              <div style="MARGIN-LEFT: 72pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                Low viscosity </strong></font></div>
              <div style="MARGIN-LEFT: 72pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                Less energy </strong></font></div>
              <div style="MARGIN-LEFT: 72pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                Shorter cycle time</strong></font></div>
              <div style="MARGIN-LEFT: 72pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                Wider Temp and pH range</strong></font></div>
              <div style="MARGIN-LEFT: 72pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                Low cost, on-site production, </strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;critical
                for
                bioenergy</strong></font></div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Molecular
                tools developed</strong></font></div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Genome
                sequenced, annotated</strong></font></div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><strong>&#167;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Discovery
                to production in one host</strong></font></div>
              <div style="MARGIN-LEFT: 36pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>High
                Throughput Screening</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </td>
            <td align="left" valign="top" width="80%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some
                additional economic benefits of protein production in C1, leading
                to low
                cost production include reduced energy consumption due to the lower
                viscosity, shorter fermentation cycles and a wider temperature and
                pH
                range than other industrial fungi. The morphology of the C1 culture
                allows
                the use of culture conditions that are not normally attainable with
                fungi
                and which lead to increased protein yields and more protein-friendly
                production processes. This ability to grow under non-acidic and low
                viscosity in culture conditions allows the production of acid-sensitive
                and shear-sensitive human proteins that may otherwise be unstable
                under
                typical fungal fermentation conditions. </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
                unique feature of the Dyadic Platform Technology is that it may provide
                a
                &#8220;one-stop shop&#8221; for gene discovery and production, in the same recombinant
                host. This has significant opportunity cost and time cost advantages
                as it
                may reduce discovery and development time by more than six months
                to over
                a year and may enable the discovery and identification of proteins
                which
                are unable to be identified and/or produced in competitive HTS systems,
                e.g. yeast. </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="dptchart1.jpg" alt="Dyadic Platform Technology"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Figure
      2. </em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      Platform Technology</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Strategy"><strong><u>Dya</u></strong></a><strong><u>dic&#8217;s
      Strategy and
      Markets</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Historically,
      substantially all of our revenues have been derived from our Enzyme Business,
      which we continue to invest in, both to support and maintain our market position
      in textile enzymes and to penetrate new applications, such as pulp &amp; paper,
      and animal feed. Our long-term plans are focused on our BioEnergy Business
      to
      enable the production of cellulosic ethanol, and our BioPharma Business, to
      enable the production of therapeutic monoclonal antibodies (and other
      therapeutic proteins) for pharmaceutical discovery and production. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      intend
      to accomplish these objectives by using and continuing to further develop the
      Dyadic Platform Technology and by leveraging and building on our existing
      business, technical, and marketing infrastructures. We also expect to continue
      to identify new market opportunities and the technologies to exploit those
      opportunities, both on our own and through strategic business collaborations
      with others.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      expect
      to generate revenues from these efforts by: (i) collecting R&amp;D revenues from
      third parties; (ii) entering into collaborative business arrangements, joint
      ventures, profit sharing arrangements, or partnerships with our customers;
      (iii)
      earning technology access fees, milestone payments, and royalties; (iv) selling
      products, whether developed internally through our own distribution channels
      for
      both current markets and markets we believe will emerge in the future or for
      customer-collaborators; (v) spinning-off new commercial entities utilizing
      the
      Dyadic Platform Technology; and/or (vi) obtaining grants from the United States
      government, foreign governments or other agencies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioEnergy
      Business Strategy and Markets</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      2006,
      we accelerated our R&amp;D efforts in the field of bioenergy where we are
      leveraging more than a decade of R&amp;D on cellulases and hemicellulases
      originally developed for textile, pulp and paper, food and feed and
      saccharification applications.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      purpose of our BioEnergy Business is to provide enabling solutions to the field
      of alternative energy and, more generally, to provide a route to inexpensive
      sugar production from all agricultural biomass feedstocks such as sugar cane
      bagasse, distiller dried grains, wheat bran and straw, various corn and soy
      fibers, wood fibers and pulp streams, energy crops and other lignocellulosics.

      Such inexpensive sugar sources may be used by microorganisms to ferment
      production of ethanol, butanol, chemicals, chemical intermediates, polymers
      and
      other biomolecules of commercial interest.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Most
      of
      the consumer goods and products used in the world today are derived via
      chemistry from the carbon atom building blocks found in petroleum. Thus,
      cracking open a barrel of oil yields, through chemistry, thousands of products
      used everyday. However, many of these consumer goods and products, as well
      as
      novel ones, can also be derived via microbial fermentation (and in some cases,
      where necessary, then followed by chemistry) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div>
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
        the
        carbon atom building blocks found in sugar molecules (e.g. glucose and xylose),
        that are locked up in sugar polymers (e.g. cellulose and hemicellulose) present
        in abundance in agricultural biomass (lignocellulosics). This biomass conversion
        &#8220;unlocks&#8221; the sugars, creating the potential for the mass production of
        inexpensive sugars from the abundant varieties of biomass the world-over.
        This
        can be accomplished through the use of enzymes - Dyadic&#8217;s core competency.
        Beyond the production of enzymes for deriving fermentable sugars from biomass,
        we will also explore corporate partnering opportunities for engineering strains
        to make various biomolecules (e.g. chemicals and chemical intermediates)
        from
        biomass sugars.</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      his
      2007 State of the Union address, President Bush called for the U.S. to produce
      35 billion gallons of ethanol annually by 2017. Since many cars today can run
      on
      85% ethanol (E85) and many can be made to do so with relatively inexpensive
      conversion, there is both a strategic energy security interest, as well as
      an
      environmental interest in seeing increased use of ethanol as a transportation
      fuel. In addition, there are a growing number of foreign countries initiating
      their own increased ethanol mandates. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      2006,
      the U.S. used about 140 billion gallons of gasoline which was blended with
      about
      5 billion gallons of ethanol - derived from corn starch - produced from 110
      biorefineries in 19 states across the U.S. This represents a current U.S.
      biofuels market that is estimated to be over $12 billion per year. This level
      of
      ethanol production represented a volume increase of about 25% over 2005.
      According to publicly announced plans, additional corn to ethanol production
      capacity is about to become available from 73 additional biorefineries under
      construction and 8 expansions, which will add approximately 6 billion gallons
      of
      new annual capacity in the U.S. by 2009, according to the Renewable Fuels
      Association. Though this new capacity will represent a significant increase
      in
      production, the resulting total of 11 billion gallons capacity will represent
      only 8% of the U.S.&#8217;s transportation fuel requirements. It is generally
      estimated that conversion of corn starch to ethanol could provide up to 10%
      of
      the U.S&#8217;s annual transportation fuel needs (14 billion gallons). Going beyond
      this level would require a level of use of corn-derived ethanol that could
      potentially disrupt the food and feed corn markets. Thus, there is an
      approximate annual gap of 21 billion gallons of ethanol. Consequently, we
      believe that significant expansion of ethanol capacity above existing levels
      necessitates the use of agricultural residue from feedstock and energy crops.
      The U.S. Department of Energy (DOE) has estimated that the U.S. has enough
      biomass for ethanol conversion to replace more than 30% of its annual
      transportation fuel needs. The DOE estimates that the U.S. has enough annual
      biomass to produce about 1.3 billion tons per year, which could yield more
      than
      100 billion gallons of ethanol per year. Commercially practicable exploitation
      of that biomass requires the use of cellulase and hemicellulase enzymes for
      the
      conversion of biomass into fermentable sugars. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      believe the development of alternative fuels such as cellulosic ethanol can
      reduce the world&#8217;s dependence on oil. According to the DOE, ethanol from
      cellulose produces 85 percent fewer greenhouse gas emissions than gasoline.
      We
      have developed enzyme mixtures that successfully convert a number of
      agricultural biomass feedstocks and energy crops into sugars. We already tested
      more than 40 different biomass feedstocks and have been successful in biomass
      conversion to fermentable sugars and at higher yields than previously achieved.
      We are conducting research and development efforts to bring the cost of enzymes
      per gallon of ethanol below $0.10, a benchmark that the industry is currently
      targeting. Thus, depending on the market share and feedstock involved, we
      believe that the potential for enzymes for the cellulose-to-ethanol market
      is in
      the hundreds of millions of dollars, as is the current market for amylases
      in
      the corn-to-ethanol conversion market. Leveraging our leadership in enzyme
      hydrolysis, we are focusing on the development of cost-effective enzyme mixtures
      and related processing and manufacturing technologies required to economically
      produce abundant low cost fermentable sugars from agricultural residues and
      energy crops. </font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
        this
        end, we are engaged in active discussions with a number of oil, agricultural,
        chemical and biofuel companies to develop potential collaborative partnerships
        to assist us in our efforts and/or wherein they may benefit from access to
        the
        Dyadic Platform Technology. For example, in October 2006, we entered into
        a
        collaborative, non-exclusive relationship with Abengoa Bioenergy R&amp;D, Inc.
        (&#8220;Abengoa&#8221;), a subsidiary of Abengoa S.A., the second largest ethanol producer
        in the world, for the purpose of initiating an R&amp;D program focused on
        cellulosic ethanol. In particular, under this R&amp;D program, we will apply the
        Dyadic Platform Technology to develop cost-effective enzyme mixtures and
        related
        processing and manufacturing technologies for commercial application in
        Abengoa&#8217;s bioethanol (cellulosic ethanol) production process. For additional
        information concerning our relationship with Abengoa, please see &#8220;Abengoa
        R&amp;D Agreement&#8221; and Note 1, Organization and Operations - </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
        Raising Activities</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        to our
        consolidated financial statements included elsewhere in this
        report.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, in January 2007, we announced that that through Dyadic Nederland
      BV,
      our subsidiary in Zeist, The Netherlands, we have joined with one of Europe's
      leading producers of bioethanol, Royal Nedalco, and other partners in R&amp;D
      projects funded by the Netherlands government to develop technologies to produce
      ethanol from sugar beet pulp and wheat bran. We expect our share of funding
      for
      these types of collaborative government-sponsored research projects to
      contribute only modestly to our overall R&amp;D budget.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
      on
      the recent and rapid increase in world interest in bioethanol, in 2006 we began
      to put significantly more focus on our efforts on our BioEnergy Business and
      in
      2007, we are accelerating our research and development and commercial efforts
      by
      opening up and staffing a new R&amp;D center in Davis, California, further
      staffing and expanding our Dutch research subsidiary Dyadic, Nederland, BV
      and
      hiring additional personnel for business development and continuing to build
      out
      our infrastructure to accommodate our anticipated research and business
      collaborations in our BioEnergy business.</font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">6</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
      Business Strategy and Markets</em></font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Using
      the
      Dyadic Platform Technology, we have been producing enzymes with C1 as well
      as
      with our commercially productive strains and fermentation processes of
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Aspergillus</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Trichoderma</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      in
      50,000 and 150,000 liter fermentors for more than a decade. We currently sell
      more than 55 liquid and dry enzyme products to more than 200 industrial
      customers in approximately 50 countries and we generated sales of approximately
      $15.3 million in 2006 from the conduct of the Enzyme Business. Our customers,
      in
      turn, use our products as key processing aids to enhance the functionality
      or
      durability of their products, to improve production yields and efficiency and/or
      to realize environmental benefits. For example:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                textile industry uses enzymes to soften and fade denim, as well as
                to
                reduce pilling and improve smoothness, softness and color brightness
                of
                cotton and other cellulosic fabrics;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pulp
                and paper manufacturers are beginning to use specialty enzymes to
                modify
                cellulose fibers and reduce chemical consumption, increase plant
                productivity, and/or reduce energy use as a way to improve operating
                efficiencies and enhance pulp and paper properties such as strength
                and
                brightness; and </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">animal
                feed producers use biological products to improve the nutritional
                value of
                animal feeds and to improve production
                efficiency.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
      is our
      understanding that the current potential market for biological products in
      the
      industrial, chemical and agricultural sectors exceeds $100 billion per year.
      Depending on the source, estimates of the size of the industrial enzyme market
      range between $2.0 and $3.6 billion per year. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Using
      the
      Dyadic Platform Technology, and capitalizing on our experience in the textile
      market, our goal for the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Enzyme
      Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is to
      become a top-tier provider of enzymes to faster growing and more profitable
      markets, including pulp and paper, animal feed, starch, and food. To accomplish
      this goal, we intend to: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stabilize
                sales volume in textiles by developing and introducing new
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Continue
                to increase the performance and yields of our existing enzyme products
                to
                improve their margins and enhance our competitiveness;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Discover
                and develop new, enhanced enzyme products to replace existing products
                and
                apply them for new uses in existing and new markets;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Undertake
                required health and safety registration processes for our products
                where
                required; and </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Collaborate
                with leading companies and selected customers to develop targeted,
                innovative technology and know-how that can be leveraged across entire
                industries.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioPharma
      Business Strategy and Markets</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      goal
      of our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioPharma
      Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is to
      harness the Dyadic Platform Technology to help solve the protein discovery
      problems in the field of monoclonal antibodies and other therapeutic proteins,
      as well as protein production problems confronting the global biopharmaceutical
      industry. For the past six years, we have been developing the Dyadic Platform
      Technology for this application. Our primary focus has been to expand the
      application of this technology beyond our Enzyme Business to enable
      pharmaceutical and biotechnology companies to not only successfully carry out
      the discovery and development of biopharmaceuticals, but also to manufacture
      those biopharmaceuticals at economically viable costs. Nonetheless, it is not
      Dyadic&#8217;s strategy to become a pharmaceutical company, but instead, through
      collaboration and/or licensing arrangements with pharmaceutical companies,
      enable them to discover and produce low cost biopharmaceuticals.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
      to Datamonitor PLC, the market for therapeutic proteins and monoclonal
      antibodies was estimated to be about $62 billion in 2005 and is expected to
      grow
      to about $106 billion by 2010. It is our understanding that roughly one-third
      of
      the nearly 500 therapeutic proteins under active development could be targets
      for expression in a suitable host production organism. To this end, we have
      used
      our expertise in recombinant expression in C1 for producing microbial enzymes
      and applied it directly to producing human gene products in C1. Despite devoting
      only limited R&amp;D and financial resources, we have been successful in
      producing a fully biologically active human monoclonal antibody in C1 at more
      than one gram per liter. We believe that our technology will be useful to enable
      (through strategic partnership) pharmaceutical companies to conduct novel gene
      discovery and low cost production of monoclonal antibodies and other
      proteins.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">7</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      human
      monoclonal antibodies represent the most exciting and largest area of research
      for the pharmaceutical companies, with more than 350 such compounds in their
      research pipelines, our initial work has focused on expressing a number of
      well-known, challenging antibodies in our C1 Production Technology, as well
      as
      further validating our C1 HTS Technology by expressing the genes for these
      antibodies and proteins in microtiter plates, and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">then
      screening for and finding the target molecules using our high-speed robotic
      system which is currently under development. In particular, we expect that
      our
      C1 Production Technology will facilitate the production of biopharmaceuticals
      that might otherwise be shelved, and will enable development of functionally
      improved drugs using molecular evolution techniques in conjunction with the
      C1
      HTS Technology we are developing. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently,
      most human monoclonal antibodies are produced in mammalian cells, which take
      a
      year or more to get stable cell lines and are not amenable to high-speed
      screening in a robotic set up for finding new and/or improved versions of
      antibodies and human proteins. We believe that our C1 HTS Technology could
      thus
      be at least an intermediate step to speeding up the first phase of the human
      monoclonal discovery and development process, even in situations where a
      biopharmaceutical company decides to use a conventional production host, such
      as
      CHO cells. We further believe that if the discovery of the new/improved human
      biotherapeutic were achieved in the C1 HTS Technology, in many cases these
      companies will use our C1 Production Technology to both avoid delays and
      expression problems often encountered when the production host is switched,
      and
      exploit the low-cost production capabilities of our C1 Production Technology.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>History</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      was founded in 1979 and throughout the 1980&#8217;s was the leading provider of pumice
      stones to the denim industry for stone-washing blue jeans. In the mid 1980&#8217;s as
      the industry shifted to the use of enzymes in place of pumice stones to achieve
      the same effects on the jeans&#8217; fabric, the Company adapted to the shift and
      initially became a distributor of such enzymes, then later, in the 1990&#8217;s became
      a developer and large scale industrial manufacturer of enzymes for this
      application. In its efforts to discover a prolific organism to produce enzymes
      that broke down cotton (cellulose) in blue jeans, in the early 1990&#8217;s it
      discovered the C1 organism. The Company has since been engaged in continuing
      R&amp;D efforts to further perfect and improve C1 for superior fermentation and
      genetic properties, which enables it to produce enzymes and other proteins
      at
      large industrial scale. Further, the Company has successfully adapted C1 for
      a
      variety of additional targeted applications, including bioenergy, textiles,
      animal feed, pulp &amp; paper, and others.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From
      2001
      to the present, the Company has raised approximately $60 million of equity
      capital to fund its growth and expansion into new markets. During this
      timeframe, the Company also has significantly strengthened its management team,
      Board of Directors and Scientific Advisory Board and in 2005, the Company&#8217;s
      common stock began trading on the American Stock Exchange. Today, the Company
      has a global infrastructure comprised of subsidiaries operating in Hong Kong,
      mainland China, Poland and The Netherlands and an international network of
      collaborators to assist in the continuing development of the Dyadic Platform
      Technology. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Merger
      </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior
      to
      October 2004, the Company was a public reporting company known as CCP Worldwide,
      Inc. In October 2004, the Company entered into an Agreement of Merger and Plan
      of Reorganization (the &#8220;Merger Agreement&#8221;) with Dyadic International (USA),
      Inc., a privately-held Florida corporation (formerly called Dyadic
      International, Inc.)("Dyadic-Florida") and a wholly-owned subsidiary of the
      Company formed by it for the purpose of being merged with and into
      Dyadic-Florida, CCP Worldwide, Inc. (the &#8220;Merger&#8221;). As a result of the Merger,
      CCP Acquisition Corp. was merged with and into Dyadic-Florida, all of the
      stockholders of Dyadic-Florida received, in exchange&#160;for&#160;all of the
      outstanding shares of Dyadic-Florida, shares of the Company on a one-for-one
      basis, making Dyadic-Florida a wholly-owned subsidiary of the Company, the
      Company changed its name to Dyadic International, Inc., and Dyadic-Florida
      changed its name to its existing name. For financial accounting purposes the
      Merger is treated as an acquisition by Dyadic-Florida of CCP Worldwide, Inc.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      part
      of, and immediately prior to the Merger, the Company disposed of its then only
      operating subsidiary as part of a Split-Off Agreement between Company, that
      then
      only operating subsidiary, and a former member of the Board of Directors of
      the
      Company. As a result of the Merger Agreement and the Split-Off Agreement, the
      only business operations of Dyadic International, Inc., formerly CCP Worldwide,
      Inc., are the operations of the Dyadic-Florida and its subsidiaries, and the
      Company&#8217;s real estate holding subsidiary, Dyadic Real Estate Holdings,
      Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="RD">Rese</a>arch
        and Development </u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
        uses all the classical, molecular and systems biology tools of modern industrial
        biotechnology and large-scale fermentation, either in-house or through our
        significant network of collaborators to discover, develop and manufacture
        commercial quantities of novel products produced by microorganisms (e.g.
        enzymes). In addition, we have specialized knowledge in the areas of pulp
&amp;
paper technology, bioenergy, animal feed, textile, chemistry </font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">8</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
      quality control. Our laboratories are located in Jupiter, Florida; Greensboro,
      North Carolina; Zeist, The Netherlands; mainland China, and we are in the
      process of adding a laboratory facility in Davis, California. Our own facilities
      are supplemented by commercial R&amp;D collaborations with The Scripps Research
      Institute in Florida, Bio-Technical Resources in Wisconsin, TNO Quality of
      Life,
      in Zeist, Netherlands and at Moscow State University in Russia. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Dyadic
      R&amp;D Activities</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      C1
      Production Technology is based on a fungal microorganism called C1, which we
      believe has&#160;superior genetic and fermentation characteristics as compared
      to other industrial fungi. The C1 strain, originally isolated from soil, has
      undergone classical mutagenesis resulting in a stable morphological change
      (mutation) that results in small mycelial fragments in liquid culture. One
      of
      the economic benefits of this morphological change is that it enables low
      viscosity growth in microtiter dishes, shake-flasks and large-scale fermentation
      (production scale). We have further developed molecular genetics tools that
      enable high level recombinant gene expression in C1 - from both genes derived
      from C1 (homologous expression) and genes derived from other organisms
      (heterologous expression). These molecular genetics tools also have the ability
      to delete unwanted genes, such as proteases or other enzymes from the C1
      background. Further, we have sequenced the genome of C1, which gives us a
      blueprint of the organism. We believe that this information will be both useful
      to better manipulate C1 for overall greater economic production of proteins
      and
      other biomolecules, as well as, for the discovery of potentially new products.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      C1
      Production Technology also forms the basis for our C1 HTS Technology for the
      discovery of novel and/or modified genes. We believe that this C1 HTS Technology
      has advantages over other screening systems in its use of the C1 filamentous
      Fungus, thereby permitting the efficient expression and screening of eukaryotic
      genes, and the secretion and glycosylation of their protein products, which
      other screening systems developed in yeast and bacteria are unable to
      efficiently perform. The C1 HTS Technology has utility for:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Discovery
                of novel genes;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Discovery
                of molecularly evolved genes resulting in gene products (e.g. enzymes,
                other proteins) with improved commercial
                properties;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expression
                of genes not previously expressed in other expression systems;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Discovery
                of novel monoclonal antibodies and other pharmaceutical proteins.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      May
      2005, we obtained a high quality DNA sequence of the 38 MB in the C1 genome.
      We
      identified more than 11,600 genes and found more than 120 carbohydrates that
      may
      be relevant as product opportunities in the markets we address. Interestingly,
      C1 appears to have approximately two times more cellulase and hemicellulase
      genes (biofuel genes) as compared to other industrial fungi (e.g. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Aspergillus</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Trichoderma</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      In
      addition to potential product opportunities from this genome sequence, the
      sequence provides a blueprint of the metabolism of C1which may be used to
      further enhance C1&#8217;s potential to make products at low cost. We continue to
      annotate the C1 genome. The annotated genome will allow identification of key
      metabolic functions that influence expression of genes, and further will
      facilitate the use of advanced genetic technologies, e.g. microarrays, to
      monitor and eventually modify and modulate these functions for optimizing host
      strain development and expression optimization in those hosts. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through
      our R&amp;D we expect to provide unique enzymes to companies in various
      industries to alleviate production process bottlenecks, high manufacturing
      costs
      and envirnmental challenges they often face, as well as to enable manufacturing
      of many products in their R&amp;D pipelines for which no suitable production
      processes have yet been found. We also expect that this genome sequence
      information will allow Dyadic to improve the Dyadic Platform Technology by
      (i)
      readily identifying and isolating genes that interfere with high-level
      expression of proteins and knocking them out and (ii) allowing the
      identification and improvement of genes and proteins that have a positive impact
      on gene expression. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      October 26, 2006, we entered into a securities purchase agreement (the &#8220;Abengoa
      Securities Purchase Agreement&#8221;) with Abengoa. We also entered into a
      non-exclusive Research and Development Agreement with Abengoa pertaining to
      the
      conduct of an R&amp;D program to be completed over a period of up to three and
      one-half years, under which we will seek to apply our proprietary technologies
      to the development of cost-effective enzyme mixtures and related processing
      and
      manufacturing technologies for commercial application in Abengoa&#8217;s bioethanol
      (cellulosic ethanol) production process (the &#8220;R&amp;D Agreement&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">9</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      R&amp;D Agreement contemplates that we will perform both (i) research of general
      application to the cellulosic ethanol field furthering our extensive research
      &amp; development and large-scale manufacturing technologies for producing large
      volumes of low cost cellulases, xylanases and other hemicellulases and (ii)
      research of specific applications for the achievement of the goals of Abengoa&#8217;s
      R&amp;D Program to develop an economically viable commercial process for the
      production of large volumes of effective, low cost enzyme mixtures for the
      proprietary biomass substrates of specific interest to Abengoa. In general,
      Dyadic is granted exclusive ownership of all intellectual property it develops
      in connection with its performance obligation under the R&amp;D Agreement.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Abengoa
      is considered to be the second largest ethanol producer in the world and a
      leader in the fields of both corn-derived and cellulose-derived ethanol
      production. Dyadic&#8217;s goal in its collaborative relationship with Abengoa is to
      leverage the Dyadic Platform Technology to enable commercial development of
      biomass derived ethanol. The primary goal of the Abengoa R&amp;D Program is the
      development of large-scale enzyme production systems and manufacturing processes
      for use in the production of abundant low cost fermentable sugars from biomass,
      with initial focus on cellulosic ethanol production. Nonetheless, we can offer
      no assurance that this R&amp;D Program will be successful in achieving this
      goal. For additional information concerning our relationship with Abengoa,
      please see &#8220;Abengoa R&amp;D Agreement&#8221; and Note 1, Organization and Operations -
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
      Raising Activities</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      to our
      consolidated financial statements included elsewhere in this
      report.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      January 2007, we announced that that we have joined with one of Europe's leading
      producers of bioethanol, Royal Nedalco, and other partners in R&amp;D projects
      funded by the Netherlands government to develop technologies to produce ethanol
      from sugar beet pulp and wheat bran. Dyadic Nederland BV, our subsidiary in
      Zeist, The Netherlands, will focus on the development of optimal enzyme
      preparations for the extraction of sugars from these feedstocks.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="RDcoll"><em>Activit</em></a><em>ies
      of Dyadic R&amp;D
      Collaborators</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      over
      a decade, we have supplemented our internal R&amp;D capabilities with focused
      strategic industry collaborations with leading scientific organizations such
      as
      Moscow State University, the Russian Academy of Sciences, TNO Quality of Life
      (The Netherlands) and Bio-Technical Resources (USA), and most recently, The
      Scripps Research Institute, as well as outsourced R&amp;D and manufacturing
      relationships via our exclusive agreements and collaborations with Polfa
      Tarchomin in Europe, which provides low-cost manufacturing capacity, and Martek
      BioSciences in the U.S. When combined with our internal staff of 14 scientists,
      we currently have approximately 50 scientists working in laboratories across
      the
      globe on a variety of R&amp;D programs for us. The following is a summary
      description of our main scientific collaborators: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      Scripps Research Institute, Jupiter, Florida and La Jolla,
      California</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      March
      2006, we announced the engagement of The Scripps Research Institute to work
      with
      Dyadic scientists to provide a comprehensive annotation of the C1 genome. We
      expect that the annotation will provide tools for identifying and classifying
      genes, their corresponding proteins, and metabolic pathways in a searchable
      and
      user-friendly format. These tools would allow us to identify additional
      commercial enzyme product leads, including improved cellulases and
      hemicellulases for use in textile, pulp &amp; paper, food and animal feed
      applications, and for the production of ethanol from lignocellulosic biomass.
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Scripps
      has a host of diverse biotechnologies and we continue to explore other areas
      for
      mutual collaboration.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Bio-Technical
      Resources, Manitowoc, Wisconsin</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Technical
      Resources (BTR), a division of Arkion Life Sciences LLC, is a contract research
      organization with expertise in areas of strain and process development for
      fermentation of microbial products. We have worked with BTR continuously since
      1995 on a variety of development programs for the production of several
      commercial enzyme products, most notably C1, for the commercial scale production
      of neutral cellulase enzymes. BTR also has worked on the development and
      commercialization of recombinant cellulase and xylanase enzyme products
      utilizing the Dyadic Platform Technology. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>TNO
      Quality of Life, Zeist, The Netherlands</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TNO
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Quality
      of Life</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      or TNO,
      is a contract research organization sponsored by the Dutch government and is
      one
      of the Institutes comprising the Netherlands Organization for Applied Scientific
      Research. Since 1998 we have worked with and continue to work with TNO through
      our wholly owned Dutch subsidiary Dyadic NL on the development of technologies
      for gene expression and gene discovery. The TNO scientists working with us
      are
      widely recognized as leaders in the area of fungal genetics and molecular
      biology. Thus, we intend to leverage their expertise to continue to optimize
      our
      C1 Production Technology to make it more efficient and productive. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">10</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Moscow
      State University, Moscow, Russia </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      had our longest research collaboration with experts in industrial enzymology
      at
      Moscow State University (MSU), in the Division of Chemical Enzymology in the
      Chemical Department, as well as collaborating with microbiology experts at
      the
      Russian Academy of Sciences. In 1992, we initiated the development of our first
      enzyme product, an acid cellulase, which was commercialized in 1994. These
      collaborators have been instrumental in the discovery of new enzyme products
      for
      us and in the detailed characterization and analysis of existing enzyme
      products. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      R&amp;D efforts conducted in collaboration with MSU over the last decade serve
      as a significant foundation for our cellulosic ethanol related research.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="PS">Dyad</a>ic&#8217;s
      Products and Services</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioEnergy
      Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      believe that the Dyadic Platform Technology will enable us to offer products
      that address energy problems more effectively and economically. We have a stable
      of well characterized fungal strains and enzymes which are directly applicable
      to the conversion of agricultural residue products, energy crops and forestry
      industry residues (lignocellulosic substrates) into fermentable sugars, which
      in
      turn can be used to produce ethanol and other chemicals. This technology offers
      a renewable approach to producing biomolecules that have historically been
      petroleum-derived.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
      Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      Enzyme Business addresses major needs in diverse industrial enzyme markets,
      including textiles, animal feed, pulp and paper, starch, food, beverage and
      brewing and other markets and has a customer base of approximately 200 customers
      in approximately 50 countries, including the United States. We sell our enzyme
      products directly, through our own sales force, and indirectly through
      distributors. In addition, we sell products through our Asian subsidiary. We
      have deployed our sales force to effectively target the main markets and
      customers for our products, including locations in Europe, North America, South
      and Central America, and North and South Asia. We employ distributors to sell
      our textile, food and animal feed enzymes, and sell starch and pulp and paper
      enzymes both directly and through resellers. We also have applications labs
      in
      the U.S. and China to conduct customer-specific studies in textiles and pulp
      and
      paper to support our sales efforts in those markets. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>&#160;</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Textiles
      Industry </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      offer
      a wide range of cellulase enzyme products for applications such as:
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">denim
                finishing where cellulases are used to soften and fade the denim
                fabric,
                including Rocksoft ACE series and numerous other Rocksoft series;
                and
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">biofinishing
                of cotton and cellulosics using BioACE series, which is a biofinishing
                process to reduce pilling and improve smoothness, softness and color
                brightness, and biopolishing. </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      identified, cloned and expressed genes for additional textile products that
      are
      in various stages of development, and have also developed several new enzyme
      formulations that can be used for denim washing. In March of 2007, utilizing
      our
      C1 Production Technology, we successfully scaled up and manufactured two new
      cellulase enzyme products which we expect will generate additional sales. We
      believe that these new cellulases will provide our customers with better
      performance characteristics at lower costs with improved profit margins for
      Dyadic as compared to the existing products we anticipate replacing. We believe
      that these will increase the competitiveness of our textile product line during
      2007 and beyond.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pulp
      and Paper Industry </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      experience over the past few years has demonstrated that enzymes offer certain
      mills within the pulp and paper industry significant processing and
      environmental benefits. We serve this market by developing, producing and
      selling cellulase and hemicellulase enzymes that improve the efficiencies of
      a
      number of processes within the overall pulp and paper manufacturing process.
      These include the bleaching of Kraft pulps, the removal of xerographic
</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">11</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">inks
        from
        waste paper during its conversion to recycled paper, and the reduction in
        the
        amount of energy used to refine and dry pulp fibers and paper. The latter
        is
        particularly important, as we have shown that reduced energy consumption
        in the
        drying process can translate to increased production rates. In addition,
        our
        products can also enhance several important pulp and paper properties, including
        strength, brightness, and cleanliness. Our products can be used to treat
        cellulosic sludge and particles during waste water treatment, thereby helping
        to
        reduce the environmental impact of the paper manufacturing process. In summary,
        we believe that our products offer the pulp and paper producers a new option
        beyond traditional chemistries such as synthetic polymers and surfactants
        that
        are based on petroleum and also near the end of their respective product
        life
        cycles.</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      currently offers twelve products in four FibreZyme product lines for commercial
      use in pulp and paper mills. These product lines include Bio-refining, Bleach
      Boosting, Deinking and Waste Water Treatment. Currently, the products are being
      purchased by customers as well as being trialed by new customers in diverse
      geographical areas, using a variety of manufacturing conditions and materials
      to
      make a wide range of pulp and paper products.&#160;We believe the wide
      applicability of our products thus far is an indication that our core technology
      is, in general, highly suitable for the pulp and paper industry. However, it
      has
      also been our experience that, due to the highly variable nature of the
      feedstocks, operating conditions, and final products encountered in the pulp
      and
      paper industry, significant R&amp;D will need to be conducted in order to
      develop the suite of products necessary to fully penetrate the
      market.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Animal
      Feed Industry</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      provides specialty enzymes for customers who process grains such as barley,
      wheat and rye to produce animal feed. These grains are not totally digested
      by
      poultry or livestock but, by adding enzymes to the feed, their digestibility
      can
      be improved. As a result, our feed enzymes can be used to allow feed producers
      to supplement feeds with lower cost raw materials and also to improve the
      efficiency of existing formulations. The main benefits of supplementing feed
      with enzymes, as revealed by feed trials carried out to date, are faster growth
      of the animal, better feed utilization, or feed conversion ratio, more uniform
      production, better health status and reduced environmental waste. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      make
      and sell six animal feed products in our GrainGain line of products that are
      tailored for use with specific types of feed depending on the levels of wheat,
      barley, and rye used. Registration of these products in various countries is
      in
      the early stages and upon completion, is expected to help increase the
      distribution of our products. Additionally, by conducting R&amp;D with the
      Dyadic Platform Technology to discover and produce more efficient carbohydrate
      degrading enzymes, we intend to develop other animal feed products for specific
      diets in which highly effective enzymes are currently neither commercially
      available nor provide an improved cost efficacy ratio. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioPharma
      Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      expect
      our BioPharma Business to generate future revenues by using the Dyadic Platform
      Technology to enable its business partners to discover new and/or improved
      genes
      and successfully make sufficient quantities of promising therapeutic proteins
      for preclinical and clinical testing, thereby improving prospects for a drug
      candidate's advancement from discovery through development, accelerating
      development time and reducing R&amp;D costs. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Relationships
      with business partners will vary, ranging from pure contract research, to
      collaborations, to strategic business partnerships such as joint ventures and
      product co-development and co-marketing on a project by project basis.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="Manu">Manu</a>facturing</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      do not
      own enzyme manufacturing facilities, but instead have employed two contract
      manufacturers who have produced all of our products for us. Our key contract
      manufacturer is Polfa Tarchomin, SA, or Polfa, located in Warsaw, Poland, which
      has been producing commercial enzymes for us continuously, and without
      interruption, since 2001 under a 10-year contract, which is cancellable under
      certain circumstances, with several 10-year renewal options exercisable in
      our
      discretion. Our second contract manufacturer, Martek BioSciences, has been
      used
      by us on a continual basis since 1994 and is currently used by us only on a
      limited basis; however, we believe that we could produce additional quantities
      of our enzyme products at Martek Biosciences, if needed.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Polfa
      contract manufacturing agreement provides for a tolling fee based upon the
      actual utilization of fermentation time, and also requires Dyadic-Florida to
      pay
      a fixed monthly fee to compensate Polfa for its capital investment in the
      modernization of the plant and equipment. The initial modernization fee will
      be
      fully paid in 2008. We requested that Polfa expand their production capacity
      to
      enable us to produce higher volumes of existing and new products. We concluded
      an agreement in December 2004 with Polfa to provide an additional 50 cubic
      meters of fermentation capacity and associated recovery capacity with the
      majority of the capital necessary for this expansion provided by Polfa. The
      expansion was completed and became fully operational in October 2006.
</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">12</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When
        combined with our internal staff of four manufacturing personnel, we currently
        employ, or retain as independent contractors, more than 60 persons to
        manufacture over 55 different liquid and dry enzyme products, including
        employees of our Polish subsidiary, whose main responsibility is oversight
        of
        Polfa's production, warehousing and shipping of our products.
</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="Competition">Com</a>petition
</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioEnergy
      Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      bioenergy field (using biomass as a feedstock) is a new and growing industry.
      In
      the bioenergy field we believe that there are relatively few companies offering
      enzyme hydrolysis solutions for biomass conversion and an even smaller number
      of
      companies employing fungal production systems, like Dyadic. In this specialized
      category there are two large Danish industrial companies, Novozymes A/S and
      Danisco (which recently purchased Genencor International) and a smaller Canadian
      company Iogen. Another smaller enzyme company is U.S.-based Diversa, who uses
      production hosts other than fungi. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
      Business </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
      to Novozymes, the worldwide market for industrial enzymes is $2.0 billion,
      while
      another of our competitors, Diversa Corporation, has sized the combined
      industrial and specialty enzymes market at approximately $3.6 billion. Our
      Enzyme Business faces several major competitors in its industry, both on a
      global and regional basis. Principal global competitors are Novozymes (Danish:
      all markets), Danisco (Danish: all markets), DSM (Dutch: food and animal feed),
      AB Enzymes (British: all markets), and BASF (German: animal feed). Together,
      these four companies control more than 70% of the industrial enzyme market,
      with
      Novozymes being the largest enzyme maker having 2006 revenues estimated at
      over
      $1.2 billion. Additional competitors are entering the industrial enzyme
      business, such as Diversa, and others can be expected to enter the market in
      the
      future. Other smaller regional producers, located primarily in Japan, India
      and
      China, are also participants in this industry and, from time to time, can
      directly compete with us in those regions. Each of the major competitors,
      particularly Novozymes and Danisco, currently enjoys competitive advantages
      associated with their much larger size: developed technologies, more resources,
      strong distribution systems and dominant market positions. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioPharma
      Business </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
      are
      many companies, such as DSM, Invitrogen, Danisco, Novozymes, Lonza Biologics,
      and Crucell, with proprietary protein production systems that compete with
      our
      C1 Production Technology. We believe our C1 Production Technology will overcome
      many of the limitations of the expression systems being used by our competitors
      and will provide the drug development industry with a superior, low-cost
      production alternative for human therapeutic and other proteins. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      C1
      HTS Technology will face competition from a large number of technologies in
      use
      and under development for the discovery of new genes. In addition to many
      development stage companies, competitors of our C1 HTS Technology include many
      well-known companies, such as Novozymes, Diversa, and Maxygen. There are also
      many companies, such as Diversa, Maxygen, Codexis, which are active in the
      field
      of directed evolution and, therefore, have an interest in fungi-based screening
      systems or other eukaryotic hosts capable of functioning in a high-throughput
      mode with eukaryotic genes. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="GovREg">Gove</a>rnment
      Regulation</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Regulation
      by the governmental authorities in the United States and other countries is
      a
      significant factor in the development, production and marketing of our products.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Products
      Not Considered Pharmaceuticals</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Biologically
      derived products are regulated in the United States by varying federal
      agencies&#160;based on the application or use of the product.&#160; A product
      may fall under the jurisdiction of one or many federal agencies at the same
      time, depending on the proposed use of the product.&#160; The federal Food and
      Drug Administration (&#8220;FDA&#8221;) operates under the authority granted by the Federal
      Food Drug and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) regulating not only pharmaceutical
      products, but also foods, food supplements, food additives, food processing
      aids, animal feed and feed additives, among others.&#160; Another agency, the
      United States Department of Agriculture (&#8220;USDA&#8221;), has shared jurisdiction on
      issues related to food safety, animal feed, biotechnology and crop and livestock
      directives.&#160; In addition, the federal Environmental Protection Agency
      (&#8220;EPA&#8221;)&#160;is the agency with jurisdiction over enzyme-based biological
      products with industrial applications. </font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">13</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">International
      regulations governing enzyme-based products derived from microorganisms have
      undergone significant change in the recent past.&#160; The regulations in
      Europe, for example, continue to evolve as&#160;quickly as&#160;the EU
      itself.&#160; There are EU Directives and EU Legislation which are meant to
      represent cohesive regulatory policies on genetically modified organisms, animal
      feed enzymes, enzymes used as a processing aid in the production of pulp and
      paper, among others, however there are instances when individual national
      laws&#160;seem to contradict EU Directives presenting regulatory hurdles in the
      registration and sale of Dyadic's products.&#160;&#160;Depending on the use of
      the product and existing legislation,&#160;the product&#160;may require little
      regulatory oversight, or a lengthy and expensive registration process.&#160;
There are other regions of the world with decidedly less rigorous regulatory
      review processes; generally accepting the US regulatory status of a
      product.&#160; We believe that these areas present Dyadic with many
      opportunities for immediate growth.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Human
      Therapeutic Products </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      FDA
      in the United States and similar health authorities in foreign countries subject
      human therapeutic products to rigorous preclinical and clinical testing and
      other approval procedures. Various federal statutes and regulations also govern
      or influence the testing, manufacturing, quality control, safety, labeling,
      storage, record-keeping and marketing of human therapeutic products. The process
      of obtaining these approvals and the subsequent compliance with appropriate
      federal and foreign statutes and regulations require the expenditure of
      substantial resources. Any failure by us or our collaborators or licensees
      to
      obtain, or any delay in obtaining, regulatory approval could adversely affect
      the marketing and revenue generating potential of our products. We have neither
      applied for nor received regulatory approval to market any human therapeutic
      products. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="Inelprop">Inte</a>llectual
      Property</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      October 2006, we were granted U.S. patent 7,122,330, &#8220;High-Throughput Screening
      of Expressed DNA Libraries in Filamentous Fungi,&#8221; by the U.S. Patent and
      Trademark Office. This patent grant will expand the patent protection for
      the&#160;C1 HTS&#160;Technology and broad claims covering a number of other
      industrially relevant fungi for applications in cellulosic ethanol and other
      key
      markets. We own 4 issued U.S. patents, 28 issued and 2 allowed International
      patents and 52 U.S. and International filed and pending patent applications
      which we believe provide broad protection for the Dyadic Platform Technology
      and
      their products and commercial applications. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Over
      the
      years in which we have been in business, we have also developed trade secrets
      and know-how involving our industrial enzyme products. Our employment and other
      agreements with our employees contain provisions that protect and require
      confidential treatment for our trade secrets and developed inventions.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="Emp">Empl</a>oyees
</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 31, 2006, we had approximately 125 full-time employees. None of our
      employees are represented by labor unions or covered by collective bargaining
      agreements. We have not experienced any work stoppages and consider our employee
      relations to be good. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="Abengoa">Abe</a>ngoa
      R&amp;D Agreement</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      reported in our Current Report on Form 8-K dated October 26, 2006, as filed
      with
      the Securities and Exchange Commission on November 1, 2006, our R&amp;D
      Agreement with Abengoa contemplates our conducting R&amp;D activities pertaining
      to the field of cellulosic ethanol (&#8220;CE R&amp;D Activities&#8221;) for Abengoa (the
&#8220;Abengoa R&amp;D Program&#8221;), as well as other collaboration partners, as part of
      our much broader R&amp;D effort in the field of cellulosic ethanol
      (collectively, the &#8220;Master R&amp;D Program&#8221;). These CE R&amp;D Activities are of
      two types: &#8220;Foundational R&amp;D&#8221; and &#8220;Applications R&amp;D.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      essential component of the R&amp;D Agreement is our entitlement to use
      Foundational R&amp;D performed in the Master R&amp;D Program, for other
      collaboration partners, in the Abengoa R&amp;D Program, and vice versa, as well
      as Applications R&amp;D performed by us for Abengoa. &#8220;Foundational R&amp;D&#8221;
broadly means all technology developed by us out of our conduct of CE R&amp;D
      Activities, in either R&amp;D program, except to the extent and of our conduct
      constitutes &#8220;Applications R&amp;D.&#8221; &#8220;Applications R&amp;D&#8221; is defined to mean
      technology developed by us out of our conduct of CE R&amp;D Activities in which
      the Dyadic technology is used or applied to specific treated or untreated
      biomass for any customer of Dyadic. The objective of Abengoa&#8217;s R&amp;D Program
      is the development of a cost-effective enzyme production system for commercial
      application in Abengoa&#8217;s bioethanol (cellulosic ethanol) production process.
</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">14</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      R&amp;D Agreement, Abengoa will furnish to us certain treated &#8220;Substrates&#8221;
(biomass which has been pre-treated by Abengoa&#8217;s use of certain technologies
      which are proprietary to Abengoa). Our objective under the Abengoa R&amp;D
      Program will be to conduct certain Foundational R&amp;D and Applications R&amp;D
      with the objective of developing for Abengoa for each of those Substrates an
      enzyme mixture and related processing technology and manufacturing technology
      (to the extent accomplished, as to each such Substrate, referred to as the
      &#8220;Custom Enzyme Mixture,&#8221; &#8220;Custom Processing Technology&#8221; and &#8220;Custom
      Manufacturing Technology,&#8221; respectively). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      CE
      R&amp;D Activities under the Abengoa R&amp;D Program are to be regulated by a
&#8220;Steering Committee&#8221; comprised of key employees of us and Abengoa, as mandated
      by (i) the R&amp;D Agreement, (ii) the R&amp;D plan specified in the R&amp;D
      Agreement and (iii) &#8220;Statements of Work&#8221; to be approved annually by the Steering
      Committee consistent with the R&amp;D Plan. These CE R&amp;D Activities are to
      be conducted over an &#8220;R&amp;D Spend Measurement Period&#8221; beginning with October
      26, 2006 (the date of the R&amp;D Agreement), and ending 3 years following the
      Steering Committee&#8217;s approval of the initial Statement of Work for the balance
      of calendar year 2007. This initial Statement of Work was approved by the
      Steering Committee in early 2007. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      general, we have been granted exclusive ownership of all intellectual property
      we develop in connection with our performance of Foundational R&amp;D and
      Applications R&amp;D. Further, consistent with our &#8220;Corporate Partnering Open
      Access Policy,&#8221; in conducting our CE R&amp;D Activities, we are assured of being
      entitled to a license to any intellectual property of Abengoa that it might
      furnish to us in connection with our conduct of the Abengoa R&amp;D Program and
      which we reasonably elect to incorporate into any of our intellectual property,
      in order that it may be freely licensed to others by us. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      we are
      not able to successfully develop for Abengoa any Custom Enzyme Mixture and
      related Custom Processing Technology and Custom Manufacturing Technology for
      any
      Substrate furnished to us by Abengoa under the Abengoa R&amp;D Program
      (collectively, as to each Substrate, the &#8220;Applications Technology&#8221;), then
      Abengoa will be granted an option to acquire a non-exclusive license to that
      Applications Technology from us for a period of ninety (90) days following
      the
      completion by Abengoa of verification testing to be concluded by Abengoa within
      a thirty (30) day period following the date we furnish Abengoa a completed
      Custom Enzyme Mixture and related Processing Technology and Manufacturing
      Technology for the applicable Substrate. These non-exclusive license option
      terms provide for Abengoa&#8217;s payment to us of certain license fees, technology
      transfer fees and royalties. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
      to regulatory oversight by the Steering Committee, we have assumed the R&amp;D
      Spending Obligation to spend (or be deemed, under the R&amp;D Agreement, to have
      spent) not less than $10.0 million over the course of the R&amp;D Spend
      Measurement Period in the performance of CE R&amp;D Activities (&#8220;Applicable
      R&amp;D Spend&#8221;) which is divided into two categories: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foundational
      R&amp;D for us, Abengoa and\or any other persons (but not Applications R&amp;D
      for us or any person other than Abengoa), either under the Abengoa R&amp;D
      Program or in conjunction with activities conducted by us under the Master
      R&amp;D Program; and </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applications
      R&amp;D for the benefit of Abengoa under the R&amp;D Agreement. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      determining the amount of our Applicable R&amp;D Spend, all funds expended by us
      in connection with Foundational R&amp;D, whether it is conducted as part of the
      Abengoa R&amp;D Program or whether it is being conducted for us or under the
      Master R&amp;D Program, are included in the Applicable R&amp;D Spend, subject
      only to the requirement that such Foundational R&amp;D was approved by the
      Steering Committee. Further, in calculating the Applicable R&amp;D Spend, we
      will be credited with spending a fixed per &#8220;full time equivalent&#8221; (&#8220;FTE&#8221;)
      scientist dollar rate for all FTE&#8217;s performing CE R&amp;D Activities which is
      materially greater than our anticipated actual out-of-pocket costs of employing
      those FTE&#8217;s.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      further information regarding our relationship with Abengoa, please see Note
      1.
      Organization and Operations - </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
      Raising Activities</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      to our
      consolidated financial statements included elsewhere herein. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="II">Inve</a>stor
      Information</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
      can
      learn more about the Company by visiting our website at www.Dyadic.com.
      Information on the website is neither incorporated into, nor a part of this
      report. We encourage you to read this and other reports filed by the Company
      with the Securities and Exchange Commission. Dyadic will provide you with a
      copy
      of any or all of these reports (except exhibits) at no charge. You may read
      and
      copy any reports, statements or other information that we file at the SEC&#8217;s
      public reference facility at 100 F Street, N.E., Washington, D.C. 20549. Please
      call the SEC at 1-800-SEC-0330 for further information regarding the public
      reference facilities. The SEC maintains a web site, http://www.sec.gov., that
      contains reports, proxy statements and information statements and other
      information regarding registrants that file electronically with the SEC,
      including the Company. The Company&#8217;s SEC filings are also available to the
      public from commercial document retrieval services.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">15</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="Risk"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>RISK
      FACTORS THAT MAY AFFECT FUTURE RESULTS</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
      should carefully consider the following material risks, together with the other
      matters described in this Annual Report on Form 10-KSB in evaluating our
      business and prospects. If any of the following risks actually occur, our
      business, results of operations and financial condition could be materially
      adversely affected. In such circumstances, the trading price of our common
      stock
      could decline, and in some cases, such declines could be </font><font size="2">significant. The risks described below are not the only
      ones we face.
      Additional risks and uncertainties, including those that are not yet identified
      or that we currently believe are immaterial, may also adversely affect our
      business, financial condition or results of operations. Certain statements
      contained in this Annual Report on Form 10-KSB (including certain of the
      following risk factors) constitute forward-looking statements. Please refer
      to
      the section entitled &#8220;Forward Looking Statements&#8221; appearing on page 3 of this
      Annual Report on Form 10-KSB for important limitations on these forward-looking
      statements. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="RISK_FACTORS"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Risks
      General to Our Businesses</u></strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      should be viewed as an early-stage company.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      combination of the reliance by all of our business units upon the expansion
      of
      the capabilities of our C1 Production Technology and the early-stage,
      developmental nature of our BioPharma Business and our BioEnergy Business
      requires that Dyadic be characterized as an early-stage company. Our conduct
      of
      the BioPharma Business and our commercialization of our BioEnergy Business,
      in
      particular, are subject to the risks customarily attending the operations of
      any
      early-stage company, including the risks of failure associated with the
      development of new technologies and products, the successful assembly and
      development of production and R&amp;D capabilities, the effective construction
      of channels of distribution and the management of growth, as discussed in the
      following risk factors. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      have a history of net losses, and may not achieve or maintain
      profitability.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      an accumulated deficit of approximately $44.8 million at December 31, 2006.
      Because we accelerated our R&amp;D activities and expanded both our sales and
      marketing and technical support staffs, we have experienced increased levels
      of
      net losses and negative cash flow. Whether we achieve profitability, and the
      size of our net losses prior to that time, will depend, in large part, on the
      rate of growth, if any, of our Enzyme Business, whether our BioPharma Business
      is able to generate contract sales or other sales, whether our BioEnergy
      Business can commercialize enzymes for its market, on our ability to enter
      into
      additional research or commercial relationships such as those relationships
      we
      have entered into with Abengoa and Royal Nedalco and on the level of our
      expenses. To date, we have derived almost 100% of our sales from the operations
      of our Enzyme Business. We do not anticipate material sales from the operation
      of the BioPharma Business sooner than 2008 or later. We anticipate revenues
      from
      our BioEnergy Business, but how much will depend almost entirely on our ability
      to secure collaborations with other companies in arrangements like the
      arrangements with Abengoa and Royal Nedalco. Our Enzyme Business may not be
      able
      to penetrate new markets or enjoy the improved profit margins we anticipate,
      which could materially adversely impact that business&#8217;s growth potential and
      profitability. Sales from our BioPharma Business are uncertain because our
      ability to secure future collaboration agreements will depend upon the ability
      of the BioPharma Business to perfect the Dyadic Platform Technology to address
      the needs of the pharmaceutical and biotech industries. Similarly, the ability
      of our BioEnergy Business to successfully commercial enzyme products is
      uncertain. We expect to spend significant amounts to fund R&amp;D and enhance
      our core technologies used in all three Businesses. As a result, we expect
      that
      our operating expenses will increase significantly in the near term and,
      consequently, that we will need to generate significant additional sales to
      achieve profitability. Even if we do achieve profitability, we may not be able
      to sustain or increase profitability on a quarterly or annual
      basis.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      could fail to manage our growth, which would impair our
      business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      business plan contemplates that we will grow at a rapid rate. It is difficult
      to
      manage growth, and our future success depends on our ability to efficiently
      and
      effectively implement:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">research
                and product development programs which overcome scientific challenges
                and
                develop new products and processes;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales,
                marketing, technical service and customer support
                programs;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">operational
                and financial control systems; and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">recruiting
                and training programs.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">16</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        ability to offer products and services successfully and to implement our
        business plan in a rapidly evolving global market requires effective planning,
        reporting and management processes. We expect that we will need to continue
        to
        improve our financial and managerial controls, reporting systems and procedures
        and to expand and train our workforce worldwide. We also need to continue
        to
        manufacture our products efficiently and to control or adjust the expenses
        related to R&amp;D, marketing, sales and general and administrative activities
        in response to changes in sales. If we are not successful in efficiently
        manufacturing our products or managing such expenses, there could be an adverse
        impact on our results of operations, our financial condition and the continued
        viability of our business.</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Risks
      Specific to Our Enzyme Business</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      market share growth depends on costly new product introductions and market
      acceptance.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      future success of our Enzyme Business will depend greatly on our ability to
      continuously and timely develop and introduce new products that address evolving
      market requirements and are attractive to customers. We are relying on our
      C1
      Production Technology and our other proprietary technologies to expand the
      product line of our Enzyme Business and improve our gross margins on those
      products. If we fail to introduce new and innovative products, we could fail
      to
      obtain an adequate return on our R&amp;D investments and could lose market share
      to our competitors, which might be difficult or impossible to regain. Any
      inability, for technological or other reasons, to develop successfully and
      introduce new products could reduce our growth rate or otherwise damage our
      business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      in the past we have experienced, and we are likely in the future to experience,
      delays in the development and introduction of products. We may not be able
      to
      keep pace with the rapid rate of change in our markets or to develop new
      products or processes that will meet the requirements of the marketplace or
      achieve market acceptance. Some of the factors affecting market acceptance
      of
      our products include:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">availability,
                quality, performance and price as compared to competitive
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                functionality of new and existing
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                timing of introduction of our products as compared to competitive
                products;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">scientists&#8217;
                and customers&#8217; opinions of our products&#8217; utility and our ability to
                incorporate their feedback into our future products;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">citation
                of the products in published
                research.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      expenses or losses associated with unsuccessful product development activities
      or lack of market acceptance of our new products could seriously harm our
      business, financial condition and results of operations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      dependence on contract manufacturers could harm our
      business.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      Enzyme Business currently relies on contract manufacturers for all of its
      manufacturing. If we require additional manufacturing capacity and are unable
      to
      obtain it in sufficient quantity, we may not be able to increase our sales,
      or
      may be required to make very substantial capital investments to build that
      capacity.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      manufacturing capabilities, and any current or future arrangements with third
      parties for these activities, may not be adequate for the successful
      commercialization of our industrial enzyme products. In the operation of the
      Enzyme Business, all of our industrial enzymes have over the past decade, and
      are expected over the foreseeable future to be, produced at the manufacturing
      facilities of one or more contract manufacturers. As a result, we are dependent
      upon the performance and plant capacity of third-party manufacturers. Though
      we
      formerly used two contract manufacturers, we let our agreement with one of
      those
      contract manufacturers expire and now only use it on a highly limited basis.
      Our
      Enzyme Business, therefore, faces risks of difficulties with, and interruptions
      in, performance by the one contract manufacturer we are currently using of
      its
      manufacturing responsibilities, the occurrence of which could adversely impact
      the availability, launch and/or sales of our products in the future. While
      our
      principal contract manufacturer, Polfa Tarchomin, S.A. (&#8220;Polfa&#8221;), which has been
      producing a number of our products since 2001 without interruption, completed
      the expansion of its capacity with an additional 50 cubic meters of fermentation
      capacity and associated recovery capacity in October 2006, there can be no
      assurance that Polfa will be able to maintain its capacity commitments to Dyadic
      in the future without additional Dyadic financial commitments to Polfa.
<br></font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">17</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Should
          we
          require additional capacity in the future, and if Polfa cannot obtain the
          funding necessary to provide the needed capital to honor its obligation
          to us
          under its Manufacturing Agreement with us, our ability to meet our production
          requirements would be negatively affected, thereby negatively affecting
          our
          financial position, results of operations and cash flows. In such an event,
          the
          Company would have to locate additional capacity with either Martek Biosciences
          or another contract manufacturing facility. The Company believes it has
          these
          resources available if needed, to support any additional production needs.
          Although we feel there are other alternatives, the fact that the majority
          of our
          production requirements will be satisfied by the single manufacturing facility
          operated by our Polish contract manufacturer does leave us vulnerable to
          a
          failure of performance by it. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Regulations
        may limit or impair our ability to sell genetically engineered products in
        the
        future.</strong></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      develop enzyme products using both non-genetically engineered
      microorganisms,&#160;as well as those that have undergone some degree
      of&#160;genetic modification.&#160;&#160;Products derived from genetically
      modified organisms (&#8220;GMOs&#8221;), are subject to regulation by&#160;federal, state,
      local and foreign government agencies.&#160;These agencies administering
      existing or future applicable regulation or legislation may not allow&#160;us to
      produce and market&#160;our products derived from GMOs in a timely manner or
      under technically or commercially feasible conditions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, regulatory action or private litigation could result in expenses,
      delays or other impediments to&#160;our product development programs or the
      commercialization of resulting products.&#160; The U.S. Food and Drug
      Administration, or FDA, currently applies the same regulatory standards to
      products made through genetic engineering as those applied to products developed
      through traditional methodologies.&#160;Depending on&#160;a product's
      application and regardless of its GMO status, it may be subject to lengthy
      FDA
      reviews and unfavorable FDA determinations if there are safety concerns or
      if
      the FDA changes its current regulatory&#160;policy.&#160; The European Union, or
      the EU, has regulations regarding the development, production and marketing
      of
      products from GMOs&#160;which are generally&#160;more restrictive than present
      U.S. regulations.&#160; For example, among other requirements, EU animal feed
      registration requires in-vivo&#160;efficacy testing, as well as toxicological
      testing of all enzyme products, including products from non-GMO
      microorganisms.&#160; The regulatory agencies administering these and future
      regulations may hinder our ability to produce and bring to&#160;market some of
      our enzyme products in a timely manner or under technically or commercially
      feasible conditions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Specific to Our BioPharma Business</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may fail to commercialize the Dyadic Platform Technology for the expression
      of
      therapeutic proteins. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
      our Enzyme Business has developed and sold industrial enzyme products and has
      used our C1 Production Technology to develop such products, our BioPharma
      Business has not yet completed commercialization of our C1 Production Technology
      for the expression of therapeutic proteins. If our BioPharma Business fails
      to
      do this, we may be forced to terminate the BioPharma Business&#8217;s operations and
      liquidate it.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      BioPharma Business must be evaluated as having the same risks as those inherent
      in early-stage biotechnology companies because the application of our C1
      Production Technology to the expression of pre-clinical and clinical quantities
      of therapeutic proteins is still in development. We may not be able to
      successfully harness the C1 Production Technology to achieve those objectives.
      Further, we may not be able to expand the capabilities of the C1 Production
      Technology to produce commercial volumes of therapeutic proteins at reasonable
      costs. Also, we may not ever be able to successfully complete development of
      our
      fungal high throughput system. And, even if the BioPharma Business is able
      to
      achieve any of those accomplishments, we may not be able to successfully develop
      the C1 HTS Technology to serve the functions of gene discovery or the
      development of new and/or improved protein drugs. Successful development of
      the
      Dyadic Platform Technology for these purposes will require significant
      development and investment, including testing, to prove its efficacy and
      cost-effectiveness. To date, drug companies have developed and commercialized
      only a small number of gene-based products in comparison to the total number
      of
      drug molecules available in the marketplace. In this regard, we are heavily
      dependent upon our use of third-party research organizations to assist us in
      the
      development of the Dyadic Platform Technology. In general, our experience has
      been that each step in the process has taken longer and cost more to accomplish
      then we had originally projected, and we anticipate that this is likely to
      remain the case with respect to our BioPharma Business&#8217; continuing development
      efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
      of </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>the
      Dyadic Platform Technology for therapeutic proteins depends on
      collaborations.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commercialization
      of the Dyadic Platform Technology by our BioPharma Business depends on
      collaborations with other parties. If we are not able to find collaborators
      in
      the future, the BioPharma Business may not be able to develop the Dyadic
      Platform Technology for therapeutic protein products. Further, our business
      model relies on a revenue stream derived from collaboration projects to be
      conducted with our customers to express laboratory-testing quantities of
      therapeutic proteins. A large portion of the anticipated financial reward
      depends on those therapeutic proteins progressing through drug development
      and
      into commercially successful drugs. Apart from risks relating to whether our
      BioPharma Business can capture such customers, or capture them on satisfactory
      terms, we will have no control over post-collaboration project drug
</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">18</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">development
        and commercialization. Further, conflicts could arise between us and our
        customers or among them and third parties that could discourage or impede
        the
        activities of our BioPharma Business.</font></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
        we
        do not currently possess the financial resources necessary to develop and
        commercialize potential drug products that may result from the Dyadic Platform
        Technology, or the resources to complete any approval processes which may
        be
        required for these products, we must enter into collaborative arrangements
        to
        develop and commercialize drug products. It is expected that these arrangements
        will be for fixed terms and will expire after a fixed period of time. If
        they
        are not renewed or if we do not enter into new collaborative agreements,
        our
        sales will be reduced and our products may not be
        commercialized.</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      have limited or no control over the resources that any collaborator may devote
      to our programs.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      limited or no control over the resources that any collaborator may devote to
      our
      products. Any of our future collaborators may not perform their obligations
      as
      expected. These collaborators may breach or terminate their agreement with
      us or
      otherwise fail to conduct their collaborative activities successfully and in
      a
      timely manner. Further, our collaborators may elect not to develop products
      arising out of our collaborative arrangements or devote sufficient resources
      to
      the development, manufacture, market or sale of these products. If any of these
      events occur, we may not be able to develop our technologies or commercialize
      our products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Potential
      therapeutic products developed by us or with our customers or collaborators
      are
      subject to a lengthy and uncertain regulatory process. If these therapeutic
      protein products are not approved, we or our customers or collaborators will
      not
      be able to commercialize them, and we may not receive the milestone and royalty
      payments which are based upon the successful advancement of these products
      through the drug development and approval process.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      FDA
      must approve any therapeutic product before it can be marketed in the United
      States. Before our collaborators can file a new drug application or biologic
      license application with the FDA, the product candidate must undergo extensive
      testing, including animal and human clinical trials, which can take many years
      and require substantial expenditures. Data obtained from such testing are
      susceptible to varying interpretations which could delay, limit or prevent
      regulatory approval. In addition, changes in regulatory policy for product
      approval during the period of product development and regulatory agency review
      of each submitted new application or product license application may cause
      delays or rejections.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
      these products involve the application of new technologies and may be based
      upon
      new therapeutic approaches, they may be subject to substantial review by
      government regulatory authorities and, government regulatory authorities may
      grant regulatory approvals more slowly for these products than for products
      using more conventional technologies. While we anticipate that most of our
      collaborators will have experience submitting an application to the FDA or
      any
      other regulatory authority, we have no such experience, and neither we nor
      any
      collaborator has yet submitted an application with the FDA or any other
      regulatory authority for any product candidate generated through the use of
      our
      C1 Production Technology, nor has the FDA nor any other regulatory authority
      approved any therapeutic product candidate developed using our C1 Production
      Technology for commercialization in the United States or elsewhere. Our
      collaborators may not be able to conduct clinical testing or obtain the
      necessary approvals from the FDA or other regulatory authorities for our
      products. The regulatory agencies of foreign governments must also approve
      our
      therapeutic products before the products can be sold in those other
      countries.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Even
      after investing significant time and expenditures, our collaborators may not
      obtain regulatory approval for their products. Even if they receive regulatory
      approval, this approval may entail limitations on the indicated uses for which
      we can market a product. Further, once regulatory approval is obtained, a
      marketed product and its manufacturer are subject to continual review, and
      discovery of previously unknown problems with a product or manufacturer may
      result in restrictions on the product, manufacturer and manufacturing facility,
      including withdrawal of the product from the market. In certain countries,
      regulatory agencies also set or approve prices. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Health
      care reform may limit our profitability or that of our
      customers.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Dyadic Platform Technology is being developed to assist our customers or
      collaborators in the development of future therapeutic products, including
      pharmaceutical products. The ability of our collaborators to commercialize
      pharmaceutical products developed with the Dyadic Platform Technology may depend
      in part on the extent to which reimbursement for the cost of those products
      will
      be available from government health administration authorities, private health
      insurers and other organizations. Third-party payers are increasingly
      challenging prices of medical products and services. Significant uncertainty
      exists as to the reimbursement status of newly approved health care products,
      and there can be no assurance that adequate third party coverage will be
      available for any product to enable us to maintain price levels sufficient
      to
      realize an appropriate return on our investment in research and product
      development. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Adverse
      events in the field of therapeutic products may adversely affect us or our
      collaborators.</strong></font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">19</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently,
        we are not engaged in developing therapeutic products for our own account,
        but
        instead intend to collaborate with drug companies to express therapeutic
        products requested by them for the ultimate purpose of their development,
        testing and introduction as new drugs. We may, however, engage in these
        activities in the future for our own account. If we or our collaborators
        develop
        therapeutic products, these products may encounter substantial delays in
        development and approval due to the government regulation and approval process.
        Adverse events reported in gene therapy clinical trials may lead to more
        government scrutiny of proposed clinical trials of therapeutic products,
        stricter labeling requirements for these products and delays in the approval
        of
        other types of products for commercial sale.</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      C1
      Production Technology has been tested for use in pulp and paper production,
      which requires FDA approval as generally regarded as safe, or GRAS, and has
      generated promising safety and toxicity data for one enzyme. A risk nonetheless
      exists that the C1 Production Technology will produce therapeutic products
      and
      enzymes that have safety and toxicity issues associated with them.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      believe our determination of the genome sequence of C1 could help to mitigate
      our risk that there are unexpected safety and toxicity issues associated with
      our C1 Production Technology and facilitate our ability to find and express
      new
      genes of bio-therapeutic and other commercial value. However, there can be
      no
      assurance that annotation of C1will be fully or adequately completed, and until
      it is successfully completed, we are at a distinct competitive disadvantage
      to
      some of our competitors, whose host organisms have been more thoroughly
      researched and whose genomes have been fully annotated. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Specific to the Our BioEnergy Products</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may fail to develop commercially viable enzymes to convert sugar into ethanol.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
      we have developed enzymes using our C1 Production Technology that do, in fact,
      convert biomass into sugar that can then be fermented into ethanol, we are
      still
      working on developing those enzymes into commercially viable products for the
      ethanol marketplace. If our BioEnergy Business fails to do this, we may be
      forced to terminate the BioEnergy Business&#8217;s operations and liquidate it. Our C1
      HTS Technology is still under development and if or how useful it will be in
      accelerating the development of identifying, evaluating and developing new
      and
      better enzymes that can be produced using our C1 Production Technology or other
      proprietary technologies is yet to be proven.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      BioEnergy Business must be evaluated as having the same risks as those inherent
      in early-stage biotechnology companies because our enzymes for this application
      are still in development to achieve required cost-efficiencies. We may not
      be
      able to successfully develop cost-efficient enzymes. Further, we may be able
      to
      develop commercially viable enzymes for only some of the alternative types
      of
      biomass, and these may not be the ones with the greatest market potential.
      Successful development of the Dyadic Platform Technology to discover, develop
      and produce commercially viable enzymes for the cellulosic ethanol market will
      require significant development and investment, including testing, to prove
      its
      efficacy and cost-effectiveness. In this regard, we are heavily dependent upon
      our use of third-party research organizations to assist us in the development
      of
      the Dyadic Platform Technology. In general, our experience has been that each
      step in the process has taken longer and cost more to accomplish then we had
      originally projected, and we anticipate that this is likely to remain the case
      with respect to our BioEnergy Business&#8217; continuing development
      efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commerc</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ialization
      of BioEnergy Products depends on collaborative
      partnerships.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
      we do not have the manufacturing infrastructure and financial resources to
      develop large scale-enzyme production and manufacturing processes for the
      commercialization of our BioEnergy products, our ability to commercialize those
      products will depend on our entering into collaborative partnerships like our
      recent one with Abengoa Bioenergy R&amp;D, Inc. and Royal Nedalco. We are in
      discussions with and are considering additional collaborative partnerships,
      though there is no assurance that we will able to complete any additional ones
      on terms acceptable to us or at all. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
      of Cellulosic Ethanol may not be feasible. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
      cellulosic ethanol should reduce the United States' and other countries&#8217;
dependence on imported oil, increase its energy security and reduce its trade
      deficit, commercialization of cellulosic ethanol in the United States or
      elsewhere may not be feasible for a variety of reasons.&#160; Among others, to
      date there has been a lack of significant private and government funding for
      research and development in conversion and processing technologies, as well
      as
      for the development of biorefineries. Furthermore, there has been to date very
      little, if any, well directed public policies emphasizing investment and
      providing incentives for the commercialization and transition to cellulosic
      ethanol. The current United States Presidential administration has recently
      been
      publicizing the benefits of cellulosic ethanol, though it remains to be seen
      whether or not such publicity will engender significant government funding
      and
      economic incentives to mitigate some of the foregoing barriers to
      commercialization of cellulosic ethanol.&#160; Our recent collaborative
      partnership with Abengoa Bioenergy R&amp;D, Inc. and Royal Nedalco may suggest
      that these barriers are surmountable, although there are no assurances in this
      regard and there are a variety of risks that may not be directly or indirectly
      under our control. </font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">20</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
          substantial development of infrastructure will be required by persons or
          entities outside of our control for our operations, and the ethanol industry
          generally, to grow. Areas requiring expansion include, but are not limited
          to,
          additional rail capacity, additional storage facilities for ethanol, increases
          in truck fleets capable of transporting ethanol within localized markets,
          expansion of refining and blending facilities to handle ethanol, and growth
          in
          the fleet of vehicles capable of using E85 (85% ethanol) fuel. Substantial
          investments required for infrastructure changes and expansions may not
          be made
          or may not be made on a timely basis. Any delay or failure in making the
          changes
          to or expansion of infrastructure could harm demand or prices for our enzyme
          products, impose additional costs on us or otherwise have a material adverse
          effect on the results of our operations of financial position.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>If
        the expected increase in ethanol demand does not occur, or if ethanol demand
        decreases, there may be excess capacity in&#160;the&#160;ethanol industry which
        would likely&#160;diminish demand for services and products from our BioEnergy
        Business.</strong></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Domestic
      ethanol production capacity has increased steadily from an annualized rate
      of
      1.7 billion gallons per year in January of 1999 to 5.5 billion gallons per
      year
      in December 2006 according to the Renewable Fuels Association. In addition,
      there is a significant amount of capacity being added to&#160;the ethanol
      industry.&#160; It is believed that approximately 4.6 billion gallons per year
      of production capacity is currently under construction. This capacity is being
      added to address anticipated increases in demand.&#160; However, demand for
      ethanol may not increase as quickly as expected, or at all. &#160;Demand could
      be impaired due to a number of factors, including&#160;regulatory developments
      and reduced United States gasoline consumption. Reduced gasoline consumption
      could occur as a result of increased gasoline or oil prices. For example, price
      increases could cause businesses and consumers to reduce driving or acquire
      vehicles with more favorable gasoline mileage capabilities.&#160; Significant
      diminished demand for ethanol, for any reason whatsoever, would likely diminish
      the demand for services and products from our BioEnergy Business. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      United States Ethanol Industry is highly dependent upon a myriad of federal
      and
      state legislation and regulations and any changes in such legislation or
      regulation could materially and adversely affect the demand for the Services
      and
      Products of our BioEnergy Business. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      United States Ethanol Industry is highly dependent upon a myriad of federal
      and
      state legislation and regulations. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      changes in such legislation or regulation could materially and adversely affect
      the demand for our BioEnergy Products. For example, under the Energy Policy
      Act
      of 2005, the U.S. Department of Energy, in consultation with the U.S. Secretary
      of Agriculture and the U.S. Secretary of Energy, may waive the Renewable Fuels
      Standard, or RFS, mandate with respect to one or more states if the
      Administrator determines that implementing the requirements would severely
      harm
      the economy or the environment of a state, a region or the United States, or
      that there is inadequate supply to meet the requirement. Any waiver of the
      RFS
      with respect to one or more states or with respect to 2006 would adversely
      offset demand for ethanol and, thus, diminish demand for our services and
      products in our BioEnergy Business. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>The
      market price of ethanol is volatile and subject to significant fluctuations,
      which may cause our profitability from the production of cellulosic ethanol
      to
      fluctuate significantly. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      market price of ethanol is dependent upon many factors, including the price
      of
      gasoline, which is in turn dependent upon the price of petroleum. Petroleum
      prices are highly volatile and difficult to forecast due to frequent changes
      in
      global politics and the world economy. The distribution of petroleum throughout
      the world is affected by incidents in unstable political environments, such
      as
      Iraq, Iran, Kuwait, Saudi Arabia, Nigeria, Venezuela, the former U.S.S.R. and
      other countries and regions. The industrialized world depends critically upon
      oil from these areas, and any disruption or other reduction in oil supply can
      cause significant fluctuations in the prices of oil and gasoline. We cannot
      predict the future price of oil or gasoline and may establish unprofitable
      prices for the sale of ethanol due to significant fluctuations in market prices.
      In recent years, the prices of gasoline, petroleum and ethanol have all reached
      historically unprecedented high levels. If the prices of gasoline and petroleum
      decline, we believe that the demand for and price of ethanol may be adversely
      affected. Fluctuations in the market price of ethanol may cause our
      profitability to fluctuate significantly. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Applic</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>able
      to Our Enzyme Business, BioPharma Business and BioEnergy
      Products</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Alternative
      technologies may diminish the need for producing some enzymes the way we
      do.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Many
      of
      our enzyme products are produced in fermenters. Some of the product segments
      we
      hope to serve may not find it efficient to use the fermenter processes we
      employ. For example, bio-ethanol and other bio-fuels production represents
      a
      considerable market opportunity for enzymes comprising BioEnergy Products.
      However, research being conducted within the auspices of major seed producers,
      U.S. federal government and corn growers association may supplant the need
      for
      enzymes produced in fermenters, which is the enzyme production process we
      currently use.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">21</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Reductions
      in R&amp;D budgets may affect the sales of our Businesses.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      customers include researchers at customers of our Enzyme Business, potential
      drug company customers of our BioPharma Business and potential energy companies
      for our BioEnergy Products. Fluctuations in the R&amp;D budgets of these
      researchers and their organizations could have a significant effect on the
      demand for our products. Research and development budgets fluctuate due to
      changes in available resources, consolidation in the pharmaceutical and energy
      industries, spending priorities and institutional budgetary policies. Our
      Businesses could be seriously damaged by any significant decrease in life
      sciences and/or renewable fuels R&amp;D expenditures by these existing and
      potential customers, academic institutions, government laboratories or private
      foundations.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">&#160;</div>
      <div id="HDR"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Conflicts
        with our collaborators could harm our business.</strong></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      important part of our strategy involves conducting proprietary research
      programs. We may pursue opportunities in fields that could conflict with those
      of our collaborators. Moreover, disagreements with our collaborators could
      develop over rights to our intellectual property. Any conflict with our
      collaborators could reduce our ability to obtain future collaboration agreements
      and negatively impact our relationship with existing collaborators, which could
      reduce our sales.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
      of our collaborators could also become competitors in the future. Our
      collaborators could develop competing products, preclude us from entering into
      collaborations with their competitors, fail to obtain timely regulatory
      approvals, terminate their agreements with us prematurely or fail to devote
      sufficient resources to the development and commercialization of products.
      Any
      of these developments could harm our product development efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      will
      either commercialize products resulting from our proprietary programs directly
      or through licensing to other companies. We have limited experience in
      manufacturing and marketing products for the pharmaceutical, biotechnology
      and
      energy industries. In order for us to commercialize these products directly,
      we
      would need to develop, or obtain through outsourcing arrangements, the
      capability to market and sell these products. We do not have these capabilities,
      and we may not be able to develop or otherwise obtain the requisite marketing
      and sales capabilities. If we are unable to successfully commercialize products
      resulting from our proprietary research efforts, we will continue to incur
      losses. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Public
      views on ethical and social issues may limit use of our technologies and reduce
      our sales.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      success will depend in part upon our ability to develop products discovered
      through the Dyadic Platform Technology. Governmental authorities could, for
      social or other purposes, limit the use of genetic processes or prohibit the
      practice of the Dyadic Platform Technology. Ethical and other concerns about
      the
      Dyadic Platform Technology, particularly the use of genes from nature for
      commercial purposes, and products resulting there from, could adversely affect
      their market acceptance. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>If
      the public does not accept genetically engineered products, our product demand
      could decline.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      commercial success of our potential products will depend in part on public
      acceptance of the use of genetically engineered products including drugs, plants
      and plant products. Claims that genetically engineered products are unsafe
      for
      consumption or pose a danger to the environment may influence public attitudes.
      Our genetically engineered products may not gain public acceptance in the
      various industrial, pharmaceutical, biotechnology or energy industries. Negative
      public reaction to genetically modified organisms and products could result
      in
      greater government regulation of genetic research and resultant products,
      including stricter labeling laws or regulations, and could cause a decrease
      in
      the demand for our products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      subject of genetically modified organisms has received negative publicity in
      Europe and other countries, which has aroused public debate. The adverse
      publicity in Europe could lead to greater regulation and trade restrictions
      on
      imports of genetically altered products. If similar adverse public reaction
      occurs in the United States, genetic research and resultant products could
      be
      subject to greater domestic regulation and a decrease in the demand for our
      products could result.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Other
      Business Risks That We Face</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      must continually offer new products and technologies.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      industrial enzymes and biotechnology industries are characterized by rapid
      technological change, and the area of gene research is a rapidly evolving field.
      Our future success will depend on our ability to maintain a competitive position
      with respect to technological advances. Rapid technological development by
      others may result in our products and technologies becoming
      obsolete.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">22</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
        products that we develop through the Dyadic Platform Technology and our other
        proprietary technologies will compete in highly competitive markets. Many
        of the
        organizations competing with us in the markets for such products have greater
        capital resources, R&amp;D and marketing staffs and facilities and capabilities,
        and greater experience in obtaining regulatory approvals, manufacturing products
        and marketing. Accordingly, our competitors may be able to develop technologies
        and products more easily which would render our technologies and products
        and
        those of our collaborators obsolete and noncompetitive. If a competitor develops
        superior technology or cost-effective alternatives to our products or processes,
        our business, operating results and financial condition could be seriously
        harmed. In addition, demand for our products may weaken due to reduction
        in
        R&amp;D budgets or loss of distributors, any of which might have an adverse
        effect on our financial condition.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      markets for our Enzyme Business&#8217;s products are, in many cases, very competitive
      and price sensitive. Our Enzyme Business currently competes with five much
      larger competitors, each with dominant market positions in segments in which
      we
      compete and who, as a group, hold approximately 70% market share in the present
      industrial enzymes marketplace. Each of these competitors has substantially
      greater financial, operational, sales and marketing resources than we do and
      very significant experience in R&amp;D. Further, these competitors may possess
      other complementary technologies, such as proprietary directed molecular
      evolution technology, which may be more effective at implementing their
      technologies to develop commercial products than our complementary technologies
      implement the Dyadic Platform Technology. Also, some of these competitors have
      entered into collaborations with leading companies within our Enzyme Business&#8217;s
      target markets to produce enzymes for commercial purposes.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Well-known,
      and better financed, biotechnology companies offer competing technologies for
      the same products and services as our BioPharma Business plans to offer using
      the Dyadic Platform Technology. Customers may prefer existing competing
      technologies over the Dyadic Platform Technology. Our BioPharma Business also
      faces, and will continue to face, intense competition from organizations such
      as
      large biotechnology companies, as well as academic and research institutions
      and
      government agencies that are pursuing competing technologies to enable
      production of therapeutic and other proteins and bio-molecules of commercial
      interest at economically viable costs. These organizations may develop
      technologies that are superior alternatives to the Dyadic Platform Technology.
      We anticipate that our BioPharma Business will face increased competition as
      new
      companies enter our markets and as development of biological products
      evolves.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Similarly,
      well-known, and better financed, biotechnology companies offer competing
      technologies for the same products and services as our BioEnergy Business plans
      to offer using the Dyadic Platform Technology and our other proprietary
      technologies. As with the BioPharma Business, prospective customers of the
      BioEnergy Business may prefer existing competing technologies over the Dyadic
      Platform Technology and our other proprietary technologies. Our BioEnergy
      Business also faces, and will continue to face, intense competition from
      organizations such as large biotechnology companies, as well as academic and
      research institutions and government agencies that are pursuing competing
      technologies to enable production of cellulosic ethanol at economically viable
      costs. These organizations may develop technologies that are superior
      alternatives to the Dyadic Platform Technology and our other proprietary
      technologies. We anticipate that our BioEnergy Business will face increased
      competition as new companies enter our markets and as development of biological
      products evolves.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may need additional capital in the future. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      future capital requirements may be substantial, particularly as we continue
      to
      develop the Dyadic Platform Technology and our other proprietary technologies
      to
      commercialize BioEnergy Products and if completion of the development of our
      C1
      Production Technology for our BioPharma Business takes longer or requires
      greater resources than we had expected, if we continue to develop the C1
      Production Technology to expand its production capabilities to manufacture
      commercial volumes of therapeutic proteins, if we continue to develop a C1
      HTS
      Technology, or if our BioPharma Business develops a number of therapeutic
      products. Although we believe that we have sufficient cash on hand to fund
      our
      operations and meet our obligations through December 31, 2008, our need for
      additional capital will depend on many factors, including the financial success
      of our Enzyme Business, whether we are successful in obtaining payments from
      BioPharma Business customers under collaborative agreements, whether we are
      successful in our R&amp;D efforts with Abengoa Bioenergy R&amp;D, Inc. and Royal
      Nedalco, whether we can enter into additional collaborative partnerships for
      commercialization of our BioEnergy Products, the progress and scope of our
      collaborative and independent R&amp;D projects performed by our customers and
      collaboration partners, the effect of any acquisitions of other businesses
      that
      we may make in the future, and the filing, prosecution and enforcement of patent
      claims.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      our
      capital resources are insufficient to meet our capital requirements, we will
      have to raise additional funds to continue the development of our technologies
      and complete the commercialization of products, if any, resulting from our
      technologies. If future raises of funds do occur, they may cause dilution to
      our
      existing stockholders. We may not be able to raise additional funds on terms
      that are acceptable to us or on any terms whatsoever, or we may be unable to
      raise sufficient additional capital. If we fail to raise sufficient funds,
      and
      our Enzyme Business is unable to generate sufficient levels of profitability,
      we
      may have to curtail or cease, or dispose of, one or more of our operations.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">23</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      will need to expand our existing</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      marketing and sales resources.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
      we
      have recently expanded our marketing and sales functions, each of our Enzyme
      Business, BioPharma Business and BioEnergy Business will need to continue to
      expand them to achieve our contemplated annual rates of growth and to
      successfully market the Dyadic Platform Technology. Currently, we rely primarily
      on our direct sales force for the United States market and contract with
      professional sales agents and distributors for the international market,
      including two controlled foreign subsidiaries. Direct salespeople are our
      employees and are paid a salary plus commissions on sales they make within
      their
      assigned territories. Contracted sales agents are paid a base rate of
      compensation plus commissions on sales they make within their assigned
      territories. Distributors purchase products from us and then resell our products
      and services to third parties. Our officers and employees develop and implement
      our marketing strategy, although we do periodically engage non-employee
      consultants, acting as independent contractors, to assist us in these
      efforts.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Market
      forces, such as increasing competition, increasing cost pressures on our
      customers and general economic conditions, may require us to devote more
      resources to our sales and marketing efforts than we currently contemplate,
      such
      as changing the composition of our sales and marketing staff and changing our
      marketing methods. These changes may result in additional expenses. In addition,
      we will incur additional salary expenses because we intend to increase our
      direct sales force. We also may hire direct sales representatives to replace
      independent sales representatives or distributors that we use. Similarly, if
      we
      increase our reliance on marketing consultants to assist us, we will incur
      greater costs. If we decide to increase our advertising, we will also incur
      higher sales and marketing costs. Our incurrence of increased costs will make
      it
      more difficult for us to operate profitably, and we may not have sufficient
      funds to support all of these costs.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      we
      expand our sales force and increase our marketing activities, we can offer
      no
      assurances that those efforts will result in more sales or higher revenue.
      Also,
      the increased costs we incur by expanding our sales and marketing resources
      may
      not result in greater sales or in higher revenue. Further, even if we increase
      our spending on sales and marketing, we may not be able to maintain our current
      level of sales and revenue. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Loss
      of key personnel could hurt our business. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      highly dependent on the principal members of our management and scientific
      staff, the loss of whose services might adversely impact the achievement of
      our
      objectives. In addition, recruiting and retaining qualified scientific personnel
      to perform future R&amp;D work will be critical to our success. We currently do
      not have sufficient executive management personnel to fully execute our business
      plan. Although we believe we will be successful in attracting and retaining
      qualified management and scientific personnel, such as the addition of our
      Chief
      Scientific Officer, Glenn Nedwin in March 2006, competition for experienced
      scientists from numerous companies and academic and other research institutions
      may limit our ability to do so on acceptable terms. Failure to attract and
      retain scientific personnel would prevent us from pursuing collaborations or
      developing our products or core technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      planned activities will require additional expertise in specific industries
      and
      areas applicable to the products developed through our technologies. These
      activities will require the addition of new personnel, including management,
      and
      the development of additional expertise by existing management personnel. The
      inability to acquire these services or to develop this expertise could impair
      the growth, if any, of our business. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      directors and senior officers require that we maintain directors and officers
      insurance at levels comparable to those of similar sized public companies.
      We
      have purchased such directors&#8217; and officers&#8217; liability insurance. Our efforts to
      recruit additional directors could be impeded if the amount of insurance
      coverage is viewed to be insufficient. Further, if we are unable to provide
      adequate compensation or are unable to maintain sufficient directors&#8217; and
      officers&#8217; insurance coverage, we may not be able to attract or retain key
      personnel.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Personnel
      changes may disrupt our operations. Hiring and training new personnel will
      entail costs and may divert our resources and attention from revenue-generating
      efforts. From time to time, we also engage consultants to assist us in our
      business and operations. These consultants serve as independent contractors,
      and
      we, therefore, do not have as much control over their activities as we do over
      the activities of our employees. Our consultants may be affiliated with or
      employed by other parties, and some may have consulting or other advisory
      arrangements with other entities that may conflict or compete with their
      obligations to us. Inventions or processes discovered by these persons will
      not
      necessarily become our property. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Inability
      to protect our technologies could harm our ability to compete.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      success will depend in part on our ability to obtain patents and maintain
      adequate protection of our other intellectual property for our technologies
      and
      products in the United States and other countries. If we do not adequately
      protect our intellectual property, competitors may be able to practice our
      technologies and erode our competitive advantage. The laws of some foreign
      countries do not protect proprietary rights to the same extent as the laws
      of
      the United States, and many companies have encountered significant problems
      in
      protecting their proprietary rights in these foreign countries. These problems
      can be caused by, for example, a lack of rules and methods for defending
      intellectual property rights.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">24</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
            October 2006, we were granted U.S. patent 7,122,330, "High-Throughput
            Screening
            of Expressed DNA Libraries in Filamentous Fungi," by the U.S. Patent
            and
            Trademark Office. This patent grant will expand the patent protection
            for
            the&#160;C1 HTS&#160;Technology and broad claims covering a number of other
            industrially relevant fungi for applications in cellulosic ethanol and
            other key
            markets. We hold 4 issued U.S. patents and 28 issued and 2 allowed international
            patents, including claims that cover the Dyadic Platform Technology and
            52 U.S.
            and international filed and pending patent applications which we believe
            provide
            broad protection for the Dyadic Platform Technology and its products
            and
            commercial applications. However, the patent positions of biotechnology
            companies, including our patent position, are generally uncertain and
            involve
            complex legal and factual questions. We will be able to protect our proprietary
            rights from unauthorized use by third parties only to the extent that
            our
            proprietary technologies are covered by valid and enforceable patents
            or are
            effectively maintained as trade secrets. We intend to apply for patents
            covering
            both our technologies and products as we deem appropriate. However, existing
            and
            future patent applications may be challenged and may not result in issued
            patents. Our existing patents and any future patents we obtain may not
            be
            sufficiently broad to prevent others from practicing our technologies
            or from
            developing competing products. Furthermore, others may independently
            develop
            similar or alternative technologies or design around our patented technologies.
            In addition, others may challenge or invalidate our patents, or our patents
            may
            fail to provide us with any competitive advantages.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not
          all
          of our proprietary technology is eligible for patent protection. Accordingly,
          as
          to significant portions of our various proprietary technologies, we rely
          upon
          trade secret protection for our confidential and proprietary information.
          We
          have taken security measures to protect our proprietary information. These
          measures may not provide adequate protection for our trade secrets or other
          proprietary information. We seek to protect our proprietary information
          by
          entering into confidentiality agreements with employees, collaborators
          and
          consultants. Nevertheless, employees, collaborators or consultants may
          still
          disclose our proprietary information, and we may not be able to meaningfully
          protect our trade secrets. In addition, others may independently develop
          substantially equivalent proprietary information or techniques or otherwise
          gain
          access to our trade secrets. </font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Intellectual
      property litigation could harm our business. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      commercial success depends in part on neither infringing patents and proprietary
      rights of third parties, nor breaching any licenses that we have entered into
      with regard to our technologies and products. Others have filed, and in the
      future are likely to file, patent applications covering genes or gene fragments
      that we may wish to utilize with the Dyadic Platform Technology or products
      or
      systems that are similar to products developed with the use of it. If these
      patent applications result in issued patents and we wish to use the claimed
      technology, we would need to obtain a license from the third party.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Third
      parties may assert that we are employing their proprietary technology without
      authorization. In addition, third parties may obtain patents in the future
      and
      claim that use of our technologies infringes these patents. We could incur
      substantial costs and diversion of management and technical personnel in
      defending ourselves against any of these claims or enforcing our patents or
      other intellectual property rights against others. Furthermore, parties making
      claims against us may be able to obtain injunctive or other equitable relief
      which could effectively block our ability to further develop, commercialize
      and
      sell products, and could result in the award of substantial damages against
      us.
      If a claim of infringement against us is successful, we may be required to
      pay
      damages and obtain one or more licenses from third parties. We may not be able
      to obtain these licenses at a reasonable cost, if at all. In that event, we
      could encounter delays in product commercialization while we attempt to develop
      alternative methods or products. Defense of any lawsuit or failure to obtain
      any
      of these licenses could prevent us from commercializing available
      products.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      the taxonomic classification of C1 was determined using classical morphological
      methods.&#160; More modern taxonomic classification methods indicate that our C1
      host organism will be reclassified as a different genus and species. With the
      genomic sequence and the partial annotation of the C1 genome to date, we are
      in
      the process of determining with higher certainty the most likely genus and
      species of the C1 host organism. Some of the possible species that the C1 host
      could be reclassified as could be the subject of patent rights owned by
      others.&#160; We believe, based on our evaluation of the relevant field of
      science and our discussions with our consulting professionals, that any such
      patent rights would be invalid, and were litigation over the issue to ensue,
      we
      believe we should prevail.&#160; If we did not prevail, to settle any such
      litigation or pre-litigation claims, we could be required to enter into a
      cross-licensing arrangement, pay royalties or be forced to stop
      commercialization of some of our activities. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      do not
      fully monitor the public disclosures of other companies operating in our
      industry regarding their technological development efforts. If we did evaluate
      the public disclosures of these companies in connection with their technological
      development efforts and determined that they violated our intellectual property
      or other rights, we would anticipate taking appropriate action, which could
      include litigation. However, any action we take could result in substantial
      costs and diversion of management and technical personnel. Furthermore, the
      outcome of any action we take to protect our rights may not be resolved in
      our
      favor or may not be resolved for a lengthy period of time. </font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">25</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may be sued for product liability. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      may be
      held liable if any product we develop, or any product which is made with the
      use
      or incorporation of, any of our technologies, causes injury or is found
      otherwise unsuitable during product testing, manufacturing, marketing or sale.
      These risks are inherent in the development of chemical, agricultural and
      pharmaceutical products. While we maintain product liability insurance, it
      may
      not fully cover our potential liabilities. Inability to obtain sufficient
      insurance coverage at an acceptable cost or otherwise to protect against
      potential product liability claims could prevent or inhibit the
      commercialization of products developed by us or our collaborators. If we are
      sued for any injury caused by our products, our liability could exceed our
      total
      assets.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>International
      unrest or foreign currency fluctuations could adversely affect our
      results.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">International
      sales accounted for approximately 90% and 91% of our net sales in 2006 and
      2005,
      respectively. Our key international markets are the European Union, Hong Kong,
      the Peoples Republic of China and India. Our international sales are made
      through international distributors and their wholly owned subsidiaries,
      including our Asian subsidiary, and direct to end-user plants with payments
      to
      us, in many cases, denominated in currencies other than U.S. dollars. In the
      conduct of our business, in a number of instances, we are required to pay our
      obligations in currencies other than U.S. dollars. Accordingly, we are exposed
      to changes in currency exchange rates with respect to our international sales
      and payment obligations. We incurred currency gains of $28,704 and $16,785
      for
      the years ended December 31, 2006 and 2005, respectively. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fluctuations
      in currency exchange rates have in the past and may in the future negatively
      affect our ability to price competitively against products denominated in local
      currencies. Also, changes in foreign currency exchange rates may have an adverse
      effect on our financial position and results of operations as expressed in
      U.S.
      dollars. Our management monitors foreign currency exposures and may, in the
      ordinary course of business, enter into foreign currency forward contracts
      or
      options contracts related to specific foreign currency transactions or
      anticipated cash flows. We do not hedge, and have no current plans to hedge
      in
      the future, the translation of financial statements of consolidated subsidiaries
      whose local books and records are maintained in foreign currency. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      imposition of duties or other trade barriers, trade embargoes, acts of
      terrorism, wars and other events outside our control may adversely affect
      international commerce and impinge on our ability to manufacture, transport
      or
      sell our products in international markets.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Business
      interruptions could keep us from developing our products and increasing our
      sales. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Natural
      or man-made disasters, such as fires, earthquakes, hurricanes, power losses,
      telecommunications failures, terrorist attacks, military operations and other
      events beyond our control may interrupt our operations. We do not have a
      detailed disaster recovery plan. In addition, we may not carry sufficient
      business interruption insurance to compensate us for losses that may occur
      and
      any losses or damages we incur could have a material adverse effect on our
      cash
      flows and success as an overall business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are dependent on several key customers.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      2006,
      there was one customer that accounted for approximately 10% of net sales while
      in 2005 there were two customers that accounted for approximately 10% each
      of
      net sales. There were two customers in 2006 whose trade receivable balances
      equaled or exceeded 5% of total receivables, representing approximately 17%,
      and
      6%, respectively, of total accounts receivable. The loss of business from one
      or
      a combination of the Company&#8217;s significant customers could adversely affect its
      operations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
      Related to Our Common Stock</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities
      of Biotechnology companies are often volatile. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      trading prices of biotechnology company stocks in general tend to experience
      extreme price fluctuations. The valuations of many biotechnology companies
      without consistent product sales and earnings are extraordinarily high based
      on
      conventional valuation standards such as price to earnings and price to sales
      ratios. These trading prices and valuations may not be sustained. Any negative
      change in the public&#8217;s perception of the prospects of biotechnology companies
      could depress our stock price regardless of our results of operations. Other
      broad market and industry factors may decrease the trading price of our common
      stock, regardless of our performance. Market fluctuations, as well as general
      political and economic conditions such as war, recession or interest rate or
      currency rate fluctuations, also may decrease the trading price of our common
      stock. In addition, our stock price could be subject to wide fluctuations in
      response to factors including, but not limited to, the following: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                of new technological innovations or new products by us or our competitors;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">26</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                  in financial estimates by securities analysts;
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">conditions
                or trends in the biotechnology industry; </font></div>
            </td>
          </tr>

      </table>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                in the market valuations of other biotechnology companies;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                in domestic and international governmental policy or regulations;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                by us or our competitors of significant acquisitions, strategic
                partnerships, joint ventures or capital commitments;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                in patent or other proprietary rights held by us or by others;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">loss
                or expiration of our intellectual property rights;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">lawsuits
                initiated by or against us;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">period-to-period
                fluctuations in our operating results;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">future
                royalties from product sales, if any, by our strategic partners;
                and
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales
                of our common stock or other securities in the open market.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      past, stockholders have often instituted securities class action litigation
      after periods of volatility in the market price of a company&#8217;s securities. If a
      stockholder files a securities class action suit against us, we would incur
      substantial legal fees and our management&#8217;s attention and resources would be
      diverted from operating our business to respond to the litigation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      operating results and the market price of stock could be volatile.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      quarterly operating results have fluctuated in the past and are likely to do
      so
      in the future. These fluctuations could cause our stock price to fluctuate
      significantly or decline. Some of the factors which could cause our operating
      results to fluctuate include: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expiration
                of research contracts with collaborators, which may not be renewed
                or
                replaced; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                success rate of our discovery efforts leading to milestones and royalties;
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                timing and willingness of collaborators to commercialize our products
                which would result in royalties; </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">general
                and industry specific economic conditions, which may affect our
                collaborators&#8217; R&amp;D
                expenditures;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                adoption and acceptance of our industrial enzymes and other products
                by
                customers of our Enzyme Business;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                adoption and acceptance of the Dyadic Platform Technology by bioenergy,
                biotechnology and pharmaceutical companies being marketed by our
                BioEnergy, Enzyme and BioPharma
                Businesses;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                introduction by our competitors of new industrial enzyme products
                or lower
                prices of existing products to our Enzyme Business&#8217;s
                customers;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                addition or loss of one or more collaborative partners to commercialize
                our the products of our BioEnergy Business;
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                introduction by our competitors of new expression technologies competitive
                with our C1 Production Technology and new screening technologies
                competitive with our C1 HTS Technology;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">27</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">disruption
                  in our manufacturing capacity or our failure to bring on additional
                  manufacturing capacity required to meet our projected
                  growth.</font></div>
              </td>
            </tr>

        </table>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
        large
        portion of our expenses are relatively fixed, including expenses for facilities,
        equipment and personnel. Accordingly, if sales decline or do not grow as
        anticipated due to expiration of research contracts or government research
        grants, if any, failure to obtain new contracts or other factors, we may
        not be
        able to correspondingly reduce our operating expenses. Failure to achieve
        anticipated levels of sales could, therefore, significantly harm our operating
        results for a particular fiscal period. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due
      to
      the possibility of fluctuations in our revenues and expenses, we believe that
      quarter-to-quarter comparisons of our operating results are not a good
      indication of our future performance. Our operating results in some quarters
      may
      not meet the expectations of stock market analysts and investors. In that case,
      our stock price would probably decline. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      may not be able to maintain our American Stock Exchange listing
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      common stock has been listed on the American Stock Exchange since May 27,
      2005.&#160; There is no assurance that we will be able to satisfy the American
      Stock Exchange&#8217;s continued listing standards, which include, among others,
      minimum stockholders&#8217; equity, market capitalization, pre-tax income and per
      share sales price.&#160; If our common stock is de-listed from the American
      Stock Exchange, we would be forced to list our common stock on the OTC Bulletin
      Board or some other quotation medium, depending on our ability to meet the
      specific requirements of those quotation systems.&#160; Selling our common stock
      would be more difficult because smaller quantities of shares would likely be
      bought and sold and transactions could be delayed. These factors could result
      in
      lower prices and larger spreads in the bid and ask prices for shares of our
      common stock. If this happens, we will have greater difficulty accessing the
      capital markets to raise any additional necessary capital.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      do not expect to pay dividends in the future. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      never paid cash dividends on our stock and do not anticipate paying cash
      dividends on our stock in the foreseeable future. The payment of dividends
      on
      our shares, if ever, will depend on our earnings, financial condition and other
      business and economic factors affecting us at such time as the Board of
      Directors may consider relevant. If we do not pay dividends, our stock may
      be
      less valuable because a return on investment will only occur if and to the
      extent that our stock price appreciates, and if the price of our stock does
      not
      appreciate, then there will be no return on investment. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
      anti-takeover defense provisions may deter potential acquirers and depress
      our
      stock price.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
      provisions of our certificate of incorporation, bylaws and Delaware law, as
      well
      as certain agreements we have with our executives, could be used by our
      incumbent management to make it substantially more difficult for a third party
      to acquire control of us. These provisions include the following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                may issue preferred stock with rights senior to those of our common
                stock;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                have a classified Board of
                Directors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">action
                by written consent by stockholders is not
                permitted;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our
                Board of Directors has the exclusive right to fill vacancies and
                set the
                number of directors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cumulative
                voting by our stockholders is not allowed;
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                require advance notice for nomination of directors by our stockholders
                and
                for stockholder proposals.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These
      provisions may discourage certain types of transactions involving an actual
      or
      potential change in control. These provisions may also limit our stockholders&#8217;
ability to approve transactions that they may deem to be in their best interests
      and discourage transactions in which our stockholders might otherwise receive
      a
      premium for their shares over the then current market price.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">28</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        have controlling stockholders. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          officers, directors and principal stockholders together control approximately
          35.4% of our outstanding common stock as of March 28, 2007. Our founder
          and
          chief executive officer, Mark Emalfarb, through a trust of which he is
          the
          trustee and beneficiary, the Mark&#160;A. Emalfarb Trust, owns approximately
          19.5% of our outstanding common stock as of March 28, 2007. Further, the
          Francisco Trust, whose beneficiaries are the spouse and descendants of
          Mark
          Emalfarb, owns approximately 15.9% of our outstanding common stock as of
          March
          28, 2007, while friends and relatives of Mr. Emalfarb, who are not officers,
          directors, or principal stockholders, own approximately an additional 5%
          of our
          outstanding common stock as of March 28, 2007. As a result, these stockholders,
          if they act together, will be able to exert a significant degree of influence
          over our management and affairs and over matters requiring stockholder
          approval,
          including the election of directors and approval of significant corporate
          transactions. In addition, this concentration of ownership may delay or
          prevent
          a change in control of us and might affect the market price of our shares,
          even
          when a change may be in the best interests of all stockholders. Moreover,
          the
          interests of this concentration of ownership may not always coincide with
          our
          interests or the interests of other stockholders, and, accordingly, they
          could
          cause us to enter into transactions or agreements which we would not otherwise
          consider.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        are indebted to our largest stockholders.</strong></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 31, 2006, we owed the Mark&#160;A. Emalfarb Trust indebtedness of
      approximately $2.4 million under a bridge loan. All of our assets are mortgaged
      or pledged to secure the bridge loan owed to the Mark&#160;A. Emalfarb Trust. If
      we were unable to generate sufficient cash flow or otherwise obtain funds
      necessary to pay this indebtedness when due, we would be in default, and this
      debt holder would have the right to foreclose on its liens and security
      interests that secure the defaulted debt. Further, not only is this indebtedness
      evidenced by a promissory note that is transferable by its holder, but we could
      decide to refinance this indebtedness through similar secured borrowings from
      banks or other commercial lenders. Any transferee or new lender, no longer
      constrained by the stockholder interests of the Mark&#160;A. Emalfarb Trust, may
      not have the same attitude about any failure on our part to meet our binding
      repayment obligations as the Mark&#160;A. Emalfarb Trust.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
      are exposed to potential risks resulting from new requirements that we evaluate
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>financial
      reporting controls under Section 404 of the Sarbanes-Oxley Act of 2002.
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are
      evaluating our internal controls in order to allow management to report on
      our
      internal controls over financial reporting, as required by Section 404 of the
      Sarbanes-Oxley Act of 2002. We may encounter unexpected delays in implementing
      the requirements relating to internal controls over financial reporting,
      therefore, we cannot be certain about the timing of completion of our
      evaluation, testing and remediation actions or the impact that these activities
      will have on our operations since there is no precedent available by which
      to
      measure the adequacy of our compliance. We also expect to incur additional
      expenses and diversion of management&#8217;s time as a result of performing the system
      and process evaluation, testing and remediation required in order to comply
      with
      the management certification requirements. If we are not able to timely comply
      with the requirements set forth in Section 404, we might be subject to sanctions
      or investigation by regulatory authorities. Any such action could adversely
      affect our business and financial results. The requirement to comply with
      Section 404 of the Sarbanes-Oxley Act of 2002 will become effective no earlier
      than for our fiscal year ending December 31, 2007. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, in our system of internal controls we may rely on the internal
      controls of third parties. In our evaluation of our internal controls, we will
      consider the implication of our reliance on the internal controls of third
      parties. Until we have completed our evaluation, we are unable to determine
      the
      extent of our reliance on those controls, the extent and nature of the testing
      of those controls, and remediation actions necessary where that reliance cannot
      be adequately evaluated and tested. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Future
      sales of shares of our common stock may negatively affect our stock
      price.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      March 28, 2007, there were 29,939,375 shares of our common stock outstanding.
      Approximately 35.4% of these shares are beneficially owned by our executive
      officers, directors and principal stockholders. Accordingly, our common stock
      has a relatively small public float. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      a
      result of our relatively small public float, sales of substantial amounts of
      shares of our common stock, or even the potential for such sales, may materially
      and adversely affect prevailing market prices for our common stock. In addition,
      any adverse effect on the market price of our common stock could make it
      difficult for us to raise additional capital through sales of equity securities
      at a time and at a price that we deem appropriate.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -3.6pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item2">ITEM
        2</a></u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item2">.</a>
        DESCRIPTION OF PROPERTY. </u></em></strong></font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">29</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company&#8217;s corporate headquarters are located at 140 Intracoastal Pointe Drive,
      Suite 404, Jupiter, Florida, in approximately 8,500 square feet of space
      occupied under a lease with a monthly rental rate of $15,550 that expires on
      December 31, 2007. The lease includes an option to extend for a two-year period,
      which must be exercised by July 1, 2007.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="Item_3_Legal"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      May
      2005, the Company purchased an undeveloped 1.13 acre parcel of land (the &#8220;Site&#8221;)
      pursuant to a real estate purchase contract with F&amp;C Holdings, LLC
      (&#8220;Holdings&#8221;) dated July 31, 2004 (the &#8220;Commercial Land Purchase And Sale
      Agreement&#8221;) (see Note 10 to our consolidated financial statements). The Company
      formed Dyadic Real Estate Holdings, Inc., a Florida corporation and wholly-owned
      subsidiary in May 2005, to which it has assigned the Commercial Land Purchase
      and Sale Agreement and the Site. The Site, which is in a planned community
      known
      as "Abacoa" is located in the Town of Jupiter, Florida (the &#8220;Town&#8221;). The Company
      has obtained final approval from the Town of Jupiter to construct an
      approximately 40,000 square foot commercial office biotech research and
      development building.</font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Commercial Land Purchase and Sale Agreement obligates Dyadic to commence
      development of the Site within two (2) years following the closing date. During
      this two-year period, Dyadic is prohibited from re-transferring the Site to
      any
      other person other than (i) in connection with a sale of Dyadic, (ii) to an
      affiliate or (iii) with the approval of Dyadic's Board of Directors (a majority
      of its independent directors), to the Francisco Trust, the Mark A. Emalfarb
      Trust and/or any entity that is controlled, directly or indirectly, by Mark
      A.
      Emalfarb and/or his family members. It is not the Company&#8217;s intention to use its
      own funds to develop this Site, therefore the Company is considering such
      options as a joint venture or other arrangement to accomplish the development
      of
      the Site. There can be no assurance, however, that any joint venture or other
      arrangements will occur within the prescribed timeframe. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      after
      the two-year commencement period, Dyadic has not commenced development of the
      Site, then at the election of Holdings, in exchange for a reconveyance Deed,
      it
      must pay to Dyadic a "Reconveyance Purchase Price" equal to the greater of
      the
      following: (i) $1.0 million or (ii) the "Market Value" of the shares of the
      Company's common stock, as defined, determined as of the date of the
      reconveyance notice from Holdings. The Reconveyance Purchase Price can be paid
      in all cash, or return of all the shares of the Company's common stock to the
      Company so long as the Market Value of the shares of the Company's common stock
      is greater than or equal to $1.0 million, or by combination of shares of the
      Company's common stock and cash, as determined in the sole and absolute
      discretion of Holdings. The Company is currently assessing its alternatives
      for
      development of the Site.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
      3. </u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>LEGAL
      PROCEEDINGS. </u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company is not a party to any material legal proceedings.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item4">ITEM
      4.</a>&#160;</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>SUBMISSION
      OF MATTERS TO A VOTE OF SECURITY HOLDERS. </u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not
      applicable.</font></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="PART_II"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
      I</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>I</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="Item5"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
      5. </u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>MARKET
      FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>&#160;</u></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      March 28, 2007, there were 29,939,375 shares of Dyadic common stock outstanding
      (including&#160;19,698 shares held in escrow), with approximately 144
      stockholders of record. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company&#8217;s common stock was traded on the OTC Bulletin Board System (OTCBB) for
      the period October 29, 2004 through May 26, 2005. Since May 27, 2005, the
      Company&#8217;s common stock has been trading on the American Stock Exchange under the
      symbol DIL. These quotations reflect inter-dealer prices, without retail
      mark-up, mark-down or commissions, and may not represent actual transactions.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets forth the high and low bids for Dyadic common stock for
      the
      quarterly periods for the years ended December 31, 2006 and 2005 as reported
      by
      the OTCBB for the period January 1, 2005 through May 26, 2005 and as reported
      by
      the American Stock Exchange for the period from May 27, 2005 through December
      31, 2006:&#160;</font>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Quarter
                  Ended</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006
                  Sales Price</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005
                  Sales Price</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>High</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Low</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>High</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Low</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">March
                  31</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.10</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.53</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.50</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.75</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">June
                  30</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9.06</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.89</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.05</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.25</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">September
                  30</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7.10</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.05</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.80</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.87</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                  31</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.93</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.65</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.23</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.50</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>

        </table>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">30</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div align="left">&#160;</div>
      <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Dividend
        Policy </em></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
      there are no restrictions on the payment of dividends, Dyadic has not declared
      or paid any cash dividends on shares of Dyadic common stock in the last two
      fiscal years, and we presently have no intention of paying any cash dividend
      in
      the foreseeable future. The Company&#8217;s current policy is to retain earnings, if
      any, to finance the expansion of it business. The future payment of dividends
      will depend on the results of operations, financial condition, capital
      expenditure plans and other factors that we deem relevant and will be at the
      sole discretion of the Board of Directors. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Equity
      Compensation Plan Information </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table provides information regarding the status of the Company&#8217;s
      existing equity compensation plans at December 31, 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td valign="bottom" width="57%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Plan
                Category</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of securities to be issued upon exercise of outstanding options,
                warrants
                and rights</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted-average
                exercise price of outstanding options, warrants and
                rights</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of securities remaining available for future
                issuance</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="57%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
                compensation plans approved by security holders (1) </font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,961,911</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.12</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,197,940
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="57%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
                compensation plans not approved by security holders</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="57%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,961,911</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.12</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,197,940
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)
      Consists of Dyadic International, Inc. Amended and Restated 2001 Equity
      Compensation Plan and the 2006 Stock Option Plan, both of which plans were
      adopted by the Company&#8217;s Board of Directors in April 2006 and approved by
      stockholders at the 2006 Annual Meeting of Stockholders in June 2006.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="Item_6_MDA"><u><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>ITEM
      6.</em></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>MANAGEMENT&#8217;S
      DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
      OPERATIONS</em></strong></font></u><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="Critical_Acct_Policies"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>General</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
      references to &#8220;the Company&#8221;, &#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221; refers to Dyadic
      International, Inc. and its consolidated subsidiaries, unless the context
      otherwise indicates.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      International, Inc., based in Jupiter, Florida, with operations in the United
      States, Hong Kong and mainland China, Poland and The Netherlands, is a global
      biotechnology company that uses its patented and proprietary technologies (the
      &#8220;Dyadic Platform Technology&#8221;) to conduct research and development activities for
      the discovery, development, and manufacture of products and enabling solutions
      to the bioenergy, industrial enzyme and pharmaceutical industries. These
      enabling solutions primarily include:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novel,
                cost efficient production strains, enzyme mixes and related processes
                and
                manufacturing technologies currently in the research and development
                stage
                for producing abundant low cost fermentable sugars from agricultural
                residues and energy crops which may be used in the manufacturing
                of
                cellulosic ethanol, butanol, chemicals, chemical intermediates, polymers
                and other biomolecules of commercial interest, obviating the need
                for
                petroleum as a feedstock, and refer to our activities in this market
                as
                our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioEnergy
                Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;</font></div>
            </td>
          </tr>

      </table>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Enzymes
                  and other biological products for a variety of industrial and commercial
                  applications. We currently sell more than 55 liquid and dry enzyme
                  products to more then 200 industrial customers in approximately
                  50
                  countries and we generated net sales of approximately $15.3 million
                  in
                  2006,&#160;and refer to our activities in this market as our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Enzyme
                  Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
                  and </font></div>
              </div>
            </td>
          </tr>

      </table>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Low-cost
                production hosts for therapeutic protein production for the
                biopharmaceutical industry, and refer to our activities in this market
                as
                our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioPharma
                Business</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">31</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      more
      and more industries come to appreciate the financial, process efficiency,
      environmental and other advantages of applying biological solutions such as
      enzymes to their manufacturing processes in lieu of chemicals and other legacy
      technologies, we expect a variety of new market opportunities to emerge for
      which we anticipate we will be able to apply our proprietary technologies and
      other capabilities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Dyadic&#8217;s
      Strategy</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Historically,
      substantially most our revenues have been derived from our Enzyme Business,
      which we continue to invest in, both to support and maintain our market position
      in textile enzymes and to penetrate new applications, such as pulp &amp; paper,
      and animal feed. Our long-term plans are focused on our BioEnergy Business
      to
      enable the production of cellulosic ethanol, and our BioPharma Business, to
      enable the production of therapeutic monoclonal antibodies (and other
      therapeutic proteins) for pharmaceutical discovery and production. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      intend
      to accomplish these objectives by using and continuing to further develop the
      Dyadic Platform Technology and by leveraging and building on our existing
      business, technical, and marketing infrastructures. We also expect to continue
      to identify new market opportunities and the technologies to exploit those
      opportunities, both on our own and through strategic business collaborations
      with others.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      expect
      to generate revenues from these efforts by: (i) collecting R&amp;D revenues from
      third parties; (ii) entering into collaborative business arrangements, joint
      ventures, profit sharing arrangements, or third parties; (iii) earning
      technology access fees, milestone payments, and royalties; (iv) selling
      products, whether developed internally through our own distribution channels
      for
      both current markets and markets we believe will emerge in the future or for
      customer-collaborators; (v) spinning-off new commercial entities utilizing
      the
      Dyadic Platform Technology; and/or (vi) obtaining grants from the United States
      government, foreign governments or other agencies. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      additional information regarding the BioEnergy Business, Enzyme Business and
      BioPharma Business, see ITEM 1. Description of Business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="Results_of_Operations"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Results
      of Operations - Year Ended December 31, 2006 Compared to Year Ended December
      31,
      2005</em></strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets forth the Company&#8217;s operating information for the years
      ended December 31, 2006 and 2005:</font><br></div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td valign="bottom" width="57%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(in
                thousands)</strong></font>&#160;</div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Increase
                (Decrease)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                sales</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,384</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,883</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(499</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
                of goods sold</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,345</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,857</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,512</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gross
                profit</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,039</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,026</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,013</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating
                expenses:</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                Research and development</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,237</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,655</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(418</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                Sales and marketing</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,417</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,809</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">608</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                General and administrative</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7,149</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,565</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,584</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                Foreign currency exchange gain, net</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(29</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(17</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(12</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                operating expenses</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">14,774</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">13,012</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,762</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">&#160;</td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                from operations</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,735</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,986</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(749</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                income (expense):</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                Interest expense</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(594</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(711</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">117</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                Investment income</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">505</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">249</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">256</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                Minority interest </font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(14</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                Other income, net</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">17</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                other expense</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(84</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(465</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">381</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                before income taxes</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,819</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,451</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">368</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provision
                for income taxes</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">63</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">64</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                loss</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,882</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,515</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">367</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">32</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div id="HDR">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Net
      Sales </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, we generated net sales of approximately
      $15,384,000 as compared to net sales of approximately $15,883,000 for the year
      ended December 31, 2005, a decrease of $499,000. Our net sales from the Enzyme
      Business decreased by approximately $362,000. In 2006 and 2005, the BioPharma
      Business generated $12,500 and $150,000 in sales, respectively. To date, we
      have
      derived almost all of our sales from the conduct of our Enzyme Business, and
      have thus far generated only nominal sales from our conduct of our BioPharma
      Business. We anticipate that we will begin recognizing revenue from our
      BioEnergy Business in 2007 (see below for a description of the Abengoa R&amp;D
      Agreement). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      decrease in enzyme sales of approximately $362,000 consists of a decrease in
      textile sales of approximately $1,484,000 offset by an increase in sales to
      all
      other industries of approximately $1,122,000. The textile industry is quite
      commoditized and pricing by competitors in the industry is aggressive. The
      Company in recent years has focused, and intends to continue to focus, its
      efforts in the enzyme business towards industries where enzyme use is evolving.
      However, the markets for our products in these industries are generally
      characterized by longer sales cycles for reasons relating to various factors,
      such as required governmental registration processes (e.g. food and animal
      feed
      enzymes in Europe) and required product trials at customers&#8217; facilities of
      multi-month durations or longer (e.g. pulp &amp; paper), and we can, therefore,
      offer no guidance as to when, or if, these new products will penetrate or
      achieve desired growth in those markets. Textile sales are important as they
      help sustain our worldwide network of sales people as well as utilization of
      the
      fermentation tanks at our contract manufacturer so we continue to support this
      business for which we have recently introduced several new products. These
      new
      products are expected to help stabilize sales in this area. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table reflects the Company&#8217;s net sales by industry for the years ended
      December 31, 2006 and 2005: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

          <tr>
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="11" valign="bottom" width="43%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(In
                thousands)</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2006</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;"><font size="2">%</font>&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2005</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;"><font size="2">%</font>&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Increase
                / (Decrease) </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">&#160;<font size="2">%</font></td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Textile</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">&#160;$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,970</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">65</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%&#160;
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">&#160;$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,454</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">72</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%&#160;
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,484</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(13</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)%&#160;
                </font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Animal
                Feed</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,361</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,037</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">324</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">31</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pulp
                &amp; Paper</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,641
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">17</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,869
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">772</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">41</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Others
                (5 industries)</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,399
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,373
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">26</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                Industrial Enzymes</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,371</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,733</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(362</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)%</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioPharma</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">13
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">150
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(137</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(91</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)%</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,384</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,883</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">100</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(499</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(3</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)%</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*
      Less
      than 1%</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      2006,
      we began to focus significant efforts on our BioEnergy Business. To this end,
      in
      October 2006, Dyadic entered into a securities purchase agreement (the &#8220;Abengoa
      Securities Purchase Agreement&#8221;) and Dyadic-Florida entered into a non-exclusive
      Research and Development Agreement with Abengoa Bioenergy R&amp;D, Inc.
      (&#8220;Abengoa&#8221;), a subsidiary of Abengoa S.A., pertaining to the conduct of a
      research and development (&#8220;R&amp;D&#8221;) program to be completed over a period of up
      to three and one-half years, under which the Company will seek to apply its
      proprietary technologies to the development of cost-effective enzyme mixtures
      and related processing and manufacturing technologies for commercial application
      in Abengoa&#8217;s bioethanol (cellulosic ethanol) production process (the &#8220;R&amp;D
      Agreement&#8221;). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the Abengoa Securities Purchase Agreement, Abengoa paid the Company
      $10,000,000 for which it was issued 2,136,752 shares of Dyadic Common Stock
      at
      $4.68 per share (the closing share price on October 25, 2006, as reported on
      the
      American Stock Exchange). The Company will use the proceeds from this
      transaction to fund the performance of its R&amp;D obligations under the R&amp;D
      Agreement over a three and a half year period, under which it will seek to
      apply
      its proprietary technologies to the development of one or more enzyme mixtures
      and related processing and manufacturing technologies customized to Abengoa&#8217;s
      proprietary biomass substrates. The R&amp;D Agreement contemplates that the
      Company will perform both (i) research of general application to the cellulosic
      ethanol field furthering the Company&#8217;s extensive research &amp; development and
      large-scale manufacturing technologies for producing large volumes of low cost
      cellulases, xylanases and other hemicellulases and (ii) research of specific
      applications for the achievement of the goals of Abengoa&#8217;s R&amp;D Program to
      develop an economically viable commercial process for the production of large
      volumes of effective, low cost enzyme mixtures for the proprietary biomass
      substrates of specific interest to Abengoa. Accordingly, the Company expects
      to
      continue to incur significant R&amp;D costs over the next several
      years.</font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">33</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      accounting purposes, the $10,000,000 received under the Abengoa Securities
      Purchase Agreement has been recorded as deferred research and development
      obligation, and will be amortized to sales as the R&amp;D expenses described
      above are incurred. For further information regarding the accounting treatment,
      see Note 1, Organization and Operations</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      - </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
      Raising Activities</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      in our
      notes to consolidated financial statements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Cost
      of Goods Sold </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, cost of goods sold was approximately $11,345,000,
      or 73.7% of net sales, as compared to approximately $12,857,000, or 80.9% of
      net
      sales, for the year ended December 31, 2005, a decrease of approximately
      $1,512,000. This decrease in cost of goods sold was primarily the result of
      the
      shift to higher margin product sales as well as the decrease in total net sales,
      which in the aggregate, accounted for approximately $1,140,000 of the decrease.
      The increase in sales of higher margin products allows the Company to sell
      fewer
      products with higher margins and therefore reduces the cost of the products
      sold. Additionally, an inventory reserve increase of approximately $354,000
      charged to cost of sales in 2005 and a decrease of the reserve in 2006 of
      approximately $55,000 was netted against cost of sales. This total change in
      reserves accounts for $409,000 of the decrease in cost of goods sold year over
      year. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Gross
      Profit </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, gross profit was approximately $4,039,000, or
      26.3% of net sales, as compared to approximately $3,026,000, or 19.1% of net
      sales, for the year ended December 31, 2005, representing an increase of
      approximately $1,013,000. The 33.5% increase in gross profit and gross profit
      percentage is due to the combination of the increase in net sales of higher
      margin products and the cumulative changes in the inventory reserve, which
      are
      described above. It is the Company&#8217;s goal to develop products, or sell existing
      products, for markets in which gross profits can be improved. We </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">believe
      we are making significant progress in our efforts to create a line of higher
      profit-margined products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      by
      developing better products using our technologies and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">by
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">applying
      existing products to new markets. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nonetheless</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      there
      can be no assurance that our efforts will successfully lead to improved gross
      profits in the future. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Operating
      Expenses </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Research
      and
      Development </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, research and development expenses, or R&amp;D,
      were approximately $4,237,000, or 27.5% of net sales, as compared to
      approximately $4,655,000, or 29.3% of net sales for the year ended December
      31,
      2005, representing a decrease of approximately $418,000. The Company continued
      its R&amp;D efforts in 2006, working on such projects as the annotation
      currently being performed in collaboration with Scripps-Florida whereby Dyadic
      intends to further improve its capabilities for production of therapeutics
      and
      other foreign proteins in C1.&#160;The decrease of approximately $418,000 was
      primarily a result of the decrease in depreciation expense of approximately
      $379,000 on the screening system equipment, which was fully depreciated in
      2005.</font></div>
    <div>&#160;</div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Sales
      and
      Marketing </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, sales and marketing expenses were approximately
      $3,417,000, or 22.2% of net sales, compared to approximately $2,809,000, or
      17.7% for the year ended December 31, 2005, representing an increase of
      approximately $608,000. This increase is attributable to several factors,
      including an increase in salaries and wages of approximately $162,000 due to
      the
      addition of nine sales employees including a Vice President - Pulp and Paper,
      in
      the latter half of 2005. This has resulted in increased commission, travel
      and
      entertainment costs of approximately $172,000. These additions are a part of
      the
      investments both in personnel and other initiatives we will continue to make
      to
      expand our sales, marketing and product development efforts. The increase is
      also attributable to samples and supplies expenses of approximately $77,000
      incurred for new and ongoing pulp &amp; paper trials. Additionally,
      approximately $68,000 of non-cash share-based compensation expense was
      recognized for stock options granted in 2006 under the provisions of FAS No.
      123(R).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;General
      and
      Administrative </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, general and administrative expenses were
      approximately $7,149,000, or 46.5% of net sales, compared to approximately
      $5,565,000, or 35% of net sales for the year ended December 31, 2005,
      representing an increase of approximately $1,584,000. Of this increase
      approximately $554,000 is attributable to non-cash share-based compensation
      expense recognized under FAS No. 123(R). Accrued employee bonuses and increased
      salaries and wages (including recruitment fees) relating to the addition of
      Dr.
      Glenn Nedwin, President of the BioPharma Business, Chief Scientific Officer
      and
      member of the board, accounted for approximately $651,000 of the increase.
      The
      remaining increase is due to increased professional fees of approximately
      $295,000 related to accounting, legal and other service related expenses due
      to
      various agreements that were executed in 2006. </font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">34</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Foreign
        Currency Exchange Gain, Net </em></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      years ended December 31, 2006 and 2005, the Company incurred net foreign
      currency exchange gains of approximately $29,000 and $17,000, respectively,
      representing an increase of approximately $12,000. The increase is primarily
      a
      result of the settlement of a portion of the VAT receivable, which occurred
      in
      the latter half of 2006 and resulted in a net gain due to the increase in the
      value of the Polish PLN. A large portion of our business is transacted with
      foreign customers and vendors in foreign currency denominations. Accordingly,
      fluctuations in foreign currency exchange rates, primarily relating to the
      Euro
      and PLN, can greatly impact the amount of foreign currency gains (losses) we
      recognize in future periods relating to these transactions. We do not, and
      have
      no current plans to, engage in foreign currency exchange hedging
      transactions.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Other
      Income (Expense) </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Interest
      Expense </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, interest expense was approximately $594,000 as
      compared to approximately $711,000 for the year ended December 31, 2005,
      representing a decrease of approximately $117,000. The decrease is primarily
      the
      result of a reduction in the interest payable related to the convertible
      stockholders notes payable of approximately $63,000, which were converted to
      common stock on May 1, 2006. In addition, a reduction in the amortization of
      the
      beneficial conversion feature of approximately $46,000 related to the Bridge
      Loan as a result of the new amortization period from the extension of the Loan&#8217;s
      maturity due date. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Investment
      Income </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, interest income was approximately $505,000 as
      compared to approximately $249,000 for the year ended December 31, 2005,
      representing an increase of approximately $256,000. Interest income increased
      beginning in the fourth quarter of 2006 due to the proceeds from the agreement
      with Abengoa of approximately $10,000,000 and the proceeds from the private
      placement offering completed in early December 2006 of approximately
      $12,100,000. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Provision
      for
      Income Taxes </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      no provision for U.S. income taxes as we have incurred operating losses in
      all
      periods presented and provide full valuation allowances against the resulting
      tax benefits. For the year ended December 31, 2006, we had a foreign income
      tax
      provision of approximately $63,000 compared to approximately $64,000 for the
      year ended December 31, 2005. Our Asian subsidiary operates in Hong Kong. We
      also have operations in Poland and The Netherlands. Our Asian subsidiary and,
      to
      a lesser extent, our Polish subsidiary generate profits that are taxable in
      their local jurisdictions. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Net
      Loss </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, the Company&#8217;s net loss was approximately
      $10,882,000, compared to a net loss of approximately $10,515,000 for the year
      ended December 31, 2005. This increase in net loss was due primarily to
      increases in operating expenses, of which approximately $788,000 is attributable
      to non-cash share-based compensation expense that was recognized for stock
      options granted in 2006 under the provisions of FAS No. 123(R) as well as
      decreased sales, as discussed above. We believe that we will continue to incur
      net losses in the near term future primarily because of our planned levels
      of
      research and development and additional general and administrative expenditures
      that will be necessary to grow the Bioenergy, Enzyme and BioPharma Businesses.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><a name="noncash">Non</a>-Cash,
      Share-Based Compensation Charges</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      January 2006 we adopted Financial Accounting Standards Board Statement (&#8220;FASB&#8221;),
      Statement of Accounting Standard (&#8220;SFAS&#8221;) No.&#160;123(R), Share-Based Payment,
      which requires all share-based payments to employees and non-employee directors,
      including stock option grants, to be recognized in the consolidated statement
      of
      operations based on their fair values. Pro forma disclosure, which we previously
      used, is no longer an alternative. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior
      to
      January&#160;1, 2006, we accounted for share-based employee compensation plans
      using the intrinsic value method of accounting in accordance with Accounting
      Principles Board Opinion, or APB, No.&#160;25, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
      for Stock Issued to Employees </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(APB
      25),
      and its related interpretations. Under the provisions of APB 25, no compensation
      expense was recognized when stock options were granted with exercise prices
      equal to or greater than market value on the date of grant.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">35</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          recognized non-cash share-based compensation expense for our share-based
          awards
          of approximately $788,000 and $77,000 for the years ended December 31,
          2006 and
          2005, respectively. These charges had no impact on the Company&#8217;s reported cash
          flows. Total non-cash share-based compensation expense was allocated among
          the
          following expense categories: </font></div>
      </div>
      <div>&#160;</div>
    </div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

          <tr>
            <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="5" valign="bottom" width="26%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                Ended December 31</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General
                and administrative</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">592,000</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">58,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                and development</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">89,000
                </font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
                of goods sold</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,000</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Selling
                and marketing</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">75,000</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">788,000</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">77,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      modified prospective method of transition under SFAS 123(R), we are not required
      to restate our prior period financial statements to reflect expensing of
      non-cash share-based compensation under the new standard. Therefore, the results
      for the year ended December 31, 2006 are not comparable to the prior year.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      December 15, 2005, our Board of Directors approved the acceleration of vesting
      for the unvested portion of all outstanding stock options awarded to employee
      and non-employee directors of the Company from May 2001 to December 15, 2005
      under the 2001 Equity Plan, as amended. While we typically issue options that
      vest equally over four years, as a result of this vesting acceleration, stock
      options to purchase approximately 1,200,000&#160;shares of our common stock, of
      which approximately 600,000 were then held by the Company&#8217;s executive officers
      and non-employee directors, became immediately exercisable. The exercise prices
      of the affected stock options ranged from $1.90 to $5.93 and the closing price
      of our common stock on December 15, 2005, was $1.75.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      purpose of the accelerated vesting was to provide a non-cash benefit to Dyadic&#8217;s
      employees and to eliminate future compensation expense we would otherwise
      recognize in our consolidated statements of operations with respect to these
      accelerated options upon the adoption of SFAS 123(R). The estimated future
      compensation expense associated with these accelerated options that would have
      been recognized in our consolidated statements of operations upon implementation
      of SFAS 123(R) is approximately $1,300,000. All option grants made on and after
      January 1, 2006 are accounted for in accordance with SFAS 123(R).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><a name="Liquidity_and_Capital_Resources"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Liquidity
      and Capital Resources</em></strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
      Raising Activities </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      inception, the Company has financed operations primarily with proceeds from
      the
      sales of the products from its Enzyme Business, external borrowings, borrowings
      from its stockholders and sales of preferred and common equity
      securities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      July
      2004, we completed a private offering of our common and preferred equity
      securities, and raised gross proceeds of $4,700,000. The equity securities
      were
      offered as an Investment Unit, with each unit consisting of two shares of common
      stock and one share of Series B Preferred Stock, at a price of $10 per unit.
      We
      used $1,500,000 of the proceeds from this offering to redeem all outstanding
      shares of Series A Preferred. After giving effect to the automatic conversion
      of
      the Series B Preferred Stock, a total of 1,422,099 shares of common stock were
      issued in connection with the offering. As we completed an additional private
      offering of our common shares pursuant to the Private Offering Memorandum
      described below, we granted the purchasers of these Investment Units warrants
      to
      acquire a total of 711,050 shares of our common stock at $5.50 per share.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      November 2004, in accordance with Subscription Agreements and a Private Offering
      Memorandum (the October Offering) dated October 2004, we sold 7,629,204
      Investment Units, realizing gross proceeds of $25,405,249. An Investment Unit
      consists of one share of our common stock and one five-year callable warrant
      to
      purchase one share of our common stock at $5.50 per share for every two
      Investment Units purchased. Accordingly, 3,814,602 warrants to purchase our
      common stock were issued to purchasers in the October Offering. Concurrently,
      we
      issued 247,730 warrants to purchase our common stock at $5.50 per share and
      495,460 warrants to purchase our common stock at $3.33 per share, both to
      placement agents in the October Offering. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        incurred $2,727,573 of costs related to the October Offering and the Merger,
        including the subsequent registration with the Securities and Exchange
        Commission of our shares issued in the Merger and the October Offering. These
        costs are included as a reduction of additional paid-in capital.
</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">36</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      October 26, 2006, we entered into the Abengoa Securities Purchase Agreement.
      Also on October 26, 2006, Dyadic-Florida entered into the R&amp;D Agreement with
      Abengoa pertaining to the conduct of a research and development (&#8220;R&amp;D&#8221;)
      program to be completed over a period of up to three and one-half years, under
      which Dyadic-Florida will seek to apply its proprietary technologies to the
      development of cost-effective enzyme mixtures and related processing and
      manufacturing technologies for commercial application in Abengoa&#8217;s bioethanol
      (cellulosic ethanol) production process. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      terms of the Abengoa Securities Purchase Agreement, Abengoa paid us $10,000,000,
      for which it was issued 2,136,752 shares of our common stock at $4.68 per share
      (the closing share price on October 25, 2006, as reported on the American Stock
      Exchange. We completed this transaction on November 8, 2006. Under certain
      circumstances, as described below, we may have to issue additional Dyadic
      securities to Abengoa. As of December 31, 2006, net proceeds of approximately
      $9,998,000 are recorded as deferred research and development obligation in
      the
      accompanying consolidated financial statements and will be amortized to income
      over the three and one half year contractual period, as the expenses associated
      with the R&amp;D program described above are incurred. We will use these net
      proceeds to fund the completion of the R&amp;D services we are required to
      furnish Abengoa under our R&amp;D Agreement with Abengoa. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      within
      six months following the date of closing we have not entered into a specified
      type of transaction involving the sale of our securities totaling at least
      $20,000,000 in gross proceeds, then Abengoa is entitled to receive three-year
      warrants to purchase 427,351 shares at an exercise price of $5.85. If the sale
      of securities totaling at least $20,000,000 is at a price lower than $4.68
      per
      share, Abengoa is entitled to have additional shares issued to them so that
      their investment is at the same price. If the sale of securities includes
      warrants, Abengoa&#8217;s pro rata warrant coverage and other warrant terms are to be
      the same as those in the securities transaction rather than the warrant terms
      discussed above.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      November 17, 2006, we entered into a securities purchase agreement (the
&#8220;Securities Purchase Agreement&#8221;) with certain investors to purchase in a private
      placement 2,787,000 shares of our common stock at a price of $4.68 per share
      and
      warrants to purchase up to 557,400 shares of our common stock at an exercise
      price of $6.33 per share for gross proceeds of $13,043,160. We completed this
      private placement on December 1, 2006. Cowen and Company, LLC acted as the
      exclusive placement agent for the private placement for which we issued to
      it
      warrants to purchase up to 83,610 shares of our common stock at $5.24 per share
      and warrants to purchase up to 16,722 shares of our common stock at $6.33 per
      share. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      will
      use the resulting net proceeds of approximately $12,100,000 to continue
      development of the Dyadic Platform Technology for applications in the markets
      targeted by our businesses, with the goal of strengthening our product pipeline
      and accelerating the commercial launch of new products in pulp and paper, animal
      feed and other areas, and expanding R&amp;D infrastructure as well as sales and
      marketing efforts. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Cash
      Flow </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;From
      Operating Activities </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      reflected in our consolidated financial statements, we have incurred losses
      from
      operations during each of the last two years. Net cash provided by operating
      activities was approximately $791,000 in 2006 and net cash used in operating
      activities was approximately $7,818,000 in 2005. The net cash provided by
      operating activities of approximately $791,000 is a result of the receipt of
      approximately $9,998,000 of proceeds from the Abengoa Securities Purchase
      Agreement (see </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
      Raising Activities, </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">above</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>),
      </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">which
      is
      recorded as deferred research and development obligation in the accompanying
      consolidated balance sheet</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>.
      </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;From
      Investing Activities</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, our net cash used in investing activities was
      approximately $860,000 as compared to approximately $445,000 for the year ended
      December 31, 2005. This increase of approximately $415,000 is mainly due to
      the
      $375,000 payment to the former minority shareholders of our Asian subsidiary
      as
      part of a purchase and settlement agreement (see Notes 7 and 8 to the
      accompanying consolidated financial statements). The increase was also
      attributable to the purchase of manufacturing equipment located at our contract
      manufacturer in Poland as well as asset additions due to the expansion of the
      Jupiter, Florida office.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font size="2"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;From
      Financing
      Activities </em></font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">37</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, net cash provided by financing activities was
      approximately $18,992,000. This amount is primarily due to cash received from
      a
      private placement resulting in net proceeds of approximately $12,088,000 and
      approximately $6,901,000 in proceeds from the exercises of the following
      instruments: (i) warrants to purchase an aggregate of 495,460 shares of our
      common stock, at an exercise price of $3.33 per share, (ii) warrants to purchase
      an aggregate of 709,664 shares of our common stock for an exercise price of
      $5.50 per share, (iii) stock options to purchase an aggregate of 274,950 shares
      of our common stock, granted under the our 2001 Equity Plan, with exercise
      prices ranging from $2.08 to $4.50 per share, and (iv) stock options to purchase
      an aggregate of 65,000 shares of common stock, granted prior to our 2001 Equity
      Plan, with an exercise price of $4.50 per share. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the year ended December 31, 2005, our net cash used in financing activities
      was
      approximately $98,000 for issuance costs related to the October 2004 private
      offering. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Changes
      in Cash Positions </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      experienced net increases in cash and cash equivalents of approximately
      $18,923,000 in 2006 primarily from financing activities described above as
      compared to a decrease of $8,361,000 in 2005 due to the consumption during
      2005
      of the cash received from our 2004 capital raising activities primarily to
      support our operating activities. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Financial
      Condition and Liquidity at December 31, 2006 </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      2005
      and 2006 net losses, when combined with losses incurred through December 31,
      2004, resulted in an accumulated deficit of approximately $44,890,000. As of
      December 31, 2006, stockholders' equity was approximately $28,189,000, an
      increase of approximately $12,917,000 over December 31, 2005. The increase
      is
      primarily due to the issuance of our common stock for the private placement
      and
      the warrant and stock option exercises described above. As of December 31,
      2006,
      unused proceeds of approximately $9,998,000 from the Abengoa Securities Purchase
      Agreement are recorded as deferred research and development obligation in the
      accompanying consolidated financial statements and will be amortized to income
      over the three and one half year contractual period, as the expenses associated
      with the R&amp;D program described above are incurred. The costs incurred in
      connection with the Abengoa Securities Purchase Agreement are included in other
      assets at December 31, 2006 and will be amortized in relation to the revenue
      recognized under the deferred research and development obligation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      had a
      total of approximately $31,073,000 in cash and cash equivalents as of December
      31, 2006 and working capital was $36,660,000. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table summarizes our long-term contractual obligations as of
      December&#160;31, 2006: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(In
                thousands)</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="17" valign="bottom" width="65%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Payments
                Due By Period</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="32%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Contractual
                Obligations</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2007</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2008</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2009</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2010</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Thereafter</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating
                leases</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">806</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">385</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">81</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">75</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">66</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">199</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Manufacturing
                agreement</font></div>
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">449</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">337</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">112</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional
                expansion costs</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">935</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">364</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">139</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">139</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">139</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">154</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="32%" style="border-bottom: white solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note
                payable to shareholder</font></div>
            </td>
            <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,379</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,379</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                contractual obligations </font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,559</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,086</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">332</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,593</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">205</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">353</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
      upon the current status of our research and development and operating needs,
      we
      believe that our existing cash and cash equivalents will be adequate to satisfy
      our needs for at least the next 12&#160;months and beyond. However, our actual
      capital requirements will depend on many factors, including those factors
      potentially impacting our financial condition as discussed in &#8220;Risk Factors That
      May Affect Future Results&#8221;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      Commercial Land Purchase and Sale Agreement obligates us to commence development
      of the land that we acquired within two (2) years of the closing (in May 2007);
      however, it is not the Company&#8217;s intention to use its own funds to develop this
      property, therefore the Company is considering such options as a joint venture
      or other arrangement to accomplish the development of the Site. The Company
      is
      evaluating the advantages and disadvantages of Site development relative to
      their impact on Dyadic&#8217;s future office and R&amp;D needs and cash resources, and
      is also considering other alternatives to optimize the asset value of the Site
      at this time. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      employment agreements with several officers and key employees of the Company,
      the material terms of which are described in Note 10 to our consolidated
      financial statements included in this report. </font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">38</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Funding
      of Future Operations </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      believe that our operating losses will continue in 2007. In addition, our cash
      needs to fund our future operating loses will be substantial. We believe that
      we
      will have sufficient capital to fund our operations and meet our obligations
      through year end 2007 and beyond. Dyadic has established a number of flexible
      partnerships in the areas of manufacturing and research and development,
      enabling us to adjust spending in those areas as necessary, to achieve the
      objectives of our business plan, and manage both our resources and cash
      utilization rate. However, it is possible that we may seek additional financing.
      We may raise additional funds through public or private financings,
      collaborative relationships, licensing or selling of certain technologies or
      other arrangements. Additional funding, if sought, may not be available at
      all,
      or may not be available on terms favorable to us. Further, any additional equity
      financing may be dilutive to stockholders, and debt financing, if available,
      may
      involve restrictive covenants. Our failure to raise capital when needed may
      harm
      our business, operating results and financial condition. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><a name="off">Off</a>-Balance
      Sheet Arrangements</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      do not
      have any off-balance sheet arrangements</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><a name="critical">Critic</a>al
      Accounting Policies and
      Estimates</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      preparation of financial statements in conformity with U.S. generally accepted
      accounting principles requires management to make estimates and assumptions
      and
      select accounting policies that affect the amounts reported in our consolidated
      financial statements and the accompanying notes. Actual results could
      significantly differ from those estimates. We have identified the following
      policies and related estimates as critical to our business operations and the
      understanding of our results of operations. A description of these critical
      accounting policies and a discussion of the significant estimates and judgments
      associated with these policies are set forth below. The impact of and any
      associated risks related to these policies on our business operations are also
      discussed throughout Management&#8217;s Discussion and Analysis or Plan of Operation.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 46.6pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Foreign
      Operations </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      significant operations and sales generated in foreign countries. Sales derived
      from foreign customers accounted for approximately 90% and 91% of our total
      revenues in 2006 and 2005, respectively. Our Asian subsidiary is located in
      Hong
      Kong, and we have two other subsidiaries, one located in Poland and one located
      in The Netherlands. Estimates relating to our inventory valuation, receivable
      allowances, possible impairments to goodwill (which relates to our Asian
      subsidiary), and long-lived assets could be significantly impacted by
      international events. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Share-based
      Compensation </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective
      January&#160;1, 2006, we adopted the provisions of Statement of Financial
      Accounting Standards (&#8220;SFAS&#8221;) SFAS No.&#160;123(R), </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Share-Based
      Payment </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(&#8220;SFAS
      123(R)&#8221;), which revises SFAS No. 123, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
      for Stock-Based Compensation </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
      supersedes Accounting Principles Board Opinion No. 25, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
      for Stock Issued to Employees. </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SFAS
      123(R) requires that companies recognize non-cash compensation expense
      associated with stock option grants and other equity instruments to employees
      in
      the financial statements. That expense is recognized in the consolidated
      statement of operations over the period during which an employee is required
      to
      provide service in exchange for the reward. Non-Cash share-based compensation
      expense is recorded in research and development expense, sales and marketing,
      or
      general and administrative expense depending on the employee&#8217;s job function.
      SFAS 123(R) applies to all grants after the effective date and to the unvested
      portion of stock options outstanding as of the effective date. The pro forma
      disclosures previously permitted under SFAS 123 are no longer an alternative
      to
      financial statement recognition. We are using the modified-prospective method
      and the Black-Scholes valuation model for valuing the share-based payments.
      We
      will continue to account for transactions in which services are received in
      exchange for equity instruments based on the fair value of such services
      received from non-employees, in accordance with SFAS 123 and EITF Issue
      No.&#160;96-18, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
      for Equity Instruments that Are Issued to Other than Employees for Acquiring,
      or
      in Conjunction with Selling, Goods or Services.</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      issued warrants and options to both employees and to non-employees for services
      and in connection with obtaining debt in the past several years. We have
      recognized significant expense relating to the issuance of these equity
      instruments. In 2004, approximately $897,000 was recorded related to the
      modification of warrants issued in connection with debt, which is being
      amortized through the debt maturity date of January 1, 2009. Of this amount,
      approximately $325,000 and $371,000 was recognized as interest expense in the
      accompanying consolidated statement of operations for the year ended December
      31, 2006 and 2005, respectively. Amortization of stock compensation expense
      of
      approximately $788,000 and $77,000 was also recognized in 2006 and 2005,
      respectively, related to stock options issued to consultants, the original
      cost
      of which is being amortized over the respective service
      periods.</font><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">39</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 31, 2006, there was approximately $2,013,000 of total unrecognized
      non-cash share-based compensation expense related to nonvested stock options
      granted under our 2001 Equity Incentive Plan and our 2006 Stock Option Plan.
      This expense is expected to be recognized over a weighted-average period of
      2.9
      years.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Long-Lived
      Assets </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      review
      our long-lived assets, including fixed assets that are held and used for our
      operations, for impairments whenever events or changes in circumstances indicate
      that the carrying amount of the asset may not be recoverable, as required by
      Statement of Financial Accounting Standards</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No.
      144,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
      for the Impairment or Disposal of Long-Lived Assets </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SFAS
      144). If such an event or change in circumstances is present, we will estimate
      the undiscounted future cash flows, less the future outflows necessary to obtain
      these inflows, expected to result from the use of the asset and its eventual
      disposition. If the sum of the undiscounted future cash flows is less than
      the
      carrying amount of the related assets, we will recognize an impairment loss
      to
      the extent the carrying value exceeds the fair value. Our judgments related
      to
      the expected useful lives of long-lived assets and our ability to realize
      undiscounted cash flows in excess of the carrying amounts of the assets are
      affected by factors such as the ongoing maintenance and improvements of the
      assets, changes in domestic and foreign economic conditions and changes in
      operating performance. While we have not to date been required to recognize
      an
      impairment on long-lived assets, as we make future assessments of the ongoing
      expected cash flows and carrying amounts of our long-lived assets, these factors
      could cause us to realize material impairment charges. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Evaluation
      of Potential Goodwill Impairment </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      accordance with SFAS No. 142, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Goodwill
      and Other Intangible Assets </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SFAS
      142), we were required to perform an annual impairment review of the goodwill
      which is associated with our Asian subsidiary. This test involved the use of
      estimates to determine the estimated fair value of our Asian subsidiary and
      the
      comparison of that estimated fair value to the carrying value of the reporting
      unit. There are significant assumptions used in this impairment test, such
      as
      estimated cash flows, discount rates of return and terminal values. Several
      factors can change these assumptions, such as economic conditions or instability
      in foreign governments, among other things. Our estimates of the fair value
      indicated that it exceeded the carrying value of the reporting unit.
      Accordingly, no goodwill impairment charge was recorded. If the estimate of
      the
      fair value of the reporting unit is less than the carrying value at any future
      measurement dates, we may be required to record a goodwill impairment charge.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Income
      Taxes </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      recorded deferred tax assets relating to net operating loss carry forwards
      for
      United States federal tax purposes, inventories, depreciation and amortization,
      and accounts receivable allowance, among other items. We record a valuation
      allowance equal to 100% of the carrying value of our net deferred tax assets
      to
      reduce our deferred tax assets to the amount that is more likely than not to
      be
      realized. While we have considered future taxable income and ongoing tax
      planning strategies in assessing the need for the valuation allowance, in the
      event we were to determine that we would be able to realize our deferred tax
      assets in the future in excess of their net recorded amounts, a resulting
      reduction of the valuation allowance would increase our income in the period
      such determination was made. As of December 31, 2006, we had $15,384,049 in
      gross deferred tax assets, which were fully offset by a valuation allowance.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      net operating loss carryforwards of approximately $26.2 million for United
      States federal income tax purposes that will begin to expire in 2021. The
      amounts of and benefits from net operating losses carried forward may be
      impaired or limited in certain circumstances. Events which may cause limitations
      in the amount of net operating losses that we may utilize in any one year
      include, but are not limited to, a cumulative ownership change of more than
      50%
      over a three-year period. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Allowance
      for Doubtful Accounts </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      maintain an allowance for doubtful accounts for estimated losses resulting
      from
      the inability of our customers to make required payments. Our accounting for
      doubtful accounts contains uncertainty because management must use judgment
      to
      assess the collectibility of these accounts. When preparing these estimates,
      management considers a number of factors, including the aging of a customer's
      account, past transactions with customers, creditworthiness of specific
      customers, historical trends and other information. We review our accounts
      receivable reserve policy periodically, based on current risks, trends and
      changes in industry conditions. The allowance for doubtful accounts was
      approximately $240,000 at December 31, 2006. Although we believe this allowance
      is sufficient, if the financial condition of our customers were to unexpectedly
      deteriorate, resulting in an impairment of their ability to make payments,
      additional allowances may be required that could materially impact our
      consolidated financial statements. Concentrations of credit risk can impact
      this
      risk considerably. In 2006, there was one customer that accounted for 10% of
      net
      sales, while in 2005 there were two customers that accounted for 10% each of
      net
      sales. There were two customers at December 31, 2006, whose trade receivable
      balances equaled or exceeded 5% of total receivables, representing approximately
      17% and 6%, respectively, of total accounts receivable. The loss of business
      from one or a combination of our significant customers could adversely affect
      our </font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">40</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">operations.
      Because we perform our analysis and establish reserves on a customer-by-customer
      basis, we do not record a general reserve. However, if we were to apply a
      general reserve of 1% to our unreserved accounts receivable balance, it would
      increase our allowance for doubtful accounts as of December 31, 2006 and our
      bad
      debt expense for the year then ended by approximately $28,000.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Inventory
      Valuation </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory,
      representing approximately 13% of our consolidated assets at December 31, 2006,
      primarily consists of finished goods including industrial enzymes used in the
      industrial, chemical and agricultural markets and is stated at the lower of
      cost
      or market using the average cost method. Finished goods consist of raw materials
      and manufacturing costs, substantially all of which are incurred pursuant to
      agreements with independent manufacturers. As part of the valuation process,
      excess, slow-moving and damaged inventories are reduced to their estimated
      net
      realizable value. Our accounting for excess, slow-moving and damaged inventory
      contains uncertainty because management must use judgment to estimate when
      the
      inventory will be sold and the quantities and prices at which the inventory
      will
      be sold in the normal course of business. We review our inventory reserve policy
      periodically, based on current risks, trends and changes in industry conditions.
      We also maintain a provision for estimated inventory shrinkage and conduct
      periodic physical inventories to calculate actual shrinkage and inventory on
      hand. When preparing these estimates, management considers historical results,
      inventory levels and current operating trends. We have established valuation
      reserves associated with excess, slow-moving and damaged inventory and estimated
      shrinkage reserves of approximately $649,000 at December 31, 2006. These
      estimates can be affected by a number of factors, including general economic
      conditions and other factors affecting demand for our inventory. In the event
      our estimates differ from actual results, the allowance for excess, slow-moving
      and damaged inventories may be adjusted and could materially impact our
      consolidated financial statements. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Revenue
      Recognition</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenue
      is recognized when earned. Dyadic recognizes revenues in accordance with Staff
      Accounting Bulletin (SAB) No 104, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Revenue
      Recognition in Financial Statements </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SAB
      104). SAB 104 sets forth four basic criteria that must be met before SEC
      registrants can recognize revenue. These criteria are: persuasive evidence
      of an
      arrangement must exist; delivery had to have taken place or services had to
      have
      been rendered; the seller's price to the buyer should be fixed or determinable;
      and collectibility of the receivable should be reasonably assured. Sales not
      meeting any of the aforementioned criteria are deferred. Dyadic recognizes
      revenue when title passes to the customer, based upon the specified freight
      terms for the respective sale. Sales are comprised of gross revenues less
      provisions for expected customer returns, if any. Reserves for estimated returns
      and inventory credits are established by the Company, if necessary, concurrently
      with the recognition of revenue. The amounts of reserves are established based
      upon consideration of a variety of factors, including estimates based on
      historical returns. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues
      under the R&amp;D agreement with Abengoa are recognized in accordance with SAB
      104 and Emerging Issues Task Force (&#8220;EITF&#8221;) Issue No.&#160;99-19, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reporting
      Gross Revenue as a Principal vs. Net as an Agent</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      According to the criteria established by EITF Issue No.&#160;99-19, Dyadic is
      the primary obligor of the agreement because it is responsible for the
      selection, negotiation, contracting and payment of the third party suppliers.
      In
      addition, any liabilities resulting from the agreement are the responsibility
      of
      Dyadic. Research and development revenues are recognized, on a gross basis,
      as
      activities are performed under the terms of the related agreement. As of
      December&#160;31, 2006, we had approximately $9,998,000 in deferred research and
      development obligation which was related to the R&amp;D agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><a name="Item_7_Financial_Stmts"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
      7. FINANCIAL STATEMENTS</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>.
      </u></em></strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      audited consolidated financial statements and related footnotes of Dyadic
      International, Inc. can be found beginning with the <a href="#Index_Fin_Stmt">Index to Consolidated Financial Statements </a>following
      Part III of this Annual Report on page F-1.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><u><em><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="Item8">ITEM
      8</a>. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
      ACCOUNTING AND FINANCIAL DISCLOSURE</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>S.</strong></font></em></u></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="Item8A"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
      8A. CONTROLS AND PROCEDURES</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>.
      </u></em></strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      required by Rule 13a-15 under the Securities Exchange Act of 1934, as of the
      end
      of the period covered by this Annual Report, the Company carried out an
      evaluation under the supervision and with the participation of the Company&#8217;s
      management, including the Company&#8217;s Chief Executive Officer and Chief Financial
      Officer, of the effectiveness of the design and operation of the Company&#8217;s
      disclosure controls and procedures.&#160; Based upon that evaluation, the Chief
      Executive Officer and Chief Financial Officer concluded that the Company&#8217;s
      disclosure controls and procedures were effective as of December 31,
      2006.</font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">41</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)
        There
        were no changes in the Company's internal control over financial reporting
        identified in connection with the evaluation required by paragraph (d) of
        Exchange Act Rules 13a-15 and 15d-15 that occurred during the fiscal quarter
        ended December 31, 2006 that have materially affected, or are reasonably
        likely
        to materially affect, the Company's internal control over financial
        reporting.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item8B">ITEM
        8B</a>. OTHER INFORMATION.</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
      III</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item9">ITEM
      9</a>. </u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>DIRECTORS,
      EXECUTIVE OFFICERS, PROMOTERS, CONTROL PERSONS AND CORPORATE GOVERNANCE;
      COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE
      ACT.</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets forth the name, age and position of each of our executive
      officers, directors and key employees as of March 28, 2007. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="19%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Name</strong></font></div>
            </td>
            <td valign="top" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Age</strong></font></div>
            </td>
            <td valign="top" width="31%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Position</strong></font></div>
            </td>
            <td valign="top" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Director
                Class</strong></font></div>
            </td>
            <td valign="top" width="9%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Term
                Expiring</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Executive
                Officers:</strong></font></div>
            </td>
            <td valign="top" width="6%">&#160;</td>
            <td align="left" valign="top" width="31%">&#160;</td>
            <td align="left" valign="top" width="9%">&#160;</td>
            <td align="left" valign="top" width="9%">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                A. Emalfarb</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chairman
                of the Board, President and Chief Executive Officer</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2007</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glenn
                E. Nedwin, Ph.D</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Scientific Officer and Executive Vice President, President, BioPharma
                Business and Director</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2007</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wayne
                Moor</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">55</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Financial Officer and Vice President</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Kent
                M. Sproat</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">60</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Executive
                Vice President, Manufacturing and Special Projects</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alexander
                (Sasha) Bondar</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">35</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
                President, Strategy &amp; Corporate Development</font></div>
            </td>
            <td align="left" valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Independent
                Directors:</strong></font></div>
            </td>
            <td valign="top" width="6%">&#160;</td>
            <td align="left" valign="top" width="31%">&#160;</td>
            <td align="left" valign="top" width="9%">&#160;</td>
            <td align="left" valign="top" width="9%">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Richard
                J. Berman</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">64</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2008</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Robert
                B. Shapiro</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">68</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2008</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stephen
                J. Warner</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">67</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director
                </font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2009</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Harry
                Z. Rosengart</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">57</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2009</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Key
                Employees:</strong></font></div>
            </td>
            <td valign="top" width="6%">&#160;</td>
            <td align="left" valign="top" width="31%">&#160;</td>
            <td align="left" valign="top" width="9%">&#160;</td>
            <td align="left" valign="top" width="9%">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ratnesh
                (Ray) Chandra</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">59</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Senior
                Vice President, Marketing-Biotechnology Systems </font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Daniel
                Michalopoulos, Ph.D.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#160;</sup></font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">54</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
                President, Marketing, Enzymes</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="top" width="19%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Charles
                W. Kling IV</font></div>
            </td>
            <td valign="top" width="6%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">50</font></div>
            </td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
                President, Sales, Enzymes </font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td valign="top" width="9%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Mark
      A. Emalfarb</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">has
      been
      on our Board of Directors and been our Chairman, President and Chief Executive
      Officer since October 2004 and has been the President, Chief Executive Officer
      and Chairman of the Board of Directors of our wholly-owned subsidiary Dyadic
      International (USA), Inc., a Florida corporation (&#8220;Dyadic-Florida&#8221;), since its
      inception. Since founding Dyadic-Florida in 1979, Mr. Emalfarb has successfully
      led and managed the evolution of Dyadic-Florida&#8212;from its origins as a pioneer
      and leader in providing ingredients used in stone-washing of blue jeans&#8212;to the
      discovery, development, manufacturing and commercialization of specialty enzymes
      used in various industrial applications and the development of the Dyadic
      Platform Technology and our other proprietary technologies. Mr. Emalfarb is
      an
      inventor of over 25 U.S. and foreign biotechnology patents and patent
      applications resulting from discoveries related to Dyadic-Florida&#8217;s C1 organism,
      and has been the architect behind its formation of several strategic research
      and development, manufacturing and marketing relationships with U.S. and
      international partners. Mr. Emalfarb earned a B.A. degree from the University
      of
      Iowa.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Glenn
      E. Nedwin, Ph.D.</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has been
      on our Board of Directors and our Chief Scientific Officer and Executive Vice
      President and President of our BioPharma Business since March 2006. Before
      joining us, Dr. Nedwin co-founded and served as President of Novozymes, Inc.
      since 1991. At Novozymes, Inc., a Davis, California-based research &amp;
development subsidiary of Novozymes A/S (CSE:NZYMb.CO), Denmark, a global leader
      in enzymes and microorganisms with over $1 billion in worldwide revenues, Dr.
      Nedwin was responsible for all scientific, financial and administrative
      activities, and was a member of Novozymes A/S global R&amp;D management team and
      its biosolutions strategy group, and was involved in technology/product
      licensing. From 1989 to 1991, Dr. Nedwin served as Vice President of Corporate
      Development, Xoma Corporation (NASDAQ:XOMA), a biotechnology company based
      in
      Berkeley, California. Earlier, he was Vice President, Business Development
      and
      co-founder of Ideon Corporation, Redwood City, California, and Senior Research
      Scientist and co-founder </font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">42</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
      Molecular Therapeutic, Inc. (now Bayer Pharmaceuticals Corporation), West Haven,
      Connecticut. Dr. Nedwin received his Bachelor of Science degree in Biochemistry
      from the State University of New York at Buffalo and his Ph.D. in Biochemistry
      from the University of California, Riverside. Dr. Nedwin did his postdoctoral
      fellowship in molecular biology at Genentech, Inc. Dr. Nedwin also holds an
      M.S.
      in the Management of Technology from the Massachusetts Institute of Technology
      and is currently a Co-Editor of the Industrial Biotechnology
      Journal.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Wayne
      Moor </em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">has
      been
      our Chief Financial Officer and Vice President since January 2005. During the
      past five years Mr. Moor has served as a Chief Financial Officer of several
      public companies, and has over 25 years experience in real estate and hotel
      operations, asset management, debt restructurings, recapitalizations and
      developing strategic turnaround plans. From October 2002 through December 2004,
      Mr. Moor served as the Senior Vice President, Treasurer and Chief Financial
      Officer of Boca Resorts, Inc, a hospitality company. From October 2001 to
      October 2002, Mr.&#160;Moor was Senior Vice President and Chief Financial
      Officer for ANC, the parent company of Alamo and National rental car companies.
      In November 2001, following the terrorist attacks of September&#160;11, 2001,
      ANC and its U.S. operating subsidiaries voluntarily filed petitions for
      reorganization under Chapter&#160;11 of the U.S. Bankruptcy Code in Wilmington,
      Delaware. From September 2000 to October 2001, Mr.&#160;Moor was Senior Vice
      President and Chief Financial Officer for Gerald Stevens, Inc., a floral
      products marketer and retailer. In April 2001, Gerald Stevens, Inc. and certain
      operating subsidiaries voluntarily filed petitions for reorganization under
      Chapter&#160;11 of the U.S. Bankruptcy Code in Miami, Florida. From June 1997 to
      January 2000, Mr.&#160;Moor was Executive Vice President and Chief Financial
      Officer for US Diagnostic, Inc., an operator of outpatient medical diagnostic
      imaging and related facilities. Prior to that, Mr.&#160;Moor held the position
      of Chief Financial Officer or Executive Vice President for a number of privately
      and publicly held financial institutions and real estate operating companies.
      He
      began his career in public accounting.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Kent
      M. Sproat</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has been
      our Executive Vice President, Manufacturing and Special Projects responsible
      for
      all manufacturing functions of our enzymes business activities since January
      2007. Prior to that he served as our Executive Vice President, Enzyme Business
      from April 2005 through December 2006. Mr. Sproat served as our Vice President,
      Manufacturing from 1997 through March 2005. Mr. Sproat joined Dyadic-Florida
      in
      1997 from Genencor International, where since 1996 he served as its Elkhart
      Site
      Manager. From 1990 to 1996, Mr. Sproat was Vice President, Manufacturing, of
      Solvay Enzymes, Inc. From 1989 to 1990, he was Director of International
      Manufacturing of the Enzyme Division of Miles, Inc. Between 1981 and 1990,
      he
      served as Plant Manager of Miles&#8217; Elkhart, Indiana and Clifton, New Jersey-based
      enzyme plants. Between 1973 and 1981, Mr. Sproat was a Production Superintendent
      at Miles&#8217; Citric Acid Division; Start Up Manager of Miles&#8217; citric acid facility
      in Brazil; and Production Supervisor and Project Engineer. Mr. Sproat is the
      recipient of a patent for his design in the purification process of amylases.
      Mr. Sproat is a chemical engineer with a B.S. degree from Purdue
      University.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Alexander
      (Sasha) Bondar&#160; </em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">has
      been
      our Vice President, Strategy &amp; Corporate Development, with primary
      responsibility for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">corporate
      development, organization planning, merger &amp; acquisition opportunities,
      fund-raising activities and investor and public relations</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      and
      secondarily, when requested, for assisting in business development for the
      Company&#8217;s BioPharma and Enzyme businesses, since April 2005. Mr. Bondar served
      as our Executive Director, Business Development from May 2003 through March
      2005. Mr. Bondar joined Dyadic-Florida in May 2003 from The Aurora Funds, a
      venture capital firm based in Research Triangle Park, North Carolina, where
      he
      was focused on investing in early stage life sciences companies.&#160; Prior to
      that, from 1996 to 2001, Mr. Bondar served in a variety of management roles
      at
      Incyte Genomics, now Incyte Corporation, in Palo Alto, California, and from
      1999
      to 2001 as Associate Director, Corporate Business Development.&#160; From 1997
      to 1999, he served as Manager, Pharmacogenomics Business Development, and was
      a
      major contributor to the successful launch of Incyte&#8217;s pharmacogenomics program.
      From 1996 to 1997, he served as Technical Advisor to the intellectual property
      group at Incyte, contributing to the creation of the largest portfolio of gene
      patents in the world.&#160; Mr. Bondar holds a B.S. degree in Biotechnology
      Management from Menlo College and an M.B.A. in Corporate Finance and Health
      Sector Management from Duke University&#8217;s Fuqua School of Business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Richard
      J. Berman</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has been
      on our Board of Directors since in January 2005, and acts as our so-called
&#8220;Lead
      Director.&#8221; In that capacity, he is responsible for meeting regularly with our
      chairman of the board and chief executive officer to review monthly financials,
      agenda and minutes of committee meetings and pertinent Board issues, presiding,
      if requested by the board, as chairman of any of the committees of the board
      and
      presiding at any meetings of the independent and non-employee directors. In
      the
      last five years, Mr. Berman has served as a professional director and/or officer
      of about a dozen public and private companies. He is currently CEO of Nexmed,
      a
      small public biotech company; Chairman of National Investment Managers, a public
      company in pension administration and investment management; Chairman of
      Candidate Resources, a private company delivering HR services over the web,
      and
      Chairman of Fortress Technology Systems (homeland security). Mr. Berman is
      a
      director of eight public companies: Dyadic International, Inc., Broadcaster,
      Inc., Internet Commerce Corporation, MediaBay, Inc., NexMed, Inc., National
      Investment Managers, Advaxis, Inc., and NeoStem, Inc. From 1998 - 2000, he
      was
      employed by Internet Commerce Corporation as Chairman and Chief Executive
      Officer. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice
      President of Bankers Trust Company, where he started the M&amp;A and Leveraged
      Buyout Departments; created the largest battery company in the world by merging
      Prestolite, General Battery and Exide to form Exide (NYSE); helped create what
      is now Soho (NYC) by developing five buildings; and advised on over $4 billion
      of M&amp;A transactions. He is a past Director of the Stern School of Business
      of NYU where he obtained his B.S. and M.B.A. He also has US and foreign law
      degrees from Boston College and The Hague Academy of International Law,
      respectively. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">43</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><strong>Robert
        B. Shapiro</strong></em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        has been
        on our Board of Directors since March 2005. During the past six years Mr.
        Shapiro has served as a member of the Board of Directors of the New York
        Stock
        Exchange (on which he still serves), Citigroup, Inc. and Rockwell International,
        as Chairman of Pharmacia Corporation&#8217;s Board of Directors and, prior to its
        merger with Phamacia &amp; Upjohn, as Chairman and Chief Executive Officer of
        Monsanto Company (1995 through 2001). Prior to becoming the Chairman and
        Chief
        Executive Officer of Monsanto, Mr. Shapiro served in various executive
        capacities with Monsanto from 1985, and with G.D. Searle &amp; Company, a
        pharmaceutical and healthcare company, first as its general counsel (1979
        through 1982), and then as President of its newly formed NutraSweet Group
        (1982
        to 1985). Mr. Shapiro is a 1959 graduate of Harvard College and a 1962 graduate
        of Columbia University School of Law.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Stephen
      J. Warner</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has been
      on our Board of Directors since October 2004, and a director of Dyadic
      International (USA), Inc., our wholly-owned subsidiary (&#8220;Dyadic-Florida&#8221;), since
      August&#160;15, 2004. Mr. Warner serves as chairman of Maxim TEP, Inc. a private
      energy company based in Houston, Texas, and Search Energy Solutions, Inc.,
      a
      private company offering energy savings services for large air conditioning
      systems based in Palm Beach Gardens, Florida. He also serves as a director
      of
      UCT Coatings Inc., a private, metal finishing technology company in Stuart,
      Florida, and AOI Medical, Inc., a private medical device company in Orlando,
      Florida. Mr. Warner has over 25 years of venture capital experience. In 1981,
      Mr. Warner founded Merrill Lynch Venture Capital Inc., a wholly-owned subsidiary
      of Merrill Lynch &amp; Co. Inc. in New York and served as its President and
      Chief Executive Officer from 1981 to 1990. Under his leadership, Merrill Lynch
      Venture Capital managed over $250 million and made over 50 venture capital
      investments. In 1999, Mr. Warner co-founded, and became Chairman and CEO, of
      Crossbow Ventures Inc., a private equity fund that invests in early and
      expansion stage technology companies primarily located in Florida and the
      Southeast, with over 20 venture capital investments in Florida. Mr. Warner
      earned a B.S. degree from the Massachusetts Institute of Technology and an
      MBA
      from the Wharton School of Business, University of Pennsylvania.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Harry
      Z. Rosengart</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has been
      on our Board of Directors since April 2005. During the past ten years, Mr.
      Rosengart has served (and currently serves) as the President and Chief Executive
      Officer of HK &amp; Associates, an investment and consulting firm which provides
      advice to small and medium-sized life sciences companies. Mr. Rosengart is
      a
      founder of several privately held companies, including: LigoChem, Inc., a
      DNA\RNA and macromolecule bioseparations company founded in 1995, of which
      he is
      a former President and Chief Executive Officer and a current member of its
      Board
      of Directors; SunPharm Corporation, a polyamine based anti-cancer drug
      development-stage company founded in 1991, of which he is a former Chief
      Operating Officer, Chief Financial Officer and member of its Board of Directors;
      and Syncom Pharmaceuticals, Inc, a contract sales force organization founded
      in
      1991, of which he has had a variety of interim positions and served on its
      Board
      of Directors. Between 1981 and 1990, Mr. Rosengart spent almost 10 years as
      a
      banker and investment banker with the Chase Manhattan Bank, NA focused on the
      pharmaceutical and chemical industries. Prior to joining Chase Manhattan Bank,
      Mr. Rosengart spent over 10 years with several pharmaceutical and multinational
      chemical companies in various managerial positions. Mr. Rosengart holds a B.S.
      in Chemical Engineering and an MBA from Rutgers University.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Ratnesh
      (Ray) Chandra</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has been
      our Senior Vice President, Marketing-Biotechnology Systems, responsible for
      business development for the Company&#8217;s BioPharma business activities, since
      April 2005. Mr. Chandra served as our Vice President, Marketing - BioPharma
      from
      2000 through March 2005. Mr.&#160;Chandra joined Dyadic-Florida from Genencor
      International in 2000. He had served at Genencor as the Director, New Business
      Development since 1993. From 1987 to 1993, he was with Merck &amp; Co. holding
      the positions of Director, Business/Market Intelligence and Director, Business
      Systems in their Human Health Marketing Division. From 1976 to 1987, he was
      with
      Schering-Plough Corp. in the positions of Director Economic Analysis, Manager
      Capital Planning and Senior Operations Analyst. Mr. Chandra has an M.B.A. from
      New York University and an M.S. in engineering from Columbia
      University.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Daniel
      Michalopoulos, Ph.D</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      has been
      our Vice President, Marketing, Enzymes since January 2007. Prior to that he
      served as our Vice President, Pulp &amp; Paper from February 2005 through
      December 2006 and is focused on growing our pulp and paper effort. Prior to
      joining us, he served as Senior Program Manager for Hercules&#8217; Pulp and Paper
      Division from 1998 to 2005 where he managed a staff of 40 people with an annual
      budget of $8&#160;million. Prior to that, he served as Research Director at
      BetzDearborn Pulp and Paper Division and held other research and management
      positions at Betz PaperChem. Dr. Michalopoulos conducted his post-doctoral
      work
      at Rice University, received his Ph.D. in Chemistry from Colorado State
      University and his B.S. in Chemistry from Lowell Technological
      Institute.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Charles
      W. Kling IV </em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">has
      been
      our Vice President, Sales, Enzymes since January 2007. Prior to that he served
      as our Vice President of Sales and Marketing - Enzymes from July 2005 through
      December 2006. Prior to joining us, Mr. Kling served as Group Manager of
      Hercules, Inc.&#8217;s Pulp &amp; Paper division, with full P&amp;L responsibility and
      management of staff of over 60 people, from 1998 to 2005. Prior to Hercules,
      from 1990 to 1998, Mr. Kling served as Global Director, Technical Marketing
      for
      BetzDearborn Inc.'s Pulp &amp; Paper division. From 1986 to 1990, he was
      Division Manager, S.D. Warren division of Scott Paper. Prior to that, he served
      as Production Manager for Buckeye Cellulose, a division of Proctor and Gamble,
      Inc. Mr. Kling received his B.S. degree in Civil Engineering from University
      of
      Alabama.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Section
      16(a) Beneficial Ownership Reporting Compliance</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">44</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
          our
          knowledge, based solely on a review of the copies of such reports furnished
          to
          us and representations that no other reports were required, we believe
          that all
          Section 16 filing requirements applicable to our officers, directors and
          10
          percent beneficial owners were complied with during the year ended December
          31,
          2006, other than a late filing </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
          a</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          Form 3
          in April 2006 by</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          Chief
          Scientific Officer</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          Glenn
          E. Nedwin to report his initial appointment as an executive officer and
          director
          in March 2006 and the grant to him of equity-based awards in connection
          therewith</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Codes
        of Ethics </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        Board
        of Directors has adopted a Code of Business Conduct and Ethics that applies
        to
        all of our directors, officers and employees, including our principal executive
        officer, principal financial officer, principal accounting officer or controller
        and persons performing similar functions. The Code of Business Conduct and
        Ethics is available at our website at www.dyadic.com.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      intend
      to satisfy the disclosure requirements under Item 5.05 of Form 8-K regarding
      an
      amendment to, or a waiver from, a provision of our Code of Business Conduct
      and
      Ethics that applies to our principal executive officer, principal financial
      officer, principal accounting officer or controller or persons performing
      similar functions by posting such information on our website at
      www.dyadic.com.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Procedures
      for Stockholders Submitting Director Candidate
      Recommendations</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
      have been no material changes to the procedures by which stockholders may
      recommend nominees to our Board of Directors as described in our definitive
      Proxy Statement dated April 28, 2006 relating to the 2006 annual stockholders&#8217;
meeting. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Audit
      Committee</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have a
      separately-designated standing audit committee established by and amongst our
      Board of Directors in accordance with Section 3(a)(58)(A) of the Securities
      Exchange Act of 1934 for the purpose of overseeing our accounting and financial
      reporting processes and audits of our consolidated financial statements.
      Currently, directors Stephen J. Warner, Richard J. Berman and Harry Z. Rosengart
      are the members of the audit committee. Mr. Berman serves as the chairman of
      the
      audit committee.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Audit
      Committee Financial Expert</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Board
      of Directors has determined that Mr. Berman is an &#8220;audit committee financial
      expert&#8221; as defined in Item 401(d)(5) of Regulation S-B of the Securities Act of
      1933. The Board of Directors also has determined that Mr. Berman is independent,
      as defined by Rule 10A-3 of the Securities Exchange Act of 1934 and the
      corporate governance listing standards of the American Stock Exchange.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item10">ITEM
      10</a>. EXECUTIVE COMPENSATION.</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SUMMARY
      COMPENSATION TABLE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets forth the total compensation earned, accrued or paid to
      our
      Chief Executive Officer and each of our two most highly compensated executive
      officers who </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">were
      serving</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in such
      capacities as of December 31, 2006, collectively referred to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">as
      the
&#8220;named executive officers</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">45</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td valign="bottom" width="27%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Name
                and Principal Position</strong></font></div>
            </td>
            <td width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Salary</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>($)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Bonus
                </strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>($)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stock</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Awards
                </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>$</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Option
                </strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Awards
                </strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>($)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-Equity
                Incentive Plan Compensation </strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>($)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Change
                in Pension Value and Nonqualified Deferred Compensation
                Earnings</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>($)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>All
                </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>other</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Compensation</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>($)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>$</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" width="27%" style="border-bottom: medium none;">&#160;</td>
            <td width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="2" valign="bottom" width="6%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="27%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                A. Emalfarb </font></div>
            </td>
            <td width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2006</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">300,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">75,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">23,765</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">398,765</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="27%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chairman,
                President and Chief Executive Officer</font></div>
            </td>
            <td width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="27%" style="border-bottom: white;">&#160;</td>
            <td width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="27%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wayne
                Moor </font></div>
            </td>
            <td width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2006</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">231,750</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">35,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,711</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(3)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">283,461</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="27%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
                President and</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                Chief Financial Officer </font></div>
            </td>
            <td width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="27%" style="border-bottom: white;">&#160;</td>
            <td width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="27%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glenn
                E. Nedwin, Ph. D. </font></div>
            </td>
            <td width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2006</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">234,231</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">95,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">50,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">349,269</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(4)</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">728,500</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="27%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Scientific Officer, Executive Vice President, President,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioPharma</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                Business and D</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">irector</font></div>
            </td>
            <td width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="5%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_____________</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">&#160;</div>
    </div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)
                </font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
                Emalfarb&#8217;s </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bonus</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                for 2006</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                has been accrued, and the payment of which has been deferred until
                such
                time as the compensation committee and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                other independent directors deem it advisable to make</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                such payment. Does not include the payment of cash bonuses previously
                awarded to Mr. Emalfarb in the amount of $75,000 each, for services
                rendered in calendar years 2004 and 2005, which had been accrued
                as an
                expense by us for those years</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                amount shown for Mr. Emalfarb represents our payment of $9,800 for
                a</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                life insurance </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">premium
                for the benefit of Mr. Emalfarb and our payment</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                of
                $13,965 to Mr. Emalfarb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                for an automobile allowance</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
                stock option grant for 30,000 options was made to Mr. Moor on April
                4,
                2006 at an exercise price of $4.60 per share and vests </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">four
                equal annual installments beginning on April 4, 2007</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
                The amount shown was calculated utilizing the provisions of Statement
                of
                Financial Accounting Standards No. 123R, &#8220;Share-Based Payments&#8221; (&#8220;SFAS
                123R&#8221;). See Note 9 of our consolidated financial statements included in
                our Annual Report on Form 10-KSB for the year ended December 31,
                2006
                regarding the assumptions underlying the valuation of these option
                grants
                under SFAS 123R. </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)
                </font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                the following two stock options granted to Dr. Nedwin on March 16,
                2006
                under the then 2001 Equity Compensation Plan in connection with his
                initial appointment as an executive officer pursuant to the terms
                of his
                employment agreement: (i) an option to purchase 445,022 shares of
                our
                common stock at an exercise price of $2.96 per share, the fair market
                value on our common stock on the date of grant (the &#8220;time-vested option&#8221;)
                and (ii) an option to purchase 667,533 shares of our common stock
                at an
                exercise price of $5.92 per share, two times the fair market value
                of our
                common stock on the date of grant (the &#8220;performance-vested option&#8221;). Each
                stock option agreement is an incentive stock option to the extent
                permitted by the terms of the 2001 Equity Compensation Plan, and
                a
                non-qualified stock option as to the balance of the shares that may
                be
                purchased thereunder. The time-vested option becomes exercisable,
                conditioned upon Dr. Nedwin&#8217;s continued service as an employee of ours, as
                to 25% of the underlying shares on each of the next four anniversaries
                of
                March 16, 2006, and expires on March 16, 2011, but provides for the
                complete acceleration of vesting of that option upon a termination
                of Dr.
                Nedwin&#8217;s employment either by us without &#8220;cause&#8221; or by Dr. Nedwin for
                &#8220;good reason.&#8221; The performance-vested option becomes exercisable
                incrementally, conditioned upon Dr. Nedwin&#8217;s continued service as an
                employee of ours, based upon the our achievement during the initial
                period
                of his employment of various specified performance benchmarks (e.g.
                the
                launching of new products, the enhancement of existing products,
                our entry
                into corporate and strategic alliances), and expires on March 16,
                2011.
                The amount shown was calculated utilizing the provisions of SFAS
                123R. See
                Note 9 of our consolidated financial statements included in our Annual
                Report on Form 10-KSB for the year ended December 31, 2006 regarding
                the
                assumptions underlying the valuation of these option grants under
                SFAS
                123R. </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 36pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5)</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
                11,990</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                shares of common stock </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">granted
                to Dr. Nedwin </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">under
                the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">then</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                2001 Equity Compensation Plan </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
                connection with his initial appointment as an executive officer pursuant
                to the terms of his</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                employment agreement. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                shares were</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                fully vested upon grant and</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                valued at $50,000 based on the fair market value of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                common stock on the date of grant</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                in
                accordance with SFAS 123R</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">46</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
          of
          the named executive officers did not receive any other compensation during
          2006
          except for perquisites and other personal benefits of which the total value
          did
          not exceed $10,000.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>OUTSTANDING
      EQUITY AWARDS AT </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FISCAL
      YEAR-END</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets forth certain information regarding outstanding equity
      awards held by the named executive officers at December 31, 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

          <tr>
            <td valign="bottom" width="43%" style="border-bottom: medium none;">&#160;</td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td colspan="14" valign="bottom" width="54%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Option
                Awards</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" width="43%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Name</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Underlying</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Unexercised
                Options (#) Exercisable</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Underlying</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Unexercised
                Options (#) Unexercisable</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Equity
                Incentive Plan Awards: Number of Securities Underlying Unexercised
                Unearned Options</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Option
                Exercise Price</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>($)</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Option
                Expiration Date</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                A. Emalfarb</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wayne
                Moor</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">277,889</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.68</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">01/30/2010</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
            </td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
                --</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">30,000</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><sup>(1)</sup></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.60</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">04/03/2016</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>
          <tr bgcolor="#cceeff">
            <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glenn
                E. Nedwin, Ph.D.</font></div>
            </td>
            <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">&#160;--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">445,022</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><sup>(2)</sup></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.96</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">03/15/2011</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td align="left" valign="bottom" width="43%" style="border-bottom: white;">&#160;</td>
            <td width="2%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">33,377</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><sup>(3)</sup></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">634,156</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><sup>(3)</sup></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.92</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">03/15/2011</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">&#160;</div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                option award granted to Mr. Moor in 2006 vests in four equal annual
                installments beginning on April 4, 2007.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                option award granted to Dr. Nedwin in 2006 vests in four equal annual
                installments beginning on March 16, 2007</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
                </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See
                note 4 to the above &#8220;Summary Compensation Table&#8221; for additional
                information regarding this option award.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
                2006, Dr. Nedwin was granted 667,533 performance options, of which,
                33,377
                were earned in 2006. The balance of the options may be earned by
                Dr.
                Nedwin through December 31, 2008 based upon the achievement of certain
                performance benchmarks. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See
                note 4 to the above &#8220;Summary Compensation Table&#8221; for additional
                information regarding this option award.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Employment
      Agreements</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      and Potential Payments Upon Termination </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      2001,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      entered
      into an employment agreement with </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">named
      executive officer </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
      A.
      Emalfarb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      agreement commenced on April 1, 2001, and terminated on March 30, 2004, but
      renewed for an additional two years because neither party gave written notice
      60
      days prior to March 30, 2003. In March 2006, the agreement was amended (the
      &#8220;First Amendment&#8221;) to extend the term of Mr. Emalfarb&#8217;s employment by one year,
      from March 30, 2006 to March 30, 2007, and to add an automatic renewal provision
      for succeeding one year terms unless either party gives the other a notice
      of
      non-renewal not less than 90 days prior to the expiration of the then term.
      The
      agreement automatically renewed on April 1, 2007, as neither party provided
      the
      other party a notice of non-renewal at least 90 days prior to March 30, 2007.
      The First Amendment makes no other </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
      to Mr. Emalfarb&#8217;s employment agreement. The agreement provides for an annual
      base salary of $300,000 and the payment of an annual bonus (based on goals
      and
      objectives to be agreed upon by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Board</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      of
      Directors</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and Mr.
      Emalfarb) for each fiscal year or portion of a fiscal year, including but not
      limited to research and other business milestones, sales, profitability or
      cash
      flow goals. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      agreed</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      to cause
      the compensation committee to grant Mr. Emalfarb options to the same extent
      as
      the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">compensation
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">committee
      grants to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">other
      senior executives</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strike>&#160;</strike></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">on
      the
      same terms and conditions. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      agreement also provides for the participation in all benefit plans, practices,
      policies and programs provided by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      such as
      (including, without limitation, reimbursement of business related expenses,
      vacation, medical, prescription, dental, disability, retirement, salary
      continuance, employee life insurance, group life insurance, and accidental
      death
      and travel accident insurance plans and programs) generally available to
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">other
      senior executives</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      and for
      other employee benefit</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">s,
      including an</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      annual
      automobile allowance for approximately $</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14,000.</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">47</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If,
        during the employment period, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
        terminate</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Mr.
        Emalfarb's employment, other than for cause or disability or by reason of
        Mr.
        Emalfarb's death or by reason of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        failure
        to renew the employment </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">agreement,
        or if Mr. Emalfarb terminates employment for good reason, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        shall
        provide Mr. Emalfarb with annual base salary and all benefits received by
        Mr.
        Emalfarb as of the date of termination for a period of one year from the
        date of
        termination. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        January 2005, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        entered
        into employment an agreement with </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">named
        executive officer</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Wayne
        Moor to become </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Chief
        Financial Officer and a Vice President. The initial term of Mr. Moor's
        employment is 2 years and 11 months (ending December 31, 2007), with automatic
        one-year renewals unless either party furnishes the other a notice of
        non-renewal not less than 90 days prior to the expiration of the then term.
        Mr.
        Moor's annual base compensation is 225,000, and he is eligible to earn a
        bonus
        each year of up to 40% of his annual base compensation based upon a bonus
        plan
        adopted and maintained by the compensation committee </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
        such
        year.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      employment agreement is terminable on account of Mr. Moor's death or disability,
      or by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      without
      cause or "for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cause</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">."
      The
      phrase "for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cause</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">"
      is
      defined to include a material breach of the employment agreement, acts of
      disloyalty to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">including
      but not limited to acts of dishonesty or diversion of corporate opportunities,
      the unauthorized disclosure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      confidential information, or acts determined in good faith by the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">compensation
      committee</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      to be
      detrimental to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      interests, provided that Mr. Moor must be afforded an opportunity to have a
      face-to-face meeting with the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">compensation
      committee</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      before
      any determination is made by it that Mr. Moor was guilty of "for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cause</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">"
      conduct. If Mr. Moor's employment is terminated by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      other
      than "for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cause</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,"
      upon
      the condition that he furnish </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      with a
      full general release, he is entitled to receive a severance benefit of monthly
      installments in the amount of 1/12th of his then annual base compensation for
      the lesser of six months or until he has obtained other full or part-time
      employment as an employee or </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">consultant.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      employment agreement, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
      are</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      also
      obligated to indemnify Mr. Moor to the fullest extent permitted by applicable
      law. Further, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
      have
      agreed </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">to
      advance expenses he may spend as a result of any proceeding against him as
      to
      which he could be indemnified.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      March
      2006, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      entered
      into an agreement with Dr. Glenn E. Nedwin to become (i) </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Chief
      Scientific Officer, (ii) an Executive Vice President of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      (iii) the President of the BioPharma Business of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      wholly-owned subsidiary, Dyadic International (USA), Inc., a Florida
      corporation. The initial term of Dr. Nedwin&#8217;s employment ends December 31, 2008,
      with automatic one-year renewals unless either party furnishes the other a
      notice of non-renewal not less than 120 days prior to the expiration of the
      then
      term. Dr. Nedwin&#8217;s annual base salary is $300,000, and he is eligible to earn a
      bonus each year of up to 25% of his then annual base salary based upon a bonus
      plan adopted and maintained by the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">compensation
      committee for such year. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      employment agreement is terminable on account of Dr. Nedwin&#8217;s death or
      disability, by Dr. Nedwin for &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">good
      reason</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;,
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">as
      defined</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in the
      employment agreement)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      or by
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      without
      cause or &#8220;for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cause&#8221;
      (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">as
      defined</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in the
      employment agreement)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      If Dr.
      Nedwin&#8217;s employment is terminated by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      other
      than &#8220;for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cause</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,&#8221;
upon
      the condition that he furnish </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      with a
      full general release, he is entitled to receive a severance benefit of monthly
      installments in the amount of 1/12th of his then annual base salary for the
      eighteen (18) month period following that termination</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      (the
      severance period&#8221;)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      provided that the amount of his severance benefits are reduced on a
      dollar-for-dollar basis by the amount of any remuneration he may earn during
      the
      severance period for the performance of services as an employee, or independent
      contractor or agent. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
      the
      employment agreement, we are also obligated to indemnify Dr. Nedwin to the
      fullest extent permitted by applicable law. Further, we have agreed to advance
      expenses Dr. Nedwin may spend as a result of any proceeding against him as
      to
      which he could be indemnified. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DIRECTOR
      COMPENSATION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table sets forth </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      cash</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      fees and
      option awards </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">earned,
      paid or awarded to each of our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      directors </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">during</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      the year
      ended December 31, 2006. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      a
      description of the directors&#8217; fees and awards, see the narrative description
      immediately following this table.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
      <div align="left">
        <table border="1" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td valign="bottom" width="36%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Name</strong></font></div>
              </td>
              <td width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Fees
                  Earned or Paid in Cash</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  ($)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stock
                  Awards ($)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Option
                  Awards ($)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Non-Equity
                  Incentive Plan Compensation ($)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Change
                  in Pension Value and Nonqualified Deferred Compensation
                  Earnings</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>All
                  Other Compensation ($)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="6%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total
                  ($)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="36%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Richard
                  J. Berman</font></div>
              </td>
              <td width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">33,600</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">14,381</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">47,981</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="36%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Robert
                  B. Shapiro</font></div>
              </td>
              <td width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,786</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">34,786</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="36%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stephan</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  J.
                  Warner</font></div>
              </td>
              <td width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">14,381</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">38,381</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="36%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Harry
                  Z. Rosengart</font></div>
              </td>
              <td width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,588</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="5%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">33,588</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>

        </table>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">48</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td style="width: 36pt;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts
                  shown were calculated utilizing the provisions of SFAS 123R. On
                  February
                  10, 2006, non-employee directors Messrs. Berman, Rosengart, Shapiro
                  and
                  Warner received stock option grants for 25,000, 16,667, 18,750
                  and 25,000
                  shares, respectively, at an exercise price of $2.36 per share and
                  a SFAS
                  123R fair value of $2.36 per share. The value shown is what is
                  also
                  included in our consolidated financial statements per SFAS 123R.
                  See Note
                  9 of our consolidated financial statements included in our Annual
                  Report
                  on Form 10-KSB for the year ended December 31, 2006 regarding the
                  assumptions underlying the valuation of these option grants under
                  SFAS
                  123R. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      January 2005, our board of directors adopted a director compensation policy.
      Directors who are also employees or officers of us or any of our subsidiaries
      do
      not receive any separate compensation as a director. Non-employee directors
      receive a $2,000 per month cash retainer, and options to purchase shares of
      our
      common stock under the Dyadic International, Inc. Amended and Restated 2001
      Equity Compensation Plan. The chairman of the audit committee receives an
      additional $800 per month cash retainer. All non-employee directors also are
      reimbursed for their reasonable travel costs related to attendance at board
      and/or committee meetings. Upon joining our board, a non-employee director
      receives options to purchase 30,000 shares of our common stock at an exercise
      price equal to the fair market value of the stock on the date of grant. Upon
      joining our board, the lead director receives options to purchase 50,000 shares
      our common stock at an exercise price equal to the fair market value of the
      stock on the date of grant. In all cases, 25% of these options vest upon grant,
      while the remaining portion vest in equal installments over a four-year period
      subject to the director&#8217;s continued service. The options generally expire five
      years from the date of grant or earlier in the event service as a director
      ceases. At the beginning of each year, non-employee directors will receive
      additional options to purchase 25,000 shares of our common stock, or a pro
      rata
      portion based on the number of months that the director served on the board
      during the preceding year, subject to the same vesting provisions and other
      conditions as described above. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item11">ITEM
      11</a>. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
      MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Security
      Ownership of Certain Beneficial Owners and Management</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      table
      below sets forth information regarding the beneficial ownership of our common
      stock as of March 28, 2007, by the following individuals or groups:
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 90pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">each
                person or entity who is known by us to own beneficially more than
                5% of
                our common stock;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 90pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">each
                of our directors;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 90pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">each
                of our named executive officers for the year ended December 31, 2006
                (as
                identified in the &#8220;Summary Compensation Table&#8221; set forth above in Item 10.
                Executive Compensation); and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 90pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">all
                of our directors and executive officers as a
                group.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beneficial
      ownership is determined in accordance with the rules of the Securities and
      Exchange Commission (&#8220;SEC&#8221;) and generally includes voting or investment power
      with respect to securities. Shares of our common stock that are subject to
      our
      options and warrants that are presently exercisable or exercisable within 60
      days of March 28, 2007 are deemed to be outstanding and beneficially owned
      by
      the person holding any of such convertible securities for the purpose of
      computing the percentage of ownership of that person, but are not treated as
      outstanding for the purpose of computing the percentage of any other
      person.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unless
      indicated otherwise below, the address of our directors and executive officers
      is c/o Dyadic International, Inc., 140 Intracoastal Pointe Drive, Suite 404,
      Jupiter, Florida 33477. Except as indicated below, the persons named in the
      table have sole voting and investment power with respect to all shares of common
      stock beneficially owned by them. As of March 28, 2007, we had outstanding
      29,939,375 of our common stock.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">49</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div align="left">
        <table cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td valign="bottom" width="71%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Name
                  </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>and
                  Address of Beneficial Owner</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                  of Shares</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Percentage
                  Ownership</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  A. Emalfarb (1)(8)(9)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7,098,559</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22.7</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                  Francisco Trust U/A/D February 28, 1996 (2).</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,769,578</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15.9</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 21.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                  Pinnacle Fund, L.P.&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Barry
                  M. Kitt (3)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,497,023</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">8.3</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Abengoa
                  Bioenergy R&amp;D, Inc. (4)</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,136,752</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7.1</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stephen
                  J. Warner (5)(8)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">289,588</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.0</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Robert
                  B. Shapiro (6)(8)</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">44,454</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Richard
                  J. Berman (6)(8)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">67,188</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Harry
                  Z. Rosengart (6)(8)</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">43,542</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glenn
                  E. Nedwin, Ph.D. (7)(8)(9)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">156,623</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wayne
                  Moor (6)(9)</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">285,389</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">*</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
                  directors and executive officers as a group (7 persons)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,754,921</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">40.0</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________________</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Denotes
      less than 1%</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
      5,822,125 shares held by Mark A. Emalfarb beneficially through the Mark A.
      Emalfarb Trust U/A/D October 1, 1987, of which Mr. Emalfarb is the sole
      beneficiary and serves as sole trustee. Also includes 1,276,434 shares issuable
      upon the exercise of warrants presently exercisable. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      trustee of the Francisco Trust U/A/D February 28, 1996 is Robert S. Levin,
      Esq.
      and the beneficiaries thereof are the spouse and descendants of Mark A.
      Emalfarb. The address of the Francisco Trust U/A/D February 28, 1996 is c/o
      Robert S. Levin, Esq., 180 N. LaSalle, Suite 3200, Chicago, Illinois
      60601.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Information
      is based on Amendment No. 2 to Schedule 13G dated February 14, 2007 filed with
      the SEC by The Pinnacle Fund, L.P. (&#8220;Pinnacle&#8221;) and Barry M. Kitt. Mr. Kitt may
      be deemed the beneficial owner of the shares by virtue of being the sole member
      of Pinnacle Fund Management, LLC, which is the general partner of Pinnacle
      Advisers, L.P., which is the general partner of Pinnacle. Mr. Kitt disclaims
      beneficial ownership of these shares. Include 68,700 shares issuable upon the
      exercise of a warrant presently exercisable. The address of Pinnacle and Mr.
      Kitt is 4965 Preston Park Blvd., Suite 240, Plano, Texas 75093.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Abengoa
      Bioenergy R&amp;D, Inc. has agreed to not dispose of these shares in whole or in
      part until November 8, 2007. Mr. Javier Salgado, President and Chief Executive
      Officer of Abengoa Bioenergy R&amp;D, Inc., has voting and investment power over
      the shares owned by Abengoa Bioenergy R&amp;D, Inc. The address of Abengoa
      Bioenergy R&amp;D, Inc., a Missouri corporation, is 1400 Elbridge Payne, Suite
      212, Chesterfield, Missouri 63017. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
      47,188 shares issuable upon the exercise of presently exercisable options held
      by Mr. Warner. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(6)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents
      shares issuable upon the exercise of options presently exercisable.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(7)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Includes
      144,633 shares issuable upon the exercise of options presently
      exercisable.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(8)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      named
      person is a director.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(9)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 13.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      named
      person is a named executive officer.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">50</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities
      Authorized For Issuance Under Equity Compensation Plans </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      following table provides information regarding the status of our existing equity
      compensation plans at December 31, 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

          <tr>
            <td valign="bottom" width="57%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Plan
                Category</strong></font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of securities to be issued upon exercise of outstanding options,
                warrants
                and rights</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted-average
                exercise price of outstanding options, warrants and
                rights</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                of securities remaining available for future
                issuance</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="57%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
                compensation plans approved by security holders (1) </font></div>
            </td>
            <td width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,961,911</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.12</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,197,940
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="57%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
                compensation plans not approved by security holders</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="57%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total</font></div>
            </td>
            <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,961,911</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
            </td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.12</font></div>
            </td>
            <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
            <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,197,940
                </font></div>
            </td>
            <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)
      Consists of Dyadic International, Inc. Amended and Restated 2001 Equity
      Compensation Plan and the 2006 Stock Option Plan, both of which plans were
      adopted by the Company&#8217;s Board of Directors in April 2006 and approved by
      stockholders at the 2006 annual stockholders&#8217; meeting in June 2006.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item12">ITEM
      12</a>. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
      DIRECTOR INDEPENDENCE.</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>&#160;</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
      Relationships and Related Transactions</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      President and Chief Executive Officer, Mark A. Emalfarb, is the trustee and
      beneficiary of the Mark A. Emalfarb Trust, which is our largest stockholder.
      The
      Mark A. Emalfarb Trust and our second largest stockholder, The Francisco Trust,
      whose sole beneficiaries are the spouse and descendants of Mr. Emalfarb, have
      made loans to Dyadic-Florida, which we assumed in connection with the Merger
      described under &#8220;Description of Business - Merger&#8221; in this report. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      of
      December 31, 2005, the aggregate amount of our indebtedness to the Mark A.
      Emalfarb Trust and The Francisco Trust was approximately $4.0 million, which
      was
      owed to them pursuant to the terms of three separate debt
      instruments:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$836,824
                pursuant to a promissory note made payable to the Mark A. Emalfarb
                Trust
                dated May 30, 2001, bearing interest at the rate of 6% per annum
                and
                originally convertible into shares of Dyadic common stock for the
                lesser
                of $4.50 or the conversion price of the Series A convertible preferred
                stock of Dyadic-Florida then outstanding, which we refer to as the
                Emalfarb Convertible Note. In connection with the Merger, the Emalfarb
                Convertible Note was amended to fix the conversion price at $3.33
                per
                share;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$741,048
                pursuant to a promissory note made payable to the Francisco Trust
                dated
                May 30, 2001, bearing interest at the rate of 6% per annum and originally
                convertible into shares convertible into shares of Dyadic common
                stock for
                the lesser of $4.50 or the conversion price of the Series A convertible
                preferred stock of Dyadic-Florida then outstanding, which we refer
                to as
                the Francisco Convertible Note. In connection with the Merger, the
                Francisco Convertible Note was amended to fix the conversion price
                at
                $3.33 per share; and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$2,424,941
                pursuant to a revolving note made payable to the Mark A. Emalfarb
                Trust
                dated May 29, 2003 and bearing interest at the rate of 8% per annum,
                secured by all of our assets, which we refer to as the Bridge Loan
                Note.
                In connection with the Bridge Loan Note, warrants, which we refer
                to as
                the Bridge Loan Warrants, were issued to purchase 1,500,000 shares
                of
                Dyadic-Florida common stock for the lesser of $4.50 or the conversion
                price of the Series A convertible preferred stock of Dyadic-Florida
                then
                outstanding, which we refer to as the Bridge Loan Warrants. In connection
                with Merger, the Bridge Loan Warrants were amended to fix their exercise
                price at $3.33 per share.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">51</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
        accrued and unpaid interest due under the Emalfarb Convertible Note, the
        Francisco Convertible Note and the Bridge Loan Note on the date of consummation
        of the Merger were added to the principal amount due under those notes. Interest
        under the notes accruing after October 29, 2004, is payable on a quarterly
        basis
        until the principal sum is paid in full.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        May 1,
        2006, the Mark A. Emalfarb Trust received 251,298 shares of common stock
        upon
        the conversion in full of the Emalfarb Convertible Note which had combined
        principal and accrued interest of $836,824 as of that date. On May 1, 2006,
        the
        Francisco Trust received 222,537 shares of common stock upon the conversion
        in
        full of the Francisco Convertible Note which had combined principal and accrued
        interest of $741,048 as of that date.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      April
      30, 2006, the then maturity date of the Bridge Loan was extended from January
      1,
      2007 to January 1, 2008. On March 21, 2007, the maturity date of the Bridge
      Loan
      was further extended from January 1, 2008 to January 1, 2009. As of December
      31,
      2006, we were indebted to the Mark A. Emalfarb Trust for approximately $2.4
      million under the Bridge Loan. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Director
      Independence</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      accordance with the American Stock Exchange corporate governance listing
      standards, it is our policy that the Board of Directors consists of a majority
      of independent directors. Our Board of Directors reviews the relationships
      that
      each director has with us and other parties. Only those directors who do not
      have any of the categorical relationships that preclude them from being
      independent within the independence requirements of the American Stock Exchange
      corporate governance listing standards and who the Board of Directors
      affirmatively determines have no relationships that would interfere with the
      exercise of independent judgment in carrying out the responsibilities of a
      director, are considered to be independent directors. The Board of Directors
      has
      reviewed a number of factors to evaluate the independence of each of its
      members. These factors include its members' current and historic relationships
      with us and our subsidiaries; their relationships with management and other
      directors; the relationships their current and former employers have with us
      and
      our subsidiaries; and the relationships between us and other companies of which
      our board members are directors or executive officers. After evaluating these
      factors, the Board of Directors has determined that four of its six members
      are
&#8220;independent&#8221; within the independence requirements of the American Stock
      Exchange corporate governance listing standards, all applicable rules and
      regulations of the SEC, and for purposes of Rule 162(m) of the Internal Revenue
      Code of 1986, as amended. These four directors are: Richard J. Berman, Robert
      B.
      Shapiro, Stephen J. Warner and Harry Z. Rosengart.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item13">ITEM
      13</a>. EXHIBITS </u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>A)&#160;&#160;</strong></font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Index
                to Exhibits</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="bottom" width="15%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibits</strong></font></div>
            </td>
            <td align="left" valign="bottom" width="63%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Description
                of Documents</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Agreement
                of Merger and Plan of Reorganization dated as of September 28, 2004
                by and
                among Dyadic International (USA), Inc. (f/k/a Dyadic International,
                Inc.),
                Dyadic International, Inc. (f/k/a CCP Worldwide, Inc.) and CCP Acquisition
                Corp. (1)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Split-Off
                Agreement dated September 28, 2004, by and among Dyadic International
                (USA), Inc. (f/k/a Dyadic International, Inc.), Dyadic International,
                Inc.
                (f/k/a CCP Worldwide, Inc.) and Custom Craft Packaging, Inc.
                (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.1
                </font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
                and Restated Certificate of Incorporation of Dyadic International,
                Inc.
                dated November 1, 2004 (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
                and Restated Bylaws of Dyadic International, Inc. dated November
                1, 2004
                (2) </font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Common Stock Certificate (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of $5.50 Common Stock Purchase Warrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.3</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Bridge Loan Warrants</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Stock Option representing aggregate right to purchase 65,000 shares
                of
                Common Stock (2)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">52</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.5
                </font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
                Purchase Agreement dated as of October 26, 2006 by and among Dyadic
                International, Inc. and Abengoa Bioenergy R&amp;D, Inc.
                (16)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.6</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
                Purchase Agreement dated as November 17, 2006 by and among Dyadic
                International, Inc. and the Investors signatories thereto
                (15)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.7</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Investor Warrant (15)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.8</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Placement Agent Warrant (16)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.1.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cooperation
                and License Agreement dated August 12, 2003 between Dyadic International
                (USA), Inc. (f/k/a Dyadic International, Inc.) and TNO Nutrition
                and Food
                Research Institute (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.1.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Termination
                and License Agreement dated December 19, 2005, effective November
                23, 2005
                between Dyadic International, Inc., Dyadic International (USA), Inc.,
                Dyadic Netherland, B.V., and TNO Quality of Life (formerly known
                as TNO
                Nutrition and Food Research Institute) (7)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Development
                Agreement dated July 30, 2004 between Dyadic International (USA),
                Inc.
                (f/k/a Dyadic International, Inc.) and Bio-Technical Resources Division
                of
                Arkion Life Sciences LLC (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.3</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commercial
                Land Purchase and Sale Agreement dated July 31, 2004 between Dyadic
                International (USA), Inc. (f/k/a Dyadic International, Inc.) and
                F&amp;C
                Holdings, LLC (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.4</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investors'
                Rights Agreement dated March 24, 2004 among the Mark A. Emalfarb
                Trust,
                the Francisco Trust, Dyadic International (USA), Inc. (f/k/a Dyadic
                International, Inc.) and other shareholders, as amended and assumed
                by
                Registrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.5.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                Agreement dated April 1, 2001 between Mark A. Emalfarb and Dyadic
                International (USA), Inc. (f/k/a Dyadic International, Inc.), as
                assumed
                by Registrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.5.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">First
                Amendment to Employment Agreement dated March 16, 2006 between Mark
                A.
                Emalfarb and Dyadic International, Inc. (9)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                Agreement dated March 30, 2005 between Ratnesh (Ray) Chandra and
                Dyadic
                International, Inc. (4)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                Agreement dated January 31, 2005 between Wayne Moor and Dyadic
                International, Inc. (6)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.3</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                Agreement dated March 30, 2005 between Alexander (Sasha) Bondar and
                Dyadic
                International, Inc. (4)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.4</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                Agreement dated March 30, 2005 between Kent Sproat and Dyadic
                International, Inc. (4)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.5</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                Agreement dated March 16, 2006 between Glenn Nedwin and Dyadic
                International, Inc. (9)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                Information, Inventions Assignment and Non-Compete Agreement dated
                May 21,
                2001 between Mark Emalfarb and Dyadic International (USA), Inc. (f/k/a
                Dyadic International, Inc.), as assumed by Registrant
                (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                Information, Inventions Assignment and Non-Compete Agreement dated
                May 21,
                2001 between Ray Chandra and Dyadic International (USA), Inc. (f/k/a
                Dyadic International, Inc.), as assumed by Registrant
                (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.3</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                Information, Inventions Assignment and Non-Compete Agreement dated
                May 21,
                2001 between Kent Sproat and Dyadic International (USA), Inc. (f/k/a
                Dyadic International, Inc.), as assumed by Registrant
                (2)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">53</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="15%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.4</font></div>
                </td>
                <td align="left" valign="top" width="63%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                    Information, Inventions Assignment and Non-Compete Agreement
                    dated
                    September 4, 2001 between Richard Burlingame, Ph.D. and Dyadic
                    International (USA), Inc. (f/k/a Dyadic International, Inc.),
                    as assumed
                    by Registrant (2)</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.5</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                Information, Inventions Assignment and Non-Compete Agreement dated
                May 21,
                2001 between Alexander (Sasha) Bondar and Dyadic International (USA),
                Inc.
                (f/k/a Dyadic International, Inc.), as assumed by Registrant
                (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                Agreement dated August 19, 2001 between Mark A. Emalfarb and Dyadic
                International (USA), Inc. (f/k/a Dyadic International, Inc.), as
                assumed
                by Registrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                Agreement dated August 19, 2001 between Stephen J. Warner and Dyadic
                International (USA), Inc. (f/k/a Dyadic International, Inc.), as
                assumed
                by Registrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.3</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                Agreement dated January 11, 2005 between Dyadic International, Inc.
                and
                Richard Berman (3)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.4</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                Agreement dated March 29, 2005 between Dyadic International, Inc.
                and
                Robert Shapiro (4)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.5</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                Agreement dated April 26, 2005 between Dyadic International, Inc.
                and
                Harry Rosengart (8)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
                International, Inc. Amended and Restated 2001 Equity Compensation
                Plan
                (12)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Standard
                form of Option Agreement for Dyadic International, Inc. Amended and
                Restated 2001 Equity Compensation Plan (14)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9.3</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Performance-Vested
                Stock Option Agreement for Dyadic International, Inc. Amended and
                Restated
                2001 Equity Compensation Plan granted to Glenn Nedwin
                (9)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.10.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
                International, Inc. 2006 Stock Option Plan (12)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.10.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Option Agreement for Dyadic International, Inc. 2006 Stock Option
                Plan
                (14)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.10.3</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Non-Employee Director Option Agreement for Dyadic International,
                Inc.
                2006 Stock Option Plan (14)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.11</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subordinated
                Promissory Note dated May 30, 2001 made by Dyadic International (USA),
                Inc. (f/k/a Dyadic International, Inc.), as amended, payable to the
                order
                of the Mark A. Emalfarb Trust in the original principal amount of
                $750,766, as assumed by Registrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.12</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subordinated
                Promissory Note dated May 30, 2001 made by Dyadic International (USA),
                Inc. (f/k/a Dyadic International, Inc.), as amended, payable to the
                order
                of the Francisco Trust in the original principal amount of $664,838,
                as
                assumed by Registrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.13.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revolving
                Note dated May 29, 2003 made by Dyadic International (USA), Inc.
                (f/k/a
                Dyadic International, Inc.), as amended, payable to the order of
                The Mark
                A. Emalfarb Trust in the original principal amount of $3,000,000,
                as
                assumed by Registrant (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.13.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Third
                Amendment dated April 30, 2006 to Revolving Note dated as of May
                29, 2003
                by and between Dyadic International, Inc. and The Mark A. Emalfarb
                Trust
                (11)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.14</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Security
                Agreement dated May 29, 2003, between the Mark A. Emalfarb Trust
                and
                Dyadic International (USA), Inc. (f/k/a Dyadic International, Inc.),
                as
                amended (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.15</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inducement
                and Amending Agreement dated August 19, 2004 among the Mark A. Emalfarb
                Trust, the Francisco Trust and Dyadic International (USA), Inc. (f/k/a
                Dyadic International, Inc.) (2)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">54</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.16</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contract
                Manufacturing Agreement dated October 27, 1999 between Polfa Tarchomin,
                SA
                and Dyadic International (USA), Inc. (f/k/a Dyadic International,
                Inc.),
                as amended by Amendments dated May 8, 2000 and February 10, 2004
                and
                letters dated February 11, 2004 (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.17</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                and Escrow Agreement dated September 28, 2004 among Vitel Ventures,
                Mark
                Tompkins, Registrant and Dyadic International (USA), Inc. (f/k/a
                Dyadic
                International, Inc.) (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.18</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                of Subscription Agreement from investors in private placement offering
                completed in early November 2004 (2)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.19</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Satisfaction
                and Purchase Agreement dated April 28, 2006 with an effective date
                of
                January 1, 2006 between Dyadic International, Inc. Agreement dated
                October
                21, 1998 among Geneva Investment Holdings Limited, Puridet (Asia)
                Limited,
                Robert Albert Smeaton and Raymond Tsang (13)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.20</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                Agreement dated as of September 28, 2004 among Dyadic International
                (USA),
                Inc. (f/k/a Dyadic International, Inc.), Dyadic International, Inc.
                (f/k/a
                CCP Worldwide, Inc.), Tom Shute, Roy Provencher and David R. Allison
                (5)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.21.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
                Purchase Agreement dated as of October 26, 2006 by and among Dyadic
                International, Inc. and Abengoa Bioenergy R&amp;D, Inc.
                (16)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.21.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">R&amp;D
                Agreement dated as of October 26, 2006 by and among Dyadic International
                (USA), Inc. and Abengoa Bioenergy R&amp;D, Inc. (17)+ </font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.22</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
                Purchase Agreement dated as November 17, 2006 by and among Dyadic
                International, Inc. and the Investors signatories thereto
                (15)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.23</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
                International, Inc. Statement of Director Compensation Policy
                (3)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Code
                of Ethics (10)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subsidiaries
                of the Registrant (17)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consent
                of Ernst &amp; Young LLP relating to Dyadic International, Inc.&#8217;s
                Registration Statements on Form&#160;S-8 (Registration No.&#160;333-122339
                and Registration No.&#160;333-136676) and Registration Statements on Form
                S-3 (Registration No. 333-121738 and Registration No. 333-139542)
                (17)
                </font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                of Chief Executive Officer pursuant to Section&#160;302 of the
                Sarbanes-Oxley Act of 2002 (17)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                of Chief Financial Officer pursuant to Section&#160;302 of the
                Sarbanes-Oxley Act of 2002 (17)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32.1</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                of Chief Executive Officer required by 18 U.S.C. Section 1350 (as
                adopted
                pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002)
                (17)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32.2</font></div>
            </td>
            <td align="left" valign="top" width="63%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                of Chief Financial Officer required by 18 U.S.C. Section 1350 (as
                adopted
                pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002)
                (17)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed September 30, 2004 with
                the Securities and Exchange
                Commission.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed November 4, 2004, as
                amended with the Securities and Exchange
                Commission.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed January 14, 2005 with the
                Securities and Exchange Commission.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">55</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                    by reference from the Company&#8217;s Form 8-K, filed April 1, 2005 with the
                    Securities and Exchange Commission.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 10-QSB Quarterly Report for the
                quarterly period ended September 30, 2004, filed November 15, 2004
                with
                the Securities and Exchange
                Commission.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(6)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed February 1, 2005 with the
                Securities and Exchange Commission.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(7)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed December 21, 2005 with the
                Securities and Exchange Commission.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(8)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed April 28, 2005 with the
                Securities and Exchange Commission.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(9)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed March 21, 2006 with the
                Securities and Exchange Commission.
</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 10-KSB for the year ended December
                31, 2004, filed April 15, 2005 with the Securities and Exchange
                Commission. </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(11)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 8-K, filed May 3, 2006 with the
                Securities and Exchange Commission.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(12)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s definitive Proxy Statement, filed April
                28, 2006 with the Securities and Exchange Commission, relating to
                the 2006
                annual stockholders&#8217; meeting.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(13)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Form 10-QSB for the quarterly period ended
                March 31, 2006, filed May 15, 2006 with the Securities and Exchange
                Commission.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(14)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Report on Form 8-K filed June 15, 2006
                with the Securities and Exchange
                Commission.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(15)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by referenced from the Company&#8217;s Form 8-K, filed November 21, 2006 with
                the Securities and Exchange
                Commission.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(16)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                by reference from the Company&#8217;s Registration Statement on Form S-3
                (Registration No. 333-139542).</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(17)&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed
                herewith.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">+
      Confidential treatment has been requested for portions of this
      document.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      management contract or compensation plan or arrangement required to be filed
      as
      an exhibit to this report pursuant to Item 13 is listed in exhibits 10.5.1,
      10.5.2, 10.6.1, 10.6.2, 10.6.3, 10.6.4, 10.6.5, 10.9.1, 10.9.2, 10.9.3, 10.10.1,
      10.10.2, 10.10.3 and 10.23.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="Item14">ITEM
      14</a>. PRINCIPAL ACCOUNTANT FEES AND
      SERVICES.</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Audit
      and Non-Audit Fees</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Audit
      Fees</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2006, Ernst &amp; Young LLP billed us $491,157 in the
      aggregate for professional services rendered for the audit of our consolidated
      statements, reviews of the financial statements included in our Quarterly
      Reports on Form 10-Q for the quarterly periods ended March 31, June 30 and
      September 30, 2006 and the review of our registration statement on Form S-3
      filed with the SEC in connection with the private placements completed in the
      fourth quarter of 2006 and review of our Form S-8 filed in connection with our
      2006 stock option plan.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      year ended December 31, 2005, Ernst &amp; Young LLP billed us $396,679 in the
      aggregate for professional services rendered for the audit of our consolidated
      statements, reviews of the financial statements included in our Quarterly
      Reports on Form 10-Q for the quarterly periods ended March 31, June 30 and
      September 30, 2005 and the review of our registration statement on Form S-3
      (formerly a registration statement on Form SB-2 filed with the SEC in connection
      with the Merger completed in October 2004</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">56</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Audit-Related
      Fees</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      years ended December 31, 2006 and 2005, Ernst &amp; Young LLP did not bill us
      for audit-related fees, as no other services were by performed by them during
      such years. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Tax
      Fees</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      years ended December 31, 2006 and 2005, Ernst &amp; Young LLP did not bill us
      for tax fees, as no tax services were performed by them during such years.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>All
      Other Fees</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      years ended December 31, 2006 and 2005, Ernst &amp; Young LLP billed us $1,500
      each year for other services. The audit committee has determined that the
      provision of services by the auditors reported hereunder had no impact on either
      of their independence.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Audit
      Committee&#8217;s Pre-Approval Policies and Procedures</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consistent
      with SEC policies regarding auditor independence, the audit committee is
      responsible for appointing, setting compensation and overseeing the work of
      the
      independent registered public accounting firm. In recognition of this
      responsibility, the audit committee has established a policy to pre-approve
      all
      audit and permissible non-audit services provided by the independent registered
      public accounting firm.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior
      to
      engagement of the independent registered public accounting firm for the next
      year&#8217;s audit, management will submit to the audit committee for approval the
      services expected to be rendered during that year for each of the four
      categories of services. Prior to engagement, the audit committee pre-approves
      these services by category of service. The fees are budgeted, and the audit
      committee requires the independent registered public accounting firm and
      management to report actual fees versus the budget periodically throughout
      the
      year by category of service. During the year, circumstances may arise when
      it
      may become necessary to engage the independent registered public accounting
      firm
      for additional services not contemplated in the original pre-approval. In those
      instances, the audit committee requires specific pre-approval before engaging
      the independent registered public accounting firm.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      audit
      committee may delegate pre-approval authority to one or more of its members.
      The
      member to whom such authority is delegated must report, for informational
      purposes only, any pre-approval decisions to the audit committee at its next
      scheduled meeting.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">57</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Sign">SIGN</a>ATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused
      this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      International, Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
      April 2, 2007</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 207pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>By:
      /s/ </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Mark
      A. Emalfarb</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 252pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
      A.
      Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 252pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
      Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>POWER
      OF ATTORNEY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      person whose signature appears below hereby constitutes and appoints Mark A.
      Emalfarb and Wayne Moor and each of them, his attorneys-in-fact, each with
      the
      power of substitution, for him and in his name, place and stead, in any and
      all
      capacities, to sign any and all amendments to this report on Form 10-KSB, and
      to
      file the same, with all exhibits thereto and all documents in connection
      therewith, with the Securities and Exchange Commission, granting unto said
      attorneys-in-fact and agents, and each of them full power and authority to
      do
      and perform each and every act and all intents and purposes as he might or
      could
      do in person, hereby ratifying and confirming all that such attorneys-in-fact
      and agents or any of them or his or their substitute or substitutes, may
      lawfully do or cause to be done by virtue hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      accordance with the Exchange Act, this report has been signed below by the
      following persons on behalf of the registrant and in the capacities and on
      the
      date indicated.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
      April 2, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Mark A. Emalfarb</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
      A.
      Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Principal
      Executive Officer, Chairman of the Board of Directors and President</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Glenn E. Nedwin</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glenn
      E.
      Nedwin </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Principal
      Scientific Officer, Executive Vice President and Director</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Wayne Moor</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wayne
      Moor </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Principal
      Financial and Accounting Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Stephen J. Warner</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stephen
      J. Warner </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
      Richard Berman</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Richard
      Berman</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Robert Shapiro</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Robert
      Shapiro</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
      Harry Rosengart</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Harry
      Rosengart </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">58</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
          of Contents</a></em></font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="Index_Fin_Stmt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INDEX
        TO CONSOLIDATED FINANCIAL STATEMENTS</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="80%">

            <tr>
              <td align="left" valign="top" width="68%">&#160;</td>
              <td valign="top" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Page</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">&#160;</td>
              <td valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Audrep">Report
                  of Independent Registered Public Accounting
                  Firm</a></font></div>
              </td>
              <td valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-1</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">&#160;</td>
              <td align="left" valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consolidated
                  Financial Statements: </font></div>
              </td>
              <td align="left" valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#BS">Consolidated
                  Balance Sheet - December 31,
                  2006</a></font></div>
              </td>
              <td valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-2</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">&#160;</td>
              <td align="left" valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#SOP">Consolidated
                  Statements of Operations - Years ended December
                  31, 2006 and 2005 </a></font></div>
              </td>
              <td valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-3</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">&#160;</td>
              <td align="left" valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a href="#Equity"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consolidated
                  Statements of Changes in Stockholders&#8217; Equity - Years ended December
                  </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31,
                  2006 and 2005</font></a></div>
              </td>
              <td valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-4</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">&#160;</td>
              <td align="left" valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Cashflow">Consolidated
                  Statements of Cash Flows - Years ended
                  December 31, 2006 and 2005</a></font></div>
              </td>
              <td valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-5</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">&#160;</td>
              <td align="left" valign="top" width="9%">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" width="68%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Notes">Notes
                  to Consolidated Financial
                  Statements</a></font></div>
              </td>
              <td valign="top" width="9%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-7</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">59</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="Audrep">Rep</a>ort
        of Independent Registered Public Accounting Firm
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Board
        of Directors and Shareholders </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
        International, Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        audited the accompanying consolidated balance sheet of Dyadic International,
        Inc. and subsidiaries (the Company) as of December 31, 2006, and the related
        consolidated statements of operations, stockholders&#8217; equity and cash flows for
        each of the two years in the period ended December 31, 2006. These financial
        statements are the responsibility of the Company&#8217;s management. Our
        responsibility is to express an opinion on these financial statements based
        on
        our audits.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        conducted our audits in accordance with the standards of the Public Company
        Oversight Board (United States). Those standards require that we plan and
        perform the audit to obtain reasonable assurance about whether the financial
        statements are free of material misstatement. We were not engaged to perform
        an
        audit of the Company&#8217;s internal control over financial reporting. Our audit
        included consideration of internal control over financial reporting as a
        basis
        for designing audit procedures that are appropriate in the circumstances,
        but
        not for the purpose of expressing an opinion on the effectiveness of the
        Company&#8217;s internal control over financial reporting. Accordingly, we express no
        such opinion. An audit also includes examining, on a test basis, evidence
        supporting the amounts and disclosures in the financial statements, assessing
        the accounting principles used and significant estimates made by management,
        and
        evaluating the overall financial statement presentation. We believe that
        our
        audits provide a reasonable basis for our opinion.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        our
        opinion, the financial statements referred to above present fairly, in all
        material respects, the consolidated financial position of Dyadic International,
        Inc. and subsidiaries at December 31, 2006, and the consolidated results
        of
        their operations and their cash flows for each of the two years in the period
        ended December 31, 2006, in conformity with U.S. generally accepted accounting
        principles.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        discussed in Note 2 to the consolidated financial statements, Dyadic
        International, Inc. changed its method of accounting for share-based payments
        in
        accordance with Statement of Financial Accounting Standards No. 123(R) (revised
        2004) on January 1, 2006.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 360pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 360pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
        Ernst
&amp;Young LLP</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certified
        Public Accountants</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">West
        Palm
        Beach, Florida</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">March
        28,
        2007</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br><br><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div style="WIDTH: 100%" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          </div>
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-1</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
          <div style="WIDTH: 100%" align="left">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Consolidated
        <a name="BS">Bal</a>ance Sheet</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>December
        31, 2006</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Assets</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current
                  assets:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                  and cash equivalents</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">31,072,824</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                  receivable, net of allowance for uncollectible accounts of
                  $240,490</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,788,588</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,039,080</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prepaid
                  expenses and other current assets</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,170,528</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  current assets</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">41,071,020</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fixed
                  assets, net</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,813,468</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible
                  assets, net</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">96,047</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Goodwill</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,808,458</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  assets</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">348,387</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  assets</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">45,137,380</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Liabilities
                  and stockholders&#8217; equity </strong></font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current
                  liabilities:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                  payable</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,238,585</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  expenses</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,905,382</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  interest payable to stockholders</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">48,897</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Short
                  term notes payable</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">191,125</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Income
                  taxes payable</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">26,730</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  current liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,410,719</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Long-term
                  liabilities:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note
                  payable to stockholder</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,378,832</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">160,808</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred
                  research and development obligation</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,997,863</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  long-term liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,537,603</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,948,222</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stockholders&#8217;
                  equity:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Preferred
                  stock, $.0001 par value:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Authorized
                  shares - 5,000,000; none issued and outstanding</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                  stock, $.001 par value,</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Authorized
                  shares - 100,000,000; issued and outstanding - 29,792,992</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">29,793</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional
                  paid-in capital</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">73,261,774</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes
                  receivable from exercise of stock options</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(212,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accumulated
                  deficit</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(44,889,909</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  stockholders&#8217; equity </font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,189,158</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  liabilities and stockholders&#8217; equity</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">45,137,380</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
        accompanying notes.</em></font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-2</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Consolidated
        <a name="SOP">Sta</a>tements of Operations</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="5" valign="bottom" width="25%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  sales</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,383,754</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,882,969</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
                  of goods sold</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  (includes non-cash share-based compensation of approximately $32,000
                  for
                  2006)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,345,144</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,856,607</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gross
                  profit</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,038,610</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,026,362</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating
                  Expenses:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                  and development</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  (includes non-cash share-based compensation of approximately $89,000
                  and
                  $19,000 for 2006 and 2005, respectively)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,236,448</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,655,486</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sales
                  and marketing </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(includes
                  non-cash share-based compensation of approximately $75,000 for
                  2006)</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,417,013</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,808,937</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General
                  and administrative </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(includes
                  non-cash share-based compensation of approximately $592,000 and
                  $58,000
                  for 2006 and 2005, respectively)</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7,149,005</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,564,619</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign
                  currency exchange gains, net</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(28,704</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(16,785</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  operating expenses</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">14,773,762</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">13,012,257</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                  from operations</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,735,152</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,985,895</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  income (expense):</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
                  expense</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(594,163</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(710,537</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment
                  income</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">504,894</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">249,280</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Minority
                  interest</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(13,355</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(4,725</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  income, net</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">18,696</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,535</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  other expense</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(83,928</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(464,447</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                  before income taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,819,080</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,450,342</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provision
                  for income taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">63,112</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">64,228</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,882,192</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss per common share:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                  </font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.45</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.45</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Weighted
                  average shares and equivalent shares used in </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">calculating
                  net loss per share:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,419,097</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,132,158</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,419,097</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,132,158</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
        accompanying notes.</em></font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-3</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Consolidated
        Statements of Changes in <a name="Equity">Stoc</a>kholders&#8217; Equity
</strong></font></div>
      <div>&#160;</div>
      <div><br>
        <div>
          <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

              <tr>
                <td valign="bottom" width="32%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td colspan="2" rowspan="3" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Note
                    Receivable</strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>From
                    Exercise </strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Of
                    Stock Options</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td colspan="2" rowspan="3" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Accumulated</strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Deficit</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td colspan="2" rowspan="3" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Total</strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stockholders&#8217;</strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Equity
                    </strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" width="32%" style="border-bottom: medium none;">&#160;</td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td colspan="5" valign="bottom" width="21%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Common
                    Stock</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="32%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amount</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Additional
                    Paid-in Capital</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                    at December 31, 2004</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">21,930,805
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">21,931</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">48,402,732</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(462,500</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(23,493,147</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,469,016</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                    of deferred compensation on </font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">nonemployee
                    stock options</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">76,673</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">76,673</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for consulting services</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,523</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">91,524</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">91,551</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for termination agreement</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">161,560</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">162</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">287,415</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">287,577</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for land purchase</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">300,300</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">300</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">861,561</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">861,861</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    loss</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                    at December 31, 2005</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,420,188</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,420</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">49,719,905</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(462,500</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(34,007,717</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,272,108</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock to officer per employment </font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Agreement</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,990</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">49,988</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">50,000</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for minority interest purchase </font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">212,501</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">212</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,327,919
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,328,131</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for exercise of stock options</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">339,950</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">340</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,348,062</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,348,402</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for exercise of warrants</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,205,124</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,205</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,551,829</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,553,034</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                    of deferred compensation on </font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">nonemployee
                    stock options</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">787,728</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">787,728</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for consulting services</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">205,652</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">206
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,063,254</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,063,460</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for share purchase agreement</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,136,752</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,137
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,137</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock and warrants in a private placement, net of expenses
                    of
                    $954,682</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,787,000</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,787</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,085,691</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,088,478</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Reduction
                    of notes receivable from exercise of stock option due to note
                    foreclosure</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(250,000</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">250,000</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                    of common stock for note conversion </font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">473,835</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">474</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,577,398</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,577,872</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #ffffff solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    loss</font></div>
                </td>
                <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,882,192</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,882,192</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#cceeff">
                <td align="left" valign="bottom" width="32%" style="border-bottom: #cceeff solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                    at December 31, 2006</font></div>
                </td>
                <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">29,792,992</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">29,793</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">73,261,774</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(212,500</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(44,889,909</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">28,189,158</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
        accompanying notes.</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-4</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Consolidated
        Statements of <a name="Cashflow">Cas</a>h Flows</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="5" valign="bottom" width="25%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Operating
                  activities</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,882,192</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adjustments
                  to reconcile net loss to net cash used in operating
                  activities:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
                  and amortization of fixed assets</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">250,181</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">534,594</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                  of intangible and other assets</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">52,128</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">68,136</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                  of costs related to modification of notes payable to
                  stockholder</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">325,027</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">371,136</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Minority
                  interest</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">13,355</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,725</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provision
                  for (recovery of) doubtful accounts</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(401,131</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">140,922</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
                  issued to officer</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">50,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
                  issued for consulting services</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,063,460</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">91,551</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Compensation
                  expense on stock option grants</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">787,728</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">76,673</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Changes
                  in operating assets and liabilities:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                  receivable</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">481,711</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">67,993</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(625,523</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,228,475</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prepaid
                  expenses and other current assets</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(365,900</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">21,521</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  assets</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(216,108</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">47,334</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                  payable</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(356,745</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(363,635</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  expenses</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">689,486</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">67,921</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  interest payable to stockholders</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(20,470</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">34,925</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred
                  research and development obligation</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,997,863</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(75,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Short
                  term notes payable</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(76,465</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">267,590</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Income
                  taxes payable</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(27,376</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">41,297</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">51,480</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">70,872</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  cash provided by (used in) operating activities</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">790,509</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(7,817,540</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investing
                  activities</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Purchases
                  of fixed assets, net</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(519,471</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(410,840</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Restricted
                  cash release (deposit) </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">34,887</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(34,658</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -6.15pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Purchase
                  of minority interest</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(375,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  cash used in investing activities</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(859,584</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(445,498</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Financing
                  activities</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proceeds
                  from sale of common stock, net of issuance costs</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,088,478</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Payment
                  of issuance costs related to private placement</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(97,764</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -6.15pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proceeds
                  from stock warrant exercises</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,553,034</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -6.15pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proceeds
                  from stock option exercises</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,348,402</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proceeds
                  of stock issuance for share purchase agreement</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,137</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  cash (used in) provided by financing activities</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">18,992,051</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(97,764</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  increase (decrease) in cash and cash equivalents</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">18,922,976</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(8,360,802</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                  and cash equivalents at beginning of year</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,149,848</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">20,510,650</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                  and cash equivalents at end of year</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">31,072,824</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,184,506</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Less
                  restricted cash</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(34,658</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unrestricted
                  cash and cash equivalents</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">31,072,824</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,149,848</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-5</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Supplemental
                  cash flow information:</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                  paid for interest </font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">269,135</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">298,214</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                  paid for income taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">196,996</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">30,710</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Noncash
                  activities:</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fair
                  value of common stock issued for minority interest
                  purchase</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,328,131</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                  stock issued for conversion of convertible notes payable to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">stockholders
                  at an exercise price of $3.33</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,577,872</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fair
                  value of common stock issued for land purchase</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">861,861</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                  stock issued for settlement of liability and termination of
                  agreement</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">287,577</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
        accompanying notes.</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-6</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="Notes"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Notes
        to Consolidated Financial Statements</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>December
        31, 2006</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1.
        Organization and Operations</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>General</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
        International, Inc., based in Jupiter, Florida, with operations in the United
        States, Hong Kong and mainland China, Poland and The Netherlands, is a global
        biotechnology company that uses its patented and proprietary technologies
        (the
&#8220;Dyadic Platform Technology&#8221;) to conduct research and development activities for
        the discovery, development, and manufacture of products and enabling solutions
        to the bioenergy, industrial enzyme and pharmaceutical industries. These
        enabling solutions primarily include:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novel,
                cost efficient production strains, enzyme mixes and related processes
                and
                manufacturing technologies currently in the research and development
                stage
                for producing abundant low cost fermentable sugars from agricultural
                residues and energy crops which may be used in the manufacturing
                of
                cellulosic ethanol, butanol, chemicals, chemical intermediates, polymers
                and other biomolecules of commercial interest, obviating the need
                for
                petroleum as a feedstock;</font></div>
            </td>
          </tr>

      </table>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Enzymes
                  and other biological products for a variety of industrial and commercial
                  applications. We currently sell more than 55 liquid and dry enzyme
                  products to more then 200 industrial customers in approximately
                  50
                  countries and we generated net sales of approximately $15.3 million
                  in
                  2006</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
                  and </font></div>
              </div>
            </td>
          </tr>

      </table>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Low-cost
                production hosts for therapeutic protein production for the
                biopharmaceutical industry.</font></div>
            </td>
          </tr>

      </table>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        more
        and more industries come to appreciate the financial, process efficiency,
        environmental and other advantages of applying biological solutions such
        as
        enzymes to their manufacturing processes in lieu of chemicals and other legacy
        technologies, the Company expects a variety of new market opportunities to
        emerge for which its anticipates it will be able to apply the Dyadic Platform
        Technology.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company expects to incur losses over the next several years as it continues
        to
        develop its technologies and establish the commercial laboratories and other
        required infrastructure to exploit these technologies. However, there can
        be no
        assurance that the Company's efforts with regard to these matters will be
        successful. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Organizational
        History</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        April
        2001, the Company formed Dyadic International Sp. z o.o., a Polish corporation,
        for the purpose of managing and coordinating the Company's contract
        manufacturing of industrial enzymes in Poland, and to assist in the marketing
        and distribution of those products. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        January 2004, the Company formed Dyadic Nederland B.V. (&#8220;Dyadic NL&#8221;), a Dutch
        corporation, for the development, use and marketing of HTS Systems utilizing
        fungal organisms. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        May
        2005, the Company issued 300,300 shares of common stock pursuant to a real
        estate purchase contract with F&amp;C Holdings, LLC dated July 31, 2004 (the
&#8220;Commercial Land Purchase And Sale Agreement&#8221;), in exchange for an undeveloped
        1.13 acre parcel of land (the &#8220;Site&#8221;). The Company formed Dyadic Real Estate
        Holdings, Inc., a Florida corporation and wholly owned subsidiary in May
        2005,
        to which it has assigned the Commercial Land Purchase and Sale Agreement
        and the
        Site.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        April
        28, 2006, the Company purchased the remaining 17.5% of shares held by the
        then
        two minority shareholders of its Asian subsidiary, giving the Company 100%
        ownership of that subsidiary. The former minority shareholders received $375,000
        in cash and 212,501 shares of unregistered Dyadic common stock in consideration
        for, among other things, the cancellation of the subordinated notes under
        which
        the Company owed the minority shareholders $171,986 of principal and $69,868
        of
        accrued interest; relief of the Company&#8217;s minority interest liability of
        approximately $117,000; and a release of the Company for a potential $405,000
        contingent obligation to the managing director incident to the Company&#8217;s
        purchase of its initial majority interest in the Asian Subsidiary in
        1998.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-7</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Merger
        </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior
        to
        October 2004, the Company was a public reporting company known as CCP Worldwide,
        Inc. In October 2004, the Company entered into an Agreement of Merger and
        Plan
        of Reorganization (the &#8220;Merger Agreement&#8221;) with Dyadic International (USA),
        Inc., a privately-held Florida corporation (formerly called Dyadic
        International, Inc.)("Dyadic-Florida") and a wholly-owned subsidiary of the
        Company formed by it for the purpose of being merged with and into
        Dyadic-Florida, CCP Worldwide, Inc. (the &#8220;Merger&#8221;). As a result of the Merger,
        CCP Acquisition Corp. was merged with and into Dyadic-Florida, all of the
        stockholders of Dyadic-Florida received, in exchange&#160;for&#160;all of the
        outstanding shares of Dyadic-Florida, shares of the Company on a one-for-one
        basis, making Dyadic-Florida a wholly-owned subsidiary of the Company, the
        Company changed its name to Dyadic International, Inc., and Dyadic-Florida
        changed its name to its existing name. For financial accounting purposes
        the
        Merger is treated as an acquisition by Dyadic-Florida of CCP Worldwide, Inc.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        part
        of, and immediately prior to the Merger, the Company disposed of its then
        only
        operating subsidiary as part of a Split-Off Agreement between Company, that
        then
        only operating subsidiary, and a former member of the Board of Directors
        of the
        Company. As a result of the Merger Agreement and the Split-Off Agreement,
        the
        only business operations of Dyadic International, Inc., formerly CCP Worldwide,
        Inc., are the operations of the Dyadic-Florida and its subsidiaries, and
        the
        Company&#8217;s real estate holding subsidiary, Dyadic Real Estate Holdings,
        Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
        Raising Activities</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        July
        2004, the Company completed a private offering of its common and preferred
        equity securities, and raised gross proceeds of $4,700,000. The equity
        securities were offered as an Investment Unit, with each unit consisting
        of two
        shares of common stock and one share of Series B Preferred Stock, at a price
        of
        $10 per unit. The Company used $1,500,000 of the proceeds from this offering
        to
        redeem all outstanding shares of Series A Preferred. After giving effect
        to the
        automatic conversion of the Series B Preferred Stock, a total of 1,422,099
        shares of common stock were issued in connection with the offering. As the
        Company completed an additional private offering of its common shares pursuant
        to the Private Offering Memorandum described below, the Company granted the
        purchasers of these Investment Units warrants to acquire a total of 711,050
        shares of the Company's common stock at $5.50 per share. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        November 2004, in accordance with Subscription Agreements and a Private Offering
        Memorandum (the October Offering) dated October 2004, the Company sold 7,629,204
        Investment Units, realizing gross proceeds of $25,405,249. An Investment
        Unit
        consists of one share of the Company's common stock and one five-year callable
        warrant to purchase one share of the Company's common stock at $5.50 per
        share
        for every two Investment Units purchased. Accordingly, 3,814,602 warrants
        to
        purchase the Company's common stock were issued to purchasers in the October
        Offering. Concurrently, the Company issued 247,730 warrants to purchase the
        Company's common stock at $5.50 per share and 495,460 warrants to purchase
        the
        Company's common stock at $3.33 per share, both to placement agents in the
        October Offering. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company incurred $2,727,573 of costs related to the October Offering and
        the
        Merger, including the subsequent registration with the Securities and Exchange
        Commission (&#8220;SEC&#8221;) of the Company's shares issued in the Merger and the October
        Offering. These costs are included as a reduction of additional paid-in capital.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        October 26, 2006, the Company entered into a securities purchase agreement
        (the
&#8220;Abengoa Securities Purchase Agreement&#8221;) with Abengoa Bioenergy R&amp;D, Inc.
        (&#8220;Abengoa&#8221;), a subsidiary of Abengoa S.A.. Also on October 26, 2006,
        Dyadic-Florida entered into a non-exclusive research and development agreement
        with Abengoa pertaining to the conduct of a research and development (&#8220;R&amp;D&#8221;)
        program to be completed over a period of up to three and one-half years,
        under
        which Dyadic-Florida will seek to apply its proprietary technologies to the
        development of cost-effective enzyme mixtures and related processing and
        manufacturing technologies for commercial application in Abengoa&#8217;s bioethanol
        (cellulosic ethanol) production process (the &#8220;R&amp;D Agreement&#8221;). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
        the
        terms of the Abengoa Securities Purchase Agreement, Abengoa paid the Company
        $10,000,000, for which it was issued 2,136,752 shares of the Company&#8217;s common
        stock at $4.68 per share (the closing share price on October 25, 2006, as
        reported on the American Stock Exchange). The Company completed this transaction
        on November 8, 2006. Under certain circumstances, as described below, Dyadic
        may
        have to issue additional securities to Abengoa. As of December 31, 2006,
        unused
        proceeds of approximately $9,998,000 are recorded as deferred research and
        development obligation in the accompanying consolidated financial statements
        and
        will be recognized as revenue as the expenses associated with the R&amp;D
        program described above are incurred. If Abengoa sells all or a portion of
        its
        Dyadic shares of common stock after a one-year required holding period, the
        then
        remaining deferred research and development obligation balance will be reduced
        by Abengoa&#8217;s profit from the sale of those common stock shares and will be
        recorded as other income. The costs incurred in connection with the Abengoa
        Securities Purchase Agreement are included in other assets at December 31,
        2006
        and will be amortized in relation to the revenue recognized under the deferred
        research and development obligation.</font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-8</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        within
        six months following the date of closing the Company has not entered into
        a
        specified type of transaction involving the sale of its securities totaling
        at
        least $20,000,000 in gross proceeds, then Abengoa is entitled to receive
        three-year warrants to purchase 427,351 shares at an exercise price of $5.85.
        If
        the sale of securities totaling at least $20,000,000 is at a price lower
        than
        $4.68 per share, Abengoa is entitled to have additional shares issued to
        them so
        that their investment is at the same price. If the sale of securities includes
        warrants, Abengoa&#8217;s pro rata warrant coverage and other warrant terms are to be
        the same as those in the securities transaction rather than the warrant terms
        discussed above.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
        under the Abengoa Securities Purchase Agreement, the Company has agreed to
        use
        the $10,000,000 to fund its performance of certain foundational and applications
        research in the cellulosic ethanol field and to spend not less than $10,000,000
        (the &#8220;R&amp;D Spending Obligation&#8221;) over the course of the &#8220;R&amp;D Spend
        Measurement Period&#8221; (the period commencing on the Agreement Date and ending
        three years following Steering Committee approval of the initial Statement
        of
        Work for calendar year 2007). If the Company breaches its R&amp;D Spending
        Obligation, in addition to certain royalty-free, non-exclusive licensing
        rights
        which would be granted to Abengoa, the Company is obligated, at Abengoa&#8217;s
        election, to either (x) issue Additional Shares or (y) remit to Abengoa a
        cash
        sum, in either instance having a dollar value equal to the amount by which
        $10,000,000 exceeds the dollar value of the Applicable R&amp;D Spend (the amount
        so expended by Dyadic to perform such research described above), and if shares
        are used, they are valued at the greater of (x) $4.68 per share or (y) the
        closing selling price of the shares on the AMEX on the last trading day in
        the
        R&amp;D Spend Measurement Period. The Company has agreed to guarantee
        Dyadic-Florida&#8217;s punctual payment and performance of its obligations to Abengoa
        under the R&amp;D Agreement. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        shares issued to Abengoa at closing were not registered under the Securities
        Act
        of 1933 (the &#8220;Securities Act&#8221;). Pursuant to the Abengoa Securities Purchase
        Agreement, the Company filed a registration statement with the SEC covering
        the
        resale of the shares issued at closing, as well as additional shares, if
        any,
        issuable after closing. The Company filed the registration statement with
        the
        SEC on December 21, 2006 and the SEC declared the registration statement
        effective on January 17, 2007. The Company is required to keep the registration
        statement effective until the earlier of the date on which the shares have
        been
        sold or can be sold publicly under Rule 144(k) of the Securities Act. The
        Company may suspend the use of the registration statement for a 20-day trading
        period for as many as two times in any 12-month period. In the event the
        registration statement ceases to be effective during the registration period
        due
        to certain events, the Company has agreed to pay to Abengoa cash, as liquidated
        damages, equal to 1% of (x) the number of shares held by Abengoa at time
        of such
        event and (y) the purchase price paid by Abengoa for such shares then held,
        provided that the total amount of all of these payments is not permitted
        to
        exceed 10% of the aggregate purchase price paid by Abengoa. Abengoa shall
        not be
        entitled to liquidated damages if an event causes the registration statement
        to
        cease being effective before the first anniversary of the closing
        date.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
        the
        Abengoa Securities Purchase Agreement, Abengoa has agreed for a period of
        one
        year following the closing date to maintain exclusive beneficial ownership
        of,
        as well as an exclusive pecuniary interest in, all of the shares and other
        securities, if any, issuable to it pursuant to the Abengoa Securities Purchase
        Agreement. Furthermore, Abengoa has agreed for a period of two years following
        the closing date to refrain from directly or indirectly increasing its
        beneficial ownership, or pecuniary interest, in more than 15% of the Company&#8217;s
        shares. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        November 17, 2006, the Company entered into a securities purchase agreement
        (the
&#8220;Securities Purchase Agreement&#8221;) with certain investors to purchase in a private
        placement 2,787,000 shares of its common stock at a price of $4.68 per share
        and
        warrants to purchase up to 557,400 shares of its common stock at an exercise
        price of $6.33 per share for gross proceeds of $13,043,160. The Company
        completed this private placement on December 1, 2006. Cowen and Company,
        LLC
        acted as the exclusive placement agent for the private placement for which
        Dyadic issued to it warrants to purchase up to 83,610 shares of its common
        stock
        at $5.24 per share and warrants to purchase up to 16,722 shares of its common
        stock at $6.33 per share. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        warrants issued to the investors become exercisable on May 31, 2007, expire
        three years thereafter, contain price adjustment and economic anti-dilution
        features, as well as anti-dilution protection from stock splits and similar
        events, contain limited cashless exercise procedures and are callable by
        the
        Company under certain circumstances. The warrants issued to the placement
        agent
        are substantially identical to the warrants issued to the investors, except
        that
        (i) the warrant for 83,610 shares has an exercise price of $5.24 per share
        rather than $6.33 per share and (ii) they have a five-year term rather than
        a
        three-year term and (iii) they provide for unqualified cashless exercise
        procedures rather than limited cashless exercise procedures. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company will use the resulting net proceeds of approximately $12,100,000
        to
        continue development of the Dyadic Platform Technology for applications in
        the
        markets targeted by its businesses, with the goal of strengthening its product
        pipeline and accelerating the commercial launch of new products in pulp and
        paper, animal feed and other areas, and expanding R&amp;D infrastructure as well
        as sales and marketing efforts. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Historical
        Results of Operations </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-9</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company has incurred losses from operations during the last several years,
        which
        have resulted in an accumulated deficit of approximately $44,890,000 as of
        December 31, 2006. The Company attributes these operating results to
        discretionary research and development expenditures to improve the Dyadic
        Platform Technology which may have utility across broad and as of yet, untapped
        markets. Operating losses have also been the result of the expansion of the
        Company&#8217;s operations and administrative support staff as a public company
        engaged in enzyme biotech research, and its increased sales and marketing
        spending to expose new products to the marketplace. In order to advance its
        science and to develop new products, the Company has continued to incur
        discretionary research and development expenditures during 2006. The Company
        believes these discretionary research and development expenditures will continue
        in 2007 and beyond.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company believes that there will be sufficient capital to fund its operations
        and meet its obligations for the next twelve months and beyond. The Company
        has
        established a number of flexible contractual relationships in the areas of
        manufacturing and research and development, enabling it to adjust spending
        in
        those areas as necessary, to achieve the objectives of its business plan,
        and
        manage both its resources and cash utilization rate. The Company has
        historically funded losses from operations with proceeds from external
        borrowings, borrowings from its stockholders, collaborations with third parties,
        exercises and conversions of equity instruments, and sales of preferred and
        common equity securities. Additional funds may be needed and raised through
        public or private debt and/or equity financings or a combination of the
        foregoing, or licensing or selling of certain technologies or other
        arrangements. Additional funding, if sought, may not be available at all,
        or may
        not be available on terms acceptable to the Company. Further, any additional
        equity financing may be dilutive to stockholders, and debt financing, if
        available, may involve restrictive covenants. Failure to raise capital when
        needed may harm the Company&#8217;s operations, financial condition and cash flows.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.
        Summary of Significant Accounting Policies</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Principles
        of Consolidation</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        accompanying consolidated financial statements include the accounts of the
        Company and its wholly owned subsidiaries. All significant intercompany
        transactions and balances have been eliminated in consolidation. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Cash
        and Cash Equivalents</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company considers as cash equivalents all interest-bearing deposits or
        investments with original maturities of three months or less when purchased.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounts
        Receivable</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
        receivable are recorded at their net realizable value on the date revenue
        is
        recognized. The Company provides allowances for doubtful accounts for estimated
        losses resulting from the inability of its customers to repay their obligation.
        If the financial condition of the Company's customers were to deteriorate,
        resulting in an impairment of their ability to repay, additional allowances
        may
        be required. The Company provides for potential uncollectible accounts
        receivable based on specific customer identification and historical collection
        experience adjusted for existing market conditions. If market conditions
        decline, actual collection experience may not meet expectations and may result
        in decreased cash flows and increased bad debt expense. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        policy for determining past due status is based on the contractual payment
        terms
        of each customer, which are generally net 30, 60 or 90 days. Once collection
        efforts by the Company and its collection agency are exhausted, the
        determination for charging off uncollectible receivables is made. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Inventory</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory
        consists of raw materials and finished goods, including industrial enzymes
        used
        in the industrial, chemical and agricultural markets, and is stated at the
        lower
        of cost or market using the average cost method. The value of finished goods
        is
        comprised of raw materials and manufacturing costs, substantially all of
        which
        are incurred pursuant to agreements with independent manufacturers. Provisions
        have been made to reduce excess or obsolete inventory to net realizable
        value.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        December 31, 2006, inventories consisted of the following:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Finished
                  goods</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,711,316</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Raw
                  materials</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,327,764</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,039,080</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-10</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Fixed
        Assets</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fixed
        assets are recorded at cost and depreciated and amortized using the
        straight-line method over their estimated useful lives, which range from
        three
        to ten years. Leasehold improvements are amortized over the lesser of their
        useful lives or the lease terms. Upon sale or retirement, the cost and related
        accumulated depreciation and amortization are eliminated from their respective
        accounts, and the resulting gain or loss is included in results of operations.
        Repairs and maintenance charges, which do not increase the useful lives of
        the
        assets, are charged to operations as incurred.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Intangible
        Assets</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible
        assets include patent and technology acquisition costs which are being amortized
        using the straight-line method over the twelve-year terms of the patents.
        No
        additional costs related to the patents and technology were incurred and
        capitalized in 2006 or 2005. The original value of intangible assets of $541,358
        is presented net of accumulated amortization of $445,311 as of December 31,
        2006, and amortization expense was $52,128 for each of the years ended December
        31, 2006 and 2005. Amortization expense will be approximately $52,000 in
        2007
        and approximately $44,000 in 2008, when these intangible assets will become
        fully amortized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Goodwill</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
        apply
        the provisions of Statement of Financial Accounting Standards (SFAS) No.142,
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Goodwill
        and Other Intangible Assets </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SFAS
        142)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        the
        Company is required to identify its reporting units. Based on an analysis
        of
        economic characteristics and how the Company operates its business, the Company
        has designated its geographic locations as its reporting units: the United
        States (which includes the Company's subsidiary in Poland), The Netherlands,
        Hong Kong and mainland China. All goodwill is associated with the Hong Kong
        reporting unit.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        April
        28, 2006, the Company and its then 82.5% majority owned Asian Subsidiary
        entered
        into a satisfaction and purchase agreement with the Asian Subsidiary&#8217;s then two
        minority shareholders, its managing director and one of its other key employees,
        effective as of January 1, 2006. The minority shareholders received $375,000
        in
        cash and 212,501 shares of unregistered common stock of the Company in
        consideration for: (i) the transfer to the Company of all of the Asian
        Subsidiary&#8217;s shares (representing 17.5% of its outstanding shares) held by the
        minority shareholders, bringing the Company&#8217;s ownership in the Asian Subsidiary
        to 100% and relieving the Company&#8217;s minority interest liability of approximately
        $117,000; (ii) a release of the Company for, among other things, a potential
        $405,000 contingent obligation to the managing director incident to the
        Company&#8217;s purchase of its initial majority interest in the Asian Subsidiary in
        1998; and (iii) the cancellation of all indebtedness of the Asian Subsidiary
        owed to the minority shareholders in the amount of approximately $172,000
        of
        principal and $70,000 of accrued interest, as of the effective date. The
        Company&#8217;s shares were valued at approximately $1,328,000 based on the fair
        market value of the Company&#8217;s common stock on April 28, 2006, the measurement
        date for accounting purposes. The Company recorded approximately $1,341,000
        of
        goodwill related to the transaction, bringing the net goodwill balance at
        December 31, 2006 to approximately $1,808,000, which is reflected in the
        accompanying consolidated balance sheet. Effective May 1, 2006, the Company
        is
        recording 100% of the Asian Subsidiary&#8217;s operating results in the accompanying
        consolidated statements of operations. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        accordance with the provisions of SFAS 142, the Company performed an impairment
        review of its goodwill. This test involved the use of estimates to determine
        the
        fair value of the Company's Asian reporting unit and the comparison of fair
        value to the carrying value of the reporting unit. The impairment review
        resulted in no goodwill impairment charge. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Long-Lived
        Assets</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company reviews its long-lived assets, including fixed assets that are held
        and
        used in its operations, for impairment whenever events or changes in
        circumstances indicate that the carrying amount of the asset may not be
        recoverable, as required by SFAS 144. If such an event or change in
        circumstances is present, the Company will estimate the undiscounted future
        cash
        flows, less the future outflows necessary to obtain those inflows, expected
        to
        result from the use of the asset and its eventual disposition. If the sum
        of the
        undiscounted future cash flows is less than the carrying amount of the related
        assets, the Company will recognize an impairment loss to the extent the carrying
        value exceeds the fair value. The Company records impairment losses resulting
        from abandonment in loss from operations. Assets to be disposed of are
        reclassified as assets held for sale at the lower of their carrying amount
        or
        fair value less costs to sell. Write-downs to fair value less costs to sell
        are
        reported above the loss from operations line as general and administrative
        expenses. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company does not believe that the there were any events or changes in
        circumstances that indicate that the carrying amounts of its long-lived assets
        may not be recoverable as of December 31, 2006.</font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-11</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Advertising
        Costs</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Advertising
        costs are expensed as incurred. During the years ended December 31, 2006
        and
        2005, advertising costs incurred by the Company totaled approximately $18,000
        and $13,000, respectively, and are included in sales and marketing expenses
        in
        the accompanying consolidated statements of operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Research
        and Development</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
        and development costs related to both present and future products are charged
        to
        operations when incurred. Revenue received for research and development is
        recognized as the Company meets its obligations under the related agreement.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
        and development costs incurred by type of project during the years ended
        December 31, 2006 and 2005 were as follows:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Internal
                  development</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,326,303</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,949,712</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Collaborations</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,910,145</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,705,774</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,236,448</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,655,486</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
        and development costs based upon type of cost incurred during the years ended
        December 31, 2006 and 2005 were as follows:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Personnel
                  related</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">807,071</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,074,383</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Laboratory
                  and supplies</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">132,033
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">204,901
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outside
                  services</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,910,145
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,705,774
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equipment
                  and depreciation</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">29,300
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">431,516
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facilities,
                  overhead and other</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">357,899
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">238,913
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">&#160;</td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,236,448</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,655,486</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company recognized $12,500 and $150,000 in research and development revenue
        for
        the years ended December 31, 2006 and 2005, respectively, which is included
        in
        net sales in the accompanying consolidated statement of operations. For the
        Company&#8217;s recognition of revenues under the R&amp;D Agreement with Abengoa, see
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Revenue
        Recognition</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
        below.</font></div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Income
        Taxes</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company accounts for income taxes using the liability method. Under this
        method,
        deferred tax assets and liabilities are determined based on the difference
        between the financial statement and tax bases of assets and liabilities,
        using
        enacted tax rates in effect for the year in which the differences are expected
        to reverse. A deferred tax valuation allowance is established if, in
        management's opinion, it is more likely than not that all or a portion of
        the
        Company's deferred tax assets will not be realized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Net
        Loss Per Share</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
        and
        diluted net loss per share have been computed using the weighted-average
        number
        of shares of common stock outstanding during the periods presented.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        following potentially dilutive securities were not included in the calculation
        of diluted net loss per share as they were anti-dilutive for the respective
        periods presented: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-12</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="5" valign="bottom" width="25%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Instruments
                  to purchase common stock:</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
                  options outstanding pursuant to the Amended and Restated 2001 </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
                  Compensation Plan (see Note 9) </font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,956,911</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,597,639
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
                  options outstanding pursuant to the 2006 Stock Option Plan </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(see
                  Note 9) </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  stock options </font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">65,000
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Warrants
                  outstanding (see Note 8) </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,405,384
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,952,776
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                    stock issuable pursuant to conversion features related to subordinated

                    convertible notes payable</font></div>
                </div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">473,835</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  shares of common stock considered anti-dilutive </font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,367,295</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,089,250</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
        are
        contingently issuable shares under an agreement to conduct research and
        development activities on behalf of the Company pursuant to the arrangement
        described in Note 8 Share-Based Compensation - Issuances of Common Stock,of
        which 87,125 and 292,777 are also excluded from the calculation of diluted
        net
        loss per share for the years ended December 31, 2006 and 2005, respectively.
        Such shares of common stock are unearned, nonvested, restricted shares that
        will
        be considered outstanding once earned under the agreement. As of December
        31,
        2006 and 2005, 213,175 and 7,523 shares were earned and outstanding,
        respectively. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Revenue
        Recognition</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company recognizes revenues in accordance with Staff Accounting Bulletin
        (SAB)
        No. 104, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Revenue
        Recognition in Financial Statements </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SAB
        104). SAB 104 sets forth four basic criteria that must be met before SEC
        registrants can recognize revenue. These criteria are: persuasive evidence
        of an
        arrangement must exist; delivery had to have taken place or services had
        to have
        been rendered; the seller's price to the buyer should be fixed or determinable;
        and collectibility of the receivable should be reasonably assured. Sales
        not
        meeting any of the aforementioned criteria are deferred. The Company recognizes
        revenue when title passes to the customer, based upon the specified freight
        terms for the respective sale. Sales are comprised of gross revenues less
        provisions for expected customer returns, if any. Reserves for estimated
        returns
        and inventory credits are established by the Company, if necessary, concurrently
        with the recognition of revenue. The amounts of reserves are established
        based
        upon consideration of a variety of factors, including estimates based on
        historical returns. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues
        under the R&amp;D Agreement with Abengoa are recognized in accordance with SAB
        104 and Emerging Issues Task Force (&#8220;EITF&#8221;) Issue No.&#160;99-19, Reporting
        Gross Revenue as a Principal vs. Net as an Agent. According to the criteria
        established by EITF Issue No.&#160;99-19, the Company is the primary obligor of
        the agreement because it is responsible for the selection, negotiation,
        contracting and payment of the third party suppliers. In addition, any
        liabilities resulting from the agreement are the responsibility of the Company.
        Research and development revenues are recognized, on a gross basis, as
        activities are performed under the terms of the related agreement. As of
        December&#160;31, 2006, the Company had approximately $9,998,000 in deferred
        research and development obligation which was related to the Abengoa agreement.
        This amount will be recognized as revenue as the expenses associated with
        the
        R&amp;D program contemplated by the R&amp;D Agreement between Abengoa and the
        Company are incurred. If Abengoa sells all or a portion of its Dyadic shares
        of
        common stock after a one-year required holding period, the then remaining
        deferred research and development obligation balance will be reduced by
        Abengoa&#8217;s profit from the sale of those common stock shares and will be recorded
        as other income. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts
        billed to customers in sales transactions related to shipping and handling,
        represent revenues earned for the goods provided and are included in net
        sales.
        Costs of shipping and handling are included in cost of products
        sold.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Foreign
        Currency Translation</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        financial statements of the Company's foreign subsidiaries have been translated
        into United States dollars in accordance with SFAS No. 52, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Foreign
        Currency Translation</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        Assets
        and liabilities of the Company's foreign subsidiaries are translated at
        period-end exchange rates, and revenues and expenses are translated at average
        rates prevailing during the period. Certain accounts receivable from customers
        are collected and certain accounts payable to vendors are payable in currencies
        other than the functional currencies of the Company and its subsidiaries.
        These
        amounts are adjusted to reflect period-end exchange rates. Net translation
        adjustments and realized exchange gains and losses are included as a component
        of foreign currency exchange gains, net, in the accompanying consolidated
        statements of operations. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-13</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reclassifications</em></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
          prior year amounts have been reclassified to conform to the current year
          presentation. These reclassifications had no effect on net loss as previously
          reported or net loss per common share.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Share-based
        Compensation</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        January 2006, the Company adopted SFAS 123(R), </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Share-Based
        Payment </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(&#8220;SFAS
        123(R)&#8221;), which is a revision of SFAS 123, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for Share-based Compensation</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        SFAS
        123(R) supersedes Accounting Principles Board Opinion (&#8220;APB&#8221;) No. 25,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for Stock Issued to Employees </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(APB
        25)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        and
        amends SFAS No. 95, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Statement
        of Cash Flows</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        Generally, the approach in SFAS 123(R) is similar to the approach described
        in
        SFAS 123. However, SFAS 123(R) requires all share-based payments to employees
        and non-employee directors, including grants of employee stock options, to
        be
        recognized in the consolidated statements of operations based on their fair
        values. Pro forma disclosure, which has previously been used by the Company,
        is
        no longer an alternative. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company adopted the fair value recognition provisions of SFAS 123(R), using
        the
        modified prospective transition method. Under this transition method,
        compensation expense includes options vesting for share-based payments granted
        prior to, but not vested as of December 31, 2005, based on the grant date
        fair
        value estimated in accordance with the original provisions of SFAS 123 and
        share-based payments granted after December 31, 2005, based on the grant
        date
        fair value estimated in accordance with the provisions of SFAS 123(R). Because
        this transition method was selected, results of prior periods have not been
        restated. For the year ended December&#160;31, 2006, the Company recorded
        approximately $788,000 of employee non-cash share-based compensation expense.
        As
        a result of adopting SFAS 123(R), the Company&#8217;s net loss per share increased
        $(0.03) for the year ended December&#160;31, 2006. The Company has a net
        operating loss carryforward as of December&#160;31, 2006 and therefore, no
        excess tax benefits for tax deductions related to the stock options were
        recognized. As of December&#160;31, 2006, unamortized non-cash share-based
        compensation expenses of approximately $2,000,000 remain to be recognized
        over a
        weighted average period of approximately three years.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior
        to
        January 1, 2006, the Company accounted for share-based employee compensation
        plans using the intrinsic value method of accounting in accordance with APB
        25
        and its related interpretations. Under the provisions of APB 25, no compensation
        expense was recognized when stock options were granted with exercise prices
        equal to or greater than market value on the date of grant. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        December 15, 2005, the Board of Directors of the Company approved the
        acceleration of vesting for the unvested portion of all outstanding stock
        options awarded to employee and non-employee directors of the Company from
        May
        2001 to December 15, 2005 under the 2001 Equity Compensation Plan, as amended
        (the &#8220;2001 Equity Plan&#8221;). While the Company typically issues options that vest
        equally over four years, as a result of this vesting acceleration, stock
        options
        to purchase approximately 1,200,000 shares of the Company&#8217;s common stock, of
        which approximately 600,000 were then held by the Company&#8217;s executive officers
        and non-employee directors, became immediately exercisable. The exercise
        prices
        of the affected stock options ranged from $1.90 to $5.93 and the closing
        price
        of the Company&#8217;s common stock on December 15, 2005, was $1.75.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        purpose of the accelerated vesting was to provide a non-cash benefit to the
        Company&#8217;s employees and to eliminate future compensation expense the Company
        would otherwise recognize in its consolidated statements of operations with
        respect to these accelerated options upon the adoption of SFAS 123(R). The
        estimated future compensation expense associated with these accelerated options
        that would have been recognized in the Company&#8217;s consolidated statements of
        operations upon implementation of SFAS 123(R) is approximately $1,300,000.
        All
        option grants made on and after January 1, 2006 are accounted for in accordance
        with SFAS 123(R).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
        options and warrants issued to consultants and other non-employees as
        compensation for services provided to the Company are accounted for based
        on the
        fair</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">value
        of
        the services provided or the estimated fair market value of the option or
        warrant, whichever is more reliably measurable in accordance with SFAS 123
        and
        EITF 96-18, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for Equity Investments That are Issued to Other Than Employees for Acquiring
        or
        in Conjunction with Selling Goods or Services,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        including related amendments and interpretations. The related expense is
        recognized over the period the services are provided.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        following table sets forth the pro forma disclosure of the Company&#8217;s net loss
        and net loss per share for the prior year ended December 31, 2005 assuming
        the
        estimated fair value of the options were calculated pursuant to SFAS 123(R)
        and
        amortized to expense over the option-vesting period: </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-14</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">
                <div align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended </strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>December
                  31, 2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss applicable to holders of common stock, as reported for basic
                  and
                  diluted calculations</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deduct:
                  Total share-based employee compensation expense determined under
                  fair
                  value based method for all awards &#160;</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,599,134</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pro
                  forma net loss applicable to holders of common stock, basic and
                  diluted
                  calculations </font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(12,113,704</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                  and diluted net loss per common share, as reported</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                  and diluted pro forma net loss per common share</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.55</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>

        </table>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">&#160;</div>
        <div id="HDR">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        fair
        value for these options (which are granted with an exercise price equal to
        fair
        market value on the grant date) was estimated using the Black-Scholes option
        valuation model with the following weighted average assumptions:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>December
                  31, 2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Average
                  Risk-Free Interest Rate</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.00</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dividend
                  Yield</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Average
                  Volatility Factor</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">50</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Average
                  Option Life</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5
                  Yrs</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Credit
        Risk</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Financial
        instruments which potentially subject the Company to concentrations of credit
        risk include cash and cash equivalents and accounts receivable (see Note
        3). The
        Company invests its excess cash in money market funds. The money market funds
        represent an interest in low risk U.S. Government obligations. The Company's
        investments are not insured or guaranteed by the U.S. Government, the Federal
        Deposit Insurance Corporation or any other government agency. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Use
        of Estimates</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        preparation of financial statements in conformity with accounting principles
        generally accepted in the United States requires management to make estimates
        and assumptions that affect the amounts reported in the consolidated financial
        statements. Actual results could differ from those estimates.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reporting
        Comprehensive Loss</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Comprehensive
        loss is defined as the change in equity of a business enterprise during a
        period
        from transactions and other events and circumstances, except for those resulting
        from investments by owners and distributions to owners. The presentation
        of
        comprehensive loss required by SFAS No. 130, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reporting
        Comprehensive Income</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        is not
        required in the accompanying consolidated financial statements as the Company
        has no material components of accumulated other comprehensive loss.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Fair
        Value of Financial Instruments</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company uses various methods and assumptions to estimate the fair value of
        each
        class of financial instrument. Due to their short-term nature and measurement,
        the carrying value of cash and cash equivalents, accounts receivable, accounts
        payable and notes payable approximate fair value. The Company's other financial
        instruments are not significant.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Recent
        Accounting Pronouncements</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-15</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        February&#160;15, 2007, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued
        SFAS No.&#160;159, &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>The
        Fair Value Option for Financial Assets and Financial Liabilities &#8212; Including an
        Amendment of FASB Statement No.&#160;115</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
(&#8220;SFAS
        159&#8221;). This standard permits an entity to measure financial instruments and
        certain other items at estimated fair value. Most of the provisions of SFAS
        159
        are elective; however, the amendment to FASB No.&#160;115, &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for Certain Investments in Debt and Equity Securities</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,&#8221;
        applies to all entities that own trading and available-for-sale securities.
        The
        fair value option created by SFAS 159 permits an entity to measure eligible
        items at fair value as of specified election dates. The fair value option
        (a)&#160;may generally be applied instrument by instrument, (b)&#160;is
        irrevocable unless a new election date occurs, and (c)&#160;must be applied to
        the entire instrument and not to only a portion of the instrument. SFAS 159
        is
        effective as of the beginning of the first fiscal year that begins after
        November&#160;15, 2007. Early adoption is permitted as of the beginning of the
        previous fiscal year provided that the entity (i)&#160;makes that choice in the
        first 120&#160;days of that year, (ii)&#160;has not yet issued financial
        statements for any interim period of such year, and (iii)&#160;elects to apply
        the provisions of FASB 157. The Company does not believe that the adoption
        of
        SFAS 159 will have an impact on its consolidated results of operations,
        financial condition or cash flows. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        discussed above and in Note 9</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>,
        </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
        Options, the Company adopted FASB No.&#160;123(R) effective January&#160;1, 2006
        using the &#8220;modified prospective&#8221; method. The Company recognized non-cash
        share-based compensation expense for its share-based stock option awards
        of
        approximately $788,000 during the fiscal year ended December 31, 2006 which
        was
        calculated under the provisions of SFAS 123(R). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        May
        2005,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        the FASB
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">issued
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Statement
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No.
        154,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        Changes and Error Corrections-a replacement of APB Opinion No. 20 and FASB
        Statement No. 3</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (SFAS
        154). &#160;This Statement replaces APB Opinion No. 20, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        Changes</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        and
        SFAS No. 3, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reporting
        Accounting Changes in Interim Financial Statements</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        and
        changes the requirements for the accounting for and reporting of a change
        in
        accounting principle and error corrections. &#160;This Statement applies to all
        voluntary changes in accounting principle. &#160;It also applies to changes
        required by an accounting pronouncement in the unusual instance that the
        pronouncement does not include specific transition provisions. &#160;When a
        pronouncement includes specific transition provisions, those provisions should
        be followed. &#160;SFAS 154 is effective for accounting changes and corrections
        of errors made in fiscal years beginning after December 15, 2005. &#160;Earlier
        application was permitted for accounting changes and corrections of errors
        made
        occurring in fiscal years beginning after September 1, 2005. &#160;The Company
        adopted this standard on January 1, 2006. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        adoption of SFAS 154 did not have a significant impact on its consolidated
        results of operations, financial position or cash flows</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        September 2006, the FASB adopted Statement No. 157, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Fair
        Value Measurements</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (SFAS
        157). SFAS 157 provides enhanced guidance for using fair value to measure
        assets
        and liabilities. The standard also responds to investors&#8217; requests for expanded
        information about the extent to which companies measure assets and liabilities
        at fair value, the information used to measure fair value, and the effect
        of
        fair value measurements on earnings. The standard applies whenever other
        standards require (or permit) assets or liabilities to be measured at fair
        value. The standard does not expand the use of fair value in any new
        circumstances. SFAS 157 is effective for fiscal years beginning after November
        15, 2007, and interim periods within those fiscal years. Early adoption is
        permitted. The Company does not believe that the adoption of SFAS 157 will
        have
        an impact on its consolidated results of operations, financial condition
        or cash
        flows. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        September 2006, the SEC issued SAB No.&#160;108, &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Considering
        the Effects of Prior Year Misstatements when Quantifying Misstatements in
        Current Year Financial Statements</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
(&#8220;SAB
        108&#8221;), which is effective for fiscal years ending after November&#160;15, 2006.
        SAB 108 provides guidance on the consideration of the effects of prior year
        immaterial misstatements in quantifying current year misstatements for the
        purpose of a materiality assessment on both the balance sheet and income
        statement. SAB 108 would require restatement of prior year financial statements
        for current year misstatements even if the revisions are immaterial to those
        prior years, if the correction would be material to the current year. SAB
        108
        allows for the cumulative effect of the initial application to be made to
        beginning retained earnings. The adoption of SAB 108 did not have an impact
        on
        its consolidated results of operations, financial condition or cash flows.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        June
        2006, the FASB issued Interpretation No.&#160;48, &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for Uncertainty in Income Taxes - an Interpretation of FASB Statement
        No.&#160;109</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
(FIN
        48). FIN 48 prescribes a recognition threshold and measurement attribute
        for
        financial statement recognition and measurement of a tax position taken or
        expected to be taken in a tax return, and also provides guidance on
        derecognition, classification, interest and penalties, accounting in interim
        periods, disclosure, and transition. FIN 48 is effective for fiscal years
        beginning after December&#160;15, 2006. The Company does not believe that the
        adoption of FIN 48 will have an impact on its consolidated results of
        operations, financial condition or cash flows. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.
        Concentrations </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's credit risks consist primarily of uncollateralized accounts receivable
        from customers in the textile and other industries. The Company performs
        periodic credit evaluations of its customers' financial condition and provides
        allowances for doubtful accounts as required. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-16</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        2006,
        there was one customer that accounted for approximately 10% of net sales
        while
        in 2005 there were two customers that accounted for approximately 10% each
        of
        net sales. There were two customers in 2006 whose trade receivable balances
        equaled or exceeded 5% of total receivables, representing approximately 17%
        and
        6%, respectively, of total accounts receivable. The loss of business from
        one or
        a combination of the Company&#8217;s significant customers could adversely affect its
        operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company conducts operations in Hong Kong, mainland China, Poland and The
        Netherlands through its foreign subsidiaries. The net assets (liabilities)
        of
        the Company as of December 31, 2006 that have foreign currency exchange exposure
        and the related foreign currencies are as follows: approximately $954,000
        - Hong
        Kong Dollar, $961,000 - Chinese Yuan, $14,000 - Polish Zloty and $(31,000)
        -
        Euro, respectively. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company generates a large portion of its sales to customers that are located
        outside the United States. Sales to external customers attributed to foreign
        countries, defined as the location of the corporate office of those customers,
        totaled $13,770,152 and $14,459,260 for the years ended December 31, 2006
        and
        2005, respectively. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company does not own enzyme manufacturing facilities, but instead has employed
        two contract manufacturers who have produced all of its products. The key
        contract manufacturer is Polfa Tarchomin, SA, (&#8220;Polfa&#8221;), located in Warsaw,
        Poland, which has been producing commercial enzymes since 2001 under a 10-year
        contract, which is cancellable under certain circumstances, with several
        10-year
        renewal options exercisable at the Company&#8217;s discretion. The second contract
        manufacturer, Martek BioSciences, is used only on a limited basis. The majority
        of the Company&#8217;s production requirements are satisfied by the single
        manufacturing facility operated by Polfa, leaving the Company vulnerable
        to a
        failure of performance by this manufacturer. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.
        Fixed Assets</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        December 31, 2006, fixed assets consisted of the following:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Estimated
                  Useful Life</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amount</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lab
                  and manufacturing equipment</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3-10</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,135,268</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furniture
                  and fixtures</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3-7</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">376,402</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Leasehold
                  improvements</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">202,178</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Land</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">Indefinite</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,003,458</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vehicles</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4-5</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">123,239</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,840,545</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Less
                  accumulated depreciation and amortization</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2,027,077</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total&#160;
                net fixed assets</font></td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,813,468</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
        and amortization expense of fixed assets for the years ended December 31,
        2006
        and 2005 is approximately $250,000 and $535,000, respectively, of which
        approximately $129,000 and $85,000 is included in cost of goods sold and
        approximately $121,000 and $450,000 is included in general and administrative
        costs, respectively, in the accompanying consolidated statements of
        operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5.
        Accrued Expenses</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        December 31, 2006, accrued expenses consisted of the following:</font></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  wages and benefits</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">767,495</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  expenses relating to vendors and others</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">595,309</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                  and development</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">437,188</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  taxes payable</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">105,390</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,905,382</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.
        Short Term Notes Payable</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-17</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
          December 31, 2006, the Company had approximately $191,125 of short term
          notes
          payable, related to bank cash advances from customer Letters of Credit
          (&#8220;LOC&#8217;s&#8221;). The LOC&#8217;s were settled in January and February of 2007. The Company
          incurred charges of approximately $2,500 related to these advances and
          incurred
          interest expense at a rate of 7.25% per annum.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7.
          Long-Term Liabilities</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Long
        Term Note Payable</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Long
        term
        note payable to stockholder consisted of the following at December 31, 2006:
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loan
                  payable with a rate of 8% as of December 31, 2006 to Mark A. Emalfarb
                  Trust </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Bridge
                  Loan), secured by all assets of the Company, in the original
                  principal&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">amount
                  of $3,000,000, principal and accrued interest due January 1, 2009.
                  </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  interest of $239,941 included in principal balance. Net of unamortized
                  </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">beneficial
                  conversion feature of $46,109. </font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,378,832</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Bridge
        Loan</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        May
        29, 2003, the Company obtained a $3.0 million revolving note from a group
        of
        stockholders, including the Chief Executive Officer, who contributed $2,185,000,
        and a group of other Dyadic-Florida stockholders who contributed $815,000,
        bearing interest at 8% per annum, with all unpaid principal and interest
        originally due on January 2, 2004, and extended to January 1, 2005 on February
        13, 2004. Approximately $903,000 of the proceeds from the October 2004 Offering
        were used to pay off the $815,000 of principal and approximately $88,000
        of
        accrued interest for the portion of the bridge loan contributed by the group
        of
        other Dyadic-Florida stockholders. The loan is collateralized by a security
        interest in all of the Company's assets. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Mark
        A. Emalfarb Trust and other Dyadic-Florida stockholders, collectively, were
        also
        granted warrants to purchase up to 1.5 million shares of the Company's common
        stock at the lesser of $4.50 per share or the Series A Preferred conversion
        price, expiring ten years from the date of grant (the Bridge Loan Warrant).
        In
        November 2004, the exercise price of the Bridge Loan Warrant was reduced
        to
        $3.33 and the maturity date was extended to January 1, 2007 in connection
        with
        the Merger (see Note 1). As a result, approximately $343,000, representing
        the
        incremental fair value of the modified warrant as compared to the fair value
        of
        the original warrant immediately before the modification, was being amortized
        to
        interest expense through the new maturity date. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        April
        30, 2006, the then maturity date of the Bridge Loan was extended from January
        1,
        2007 to January 1, 2008. The then remaining unamortized portion of $76,848
        of
        the beneficial conversion feature related to the modified Bridge Loan Warrants
        is being amortized through the new maturity date. Approximately $69,000 and
        $115,000 was amortized to interest expense during the years ended December
        31,
        2006 and 2005, respectively. Interest expense on the Bridge Loan excluding
        the
        amortization of the beneficial conversion feature, was approximately $194,000
        for each of the years ended December 31, 2006 and 2005. On March 21, 2007,
        the
        maturity date of the Bridge Loan was extended from January 1, 2008 to January
        1,
        2009. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Convertible
        Notes Payable</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        May 1,
        2006, the Mark A. Emalfarb Trust received 251,298 shares of common stock
        upon
        the conversion in full of its convertible note which had combined principal
        and
        accrued interest of $836,824 as of that date. On May 1, 2006, the Francisco
        Trust received 222,537 shares of common stock upon the conversion in full
        of its
        convertible note which had combined principal and accrued interest of $741,048
        as of that date. As a result of the conversions, a total of approximately
        $1.6
        million of notes payable to stockholders, bearing interest at 6% per annum
        was
        relieved. The balances of the related beneficial conversion features were
        fully
        expensed in April 2006 resulting in an adjustment of approximately $171,000
        to
        interest expense.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
        each of the years ended December 31, 2006 and 2005, approximately $256,000
        was
        amortized to interest expense related to the beneficial conversion features.
        Interest expense related to the convertible notes excluding the amortization
        of
        the beneficial conversion feature, was approximately $31,000 and $95,000
        for the
        years ended December 31, 2006 and 2005, respectively. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Mark
        A. Emalfarb Trust and Francisco Trust are major stockholders of the Company
        and
        are trusts whose beneficiaries are the Company's President, Chief Executive
        Officer and Chairman, and the wife and children of Mark A. Emalfarb,
        respectively. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Notes
        Payable - Minority Shareholders</em></font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-18</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          April
          28, 2006, the Company purchased the remaining 17.5% of shares held by the
          then
          two minority shareholders of its Asian subsidiary, giving the Company 100%
          ownership of that subsidiary (see Note 8, Share-Based Compensation, Issuances
          of
          Common Stock). The minority shareholders received $375,000 in cash and
          212,501
          shares of unregistered Dyadic common stock in consideration for, among
          other
          things, the cancellation of the subordinated notes under which the Company
          owed
          the minority shareholders approximately $172,000 of principal and $70,000
          of
          accrued interest; relief of the Company&#8217;s minority interest liability of
          approximately $117,000; and a release of the Company for a potential $405,000
          contingent obligation to the managing director incident to the Company&#8217;s
          purchase of its initial majority interest in the Asian Subsidiary in
          1998.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
        expense on the subordinated notes payable to the minority stockholders of
        the
        Asian subsidiary was approximately $3,400 and $10,300 for the years ended
        December 31, 2006 and 2005, respectively.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8.
        Share-Based Compensation</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Issuances
        of Common Stock</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        March
        22, 2006, the Company issued 11,990 shares of common stock under the Dyadic
        International, Inc. 2001 Equity Compensation Plan (the &#8220;Equity Plan&#8221;), to Glenn
        E. Nedwin, Ph.D., the Company&#8217;s Chief Scientific Officer, Executive Vice
        President, President of the BioPharma Business and a director, as a signing
        bonus per his employment agreement. The shares were valued at $50,000 based
        on
        the fair market value of the Company&#8217;s common stock on the date of grant.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        April
        28, 2006, the Company and its then 82.5% majority owned Asian Subsidiary
        entered
        into a satisfaction and purchase agreement with the Asian Subsidiary&#8217;s then two
        minority shareholders, its managing director and one of its other key employees,
        effective as of January 1, 2006. The minority shareholders received $375,000
        in
        cash and 212,501 shares of unregistered common stock of the Company. The
        Company&#8217;s shares were valued at approximately $1,328,000 based on the fair
        market value of the Company&#8217;s common stock on April 28, 2006, the measurement
        date for accounting purposes. As of May 1, 2006, the Company is recording
        100%
        of the Asian Subsidiary&#8217;s operating results in the accompanying condensed
        consolidated statements of operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        May 1,
        2006, the Company&#8217;s two largest stockholders, the Mark A. Emalfarb Trust and the
        Francisco Trust U/A/D February 28, 1996 (the &#8220;Francisco Trust&#8221;), increased their
        stock ownership in the Company by 251,298 and 222,537 shares of common stock,
        respectively, as a result of converting in full their convertible promissory
        notes due January 1, 2007, at an exercise price of $3.33 per share. A total
        of
        approximately $1.6 million of notes and interest payable to stockholders,
        bearing interest at 6% per annum was converted. The balances of the related
        beneficial conversion features were fully expensed in April 2006 resulting
        in an
        adjustment of approximately $171,000 to interest expense.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Francisco Trust has as its beneficiaries the wife and children of Mark A.
        Emalfarb, the Chief Executive Officer, President and Chairman of the Company.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        October 26, 2006, the Company entered into the Abengoa Securities Purchase
        Agreement with Abengoa, a subsidiary of Abengoa S.A.. Also on October 26,
        2006,
        Dyadic-Florida entered into a non-exclusive research and development agreement
        with Abengoa pertaining to the conduct of a research and development (&#8220;R&amp;D&#8221;)
        program to be completed over a period of up to three and one-half years,
        under
        which Dyadic-Florida will seek to apply its proprietary technologies to the
        development of cost-effective enzyme mixtures and related processing and
        manufacturing technologies for commercial application in Abengoa&#8217;s bioethanol
        (cellulosic ethanol) production process (the &#8220;R&amp;D Agreement&#8221;). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
        the
        terms of the Abengoa Securities Purchase Agreement, Abengoa paid the Company
        $10,000,000, for which it was issued 2,136,752 shares of the Company&#8217;s common
        stock at $4.68 per share (the closing share price on October 25, 2006, as
        reported on the American Stock Exchange). The Company completed this transaction
        on November 8, 2006. Under certain circumstances, as described below, Dyadic
        may
        have to issue additional securities to Abengoa. As of December 31, 2006,
        unused
        proceeds of approximately $9,998,000 are recorded as deferred research and
        development obligation in the accompanying consolidated financial statements
        and
        will be recognized as revenue as the expenses associated with the R&amp;D
        program described above are incurred. The costs incurred in connection with
        the
        Abengoa Securities Purchase Agreement are included in other assets at December
        31, 2006 and will be amortized in relation to the revenue recognized under
        the
        deferred research and development obligation.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        within
        six months following the date of closing the Company has not entered into
        a
        specified type of transaction involving the sale of its securities totaling
        at
        least $20,000,000 in gross proceeds, then Abengoa is entitled to receive
        three-year warrants to purchase 427,351 shares at an exercise price of $5.85.
        If
        the sale of securities totaling at least $20,000,000 is at a price lower
        than
        $4.68 per share, Abengoa is entitled to have additional shares issued to
        them so
        that their investment is at the same price. If the sale of securities includes
        warrants, Abengoa&#8217;s pro rata warrant coverage and other warrant terms are to be
        the same as those in the securities transaction rather than the warrant terms
        discussed above. For additional disclosure regarding this transaction, see
        Note
        1, Organization and Operations</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
        - </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
        Raising Activities.</em></font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-19</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        November 17, 2006, the Company entered into the Securities Purchase Agreement
        with certain investors to purchase in a private placement 2,787,000 shares
        of
        its common stock at a price of $4.68 per share and warrants to purchase up
        to
        557,400 shares of its common stock at an exercise price of $6.33 per share
        for
        gross proceeds of $13,043,160. The private placement was completed on December
        1, 2006. Cowen and Company, LLC acted as the exclusive placement agent for
        the
        private placement for which they received warrants to purchase up to 83,610
        shares of the Company&#8217;s common stock at $5.24 per share and warrants to purchase
        up to 16,722 shares of common stock at $6.33 per share. The Company incurred
        $954,682 of costs related to the private placement. These costs are included
        as
        a reduction of additional paid-in capital. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
        the year ended December 31, 2006, the Company received an aggregate of
        approximately $6,901,000 in proceeds from the exercises of the following
        instruments: (i) warrants to purchase an aggregate of 495,460 shares of its
        common stock at an exercise price of $3.33 per share, (ii) warrants to purchase
        an aggregate of 709,664 shares of its common stock at an exercise price of
        $5.50
        per share, (iii) stock options to purchase an aggregate of 274,950 shares
        of its
        common stock, granted under the 2001 Equity Plan, with exercise prices ranging
        from $2.08 to $4.50 per share, and (iv) stock options to purchase an aggregate
        of 65,000 shares of common stock, granted prior to the 2001 Equity Plan,
        with an
        exercise price of $4.50 per share. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
        the years ended December 31, 2006 and 2005, the Company issued 205,652 and
        7,523
        shares of common stock, respectively, pursuant to a Development Agreement
        with a
        third party for services rendered to the Company for research and development
        projects. The original term of the Development Agreement was a 26-month period
        ending September 30, 2006. In December 2004, the term was extended to December
        31, 2006 and in December 2006 the term was extended to April 30, 2007. The
        Company originally placed 300,300 shares of common stock in escrow which
        is
        being issued to the third party as earned during the contractual period,
        at
        which time they are deemed to be outstanding. Per the Development Agreement,
        the
        price used to calculate the number of shares issued was set at $3.33 per
        share.
        The stated value of the services rendered is then divided by the share price
        of
        $3.33 to determine the number of shares earned. The Company has recognized
        non-cash R&amp;D expense of approximately $1,063,000 and $25,000 for the years
        ended December 31, 2006 and 2005, respectively, based on the fair market
        value
        of the Company&#8217;s common stock on the measurement dates. The number of shares
        held in escrow as of December 31, 2006 is 87,125 and an aggregate of 213,175
        shares have been earned to date. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        March
        1, 2007 (the &#8220;Effective Date&#8221;), the Development Agreement was extended for one
        year (through February 29, 2008), with an option to extend an additional
        twelve
        months. The total cost of the one year extension is $1,650,600, which will
        be
        billed to the Company on a monthly basis, based upon the actual amount of
        time
        incurred by the third party. Each monthly amount is payable 86% in cash (the
        &#8220;Cash Amount&#8221;) and 14% in unregistered shares of the Company&#8217;s common stock (the
&#8220;Equity Amount&#8221;). The shares are payable in two installments; the first
        installment to be delivered on the 35</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        day
        following the six month anniversary of the Effective Date and the second
        installment to be delivered on the 35</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        day
        following the twelve month anniversary of the Effective Date. The number
        of
        shares will be equal to the Equity Amount divided by the closing price of
        the
        Company&#8217;s stock on the Effective Date ($5.91). The Company may terminate the
        Agreement upon 60 days prior written notice.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        December 31, 2006 and 2005, 6,405,384 and 6,952,776 shares of common stock
        have
        been reserved for issuance under outstanding warrants, respectively. All
        of the
        warrants are fully vested and have expiration dates ranging from October
        29,
        2009 to May 29, 2013. Information concerning the Company&#8217;s warrant activity is
        as follows:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                  Average </strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                  Average </strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exercise
                  Price</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exercise
                  Price</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding,
                  at the beginning of year</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,952,776</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.88</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,500,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.33</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercised</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,205,124</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.61</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Granted</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">657,732</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.19</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,452,776</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.30</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding,
                  at the end of year</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,405,384</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.06</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,952,776</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.88</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        December 2006, the Company issued warrants to purchase up to 557,400 shares
        of
        its common stock at an exercise price of $6.33 per share related to investors
        in
        a private placement (see &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Issuances
        of Common Stock&#8221; </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">above).
        Cowen and Company, LLC acted as the exclusive placement agent for the private
        placement for which the Company issued to it warrants to purchase up to 83,610
        shares of the Company&#8217;s common stock at $5.24 per share and warrants to purchase
        up to 16,722 shares of the Company&#8217;s common stock at $6.33 per share.
</font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-20</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        warrants issued to the investors become exercisable on May 31, 2007, expire
        three years thereafter, contain price adjustment and economic anti-dilution
        features, as well as anti-dilution protection from stock splits and similar
        events, contain limited cashless exercise procedures and are callable by
        us
        under certain circumstances. The warrants issued to the placement agent are
        substantially identical to the warrants issued to the investors, except that
        (i)
        the warrant for 83,610 shares has an exercise price of $5.24 per share rather
        than $6.33 per share and (ii) they have a five-year term rather than a
        three-year term and (iii) they provide for unqualified cashless exercise
        procedures rather than limited cashless exercise procedures. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.
        Stock Options</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        January 2006, the Company adopted SFAS 123(R), </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Share-Based
        Payment </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(&#8220;SFAS
        123(R)&#8221;), which is a revision of SFAS 123, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for Share-based Compensation</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        SFAS
        123(R) supersedes Accounting Principles Board Opinion (&#8220;APB&#8221;) No. 25,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for Stock Issued to Employees </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(APB
        25)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        and
        amends SFAS No. 95, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Statement
        of Cash Flows</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        Generally, the approach in SFAS 123(R) is similar to the approach described
        in
        SFAS 123. However, SFAS 123(R) requires all share-based payments to employees
        and non-employee directors, including grants of employee stock options, to
        be
        recognized in the consolidated statements of operations based on their fair
        values. Pro forma disclosure, which has previously been used by the Company,
        is
        no longer an alternative. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company adopted the fair value recognition provisions of SFAS 123(R), using
        the
        modified prospective transition method. Under this transition method,
        compensation expense includes options vesting for share-based payments granted
        prior to, but not vested as of December 31, 2005, based on the grant date
        fair
        value estimated in accordance with the original provisions of SFAS 123 and
        share-based payments granted after December 31, 2005, based on the grant
        date
        fair value estimated in accordance with the provisions of SFAS 123(R). Because
        this transition method was selected, results of prior periods have not been
        restated. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior
        to
        January 1, 2006, the Company accounted for share-based employee compensation
        plans using the intrinsic value method of accounting in accordance with APB
        25
        and its related interpretations. Under the provisions of APB 25, no compensation
        expense was recognized when stock options were granted with exercise prices
        equal to or greater than market value on the date of grant. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        December 15, 2005, the Board of Directors of the Company approved the
        acceleration of vesting for the unvested portion of all outstanding stock
        options awarded to employee and non-employee directors of the Company from
        May
        2001 to December 15, 2005 under the 2001 Equity Compensation Plan, as amended
        (the &#8220;2001 Equity Plan&#8221;). While the Company typically issues options that vest
        equally over four years, as a result of this vesting acceleration, stock
        options
        to purchase approximately 1,200,000 shares of the Company&#8217;s common stock, of
        which approximately 600,000 were then held by the Company&#8217;s executive officers
        and non-employee directors, became immediately exercisable. The exercise
        prices
        of the affected stock options ranged from $1.90 to $5.93 and the closing
        price
        of the Company&#8217;s common stock on December 15, 2005, was $1.75.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        purpose of the accelerated vesting was to provide a non-cash benefit to the
        Company&#8217;s employees and to eliminate future compensation expense the Company
        would otherwise recognize in its consolidated statements of operations with
        respect to these accelerated options upon the adoption of SFAS 123(R). The
        estimated future compensation expense associated with these accelerated options
        that would have been recognized in the Company&#8217;s consolidated statements of
        operations upon implementation of SFAS 123(R) is approximately $1,300,000.
        All
        option grants made on and after January 1, 2006 are accounted for in accordance
        with SFAS 123(R).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s Amended and Restated 2001 Equity Plan and 2006 Option Plan (see below)
        are each considered to be compensatory plans under SFAS 123(R). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Description
        of Equity Plans </em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Amended
        and Restated 2001 Equity Compensation Plan</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective
        May 2001, the Company&#8217;s Board of Directors adopted the Dyadic International,
        Inc. 2001 Equity Compensation Plan (the &#8220;2001 Equity Plan&#8221;) under which
        1,302,989 shares of common stock were reserved for issuance. In September
        2004,
        by written consent, the Company's Board of Directors and stockholders approved
        an increase in the authorized number of shares of common stock under the
        2001
        Equity Plan from 1,302,989 to 5,152,447. All employees, as well as members
        of
        the Company's Board of Directors and Key Advisors, (as defined in the 2001
        Equity Incentive Plan), are eligible to participate under the 2001 Equity
        Plan.
        Under the 2001 Equity Plan, the Company may issue incentive stock options
        and
        nonqualified stock options to purchase shares of common stock, or the Company
        may issue shares of common stock. Such shares, if issued, may be subject
        to
        restrictions, as disclosed in the 2001 Equity Plan. In addition to stock
        options
        and stock grants, the 2001 Equity Plan allows for the issuance of Performance
        Units to an employee or Key Advisor. Each Performance Unit represents the
        right
        to receive an amount, in cash or in the Company's common stock, as determined
        by
        a committee of the Company's Board of Directors, based on the value of the
        Performance Unit, if established performance goals are met. </font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-21</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        2001
        Equity Plan was amended and restated effective as of January 1, 2005 by the
        Company&#8217;s Board of Directors on April 1, 2006 and approved by the Company&#8217;s
        stockholders at the 2006 Annual Meeting of Stockholders in June 2006 to (a)
        reduce the number of shares of common stock available for issuance under
        the
        plan to 4,478,475 shares from 5,152,447 shares (b) to conform certain provisions
        of the plan to the requirements of Section 409A of the Internal Revenue Code
        of
        1986, as amended, and (c) to increase the maximum limitation of shares that
        may
        be subject to awards granted under the plan to any one individual for any
        fiscal
        year during the term of the plan to 1,200,000 shares from 100,000 shares.
        As of
        December 31, 2006, there were 2,956,911 stock options outstanding and 1,502,940
        available for grant under the plan. The terms of the options outstanding
        under
        the plan range between five and ten years.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>2006
        Stock Option Plan</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br></font>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Dyadic International, Inc. 2006 Stock Option Plan (the &#8220;2006 Option Plan&#8221;) was
          adopted by the Company&#8217;s Board of Directors in April 2006 and approved by
          stockholders at the 2006 Annual Meeting of Stockholders in June 2006. The
          purpose of the 2006 Option Plan is to retain and attract key management,
          employees, nonemployee directors and consultants by providing those persons
          with
          a proprietary interest in the Company. The compensation committee will
          administer the 2006 Option Plan and may grant stock options, which may
          be
          incentive stock options or nonqualified stock options that do not comply
          with
          Section 422 of the Internal Revenue Code. Under the 2006 Option Plan, 2,700,000
          shares of common stock have been reserved for issuance. As of December
          31, 2006,
          there were 5,000 stock options outstanding and 2,695,000 available for
          grant
          under the plan. The term of the options outstanding under the plan is ten
          years.</font><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Amended and Restated 2001 Equity Plan and the 2006 Option Plan are sometimes
        collectively referred to as the &#8220;Equity Compensation Plans&#8221;. All options granted
        under the Equity Compensation Plans are service-based and typically vest
        over a
        four year period except for 667,533 options which are performance-based and
        vest
        based upon the achievement of certain benchmarks. As of December 31, 2006,
        there
        were 33,377 performance-based options that were exercisable and 1,259,593
        service-based options that were exercisable.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company recognized non-cash share-based compensation expense for its share-based
        awards of approximately $788,000 and $77,000 for the years ended December
        31,
        2006 and 2005, respectively. These charges had no impact on the Company&#8217;s
        reported cash flows. Total non-cash share-based compensation expense was
        allocated among the following expense categories: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="5" valign="bottom" width="26%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General
                  and administrative</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">592,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">58,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                  and development</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">89,000
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
                  of goods sold</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Selling
                  and marketing</font></div>
              </td>
              <td width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">75,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">788,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">77,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
        the
        modified prospective method of transition under SFAS 123(R), the Company
        is not
        required to restate its prior period financial statements to reflect expensing
        of share-based compensation under the new standard. Therefore, the results
        for
        the year ended December 31, 2006 are not comparable to the prior year.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company has determined its non-cash share-based compensation expense under
        SFAS
        123(R) for the year ended December 31, 2006 as follows: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Valuation
        of Stock Options </em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Share-based
        compensation related to stock options is determined using the single option
        approach under the Black-Scholes valuation model. The fair value of options
        determined under SFAS 123(R) is amortized to expense over the vesting periods
        of
        the underlying options, generally four years. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        fair
        value of stock option awards for the year ended December 31, 2006 was estimated
        on the date of grant using the assumptions in the following table. The expected
        volatility in this model is based on the historical volatility of the Company&#8217;s
        stock. The risk-free interest rate is based on the U.S. Treasury yield curve
        in
        effect at the time awards are granted, based on maturities which approximate
        the
        expected life of the options. The expected life of the options granted is
        estimated using the historical exercise behavior of employees. The expected
        dividend rate takes into account the absence of any historical payments and
        the
        Board of Director&#8217;s intention to retain all earnings, if any, for future
        operations and expansion. </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-22</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>December
                  31, 2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Average
                  Risk-Free Interest Rate</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.71</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dividend
                  Yield</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Average
                  Volatility Factor</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">73</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Average
                  Option Life</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5
                  Yrs</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Forfeiture
        Rate for Options </em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company is required to estimate forfeitures at the time of grant and revise
        those estimates in subsequent periods on a cumulative basis in the period
        the
        estimated forfeiture rate changes for all share-based awards. The Company
        considered its historical experience of option forfeitures as the basis to
        arrive at its estimated average option forfeiture rate of 5%&#160;per year for
        the year ended December&#160;31, 2006 for all stock option awards. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Equity
        Compensation Plans Awards Activity </em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Information
        with respect to the Company&#8217;s Equity Compensation Plans and grants of 65,000
        options to nonemployees prior to the Company&#8217;s adoption of either of the Equity
        Compensation Plans is as follows: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td valign="bottom" width="57%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;
                  Weighted Average Exercise Price </strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Per
                  Share</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Aggregate</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;Intrinsic
                  Value</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding
                  at December 31, 2005</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,662,639</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.61</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Granted</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,711,722</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.61</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercised</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(339,950
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">)&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.02</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expired</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(12,500</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.50</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cancelled</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(60,000</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.54</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding
                  at December 31, 2006</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,961,911</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.12</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,895,441</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercisable
                  at December 31, 2006</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,292,970</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.65</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,189,243</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        weighted average grant date fair value of options granted during the year
        ended
        December 31, 2006 was $2.72 per share. The total intrinsic value of options
        exercised during the year ended December&#160;31, 2006 was $820,348, or $2.41
        per share.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
        received from option exercises during the year ended December&#160;31, 2006 was
        $1,348,402. The Company has a net operating loss carryforward as of
        December&#160;31, 2006 and therefore, no excess tax benefits for tax deductions
        related to the stock options were recognized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
        further
        detail of the options outstanding as of December 31, 2006 is set forth as
        follows: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td valign="bottom" width="43%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Range
                  of Exercise Prices</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options
                  Outstanding</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted-Average
                  Remaining Life in Years</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted-Average
                  Exercise Price Per Share</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options
                  Exercisable</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted-Average
                  Exercise Price Per Share</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td valign="bottom" width="43%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$1.83
                  - $2.90</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">394,467</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.69</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.46</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">266,154</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.47</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td valign="bottom" width="43%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.96
                  - 3.80</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,180,411</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.45</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.23</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">706,439</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.39</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td valign="bottom" width="43%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.39
                  - 4.66</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">604,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.83</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.57</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">182,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.51</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td valign="bottom" width="43%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.92
                  - 7.13</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">782,533</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.15</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.95</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">138,377</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.14</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td valign="bottom" width="43%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,961,911</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.36</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.12</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,292,970</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.65</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-23</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Unrecognized
        Share-Based Compensation Expense </em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        of
        December 31, 2006, there was approximately $2,013,000 of total unrecognized
        compensation expense related to nonvested share-based compensation arrangements
        granted under the Equity Incentive Plans. This expense is expected to be
        recognized over a weighted-average period of 2.9 years as follows: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fiscal
                  Year 2007</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">683,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fiscal
                  Year 2008</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">662,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fiscal
                  Year 2009</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">591,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fiscal
                  Year 2010</font></div>
              </td>
              <td width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">77,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,013,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.
        Commitments and Contingencies</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Employment
        Agreements</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          2001,
          the Company entered into an employment agreement with Mark A. Emalfarb,
          the
          Company's President and Chief Executive Officer. The agreement commenced
          on
          April 1, 2001, and terminated on March 30, 2004, but renewed for an additional
          two years because neither party gave written notice 60 days prior to March
          30,
          2003. In March 2006, the agreement was amended (the &#8220;First Amendment&#8221;) to extend
          the term of Mr. Emalfarb&#8217;s employment by one year, from March 30, 2006 to March
          30, 2007, and to add an automatic renewal provision for succeeding one
          year
          terms unless either party gives the other a notice of non-renewal not less
          than
          90 days prior to the expiration of the then term. The agreement automatically
          renewed on April 1, 2007, as neither party provided the other party a notice
          of
          non-renewal at least 90 days prior to March 30, 2007. The First Amendment
          makes
          no other changes to Mr. Emalfarb&#8217;s employment agreement. The agreement provides
          for an annual base salary of $300,000 and the payment of an annual bonus
          (based
          on goals and objectives to be agreed upon by the Board and Mr. Emalfarb)
          for
          each fiscal year or portion of a fiscal year, including but not limited
          to
          research and other business milestones, sales, profitability or cash flow
          goals.
          The Company agrees to cause the compensation committee to grant Mr. Emalfarb
          options to the same extent as the committee grants to other senior executives
          of
          the Company and on the same terms and conditions. </font><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        agreement also provides for the participation in all benefit plans, practices,
        policies and programs provided by the Company such as (including, without
        limitation, reimbursement of business related expenses, vacation, medical,
        prescription, dental, disability, retirement, salary continuance, employee
        life
        insurance, group life insurance, and accidental death and travel accident
        insurance plans and programs) generally available to other senior executives
        of
        the Company, and for other employee benefits. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If,
          during the employment period, the Company terminates Mr. Emalfarb's employment,
          other than for cause or disability or by reason of Mr. Emalfarb's death
          or by
          reason of the failure of the Company to renew the employment agreement,
          or if
          Mr. Emalfarb terminates employment for good reason, the Company shall provide
          Mr. Emalfarb with annual base salary and all benefits received by Mr. Emalfarb
          as of the date of termination for a period of one year from the date of
          termination. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        March
        2005, the Company entered into employment agreements with one of its executive
        officers and one of its key employees, and in connection therewith, promoted
        them to new offices: Mr. Kent M. Sproat, formerly Vice President, Manufacturing,
        was promoted to Executive Vice President, Enzyme Business and Mr. Ratnesh
        (Ray)
        Chandra, formerly Vice President, Marketing - BioPharma, was promoted to
        Senior
        Vice President, Marketing - Biotechnology Systems. Mr. Sproat was also promoted
        to the office of Executive Vice President of the Company&#8217;s operating subsidiary,
        Dyadic International (USA), Inc., a Florida corporation (&#8220;Dyadic-Florida&#8221;).
        Currently, Mr. Sproat serves as Executive Vice President, Manufacturing and
        Special Projects. The annual base compensation of Mr. Sproat and Mr. Chandra
        is
        $195,700 and $175,350, respectively. Mr. Sproat&#8217;s and Mr. Chandra&#8217;s employment
        agreements include provisions that might entitle them to extended severance
        benefits following the occurrence of a &#8220;Change of Control,&#8221; as defined, of
        either the Company or its BioPharma Business, in the case of Mr. Chandra,
        and
        following the occurrence of a &#8220;Change of Control&#8221; of either the Company or its
        Enzymes Business, in the case of Mr. Sproat. Under both agreements, upon
        a
        termination of the executive&#8217;s employment by the Company or its
        successor-in-interest other than &#8220;for Cause,&#8221; or a termination of his employment
        by the executive which is a &#8220;Constructive Termination of Employment Without
        Cause,&#8221; as defined, within 12 months following the occurrence of a Change of
        Control, he will become entitled to a severance benefit of monthly installments
        in the amount of 1/12th of his then annual base compensation for 18
        months.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-24</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        addition, the Company entered into four other employment agreements with
        officers and key employees during 2005. The initial term of employment under
        all
        six employment agreements ends on December 31, 2007, with automatic one-year
        renewals unless either party furnishes the other a notice of non-renewal
        not
        less than 90 days prior to the expiration of the then term. Each of them
        is
        eligible to earn a bonus each year of up to 40% of his annual base compensation
        based upon a bonus plan to be adopted and maintained by the compensation
        committee of the Board of Directors of the Company (the &#8220;Compensation
        Committee&#8221;) for such year. <br></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
        employment agreement is terminable on account of the executive&#8217;s death or
        disability, or by the Company without cause or &#8220;for Cause. If the executive&#8217;s
        employment is terminated by the Company other than &#8220;for Cause,&#8221; upon the
        condition that he furnish the Company with a full general release, he is
        entitled to receive a severance benefit of monthly installments in the amount
        of
        1/12th of his then annual base compensation for a period of 6 months for
        a
        combined potential severance benefit of up to approximately $553,000.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        March
        2006, the Company entered into an agreement with Dr. Glenn E. Nedwin to become
        (i) the Company&#8217;s Chief Scientific Officer, (ii) an Executive Vice President of
        the Company and (iii) the President of the BioPharma business of the Company&#8217;s
        wholly-owned subsidiary, Dyadic International (USA), Inc., a Florida. The
        initial term of Dr. Nedwin&#8217;s employment ends December 31, 2008, with automatic
        one-year renewals unless either party furnishes the other a notice of
        non-renewal not less than 120 days prior to the expiration of the then term.
        Dr.
        Nedwin&#8217;s annual base salary is $300,000, and he is eligible to earn a bonus each
        year of up to 25% of his then annual base salary based upon a bonus plan
        adopted
        and maintained by the Compensation Committee of the Board of Directors of
        the
        Company for such year. Dr. Nedwin has been elected to the Board as a Class
        III
        director effective on the Effective Date, for a term which expires at the
        2007
        annual stockholders meeting.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        employment agreement is terminable on account of Dr. Nedwin&#8217;s death or
        disability, by Dr. Nedwin for &#8220;Good Reason&#8221; , as defined, or by the Company
        without cause or &#8220;for Cause&#8221;, as defined. If Dr. Nedwin&#8217;s employment is
        terminated by the Company other than &#8220;for Cause,&#8221; upon the condition that he
        furnish the Company with a full general release, he is entitled to receive
        a
        severance benefit of monthly installments in the amount of 1/12th of his
        then
        annual base salary for the eighteen (18) month period following that
        termination, provided that the amount of his severance benefits are reduced
        on a
        dollar-for-dollar basis by the amount of any remuneration he may earn during
        the
        severance period for the performance of services as an employee, or independent
        contractor or agent. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Employee
        Benefit Plan</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company has a 401(k) defined contribution plan in which all employees are
        eligible to participate. Participants may elect to defer up to 80% of
        compensation up to a maximum amount determined annually pursuant to Internal
        Revenue Service regulations. The Company elected not to provide for matching
        employer contributions for the years ended December 31, 2006 and 2005.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Manufacturing
        Agreements</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company entered into an agreement, which is cancellable under certain
        circumstances (the Manufacturing Agreement) in October 1999, under which
        a
        foreign manufacturer conducts contract production of certain products for
        the
        Company at its facilities. The Company provides the foreign manufacturer
        with
        all technical and technology information, instructions and procedures available
        to the Company and necessary for the production, packing and testing of the
        product. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company made a request of its product manufacturer to expand production capacity
        in order to produce higher volumes of existing and new products. The Company
        concluded an agreement in December 2004 with the manufacturer to provide
        an
        additional 50 cubic meters of fermentation capacity and associated recovery
        capacity with the majority of the capital necessary for this expansion to
        be
        provided by the manufacturer (&#8220;Additional Expansion Costs&#8221;). This expansion has
        been completed and became fully operational in October 2006. Dyadic made
        direct
        payment for certain removable equipment for this expansion of approximately
        $133,000. Should the Company require additional capacity in the future, and
        the
        current contract manufacturer cannot obtain the funding necessary to provide
        the
        needed capital to honor its obligation to the Company under the Manufacturing
        Agreement, this will negatively affect the Company's ability to meet its
        production requirements and therefore impact its financial position, results
        of
        operations and cash flows. In such an event, the Company would have to locate
        additional capacity with another contract manufacturing facility. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Manufacturing Agreement requires the payment of monthly charges based on
        capacity usage, ultrafiltration costs, disposal costs, raw material costs
        and
        reimbursement of plant modification costs. In July 2001, the Company agreed
        to
        pay a total of approximately $1.6 million in plant modification costs in
        monthly
        installments of $28,088, plus LIBOR (3.6% at December 31, 2006), and in 2006,
        agreed to pay an additional $1.0 million in expansion costs in monthly
        installments of $11,546 plus LIBOR, both over seven-year periods. The Company
        agreed to make a prepayment of $225,000 of the $1.0 million in January 2007.
        All
        payments are denominated in Euros. Remaining minimum payments under the
        Manufacturing Agreement and the Additional Expansion Costs, including interest
        at the December 31, 2006 LIBOR rate, are as follows: </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-25</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  ending December 31,</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Manufacturing
                  Agreement</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Additional
                  Expansion Costs</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2007</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">337,051</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">363,552</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2008</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">112,402</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">138,551</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2009</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">138,551</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2010</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">138,551</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td valign="bottom" width="71%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2011</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">138,552</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2012</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">17,465</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td valign="bottom" width="71%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">449,403</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #cceeff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">935,222</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Manufacturing Agreement is being accounted for as service agreement and the
        Additional Expansion Costs is being treated as an operating lease. Accordingly,
        annual payments are reflected as a component of cost of goods sold in the
        annual
        period in which each payment is due. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Agreement
        to Conduct Research and Development Activities on Behalf of the
        Company</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company has entered into several agreements with independent third parties
        to
        conduct research and development activities on behalf of the Company. Except
        as
        described below, none of these agreements are for minimum periods in excess
        of
        one year, and are generally cancelable by the Company with advance written
        notice. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        July
        30, 2004, the Company entered into a Development Agreement with a third party
        to
        assist the Company in various research and development projects over the
        26-month period ending September 30, 2006. In December 2004, the termination
        date was extended to December 31, 2006 and in December 2006 the term was
        extended to April 30, 2007. Under the Development Agreement, the Company
        is
        required to utilize, and the third party has committed to provide, research
        and
        development assistance valued at approximately $1.25 million. The consideration
        for these services includes 300,300 shares of the Company's common stock,
        valued
        at $1.0 million, and cash, $250,000 of which was paid upon execution of the
        Development Agreement. Pursuant to the Development Agreement, the 300,300
        shares
        of common stock were placed in escrow and are being issued to the third party
        as
        earned during the contractual period, at which time they are considered
        outstanding. The Development Agreement imposes cash penalties upon the third
        party in the event of nonperformance under the Development Agreement, beyond
        the
        forfeiture of any shares of common stock placed in escrow. The Company has
        issued an aggregate of 213,175 shares of common stock pursuant to the agreement
        and the $250,000 cash prepayment has been utilized in full. The number of
        shares
        held in escrow as of December 31, 2006 is 87,125. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        March
        1, 2007 (the &#8220;Effective Date&#8221;), the Development Agreement was extended for one
        year (through February 29, 2008), with an option to extend an additional
        twelve
        months. The total cost of the one year extension is $1,650,600, which will
        be
        billed to the Company on a monthly basis, based upon the actual amount of
        time
        incurred by the third party. Each monthly amount is payable 86% in cash (the
        &#8220;Cash Amount&#8221;) and 14% in unregistered shares of the Company&#8217;s common stock (the
&#8220;Equity Amount&#8221;). The shares are payable in two installments; the first
        installment to be delivered on the 35</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        day
        following the six month anniversary of the Effective Date and the second
        installment to be delivered on the 35</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        day
        following the twelve month anniversary of the Effective Date. The number
        of
        shares will be equal to the Equity Amount divided by the closing price of
        the
        Company&#8217;s stock on the Effective Date ($5.91). The Company may terminate the
        Agreement upon 60 days prior written notice.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Litigation,
        Claims and Assessments</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        the
        opinion of management, there are no known pending or threatened legal
        proceedings that would have a material effect on the Company's financial
        position, results of operations or cash flows. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Leases
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s corporate headquarters are located in Jupiter, Florida, in
        approximately 8,500 square feet of space occupied under a lease with a monthly
        rental rate of approximately $15,550 that expires on December 31, 2007. The
        lease has an escalation clause and an option to extend the lease for two
        years.
        The Company leases a 3,500 square foot lab facility in Jupiter, Florida,
        with a
        monthly rental rate of $1,500 that expires on June 30, 2007. The Company
        also
        leases a 3,150 square foot lab facility and a storage building in Greensboro,
        North Carolina, with a monthly rental rate of $2,035 which expires on December
        31, 2007.</font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-26</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Asian
          subsidiary leases its office premises and staff accommodations under nine
          operating lease arrangements for terms ranging from two to ten
          years.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company's Asian subsidiary leases a facility in Hong Kong from a former
          minority
          stockholder of the subsidiary. Rent expense under this arrangement was
          approximately $27,700 and $25,000 for the years ended December 31, 2006
          and
          2005, respectively. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
            Nederland B.V. leases office and lab space with a monthly rental rate
            of
            approximately $4,000, which expires on December 31, 2007 and can be renewed
            for
            a one year period through December 31, 2008.</font><br></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Future
        minimum lease commitments due for facilities and equipment leases under
        noncancellable operating leases at December 31, 2006 are as follows:
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Operating
                  Leases</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2007</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: 3.75pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: 3.75pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">384,644</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2008</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">80,945</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2009
                  </font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">75,280</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2010
                  </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">66,102</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2011
                  and thereafter</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">198,710</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  minimum lease payments</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">805,681</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rent
        expense under all operating leases for the years ended December 31, 2006
        and
        2005 totaled approximately $307,000 and $316,000, respectively, of which
        approximately $81,000 and $81,000 is included in cost of goods sold and
        approximately $226,000 and $235,000 is included in general and administrative
        costs, respectively, in the accompanying consolidated statements of
        operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Protection
        of Proprietary Technologies</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's success is dependent in part on its ability to obtain patents and
        maintain adequate protection of other intellectual property for the Company's
        technologies and products in the United States and other countries. If the
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Company
        does not adequately protect its intellectual property, competitors may be
        able
        to practice its technologies and erode its competitive advantage. The laws
        of
        some foreign countries do not protect proprietary rights to the same extent
        as
        the laws of the United States, and many companies have encountered significant
        problems in protecting their proprietary rights in these foreign countries.
        These problems can be caused by, for example, a lack of rules and methods
        for
        defending intellectual property rights. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company holds four issued United States patents and two allowed and twenty-eight
        issued international patents, including claims that cover the C1 Production
        Technology (a host organism that performs protein expression and related
        services for laboratory research, clinical trials and commercial production)
        and
        5 PCT Publications. The Company has fifty-two United States and international
        patent applications filed. The patent positions of biopharmaceutical and
        biotechnology companies, including the Company's patent position are generally
        uncertain and involve complex legal and factual questions. The Company will
        be
        able to protect its proprietary rights from unauthorized use by third parties
        only to the extent that its proprietary technologies are covered by valid
        and
        enforceable patents or are effectively maintained as trade secrets. The Company
        intends to apply for patents covering both its technologies and products
        as it
        deems appropriate. However, existing and future patent applications may be
        challenged and may not result in issued patents. The Company's existing patents
        and any future patents it obtains may not be sufficiently broad to prevent
        others from practicing the Company's technologies or from developing competing
        products. Furthermore, others may independently develop similar or alternative
        technologies or design around the Company's patented technologies. In addition,
        others may challenge or invalidate the Company's patents, or its patents
        may
        fail to provide the Company with any competitive advantages. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company relies upon trade secret protection for its confidential and proprietary
        information. The Company has taken security measures to protect its proprietary
        information. These measures may not provide adequate protection for the
        Company's trade secrets or other proprietary information. The Company seeks
        to
        protect its proprietary information by entering into confidentiality agreements
        with employees, collaborators and consultants. Nevertheless, employees,
        collaborators or consultants may still disclose the Company's proprietary
        information, and the Company may not be able to meaningfully protect its
        trade
        secrets. In addition, others may independently develop substantially equivalent
        proprietary information or techniques or otherwise gain access to the Company's
        trade secrets. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        inability of the Company to adequately protect its proprietary technologies
        could have a material adverse impact on the Company's business, operating
        results and financial condition. </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-27</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Litigation,
        Other Proceedings or Third Party Claims of Intellectual Property Infringement
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's commercial success is dependent in part on neither infringing patents
        and proprietary rights of third parties, nor breaching any licenses that
        the
        Company has entered into with regard to its technologies and products. Others
        have filed, and in the future are likely to file, patent applications covering
        genes or gene fragments that the Company may wish to utilize with the Dyadic
        Platform Technology&#160;or products or&#160;systems&#160;that are similar to
        products or&#160;systems&#160;developed with the use of it. If these patent
        applications result in issued patents and the Company wishes to use the claimed
        technology, the Company would need to obtain a license from the third party.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Third
        parties may assert that the Company is employing their proprietary technology
        without authorization. In addition, third parties may obtain patents in the
        future and claim that the Company's technologies infringe these patents.
        The
        Company could incur substantial costs and diversion of management and technical
        personnel in defending itself against any of these claims or enforcing its
        patents or other intellectual property rights against others. Furthermore,
        parties making claims against the Company may be able to obtain injunctive
        or
        other equitable relief which could effectively block the Company's ability
        to
        further develop, commercialize and sell products, and could result in the
        award
        of substantial damages against the Company. If a claim of infringement against
        the Company is successful, the Company may be required to pay damages and
        obtain
        one or more licenses from third parties. The Company may not be able to obtain
        these licenses at a reasonable cost, if at all. In that event, the Company
        could
        encounter delays in product commercialization while it attempts to develop
        alternative methods or products. Defense of any lawsuit or failure to obtain
        any
        of these licenses could prevent the Company from commercializing available
        products. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
        the taxonomic classification of the Company&#8217;s C1 organism was determined using
        classical morphological methods.&#160; More modern taxonomic classification
        methods indicate that C1 will be reclassified as a different genus and species.
        With the genomic sequence and the partial annotation of the C1 genome to
        date,
        the Company is in the process of determining with higher certainty the most
        likely genus and species of C1. Some of the possible species that C1 could
        be
        reclassified as could be the subject of patent rights owned by others.&#160; The
        Company believes, based on its evaluation of the relevant field of science
        and
        its discussions with its consulting professionals that any such patent rights
        would be invalid, and were litigation over the issue to ensue, the Company
        believes that it should prevail.&#160; If the Company did not prevail, to settle
        any such litigation or pre-litigation claims, it could be required to enter
        into
        a cross-licensing arrangement, pay royalties or be forced to stop
        commercialization of some of its activities. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company does not fully monitor the public disclosures of other companies
        operating in its industry regarding their technological development efforts.
        If
        the Company did evaluate the public disclosures of these companies in connection
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
        their technological development efforts and determined that they violated
        the
        Company's intellectual property or other rights, the Company would anticipate
        taking appropriate action, which could include litigation. However, any action
        the Company takes could result in substantial costs and diversion of management
        and technical personnel. Furthermore, the outcome of any action taken by
        the
        Company to protect its rights may not be resolved in the Company's favor
        or may
        not be resolved for a lengthy period of time. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Real
        Estate Purchase Contract</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        May
        2005, the Company purchased an undeveloped 1.13 acre parcel of land (the
&#8220;Site&#8221;)
        pursuant to a real estate purchase contract with F&amp;C Holdings, LLC
        (&#8220;Holdings&#8221;) dated July 31, 2004 (the &#8220;Commercial Land Purchase And Sale
        Agreement&#8221;) (see Note 9). The Company formed Dyadic Real Estate Holdings, Inc.,
        a Florida corporation and wholly owned subsidiary in May 2005, to which it
        has
        assigned the Commercial Land Purchase and Sale Agreement and the
        Site.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Site,
        which is in a planned community known as "Abacoa" is located in the Town
        of
        Jupiter, Florida (the &#8220;Town&#8221;). The Company has obtained final approval from the
        Town of Jupiter to construct approximately a 40,000 square foot commercial
        office biotech research and development building.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Commercial Land Purchase and Sale Agreement obligates Dyadic to commence
        development of the Site within two (2) years following the closing date (ending
        July 31, 2007). During this two-year period, Dyadic is prohibited from
        re-transferring the Site to any other person other than (i) in connection
        with a
        sale of Dyadic, (ii) to an affiliate or (iii) with the approval of Dyadic's
        Board of Directors (a majority of its independent directors), to the Francisco
        Trust, the Mark A. Emalfarb Trust and/or any entity that is controlled, directly
        or indirectly, by Mark A. Emalfarb and/or his family members. It is not the
        Company&#8217;s intention to use its own funds to develop this Site, therefore the
        Company is considering such options as a joint venture or other arrangement
        to
        accomplish the development of the Site. There can be no assurance, however,
        that
        any joint venture or other arrangements will occur within the prescribed
        timeframe. </font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-28</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        after
        July 31, 2007, Dyadic has not commenced development of the Site, then at
        the
        election of Holdings, in exchange for a reconveyance Deed, it must pay to
        Dyadic
        a "Reconveyance Purchase Price" equal to the greater of the following: (i)
        $1.0
        million or (ii) the "Market Value" of the shares of the Company's common
        stock,
        as defined, determined as of the date of the reconveyance notice from Holdings.
        The Reconveyance Purchase Price can be paid in all cash, or return of all
        the
        shares of the Company's common stock to the Company so long as the Market
        Value
        of the shares of the Company's common stock is greater than or equal to $1.0
        million, or by combination of shares of the Company's common stock and cash,
        as
        determined in the sole and absolute discretion of Holdings. The Company is
        currently assessing its alternatives for the Site.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11.
        Segment Data Information</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating
        segments are defined as components of an enterprise engaging in business
        activities about which separate financial information is available that is
        evaluated regularly by the chief operating decision maker or group in deciding
        how to allocate resources and in assessing performance. Utilizing these
        criteria, the Company has identified its reportable segments based on the
        geographical markets they serve, which is consistent with how the Company
        operates and reports internally. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company has three reportable segments: U.S. operations, Asian operations
        and
        Netherlands operations. The U.S. reportable segment includes a subsidiary
        in
        Poland that is considered auxiliary and integral to the U.S. operations.
        The
        accounting policies for the segments are the same as those described in the
        summary of significant accounting policies. The Company accounts for
        intersegment sales as if the sales were to third parties, that is, at current
        market prices. The U. S. operating segment is a developer, manufacturer and
        distributor of enzyme products, proteins, peptides and other bio-molecules
        derived from genes, and a collaborative licensor of enabling proprietary
        technology for the development and manufacturing of biological products and
        use
        in research and development. The Asian operating segment is engaged in the
        manufacturing and distribution of chemical and enzyme products to the textile
        and pulp and paper industries. The Netherlands operating segment is also
        a
        developer of enzyme products, proteins, peptides and other bio-molecules
        derived
        from genes and to date has invested solely in research and development
        activities. In 2006, one customer in the Asian operating segment accounted
        for
        approximately 10% of net sales. In 2005 one customer in the US operating
        segment
        and one customer in the Asian operating segment accounted for approximately
        10%
        each of net sales.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        following table summarizes the Company's segment and geographical information:
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="14" valign="bottom" width="54%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31, 2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>U.S.
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Asian
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Netherlands
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Eliminations</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Totals</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  Sales:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">External
                  customers</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,330,948</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,052,806</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,383,754</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intersegment</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,057,910</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">393,274</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,451,184</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  net sales</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,388,858</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,446,080</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,451,184</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,383,754</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Loss)
                  Income from operations</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,125,912</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">151,794</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(734,120</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(26,914</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,735,152</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment
                  income</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">562,707</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,037</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">55</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(59,905</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">504,894</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
                  expense </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(580,961</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(73,107</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">59,905</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(594,163</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
                  and amortization</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">142,626</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">103,558</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,997</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">250,181</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Capital
                  expenditures</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">391,192</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">66,033</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">62,246</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">519,471</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  assets at December 31, 2006</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">45,033,599</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,357,972</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">90,838</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5,345,029</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">45,137,380</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-29</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="14" valign="bottom" width="54%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31, 2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>U.S.
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Asian
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Netherlands
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Eliminations</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Totals</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  Sales:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">External
                  customers</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,697,517</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,185,452</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,882,969</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intersegment</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">883,054</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(883,054</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  net sales</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,580,571</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,185,452</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(883,054</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,882,969</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Loss)
                  Income from operations</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,167,942</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">141,866</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,037,308</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">77,489</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,985,895</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment
                  income</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">291,407</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">742</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">20</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(42,889</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">249,280</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
                  expense (a)</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(511,793</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(65,603</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(176,030</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">42,889</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(710,537</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
                  and amortization</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">154,177</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">61,917</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">386,636</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">602,730</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Capital
                  expenditures</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">216,187</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">167,101</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,552</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">410,840</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  assets at December 31, 2005</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,886,076</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,406,963</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">73,768</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2,613,743</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">23,753,064</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)
        Interest expense relating to the purchase by the U.S. operating segment of
        manufacturing equipment is allocated to the Netherlands operating segment.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.
        Income Taxes</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
        provision for United States income taxes has been recognized for the year
        ended
        December 31, 2006 as the Company has incurred operating losses and has
        established a full valuation allowance. The Company's operations in Poland,
        Hong
        Kong and The Netherlands are subject to income taxes in these jurisdictions.
        The
        provisions for income taxes consist of the following as of December 31, 2006:
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current:</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S.</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign</font></div>
              </td>
              <td width="2%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">63,112</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="2%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S.</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="2%" style="border-bottom: #cceeff thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">63,112</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        United States and foreign components of loss from operations before income
        taxes
        are as follows for the year ended December 31, 2006:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="2%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">United
                  States</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10,174,577</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Hong
                  Kong</font></div>
              </td>
              <td width="2%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">89,562</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  foreign</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(734,065</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="2%" style="border-bottom: white thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10,819,080</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        primary difference between the Company's income tax benefit computed at the
        U.S.
        statutory rate of 34% and the effective tax rates for the years ended December
        31, 2006 and 2005 is the change in the valuation allowance in the respective
        periods that results from the Company fully offsetting the deferred income
        tax
        benefit of its net operating losses. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-30</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        significant components of the Company&#8217;s net deferred tax assets and liabilities
        consisted of the following at December 31, 2006:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="80%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current
                  tax assets and liabilities:</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred
                  research and development obligation</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,762,196</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  expenses </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">244,937</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory
                  reserves</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">218,664</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  items, net</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,825</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incentive
                  stock options</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">88,573</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
                  and amortization</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">219,227</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">&#160;</td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,544,422</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Non-current
                  tax assets and liabilities:</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #cceeff;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  operating loss and tax credit carryforwards</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,839,627</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  non-current</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,839,627</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Valuation
                  allowance</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(15,384,049</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#cceeff">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #cceeff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  deferred tax assets</font></div>
              </td>
              <td width="2%" style="border-bottom: #cceeff thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #cceeff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SFAS
        109
        requires a valuation allowance to reduce the deferred tax assets reported
        if,
        based on the weight of the evidence, it is more likely than not that some
        portion or all of the deferred tax assets will not be realized. After
        consideration of all the evidence, both positive and negative, management
        has
        determined that a full valuation allowance of $15,384,049 against its net
        deferred taxes is necessary as of December 31, 2006. The change in valuation
        allowance for the years ended December 31, 2006 and 2005 is $4,044,688 and
        $4,279,185, respectively.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        December 31, 2006, the Company had approximately $25,956,409 of U.S. net
        operating loss carryforwards remaining, which will expire beginning in 2021.
        As
        a result of certain ownership changes, the Company may be subject to an annual
        limitation on the utilization of its U.S. net operating loss carryforwards
        pursuant to Section 382 of the Internal Revenue Code. A study to determine
        the
        effects of this change, if any, has not been undertaken.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
        reconciliation of the Company&#8217;s income taxes to amounts calculated at the
        federal statutory rate is as follows for the years ended December
        31:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="2%" style="border-bottom: #ffffff thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2006</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></td>
              <td colspan="2" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Federal
                  statutory taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(34.00</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)%</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(34.00</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)%</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">State
                  income taxes, net of federal tax benefit</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3.63</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3.63</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nondeductible
                  items</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.06</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.22</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Change
                  in valuation allowance</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">37.32</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">40.50</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                  and development credits</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1.75</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3.09</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--&#160;</font></td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;%</font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><a name="Item_8A_Controls_and_Procedures"><br></a></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="center">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-31</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="left">
        </div>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">&#160;</div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">&#160;</div>
      <div id="HDR">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21.2
<SEQUENCE>2
<FILENAME>exhibit10_212abengoard.htm
<DESCRIPTION>EXHIBIT 10.21.2 ABENGOA R&AMP;D AGREEMENT
<TEXT>
<html>
  <head>
    <title>
      Exhibit 10.21.2 Abengoa R&amp;D Agreement
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      AGREEMENT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>THIS
      R&amp;D AGREEMENT</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      (this
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Agreement</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      dated
      as of October 26, 2006 (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Agreement
      Date</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      by
      and among DYADIC INTERNATIONAL (USA), INC., a Florida corporation</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      with
      headquarters located at 140 Intracoastal Pointe Drive, Suite 404, Jupiter,
      Florida 33477 (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      and
      ABENGOA BIOENERGY R&amp;D, INC., a Missouri corporation with headquarters
      located at 1400 Elbridge Payne Road, Suite 212, Chesterfield, Missouri
      (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      Dyadic
      and ABRD are sometimes collectively referred to as the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Parties</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
and
      individually as a &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.&#8221;
      Certain capitalized terms used herein have the meanings assigned them in Article
      I hereof. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>RECITALS:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      has
      developed and continues to develop technologies (i) pertaining to the conversion
      of pre-treated biomass using a proprietary technology owned by ABRD into
      compositions containing fermentable sugars and co-products (each a &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Substrate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      and
      (ii) in the field of cellulosic ethanol production via enzymatic hydrolysis
      (collectively, &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      Background Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      Employing the ABRD Background Technology, ABRD has developed the Substrates
      with
      a commercial goal of improving their consistency independent of the identity
      of
      the biomass.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      has developed and continues to develop </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">patented
      and other proprietary technologies pertaining to genes, gene expression, protein
      purification, protein characterization, enzymology, protein engineering,
      molecular evolution, high throughput screening, strain improvement, strain
      optimization and associated refinement, development, processing and
      manufacturing technologies (collectively, the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      Core Technologies</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      is
      engaged in various research and development activities based on these Dyadic
      Core Technologies in the field of ethanol production, including but not limited
      to the development of (i) enzyme compositions (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Enzyme
      Mixtures</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      (ii)
      related Enzyme Mixture treatment processes for the conversion of various
      untreated and/or pre-treated Substrates into fermentable sugars (for each Enzyme
      Mixture, an applicable &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Processing
      Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      and
      (iii) related Enzyme manufacturing processes for the production of those Enzyme
      Mixtures (for each Enzyme Mixture, an applicable &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Manufacturing
      Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      as to
      each, for the production of ethanol (collectively, the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CE
      R&amp;D Activities</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">D.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      intends to conduct a series of related and unrelated research and development
      programs of its own, and/or in collaboration with Third Parties (each a
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Collaboration
      Partner</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      principally, various energy/fuel companies and/or vendors to the energy/fuel
      industry (each an &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      In
      connection with each R&amp;D Program, Dyadic will be performing Foundational
      R&amp;D which may have application to all or most of the R&amp;D Programs, and
      may also perform Applications R&amp;D for the specific Collaboration Partner
      with whom or for whom Dyadic is conducting that R&amp;D Program for or in
      collaboration with. Dyadic intends to conduct each of its R&amp;D Programs in a
      manner in which all Foundational R&amp;D will be applied by Dyadic, as it deems
      necessary or appropriate, to all or any of the R&amp;D Programs, such that for
      purposes of Dyadic&#8217;s dealings with its Collaboration Partners and other Third
      Parties, Dyadic shall be deemed to be conducting, in addition to a specific
      R&amp;D Program in collaboration with or for that Collaboration Partner, a
      discrete master R&amp;D program for the performance of Foundational R&amp;D for
      the benefit of itself and, to the extents same is incorporated by Dyadic into
      products or services licensed, sold or distributed by Dyadic, for its licensees
      and customers (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Master
      R&amp;D Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">E.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      desires to (i) support the development of Foundational R&amp;D and improved
      Enzyme Mixtures, their related Processing Technologies and their related
      Manufacturing Technologies, (ii) license and scale-up the use of such Enzyme
      Mixtures and Manufacturing Technologies, and (iii) demonstrate the value of
      such
      Enzyme Mixtures, their related Processing Technologies and their related
      Manufacturing Technologies, when used in pilot-scale and commercial-scale
      biomass hydrolysis processes using ABRD Background Technology.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Parties understand that the field of cellulosic ethanol is in its early stages,
      and that a very substantial volume of Foundational R&amp;D will be required to
      be completed before meaningful Applications R&amp;D can reasonably be expected
      to yield commercial-scale Enzyme Mixtures and related Processing Technologies
      and Manufacturing Technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">G.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrently
      with the execution and delivery of this Agreement, Dyadic&#8217;s parent, Dyadic
      International, Inc., a Delaware corporation (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic-Parent</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      and
      ABRD are executing and delivering to each other that certain Securities Purchase
      Agreement (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SPA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      pursuant to which ABRD is making a strategic investment in Dyadic-Parent to
      enable Dyadic, in concert with ABRD and other Collaboration Partners, to fund
      Dyadic&#8217;s CE R&amp;D Activities. Dyadic expressly acknowledges and agrees that
      pursuant to the provisions of Section 4.6 of the SPA, Dyadic-Parent has jointly
      and severally guaranteed each of Dyadic&#8217;s obligations to ABRD created by the
      terms and provisions of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">H.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      now
      desires to engage Dyadic to develop for ABRD one or more Enzyme Mixtures, their
      related Processing Technologies and their related Manufacturing Technologies,
      for Substrates approved by the Steering Committee that ABRD will, within a
      reasonable period of time following the Closing Date, deliver to Dyadic (each
      an
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      Substrate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      for
      the purposes of having Dyadic develop and demonstrate a cost-effective Enzyme
      Mixture for each Applicable Substrate (as to each Applicable Substrate, its
      applicable &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Custom
      Enzyme Mixture</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      a
      cost-effective Processing Technology for the processing of each such Custom
      Enzyme Mixture (as to each Applicable Substrate, its related &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Custom
      Processing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      and a
      cost-effective Manufacturing Technology for the production of each such Custom
      Enzyme Mixture (as to each Applicable Substrate, its related &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Custom
      Manufacturing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      ready
      for scale-up to commercial application in ABRD Background Technology, within
      three (3) years following the Steering Committee&#8217;s approval of the applicable
      Statements of Work in respect of those Applicable Substrates (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      R&amp;D Objective</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      and
      to perform such Foundational R&amp;D as Dyadic determines to be necessary or
      appropriate to facilitate the achievement of the ABRD R&amp;D
      Objective.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Parties further wish to provide for Dyadic&#8217;s grant of an option to ABRD to
      license the Custom Enzyme Mixture, Custom Processing Technology and the Custom
      Manufacturing Technology for each Applicable Substrate from Dyadic on a
      non-exclusive basis, with the express understanding that Dyadic shall have
      the
      right to sell each Custom Enzyme Mixture, any related Processing Technology
      Dyadic may develop for such Custom Enzyme Mixture and the Custom Manufacturing
      Technology, or to license any or all of same, to any other Dyadic Collaboration
      Partner, or to any other Third Party, subject to the terms of this
      Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>AGREEMENT:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOW,
      THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
      and the foregoing Recitals, which are incorporated herein and by this reference
      made a part hereof, and for other good and valuable consideration the receipt
      and adequacy of which are hereby mutually acknowledged by Dyadic and ABRD,
      they
      hereby agree as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ARTICLE
      I</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DEFINITIONS</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>AAA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 10.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      Background Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Recital A hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      Facility</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      any ethanol manufacturing facility owned or operated by ABRD or any Affiliate
      of
      ABRD.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      R&amp;D Objective</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital H hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      R&amp;D Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.2 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Action</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 8.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Affiliate,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
with
      respect to a Person, means any other Person controlling, controlled by or under
      common control with, such first Person.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Annual
      R&amp;D Spend Certificate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      New Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 4.4 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      Patent</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.2(b) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      R&amp;D Spend</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      Royalty Rate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.2(b) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      Substrate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital H hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applications
      R&amp;D</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      CE R&amp;D Activities in which technology, whether Dyadic Core Technology,
      Dyadic Improvements, Dyadic New Technology or Jointly Developed Technology,
      are
      used or applied on a specific Substrate or untreated biomass for any customer
      or
      Collaboration Partner of Dyadic. As an example, by way of illustration: (i)
      ABRD
      is a Collaboration Partner; (ii) Dyadic may purify and characterize such number
      of different enzymes as it determines to be worth characterizing, which
      activities shall constitute Foundational R&amp;D; (iii) when Dyadic engages in
      testing these different enzymes on the Applicable Substrate, those CE R&amp;D
      Activities will constitute Applications R&amp;D.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Best
      Efforts</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      the efforts that a prudent Person desirous of achieving a result would use
      in
      similar circumstances to ensure that such result is achieved as expeditiously
      as
      practical; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>provided,
      however</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      that an
      obligation to use Best Efforts under this Agreement does not require the Company
      to dispose of or make any change to its business, expend any material funds
      or
      incur any other material burden (except to spend the Applicable R&amp;D Spend,
      as contemplated by Section 2.1 hereof).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CE
      R&amp;D Activities</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital C hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Closing
      Date</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in the SPA.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Collaboration
      Partner</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital D hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercial
      Rules</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 10.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Complex
      Procedures</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 10.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Confidential
      Information</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 6.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Custom
      Enzyme Mixture</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital H hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Custom
      Manufacturing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital H hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Custom
      Processing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital H hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Demand</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 10.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Disclosing
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 6.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dispute</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 10.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      Core Technologies</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital B hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic-Parent</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital G hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      Improvements</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 4.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Section 4.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Enzyme
      Mixtures</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital C hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Foundational
      R&amp;D</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      all technology developed by Dyadic in connection with its conduct of its CE
      R&amp;D Activities, whether related to Dyadic Core Technology, Dyadic
      Improvements or New Technologies, excluding technology developed in connection
      with the conduct of Applications R&amp;D. As an example by way of illustration:
      (i) ABRD is a Collaboration Partner; (ii) Dyadic may purify and characterize
      such number of different enzymes as it determines to be worth characterizing,
      which activities shall constitute Foundational R&amp;D; (iii) when Dyadic
      engages in testing these different enzymes on the Applicable Substrate, those
      CE
      R&amp;D Activities will constitute Applications R&amp;D.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FTE&#8217;s</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.2 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Governmental
      Official</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 12.3 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnified
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 4.5 and Section 8.1 hereof, as
      applicable.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnifying
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 4.5 and Section 8.1 hereof, as
      applicable.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Interchangeable
      Foundational R&amp;D</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.6(b) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Inspection</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 12.5 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Jointly
      Developed Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 4.3 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>License</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      ABRD Facility</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      Enzyme Mixture</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.1(c) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>License
      Fee</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.2(a) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      Manufacturing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      Processing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Section 5.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Manufacturing
      Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital C hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Master
      R&amp;D Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital D hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
      Technology(ies)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      all Dyadic Technology which is derived from either the Master R&amp;D Program or
      the ABRD R&amp;D Program.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
      Applications Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      all technology which is developed by Dyadic (whether exclusively by Dyadic
      or
      whether jointly with ABRD) out of Applications R&amp;D performed in connection
      with the ABRD R&amp;D Program.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Option
      Period</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.1(a).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Other
      R&amp;D Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.6(a) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Person</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      a
      natural person, a corporation, a partnership, a trust, a joint venture, any
      governmental authority or any other entity or organization.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Processing
      Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital C hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Program
      Completion Date</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 9.1.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Qualified
      Manufacturing Sublicense</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.1(c) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      Plan</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.2 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Recital D hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      Spend Measurement Period</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Receiving
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 6.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Royalty</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.2(b).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SPA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning assigned that term in Recital G hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Statement
      of Work</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 2.2 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Steering
      Committee</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 3.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Substrate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Recital A hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Steering
      Committee</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 3.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Technology
      Transfer Fees</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 5.2(c) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Term</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
has
      the
      meaning set forth in Section 9.1 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Third
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      any Person that is not a Party (or an Affiliate of a Party) to this Agreement,
      including without limitation other Collaboration Partners.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      II</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      R&amp;D PROGRAM</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Commitment
      of Dyadic to Engage in CE R&amp;D Activities</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      covenants to ABRD that over the three (3) year period commencing with the date
      of the Steering Committee&#8217;s approval of the first annual Statement of Work (the
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      Spend Measurement Period</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      Dyadic
      will spend not less than $10,000,000 on the conduct of CE R&amp;D Activities
      approved by the Steering Committee (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      R&amp;D Spend</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      whether related to Dyadic&#8217;s performance of its obligations under this Agreement
      (both Foundational R&amp;D and Applications R&amp;D), or its performance of
      Foundational R&amp;D (but not Applications R&amp;D) for its own account or
      Foundational R&amp;D for the benefit of itself and any other Third Parties (but
      not Applications R&amp;D), including but not limited to, by way of illustration,
      and not in limitation: (i) the employment of scientific and non-scientific
      personnel to perform such activities; (ii) the engagement of consultants and
      other independent contractors to perform such activities for Dyadic&#8217;s benefit in
      whole or in part; (iii) the in-licensing of relevant technologies; and (iv)
      the
      purchase or lease of necessary equipment, materials and supplies for use in
      connection therewith, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in
      calculating the amount of Dyadic&#8217;s Applicable R&amp;D Spend, each full-time
      equivalent scientist employed by Dyadic in the conduct of CE R&amp;D Activities,
      Dyadic shall be deemed to have incurred $**** of Applicable R&amp;D Spend for
      each year during the R&amp;D Spend Measurement Period in which such scientist is
      so employed, pro-rated for any partial year (treating any independent contractor
      as an employee for purposes of the foregoing proviso), </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>further
      provided that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      any
      Applicable R&amp;D Spend made by Dyadic on or after the Agreement Date, up to a
      maximum of $****, shall be treated as if it were expended during the R&amp;D
      Spend Measurement Period. Within one hundred twenty (120) days following the
      close of each calendar year beginning or ending within the R&amp;D Spend
      Measurement Period, Dyadic-Parent Chief Financial Officer shall furnish ABRD
      with a detailed written report (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Annual
      R&amp;D Spend Certificate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      certifying the amount of the Applicable R&amp;D Spend made by Dyadic in the year
      then ended and the cumulative amount of the Applicable R&amp;D Spend made by
      Dyadic since the Closing Date, with a final Annual R&amp;D Spend Certificate to
      be to be furnished by Dyadic to ABRD within one hundred twenty (120) days of
      the
      Program Completion Date; provided that representatives of ABRD, upon reasonable
      advance notice and at ABRD&#8217;s expense, shall have the right to have an
      independent accounting firm review the books and records of Dyadic and
      Dyadic-Parent upon the condition that such independent accounting firm execute
      and deliver to Dyadic and Dyadic-Parent a confidentiality agreement in form
      and
      substance reasonably acceptable to Dyadic-Parent&#8217;s legal counsel, to verify the
      accuracy of the calculations set forth in the CFO&#8217;s Annual R&amp;D Spend
      Certificate, further provided that if such examination shall disclose a more
      than 5% negative variance between the amount of the Applicable R&amp;D Spend for
      the applicable year, Dyadic shall pay all of the expenses of such independent
      accounting firm.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Scope
      of ABRD R&amp;D Program</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      shall use its good faith Best Efforts to supply the necessary scientific staff,
      materials, laboratories, offices and other facilities to perform the CE R&amp;D
      Activities described in the R&amp;D Plan attached hereto as Exhibit A (the
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      Plan</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      in
      furtherance of the ABRD R&amp;D Objective (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      R&amp;D Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      including without limitation the performance of the CE R&amp;D Activities
      contemplated by statements of work to be approved by the Steering Committee
      for
      CE R&amp;D Activities to be engaged in for each calendar year falling within the
      Term (each a &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Statement
      of Work</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      in
      accordance with the provisions of Article III hereof, which shall identify
      with
      reasonable specificity: (i) the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">tasks
      and
      stages </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
      the
      ABRD R&amp;D Program to be completed, (ii) the cost associated therewith
      denominated in number of full time equivalent scientific personnel
      (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FTE&#8217;s</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      committed per year at the rate of $**** per FTE, and (iii) the applicable
      achievement milestones reasonably expected to be attained with each task, stage
      and phase. The Parties expressly agree that the R&amp;D Plan necessarily
      comprises both Foundational R&amp;D and Applications R&amp;D.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Funding
      of ABRD R&amp;D Program</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      shall be solely responsible for all costs associated with funding its
      performance of the ABRD R&amp;D Program.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.4</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Commencement
      of ABRD R&amp;D Program</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      shall commence performance of its CE R&amp;D Activities in connection with the
      ABRD R&amp;D Program immediately following the execution and delivery of this
      Agreement, and shall ramp-up those CE R&amp;D Activities over the next twelve
      (12) calendar months, as it reasonably determines, in consultation with ABRD
      in
      accordance with the R&amp;D Plan.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.5</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>No
      Assurance of Commercial Success</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      covenants to ABRD that during the Term of this Agreement Dyadic will use its
      good faith Best Efforts to achieve the ABRD R&amp;D Objective. However,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      expressly acknowledges that due to the existing inchoate state of the Dyadic
      Technology in the cellulosic ethanol field and the inherent risks associated
      with the CE R&amp;D Activities, Dyadic can not and does not assure ABRD that the
      ABRD R&amp;D Program will culminate in the successful achievement of the ABRD
      R&amp;D Objective, let alone any Custom Enzyme Mixture and related Custom
      Manufacturing Technology that ABRD will have any commercial interest in
      licensing. Accordingly, ABRD hereby expressly agrees except in the instance
      of a
      material breach by Dyadic of its obligations to ABRD hereunder, Dyadic shall
      have no liability of any kind whatsoever to ABRD by reason of the failure of
      the
      ABRD R&amp;D Program to successfully achieve the ABRD R&amp;D Objective or to
      produce any such Custom Enzyme Mixture and\or Custom Manufacturing Technology.
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.6</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Dyadic
      Entry into R&amp;D and Other Agreements with Third Parties and Use of
      Foundational R&amp;D Not Performed in the ABRD R&amp;D
      Program</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      expressly acknowledges that Dyadic is in no way whatsoever prohibited from
      entering into research and development agreements or other forms of
      collaboration or research and development agreements with Collaboration Partners
      and other Third Parties of any kind whatsoever, whether such agreements pertain
      to the Substrates derived from biomass of the kinds used by ABRD or not, or
      otherwise conducting any other R&amp;D Programs (each an &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Other
      R&amp;D Program</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in no
      event shall the terms of any such agreement with any other Person (i) impair
      Dyadic&#8217;s ability to comply fully with the terms of this Agreement, including the
      Dyadic&#8217;s obligation to grant to ABRD the commercial rights described in Article
      V hereof and (ii) require or contemplate Dyadic to breach any obligations of
      confidentiality to ABRD created by the provisions of Article VI
      hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
      ABRD expressly acknowledges that Dyadic shall be free to use Foundational
      R&amp;D developed from Other R&amp;D Programs to satisfy requirements for the
      performance of such Foundational R&amp;D for the ABRD R&amp;D Program
      (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Interchangeable
      Foundational R&amp;D</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      and
      to have such Interchangeable Foundation R&amp;D performed in conjunction with
      one or more Other R&amp;D Programs if Dyadic determines, in its commercially
      reasonable discretion, that performance of that Interchangeable Foundational
      R&amp;D in any such Other R&amp;D Program is cost-effective or otherwise
      commercially desirable, and that doing so materially improves the prospects
      for
      achieving the ABRD R&amp;D Objective; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      (i) the
      ABRD representatives to the Steering Committee shall first be furnished with
      a
      complete presentation of Dyadic plans in connection therewith which, from a
      commercial reasonableness standard, demonstrates that the use of the
      Interchangeable Foundational R&amp;D from such Other R&amp;D Program would not
      materially diminish Dyadic&#8217;s R&amp;D effort being applied to the development of
      Custom Enzyme Mixtures, and related Custom Processing Technologies and Custom
      Manufacturing Technologies, for ABRD and (ii) the use of such Interchangeable
      Foundational R&amp;D from any Other R&amp;D Program will not materially impair
      or limit ABRD in its enjoyment of its option to license the commercial rights
      described in Article V, below. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      expressly acknowledges and agrees that certain Foundational R&amp;D to be
      performed in the ABRD R&amp;D Program may be performed by Dyadic in satisfaction
      of Dyadic obligations to perform the same Foundational R&amp;D for Third
      Parties, whether pursuant to Other R&amp;D Programs or not.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      III</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>STEERING
      COMMITTEE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Formation
      and Duration</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Within
      ninety (90) days following the Agreement Date, the Parties shall establish
      an
      advisory board for the purposes set forth in Section 3.2 and with a composition
      specified by Section&#160;3.3 (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Steering
      Committee</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      Except to the extent otherwise provided by mutual written agreement of the
      Parties, the Steering Committee shall not disband until the expiration of the
      Term or the earlier termination of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Functions
      of Steering Committee</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      functions of the Steering Committee shall be: (i) to approve the first annual
      Statement of Work submitted by Dyadic, which shall occur not more than one
      hundred eighty (180) days following the Agreement Date, and thereafter approve
      annual Statements of Work for each subsequent calendar year falling within
      the
      Term not less than thirty (30) days prior to the commencement of each such
      calendar year, which Statements of Work shall reflect decisions of the Steering
      Committee regarding research strategies, levels of effort (resources assigned)
      for each task listed therein, and to prioritize activities; (ii) to determine
      whether CE R&amp;D Activities are Foundational R&amp;D or Applications R&amp;D;
      (iii) to determine which ABRD Substrates should become Applicable Substrates
      and
      make adjustments or modifications to each Statement of Work, as necessary to
      improve the prospects of achieving the ABRD R&amp;D Objective; (iv) to monitor
      Dyadic&#8217;s progress in achieving the performance benchmarks fixed in each
      Statement of Work and provide overall guidance to Dyadic&#8217;s assigned researchers
      with regard thereto; (v) to monitor and control the ABRD R&amp;D Program budget
      and to consider whether any proposed changes should be made to the R&amp;D Plan
      and its execution; and (vi) to exchange suggestions, ideas and recommendations
      pertaining to the overall achievement of the ABRD R&amp;D Objective. In addition
      to the voting members of the Steering Committee designated pursuant to
      Section&#160;3.3, the Steering Committee may also have non-voting members
      nominated by one Party and approved by the other Party in its absolute
      discretion. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Composition</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      shall designate a total of two (2)&#160;employees or officers of Dyadic to
      represent Dyadic, and ABRD shall designate two (2)&#160;employees or officers of
      ABRD or its Affiliates to represent ABRD on the Steering Committee. Only
      representatives designated pursuant to this Section&#160;3.3 shall have the
      right to vote on the Steering Committee, provided that if any representative
      of
      a Party is unable to attend a meeting of the Steering Committee, another
      representative of that Party shall be entitled to attend and vote in his or
      her
      stead. The number of voting representatives may be increased upon mutual written
      agreement of the Parties. Each Party shall appoint or nominate its respective
      representatives to the Steering Committee and, from time to time, may substitute
      one or more of its representatives. Additional representatives or consultants
      of
      a Party may from time to time, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      the
      consent of the other Party (with such consent not to be unreasonably withheld
      or
      delayed) attend meetings of the Steering Committee, subject to such
      representative&#8217;s and/or consultant&#8217;s agreement to comply with the
      confidentiality obligations equivalent to those set forth in Article VI and
      provided that such additional representatives shall have no vote. The Steering
      Committee may establish such working groups or sub-committees as it may choose
      from time to time to accomplish its purposes.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.4</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Governance</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      Steering Committee shall be chaired by one of the members of the Steering
      Committee, who shall be a representative of Dyadic. Decisions of the Steering
      Committee, shall be made by unanimous vote (with each Party&#8217;s voting
      representatives participating in the vote collectively having one (1)&#160;vote.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.5</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Meetings</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      Steering Committee shall meet not less than once every four (4) months in
      accordance with a schedule established by mutual written agreement of the
      Parties, with the location for such meetings determined by agreement of the
      Parties. Either Party may call for non-scheduled meetings of the Steering
      Committee for good cause, which shall occur at mutually agreeable times. The
      Steering Committee, upon mutual agreement, may meet by means of teleconference,
      videoconference or other similar communications equipment. No meeting may be
      conducted unless at least two (2)&#160;voting representatives of each Party are
      participating. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.6</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Records</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      chair of the Steering Committee, or his/her designee, shall have responsibility
      for preparing minutes of each meeting. Such minutes shall provide a description,
      in reasonable detail, of the discussions at the meeting and decisions made
      by
      the Steering Committee. Such minutes shall be circulated on a confidential
      basis
      to all members of the Steering Committee within thirty (30) days following
      such
      meeting.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      IV</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INTELLECTUAL
      PROPERTY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Dyadic
      Ownership of Intellectual Property</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      is the sole and exclusive owner of all intellectual property rights (i) in
      Dyadic Core Technologies, (ii) in all improvements thereto made or contributed
      to in whole or in part by Dyadic outside of the ABRD R&amp;D Program (&#8220;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      Improvements</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      and
      (iii) except for (x) certain &#8220;Jointly Developed Technology&#8221; (as defined in
      Section 4.3, below) and (y) ABRD Background Technology, in all Enzyme Mixtures,
      Processing Technologies, Manufacturing Technologies and any other New
      Applications Technology developed by Dyadic in its conduct of the ABRD R&amp;D
      Program and the Master R&amp;D Program, whether alone or in collaboration with
      any Third Parties (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
      Technologies</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,&#8221;
and
      together with the Dyadic Core Technologies and the Dyadic Improvements,
      collectively &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
      Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      in
      order that Dyadic is able to freely research, develop and commercialize for
      manufacture, distribution, sale and/or license such Dyadic Technology or
      otherwise grant commercial rights to use the Dyadic Technology to Third Parties,
      including without limitation Collaboration Partners. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>ABRD
      Ownership of its ABRD Background Technology</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      ABRD
      shall provide Dyadic with proprietary samples of various Applicable Substrates
      from time to time, as approved by the Steering Committee, and may disclose
      certain proprietary ABRD information pertaining to the source and composition
      of
      each such Applicable Substrate for the purpose of enabling Dyadic to perform
      the
      R&amp;D Plan. ABRD shall remain the exclusive owner of all ABRD Background
      Technology, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      to the
      extent that any ABRD Background Technology is incorporated into any Dyadic
      Technology, including but not limited to any Processing Technology, any
      Manufacturing Technology or any other Enzyme Mixture that Dyadic may develop,
      ABRD shall agree to grant to Dyadic, a license to use such ABRD Background
      Technology in accordance with the provisions of subsection (d) below in any
      manner Dyadic chooses, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>further
      provided that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
      shall obtain ABRD&#8217;s prior written approval to incorporate each ABRD Background
      Technology into any Dyadic Technology, provided that ABRD shall consent thereto
      unless to grant such consent would cause ABRD to suffer a clear and convincing
      material adverse affect on its business, taken as a whole;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      order
      to be eligible to such approval, Dyadic shall disclose in writing to ABRD each
      Dyadic Technology into which such ABRD Background Technology is incorporated
      and
      the method of such incorporation as promptly as practicable but in no case
      later
      than two (2) weeks after such incorporation, and Dyadic shall not enter into
      any
      agreement which restricts its ability to make any such disclosure;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
      no
      event shall Dyadic identify or otherwise disclose to any Third Party as ABRD
      Background Technology any ABRD Background Technology incorporated into any
      Dyadic Technology, nor shall Dyadic disclose any other information in breach
      of
      its obligations of confidentiality as set forth hereunder; and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">any
      license granted by ABRD to Dyadic under this Section 4.2 shall not be effective
      until the Parties have entered into a definitive license agreement granting
      to
      Dyadic a license to use, make, have made and sell products or services
      incorporating such ABRD Background Technology or any derivation thereof, on
      a
      world-wide, irrevocable, paid-up, non-exclusive, royalty-free, but freely
      transferable and freely sub-licensable basis, in consideration for Dyadic&#8217;s
      payment to ABRD of a one-time license fee in an amount which shall be
      commercially reasonable in light of the relevant circumstances, provided that
      if
      the Parties, after negotiating in good faith, are unable to agree upon the
      one-time license fee within a reasonable period of time following Dyadic&#8217;s
      request for any such license, such license fee shall be determined by binding
      arbitration in accordance with the provisions of Article X hereof, further
      provided in any event that such license fee and other terms shall be not less
      favorable to Dyadic then the most favorable terms offered by ABRD to any other
      licensee of ABRD Background Technology.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Jointly
      Developed Technology</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Subject
      to the last sentence of this Section 4.3, if any technology directly or
      indirectly related to the CE R&amp;D Activities, shall, under applicable U.S.
      patent laws, be deemed to be jointly developed by Dyadic and ABRD in connection
      with the completion of any facet of the ABRD R&amp;D Program (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Jointly
      Developed Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      then:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)
      if
      the Jointly Developed Technology relates to either (x) Dyadic&#8217;s Core Technology,
      any Dyadic Improvements thereto and any New Technologies other than New
      Applications Technology or (y) any Enzyme Mixture and related Processing
      Technology and \or Manufacturing Technology developed by Dyadic, ABRD shall
      assign exclusive ownership thereof to Dyadic, and ABRD shall enjoy no rights
      therein except to the extent of a License from Dyadic on the terms set forth
      in
      Article V hereof; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      the
      Jointly Developed Technology:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">relates
      to the ABRD Background Technology other than New Applications Technology, Dyadic
      shall assign exclusive ownership thereof to ABRD, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      ABRD
      shall license such Jointly Developed Technology to Dyadic to use, make, have
      made and sell products or services incorporating such Jointly Owned Technology
      or any derivation thereof, on a world-wide, irrevocable, paid-up, non-exclusive,
      royalty-free, but freely transferable and freely sub-licensable basis, in
      consideration for Dyadic&#8217;s payment to ABRD of a one time license fee in an
      amount which shall be commercially reasonable in light of the relevant
      circumstances, provided that if the Parties, after negotiating in good faith,
      are unable to agree upon the one-time license fee within a reasonable period
      of
      time following Dyadic&#8217;s request for any such license, such license fee shall be
      determined by binding arbitration in accordance with the provisions of Article
      X
      hereof, further provided in any event that such license fee and other terms
      shall be not less favorable to Dyadic then the most favorable terms offered
      by
      ABRD to any other licensee of ABRD Background Technology; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">relates
      to New Applications Technology, Dyadic shall assign exclusive ownership thereof
      to ABRD, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      ABRD
      shall license such Jointly Developed Technology to Dyadic to use, make, have
      made and sell products or services incorporating such Jointly Owned Technology
      or any derivation thereof, on a world-wide, irrevocable, paid-up, non-exclusive,
      royalty-free, but freely transferable and freely sub-licensable basis, in
      consideration for Dyadic&#8217;s payment to ABRD of a ten dollar ($10.00) one-time
      license fee;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      the
      provisions of subsections (a) and (b) do not apply, then each of Dyadic and
      ABRD
      shall enjoy identical ownership rights in that Jointly Developed Technology
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>except
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      ABRD
      shall be allowed to use such Jointly Developed Technology for any use which
      does
      not constitute the conduct of a trade or business activity which is competitive
      with the enzyme development and manufacturing business in which Dyadic is
      engaged (or in which Dyadic can reasonably demonstrate it was then planning
      to
      engage) on the date such Jointly Developed Technology was
      developed.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      agrees that the term &#8220;Jointly Developed Technology&#8221; also includes any new
      conceptions, ideas, inventions, innovations, concepts, reductions to practice,
      solutions to problems and other know-how or technology which directly or
      indirectly relates to the CE R&amp;D Activities: (i) in the conduct of any
      Steering Committee review meeting, is revealed by ABRD at any such meeting
      or
      arises therefrom; or (ii) is conceived out of ABRD&#8217;s review of any confidential
      information furnished to ABRD by Dyadic in reports or other communications
      furnished or made by Dyadic in connection with its reporting to ABRD on the
      ABRD
      R&amp;D Program. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.4</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Dyadic
      Disclosure of New Technologies to ABRD</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      To the
      extent that Dyadic or its Affiliates develop any New Technology during the
      Term
      of this Agreement, whether derived out of the Master R&amp;D Program or derived
      out of the ABRD R&amp;D Program, that might reasonably have commercial utility
      to any of the Applicable Substrates (each an &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      New Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      Dyadic covenants to ABRD that Dyadic will promptly disclose in writing to ABRD
      each such Applicable New Technology on a timely basis but in no case later
      than
      the next Steering Committee meeting following such development. Such disclosure
      of an Applicable New Technology shall include without limitation, descriptions
      of the nature, the perceived utility of, and the new and/or improved product
      and/or process aspects of that Applicable New Technology; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      shall not be obligated to disclose the identity of any Third Party contributing
      to or expressing a commercial interest in any Applicable New Technology or
      information owned or controlled by a Third Party in respect of which Dyadic
      has
      an obligation of confidentiality. Dyadic covenants that it will not enter into
      any agreement with any Third Party which restricts its ability to grant ABRD
      a
      non-exclusive license for ABRD to practice each Applicable New Technology and
      all Dyadic Technology or to make any such disclosure to ABRD pertaining to
      each
      such Applicable New Technology, to the extent each Applicable New Technology
      is
      owned by Dyadic or its Affiliates; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>except
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      shall be free to grant the first license granted by Dyadic with respect to
      such
      Applicable New Technology on an exclusive basis to a Third Party for the first
      year of such Dyadic license to any such Third Party.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.5</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Third
      Party Infringement</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Each
      Party shall indemnify, defend and hold harmless the other Party and its
      Affiliates and their respective officers, directors, and employees (the
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnifying
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
and
      the
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnified
      Parties</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,&#8221;
      respectively) from any losses, damages, liabilities, fines, penalties, and
      expenses (including reasonable attorneys' fees) that arise out of or result
      from
      any Third Party claims of infringement of any patent or copyright, or
      misappropriation of any trademark, trade secret or other intellectual property
      right, private right, or any other proprietary or personal interest
      (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Infringement
      Claim</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      and
      related by circumstances to the existence of this Agreement and the Dyadic
      Technology, in the case of Dyadic, or the ABRD Background Technology, in the
      case of ABRD, provided by the Indemnifying Party to the Indemnified Party
      hereunder or performance under or in contemplation of this Agreement, except
      to
      the extent such Infringement Claim is due to the infringing acts and/or products
      of the other Party.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Indemnified Parties shall furnish the Indemnified Party with reasonable notice
      of such Infringement Claim and, upon the written request of the Indemnified
      Parties, reasonable assistance and information (at the Indemnifying Party&#8217;s
      expense) in the defense or settlement of such Infringement Claim. The
      Indemnifying Party shall have sole control of the defense and settlement
      negotiations. The Indemnifying Party will not make any statement in its defense
      that is against the interest of Indemnified Parties and will not enter into
      any
      settlement without the consent of the Indemnified Parties that requires an
      admission of guilt or wrong-doing on the part of any of the Indemnified Parties
      or a monetary payment by Indemnified Parties that is in addition to the amount
      Indemnifying Party is obligated to pay on Indemnified Parties&#8217; behalf under this
      Section.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Indemnifying Party will have no obligation to indemnify the Indemnified Parties
      under this Section for Infringement Claims that result solely from: (i) the
      Indemnified Parties&#8217; combination, operation or unauthorized use of the
      Indemnifying Party&#8217;s intellectual property or products supplied by the
      Indemnified Parties or others on behalf of Indemnified Parties where such
      product alone would not be infringing; (ii) any alteration or modification
      of an
      Indemnifying Party&#8217;s products by the Indemnified Parties not approved in writing
      by Indemnifying Party, if the products or intellectual property of the
      Indemnifying Party alone would not be infringing; (iii) the use of any product
      or intellectual property of the Indemnifying Party other than in accordance
      with
      its applicable specifications or documentation for such product or intellectual
      property where same was used in accordance with the applicable specifications
      or
      documentation would not be infringing; or (iv) Indemnifying Party&#8217;s compliance
      with Indemnified Parties&#8217; designs, specifications, or instructions, where the
      product or intellectual property would not be infringing if it were not for
      such
      compliance. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the
      event of an Infringement Claim, or if the Indemnifying Party has reasons to
      believe its product or intellectual property may become the subject of an
      Infringement Claim, the Indemnifying Party will (i)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procure
      for the Indemnified Parties the right to continue to use such product or
      intellectual property, as the case may be; and if such procurement is not
      commercially reasonable; (ii) replace or modify such product or intellectual
      property, or portion thereof, so it is no longer infringing; or (iii) if the
      Indemnifying Party, using commercially reasonable efforts, is unable to do
      (i)
      or (ii) above, refund all moneys paid to the Indemnifying Party by Indemnified
      Parties for such infringing product or intellectual property, less a reasonable
      amount for use based upon a five (5) year straight line depreciation
      calculation. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.6</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Restrictions
      on Dyadic Entry Into Agreements with Third Parties</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      covenants to ABRD that Dyadic shall not enter into any agreement with any Third
      Party which restricts Dyadic&#8217;s ability to license any Custom Enzyme Mixture and
      related Custom Processing Technology and Custom Manufacturing Technology to
      ABRD
      for ABRD to practice.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      V</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      COMMERCIAL RIGHTS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>ABRD
      Commercial Rights</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      In
      respect of each Applicable Substrate, ABRD will have an option for a
      non-exclusive and non-transferable right (except as permitted by the provisions
      of Section 12.8 hereof) to one or multiple licenses (each a &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>License</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      to
      the Custom Enzyme Mixture, related Custom Processing Technology and Custom
      Manufacturing Technology, (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      Enzyme Mixture,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
and
      its
      related &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      Processing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
and
      &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      Manufacturing Technology</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,&#8221;
      respectively) developed by Dyadic for that Applicable Substrate, and on a per
      ABRD Facility basis for the internal consumption of ABRD and its Affiliates
      only
      (and for no other purpose) and only at the site of that licensed ABRD Facility
      (each a &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Licensed
      ABRD Facility</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      except as permitted by the provisions of Sections 5.1(c) and 5.1(e), below.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>License
      Option Exercise Periods</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      The
      option period within which ABRD shall have the right to one or more Licenses
      for
      each &#8220;completed&#8221; Custom Enzyme Mixture and related Custom Processing Technology
      and Custom Manufacturing Technology for an Applicable Substrate shall be the
      ninety (90) day period of time following the completion by ABRD of a
      verification testing period of thirty (30) days after Dyadic has delivered
      to
      ABRD for such verification testing, a completed Applicable Substrate and its
      related Manufacturing Technology </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(as
      to
      such Custom Enzyme Mixture, related Custom Processing Technology and Custom
      Manufacturing Technology, its applicable &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Option
      Period</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Dyadic
      Technology Transfer to ABRD Facility</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      Incident to each License, Dyadic personnel will, promptly, but in no event
      more
      than ten (10) Business Days following the date of the execution of the license
      agreement evidencing the License for such Licensed Enzyme Mixture and related
      Licensed Processing Technology and Licensed Manufacturing Technology, provide
      ABRD with a complete technology transfer of the relevant Licensed Processing
      Technology and Licensed Manufacturing Technology and know-how to use the
      Licensed Enzyme Mixture and related Licensed Manufacturing Technology at the
      Licensed ABRD Facility.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>ABRD
      Licensed Usage</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      Each
      License will permit ABRD to use the Licensed Enzyme Mixture and related Licensed
      Processing Technology and Licensed Manufacturing Technology solely for the
      production of ethanol for the internal consumption of ABRD and its Affiliates,
      and only on-site at the specifically Licensed ABRD Facility. Except for
&#8220;Qualified Manufacturing Sublicenses&#8221; (as defined below) and &#8220;Qualified Entire
      System Sublicenses&#8221; described in Section 5.1(e), each License will prohibit ABRD
      from selling, licensing or otherwise transferring either the Licensed
      Manufacturing Technology and/or Processing Technology, in whole or in part,
      or
      any of the Licensed Enzyme Mixture it produces, to any Third Party. ABRD shall
      have the right to grant a manufacturing sub-license of the Licensed Processing
      Technology and\or Manufacturing Technology for the exclusive purpose of enabling
      that manufacturing sub-licensee to manufacture such Licensed Enzyme Mixture
      solely for the internal consumption of ABRD and its Affiliates, and for no
      other
      purpose (a &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Qualified
      Manufacturing Sublicense</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      no term
      of such sub-license shall be in any way inconsistent with ABRD&#8217;s obligations to
      Dyadic under ABRD&#8217;s License and ABRD shall, except in the case where the
      sublicensee&#8217;s principal place of business and situs of its usage of the Licensed
      Enzyme Mixture is located in North America or the European Union, first obtain
      the prior written consent of Dyadic, which consent shall not be unreasonably
      withheld or delayed, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>further
      provided that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      no such
      Qualified Manufacturing Sublicense shall be entered into until Dyadic shall
      have
      reviewed same and commercially reasonably satisfied itself that the terms
      thereof fully protect Dyadic against any prohibited use of the Licensed Enzyme
      Mixture and the related Licensed Processing Technology and Licensed
      Manufacturing Technology </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      the
      dissemination of Dyadic Technology outside the sub-licensee&#8217;s use and
      control.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Most
      Favored Nation Royalty Protection</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      If
      Dyadic offers a license of the Licensed Enzyme Mixture (but not any other Enzyme
      Mixture) to any licensee upon royalty terms more favorable to such licensee
      than
      the terms of the License to ABRD set forth herein, ABRD&#8217;s &#8220;Royalty&#8221; (as that
      term is defined in Section 5.2(b)) for the usage of that Enzyme Mixture shall,
      effective as of the date of such other licensing transaction, be reduced to
      the
      Royalty fixed in that other licensing transaction. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Qualified
      Entire System Sublicenses</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      Notwithstanding any provision to the contrary, ABRD shall have the right to
      sub-license the Licensed Enzyme Mixture and related Licensed Processing
      Technology and Licensed Manufacturing Technology to a Third Party solely for
      such Third Party&#8217;s internal consumption of the Licensed Enzyme Mixture upon the
      following conditions: (i) such sublicense is made incident to ABRD&#8217;s license of
      ABRD&#8217;s ethanol production system into which Dyadic&#8217;s Licensed Processing
      Technology and\or Licensed Manufacturing Technology has been incorporated;
      (ii)
      except for the royalty terms and the right of such Third Party sub-licensee
      to
      use the Licensed Enzyme Mixture and related Licensed Processing Technology
      and
      Licensed Manufacturing Technology for its own internal consumption (and not
      to
      produce Licensed Enzyme Mixture for ABRD or any other Third Parties), no term
      of
      such sub-license shall be in any way inconsistent with ABRD&#8217;s obligations to
      Dyadic under its License; (iv) such Qualified Entire System Sublicense shall
      not
      be entered into by ABRD until Dyadic shall have reviewed same and commercially
      reasonably satisfied itself that the terms thereof fully protect Dyadic against
      any prohibited use of the Licensed Enzyme Mixture and the related Licensed
      Processing Technology and Licensed Manufacturing Technology </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      the
      dissemination of Dyadic Technology outside the sub-licensee&#8217;s use and control;
      (iii)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      such
      Third Party sub-licensee shall pay the same License Fees and Technology Transfer
      Fees to Dyadic as are fixed by subsections (a) and (c) of Section 5.2; (iv)
      ABRD
      shall, except in the case where the sub-licensee&#8217;s principal place of business
      and situs of its usage of the Licensed Enzyme Mixture is located in North
      America or the European Union, first obtain the prior written consent of Dyadic,
      which consent shall not be unreasonably withheld or delayed; and (v) ABRD shall
      pay to Dyadic a Royalty and License Fees on such Third Party Qualified Entire
      System Sublicense at the same License Fee rate and a royalty rate equal to
      the
&#8220;Applicable Royalty Rate&#8221; fixed in Section 5.2(a) and 5.2(b),
      respectively.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>License,
      Tolling and Technology Transfer Fees for Each License</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      part
      consideration for the commercial rights granted by Dyadic to ABRD, ABRD shall
      pay the following amounts to Dyadic separately for each License:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>License
      Fee Per License</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ABRD
      shall pay to Dyadic a one-time license fee of $**** per **** gallons of ethanol
      capacity for the Licensed Enzyme Mixture and related Licensed Processing
      Technology and Licensed Manufacturing Technology for the Licensed ABRD Facility
      upon Dyadic&#8217;s delivery of the that Licensed Manufacturing Technology to that
      Licensed ABRD Facility (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>License
      Fee</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      (i) the
      maximum License Fee per License is $**** and (ii) not more than **** License
      Fee
      shall have to be paid in respect of a single ABRD Facility without regard to
      the
      number of Custom Enzyme Mixtures and related Custom Processing Technologies
      and
      Custom Manufacturing Technologies, licensed by ABRD for that particular ABRD
      Facility. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Royalties
      Per License</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      ABRD
      shall pay to Dyadic a royalty in the amount of **** (US$****) per gallon of
      ethanol produced at that Licensed ABRD Facility using that Licensed Enzyme
      Mixture, related Licensed Processing Technology and\or Licensed Manufacturing
      Technology, on a quarterly basis thereafter, for a term of the greater of (x)
      the life of any patents included in either that Licensed Enzyme Mixture and\or
      its related Licensed Processing Technology and\or its related Licensed
      Manufacturing Technology </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(each
      an
&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      Patent</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">or
      (y)
      **** years from the date of the commencement of commercial production of that
      Licensed Enzyme Mixture on-site at that Licensed ABRD Facility, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">provided
      that if the last Applicable Patent shall expire prior to the ****, the royalty
      rate shall drop from US$**** per gallon of ethanol to US$**** per gallon of
      ethanol (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Applicable
      Royalty Rate</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      provided that commencing on ****, and on the first day of each subsequent
      calendar year, the Applicable Royalty Rate shall be adjusted for inflation
      on an
      annual basis, using the United States Consumers Price Index and the year ****
      as
      the reference year</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
      and
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Technology
      Transfer Fees Per License</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
      ABRD
      shall pay to Dyadic fees (calculated at **** of Dyadic&#8217;s the fully-loaded
      salaried cost of the deployed personnel performing the applicable transfer
      services) for time expended by Dyadic personnel (and reimburse all reasonable
      out-of-pocket expenses incurred) in completing Dyadic&#8217;s transfer of that
      Licensed Enzyme Mixture, related Licensed Processing Technology and related
      Licensed Manufacturing Technology to that Licensed ABRD Facility, and for any
      additional technical services furnished by Dyadic thereafter at that Licensed
      ABRD Facility (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Technology
      Transfer Fees</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Other
      License Terms</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Other
      License provisions, including without limitation, provisions governing (i)
      royalty accounting, (ii) rights controlled by Dyadic which, if enforced against
      ABRD would abrogate or abridge the rights of ABRD under the Licenses granted
      pursuant to this Agreement, (iii) sub-licensor liability for misuse of the
      Licensed Enzyme Mixture and related Licensed Processing Technology and Licensed
      Manufacturing Technology, (iv) confidentiality and related restrictions on
      sub-licensing, (v) ownership of, rights to, and license-back provisions for
      improvements to such Licensed Enzyme Mixture and related Licensed Processing
      Technology and Licensed Manufacturing Technology, (vi) indemnities and (vii)
      other customary license provisions, will all be negotiated by the Parties in
      good faith</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      VI</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CONFIDENTIALITY</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Definition</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Confidential
      Information</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;
means
      any information disclosed by one Party (the "</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Disclosing
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">")
      to the
      other (the "</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Receiving
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">"),
      whether oral, written, visual, electromagnetic, electronic or in any other
      form,
      and whether contained in memoranda, summaries, notes, analyses, compilations,
      studies or other documents, and whether same have been prepared by the
      Disclosing Party or the Receiving Party: (i) which, if in written, graphic,
      machine-readable or other tangible form is marked as "Confidential" or
      "Proprietary," or which, if disclosed orally or by demonstration, is identified
      at the time of initial disclosure as confidential and is summarized in writing
      and similarly marked and delivered to the Receiving Party within thirty (30)
      Days of initial disclosure; and (ii) which is (A) technical data or information,
      including proprietary host organisms and their strains, plasmids/vectors, DNA
      sequences, gene expression, fungal high throughput screening, enzymes and their
      applications, research and manufacturing protocols and practices, formulae,
      charts, analyses, reports, patent applications, trade secrets, ideas, methods,
      processes, know-how, computer programs, products, equipment, raw materials,
      designs, data sheets, schematics, configurations, specifications, techniques,
      drawings, and the like, whether or not relating to experimental data, projects,
      products, processes, research practices and the like, (B) past, present and
      future business, financial and commercial data or information, prices and
      pricing methods, marketing and customer information, financial forecasts and
      projections, and other data or information relating to strategies, plans,
      budgets, sales and the like; and (C) any other data or information delivered
      by
      the Disclosing Party to the Receiving Party or which the Receiving Party has
      acquired from the Disclosing Party by way of the former&#8217;s inspection or
      observation during visits to the research laboratory, manufacturing plan or
      other type of facility of the latter Party. The Parties expressly acknowledge
      and agree that all information of a proprietary and/or confidential nature
      furnished by the Disclosing Party to the Receiving Party in furtherance of
      the
      Disclosing Party&#8217;s obligations under this Agreement shall be deemed Confidential
      Information to which the provisions of this Article VI shall apply.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Confidential
      Information Exclusions</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Confidential Information will exclude information that the Receiving Party
      can
      demonstrate is: (i) now or hereafter, through no unauthorized act or failure
      to
      act on Receiving Party's part, in the public domain; (ii) known to the Receiving
      Party from a source other than the Disclosing Party (including former employees
      of the Disclosing Party) without an obligation of confidentiality at the time
      Receiving Party receives the same from the Disclosing Party, as evidenced by
      written records; (iii) furnished to others by the Disclosing Party without
      restriction on disclosure; or (iv) independently developed by the Receiving
      Party without use of the Disclosing Party's Confidential Information. Nothing
      in
      this Agreement shall prevent the Receiving Party from disclosing Confidential
      Information to the extent the Receiving Party is legally compelled to do so
      by
      any governmental investigative or judicial agency pursuant to proceedings over
      which such agency has jurisdiction; provided, however, that prior to any such
      disclosure, the Receiving Party shall (a) assert the confidential nature of
      the
      Confidential Information to the agency; (b) immediately notify the Disclosing
      Party in writing of the agency's order or request to disclose; and (c) cooperate
      fully with the Disclosing Party in protecting against any such disclosure and/or
      obtaining a protective order narrowing the scope of the compelled disclosure
      and
      protecting its confidentiality.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Confidentiality
      Obligation</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Except
      as provided in Section 6.4, for a period commencing June 10, 2006 and ending
      on
      the fifth anniversary of the expiration of the Term of the Agreement, the
      Receiving Party shall treat as confidential all of the Disclosing Party's
      Confidential Information and shall not use such Confidential Information for
      any
      purpose whatsoever other than for the purposes set forth herein, except as
      expressly otherwise permitted under this Agreement. Without limiting the
      foregoing, the Receiving Party shall use the same degree of care and means
      that
      it utilizes to protect its own information of a similar nature, but in any
      event
      not less than reasonable care and means, to prevent the unauthorized use or
      the
      disclosure of such Confidential Information to Third Parties. The Confidential
      Information may be disclosed only to employees or contractors of the Receiving
      Party with a "need to know" who are instructed and agree not to disclose the
      Confidential Information and not to use the Confidential Information for any
      purpose, except as set forth herein; provided, however, in the case of Dyadic,
      the term "employees or contractors of a Receiving Party" shall include employees
      of each of those of Dyadic&#8217;s independent contractor research organizations with
      whom Dyadic has written agreements pursuant to which such independent contractor
      research organization is bound by an obligation of confidence to Dyadic that
      makes such independent contractor research organization liable for any breach
      by
      its employees of those confidentiality obligations to Dyadic. The Receiving
      Party shall have appropriate written agreements with any such employees or
      independent contractor research organizations sufficient to comply with the
      provisions of this Agreement. A Receiving Party may not alter, decompile,
      disassemble, reverse engineer, or otherwise modify any Confidential Information
      received hereunder and the mingling of the Confidential Information with
      information of the Receiving Party shall not affect the confidential nature
      or
      ownership of the same as stated hereunder.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.4</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Permitted
      Disclosures of Embedded ABRD Confidential Information</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      preceding to the contrary notwithstanding, Dyadic shall be entitled to disclose
      ABRD Confidential Information to Third Parties if the following three (3)
      conditions are satisfied in connection with any such disclosure: (i) such ABRD
      Confidential Information is not identified to any such Third Party as being
      or
      having originated from ABRD Confidential Information; (ii) such disclosure
      of
      ABRD Confidential Information occurs solely by reason of the fact that such
      ABRD
      Confidential Information is embedded or otherwise embodied in Dyadic Technology,
      without regard to whether such Dyadic Technology was derived from Dyadic
      Foundational R&amp;D activities or Applications R&amp;D activities performed by
      Dyadic (whether in the conduct of the ABRD R&amp;D Program or the conduct of the
      Master R&amp;D Program); and (iii) any Third Party to whom such disclosure of
      such ABRD Confidential Information is made is a party to a written
      confidentiality agreement with Dyadic by which such Third Party is bound to
      hold
      such disclosure in confidence. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.5</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Confidentiality
      of Agreement and Superceding of Prior Confidentiality
      Agreement</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      Party agrees that the terms and conditions, but not the existence, of this
      Agreement will be treated as the other Party's Confidential Information and
      that
      no reference to the terms and conditions of this Agreement or to commercial
      metrics and activities pertaining thereto (but no disclosure of any intellectual
      property of ABRD may be made, other than to list same on disclosure schedules)
      may be made in any form of press release or public statement without first
      consulting with the other Party; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided,
      however</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      that
      each Party may disclose the terms and conditions of this Agreement: (i) as
      may
      be required by law; (ii) to legal counsel of the Parties; (iii) in confidence,
      to accountants, banks, and financing sources and their advisors; (iv) in
      confidence, in connection with the enforcement of this Agreement or rights
      under
      this Agreement; or (v) in confidence, in connection with a merger or acquisition
      or proposed merger or acquisition, or the like. The Parties hereby expressly
      agree that the provisions of this Article VI shall supercede the terms of that
      certain Confidentiality Agreement dated June 10, 2006, which shall be of no
      further force and effect, and that this Article VI shall apply to all non-public
      information furnished by Dyadic to ABRD since the June 10, 2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.6</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>No
      Confidential Information of Other Persons</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      Party represents and warrants to the other that it has not used and shall not
      use in the course of its performance hereunder, and shall not disclose to the
      other, any confidential information of any other Person, unless it is expressly
      authorized in writing by such Person to do so.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.7</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Required
      Disclosure</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Each
      Party shall be entitled to make such disclosures as shall be required by law,
      provided that if </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Receiving Party is required to disclose the Disclosing Party's Confidential
      Information pursuant to the order or requirement of a court, administrative
      agency, or other governmental body, the Receiving Party shall provide prompt
      notice thereof to the Disclosing Party and shall use its reasonable efforts
      to
      obtain a protective order or otherwise prevent public disclosure of such
      information.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      VII</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>REPRESENTATIONS
      AND WARRANTIES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Representations
      and Warranties of the Parties</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      Parties represent and warrant that:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">it
      is a
      company duly organized, validly existing and in good standing under the laws
      of,
      in the case of Dyadic, Florida, and in the case of ABRD, Missouri;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      execution of this Agreement on its behalf has been properly authorized by all
      necessary corporate action;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">this
      Agreement is valid and binding on it and enforceable against it in accordance
      with the terms hereof, subject to applicable bankruptcy and similar laws
      affecting creditors&#8217; rights and remedies generally, and subject, as to
      enforceability, to general principles of equity; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">neither
      the execution nor the performance of this Agreement will constitute a breach
      or
      violation of the terms of its charter or organizational documents or any
      contract, agreement or other commitment to which it is a party or by which
      it or
      any of its properties are bound; and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">there
      are
      no bankruptcy, insolvency, receivership or similar proceedings involving it
      or
      any of its Affiliates either pending or being contemplated, or any other pending
      or threatened actions, suits, arbitrations or other proceedings by or against
      it.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Disclaimer</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Except
      for the foregoing warranties (and commercially reasonable warranties of Dyadic
      to ABRD that shall be included in the license agreement evidencing the
      License(s) granted by Dyadic to ABRD in accordance with the provisions of
      Article V hereof), THE FOREGOING WARRANTIES OF EACH PARTY ARE IN LIEU OF ALL
      OTHER WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW,
      STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF
      MERCHANTABILITY AND FITNESS FOR PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY
      DISCLAIMED. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      VIII</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INDEMNIFICATION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>In
      General</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Subject
      to the provisions of Section 9.8 hereof, each Party (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnifying
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      shall
      defend, indemnify and hold harmless the other Party, its Affiliates, and its
      and
      their employees, officers, directors, agents, distributors and licensees (each
      an &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Indemnified
      Party</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      against any loss, damage, expense, or cost, including reasonable attorneys&#8217;
fees, arising out of any claim, demand, action, suit, investigation, arbitration
      or other proceeding by a Third Party (an &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Action</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      based
      on (a) the Indemnifying Party&#8217;s breach of this Agreement; or (b) negligence,
      willful misconduct or violation of any law or regulation by the Indemnifying
      Party, its Affiliates, or its or their employees, officers, directors, or
      agents.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Procedure</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      If an
      Indemnified Party becomes aware of any Action it believes is indemnifiable
      under
      Section&#160;8.1, (a) the Indemnified Party shall give the Indemnifying Party
      prompt written notice of such Action; (b)&#160;the Indemnifying Party shall
      assume, at its expense, the sole defense of such claim or cause of action
      through counsel selected by it and reasonably acceptable to the Indemnified
      Party, except that in the case of a conflict of interest between the Parties,
      the Indemnifying Party shall, at the Indemnifying Party&#8217;s expense, provide
      separate counsel for the Indemnified Party selected by the Indemnified Party;
      (c) the Indemnifying Party shall maintain control of such defense, including
      any
      decision as to settlement, except that any settlement of an Action shall require
      the written consent of both Parties, which consent shall not be withheld or
      delayed unreasonably; (d)&#160;the Indemnified Party may, at its option and
      expense, participate in such defense, and in any event, the Parties shall
      cooperate with one another in such defense; and (e) the Indemnifying Party
      shall
      bear the total costs of any court award or settlement in such Action</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      IX</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>TERM
      AND TERMINATION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Term</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The term
      of this Agreement (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Term</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      unless sooner terminated as below set forth, shall commence as of the Effective
      Date and, end upon the first to occur of: (i) the third anniversary of the
      date
      that the Steering Committee approved the initial Statement of Work; or (ii)
      ABRD&#8217;s receipt of Dyadic&#8217;s written notice of its full funding of the Applicable
      R&amp;D Spend (the &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Program
      Completion Date</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Termination
      for Default</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      If
      either Party materially breaches this Agreement or the SPA and fails to cure
      the
      breach within thirty (30) days after receiving written notice thereof from
      the
      other Party identifying with reasonable specificity the nature of the alleged
      breach, the other Party may terminate this Agreement upon further written notice
      to the breaching Party at any time that the breach remains uncured.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Termination
      for Insolvency</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Either
      Party may terminate this Agreement if the other Party becomes insolvent,
      voluntarily files a petition for relief under bankruptcy or any similar or
      other
      insolvency laws (or has a petition filed against it and the same remains
      undischarged or unstayed for 60 days) or voluntarily or involuntarily enters
      receivership or any similar or other insolvency proceeding. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.4</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Effect
      of Termination</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      In the
      event of termination of this Agreement either on or prior to the expiration
      of
      its fixed term by ABRD or Dyadic:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      this
      Agreement was breached by Dyadic on account of its failure to achieve an
      aggregate cumulative Applicable R&amp;D Spend of not less than $10,000,000.00 on
      or before the close of the R&amp;D Spend Measurement, then Dyadic shall grant to
      ABRD the Licenses fixed in Article V for the Custom Enzyme Mixture, related
      Custom Processing Technology and Custom Manufacturing Technology for each
      Applicable Substrate on a Royalty-free basis (and free of any duty of Royalty
      accounting thereunder), and further, ABRD shall have the right to sublicense
      the
      Enzyme Mixture and related Custom Processing Technology and Custom Manufacturing
      Technology in accordance with the provisions of Sections 5.1(c) and 5.1(e),
      on a
      Royalty-free basis (and free of any duty of Royalty accounting thereunder),
      except that no consent shall be required of Dyadic, provided that the
      obligations of Dyadic to deliver such Licenses to ABRD shall be only as to
      such
      of that technology as has been developed by Dyadic up through the date of the
      breach, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>further
      provided</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      that if
      Dyadic and ABRD are unable to agree upon the material terms of the license
      agreement evidencing the Licenses referred to in Section 5.3 hereof, such that
      the Parties are compelled to resort to arbitration pursuant to the provisions
      of
      Section 10.1, then in that event, without regard to the outcome of such
      arbitration proceedings, Dyadic shall (x) promptly following the execution
      of
      the final form of agreement evidencing such Licenses, reimburse ABRD for all
      reasonable costs (including legal fees) incurred by it in the negotiation,
      arbitration and resolution of the all matters surrounding such arbitration
      and
      the execution and delivery of that form agreement evidencing the Licenses,
      and
      (y) pay all of the costs of the referenced arbitration;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      this
      Agreement is materially breached by ABRD which breach is not cured within the
      time period fixed by the provisions of Section 9.2 hereof, then any provision
      to
      the contrary notwithstanding, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      ABRD
      shall continue to enjoy the benefit of all Licenses granted to it by Dyadic
      pursuant to the provisions of Article V hereof prior to the date of such breach
      (including all rights to grant sublicenses as therein set forth), all further
      rights of ABRD rights to license Custom Enzyme Mixtures and related Custom
      Processing Technologies and Custom Manufacturing Technologies, shall
      automatically terminate, Dyadic shall have no further obligation to continue
      to
      make any Applicable R&amp;D Spend, and Dyadic shall be entitled to damages in
      the amount determined by arbitration pursuant to the provisions of Article
      X
      (except in the instance where the provisions of Section 10.3 shall apply, in
      which case such damages shall be determined by a court of competent
      jurisdiction); and</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if
      this
      Agreement is materially breached by Dyadic for any reason other than that set
      forth in subsection (a), above, which breach is not cured within the time period
      fixed by the provisions of Section 9.2 hereof, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>provided
      that</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      shall continue to enjoy all of the benefit of all licenses granted to it by
      ABRD
      pursuant to the provisions of Sections 4.2 and 4.3(b) hereof prior to the date
      of such breach (including all of the rights in respect thereof set forth
      therein), all further rights of Dyadic to license ABRD Background Technology
      under Section 4.2 and Jointly Developed Technology under Section 4.3(b) shall
      automatically terminate. In addition to enjoying the commercial rights set
      forth
      in Article V hereof, ABRD shall be entitled to damages in the amount determined
      by arbitration pursuant to the provisions of Article X (except in the instance
      where the provisions of Section 10.3 shall apply, in which case such damages
      shall be determined by a court of competent jurisdiction).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.5</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Dyadic
      Breach of Covenant to Make Applicable Spend</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      hereby covenants and agrees that if Dyadic breaches its covenant to ABRD to
      achieve an aggregate cumulative Applicable R&amp;D Spend of not less than
      $10,000,000.00 on or before the close of the R&amp;D Spend Measurement, then in
      that event, without regard to the consequences to the Dyadic fixed by the
      provisions of Section 4.6 of the SPA, ABRD shall be entitled to the remedy
      fixed
      in Section 9.4(a) hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.6</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Effect
      of Termination; Other Remedies Available</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Notwithstanding anything in this Agreement to the contrary, in the event of
      termination of this Agreement as is provided in this Article IX, each Party
      shall have available every remedy allowed under law and equity, including but
      not limited to specific performance, suit for damages, and
      rescission.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.7</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Effectiveness
      of this Agreement</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      effectiveness of this Agreement is conditioned upon the Closing of the purchase
      and sale of the &#8220;Purchased Securities&#8221; by ABRD from Dyadic pursuant to the terms
      of the SPA Agreement on or before the &#8220;Closing Date&#8221; fixed by the SPA (as those
      terms are defined therein).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.8</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Limitation
      of Liability</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      EXCEPT
      WITH RESPECT TO DAMAGES TO THIRD PARTIES UNDER INFRINGEMENT INDEMNIFICATION
      OBLIGATIONS SET FORTH IN SECTION 4.5 HEREOF OR WITH RESPECT TO BREACH OF
      CONFIDENTIALITY OBLIGATIONS SET FORTH IN ARTICLE VI HEREOF WHICH BREACH IS
      EITHER INTENTIONAL OR ON ACCOUNT OF AN ACT OR ACTS OF GROSS NEGLIGENCE (BUT
      NOT
      SIMPLE NEGLIGENCE)`, NEITHER PARTY SHALL BE LIABLE TO THE OTHER UNDER ANY
      CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER THEORY FOR ANY INDIRECT,
      INCIDENTAL OR CONSEQUENTIAL DAMAGES INCLUDING WITHOUT LIMITATION LOST PROFITS
      IN
      CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT OR ANY PURCHASE ORDER
      IRRESPECTIVE OF WHETHER SUCH PARTY HAD ADVANCE NOTICE OR KNOWLEDGE OF THE
      POSSIBILITY OF SUCH DAMAGES. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      X</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DISPUTE
      RESOLUTION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Arbitration
      of Disputes</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Other
      than any dispute arising in connection with the obligations of the Parties
      created by the provisions of Article VI hereof (pertaining to Confidential
      Information) or the right of a Party to enjoy the benefits of all intellectual
      property of which Party is the sole and exclusive owner, as to which the
      provisions of Section 10.3 hereof shall apply, any other dispute between the
      Parties not resolved within fifteen (15) days after one Party notifies the
      other
      Party that it wishes to discuss the matter (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Dispute</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      shall
      be resolved by arbitration in New York City, New York under the Commercial
      Arbitration Rules (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercial
      Rules</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;)
      of the
      American Arbitration Association (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>AAA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      including the AAA Supplementary Procedures for Large Complex Commercial Disputes
      (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Complex
      Procedures</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      as
      such rules shall be in effect on the date of delivery of a demand for
      arbitration (&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Demand</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;),
      except to the extent that such rules are inconsistent with the provisions set
      forth herein. Notwithstanding the foregoing, the Parties may agree that the
      Complex Procedures shall not apply in order to promote the efficient arbitration
      of Disputes where the nature of the Dispute, including the amount in
      controversy, does not justify the application of such procedures.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Arbitration
      Procedures</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      arbitration shall be conducted in the English language before one (1) impartial
      arbitrator selected by mutual agreement of the Parties. If the Parties are
      unable to mutually agree on an impartial arbitrator within ten (10) days, a
      neutral arbitrator shall be appointed by the AAA from the panel of commercial
      arbitrators of any of the AAA Large and Complex Resolution Programs. The
      arbitrator&#8217;s award shall be a final and binding determination of the dispute. If
      awarded by the arbitrator, the prevailing Party shall be entitled to recover
      its
      reasonably attorneys&#8217; fees and expenses, including arbitration administration
      fees incurred in connection with such proceeding. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Judicial
      Action</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Notwithstanding the above, either Party may seek from any court having
      jurisdiction hereof any interim, provisional or injunctive relief or specific
      performance that may be necessary to protect that Party&#8217;s intellectual property
      rights (including its Confidential Information) and tangible property or to
      maintain the status quo before, during or after the pendency of the arbitration
      proceeding. The institution and maintenance of any judicial action or proceeding
      for any such interim, provisional or injunctive relief shall not constitute
      a
      waiver of the right or obligation of either Party to submit the dispute to
      arbitration, including any claims or disputes arising from the exercise of
      any
      such interim, provisional or injunctive relief.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      XI</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTICES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Delivery
      of Notices</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      All
      notices sent under this Agreement shall be in writing and (a) hand delivered;
      (b) transmitted by legible facsimile with a copy sent concurrently by certified
      mail, return receipt requested; or (c) delivered by prepaid priority delivery
      service.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Addresses
      for Notices</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Notices
      shall be sent to the Parties at the following addresses or such other addresses
      as the Parties subsequently may provide:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      to
      Dyadic:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">140
      Intracoastal Pointe Drive, Suite 404, </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jupiter,
      Florida 33477 </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facsimile
      No.: 561-743-8333</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Telephone
      No.: 561-743-8513</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn:
      Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
      a
      copy to:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Greenberg
      Traurig, LLP</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">77
      West
      Wacker Drive, Suite 2500</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chicago,
      Illinois 60601</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facsimile:
      312-899-0431</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Telephone:
      312-476-5015</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn:
      Robert I. Schwimmer, Esq.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      to
      ABRD:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1400
      Elbridge Payne</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite
      212</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chesterfiled,
      MO 63017</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention:
      Gerson Santos</font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Telephone:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(636)
      728-0508</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fax:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(636)
      728-1148</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
      a
      copy to:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Squire,
      Sanders &amp; Dempsey L.L.P</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">127
      Public Square, Suite 4900</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cleveland,
      Ohio 44114</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -108pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Telephone:
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">216-479-8552</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facsimile</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>:
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">216-479-8780</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn:
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Laura
      D.
      Nemeth</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ARTICLE
      XII</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MISCELLANEOUS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.1</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>No
      Authority to Bind Parties</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Neither
      Party shall have the authority and shall not purport to have the authority
      to
      enter into any contracts or make any representations or warranties on behalf
      of
      the other Party or its Affiliates or otherwise to bind or obligate the other
      Party or its Affiliates in any manner whatsoever. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.2</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Relationship
      Between Parties</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Dyadic
      and ABRD are separate business entities, and shall not be considered as joint
      ventures, partners, agents, servants, employee, or fiduciaries of each other.
      Neither this Agreement nor the relationship between the Parties shall be
      considered in any way to deem ABRD a franchisee of Dyadic for any purpose
      whatsoever. The Parties specifically agree that any obligation to act in good
      faith and to deal fairly with each other which may be implied in law shall
      be
      deemed satisfied by the Parties&#8217; compliance with the express terms of this
      Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.3</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Foreign
      Corrupt Practices Act and Anti-Bribery Provisions</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
      the Term of this Agreement, the Parties will not, and shall cause their
      Affiliates to not, make or provide any payments or gifts or any offers or
      promises of any kind, directly or indirectly, to any official of any government
      or to any official of any agency or instrumentality of any government, or to
      any
      political party or to any candidate for political office (the foregoing
      individually and collectively referred to as &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Government
      Official</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      If on
      the date hereof or at any time during the term of this Agreement any
      Governmental Official or an active member of the armed services of any
      government (a) owns an interest in that certain Party or its Affiliate, (b)
      has
      any legal or beneficial interest in this Agreement or in payments to be received
      by that certain Party or its Affiliate in connection with the services to be
      provided by hereunder, or (c) is a director, officer or employee of that certain
      Party or its Affiliate, that certain Party will notify the other Party and
      will
      take such actions to assure that the affected person does not take any action,
      official or otherwise, and/or use any influence in connection with the other
      Party&#8217;s business.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      Party warrants, on its behalf and on behalf of its Affiliates, that they have
      not and will not pay or offer, directly or indirectly, any commission or finders
      or referral fee to any person or entity in connection with its activities
      relating to this Agreement, unless it has obtained prior written agreement
      thereto from the other Party.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 99pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      Party, including its Affiliates, and all of its and their directors, officers,
      shareholders, employees and agents, have conducted with respect to the
      activities contemplated in this Agreement and shall during the term of this
      Agreement conduct all of their activities in accordance with the U.S. Foreign
      Corrupt Practices Act and the substantive provisions of the OECD Convention
      on
      Combating Bribery of Foreign Public Officials in International Business
      Transactions dated 21 November 1997 as well as any amendments
      thereto.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.4</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Governing
      Law; Jurisdiction</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Agreement shall be governed by and construed in accordance with the law of
      the
      State of Delaware, without regard to its conflict of laws principles.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.5</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Recordkeeping
      and Inspection</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      During
      the Term and for three (3) years thereafter, or such longer period as may be
      required by law, the Parties shall keep and maintain reasonable records of
      all
      agreements, approvals and other activities relating to this Agreement. Without
      limiting the relevant terms of any License pertaining to the subject matter
      of
      this Section 12.5, Dyadic may, at its expense, during regular business hours
      and
      with reasonable prior notice, examine, review, and inspect all facilities in
      which Dyadic Technology is being practiced by or on behalf of ABRD and review,
      audit and analyze ABRD&#8217;s records relating to this Agreement (in combination,
      conduct an &#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Inspection</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;).
      ABRD
      may, at its expense, during regular business hours and with reasonable prior
      notice, conduct an Inspection of all facilities in which the ABRD R&amp;D
      Program is being performed by or on behalf of Dyadic and review, audit and
      analyze Dyadic&#8217;s records relating to this Agreement. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.6</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Severability</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      provisions of this Agreement are severable, and the unenforceability of any
      provision of this Agreement shall not affect the enforceability of the remainder
      of this Agreement. The Parties acknowledge that it is their intention that
      if
      any provision of this Agreement is determined by a court to be unenforceable
      as
      drafted, that provision should be construed in a manner designed to effectuate
      the purpose of that provision to the greatest extent possible under applicable
      law.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.7</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Construction
      of Agreement</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      Parties acknowledge that they thoroughly have reviewed this Agreement and
      bargained over its terms. Accordingly, this Agreement shall be construed without
      regard to the Party or Parties responsible for its preparation and shall be
      deemed to have been prepared jointly by the Parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.8</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Cumulative
      Rights and Remedies</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      rights and remedies provided in this Agreement and all other rights and remedies
      available to either Party at law or in equity are, to the extent permitted
      by
      law, cumulative and not exclusive of any other right or remedy now or hereafter
      available at law or in equity. Neither asserting a right nor employing a remedy
      shall preclude the concurrent assertion of any other right or employment of
      any
      other remedy, nor shall the failure to assert any right or remedy constitute
      a
      waiver of that right or remedy.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.9</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Assignment</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Either
      Party may transfer or assign its rights and obligations under this Agreement
      or
      any License to any Affiliate or to any Person who purchases from that Party
      all
      or substantially all of the assets of the business to which this Agreement
      pertains (and in the case of ABRD, the ABRD Affiliate owning or operating the
      ABRD Facility shall have the right to pledge its License to secure funded
      indebtedness). No other assignment of this Agreement, or any rights or
      obligations thereunder may be made by either Party without the consent of the
      Party, which consent shall not be unreasonably withheld or delayed. Subject
      to
      the foregoing, this Agreement shall be binding upon and inure to the benefit
      of
      the Parties and their respective successors, permitted assigns and legal
      representatives. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.10</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Headings</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      All
      headings in this Agreement are included solely for convenient reference, are
      not
      intended to be full and accurate descriptions of the contents of this Agreement,
      shall not be deemed a part of this Agreement, and shall not affect the meaning
      or interpretation of this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.11</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Publicity</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Subject
      to Dyadic&#8217;s SEC reporting responsibilities (in respect of which each Party shall
      furnish the other reasonable advance notice to the extent practicable or not
      in
      violation of applicable securities laws), neither Party shall, without the
      prior
      written approval of the other Party, (i)&#160;advertise or otherwise publicize
      the existence or terms of this Agreement or any other aspect of the relationship
      between the Parties, or (ii)&#160;use the other Party&#8217;s or its Affiliates or any
      or their employees&#8217; names or any trade name, trademark or service mark belonging
      to the other Party in press releases or in any form of advertising.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.12</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Amendments</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      This
      Agreement may be modified or amended only by written agreement of the
      Parties.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.13</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>English
      Language</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      The
      Parties shall use the English language in all communications relating to this
      Agreement, and the English language version of this Agreement signed by the
      Parties shall control over any and all translations.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.14</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Entire
      Agreement</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      This
      Agreement, together with the SPA, constitutes the entire agreement between
      the
      Parties concerning the subject matter of this Agreement and supersedes all
      prior
      agreements between the Parties concerning the subject matter
      hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.15</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Counterparts</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      This
      Agreement may be executed in any number of counterparts, each of which when
      so
      executed shall be deemed to be an original and all of which when taken together
      shall constitute this Agreement.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.16</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Survival</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Article
      I (relating to definitions), Section 2.1 (to the extent the terms thereof
      provide for obligations to be performed following the expiration of the
      Agreement), Article&#160;IV (relating to ownership of intellectual property),
      Article VI (relating to Confidential Information), Section 7.2 (pertaining
      to
      warranty disclaimers), Article VIII (relating to indemnification), Sections
      9.4,
      9.5, 9.6 and 9.8, Article X (relating to dispute resolution), Article XI
      (relating to notices), Article XII (relating to miscellaneous matters) of this
      Agreement shall survive the expiration or termination of this Agreement in
      any
      event. Article V (relating to ABRD commercial rights) shall survive the
      expiration or termination of this Agreement except in the instance where this
      Agreement was terminated on account of ABRD&#8217;s default pursuant to the provisions
      of Section 9.2 hereof.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN
      WITNESS WHEREOF, the parties hereto have caused this R&amp;D Agreement to be
      duly executed by their respective authorized signatories as of the date first
      indicated above.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>DYADIC
      INTERNATIONAL (USA), INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 12.6pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 199.8pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:
      Mark A. Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:
      Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABENGOA
      BIOENERGY R&amp;D, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 12.6pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 199.8pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:
      Christopher G. Standlee </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:
      Vice President</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>EXHIBIT
      A</u></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong><u>1</u></strong></sup></font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong><u>
      Five (5) pages have been omitted from this Exhibit A as a result of the
      confidential portions omitted herefrom and filed separately with the Commission.
      </u></strong></sup></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
      Plan</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>ABRD
      / DIL</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>26
      Oct 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Capitalized
      terms not expressly defined herein shall have the meanings assigned them in
      the
      R&amp;D Agreement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>1.0
      R&amp;D Objective</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>2.0
      Background</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>3.0
      Scope of Work</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>3.1
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.1.1
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.1.2
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.1.3
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>3.2
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.2.1
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.2.2
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.2.2.1
      ****</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      ****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.2.2.2</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      ****
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.2.3&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****
              </strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>3.3
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.3.1&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.3.2
      **** </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.3.2.1
      ****</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.3.2.2
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.3.2.3
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.3.3&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.4&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.4.1&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.4.2&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.4.3&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>3.5
      ****</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.5.1&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.5.2&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.5.3&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>****</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>4.&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Resources</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>5.&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>R&amp;D
              Steering Committee</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 18pt;"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>6.&#160;&#160;</strong></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Milestones</strong></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>7.
      Project Budget:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">****</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>179568405v2</em></font></div>
    <div><br>
      <hr>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>1</sup></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
    </div>
  </body>
</html>






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>exhibit23.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. EXHIBIT 23 12.31.06
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Exhibit 23 12.31.06
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      23</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Consent
      of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm
</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br></font>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        consent to the incorporation by reference in the following Registration
        Statements: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)
        Registration Statement (Form S-3 No. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">333-139542</font>)
        of Dyadic International, Inc.;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)
        Post-Effective Amendment No. 1 on Form S-3 to Form SB-2 (Form S-3 No.
        333-121738) of Dyadic International, Inc.; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)
        Registration Statement (Form S-8 No. 333-122339) pertaining to the 2001 Equity
        Compensation Plan of Dyadic International, Inc.; and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)
        Registration Statement (Form S-8 No. 333-136676) pertaining to the 2006 Stock
        Option Plan of Dyadic International, Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
        our
        report dated March 28, 2007, with respect to the consolidated financial
        statements of Dyadic International, Inc. and subsidiaries included in this
        Annual Report (Form 10-KSB) of Dyadic International, Inc. for the year ended
        December 31, 2006.</font></div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
      Ernst
&amp; Young LLP</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certified
      Public Accountants</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">West
      Palm
      Beach, Florida</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">March
      28,
      2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit31_1.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Exhibit 31.1
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
          31.1</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
          International, Inc.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Certification
          Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002
</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I,
          Mark
          A. Emalfarb, Chief Executive Officer, certify that: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;
          I have reviewed this&#160;Annual Report on Form&#160;10-KSB of Dyadic
          International, Inc. (the "Company"); </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;
          <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
          on
          my knowledge, this Annual Report does not contain any untrue statement
          of a
          material fact or </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">omit
          to
          state a material fact necessary to make the statements made, in light of
          the
          circumstances&#160;&#160;&#160;&#160;&#160; </font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          under&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">which&#160;such
          statements were made, not misleading with respect to the period covered
          by
          this&#160;Annual </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report;
          </font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;
          Based on my knowledge, the financial statements, and other financial information
          included in this </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Annual
          Report, fairly present in all material respects the financial condition,
          results
          of operations and&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cash
          flows&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of&#160;the Company as of, and
          for, the periods presented in this Annual Report; </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.
          </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 22.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
          The Company's other certifying officer and I are responsible for establishing
          and maintaining disclosure </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">controls
          and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e))
          for the Company and have: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;Designed
          such disclosure controls and procedures, or caused such disclosure controls
          and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures
          to be designed under our supervision, to ensure that material information
          relating to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
          Company,&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          including its consolidated subsidiaries, is made known to us by others
          within
          those </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">entities,
          particularly during the period in which this Annual Report is being prepared;
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          b)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's
          disclosure controls and procedures and presented in </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">this
          Annual Report our conclusions about the effectiveness of the disclosure
          controls
          and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures,
          as&#160;&#160; </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          of the end of the period covered by this Annual Report based on such
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">evaluation;
          and </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c)&#160;&#160;&#160;&#160;
          Disclosed in this Annual Report any change in the Company&#8217;s internal control
          over financial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting
          that occurred during the Company&#8217;s most recent fiscal quarter <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(the
          Company&#8217;s fourth fiscal&#160;</font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          quarter in the case of an annual report) </font>that has materially </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">affected
          or is reasonably likely to materially affect the Company&#8217;s internal control over
          financial <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting;
          and</font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          5.&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company's other certifying officer and I have disclosed, based on our most
          recent evaluation of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">internal
          control over financial reporting, to the Company's auditors and the audit
          committee of Company's </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Board&#160;&#160;&#160;&#160;&#160;&#160;
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          of&#160;Directors <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(or
          persons performing equivalent functions)</font>: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a)&#160;&#160;&#160;
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
          significant deficiencies and material weaknesses in the design or operation
          of
          internal control </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">over
          financial reporting which are reasonably likely to adversely affect the
          Company's ability to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">record,
          process, </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          summarize and report financial information; and </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          b)&#160;&#160; Any fraud, whether or not material, that involves management or
          other employees who have a </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">significant
          role in the Company's internal controls over financial reporting. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
          April 2, 2007</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/&#160;&#160;
          Mark A. Emalfarb</u></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;
          &#160;&#160;&#160;</font>&#160;&#160; Mark A. Emalfarb</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;
</font>Chief
          Executive
          Officer</font></div>
      </div>
    </div>
  </body>
</html>






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit31_2.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Exhibit 31.2
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
          31.2</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
          International, Inc.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Certification
          Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002
</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I,&#160;Wayne
          Moor,&#160;Chief Financial Officer, certify that: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;
          I have reviewed this&#160;Annual Report on Form&#160;10-KSB of Dyadic
          International, Inc. (the "Company"); </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;
          <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
          on
          my knowledge, this Annual Report does not contain any untrue statement
          of a
          material fact or </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">omit
          to
          state a material fact necessary to make the statements made, in light of
          the
          circumstances&#160;&#160;&#160;&#160;&#160; </font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          under&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">which&#160;such
          statements were made, not misleading with respect to the period covered
          by
          this&#160;Annual </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report;
          </font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;
          Based on my knowledge, the financial statements, and other financial information
          included in this </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Annual
          Report, fairly present in all material respects the financial condition,
          results
          of operations and&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cash
          flows&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of&#160;the Company as of, and
          for, the periods presented in this Annual Report; </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.
          </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 22.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
          The Company's other certifying officer and I are responsible for establishing
          and maintaining disclosure </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">controls
          and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e))
          for the Company and have: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;Designed
          such disclosure controls and procedures, or caused such disclosure controls
          and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures
          to be designed under our supervision, to ensure that material information
          relating to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
          Company,&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          including its consolidated subsidiaries, is made known to us by others
          within
          those </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">entities,
          particularly during the period in which this Annual Report is being prepared;
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          b)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's
          disclosure controls and procedures and presented in </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">this
          Annual Report our conclusions about the effectiveness of the disclosure
          controls
          and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures,
          as&#160;&#160; </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          of the end of the period covered by this Annual Report based on such
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">evaluation;
          and </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c)&#160;&#160;&#160;&#160;
          Disclosed in this Annual Report any change in the Company&#8217;s internal control
          over financial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting
          that occurred during the Company&#8217;s most recent fiscal quarter <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(the
          Company&#8217;s fourth fiscal&#160;</font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          quarter in the case of an annual report) </font>that has materially </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">affected
          or is reasonably likely to materially affect the Company&#8217;s internal control over
          financial <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting;
          and</font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          5.&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company's other certifying officer and I have disclosed, based on our most
          recent evaluation of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">internal
          control over financial reporting, to the Company's auditors and the audit
          committee of Company's </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Board&#160;&#160;&#160;&#160;&#160;&#160;
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          of&#160;Directors <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(or
          persons performing equivalent functions)</font>: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a)&#160;&#160;&#160;
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
          significant deficiencies and material weaknesses in the design or operation
          of
          internal control </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">over
          financial reporting which are reasonably likely to adversely affect the
          Company's ability to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">record,
          process, </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          summarize and report financial information; and </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          b)&#160;&#160; Any fraud, whether or not material, that involves management or
          other employees who have a </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">significant
          role in the Company's internal controls over financial reporting. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
          April 2, 2007</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;
</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/&#160;&#160;&#160;&#160;
          Wayne Moor</u>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</fo
nt>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;
&#160;</font>Wayne
          Moor&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;
&#160;</font>Chief
          Financial
          Officer</font></div>
      </div>
    </div>
  </body>
</html>






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit32_1.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Exhibit 32.1
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      32.1</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="Certifications"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      OF CHIEF
      EXECUTIVE OFFICER</font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I,
      Mark
      A. Emalfarb, Chief Executive Officer of Dyadic International Inc. (the
&#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      18 U.S.C. Section 1350, that:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Annual Report on Form 10-KSB of the Company for the&#160;year
                ended&#160;December 31, 2006 (the &#8220;Report&#8221;) fully complies with the
                requirements of Section 13(a) or 15(d) of the Securities Exchange
                Act of
                1934, and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                information contained in the Report fairly presents, in all material
                respects, the financial condition and results of operation of the
                Company.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN
      WITNESS WHEREOF, the undersigned has executed this certification as of the
      2nd</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day
      of&#160;April 2007. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;//s/
      Mark A.
      Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:
      Mark A. Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:
      Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      certification accompanies the Annual Report pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by
      the
      Sarbanes-Oxley Act of 2002, be deemed filed by Dyadic International, Inc. for
      purposes of Section 18 of the Securities Exchange Act of 1934, as
      amended.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      signed
      original of this written statement required by Section 906 has been provided
      to
      Dyadic International, Inc. and will be retained by Dyadic International, Inc.
      and furnished to the Securities and Exchange Commission or its staff upon
      request.</font></div>
  </body>
</html>






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>10KSB
<SEQUENCE>7
<FILENAME>form10_ksb123106.pdf
<DESCRIPTION>DYADIC INTERNATIONAL, INC. FORM 10-KSB 12.31.06
<TEXT>
<PDF>
begin 644 form10_ksb123106.pdf
M)5!$1BTQ+C0-"@T*,3@X(#`@;V)J#0H\/`T*+T4@-#8W,3@-"B]((%L@,3$X
M,B`T-34@70T*+TP@-CDT,S`Q#0HO3&EN96%R:7IE9"`Q#0HO3B`Y,0T*+T\@
M,3DQ#0HO5"`V.3`T.#D-"CX^("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`-"F5N9&]B
M:@T*#0IX<F5F#0HQ.#@@,C$-"C`P,#`P,#`P,3(@,#`P,#`@;@T*,#`P,#`P
M,3`U,2`P,#`P,"!N#0HP,#`P,#`Q,3@R(#`P,#`P(&X-"C`P,#`P,#$V,S@@
M,#`P,#`@;@T*,#`P,#`P,3DX,B`P,#`P,"!N#0HP,#`P,#`R,#DS(#`P,#`P
M(&X-"C`P,#`P,#(R,#,@,#`P,#`@;@T*,#`P,#`P,C,Q.2`P,#`P,"!N#0HP
M,#`P,#`R-#,Q(#`P,#`P(&X-"C`P,#`P,#(U-#`@,#`P,#`@;@T*,#`P,#`P
M,C<V,"`P,#`P,"!N#0HP,#`P,#`T,3,U(#`P,#`P(&X-"C`P,#`P,#0V-#@@
M,#`P,#`@;@T*,#`P,#`P-#@Q-R`P,#`P,"!N#0HP,#`P,#`U,#,W(#`P,#`P
M(&X-"C`P,#`P,#8T,3(@,#`P,#`@;@T*,#`P,#`P-CDR-2`P,#`P,"!N#0HP
M,#`P,#`W,#DT(#`P,#`P(&X-"C`P,#`P,C@T,3$@,#`P,#`@;@T*,#`P,#`S
M-C`R-B`P,#`P,"!N#0HP,#`P,#,Y,3`S(#`P,#`P(&X-"G1R86EL97(-"CP\
M#0HO04)#<&1F(#4P,#@-"B])1"!;("AB<W%K>6%W9FER=6-T87)N*0T**'EG
M=W-E;W=D9&AV;79O>6TI(%T-"B],96YG=&@@,`T*+U!R978@-CDP-#<W#0HO
M4F]O="`Q.#D@,"!2#0HO4VEZ92`R,#D-"B]4>7!E("]84F5F#0H^/B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`-"G-T87)T
M>')E9@T*,`T*)25%3T8-"C$X.2`P(&]B:@T*/#P-"B]/<&5N06-T:6]N(%L@
M,3DQ(#`@4@T*+T9I="!=#0HO3W5T;&EN97,@,3@S(#`@4@T*+U!A9V5-;V1E
M("]5<V5.;VYE#0HO4&%G97,@,3@T(#`@4@T*+U1Y<&4@+T-A=&%L;V<-"CX^
M#0IE;F1O8FH-"@T*,3DP(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O
M9&4-"B],96YG=&@@,S4Y#0HO4R`Q-#DR#0H^/@T*<W1R96%M#0IXG.V43R@$
M81C&G]T=]IM99EEV"ZGEB.*B)%<W#K;<E(OK<G`@!P=7Q47B8@\N(CDX*Z74
MXB3Y>W*10J24DO*;V4%R%0?[3N\\[Y_O>=^9^=[Y)(4E*Z>T9"J]^X>D@VL(
MNT)?)11H47Y<5J(%=":D6%[ASE;I>5\JPS=3Q*XE&]]>EZ(M8([X)?A$;@?L
M(X[MK!&':]^!V\2H:P;PM]`D]JY4L@<:=%)R,_!GI!3[G81G!N&\$EL"9QF!
M16H>PKT'-U@_)I6/DC^@SHE4LRK%L>NNX':SI@.E;BG]K28I<HS=B^89N2-B
MS8Q0&_89O$UZ+DNU%_3WZJ7HR7/$AJDQ3SVX=@/Z2,];\(5X._D>_'[63N/3
MQZ6N<\JWHG?U`_D1_'/\.)QQ;%=*9*6J1G*1/]WF?R?%N?[=N;9X/R4"E;+^
MV7XC_[SWSVYO/][_`>I9/$-H#KOKNY^A=[WW'1<*^"EO4,9Z$PT*96YD<W1R
M96%M#0H-"F5N9&]B:@T*#0H@,3DQ(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@
M,C`W(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y
M-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B
M8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO
M1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B])
M;6%G94(-"B]);6%G94,-"B]);6%G94D@70T*+UA/8FIE8W0@/#P-"B])86)C
M,3D@,C`U(#`@4@T*/CX-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*
M#0HQ.3(@,"!O8FH-"CP\#0HO0F%S949O;G0@+U1I;65S+5)O;6%N#0HO16YC
M;V1I;F<@+U=I;D%N<VE%;F-O9&EN9PT*+U-U8G1Y<&4@+U1Y<&4Q#0HO5'EP
M92`O1F]N=`T*/CX-"F5N9&]B:@T*#0HQ.3,@,"!O8FH-"CP\#0HO0F%S949O
M;G0@+U1I;65S+4)O;&0-"B]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG#0HO
M4W5B='EP92`O5'EP93$-"B]4>7!E("]&;VYT#0H^/@T*96YD;V)J#0H-"C$Y
M-"`P(&]B:@T*/#P-"B]"87-E1F]N="`O5&EM97,M0F]L9$ET86QI8PT*+T5N
M8V]D:6YG("]7:6Y!;G-I16YC;V1I;F<-"B]3=6)T>7!E("]4>7!E,0T*+U1Y
M<&4@+T9O;G0-"CX^#0IE;F1O8FH-"@T*,3DU(#`@;V)J#0H\/`T*+T)A<V5&
M;VYT("]4:6UE<RU)=&%L:6,-"B]%;F-O9&EN9R`O5VEN06YS:45N8V]D:6YG
M#0HO4W5B='EP92`O5'EP93$-"B]4>7!E("]&;VYT#0H^/@T*96YD;V)J#0H-
M"C$Y-B`P(&]B:@T*/#P-"B]"87-E1F]N="`O2&5L=F5T:6-A#0HO16YC;V1I
M;F<@+U=I;D%N<VE%;F-O9&EN9PT*+U-U8G1Y<&4@+U1Y<&4Q#0HO5'EP92`O
M1F]N=`T*/CX-"F5N9&]B:@T*#0HQ.3<@,"!O8FH-"CP\#0HO07-C96YT(#<W
M,`T*+T-A<$AE:6=H="`V.3D-"B]$97-C96YT(#(P-0T*+T9L86=S(#0-"B]&
M;VYT0D)O>"!;(#`@+3(Q,"`Q,S4X(#@Y."!=#0HO1F]N=$9I;&4R(#(P-B`P
M(%(-"B]&;VYT3F%M92`O3U5.4$18*U=I;F=D:6YG<RU296=U;&%R#0HO271A
M;&EC06YG;&4@,`T*+U-T96U6(#@P#0HO5'EP92`O1F]N=$1E<V-R:7!T;W(-
M"CX^#0IE;F1O8FH-"@T*,3DX(#`@;V)J#0H\/`T*+T)A<V5&;VYT("]/54Y0
M1%@K5VEN9V1I;F=S+5)E9W5L87(-"B]#2413>7-T96U);F9O(#P\#0HO3W)D
M97)I;F<@*"D-"B]296=I<W1R>2`H*0T*+U-U<'!L96UE;G0@,`T*/CX-"B]#
M2414;T=)1$UA<"`O261E;G1I='D-"B]$5R`Q,#`P#0HO1F]N=$1E<V-R:7!T
M;W(@,3DW(#`@4@T*+U-U8G1Y<&4@+T-)1$9O;G14>7!E,@T*+U1Y<&4@+T9O
M;G0-"B]7(%L@,2`Q(#`@,B`R(#<U,"`T(#0@,3`S,"`U#0HU(#$Q-#0@-B`V
M(#$S,#$@-R`W(#$S-#,@."`X#0HX.3,@.2`Y(#$R,38@,3`@,3`@-#4X(#$Q
M(#$Q(#$P.#,-"C$R(#$R(#@Y,2`Q,R`Q-"`Q,3,R(#$U(#$V(#$Q-S$@,3<-
M"C$W(#$T-#`@,3@@,3@@,30T,R`Q.2`Q.2`Q,#DV(#(P(#(P#0HQ,S0S(#(Q
M(#(R(#8Y."`R,R`R,R`X.3$@,C0@,C0@-34T#0HR-2`R-2`V,#(@,C8@,C8@
M,3`W,B`R-R`R-R`Y-#<@,C@-"C(X(#$P-S@@,CD@,CD@.3,Y(#,P(#,S(#@Y
M,2`S-"`S-0T*.3`Y(#,V(#,V(#4X-R`S-R`S-R`W.3(@,S@@,SD@-C<T#0HT
M,"`T,2`Y-#$@-#(@-#,@-30X(#0T(#0T(#@Y,2`T-0T*-#<@.#0S(#0X(#0X
M(#$Q,3`@-#D@-#D@-C8P(#4P(#4P#0HX-#D@-3$@-3$@,3`X."`U,B`U,B`X
M.#@@-3,@-3,@.#@P#0HU-"`U-"`V-3`@-34@-34@.#$R(#4V(#4V(#8S-2`U
M-PT*-3<@-S@U(#4X(#4Y(#@Y,2`V,"`V,2`W-#8@-C(@-C(-"C<R,B`V,R`V
M,R`V.3,@-C0@-C0@-SDT(#8U(#8U(#@X-0T*-C8@-C8@.#DQ(#8W(#8W(#@Y
M-2`V."`V."`X.3$@-CD-"C8Y(#$Q-38@-S`@-S`@,3`U-"`W,2`W,2`Y-C,@
M-S(@-S(-"C$P.3`@-S,@-S,@.30P(#<T(#<T(#DS,R`W-2`W-2`Y-#4-"C<V
M(#<V(#$P,C0@-S<@-S<@.3(X(#<X(#<X(#$P.38@-SD-"C<Y(#$P-C0@.#`@
M.#`@-S<Y(#@Q(#@Q(#$P-#D@.#(@.#(-"C$R-S`@.#,@.#0@-3,P(#@U(#@V
M(#@Y,2`Y-2`Y-B`Q,#8P#0HY-R`Q,3D@.#DQ(#$R,"`Q,C`@,S$R(#$R,2`Q
M,C$@-#4W(#$R,@T*,3(R(#<T-B`Q,C,@,3(W(#@Y,2`Q,C@@,3(Y(#DU,B`Q
M,S`@,3,P#0HS,3(@,3,Q(#$S,2`T-3<@,3,R(#$S,B`W-#8@,3,S(#$S-R`X
M.3$-"C$S."`Q,S@@-3<W(#$S.2`Q,SD@.3@V(#$T,"`Q-#`@-#4W(#$T,0T*
M,30Q(#<T-B`Q-#(@,3<R(#@Y,2`Q-S,@,3<V(#$P-#<@,3@W(#$X.`T*,3(U
M,B`Q.#D@,3DP(#<Y-"`Q.3$@,3DV(#@Y,2`Q.3<@,3DX(#DW.0T*,3DY(#(P
M,"`X.3$@,C`Q(#(P-"`W-S4@,C`U(#(P-B`Q,#8W(#(P-PT*,C`X(#@Y,2`R
M,#D@,C$R(#@W,B`R,3,@,C$T(#@Y,2`R,34@,C$V#0HX,3`@,C$W(#(Q-R`Q
M,#8P(#(Q."`R,3@@.#$P(#(Q.2`R,C(@-S@Q#0HR,C,@,C(S(#0X,2`R,C0@
M,C(T(#,X-2`R,C4@-C4U,S0@,3`S-"!=#0H^/@T*96YD;V)J#0H-"C$Y.2`P
M(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0R-@T*
M/CX-"G-T<F5A;0T*>)Q=4TUOJT`,O/,K]M@>(@(4=I&B2'Q%RN&]5B_M#R#@
M1$C-@C;DD'_?Q>.FZD."D<<,8QMO6.WKO1UF%;ZYL3O0K$Z#[1U=QYOK2!WI
M/-@@BE4_=+-$_.PN[12$7GRX7V>Z[.UI##8;%?[SR>OL[NJIZ,<C/0?AJ^O)
M#?:LGCZJ@X\/MVGZI`O96:V#[5;U=/(?^M-.?]L+J9!EJWWO\\-\7WG-SQOO
M]XE4S'&$8KJQI^O4=N1:>Z9@L_;75FUV_MH&9/O_\LD:LN/I]_L/T%ZV1!%(
M0%2#3#A*-$.\9C(Q($N&70FRXBB-`2F3*>3I"XSP39]C,@,)>0J'M&'(,Y`[
MCC*4I`V3&1PT!`8E:92D<\@;D`5(0%:!++]U"Q01DP8.`AGJ-#`2*&!DT)%`
MH4&B/X$,[@9M"A0HWJ!I@^(S3-Z@>`$=@T0K`EKJ1"L"6MRE(X#&Y`U^AZE!
M)B!ENC`J<B9SF9D88?(Y'$K\@/*%R0HSJS&0NF"RQB0:Y!J,KL$@!60OOQ=P
M6='E)#WVO[LYYU>?CQOO_++M@Z7'B9S&:5$M]Q?C!NK=#0IE;F1S=')E86T-
M"@T*96YD;V)J#0H-"C(P,"`P(&]B:@T*/#P-"B]"87-E1F]N="`O3U5.4$18
M*U=I;F=D:6YG<RU296=U;&%R#0HO1&5S8V5N9&%N=$9O;G1S(%L@,3DX(#`@
M4B!=#0HO16YC;V1I;F<@+TED96YT:71Y+4@-"B]3=6)T>7!E("]4>7!E,`T*
M+U1O56YI8V]D92`Q.3D@,"!2#0HO5'EP92`O1F]N=`T*/CX-"F5N9&]B:@T*
M#0HR,#$@,"!O8FH-"CP\#0HO07-C96YT(#<W,`T*+T-A<$AE:6=H="`V.3D-
M"B]$97-C96YT(#(P-0T*+T9L86=S(#0-"B]&;VYT0D)O>"!;(#`@+3(Q,"`Q
M,S4X(#@Y."!=#0HO1F]N=$9I;&4R(#(P."`P(%(-"B]&;VYT3F%M92`O5E-6
M15)**U=I;F=D:6YG<RU296=U;&%R#0HO271A;&EC06YG;&4@,`T*+U-T96U6
M(#@P#0HO5'EP92`O1F]N=$1E<V-R:7!T;W(-"CX^#0IE;F1O8FH-"@T*,C`R
M(#`@;V)J#0H\/`T*+T)A<V5&;VYT("]64U9%4DHK5VEN9V1I;F=S+5)E9W5L
M87(-"B]#2413>7-T96U);F9O(#P\#0HO3W)D97)I;F<@*"D-"B]296=I<W1R
M>2`H*0T*+U-U<'!L96UE;G0@,`T*/CX-"B]#2414;T=)1$UA<"`O261E;G1I
M='D-"B]$5R`Q,#`P#0HO1F]N=$1E<V-R:7!T;W(@,C`Q(#`@4@T*+U-U8G1Y
M<&4@+T-)1$9O;G14>7!E,@T*+U1Y<&4@+T9O;G0-"B]7(%L@,2`Q(#`@,B`R
M(#<U,"`T(#0@,3`S,"`U#0HU(#$Q-#0@-B`V(#$S,#$@-R`W(#$S-#,@."`X
M#0HX.3,@.2`Y(#$R,38@,3`@,3`@-#4X(#$Q(#$Q(#$P.#,-"C$R(#$R(#@Y
M,2`Q,R`Q-"`Q,3,R(#$U(#$V(#$Q-S$@,3<-"C$W(#$T-#`@,3@@,3@@,30T
M,R`Q.2`Q.2`Q,#DV(#(P(#(P#0HQ,S0S(#(Q(#(R(#8Y."`R,R`R,R`X.3$@
M,C0@,C0@-34T#0HR-2`R-2`V,#(@,C8@,C8@,3`W,B`R-R`R-R`Y-#<@,C@-
M"C(X(#$P-S@@,CD@,CD@.3,Y(#,P(#,S(#@Y,2`S-"`S-0T*.3`Y(#,V(#,V
M(#4X-R`S-R`S-R`W.3(@,S@@,SD@-C<T#0HT,"`T,2`Y-#$@-#(@-#,@-30X
M(#0T(#0T(#@Y,2`T-0T*-#<@.#0S(#0X(#0X(#$Q,3`@-#D@-#D@-C8P(#4P
M(#4P#0HX-#D@-3$@-3$@,3`X."`U,B`U,B`X.#@@-3,@-3,@.#@P#0HU-"`U
M-"`V-3`@-34@-34@.#$R(#4V(#4V(#8S-2`U-PT*-3<@-S@U(#4X(#4Y(#@Y
M,2`V,"`V,2`W-#8@-C(@-C(-"C<R,B`V,R`V,R`V.3,@-C0@-C0@-SDT(#8U
M(#8U(#@X-0T*-C8@-C8@.#DQ(#8W(#8W(#@Y-2`V."`V."`X.3$@-CD-"C8Y
M(#$Q-38@-S`@-S`@,3`U-"`W,2`W,2`Y-C,@-S(@-S(-"C$P.3`@-S,@-S,@
M.30P(#<T(#<T(#DS,R`W-2`W-2`Y-#4-"C<V(#<V(#$P,C0@-S<@-S<@.3(X
M(#<X(#<X(#$P.38@-SD-"C<Y(#$P-C0@.#`@.#`@-S<Y(#@Q(#@Q(#$P-#D@
M.#(@.#(-"C$R-S`@.#,@.#0@-3,P(#@U(#@V(#@Y,2`Y-2`Y-B`Q,#8P#0HY
M-R`Q,3D@.#DQ(#$R,"`Q,C`@,S$R(#$R,2`Q,C$@-#4W(#$R,@T*,3(R(#<T
M-B`Q,C,@,3(W(#@Y,2`Q,C@@,3(Y(#DU,B`Q,S`@,3,P#0HS,3(@,3,Q(#$S
M,2`T-3<@,3,R(#$S,B`W-#8@,3,S(#$S-R`X.3$-"C$S."`Q,S@@-3<W(#$S
M.2`Q,SD@.3@V(#$T,"`Q-#`@-#4W(#$T,0T*,30Q(#<T-B`Q-#(@,3<R(#@Y
M,2`Q-S,@,3<V(#$P-#<@,3@W(#$X.`T*,3(U,B`Q.#D@,3DP(#<Y-"`Q.3$@
M,3DV(#@Y,2`Q.3<@,3DX(#DW.0T*,3DY(#(P,"`X.3$@,C`Q(#(P-"`W-S4@
M,C`U(#(P-B`Q,#8W(#(P-PT*,C`X(#@Y,2`R,#D@,C$R(#@W,B`R,3,@,C$T
M(#@Y,2`R,34@,C$V#0HX,3`@,C$W(#(Q-R`Q,#8P(#(Q."`R,3@@.#$P(#(Q
M.2`R,C(@-S@Q#0HR,C,@,C(S(#0X,2`R,C0@,C(T(#,X-2`R,C4@-C4U,S0@
M,3`S-"!=#0H^/@T*96YD;V)J#0H-"C(P,R`P(&]B:@T*/#P-"B]&:6QT97(@
M+T9L871E1&5C;V1E#0HO3&5N9W1H(#0R-@T*/CX-"G-T<F5A;0T*>)Q=4TUO
MJT`,O/,K]M@>(@(4=I&B2'Q%RN&]5B_M#R#@1$C-@C;DD'_?Q>.FZD."D<<,
M8QMO6.WKO1UF%;ZYL3O0K$Z#[1U=QYOK2!WI/-@@BE4_=+-$_.PN[12$7GRX
M7V>Z[.UI##8;%?[SR>OL[NJIZ,<C/0?AJ^O)#?:LGCZJ@X\/MVGZI`O96:V#
M[5;U=/(?^M-.?]L+J9!EJWWO\\-\7WG-SQOO]XE4S'&$8KJQI^O4=N1:>Z9@
ML_;75FUV_MH&9/O_\LD:LN/I]_L/T%ZV1!%(0%2#3#A*-$.\9C(Q($N&70FR
MXBB-`2F3*>3I"XSP39]C,@,)>0J'M&'(,Y`[CC*4I`V3&1PT!`8E:92D<\@;
MD`5(0%:!++]U"Q01DP8.`AGJ-#`2*&!DT)%`H4&B/X$,[@9M"A0HWJ!I@^(S
M3-Z@>`$=@T0K`EKJ1"L"6MRE(X#&Y`U^AZE!)B!ENC`J<B9SF9D88?(Y'$K\
M@/*%R0HSJS&0NF"RQB0:Y!J,KL$@!60OOQ=P6='E)#WVO[LYYU>?CQOO_++M
M@Z7'B9S&:5$M]Q?C!NK=#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C(P-"`P
M(&]B:@T*/#P-"B]"87-E1F]N="`O5E-615)**U=I;F=D:6YG<RU296=U;&%R
M#0HO1&5S8V5N9&%N=$9O;G1S(%L@,C`R(#`@4B!=#0HO16YC;V1I;F<@+TED
M96YT:71Y+4@-"B]3=6)T>7!E("]4>7!E,`T*+U1O56YI8V]D92`R,#,@,"!2
M#0HO5'EP92`O1F]N=`T*/CX-"F5N9&]B:@T*#0HR,#4@,"!O8FH-"CP\#0HO
M0FET<U!E<D-O;7!O;F5N="`X#0HO0V]L;W)3<&%C92`O1&5V:6-E4D="#0HO
M1FEL=&5R("]&;&%T941E8V]D90T*+TAE:6=H="`Q-C,-"B],96YG=&@@,C$Q
M,C4-"B]3=6)T>7!E("]);6%G90T*+U1Y<&4@+UA/8FIE8W0-"B]7:61T:"`Q
M.30-"CX^#0IS=')E86T-"GB<[;T'E!W'>29:'6^<A`R0&`"#3-*RM/9:[^W1
MAJ?W[+5E2[*L2%%B)B&"(`F(!$&`((B<@1E@!H,)&&`PR`23*<O:XSW'EOWL
MM2V)M$A3%B5*8D":='/J7.___^J^]PXPH"R/M<1YY]:IT].W;]_JZK^^^G/5
M<%XKM5)5O*!6BDO5OJ:*Z[52*]<4[P.`=%6ME5JY3O&N!Z1:J95_=?%^Q5HK
MM7)MJ:&H5O[=2PU%M?)O*>XX]E<-0K7R*Q1`CL6Y04>[9HC5RK^I`'(,PTIP
M7C2MK.L9Q5+6-$OB.],T"X6<8%;P%2"M6,K4D%8KUQ2[:"0\#E`I`IP\;B)@
M7#N7R]&W*.9,JU`LI4P[+>ZIH:A6KBDN@:>4R8ZZ'D#(M2Q+?%$L&J52R3"*
MGB_RBHG4^P0D^\/M<:W<D,7U/,<_]?C(<!J.ME6M3ONZ4Z$T7$-1K8Q;TJF"
MZR!2<AG/`I;C^-4H8A58RF:S0H,"W:DFT6KEZN(1*!QN$H\Q"WC,)OWH:RG/
MLRFZP>.NBSIVH5C3KFOEFN(AA$:NH,@J`9LQL192>,PF$$CY-+$FEX^.9*[Z
MW1@WTAC99^$)?>%Y9<'HBI]5W6P'-]MC&A4.!Z_Z-@./GH]GNNYZ6,4GU_,;
M&>OUJO9Q5;KGCDU1*!=WS$4ON/<Z7C*\'+Q=53OT&_<#'&NV3YQRXV-*I0]C
M772NT$M]AXQ_U?($3?Q&K`J5JNIU''[CAMK=L5^-TY.J_E1E>GBN0%$FR<&.
MGS7Y]R+R[RCL-^?,_%U=6CIMTL>'+W//YL4\WE@L.:@OV?Z(F]RUL9+T(WJ*
M5RN:ESE/V4X)@>#P0A%OR)L%EULX\"Y8@!P$*)YSN)BTW$'.<\5\P0<@W%!*
M<OBY@YR0V@1K$?2Q7"%;\6G97LGTH$.\9,$%`]X@6X29D,_G!!MU<YD\M.`%
M@U9(Y\6[TPWY7&'0XV`UV*:%'7=L[K@P!'FJEM\3FE#0@H"*ZUB.;98AE,G;
M-C!P&Q\&[:22.;QJ&T@2H$O.J<R7,OCQ#R`A-31X`5HNIBMSQ79H*GCPU(*'
M9#%Q>#RDE8,W6"7[_9+S,\X'/2<1#'BFZ*3S.22RAQ2%.3]:-$;@J\%+^%:%
M`HX:-`PMF*XGAMSQ86`'J,-:!)K0]Z.CPVBA<\M!@ROO\+R'YTA?F]I)YPLP
M=*GL"+R(YV71`DM=X4`Z%\$&-(C'?M?(HT0S"D!<U*Z-$F]H^(^.Q1TB%S0R
M/)(HSQZ3[O*!Y&&'!8K@73A/C(PDX(?8E(7=\E$+9!&4M_&$7LJE#M+/;7[E
M/7H,8MM.)6@TH0%[B//+KC<*'XM9#G;DX&4'GEBB1N"8R'L%#QJQ$LG+`D*N
M6?0L;,H!#!?P,?#1MHH"2'`;W`R4264YV*-`/XN\%\-#E[A70,)Z/HI@5&&,
MB/+8?;-DX+C3T,!+P2=X%Q/;L<7(.OFLF\LB_"P^#HH\@:*$#<^#69(#>YBH
M`0/D^@Q?<&]XF.EARU`+@#<8`L0\X"3ANCFD&K*<E,-S\,-BD1=*6<.%=X>:
M$<H)O)1)(V08V%6:$-4H*KN:BSZ+@VE+Y,[EX9D\5^(%PQ^O*\/<@*&T>3I+
M7<(IC)U$5F!:@BTE!I-%DT^>^3'#Y(S]D<*^UA"[E['_*.@#599NA7XFT[[2
M/9I)!*S9HFK[PQY,MY(U9-II)#7@IXAO-#(",Y<7+"0(L*9<@1?R>`+]A$=#
M][(Y;D*?2SB5X5?)41I<(,K0^\`T8/*F<[^`HQA?Y&\YHD^))Q+`(7G)Q-<$
M>J8S!0"M)6:/D\=A+6+%$_@(CS(=N"&3+CADA,)#K3Q/#P.'XEZ)&S[K,WP@
MN65Q#".8%Z)DZ`KP)$1=J03M8`M`2)CUP@PQX=T<O+$P5*A(TC&"V+:L)"+V
M/8`<O@70.9/CJ102"BHT6S0`%3B.T!C2RN2)'"]YV*T\L3[!^0OF2-%,EHHX
MF@203"+S4[@%R`+@'[Z(N$#ZE\`RPODR!D5>F3=:HT/O`I!R^91'+>>+?'"$
M8%/@(>4>QKZZ9$$[8X]#C:A/:?+#\?C]N1RP?B0@\'"K1(0A'.C1WX"YF<YP
MG=UGIO%U0N'?3J3P!9L:_HM-8P0=2&233J`Y.,CGH%I"0_"G$I9B.IM))OB,
M*9\+27<P]J7Z^%WQ^J]$&K\4;KPC$G\X$GTB$ED;B3X9BST<J[L_%+F3L<_.
MG/&DQ.X8'L0)#J\`L^_"E6$8/I@!,#,`EH42L+@,T!+(7E_W?]9%OA37'VRJ
M6R&Q>R6V')Z2SR+`H*N%/!"L:!A)?#$!?=O!C[P(7]G$7D`02.P/57:/RAZ>
M'%G;H"YO#'VI*?9QQQ+L-$.B#<!C$(3@N3D26P[<(+'_%-6^'`_?U5CW547Y
MM*Y\(:S]/M!S>+CH`X8LE&"8KE5*;)`;+3.7J^PNQCZEJI^IJ[]GVK1'ZV,/
M0HW''@*R1&(KP[$GPM&UX>@:+?P8O%WCM+OS%L^:O`0\T$%.)3BDT,WH>?F"
M<05=?Z#!7N$M-]VIL\\S]A6-W=50=\_,69\G"-E>-8H"A6IH]))'38PDD?@P
M!(Q]@;&5FK2[*=[#V!;&VAJB)QG;J4F`J"VR])2N+P<^`(QN>`2/H%?`;&)L
ML>%B"Y.BT.>[P^H?PT5D:![7U=^"P14H`AYFN#[K(PH;GG!E5^F*XM5@EL7T
MK\CL$84]'8]L8.P;3%W!U%5,>I:QW8RU4MU)/=P0C>QA;/64IH.$^?OB3?<!
MXP)"I7)9QQ]*H!%,QPSP&^@&L+*8]H#$UM2%=REL!V//3FW<;^;YI?>1.>)(
M8K"FF$D.D5ICXPDOPD645#;>!H)[VJ1-C#VAL[V-VD&9K8FK#X&B@MH!DC-!
MFM@H,<`,H2AO@E!T^<4+O#&V3&=K)+8Z'GTD%@$`/](R>\O0$)+(=[(YOD2K
MZ#U5%;7$/(](]X?9NEAH=32\6F+KX/4E!E0"XFPG^NP/2+0_WM`C:W#E"5E?
M%9_\,&/_%Q`E4>1Y8,*&/V]SV30]LFA:!61361Z3[XBRQ^O4+3%UN\*>8NPS
M*(:0F&[%<*!3TX49P)-9&%D4#77U=X;T%9JRL2'6Q]@A&J-]LKI/#76$HWVJ
MVL]8>U/#BXSMC<?AJR_"E`4U;B1/X)GRN]`KD`Y1^0'@1>DAKJD?!7&6*P+`
MECHFDF@H`8S(S:,OH&P46+R,HD#B6HX)/!ED34R_G[$U4^N.A^0V7=_+U,U,
MW<YD@$HO8\>I0C^[5>4(8QT-L=.,'5#E`XJRC;&'U/`]@T,HT"^-C#@HTE!B
M6FX1M&C0I4$T1[7[9DWJ)H)WQ$/G&-LDLV_8!60_0Z.9HE%*I86#5"C,1?@(
M%^$KU,<*7&'0MZ?JPT"3-B#4S9,.1Y6'@?\["$(W0-&P8$H>:9?)?!Z>"WQ^
M6OT.E1V(2EV,/09(UMA>:&IT!!4&G&B.5<P4?.WN*A0)19KCM(VI3\34MHB^
M2U&@PHMTRJP#:D"<@8`^\'&OK/4W-;T`[]@PN8V%'V'A/\F2>@E63S:;%W:9
MYY`?II`#%,%XU:F/-,C[XW)WB'6'I,.*M,)&Q.5]<]CS#4Q'<#&07V#GY&&L
M_T!1'V7LF_51>/3!^C@\M!.(+*F`9QB7?=A/!2X>5I03<&7&S;LGSUK^UD6>
M]9`=Q>*?A%=+)GE4O7/H?92G,Z;_WZ!?P*-C85*PZ8F&8U=L4Z$0HU!T*YHA
M\2NX"83C]$E/*8!8_2ST!ZNTE\E`<&")0']`SA&)]4BL*Z0<A8L*ZY<8G+2I
M:D^\#DCWM,P>`!$_G"*]EF20@_8\$"^5<P777191CX6D\XK4+[,#D^/PCI\#
MHN(PD2WENAG3O@P53CA=A*^R2*O/P<T*.ZA)1\)J=U0'$BT#>Q!8A..(`<^3
M85BAN4/:Z4@&?@OR=YO*3C=%7PDA;;?6ZV=DMF_FS%47+@/#XN1S<%W;&=?&
M1D;JH.ZA,9#@0`H@2)LD/\_8<S`T<$5"R@"V@10]1*OV^H:ST0C<T!6/?CL<
M!K&R5HD_KL6_!F(1#(U\3MC:8,^D!?<#2Q*4JS"RV4X)<7A49V=U]5GD.'[F
MAA`E%0C!>P'S5Z-?:9R\7M6VUM4=H^G9W5#W<B0$L[M5UXYJ.G2L-1(YI6F`
MG\YP#+KW#(@8-?9@N.EK,+<O#?)Y<V_/97A][$]NGGIO7/\CT!4MD\>C_R&3
MXG-F?[)`JF*AE,='5[M&A-WA5=D7W"W:J)>`KJY*WU!PIG<KTDE%[6-R*Y-W
M,7F/+$'=I6#=J;*=,MM1%P9<[0O)1Q1V1,87[PMK1Z(JO,B7A8Z$YKR-0PRJ
M>*+T#JA.8%1&H@\2UX7?=FI*!_"$N+8:GHL\`72#1)9@,$HU#Q_A(C(3>"]M
MM<;:-.DH3;1-C0W;H:ED"@&:2(L!=\OX\8TOF!<&`@"D0V/XA7KM+V"48^'C
MQ#WZ-.S#UT')AQ=/Y*Z03/<J@L-7D%PR:_`>T)PCVC,R]1SHP]@KP'Q@(BC2
M=I6U*G`"0D3>+JO/0`78Z'I/2`4.`//Q>#@$@[B)*8\VQ>X;?A]UO%()L6L4
MA!_&1+=`B=<IS^CLN(H_.2,Q^.W3P*!HXEO"+G-0MJ/:`%K62(K+H3MD#;C0
M!CT$T-W64'\F'@:</-78T*JJZW'"QJ$G3\K*)A@^QJ#N4K4#N@Y"[8E(W5-,
M^C+,Z^$A/FO:W<EA;N9]`QYF+HC7N;,_!;S:\1FS[0DGE"A.(,6JK51T+Q11
MNS6YIBT#:B@XLXZ0A'VVJ6D78\OCT=6,W1,-/P2Z7RST(`@7C3W2%-^JLLUA
MY5!#&,#?/JWA.V$)0+4N$OMBB4Q%8&[HU8&WYFF3YV!2%5"=6R7C0.Q5M4,R
M<KQU#75W`_"@$ZC(>3D221DX<803Q.)P`]P&O](E&(XV10%5Y"LP'T%K%205
M+RN,07BI4L%'48FF+2AR(?92",?]6"P"8P3SO9\4F-5@6)$EE?/*3E=W#)`\
M\HH(4TN1UU#/VYD$C/<E@(>JK`MIRR/*8R'U,3@)A>X)1;ZD1[X"^&RH!^UQ
MK\2.Q=57)#:@2CUA;;?.'IT<_QK:%%7>4=.$+N0!'V&V!E`D,WA'H.=92=KF
M&&5;%=3+D:([8E`8'KF0_G5)?E+38'2V1*(`GLWU]3#]'PQ'OC:<Q+D#-!C.
MXXD:_JS$5BAL=TR!=S\V)?X=T$,8VQ&-;`!97\B@MJ"R3TZ;_/N:>MNDIH\U
MU']D2M,G!H77$8T/NVAFN8C2!J9^A4J^@>:2"D$VDL4U_3Y@.,2B8=+MGSYM
M_R_>1D<B,+J<,.T-U'+1&LWQD'2[C+K*JJC<'I7/`'N'7\EL6UW=(\DL2FV<
MPCEA=<%8&)=3PT"O63>!WOAT&*?/@9A^M"$&X_(`"";0HPH&=,8>'KD`%4[@
M(_"90@Y@\`#<%M-.P.B'-:#8PS/F+`/]\&(2N!2]A]`9')Q-G!RDENDE4G;&
MX'+D<QI*F=,:.Z\IIX5T#H>!I^VX:09PQ=NIGW;!RJ$M5V;1%12A>PU1!#Q-
M>1QA+[4Q&8@#>MUA,!F$L6^2>6Z2$\!`+1!LTJ_7AYYN"@--]M=KH-FV:^Q0
MG;)=8G<*70[L_7S.")Z2@_D2EE;K[!@I"2">!B1Y$SJ$2*AY?,3CET%#-VE>
M7+S,IT_?IB![.:@K7:@%:9MAF@-#$Q96U@94@H(,DQ<A!\,G@>+*=L^J@ZET
M>$KLSU54X39/:7CHR@6>&$:Z%0N^[$BG>2J)/01)1^S9&DE>J#(/*_RG,NF0
MY/#>.7^ZA>Y4Y*V2=!CA*L-LNA_@"N"!9C,9/,FE\;V*&93O\([%'&^,KI#9
M$U%V**H<5>3]LKZUH0G>Z+,`F"NIC$,N!2`O"73KW<%<P>3A*+"CG:3X;8F%
MNN/`9I45PJ4\,IH6/843FQRP87D%W`"W,;3LND#@AJ./`B7?&33)Z6R4G((=
M,%C'%HYZ("2\%+*I:/TR8%]1^3O$8'<U3CK!I/UD^<(LWA`+K\T;^.(.2?_*
MY*I"D<`FB!--60F,FDF[R=P88/)N,&U@AKHF58M\>N3?@Z',9?G@13ZU#DRY
M]1KKO+GA.Z!2ZF"^J<\T1.^'.3Z:P">D4P5BHGE`480]KK-N"45`)Y.Z)66]
M5R1IBN)LU.,735`-R',;CSTDLXT*SO2ND`;3<)T:>21KXA@!EROD36*MP&`S
M```R'W#@&/OO8?E1C6V$UY\<.1N5#BKL/H"T36H#O&1R5$0$<,@`5!B91;\6
MS#/0-*#9@!E5QY@JJC40/%^%HLV*!$Q[OZ1LF-KT&$PQX=4A[UO!R&?$>"5'
M+>$M3XWR^NC#C5%`Q5.2OI7)&T+1/4QZ$'02)+Z-&9@&^:+3V81-'"\4^0+<
M'-&ZPI%NM/+0J'D<1\1#/P;HYUC)#0L7X2L%;S@0#?=$4:M_)A3Z.LXO0%KQ
M$I"G9*50#S<\T_`"AFLD,Y>368^QC]?7KU=Q:@,3.Z+J^_#G=8"?9V;//AY1
MCX25K:KZJ51.^(K&D6AD);@"1;KR*$Q_2=K!Y'W(+I1-ACV.)X<J(@JTFFR*
M1^05LQIA5N[2D,GLBBB[&F+K,4#@\50^Z0MB;@'OB$BK0FCT`:^#*=PAJ6O1
MK8J3"9WG'J@PF8NI/#IL-?D14(3J]),ZM@DT?R0#R@P!`)4L"N'E"U=(-\A9
M=C&9M'!^E?BD^@>`X\6UUI@,?'C+I##(A8_C`[R<9:'W&'"83+LETRBA4QA'
M+9L?HG9X0%Y?]Z2I&EB.Y->R<="$1+M;E;8J.!WVRS)H:)^!+QP_+%5R/70#
M8GS"<T>'<2[E"^1FSW!9OC\46<?DU5)L!_)\]OCDZ5\RT!"TLKD1&*3T$&B1
MCK":4UD^I>%)7095?"_9$9VS)A^/1[\.MIB8"![%%^`C7(2OX`8=;]L;EG=.
MJ5^/3F,,T`!5AD?3[Y':PBW?#V.3;\&@.!>?.>TQA6V)RJ<`A(WUQYBT83@+
ML'P0I#!C&^O"H($\NVC>MG0*=<)\L<#'0,(-%&SL,W"`L+Q297O`LF`2H*@7
M>(6!411@#Q;F>KE^6`U8D6%FBD8.WK9@(%-B[*X0VS.U_EQ3W8"$''B3)MUK
MX"N4DJF\`"],2>!%(790!AL0VI</RNKC'DPE4-V\@F$.>3C+46(FT2&SOB'4
M10KSGDCXV2DS'KLT"G"AR6X*6ZZ`0<S<Q5)^Q"RAUQE4K-PHZ#_WR^RI$)J9
MV^OT#H4]$%;^<]$&[2F5RKAH[5;4Z<"*1\LWX<=,>>!=1,>UA2]<Y7RP4=\A
M[5J_#TPP%?GJ`4!14\-]:&M33"V5N6A:Z,]QK8*'/G3;@=GO\G2)@_H![)2%
M'@Q/W@[F";#9AOJ><.2^BY>$Z811)#/CB0F>+V:0A18X>C4EX&"@8P.OV!M5
MOVF29S67-Z'""7R$B^A[P1L.T<WWHRD!4P:].V!^)@JE(1'F\/R8@@7#ER^8
M0(WW?H&.!9C^]?JY65->02N)?3-A<'W2-Y3(FECL`)D/()N^:0;N@G$CYD)7
M`E4G+*W2P1!C.V1"D2RO,Y'F.3\)L*(D"$TF#ZP#1C9=P,A1+`1R9`/Y`T&?
MZ8J'U^;0B8$6M$N3%`8@PE97H>B`K*Y*C7"*]@J?/'*A'[W)8^%[T#ND']:Q
M\]#L_:``@;0QN:_N%M)Y$Z/@%!5R3/$"J+89J(S5U3VFZT_6U^_4M#4S)SV6
M2Y$T=P=%E+Q0!`*60+@7@1\5A8\=0\;)T40910XR9E'M(*_-C[HBB@RPT4`'
MVZ>B7^B0+&T$A?_R(!>!)M_>!/21!CLX",\%TMK"1?C."`]/@3G^1-WTY\D0
M;@\I&P`JU(V4:R:!&E;.,H&@/(>#4N)-30]%XF`H[=&T[K#2WJ""NO)E<B%2
M1-$&#'P9+L)7<`-.NGCKY,9E\&IDD8$^?+EH74"UU\!I8A1-QRX9)HX+(&KH
M"I\S??GD\"'RX723(0R3]QL@4UGDCYF^BAS.'3/B+TY&=?UNQQ+^D.J\%[?L
M=42OES_*8-'O5EBKS/H4:7T1QRYC>P7;1=T<YKM#XV;`BSJC17[%0.+QRPG>
M.`5DQT8]TE'?`&9(/R@G,`^OY-[)%5V,[SMHL$39VBH4=<C:2G++YSPK5<BG
M09-',[S(&Z(KX]IV\O]O!#-YUO1'AT8)M29*HK+7"T4;G:12"6`K6<,0"1!J
MTV\K39]\ZS+/6*A(HW?:XT/)00P3P[VY2UYY1B#K2Y:LGUO.15X.+%:A2'@`
MJMD1/!-0I"O+5=:JLJ,2.RQ+FT`#`?$(,ZZ$0A(L*".?+915=.!%66#=H"*Z
MV#TF_W=0BIA^DK&38$S5APXEA\C!`;/5(WO2%=Z/1,$<@2$#P022!50C38$Y
MM;5![8\IS\#C8)+F*%8+'^LU4(FWP@VD0:V"GSB8N&)1$`=]C*X+_;&=DAAQ
M-YD$+109&K"7$%L!K*8I\N?`<T(JF&;K@(-ER,Z1]6]&0Z"4]FBL7V$'Z[7U
M-L7Z!1OQ(^:>'R1"$GG$B]`2!XUT/WF'>C5IG>GP,C%]S5PX%)&J`.[+8)?D
MR+Z30W<H^M.2`J)D=UAZJ2%^X.>8:>):9!$$*%I#*&IC$NE%VDIX6<=*&(51
M3@D8B5&,/H/%"LH5@#DD[8J%`)R?1)>X)5PXKO!ZH2?*]?U1'&/=F$N0,8=!
M0@X;=M)!=3E+KB%X>E&X[7DNE?^%"#[";X%WT4HBS/#!S`10:/+N51+MVC@:
M?%$"%*G+0/0K:.D?EJ0MH=!=F$KA2TCTS?C\753J-EGQ7%B43-E(5BJ8JUTZ
M.Q!6'C*0SD:53F91G"N'F@"HV=J#&EJ"NT(R/!&@NT\*WYYQT3D")Z1"'`U+
M1U`UE;>$]/M-)Z!5.4Y!KR'(!9]&TL,V6OD\,\I#Z+(X$0J_S%AK7>0`:*1@
M"&-@U.:-==#/5H!Z"#TS>QKJMX'V`08&JA56UL"LIQSR)N)):,Y76?H2:Y,1
M2YV:_#CUQZIHUH$CSA.]Q,E7,DF\@5&FJZLDC+4=5=D)G6T/1SYE^)DV%,0S
MA78-*$*'B4`1Z%VEDH@3NZ@Y4R)K5-NBHIG9JBJMLOQ$B5(4N&#!9>N[HMW9
M8Y))@MBNY_E)'>683V!Q!2_B7[(#YWFE$/V#Y$"GXC+"2)J'4B:L/E!&$5CZ
M`D6VGQ,`:"J,09'_3%LX>(%[@!!DZ#?K`U+`M`4CG30[6]C[@0F3(8236QMH
M*Z^,J?NCRC&=G5*4PZ'ZM3^]S*'J]6LU&1HY!5_!#7!;J232KNS*W`\L*8N$
M_V@Z8Z,]95T8XKKTC:88X/F`'#ZM*"#7UD3UK^;),AI)8DPDH@(#[)K2^!*-
M[+*ILU:DBZ)=Q+EKC3A@FA;\K$!D?`!L;17I40<(11VZO(I0%,3<A?/<\_\2
M$\,T*(?X/+QI2'U$9OL!NBKK1Q2%T,DO$LD011:@Z%$=4=2#D3BY@^DK,=4'
M0>IF\QGDL38/*:`>;Y70U7!05MHE^4F`J250Y%I7HZ@BH`T_%\1SRU`?`[9Q
MZYA2T?E^=13=<S6*JG_HCZ5%3A5\QVM0]"BAR!T?12Y.5$6YG;&GP2J4T"V\
M4PEM;IR^"ZH<W@P?X2(9C$_#;263CY,I$<2Y+<R>1%=1UG)@CL^:`C_?4C_I
M'+":>'Q_.+P\D_/-!&`.R12?,NE9TG6W3IY\.%[_-&.?`TL9Q#4HYV1$I)'%
M.F!:FM>@J%UF8-UTCH\BW^(2*'(HX<L-4/0P2*L/1-'*JU`$5JI'$3Z1:0QM
M,79[7>2@)`%-.F3@5P)%-CW=*XW%@!MTR2Y3Z6J?<S54O*KC!Y9_'Q2-\:C8
MQ+"M*A0-!"CJN!I%_OTB9HK3`EK,@]407J^PO771;O)#[F)L,U4XV0<7-?@J
ML@YN,[RQ**H,'%[)&[YC)UE`^YJQY4VQXQCFD`!"&U7M*X@0TQ.:"W15CWQ5
M8IM#*CST:36TGK&O#29\V4T]S*!Q!-PRBST7*`*C:2R*A$1SJU!D^>S(+D,;
M"6`2;7\)BDR!H@X9B=_'I$XP`=)9(7TP-[=D.",)OG0!6/?/D%OXL"QW5J$(
M'IT-XK95M1I79?PXXZ'H7UU^913I]U6A"'2*'.?V6!19(C'L`U'$JU#D"KM5
M>*M$SIRFW042A['UJMP>#O7+\E&H<`(?X2)\I6E?-TB+)0BY55E>OJPW3%=D
M4HUD,:LV$OY"1-XB%(SZ&.CGCTOLLW[HGU(7#)>KX=_7-3!S>NKK0#7:,GUZ
M^Z3)CX#ZC:DDV&RNF$D(FAOD/@5-#E!$D=Q#,G+(+NUJ%-D5%#G"EP@J6`ZC
M,623AK3E51)M9UB_'4W<,2A:I6.V"45`I"Y`D8EA1'2J9')IU/H2,#ONE5&C
M0\-3EKL0112"%/YM/P6]VL:LQL\X;@P>_+GV^.M#$:'=]:K$F4')/$7,A0,4
M@8WV2U#$`PO(SU4&;00>,;<9=.QUC&VB9"K@#[UTL@DNPE=P`RHM?H)Z&45%
M$HY%P8M\2Y-CB%^5[XNJ>]%7B?'Q7?619\T"QN/`5O$H=`O,X?(H#X>W8@1!
M/:>KIS!B&UH#(Y(I\0PM%D!>A#$TGB\@#/*N0%$G>9FZ"$6K`VV_C*(@B\-'
M$0I)\H<(%'TC0-'`^"C""$B7C)&:XT@$0A%(6#"-+0==TI2:>/_4AE,4:^NM
MH,CW#0[1T;@:1=>"9XS:4_V%?2W(_GU05!H/117Q5/S54>2OK"%SV,T4D7N`
MN5I?MRT>.4KTZ6+H]CP*'^$B?(7+18H"0D9%X)-/5<R^?!&,-'XIF<!X=YY/
M:]H6QL`*:.SG&6O3V0JPHUWT\*,X!N&8,S'8K8?7D-P$I)T%+-77[;M"CI=,
MP5_^DQX9%$,!)CFAZ'%"T>$/1!&M#/(-V'\%BMQQ432`JI'V>)%RGRCAT\WE
M;$!10W@=J8MP3]]8%('E>V5\%%VC,`=9-.657.5ZU16W&CK_5A1M`^/Z&A09
M%8O2SWNY"D77:M=!%F$UBGRA[18M5!N2&1X)/4'FTMYH]"Q42JO8#Q?A*_1E
M6;971E'%,S]*3T?='G-1,-N;*_+=,GIT]X=E=%O%0X?BH7LLP[>^A;.C1#]C
M[`N1^`$0'ZKTBJX\Q]A3T<:O@7V'\0ZPKSW;*N;("8++7P!%9.EW"9#+U2CR
MKD&1*ZB=NPZ*^J^/(FCY>!E%E+F:(H<\9M4"BE3V6%0]<AT4#042S1Z#HDIQ
MZ>U%7CJ.6A7S*:/(&M/".+;_OS.*'(RT%EU4;+.@#0"*-&U3-`K#<:`^<CR,
M*L0]F!CL6-=#$<=XJVU1`!ZL#Y!?\;H^D2Y()^LP<\-&(Q!N"]37,;Q(K%"#
M]M,&YH$`267V:!P3``ZJ[$A=&(9C.6:JFZ2=X%8\1;$(:12DI,V5V$KT5NE@
MRK5&8[NUV%UYAV=+/"66PGFV7<+E*..B2%%6B[5:52@JEE<I8AX:3B[4BRZ/
M.B8J_%\+:Z"<]RFLKSX,\^4SA9*??'`-BDX*%!50\F-@SO%LUQ42[;YIC6<I
M*?>(C`DJCY%#F)-=.>H[2ZOUZ@`DHZE!D0)$:]9@MB4I=F.72J5`KB$P"L7T
M&,WJUX*B]%A>)/9',L0XDF6T%K21D')4EX'M[YY<MR9O7F6C522:Z&.Q@*L#
M@76G,GS2U(W8@GR(H0VR%C["Q2*YZ.&V0(:6U[$6*4O?*KL]`;'0AX@*]MT.
M%?EA%T8#U=4ERJ4T:06#ZV)GAK-\N(@N=Z7A`:;N$B$;6H9P>Y;RF>&)R=&4
M\,HYR&6M(GH=5\MX)UKB'XPB"JQC#_/6J+#1?O$S/FWR>HQNL&X5R?OXG.85
M8,B7K&LEVAA>9%@%X4O)Y<U$BC?/V,[8=EGJP^QEZ?"4J;LN7L'>$A>B=8YC
M7(Z^Y!)LO&2E,J61HI.F^`5@R4BF4Z+K)N8KN[1*U*;=KH*UTK]F%/D"@EIS
M//3D@]T:1B?/OFBH'\->TL&0_%"Z<!6*A`44Y(.)U7P.?^=]U"&TZ)V,/:OI
M1S3]*)Y$[X2+[U"*J2E6-_H!!O$V%@&84)%.HC$.,);^1)-V38H_#_Q0D6'"
M[IM^<\?/WJ75E";E/&<P51MPE37Y3R]RK7$Y!30[FAK/A:/MT<8-H?H[AQ*8
M3H!S&B-VKF47JU#4*U"$JI'R^'5YD4L9:&2#IO,Y=)%D>3S\)&/;XF'0Y/='
M5%#L_Q^1[OL!*"HAG<`"S;GD(0<;+20]++-]D3#<LSL>A]N>@'<9P;"/1<'*
M:M78+0O9;&$4DV[<8M;,HDO-,(:2&9-4TRN7TKDL/B:=SG+.QXJV7[-$0[*8
MY69'$[BL`:3\].D'2/D$OKU]SHS3*(^\*M]U!46&0!&N<*)NP!WO7>9:_`M-
M4]OIYQUP`A_AHBT""JAX.542O.Q']:TS`Q=0\Z:F5;K42@-]6%%[%/T88T]/
MGOZ4IG^)L=^KTS_?%/_LS3/N!U$;CCT9;EJ)62+R#CTR0)87KHV*-CY:H-"A
M(*&1SU&.B05ZEX89L[V4"(HH`F7[`U`DIMA@XC(TE2N)^-<*3')C';.FOE`7
M!I;R>RC1@(>;5N!U%)9^8*-IV'XZFS*M/,DU]#JJ[+Z&6`=Z':5N6M+U34"1
M`U(XG4.C<HP3Q@TF&CKT$MFD(-R%RP53K)!Q^:4+&/5QR/5M&EZA4*JB\*]9
M+R)+']0]O%2T>9`.E,)L.IC:':K<06M8-MX\8VT*>9'A5+I@$^_UU[&*/EBT
MH!A:ER.?590=M)BB'T[@8XFV"+",,G`$9?(5_5RL<_'0C!'.1EWNB(5.4MK2
M'B8/D!JS.1QZ-B(_.27ZC(Z914_$E,.T'&FU@KK0(5D'`7$B&GI^\K03`#"0
MPABW30?:./*A,HKZ`A1U7A]%*',O71SE%&1T:/3S*3YKZIX8YAA@AJ?"UM77
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M7S1LGP%F$DD"@PW#K4EK:;5+&46KC*MMM`J*<*(95JYD`&$'A_FD^/VX9$\"
MO6C+G)M>G#%E'PRH283-%/)CXVA'RB@J&CQ#B]>$@Q;8VO`5?M/,3DG9&V\X
M2K+XH8:&+V;)T>XS91\2=F!!^UJK22*A6.+U]9\)J9\;N8(I7LE!_,G0)7R-
M;)H2;NRRX_'7CB(!`-O@^:R+FY,X.!T:&_\8>9'<WEC?%X^"5%H#."]BZ*I8
MA2*+B[0N0I&1-*D#F)X-RFS3I!4ZIG#@\DDX@8\C:>%Z0109R5*`HE&1^59>
M5V=C-)_7U2VCM;HP4AV3IYTB7]!!)M,R.M21-JI@7P//8=]BZ$<Z&8T`EO;(
MN-QF=4/]65T[K^&2Y/5*^&N8+FI6%(PJ%!W[Y2CR_*PP6VC.GK"MOCBY;D<\
M(A@UC/[#)8/V9\![D&6-11%%0$BBB99SQ43)RH"J5<+LOF^2/W;']!EGFYIV
M12*?<\BB*J6"E?2^$\8(4.2FLG:!N"OT*JK?P=A=TQNWUFG+8\HGX,;TJ`\_
M3!_P][SZ8!2)S)`J*\D7H"B2`A3M5%"OZ)'8SHCZ#:L@%I]"S8+A4A8EF'^2
M1V$-5(+Y:M*^$_7U';("%-XJL8TSIN[$;F-.1:H<)J`.^!$3T0$7]VL83182
M,$RR=C\)FK-4V^`CR)%D`1XZBK>1=DVK%Q."%WF4:6Q2QGC!P44!C*V;U'"2
M@I7/RM%=++:-82KXWI`.S:X-2<_J:(MU1)5C)%EV:Y$=3%VAQ]?1QVXTX;4V
M/;0*['L_W0*LR'S)(UX19FM5E&A'RR@R1?Y.Q2;R'7<FJ<4>V:TF95(I[`$%
MAWYK+`*6XY:Z.&K%!8M\4TY!>-L$BB14++N)%ZV&/I#/P<+T?IZU*<,D'EU3
M%]\/3>E*CXA3`_&!'56),R'+\L$:8<J/,C#749,_7Q]Z+(P+"K;%Y+63XG_$
M6+-'ID>0%RW8T7@H"HHP\3Q:\.5'13U_[@!+!,"$E66JM%G!%^F76'NCOL9.
M87N8I%AXEY@`HLCR\XRLX?PH*/@%=#Y_1I*>EE$/.:R'VO4HV"-_(#R!!3LE
M%+P@&0D73!ATI)?-V1PMK+S+U<@#I.6^1/40?,R[0EL5$2+@_`F'I]!C1AI^
MD3(]8(R!I:EU7Y.TC8K61>K]OF@4U-<'U,@=:O0K:O@>/71_2+\OHMT/\R*D
M/1@*W3-ER@K&OAJ)+HM%5T8T8$?/-D;.`#QT[2AF',66VTBYM"]V/0R8QT'W
M9KV4V'8,0VGJHR@JA"X]9@31!9',7A`1M)$4GSSY(6!W<;U'P:R2':'0&L8^
M!;#)H';M9LRD3;PN+*U2*7\)UYB`\JRN*]"N)D4SZ>'>2T/0]*7+O"'^0$S?
M$9:.`)XU?-E'&?O]/.5_HZ::RP>R+%,P!V'$P2(KT"XTR12OKP/%]7'L`^L)
M2]LF-7RIKNZWP&BU_<6`/%MP@F3)L7XGKUHIL2FKJNB'K85P(=R!%6SE@1?=
MIRI/*YA^?Q10I+*'K21F*5+'AAW[<K&0$T0#NR)9`KF-2YZRR+$?F]P(HW`F
MI#\'$R3:\`CVW,.-`KPJUEJVIPA%(E\N6,<$*(K>2[SH'-4V^!B@2#CVBQ3<
M+&+&A8UOAQL!67PPA1L!Z/4KT4LI]S740P>>K8\\`_Q9[.&#1]H4"*OI7_1W
M^#%P2SHCPV^9<XPBO^TP-%$9=.R':*5;9O!*RD>1P>O8XS'6K5>CR.452\$N
M:VYVT1BQ*3\->@SLJ*[N:956K$>4PQ)[)JRC.,N3@9;,C=IXEXM^$NEQ0M%N
M7&,B=S%UO4FI^"/)"[3Q42H-EKK+1X8QZQ*4SR@[7:^?:6PX(.O+T@X?HL0Z
MCDLJTHZ'RX@,GLK;.9%`F$AQ3;\=).F\FT!A.*"1_UR1/B5V*\H;N-7,2-(M
MJY\?@"*'DC^K5!2#,I>X,/=`HNFAKZKJ-R5U!\/%1#OK(LMMVE`B71"[<&"N
ME$6+1G#A,^;Z8@4YJ\N'R+;JKHOU12,@]S\/9!GU?5I&Q=-(?2'-C"*=0JC1
M!$8C*'J'S+91``7J-OA8<@)7/KV0$_@P7-OQ["QQ)_24)7'EXYU3IN#:3XT=
M4U&[?J"4I]V::($MGEA4*:9K4:)1FE9<@G:72_`0^[K"5L;][)1#874]*/:I
M0LX+5"/7`EZT*L*Z-':4=.PN25M9PG1(](>*1#U1;9K4N)V+@[(>B".A+#M(
M>96[9D]I5]A=9I&GA%<*5YZF/5\O`DN_%=>8X*KV#DE9EZ+].1T/3'-,BDX6
M1S)%G`AUX14194<]LLTV7.^&O/3+,)<Q(N.'=W%NFI@$S1,%D98O'%:/1Z2.
MN(;+:C2V,1[[-!`!UW"Y/DUH"R_KEZ!(+$9VJ^4XWN:);$R0F^$O*_ICDK:%
M5H#N9&S9A0LT9T4ND-B(S,0M)BY<Q-DT=<8#JKX\'MNM(F&/3:J'[CT:TI;G
MLBANH-D4VC@&;7`6I)0$RY?\B!BM7D&M#%AZY'9%VJBP#I5U*+AV`,,??H=M
M?ZLT8)BX1Q;B#K<I2V:&1]-<#__)3;,.DNK;%6;'H\JVALA]MNE/F>KL4"'Z
MD^D41J8X*@-Y,+?3?.ZTKT?5!W&UHW9T<M/+((#4R'^#(1@>%>-BX*I#:64(
MX[#"Z]@+O`+TL9(`#"8ETMI8JN^^1UM;2)^IKU\9UC=I4ON4AC^CE=T;0^P1
M.X>OX/I;.-CY`FYF%:PD.J"PG;2LOE.6-^2R?G)BJ@#B+`6HR)(7`JY+[.'I
M38CYR?7]Y,K8H8<?@8<63'YYQ$^(*N'B#M0W1A-<D1Z;UM@5P:U.]L8QFWT/
M**X`R))8XP-:09;FLNUG^WX`BKS`@"V[Q:B2'4%K];7P[;*^BFG;<&&=="`<
MWCUE*E@Z(-;OT=05D^K72^R;*ELWM6%?8VP7Q3N`M:YJ;,!XAZJT1K0-H%DU
MW[0<)CA8*.DD,3J8>)0W6&6'BD=7_%OHG;9X-'R'QC:H:(P?A!/X:-(:*\\)
M]FPTN)43*=_0YD7.!S'(!>),OH<\5#V3(G\Y.8H^'V"AEB%@XWBNWX@GUENA
M`Y1V`B]F?,X(O<URE7U!BVP7RXLT=:\6^NI0@J(JJ-VAADWKT;H"[;</<^R5
MIR3U85EY1%8>4^65FB3J-Z=-V@(B/H:MK8[A(FM0Z5M#<D=,6M4R<X4#TY^T
M3=MT+EU\1W!IH%B4K8W0XE_:ON"8+&WQEY22!D&\A3;EH.R763<]PMA]Z!A!
M*7DXJ@[0VN$'8_5W%4C'`&7@G4%4RF7U=DU>$]705:6PXS.:7L*U>'&P9+^<
M+U"[Y,QW<$$B;O5(\TO8\M>QT9RJ?09\#<6WLRB5A8.1*^M/,'4W1;)Z:$N$
M#>%(MZ[C8O`(+KK9'\8@X'X,,;".B-85Q7TJ-I%]O2ZL+V/L=\$T<VCT:26"
MZQ7SOO)9=F65V:#CY[H[)%EBH3MUMDE'%'7H;&-,OQOFM1?XKOUM&_U_1I&S
MS7<QS=[E[_V<3XYMABY-B_^=C";\QDEURY#)%`MC9E/EQ5'(#@Z]A\*9&(V9
MY\4$GS;I3I@1:A1]GIIV.!I;`[P75!8,.&$Z"::(J_YN#UWDCNA''5@^),D'
M);D-E$E5:L.-31`#^VDKLX$P6:QAO4M1#\9C`*T_1(O3])4/RT0'K..2#8@K
ME=:'6*^"67#`,4[+;">@:'3$3\##901.(F/G4@9B^YWW^(P9*R,Z3.3UNMBS
M13H3T0_A:NO0-T/QY4S_JAJ].U('=NOCH-ACDGGT?TR._BE,M\:&UE#XB3P%
MKYUR@I.'^Y&B9$8!:G\`BH(384<(!3LOHID&J5A*Z%[<.`67]@"53JCA8TP^
MK.$:4J1,/-X?#B&N5'5[&*/2>VCWB<Z&^*FP?EA1U\GJ9PS2UJX,NOZ^MI[K
M%(N^%5/F1;QB%'/:ZA37.<)DU._7V0X=UX^`$KLMJC]@D'O?%>X(<I(72X[C
MY&V3=KL"S?,RGST=3->]433KSH;8657")-*1#(B)45PIYGBT>)^VK+1I(3_I
M^+C"S,P[1*?$"(YL<H1+H;4AW`@(MVB0V.:&!MS@".1""06I6*??@:J(U$FA
MKA/,SX8ZA'P)UV6TT79&<*5W2L.W:`[NGH&>*]P"CK$OFN3@HBBZF\Y><;PT
M+V\):X#.O)'V#.DA_^=YB>TUB9WB2L^24;0+:"N3(Q^[Y.\']>6(\DQ,Z8RP
M4RJ:)$=#ZGD:E]:0WA8.P>AL;HJ=TU`EZZ/>'M25K;1KUF<+M`?LI<LC`B"I
M3+HJ[^B#8OK!/7G"#^@5*5+;*BC2]'L!##"S1!@"Z8`+*&!"G8W&OD4>E1VR
MMEV2-TK2%D+^/EK8]31C*_7876"NI@KX@B1A8:)7);I4A7@"QY'OG[?%GCP8
MS+U78YL"B;8)/I9HES\RNFDY#JX%QOS_9.9=7'1":E*(+5-HA4Y(>H'V,/PB
MZ>29K/,3BEP+B5!]I/T`O"P]VK))(P4@X?9-X2=H!K5/G_RRCDT]"".5+%!'
M7421R@Y(N.I0S+(S9$N>]EW-<@==1PAIF-K1/KG^G&#12NCA:-,]H$29N%4Q
M/K>(L7X@?B9KT-(GL;Q=6B]6)=,620-`X32)W&`3(9XM%@IV2>P]FRK2.B6#
M-\8?":%JL2'*3@`KEMDK$>T5QDYI\CD,).%62-"9XW7:V;C2([,-(?61AL:[
MLR5:UX\>4=0/<.M,-%EPV]`@IO\!*+("?U0FV/\0>5')]O4B6?E\70PT^6=T
MI4T%22KOH+W4@&(O,G3YOB@\`/$(3,FUFK0;O5[2HY$8!M_SE/TE[#':6%MX
M%>RJG=*Y5Y%L+EE+H*'3IC<NOA1CGP8=+!;='8_L)F7LTW"Q2'[%$GH6Q7I'
M,&!'*,D*E4S:>P>TXJTA#1C(CG!\G1S]PS3\BH-.=M&FS0`=?UM=FYXH9!1<
M3]$Q1^8,K81RN*PO;V@"4L/L.!23>V/RIFR*-&?Q+?L&J+[UZ);?&0^?DG`O
MM6]3?8Y(U$,Z%6HI"DXWX$O;%7D-[J-HH9:;<\2>L8;H@ZAD1EE"#:8HY+9H
M`Z@W3X7JV]50X(\*!C'85P'F.R[!+)*@!:DGL2],BJ[1<1<1Z-MAC0W4A5\@
M)G"J`9?C'0BSSJBZ.ZJO4>2[0J'/`OQPJ8+8],LS*4_,#^6+?X7VP7&T*H[D
MKW2C.>Z*O;X'A_C4J9^/1[\>"7TC%@$L/:A&[U4BRQ1MO2+O55D[R'U5W:AI
MJ\%ZG7TSJ"+W-L]Z.D];X!KDV"FA<\XB+VF)=E,S:6-DQZ[HT8)=>K1!A96W
M<Q;-1&`Q8%DLO'69'OZZI-X'58W<L>B697"1E%N.-SN9H?S%/$_B=NN%48_V
M96+LXU,G/:QJCS'YT5#C8TSZ@SS9)A='+CBXAKA`&ZF6:XFNP$-!_4S3,1?<
MX\`K9#"^\-7ZV/JPLE9#B^G>^7,I(Q$9/F^>]:#"[M.4^V5I&6T-NA78IB(=
MQ&T>M8VJME;55ZOZ&DU=2[Z.E7715:4"*J[O7,1$%%,D[58J$`II54(4V4,Y
M/O.FE0BDT%TL=#M3[Y(CGR9_5$XD40@;1.PJ`>.9SF+8"-A4(H$JY:3XEP"N
M$GLP%%D7TK8"#A5VH#&$,<W),5`R8<B^J+!/X[9U%B8_@,6=!1YK`#_/N\2"
MQM8QB1-5NI`P]:]2,GV(H;)!0!H=Q:>`6@JZ#&ZL)S)B79HV%AU=RK9T>"*+
M=PY?H2V:#7^C<G*E%\F-YF^)3$D?OB^K7,N(JEQ!U8Y?&L$%R<!_"KBM.K\\
M[&_W/?:'&%3R@AT>T@F41&"5#&5P16W"PL5.!=ICRO/X5<\-JCNV5AHW*&`P
M-$(A,!/CE13%N)(S?@I"+S%*^[>(;>)R&(X',50DFN2).>*)@Q?SM'/..[]`
M<EBX&PG:SD4SZP0N._'ZIF]WVJ/F(")_"%V4>5K^/%SD!7^^9_RH4Y5B&>Q/
MB\F\N/6B@SM*.;0/>:CNOS+VB=MN>49A]ZIL69W^2$R]9VK3'13T1"^$*UPK
M(I!MFX'TP#W8/=<8APN-JQ8Y8[#DFR^XOJ:83EO"J0(S"&,<^"VP_4'BP&4Q
M!%#*X,:?I2(N9(<13/I[Q..NP%X1:`"TA!/@C:#MN^0?'%M=OP;)#$`$R\)(
MD$/RS[<0B-KI+&67!7W.Y<3F@G8F,8Q:\17<>`A,0H/\_WE2.],ELD--GKI,
MDY_4/H?@XM`V:_YY]='UC[DBRA!;!#\2%#+&?WDPRKWW:?=:7!ABFF;)<(Q@
M73Q-%I2V5(O^_S5P,=S@D>$IZ)R#WD`W*6Q=9DG"_TGNWA&Q?9=!,CMK8T81
M2C(OP]T$>I<L7U$(_D<`!H]RF4LTRUVSZ*^!+YC$]EW<M<PDQUIN&,6#F:U8
MQR-#M.I?2`4_XF;81LXL9G`K&'0&61^,(M]AXE:2<RM?(T4`168ADQ0[3F/N
M'#ID!HEZE<PK7!R1&O8]+67^9X$BF`KB]<+'2(]Q7=%:(,K&+O(M<#OM5;"-
MG;&-4M8J9<M.=9\!P6V%X%E&X'RT;6,4P[*I5(D:*!H._DN1U)4LSN>"GS+&
MJ[,FJL1JT//*MR7:*<Y(<R_O^FH]2,$1D]+]N;^2/YA1V>$2C9U%WH>BG_$B
MUL<53?&"9KJ`KF''X(51#EJK';@LK."Y%$/Q^*!E)\R<R"OW_Z%&-O4+U%V]
M'+KGJW4"AUQP'EB^Z+U/#+Z/1/:#+SG#',FD1Q%71N!D`UN,G&Q&-DL[OMDH
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M2[AYSV4TF=,B.PGX#UB@%[DW"!,"YXME5.AITN(#`)R;IUK$=`!@QS8??O<=
MCA,_0]=I\S(KV*T*W=.VE4I@/TLY]-<[EI5.>L4<[A]A&V+6NZ62D<_A[D`?
MC"):/R(B[#[+JGCD*#H%X^+FK.2[W!W%D3+LRFX3"`D+P>#D[-0%(G*1WH@V
MQLCE*-AI^7JV4<V!:9.M"HIHZ8OX-IO`F0\`QNTU@=I%PF&*:A8_6G2]D$9$
M@;WD4SYGOO\&+UWFUBC]/P_7'":VSP>]TMO<I5UWLV)MEDL/S7$G@Z^#QQQ>
M0<56_%<8`S_"=9@O3@I?`2$!MUWF^=>Y]:YOT0Y2:Q:,W2"*\&+&;U#0IT0/
M,BE6Y]!\,4:Q.AEW]!+M%V.CIH__ER6!W;-S]/2`.$#)_$]!.?+AFH/VW^/V
M($Y,JTC_Q4=4L4%2$4%BY[S\"#W+<#/$XLB4=1.&:-893="+&&YR1!#<&DK1
MXUS4`/"'N0!LXE]]8+C.R.8K2U:OCR*'(JH![[4X#S941Q4$9KWYU\?ZWSA[
M[J\/M/[P6.\_='2^?O#4&VWG7S]P[H?MIU[K&'CMT)%7.[N_WW7XASU=/^CL
M_,&AKA^T=_]3>]^/NT__8'_?#P\>?[U]X(=83^#]5%_M./'JH?Y7.^&'O:*^
M=N@H-M5^"NY\]4#[+X[W_[\[=KW5"[_J_9?>XZ]W=+]QN/>?.WM_>*C[QSW'
MX2)\!3?`;7#SF[W/_4-;WX_[CKQ]M/N-]KW_W'[@S4-'O]_:^[.3+WUW;]MK
M1]K?/M/SW1T;?GJD[V<=9_]Y_XD?=ASY?M>A5[LZ7NTZ^&I7&]3O=Q_\?E?'
M][H.?Z^KF^IA^`@77^W>#_>\V7_R;]LZ_O;`OK?.=/YCSX8W3[;];6OWZYU_
M_GK'=[^__Z77.@^]?F3_/[2W_N3TB?_5L>?U(YVO=QQYX^#`ZP?A?0?@I5Z%
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MU*YPQB,4\^8/.P<>O>DWUDY:O'72TNV3%N^H6[`O>DM;^+:VR"VM4*-+6Z.+
M6Z,+]\46PC&H<&5Q6V1IN=)M2UO%3_Q?B1]6UZ7BJ[;HPK;H?#Q&H!%JBIKU
MCW01*]T&S]U9MW1[_=)=]?/WQ5O:HBT'H4;P9OAJ7PPNSMT7;VZ+-;='YG:&
M%G:$%N^-+=U9OWA7W4+XR9ZZEEWU<W<VS-W>.'=KT]S-DUHV36J!X[;&ENT-
M\^F&A7OB<//BG?7SMS7.W=;4#+=M:UB\O>ZV7;&/[HW>MK>N96]=,[73`HU`
M:]"K]LA\T=N]<:CSH4+?6F/8/?%J\%+0C5WQ6_;$ET(GX:M6..+U,F46XD4X
M1C[2%OX(O>_\X+=+]Y5K;#'5A4%=[%?_AEN@MD9NHWK+-31?6J9Y*S4%CX/W
MW=ZX9%/#(B#I[H9;M\>6[&BX=7-LZ5\O?X9R`:K6R3H4\K=\:-'6OH%R2P::
MOV(!9&C&^'G;P+.3;]T?6MRG+SVF+3XFM9QD"T_=,'6`+3RJ0)U_7)I_DK6<
M9?//L99S>-)RALT]115.SK+F\ZSY13RVG&*+!]C2DVPQ_/P,FP\WG)3F'I>;
MCZK-?5ISGSH7:K\\?T":3S<L/D-WPEL?EQ;VRU#Q6?0M/J7\+&AD0,+C63;W
M'&N&)YYAS2?I"M0S>+'E/-5S>#_T%MN!-F\L>DKSCVH+>I06>,V3\N)^-G]`
M7M++%OWS/>MPJVS4?"S__VFZMH\B5_`B7DY5#5!$N`*QFRG^HJU_2],M![6%
M`^K"T_*"$VP>O#L\XH:JQV7`=@NA!<8(Q_$LX:<\B*>8&-RYA+&%Y]CBY]GB
M%]G"E]C\E]C<%]G<YUFS&'IQVWDV_T4V_V6V4-27Z./S;/YYK"W/LY876<O+
MK.45JB_3Q_,^HO!!9X*G#P30*G?@/!T)>-AG`M*'3\!RA?EX3)W?)\\;D%I.
MPY1A\P;D13UL@4"1Y__#",L/RPK=R:NXBZY!$84JT\7W]A\%%M>ES#\C+SB/
M[SX'VN\GK-X(1X&?4P%RSOEC-,XXBJ$\@P,-*%IXGBU\'B'4`BAZB=@4U.>Q
M`J+F$DCFO\(6OH)'@!-"Y:6@EO'SK7%0U'+5HP>NAO&83B*0Y!N(GG`<4.8=
M9W.05O*"`39W0%X`*'KCWG5@+]/_N3-H;R37\5,C?!3Y3H5R+G$%109/YR_N
MZ]M=O^B(-.\%UO*G2-[9Y^CUSQ"Y/O2C$!_GJVI9FI2'\KA<7?WI/T`2\(S/
MP9JKJACN%A)`@OG,K:[/5RHRI?.$')!N,+FP9;EEH`H_U2@Z0^V?JZJBMV=N
M)'K"\;0\^S2[";KZG-1RPD=1RQOW/@4HHK"J04X*3))WQMAHP1\?12ZA"$U"
MGLY>VM>WMW[140G9_I^QYC]E-YT/2'TCU'/(0VY^B=T,Q^?9S1^`HGX%ZU&E
MI4_%"B=0Q<4!N1GJ20E^TGS*UZ:0Q9U$[:6%^!A^=::",?'T%G&;8";4,DH$
M.(?'5?-`@:*@!8$EZ"IV&.JY&XF>"!XV^RR;>1Y[./<$:QY0YG=)<Q%%A1SQ
M(HO^IZM;(BO,KOBG`Q39XZ*H=V_]@J-2,Z$(QFOF.2:H?4-4>&N`T,MLUDO^
MB-Q\AMT<?%M1C9!15,8:ZMQ>#6N/CA4^'E413C3Z/E<12@+>KX'B??/Q:Y`F
MVA0-]JKS104@$3L2<K8EX#,^BK!*V,.SA*(7V:SG\?S#)V.YGB$4/4<H>@[H
MQII!3?)1A`M)BK2&!?_#=RD(`E105`XKN%4H<G`1YOO[>W<T+NA6FL_)<U^`
MEMG,,Y4Q^O"/9P->=)Z&!D89QCH8<=]`HT%L$8..>I0DC#)$C@`2'`$)Q$-:
M"$4H\@!"`(E>K06_U9K[E4J;@5F'/PDX&Z*.I.3\`#\M957_C(\ZM`2AG>,*
M]O,,]?D\POX&HN<9Y).SS[";H'NGE;E'Y.9>?7Z'TO)/]PL4&<%"C<I_TQZ#
MHDK8/T`1_!U-OG?H^#.-\_LFW]8MS3H1FG,,>)'4`A+S.;;@!CF"9@*S!EYY
M`(8[U'(DW`+'?KWEE+H0],.7M*4G@"!L[G%@6?&/P/$O]%M/LTDOL'GGE05]
MK!GLD><:/M+!9IY0P`A=>$:"NOBTO/B$LKA?6WQ,7WA,7P"MG51:SLCT1*K0
M,ORV'W`2N160\QQ;>);-^5.VZ&4&-L@">-QS;/YI-AL4IY>D1>>D!0"A8SKV
MK1=J!/L)O84^^\3\L&E8/D)_^MFL/C;K=&1!*YO2'5EPN&[Q?FW^W]^]FA*$
MRRZC2CH$OQ9%CN]!,BD>SS.YM[M//-(P9UM]R][P[-YIMQZ.SS\L-?>P.3=.
M[6;-G5+S0;5YO]Z\*XQUKXX?>Z0Y76S&>0G,,;"A%@ZPFUX*W7*2S03M[EML
M%F`)!A<@M(_-[*Y;<CBVI%V>W\GF'V;SNQF>P,<V97ZK.@]JFSKGD#SG,#WN
M"!WA_%A\::<RMY,UPY5S;,&WV=*_8$M?8+.>0R5\P9^IM[R`]MVBE]0E?>RF
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MAT^]J^HNH&3#PC7ZK/7QEB>BS4].7OQ(=,[:^B7??6PS_8NJ`$7.U>D?8U!D
M^RC"\"8&)6W^\TO?V]_UX];>M_?U_+RC[\U]A_YE;_>-4W^RI_O='5C?WMW]
M+_NZ?K2O"X[O[.H<WM+QQA=6]$06];-Y9\EAV,^FGR/G(>E1\XXP8`AS,MN[
M+NSK^?&>PS\^<.1'^WK?VM/[]N[>G^W"XUM[NW^TK_O-_=UO[NL57\'UG^_J
MAOJSW5T_V=/UUM[.=UI[+NSH_/'R9_:'YW6A]3KW961$+>2I!@8UYPR;!\I2
M5VC!S^]:`UV"CD'WWMR/G82>O[,3*YQ\Z&2LIN?E]A,76H]=ZCCQ3GO_A=YS
M[QPZ.7KX>?[V"'<P@NXO%*S.2?.]CK1"Q`E60KI^[FS)I70@L.V&LSQ%^P)G
MBYCO:-*ZLANDEBC+-6EA?#Q'.<?0R=$\OYQ+;.[LF?K1'@D]>\"%3J`>"X,[
M[SDVYQ0(,FWVCIMOXQ=&,>)<H)V11>9LGA)F\P8R\*+A7Q<YT5F+9PVL<'\Q
MC_^3,I_!/4S_^A]W-W]DMW33,38'9-F+^M+3;,X)-OM%=<E9=7&/TM(U[:/\
M^>]"E[!CF2)M:&M@MQ/4^=*'3</J:@`QBSQ%'1O,X/EHD;^?Q7^RA(D.%-UW
MJ[0BMQR-'0=%)7\C&%+$2X2E9,9-)3U;>`R<&Z3B#@^F@RNQ+5H0C@O]2_A_
M_D9RPZW]NR?=>D!&O]EY?0D83>C]0([1<B:\9']\P9,S%O$$Y=*88@L.2LW"
MC'[+SX[UL/K_+,^FQ3TB:\C%?W*'259.#O]%S0]>>VK&HGVQ^:=#BU]0%@-$
MC[/9_6SV2['?.!5:TJK,W=&TE/_C3Z%+^"^M</<9^G^6)FVS8>`K?.AD+%>7
MTOHHX<=%%Z-%.Y$!J%+%`F98NF8YS.&.09%!MEL0HJ5%-4&BELV#+0MHB9C8
MV0-)ZMPPE?YK$ZV#\C*8`H@YIPBD3.'GK7WKZA?NU><=U1:`O79:FG\"6<3-
MY%5K.11?]$33?,SDSF4\UR!/FB"C1_\<P:+<()/2Z2F-5#A#,$O>H30[!`'W
M\CPQQ/_I]54-S=#@<V#BL=E];.:`,N\H:SX96@2,:(\^;W5L'O_>CW$9@(6+
M^(N8RH/;LOAM?N@T'$O/DF&1,,+_(.)CAAQ#"=H[NU2=%E*E%YEB1RLWD'>D
M.AG^_QJD>S!G%E?+DL?2JQAT-T*E;$21R96EI';ZCVL@FXR?'.A[JK[E0'C!
M$:6EC\T>8'-/R/-AH%]`3:FE)[)D3=T\GLS3-D\5-UJP/,T526!FX*%URL9L
MY5LB4G:$__BGCX=G@0[VHK(8=*%^UOQ"_4>.R_!0-.4.-=SR9$,+_]Z/1&9%
MB5):"T%6HU,]3V^$2A`HT#_.R5,67LXTA;:<Y'R$NNV-EZ8VYC^+>7XHK9SR
M7`%>V3_@W4C5]TL$_]E4()_C+A5O'^S;U+C@D#;WC(I<Z#B;<U(!>W\>^0,7
M#,B+-L<7H9:"DLOQJG'B4Z"\N4&5AS]@X)[`*F;#YOEKKV^KAP;1CW06Y>:\
MT_)"C(RPV:>U!6#.;YJRF/_]Z[AHDO[SM<_A78'&JN32&Z-Z5:GHU7/'+,.^
M7#S^_X]"F\P@TZ!]4O"]Z#5Q!3*@:$M#2[?2_)PR[R2AZ#0ES,#XGD;'X*+M
MT46X&M*K^O<3GB_K/1ZTP]URJH-_H1R]QNW&"A@4^.'KNV.+SJ++;@%I7_//
M2(O16\YFGU=;.N6;MTY>B"@R#;'B&`OEJ1*HZ%_ZULJ'6FHHJI6)EQJ*:F7B
MI8:B6IEXJ:&H5B9>:BBJE8F7&HIJ9>*EAJ):F7BIH:A6)EYJ**J5B9<:BFIE
MXJ6&HEJ9>*FAJ%8F7FHHJI6)EQJ*:F7BI8:B6IEXJ:&H5B9>:BBJE8F7&HIJ
M9>*EAJ):F7BIH:A6)EYJ**J5B9<:BFIEXJ6&HEJ9>*FAJ%8F7FHHJI6)EQJ*
M:F7BI8:B6IEXJ:&H5B9>:BBJE8F7&HIJ9>*EAJ):F7BIH:A6)EYJ**J5B9<:
MBFIEXJ6&HEJ9>*FAJ%8F7FHHJI6)EQJ*:F7BI8:B6IEXJ:&H5B9>:BBJE8F7
M&HIJ9>*EAJ):F7BIH:A6)EYJ**J5B9<:BFIEXJ6&HEJ9>*FAJ%8F7FHHJI6)
MEQJ*:F7BI8:B6IEXJ:&H5B9>:BBJE8F7&HIJ9>*EAJ):F7BIH:A6)EYJ**J5
MB9<:BFIEXJ6&HEJ9>*FAJ%8F7FHHJI6)EPJ*'!<.8MCQ/&_]O*U_4\.B#FW^
M*771";9@`$:9W3K`%O=)BWJU)3WZ+1OJEO*TQ2U+C*0`D8!+!44!NBK?EO$$
M*#)+W#'<U][<U+"T5[NE3U_:C_A9_!R[]0Q;>)S-/:4M/JC,V31E*?]?;_`"
MP)4:A![:V$FGAJ(;H\!8&P@D&@@Q.@;G><X3[F#G"QLF?VP+`\S\ASYVVY^%
M/O$\^]@`^\A>Z99]4_^/39-^Z['I'X7;>,'E64/@Q0ZJ4\:,@*7G/ZM\`UYP
M'.`G?"3'7WU[W=S_M"YVVP9M27?\=TZSW^QE-WTG\HE3ZD>/1CZVB<U[9NI'
M^=_]A*=L7@#@N0AR!_MJUU!T8Q2O>EB]*A2E./^[GYZ_:^W93Z]X^?>6O_CQ
MN[[[7Y;_S]^ZYZ_^\T//?>*>LW^X_/AGEI^\>PV_D.<Y#P?7$X#$:OJ,:!P4
MF<$]CO@6/B=-_D[ZA8<V/O?EQT_\W@,O_K<'7ON#)_[JM^_\F_^Z[-QO?>G<
M)^\^__D5WWEL"Q^U><;F14`1L$T;^1BW':RN]^%1KU8JQ;NF"NT%)-5@DF=,
M7O`05UF`ELN3G`]Q?H7SRQ9/TG7`A.T9AF$'"+&K&9'C:TI"J%7?4RJ5D)$(
MT(XZ?(2:'81CB8\8/`LL#F#C`G+LT10R']<-0$G5HRN>RVLP^M!+-7@";B0X
M1L(L#.;3)1CNH`[ETSCU1XI\V.!)BQ<YSY0$:`2?,:]E1%4HXOR:V^!BP>0Y
M`FK6XT,E/EP`;-C<-4G.PH<\U4$S`^<ENNZ4421$6PU%-T()1L$)>`4`IL!]
M]@,5H"-.1H#E<)]-$=I0D%F.73"-DFN/T8AXE3BK$FI>E79D>`ZVY-C%?,%7
MR2S\VL;'60";$5Z\9&6&>0DZD,&+""<!)*\,I!HONC&*%S`,.^`20N@DS4*>
MVSG/RCFF6:48`V9,UX$ZFDW;8S7J"H3X>(+RFL=55\`AM`RX]`@D9-0C.\IQ
M$T"6<`H%8DT&H<@N`ZFF6M\`Q:L"SSB<1/`'D]@3R*^\RU,%!]F4!Q>RGF56
ML91K6QX/1)52-$J(1D0%)X1@LRCF0%=/@9AS>-9"80=&F>V5!>)5\'/&:[E6
M_C>7,HJNAE"9-^5MA!`HNFD+A9R)WXRZI0+QJTRI8'FN_Y.Q^M5UAWOLG8:#
MHC!MEX0,110)?1OM1`,?#7W(E=`G4-6R4T/1#5;&81?7\I&R[1;H3O:_0HLV
M`K5\'//_FOO+S5:`XHZ!Y0>PM5JY48I7=0Q.RU.^K"Q5#'E>A8=K.$ZUEEX(
M@&1?VZX]!DO>6/7,K!*U5^M=-53=:.7Z:K`=Z$1EDZUTE2_('D=N>=='D?_;
M<7\88,FH^E69C_U2ZZ]6/N1R/?EUC0=)*"G7M;*JO(O7DVB_!('.&-?3^"JT
M5T/1C5C&<*"R:79M=:K4E7'KOU*[YN,AH;H*P]"Z_J-K@NP&*^7A'J/ZVE5#
M>>V`_BK#]RL/M3?VN=4=<,8PGQJ4;ISBC6N)NX'0J9[[UQ=EOT3['8]-?4`C
MX_S\*A;DC?F^5C[T4LV+QK?TKS'6RB?CFE%C4'2MO+NFM>O98DYU%ZKLQ^N8
M`K7R(9?K#H<WSCV_M'[0;W[%UFJE5FJE5FKE?W/Y_P`,P/YG#0IE;F1S=')E
M86T-"@T*96YD;V)J#0H-"C(P-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E
M1&5C;V1E#0HO3&5N9W1H(#<U,3$-"B],96YG=&@Q(#$T-S0X#0H^/@T*<W1R
M96%M#0IXG.U[>YP4U97P.=6/ZIX'##`@,BHUMB`R+V88WH@#PXS`B`X/9<9'
MF.KNZNERJKN:JNIYH#$8->B`9HQHHO&!#Q14M$?4@"&1J"B)B<9$C:^HR;*;
M_>T7]LONQLVWW_=3OG/OK>KI`71W?YM_]O?;+FZ=<\\]][SOK>K;`R``C($M
MX(.N2];5-=2_>G00`*N)>EDLI686_>_7%E/_1B"&6*^C/%6W9P^`G_J!A8E,
M=^J5/R_*`80/$6UCMVIG0A$H(H$*S2_O-@82I?^L=U&_D?K?2FIJ_*=;$^NI
M?Y#Z<Y-$&#^AZ#;J_YGZYR133O_*98.W`(R=3/IN-LR8.K%U8BW`^)UDPZLI
MM3_CNRPXDT0GB5])JRGM^EU5]U'_9H#3%F5,V^DT%FX`J'H%H.C&C*5E+GGM
MW(VD:@7)([W_Q0_*9^$0!,C7-_QOD,1)'H2X3REA`U_R6;U.4:#I3\J?C@>K
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M3^$/@@PA"%,%%D,)E%)=CX4R&`?C80)%=B),@M-@,IP.4Z`"SH`SX2R8"@I4
MPMD0@7-@&DR'<V$&G`<SH0JJH09JH0YF03TTP&QHA#DP%^;!8C@?EL`%T`1+
M81DTPW)H@5:X$%;`2E@%;7`1K(:+X1)HAS6P%C;#]7`C?`NVPBUP,VR'6V$;
MW`V#L!&Z0(5+X3)8!Q1FB$$<-$A`-R1!AZNA!PQ(01I,R,`FL,`&![+0"WVP
M`3J@$RZ'*^!*N`J^!OTP`-^$:^!:^#I<!]^@E7P#W`2WP;=A"&Z'[\`=L`/N
MA+O@N_`]N`>^#_?"?7`_/``[X4%X"!Z&1V`7/`J/P6[8`X_#$_`D[(6GX&G(
MP3`\`_O@67@.GH<?P'XX`"_`#^$@_`A^#"_"(?@)1?YE>`4.PZOP&AR!G\+/
MX'7X.?P"WH`WX9?P%OP*?@UOPSOP+OP&WH/WX0/X$#Z"W\+'\`E\"O-A`2R$
M1?"[__*Z_&M_WOK2D7JZ8M@A72]=3MCW*7/U%-5ZREX]Y74'[)#V"1ZJF!C%
ML)YJX@^!(U1!%J?/ICS54\W\']Q-5<$HBR%*XZP"#A-<0F,Q@LAE[,#M''Z=
M:F@'_).T3WI)>HF/7D!R5S$.<4G[`D>(SN3=0-G[&`\1SS4\]P?@+3:+).^@
MS/X%9]"U#?\6CTGM1$6FG^3T$/<.LO?'E*5_P7)<@H-XD'C&2]=S6X2V+<1S
MF*ZWN!1VK48#3;3P%I)Y5/))<TBJ*=TL[91RTDN^3O^2P)'@^.`\V2`IM()I
MG8XC#YFTBZGRHW1MRDL5UR]1PC6X'I-X%^XD&P[C,;K^+-5(%U#4V76GK\M?
MXO_[0$_@(;J.!"^5[PL%239;_U-H/4^CM;J85N4J6H%L75U-JY!=U[BKY)MN
M]>^A"G^!JIAT4EU^#'^AZ(REB_DU#Q?@!KHZZ;+P.KR1XK&MX+H5[\5]^`+9
M]SJ^(TTEK\5ED/?"RAND>Z1GI=>EGTN?2$>E?Y#^R0>^L&^C+^JS?;M\C_O>
M]+WI7^'?Z7_0_Y'_HP`&<CQ2XX/EP:N"V^C:+H?E'OE&^7;Y/OGYHEK:N:;1
MGK28O-I`7@V0)]?2CC+(LS9,%UNGS]$J_`?F!UW'74_8M0"78RM>2E<G7HY=
MF$(;^_,>/8*/XFY\EGQYAZ[W\$/\'?XO_$=^_44*2I.DJKQ_[=(Z:8/4(]TE
MW2W=*SU!%;E/.BB])WU,/AZ5/B,?BWWC?1-]9_E:?*UTK?==X>OWW>#;ZWO)
M]Z'O&.6MQ'^^?XG_4O]5Y/NK_J/^OZ=,2@%?8%I@3F`A7<E`.G!=8%O@?JKH
M8X%CP1(>E?'!"<%%P:W!!X+[@N\'/Y<GRI/DL^FJE>OE=;(A]\J/RT?E/X2>
M#"\-ZV&KJ)KVLEFT:XW^/$?5_;)T5;`.IN"'5`V;?&.)2V%K3RJ1C;`N[6/6
MR>MP!F7JM_`77QC:_*_"!M\58`2BOF+YC[`;;?_U^(2OE7;*77(O'O1U^8[Y
M=@6F!1>)>$KW^!Z7!^0N^0]DZ9]]=P22<BTN#6S#W=(%M*(M7`/_BI_1SCT+
M'&DF[9WT9,!>>F[M"#V)I;36#DM3<5O@(=\S_IV^EL!U>!YEL")PQ'<3/8$F
MTG-M!CVO`G25LQ>.IGGSYS7.;JB?55=;4UTU\[P9YTZ?=D[D[$IEZEEGGE$Q
MY?3)ITV:6#YA_+BRL6-*2XJ+PB$Y&/#[)(3JEDAKEY*;WI7S3X^L6%'#^A&5
M"&H!H2NG$*EU-$].Z>)LRFC.)N),G,#9)#B;\IQ8IBR&Q3752DM$R?UB>439
MCY>OZ2#\UN613B5WC..K.>Z?SCNEU*FLI!E*R^3D<B6'74I+KK4W.=C2M9SD
M#1<7-4>:M:*::A@N*B:TF+!<:R0SC*U+D"-2:\O"80E"I615;E5D>4MN960Y
M,R'GF]:BQG/M:SI:EE=45G;65.>P.1:)YB"R+#>VBK-`,U>3"S;G9*Y&T9D[
ML$T9KCXTN'U_&42[JDKBD;AZ94?.IW8R'>.J<A=&EN<NW'QT<DWU?GQT?4<N
MW+P?87W'`5AU?,OPRBW+EW<R;>.;.[9R]M.(_;3-1RM\@RV3=85U!P>W*KF=
M:SH*1RO9O;.3A-94MZWMJ"2K(RW;%>;&V@[N`0G%R75D)*,Q-X7#6J2%4;JN
M5G+AR+)(<O#J+DK6E,$<K!VH?&;*JJ8#QS^%52W*X/J.2&7N@HI(I[K\C.%R
M&%P[L&]ED[)R]$A-]7#9.!'IX3%C7:2DM!#1\F,<X^P,(ZN]4".S*+*22B2G
MQ!2RI".2DZ;-9S=M/@S&YA,;?3J1(JI3_+H&RQ:R1`2FE464P<^`"B%R[(^C
M*:I+"4XK^PP8RLHE7W(T[N&YJJK<S)FL4N1F2BU9MH3WY]14]^;:(IDR)==&
M(8/V#IK4N;".0EY9R;*\;7\31*F3V[*F0_05B%8\`TUU59TYJ8N-'/)&)E[*
M1K9X(_GI71$JYV?YZ_S$7&AZ_M_8LDD36I(+<SCI*X8U,4[+IT49]@>F#;9W
M3%<'MU5,[QK<WDFI::6E.#C8&E%:![L&U?W'MT0C2EED<+BM;3#3TN6YM/_X
MH6T5N:;MG4FDH.9FBVCD)C1W^"JD3H%)%;[.&K9K^FEODNA]&4/TGLW?NR5Z
M9H-O"[UQ^.B-.](T5GX;_6_CP\1['`+'?0?P;P'JOCA6=@PN^$>ZU\^:/:YR
MW+3*<95;?/#Y%@F^@,"1_SM_B_\(>X/?BP>ES_TE)*O\1X#2/%+@PQ@).$;_
MZF=-H*E[I79B:O\\-WH_9S&2ML#%Z[>?NW'LXL]"%2%.WK7WCB\8''Y=?AO@
MB_:B3^1ZZI:,?)T"D.N_:`<HW@YP_,VB3T[Z;O5[/S`?V5</`"8UM`16A6?`
MCB*=VB%8)4^''>&#L-?W.!P.T3NS?#;L#8]UVT;1BK=2VPY[0X=A;]&+L#?P
M7=$8K]^D]A:-T5N9?">L"NTDF3<27BG&>6/XA42GYM\'>X,=-%\33;Y%-']<
M-,8??!$N\UKH;XAO!=%>)QW/TW@%M6*B-1+M>H(384=P)>SP=`7^S6U'J)'-
MP2N(/M&U8Z:P)=Q$LLANF>2%#A`D_^0^:K=3?S;!M/`U=!/-/Y]@`O855<'-
M?HH=:YXNBN>J$]K\4>T:XKGFA%C\E1N]U^[U[1$^<STGM@=$^_?X_(SO:"$/
MEKEC;Q$^]I2R></H";2M7\[['VNAZ`F-OJ^$1/W6?U4K"E)]!D7.>=Y'R_U-
M'G_7;6X_.&=T"PV*EA__?Z-;GGXM'&:-Y9CC2PD6--^'$/--A%CH0GI[!_I6
M_C_7=/K^]M_Y$GOU[[$$ZN!6&$-/D#+"%A#YC_Z-_+LAP+GX07X?SH!WWH40
M!L?%)9"#9[FX#RJ"Y2[N+^`)0`F]WPL\".."BUQ<A@7!BUP\!.7!FUP\#%/A
M3A<O"CQ"F@5>#`W!NUV\A/#7V<F<GWW/+`E^SG&9>2&'.1XFKD_ETUT<87P(
M75R",1,N=7$?S)VPU,7]!3P!F#RAS\6#</:$;[NX#-:$81</P8SRB(N'84FH
MV<6+BE?(_^;BQ1`O;W/Q$L*?YG@1LWGB!(X7,YLG5G*\I(!>QNQT\0F$CY]8
MS_'R`IX*/E?H/;.`?@Z?NX[AH4DC]!)7;[.9&;#T[J2C[%'J%RQHJ*';'&6U
M'K-,VTPX2K-I96J5I8:AK&5<MK)6LS6K5XO7B@FSV(1Z9?U`1E/6F4;6T<VT
M7:VL3,=./6M]4E,VZ.GN.#5;29AI&NS3+$V):[;>G=;B2G1`:;-T6UEA&BG-
M5M1T7&E.JI9!^#*]6S/,/D5/EQ8QW7R0Z:]5F-P":2;YI*=5PQC@Y]!QY:)L
M3(^KRLH8-V^I99E]!-G\=8YJV8IC*C$SE3&TE)9V%(>DN3,<K=_ADI6$FM))
M'MG'AFT2ZQEMV;7D(5=4K5B::76K:7TSZS`%EF9HJDTVZ&D>8D6U"P*<#\:,
M]:O/J^:BG:2E>=YD++-7CVOT18]BD#+3NIFUR8A\M&S-4<R$HC._2%/&HD"G
M'9+')9%+-(=[9J8U)H]X,V2O2;'AY*RC68H]8#M:2L2:3=-$&#AWMZ5FDGJ,
MV+.40O*!)B34F&;SF%.H56I"?<*TE/;F:H69Z9A6M=*C#41-U8HS$LTF[RPU
MUA.EM%0S=^)*W-)[B1S7[1[-<1B#2G444VU;=#,6UU=-L>^O5C0G5EO-HM>G
M4641'%&;T`T6,2-.OI$\,Y;E#I!B53?$/6KV:T3HT]-QGON8H6=<ZYC??2K%
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M3S@6I$`%`];12XI*E#C=+;HW\Y]W!@C7^0\_#BBPAUH]O1@M@`:H<;$Y1%M-
M/#'B-,&FEN"\S5QV!FH)7TKR#8)K\[)LWM,(:L352_<XYQS1,"NOH9YHZ\F2
M#'$I9*=)LK(D0R<L31*JB;J2L-A_2M=Z&F/R-A!?FCCC+F3<"2Y9S.SCLQAG
MG,M@4M-<A@)1LDJ!-AXCQKN"VY;B?(H;31:))(^IX=*7<1D:]4V2KG"]I5"4
M]WMDIN=_+8^`L/?4MIENGI@LE4>`6<;PE&OK112S&(VS_+)XQ0JBMY1F6]P:
MT??TBYJPN"Z'QA4^*T698+XPR6F>:\>U;;0.AVC]?-RSF6',(MVU3\3/FVV[
MUIX8:::_ULWAB$?,3N8[\[R;6ZS#YOR(YX'%XZQ1WW;CP"(T4L4*'SEU!9]<
M&3,H"ZOA/*[!LYI!IN7$W&2XM%X>#8WK4=PZ2'$N5KU9XA21.+FVF+T.SVR"
M6^WE2_B4X7?;S8"P;\0FD26A9R1G)I?MV2?D9MSXFF[=C'!G>?XL;LD`_XF7
M9;RPKCUMVJAJ&)'=3;-5DI3DU@OI67<5BCP(#:PF8MR;D3JWW)@)6.A]@F=<
M@79:5RP/7C0=3F>4'IHS0+5ENCN9QR5TB]Q97&</<8G54IW/3IQG@ZVF7I<[
MSE=W#\^'DY>@NOM1C%>0/6HTP^=[_E6[==_/,<;'=JKJ?.WU\0@:^?ZIO$WP
M->/5F,'KQ7)7:YPH,?)N)`/"8Y7/*<193/IYI*NY7IUG<F3=QXA')^M'Q\[+
M=Q^WC_D4Y9B(2*V[^S*^.(^5MS-7?\GNJO.]FNWA<7='+/2XCTM(\MW!=#&1
MKT+9JALO8=FI:E:L)9U'+L8Y8VYV;+Y+)0OB;[F2O55D\A@7UGK2Q>S\OJ/F
M?6*5;N2K8'0D,WD>F^^,-E]K7N:B;N:K76]3=!>SV1I@]:F<D+-35TR*R]2^
M(E(ZKX%N-]XG1X#YX[@K;R1Z(]X:[M-%K"*Q)Z2X;4:!90[?\]ASK;M@S8^6
MIO%,Z,09XQ4=Y\\I4;T6G^')$WN@P2/A>>/M+2K/MU@#7F9&LC6R]I@]44[O
M=N5F>.79^7U+/#O$LTD\D37WB>=)$_2L^Y1/YG>J=J+JH_;?0OUQ-P*%HY:[
M@AG<1!*UO.8LC\K(.XWWG#K5'GJJG5/4M9F?-[H&O*>WZJZON/N\_;+H9D[R
M;'3].__!=R>13=.5FW"K2RUXV_#LC;G189$P\G['W?AY,1'6L0R-O)-Z,8_S
MM9YPGQTBKG%>9]H)D?5FL'H=<-_*6#Y;W;VVE]NB\]UM8%166<VI7)JW<J+<
M7H/S%JX#S:V6GA/>J)@&[QUF9*_>D*\8+XJGBISM9G#$OI/?$[KY&U&*TRQ>
M,\JHU>95"JL^U7V'J'8SSMY$N@O>"L6[7_<HWT8BI[KO9:>J@;5\767YKFC!
M0F#O5^LX]+XS7.9ZY-5=`TF:0]?)TFI.D#;ZO3V>KR.QZX@5X$7*VPTUOOM9
M?#\5<?JJ;RPFG^553.TI><7W$;-@?0[P>G0(7PAU=/7QJY:_[8Z>7>L^K^JX
M?5FWSMAN5E>P>NK<YW-A+.K^*CI.?KNN<_?(.,FO@XL+OA5J!3V5/P4*OR>*
M=P2/XW<TGN8S5%ZC<?[]$B1Q:'Y\/O^]Y.3/[]V?/27TH1\#&$090QC&(BS&
M$BS%,3@6RW`<CL<)6(X3<1*>AI/Q=)R"%7@&GHEGX514L!+/Q@B>@]-P.IZ+
M,_`\G(E56(TU6(MU.`OKL0%G8R/.P;DX#^?C`ER(BW`QGH]+\`)LPJ6X#)MQ
M.;9@*UZ(*W`EKL(VO`A7X\5X";;C&ER+ZW`]7HJ7X0;LX'^K=`5>B5?AUW`C
M=J&*48QA'#5,8#<F4<>KL0<-3&$:3<S@)K301@>SV(M]V(\#N!FOP6OQZW@=
M?@.WX/7X3;P!;\2;\%NX%6_&6_A?0&W'6_$V_#8.X>WX';P#=^"=>!=^%[^'
M=^,]^'V\%^_#^_$!W(D/XD/X,#Z"N_!1?`QWXQY\')_`)W$O/H5/8PZ'\1G<
MA\_B<_@\_@#WXP%\`7^(!_%'^&-\$0_A3_`E?!E?P</X*KZ&1_"G^#-\'7^.
MO\`W\$W\);Z%O\)?X]OX#KZ+O\'W\'W\`#_$C_"W^#%^@I\&[(P:TX(9=D9F
MA+S3NK$>$LLZ[)QIC'O`YY[O^=E9GC]JFCW!F)J.&]H81S.T3-),:[9IZ''6
MY2=3FL..<$JT=*]FF!DMJL9Z2KU.PC+3SACWA#-AJ-WQOG1I03>;$8/]9B:=
M,*@[MK!+S$%Q;EHD`$E,E[+C5$<U#';X75]2V!LU-+N8]6)J5$]K3CAI9BWN
M6,@[]RWAQ[X-47+>3(?9N2\_<),RL1`[_F7'OG*"?,@,S';AG!`[`;8TS0@S
MQ]E!J5::QPPMX018KS?([F:/["2SJ6@V$^8P;O:EB]A`QF&<Q0+EOVZ$!$Z<
M`B&W.2FI&D[83I$7[-BP.*UE'4LU&!ZFN/:E&>9G9ZUC[9ZL8;!3)3O*TN-G
MH94I5FDU[814W<H8:EH+V=FTG:1HR'$*)`4J;*?-/F+MT4+][`PL:L1#_-"6
MD&)*D$=DN$<OX5K,K&.0H&+>L9,J.2?PF&8X>DPPI<A\S=:*V;F=F8BKO3J;
MK1%/VF$T>4!/#ZCI;LE,!?J2%-4`.R&T@XZ:M;)VL%M+Z6D]R$^G+9^AF8%>
MW>HV`X8>M539CIE61C>+;;6[6R=A>M8.Q]2,I1,]'5+942*1@AF=U-FE^9-?
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M'`TEM7XQ:L9<4G'<C-,FQ?#9>6HC;<7=.CM@%R;FN\*C4"QK9]A6&/:0^E"_
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MM+5@-*[:R7H!&HK=7SK9+S%-)=#:2N^8X\>%FE8H^Z6YSZQH('`#!_BD`$\(
ML$>`W0(\)L##`CPHP`,"K!1@A0`7"K!,@"8!E@BP6(`%`@0%\`O@$P";+B'X
M$;4/J7U`[5UJ+U-[GMISU)ZFMI?:D]1V4WN,V@/4[J=V'[7MU&Z@%J.VD<M\
M6HC>*\#C`CPJP"X!'A'@?@&6"[!4@/,%F"^`+$!``$D`:&HB^#ZU=Z@=H?8:
MM5>I':;V`VK/4MM'[2EJ.ZE]A]H`M?B*AO)P>7C>T'[L;5HI#STH#]TA#]TJ
M#YGRD"$/)>0A31ZZ4AZZ7![JE(<ZY'-"9X>4T%FA,T)30I-#DT+EH?&ALM"8
M4$FH*!0*!4/^D!2"$.0F^-JDMG7+L"UW*`9M427WK^LB^[%HS>6Y0&09YL:W
M0=OZ99-S\ZMRTLW\KY[WX_%AQ-MNJF!_\'P`$(_?=&N%"SL[85+5R9_)HWIM
M[0,'82K.`YGNL_?)4U^1&74=48<X=8A1ASAU,C[3#@UMZK:N,^$4@D<^^)6C
MHSA;=.9N>\=P")9U-E\IX#ZIN(C\Z:JH[%PVJ2RSA#NWJ'+R=14O^`%W0W%5
M9ZXDLBQ72HT-U2RM6<J&_,"'QK"_,7>')E^WJ++B!=SM#I41>1R%\O\#.8%A
MO0T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HR,#<@,"!O8FH-"CP\#0HO1FEL
M=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`R.3@Y#0H^/@T*<W1R96%M#0IX
MG,U:6U,;R15^IXK_T`]Y("FL[?LE;QCP1IL8;T"N=5)^&:0!S:XTP\Y(B[V_
M/N?TW"2CZ39"5*5<X$9]YO1W;E^?[M';3\='OQ\?T9%VBE#\YT=VI&3]:[H\
M/F)^AA&N"=/^$TX8&SG'+;$49JARI$R/CWXAN==EI$)%REK\CY3WQT?SXZ.[
MOZ$J_+?Q`1U)*6"!D11*P'_"<;X][Z3">2<,SENKQ6Z%G+RQ1AD`SR@!,:D]
MICMO8#VINTFA>\!O)\='/[Q+;J?>O`D\X!WAE;:F"VG!3"K(!*QW:J2<Y&3R
M)^)C1L/P\?CHY./5>')Y06XF9Y/+F[^2R:_'1Y>@^]_?C\`0S@80,*N),[8&
M8$96J1K`&T`@C*P1W%R>?[P>3\:7-^3LZH)<?CK_Q]G5CY?D_,/[]^.;F_&'
MJSUA,3'D&.&(@_`C+#JBPADRF7I4W.(84?V25/,LOU\5^2FY&)V/"*=*NGV1
MN,$0">*8:9`(KFR+A!H<(Y)W'Z[?0QP/O;3DIEO:R9$5.(;8G+PY^$JB-Q(M
MHU`-:.7)/V_>[K56(.>E8=U:)V1?[8.)8PRQIDL<V8>+NS9<GZFB[Y/R-U+D
M*8S9H9.70;79)GFQJ)76==P^,R.^P"^U[XI#/H52[58\^<SEWJDX:)+<,$F,
M+`=5#4U0Z1J:.+NZ^GCV+W)]^?.'ZPGY>'5Q>4V`.B;`#ZCYPS5A"GT_0Z>3
M#^_(Y!^79(-;.EXY.Y_@-'-"'CK[M!.]I_;.OL'<IO"H>,4X<*!K"UM90]>2
M8TG7<>#4M'14E&0U3\E=5DV3!?F:)B5)\UDZV[:WUG[](VI_1&@_P2^K1P".
M4_@-2X#^[L_%\='-06R0@+^U`=+'82K5)2HDCM&$BW2:+F_3D@AV"KQ.=10Y
M:-U$KK@Y/')&'3&V\[YFEG6;I8$VIF87*'+R*D4./FM7?YTB!Q,Z\\3(6=69
M!SMK$YG)]=G5S=C7]/]UH1LJ>V^]2J'[!NU%L0CL8TBPV._Z6/"1H*;9^W&Q
M]N?@BT+#URX*A"+1P+HRI6N[4=*RRZI,\BI;945.'M(R*V;DKBR6GV$K&OHA
MJX*$Y@].E@[RF7:]K3%(D`U9BJ:)W'1G^T/.B^4RJRHT[2Y;I"1?>RXZ-#X\
M@;3XD*=\QR6$B'.=0EHV5#<L;?H_#\?2AO?.XR-)*=O5?.Z$9_@V//4:\/13
MWS'*-7??@4]OXE/,[(DO0!"*V0[?X;M<QHGHC*?.L6X'M7B8]&>V=+HNH3S3
M"E3?9]4J+:$!6$,;4!*8\W7+.++TK6?IXLY7]>67Z3S)[U-R-EW]_55HDUO[
M>K0)CF'&',@Q]P=V3.B\*V4'W.F1$[RFJI,K.*.\AI.`Y6HG,8&-2^NDMHDY
MGZ?3W\CC/`73:[H'/ES#,*M(7JQ@O=_7&?H-*-U39)D^%.6J(@_KLEHG^0HG
M.F\*`GO&9DNPPZ<C\K+&*6)O<\<"]E+;VZN-BMB+F)G'C&;.2+)8=+9N.N$V
M;01NOS[/;C*#;,SO_></2;5"M,LB7\TKOS8HN(.?:CV=OP:+H"]JMUC:7;%(
MV=9*-0=#P0O-!K^:)RL/M"Z<$N/\F%1/L\'#;=R$AI^2))]Y>[CWPQP>NDW3
M'`1O?P5OX8/^&7@:G=$H7*8YN/FN:3B\=QPEL^1K-2+_@?K%C/F$&?,:KM&N
MNPYQK#NB,&6;E+DJ7IZQPZT^D2\]HX;V#MX5@^BB+E3;$]7%D/E<+=.ZY,D,
M#I.+HEK#!Y#%LQ3B]/L:XN,#7E8DRP%&]5#D58K1'*_2I:=[$+Y.[]>+Q)?$
M?O>7`6LD9'!C3J!+.<1"D'D;?I-\@S1KM[TE4ZC;),NA$,`;JWGF<W=9)_^V
M"Q\SX!'@C->@NJY_-W@/5H.$X["K47883S%,6%>W*=15PTQ]81_\;`')WD"3
M=;?VF7-^\%4X[1U`C=NX6E!-F"KR6UX\`E7?IZ<8IUEZE^70#_P!#%,67[XB
M9V<Y!JY.V6J5K!HFRO)I40*IP0>>Z,OT#@HDGZ:HY^>D7)'Q>%R[$F(/!Z7E
M=H#]1H2';,PE;UAO`;YU``<P)VM3M"`"?*`D\Z]&?AB#X<R1BZ+6U+V?P`M\
M134VLJ`>1XMF9/W(3_OAO%^DGF9PW!/BV<RDN!YHX'I4RID.50-P&TPM\"VN
M9EXRMAN8@2/J4.2AHU%=Z!F7=>AQJ-I+I:_)+)N2<0Y;6NZ#FRQ.X<_I:,`*
M2WEK16O0-O1:X!LKVGD.[/=<]_IG!_U;ATY:XT/'W!Z;"@NH!N^C;O3^D.[A
MFP,!RKL>BXF^\+10_;7[5;+T^T>UQ$;J=ET!$U55UUSF)(,R@^8(NXY=5_/H
M'\2(OGVN_?[9H`/`0=KN[5L3N`[ROM4VZ-M!W?AL2+DW3-O]G3*HO"\%?)LJ
MH2>I:09'-<W@'<:BF:Z'6S2#GTG`Q,PSKR(=V*Q4>QXRAM;O&TXNTD7RF)1I
MH&(;F"WB;71>X%N@[;PP[-E(E14=TNXB0C[I"%^T!,9(J>]H<EZRBJ;LJ2$4
M^BLCG]S,1=<)O8%1M%OG:7>+.0-MUF#.!#A(2WBT.\]0[?K.5KN>@FYP/\=-
MOO!GO5_A^%7!MN#W>F"F?H_W'X!8>9_DV9_^[UV4Y'T!D$.^&(PL[S'[@X;0
M_4%#RQ[T>'0]NAF1R^7#HO@*J,<S:$BRNVQ:P[PJ1KN@H3-A;>_,/0BM?4F[
MBW.\U:";:?ULW?6S`>4^X4'YWH0VJ'R;T`0T6S6AX6C1C'1+&<UPB]#PLWT(
M#;F?TB[0^(62-M".-QLD7LI`<U(FTP*.NLF"_%QDT*N0BQ*:TU-RL\[@#TDE
M^6G]`,/RE+Q;%&4V2P)DV)C86KMM62V@GY(A?K@?4[G.S(T;;6F>,`BZTIB]
MZIS!`\*R[I+/R+[)-QLU<S:;E=A<0%$_E%#6V0.X-/V23M>^V2_NH'S2:JBD
M$=U>)6UMAPXCS4Q7TM+R#7C_S1[(>3'SWT#818-"V7TK5X3>3'GC0+<W;H_*
M#2K'Q>'$@@><YSJ..WRVW7_:6\F3L6\-#[B.@')KUPF<1%^T@MNPA`LJV@S0
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MK%.\GR?5/'PL:@QJ;=NVPPM\:U([OX]-2O`MH_JVMOFNV#(MH7MM+.K>B.Q*
M)$;W3B0F(XFTI^[ZV2'EL/(;@5\_`<KA.Z[Y<)X)\$1(@(OFHG!(0`CE@@*P
M"8274'@;$1+0>'X."<#1D`8%K)1A*YR,6,&HE&&4C/DO4H0D@#!BX9`Z;`F3
M>+\5E%"*1FS1>/\4E#!8.$$)_Q7MH(13$:2<:AJ18%I$)+@685NXT":,E$NM
MPNG!M381":.M"4M8;2(2SM!(L5&M(Q),T["UT'A&<DR(6%P@365D%:55V%JA
ML=\(2ACE(M9:'?.8TR)LK02?1B0@"VU8`A(D7-D2LC#"DQ*/C4$))5T$AY8Q
M'$:Z"`X;8QCH>2-TJBA^:2\HP62$/Q2/2@A\[1K>6E0DDY7"KY0&)30W8:\K
M@Z_(PA).1%:Q.F:+TY'(02U$:DXS)<.V:&"'L,<TMY%]#JI%1G1`DH7]H955
M89]J;6T$A[$1YD<5$1S.LG!%&6I$1(*92`MD8/L(6VL$;#"Q)BBRJQME63C'
M8`T>P6%BD3/6\@A29W48J:6QR%EF(VP)*"(99(6-Q,7*6"9;92+-J84M.UR5
M8$G`I]#)7WXZ/CH^^A_A]LN_#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C(P
M."`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#<U
M,3$-"B],96YG=&@Q(#$T-S0X#0H^/@T*<W1R96%M#0IXG.U[>YP4U97P.=6/
MZIX'##`@,BHUMB`R+V88WH@#PXS`B`X/9<9'F.KNZNERJKN:JNIYH#$8->B`
M9HQHHO&!#Q14M$?4@"&1J"B)B<9$C:^HR;*;_>T7]LONQLVWW_=3OG/OK>KI
M`71W?YM_]O?;+FZ=<\\]][SOK>K;`R``C($MX(.N2];5-=2_>G00`*N)>EDL
MI686_>_7%E/_1B"&6*^C/%6W9P^`G_J!A8E,=^J5/R_*`80/$6UCMVIG0A$H
M(H$*S2_O-@82I?^L=U&_D?K?2FIJ_*=;$^NI?Y#Z<Y-$&#^AZ#;J_YGZYR13
M3O_*98.W`(R=3/IN-LR8.K%U8BW`^)UDPZLIM3_CNRPXDT0GB5])JRGM^EU5
M]U'_9H#3%F5,V^DT%FX`J'H%H.C&C*5E+GGMW(VD:@7)([W_Q0_*9^$0!,C7
M-_QOD,1)'H2X3REA`U_R6;U.4:#I3\J?C@>K\!&HE^LQMZ6000+DL)S"S!1-
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M&`?C80)%=B),@M-@,IP.4Z`"SH`SX2R8"@I4PMD0@7-@&DR'<V$&G`<SH0JJ
MH09JH0YF03TTP&QHA#DP%^;!8C@?EL`%T`1+81DTPW)H@5:X$%;`2E@%;7`1
MK(:+X1)HAS6P%C;#]7`C?`NVPBUP,VR'6V$;W`V#L!&Z0(5+X3)8!Q1FB$$<
M-$A`-R1!AZNA!PQ(01I,R,`FL,`&![+0"WVP`3J@$RZ'*^!*N`J^!OTP`-^$
M:^!:^#I<!]^@E7P#W`2WP;=A"&Z'[\`=L`/NA+O@N_`]N`>^#_?"?7`_/``[
MX4%X"!Z&1V`7/`J/P6[8`X_#$_`D[(6GX&G(P3`\`_O@67@.GH<?P'XX`"_`
M#^$@_`A^#"_"(?@)1?YE>`4.PZOP&AR!G\+/X'7X.?P"WH`WX9?P%OP*?@UO
MPSOP+OP&WH/WX0/X$#Z"W\+'\`E\"O-A`2R$1?"[__*Z_&M_WOK2D7JZ8M@A
M72]=3MCW*7/U%-5ZREX]Y74'[)#V"1ZJF!C%L)YJX@^!(U1!%J?/ICS54\W\
M']Q-5<$HBR%*XZP"#A-<0F,Q@LAE[,#M''Z=:F@'_).T3WI)>HF/7D!R5S$.
M<4G[`D>(SN3=0-G[&`\1SS4\]P?@+3:+).^@S/X%9]"U#?\6CTGM1$6FG^3T
M$/<.LO?'E*5_P7)<@H-XD'C&2]=S6X2V+<1SF*ZWN!1VK48#3;3P%I)Y5/))
M<TBJ*=TL[91RTDN^3O^2P)'@^.`\V2`IM()IG8XC#YFTBZGRHW1MRDL5UR]1
MPC6X'I-X%^XD&P[C,;K^+-5(%U#4V76GK\M?XO_[0$_@(;J.!"^5[PL%239;
M_U-H/4^CM;J85N4J6H%L75U-JY!=U[BKY)MN]>^A"G^!JIAT4EU^#'^AZ(RE
MB_DU#Q?@!KHZZ;+P.KR1XK&MX+H5[\5]^`+9]SJ^(TTEK\5ED/?"RAND>Z1G
MI=>EGTN?2$>E?Y#^R0>^L&^C+^JS?;M\C_O>]+WI7^'?Z7_0_Y'_HP`&<CQ2
MXX/EP:N"V^C:+H?E'OE&^7;Y/OGYHEK:N:;1GK28O-I`7@V0)]?2CC+(LS9,
M%UNGS]$J_`?F!UW'74_8M0"78RM>2E<G7HY=F$(;^_,>/8*/XFY\EGQYAZ[W
M\$/\'?XO_$=^_44*2I.DJKQ_[=(Z:8/4(]TEW2W=*SU!%;E/.BB])WU,/AZ5
M/B,?BWWC?1-]9_E:?*UTK?==X>OWW>#;ZWO)]Z'O&.6MQ'^^?XG_4O]5Y/NK
M_J/^OZ=,2@%?8%I@3F`A7<E`.G!=8%O@?JKH8X%CP1(>E?'!"<%%P:W!!X+[
M@N\'/Y<GRI/DL^FJE>OE=;(A]\J/RT?E/X2>#"\-ZV&KJ)KVLEFT:XW^/$?5
M_;)T5;`.IN"'5`V;?&.)2V%K3RJ1C;`N[6/6R>MP!F7JM_`77QC:_*_"!M\5
M8`2BOF+YC[`;;?_U^(2OE7;*77(O'O1U^8[Y=@6F!1>)>$KW^!Z7!^0N^0]D
MZ9]]=P22<BTN#6S#W=(%M*(M7`/_BI_1SCT+'&DF[9WT9,!>>F[M"#V)I;36
M#DM3<5O@(=\S_IV^EL!U>!YEL")PQ'<3/8$FTG-M!CVO`G25LQ>.IGGSYS7.
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M5.>P.1:)YB"R+#>VBK-`,U>3"S;G9*Y&T9D[L$T9KCXTN'U_&42[JDKBD;AZ
M94?.IW8R'>.J<A=&EN<NW'QT<DWU?GQT?4<NW+P?87W'`5AU?,OPRBW+EW<R
M;>.;.[9R]M.(_;3-1RM\@RV3=85U!P>W*KF=:SH*1RO9O;.3A-94MZWMJ"2K
M(RW;%>;&V@[N`0G%R75D)*,Q-X7#6J2%4;JN5G+AR+)(<O#J+DK6E,$<K!VH
M?&;*JJ8#QS^%52W*X/J.2&7N@HI(I[K\C.%R&%P[L&]ED[)R]$A-]7#9.!'I
MX3%C7:2DM!#1\F,<X^P,(ZN]4".S*+*22B2GQ!2RI".2DZ;-9S=M/@S&YA,;
M?3J1(JI3_+H&RQ:R1`2FE464P<^`"B%R[(^C*:I+"4XK^PP8RLHE7W(T[N&Y
MJJK<S)FL4N1F2BU9MH3WY]14]^;:(IDR)==&(8/V#IK4N;".0EY9R;*\;7\3
M1*F3V[*F0_05B%8\`TUU59TYJ8N-'/)&)E[*1K9X(_GI71$JYV?YZ_S$7&AZ
M_M_8LDD36I(+<SCI*X8U,4[+IT49]@>F#;9W3%<'MU5,[QK<WDFI::6E.#C8
M&E%:![L&U?W'MT0C2EED<+BM;3#3TN6YM/_XH6T5N:;MG4FDH.9FBVCD)C1W
M^"JD3H%)%;[.&K9K^FEODNA]&4/TGLW?NR5Z9H-O"[UQ^.B-.](T5GX;_6_C
MP\1['`+'?0?P;P'JOCA6=@PN^$>ZU\^:/:YRW+3*<95;?/#Y%@F^@,"1_SM_
MB_\(>X/?BP>ES_TE)*O\1X#2/%+@PQ@).$;_ZF=-H*E[I79B:O\\-WH_9S&2
MML#%Z[>?NW'LXL]"%2%.WK7WCB\8''Y=?AO@B_:B3^1ZZI:,?)T"D.N_:`<H
MW@YP_,VB3T[Z;O5[/S`?V5</`"8UM`16A6?`CB*=VB%8)4^''>&#L-?W.!P.
MT3NS?#;L#8]UVT;1BK=2VPY[0X=A;]&+L#?P7=$8K]^D]A:-T5N9?">L"NTD
MF3<27BG&>6/XA42GYM\'>X,=-%\33;Y%-']<-,8??!$N\UKH;XAO!=%>)QW/
MTW@%M6*B-1+M>H(384=P)>SP=`7^S6U'J)'-P2N(/M&U8Z:P)=Q$LLANF>2%
M#A`D_^0^:K=3?S;!M/`U=!/-/Y]@`O855<'-?HH=:YXNBN>J$]K\4>T:XKGF
MA%C\E1N]U^[U[1$^<STGM@=$^_?X_(SO:"$/EKEC;Q$^]I2R></H";2M7\[[
M'VNAZ`F-OJ^$1/W6?U4K"E)]!D7.>=Y'R_U-'G_7;6X_.&=T"PV*EA__?Z-;
MGGXM'&:-Y9CC2PD6--^'$/--A%CH0GI[!_I6_C_7=/K^]M_Y$GOU[[$$ZN!6
M&$-/D#+"%A#YC_Z-_+LAP+GX07X?SH!WWH40!L?%)9"#9[FX#RJ"Y2[N+^`)
M0`F]WPL\".."BUQ<A@7!BUP\!.7!FUP\#%/A3A<O"CQ"F@5>#`W!NUV\A/#7
MV<F<GWW/+`E^SG&9>2&'.1XFKD_ETUT<87P(75R",1,N=7$?S)VPU,7]!3P!
MF#RAS\6#</:$;[NX#-:$81</P8SRB(N'84FHV<6+BE?(_^;BQ1`O;W/Q$L*?
MYG@1LWGB!(X7,YLG5G*\I(!>QNQT\0F$CY]8S_'R`IX*/E?H/;.`?@Z?NX[A
MH4DC]!)7;[.9&;#T[J2C[%'J%RQHJ*';'&6U'K-,VTPX2K-I96J5I8:AK&5<
MMK)6LS6K5XO7B@FSV(1Z9?U`1E/6F4;6T<VT7:VL3,=./6M]4E,VZ.GN.#5;
M29AI&NS3+$V):[;>G=;B2G1`:;-T6UEA&BG-5M1T7&E.JI9!^#*]6S/,/D5/
MEQ8QW7R0Z:]5F-P":2;YI*=5PQC@Y]!QY:)L3(^KRLH8-V^I99E]!-G\=8YJ
MV8IC*C$SE3&TE)9V%(>DN3,<K=_ADI6$FM))'MG'AFT2ZQEMV;7D(5=4K5B:
M:76K:7TSZS`%EF9HJDTVZ&D>8D6U"P*<#\:,]:O/J^:BG:2E>=YD++-7CVOT
M18]BD#+3NIFUR8A\M&S-4<R$HC._2%/&HD"G'9+')9%+-(=[9J8U)H]X,V2O
M2;'AY*RC68H]8#M:2L2:3=-$&#AWMZ5FDGJ,V+.40O*!)B34F&;SF%.H56I"
M?<*TE/;F:H69Z9A6M=*C#41-U8HS$LTF[RPUUA.EM%0S=^)*W-)[B1S7[1[-
M<1B#2G444VU;=#,6UU=-L>^O5C0G5EO-HM>G4641'%&;T`T6,2-.OI$\,Y;E
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M=8Z5I9AEM#J>GKH^SXJZ?W]&?KNNHXJ,)^OX3S@6I$`%`];12XI*E#C=+;HW
M\Y]W!@C7^0\_#BBPAUH]O1@M@`:H<;$Y1%M-/#'B-,&FEN"\S5QV!FH)7TKR
M#8)K\[)LWM,(:L352_<XYQS1,"NOH9YHZ\F2#'$I9*=)LK(D0R<L31*JB;J2
ML-A_2M=Z&F/R-A!?FCCC+F3<"2Y9S.SCLQAGG,M@4M-<A@)1LDJ!-AXCQKN"
MVY;B?(H;31:))(^IX=*7<1D:]4V2KG"]I5"4]WMDIN=_+8^`L/?4MIENGI@L
ME4>`6<;PE&OK112S&(VS_+)XQ0JBMY1F6]P:T??TBYJPN"Z'QA4^*T698+XP
MR6F>:\>U;;0.AVC]?-RSF6',(MVU3\3/FVV[UIX8:::_ULWAB$?,3N8[\[R;
M6ZS#YOR(YX'%XZQ1WW;CP"(T4L4*'SEU!9]<&3,H"ZOA/*[!LYI!IN7$W&2X
MM%X>#8WK4=PZ2'$N5KU9XA21.+FVF+T.SVR"6^WE2_B4X7?;S8"P;\0FD26A
M9R1G)I?MV2?D9MSXFF[=C'!G>?XL;LD`_XF79;RPKCUMVJAJ&)'=3;-5DI3D
MU@OI67<5BCP(#:PF8MR;D3JWW)@)6.A]@F=<@79:5RP/7C0=3F>4'IHS0+5E
MNCN9QR5TB]Q97&</<8G54IW/3IQG@ZVF7I<[SE=W#\^'DY>@NOM1C%>0/6HT
MP^=[_E6[==_/,<;'=JKJ?.WU\0@:^?ZIO$WP->/5F,'KQ7)7:YPH,?)N)`/"
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MN@O>"L6[7_<HWT8BI[KO9:>J@;5\767YKFC!0F#O5^LX]+XS7.9ZY-5=`TF:
M0]?)TFI.D#;ZO3V>KR.QZX@5X$7*VPTUOOM9?#\5<?JJ;RPFG^553.TI><7W
M$;-@?0[P>G0(7PAU=/7QJY:_[8Z>7>L^K^JX?5FWSMAN5E>P>NK<YW-A+.K^
M*CI.?KNN<_?(.,FO@XL+OA5J!3V5/P4*OR>*=P2/XW<TGN8S5%ZC<?[]$B1Q
M:'Y\/O^]Y.3/[]V?/27TH1\#&$090QC&(BS&$BS%,3@6RW`<CL<)6(X3<1*>
MAI/Q=)R"%7@&GHEGX514L!+/Q@B>@]-P.IZ+,_`\G(E56(TU6(MU.`OKL0%G
M8R/.P;DX#^?C`ER(BW`QGH]+\`)LPJ6X#)MQ.;9@*UZ(*W`EKL(VO`A7X\5X
M";;C&ER+ZW`]7HJ7X0;LX'^K=`5>B5?AUW`C=J&*48QA'#5,8#<F4<>KL0<-
M3&$:3<S@)K301@>SV(M]V(\#N!FOP6OQZW@=?@.WX/7X3;P!;\2;\%NX%6_&
M6_A?0&W'6_$V_#8.X>WX';P#=^"=>!=^%[^'=^,]^'V\%^_#^_$!W(D/XD/X
M,#Z"N_!1?`QWXQY\')_`)W$O/H5/8PZ'\1G<A\_B<_@\_@#WXP%\`7^(!_%'
M^&-\$0_A3_`E?!E?P</X*KZ&1_"G^#-\'7^.O\`W\$W\);Z%O\)?X]OX#KZ+
MO\'W\'W\`#_$C_"W^#%^@I\&[(P:TX(9=D9FA+S3NK$>$LLZ[)QIC'O`YY[O
M^=E9GC]JFCW!F)J.&]H81S.T3-),:[9IZ''6Y2=3FL..<$JT=*]FF!DMJL9Z
M2KU.PC+3SACWA#-AJ-WQOG1I03>;$8/]9B:=,*@[MK!+S$%Q;EHD`$E,E[+C
M5$<U#';X75]2V!LU-+N8]6)J5$]K3CAI9BWN6,@[]RWAQ[X-47+>3(?9N2\_
M<),RL1`[_F7'OG*"?,@,S';AG!`[`;8TS0@SQ]E!J5::QPPMX018KS?([F:/
M["2SJ6@V$^8P;O:EB]A`QF&<Q0+EOVZ$!$Z<`B&W.2FI&D[83I$7[-BP.*UE
M'4LU&!ZFN/:E&>9G9ZUC[9ZL8;!3)3O*TN-GH94I5FDU[814W<H8:EH+V=FT
MG:1HR'$*)`4J;*?-/F+MT4+][`PL:L1#_-"6D&)*D$=DN$<OX5K,K&.0H&+>
ML9,J.2?PF&8X>DPPI<A\S=:*V;F=F8BKO3J;K1%/VF$T>4!/#ZCI;LE,!?J2
M%-4`.R&T@XZ:M;)VL%M+Z6D]R$^G+9^AF8%>W>HV`X8>M539CIE61C>+;;6[
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MYH8,<[.6[M8:/61NB%8TJ^V&,%\"#"NB=>BH'`TEM7XQ:L9<4G'<C-,FQ?#9
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M)=#:2N^8X\>%FE8H^Z6YSZQH('`#!_BD`$\(L$>`W0(\)L##`CPHP`,"K!1@
MA0`7"K!,@"8!E@BP6(`%`@0%\`O@$P";+B'X$;4/J7U`[5UJ+U-[GMISU)ZF
MMI?:D]1V4WN,V@/4[J=V'[7MU&Z@%J.VD<M\6HC>*\#C`CPJP"X!'A'@?@&6
M"[!4@/,%F"^`+$!``$D`:&HB^#ZU=Z@=H?8:M5>I':;V`VK/4MM'[2EJ.ZE]
MA]H`M?B*AO)P>7C>T'[L;5HI#STH#]TA#]TJ#YGRD"$/)>0A31ZZ4AZZ7![J
ME(<ZY'-"9X>4T%FA,T)30I-#DT+EH?&ALM"84$FH*!0*!4/^D!2"$.0F^-JD
MMG7+L"UW*`9M427WK^LB^[%HS>6Y0&09YL:W0=OZ99-S\ZMRTLW\KY[WX_%A
MQ-MNJF!_\'P`$(_?=&N%"SL[85+5R9_)HWIM[0,'82K.`YGNL_?)4U^1&74=
M48<X=8A1ASAU,C[3#@UMZK:N,^$4@D<^^)6CHSA;=.9N>\=P")9U-E\IX#ZI
MN(C\Z:JH[%PVJ2RSA#NWJ'+R=14O^`%W0W%59ZXDLBQ72HT-U2RM6<J&_,"'
MQK"_,7>')E^WJ++B!=SM#I41>1R%\O\#.8%AO0T*96YD<W1R96%M#0H-"F5N
M9&]B:@T*#0HQ(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,B`P(%(@70T*+TUE
M9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S
M;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T
M(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&
M86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HR
M(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,38W
M,PT*/CX-"G-T<F5A;0T*>)R]6$MOVT80O@O0?]A##FXAL_M^I*>X38JV:(O&
M!NH"OM#4RF(CD0Y)V7%_?6>7%"DEUBZ:D(%AB>2.9N:;F9WYEA?7\]G[^0PG
MT@B$W9^_THG@[4>VG<^(7R&(2D2D?T*1XBHQAFJD,4:,,E39^>PO5'A=B@NG
M2&CMOE!U-Y^MY[/5MTZ5^SMX@!/.&1A(.!,,OIBA]'C=<.'6#5-N76O)GE=(
MT;F6`AS4!",0X]+[M/(`VT7<+S(Y.'QQ-9]]]R:]S0`>0U?P`Q\(KW0/G5!$
ML%#H"L`;FC"LX/K?^>R,X&_0U3_SV6M0\N<HIB@_,L4Q)JVI\]$MZ<$23C!A
M()C-9^<XH=)=/X+17R\O4%FAM'A"Z=862_AO4%.B9IW7Z$U9;=$$$6#BJX6`
MF0-3(L%:46\*@D"8$'T0$G1#H`#A0Z#/=4*>S(,:G#C[;/7!VJ6X2S,AC.[3
MS*2[=@A_+I9YEC86W3ZA;&VS=VB;5N_0X]HV:UM!MBW8O,OKIDHA_Y#Z%-5K
MN]F@K-S>N^*XP0*G-5K:55[8)<H+]':WL6#[=FPX7)D!S[35P34[#!V61/>A
M4[S;(125*Q^@UQ^R=5K<6?0J:R`<)!D]DQ)^-D"'!@P];E^L>I_*OVU]4*N_
ME^W-M;L;NW"EX8,_DQ2N@0RTP:><]L'G;O!XL)>-*]J\KG>V&MN\XKUY[BV?
MW5!*1[>B#T`2:50/4L#X]2!KT/A@BQTD=@6].&]JM"WK!IYFKANO\CI+-^C)
MIM7+T7-`S>#?T>![0<2":;90@A_9;%6\_<FI>'3V?X$/`UP"U!#X!#U,J/YV
M,Y]=CE*+3`R.3E.*;K.UI4C=99<EY:Z'4G2-(+V[@V;I[EP3M0UZ2#<[NV\3
M#V63%W<P49>H*(NQ'668]YY.VQP9UH<Q&5HCE]WF[)#"B-B6!;+O=WGSA&!J
M+-V4F0`[!^;Z=;!S8PZP$^X,=>")ZM"GJU6^R:$*:C\D=XWUN"N[LI4M,MNR
M*(ONJQQNT@:&;9ZM_:,IJI>:OL<,+09X7NOL<8X>89+7Y6:Y<-3/5_2#K5*8
M;+?YTA=N6K\#-*WG4-;U#AP_4K$`$;<"-.'>9ODJ!_&EVQ&/.3#'H@6>0@^3
M&)X_U8DG$)?6M@PB;W)0!;^?(A+PW\U/ZC3M!ZC$\J/$3<EB@(8-GDQ:JX2H
MWA+`Q-+T'$:XZY,<)G$D!KWR>?PMK2#%5"\0Q5B%NMR$^ULH_)5B)MSL[RQ!
MH+`C@ONC$89X?KS!W89)[^^K\D.^A0>;)_1B=)X`&_@`_,$)E.(%,WH!IY7Q
MN<D)F\G83%*986-.,KTU<.&.Q>/^_$,-ZW+Y7)4O7)E7T++<Q^@N06CW/AV%
MEIJ%86;!ON"<>?K-@CR(`Q4#BQ%XSV+J=5I9'XSAO#<Z<^`#]@F9M7NA=)!V
M[4[S^W,O%GMJW8VMNBGAT%ONFKJ!`0>T90'SJ>IZVHO$M1HWH?(BV^S<\@V%
MH6\6$NAQ%S+?^&!B3%&\P&T[%$JT23NS=5:5CU]VSCRU&YU)UIH\<T"G@$1)
MOQ]93QVIDEUBKJ#P:D\#X&ASN4TW&W2QJ_/"UC7Z$0X\F[+>P;9T;Z"`.KG4
M_.!?6_Q16!>3E^CH&/S]_AQ\_>D+''"&0G%`"\*H?8TY..S>,+[W(DIS+T'8
M\U#)*:8(E::TZO?<OMP_#:HS(ELC<*+^7_GR1N2IA#G%HL5'G\$'R^<4JBJT
M3BB0QJ`"AG%0@#$2-L&9H$$!P4S8A.2$!`44TV$4FD=0&*;#3A+,3$2"<!I.
M!G&M)2S!..-A"<Y%&`H1G$4\E1RV3U!"<1.1T"+FJ1$\+$&QHV-!"2)4&`NE
MDH0]I4R82(T+22(24E(=EE#N'6)00D/8PQ)&XK`$PY#<L`01D1IC-)87QH2.
M6.'"A-$"::61QB$%BZ!5(A(QIH6*H(68AB6@QRH3EB".5@0EJ(R@A7U-(CHX
M9Q$_!(_Y(3F/^*%B'0:.1)%NR@W'X?H0T"TC$B0J03D-^P$=*%+)4.DZ/)V@
M3$DXZD)2$:X@(;6*6%$RA@6Z0SASPL3VG(3C;!B+A.X0CAATPLB<`R0ZHH.I
M2-2A$YIP3*70-.*'U)'.+Y6*T!](7(1`22-56$)A%6%`BJA(#U)4X7#F%%.1
MJ:ZX$N$:@W49\4/&,J>4DA%/M<813TTL<QKK2+?4)%9!FNI(7C2+5;+F,L)-
MM9`XO"OA%!6(*=#XU]?SV7SV'P#P\'\-"F5N9'-T<F5A;0T*#0IE;F1O8FH-
M"@T*,R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#0@,"!2(%T-"B]-961I84)O
M>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E
M<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@
M,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@
M,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*
M+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM
M86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-"`P(&]B
M:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0S-34-"CX^
M#0IS=')E86T-"GB<M5W=<]LV$G_WC/\'/MWD;J8Z?'_,/<DR[>AJ2ZY$M^E,
M7Q17=G15Y%26T\G]]8<%`5",*8""?=-)0HC48O';#RQV5^S9A].3/T]/T$!H
M7B#XSUZI`6?U7W>?3T^PO8,+(@HL[">DX'J@-5&%0N8.PKC8+D]/?BDVEI9D
M'`AQI>"?8OMP>O+I].3^'T`*_MO[``T8HV:"`:.<FG^H)J1]7S,.]S65<%\I
M0;L)DN(');"FA<*H,(\Q87FZ-\^0@C"D"JE10>V'=J7V6Y8&,4N0]7W2<?]/
M]PB7]A%,F\6>5:<G_[Q8?+S3A<&@NJ^_6C/D8;/?%:BH/L-R,#?CZ@XND38`
M57^=GKRK%A_7R^+QOA@];G;+S>[I[T7UG].3TE#_R9.<70+)OV"A_P:&!AQ8
M,D(J#%V]-UR?GLPMTU2`:!0LKL"Z@VDK3\\T:C%MOVM$`4R_^\W`U^(($&&T
MILZ8[J8N`:D#U!$&\LR2UW)`I)%J]5]`8GCVMC,1N3<3'7!JB,!,/QC\J=8U
M_E=E,;TH1M-)54ZJ^?<,<$UJ!J0X&L?ZNP>!;-075JFU%:;!'J[6[DK"57W;
M7GX*6NEN@WP)/A(7D"_B'A;--0NP<"IK6&Z&LZH8'V`85N88]KP'/C5<U@_H
M-LO^_D%91K"L%0'1))9"*,^:YS+P8R&L'_@.37_?2/E8-`6F>W#B`972Z?/-
M\++\7I]`;*!*>6:I%8I;)=#.A3=*W`)DB&>:090V+(S7F!#433NBRMJY5RT&
ME)K-QVDR$=AI\K@JKPL\*#*F/;0D1<*TN2LZ2+I9T;L7+%LQ\5K$::CP2Q&+
MVH`T&T@!+#BKE]IM1N?E?#0;WU3CZ02\XMGM?#PIY_/TEL2,>S7D<;TE443"
M,&Q)5@^X5:%CQ2R,)P^\DP%%4M8F1KN0IS+;OAA.V)>A';.O@^`+LP!&?1Q`
M3/0$<8#!GDKB`X%/2Q,#?/ZRV'Q+XRTD`,P<WL1>U,,VWE1FFVP,"\`J/[K0
MJ>!"QW;\%,QNPP>U%A;E=^??%K^O[OJ"2H@#%;$P#*"^ACN">.".U9S]1@A)
M\F6^U^9+O35?>@\UHA'SRLD97(-R/A7SW7:Q6SZD==.0:[$KR&O9;2L0,8Y@
MCUT&/O_.*=-B\WNWT\R%1NU#@R%ZL7-=+[9_+'N$ZN;[^UA0FHG%06.B#18O
MMPMKQOFQ:]1,C1DK@T:N!S@8R3E`U"OBQ!;Q[_]TJD=JMJB_0<&M"Z2]Y3",
MW/EBMGQ:+K9WGPK0S?/EU^7Z\<MG<\[KZXX0<KICCWWUL.7C@?E<"<?$`!)6
M*%?"2K&$A`WM7`FWB/>3<&*VF(3];&9'$42$C1O#-4AX>+=;?5WM5LLG.,;7
MFTTQ^]NYV<W7Z\7'1^,W'[<]CO56WDKY&$JJ,&S+VRPE4]Y1H8#0!,Z6M^`)
M>1O:V1(P?UZSIQOF]O?T>MARP+G<P9[NN3M^3]_C2[TU7WH/-:)PLZ=3'/;T
MF^WC[\]WNR?KF^;+[=?5W;+'IF8W^,`[I2*/]\.;6B/Q[DT-*.>:0$Q/08\9
MR38!)A(F8&AGFP!37I@8*1^%;)[O%W>[Y^UJ\]#7%)CP9P81AFW_8KC,!3>&
M`"!$:#:X1";`-;2S]Y-]XOWVD\1L45&ZV>#DC5Q&^!V<_)8[LXL\;OI*DC`G
M28K#L"U)PV2N)&-P@SC,P2!7DD@E)&EH9TMRGW@_229FBTH2>:-$3(8C/='2
M'>DO'[\NMQN(]HK9\N%YO3A&O,CO#3;!7P_;XC6<YXHW)@,C(ZEXKGBE.3)%
MQ0NT<\7;(MY+O*G98N+ULQGQ*HE#X$?AVF86-[OE>KTT#GBQAKWTRW*[ZYN[
MD<K[8<G"L"5>X#Q3O%$9@(Q$=@I:RD0*&FAG`RZ)!YQP6CO&\O.7]>.W98^X
MQ`$KW8&)6(=8#]O`BNP\=G3U@`[+SCU*GL@]`NV<?(G]+F<ODZ==-A2WI=X<
M=(B6ARR*<**UQV2XMH>HC\O-P^/"GIN&#]OE\H@SLN0^OV+#Z'K8%CG+SH-&
MY0)R(]EY4$D3>5"@G0TX#8"3)B]!I<]+C#=?ET_F8%J,-_>/V\_';$V2^MR>
M%&'8QIMD9YVBH`!H*#OK)'$BZP2TL_'&/*0)FRP!8SY+,%L]_5%<F&C]<?M4
M[#XM=L7UXELQO+\W^T=Q\6R"^*4)$IZ>UWTZ`&HQ8%J+@=ER2SULBP%EIX:B
M6!DLA=)9]2WXJDZDAH!VK,05BQ"$CO`-"P/BD1)4#),HX[`P$<<D4L44DO:H
M8I+.*F9JVD@5TT^;NZ)(%3.0[MQ*@'!N%5-(X:N8D)_W14S!6&<1\V8VO2EG
MU:\]BYA",K^9B#!L617PGE7$9`WK^_LPT5W(LWQ=XJ*'+M&7NF3!9:\0#&]*
MM)C*(!F$B.^UN1Q>@4!&97D^GESV+2P+[F,ZZ_CJ82O7E&+[D*(2H0+;+XV@
M,_LE5(LCB=^8(Q,#!XXZLU]`.5?_>(?^T4[+)_GZ1_OX,M;MRQ+3QGP93?BR
M7-+-B@[X,O(*DZ%.('P@!*,>*XRT.V/.;\^NQ_.Y\V77PZHJ9_.BFA;#XN=I
M97O7YN7H=C:N?BW>3Z_.S=V^1D6=H^,V:JZ';4='\A6-]E8TG%UC$C@52.#\
M&E.4N$4'9]=A#M-N-P5RHP5U4R!<K=T5]<UV[K+5%`B?63CET4V!7,N7,JO[
M`,==Z`)/N>AR'4G#`T1`/!/=*&U8I\Q.\7.92/$#[6Q,8L3MPF1V9CY*&Q;&
M2:Z[Y[W"#=[I[E/31MR]GS9W11%W'TAWNGL@G.ON.=?>W6M(P3IO3Z$H!5!=
M#V<_EE5Q,9T5H^GUM7'ZY4^WX-J'D_-B5EX-J_*\F%?3T8^UKR]Z^GK.I?/U
M6(=A*US)714W7_"K@EA/<]\B4V]5208-@1:#LH-!J\&<Y&Y&`?7D9L1QG?>F
M7=XS8094]S`#T6T&B6EC'@G7TU+1=$&]X0SR_SX#QLT4;TX;E-/3[C9F7)<'
MT@+O,&8:U!XK2;W:3X:7Y74YJ?J:)I6^C,?"L&V:F3P2R@./1_4F4-[F2[TU
M7[IE+5HT<2]WCG!>G(_GH]LZ\`7G9V"]^G4^GD/`>S&>#">CL3E*CJ:3\[$]
MZ/=8E=Y?E?,S;[<J^UW7,6=6A3EM_#MQJZJ]^/SVJK+K@+S$$+CO&[+7OA)L
MD8@P;'M);(M&Q_HOZR5IEY?$'>;(=';YB*-$^0AHYZ9@.2+A5T482DFP@LOE
M9KE=K'OF5+EOMR,V^\-?MML!@[E!6&SQ@*O,KAXQE:@>`>U<7)GR+8[$_IS)
MI;:MMKL61TA;0_?;](L!&TH)?9/8S/>[$47"L`VXS*[=1%$!U'AV[8:)1.T&
M:&<#+D+M!F$>:C=@W'4>;?7G\^KWU>Z;;=P:+;ZL=HLU5`\>G[=].K@<]"*T
M)8LP;$//L\LX47P`/YI=QF$L4<8!VMG0,U_&09HUT-N/`?KI_7UQME@O-G?+
M8OYIN=P5P^UVL7FP]<K>R#-7N:$,A6$;>9I=N8G"`_"1[(0+(XF$"]#.1IZ(
MT.3)FM_'$.:::4;;U6YU9_1\>'?W^+S9K38/Q<WC>G4'C;=@!^73;O5YL>NO
M_[Z!BFH<AFTID.P43Q0J@!)EM]HRE&BU!=JY28@H<;LPE)V8B=(V"Z,*YR8A
MJ.(]3E^R\_25FC:2A/#3YJXHDH0(I#O/+4`X-PE!E?)ADD2BB5*E#[Z;^'I>
M#2M[F.D;H=+0UJ1%&+9L"CC//,<'QO<C5-85H5+7AT/9\9HD^FB2ZM:DQ+0Q
M37+3)D[9N3-@TDSQ]K0;U`YHJVL<2HNC0UN%\O(0D-SVVLI\&_OH_7!R6<Z+
M<7U0-.?&X>6LK+6V^&5<O2^&H]'T=E(-X8/II*\F"^'+(SH,6R?%5ZW*=15I
M/I"<-JO"+J1V+(\GEW91C47"L?AJ.K\UQ\B^"V':M8E@'(9MDZR[HXXU%FN2
MHK=)$IGMW"D.B18"18K0RT3W37+8;9.)>0]I->!"X\>';-+-D@[8"Y'YWMWU
M?6DV4%*14(17U'EW>-7%;'HUMXIE:_'GQVB3[_VB-OE`7_9^`?.Y#IYVM"EV
M:Y.O&AZ?J*6N^`8E5XI"_PC!8E^9SKK;(ZBO*&9DA\+$8B#M[UN\)^-NYFGU
MOIP9/W8QG5W;O%!?F>#0C\?#L"T35ZO,2`L%KELR(1TR(3H[I"6QDAU@1UY1
M:XP2!W1(?JWQ,.UV)1>Z.NK=':[6[HKY2JZ[;%5RX;/,2BZ1SBNC@5:B?KL+
M_$:!Z/V7NW17=<DK*I@D5<$D^17,*&U8,\TNW9!>%4S=N;VDIHV$?"11P<PF
MW:RH>WL!PKDI;N)K:<PX+O_FIO/QK!Q5T]F\;SV2^'(?P<VP%5SE\DB,N]KC
M4:HF9$0*.7F6'\K1;37^&=IG+L8CZ*@Q&^'UU/;6P+;H]LCBQGPPG<S_E:XN
M8+:_+&Z[PMYP6?5W0_%8,=6<VS#'?F>_OKD:FT"QK./>N1$*U$:P^`UQM#!_
M82@[F%VF*#_48;.)C?L6J@AU`3&S+S6HAT<M[I#",GCY&CU4`NSBR'RCQ9&F
M;\T1:SCJ;,(#RIF%%M)5CN[>45W=,R-F)C@HB[&!\((O`F_/V'LM$NIV:HEY
M#WH>%>8]Z-0R20/DT4HN<76[G)B9^+H=&^C&L.H??;7]!9A8.9D?$YV14+2S
MYR_RLFA'ZJ)=3L0<.&_I$N\`'KM45$9*!.M>NM3]CJW4O!%=\O,F<B*Y,V#2
M3/'FM"EI:'?J*W89O)SL`?&%3CZ@@C<M\%J[G$AH"9W^,C%;V/OQC7W)83FK
MAN-)<59.2K/M03JAO@][7E]M]@527N]XZ$7C\VL6AEW2\W4M%5C1_9:*>MBR
M.%PG(7,R'@'[EL5UM?!CD9W.QCX)&;>X[M^#I.:-65PB19A+&B"/9@BQR,]G
MXR9#R#21>UUU+BQR:F_[YZ#;PIC#O-515\V&QJ>/CFG%P")$0SP,VSHFLA/=
MN"NKQKOR()CEZQCKI6,=OQ/I,6],QUA"QS))`^0LJF/L%3KF7K]A(@0N4?WF
M1!,6O!^?C7O71K!_]0;6*@S;*L/R589UJ4Q74(E)OLJ07BK3_=..U+PQE2$)
ME<DD#9"3J,J05Z@,41XL9M\V['_:@5U!^V8VGHS&-V87;@H4Q459UKYI7LY^
M-D?3WLI%O#_"*@S;RD7RE8MT*9?HD@3*[JW'*-%;#[3SWQV<R$P!\>QW/,<8
MAQ>T'7YWN-A_=_AW9U#[NDC?>,4/A\#8<IXW!3/?<U.X&=HN`\-O1`^^'=W<
M_4$S%KV/M8P3(%K3Z`,,$1U]@*,$CP*IPZ]XAP>,2X^O0J'$*C3B<28Q0B+Q
M!+9*&'N"Q-Y5;Y\PATP<?X)A$E\*YO#RPN@3`G,4?T)BF7A"D12GFI#X$R86
MYXDG,&'QM9@3M(YS2BBDXJ-/<*(33PAJS#GZA(1:0O0)14EB%DU4_`F*"(FO
MUBA00L<H2<F%4B(2LS`BXZNE'.NXGE(!R=[H$Y(D$*,*^LNB3VB2P,/X)R[B
M3Y@--&[9C)#$:AE%.D&#P6\IHD]PE.)#&/''GY`I#\-4RILRC51</SA""?]A
MG%3J"8)1G`].<4*3.<,BOCMQIG0<=<[A_Y82?4)PGIA%TM1:%$U(SK"1L#F!
ML(BOQ:B'BB,FS+DF[G%-1"D2-"A+H"X8$W%,!6<ZP8=@"<\O)*,)/A2C<8L2
MFO+X$Q+11`0D,4WX($FHBDM.4I;8U25C-*YCDC.:X$.D)"?--`E.%9,)3G5*
M<@JQA+=4.*5!9FM(R$71E"8;]4C$IHH3%;=*)5`$4Q.DEQ].3TY/_@<O;:+G
M#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C4@,"!O8FH-"CP\#0HO0V]N=&5N
M=',@6R`V(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R
M96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P
M(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO
M1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2
M#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-
M"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E
M#0H^/@T*96YD;V)J#0H-"C8@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E
M8V]D90T*+TQE;F=T:"`T-CDP#0H^/@T*<W1R96%M#0IXG+T\6W/<MM7OFM%_
MP/3)[<A;7$FP?;)3NW73IOXL==+.Y(7B0A)K+KGA18KZZ[]S`!#DVKMDK9`[
MF5B[(L2#<[\";_]U>?'SY07=1(DB%/^SG_1&2?=/MKN\8/8)(SPB++*_X40E
MFR3AFF@*3RACI#:7%S^2TKXKE@I?I+3&'Z2^O[QXN+RX^QV^"O\;_8)NI!0`
M8".%$O!#))P?/D^DPN>)B/&YUI$X_D).7FO%-">:40++9&3W=&<1=`_C\%!$
MPX;?WEQ>_/Y]>IO%A`ER`W]@"6%?VJ/..&#)%;D!Y),(4&>2W/SW\N(UW3`%
M.[YYNKQX];ZJG])Z2_Y659_S\IY<MVEK=J9LF]^2F_]<7KP#0/_7O_W3G_'M
M3[BUO\(GOE$(0<`/I'B4#-^+RXOK_QT)RZ/C2$3(*NJ0>$4.]O0-;S]%(GA[
M`@S'E],-U2HF-YDED!#X&0ET\Y`WY$U9=FE!/IE]5;>D*@F0;0<;6WH_'*2S
MWU#"-Y)29EGVZO7BD`0?(,E-PN+$0?K^^NWBL%0TQDK0.':P?N)R>1*J9,13
M%FG9\U0R_(P\S:JR3?.R(7=.^I?>@Y#)F=B(!F@DP4G,@@1'8'0LMH57[2:H
M-GG*VX>\).V#(3N3EOBTNB/7)FMS$&X>O\&O^!1^U=5YFQO0@:S%W[)$B,7U
M$$R5W;KC&8,_#UC@9\0B+;?#!MF[(QM\]TOVD);W9K13>06+TI;DY6-5/!K2
M=+=`A;+-09GKO/G<$'QM5V:F1H'`UVS(^W6$(J))0')=H8C@R4!.+M!\.G*J
M2.B30I&E);DUJ_`6G++?#$\";R7Z8KN9?`L;R.]RLR6WSY:M=RGPT+(.OCV3
M;47*J@6X!>P6]ESG65O`RHJ`=6XK^`H,K6H"LE##J^R?`R=O\&^[QI"GJMXV
MP/WL@:3-XABJ>$#180>6C8OEP>@`!GTXU\Y=O=JES\L+*SV"DEP>3!3`''B&
MJ^5=/3L+DR(V,$GK3:+!]UF,GO*B6!R8B,[")<G/QB6IS\(E`#$8)4@%O":9
M7_;@8A:'IH\AM3R;$GDN-L5'S</B;(I'Y@%\AW-CK\!/FW)Q]QS+LUB\6)[-
MXJ'!$_':/$)[YZ&`3Y+*@\(@*\OWX*Z7%XHC:"W/IRA`69E-^BQLTF,VT4BY
M/.'5K2ER\[@XCQB/SL$D)OBYN,2$/HLV23GFDQ:)=TQ-F^]64":FCZ&U/*,2
M>2Y&<7K,/BS.*$ZC$:-XK+USPM)"7G:+,XICHK\^HVSUY$R,BM19&`6)\,A!
M<5\/>K6OJ_^L$.L)>A:%$NQL"B7X611*\+%",26\0NV+M%RE/G<&)BEU-B9%
M["Q,BN(#]Z0]K.8A73Z[%<FQR&AY+B7Z7%R25)Z#2Y+1$9>$A@C3<ZGJBL43
M)RGC<[!)CAS@VFP:.4$P1?&HA:"243FZ:A],39I\EQ=I[6J,&_+OJB..T``T
MW8X+K+:>N4:6!Q;:[S51?-AK'!^T.["4&FJA65J;NZXHGLFMR5*LD;I":]YD
M7=.0JJO)7==VM2&N)I)BX;VY(KO4EHV]]\3?8:E]M+PV35>T[K=[4Z=^3>W6
MY&5:9EA]7X,,5/3A&$W8B&4LD&&;V_X![,:RQ7/P-RNU@9B.PZ;6K?@SP'%`
MGS(:&ID\HO%!Q?\W)"\!WYUES&K-#J'8F5"W3C:@SI*`N8SYR59'WP_Z7%9/
MI>\!N<\GND).=W?I\QJ":]VHV[Z(AQ9THKVM"?I)TJS%/K37L2L""F9Y"5M%
MH4ZS!\SF'8Z^0?9=M=NGI>V5W!J".60-^E>@JM_=&=<MJ:L=K*TL$(_FK55\
M`-28+;XZW^T+WY^Q;90UR!`E@0QTZ&-BO]&28>#?AGS882<^]:V>JO8,RJS=
M?0F]CI#+$6A,,D^H57ID&BVWK\X@QNA'_6:6;QL$:#(X;+XXE'B,4P)15L]1
MF?B^WVH->"SH]\!7MKR<C=!D<11ZK1(3W-,&*"NZK2$_445S^(>1M&FZW3YX
M2Y!A_)S6ST'"O6\&)01?#LZL]-UP;.:3E.S3NLVS#D.1E:@:X^S46:@:BP.%
M$-J7P7I*KJ%_0O7@8C;(*F?Z"^N#W#%%8YX@=##$AE5YL]I`$%-A9RL/!+%D
M1`-&J1CF9OH^_??7;Z^\Z"(7T!(V7@C;O"U`,I=/SF38U9H9$Z4CY#D-`;_"
ML2A$_4^FR>I\[\+'._*V:_(2G./RLP2"G8GA6&'I(2T_6:>$'HN3%D-<)H2/
M2#]!K$7>>^MV@_[[[Q!YO`&OF[7DO4LG/CG7O;B!B?41N5J^BZ3EF)NKMF23
ML0A3K7S]#*S5&M:2A9FS>#PU&?M<R_HUY]B.>++&M.BCP&V!^<29+/-S9P/1
MO`"[\E7HNDO!4[K8*]\9#,WL3^OWOI@!P\`]S('!W^_RIK%YSIMBE9Q34];/
MXU#NLZY7*[E?)0*XE2U#'`!A2U</N30[&="D;5OGMUV;WA:.0R/^I75()B"(
M_ADB<C?KY4H2.;A3R+%JTS[[Z2\(WH?RBI>9#;+5[%N<WZI!7&"]34:*]&D-
MOMJ:CP_IV%#^X<Q/D()6U>8>@BT4[2OR9/H1M:[<8M;X&5%X)M5MD=^GSD%6
M9-_!UPQ(T.VW6'U824XD>/)^_^L*BN1B1"G.Q!#\:GTZ^`52U.:N0"L/V9?-
M52'@S>NLV^%T9H9Z?`=)EQ4B2RF@WQI,CD*-+^&#?Y+<^Z>GASQS%F8(_B#4
ML^8(=CQ"`]=4F9L^Q-3R#N1@F(#8>C0W+\)A8L)?Z`A"95?\2\0F44F8\*>J
M][(?WWRZ(1]6F)R/$A%L'XV&<#'I(=\`58"-N^5YQP;H:S;C613`8$MJ<'22
M]L<#1G9NC?+AUUBNT)L7`<S:0Q1)<@Z^<:I&?*.Q!_6GYW2;9XL#D^(<7.(R
M.1>7N%)GX5+$#DQ(['/\I^5G)^+H+"S2_&PLTOHL+`)_,BA2C,4("ZM;/!\#
M8IV#18(-RKI\SBL._,6J*9@09_&`0HPQ`@`^PZFZ>OD^CCR+!(P"EQ4D(!)C
M>M&AD"1CY5,'B!E-;8-@YY#(AQ*"I-)F"6EQ!5^SC<U_<CR34Y5-5>1;&T5B
MIIQO\[2&3/<*(LP""U`KM2.B./2D9`CM1"*&CK+Y!<]5`0*PM\8E:T]Y8UX6
MY,Y$FJ+O#'$9#R1-8D_2'R'DOL56G7']]KQI[8D@(%N*+>OZLVGM%TM7W];S
M^26@T#5M_3P\A[3,9&D#U.^PV-X^U%5W_U!UK:OT?G46=/FJ;RQUP'GE0KOB
M`Z0OCH&N(E8\M$HP>0SA=%]FM54>S[#:-":MLX>K(7%.'].\L"6&41/;*4O/
M1K?6C1UL0)F._)K<F]+4MJ/GQ@"&@V9.C'Q98@W\:2B)XGA3P)_YRLH8+4N+
M!DQMUO>?[1;]R+9OZ-;P#0ER16Z[P\-R]UU:0PYJ^DXH9*=I]NPT`!*6PK3&
M5K!]L>U@*N#:S;04SZN<2E"CX[G10`0,T_J\&SC\9`94/?)'E'M*??';%[)D
M:U$#S0#&0PH`D%[P)K,W)1Y%!,%X-+4K4OD:1+H.)893FG@\M&\ZX'!QF#(:
M:DN[OJQ4&RRFP4:]_#=]Q2UP^1A3?QPAVZ!)<S1%%S-J@`>!L]4-4_M7KZ,.
M*ASN88D*33=%M>A])1K9)G39#FSOYF4[TM,[8L/<U]`"B^QGW-&'FW=_)^P+
MT.Y-1VY'4$RZRQ$B%KY]V]4($[N-QKNU%L1FN>^NOYO=7'2PN40MO[DD"IMS
MR5VHG;!`RT\?/MY\^,</Y!_OR=M_7G_XX=WU]>S.DVB\<R[D"[<^?6^&U*&H
M%C$5AZ*:Y&HH;1TK^YR4!!EKMV6MPK?%+LG04=CQRV/:4R]'<D2_ZN7)-*WE
M,+R5^!K`GYV#7AH5%05HJ]PE(ODPR&41P49Z[$7F=+0/OCOU8QU_[?8Y/+\B
M[XNJAK#_RG6Y1I.4_MJ&?Y8YI@3VNA9(!OY2E??D>_S'.;V\+/##=P]Y">_X
M6-EO^/_-.NF"I*,(?;AN@$6^3/J#P6`;=P&;!4.>DONBN@53?IM7K<D>RJJH
M[I]M8&*GK]#A0_3=V"0(:^@E8HL([.MJ#PE0B_W$\)?8^L.6XQK)$)[N[]%;
M^73_0$4:QT/6Q6-Q($(?B[1%OTYN`N66'\!A1Y!>OC\NX@#F(-&QG>/ETRHY
M(K&$#*0G<6(_VWI^A0'1MLM6F=2V,;]OEGGHX!QX'_T/42H(^A8BWZ+:VZY3
MFK7YH^MPWU6^+Y8W6051*H3HHY577O_+#ONF.$`!81VH#"+D`F)30NAK&W)5
MT3F3XH-'4$4TN_?K!/TB'F:+AHZJ4'U'U0?R.!MNRO\^[UP/>/^00OR:F<[%
M_/TBXR[W:,PQ=,`\0-2?0Q#OI^S^L+@?H0,^JS@2*QP^0XJ'"U,$]X;@34-V
MD.8X9E=V#*TG#-I0FQRF>T@2LMSEMV88O;]"><@P\S-W=WF6FS(#CIOR,:^K
M$F4(Z#RTW]/M(R21Z;VQB2*\LWA>:0"/<37@/,H*^T8RB"=:>A2#@=?]E2Y.
M9)HA61E4P!]70(R-=9^04W:(3/9@=OBZ9H1N8>XQ?1H[%ILEND,0X+8>L?K6
MV@2K-*N,'C`Z7$C&1J,US+M2G]%6>\R!NM)9!<#;[$!W[5`!<8WK)Y2/O@>-
MW_`*$JP9]#,:EIM6.$X[EL-R'NJQ'2](*!$6LP$%>[,=)YQJ]YP??PX!D3[Y
M_&>_!$)N7,+$\6B2!>JQKZD7A<,PBG$?A5%[1Y8-W"WRP+WOL(1Y[)H[=OR:
M.^7C]V3T-03PB#?DK%BVTT>VS.C$#(4FPI\UXAOA#]2]QKS#&\:?.`117PD:
M8(D08S`41T%.VQ<A])$LE_)^U/X'\"Q@*+*J:8.5:'L_@B4'L#5X@=I5;ZMW
M^2]^^LK=T;0=J=RA1[*#H^.XS=_99,VU%<8#+[@PWCR,-25#Y8GV)X3&+K=!
MHV>UR:&-^TYONW*+APZ*ZLD1Y\[4UF2B4#7=?5HWKFR7WM<XBPWXNN,'^;8S
MO?]%%TLR"&,;KZC^O$7G<X"%4:;AFILH'N::A53#`,,A=]`TFJ+HBJH!FP"!
M>PJ\LO5%]R'8S>$CP3M9@!+;W*4C^ZH`J:C'EA7,]ZXJ#!#%N1)P4[#"G@6S
M?VR:]NNXX]>A;B_(\AZ%#<5F;#R[(:[;1]AO/\E<&K-U_#9M#3OM=NA84F"Q
MV39ME7V^\O+MBV)XGFT4E_4E*F^>4W>&[EL1FBA+J$B-,<*K(GMFQOV`]MN\
M>N?DJQ]07I*B<3S:0&^J7OWQ!2!.WO:I60#Q=6"%5I8GUF+*;[>R.$'Q$BL+
M$!&5HR!GY$\%5T3]11Z0$^O(%W??^9CE0$?Z$"?$["B1!V''*%#VM?Q>C]"?
M]SV.;Q76A3$71WO&WPQE0AU04@*4<$($3SQJG8P)/*D*+T21H2H$Z)(.@X^)
M_8S0_WC2?\T`/:4<.%_<`SVJ'`Q2DA<J!TO42Y0#(;Y01%CB:F58T.4^Z_];
M];0@$+!!`<AD$_77P(@###SET,>;$*TG?:>\.0B<'JJF#4E\G>YM9HL+6@-*
M.5K8Y_E@$XXGP<_?I.(+,R_NJRAB=,&NCOH+=D][OTF@$^H.1!Z`LI'""=4K
M'#B_CY924QK_4J2YU:]0J1J&N[Z:=_@?@)S4<*8"D*,:#CF1S8M.O)>=4G"*
M%Y'T%EGU];RO+U^V0]$O!"%)X(^'(+[,':-X*C-\G431Y'.6@()-+1"4G<XM
M<0$08AJ$0KY.+8BH$I,+8CJ#A:9R>I,)))?3=*"8L4RN@#1X&@_&X2W3*P3.
M/T^ND)!73Z]03$Q6`UY#9*YF5L1\;J<:D)F1'!#VR14<DM]I7,`"Q-,[Y9Q'
MT\+!I8V,IU8H'+J<7!'A'5:3*V*<<YQ<H;&G,+DBX70:6U"V&1D3;(XO@F-4
M/KE"\&@:6R&9GI93H3B=QE9$?(9BD&.)&6PUGZ,'2*&:L4]X7=GD"L9GL)6<
MZIEW"$9G]B'IW#X4F)CI%=&<A9'QG#&5FD;3\B'!6DZO4'1V!:/)]#ZP13.-
MBQ),33LG)?!,U.0*F;!I"5)*R1DH$9_#)18SG%-Z3N=4PM0T+A%E\33%(BIG
M_!SD'VKF':!0T_2(A%0S'EU*/;,/)6<L?Q1)/K,/B`>G-2K28,FF5R1B)@"*
MJ9BQ03'#QM7D"BYFO'HL[,&_J17V$-WD"C7'N3B28F:GL8QF=JKG.!<G<L9:
M0KPV(T&:R1F^:#XGR5J(F=!4`TFGM5(K.D%3",'?_>ORXO+B_P&C-ERO#0IE
M;F1S=')E86T-"@T*96YD;V)J#0H-"C<@,"!O8FH-"CP\#0HO0V]N=&5N=',@
M6R`Y(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y
M-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B
M8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO
M1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B])
M;6%G94(-"B]);6%G94,-"B]);6%G94D@70T*+UA/8FIE8W0@/#P-"B])86)C
M,CD@."`P(%(-"CX^#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*
M."`P(&]B:@T*/#P-"B]":71S4&5R0V]M<&]N96YT(#@-"B]#;VQO<E-P86-E
M("]$979I8V521T(-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO2&5I9VAT(#,U
M-`T*+TQE;F=T:"`Q-#,S,3$-"B]3=6)T>7!E("]);6%G90T*+U1Y<&4@+UA/
M8FIE8W0-"B]7:61T:"`S.#(-"CX^#0IS=')E86T-"GB<?)UYV"5%>;[=,6I<
MXQ(U+B@,,,PP,]]VSO?-8)1]D1UD1XCLJP@B(HSLR*Z`@`@!430FDK@@CA(%
MC(#**H((*@H8Q9A$B8E1E/SNJ^^KGM][^@S6'^?JTUU=W5U=]?3SKC4S,S,Y
M.3DQ,3$8#.;FYH;#X717V.#OLJ[,SL[Z=]UUUYUJA3J#KLS,S.24I4N7KML5
MSJ(^)]HR^]_TIC>]^<UO7F^]]=@8ML*Y-,4OE:E#_=J.EZ;"DB5+5EUUU2..
M..+66V_=;;?=J+!X\>*WO.4M5.;F.9<VO7GJL\$5V?9$?ME)4[3)3FJR006?
MVJM3@=\E7?%9)KIB-?YZG^SA+XWXC%Z".FQ[`_Q=>^VUW<D=+EJTR/9IULNY
MTT:HPQZ.VK>Y)7O#9_'&W,]MV)\4&ES4%6_86Z*FU=*QWCRWM'#A0IZ:3O`&
MO)SOSFK6=*=CP`MYU`>Q9[CB@@4+YL^?3YMLK[/..K3)AI?V'K@B9WET[:Y0
MF6H<XL2UNI+3Y\V;]]K7OG;UU5>G6?YRB#W\<A:5UUQSS36ZPO:"KG"(RE;C
MJ-7F=65^5SBT9E?8R!Y.L3*%C=ZYJZVVVNJM<"WV<V^<Y7[O@6K\>H?LX4X<
M,#P(>][XQC=RB%ZR@L_"(6K:,_0AS;+3=V>'V&/VMCL=*@XVVW<\V(CO@IV^
MJ5HS;Y!?=O[U7_]UYN!<5SSDN\[\=5)3V<'F-'2R>*[;(H#%FDN[8LO.5AIA
M@CO3V<Y\=V=FI:TY;6>ZXCVXWPOEGG-=-S(^K>`>J]6;]YZ=U[;#'NZ'7SO!
M9_=TJO&;)[)DWCD,MMEFFS///!/`\2R:8K^=0_$.?4#>104WWX57#"KF02Q>
MRYH.`P8)OR*#D]&1(+!X19NU*ZS`N?:`[=BW`32?A0V[2USR<2I6V&FY>?=8
M,FR\U0PA;\;QR=_@"7N8!3R(;\%12N5<R'9JL][GXJ[8@O`B%K$A`@BA3B4/
MV8C0),0Y^_C+[SI=R5]G$+].6^:X$Q,H8()7Y`F&9(^X(10$6(2(E`H[5.,2
M`IJ0)<(($6E*A!$5A2/13*3UEA9V1?BB$2KPUX\"C[^P%;M%V/=$_M(G0A\;
MZ5)[V*'EZPN8I$M](WDO?A-]RU:V9L:)0]2F,@$=415),O@SA?.Y=R=[IDO)
M#+61%.>UR.,VQ:]SYGLE,`Z_S%E/$9V"/P&-8&80IN(2A_SH9Q8O:\4ZSESQ
MS3EN:WZLG:>2D_KLF1?A&UMLL06OE;^!+Q\GK\;7P6OUD$V)).)`^BKXDS<5
MI/+V>O`8#/1"WF'%M&S;@=:WM4"0<SS]8.,57GP0Z@=UO;=*?G*WN0&;M8ML
M)"#I@&=_QJK5',"]BZ9P---'9B)0Y'LM\MBQ`1S)C]-JX5CAE,S<1:VP+9@P
MS<4!_P8W@D).X35*<>(+%YP.MH@G8DA:$%C>\(8WB"1"2BH'>2JQ$5@"3?Z5
M(WF?/*,SFBX-";0U7S0]P#;]PTB0!/*DZ7E[+T44<ESY!0GL^V9#A+*=X51?
M?9`G+S1MSHV6V5+<X[B5*67H.HPSJ4.00)A@BU-)D!$$,KGD0C;N-'>G0.'L
M\]X"AJG@Y80XQVW0LD<JO&@5N^H#!I_#'[B34!>VG4&A6\Y'2T[A!;'!F^*E
M^(FQ9]+/(GP@0BE/:A'8Z7&Y3,9<W:X6G:CL_$W_AYOE%?M<CD/.\DOG/62$
M.`#R.;,?O'0/-J70<JU`625%]7X"9?E$VEWL=$@'Z"I]LGV19+*58$[@169B
ML\*+12`*;XD@%K!RUJP4>9RAGJO<%'["C(XT),$(\G@*^X,VPLN\5MPOG@1`
M*HT)\J2:+$O`8:=`Y"%^*R+UN)`W)LNRIO?I`/"#R*UR.<ZE<SCD6[9C_5BD
MZP+1@KP]*?*'$=GG>35N!W-";CUW9JS4J5H%EDP$A[HWZ;3-MSC?Z%H$'$0/
M\$>I*A1(2`G%4O*B<AA%I4G./NMGWH6HA'3EFUN%HQ`#[C/\(8)8.$,FJ6_'
M;[UZ"1H,,W&C4HY:\O5WD(L\E2YF<GG_F7%55!1YZEO(!$\/.#>%",=#;2I?
MC<I2(G/Y@<NH$$^"-C--HJ\,9-B4*H%ED:%B486@'L7*J$L+(JTLQ:.#IKKQ
M)@>=-!H129RIS%^H45/ASHI1LII\K]GV>?V4!WFL$\!Q<K&'61SY)5*/V\[N
M$!41R:/"48_G]!"&#7`C#$H,"5*M5DH]Q"\HL>JJJPI';/!7P8V_`H@WX-.I
MCPIO8?;MN...^^VWW_+ERR^YY)(O?.$+UUY[[:<^]:FSSSY[__WWWVRSS3C=
M^B)VV*,;/?!)EX9YAF.GS_/BHMZI0\(QV1.C*A!5ME./9I[FQ.!25>GDK+_N
M2@2KH$KXE=/-.H&@"$%5L5.APQ;&H2.<)W,YZHC>GLR72@*5Z0350=-W.1TB
M'E8D&18MC1_TS$$QBA>17A(T?%FYGP!.GJY*N+6?O1]/%.CJ:\U5ZH<CK*,*
MVNF0<`R'4&:]\S1H$,Y3=U:X&Q1E>!U%^>19K;80Y)$CY<OH[3DJ0G44CGH4
M*#`26%M<RI)2,DW$&2=.?L>11]$I4E55Z0@FJF*R+?ZX4:'&C1`/3P$H;(>=
M;`=A4D)X@D@BCV@C^;'!$!YO/C*@#\6S@#F'''+(IS_]Z?ONN^^7O_SE?__W
M?_]?5_[W?__W\<<?9^/?__W?[[SSSC///'/[[;>GS=>][G4JLJ)\#M2DEZ)`
M"_)$2^!KRK<@%"AC8*;([,.BQZO[,\CKK(E4$OSI?60K_E0(BCP544ML"<)4
MSJ,BR.UAD;""/,ZR<(-!T4*$%?2H6O;$(#5L6AU/3U.S11NL@,;KDTUYDY+5
M6JJ,D&DER$AL,LWM/=^7^VL'#HNX4>&T7LOW:#<*<>%@M3B+>YT3J<<.J830
M6Q(6!DWW&[XT*+J:P:B^?::H?R>+IG&JE8PZ;SX\7!Q0[@M+B;K2]YMV,L*%
M%)L5>51-6*?J3BNK\4*!+V?$DXE:`DX5J:(ZU@PDGXGR-BC4DY[4&`LC@H;(
M`&.)Y%5E*ZF+<!1$"G:Y)T#D=</-(G:Q07^RL?GFFQ]__/$K5JSX^<]_#L(\
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M#SLE/[;`!J-BN^VVN^BBBVZZZ:;_^J__^L,?_O"K7_WJW_[MWW[]ZU^#-NSA
M]_>___W__,__`$3LYRC;0M.--]ZXUUY[<>=T")T?9X.`L$3(-UMA/-K^J:9V
MGFFJO(EF9Y\>LU,X&C/U>@.UTIB(`+*".(>L5"]:I:WH?"I*U`$\Z)0>"F4B
MF_6%H`TVV,#&\_V-D#(HUO\JX*N9B04M`EH%R=GB_S/1&;B#*A&LP)!]]]WW
MX(,/WG###>EV]M-FN,J@V._B75#5PF$@<\WHEJ<6/VMO5&(3[=94\R-2]`AA
MZ/$-43I?@6%3RPR*G6C0=,Y5[!HTM;!?*P=/+A<-20`J'Z8>6-E('(%FFK(H
MG\+<0^B<K(/]<K;I4?N7`[MRH5`O>Z`:LW(6LT:J+_\15:KN(EH+'[9N6U\,
M$8LD$E6'(RA%[`K)D>>D5#FK0@>8(X`@U$11(TQ9)Z=(?E[?%>F0YU86)'"Q
MAP=4F[KGGGM>>>65]]]_/]@"F/`+GP%\H#0@S^]^]SOW_+HKO_C%+W[RDY\\
M_/##"%R`#]4XY99;;MERRRUID`=,MU2V(\]QCXA4B5"L7;Y0QT,5N*:*+;[R
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ME:=202R*AB?5M'E9/^Y`[GS%*UY!O[WSG>^\^NJK[[CCCH<>>NBQQQX#88`7
MN`V"E2`#MWGDD4?^]5__%<GKX:ZP!\!Y]-%'P1\J//[XXYP(\O![SCGG\/:Y
M%N^TI]N)D!4=>ZR'Z?-\)N0_09XHG*.%FRCN0#U&,=F<.O(1[\E9@U$+4<_&
MW?,3GFLN0)["AA-P:?$H%KHC(@4B*B5S"BA551$O:F'5($'(R%R5OU6E2L2H
MZ+27-5_BJO4*J%IM4*PY82Q+F@->[F2B67.L+&OB&66,@:ST6"X];,XYTTWC
MVNOSBCR>$N6,-R/X]!!C4-RE`IY"A#@P->J'$TEGT!3+4>8($0ZDJ6*"%XZ\
MDW`/X4+0BW]:!IZG1.WC+>4#ZK5B0Z_JA0HO&?RQO"QIMO4>[/B]=N)(<H07
MC\IMXIRCMTS5WXYKDA6I4JI9*FID*4H<=:0QD!^$+'ZE-.P/SZDV+*[^JE>]
MZN4O?[GML$T=N@4V?O'%%W__^]\'.B`VX`:``WL1<Y"MV`/(`"^__.4O'^T*
M$/33G_X4V*&"`A>_G$L=E3^WW7;;%EMLP:5IOW*;B*5:X:N@6N$EM#Q?I;#N
M,-@EHS;W2L(C$8R/\T'S!,Y,C':T2AR9X#FWSNAAT_1FIE=+UJ"H>8,22TNH
MPFQG>5>=4B=OY3S#,75QY4(1'JN>:FES(A(/V:\92U#5,2`2W&PQ;5?MF5=4
M#LT4"#3UI%I+Q<9A,RA/%<_A2!D]G?-,L;;/-)>M')WNG.&7E)B()2V*(<\^
M7<I4LW^%!D=Y,C5JF*CW4Y5+XXKBB>9HG4^A=:I.,MS):M/-+E_;207'>2(=
MPF>BO:E$:%%S`NQ1G4"*@D-%GKCG5;MYG';&Y:GJJ/.&5F*64BDD'(E%'`)G
ME+R$G1[RN-._02%VJB;B%_SA$KOOOONEEU[ZX(,/_NQG/U-I#,[`=H`.?E7O
MB"T0(:@.=1[KRG]VA0VY$%BD%@@LXA1.Y^]!!QT4MB-$5X93-6D]2,\0RF"H
M(G9P)B"3@5K%F?#P"CY6R\ZY%FL0T:G*#@&H2!`:AJQ0?0BC6U8`$=RBZIEM
M<57N"0NJ>N!!,>[/MJBHJB[V:UM1,61LT)2N5?,C\E21S?VQOGF?(466L*^(
M%?+&J>8!)5Y--#_>X$]%F,GFVI>=4\5"5$M`HP)@?9OK%$MTU3Q7#<Q,\RXS
MWJT>6M)BFH)=L7]-="ZOT0()%$&8L*R8-@)]J1^,BEP6I4U5XXS;=IT+(D_T
MQA*V/*\*S\R::J")Q0H`T3I6B4U<!X,VL8\SWX,YT<98%'\$'XE*#-]J=53L
M2&E>TY4`CB!CT3]':`HZL?%7?_577HA[VWKKK2^ZZ**[[[X;EH(`!5`@6_U/
M5[15P7\`'S`')`%/0"=X#MON`7/D0K(@*O!7C*)!&OGC'_^(P,7`BU=VS\`7
M@]>X]%J%J9#8<.^*/-$)9-Z%14\WKX\>\LR,V=.7-;?DT)O9$C<1JB/RQ&*E
MM"5DK=<5C]I.&,Y<,Z/+<\2NJM@9%!-PF(.-^"`A:9&89HM:."U4/56(5D0G
M9ZZH-=V9VH6705$.BSQSH\9Q6^LASV2)30B\!S$XFBB/Z>;Y/-.\Q'O%LR:*
M7WKX3^CN9/&Z$?<B-U5RU?OZ]#2]020_/2*/H#3HG'G6:6Z!-I6K3[<(34>I
MKU+U8Y!G<C0L(F*4OSV3BLXD5=JJZ@C/4C2+FW'/=)[95*>5<\J20XG3Y%=D
MJ'$-\TJI:F2A1E0!8<`-H"94ASVO?O6KLT>:Y"%N/EHC<2SDYY6O?"4W?^BA
MAW[M:U_3(*7V!@+SQ!-/@#9@".C!?I#$;;F0Y(?]_-6`KB((Y`%J@*#?__[W
MU%$1)&NZZJJK>"D&:(P'M\H8*P4*_OBR(K?J&C0QZA&:[Y%#<:;8=O,='SY)
MJ7J/^G6>+5XT57L3Y(F>QVFH)4L34D_G4T$F2ICQ,EU"/V9&C?NS+;@RMUH)
M1K2[PD[H2@`J8%656FDY9*RVK%`V6VQ,D017>@,]L6M0_&3FBBULJ@4CS'56
M^U"7*GE5Q4O$'V?W5'/1F2YF<:GC3--$Y0LU5<ID*6DGJBTM7R))<"9R996J
M)EO`E.-SJGAZ.!IC@@]:QDNV"F4!P\B/%7R$BZI,=MMI4OU2`CX4Z4H5K/(W
M#LQ2%T4JC5!B1<Q,T0!7V'EM*Z\I19Y#"18%6#Q%]^E0IB`/-[/MMMM><,$%
M=]UU%_CPDY_\!*``84`)A2:@0]"@L)\]0`UPA-@%+G$(P%'_\[]=`7D4N]A#
M-42V'_[PA^"5[H4K5JR@8^>UL/H(F`$?-Z+G29=61X5J6QQW_HDP/M,L,C/%
MHC'=3$C#X@CGE[>G*\BL[^E+J[N@UJ[*>:+G"2)YN1C%G.#1"`V*Q3]:W.R)
MW$>9:GXRD<@"L)6P#5N2"@4H(^7K)6+PG6U6O]E1NUN%E*EBW1ZTX`X_][H*
M.-%F2HAW#Q`"DHH/[/2B4?_FPQ%I.HJ73.=%)2M%]+HSS;]TLKDU3A6OYK13
MQ9\J=^M=YE=I40N05R?CLTPV\WH/52JL6:+5L3Y'\V6<;F'.T=MD8Z(9_2/0
M54VR1VDG&PM;,)>^?SWD"4>:5Z*\XZW'1B:19";3[<F0IR<T]6A/F`]4)YBS
M4H#BQFB_ATB4`P\\\)IKKH&B_/2G/P4B("K@":`!8@!!((9X`FX@*X$S@A)0
MHR`&O>%$<.;G/_^Y5BT*?U4-44TH8T,Z],UO?I-W*@A'G1[DZ8E=T9OIC1`K
M0$R-D\V_JW[+\ND<EM0-H>A55,D$-)1IN#*OF(A7E;HH58DD<!O50>IV$L85
MU;'TYLU=T02?1L)&/-WO;(7*'(JR:-ABS!WMX\;TL(Y(><X[VYEN!O%J.(O*
M96D+]!;QALV%I@)+.BJ:GZKFM<&@2A64HDGKD:69IE+.AV/0.?\$.JK8,MEE
M%ZD":?8/BA_U3(MF3860+D&FJH:"5+GM:)"B14P717M625%,&^NT%#$<6M`%
M#=6K:$!95$+.P\^#>U46\[;K5WA^"2=?6'P%E2"L6:,A5`6#/-6!L-K3JSMQ
M0J4X5R=`68IPH=@%R/2(4"#%HQ3!YU6O>A6@),/A7""(9GE&*M!U)Y]\\D,/
M/71_5QY]]-'?=@5A"O)SSSWW//SPPZIKV/EX5\`<M3IJ;\"<1[KRP`,/@#"@
M$#LY!>0!:D`J\(>=@!*8P[D`VF<^\QD?N1<AXD;MQIZ93_7:@A;DOK!YC59;
M0+X7ZB$=@:'03NHJIUAF6[SD[,J\8C)#H^V)!#?;8D)%%0&A(D"TOE7](G2`
M5Y7S#(O2:6EQ-*JJH66=,\RP16`Y:.-"4[4QJ1;#]'3S[8G"?%BL>]/-DRU`
MM*SS4YIMCD,K%3^K7JARMNGB+5SEE)Z8UH.@Z;%2>4L5E(9%:STQZM<7?>]4
M">2<+!9S1U&<9V(/C;25/2FQ*,7>-%&,YNLTS\"P%*?V1)><)[ADFR+/DF(6
M]Q*+6NJJ:!+\^`J#M68F2/02U2/71XN1RXFF2D<I+*XU-80ST>*)93`"%`#Q
MJ`Q'#`$W(D8!)G]5RLM>]K)7OO*5VK!D1/Q]^<M?#B+IF?R*5[R"QSGBB".^
M]*4O/?C@@\#+CW_\8S`$E-#WAK]WWWVWQG$@B#ILZ#UHE$00YD<_^A&5`9:?
M=07.XR$0!N2!$:FIUJM''='%%U],UXG#-6I#DY_]5E5D$<>JPK\B3\9/OCN3
MHWY?58$P:)'7&=Z5&F5N]E3*RT9=>:LJ.*+*NJ.ESO'0GBJU1>$S*#ZT<R4F
M8E!\B:VF=%,)V[!SI)&SZ=P8#8]W6&F&F"9""D=.S+F6E&^JA65)I=9MR31B
M\`HX>_79,5W];-'GAUY6#7`/9&9&+>DA2!/%/6:J&;^"%>%(5;D7_)EJZ0Z<
MML,N24(4PE&V+"Y.8D&>Z5$K?!6L%K>L7`M*D@H'9*5D\<]1)@K@+&J!G'H!
M"2]1'8LG;H2]1)C2#V=1BY6(%+#F:`ZN<)X$>]9HT/DMOX0`(I((05JW<\C]
M`HY$J`I9*G8B3`$X<!L0YB__\B_Y]12H#H##?DD4Y<4O?C&'=MIII\LNNPP\
M@8?P>]===T%[-$+]X`<_N.FFFZZ__OIO?.,;`(BZ'=`#;('V_+$K2%Y`BOH<
M\$K#NGZ#@`SX(\YH?)<U16N$-'?HH8<:^B%A2Z1J4G/THDM2PGG",,-75UI"
MAMW._)H<]2T,%%3Q:J[%0\5/)O@3")+#1'$T5U+W1)E3O^]11Z=DJLX4WVG1
MHW*,83/9+"U>0TN;F[2>AX&R8=$;#UH,5UQQ9CIGGMC()IL&.RPBR#-7$O>-
M:YA3?[HX&`=\@O/I9U4?.6NJV--%GE`4K[*D\TA9IT70I#5G<65!`8=0G9F2
M)\=YO;#+7#<LEJ]PCYZRUQ:J/J>V'S%_G=&8A7SR>HJ:2FD"=]4.M79+T9E[
MR)=W80G1JB)2;%MQ"PP0):XS,0B)O0KX:&.JGH$B3Z`FEJD(4-4SL.IP\A?\
M`6K$F:B`V*FT91V&TTDGG?3=[WX7$``QP)Q;;[T5W@(5`480EVZXX8;/?O:S
M7_O:UZASVVVWZ8WS_>]__]O?_O8==]P!O8$1Z;VCY,59_]85P8<VY4Y&5=`L
M6*0)3!"#93'LE?BJ&V2VX]<4F32.A?D<Q$2HJ!LQOPKU?N:BF9QI;O!+2KAH
M)OYL<Y69&\U^G._[7$F1&NH2O6L/>:J'<\Z-3%2=?*9'@]![:I!ZAS/->28D
M)&KJF.-SN0A3T\W!6%"R<X;-O!X0".(%]Q3-5)M426I8K'[9D]O.U2=;;'L4
M^())A=DP')\T\SUOJBI/JK9Y<4M*TS-73;3([LD6@*:<(I&>;`DM`P4*1)75
M!'_BU[%HM$R5Z(9PF/#PQ:TL*>:M"D<1EZK19)V2['0<>7+_.:OJDQ/RL%;+
M,CJOY</)=G41U)*EK%'M5FX`$4S,Z',`C9Y5*Y8L]<D!GXH_4!U^O1FY$*WM
ML\\^G__\YV$F0`=0`+U!I'KDD4?X"VY\YSO?N>ZZZZCPU:]^U?T`SO>^][UO
M?O.;_]P5X.A?_N5?P!^0ZK[[[J."?C[Z$`)0R%D*7.Q$+F.GHADH9/0$-.F8
M8X[A3KC/^`^H2Z_Q\C5:K4JR09X@OSOSNGM2>>7`E4M'SSP]Y@4TKN>9*V$.
M(3R1GC+?A8+D)(R%J!X:CCH\S[0$[-'2S#;%<L_('I95$2E(F$/5]A3]3"`Q
MZA?U+9'%<E;U.QIV.B*I2)`D(EX%JS12%<7.?:&UVHEJA<HQ\N!Y"_5:DZ-!
MH#$BC*N`G+DQ3DVW9'WY!D5.K\-C28E6"%<9E\@6-W?BBD4!A`#1HI:MPJ-+
MFKM.FE*JJHJC:C&/DJ?J'!8UI^7XYT0*2VQFIHSVK.B-JYQ5W07SN0_4*#H9
M<JZGC;H:]38:S2FJCN4S0E`*L,-9LIV_^(N_H-F==][YW'//A>$`,O`0J(MF
M<:D.L//``P\@7@$[UUQSS;>^]2UXBZZ#0`=G??WK7T<$^Y>NW'[[[<+1G7?>
M"?B`8_(B77UD1,".8:3@&W_9[QZPB[&MY2X.C?*<&IL?1\J>)!O=6J2MA:.N
MYKV/5.`E8\P!666!JK>,1G>N1'1&@AA7\EB6EMSO4HNJY$D=%;8JHF/\"G^8
M:V%33I:(>#WBM'34GR?@,ZZMG2EI1>=*BN9AB[:HSQ59TFTK>WM3G4E]HL0]
M55U-5#39B)+$EL6'N98;N5*46O(NIHI1TMN;+FF-8Z[J"4<5R@(1D\7Q9M#E
M1EC44IDY9F:ZK!W5EK2PY9H89U/5D.&LK\A3U;_1VX@2%9&$09$D^ZL?3KC6
MPN:H'#_`&O(08:T7;U61)WFWS%V\9DNV'&-6]1*,>"6-D>HH*`DI[E&E$]DJ
MY=5=$864L_A+OQUVV&'(.,"+2IB''WY8V@-B(%[Q>\\]]\!_8#*0',@,%<"*
M)YYX`JX"8G`*(`/RW'CCC;?<<LN]]]Y[__WWLP%`L0%D\0L$@5$:V0U:%XCT
M+80+L9-J!QUT$#=F*H\P/9%'"F0^V$2_]D+UQQW"'2JQ".3%+6X&]`R;1<T;
M9';4ME5EAVATE[;(@IZJ)])-M#11L`12EG:>A#W3N?BP_OKK&U-9]3PQ;(DS
MTYUC212MT\4K1J')Z>S3S3:[6[!KMN4]%BC$NKEB!9-ZQ<HVVQQ^JL?.9%,U
M._5$GHEFMA9+U=9.-1/SLA*PKY@3Y%%EY$WV,#Q*L+#0?"/2\F3G_;*PK=N2
MMUE?<=[RH-G9EW2I*ISX(IYF[@TWW'#CC3>>Z9*$LS-6Z0RG*(MR,\$E02"4
M8_%H(.?DJ',.U?306UAR5KA_C9;<N%XZS2XJ41+9$R)4S2L!I>AY>M*6FF%F
MF3CC1DSD58RJ>IZ(4?Z*)Z(3>`*E<8]N/#WPH7$%+E[$&6><H;D<K@)*0&``
M&5`(V@-U`5*@,3???#/B%2AD1@MD(F"$OS`?H(.=U+RM*YP.-%%9%@1D(:.Q
MGYW`&F>!-D"-+LW\NFW0UE>^\A7ZTS1!+WO9R^@NY<V:`B@962OX5/Q)P%J8
MYSHE"J:^NXF6P[;W.8LNMVH;(E7-E3#/83&:!T"6E34F0AA6BCQO;J5F3)TM
M.1\&W9H1T0E/%>O;;$F",6RY@`"NJ1;]D0D>(A?R,RA1456O,FRV^*F27SH/
MJ%/!H/-UH:-$!AOG$2),#3M_`)Z(FG3IDWD8+FR9-V:;OCHD:K)%J2\M4?/3
MS==N47&*F.K\(GQQ4R54G*O4:A/-6SAJZFA:HL^9[M+9T=I;W_K6[;???MTN
M^5A(T9*QV'"OY8=L<0L/7UP"N"H+ROXHG[TEXZ<<@:H(!$F':RPI55<3Y5+/
MMKYFR=%7W?[7+-FZG#CS6DZ_FG<KR2YZ00TUD+SG+NB>6*\",G(;CK+]TI>^
MU`H(5OQ54_3\YS^?9SSQQ!/!&=`#?'B@*P`.$`1B("Y===555U]]-73HNNNN
MN_;::U>L6`$*`2-4!FHX$3KTT$,/:9SR1(Z"8]_][G?A/[0`3:+FM[_];7XU
MP2M8`3N@D#EY0#DX#U?<???=M?4;)R)(JO`)"U+QWG.DC%BZ1DE2'0/BHB<O
M$W^R1&$[W5:$J89CYY=3,@KDGF5J,!KLF0IA*4M;$F:G9.2O@%7(S%R+7PC5
MJ9HH$2#:H9EB,8]EJCH=S965;JK!.E`P4\*=!BW%V;`Y`>96?9"JE9IJ*_<I
ML^2&`Y+3+7'69(FW2HFB:;H%4$RWV-YQ,2IU9EJ>MXAF4\WGT%L*"UHTFGPX
MSG)+NI10%"\M]XAD%*U+E8D2IQ-\LY&U6XJ;J&*JD;WB9.4_0H=U9&*51U7J
MLG;)J%.]=")_K5D2L$<7L499>B8^R4^&/$ZQ7D:O7KR#>ZK=BLE;P8>B5B>F
M+G4[//N%%UX(;V'B/_C@@S_\X0_91IB"Y'REE4]]ZE.?^,0G/OWI3P-!;/-[
MY957_MW?_=T7O_C%KWWM:S?<<,,==]P!L0%80!@5SH#2O5V!\X`\M`PT?;\K
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MI9+DQ(85V/G+KKRR*VQ0@5^@A@U:H\Y+7O(2WL5%%UWTLY_][+'''E.!`_X@
M(OWS/__S=5WYW.<^]P__\`\?^]C'+KC@@LLNNPS,^<=__,?/?.8S5UQQ!>!S
MS3777'_]]8#/M[[U+7[95JL,U5$+!'=2X<Q._B*4`3NP&GB1$5[0'L''N%%N
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M<I7&Y-Q*PQ:T-4`7CI:*/`N;]39AGNH_$Y`5W4[^RG-ZF;N"/&YHI0KRQ#DG
MYG(93C3&@9U7M!+\<3_(8YT7O>A%U-]WWWV9[,(.E(/?6VZYY7-=`48`$,`'
M;O/QCW_\(Q_Y"#O9=JD:A"\H$"CT^<]__I_^Z9^@/5K2H3VZ%X)%M`:#XB^-
MW'SSS8#/OW8%4(+YJ"DR72K(8Q@%K3&H%`^Y>2,X9&L:Z0PJ4:ZD)T7FFG<Q
M.:A7;^N"U:C;7JA7V,Z"YG->M9=+BK^9,W30`@TR$X6:9-U1'I&]5+5&-7D+
M)E:(+NA-;=G00%/4R]']#HM_2]!FNB67#I[DH@&3Z9923]=E^9@8LK1Y^\R6
MX*;9EG-^LD4?#$ILNWMTN?$&(HU&=)H>S<#3Z\9(@E6'%I7:3/,#G!S-G#S=
M'(=B&JNN-5'4.%NG6_*N,(WIDIUR8M0:'HA8W+R(<Y33E>N#'HM;WIOJLYI9
M'QRHDE&.TD)E(U$"3#1_Z9X2>YU1ZWEML$I;:Q<W_KCK)$IT?EO-?*VR$&>0
MIV;T"N%Q?L4M.<)42$YU2([J6(;#M'UY5P0?E3P>8ON%+WPAO&*3338!0"`A
MP`6``R`@6#'W$8Z@+DA;]]]_/V`"I'SC&]\`;<`01*W/?O:S(`G8PA[`!_)S
M^>677WKII1SZZE>_REF<RRDK5JS@+]B%M$6S;(-%`!&T!T32PP>V\\033X`\
MO_WM;^%:8-'11Q_-#?.8/"\W*>NS$]2,58*W:LM.GQ#^.$;:_R)_Q%M1JR+/
MHF(J73P:I!R%P.(64QR-2B4`2UO@9U0<2[N@@T1:Q4!3&86D*'KC:D]W:J_;
MUA@-@,0(-3?J+#13PD7GBJ_.H#G>*&$Y&<63I2U)SO1H-K!A\2<42$/_HK2)
MD5T];25^PY9I/Q2HNM8,QDI%T4'S_9ML#CF+6V#I;%LEIWX(9IJCX#HE!?I4
MR:8UV;P!%Y44[A.=N^#"EA&]HE:T1NQT+"FYK%U23$2C&^6MFMX:=!!.,G]E
MJ\:$(Z5:&NF1J,A]3Z9AKGRI&LWGC^:P$G8R36QDC;:@WNIEN9D@3T]U'+_!
MA%SUD"?@LU+D82<3.28MMKGZF6>>^=!##X$ST)@O?_G+X`-"UAUWW`%<P$EN
MO?568(>CU$$<8QN&`\Z`-M0$J8"C+W[QBY_IRGGGG8?4AES&?KC-=[[SG3"?
MKW>%RMK%`!]$,"0O&([@H[8'V`&4=MYYY^<^][G<,!W"G?/4NAO%0X";IZLW
MW713!!#5/DJCT2W/:RL!Q=25#\$X\N33%B5/SR4C>I[H/*L*MRJ9$VB@J*(`
ME<B(JI^)A4C;]]+F^9QPJA"#X-ML"R$?E'"MV>;%-VQA5L&Z2$`RG&'SS=,L
M-6R)7J>;JY*F;2O/CL:'1ITU.YHEHZ?KCB!6A:;IDJELK@5H3!47J<FR_&A4
M-],M[Y9XXM&)42_EF9(#4,ZPN*RA&7*BUC=6]=BR%Y?D6GG=OGUMV7ZP'">"
M=F^F!P?6;KE#HW59>S2$H4KZ"TK..LK:W?+?FIFJ!5:)::TN)CHX5BTFU6E_
MK1),'65"K%I1.[RA+?00PN-WN8<\<5&./:O"SDHYCT5)*LA3!2[0AJ.B$#O7
M7W]]):`;;[P1S@-7T8S.-B(56`$*`34@A@IGT.:RRRY#YD+R0KP"<^`\_%YS
MS34`UR<_^<F__=N_!9=@1/H0TAH(QH:-`VA<#B"Z]]Y[01XN!/@8+JK`A<0'
MZ>*N7O:RE^F,;=8R_ZK78O3NM==>%U]\,:UQDTS;ZLL==X*ZE$]5LLUK2Y+-
M'TMIF(WP'-EO%5ZJGJ>:MP(:,8A'A@KRB`R]G!B9DO'\R>F9]9'(,L=[]GWA
M;E"\=#*1O3?;C&P5K5142<,6H"UF*F1-M&07X&?%&1M?VG(R)[XC$IDRT=(6
M-SILJ^<L:PM)+!E-!QJ;UU0K(4)1!(5-!?DK\FC:7MBEP(W);**M9#?1&>X7
MC.:@6-(E?9+,5%C0NN086+N+UZZ.&?-'2^KGZ(*VJGB^<0M:BHF<%91P_[RV
M/F:01_'*TQ<W!Z%QSA,;2MR/?9P*1WZ+U2VOVM:EFE<R"J[1LO^M%'E"?FI>
MG02!_@GDJ;!#0;S2GLY<9F.''7:`8\A/?M05)"`@XLHKKX35`"9`#;,;>$%T
M$FI`%0]1V$"\^MSG/L=^CD)[/O&)3P`^'_O8QS@+D0WL4EZ[YYY[U#E_HRML
M<"UX%)?[]:]_G<7^?O6K7\&O3`IDC/Q+7O*2^"/118<<<@B`\]]=H3XT;/GR
MY9`?P(KQ1I_K^&27II_7*F5^60:ZXD_>U[C^)Q:NWG3.I%!MJW_=7+?"74A(
M3ST;]<ZRDC$LHDW$J\S3:)NA3QMNN.$&&VQ@I'DTWK,EKY=JG+D2S"[:5'/Y
M8#1N76R<:TL8CZM<G/)O:HL,AN',%4=$>R"$1WHP,1J8$+.[YTZ/+@H<+A3[
M5U3*-AC34NSF4\6W.=M575Q#8R;:>KX]#?"XE!3'F,4M+&*E]JPH>6J(DRTL
M:CD`XT(LIJU5EL(,T5JG<UT.68K5N]JYHIFIB">3J;>Q9LF-'*H?MC.OK0VQ
M6ED..%1GU5+&`Z]";Z)#!DFD!&J88\D*U+`!PKSTI2]]65>TIP,^;,@BF,A@
M`N(/5$112(L58`*2('SQ%]H#_K#GJU_]*D@".^*02AO`!]F*.OQ>==55$"$8
MT4<_^E'!AW;8`S31`A0($8SVV4`$@_;<=MMM:IM!F]_\YC>_[PI@<OGEET=5
M3A<=>."!1QUUU)%''LGO)9=<XA*E?_SC'UV3ZW>_^QVMT3[<Z=ACCU4B6[4M
M4[AJ67FP9C&*_-7SCJA2?)PWQ!P..<$7=Z$*SG<Y`S-EL\TV`_W8"3XX7YS1
M;"MS,<SD0O$85*2*;;HJ;:K,5??/-O>_GB@T**8N*SMS9UOBQ*FR@,NPA']:
M/PY[D7J&)08DUZV*FNFVT$,$JV4MN>N@\QB<+IXY@:_9MD17H'*RY7COJ<T#
M.YK)8BQ;U$6=+VX.,!,E+6$83L]HE1+;97SY*C>87W)7+NA68:A^./DP+2BE
MBC-IH;H(5B0).,QOE@X!;4%9;D:F%-MWU=ZX4:VW<<Z?7SQV*OCTZ)!8%`C*
MI%AUM,17^;6E]&!'=4=T.\&B@(SP`NS\15?$'WV5W4]3^^RSCV`"L'SI2U^"
MNLAAF,O\0F_^_N__'H0!9T";ZZZ[CFW@"(R"`@$[$!L`AU^J<2)R&=OP)6`'
M"`(H0"'PAZ.VOV+%"GYI@7:XZ*VWWHH$!_B8!,QP]8LNNH@;X_:XSX,//AAV
M!!W2YU"T@>TDU:HTR3T(=$<<<01SBBZE]Q@`%<^36J0&>5457#Y8O:^;>AZA
M0SE"M7`4%/'+5=6SR2:;R`<VVF@C.0Q$);X]RTJIVN8X\U1+>L2N*(TG1\-4
M(X[-M*BK1'K.E,6GHGF.?F9V-(5%Q)R@1/1(GE4U4;US8U"+ZF9)6\PN9"_$
M9J9Y',7'+[#9`ZNH]Z=;N@P%P)ENV;7@3(`E^N$EHTE'<W2EG*?Z8%1?"Z-R
MG-UKMZQ]6DCGE\Q:/1U+;T2M64IXD0U636^U<_7:";<1H,)DPLQS^KRRCGF0
M)Y>N^L_`SAO+<I^O+Z67UZ(Z!Z:P!]@!1N`V_&7"ZJL3G`GL*%XAN<B+V/^B
M%[V(C1UWW!&XN.:::T`,P(1MZ`HX`SB`)*`'$A/@`#_YNZZ`1:`3`A'37-TR
M.Y&PJ(SD!<)\NBOBSZ677BK_H5#GZJNO!JQ`'BD0M.?VVV^_]]Y[?_*3GSSV
MV&/0F,<??QP8X:*(3MMLL\UVVVW'Y4S4DP($07L,$X,C_?*7OV2/B579^<`#
M#P!QAQ]^N$II]?GVH3Q3)5MUH*J"V((G2>;O'LU#4YV/KO-4_0D(0V5`@\Y$
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M[;77_N`'/P`E[KOO/L`$5)'Y<`JM6<>_@@_D!_#A$,0)Y+G^^NL!+B[WXQ__
MV(5R#-HR,SP<#+A#$`.4^`O")+?&3W_Z4Z[X\ZZ8P!E4I!%(D1E9`1\0C/O1
MD*HS5=*I)9=C+QM)19ZHEZMOL^-YNO.BG^SB@":[I%M@SG[[[7=,5^@!\%E$
M!9"!33!DZZVW5M,B+^KY)R\KJ^0L;<L<QZ]FMKD%A@(9B1F.$;>?1%%-M23,
M<>D)/PE`^3="TW0+])AK^7^FR[(.T295A79%,RUE&V^\,5VAP5I1L?*H0<EZ
MFNO&SR=$;GHT<U?<"`==V'B,W<):S-\3)95-]E3/Y$6CT>5YQ0M;LIKJW**0
MI<UK[99S6&%G00N&JI@35%FKQ'2O.1H/7L-Y*N6H7[U>.U4/N6;+^EO%NK6:
MNTATQ3W$$V0"1*N-KBS\QK:R9^9%S5;:*]4_,/J<ZKU3-<GA/*$]"B^4/__S
M/Q>%X#QL,QC`!]#`'#O`!93CIIMNTDOGHUV!$:E`!I'8ALR`+>I;'GGD$04T
M0RHXQ#8813L(7)P+CEU\\<6"#RV#"?`B?8%NOOEFX`O2(NR`)*"'>39H'##1
MMQGDD<]0D_KWWW\_&P\__+`YG%VZZQ>_^(695TV'>.211]J3(3D18\<%KOH1
MJ0;0N'Q,MD3?:AZ<PNQDNH'/W`.0:-YI[OF)KMQRRRT'''"`*V=-MVS&S%GV
MU)07`9\8MGK[0VEB)JLZDQQ-2*8JEVIIRF0/\L0'8+8Y#<:79K(ER!J41!;6
M7#*:;FNBY"NFV<TWWWR++;;@'H)[R6%8SXH">:JLV!OGG^D6^U"]I^0\Z[2U
MBM2V*=#U<*8:K<)7*\.I9J/*BR+(),6EOH@BCP,FHE"PHJ**%2+4!`'&HP@K
M[`1>:E,]I4T]6EF-9)X1WN,SJ=G3Y_1\=4)X>L@S[JY3X\JKKTZHCLQ'2-&`
M!;=1R'IQ5_Q+M><][WF>R)[G/__Y=.]IIYUF4-4--]P`2@`.8`)8!#ZP?<$%
M%X`GT!4@!3@"?T2J1Q]]%'8!`S&P`BRB,C4__O&/4P'`^?"'/\RO1G;.!8C<
M_EA7M'PAW[FZ#;`#I(`YH`WSEY;9:8H>]L!_J`;^(%A!>[@T\STKDSK9__"'
M/YAAGDLP\NWP>".\OJR^P=_>-ZAGX:IJ'R?%HI8-?J9;H<DY\O:WO_W!!Q^L
MDJ!>211N_OWO?S^S[VUO>]OQQQ]_R"&'($8AB`5YJG]@-7(%=ESU;UPH&XZM
M=CILD>GA/%6#%,XSVR*M<FY/VZ.Q>SB60ZR2G%CDIUI^>&\F=QM=]-+1:-;P
M*/MSIN4WCN]?`J\B+HGYO!KW"(P+NBCRG#O9LELL:`%3-0@BX!-5;82IQ26<
M(:X[U7LG>N#XP/?4MCUL"015E^#J8+9&\2B+UVOP9*7<J>Z?5_('AM48F5BO
M6X%N]1(34;^\,:!71\$@3PV%X&\\D`,^U4LP18:C2"7LL`'LO*@KFK3@.;3@
M3O?LM--.@`PR`E``7``C*U:L^,QG/@/.`":@!VC#'DWGU*0"Y`<9QZRG5H;)
M@$[JEI&P/MP52`Y`9)`IARZ__'(K`$%L<`H,RG09/_K1CY"_1!5SI;)?TSD[
M[[CCCB]_^<M4@/FHTOG-;WZCVID-UVH'FLPY?^>==[H:,OT3`OFZMJ:J9J_5
M2EF]A+17L\7:;<7JR9:F("Y\[$2X..^\\[@'`^VE6Q17$V.#+CKNN.-X?.C<
M-[[QC6VWW7:##390C=,+R'I3*Q5\D@.GIXL.(8G&6&+0\WL)SQG7,`^;HW*@
M+(J:8%0<DY:6/!559(N6AFKI'TU:U=0^5Z+,9EJNXY5:U1>/KCL3M3#O2W32
M$4@?O/@!+FDI^]9N"TM5V]:BDD1K24M^LF`T*G/AZ((OU=E87%JKY9WK3?!Q
MM4S=KA0H@3Q^SO1EK4A50::G,DH+:XVF3:Z\JX=XO7,KO8F3VVHMM6#T.=5C
MIR8/K#IDCX(\0HVLAM_*9*JH)?A(>T`;CM+"<Y[S'""(LU99916Z]_333U>]
M#&CHKH/H!`5BX@`@7_C"%VZ__?;O=(6=_`6"0`8S*B-9@"'4_'0K0`V80U-`
M#2`#=HE%%UYX(?L-LN`7VH-8![`@'QDI!@0]]-!#B%%<#MXE!0)JQ).[[KJ+
M/=`A]B!A\>M2@/`?8)`*G$A]@.CLL\].?FGU8Z87DSSS-["?W*K5QI$/910%
M"BG1N#(U]MQS3UBB&F\QQQ0?"HQN7W_]]8B9X"2<;>^]]]YTTTVC0TYQ3])H
M5+UQ@D;7+1D+!RUD+(MVS;4%-ZNC3F9Z]2J<:VD,10PM3=7-3ZVX6EROF);#
M@F9+FHM!6\QW89=))L1FV*VLEWBK:C&/*W@5]Z(NCG].>,N2T51:DR6YJ++5
MPK9TK#A3A2^W5>?J9-@S":U5_'[GM\5J5^^<,7K2T.HM)&>M%D/!AJQ&U5#E
M/TYM!3<G^[P2#%[I1UB*`]5,6=6=N!;/DA?)G;S/>6/!GM'J1+<0J/'I\CE.
M6(2NQ3KK)A\[?Q/[4+4Z"E:JBV//4MOL3G'FS[O"Q@M>\`*KJ>&AR(4X=,01
M1\AYD+9T3H:3\-5F`\2`_)C.@DD$R>$+#OV`8[A.S2.//,(4@PB!/V".OCV<
M+K&A-38NZ4HHD.!#@?.X".D]]]P#E`$X_((G4"!:5I/L8G^F#F-><SGW@S-*
M-X@\G*)C(=P#^/J;O_D;GDO_`5\E?<+0VJDKC!,..2;I]K6[7'#`D9\Y_4YU
MA:7_K;96M[+DF[K5AYD^2!877701&"C(J(_B[Q.MB$7F&V$_`'O,,<?`"0\_
M_'"A8+/--HOD!1=:UA)EL'/]]==WCB?L(E@4G7-U\AF4=#J6Z;;P[DQ+RQ.R
M-!S-719A*FKGZ9+@?;9D1:[V[L!([$T393'?Z1:D&3-93IQN2W3%=I:[K3%3
M55UCSR0.:W')<FS[BUJ*&^O$-R]&*Y4Y>B&N61;P7:-YTU439T`F<+36:*;T
MI/I<JRWTILHEJ!*):=6RPEV@1CCBQ'FEK%["IGK\J@I'-A*ED]?MG1Y-3O;4
M[>1/C@'K=671\YYGLB`3V*E!Z,*+):;S:KV"Y[SPA2]\05?88#)Z5+2AB#Q`
MT/[[[\_L`&?X1IM[!XBX\<8;84'0&Z8/D\N%_&Z]]5;$*V@/X.`LT^0$<($\
M0`JG:U6/G9UMB=`55UP!"FGMLN;55U_]@ZZ`9GKXW'OOO5S(R0NX\1=&Y-JC
M\AP#+MB`;ID]54T1VRJE.9T)3E>X<"$])O=C(@,78-U99YUURBFGO.]][]MB
MBRU\H0M:0J=E;:TZDUKKP.:89R<UX2W<.2@*?^/&7,I0"+*XIJHK^)CBU9`0
M^@<ZQ^,???31>^VU%PBC;D0U<LQ;(H\\1\U)!)]U6ZJ?^/;T="^Q)544&K9<
M]%7L4E45((KIO/*E&*&$Q$!3S\FPI@&II\^UQ<HC3\V4R(BJV+'9Q6,+GXD_
MMA]HJL)4G)9KV)W*X9`9E776F5\"*B.YK%1Y&R_?*C2)6CP(GZK7MZ5>@B=K
MM9!`T2.6ZPH+2CURB35*_$*(=T]'75'EC67=F0AE56E0PQ^\AUPTE"FQGSVH
MB4D]&F;U.3H>5S>>B%KC*AVA1BS*7V$GNAU^A2,K/.]YS]MCCST0=L`3IA68
M`S+`6VZ[[39^X3/,<284\(*TA5"#'`1*($%`/YA-3$`PX;O?_:Y!%D9R@4XJ
MA4`SJ!3D1VT/4`;:_'U73&\(X@$OR'I4H#(S%-&)F4NS=]]]-_CVZ*.//MP5
M$(;M^^^_'[:C.<P%!*$6W)M>S>J<N0$FHP*F^?#9YD4@5/ZX*]P\Y](^9,\^
MIP>0"M6T<]L'''"`TX%WP?CGS1K@O'SY<O"-NX+`<"?`"[>J][4+I+K'Q9V#
M1=D09KF][;???L,--U34T@0F.='#6=T.AP0EV5&\:*J=:*8%Q:O7C7`4Y7.P
MI8=4U6X>*C778BAR5KP*JUJ[\JB(;[DW[Z$G9&4C^NH$I(A+U8P>VWJP*,1I
MNBT)$9_/7M::ZAI1(PL6ML7L*HU9H[C>]?QA>AKC:&Z=GDQ>I3.ICM,\XKQ$
M8E[G+?_&+G&HTUECJ_=0L6C5EFS!=GIFJ=7:ZDYQB%V]K!/QQM&2-H7!BC91
M(R<"5!KCC24((@PG*N6>`;TB3]3(X@QD)O`BMPGXL"'/"1:Q\=SG/G>;;;8Q
MJ%Q1"&X`=``F0`$0P2&SP<-Y[NH*H(0LQ@R"`KF6,94YA1:,IU#S\Y&N`#N(
M8$QG?0A55NOS`SJQD\G.WP]^\(-(=E36VLXOPA<M_^QG/P,5N0=P#_:%N.=J
M7]JRC3:5%^D.K5U^EUUVL:]X1C<8SU`.3I$U"1$WW'##"2><</+))P-]G$4[
MLA0NQ)T<=MAAC*XMM]P2E``3WO&.=_"`8HCK&)K03'HC^:%DIS5A98*/.B@V
M>!#H%MQ&Q8NX,=O2=KDMVXECLZ:K<:OW;,NV$>0)2TF#=7\@)0JBZ9*G:ZJL
M3=-3:_=@9*9%-\R,E5C28^&*>D?GGW@25N19J1NAOG_2FQC(-+O'&[GGJ+-&
M<\A)-1E.=12<WS+51(TS[H>C)U@BN]7J0`\4V>8UET(V7MLMR&NVEE7;0C`R
MBLSK-[;54E0S,G]?T[*F!WG"3-[05I0+[-0*U2TDH-2#'?4Y5;=<G9,C7@DU
MAE^Y'4M6K.IQ'8Q)*^Z"5:IZ85<$EJ!0D(>"8)4*(@^'0![>+,(17WP00!6-
MH0T@`P#"]YV)J=/R====!U8`+Q_[V,?8#SC`B*`<P!'@P'[J`UP77WPQ\LCY
MYY\/?0*%@`XS^=`^9\E_-):Y;@X[02>PB$-4UB7/)//`G?$==]QQ!_?`M`4Z
M3-EA)F<*TUPKFUY&]]UW'W.6]T+_T(?0AJVWWAK<X'*N3@CRN$;SHUVQG?@+
MJ=,&@B!CYYQS#O?,HW%CM,]%`;K0&#5=U;#N@JI6T"M;@Y?5#/W@>9F2&W9%
M]?*REO&F6L.7=E&H544<BWF<>8(,LZ,![(-6>CX\L:0G$F2ZN3''R3!:H$AV
ML5A5A=)42T\:^2@:GB5MG0L;<4^UK\V4>,_>#5?S5M3(X3EJ;*:ZW(-1(R]I
M>4?Y&^?>&`@L\TL@^?R2(ZMGQ0[GJ6*78+5:M^Z22,(<I_$--MA@UUUWW7OO
MO??<<\_==MMMJZVV6K=+J4WO;;[YY@CFO+YY;;5Q115^S6LG.JEXJ>+82K%H
MU9(;N:>"SD:-NE)7T$,>P3!93%\SFBTY$E9/GQSO'3$GGLD]?8Z9OM3DA-L$
MCE3I6"V5Y3R<<M!!!S'Q-6P92<%$,],@L`#.&)_.-+SBBBLNN^PRT$GQ"BQB
M1O]C5ZZZZJI++KE$>[I@\I6O?$6?7K8UK',ZLYC*(!AS$%RB<2X$F(``+H@#
MPH`>+FFJVIE&KN\*?Q&7``V.&K$%SP$E0#_._5U7$`9Y%W3.)IML@CPE`3OV
MV&.Y*Z'I-UV!M,A\_JLK:HF5UW2'IG$5Z<*(4A4G:LTWB`Q4<>D-DRNJH1)P
M],JNIG9W\A0[[+##1AMMA!C%Z-UXXXWKNC8QK(?_!'.,,UW:HL)3(9.WIRZN
M"ISX/,^VE,MQXYDI:YX.2H[Z05DI3W$O-2-8+6G+BT^5O.O)K1'GGX2;19BR
M]!13$:D":U806Y(G9ZH+X%W0%JK6PA5]3N(N$WLN%XK=7`*S>DM3,Z^$-E3]
M3#6=IPXSE*_8&6><P7>3P<E+=\UN!B2CE$_SE[_\9;Z2?!]=<I=WS30Y_OCC
M$2NXM'-91I%%@:N*IJ;$2?%0C^I8K5*=NI1YCP(%:A(-$2NY5"?;-7-R)3G5
MC.5V%;7BMS../.$\:G@D0M'S_-F?_1GOD?Z$^3!/$9?`!*`&V&&#OWH#&L!N
M'GAC0N$VYW>%#;#(*%%^Z6TI#2\"$+OTTDO9SR_0]`]=,0H,6>RLL\XZ\\PS
M02'HA-$38`ATRUSTKIL#%>%MFHB,/2ZO\\`##[@*&.P%WJ)'#5#`2/C>][[W
MMK>];;/--N,&7(401F3>,\[5*4CUKS8[2E9>=BUXJ10L2(&.#>,XA)&JQE''
M#@R"AS1K'6\FR$-E(4X6!+2>?OKI$)ZI+O)+VI-LJ#50JP<:*H*&+96ZY$0@
MJNJ:JI_1,B6F12$SURU/PZ^"GA9G726M'.%.4J2F5VW,DI+I-`+7L(2L6BWV
M]V"+UXU]JJ?8J6PMM*=Z#$Z.KG&SH"1;7MQET9G?Y>XS?V#BK=0VQV"DCF6-
MEHYF7)\3Z4:=S!IM<27E%QH\Y)!#&*N^?=C^(UUA4/'V]697]ZC+APR9-\XP
M`)J82LN7+P>X>,!PCX",\%*%H\IVWE!65UFMRP,CA@2%Z@(05:L<N[FLIKH+
M"C[&6X7A!'E$I(HY42FSIZ)-\"<E(!/;>I#'C2`/&X#/H8<>*CB`"8`#\$)?
MR61`(24CHSXY"M2<>^ZY"%9`D#$1[.<7;D,UYCA<2-2";]"(6F7SQG,*8,7L
MT\;T@0]\`'1"JH*],#>!%+/W\#8-3;WYYIMI',QA/TA"!=`&\D,=K5W\NF@I
M*"'!X)X-T`#$A":&!Z0(`8IV$-SD2\9N<"Z79JCH"*T1C0'C+P,L$?&BBJ(3
M-96VJ,.0$\34^00&K>_?JORA,W???7<(.9PG$1#5P[!2'7F.'_HJB,6N--=2
M)8=@1,<B+D6I,BAE6$)'!RUI:FA)SITNR\WTU-$"3NSOFK2&+6]&52().]QP
ME#93;>D9P<2;3-Q$E,Q3;7DL049JI.D\$>CQ)%S<I3"M[GS5F!6=;34W/YEM
MB!--`,ZY*F-YY&...<;/D`5@<=ENUS50A#?3+]48-@Q@/GG\U<O+3QMCF-F!
M[,^CZ8FG1H6KQ#.GTI)HIT65`%%TW16@]-6A?M!&A(G'8""KQF2M%',2$U%=
ME*M;<BU5R0R>/.<YS^$O]4$5P0?!"G!C/Y6E.MS)LY[U+.JLLLHJ?(5//OED
M@`)XT?:-Q&1&BVNZ`NOX^M>_SEQFC^`#AFB],KR=R0Z&@"U,?#75$"2C)*C,
M'A`,O#KGG'.0R'B/[WG/>QB67!3T<&4N",G==]\-VH@S7(N=)@BZZ::;S$6O
MY=W%=-A@OC/K_=PH-\E\P"AN"=Y+@]0$?&`F=]YYYSU=`:88*M!C*C!:OML5
M&I$\TR#M&`4/O+!?X4MVI`T+/#%0BVU.45[S+[]JF^/AXRFNYBP<@9_O?__[
M-:_KNE-EKD0_94%`9W?8130PD6*J77M8')6C)NJIAJ9+V&:DI_@EQJ05OYWQ
M1@;%I3`7G6E9=*9*OM/$>?4H4^)#Q_-=+&Y)VN-^G+2TBTIN]D6C*S6L64J-
MOJRB4RA0-4Q7V''^TB#/Y?S=<<<=^6[R[D`;EX(";>#D[/'5Z_BA0[O?0="&
MH<+WCK'M&D\&!#D8&'577GGET4<?O>NNN])%1C]%ZRMT\-?%8N!IU0A>%34]
MG]BXZ_20)XXZ-:-I]NB9G%*U.CV9JQ<6$<&J2E)4I@)0(_YP"E##SJ=T1<F+
M1FB9O]1Y^M.?SH<#-``KU`-?<,$%UUY[[0TWW,#\-?T%C,4LA:`0._E%I!*1
M7!F'$Y&Y-%%=WA6)!P`%L0%SP)]33SV5&7?444<A$#%^Z`2D/.H@3P$1X@_(
M9KIF?J$]7(L-D('7[7+);""%\<71!5ID`"Z,:N>-\]X9'IPB&4;<YD%4@X-(
MG'A35X!-;@ED8P^5C04SCDSRH_+YL:X8LB&P*&>Y85HAUUJE:!VSPA];267!
MBA%(RSH7[;___E7.JLBS=.G_7[Y\NJ6IB5IXIF7GBU159;3HG*M'7TQ4IA@2
M$&1<LUV2YS@VIW*`;G8TTW+LXQ&49EM8!`A0:94L1;DLZIWI40_#A6WQA>I&
M&!2*&7VR92:LV=O6:<G2URRQY`F"2+#VO!*['95RC^V$0G"B7W\VD`48EHP-
M/EZ.QL]^]K,K5JS@^ZB/!U\T315\!_F*@2J,-.5Z=8;@%?CCUXT-!BU#BPI^
M\O@TGW;::6]]ZUMU?]47D9N1"`D@/4U.-9%GW:N>`>NU;?6K&*IJ6%8OG6G%
MG,!..,\X\HP+5HI4T!@QAU\`A_H<8B>'P!FOPL:SG_UL&J1[>63X#_=SY)%'
M@A*77'*).2Z4K1*T?EE7J``O0EY@PG*4MV!Z'Y#JO//.._'$$SG]UJ[P:G@I
MO!WJ(UL=>^RQ)YUTTIEGGLET._SPPS?99!,&#+0SJ<;N[(H:9EXQK]N528$@
MG7#X=FC>`GQX@^QD@YU0W^AX_[<5>2^(P5$>A.M"Y+@3*)EQ#9K2@$1PU07"
M#!E3>#=38I3)?,O8T(\ZEV!;C;3[J:;N6M\>B]N!G81:&!O+N3##7KAH+-H5
MB)SFE7O,E@3O4Z-IX4-L$D09O8I`8:;EF=&$J)-=`I``3LI@-`%U-47%,AY$
M$@]G2Z1J-:R'Y$R7Y0*GNS2#DRUIAA*6U*BFPDB(:)"GYI!4G[-V*<G9-:_%
M;E?GP'$AJYJ'^,N\V&RSS3[TH0\Q-AA"##,(OTLDZ/5J8>@RU/D@4DT@8B#Q
MH:2R[J/`#H-3M2$TVYS###-V&A#-9XA?FCKPP`-7ZU:1T^F7^1CS=R0I.4\T
M.55T>MUHJ?J<2G5>4_*W)PZKIU(6<_C[%Z54C\&>];S&2H`Y[*<U_@)!3WWJ
M4SF+!F$:=";3C0W>(,_XM*<]C:,\,OT,YX$#("N!)X:<JVU.@O?SSS^?*0S(
M`"\<$G:@1DQG`(H*'_S@!V%-@`/=#O(S?^&90#K\!VP'KV@'IF%H&'B%X*,:
MF?JNCR/F\"K9`")X(]JY1#/@CE^_&F`+KU@JRYZD='8!+YT,P0$^1HR6XXX[
M;I]]]D&^`QN1[T#""R^\D%]$/P"3)^(>)$A<CB%DUB"S'0HR_@VXL8>/&M4D
M7>SGZM%(LT=J724O_9D5N,0?ZG#I0$UXSM*V)M=XW-:@+>&WK*1ZGFR+;84C
M95X/2L#XH.2%COD^?,86JA-@-9-%ZQNH$7FFBYN?+0!E,UT*4[76P[;>:`TG
M%T6K%GJFQ5_$VA[I;*(M1!7%SI]&GH3]KE52H(L\:XRNB]0S7D>[R\2AYBFG
MG,)@X!O'9]&UY[[TI2]!GAF!KF4`I=>&PDZ^B4C0C!_&,']-?T=-AC&5&:(,
M##],\G.).N.'T2)#YDL*_]]BBRT,F`(9G/XQZ"=G1<2N-X[FNPB*AO!$DZP-
M/;J=.`J:,+DZ"EHTIM>L%Q5YE+,J\BAJ643.9S[SF=`DA"D@"+0!F7E>.H%>
M0B8"9GG%O+N##CJ(I]YWWWW?^][WTF-,0_@D5('^='D(YA=X(O[P%D`2_9#U
M&$3(`OSI<."%/N<LG9G9`)V8]<`1;P$`D208'$K+9COD`\';X;J\-?"'IOBK
MJAGD@0C)2VF?=\V]^1VA`F\?E!":='A6(>.*I8(`X$9-Z`V/CUB]\\X[`T$G
MG'`"!`R.Q^A:OGPYOUR"5\\O%$LQ3<61%C?EN.AY)#/&=)@7D0WN2A]I;HGM
MB%W6-*I"/5(2NM(^/5\#16M,5@^.0)L0"=$C`E<B(T2>V+"J*C@$28:SK"SV
M%UO8L"U/DY8C?*T4>7)T4+R7318D2DR5Q(,A/&DD9JR9DI]':'*G#CR+V\+E
MZ[34ZW]:VDJ^KU[4E0H?_8HE!E7"ZDDNG,5<8&0BE>L6PK#G$\:\D/:8KLK%
M+AGDU)2!JV"DCBG'F0*,6,:S(4+&/#(\5$HSK0`?Q[/C@0%_V&&'<:O,<>W=
MS-_$4L7W+Y:L:M7*WU[4>33)/1M6+]]7E;;<$'GB.JC'C@XY09X:&8KH!.=Y
MQC.>P08OA0Y$M*%9B(KJ35.,,J%X:C!9L=0T7SQXO./8HT$GOBA:#)GCX+_)
M`Q$6D)Y`'E`=GLD<YY?)3C^K=M;GT(QAO`O`@4E*!3"$E\A.Z@!?;-"L$:G<
M$F@#`C"%S9A*`0U4W0`R@A(74B[CJ$L',NO]LCC'N54NQ'>*IP/W$-BWW')+
MYL7FFV_^]K>__9!##GG7N][%6X8(@:*\?1<_Y39H2D]%+5;R88N+ORN_FY3,
ML^@K>D`8Y-X85$$>SE)><W3]7Y>^C'N&UR'Q)40T(!/DZ67L<<7VBA*A!X.6
M.B-*H:F6,2,ZF1B;;#-R7(B3R.;E!LVE.=+38,Q3T<K3+1]UF%(XDI>K6O$>
MYL2W)T)62I)WJ496>I+DU-21XQKFM48S(<];69JL5<=*IFUF+JV=>NJI?.ST
MNK<P:/5J`VI4-9@?AH\OV\`+@U.7#X:EX,/W6B,7Y_K55@K32U9VS5^C([5!
M,`VWVFHKLZ:#C<SWF@E96U540)781&E3D:>FUA%_PFIBS'K9:(E*1_82-Q[W
MR&IBR5*E$_#A$&P'=-IIIYUX<)[Z^../!V$4$_1.D?_K<*M0D)G"I*L!1PJD
MGL@>.DTD5]O&VX&Z."4I(`90#V*`(6PPY2$_RFM4-IB=;2U6O!IXR]%''\WM
M,6&ISV2D-=<S=94N&C2BBMFM`S.7YBSF.(?`0/ZZ=@\M*&%IWN)M<@FNJ&(9
M4H=$:3YVP&?[[;??>^^]=]AAAX,//AB\!7#\]#`23#ZF/X\>@Q9UU](;L9KK
M<C\Z/_/+D&.,\5$#6V0U.A_*Q+3%:V3GWGAD[H=Y5P-"J\VZ+GQCA&ETR!%A
M)ELRBD')PSS9TK=&\3M7ECR.2!6B4N%"4(KA3+5PXK.BX1$Z3#1M:*T@IBDJ
MXI(2F7N6=KD<1<AA61)K:G05F^F6M##YOI*$)T#T)ZSJ:[:%9D0>53H]J[I%
M7YUQV#$@@M;./?=<1@Z#EJ^GB1?,.NZ**OJD07@88&"1OXQJ<]PQ0AB-KK?"
M,`:4V-8[EX'-(481'RQ&"T-%DQECR<'&N+KLLLLVWGAC9_JJ75+QK&`E[>D!
MCBPH,>:!J1[RJ#52PHHR)_J<<2_!ZI\<V#$4(@;TZ)-5[%!YE556@?8PBI@(
M^LC]7[=`%8,_8**3B13(3S,3UO`E:8/.;UJ0F=2&;M%+X`"0`DK0F;0/5BA,
M4<?5U:D#JH`PO+NO=(7]L$U7(^4M,'/Y[O.F@)V--MH(8J;4S-MT_2_J?Z\K
M7!'D`1EX4TK-TE=:T+$'5&&;G>JT#97BACDDRIGHC`\3,QUI:Z^]]CK\\,/!
M9(2O;;?=%N3A_F4[/'M\-DS'H>Y(#^<@,SM51T.K.$6VY@KR;"CT*93IK\B'
MS`Z7"*EJYJ(\>TSJRUH)\BQM0>C1STP7%^+0ANENP>*XS8@\.L:L6TIR=B5Q
M:(S=XH"VL]FV@)?6)4WM84<RDRBTHT&:*L4]HE\D*4,;("0R*-M/:B_==3PQ
M^N2IE@2C'K6="%E)YB8=JJ:K6+68N3T'O*JDC9Q5,Y^;*N>XXX[3T_Z\\\[3
M45;O?<#'/)R&*&H+-NL=0,0P9G!JX&"<,)(UK?*K79A9PWCF(R5M_H^N@#9,
M+@<;@PK.C(3"D\(?S/>B*EC]CYIAXZHB3*ED[@5;!:;RUW:JT0JH&;=A):E7
M=12L<5A5MRSS$7\`GT2R'W744<P%A[W?=.:%F&.>A^KP%@]>*Z@[Y1!(3B=?
M<<453&&Z""IR^>67GW;::1=>>"'<@SUZ&/(6J/#YKK@^(+,2N(!4`'H`!;^\
M$7ZY#>#BPQ_^,&,)B4/]DH(S;X'Y"Y)PEG&IT#;>%"^.2_"K$I@/!SO5\-`@
M"*">&=!0E\)+_U17.(MV>)6[[+++_OOO#^"8IY1MYA2?-AK1?8A?;A+`T1ZA
M2P_]('J(P&H(Z5(7PI!@\U<BQ)"C-Z+<Y@X-">&N$MB>"`N>Z\`##P0WF-1O
M?O.;G95\[&::2W"L5%'F1-Z)^G?0A3S$ZJV3WDR7N#44)<QGV`(BHI\)AYEI
MR=A3)U$/B;<23Q(36L^MTE.PL>X74CPQA,?Z<ANQ94E;R]ZCBEIA-99JO;+T
M)*S$H2>0?#PU:`]V:MISQ9P]]MB#80R2`#4,'O#'V!^&D_[\4B!=;5ULCL(V
MWU-&+R-!"PL$7D,,^Y&DM-KP1>93Y=<-G&$DZ`LMBV;4<?KYYY_/U&`N:WYZ
M95ON0:G*5`RA-(E4K7J;)XN&,-E@W5DCLX(\/4?!E.>5HAG]S[HB\X'P/.4I
M3^$U77SQQ4P*%37ZI:C)T>V-(L=S.CBMS/"9))^@!/VOZR#0S8P&M#_XP0^^
M^]WO7KY\.;0'#@.J@PG@N0N/TLEZ\=&?S#ZZD:E';[M$NYGZ^#1P%E^6_;O"
M&X3SF!R#<Z&I7`OLXA38BVNX\PL^@#R\4.I`&WA]:IB9YC2K?D:.QT[0\H(+
M+N`-.C#>\Y[W@,,[[KCC`0<<P'4!(F0N[I;;`TNA3*[Y#E"`8[KWJ!*/YRJ7
M,#$(1S7KZXNHG51U$_=F!K-'6^&NN!E)IICCPCUL,$0/.^RPQ=VZ.2*#B#$L
MF7"B`AH^2:E6*FG)H$N//-4RX<RT7#UQ(QR.KE+A7^G0<#0$-?`RU4+%E[2U
MB>L]1%T\T?(Y!ZQJ/&GP4Q`SA*3&?_7R@"E/J3K.LD1A.]6,7NU9O9"KFNNF
M)U[54*;()DQ)*G#_^J0QJD4>HX1,Y*O3/N.*26%**Y/@,<Q,+Z/:A\'#8&`P
MNZJ"08MF`V8\P[2U<*EPUN9N6@8&'B,'<-MTTTT-6)#Y`#C&0>B/E^C.F*YZ
MZN)Q_\`L1E-W]C0\-:E.#W8,,U\I\B!GJ62FG^$D/!%S7YUG(JEC<S&K0VS'
M*7[<%2Y@`G0:'0MB,U.8Z0`++9]RRBG("V>>>29'`027&=6\96H+2(N75LFF
M:.P;D6,@*`%B?$J0@'A?3&&#5;64\7[9YJUQ4>:X\5QJ@)G7_)H$U>^+2^$H
M`>GUQS9R%@BI&])%%UUT]MEG?^`#'SCUU%/9/N><<Y"Y/O2A#RF&N\0J37'#
M+L=CW"A-28$$EAP2>92P8E.+8?T773&F0[]63>UTIOVOL<P7P9@T1&*]]=93
MHJEX$IN723.JD3WJFIF6/SG)DZ=+5IRH=\*=ABTBK'HX<V*U=P=,4GJVI[1<
MZT^U^-!HIWOQH2IJW*_I2O$P<+2X+#D49;*ZG>2J3>GA3WQX5A\M/7WRZTJ"
M[M>UC%BO+L5U,*$]?)Y4*9O#@3'_T8]^%)QA9"*(07O\HKFHKLL?*([INL\7
MDY?.`&"H,,Q<P)=S]?.G#J/:I':.'$T5?G:IKSX!C.*UNE(5=R56J(P*I5'_
MXU-4,B.\).3<C0HUXLQ+2QEW5.ZY[M1H+$6MX`_5GO[TIS_K6<^B2WE2Y@O<
M@$=(:&0\;T48YH+*8>4OO79E06Q``^@HP)P.1R`"=N@NNMUE;@"?0PXYA.D,
M4)ARF6^$.<24D16%F*'((+P+Z2L8PAS7'9&=?%EHA&\!](8O"\S'N"UPR75(
M'^B*V[3#2^&=<HG\LI^K)$6S>A5:H&7NC=_33S_]T$,/92"==-))9YQQ!F@)
M_@`^8"/0`4@"@+H3<&D3:"0HPR\7?X50A@==RJC@BN*)6>BE6W:IX:)T)L"E
MY90-FG*_^GR]@PP0@STRZ5P=GMDM6ZCPH@ZGK@-8?6\"4_%%'+28\=C"EK9L
M.36B,X)82$[/8EY5-U6>"D6)ZJDRGVJ"'[2%<DS\J$+&9D657"6N.]5B7A?,
MRD(V/2_ENE+,>+H_D*=&4U8)JXI:-4[*8$E^=]AA!V!'=WV`A3&OM.5"4>PW
M/P-<"/P1=ES=TM55^)SY->0[JXX4+L28!U@TF;'-?BIHC]`AEF&&1*!!GV'/
M\*9-7M"SG_ULQ2[SCO;`Q%3M%`XE?Z"<IR=P59P19.*TD[RF/?5.M9ZK6Z[(
M(^RH:G[F,Y_)'GZ/..(([MR%^?+!->=#+,5\TY6P5%R`NLX[)A%]!9B?UA6`
MQ<X$*\!AL[LS>=___O<#%[J4\Q7@"VXZ"\Y5[2R2\TNSL`N0API*3^QAPX7:
M>9N\._D2E9G.:J6``MZ.GI_WWW\_2.C:[KP7`,>D8>"A"CV]E8RD8`_C!(0!
M?/;;;S]DJW=WY;WO?>^))YX(2/(X!HAQ/_I:F%Y,/;-"%O=OPE6`A?&@<8UJ
M4N*?=(6[XKG`2>Z38<-]VMNNFJK\SI,:!68@F"IK0^-Y(X#M=`MJF&G91*-J
M%@J&HYF^AF4Y"7UXG+F#;L'EY`J+)"53B@&KZJZSOZ>WJ:KCF+JF2TQ6+Q2B
MGA[RHZ@HSJA23DJQ)!Z<*MG`%I4R55)D*$\I;8TO]!G%<DUVD?P2XT'<-?H@
MR%-I#S..B<E=@2H,#P8M$T'O'3[$+ECIFICL,<Z1FGKRPZCY*"MS&4VL+H*A
MRP@!=ACA?.94.QL\R*@SU(O/EM]-1A&#S='%[T$''60,5/4KCL2D`!5=4$6>
M:CT/I=&2E0P8L5Y5V*ELY\]'BR!C4=1Z=E<`'+:IP`93C#$/@6$V)6EG?.&T
MO##UU.C2"<Q$U;EL0T+HQO=UY>233S[KK+/T<!;GD6*8U."/Q!+\!Q"4L(`%
MNI1&=&9F5M)[K@?*7SUP7$64PBG:JGA]4!'>".=R&Q(/_D)QH5MTO@9]VA&L
M>(_,8BW:[#1CC]1"=L';!'G@.?ONN^_VVV_/+SB\^^Z[\\LX^597:)_[X?X9
M132H#MQT8=H]N4]`#PCBEYL4>=BIPR%@I<,J!>RR-78RP'0F-!4AH\BLK;1I
M?C!U:!JYV,,5=]III[FV/)^`$U83X2@&INJ9DXBMZ9:5:ZZM+1@H&(P&>_8T
M2+,M_+,GH%4'OYX?3CA/9401LG)N=$'13D>JRD9\FP,XT20KG2E&Q8!535I9
M'RWZY#"?I.S+T@P]PE-CEV*&3L)A9I\:DKWWWOM+73&I^"<_^4F3P+"'3ZV'
M&)]\-`&<#W6%#6@V8P^\TAF>46'"!P,&&6\<8HIE%$'=&6#*'5JX(,;ZR2OL
M<]'MMMN.6W4I!TWAT0PK,7G#^B2[$7V.AR))5?]`5X6HQJP@3PW+BF)'Y*E%
MY%EEE54XRN]3GO(4V@%X%9V8C#K%J566[1N^S4QW.6.ZBPU=A0%V^`S3]EWO
M>M?11Q^MTZ^A!^`#?Y%90'@ZGVYDQK&AN1#0X`MNF`,MZU[N#*6?F>QF%=#C
MCMN3*IQ]]ME''744W:OQD<J`"9#"AP:@`'R4I^[K"O?,6^/F>1RM2]3DQ9D<
M59L4#TM-^-@VVVSC)QCP879ON^VVAQ]^.$_J9XA[T^[/EPA@T0V5$X$XL)K[
M%(X`(O7)^@V*G#Z48\]0?0KX8SBAZ\7K\ZP@_].NJ+IGO[E]DCT5X(W'3DSG
MT:((.V]YRUNJBW)=B484FFF^?#**Y!(,6-G4H+D.)@F8%ZIYCZOJIBIV*A'J
M85%O?U4I"T$:W32.ZP54N5#$*XF0`EH\>:QC>L#8LWK+3JT^NJ9>!*X@3R\=
MWVO&5N^U,.D,'F=:<3\F">?E@C"ZQ?Y]*R;UA?"SDS<(YB`(N+H3'V5F`6.5
M\<F($KN87PP/$WBRP2A24<DL8%`QC,WN:Z(\\_PP"+50P*,8(3K85.21M&3I
M*\G/R]NJ-%F2)NRHLJ:JS^G9LVI\1$6>7HFH!?X\_>E/-S/&EEMNJ87%!,5J
MF*-2!HV9('HC`-3GGGLN?06K038Q@AL08.(#/C"]@P\^&`AZYSO?R38;^^RS
M#_(7'0[],$LA&**'N6%TM&PHEF[&QKFX<C%=#1?B17`YL(L-V!0CA)$)FZ(:
M^,.+YA3U<C0(&G"N6<*<O[P+#5CJY7AE4"R8B?8[W08XG?OD$TF',[J82IMN
MNBFPP]WRWB%IW#_PR-T:P:'IC1LP(P=7X:7K:,I5^`L$,1BX',-)CR.`2T=Z
M9$R>'?K'X["34:2NV_&3P-(DD=:]*DIF"H-PJZVV<@GCJ9)+IZJ:>WJ5.K7#
M:H9E@9NHCFO*BT%+X%RC)&PPFAF9E4#A&LW#YCBM9#1H"YO*502*Q6U5XJHO
MRJW6NXUBQ\B(F2Y00D>=7IIES57JB-AC:J]0G9K15$1::5AH36OS^I8"_55M
M,9<$0^F))Q,`=A@VS"/.8A2YM"ZOF,E2?7L`',:2*>],O,G<`8(8P/H_,\R,
M6'1]A)C7F3A,$%-1^>$&G1CG.N=G0_4"VPQ^P(=+\%PNEB<K4Y.C>L>$76R`
M`^IPJ,:#@#GL-Q`C2,51-<P1IDQJX8)9)M6!P(AIBEUR&X[2/F>9]0*TT=3U
MC&<\XUG/>A8[Z4.>73LOOVI?-9TSX)G^S#NF_#'''+-\^?(/=`4P`57VW'-/
MH)M^H$N7=^700P\%>0X\\,!WO_O=_!YRR"'[[[\_HA93#'3BI6AS1/[2F4=Q
M@_G+#&5B\JM$S,SE'OC+YX.7)5YQ"FWR=."D[TBQFA/I;75$YE]BLC-_=>0S
MG<5#77$CFF'Q1V<`)@N]@=3INX#V,%IHGT\5ES:AD!&L]`8#0`%<DB;MT4>(
M.]>8KC^23DK<(52',:.>G+^TS.GF2Z2:,?6>:+0:M\=?EU(UI8]I-TR=`;MC
MFOO1-_JI:FZC71F6/!A2B&I>CUXZ-J^>OBB`,"@KDX[S$W71*H5J\&G5/XM=
M28(1J:H*>E%*UWCY2&3BB2RH)G4?C]A:IRV/GJ6*DWXG?CMU3_3,1E`*/D9_
MBS_NU$A4PR3E!E67PDTR+_08^?C'/RZ?4;$#R(`VG^V*]E]'M<FL3.`I.ADN
M1"-@E_I2!IM"%F("1\6BVV^_G6\NPPF@,Q$08XP*?!`YA1&%],?<!VT<TM'8
MQ%RN)IEGY*])<LRXSH/PJRV>1^9$TP/RMZ(-)9D#:0V$`5N8078%?\$?X$4#
MNAG`F&+NY*RG/>UI_+[O?>_CGIFP3$D_K%J*F1I@A;FY@!%H`-O[[;??.][Q
M#GX1H^@'H..PPP[;8HLM]NP*SPO;07A!SD(L.O;88SD%X#(:"R3G6N"5>F;F
MH'$3KA8*;C,EZ7"0D)Z'C@)6T`PJTYF\Q]UWWWWSS3?GTKQ*.A\:1@O<-O=I
MB`3M,-/E'FIRG,OF^V(;<##D4U6V-B9^D2;H$/J-7[YKB(U^?5P1C`U>JPOQ
M.!@T<E&XHFXY_!I9(^EECQIO0^G-AZ_M@T>C0<[E%.Z<VS9_E-X::JI-F\!M
M*QC*/Y7(`!_Z5G]"=35UD@Y:]JTH9RJ\Q),PYJW9EN!]6$)'9TOD1:2D04N"
M,=EE0XTM+*X^LVU%,.]GMN7A<1FRRHX,NP`B*N;41;(B3"5IAM@R55;42C8>
M251$,%.;NK1$D">>A%'R5$^>N`[RZE?MELE[?;?B599@\.]?MF6DJBNOZA0.
MZ9?+(YN]REQ5KN)-,2&P:3SY-<["-.-,!)>9T\CN=\K<PI)MF(PI7PPR]<O%
M68PB6N`4'3P86HQ,F+_KTW&([M5MIN8CC<%+A%&K`X:`*L:DR_Q-0^JC::D7
MCFKT1*0P:MJL:4NUF+,3X'):<2>[[;8;C;--'3&*[F(_&*+VU8A(=;#,&L`9
M`K/SSCN#(:`W!&:''78`>8X__GB.*F5`=7;==5?P!\)SP`$'*'"Q$XA@)WN8
MR/0\\XX>,XT/W2Z?-/!<)V0SF>BT2??2[50[^>23+[SP0G``KK7UUEN_[6UO
MXQ&X)5\!\Q?,H=MY-=R)MC;S\+"1W!2@J%8PJ1U3VW"JV,1//_UT2*;9S\`W
MQ@8OSL\62"AHF-^#U\K[U<AE[#SO/0Z!^D/:C>`)3^=(X$2&H@AF(C5M7FJM
MZ7ESKC*Z7##(=T&;L;!K`M/"=?;99U=/OW$GP/&H4I&D9KV8+3%9T=C44V9;
M\AS+7)?\4*!+0$340>*#RJ6IEH@LMJHDP1`H/`5P",D)GD0<2SKEX(ST)H&B
M<>/I(4\L7(G5JF'I\5ZN2_@E3?%?=2M<1\\3-YZX\D:QK+;6B2R+D`DPU[@!
M!JW`HF_/%5V![0,^?,JA\:XH%\]Y;6&F-#<_C!&F;,1%!&Z@9E6/,I%-5:'Q
MR,P1QI)?9.8.1(A)RBTQTUTIF%O5_"UH))%%=KKH>9(ABU?\%;[$HL2!^KP:
MJF0X%-4X7HXZ?LKIX7/..0>J!B!P"6<9G(<-Q@_/POUK3S&Y*%,#UG'**:<`
M'5MMM15PP3,R)9GUD!9F)8AA_!$=HM+FPQ_^,.*5Y.?M7='K&/)SW'''083`
M'_K3[,V2&0&'7F+"TCYMFK'-]%]<1;<WH(\VM]EF&^.GD-?H>?J9B<R)4`(!
MQ^EIM*;&;I-W&66F($/CLA0M4WIP\;X8A$#Q=MMMYQOGV1DD>CR:+-J@&X8*
M%V5X:+8P#0L-TK@>@R"A/H3</W6,%N%AJ2RW42X#%<$9U=<NA\$IKD1@/T"9
M$N*A]V:2IO+XS+6PEVAUHF&N(:45>08ML&NV^3!+9B*=]?`J=BA5TTGU+-S%
M15G#DSD&H[OVBIJEI#?\%2+$.A&IYL1(E,3L:`A&$G\%?*IX)4`)+"*;D10N
MY_<GD&?<8WG5MK"F.8W-LJ73SLO;2IJO;#G/F432`+?E`TQ/IAXC]J233N+M
MPVWX3#"67!E3#U6F"0.,\<"HT+9EE&+@R"4O&3;LT<_0)`Q\I_B6,3R8Q7[%
MS,GIBBJVR6>+7V8H\Q'I?L<==P08N:4D5$^&'#9X*'UOE,+4U<B"XK&C_P]_
M@0M!"?QY5E<X47<F-CBJMOD975'Y`W="4.)QG->,=C[KW(.(1`_3)R;3TW3+
M=YP/.I.1'MMKK[V8[[OLL@N@80HUNHL-4P$`&@8?:?EE;@(1U(>9`#N<I>8'
M^0MY[>RN[+///J`'LAN-Z\%"!]*3]"?3UDE'AW,)CG(G^^Z[[Z#+^[WQQAO3
MC=RY[`M8T,-0+QH]]UQ15*ICVEM-C3R=SDA:N*!J;#"I3:0,<`$O=#@7HF7&
M`"^.KQ7?%%XBCTQO,"1,W&JF,A=W-NX8;#$]D8[3("&$A_89)%333D%-NHN;
MU.5;H4]C/<7,TCR%3@OZ#IG!GH>2]KCXCM*6R!-GFZJJK3J<ZKT<02S(XPS-
M-`_"Q&-PV%:OB#B6"'?%*/UP!BT$+&G;9TJ\F-M<R):5FY+OHJ=&3M:+V98<
MM28[E>=D(TO59`FMGH;9Y3M7*FU5V*F6]*SU:=R!N4:97(FF5+$3H8.IRJ33
MI4>1Q,\]1_F^.SR,RM%[&?X##UF^?#GREZ/B8UU1\\P@]#OU\:XP_(RA!D/X
M9NG$PHPP$9!)#K5W<-3/'!.'H<AP=3$I:1+]H\E)Y;`WZ;94C;OEZ7@HZ_`K
M8]$F9?BGV/+J;L%EG<&0][?88@MF.K-RIYUV@AA`,-[YSG>NM]YZP#7(`[9L
MOOGFC&<]C0V11E@`D^G\M[SE+6>==5:2WD,8#"!R$O$@(`8M@S_0144;<XD8
MA"[5H;(Y0VCVG*YP#VI[@)ISNT*?2SXA%0P,AC$B&W`-1(#J(`_XPR68^&IN
MF<A&X\*+WOO>]W(#6W8%@0MDHW$=L>A8)3[N!.`RUX2AE_$VUUW9Z'MFMW%;
M:IC-PLV#\Z(WVF@C)'1>M_I`!H-N8.:Q!R?Y5`%W@$]68982&_K'L[C",B,$
M<.,CQ?#P<Z92D5]S.X,G5*8#33%D3FE]F]56F7_>J'::DO;H22[X(!OJ%B@F
MU_DK2O0B)H(>@^(0Z$Q78AJ64-,8R@?%O5D,B8@7+Z`0FZGBJUR+=:HS<Y4-
MXQ]H94G.N-].4@O69._1+6M,KYEYLE3HDVF8GRPRM&:S<0D&,_[%O!6V$X7M
M"]IRO2Z78-YR?NEDY@[CF5%]<5>TH3,CF'K,$9>(8OR858.QY`*[:F_<KT;"
M"6+L#T.%4>3Z=,Q'CNKMH^V5L\R89\H.9@=SDT\_3Y%$QZJ(A1=O6Y.6&A@>
MGT^PI$CFLTI7Z%@^^F><<8;&.RX!$^/[Z*5-QZ<-CKOEJ2$8]#!S"CQ446E(
MD9$..LM1F<^H]BS&/^C$V&:&\@A,[=-..XT[!TF81\P13M>IV.`(K@)*JQ=R
M@JL4I4]X=JX"1+L&C88M9K1KD?/V@1%E)7YY!;P1\81)YUHA=!JOX-133X7D
MP)VX6P@5,`C2`D0`)IP*$&"RZ\S`I8UBT*]&SI,@J6B;S=9E4AV5/$QGG@6H
MX?;`1I[:5\\C\!EB5+`'FF$PC@*C$KK>DE13/6ZR0<&'/?_4%5Z3(?F,(F@/
M7RC3=P`O!GV(/(J!O$WVJ$XT&(1.,*1"Y'']+]Y:/(<SQROX]&`GA\8=`D.3
M9D9C-F/2BI5\4#+V*(A5D[>25RQ?(3\I@90P--J)!XY8--V"*4)UJH;9FJ*3
M5G6YEH`3[V7MZ2Z2_F16]5[6P?@M)X]?%I%AVW!O]:XN1AR3EJ9GZ8&2%Q-<
MJS$3F2O"`1CY!@.JH^!C!`3!@N!"[-?;1\6.:T(IRV<U3..VU"2;B9=QPB>)
MH>)Z+CH\\PECHM$^YS*$#%`U@Q\SG9[G;K5K"XP&3ZF]8<^SG_UL8(=O^IEG
MGLD<W&.//>A#CO*[U59;(:$HOKF`IDI4)I3>+X:OZFAD$B$^EU`O9A,SESLT
M000CV:1G[WK7NWC7O!1@T[!TFC+C'PV:+(*GYEO/I-,5A]G$@W.)%2M6\*2*
ML9X"(C%!='@VL95QUHHS=`YH"8@Q6T\^^60>D+</6V,&P6=X.]P,%)2_XAAH
M`':!HD<???1NN^VV]]Y[([MQE!8`HA-//)']@,^FFVY*:SRCFA!UXTQ,5[0Q
MME?.PQ,Q9TU;"A9Y8VK1K<_=\D+Y)/'*Z#%7!'.<@#8?^M"'@!TYL&OT.'[8
MIF?H#9?+4>ME^@+>N%DQ84U:Q,RX8@H@>!W=",+HQ60L!HUH+Q-YS"'&^PKG
M,7L&?W?==5?GE()/3[0)L4D:GV%+F)/\//$GC*(F-O>>.TUP::ID-XU97%*4
MY!C2I-R;0E]DL2R2E;N-#;VZ-:JZL>;4Z'I;T>28X%W,4<F3*'77-%>2$G#,
MJ"S@>"@HE/5?DC4]L%/7F5+#;$Q3.(]>+EJB:UZ(1&13>"AMZZ`$WTJ&EBKE
M8!%[&$),,:5[E<.&6C#`_!2ZY"Z3$20!540>)AV#A+%GY)%QTPP>3M'@RP:#
MEFWF.U]M9!_CI,0<H$9'8O549JO@*H";EA&(V0DGG,!%S5K/!U3//>:RWT3M
MN6QG^6\FE)$"N@$8\:WDPJ1@J,/TD'2@'%QWDTTV,=S`G#S`FO[\D!E$)`!0
MO*7?8/A,-\#''+/<DG8K1"INAHD?RS(-NN:X%B5NF\>GTP!Y0.;``P_D1,"$
MEP)IH4]`%7I><P]7Y^9A(W0O$Q:\0B[6+PC8`0P_\($/@#QP,*"8FV<G+?OL
M7"AY(^D$38TN]"`9J\@C8BN1&9O`%1D2\AF]OWAJ?O79IK"3;Y!_>1;N37'/
M"'1^N9SKL)LXVJ[3/<-P0N@3XT$--OL!'QV;;^Z*F6.5OQ@`-,70TL,9M#%7
M!H43>?"IEN.BIS"9;EDF9D;S743Q*X4(GE35=`"D-AAWP8F2Q=U5C!/1,%-6
MVAJTQ?@TH'O%L*;0L\23QIX>B6RZ+8*<4U(YT:`)/$]8>A)_F6Q9P2I`I-^R
M@--S'4QQ9?/>\GFO;@O[CCOWOK2M&%XCE33W,+,XEVG.'3)K7$B7T:4_OW9V
M!@_,!X+!=XU?/O'FQ#"!*B.'<=C+,\9._7]TYY`#L,VD9O#HVFHL/"C!\%,M
M26M\KP%2[@TP%"K!']4X>O+`TR!^2!;<JLG/7<_%.&M:-AT$>YQ6YMIR507J
MFV*"F@9:@CG,93:8AK`18Q*Y6\8_,PBV``@P"V0I*FJH#.+Q;05\N!SWKY'.
M\'\J@X1T%,]"/P")(`;57#;118*X)>Z9>X!?,>7I"F581;_MMML.PL/&D4<>
M"9@8X46?@['ZL;A@%A/-94&`+`,QN)!+/_#+N;2#S+7]]MM#YVB!-\*34A_\
M5Y$"O!B\J4B5-4:E.H;ZFM'"1*9P"7J2U\0EN"N&A`38L6%\#9C#1X0-_3%X
MOQ!C+FK<:!:+-#DSC\-K,G."](E?&92QS-HRI%7:V8VJ,!FX*9KI3!['];P,
MW>5"D$.G<W*<QB04\:>G<PXL#%L8:6*XABUS14`LX9DA0L&KF>;#[&HXL8Z%
M"T4ZF^Y"PP2K2'PQ8P5D%I<EC"OY29VIENHGF0D5K!*?E973QS.]`SYQ+%2Q
M$^2I:TD$=B@U2B*Q$K(=-3SQ9DD<D]K7A&,SD4$>)K)_]]UW7UXBLY7OBSEY
M&.V,,2:1&E&3^3`>]#E4B&#84!^0$8(2?V&29Z')J"X*;$%;#RC!D&/<TB:#
MB@J,/2[D>IJ\99`0,5"<,9!!DF;D.-W(;`)>U&-#)_1.@5$8=J3OM%[33%@&
MOQ]*ABYS1_=IBLZ-\BZ36@!-28FL7QQWJUA$^P9*.-2ISQ[SM#/L^?)R)]JX
MF?+O?O>[06.ZBX>B'ZCI&D/,.&X5S*%]>LGD`$"]'WVF+50'L.+ICCON.!T;
MH)3T"3N9>N;EX[UP(KC!MH0M0HU.GKP="`^<#?QYW_O>QS8O=Z>==@(3N#1S
MEGO0,9CG9;9"&$1I$[CIV_-8*YK=S:E(!_)$P`Y-,0!XN5S+_):N[`-<<S,J
MDPW=TEZF-P7W3P_HP:XS(=L\EYGH=!)SZ:Z8QG3S,`B.-T@?NAZ'7O'@IPS0
M>`J=>7B#ZZ^_/H,D@9^5X80DU!C2BCRB38SOH2*9Z3T7XG">:)BK1W00+$IF
M>4ZT1E$9Q0DG3CL>XD%,/S@HBU9(I>+2$YZC8+5HM,3(56N*-H",Z#2./#5*
MO>;^2B+BE%>TU5Y@.X9)!GQJCHC$2^K<J]<*5U%[P+1E/C*0SNB*ZWTS_EV-
MQ1$B"V(\Z-XCSJAG5E.DG?0?NF+DHWI(QIB6+'8RH[F0CHL`%Q7X9`-TC%N^
M^('$IS[UJ=JJ*.P!?'@I""^,/<T?IJ_1N\R8)M62'#+PF0O!4LPESGZ7G>(L
MI@.()TFC,A.$J<<PYI!AYG[QC=(R,XS^^>S7T87!;VB`^EBFDJY*1Q]]-+1'
MRL03<47F.'<"TE*-J:'51L]`KL6=<X>Z90(XAQ]^.$0%KD7_FYF->4<O<6^<
M2PNT#%YQ/R9GYC%Y"W!%"!+?>NV29Y]]-M5X?7I'`$&[[;8;0AGX9@0]MZ2W
ME?H<&G?-=)I5S9Z@+>WL+O<`4'.'M,.+YE6JW^,9S2\$!'%%MO57--+!96XD
M//PJ'T40YGT9#"+MB6\JXT?3/.#C%XW])D!S'4,_*PQ7DV9(R1`)^33P3OV.
M2SG4G(3/Q/%XN+(R*&6F1#?$V%3MZ1:UN&E?G9*X(;"(8(.VBNAD2_95P7"J
MR]TZGB@U%O;I%N<>K?*XAV&RF^H)$*_FNLR$5$?E#WMT%'2/4%.7,.ZE7$[B
M'<6KFJ-83YX@CXJ1&D094W7R#',(Y`'6F,Y\J1GV_X^T.X^]]B[O_/ZDS(A1
M_X[:CBI55=7.,&"\;PP8/U[POCQ>\&Z\8+,$PIXF@8S4F:@TBJ8SK5(IFK;3
M5)&:J=(9D0XA$D,AE&5`#,$L#A!(!N/8&`_8!(RQ#2;TI?/6N?1][M_S>%!S
M_W%TG_O<YUZ^W^OZ?*_]^O5?_W5$A5Q#GM_8;=;?M&^41O[)H!IY1'XH_!_O
MMWP<*5"0"H/43,H1*V;A9X`H>T@V(C2&R]S:3S_W<S]7U[QQ;/W,;K/_\I>_
MO!"7^C)7;0.>Y%ZI:G3IW@`!K4YONX0B.]`&JUKZ\V%5UK7^X/E34M!<>6K\
M)L#CP2)&'*DR,.+/!%'"2(E%GL=7SV.L#(*7<B^@A'V,F)TZ1(,OCU2E8@AF
M?+R7P4&BIKAZGF]ZTYM(%P:SFDBI>Z`O>2Q#68K/V]_^]AMNN`'9(#_B32J>
MJ[WSG>\L68SN=LUNLU^V'2FK$KB>>9(NRQBMQ-:41RY"KWJ`WL6B\P__X3_,
MSNSN(-'4(P]W-/6^`I#*'H8)10258&O0"BN:6'<0%.IF,S1Q93$3>T"9.76U
M\I>12FTR[%0)H4R6C%2>[2__\B\]MG-NNNFF^''X=^+QUFWDEK..SL<\<RFM
M\Y)]2/-8>PZ:>JJI?L:2?WKF+ANB+C9!T!G[%/6_NU1X/GU?F;FXY8G\.6A5
M[CKC-!_LVNA][<.->=]21_..E4.:26>\6N/&*B%]FMI,].`(/&M1]U&XUN3T
M))_09JU.,U%Y23MC6'[>\Y[GX/.?__P"9ISLCK?>>JM5$A8!GR`%MJ!SK`V%
M$!Y<0FEA"/YRL--P@86>A(_F_=U"C#A3Y)T)Q_SJ3"(Z4,I>BM[\L8JL3G#:
M+_W2+_W-7<M@BI5'JDB%-Z(O($6`@Y*S5Q`GRFG-]!2MHN2$"L2),NMH4)ET
M`)+%NTYV1)?DG,ZW$Z95';38W8S`[5<TKY@?=`[B/+G7\?!%\$(A\%7$LLVK
M&:6"7O)$^[44@$IUN6\:J'$&#K?<<DMUJ(R>KU`"@[N+)Z\<A"?Q(@:J;$K_
M>M6K7N7\4W8]2HJR\)6\!(ONOOON.^^\TVKRZE>_&DTBO`LNN(`\!@,]B8F@
MTYE*O%P-$ULQ/)5U;7RJRH6[W1=0%+=36952B>&;B_BL.*$']K+3K::J[UZV
M/CY>Q*5<ME#`BH.9II1Q%Z\+\W0B2!8"X]5#J)!:096U>,OAF)TJ9#8=AB)I
MI_3),;;,%MI,M8KQC\?.+]EG6F7>F8;(JQ-\U;FFOOH@23)/@8A)1&-G'A`[
M?5]F,`$LQW>H,N;B,7=WG2EY,;]V]S$$C9%GTS^K(R&/_>2<9*'DG*)Z0IY*
MGDX8SZIG3:7EM:OX*%^K;6=$G0WR9.&QY=MR<I&Z4"@V)UVXF@$A]I-`L$`V
M!_@#9W#3K_W:KU4)$[`@8\??_>YW^XH3D9_]7_W57P4[@`A]9AM$/_9)-;_X
MB[\(N%S0TE:2<J8DL!:4N;@Q+$F\O"JO3Y5PG;(%,1W-Q3H(P=PBVV;9BU/H
MK_"Y=(0R#:OV`%MJ'V;IS)S>#@0CYP0LU1&JS&;5.%TD#06I)WBXH'<A:>!K
MG%Z+\^QCY=MZ@'Q;V/_-;WXS'/:^F!?LD'.2!PHS\-:WW7;;99==!O"-9$J6
M%S0RSJ_77M*"9R.SF8Y,(F]\XQO-$6)`*D5.(B&TZJE<R@5!#27+Q6N"^8YW
MO..W=IO1+DV>WN0N#0BXJ%9A*%0:>"\.G3(L^V."7%8=K^S%6R]2EJM,F':6
M[I/65M1T!;Y25`NR@CP5YRG*JV)!366>@F)6\U=60R.?Q2"D"U8P"LJ9QR-'
MCAB-Q`R<-9[Q%7/&:77V@?JEN;16.2=D"$!6O]*9^P32U15UUJ[X84AURK[+
MU6K&<:.0:J2RT?Y.W36C616N1+):160="@]SEY^]CXM>X:B+3,96F-,Y(=L@
M3PII*E7^K]Q;;5,*8_6G3R?Q306>_%EI6%,XHBH3.8FF0$TR3U7X`!$&Q]WV
M0YYA^2E38RK)&Q1\B('=HC<[B=FH$<Z\ZUWORJ5;8=7(H[*H:+@FE<C,KV]]
MZUM)-6@>BUG1,#YVL_[Z6ME5GP1F[^LQ*%G>Q<I.I:IZL.7>19*:$#]B"V>R
M6V8!R*>&55&CXWBADGT%X%66P14P$="#%78\N>,Q"WI.OTA3R,[C.MECL]7X
MB=@`56`+6>7G?_[G84NF+9?*?^?*7O:ZZZYS&AG&(_F7Q;H,4,A6++'_GG_^
M^;#BWGOOS56$KTE':4`U?+&3,XN\<>655]YUUUW.-T0M7N@!_9AE5''ZK@0Q
MP*FU(HJZ^NJK+[[X8J!T_?770YL[[KC#HF#A<*]4F%YS<K@*6C9Q>;[PN^GV
M(@@@;=K4Y^*$-A&`840,GBU/=V&33;V+V`%N69#RU[MLZBW8<;[5Q/Q66,SM
M@IIB"\L>!3AE;^5)-!=H*?UW"F*;TTLNN01_8;VXS"N/X#'!O:-,0>.2"+(J
MQ_XOW?553WO:].F;K/;5_YX]>3Q09QX=[;QZJ5*7/-AZL.N,2+.Z\@?<1IL[
M?9_YM::%'C3XM%^3T,;AI%WSK&DG,7UM\G]-0OK$,Z\%>4;R6;>UM<WT$Y\D
MIF.:ET?5^AO[K;C?DIM(/G_MK_VUY^VVN-Z.3_O^?NZYYUIDP0M**^8MAR^:
MM`JGZ11W@38*K8$5=K[\Y2\7EH](,!%YH`XO)`'4B_X1,"`B"SE8MA$BMUXG
M@%U^^>7@Q1]=QY5SK>;:K@7A0[NMVN#D'`]0[T(K:9VM4@="1=B%;I'T_[S;
M>FP[%FY$7F,^7%/)A?(6(1*&HABFBU5LW(TL\30:[(S'"1C77GNM]X(V&8[\
M)2]YY?OLX*PJY'BJ:O1Y*:<YP:_^2.ZJBNR$$V.HV@RELZ0PPFWD5$7<IM[V
M'^WZMT(>2U6LA-C*]'<$%GE"`&B^C'^QQQZR@EV]K_UZX@"$7.U$%R!02JS9
ML;[8@5K&*L..S:IA>#,WV2^5C)B4T[R(QXQR)8*!4U3AN*^U4K+!83<U-97T
MR?M0X]1R\[,\UX"UU`G(L[9J=0[1;FP:HWVL=MI)0SAKG]V9N`*"T';ZU$37
MC,EWX@/'L+R)2%REJ15)SCIK6PVUQTC#FOH;8R^:0.6QWDQ\SBAT8T:>G=6W
M561.IQF'.O0EVS0RT\5FDRO1MNFKU;8BSRA<&U-S<DZ?:PG02;T<V!FHL0WR
M_/7=-LC3UM=#N\T5/)(%-^\&(>=M;WM;NABI&!I8FY**,WIDQD14Q?,D;V1,
M0#F_\BN_\LN__,L^R5&D%Y1LQ7_[V]^.>5W9UW>^\YW>RWU?][K7E8L!2:IT
MYVJU!8]</[[;JEJ,1-_SGO?D_6_1=*F4.\MT'5M*-\LQ]T__Z3_%6?0US%B4
M;.47ZJ7E48N?:7T'"UEI0('_$CS(*H`14R,MDXN02!0PV=7<"$MZ"V*&5_!J
M]=+RV`&(8?%2GO;22R]UCD=U7S?]VFZSDQFD4/#B=2O2Y8_$I,R#Z*&YKD(1
MDG!D*G7711&]$7L2S"I4:"3+L'/E^HUZ:Z/TBE>\@B`'I?T*<^BP<(:.9HV@
M5'J7_VZW><%W[S9H0_Y)6#4^WA>@E7([/0*RB25J%D`(=>L_"$;@3`L9J"DX
M,,.7>0QS\D76$:.6S0C`&E2*>BZ`QM!;G[TK*[$BSWB"UOH2'4\G>LDNMRL4
M*IQODD,#EM#C['W7X]62?/8^DOGLHVN_3WCA!`NM"EU>_FZ:DC5QRYNM6^<9
M'R`:L\_(.1OP"=]08V"22VL<6Y.6/AD3@SRK/VL-YEGEG-6\/-4P2I18]:RU
MS\(T#<^V\_RCMQ%X!GDJ#>'33^VWH?/#AP_?>..-EFE8@:=^]W=_%T/E%45X
M`*=*/F5-(I@TG0+=K89UN;6<@2\7@3^U]_H'_^`?8(W7OO:UKW_]ZQ$_%C!E
M>`%*^"]^<67LZ8]%O^3*!R#^6T>\?/H9G+$8_$'5&"3,*3#2>EU^JV=#Y_C+
MU[H`XQ%$[JFLW371R]V,"[`5O$7_]1$&?6`6")M*R).0;T9\-6O8_`UO>(/S
M<XC3PK"M-RWWS1U+UO:T7LV5:498&(O5$=AG1NQ'=EM!.T888^:^)Y]XSB+&
M@0#-%#U4CJ`"*7;0B:>BI9HC@AD\_X5?^`70X8XIPNY2+ELM)PP+T0N=E_IJ
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M@:$1P&+(K[@X0DY!R]7Q+C^B_.@$GIH:%(:'"'_\XQ]C>1R*-5RDX!`,8GE%
MY+G&WO*6MX"+/*W(#^SDZ7"[.A+BCHDU@BUU+80Y\(>00SNHN#K`*9B_2C(>
M8-J%5PH&'J)DR[%+P0&K/%AS&AZW?.=YSX$%/2IE[*6NN.(*TP1_@$_4B$D=
M-"RHL2[#'J]H3#A#/'-WSV"(*BWH4A[;`P.Z%)"Z\H&7G%\>K/X1!K,Z[80N
MHU?BDL$L'A(^H*OJO^5W,#M$,@,(TXBF&=:,B3G"OZ;,>);P2S.%'H`1YE.I
MR&955_;8M+/SSCN/.&&:C`D!]>_]O;]G2%TS:T]!7[`HY:M,.K-@9J?;=2'0
MA0:5!0]SC"U<*C8,/*)>Q&SDD8'W>F"W>3O/F?GN\[NM_/J:+3IN2,$I@,4:
M.(A<@7TF9&[MO'#JT:TVX]8QI(S_Z.Q=CYL8_&"<X4OVA70F"#D%;:UBNB9V
MK0"R4=`VR1&CE`4:ZW-VS=.6LLR)28473J#@O.P(>",(#02UOW8Q#F<.MKF9
M:CP;\,FPLQ9^7\$G4T]*UEH"?=-28:!FA9V0)]BIG^^Z`1P'0Z2LT*8)Y6"H
M,>^DJA,2',&GN`:=UZ[7/KDB?1_99'5$J%@5A0,?K&'YPR\$*ER`L`L9(B3@
M%P)/@@TAI])DJ-3=,36:GW#'ZC/8IP/BE/*&G.9&]BO552.PJN74])PZ\)WO
M?,=S.L%%"&^>,#4!_;M1N1@^,9=?G?F/_M$_0N3&O%6/;';====Y^#>^\8TD
MA,HN445A(`:O*Y"_EQ3I=>B)8*="J<0`X],Y?@5K$*^TK(F4RS8%@BA<V!8P
M5O4(@!A/.\8!1%AWRCK!#AZ&K&4<WOK6MS:84S?2U0`+Q`#U&+\RK560=MP+
M>D+7A%?>Z^:;;S8O]$%L[H@5`?)X?:).IN;BOASQ#,3%6F;76L);%$]82$"I
MG41?<&>@8A-C5;='%$[D`'$&W%`D)Q=9[8\%/R.MW_S-W_38EB=LB`5PDRF(
M93#U&J,[_#B&V3&8%&%XYJXP\C38&NEHM>JLQ0G7\+\U1?2,I9![1ND-[(P[
M;`)^#EJ'QMN^D=;.V">$)L^<L6^;-?"R8L[8B`:"CHD\:W>MB55>;3O3R&_5
MN::7:,@S1<"F[7AJU\&@Y;5[Y@I!QQ1X?F:_'3JPY8*W(47\8LVM&T+%QJM!
MD07&06A3$QS(4__<<FU\19;.M"ZCMSONN,,..K</BXX<.8)MT5@)31BACJ@3
M2X]T,74NE0S(R3]^@C-6Y'I:I=$XXC2,YBOH*]C59CDN+*1D@6J:52NO!$EL
M;MDE$F#&`-.E[$,_NHEAKZJA&;'R6K)Q,=A!>Z:)S.,)2Y"L5%$J2>93/Y&(
MO'*%0V%"0&T_@:>HZ;2M6C,0C2HM`K$3GZKF5^,JFV>[[;;;$)@'PVB$,1A^
MS377D&$J(``B#(O3H`J$@2>W[S;O`J,,D?<"?:7W@GI#2LCQG,YQ@NM0(0N6
M`#LN99Q).P;?9YE<WK&N?Z5CY)?W:1!JDEZ#0FA&,B^$'G&B;5R`ABM^@CT]
M$N4.CI7.!MG<D3P,7?,+>\?T!;P3,[I"OJI1*$Y:FOD.+Z]>H8D,W,@AJ4L=
M/'MIVM6V*:^Q1B^O'0#GIS7EX<PEM7-U2&7\F?-7X\]H25,!8ZZVVK+F^B/@
MA:*3P'72ONO-VCE]0I?7S-"I/3BY6F'1JFT%.&L"11ZN\6>-87G3O7?`9V-;
M'MA)R%E1:)#'$7^_Y99;2-0X%\N4#82G*MJ3>W0J\<(?G%*5)SL(DJ11IKE]
M?\&P.7RSIS71=!;$ALW1'IRII&I-%D"0X^0?!&G9Q0NX)L\XCO8K*:@J0_Y(
MAL$13GCWN]^-DK%5@6VT+=*.);B0N1HQ3%/"2IX6TX*S>I*T/`]LWYI+*$T)
M-?*!)VW%6Y@CX^F-,#B\,D3>M$YYN+5@%<^,G:DVO_=[O^<TT)J&:+]$)YLA
M=3NW)F8`"J#JE;UCD3"U'*KV?C&]AA1V05<B`0BZX88;;KKIIG///=>-@#-Q
MY?#APUB#8A50E]YN^7"$/D4XS&UMFFKR[B&-*D$(RWM4*$2!]17(^,DY]6+[
MGW:;B:@=I&&O?GL5BO(,5O*B$H)>&=FCM]IMHU(P8HE$S%&^\43`#D*8^D>4
MP%A1.)^%P)5>5#AN963"F2E$DR<]*6C#YL%+8DQ`5"A.G4DKG3$1R(-.4\EP
M]7!-0$XH,3K7&G8X.E1H,'$[A3O.3Z-SK?63QW2\!@:,:7K]=9`VX.W=LR>?
MLB](.+ZMM9WQ:%@3M[QFB8[R-5ZM#,O_R;)-WL3:0#S#<H:=\:1CC7#FK^^W
M#?+DV!IKSX!/'1D\/,I'2,"G=B<MY>@-5Q;T7AA&9HHJ8+QOM]&_*JZ5(D^Y
MP'38UCI([#=*WM'@D\8KQV$-A1A=-E2I=E])II7(F`B32N%A*WR*27$$)<X)
M^+<^X`423TN%.G$7`)`*UKI<P!L)#6ZX(,YUZT0"CU'--%-9O(%)QR#PT\7=
MSBP83\^/Q;Q:42[D);@!0X"GXU0;`HD'*R08+'MREX7,P`H2&D\2$>B`&-[+
M.3C:ZN\B7IP4!'P(/,42NV]9*K4Y,^!^JHVC%R<]6B:0.AHC59)>:#29=.SX
MZBXT4X/L\8@QANZ_W6VEA3J8>`-SC.&T]8$\:5A%L,,B3^B.0-*EC+QGSM=)
M8*M;J#7(4`,NB%%S(K2:0P0Q1]5(&K9$\!5_RV%GW\&8)1EIC!(V4U`02Z$[
ML=M:"W03\7+6OM%,'?JF7'.=LUZR;TN1(&30#&`%EN>G4;YJE;7QR(]1:.2K
M`:)QK$\HX#Q/)ZQQ.X5AG[;OD+Z&,8<VI^[S83MA@I?R\76=("M5*\P)F0>(
M1MLJC*?2RFO;XK'VU-=F!)Z!G7&I'VP@[G-<ZFVAS<#.(,\(-AM3SWQUD3OO
MO!,)66?Q$4:PCE-JJAM6?>;J?542JCQQG_9+NBFB@T1AI]PE_S*YIMB0(CPB
MQ+O>]2YD['A23>9EO(!NW=2E0@`_E2Z4@RRY"._4+Q@^5-.UGIZX^)=WF]-J
MC_['?_S'M=@K4:LRZ>2?@OQK/>_*/8D7K/NA1W(U4DVEV,P[I8;8X'EH-'B9
MP%:H]H@3X,M?"!B&R%MX!E(3F:T<!#=RW$L5]&)`<#0H+F^TJ"=\G5'+DP`H
MJ%@P,(3/M%6%4A!=60`LGQ)7L+=[N91Q2)*!&_?>>Z_GK*J/D7&O\C6\<IVS
M/#94^?N[S>MX9F+/?[/;8*:W<\VQ-GOWTDAK$.]Y?(4Y6>JR8KFL-S4F.>"J
MDUDD$F(N'FE*3E6$RD$X,Z[>"3N9<+@QF:Y?RXC<&'DF'B_>'.?4""HASQB'
M)V$*X-#RJA@V$#%NKZFW/#:<2;::8,(SEKJ(D[71Q5=CSFAA:SS`Z?ORI^.S
M.VU?[#2DG0">Z>Z7)C6)HHE/F[%:BZ"NR)-X60N;Z5F\!C!O;,LK\FQ21)-Y
MUH(\FQB>C=@SXLU`S83W]/7RRR_'1V"GXE<U2,KK9(V#0HBVM1@95U`%\M0^
M.]$($9;9;7OXX8>_M-N(,2:W4;K@@@L0.<I'V\C8?B!0.FI9A"Z.^!VI"R$]
MQ4&47UG.U`$<X9S$'AO^>NM;WXKE7=!CD[N@'V#QD^=_\,$'O__][S_^^..D
MH+K`UT2OU-?W[#:WSE^/6V^]]58381A](C]*#;YV3JWZ/#FM!Y?5UZ_B.7C6
M']VN+`F/9]#`($&EGL)U@H;/!)*R&S+8EIGKOE4)\+ZY#HEDT)L*"7]J/U3I
MVEHY&#%GUHG/^Q;U1/XLW=LU/2'9K,`J(VGZ#*"A\VQYY=[YSG>2Y6!@?9E!
M4T!4=HSG+X`Y_&F@H)P_UC(RY#$U]1LEC'D>:B`JK29_Y-K2>4SPJ;O3^'E]
M3C>6C<H00TWQJY..WL8P$F,Z?]K-3&["!"0G&HT+.]5L&F]-^/%!A]=H<&<?
MW9AO3;L806C=3M_G?R4RC27GC'VMPM62O`;P!#4G[;O83/F+]J<.X<B!TUIB
M!FUM7CQ)6XD]Q8:-GM61B2$<G2ODV;01G[CEZ;"Y!A"N(86!S^I2'VUK5;L\
M&-JVX!)=<C"52ER^9'7@'8E#,?5808OB0'Y.R]H\!0,!$?6!$/+F-[\Y@+WL
MLLN0-T8&%+B#D.\6V7:P*OBJF@T*;VU%WC4^2`K"$12$";>&,S@+UTP_/HH,
M*"!NU6'9+3QV#:&R153LA3Z8D.,6U6",BW%TG:TJ`HD8+KGD$B*$>P$';%B1
M$`\/G4(>F.-U[-QUUUU>#3,:!$-1[$JM7CQ`>?&8%R`XS2L8PXKG&SJ*JI/3
M8;.;5?4Z7Z%)@44%(5<GS1SYK+K^M#NO&%JEZ0VF42VM'H"XEX>$-D;,&'K:
M"R^\T&N2BPQ:'>';"NQQ<N7KG4PAG5+>E<]MIFI?F+O!CGMAX19$5(J`4[BJ
MI5FQJ;:!H/K*)>T7)%EBXQJ",L'_)RZ]-6?IWP3]CD5W0&.-#%R1Y"7[!L2K
M/6?]RR1DC:M]4T-LA9WQ<*V1C:<OV\00KKKA!G:.:=YI2Q=;ZRUG@:^US1K;
M,P$\#9J=C#EK69[:AK8_K;7,0I,R^>GYTVNLN6Z3I56BZ(H\V7R.J7`E]G0D
MS2O8<07Z`II'ZG@P?Q,V1$XE++15R?PW=YL=BR_ZKX(-QL%TQ6E48,=GG<$+
M824Y`-*++[X8.$")=[SC'=9<A%UUNQSW.!&_5*:^:!DP@@6PJO/!2)8?.``$
M<(=G#KZJN.4TGSB%2).7S4(,<&+>28)^XHDG0)-72XO!0>F2A1*1/;"D>:'^
MWWWWW74.A6\$+5!3N-UUUUTWA$21O/;::P$4B=$#EZ^40;@TMY(('GC@`<*/
M$SQA$<+NE5':KQ[/F7^PVW)\9\S/05^N4U`_;8)=U@5]EH!0U7W@$V1Y#/*2
M(:V'(^@H,\N+&#$Z-77,V\'/1".BSMC-O&"5!RH!5`5=KU,%2X]=%3B#%A@6
M?`ZF$/F4Y$7#TX$ZY%G+;+;.3B_=>JQ,5N,@3]NLZ8%/JSS.2J09(2$#[]_=
M-P!=L]3/7+8)6CYSG[1UZBXM:_!D;#*K&6>ML3/!S!O?^EE'IW2MLM!F6T.4
MUPB?4_8]^S;&YXV!?:WTOB+/U$'-2C\6YK5$A@&ONOMT]VM12`H]&,:3GK5N
M];RKH.@@SUB;?4*54:96QU;[.=`'>;P4FJ^.7!G9]4=.SB\3`9]2):H/`WFJ
M@%$$"\(K,+X2S164PU#8'YODUH$_"/Z**ZZXY99;?O$7?Q$^@(OJK/JO=1./
MI%(5/>*$$";O%>Z@%X":M"V?.`43`;%D'M"4O<+?L6H=#:I06NIB2=80`$>[
MT4A66;&J4N6@*[_RE:\\[[SS,&;1O+8`$'C"&1-:4[.&S@Q>==55M]UV&Q;V
M(N[BCD;&<%7RHB[SGL$HX5SOWM`1'9-&8"-US.MC:B=4X-2`$&\*6LC"7[/.
M5-V,-F[GA#*>*A58TT!7*\>J?`T_U<K3F2Y._CQRY$CQV'?<<0<X+1QQD,>P
M9^KIK0O4!%_&JFR4:E^4Q69Q@3_@SF71:L7\T>08?.IAO2+/B/<I`L7P)^V,
MS+-J#:E:U;F:Y3[/5SP[YM:X>*S$$\F38+/!BAQ5Y+02$]*_3EU2."<4YXQ]
MZ;`)]1F!Y^Q]T<)5^-DD2JP@LR93;/SF8_9)_CEIZ9">,#-8%/8V2@'.:E@^
M&#HX'8U7(W/:UA1>7BW,N='7DLMK\[NRU-?RIR/MI&&-ZWR%G4&;D(?DX[A+
MW7///4GXY2RTAOJL2$X%Y'W"G]_XC=^H,&8!QDZN;Z\EN["?<I'0?VL]IJMX
M.XT#"D$/$CZQ'WE74M5/V2<KUF'#CY5,M-6LI[Q%0@Z!H8!;^V`ACPQ]!^^@
M?$H0""K/T<-_:[<]_/##'@F/U`48G&;HF,^*XU5KR!NY0II@"E'M_/S1F>>?
M?W[UUB;\R6S>=---;IW9'+\3JPP(K/;Z<"_U!SX`%H*'TR!/I8W`G6'T[L%.
M78^]/JX'[)[36D"9<IW*3=LJJVC$PLD*312]7++;'^TW?REOZ[O?_:X1@&,E
ME4-%<^H%K[_^>K+<FW>;ES6D(4])$\%^JXSQ3P8V'1[2*!G;O)G@O:*1GH$>
MG1%@&JC9SU`0\HRJ-0V[<^_F9!EU8)2%Z5(79^5G'PMJBL9$]4R0H6T3T;>F
M2TS4S5E+=5-_"9I.VU?=.7.7HCY0$SA,D.$JU:PFH%,/]*\Y?2FV,ZZHP9FN
MLR+/^K6(G20]KYR;;]YQD&=L/F,6FQ2M8&=%GM2K*92Q1A)ND">9)_R9LF!K
M)&%&GK731*U^1\Y)\EFC=]*S^LSL[.X(OHJFD5D]"+!2C>J@35:7O!NV*N>D
MD:7U0QX<`;BLL,7SU.ZVQBM9/RAE>`U<))RX([#"F'YU?:2.SG%ECB2/E*!5
M;`EF#'\P;V%OQ</8L(P+IHZU=EO-_1'LU%@*:^28<T%XY8U*G$_;\K[8/.1)
MKB-X6.)Q%OCU.I5G]W<36KT1@VEJ7O:RE[WM;6_S`.[NUG`5)_KTG#X???31
MNKI`&"_KD4`NA/<BAM=HP'GO;JP,8/B97)&QNCH5%2[V)$XVF%4"]`E&DF%`
MEB<'7\8_JPO)JE`'ST"Z*^H//CBYJ`/#DN//0-$EH9"WL!;\ZFY+:<W'5X_"
M<O\+[P'%9KG$NLH>ML0@`\1?M:CQ@]1TN[3Z?+69FEMSLRWD:K&?1K`:><;.
M$_ZL(M`)RY:NL;J'SM@7MX$JYYY[+JT9./@Z1N;3=N5T\KG'[Z6%QN\C($T)
MH,25L_9E!@<<)N8YS:Z4JS%?G[+TX9I(GM4QMQJE5RO0:?OL]?'<50UC;#XG
M[[N(=O#$?<GW&;<,RQ.W$VC[U=?5JSY)6VMEGH->]5SJ.=,G5ZO"I__ALF7A
M2>!YWM%;^#-5>@KF*88'=T"/?#<6TTK^EJI01`W2LLY6=R(O#`XM<QSQE]+E
MUXP;2)&<@V$K3%>U4AR!"YQCT2]7"-<7&HV_*%`XKJXNX5)U@:!0A8,2AR!2
M[1C**G*.Z_BC\[NL?<]L-8>*3SWU%$$+^X.47]MMEG*?."BQK88^X6>M,.-W
MMP!-F<?K1N?3@%3RR"";*1A2?G<U'CV&=W$:KC<(1(M,22[BRD4TX7%7KG\'
M**@Y#AG)^5ZP9H+^0O"HVU>0^[_N-D_K)Q`$3(!AV0<TJ:_L-N,\Q0#MP'.H
MGG<`R!C_VF`9BL2GV@,15&`+V,GR9E2S0AM5TU$Z6'ES4S&#O#1EE+Q%=2#=
M$84@7>MCT<NI7:V5__'1&]J.^-<&3SY#GM7"W-H]7U,])IXGHT?Z10%U8SPY
M8^G0-[I50DL'Q\X<)DR4\A0-.VO?4703`CW.KY!A!)6NMB9J;?2OU>UUZKZZ
MEVT<;:,8]JBG[Y-#"V<J5V*R0<?:TS@8M#!G!LJP-)Z3I3X^Q(GA:0H*>PAM
M2IU(U9IM+,P'DR;^QK*M6>H'C3SC5<<[DZ)EPQ0UTL("&+/"[Q`&"Z/&6![Y
ME9$=*4ZO0"B$KZVYR#C5#(A5#]E6Q4*?R+X*I=BS$#@R@(MGV<!WEEIB/RZH
MR,;/[S9\6CPA+@!*&;<QA7T7\7C0YA?V&Y;)B>P3CWM.?(']I];B0%9%]ARO
M'F--G"LH#>@\FUNX+USUB>.\8ZVO+!G&\^*++QY[2!:PTLU<UB.Y@E>&M[5O
M(/,``<_FP<!(W;O`4342#0O)I*HC50OQ+[!?-T^PX`%^?;<5XV>@1OZL[(]A
MKSQU9GSWS;93/4`;B*L5CO&G#%8>&?X0!<OC\'@5$TB-!4$&*K'3$%6)T4W=
M/5>C:[IIO0#<Q37AK>EK923M1+&S7X&7!)XQ9N9)&;4K=BC(\&"%F=@GB\<(
M#&.)G0R"M:;-Z?O>Y:LI9NI=3$Q@R+,ZK3;IYQNC\1G['J;CS!KY:N->'X_;
MR;NR8(.*ZT.N=3_&MIR=9R($`M63=\70UFSTM<'6ZLE*":V2QG^U;&M3OS'R
M5&7W/]UO!Y'G.=I,V`["3DZNYT">"G,E%]FY\\X[R2TX`L'3H<JJ+K4'LSB"
M]2K\7OENGU8]._@.%X"CE*G`!^/@+PSUR=V&IPHRK!G3)S[Q"?]"WJ]YS6LL
MM?C7E7%W,)+%.#PI+;1R,<E='L#)+<W!49_U?[%YX)PR.-1CN*]'+2BN*J]X
MRDY*1-:D3#WX"^SX=$?H1PXO^A<5F9V++KJH)GVWWWZ[S_'U0)LL+=X7_D"\
MU[[VM9[<?DG]KFPP"7O&MI#"&@626P!%1EI:DA,,5^6(P;4C)$,JK;<S+,2J
M`H^KV!8FE%=2L$U&:8]4S*<;N4)-<\IF+7<U$0Y6E(M7<ZY:M9H^P%(H9LN-
M,4^W`N"N7'U",VY^:S9DTMT+K-&@/;/!3R#W&<56+3PR'N09;6N4K'4)#GG6
M>C*S:J=M353/+/V3V7WB?IN(W[$#CT\\[6F09\IH3)6,@@;7T)W543Y^KHEG
M'FEJ?EUA9SSF!Y&G"VY<YR?N6_B%0@7GG+#K-U$=PD&>>?>NL%J8)^IR3#T'
MZ[VOB>I3"BS+_XH\&98K1=C.Z%P;F6<3QO,<R#/6YJP]UKO*1&"]XN$Q`MY$
MA*0=L)/*4_>E.K5A#2=GI"W[SQ_S"]<<!S0%.(B<`N)7^Q9<7.;D4@RNOOKJ
M\AG+9\^Q2SR8J-H<NS6YJRXT!DF?RC"2F@.L\#L=P16`&$"HFIEG:+%.9G`7
MO(RGLE/ENXEG@UP'H=-UUUU'93#[524-J$_?)7UX/&="LU)<)\#833WPZU[W
MNE>]ZE75S'%'UX</V6,+@BIB.==YN6E>JJ9@A@XO.[FBH#7U2.QQ*:_9F!0(
MY+(5"2D"IS+^Y5BY1>_B^I54ZH+5>*\!>N:OFM38:K8.#(T,L3/T=D=3;`9=
MIR8[[FLP7=P%X6H&J/)P(9L_9@1`G.,-\9E_-CO/($^8$^R,G7.0I\\5=L*<
MC>5Y;#XC1;2-:65J>4U(3Y"R1@R>O>]#,3;A,Y8<\XF%7K%E5;76$D`C`JVV
MFC/V%>GGZZIVC?"SAF2'/'U=!9O!I=$Z!W`F172MDI%5N3%<^TTDZDQ-L$&>
MJ8`Z+O4)70YV\J>O#6ZF`NJ:GYZ1^3E2U/-MY0*SH&.-^DC6V*4,J?I06%BK
M%E7D?-I6Z^`::6:IK6AA7IM*>U76^R,?^<C$R]61'(-3\2Q`5UQQ!9X"&GBJ
M4)D\5L`$!(48^5DJW5"IPXPVSL<@1<=-7PR(Y/GQ`NZHDGD!*E7;*\5@JDQC
M_'+>Z]Y;<++U,9FPB*F44\]99%U9\Y6,2!1TG9QNV9K>N-O>\8YW)),4>USE
M"L]6,DAV[!`UB=%`U?XC.]N'/_QA6`T\B^&!6LZ?*MEN5_Q2EG;/``/K`5K@
M<4'4]3.JA*.KD7:,/_S_\I>_7#'8PH'@WE-//?7$$T^0P=PB@[.Q\G;^F!Q8
M)PY'7`T<&=N*EA"?Z&M`S"LCR&2>6273LU:!)X5K]*RU5L.:0+TBSP#.IM3G
MI"D59#CZSNJW&H?X1.^L%MW1K<Y:JNNL60]K$YPU8GF`Z.Q][^,!F3./KL_3
ME1/,!II.6PJ"K:+1).-/ZGKNK?0L)P_FK-@[P813=7F@9JS-@SS32W0ULDUL
MY_0R'N29'EN;+/5Q::W(LZE`>!!YUCH\?H5CU0S/8X[\"CP+6Q!S.3YE-[2P
M9OFL?DM&8'R!%"W3D"?W.O!)*<,XZ6))^"@_[\]MM]UV[KGG4F3NN>>>TJ7Q
M4?CFLF`D#R\(\E/1RXX7;=O)=B!/J(4EZ_9"[*&S//+((^X;<.&FGC-WV+3[
M2>0H:M'[5I28NF3N`IS9+KSPPCQKWCW430T$(,;-3RYE0!RO):A+>?=ZMB:W
M5$&Q0NO.+%K&:6-K<F:=@PH>SKP/E*K54_,O^UXJ?=9_O9U+Y>FN_#)AK^R/
MU4OH-+-#/JG+89$_=1"#&!2NLLXK!NBXQZ`%-V[>K@OFT"R_U11[I"0KZX@_
M?O.;WX0\!!ZTM+9DRDIP/.3)MW5,Y!DO\%B8__:N1>:L]1/DDQJ22C(NH8.1
M@1/#/!$[:TW"<8Z?O:N]/"K2)F)Y0I''@O22?8O2%*@)[%D#E4_;M26:+(\)
M?=P8ID:J>?'25Z(\=.]>>?D1>`9YVHKVF8':R(VKM-,V25N3KA7XC,#3-L[T
M"5TN7>N8R',0=@XBSQI#Z--;XY'\VABY!J-E.Q8V9FN5K^M-@3054D"?B1`%
M?E1%H6;H@4\ED3%%O89S)9-_'"<57'SQQ>><<\X--]SPAC>\@;I48$G5J-RB
MBY,3<%"M'U!^P<^0RO'4I5)'JRI3J>'JG+MI2W]B6V)/$MI_O]N*Q/::@RI`
M[)6O?*7Q3&)L5%%"5<B2D<*68#`=,`&LXH3EE8`=;VW$RJGW%A,A7`)F*F08
M7OR27W/G^:STF<UE$ZL275RS?C'%,!M>7TLM\6N8;QZ)<'"L?L0UZ0O<&D93
M4&.(!QYXH#*`=D@^5H0''WSPZ:>?_OK7O^XTSQRN%D=12&$&Y_SUI?%6%I[8
MD\R3P!.MCLYU/&UKP&<*`A\/>=K6[*W1,L9)-!Z?$Y>6>:-MC58UMN75C376
MFXUA9\V`6-U;J^UZ'.C%*ZX*UQAV)OUS@A[#R57/ZA4F0FD@:+(D5D/0JE@E
M^.6Z"GPVB5J;%L:S%<:S(L^:J[6*/9.EOG&I#_)LZH`=#WG61'6_TB/*_2RU
M!XTA:5278:>R.?%=ZO^$T+3N^TL-N>HQBOM*J<[/WC)=?[?23L,?.VC[ZJNO
M/GV7?5``<`ZO(OF+9TM?J"XBGH*';@VC/(PK8Q;7!"F4K!20K,=Q:/5G6J^S
MR@[X9)A-Y,"/7M-;._[J5[_:I$_Q$)]6`8]4KJ55/C=?F%SI^`IT5#(]]7/T
MO@:SSD&Y_IT&5<J<"E(J,>HT;YV!W=N!5I^^YA'[M?U6%J=_E3E>7:.ZNWH+
M4DTY%_#'X%2\.@]484*)7MF-34K!U?6IIYQ^ZE.?,LBPZ"<_^0DDR<KD7Y7+
MZ'W=-!]HJ1.EB];GPMQ9!Y-Y6B*+0.OSF!;F;`LK(V3J*;9Y=:RO.M>8-5:H
M>?%2D6]<U5.->=(_JPDV57K.WE=]G\#C<::?OI2S.&6I=C@H-/$\(Q&-C7I$
MHQ6L1N(:UUOQ/Z-S]5(C&N78&F@=O]Z*/^L6\C10(<\H60>19ZSZ&SO/`$Y3
MMM;'.*97_6`=U-#FN>T\&7ELM]QR2_))MD1<8*<.%/6^27+(PY(IID4\KU,J
M3TT*D'1M>5$[WD_/LD;#H@)F'$&WN`/0H><;;[RQ>;GJJJNH.56)MQ6*[)KC
M)@,^:!XK81P8Y6JDFB>??/(#'_C`V][VMMMOOYV\A$<J^.,5/"3&C]=&R*GR
M3)7WLK&D-K:@`P0RF&%LB+*8N7(V]F!JG#YU@H8&98H5?9<TF'@3SI19YMG`
M2)GL+GCGG7?Z6H6<LN\-K[L[,_QQ/D8V&A7;,1ID/#MIH.6;IT(&IZFB'JDJ
M])5`)%M.3YD2\4Q041`PJA!HGP:0JE6&+U6KYJTU'W2"\2R,IQ$P[+`(J51`
M&^Q\>K?1VLP:(LS"7+7>$D6?PZL^\<S#$2%/OQ:C,MO?V?6JR[=^<-$?Q_K$
M,)^V+XYQ]KYYQ`#%"D>I2]4*F\"_U*@JO8_9Y\RE#N%Z/(0)4DY=JF3,.8DT
M8UD:76S4NHT7[,Q]3XIQ>&V<Z2?L6VNM>6WKUQ?LFVI-E8R)TH0YAGTM0ICP
M.:VUUJ2)25'OR$$[SYJ?OE8&>]ZNP'O9Z,46/F_7[[B[S\ING24Y)-X@K7*4
M$//K7O<ZU![/YL:-I^*U`HGQ0J:)=")+<!1><]*J>%4`QU;^.T1"NO#':7C*
M%!O,"R^\D-CS^M>_'JJX,MFC2GV5YO-4&"J!`:,54HORZUP#CAS'UV2S/$35
M$_:9/38?4]U.'<_ZX3JI#Y4=MMU]]]U6A]4"AE3\T;MD?/:^7<U_O7AB23ZX
M%*6ILAYB%"'00%5ZM%A'`UNBARO40M&S%8E4,)*+9.;U67:#_7)C^^SD[&!%
M4)>%:LR]73%^P76A62EH1KZR\"6\V`BBE26!(<4$TL*@$)GGV6>?]=5@%GY9
MK4)CE0?0U:AL)J5N%.0E4(D@(0^:1)P5`9LU%'FW@!:Q%IT7R58PFX/(LB#;
M*9<WAHMQT!2U&_@,&TY4<+E=3LOV<N:^?F#@<\;2,&)5EZH?N*9WC3EH4BU2
MV:9N\^A38W/.&KQZN%8[SR2$SL'U^*G[FJ@C8JW12@=A9W!F8#G_^PK4F7=*
MU-HDJD#[\6J-M:<9696L-5%K%*Z->?E@3<+II143@1>BD1V/49M:)/J:U[S&
M8+I%;12P1GE#F"MCK#6W3G]9%S/RY,5^UVXK3],19.\B\*I2F<BUUC;9:A`J
M`*D41HR0%\QZZN]77GFE03/=UUY[[5UWW77//?>@8;Q9W)I;N"G9`'!A>7?Q
M1PH"KL$"1+7O?.<[%FC+=/%LG_G,9W"3)RFG'L=ABEKD^(2NB0<9?TH%S?,%
M(LX]]]RJ,K:9"$]2;PL<5V9!X7S>-W```D7\XGV8X,B;WO0F0)'T4FQ,P4A)
M1Z%*(LV]]][K-!?W1H8]R$JPR7X>N)7.Z4;=,;S*G1?R9&_OR$0FN&-6[F*N
M?%:NV58-M&I]F`AC"*"*>?C\YS^?Y9GV5-9)A?%[!?=*V73$+!-[0IZ/?_SC
M]N^XXPXDAYPJN5RP!T*MP)KC54!%\!5'/6%7H')R1>.45+!-5,]&\IF0E6'&
M25J?V.#B`\_>MQ[.5CRQ?Q,<.%ZP`:*DH\G,&G7IS*7K:-=<DSTG#G"TK4T>
M^IA]QO4_(3VG[BMCC)UG+3UT3('GH(5Y$W6Y`G7I$I.B&^!L>HF.2VLR)M9@
MGNEWL[;66LW+!]U;HS5D3#:;H*#VUB@0^:'5:ZZY)H\,TL6>Q)["B1&;U3G#
M+Q$]8PC)9\*&?89"24%X"G,1;VA2B!SR9$K-_X+R,SA`#/B#8CT#H*L.<.-F
MQCT,903^5`P'VM3:.Q4/IWBVSWWN<Y0L4/.AW?;HHX_^Z$<_^L$/?O#C'_^X
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MJ/$+,L8:."*/L\4.DCAGROSZJ00?])^5PPKN%A;Q_-1N45&[.M?`G[KO54(S
M$P>F,,45##?[1XX<N>666ZJ6`]E<V:7`'=PCU>`+R[&=!Q]\L$+T?_$7?_'T
MTT\_N-M`4-VFOO"%+Y26WMJ=32FM(6MS\<`5W_,Z5UUUE5F8T,ITU?///[]L
M6><`@0FAJ1S'6W8;6*`>)JZ4_11*&%5B6Z`4%(PAJ,=()O1WE\KHY*M]D-45
M7,K?7=G7E%#73\3*^96%/YTQ[UA!!14U=5./W9I2O$&^//-H(LA"I@#@Y'DT
M(]"#V%/,53W4J%J&#LC#J$K.%H20+1WFE,2!8."8_]Y\\\U(+E,DY,G)E<$Y
M,,$LIAB1Y^2M('.FT<EA+'MKHVT-\FPX;O5SC8<ZPRSQ=;I%Q.\3YS-^]LD&
M/75752,[SUIM8W)+$V-6Z-@D9PTBC:GG]'V-Q!5Y5C-U-QH@&ISI"O/U8-#R
M,;6M,2:OR%-!C'5;N]N,2SW8:=M(.P<++X]7:^/;VM1!=634!Z\`-)!<ID(D
M5/@K,>.VVVY#O87S(21+</6-T3D60&EX/U6EN,&R%2HPE>FC$N)U7;%T8GF4
M7%!0[(!64:FO2+W:#F@U4,(U&-_K>TTD5VQAU>;I@_Y>VN-7OO(5"(,1OOG-
M;Q)LK,7EPEN7O_6M;Q%R'GKH(<>=#/<\`%G(\1H66Y>+3BR*)F=3UO+7OO:U
MZ!/4CY*5P&/<[K[[[KSVGC^H*2\LBS%`\$F\,4198Y)A7K_;?FZW);=4-3'?
MECO"@5SJQ6?FDZHH4.IMHUJBA(/VJWF8O3K%-MM1$^'3F4%K8E*-I!WW_(&2
MFWKWZHT4HV45J-1;/<[,B'&KX$!)%M5O?/SQQ\&XZQLNE)--SSSZH^>I7']I
M>M:++)"&KBQ^\V@I0?`&I`H_-]UTDZ&&.=F3D7?%,29ZL&#^-<-Z51_6*A"K
MVI7#Z\1]676,?/CPX4&>N#X8.1[R;!2QL0F?MI19WH3H;(Z?MJ_(.B'0!TT]
M:X9%(#GRTL00GK@O?780=GK3*8*QRC;KUXGAF383F^XV$ZZ<P#,=M>JBO@80
M;KH8#_*L,L\FF*<M)FH%=V6:>/%IV6VR15QTT4477'`!7LA<4P\:8`)YTK:*
M3ZX'04W?"@;NLTB/F,@5$#F4N/_^^RLMZ%Y%'8,X5W!WEZK%S`<^\`$L4-0<
M0=V[>P5O;7@OO/!"ZZS3RGXJ,X@\@PN^__WOU\.]7A(./O744U2#/_JC/\(F
M%F)<`'#Z%2A]][O?A53XNM#E9!AO5+ZG=T0A$]<TY8PR\AB?%,;ZIV.?2F'`
MA]?L-G)(=N`*=(0\"2>I5)G":H<Z985*_9A0A)HU&Y8\7QT/(0LQ*OC',Q?:
ME&;7E3U8!N=R_/VQRD*0)R&M$'2(X5+)>VY7)&3A/6;$W:L"5\R5B?OTIS]=
MGQUH_\@CCQA/,)6)WKW*X@=H^13(3O4WM'XA3@N?><3U3J:"01M#X8*6@&>?
M?=8?29*9>I),,$A^]JK!Y\`ZGH7YF`:?`I@W$3[UC"AH9R!EHHC7;>26M#-J
M5W\Y;:G</H&((]NL&+)!E8&C%:-&_LD*??J^7,\J\ZPQA`?3)3;1RROXK$.T
MELB8PFLK[(QA9PJ?KH6RQ\@S`825E]QT,5XM/*MAN6V"=LQR=F;C@!0+PB_L
M!+_D542H5FW'D:45$,$CXWH6U)NRZIU913`(\BLJIO#FTHC2O%#IQS[V,7([
M]*A%10YKY^`")U17^?WO?[\SNQ1!W<MZ9G`*(<V^<PHQ*N"$///H;GOFF6?P
M`N'GB2>>`"F8XL<__O$/?_A#)Q![*`BTK9IZT\(`%+W,<?0?A@Q(9JJZ_/++
MIZZ@T<L;6+R3Q<*`9%4V.'!F]"D0].K=!F=6Y$GYFFKJ7JU4LF3+9)7TTZ`X
M<].D@C:>5<49U"H?U@F9US(KC<*51:BPG_+1''3"A!@57E[`)"A(Q/JMW_JM
M\D"+8ZS!678;4P9#Z+`5>:[C,/$RQZ*;>@`W(CB935]=(>LTO')?)(J<B)'N
M@@`>VFU_]F=_9A6P=I@7TT&R`N.77GHIZ`--M]]^>^P34X0\FU+,LZU%P]:L
MI0G/&TUDO.KCV[)SRK[OU53+L17D$UR\9-_7.%'$D;(8)F)P!:N*HW;^FH41
M+HT`T]][PK#EE'TUCW+55^OQ:%L'!9[>]WA>]8&=,?M4`6SB>29N)X//5&D;
MP[*=-9)P#2`\F*BUZ9^^5@,+?$IU'`ARM1MNN`'9U"`/D9-^W<O+ENA=$^%_
M]L_^635[D;$5O'"XXGE:=K,VI+\4H3?,E2B.>A$>>`G'H%,F2LLNTK7(.OBO
M_M6_0N<E%-1]>R(;C3S]KFPOA/JA#WT(W?[)G_Q)$?ZU\"/_U$$&;4.AL(B0
M@\ZI8'@AGS+L(@[AK&E@UV/#C>NOOSY_'Z@I2VM-I#5!SAF8O?766V$+GDJ?
MJE,Y6'[3?AO#<K9W0Q06V4]=FIB?_'V9>BH/$O@8QA2Q//[I-5EL@AU7@W+C
M3,QW%D9E<^[MQO.8(E9H90%(Q026Z%')M4)T*HQ&7/R_=UONJGJ=&WF#;+(J
M<5\=;%.<!\TUC7-&:9<R.&1F_S([M7:U0^R$.3[_\B__TD$HY*"9_<YWON.K
M04;S,8M%.8O0RD>K5?EX7O6-&SI%J8"<XGDFBN:,H[=QLH^LLLHG)^XZ>263
MG+$O:CI(LLHP9^YK9:SY\J<>W3,T(6<2LE8-:P,^8^29-QKSS@OVR;.C?/WM
MHQ/2UX(8$*;Q'*MRH8.3*#&9+,4_3+;+6A-C[#P;(\\40=UD;%7[?<W/LN_,
M(T>.%#J+"-&JV7'<4Z$HM(UX*"Q^0HI%K61V1G4M=B`H?U;\FX5S`N=0>Z8>
M_(X:P<XT$LVDDT47DGSRDY_\\(<__`=_\`>E?.)6P^4A"74^C17TJZ5@WMY/
M?.(3)!_RC_47['SC&]\@R<0:9!N4C#N>V&VX)L-U/%X]U<Q6'@_GWGGGG0G\
MJP/]X&9,P$B5:F#(77?=Y2&AS3WWW'/OO??B09C\NM>]+@BJ?</;=ULVYX`H
M(W.>IH)P!H6*VYE4V0(4$WLR+I5;D6Z81!3L3RRT@RE6:<WFJ`;'25:!4J5B
M2VHSZ<4/%&M=IE@5,*I"UEHP;1PK[%/]:L==UHM[4W?W;$;&K4WQ)W:;.2T=
MGK1)_P4OI%,SE5SZG?UFIAY[[+'J<GQOMWDD/%L[8[QFP<50M44H%RE#T,@S
MJ]]YE)'9'Y;?(,]$#!Y4M=9"J9M\S_2L">9)4NK@ZJ4:"\^I2V6,4Y<&6ZN$
M<^+216L-2%YA9_-VJW2WD0/_]K[>U_%*\6S*\DSTSO35&LDG.6=U:6W,RZN%
M9UH8;[H8SS9-TJOW[N*H%*55:\ZD&\-*H>95(21#'DLAP;L87<?C"ZR$C`N,
M*?\(0TT\3.)$>=/$%=J61:W\B]965QXFJJH8V*%P0;E"7!!)\H8WHFU5B"P'
MG).KF'K????=?__]M`#[1"`K*0F'(&1=KMI\2D%LV&,G47AK$'K''7=<<,$%
M7M;0';.G_+HY+:9.V*A><<ACPX#`)^3Q.?)/-N=@I[AE?)HSO2#`W.7_]6YK
MS$./J4KTCMV6#%.6"NAH/WVJV$@7='UW]R354@O-*N:3#MC#VZKNGDQE0&KD
M6I'#8(?R5?>N'.Y$5FL'L:>>7\#'VF$0O'@::(I>A<XR+UL%+`H).:#&TD"Q
M:FKZ:GMDMPT6U5_>"63C*Z^\,CO/6IEP4D0+AZN>YUH<8[SJJY!PZC[%>P+\
M3MNW#)ZPP-E&\EF5J;$%K6$_'9D8GC4R<*VWLT8)3F!/0)2V=>+1/0H'?"8-
MY*1]L=.B!3+IS/NN$N"FZO(&?/Z+I7_Z=/>;C+EI?[9)3E]#ET?5VD3RC"<K
M\68P9RWYGM4BL<>.6\"-O#_O?>][D1]:NGBW5?@E-Q8ZK`<E$L44:"P?$'HN
MOZG<QK$ME(^`V;-J(FG(@'JK9%[>=-U2\N87(^TQ++*(OS0'ZDR5U4T9F6$"
MX2HH\;[WO2_6J)VN':Q1.71H@WV*KW8OSWGWW7?G;"+\$^:OO?;:5[SB%<C&
MF#^WG#.;H3-9WKT&7N/)2L^"0M`FOWD[AM%QMW/R^+Z3`(L\-%!3+[&F/.E3
M6#BK=345L]*GE/G)`[A^4E8@@_U=(=[/[...D"IS4-=QA6(>0K-0KLI%;EJ]
MBRE!4)B60:[D5XU<R3P6!<L'L:>2@PY6>JCHZT(1O*F_.X><$YX0<C+L?/6K
M7R6.5K*^WA_M5[65.EP76BH8Z8@6AA*\7<$5!1864F@')R;YK&E<+]A7WANF
MWJ@YIRXM1T<A&K7HC'U1BS..3MI:=:ZQ`X]4<_I29G!\6RE9)^^;2JS;Z4M^
MZ*17;`)XULH8(\ZM<+2&$!STJO^=I9W?U,%8ZX#-MN9G39OIL,A^21/P9UI+
MK(ZMNAAOD"?;SL'FZ>.CR=K3OO^B2?(#PL"YD*%Z,H0!)(IM<4%.7M)U==?3
M('!*029Q=YI+9M6LG2W-*-PGDJ[O&PC*SEDUT;+"R3"9.&JKYVOMU'&6F3*&
M&,W5:I]7PC5T0IE5VX`\&*38.0SRT8]^%!_=<,,-A)D;;[SQBBNN*-7.+/LT
M_N3)6C]/<Y^,R1-F>;S-$@"UO!K6AH3ACYW`)R6K[77[K4RK\&K,R%5!;,12
ME!J3L&52O2K?X;VR[3CN(B[^JMT&EHON]D@^/8:ASIZ30ZW5H0"&R<*8N,12
M/*HTV%W2Y@J3('86>64M*#BP%/BJFM2P`^PC$H_1N_=&1IYDFY&M[AYEGA(^
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M^[G^R^#PQP(1TQ<\9/UKRO$\M(O`>6Z1)K7TIY%Y.OG22R_-FP-5,G$4(F@?
M`GC@-"_[1)$`*HSR-37*H$UEU]+/"U1.E'*ID&H"$6%(K%U0D/NZ%'@IP@>.
M&<]B"S-TNZ9/H.3,ZC?6&"A82TW+\]ZML[.MR&,S%Q2NFK:CC6*2$4#5[`L+
M-_B`_>:;;^Z1@+#)A2V//?88.:<F1SY#FXJ_4=;^\`__\$,?^E"AT;/!(OCC
M3%!381\7>>:99T@^-"^OD`\K9IR,@%CL[QQH<SS>HC'#MAVL>IK%9@W\VQB<
MSUJZ2&SP9%SD$\"\"DMKT,YDA!T\857*YM:;S*QY_GG!MDWTX&I5WH0K3Q)Z
M<DZB8SC3UUSG4W@Y56N2T]=&HM,\O72\C4L];6M,/0>19U9V_RJ!-`-RY9YR
MRUK.T"H!(X.G7VLP02@J<"Y@2<XO,SH6P"R3VQA'X!'$_SN_\SM("[@YK>I_
MA>F64H&#H%P!;*EO3HB/W,X23SG"]1[,`[B[QR/,$&P0OQ,PG;M\ZE.?0K2>
MJA)>HU<>U)O2-#<=QYY[*[46G:2G>"\XDSW'!FKNW&WYUNV,AZL\T-`X9W?V
MG)"G42H"!T9!F*Q#Y7"-/#/6H424]*/RYJ:R(DC)!&?'!5VG*J8IOX%/@FC`
ME7V[X*)B%`O$JKP;V"FVT*1D7L[)!2@@SWWWW><9;KKIIE>^\I6WW'*+<?!'
M\$)BR>=(@*G:874V"$LTXOJB5K4CPU$UA8A)SOG,9SY31>BLS2#HR2>?3/+Q
M+C@KPS)>PU!%+[>S>G9&!EB%A/Q-:X'!"5W.^#.!?ZNY9F-Y'FB::)S`(>A8
M99BY0C+2>-5//3KG8C4!#00EGP_"K.[RC:@SD=NSL\D/W93"6-.RIO;.6NQT
M0I?77"V23R;E#?*`CG%FC3\KM#F>G>?0ON3IH9U[W:\NB/>M;HBG1"2<<N&%
M%YIN"U]1/30C*%36<UJ57ZO$5:RL/Q9#FYW93Z42%-\"EXCNEDNDFPI0A9PJ
M+10F9X-.%D0WJKR&"[H"[H,YAP\?/G+D2&83=$X6NNZZZ\QI`0`77721Y[=*
M?O>[W\6P(Z*L@LV\?ML,PJ&]#[T:L,=#GH;4U'B>P#E_>O86G\0,/Z5J@8L`
MI!3U\6%EV\GV4AC/9*\G(SE>R8N<@^5^)B*6F`D3"CW*>ES2J+]G7AL=;<)X
M7-8#%$%4%:#"I\?5E5Z\A@_52:U[$6-*J8,8)79!";(KT/!WR`/Y*5SV00?`
M@1MFV0DUW($V-?D*9$(>&]BIH&M]G.L@F2H'K.HWG9^+V//LL\^ZSM577YT5
M%(MA*$"$5<?"_,*CMXK8C(5V7.H37;.6W-EH6[--LL-JQADIZ*Q=OZT3EWZF
MHT:-*RVG^>P,!JX&ZB!H#1J<QSYQ7V(H2!DCSV!+L#.`,SFA:Z+$.+!F9^JP
MC3\K3WH05(I6`<QV?O9G?Y9ZM4&>R4P?9U9;@+/IF;[6X4D!&=8S%'DT*I50
M&U\'L14I*!\6RB]-TI9[Q:_8JOB-2H86KEQD[#AN4KY<T\71#Z$][$+S]7=`
MY_Y88"$YQSF__=N_71EAW(>CD=PEEUP"6\QXW@TK':W3V/8B>;[(_Q9<I'O-
M-=>LF'-H7]!^!)[U,WS^:62>`,J]+K_\\O2=M)MLRRE?/A-RDC>2<Y)P<DXE
M%A:$`X)"CW*XDF>,1KD,C2?D2;;)/5<-6%>`<J0^=P1T]N&P3S<MK+''2Q#-
MTYUTFI;W2[NMG;$R36'&PGO,:27@*AU)C2VK-/<6X00BN:FI(=VYN'/J&%@G
MY4]^\I.Y*:MJ"*R@#9R!-I5C\I,3'+0#=@`17*HC[?WWWU]HA$6D;!=BCWTC
M`QQP"B9-B;"#'E:E8^/>VEAHSUH:[67>"5["I54).F/?)VNLRAO?5@K:1/*<
ML4O.\IGO*13R&89T9K::TY9N?9W\XET/Y8(8>_Y)-SMIUVEB]6%M0I<#J!?L
M2YXV"&N\]VK>F7I'DR@Z>1,3.CBY6FE;N;2F:4@6GMG6&N^;&)[C50#+!!U+
MPBXOE9DEPR:"I-W@+_A3C1U<XWB-YXK`\36K1>D#>=L='^M-L27H'S,6ZI-W
M#"5CJR3\6CQ47Z*28H[49*J2JI9IBH:',41US3BTS_M8`<'@G'/..3`'89OE
MQJ2?QIQUO&U5N"8A_2#@K%V!+`2$'&_MLUP2"%`=C]6![F`^IJ`FR<10%%@X
M25@YQ(L)-XP5)&Q,*G#1?[N@.Y;P[F`6)'<'/AF"@`_QPY-,-%&QG<5939UJ
MVU00FK*-Y:_]C[NM(O9V,'MEM&&.)2EC/N&$?@2@KKSR2E*HAR>T4*FJ1F*G
M;N\@!9*`*;-9`0$XDX^^-K753G3Q][[WO?7=\)=,0$`,\GSC&]^PE'S[V]^F
M>0&?+W[QBR87K>81QG&I6I,W,4;FL?:\<-\3)R@HC&>-3)XN$JME>)(C5C_X
MZG,?T]`H96EM*ZR%16':1I\:&_(I^];&W6B-7IZH@-7(O%8_VV2+C'<O):O`
MRTF1&.1)YEF;2AS4L-H.5GJO#L\:-[C*/*NV]1SUEOUK>#.&NO;::U.7<,WM
MM]_NJW?$8G0N*('.$6?R3X!0<YGL+0@^H27_["19`Q,G9.>L,UT6`\SE1KG:
M42"0:>FO;6Y9BF2PHFX\C[5U2I8=$Q!"@R.[+4%NT[[GN;>-AG6P2.-L7<V`
MGW_^^07A8//R0^U8_?%[/JRW[[=<^<%.77@*5*AE0V%[I:Z$(7FH,_(#%D<R
M_MQ]]]U4N0)UZJDQ-3K<K@3VC&RYV,*BC&Q%)TY/0W\,=D:]2CJ:2OAUL<G4
M5ONPBJR:FC(I@(PK7'_]]=X='`$<".-@LHVMKB*0!,CTKXIO^TJA+B*TG;(S
M2,*9DO+:9^WY^M>__MA^>_KII^E?U>''1Q4_'XUCW5:#3T=.V">M3UC@2"_C
MS)J0PI%Y?!VW^.E'IX7.P=6D<_*^GU=7\VM:GNM/5/,$.<^5@Y>^3@#2FA:Q
M0M#8=C;E+TJ+6/OTE9RU%M)??>AKN&"JU@@Y:R^_YP@=G.C!5>P9;6M%GN-Q
M4ZSDLK3US))V#A\^_+*7O:Q`&N-6@2R$BD%*K':DD#RLAQV(1CE5RWZJRHUS
M"FPC":1*^#6+08:=\I0)0E7^R6OL3&2/2IU&B,(7'@E33[6*%2M\;MQ2=1F>
M$XYG8?[W`M%S&)\[`NANOOEFCUW<8($]I:)7R,N(K?4#TW=ZQYJB_E^[C0)K
M*.`)J,?(]$2"!+W26MP:YS-*OOCBBZT(^;:ZR[3>RZ7HIN6<9K6&5QFH_:7J
MA04%M6KD>2Q`NI(:MMSZ)8%ZPI1H<P0N:A=2&PNS`TP\L$7'ORA6D*>6IC1E
M$@OM"9*DH_FCOU0`O_9):?0.5ODPY0OXN&:]2,!."M=7O_K5P@LASQ-///&C
M'_W(^88"![UHUWGAQ?MNFZNY=7(KUESUJ4HQ3JN)KMFXQ4?@(1$5@C@ZUVH-
M/FVI#]96S,9XLD[9-:9)GCEIZ>T^4<I3<F<"!=>0['G^?DI^6\W(XT#/I#,.
MK((#-TU:IQ3&VCETNGZ,AC7ARIMJ&(,\!Y/3-TVUUGK+J\`3[ZP*2">#/B1Z
MZVXC8$"2"RZXP-V=X,4K@EI>N96NFJ)5_FQQ)_/<<LLM-0:M1&JIB&"DE(%R
MA<@SUKCWO.<]5ODI5XX@47B5M7+-U.?"NIG;*\')1(Q7+N/,(.=J*&[?:*R&
M].>080X=+3@=.EK^V?RT/L"A73:'L4K,R+32CE<N,ZMWR58<]M82L6X158^'
M6M===QW%%K#`?#LXRR)5[MBA?911SCB4@&!0$3ITFCD"4_#*?-UTTTUF$,J-
M>A6\3*9\_GUB5>:F7),IUZ7T5J['+)O9].4,VCUP-=SR/'IR;T<8=@48DG.J
M8$X0]-G/?M8^O*KG#@BJ4'9=X"L^G[95+<J:L<*?I*DLS/?==Y]+$7L*+*1M
ME=M%_S*V1B"OU@G[[ID;1\_(/!/;,Y%[FYC`PG56V#EUJ:Y\\KY7Q5E+?_/Y
MXS3$Z9IV3MD7/CU]7VEG_/NAS4@^&7#6I(\@R/.#D=2N-51@DK/62H,C\(P_
M/?-R_JP20I-_1N`I./EXX'.\+(G!G(,U,58+<V`RJ_8&=@XM+8SG"$'KAAMN
M0/9&[Y)++KGLLLN\M8N[%)"<=/+:O=G*2:_J2]Y;/(CR*]7EY/]MMSD-Y2,5
MI%YBEU]KEU-5,11(NT><55>HKU9]D_U4Z\`LS^9BM0QOVF0<VKN\-]`Z?7R.
MJ4\=$VV>>QM9JV<PRQ@?Y^)!'%UR:';@TKM*FS*`:5B4ESI!>R]?*5"77GHI
M%O8)0Q"VV9^'&5M<]TJ)]FGVHPVSAIS0(:HFHYHUDV@)R%%>9<4J^02#!0O5
M0JC4B6IHU*JLHOT>N`2N,M8K.U#0.-"H=+9)A),$*C]5S[^<N[JW4[+,*8"J
MGCQ@@5JUG:T7P._L-M!4+T5G5LS'=<*NCW[THQ2N6O!\\YO?++?K>]_[WH]_
M_&/@0R["YN4\'G1IC=%U),8QU;YXUWMBD\B0/#,.KU&I1CXY<]\\ZXRE",8I
M2WI[7W/-KP',@WAES?<`8V%V/*CLX(3H>".(,?+/1LXY9HW3\9Y/(ZU1N-8J
M^J-G37>S`9\U%7V5=@9SIJG$INI7T8-K[:^-&_V8G+4>=!?H?>ZYYU:@TC8N
M,#]AHCI)`0%$BWJA3=X01%L$+SK$1P4VU_8.=?G+!*LDZN>I*6&S]91`CN00
M9]+^U(JQ(5W''0%99J%''>190>`@>FRR8C<XLPFD7+71Y[8P5\CQT`Z].].L
MO>(5KP"P7LUH>-_R,3%XKJM2JRJ37C\+@&`8B9=`WIBC5<13(=">RK"[['1X
M\>Y.N^JJJXX<.7+-;H-4H.:\\\X[?[]1T"[?;3#AZJNOI@G"&3!>6.`T]\F>
MEK`:&):W'@15K:B>R"6VU*;0*E!?FZPT7O:<<\XQN::O1LD?^<A'@$8A.I4T
M3)FJH%RP\T_^R3])YBD+'@*[<DVQ3;232WXA\]1VN<#"AQ]^F,)%\JD*$^2!
M0HAMDI+R*0\$K5+$&&8WL87C8QJU:XP\HS<-^)RU[Y*3B>;T71GGN4).JT2L
M!*2Q-I^RE-S9:%CS&"E3JS^]4*7Y]6"EB[:-G6?"!3/I3('!,2E/O:^!FFDV
ME.M\NDYOD&?-20]VGG_TML+.)F/BH*)1U(J+K&I7C2`/[00&@.:<,:%8UM%A
M2R$J+2G2HND(GLJ^X3//"_FDWD]H-:3*[$#^J=QHT2.Y42K.@,XKS%[V8F0?
M+G40OYBXC>+3JXVJ-0ZOCGB[@9>#H)2.E@A1A<8P?-J33?VT%:P.[<7%0T>7
M&;&/V`!O(<>E9&9)3ITI5&9RLB`Y_>BE+WUI:RXRJR+WBW;](N$)^8<*1H!Y
MU:M>5=.?XI_SFB5-%?-L>$L1=?<[[KB#S@67`!HP=!%:L'-6T)N&AAF3<Q;4
M*-;!M<7J_[+;X(-YK&*\'4<\_[777@O93+%?IU<1""+/.">C4#*2&:SAR#1/
MA$*E@]5VN1[T59XG3;E:P3\D*#K7YS__^0<??!#L//KHHS[I7#_>;?Z5>).=
M>=U6M#EYZ=&9M60B9T[=-]Y*VEECF,_<IY&.#ZO0G=`CY%G]\GG2L_",Y!.>
MC-OKY*6+S3S/*?MZ&FE>26@G[,K`CIUY"A,5GK1:F'-:M1W/PKRI;CI"SMIC
M,<-R:+-IX3?(,WUMQK!SL(7H3X,\JU2P$0S617]6>0M<9=YKN8O^Z5851,TX
M7-0*Y'$<Z]4"!OGYG.8+69XC]>)\[!0]XG@1+$6SU#\E?JEW%?[%I\=,@EC?
MXF?V:;"'EAC"8_XE7"WQI.&=ZH[U3#>J:P[71DQ:1\F9G6;*Z#ME250B-9.O
MUZQR-1BY\<8;04J.CY>__.4@'5S@XL*`DVKL%(\]?44S$Y5M6M>)PG4*""QK
M/@][>19$4'<A)@$Q*.&(<RJ4E*T)^P.$U)^B(*K5DV12`#/),\\CZ<7Q<,8$
M90EW*4?`18D/5:G]W_<;P`$.TV1M-M/J2`J7*R?9.A/RY%LG,A&?JD*6X?J!
M!QY(Y@EYGGGFF1_\X`=`*83)8SX1@VOA"`<'9T[>M[7:="6>+,Z.9\FOD<1D
MJ6]4L#7W*HQRL)MVPAG[7/AQ=>7;&O`9H6N<7"?MR[QG20Y.3SBZ4^$:,9B0
ML_::WVP5'IR27QOO.=@I::O,K-6DG%?+#BZH)R.E/D\6?JEO$38L>CFT:=4.
M:B81:>6^@SI72/73F#@\#"*/7,OJ(O/<>>>=6``M(6:D7D4(/[WZU:^>IL:U
M02\<Q0Y:+:4]%2P?>O[W(ORA#2)_W_O>AQH+;W-",L_APX=_^C2'S7;0R-,P
MKK4<VQKDM-K,7.L`SM\/7K`=LV!^T1Z1XXHKKB!^0`!X0ANJ;0H,MP.@`$XE
M>J9=1753*ZIFZ`)D8P5PRK<J\KGV-_G(2DLO9=7XET2658T(1.V*?6K5ZBXY
MUI.[ZM.7;%/-G[+4^TQ9I@?5!1XR.,VLT>8`6GF[3@,7-*/ZEE8]P/S6R=V_
M?"TCK^3W[D7"<<W:RD.A]*]2`M^[W^H5^,4O?O'3G_[TQS[VL:]__>M//OGD
M-[[QC:]\Y2OEL,,E(YG=X\6[S/03CZX=,0K7BY<*$H'#(,;$$/KOP2R)55%:
M,\W'L34@8R?<&&_[&*OGZYH'.L;DL?PDWK1?L9WQ;:T6YK7VQ4&H646@%*Y@
M9Z-D3:7!8.=G]UN6PT0:?`&=?*V&K5\=F1+N"3P3#=@JO%FFTQI*X%I-LGAJ
MU;/*VWH.(<'Y2+JV$>@'"_AJ:08R>74Q40V(L0]&`!=YN*:95,E*)4'#DU0P
MR%-[7"?7$<\Y3J#OHTG\50ZCQ1I_F<=YVK\B\OP'NV)H`&>UFZW=@OJISE`#
M.`WO.FAK\',Z[YQ9#SNT3>K`K209H@*!A]B3!\J`5*$]SS4VK`%BS#LE!*NA
M8;A"YIJ'9J_NUY(C,K45"%2P(I2`-MBS=`.T#8A:&C;-#8%,6FU]0/)ZPXTT
MK/*(31Q8@YQ@DWAF.CR`DZ'$^]___G#&=5*F:MV5>)PHE>DOJTZREM-<O%J7
M#E8&P8HSF12?^M2GOOSE+Y-MB$!?_>I7O__][S_^^.,//?304T\]]<,?_I"4
M96`+V?4YS+N&]:YA>)-`<>I2I'WP8>PS$QPX@'/24EWPS'T5Y9%>DG]&K"H(
M>>XR,-61@9V3C^Y$/,#20YZPJWN673K;3B=D41]3\YHP>[#\Q5KC=`I\36/B
M-4K0MCJS:H+66HP%)H#'KU44#)<JU^_,DDQ=TSECZCF>I71EG^PD_]Y8.Z==
M=-%%J>IHU7I7)CL^0O/%DV1D+L&S$-Q*H9:E6);0Z%85ZO03%HC=H%!\A",0
M8;W\LFD7%&2T>YA5#OG_MQ6VW9"N85&3]68_\$G(7#76@R;HS9":1R1WY957
M0N8<244+YUJJ.'-)51-,F)LOV0#L&);I$S'U?`KYJV91%0@+Q33R)4?4<K2L
MTLS(OEY]]=5(&I&$/`0P`.CDFK$",0]0G=L"JWSF>$I1`B"U>J1>N0X"QFBW
MWGIK_<+\5'A/@3J]"`R!1<`D?RC`00S)5P-Q23O5?*X0F7_!*YA3,H6-S'/_
M_??_ZW_]KZ'0YS[W.7H6S/G:U[[V\,,/4[C^Y$_^Y-)++\VK_H)=OZV#[JT)
M8UYA)ZO.I&*-`;FXP0IH).J,K'+:OH#8F*`/IJM/O<'DF9/W#?M.V362\$AK
ME.!:AV<5:5ZT+UG?^4EQ+]QG@_ZM70/B@[ULII;[P0*#J[0S-;XV;;.F\$X&
M!P<SYOB:SI5)^=!._/!4-]]\,QK.8YL(4>_:]O&O$SRYZX]M9+J+#K]LW#W/
MC3]>"K%E>XSX43C.NOWVVPN\?\UK7D.#B-V<@_"FWVC^=!PW'?3B#CL19SE?
MA1'ZKX7/@MC7*I]C%J,=YOP5D2=1$+`8VU&OUCCPS,YA?KWI-SKI07?A#*R'
M)!(00FHHG[6VEN7>R\MF-J_6J(.U*&V@O&RR4![`:C)7<2CO=@B?[3H5K)CD
M:B\7+)T&-[&"UH(<83"'_@4/<[Z[/OW(98.O7(H984K?JX!_#1^1=RAM576%
M>IOZ(PSYY__\GU>[`(S4B+8>):7A5.39"-1Z/NG.NX.IPA0!778A#U,\X40R
MY]NB57WH0Q^"/(\]]MB/?O0C,L^__;?_%@3]V9_]F9?"05@2%V\`9[9-WA;&
M&>2)_3,7UU2B9(J09T)Z3C^PC3MLO&"K&G7JT=N(+N-<&^1I&]_6FB)ZPK*E
M9`W4K*F@HU[5=/Z8R#,.]/%A33O[R<G*G@QD6HAQ@:\@RY%HVZ4,RYUWWFF6
M+0>4WS_]TS^][[[[_O`/_]!\Y0BH+U()PD@(A=QPPPU><!+DW;&:QL-$11L^
MM_TD10.J%-U1X$=IGNBY*A85^G,[3QCRM-#GZ"G1H,R++,:M^#5]J%9\/1<0
MI^6O!L>N4-4=O&R$PYR?/KOS>.\"7J"*X<U6MBDA.SZO<,GQ26!?;UTPPV".
M@3U\^+`12.H(8[-<U4HO72/CJJGQFEX?()?SE7T&>OAOT5"C`?EO`7X5FYV*
MH^W7EC2Q9]J;-L)PP_)TUUUW%1H-$NE?'A(QFS4J+98O:[7N@<U1-8)NNNFF
M"RZX`$8AZ<1"Y(H3";K5]G'W$*,,K]SH1!=X4A.!&O?4G:2=&D?6%3H[-LFV
M-RU&L0X[\"??5LFGY;Q_XQO?R+'UR".///GDD_#'4!?/<_*^=\-JQ1VY8HT*
MSLXSH<MK[/$:4KAJ6V?L"[^/HC17F#(7(]Z,O6B,TNLSC.EI))\DHAYUY)\P
MJOC`28.=_*R-;6?2(L:E-9[TZ9FU@L\TCQA_UD0,ML[6AS%Q!?*<>^ZY%AIS
M;3D@?U;&]C.?^0Q!E!INX2@2.'^E(Q_XP`>J-F`>_6JNDZ*1.LI!44`L0-LL
MV<?;.L%B@060%JJN22[BR;!3Z6#L0_]"ZC52*9JNW,ER!\HS*M6HW@<UFZMH
M3'V[/*W'1IFQ<&VAB'!&;*#CKX(\(_.$/.NVUAC)MM;Q,E6/&0'NH"E#MWBY
M]TJ6PW<>OGCO6LQXD?+-4Y2P?+GM4WC'J$[KL1J9I925J))59YQ9*6*54W:7
M]HUV\)5V5ITE@NCYYY^?(@!\+KSP0K0-@LI`SP*<Z%6TH4]@Z#1$@KP;`?MX
MAYAA?:EECQ?,A^4Y`8C%XE_\BW]!YJDWO5^]+^1,6JL5=4'1F9KK:EIC4W1;
M@D9ABK^_VZH;]L4O?I&<\\`##WSI2U^B8=5>Y.FGGR;V.!.Q&?G<6QM_^F#1
M:F&V;0(()W1GA:/51#/(L^8X;&)UUK#DN>RD@O9KT3XC!;UP7[)UPIL3C<9/
MMTF#G2(8!\6>-0E]%7C6#J$'6Z('.^/2'5>+M35UP)5I,91?:&/D"3/6`H(-
M",KU0+(M!(N4.WTA"_TUE:;/D23G9CP9`T&B/:\\\H\[K@FDQ]P\,\*N+&=(
M4D>MLK.QTE3'0LDU0<[X6;?->*1$Z4+LIK-G/%N[/4Q7N_.QP7IL8G"/]U<W
M\OS,/F'6F*]6Y=D<#'^*6%@KK1W:BTQ=RD7BQ[1"_)75I9HYE<L(B&9S)BB>
MXO#&P0O69:8)JAY^3:PJK^%JM>HK(+,0A10K]YH:SI,T6NW9R8:`%6`$E:*]
M$W9%^<@S!K:\ALE<J(>[K8PJCV'N,`)\1K=8YIQSSDF1=&NWJS]7"E154E$@
MZO*.Q3]7U;GZ'JG57M.TYL&'/`E^`SM%MH.O]^TV8@^Y'<%73Y5(3_EZ]-%'
M23X__.$/?_*3GY#Y+60$C#5[XF!LS^P'1%,68Y,EL4+0Z%.G[+H5KV+/;"E6
M:6USVFK>*2;0??NU\.EDI,*0_!HP=L$7+9UK,OAD/)]\6#/XG^_Z9$T+O^F9
M!7S^LZ.W]"PS/N$ZJU6G_9%SQM62Q]Q7!&-2`/Y7OO(5LT#"R>.`6H"/%:$"
MMJ0@<&2F2C],H'5./4=,8EE[2;:%[B,M5T82I!1,[0E_&B.SSY*S$N,1>07!
M*H&.H:Q!8.?VVV^O66>K<,%OR?,^\PM7H*_\KPH20JIJZR%F#^PMICZYYS3^
M21H30OQ7V;(PK\@3PJ1>9=N9$/%5'!J@]C"FGA:#]SUV"DNEBNJ&,_%^Y7U/
M?ZY*^H`=KP\<RE6O&4>1S^D[T_NX")P*?/E+3;7&O3XU(3/UE)W:P$[+1;]2
M@9%N[XO++!;%WB`#:]/[W_]^Y%1=BQI&.P+\:[Q>C5.O`W9<IR3ZZ0A@FM"D
M_UH<'?&.WK>,K4H6-+\)/"%/#5+K:1LU3@_W=*XBHC_ZT8^Z[+_Y-_\&PGSU
MJU^E=EEY(0_8^<$/?O#XXX__\1__L??%JF.T.>GH;>P_(V#D>\JD/'ZH)!Q'
M$EK"A]&G@$;P96?.F?2'T&P@:,W/FFR(D_8](T*2!)@`Y&`=Q;6^4,ZL&OVL
M5N7_<MFF5=]L:_^:]*R\YZLQV6J"Y8L,]-6GM=C7$@.).I_ZU*?`3DU;T$#=
MA_/#FB:H`EM,318>LT,T!5#(ICJW__)?_LMBQE`1_0M%F=90"[T5^E7XEJ4'
M494?>FB1*R8P;Z*#O`7PJ?QRSBFWP`[5'X8\U"*7:DW$%'E["?SYW"O!ER4!
M,>.=2F=D*L\Z@28]%9K,0>/%_0MH']KK63^S3T(_&&PSBMB:&3'OTA\36D:V
MR:N5D).IN7U35MI[<'1HG[EII4`5!J%*1!5`J[A?X<253*RX<4)F!4MSWME*
M;6NYKRI:%<!*/$]%S?!;0$+E,@J(JK=I(F)&YKZ&2PF9U>(HVJ?:`D;^Q%TI
MF\.'#Q.W+$PH(0<ZQ,B<:_TJ+(?*XV!Y$'XR%Q[//.8[\VRN7`0RY+$:DL:_
M\(4O`(T\_L6?>^4:>/7Z+2O)MZG/-3S*"]]2.$4S["/XUM-/?_K3M6BT^#[X
MX(/N]<PSSP`?.I=KGKYK#>`SMIU8OMQ#DRZ1[M,Y)8U647EL.]48/'/?\F_"
M>)*.TMTZ^=1]^?>UV$4W3<Y9,7"0)[":Z)UTJQ<=W:WFA4?7VTGARI[3P8GA
M&?-.6\BSZ2(Q$8-K9L08DY-V[(`=)`US'#^TJ_.`D*`*#??C'_]XE6^11-IQ
MR4V9#LR@F0(=)JNP<Y#RL=U6J?;:79EN=%()`M"$S&!1U;<^N-N<7'R@]RT5
M>N0W#TD&R+,<V[[\Y2^OLTEU.[-=@)&[[KJ+&)_?%O<5=INV52.J9(!*$>8L
MKLF"SVP^10'E,4'5$"GYBH1@E/(H;8#ET(&TRD/[$.6-^WO-)PU%<Q<.VA1;
M..6L<ZE[?;,6Q)D[DW[DR!$/7,DL3YMW*8$G<TT&U6I6>PLK?FZF[/"ED-3E
MQX0:O2"W;0JE)NSE-"_8(.?7-*K(5I]&ENLP*PV0J0-.!I8`'/)C`<QE%I!$
M'J6@`+-C<X1!A"97H+<`Q_*$BO`^.JP3:T%<YL(DHB64YGQ00";QW]+N4J-J
M6IJIIPBNM;QS6\%+D[?U?^ZV0A;-/NAS3;?V/-60M]6KZWO?^QZ9YUO?^A:D
M+='@A'V3S?27,:2\Z.A\S+YFNIF:/(4KAS"G[ZL.3GI%61*;;1SH`SCK-N+6
M!G\R)J_>JXV2&/*,>K5"3;K5Y(2N=97'F%QRZ,%B.VNWK%&RB.XH/!_ZH5WK
MF=*F+KC@`I1`MB1PABIF9'KR6I@L0R8:5E1^`1&B(O-8(AZJ+GBX`C@MN#EG
MZV.27:@^`JX\?H?2>;*N%&V2PI[E`?N@NDLNN>2JJZZZ>[=5"RN?%#*X]]Y[
MDWEL="[7*0DZ7<SY(55^KH2?I(4*I4:WY2H6LEC,H?M2:B9([]"^CBNX'@.^
M>;SXXHO)(5=??755\GR>?_[YJ,B,3`34N**J$[L1?C(I3PRAK4R*T,Q4$ABP
MN2>L>WB94Y5*SMB>_H)/4V9]K:!H<04U=YC$J*(%Z@21TZKLAF`Y@Y@3JB((
M3,8^5A4+#)O[,O-REFUC6Y,O%S>SQM!IGMFP(/LKKKC">!8N6$_`2M<6<HS`
MX(Q5B11-TL#UKI^#"031?[U+,44(IA827_[REQ][[#'2B+\#G,&6!)Z0I_38
M$C0J[#SN=>.3[%0FA:WB8X@3^M6H`@"2Y__T3_\4\CS\\,-$G2>>>(+,\Q=_
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M7U*6@RS$4V'`*IU2<SZ]VTQW_5OM$*<K_`6:$`,T2'.W[_PJF4RCKJ2XZE+6
M"_M_V&\%CE8?K(RM\"<+<TGK!K/FI*5.9$F`;ZB1M%.+9(AWS3778,\)W4E(
M&+2)D2>`^:1]9OI8>$Y:RK"G7H45`RFG[-N=_WN19W#F.9`G0]`:ECS)'1-T
MM'8-ZW7"F?)`)R=]"GRMR1%K2]"UHNDF7!#C%)H%<Z)PY^`(?\>GT!X!5/8-
M&>,FG(6*3&YA(>:HMD?5?[.#*BA0U@N4;YVR;)&7'!\VJ<1Q7MH$B:@:7R"\
MG!I(PB<4\G?$]KG/?>X[W_D.V"&`54HW&1BUHP?459@NQ<I%K-JE#A'L:SH)
M:FJM4M<_'&&G>,(<\=E@)Q!W5+"LHW5C=Y``4VG$0_M2'B#.>U4SO/`84.QI
M<0<5LCQ$+S6%Z+'PI9=>:G(-KRD;[WS"3!`TR?ZCA=DW1V8?A7O"W]YM21'N
M:+2K9%[\2;WP<)`[CC$Y02XA9PIM%450GGC3,8U9<\&',%48"XN*,VQ`<F#E
MP<?U?_[G?PY)FMRU79=SG%#;=^].BB8W0H`*4WB=7(V)G:;/L_FI<I'6+P,+
M8>JH93/CG_WL9^'`_???3[V"`(BA5EP&88()K6[)-OFS,B,7P)R\5R$"9(:`
M80X@JEB*(2U3H[%%]M7'\`SI=+4B];)//ODD\'GVV6=-][GGGEMV_PG[#ILC
MYTRBY0@2+]K582YB^91=J<`7[_N03F;$Q"?GV_*K_QY/V]I\7:'FF-I6HE'6
MF\Q-)R^)H@.5JZEGDQF:2RM5:Y5YDG:F*^CJ0!\WUMHJ*S-"YDU$GH7GMMMN
MP]WX&@V@<^1M[A"&V<F>4&/*[+'-(+3)#9I_!'79\4=8\84O?(&.;$E*:BH"
M=KI,UGH@8PLJK3`IP09I/?300U4G>.:99VK,5V7=HH9P&5AS3=K699==AC$K
MBXI32B.MS=QK7O.:_"_)-CFY6K(SAY;074VJ0II;B+-C>+!*B9HRDHG1ACF6
M;Q0+F7-\U+,`['A(3UYW%0]6VE&5?CTP[,7^F7!M1#7:<=).BMBDKD].'/G3
MA%)//%7L4%Q?P;<Y@G/]!#+M9-JM((^W*-+X5_:;42J%/[''=(P84Z>M9+_^
M6R.;)BBXGNA!GT`>`1@'2)OBAB2,U1MVF]&NY32URP1AJ(LNN@C4@TW/[^[3
MKLBC9@9,K48YV!]%I7Q99=S"V-:J#R%5A,=-JZQHA(&/"Y9D.OV_DK$+W4D$
M,C[S4_$>/EOUW-0<F:G<KQ8^=T&$2+>*\1"OWJ/D',CS]--/V_$B"`,;CL(2
M@X]+^J1]Q9NQY88S4^QB@G8J=M'GY+#G_O;?XUF83UU:)X\@-"[R@Q;FD<2R
MY(R<=C!0>1J#MG,P7'D*N8^1!_),R:\!'YACR>[S8"'3*2=HG85"YH7$4IW;
MTGC-8`%ITP@[7VJ6S`)<36[9E_@K\:/`==Q1+UHP8A'!JI:G3"AU,\%0F#=A
MQBQ;8O`OL=:GM0QV6>,\24)772;1I$_\CO<=O_'&&U_^\I<3XZNNZ3'L3\P)
MVO;D9)OI>KE6#:TZ<7E,"6`)2#&L'3AV^^VW&S1HX!SOXL'0(6SQ+KT7>,SP
MV%KLF3V>]ZJ[`3[RY`79IETZB`L\-I(P@V7@'MHGCP0[)L)D77755=#>O3""
M]\4:_HM3\-$T()YNSKF?PMB&`FO7;+18)D?JOI&J-7;C!F&V9GG<Y0,X15H&
M2NX"6/PWG33AJKK][D4$=1'05'%L@L'+7O8R3X+KRTFO1$E%A#Q/4K2!*A3'
M9TA;2PC"#\(HEL:,^PJ7ZCQ2$Z[JQ=FFMGQ1!.7W93^W&J+&['AHQA_=(E#*
MR.QV+I6VA2#)<M0KU(@(H1SQALP#_6J7;#7T%2U-5$QZ2AK0>+5&]EB=[#;K
MUS2>2/[)F`P-"KR9D.94L.-YU;-"K[+32;L:.\?SJH\:^,)]4YO,XVNEK_&8
MVP$I0";\J6=6(+/&#:X-:U;;SEKLJS(76977B$&?Q=,B>R<8>40.^0LJFW@,
M1&)F4?6(Z-6.:[$KF*1:-SX3,%I\,^Z963.(*_]HMYE3D.(KP$%=M7BH'I=]
M#.Y@.34(LAP'ZU&=MH9"$CFP'MHF&P"<.NW6YR[PR<E"U''$3Y4FSMN5?[:P
MM!`UC:."#P[ZK(6H:;KIIINLO`C2*FR'D&,%_//=AD2]"U($.P\__+!]Y%KR
M4:D*]36HJ9PG=QS!@T3`@GX(I6MSG-Q;E@8:B@>.<>JP:;^PX<*PO7@)^$5N
M%]3G:T6Z*KI>_'9M_FKJ%^`X4G_/RHCU^G8*]N[UC=O$]J1J33B0,Y,,ZR7:
M5M2-(_X>`5QWW77GG7?>V6>?[4WQ/D`N*J/SLT@7AYR<DTE_MIH:H\;T^FP^
M*`=M5,<CR[!K`BN/ZI'*J4%(Y7_E6\_57B$4CU&8_9B=B^K)O%,E,?<",H`.
MXGDJ$V<IS+?UW>]^M^AEBXY7FWXWA<<$""?NJHF.V#/L/\+/JE)-"9T)2!ZO
M^@06KD'+JZIU,`5^_%RC0W5RDMA(0:-8)<\<=&--EL3T)I[V6*"FAA$U0Q^=
MR]?<6-EVIF>$C4CC"(1Y_O.?GYTG"W-*5H%MKI_>5%?Q`A[J%YR87>!9.G+B
M3?VRS74YOX%5;0BBZD(^$O(G?,(4NXN+E%^S=J7T4Z7ALB\5W%[]J!S!KE!-
M@WSTSH<YR`!$E++DUA"CZECUMIM&X0DSK;98P_D5;:C5R\_O-JLS""(JX!?L
M;]4FS"/[KWWM:V2;1QYYY)O?_.;CCS_^[6]_F[2#)JG_P`=9$GL@CW,`%%0L
MQJ!@I]PT6*\BY-@!\D`SF@@RFU9!>>$)/*ANO#.99<9:]?>7+<"O'E<22QU"
MO8NW@#_U-4X.*0!O/%9YPQN*U>1>MYK.G[:`F7TJRS.M^@H";^Y<-@"OV;VW
M(RM><,$%N.#RRR]W0I'M9K!`ZRH0IF<!@7J/.BW?=Y4G08=YKU(]-##7%AJ#
M2><*;8H<`!HEH"7+33I>'K3<6%%R?JY`J:2MHM,K29V/`&U;$$TH;*E<AOFU
MUCAH<LW[][[W/?CC7;*^8GQ<`TSBV0&<29HX99_Q'>\7,;C&[23>%,,\*15K
MT;!1IDXYNJ+7N+3FUY.7]/,7[GM>=/<7[/HL#P!.*M9D9DV@8`[T:=L7(DV-
M0=I6L#-;AN5\6.-#G[2(,LVKNI.$4QYBGII,S<`'_Q:[:PJJ_Y85KL!XA!%5
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M)J-2,VZXX0:DZ]7\!73D`ZWJ;,60<X*7_U[XT`#1A-S8-VA&P'3_O[N-*`+,
MT4-1!#D[JI7MM$FN]\<*JN3;JH%.WM6^5HBLJB#U`K!C:DA9EHF*8Y@X@&-"
M:5L4/3-.S_K)3W[RK6]]"SV74S8%BHOR3<]:)9RU2D9>\NP\JRITVJY)S13^
MVN1MC3)5B')NLHU7:X6=4&4,W8,\&]@9'];T(UY;$D]:^IJ9%?*,D%/HSJ2?
MV_*G;W(ER@`%/NE98^0!/HX49'+CC3<BDG(?BB_%X]7%*@W'4E(]I4"IBMS5
MTZZN2PZ.\@HKLV!^"]3)AS*Q(I-@:$5&[;YV<4P*Q!*'JHP7`R+76;]&YK$(
M(FG,B(O//__\"R^\\,X[[\QZW&=R5X)!GBS,!5M21N`,%JNQ7?UY;[[YYE>]
MZE6X!O*X.T0%'52J?_?O_IW/AQYZ"/(\^NBCCSWVF$_X@RR_]*4O`1G$^?G=
M]IG=EE[PR4]^$L5"2`.5YO5_[#;[.`ZW7G_]]0#SDDLN,5G%')HF2%B`4RH;
M3DGK\9K9^2<SJPB<LL5]IFJ5I%:GX_JM5ZTK@20#G8ND==9UO22L(#HH&^TL
M?,L(G[;5JI%K,LVK)/?)%#.\!1(@5T/Z>[NMHM;Q>V4K4H)<+1-B_3[2UNOW
M5\/3H./W?__W[[OO/IA@8`%"3O,$0H,9LB'"BCQG(O!3M.?O?>;@RQ9=`D69
M7REZY8M91BN.X49@AZR;J=E74__LL\]"'C-.&,:&+]RU5C]IU^9X;;4Y-ML7
M[4O?G'AT3;"3]QV'Q^$^B9^KTC2ZTBG[SJ&#//GE`Y.1LE:'VHN6GA=C>CIA
MZ8<^3[MZS%?8.:8]>2VJ/&[T8`?4C,*58ZNME)GB@3,F^ZQW2?&TCN#$\LH'
M?&I9]8^7+:;(4U!ET32I0O'S_!8]:Q(M4M59(K4BO^I55AVW5:]2I<6-N%3_
MK1-6\8>5!,^26;9UMB"\'+V1D=P:S5][[;7$^ZNOOAKG`I;6\2`ENT?F5OMQ
M93$_=0:_8;?5.1T:].EI"VFSV!&P@<\W=ILE[_O?_[ZOI"#2#OF_&/N$'!#4
MD4*>D'&^F")CRU^KYA7>P>\@COAMN3$1Q$[X65N6^*(,[E%7,V@D0!;/DST_
MX2?T*)%V),^.9SK.`-L5*HE?D^)4L`QW>0D+$&V9R/-8"=/!G+%.U^\O:<>0
MWG+++2;"6R!L^%,>2HM7+NQ2J,K\*K*Z],\,.^@A\V"5G].UX3\AQ`C_/[O-
M2/I[[^ZIT$GN3B3G=O`JY)G:_A%/U10K#I:/(Z=\D3R9G5W$<D;/@G)FTZKQ
MD8]\!.Q\;;>9]Z>>>@HED(O*IL3(&'/LS&O[B0D/7KU+;9,<VF?P,F4Q-I')
M)^\S0R<5?7+/!VH&?.;KV'^ZYDG[VCOC-Y]`94?&AS6ZU4$WUB8)?6U>,]5-
M2X48'_IDH&?J2>W*GW5H27ZTXSI(J-CC3#>%9E6N?[9\*RE-D^C4R?Z5LZ`>
M`;EUT'`DUW]-/7*J[&W-2J"'J4]]JT93(="NAH1R_D;S"5V>I^B+FF*78.5Y
M0`?-A0AA)_$&4X":5^^V8"<+AD79.0#'03N50/<)>:QE&.>RRR[S]XJ!/_#`
M`TDXE*G6000)6"Q\]"SJE?61D(,UP`[,*1(I+.J@\XNZ(?R`WZDM;$P,'0PL
MU-GX(P`\E2^OZ*GB$$*>I)U\W.5%3JRF$_+K)1H5Q]**7\Y^MIV\/'DJZX<5
MR"1@-'U9D*;D8+.<>3:;=J;[8A*,,S$I8DC#LAD]I&Z0BP^L/71$%25XL,S+
M4P0R1=ZTENC1&X4\I?#07M%)K0EKH#-]-+(]H@3T4$F$0#NI9CS^8U]JB:SD
MNZ&N"F+"=K%8%LK/[;:2@,Q@76^0`6W+OI'!CQ/NBRM#GK:-Y+-ZMX.(:>I7
M,/.:AW6P2L;FUT&DL&C*[ZP"SXE+.:#Y:?(C5N19,],WH8->:K(DU@*G&X%G
MTQMTA)\)V@$LCN<Z?_[SG]^_2CC*R%S%&*2+0N`/4DQ^'K]YUKD:/F8ER-Y8
M&P)\FI`\@1EV6D"MMLAUZG$531J:X3[,^.'=EI.K9B7E,(9I42#JBDTF%K>`
MF?I..N)7Z''>>>=5A`&D9.O(7EI6Q4TWW42=Q""8A5)VS377`)E7[C8K]9$C
M1RZZZ"+_K2BE^Y8Q3<D"+R3\W]UMY)80+YHLM+6,0MQAB?S@!S_H7Z6DU3:%
MS#/(T])<OG_US8QS3:]>\I*78&>#4`#55#P.>!N]-=FAP*H,LS%74E!AF?71
MJ(I[$71=LZ#EP@6SKZ;5SFB'.66&!F[F,3EGW((I:&EDI;S9,;S&$'0;/2R`
M6KPL"$4J3DB-&@-RNM($&R<_FU;(T`L6WV4T`'[N0A!15)@+%A\^L.F_S4O!
MA.5'S(HY+UAYM'3>JD658U*N:!9LR&;'35.XX`^9!]J`G6]_^]M4+<H7=,5]
M=2*#!A4(/5XIU+5B3Y))@3KCVUH#DC?;&B5XRE+7/:OU6BYLM6F/M>>%^\Y?
M8W->#<LCY&R*NH^H,^'*4]-OK>@^B1)K7>7960OO4+)*'?)W*@;B.>><<ZZZ
MZJH\T17+I?47=SIIR.B'1&%VS&"U5I+`,Z%DJ\F!4L!,9)-K]?_C[-YB?[VO
M.K]OS(1H@F"4F^F@J6:JMLR`D]@,HO%A^["]]_;>VV?C8QR3@`F,0!G1:BIQ
M4PGU`EJUO>*N%Q6JYJZH%16*RC"0]"(D*(3$0<:9D(`/L>/X$&S'L1W'29R^
M]+SU6_KNY[]WJ'@N?GI^S^_Y/8?O=ZW/=WW7=ZW/&L.CG7][V/S:ZK#KY]NA
MR"9-A`?R%/W24-X0/\5Y2^JL*L&_.VRE?7DP$'?CC3=6+\9HXAU_[N=^CCI`
M%?MEJ3N-,'_RDY]TH]S(S;".'S_>^B_DN6Q+)?9@!D%(0NI"'GH$3/RWH","
M"6V>?/))R$,:G6:G4=)IU2_XV,<^]JEM8_94UR`O5K/.LMX\Q@,//,!.`(G1
M4A6ED!V2J3/QQA7K;&[5`I.7RB)J+MQZ=/RTH5/Q#VU:LK"ER1"I:GR&92&"
M_243*'/%7?3F%+O1T04!SG)GWG*O8+8;<SBTSP?8(#5WKSB:G7$FM]P90:MN
M=:1X3G_,V0NW-5?#33F\K5<2H>*(0AXG:[V6S)IG9=XD)(2J(<\MX(PNJ$I%
M"UN&B8]\Y"/&OE(4=;H>-YKH8I9M-L_++[_,[H4\1A:S8[J9ME+J%796S`D-
M5D]O\Z"0YZ<7"N7)SUJW^<M@2Z&&N8G>M=39V<VV<E_OD&?-C!B<F4"=R8]8
MMXGA:3U]6"]FYZ@_)V?R9$FT-?ER-2,L,'_EE5=8&MKVV6>??>.--[2S_BH&
MK($UAA.PHU/T1<5_R:U.'W+C(I8+$2FVY-</6X%M+=3&4V$+COI:U(USBB4K
MJ#[/S_@36L!M_"T%J<619NB1"0,BSU!:*.'/QC-_\3"F5ZR:N^^^&S"26_A0
MO1*?0,,?/0;D.7WZ="5@F$9N[75H!VPA<H2M550&/V`QO3+?AS8:[<TWW]1N
MSSSS3+[E+W_YRZYIH$Q9$N/"(XN#M6G)D(=6>M_<93$T0CRZ27?`40%4=">R
MZ-;^<N;4PM.P&1XM2?]/VY;I4MIX*M]@D8&:)R<0FZ+#Y4<4FA5O:O[8J*>+
M0FQJ%@-&%=*K(>B.KJPK-?AUUUU'*0QPC+=>/X$I`&E*^V5WE<O0`@0T:!&S
MV#^/X7S_;0W=D-0RG]-:U[/%`=+;524P/`]P<DI/YF^9;LWW8WTG#*VJ.\<)
M;A1_2_P86;.,'`:MSC70Z.5O?O.;/E][[35_*8^`^M,F"KAZ>%8<R%9IV3H8
MN70C43]QXD0\7>52E:4^03NYE']J8_()HV89?>9B@=60^?STQO0U7%[CW+[T
M_&T8!:%*<8\.,F9VJU<Q*CNXSK#6#?)XZS!GIE>@QHXI5:'+.9`]"17+Z-6S
M8"?^_"]O&\-2DU(EG]2MF;)I0N[3`D>AD.XN'KC5S\2F],_6LR8U("!J?20W
M)C4AP`;W7]JVRH`6[VH21.4I1>N;;MTXVW4*VF^9+(.94A">V+P+;&XVT;C,
M#-8FVJJ26S"'.NA9TE(Y;!CRG6WSLH"(4)')A#]Y<[!5<E#STDLOD313>_]]
M\<473;O\RZ_@VGZ_^@J684NLU'F!'&G"Q5**]NH/_N`/XBR*)*UX$L_O34T,
M22-SRXO0`BKIH$:N%FJNX)S`-7)9]OE;RE/SF0T9^-?F$SU8EDJ1.7F/`S&?
MY9Z7>9'.Q@D0EZ,.:JY:K>0B%<N/R#-3]""3T@SKEEMNH4?F[X0-II72.^M6
M_MZ2Q!1V)S;>97S.4QNB>;HK0`#2J&'9)`511&+@7^5ZY-1J2*JD8WZ>JMBT
M>E7(67=QO'.R=D(A$-326Z$[=GQ2$*/,\\\_3Q@^_>E/4Y`X,8PU),0T`0C0
M/KV6P4-)6[:>E:S4?$BW)B"G"911)BJ>7#U3]6^6HCHYA!D0F^G8Q">W0!:^
M!7UE0XQS^]V'@EDSMPJ"6KWJ()S)^!FO<K!3F8F5!V/-21_DF2)]D(<)E,%3
MI6`FD/>B7_&J13;R\,,/QT)@[F"`-AW0RW1-"S-^Z"-HHEF//OJHOB`2H"-*
M"H(4>45A;`EP*Q1C>\=3ZN19R6TZ$)?O++B0ZC@N/O"!#Q1R'.]H@+9F,KIL
M[L$*C+:F/TMLF?$Q]]YYYYUZ0<^VK&P:!7R<D[4#=KP4)&$YDZO7M\U!&`LN
MO*D&T3@D#2`;XUA'/IUC^(,P6H/@:3'2Z.^OOOHJ1-)<(0^$J4A!!5-<+5)-
M(MV*"=WY@VVS7\Q`91<\)($Q*\P_EDND*)<:>8B.FV'%-1K(:.%"`B*#+25D
M-3+C'F2TM!P6:K6JKF%=?XH.YUCKCJX?HY$^*OZPJ4W!TJZ3$\^O,*>\.6U>
MV*HW8MI1<W?)/"N,JHE5XF'?W^-D6[W!&3P>0_M4\4I[EC-B$JKWRV#M%8:C
M-6.X!<%"T>(5]%G%V-Q?P*WB[$UUF[!WY7(/]6"KDSX+S2(,=.%KVT8CB)`.
MA0#%]%9K/ML@\%E=M6,"K1.B_"T_=2BM-4SO$:+.4M0DH3>KNOS\Q/-QVDQD
M<LC3NOENTM<R>@Z<R>\H:6)=TMHQ#?;3?[9LPP83D?N/_=B/[2AWXKX@`Z6B
M1V;E%;08C:-!Y=RQ8#5XJ>BQ<-M@$2USFI$="AG6C1%9UXEZ\_2F`$5Q9/0V
M+L>#5PA]">"ZNV6LK)1&HN@1)M2-9?)SV\;X`1=%IQ0(%%(%:"[5^G[9UE$Z
MQ\#<<!R9N?&H`<4XPO[Q1Y8,<^X;W_B&=X<PA(?!XRO<`"P%AK%GB"N9)^>F
M5\0,L&3MP"AS*"8WM(F2CFUCQ_#GLE"+B/H)9`4R8#QXT:K1O&CJ"'.BD`V7
MBCS)5#MSYHSIGC>E.[E6\K&4+!]_18Z=F-`&84IV\-;:;1(?\L,`C5_8MH<>
M>BB$+YR[?FPZF>&:O>%VK8ZY@O\6>)E_/H/'KYE5E7[65@"P:`0/;VAK.>/X
M\>-1#53.K"(X[NM%<OQFQ36?"@]+YBI,U%8]/DUDOE;98FU5/$8%=+*:"B5*
M,/)1%YE#P#)L*@YHD"J8L!55)[A.V3>1H!)[%__H1S]JZ&'>ZU]#25[E!AI'
M2`MUT-<$QGUC&X@-;.R'GSP4')\%KS6J9\!GC)#+#IGCX\D9")KE]2&UN'Q)
M/)]UJQWRA#:=_YYEFP">'O*R0_'BC)PB(=>$T-7ADWMG#)[)0^_S@M6R^IS0
MG=MNNTW#FEX!DZ8#]4OAQ[HI[ZZOZ9?QO40`YY!&@Z9.G\#CID*%8>04*FI]
M*N'F$,[;2:3SEV8;QY)!DOVW0-D''GB`S4/:"YI--5K:L!4N6UX\H<IWZGBW
MRQ=1!D&#.\L![-2,?F7(@0@@PU2&)[`"^#@"?-YXXPW8P@2R;^>/_NB/("14
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M>0!=4WFRZM24!M[";LP`\7W1"VU;@#KP@3Q4%1;%KYZ;,==QM08R3HK:JEY5
M3LL4QY!$0>Z__WZXQQHW.-(O.!-Y3NE%5*D5L10G\[OXYTFR:)TER1\_DL]H
MKW)KQ$;8Q"TOG.M[A>>WK:AC[YXLP1GP`HN*#_SVM[]-J,`1HPA&1;'K$S3Y
M"GF<1O!*E#`(%IQ<:&ND5>06PI25KSTKI@!A[#"BFEL9S1TI733]JA85;7K_
M^]_OL2N2V&=QPC$EEE#VKP];`<D^V8KM#]_R1#CD`0Z"M+9FJ>XG)&F=,1K`
MYBF3[5N6:+S6S>R<D-LG+VY^F](QW->5@3P9BV+H;6][&VET\<BZ]8XKE"]6
MTD>>ENRE0+6(Z`*SBZXLNX1\DD.02/U-?*+R+JVUB;P>;U)6H%$^(I921.ZZ
MH!LU\^J:)5D4+=:]"M$W+NA*=_GDMI$9HP\3Z(__^(_9NL2#,&3KPJ5[[[V7
M/D[21'HZSI/5VIF<A:J3[]S.:QS.+I)GZA2/Z_CR"VU!4\ZE+C[$%_'Y7+[0
M#XX!UO,,Z_N0P%^P>);M/UVV=0U]]>UDX;2`54U/F),!;%32%YH4I#3/,A?0
M_A,ZWG"@?QW_?[8M:KO2L7-Q.$'7:WD88D8#0^)>2,*+[C`(%JI')B$,S($V
MSK=/N6)EO^NNNPR4#E9NLJC[<*SI0^LI^50;<',KD5*GA5?!8-"7Z>6GUJ:A
MG#9_\,$'R0G$8+1D[3!U\M[D*`9'1C?0"EZ<8TKELX("L:_X!%9$#@@S_*@`
M^'(=TNCOKJ9-7`WF$%3@7"E>[1:Q0R8EXR<VLY(EQ[V3V,-5[ZBM-(5&RR0H
MTJ\)9L4CFC=IJSS)Y:'GI2\'MK)Z4URXTC_Y8&F]_SJYO*UF6U2^%:6,AUB7
M"WYNF:Q5IQS^U9HO_@'^9*E&OG']]=</OUGTL(368Y0AI<L\0Q-P(T7Q2*W[
M.R%3M@7Q"-O#`2T`%N"`3]#!O-2`E:$!-5'0#Y-;,0:53RWD-0]/:_21P%<L
MOB7:8L!B_R;M!7+HHQ)>"$S6?N$3>MQ88TC*[:"+-74A+A%'I.EY5SJXYFUE
MF60"O?O(MF9&C`TSZ17_ZL!#^*\.-;!VULY\79&GN[][8_V::=U*;7KI@=&]
MM-;V\_.L3*=KKL0_W;8)%QR.P<B^0IYR0J<V7PGI525^[WO?J]>@2D1YL03D
M*HGGO,B]B$QU2A2^3J[8F3:G=%2,P-QRRRV>TP5)G?T6K'V"%,I.%_+KPAG'
MH5,J$SVI$T!3GH=.@!+^&&=R>5*..,=?&E5;NDWR@R/'FY25A9T!5DHU&P`D
M7K]M$*F\<F-6S!4`!]HP8(!&V56D.B,'PD`G`E9X/-AA!<$BK^SUB:X6TR#$
M\I5M:YF#M:-E7!F@Y;=Q#I#Q%TU7P&%NGZB'\O_`>:JG_2E%W!W>%PY3V/(9
MRVMHE:J,MFJ'E646PE<['IXTU6HR%>-02^TY=?N[ALJP]),[%O93N?DA>6MA
MO8K&Q?G$#!DIBI9O;;'94X'*Q'Y*%,7R>LDEEUQSS34N4@Q\52<\<-6HW3&X
M""5:!@T]8N7*???;O_W;T%O;YBZ&ZLQ+R*.I-5K&7O6I\RT7#)DG)P^VBZS5
MG,LOACE%;T9HZ9IL4=U1M)7!12=&>.+6$2"8?.EE?9V=K$V`@!G',$MDS(QA
MDTMV7=X:A_/J<IEI5P$\U4Q?4QX&84*>RS;"C16@)E?BLD/U\TX.8;)Y=ML:
M-QC"]`HAS-$HY:,ARO_D_&V09U(DI@"ZDZL7;,[E1H0P3XY^T7&E`$=$T"B0
M)6RV92QH:MS\*Z\%XY,,T$0F*[/'5/?,F3/4W#[#I@E44-"0-#&$))_6_/*V
MT9VBB.^YYYYF7GF5RY:*C^+&&V\$:*Y91F>3LICQ*K\;ZW(NBRSYLB'<W5_\
M]X8;;K#C=8R5D">[!>9`'O/W%LJ-9;D0?357,MB!HY`*X,1U"9$<T12M4-,4
M^T2TLK:LG1PX+NOZ275NY*+QM6II986HD60BK26KQ%'$3BYZ;^3UZ2GUJ7A-
MC.YY;$IBU;P^LR>C\LA%MD+TI*+GA<X1U-S*.96)*<.%LI<$427Z2)C#G"IR
MQGGHG')I*7CQ11K<>$'.C6O#)C1%?,RVSIT[YWQ"4K7!#%2W*^FXM`X073Q/
M&T0J\S=V+XC1<I*O)#`[!&@SOSUY1$-UQX0^5B@D;KJ6/S2O!RABN=FK'M$=
MY)PEDQVK1Z9TA=LY2"K<KK)?Y?\6,J''_^1/_H3`-Q^AE90]\R`+)XV&,,UB
M@I=+%T[4,50F#OGR)=.\25;<@R%/ID[8-5=HYC7NZ`RJRP[%+&81K0G4N*"#
MG7$@#]E.*><%"E8SHK=K+KEFAN;;L:U+6GEU5IK3W#O5+)A2W6Y$S#0R/-$I
MK6@4,A&=.`6)*:ZH"7U4[2%*5-DC+0]\JL+F3`)_\N3):Z^]]N:;;SZW;02R
M%&]:#VK&C1-6.%(L,>L(O/BO">!-V\;.\?<3V];B[)1LL%-2.0.IB8:-.,'/
MCW_\XZ;D)(<TNE'@!L'.GCWK@A[&$6H(+6-3"7^\0@2;!(^`>>O8/X@Q.2=C
M)E.$S9R+S?/66V^QE\B\6WB=R`F-VFZ=S]FGH1!V^73-6BPVX%@'84ZUZMR4
M,)/J2``*UZ'LT$!+:A,MXV#<:(7O%@08PFB$4ES'MU,IPY:KPJ)F4IDN,">/
M?4.`EI\:H"E[[J!LI-B*FG_IV9:$2(+6<]G29_REG'HR'X,9:P?FQ&`_LRT2
MZT6\FJ:H53TV`8L9(_.F18'\2R5]$#D"IKDZZ+__[[9IJ'BM8VGV4P&-51LL
M&&`21K)PBJ^H"DDY8D5B`*4XP_4(26`#ZT3J$*!%)D\\#*Q_NFV-2N4%&[-,
MQ+1V24RT+T7.YEEITEM57Y?.9V%]%R+HIS4)XJ</1?U^ZE"S;_+39YOEK6';
MV,VJ9AXWSS-AU8%/R!-(5I@/R&3_M!_RV,^E/-$[.^29):VF6I$J#\?IE(W+
MR4P?J8/VU/ZQ[Q8S7]Q(+$E90<0@_W]C1(M?$V=5G&<E^<BD4:#(<*UG@G/Z
M].D[M@UZQ'ACQ*0"`SC0!L@$-<X?*MI+-YX!V!M_B"/'CQ]WLNO0&M++`/!4
MK"^RP1YFEC!(3)38,![)_,4\`DP!*_>B=_X%A6BHMR-(S;F<[+WB9*C&"I0@
ML<TR#(LL'-=LJN6S%2[W(I8$%:H4#4M0FW-Y&)A301:S43:Y)\S(B9"\`.88
MVOU$SB-2IA%%N5!/3ZYW@':.%UU38%*&5K9<5LW,L,(?#1L>YD:.>B@_S^[,
M0'@M&)I':.A,B4&8$\]J_K0H!ZEY]&7FUT3N:&75*5Q8F:2"=BK'UGH<Z8+#
M,[W*OFK5TLN"%S*FQ<R&@`:9A#S&BUK/X$**R#9UT+\A8>'Q.C$^EOP\A27'
M=NC@_[QL42OD>39E,[A4R*DJ6B79/?+((WJ?':NO8SUM)1WL>#RM`2(H'9TU
MXH_^CI]G[(IU)7UF56'(ZAF^_%!(8E;`!VI63\[X@@*K-3GB/0<NY5DU&PCJ
M2.;-I()F"!6W[%']FE73JE:SK:RXJF5-_9HF7*5BE1.:>WF"EJ=X33GIX4^L
M%PX21<(/NJF>X6PJ$+4V5$*T/@IYBA<MMM-X;?0A`U2F-.$JL@$BTD6P"60+
M<)=N-1;-=&+(@3-F3VP/`Z4962X=4Z%,&K#C-;/0=@7*#:/&4ZU!9=@`[DY.
M``(QH.SQ<3$S6FEBI<2X3IV)Z'777>=V]-%_@5[D&%3),P,'\ER.<Y3C,"'&
M5VWBC<@;]##P&1,9,SY)'?PI^*?RV5_ZTI<,EQ#&\_C*@"2ZM".'0$A(I!O!
M/7SLKR5-1%]6>+^F:XX#`*FY]F$63D`"!80A5*QZ=D4)MHP>GN1>[@4GY&;"
MJ)J!QLD#<_P4G]B0P+<Z&<URZ4XEWA9(D\>^5;#(V_4I$1W,60L=#OCX)`/N
MZ((M*FEG!IMWC'^RG-/LG'$LD[<HN`UGY"UR'EWYJ4]]RG'6M9Z:NUQ]]=7%
M8Q>;VEI\1E1T+DUO*RX6CU-<!P409M@7"U%E6SV5"\[=W=&4R@@%CB)^UZ'Z
MV@19"]!<&D<3"7G1@RMW7^`SJ=_CRWW7@>]]R+L"DZ$%Z^":S-[.6#690]DY
MJRTT(3T_>:AG,5;6W'>U>6;U?[SBS:H&><J;:/0?P&EB-5S*X^$)<S)[=I.L
MJM@P==@\D?#HTXI^1JT,:J(1*&(MDI.0IP7?EB!M-*44@(JJ&#5BL1B#@6P3
M"4_K\=9I:0T>P?4UUUQS?-OL.-FOGG]*5I%;SSF5[PKE)3:$!-30_:+^"(/Q
MB(UA/'IDV^S$4)$3TGNU/'W__?<WE!/1?+FQ>P&Q2@$RU0"CE_)'S9*)TN2+
M*+I@"_'`AV7UO</V^NNOLX7,Q9Q`((FK%JL"1>$*>9`\E:N5#D")[.>E+Q;7
M]8%V]$>5G@$UGI8!HS%+1J"2F2Z.%X%<@(VOF3%5UI@%)@9>G/;Q,+<X7A'G
MEO^*&:Z*7_GFN70,0&EKXU&QY>7'V7%EDU_=$5.BKHFI=3IN:H?Y*2JSYF[E
M0VD<K]!,I\$N/J["L>+LRM!J.14R)(<>)BM(WT4;-7782Y<`:/G]O$+\+9'%
MZ6@R6=T?\%[AMDR@2I*Y471)F?&L4)T"9XI:-^Z`&KUI#&(7,9))H*:@_L0U
M(O1F,9.),`D(JQ=WW;_T4$A]G4D-Z^G,MO+\_/16#7FB!-^S%-4:5\^83(,S
M0SX_0)2=,Z%$@XKC7N[)PYGLG!*UFH*%.7T.VOPGAVUH!F-7;JI5*GHE)*I<
MT,(Z3-";G_O<YR!/523*Y"VEMRC]M1)<E-K%EH<_)*'L/UUFTD''G:/O""W@
MHC5>Q*W=*!-K)GWC\9Z']]C.,6B2X6J[)+W.!TW&9;H9XU;K1W']Q7ACOX(R
MA9LZPI*)^L_;Y<6"+5D"$7*V<D<(S8F\Q0<_^$$6EUYV0JQE<5TR[:`$E:<U
MCK!MC(#Y?+Z[;=_ZUK<`H*<BEI[!-4NEUQ0E-0,<YCK1]4B>,&8S>AWI4.%J
M1)W8YY=V!>@$$-@JL9/5!1D#T6VU:#4QR7GI@Z-6#//A3QYNR)-N%G/>*G8,
M-L5>3I`GQ:\R8^9N*:+YMP&(V;%QV1R_^,!8XZK(TWK6"D'&'4B>+\C%O:]W
MI[/`L"6\2`8JKA?EX)K%64>T]J'[*I.MO[3)D$>YJ;O`V(@3:Q^0,N4\8C'5
ML(51N6;,<D5-NU>NML]M6QPFAH,<SL8OAA#PT;GZG>`9\O2I*X`(@WX,&'%B
MV/%U@GY7Y#FZEC3(,Y2`Q1A/EGJQRBO9X&[]:\R;/B<*NEM,:MB.^Z)`Y>ZX
M/FH>GH&@`*?*$>W/,GH+6Q,T.-N0NF?;M%4A-.Z=N,0#'P]O@-;@T&-J!$_P
M:@/-)'XZ&`E_K`(FR)D-Y?!&CUS.PI`/D"O3J*F"=W0CI;F>IG3X.K>"5^9E
M;LIL>//--W6ZF125I^:,'&C9ZJ>M*K=F-P:IQJ;XN.P/^Z@W]<"M2E.BZ,')
M)&$#`O%(&]!-QSSSK;?>2M_]5$)0Q$3@HLJ2["O/P-P*?Y@]GH?$>@":DDD/
MH@/#1MO20C/@(QJJ_!,5\&OSUBHATGHX$.W\![;-LV4/%(%9=$T\I2'/F$#M
MLS&HMO-SY'JCHI1S[/L$,HTR>6BG?FA+V[&W!7<1XSC9:>9])LO$LGK*:\W!
M^JLA0S]FIE+,.^ZX8ZJ2953'-^AKU!;%O4=I6]1?[L16THF9QM%<I0`[IYK%
M3(*FWHD*V6:#U:W-!(L*\`J>O-6K'`5)9CGOCA#[:-Q*_&3H^AH)CY-U']@A
M2TWD=3?+%O@X[KWRJ>9ZI8QY3AR<T+O5R3S^Y'&V7'9@#BP:\#T'0M1)",V!
MLWJ/YYS5I3.9H9.$'L+,`M;,[\8>VZUJK8&"(<^ZAA7R="2#IU7UG,D#/N/;
M:9(UUD6,[L:(3)T*21"8<^?.D7GZHA<FTGA*GA48O#(G&`1C52J,OS")H":'
M0.G5MFII`0UBH!EGRG_L4#?*W3V#!\OU%#P:1CVYU]0=;DKD='V,?\R&+VU;
M51OH+WN8,5-]G#8(0XI"I!:L*7MC6:2CCL1=#S!+THPW-1I`,FFN41%G5I;6
M(/8.IBEL^'(567=Q8)K[>[9B@:H<08#I15F''D##&F$UH%8J"<5-/4,TB25Z
M>(`B$[('*L>9E5*DGTDBZ,@^*3EN4ON;-S7G*DJPZ,%H`/W%9QEP&4C%6,9I
M7.97AE!D2B6P1&98B&^1-MH$FIF'DEB"I[_RYV0_MT(Z5>")F1,T($DS@X9R
MT,`S`#'M3'XB]/``&I^TN#[[)"DJA*SNB(5):U3`*)Y)2&4H\5Z$?##'O3P&
MP\"]HGX:LL0!G\"S\;0B<<25;.A'4*/+B(<KDYP\EMGV9*E8B^;48`?XO/SR
MR_YRXXTW-LDJXF52G&89:.(&1\U79IY=9.!NFU+%8PA-(>,UF'`\/'YMAC4V
M3TMF%UM5GY3/"5%N8M4S^\R\*0'M*/*TL,4J&%[E*2>QKF<-Y:#-3JX>75:1
M;N,I9:$@%*I%QO`G_J@H?',OQ,15-'O2$G-@CH+ASZ%Q.0Q]%A46JUBLAJOW
MAGSVY%ZA`&S/[_.&&VZ@JF8?3S[Y9`'&<?M#CT<>>02\1&@#9$J,@D5-M4B1
M?P5*\6Y%^M>$BU`5GE'D#$@)'XJ*M..3W!I,&\$A#Q7V=EZ-[M!]PO;``P_$
MQTATR:VKN7O5M4@R-<FVR?RKM'')5LU)*PN5P>/D\)QFE;K>*)^[B75Q[[WW
MFD'HH/OOO]\$IR0%/VF<J?X0^!2NDQNG=(FRKKQ.@%.VK#EFO/<%Z46%L;J4
MA\8G8D!##!5F/MUVVVW777<=M2)1E3T%,N1*]_DD5WD104T@T-JZGO5'#P:U
M`)K7K*QP"2_Q!U;6*L%K*<I-]8CC$5U6503@M"@6F+-(6S6;R9U/S_"S/_NS
M@6=25^'XHJ.SW[+E,D=U7^6Y\QV1'R-:]2\\@!XD8R30F-)J)E%L3@V@=*N6
MS!_"R"E+BS)"(:K=8O3$#;[K4+CJ/0L;V$02CJTRZ^,.5BMGTK)FN6KU"$T`
M3[.GH=^Y_%#:KQCF;IHA-(_T?9!GY>&96.4`=OB^FG/9U\4YF7/O]#EK6$G%
M#R];6J^_[)-#+4P]=4<#7'EVQ<;'OEYBYE3%RN#/0B[FN<RI*F*7\S()PD7#
MWG???5!Z;'*BZR&]2UYQ+^LM?+WIIIN`E6F+489%`4EBG(`;<5/X--.!,S"G
MFGJDI84A;^%\@Q=X*=RQ&DQ>S6D5%X8Y+7-7A(N0EZ3I91D#]]QS3W3''J\1
MG*)I;3VBG4OJU\ZZU43,?\&LL1B@_<ZVD48*Z[[E&%91:U@T6RB)4-J_RL_*
MCQI",H0<+$JY4CNM^D6'2/&U.36,E!ANP!/F4`$`VCG_+80!5M`F3HF*"C6'
M:L5Y+)S8>(H9R$XH#ZM`7R]2S0A(JTV\LK&L&3K)@3#9S)6`;'HU12$UG7;3
MT?2BU!6W*%6A@$.O0$XT#D@I27SJ0GH&0M@*N%<K\*DH5B=K6.BMG2G"SH^=
M6XD*_-(O_5(I?N6*QO4:D+9H&S5N,;%Q943(1A)B(TQL=-]?__5?/_'$$R;X
M+;5'_$6$")MA6K__XB_^8I:`&5,+6Y&]#^S\RZ4TWLRSFG9==J`JS10I%'#6
MN=Z]D>KD0)Y%J_'MK.OO,^U:PZ''R#GJ0QYVTUF#6UF_=NRF$[&\\@VN14+-
MMG+2%BY8EE:SF(&==RP;V7"D.NGZNB0LLA%Z%&U>.9LIIU*X?C0X\2'X6D*-
M@Q%2V?+IE5!0BF+LA028)0,ADQ,/7)>UYN6-KKKJ*A<$'5_]ZE<+(08XN5/,
ML_0XN"CO@(04.Q2/30%@U2YOA:[ZMB67`2ZFD8,4GSD-?RH90(R;RT3[257!
M#CPY>_8L'=>&4]-3*ZV+:XX#(D,YO2:T[NLND1]Z'HU#=%LI<SL/_+]M&SG/
M"5]^NB/-+&A6E?X\>5GJ6B_DT6*0IW0/C7/MM=>R@DH&CX%-%S@M%=`L.BB2
M+@=S\N1H!3B4T9&6P\J3BL"M<.C8(W6Z7HM9RW]=JEN3S`P;4I1T9>U4*<"1
MI(NDC>5#]ASQR4Y+;+0PZ(@9LMF<%Z?@'CYD&%K%S)7B^@KY+LR@&7&I4OY2
MH=66[]=@10>ON.(*KTSJ0M1<E!&`YRB(,36OD8MGB.I*=C(A(6\F]>QJGP3/
M"!A[MA$M-IYL9KWF(/DOAJ>8.HIOA&INDK=Y\B/>?:A7'AKD6V[&-*GKLU"^
MEIS(8AGS9I:&+S\49,_X69%G<J]:QLI=#%[R+??U:/1RK!<YF9MA%0\S`3SE
M9X4S,\,J"706T%O)FF%HW#NS-4,G0JY`.%L33^:CF\CA']MVQ6IGXARY03&Q
M^K2*`\6?.">F[C@#29'92L8\O68A:Y-&2<_C72[?BA!Y%Z.JN^MEL$.Z4L;H
M;9MD^4K!R5XZ'B,E""*9/3SAL>^<O(41?60O01Z`TU<*[BOD(75L@^KWT<<2
M--CJYE-ZOX<\Z@P/L3TMW?0D(4_!.8398WLV#Y/3!O(`A!P+9:!XU"Q\0VW)
M*?[[\6V+A]`YI:B[?FGUGNKJJZ^&`)GBIEV58(AXL-#B(J\H6JP[-JH7DQ6-
M*]\?M%;KO(Z+1FSJ*I;C#XX^^,$/ND5K9'#/K0E>XI0;N:EZ:Q.E`>:7B]PR
M>2.?3O#?F*(GW[/')D6TOB39,;-CM`@BHMUNC=+P4=%5,*7OR`.8O?GFF_,5
M--7*.FV%J\_3IT]#W:H0AFFA7VY_DI9-E1%E.+##$#+JN7X9P:SK+W[QBTR=
M4D$C<':RN\<VZ2<F$"D:SPFT,4_W>=F!-G"6O`=\!AG::39$\7>1@:VMEY,>
MO(S],PZBKC/NY76UW4Z63(EC:Q[90,W*L3S3KLPA:!.0[M:S)G1GF`9S[$RI
MON%RSZ4SL*.GWG[8*I5KMD6H'GKHH<H)Z>Z"YR/?C@VFI<SB^?N)E&:'9_-'
M5%L,6*0NG1RC';&O4O!MVV;N4/@'M`E%M;#AU5C#LM7=U%;_0H:H$5O4B*;#
M$Y9$'___?SAL19HYAR$!?S(V;/Y.3EKJ"HC"'X+DDWC'4OZA#WWH_=L6AY6!
M1ANNZVXMH+1UD`"8YDQH958-$RCYG-D?`/1XVC:.30\?,%9'(T+"0I<]?P4U
M>HM)J-1TGA!HP\/$QN-!(1!!@S1RS/P5G@CG,^3H\E]MFZZ)8*0:?[&59NI4
M)*(T=KC$H`([#F;Q5MK&R57ET#A77GEE^$/VPJ)\B9DW#7_)GGU2ZH^5"8[K
M8(*?B8>WUK]0I7B;(A`F9<R[>[MZ5G='9*0K28B_$*&6\C-X^JQK2'AA&'2V
MV58^GTKPN'Z+^)4!:EDS#Y*^\X05LFD-J\*O)8?J#@(<PY@G8?,\]MAC;[SQ
MQK>^]2UH26V9!*6BM[;.G%CYBIV0LS<FY,F>"&U*YEH+263,#/A,,.$D9_6O
M]5+E9\UI[]GX5T.2,;J&77GLGQ5Y9E6]%PEYFG#E55[+9JW@,\1?S;-"GHO!
MCBW?LEXC*@2[BN2%B4Z-VHBO_12C3N5IRGF)FRX2GF;3G3,#L9W846:=>O*M
M/)L'R"EW[MPY_XUDC*2QP(>"B7!6\Z6QNZ(#M)7F1LI48=DQE2L'[&1'((P3
M:#?U]QGI,30(=EA00,##5V;+R.[!*G9CGJ5AUS7]DH_F2(*M]:ZYYII":HLH
M*)>S)3_@64":49N4NF^5^T`H]0&)CL3H6]Q1]6XJ)EX;!A39F:#@5W[E5TZ=
M.A4-+S'0<:017&CYG*7-B.N1Z-^U/)N09GG(%@6</P4^HK^NT"=(*>E`'[F4
M9XO_-G=93A7[N;"TDEL7M@%S?(9"3;NR?-KQM-EF^?UL^:_*@-,(E+<0G>J5
M9P&6LU-5/K`<A5>M1"K8PQIDNF;GYYDC!(Q12C)=/![%J(=TS1`LNU%%;UL0
M(769RHP9._$FZ4<-"^AH(G/=132XAZGD1%$]_J@!JZ45#46$&*/(Y83.8M;*
MCS&9YI<>..$O7SC!'"E=R_XZ7ZN$>O.U<29GVXR;NFST,7+R+]DI%#`P'.?/
M4:;!`GC^V6$[FI.^(L\$\/0YOKZ+(8\Q(K.'V$"#(KATS1`=$$Y@$G5DXVGS
MJ;*5Z0A!C9+.P4+02P2.>-G?XPS,DG>0T.I$(M$HZ94I`AQX\<47#7\%RA+[
MF+5(HW&P%8?6-QE@,)"&4F=:`'-\YB%L);HB@&0IXK*@IC/)4O%[CK3^3BO+
MM00[IC-:X*:;;M++FE3+_,"R[69;D$=+ZDHV3\,E\<Y3[4D\;1PR[OCHHX]Z
M#():/A=1ARVA8ED29:_'>F1@]?"YFX`A83839(9%N>,K.\?D1=='+T#+R`,+
MK?B69C'5M"K-O+#`#)NH:,L)C6;'B[M^A`#PASJ[NX?75MJMY3\=454%XX+]
MSWSF,XY[3B<;BS547IU$<8AVRU,V/GKXUC>;'==$I;3KJ0*VBY/7/J6N1^$5
M)6#!&)WLOC%4&#*TP[&-YV>'-L>VM?5VB)9&:XG$Q35[4<K:O!E<V7->=KQ_
M8"TN4[W3\[AU!;.\%'VLJJ-+$<Z(*[^U;?!']QE`<YYX\7<=F+Z.+C\Y(9**
M<1%/ROEX;X:39^?;62VER0"=!:^!D:X?\@RUX!`,!C+C\1Z;9]S+XU4.?"9<
M.7]LVR!/G0YY,GU#GJR=[X,\I)<2T3+'3YPX$:MVY66)5H5N#191],1`E>@:
M/8MMSK8O/"S:VTA.$OC_>MO66I,Y$&BZ(<F;TA36K`GU$T\\$35H9/X.QHY5
M+%DK4`70EN74Q+^*>*T35=>FU2)#9)D(V>IDK/5W0FL<!PB5PR;;E-J(7RZ\
MN8S.:NGJV!)TM,ZYQIF@]:Z]]EI_C[ZU=`/J']-@!6O<"+Z1:C(<*7HYW8#"
MVV6J0=?B<S+5(B%T*:T*UHC][;???M===^5Z(DADH(>9#"G]3GI!>D6!,SL+
M^,QADH,NXH@J8<5?],`##\25Y`A\B,188V;A:"Y]H2,*E`(^@(C9`WR@$,W5
MW5J`$.;2(:(-B!GDGLJ\K$)[U;.N1'4+6"UJ.U+>O7U=:;^IEI.;7)?;Y8WT
ME(XS_3$!!Z?D/"=_+;`NJ>>7\RM@U.`$QM7`::'(X:H7*;C4O@ZJ]FN,D6[Q
MZJNO/O/,,_ZE<[5J5CH(U1T:TP5)%VN\]8Z77WXYTG)'-&,XP-(#&BL/ZIHE
M6EQ-R#/>F\D#70F6!W::6+W[4#PB2)EYUIJ$/EE7?5UG6[LGZ=G6$A(#/GEU
M)E&BS*RB=]9$B:$YS;U<]$ZV;H`S*^E'P6=-3/"F5<C5UTVI2H*&&V7V$9A6
M*.+@RF4::57+)1%#Y7$E;P61NH+CN3=;7C'.&K.8%FY!C'49&2A>-!IMR$-.
M6G[-A"!X+8RV8$2U'?R];6N=VF>Q,;/F59J/Z_@,@@H;9DN7ST6;/'^KYW3$
M#$O_3A;`#G;R\\S!"5/1-;J>%0<Z@`^U:AX*6&+.I+RES<:"'I40]*9T'LGS
M>TVMJGVB=*!E+?M6`HQ!<N;,&<U%W@C`1".,TLV"CL[U,$YFR53A)6+2*&1U
M:%SZD-_0?/;LV=.G3P,T3Z5GHS?7_D`FFD0-%587G^"GF&^KLQ#7-%/!-3V;
M!RNI,(.<?!)4,R\Z&].%$:%HG,+#(NVO9$;9&7K-]7T6`U#08&$\\;$7F0D6
M/"=-G'Z9D/ALU!%F.WZB>G`;@$"P@+3)5`L6.@C:&/+(&V'P1LP8MO?3VZ81
M/%[Q!A[#RWKQQQ]_7"/X+RE]_OGGS?M@SO>^][V\/4#;O70B#*<1^D(/&F?-
MD2%)RAXTK5.DU5'3VM;*R>-K6#3K69<O=<\O/9`Y3VK&NF0_*-3QE;5CTE<C
MWIGXY$&A@I:'9KFR6;.8-=3NDRBQ^I9+2&^%:\6<XB[:VF^(=RD2&\$O"(HI
MSG1)Z]EA?E1ENZ@,J))O!\*4$%1`?IP)+6_Y;P<-K#X-?U%7&3[8/&Y4A7%=
M21CB7++9!QU5<ZNP;'-`<DCJ(!6!(16.EW<#A8S1P4M.2%N(1%^BGH@UFEHU
M\VJIR\#M20`R$=6J+:#G0%[79R^X[1:\6"/5R/.^-!J4T3+/`#`]6.SB-$X+
M0-VKKKK*?<VGC)[>`D1HG&9\+)S6I(H2A!BWW'(+2=._10C_P,6W`:)2\#R#
M^:-KDO^L&@])EDA.N5205F?!O=;@M%+KUSZ+>ZSL%^315L$[M6UN`E&CM2\&
MH]HNE3Z)'8),$FPOHA.-1(P9#:(%JDA87/00((`:'53L@9.+8<[TRLGC[SK=
MU,8=26:CPU"-U1UUV4R[YJ=BL8BB%VSQPL-#&]!1O6D``CWL.PAY\B/%B.O7
MQQY[K/IH9GE`Z<TWW_S&MKVQ;;'CLI&^\YWOV'GAA1>*9O<3=-)Z_N@BFDBG
M%X=)TG(@AT5#E%'-],F>,-`8FOTK:IW!J)!GD&K6RU8'\IH?T==9V%I]R#/)
MRJ73#"OD66M)!$IKG=`U5GG<.U.>>$U(+[AT$K6:7K6M([LK4XW<_GJ_$G(E
M(Q-10!$W0D9['H,83JI$4#&^$H2C=@'[OAI8^TO$I%3/N&\,"FH*K2FCBDBT
M!D04*U#;;"ORYWPC-NA!J1-(4S!"6_WQ\JF'+)?*-.7I!`A@[*8X3G!3YY`*
MMDIQ_LV>4NU:8[5PCF[]9?(B=0$Q:*#/.HH&#6YX%T^EN;2#!C&S(PR%26A8
MZ!VUCF;)#KESVYQLK'0%,J-S+[BR?_1YUJT8+7\$6798(ZZ324!)CQ\_SO2*
M<ZE2%]&AQ\Y:(+>#U5RNS<N@!SZ0!PY059:/4<-I'GY"7HOF):YL(3(094&1
M,__KME6&IM6'5B7@C"9R\5A6HEZ/&).<Q#'2DA:])D4S+C3S7>/AUP:9V&8M
MH)$CXO@_#AM<-<8]^NBC8.3UUU^',Z2B!2Q`07B(1ZGH3S[YI(D5+`)6X`7^
MA#:55[-E\%2%)$;ZJ)GB3K$QU=Q+<\%5>%(PH59JJ:LY5.OFLRQ>>&'518OM
MN?Q0L&^<0H,_*P1=+#/T7Q[*H*\E)"(;G!E6OZZU)-J&"B/W78"S%L_*I3R8
M,T&#A>ZTC!7L_.!AN^2P'=L6N(%&SM)JD>3MJ6Q?:5D&Z.9651S(;UP5N32(
M\6.\KK1N3(-#>><$QH_AGC22)7T-<'+4,$*(%G"(Y[E0>>('A6+^:>0E\'"C
M->M\CX7Q4)8PRH[32`6984A7EZU*809Q4N&SX=70YJ:01^N-3W+G3-XQ`JU;
MIZVFT0ZF&I>AF2;U%M[:"03FUEMO9=@P/V*3T._&-4<@D@$Q7@Z?!$F/%W\^
MB_A'G_#H-FMPXP:9MYC5'V*LCQ@;&J>E0+#0NEOKR]4[\Y/V#+1SP>F(P%_W
M&=--23)[:"LUJ;`4S2JQD7W+<"U.VZ6*F6Q5JP)>4>PZR(S1H=5`S'RM[EA>
M(*#7?#S&=88<.1\H'K?;L<7;4Q/EE,LTHCLZVF=ZJME_YF=^QJ7<%R9\]*,?
M#>@\3,N([@N4X`GDB<P_AH'H!U]ZZ:5(MK_][6]_][O?]<D6>NVUUY@W1C00
M2K`=<5IL4<#*R9!*T[%O=;=>IMU:27-YGJF3OI:9J,#?&DRX$BROON69>:WI
MJ!,K.#')*_+,,M;L#^Q,<D2`,XM9P_<UR#.PDTMYMJ*\FF'U.;`S@%.6<5WF
M+U"BQ)FA<2,D!<3&"5S5MI`G\)G*3<;0F,;+0ZSVDR/-U_S%3Y2+L0USBJX)
M1HP^8(?(#>%&U$`$CQ"V,JXKB673J](&#8Z4I0`>(VEIR"W'4X=6RDA4T!1-
M*UF"/(4),;?`4:D<NDD+CP"O4OW]D6?]FN^EB<PHNV[2;IY38V90Z34H!)F)
M/=G0*>X>IR(8O/WVVUMB(X$E8S9\M$RP=M\%GZH.W3WV?`V(2"#E&D:(Z&WC
MRPKSJ\50/=___;!Y!6?&`U!P%&OG;[:-\0,<6@`BP]J3OM`LL_7<;KI5U^0\
MI-3%!]H<S+IVQ-WU;]1_;D$P6EK2<:7]4GR#!;!ZX($'8#4=F?&BMQZ2YS%B
M!WR.':S3FFY&#0T"\,N,KA!V!D_<FQZFD8ZH%.Y.KLK>^OJV`9.WWGJK[-%`
M!BY5.X!19/[EA+@+?,:G442B'?(0U`34@(4PE*L^^>EAS@3VK/!RZ5*9Z^A/
MP[\Q=L[*US%;.#.`TTXNG15V5E+WW9+6BCP_<MC&YAE_\FKPK*;.](4=%CZ!
M80/GYRD/*Q9-RA)%6(%G!;[&U9E),T3BQ:2UC,M8<LU?^(5?@$Z$TZ>Q4LN7
M)I"P%>S72E94%8DZ>8-1)#QJIER.Q7W9+\?S]W__]^U7_J#_MIX.9,S08_S(
MPP.[7*UD0&8S7"+Y)C4G3YXT]:`L&GP0XV*J?11\5F?O;M/@^K$Z#J#;?IBF
M[]Q10VF-ZZZ[[MY[[V55L@;OV3:XQ%KXX`<_2)PB+*JO?;[SG>^L6XN4FW[\
M.[U2LQFJH%S63C4TM7.5+$K1R@.<DRT';SO.`?7EUQ?8\^EMJ[*/UH8JQN+\
MF2PZYFYKV;$!Y#FL6E8SNWS.$1U0=@]0</)'MZU(B:I)!G3ZRQ^U3&$&S$):
M.3DX1_D/CV[K]'F0BL;E0,Z]R20SMOH:".LCXLW<JDICI2VK3M*$*V`I;YW-
MPS8C;%7';FL6QOYA'WJO276'QIY?<T6V`UMH?>&"DXHUD<P3HC/ARK,H=G2V
M-;`S<ZYA01R.LF%W'P?RFA:ZD@VNH3OKMGIX)B%]3=&:>=;%;)Y5B9Q)X(E'
MT<B1:4,>P/*A#WV(+$V@3N66*C$3\DQ]AP]O&R`J+3%^FRCR`)'QBZQ&IEV,
M3<L-!M_&W";X#N;ET]=^(O-);^D8Y1>72F;H!#AQJF<1-86'5!4%J"*&.Y;>
MKO<-9,8FXL2<R\`@QE=>>24TT#59/BO?R\5@9U;>=W@USI]CVTRGM8.2XV8(
MMN7@U5!9CU.)QL%2J#Q;X1_K0D/F;D'"T;O5Q2T6K`Z0PK2:;NCZS">8H,O,
M=PI*#V&R.FR&?MWMLZ\M<,.$2@E7(,/&SBP#!8P7`&,H,8<UQ#1J`])6QO61
MSJJR3-&57<0`$>MR]#C5%`!'#!X=U^0NOYQ.A#QTV1'M`YD-%F"<H.89TRPM
MD6@$8C\BO0/DZ:/</BF"]M&,1LRX$/-AQN58C.4--]P`ZPA,1?T2(6;>L\\^
MR["IU.-WM@T$^235VA:>YP+R:P4"V@%99FK.].MO_=9O@10=VAH6A($,94E,
M(;^V8;TH%V,JBE[,P_RN0SK\N)KGR(H\JV.Y<,%\CQD\(<^`S]@Y:]S@E`V=
M6C:Q8<QBUFQC]OS@^=OHD4OIA02/O!'^HE[I0H546O#]C=_XC4K5&,JG3#GD
MJ>1!B8H1`M.CN!W8/,3&B,;:+(LS8HH&T"*3;5&-.8TPLTZ9*.9*+;,V'$<6
M5-I@([6MX-@F7TT*XJ8`,L38N!F-AJU\]HJBTA1O!!4K*4C&3!"NO_YZ?:'=
MUG63"VX[,T/KE<IT[.!M&%$_>BF]H+\,6[%5Q%$S%<"K#0W_-6SI6A4%)BK^
MTLR]R)EA0;$U!V<`EXNWNH/<+A8+4JW7X$Q=/.L(95!&>.MA?O,W?[-L\2@L
MHB\N.+/,S=;?P0[P:7U93^E6)^>G\E(%5.<L:B"SWPPKM''WRK=5:Z8Z2@:F
MEB-C>#/'84W%I^0A66MZ"OC$+QTKD1ZD7UJ#%E^^59(JYZ7:.C-,K-VQ3JNU
MC.E;X<W%S59:Z.=__N>U`+'WDU>K[%H,"56WR<]3J<?J7T?$#3P-A<0,S@"<
MU[:M\J/LHJIW:<-;;[VUNI\MG5]^J!\:\OQ7AZV\B37F>9)#+[:J_IZ%8'"6
MSB<A8C*SUL7TXI,K)#'^Y"D8NLO2FOI9S;8`3N&"DS'12E8>'MO%/,SKHHDK
MTX6H6LB)SP)BF30Z@A:4%DH@*]+7Z!G[`6NGD+RJ];7.'B>PX>GNN^\V<39'
MUGW5UJRJ6@1]1%%G00S'@0.#M@(QI-IX5X!9*VN5U6[$!#@L6]A%1`EMOM#8
M>`KDB_*E11.7TND5E(E%A\#??//-E/K^PT9E3I\^#8)T5LWR?0SXU:MPP1,2
M];5YQT;21R1'UP.]"LU7$EU[:D9-#<9SLT`&[4^_KKWV6M(R462Q3A&2,8;M
MM"I*5"(ASWB>H#(FEE'`.!Y1FSD%K-:P4685QZ7'\P"'A.,*KLQ-%NF4)JPN
M&&OGN>>>TUFL2M!424>8J7G]L3+-/EU_9FV1%_E:1#H8+)G+E4N8]1=S9!`$
M=M)TIY$B@*#+JN-3]:*XB>Z\\\ZKK[[ZFFNN\:N[4[3="GO3X7$!!4I-`?QD
M[@8;X[W7%T4/$FG/4V9]@4PDQR?KB]%>D4?``DQ8/M6\AC"5`"##VB>GD#.=
MPT8B=:Z@>2O/,=8.5`D*2HY8LR>:=DU*Z5I@HH7X@9V=8V=HG\.<$.;2K?)7
M>1#E310NV)%_?M@&A68]:ZR=%M-ABQTB%PE&H8/%[<QZUBYZ9S7%0Z%=*(@G
M*6&Y,8M`^DI^](A)DQX!,H26'(8SA0BF+Y%0&3Z(1#9/>.6/8(>$`(3''W^<
M^D?C4_`8T"#&$7T3-MVJ@W0TT""!!+N@"#J8S0])LFTBQ(B2?0`'VA0K")&F
M$+PC.27(@S&Z@#$2'N^-8=3HXSF-=$4+&[4IJ;Z.6&:WO!5]XL7@Z/MOK7:Y
M0F4%2`43*U*O#(RJ956DN&J`A6V3?ZW:I)Z*77'%%=GG0[V;<+I@LE3T:7$@
MF>A4TA5:66YNI3&CV(HZJ;7(EBE+UJO$5;!3%;QRTV+PJ,*(#M*8;!ZFK.X#
M\C5IC,W@I4[)"^=="A'4*7"&1>0T#P!VXM$%:Y$>^Y<1A_U#'F)$\0Q#8F^,
MJ/YU=6G9TH10T\$?<TGH1-?6Z(CF8F,'MA6Z7\D5`D"PM4#+LI4&L*,12H$Q
MVGHDK\G4@23P)/=RM-N`-]K_8,<.@-(^+[[X8G5,'#<GA:)@7]^U\'WY1;;!
MF?P\)4T$.Y-)NC*@KN0;[SHPO:_YY@4Y%*CSGY^_9?#L5L]GAC7SK-T,J\ST
M%K,B]"L0CKZ4`>HGXDVAR%)+X="`5'B\DL1'E<9EX?%*LS+>:>VQ_'5*1`WE
M/A,JU\SM;(M=*B[Q2O55H3CP`3OF8H2*UI,E/1+!7:'L\0P7%%04:PZ<;/+\
MF492\EF$3W&P)=27T]TJ<$>*@K,5V&/<:=6,@A0M#\?L$P;W,G0:'XDKP?-J
M+?<39OC#GC]W[EPQPV.NM&[U]\.<:>ICFV%I=#;J&:0@C_;15JEV[!89#-XT
M.FN/JD&TX9577DEN_7%60-9DGQ'%D<9RG*^ZZBI8ZJ7<Q80BOB^=J'^C6`<[
MY=.5[5Z85@1BU>!K+N9?=5R84Y:KMJ537]NVG,856R]<T%>C0&DO`4LU90H-
M#<H<:9VKM-9ZO`5-W01Y*AA:R0SM4_):U50KJY$[L8(:H`DBT;X:O!(8TX,#
M.[F`0IYC6Q2TOM#IT>,7M._*A,&GMLHAY@4KEU8U)?A3P6L(\\UO?M.C@B:(
MQ/YQA+`Q@5CX46W'@GC;;;<-3T5&RPHR$[2SJ_0WV:/K%DQ-7Z\AS3.]FAG6
M1`9F`T_`58/4#GG&BNYS74!?4]&+3W[GMCGB!%_=CCQ[T]CP6'T1AQ;-0AX,
M9Q3-::M:'=M*`V1X#_+$J^`KX-+71I;<$44)1C,5M52LOX3!>/'0ME%D!W5E
M22ZL#JI4S"K8*0,]L[]T@V%N(:+_Y[;EMR&0$>?:DE5RVU)OE!1Y+PMI+HPY
M7#+:1N\3RT$#$)&@+/X5%09Y@\85-AV75.]%3A@80Y0QG&#'+I3/]7=N_07X
M$`QS.E=FM\"$'/75^*#I>9Q:#ILYCI^T;3[P*P[;E=MFIX778&=R#^W`*,;;
MB1,G[KWW7C#KI6!"9!1N5_4BS5X!G9`G@Z>=$GXS?N()K!S5%*"!/-2J^E,O
MO_RRIM:A0*R*YSH%F!AK0(>.@%?ZL:A%9@\A9,=&BZ%/QU/G3#-B@%;TCEYS
M?M'=-12<*4EPG=$7UQK#H2.:M[$U'_L(^6RY>OHU<CR?NCM2EX+/*T61ISW_
MLX?WCIZ*-O7ZIEUYF%]ZZ272Y2<[OK[RRBOV891/C69H`PO,`%U/Y2?3:E(A
M!GE:YQJ"Y;;=TM7,R%::P76VM=;,6@E.LX0[V*I6X#-1RLVSFF'M,K/6!73'
M6]W(I0.I*%%,_E5`>^:99XQ$%4/4CYJKA>RBWS4=6=*A-&N=;87PNJ!**W5W
MK&X$@%96_+$U].)\6CT/9#*KZ&],>H0$@/S';3.!JI@%"22-(*44U$I)5K>N
M7#!_B;.=A#LY?KQ<H,W+BD7Q4RNVY!P650.E5*.R)PS-Q*.2-Y_9-C:/UM`4
M;E?EWPJ;!JK-N7P6&V#?)`5$:/D50/[_+V&O6[,VG05PJ`9KIQK-Q2TTP=$@
MFC&'3/1'-FU8%7@(PUBZ:MMR:U25K&"SX=)L*N><DR=/TB;=T20.FK5>7+;=
M4*]'(P!D`I^XW\M_J;IQZP@5H2CKDX!!%2(4\8AAQ2BOBZ&'/Y*<(@!U1SQ(
M$=(6<UZ<JB[.RP3'>BI="7;,MG23_LJ]HQ-C)=("D_?G%@7,EW[;*FH(F7WN
M)VW8I+AUO7;:IDS&5%V)_"V'?^1X[/-8M3U,B3RV*@#2G4++C&*PI?RUUOA\
M9?.P?XH>;#KFU?1.@7R7'^IA3=+6:L-,B.#,D>O'G2=YULIGN7R=6-DF,W22
M0"<5=,(%BQX,?,;X&8[3W1KZNH#>QKPIGD=[^M0U-$M35`&JHO,5GM:2Y>#$
M&EK)@](P#85NG7:X=<FA!5/IQR;1174"&1I1&`]YJ!ZN@\43ZNX*FC^X;?:)
M.KG*G4O2@$8F*^,3JI!A(RG](M49]O"MU5Z_$E>/6O4*F$,%&GE;=',P"H4X
M,7+&YM4AO;F7"^-A61DWX_DA*F`'%(,C4`,8&><0TKX'KK)#/H0DT*=S?*7=
M^F+"8O_.1(8+;LUG]2-9.G7JU,EM`S[03Z/%WQXS54V:MGI?CP1A()5/?[GZ
M_&UL'O9/A9F<>=---\&<%+;`*AN$B49#8VKJ2N#%GJ2C*XFN(ZK.Z0&FKGJE
M<`P9,447<P5Y-.-`.I'3MIZ_ZL]^;5)68N]:E(T,.&VP*)^/(S%7M`H)<YYZ
MZBG"[-E:1B>E^=ZU%6&K'*J'C(8ELM-\99'7.<@^K.7+Z`]S!G8F8]JH7<YI
M?".TWA-Z!C!"@TB+D2MA(TL1!%$Q<ZL2NYK.EPAFYL7V,P4KA@<$/??<<[3I
MLD/!&F/$3)&FWL3J-RZ8N3E7\<Q%..]"E(^NE0^1<GGH0[:S;FL\\]#O%+TS
M_N35L?./EVT-W:D\:'$=YDIN1$AB\*OB?+E+S3+L5T7(5C83^8E0PJQ$;Y+8
M>@=\-:F!#&2U0)WJ$>AZR`-S,LZS"BA.)%3-B^ER%%O.U.;5$X<`S28,8:5(
M5%F2J%2N/=Y4SQ,+=\Q=DTGAIPB<63M)?EL+7M6IS("/'#5'`9F/?;W!J_1&
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MPI^,V/892T:67=S.%,Q:V7@&>8;F-`OG@ED2+4/,,OK1<.698:UD@^/>,7IJ
ML0Q(SZ8+M`.8+<B\A.[6AF*$B(>*4I<=`WRJR$`]M2K!\VJZAJQFC;>*K1>8
M/;'U4@VZ"6KJ8E\I::,J)1V#P0X+GYS0?4.&^[H^<``(L5N`E\J:`!\"2;\"
M'&-*L1#5?R20E(*E%!=]6IF44B(7G-*<"79<A2[E%B[5>GV5L,!.GBY#E<;Q
M4G?<<0<-A2K>2],!SZ@^"QZN%MY_NVV)NLU+Z:G5@/E[;+F73?Q-N&#([;??
M[G9:H[<P[I=`I`4,W`5P`CT@4_ZI?<:,SS-GSIS:MI/+!G9`T]W;YLH4MHS4
M2H@6^-W4-69"(PZ=B@^PV5;>DDF*:0NXRBW-O:;9-7)$/:61FES04'U4-5(0
M5,Y726%Z)^=/G`/Y=B(;]*9$L5!JHY(Q`HAU-5VCS;.T;94)FVIBU4S/?JLP
M062P4;M';.@M9DC-V@EVAH2\Q=_J>E,ZTRYJI=',$1@\3!HCM;<H]#J/U@LO
MO.`)/9Y7(UW//_^\IO"0VIQXLWG\^L8;;[3.[N^.YX5K+CRU)T*/87J?=*V9
M._LTII"6G9]G4D$G,VMF6S/AFKG50$TY$=6R\5EM/E!SP;30*2&Q\RH/_466
M#_@R0$-=9EY1*[9/';;(0@E)Z09F7CGA\_LUW8[ECYQ[%TJAORJ_6+F3B"_T
MLAZ/U*OQQ5>P0ULK?*"_6O\RX))YBN.1*M';O-Y3T2DB5VU<X);5'1TQ2&QB
M&+Q$:NH!FF15FN'_VC;PXK^508D?PWME!?EO\ER8HEL;=(@0><[;8ZB":1XR
MLHY8WPM9*9`L-B$O-8LI>5PI(.DB#']GG,_%MOZBOXQB<`]TP!#X1HNAC>>L
MK`^$S"8$X(P<:*-';KGE%DC"3O/98EQ9[9#'.2[EJX-.Z$Q?V47.;,ZK9S5X
M?"-Z5G=G*L!;+:;-'?2"O7Y3LZE&$18YV1`0,U()$;K2`Y.N"J<:Z'5BD[)*
M/[>,5:0TM05*Q<:7C.QJNBF8U2,&09)`0IYYYIG(*_R%I(%]?01S&A3J%]9:
M*8$>LC($/D/(4@Z]IAU]ZCE!M]G6Y">&,ROR%`5GGW[9H<ON^(=_^(<0QA-"
M;.]+62HER:KQ>(8P\P*-3'*^\I6O>'@0P=)P,"*C9AE`R=^CPBBD:J9=*V'[
MP$[H5&9HQZ.-FDI_S:'&1S2(-'RG65,KM>EJYPP=],0MKY.LR0F=%*U(;J=L
M5HD\A<OZKZ8CO1439^U,2E139H-(*7A10^@1_:M;-4N!E`0#PB0;!`.P$%V=
MV\*K(W1?A[9N7N"HT4?7^XE\ZJ.BN?Q*,&BT$ZKBG2/.+)B<&\[*$"=XKJ:_
M0(>NS"IK(<-C>_@J<K;`VLILD1ZM536?JF*R@\2[BNU3U3V'#RRM.@"<,==C
MY'C]LD2U3&47\B=[>(I92;O\`Y5=B("H]>5?VS9B[!S_TKG'-G=QE>R.72@3
MO(-K]%0[3=9("V1F+A9F7XX`;-1];#,=Y*::%/+D_6[U#4Q!(3@#3V[?MHCR
MV#\.0B&_QL9SUUUWW;QM_@MY@$GUB]/Z6LF[Q.VOZ?2.(U[<:;J^E?3\;],L
MU:9YZJFGZ&#^F6KT%.]G[-#4CO27LB1T7,'GE:G-AQQ71K^Z=13'I7%IA()^
M=9F?\GU5LKFUC/R*-C]%&^6E*D:9DSR'N:]Q<71'`L-L:`$K@Z?8MK%\"DHI
M#X7":BYXZ!G,E>!J58]-KQ@S2:EN\LS-H1Y\\$$GZ(4<R"9WS$Y]H7<TON.^
M+A74STOS+-@X@V=6R6=M??(F;/`!>DP`\V1&K.Q>,\\:-K!=]$YH,UNP$^:L
M;N25^\*OYE;0>,!G4K0@N=XQZ#SZZ*--*(P:A9V39T-):]/$XQ/;YB"TT='%
MP/NI05`?&2,H($%MH:<2DX8P@A<G:M15>?E\MMJ5V4`DG$!(FF<Q+^&&IX(V
MQ:(49LP.;YH6M85'#0\SVHV8%2*OL@E="'`\9)2G/B-8+I/:?C9/UE&!:MZK
M$MCDS<4)S-2P<`OMXQEF#8X,-XQZ-2!3Z4E:EL<[,[[,$<TR17+ON^^^(@S;
M"M!:$V_7O&EG1G108F/(H\>!B;;52H3<ZY<#7FHDV\",E4CKB`>VK>2.2'M"
MF_+9M;/K9`+-9N``08P?9WJ[RFF-`]9,I"3-W#O5@]!T%4JN]E]TJ4[(PTR7
M<YMX,/T83U<%8N)-90F`3?,C[0\S"4Q%V&&+`2+Z+VA0>%*L`J5G1GM8Q++7
M)\,Y3PP<KE,:SK_9MFK!1^[4P5ZJ(2R2C4C&^JS<;<8SD?`61O9!GF)KFV%!
MF^81)5E#!I<U('J=;WSC&V^]]59YY:P7EG/D\SZ-K0#$-<&"B3`M+J1\TC`+
M%(02L:'.]JY#"?6547E7XV;84"=OZZJKKLJ2Z0KC1AX6Y9EY=?<U%72%G5V@
M\AJZ<[2*A,VO%<PJ7"<4JM2:AP$F+[WT4G'=6JQ(O`81.T6#5*TU"[""W3;]
M[IR&(>J<#:-#J:2&;1Y-W:A>-,LQ8%#2^'9B#"/;%(05Y&3'(U&W7R6[<(!P
M@A2W,_R1$[)'USR,<UIFA0Q&ST;2*F\VU\N-&<%.M&"%@DQ(#]$*D?(G.,?Y
ME>SQ:E&J1JP1#;LK4"C/W.)LH<(M;U&WM*RPNC((?`7(+>0YV2NWRG;\^/$2
MN_174U&]/P;/2E)!,#2.NYC[Z,0.ZCN&.N1IPN@%6_7S%@`3`H"=2%#SFU7.
M&,*`FOBK\^38G]JCMKCKFWPYF?GJ-3/>:&ANV-SX,*=<K9A(BQ<JE*6H]?(I
M&B8B8Z?(XVJ+91%65(L<=-!-LR3'*SX8]Y>KQ;62K55F5M&#<T2OZ2EVU%/;
MI@6*I<S;#V>B>/)5-Q&P2F;4YO&T5-4BYBCX5I!2$8^>APBY/H2D=R7638)M
M='EE54,>FI6K65.3DX*38_WZWO>^1X#=R$VU`-RK^`OM+DN%AE+MK)'AVIK$
MS#61<T('VR8#O;E50:'M3X'1Z+6!3ZDQ[SK4!PR"VDKI:MI5%9L+>I@OACP[
M.O<!GXP<^Z5(V(';%8W5R&8H)>LQ,"`/2:@48[$N.0.K/%7M`#,O!UOQC'2B
MO._R5B8R.:^.SJV0<2&"A"$>'E(=`T]H8U!./(RYCA2D2J$JKF0<UW$Q4(&C
MRIH#GR*U,HD+[8C^HH+(X6=<Z,YQ*?\MVG^DJWE<U?U*40<R+=B5ZEZE;(U#
M-9A8WK&$#@(<'7WXTU8T6MS%K2971+7RY;&"%/VB-3(P@)AFU/+$]6C)E18<
MV1X1II&'C"(]"!_<4:-%O.;ZS>:*57!9BJ:1/6HAC@%.0`27^OJ^;;,#HWQZ
MGB99+"*GZ0ZW:&)233TOE;,7F,1%7P1%.!\@1$3?4\&?DJVB"$A4,EVJI:BU
MV:CT%+P[DNWQV]NF9TMZ+0RO8:))EJ]NEY#D52X8V$7<M`EC5!B:`@SJIHJ#
M>*-,N(F9KX2-IBN^W97#.CL>8!BYW8N6A3RQD;<N7(9UZUDTKCQW>JJO_:M2
M:$\__?0;;[QAV,VZ``A.H(]Y>FENT`%_,GLH>.3J$]1W%'DN.[^<^JQPK92#
MJ\^9677I5JA](H*:6*TYZ8-(L[:^(_NJA,0%D6>=;<TR%A`N_=QQ+::M`F=_
M]#PM7<5M3@"B8<S82(5CLV1(E$%@WDIL6K?*;5*1)N>3*_U>/8(/?.`#+2)0
ML98\[!3?"VVJKTT,6F<O#+AH+DI!V`I8-12646Y$*XLJ:L$(QN.)FF@<=V\T
M;%FV\K4Y!(;OJY(QL4L96V%";/#_?MLBOB-IQ>&#&J\,>:IH7)HJU2/5)7=4
M>;SB+]XZ?T($[)D]N3NJ.N=X9E(!,(W7!22XA>O[]=@16@;&3PDLFDNKF@=E
M%9,NR`-52CO2@/:K@PG!"I%R)'NL1-UU&\]/IL[/;IN=5NNB4=4138T+3-)E
MGMQ[5</%O4I3\BXA0Y.4$`.TQK!=D872'"I*Y7U;+"B=')@SM@$[\:L:H$XI
MN4:WYB=L!N06%1#)#*[$3ZN9YB^&3COQ6"9LGK]E]+("6V',MZRSFA42Q18?
MW;>U?H#F,1K1;)6==2]-:D`O4'_(@8O\IU#E'Z5B!>C27`H.^8%AI#KQ8%-A
MGP7Z3KIEP7B^EJOKUW`@9\LL10T$O>=0;VL@:!<].&9/4RWR$XQ,\8C6QUOJ
MVM4,;1OZBY5RYY^?O^ULGETAB6$_")9;S,KAHVMT(ANF0`+]6,@<D&'VD`H'
M6PFB[VQC;4CK'2Q>G11EA&3Q1OY670D2FYW?^G)=K\>C0VFQ-66)>]GP2NRS
MATFL.T*\".6`0+SB1<Z3M'S:Q&/(EV!.IG*\#8[0](+-2I=HN&S.Z"+@R-_+
M[ZY*"\F'/$45MD#O]9E5Y4V0ZK_YF[]A#;HO':2D.:9(<M&P$*8PR-:`REF(
MZ+[59,_FA-*IRCXP=<TQ'JBZEW-TV<K).?ND@AU2`4%;:?MV#-;5[,A9FF>[
M^9$NH'?-L_2%\XLRJ@2A(T"&A9.W)ZC)\O2KDQVQ4X6+5J+UCH<OP<2KA47E
MH8<5+59F1@XM3[/:;)CP'WH`+F-*1:*_]*4O`?96N%H&[0J9.F4JV4I)JW?(
M0$&&VJT:$.#+$>_NL35RSB5/Z)D]_SB3HY[+-`UY6L^RHYO<+MLX\(P^KB0^
M;P$HXBEJDK4B3Q51TZQJ**1]CA@I*C1`UZ:P>.O142B;<`4O62/O/M01SIE<
MJOA4XEO]/$/G%<+,FON40AZ*GI*"IT1@R1<>HV*"X[B>E:QF>1=#GJ)WIF;?
M+*"OW%^KV>,@,<XRS#AT'9W[E:]\Q<A>&D++Y3$U09XH+F'._[UM^0,=SZ]2
M\$S#@0XJE:;Y#L-5[Y/AI+>90G&M%-81ZDDPG&`<IS4%]J?.A+Q*XJ69$P,/
M``D3B8:A[.&&PI8\\C8DI46,D-[8,)(B0ENYI0E1KN!@(ZD7)[K-YJHBY]68
M58\^^JC!M%0UQKQF@9]E8]%][Y@CJW&V(9X,-P'Q)"09N+6:[*M/QROUJR6K
M!0;JC?A`SUTT_KESYUIP'^[?D(<DLTYS"(.[8O/<URMX-;>.`S#ND1(V6W<;
MFR=O<SP>N9W'PKEKV\!.L=:V3%!C1`D@KJ!??'J7`H^]0LO0D8^5D.[6-7Y)
M*%$[9D44>].\N"!`</'XXX\_\L@C#S_\,'M`V^IEXY0G<65_;VC(7/27*:H%
MN)ID$8PRW$E+C)?>R,.[@M[QJ`V"T7WGJJK1\O!,-OT$.K:DY5$C.O/8%7(U
M^FC2^J+ER"G_5"'XW!<4+::CW*<QL$$>;W'333>EL!23JCKNS&P/IX4MOE:Y
M;ZV7E[<G^^=B?IZ96*WNY>R<B62N8-9L+8>Y5%P$S?4NW8J9YM+)_CG*=)I)
M-MN._F(`9V47K(!UQ=0*N?2.&KE:3BTW-'Q\XA.?8/?239U;9@V5I!0..JU5
M]:R=:N'EYZ%6Q*.8+@INK)GU%(,U\Z`J$E2`J/NJ.^[;MMQ]L:;0"-I*D`B8
MARDKV7T+A\XY,^17>:V)Q,QK6H_(J=(BJ9\RBBK4GA@S?CRG9W:D4#2*7PB!
MMZY8K;<NH3B^TS@/P5$>\JA="G]MN=E.VA?%66[D!NYB?7/^>"KZ6.6^QQY[
M+-X\-W+]5LVH3_4N!W,"(J.&P<M-Z68#M-N!@C-GSFA><GOJU*G8&JL[KPM:
MRRX7H*@;35TIG`(;H#T4NN^PY>2O9I\MV(GMT/LV<W&=9M\^R481"U4FHKGN
M6$W/B&0)1G5J!G]:`M,R1C&M6I7/*N-H7L!";AD2[ENP8@P8S7T*77:I0AVJ
M:P^N&21:@)Q?<<45!*FH#&)FGSW6XV7J5&B@>7%SY(H5)D49;\YW+\\</%:5
MV$-Z09K5>E:%Y^*0R<YQ]XHI3-$H*@EJC/@.4ECGT-/*=NBLRJ9G/U0CSQ$[
MU+\EK15DQH&\!O!,KE9NG,"GB56LIRUL09[WOO>]05"&T[J2-5.J]<BP84SH
MSJQS>6#O-50\.^29N.4=KS*LCE`N&G!-1VZA1`,NI6/,$(`J(K4`3=$*"K4_
MZ5HDJEEV4:-5*M=-94O1+$<J.6=H9LF?/'FR'.?6.(HA'%/'P&J?`/@*><@_
MT8J#M%BU*"S@3/.IYB\%7>13+<7&\<;Z0L)*",TG^>^VK7*]+3.YIB-%(1(S
M=V3>Y%>O*+![.6)$ACQ///%$]70TCBL;4C,&6B7Q"HFQ)TF8\Z7'%%&48X4V
M*G?HP8H=J@)+-!$/;QOQ-@2`1#*S\MU-G`]),*93HD+IP)TSYQPVDEXFEH97
M`.6TO,'EB:=9-5I1CN&)UVFA.5HA7ZFMMVO(H+^NXP6KZ^<=]4B)>%HR!A)?
M=6N>+K>#$CG3J@O6?4M9;4V\!?&"_2JOT*HE@T?#AK>G3Y^N/'HIEG%(:LF"
M&`FGSB*H7__ZU\FM">.05-QXXXWE(WL%$.0=&P4\1IFA'K+DXM;]U]7_Y#.+
M-.Z"PBV,Q:2"T%(<G5+03OFA^4Y;+%XY9V@B-8R:9F4!K;QFN@QSJNR3IN=U
M*24J*)B:>@'1;I(U6Y.I87J?*J)C_*SYI&/Y=+6QKR:!=.!HMYX^T<NKM3/O
ME:DS=.X3KM.6^ZMYE@TH&0(J`6#8K;:FKZ;;3%]ZYV"E:7,[^\EG7FB(%(]-
M2]41Y.9=S(58I$=4[<9B$D6&BV4EVP63Q`!F'^`47L@N)=X4O_0'(FK4B\;?
M']TN"[\1W,,7+%3P3"%MK<!&`DS?6^O/O'>07#6]"LUB8,A;Y7T)6.3`M`8X
M4(JGGW[:5!3RF(V:@7J2*,O*0R\MG4JFFR6&T.N6M,I7LE\*23FM+3R5ZT'7
MJ(][:><2_R,B]FP$[]BQ"]2MT'TDC:%5V,EMM]VFEW<\&Y=<<@F-,"I===55
M8(IA$]%-OO1FHY,+"7"J65:XM?<JGL%.04JEH7EK*%>>70M8!3]H:LVE;9MS
MM;;>`K?W:BS0`D7[M.!80D<#7%S$P2_8\9PD^=BAO)<G(5<ZHM)^DV170FBY
MI:[C46..K1X6@7>DM-E6]ZJ45!1K'50J>LG+^7DR5BOBG&^J`$6C@.?44[J[
M8(8ILZN16REN?!_D6>MF%M"[LO,-E<1:"R\=+Q^AY>P=\DPMXW$@KS;/BBV3
MJ-YL:WB8F3T,PEE_'Q#;U>Q;IW@]TIJ*_L_.WW;)H;9:8RW5UZ:M]$N!3Y#'
M!<D#!8?G3)I2L:!*J0<:/"X(XE%-F=(GFX\3GI:P2U<W\!7(8;Q(]EK[T+D,
M^!,G3H"7BH;K:&-'$2-DF_`3,/LDV=<@R`7=FJ8;<5RM\/6"Y,MWR+W0W-PM
MFG9E\!.A_+H4S7^+[2%1H.!_V#9GQMY9,E?K%S$V4X&6F0H&+H\8&I@4V`>\
M;I=)4`0LD1[J/[(=]:ZGBJDFGT]Q^"W.9F[E:F@UO^*\&HJ>:M7/?O:S;@W*
M&ELS8XZ=GV%AFJS'CQ\_#E@FL"=.I,C;5PAJD9?L77_]]2V1ZP4PXMDT4>'E
M'M@0D!>Z5\N*J_"9\X$/S`&DK947UNL*K@-+H;KG=[Y_>=DB=0E`'$$![T0"
M#S.`URPOVRN3.CVNV>E+3UY<`>F%(:X&GY.QPJL8AP8"<JM)R=54A)]WIR\@
MUR-YKQ8XBMYLSAN5RJ3/Z[*$IUQ[+UBBJ.=O0?S11Q\%=*[@\?)7T*G2)5I2
M3[/L!#MASC\];+1RN(@CU,IR<&17%^]?'&J4#Q1,7'%1RI/CL)MP-<G*GS,.
MY^99@<\X?&89:ZTEL2.^6(V<@:/F687Q]/P[_`EC=PFAM8Q-6]5T?O))>LV;
M*'@5ZD%*9:]+D8`VE*X,XEC6XXN@(,[4*7F8(5+!>WJ*UI>9GN>'I.E9,N!&
MC!D:6KH!+"IU*!\@F3]W[ES!>,P)G<X.I^DLD%E^@AC5K\G^\341:L)>!G2T
M5$6O@292!%7*P^K\1K3XQ-8ZE>57Q@]#*8J6I!$`YR__\B\A\.<__WF/1,YI
M9<:`1QUJ:%LKZ5.@)^9/K=$TAW:7W%V`][_=MBRB:(OL^-4=-:8K-^X/S>^`
MSVZ=?4?+/%.S*/)VE,X.%D%*X,F>^:]^:486;_/$]V8MQ">6ZZR51T?@I[8"
MDM!`8U;XO@!";^H*_M+4%?[D]LG0BCBH>GS%!VKDZ$]!"F$C8ZZ6^W'%4@+,
M&*MH2,74HH0B>Z2(FM0X4Y5LJ-J](\PTS.F:L#2PC:^UL.J,Y"9BN9>+D7:.
MMXC'LG(5#5*&2$KDCBZ>`\<X7A8DP-&PD*?Y5!Z>U0$;',5H/86H!GF"G69`
M$T*\DJX707&T2%;X\]YM`RS#ZI;SAY'C8'.QIF/KTOR:)3JA.S]^_I9[)^2)
M!,-CVUEQ=2TG,3FA3;6F<DW(TZ=AQ7A15`Q9BE6`LL<I4>B.?;I0##-L<3!2
M$0)`57/TA5>N4+F!5H7HN\XB?G1*?QF=;[CAAI"GV4HV#^'1W?#GS)DSN6UI
ML7NQLK[XQ2^Z+'VDLZU/E8*=D1#"1`N3IK>2GJDSQ58\`+#*GYF7LL\(0FTE
M5K@CP:Y(NKNP^C1%F37&N^@'O:DG]\"M$^5;ME6=A](U'R'J:1PDC)U,"]@I
MX3J'F,?SS``'RM$I5ZZ,>TYL+7-L(2I<U[;*$CJV9'5%SG#LR+;2Y8WAM&Z%
M^I,90F5`/'WZ=,792W'R"GG"FZ(V<Z2;$P28L11%0(S*,084TD-M?1V*M@"_
M2,+*C]+H@)TL:?`27NC(6F[,XP6>U*T4/^A1Q.E==]WEY*R.3LXA/\9A.,P>
MT$%>)'X2SU_L=,R3&=*%9!?VX,S_9=L\?(E@^OWYYY\GC3FF/$",(NX.*U*Q
M9EA4CU8VR0IV5GM@>"3BN)@%ZXD-'M@9G"FB>!PO(<_*KK-#GK%V)H'"1N_B
M7&K.Y9P=T^E/'@H6KX715QZ>=<)5`.'*L7RTD,V:D%Z,4\@S3A[22/:T)%%G
M[="(/)RTKU(.)"1>=+!COT`=?5%%[$)]<D$W!I4Y3I?SG>8*T+.MH6L!>'O?
M??<9/2$,_;WYYIO/GCW;0@FY8O,TU!(/4,;6,B#&--CZ)O0HUBCO1!/S^.XR
MC"?=IC0?PI/#IY7<PDBB,<SG0`L*[RDZR,N67E&^81SO4?$0/&:ABQ??&\>.
M#<Z4MY4]4'!@[I1BY_+V-!]LQ2VS+:<]?=107_WJ5Y]ZZJF*\KSPP@LF=YHH
M>!G*TYTQLZ,Q;.4]C8L6YF@!BY6]<V<(C:J2%G)+K4Z=.E6)J!QB7J2Y2=RV
M7J2@7Z]9Y;[H](TX17S1V2:PA5C$]YC?+(^BMM6_WK2:FS:M00:89%EQ4T0X
M#O!DU4X"/$\^=D[-,N`\GRY()2LK&>-NI9>*%-(=6<(M560G1V17(9)JT9+Y
M%CN*%2%+.HCFTK76TZ=*E)T<.RU@K36GUISN9BOAS\#.CA5GO,KC!"ZI865K
M7V=;D?#T-1Z>'<]VP82^#CG&RD`X$ZZ!G35B>9:]<GU[BZ:-ZSQKUK8`S@61
M)R=/W@`MH)&--?%(&-SMDQ^JJFM(2UZ="$\F0#WP,50Q2/+\Z!3[COMOB>3Y
M@0LS8\-05:]L7-`4%!80L7D8/)`'U.AQYT`>\W%"0A^K?F):1PQB5-#C!AV"
M[18A3PKN9#!2#+,!.L]S:41V.B<:L4R=#&G"4QB_/\;)4R9I<:K$C($=)5&<
M&)0EQ[*A-A(AYL'0G):'1:K[9.&0Y]A=XBNCMJ4/1`'JIJ0:7--63P+E(,]S
MSSW7YY>__&7WBBN^@GHASTHVGM)5[R-U6]%IQ9G^LJ+-7&$]OD.SDL5(E#ER
M@9W%^F;1>9'F)D,4T-(G.:E@/0R?FD$Z,19]0I))Z7T9$L\\\XS1RK^*)S3U
M'J[C8YLA-U7&IH+;^FP[7,VNZ^VF34(M?Z1<!::V_EAB"\F9Y89J].2"(Q@>
MON<D`'H*?OHLO+\22`8L6DSO2M&J5)F=K)W\.8,\>9*;H:PV0_3I`SMK"$V`
MTSQKUM,G)VMU*<_6E&HML!7X[-:\J.&Z=!6VA"H_<?ZVVC^YFX9YM0#(F6J%
M.2O-8,OH,]N:\L2-'8"(':(QFS(S8PSNM`]<D"7"'\*0F>&"FXRG.'#H([G*
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M&D7+9+&T8E71AY4GI-(S-<L.5U>`G7W*HM>@35YQG45"&J$(:K4#<BSK'9*L
M.R"/G?R!1%JG>/<[[[S3?W7?U5=?#4G2H[RI!3#/'&3\(87$4-+2(IJSE(K.
M]ABM+V,B.!K';W9.M?:&=7`%G$F=&&:>%M,[V?[X>8(C6#25LU8/]GAR\CYE
ME;6^GY'F'+>`M]X"S);NX9R,'#UE?Y;.VW2-KT7R.$%G^6Q!1.-__O.?)PQ:
M.P<^1=8==)#\,SS@299`"72E,MGT`M@!043+5[K/^,E99,C3:\ZG?7HY@P?^
MZ(C"/K5`^4%GM\VOAB&"'0,5\2"K?_JG?TH9X:&Q"4JX2\@0Q_M_MVW5V*JF
M6Y8/*2I,L1PB:EY(<P'\N2/*YRI(+$LO\HV8"4F@^X(=<P$*HA'H"'1U?NSN
MI9OE6V:M#?(4&3N4@QZ[!.V\"@4;E!_JH*L-^4]65@KKUN[[V<]^5O,Z,R=S
MP+*2C6?>K`SDL\4)'#KU]6CYZ16X`J6U1-H*5JOY1+](>,&?6K@D=!`4HZS&
MU/[:/,8P.*.1XS;Q=I4P*Q6%\?!G?_9G#%K"HY6,?94Q[2'7MQBD[:<!X7GQ
M]>O:"*M;+,NP?9KB^9M/5?0M(Z>,^]P^+:)5S*C56P_,[#?F&BMIHD?UP.P'
M0WP#>E&".Z]R9D]9$D/E-Y;/6BEFS<?,X&EM:R4,7+>543!JY1(BXAY<;:%`
MJ4E6JUKCYQGBT]6?/$^R4BL'@U[*3ZT'P2X3*&]7K++7]U+VJQ^A<5KL\U-1
M!RR??[`5@!XND9#'C+O<AW(EB)#6!D$:OV3,*"G"G*(**SN5,X>^E"L*H%@I
MS(,\110M4SQZJ(<>>DC7-%1YD=MNN\VTA<%S^O3I.^ZXPSEQB)TZ=:JP1D_B
M^LW77-]]B3?9*#Z_3VI;)(`=`M_R:'R;Y2E,2)A?6[!H7&O9HIEC[AT7+]_9
MT&9NY?7!#I&KEI;C1;FP=N*%CNS%YTRX6M(J(!\*E8'8NE6+7!D\Q3JZG5N[
M?AX/]R+P7M:3$'O-R`KU/!IJU;X56';;JG$71*I585?-_8'SMXLA3SL,C\;T
M&VZXP5O7"[%>`/\\ZF6@?&3;**S)5[&ID4M`\GC5H.[UUU]/L/.3#ZK,&QU%
MGAV\S,&9A*X33-N4,QOCS:6H`]4SVRHN>E@[;`3&$QKR=$%I,JQ?;]$1N)K1
M'IKEM6C5ANKE5<Z],XZ==:IEFWB86:=NLK,R<0T9UPH^:PSS!/.$'@&+!R,J
M4ZAQI>A9D[;"GTCC,ZC"GR9<0PZV2]FP==P5JF!BY"URH&EF&6IE@V;>A/8M
MG<]*5C$\,1KI$4I*##*`JW%/'PU)M,]^535+#*\H"=48@CZFPA!HE`#H4M7L
M@$@EPE3QC58R:;*RR(`>,;%B\X":$R=.G#ESIF!:<$2D6<)L#)?*4^3*%<LN
M_LT6H)&$HO>KZQ?@-,,J0SDW2^FB5:#+\FGQ(NJ>XM.\$>R*/Y-J//'$$P55
M$CD@X""=*N^LY-""TZ(5&D;-/#Q3E\%.*T'^^]\?ME(Y<I7'^5P8(=WT#*TR
M-_.JL"\!FZE'NK;J8YQ44_)U-'&GJC,[NZ!A<%1ACZ+0S@74K4F=Q],LA5+3
M7&_4"`6%>KOX<VP50R=(U-D41@>1^5Q8/[B5IJ*_.<9]SCOV:O-V/W3^-G@[
MF+S#80\99OZ#K8KK.JF,YJA:R967S3EIJ(U8C`#H%SOC;3;7CC0I'W(5>%M/
M]W5P9DJR3I3@</>-V[:=P&>E4!XC9ZUXM<;[K7'+4V^B+*VR)'948#/#ZIP*
M3[!8_#=@Z8[!2^GPZU+:Y(UZA>"(SC:[,3V!L>:;CKAL[*\:W)6;;54A-/J=
M?G4\FZ>^HQV`G<#3=%+1W#RZ8[H0V6GP4BTDO^9AKC!9\3PQV-!B(S5K@=:0
MPR)F6S6@DNRT\?OI+_`+9VZ]]=:HR+,36$$0B<X60@_K2&Q5LUTPPY[YX;)@
MIR1$D$*=2Z,HW<9GG+I1^%+GG#S^,JL8=*'\"!=Q98V9RILG1FY/Y'R-7!IX
M`OD2F@K%S^PI[ZFU]?@6(GO)N518=:97<2.9!$"O"N`MPWF\/-N10H/<Z*.U
MI/8G0M\?>5;P&5MH9R-=S&;8S59V*+0ZG[MOUL51URX)O/?>>TUAALDDAO]>
M68]H[58/"R/_]5__=</NL4,P0!-_GUT_E%BW>>4I[K##VS&0=DV1^=<:;I>-
MQ2LYM$_8/$Q+#`8X@D1R"(/&)S-$B%UG6`0C<,!GLXG\I:"R2%VFSD0&MES5
MHD^VS7]Q_A;@[);1)T]SRKGN"D"LZ1)30K3$TO(]6])JW7P\S+.,GI.Y?^5A
M#FT\7@C3Q"J_<6Z?79Q/<=0,&Y^$.:6HI@P$T,4WWWRSQJ3..MU`[/R:2+?F
M8*F/](CCB1-UAB<&HT(!#?05)VJ)G!E082,[3O"K?FG]H@R+'!1PB;Z8-3"6
MBDC,CU<6'NWS,%YY-=HUNXF5!V9RVV%+?/C#'W[?^]X'H/S%+<!"K*J5,JEH
M!<TE)UZV^&J@5^I-2RTPIZRHD,=7`U9A/."%:I1+%765MV-$M2A6S+9ACL$#
M;2HEQMIY_/''(2W8+'?;X[W_L%5ALZ"[J2L1641V3F47PM[P,..'>,?40;9C
MM8JF)MO2DT"\8NK<^IIKKAFRS9T#9)#GZ+86OM]-6"Z(/#LK:'4?S=+8>(0Z
MF#C-4$('R3DMC@0C9BV]`TYAJ1&DD0ATTP(J;#1L'!SSNV?.)F_T7$%F3COZ
MCA<#U6`GJ!G+)ZKDA+\7ITVL;H,@^<PSHS<-<'???7<+QRT$=QV8DV_'0=BR
MQO`,^7D[P<[,5@*<<9L,\N1:^?%#\8B93TV8S2Y6,/28S[!HB)>#G1WKLGUM
M7O:HK06OW-IEI`*6<7?WS!.[N$X#G<"T<T?M0V6JU_P7?_$7E"7FO4R1/__S
M/S?ZL(7RK=53A>+7+QK_DBVHWA#L9*).YIG!T,QTZ0M?^`+)!T%L@#*8RMNB
MK17KI*'^DI,'-)7;'@VR,XE<B8&>+7=KMMGJ,3!8:)9JK-`OTR[&`XN"\09#
MW,@U22\QCHB#PA8/XQT+L89.Y2!4L](X6YQ&@6&%P$5QT'*2AW&R"S8]S.I@
M?KA1O*_`-@)J4&S"^-133WDI$`IA6#4:/`]SI=++<LK5XQW+V*JB5O%%S?[*
MG<S/4YODWHSG(3[SH@4*(H+M.>H??OAA.V`Y?6G@?MM246YL@*EZ\([#-HJY
MGCSFP3HEF=G9.DF9[=A"T#&3+SMY")MV$:%)6Z`+(!K^Z!>OYK.PF0<??)#P
MT]!LFRY>&$QA'D-QT]?>8L6?7O."`-NK7=#F<9&W;_6C?W`C3,[/D#KD^7S;
M(1"H07F:D7`25PC3BDS1_N5*#`]/&=DE?C:9:CVK"5?Z.ZL_8<ZXFM?<J$F5
MFE3-\2KO*DH,K^#X<)IV#?),ZNC*NIR1TTY3+>HV*^:[<.4)'?SQA7PU:/)J
M_DB>:3V$(?]F**24*M$12@0NZ`XE@B0&XA9'&A&2WB:\(9)?B3TMJWC?Y[;-
MH/]7?_57\.?UUU]_^>67GWWVV2]^\8NPJ.I:X*6OSH0)P9T9F2LP$L($DZ^&
M>)A3M4UM]4.'\+`)=-<1L+&RO"#H_OOO+YF"N!;.5P1R">_9[7`C1*I0^]2"
M+/H]M])4N,C#T)F91K1>0T7Z$<5<0<LA;?$#T,9D$^QX';<#.Z#&6T3PWO2J
M%2X[D4U5NS`ZW\R>(2<<LI=R!_[';2N&+;YTLT4SD6&XBOA(.YOQ@7$MT[Q@
M]&[&W^$;O^"VGC]%H(YNJ]H>]9,<.ZRY[WZ:X^MTC$K:H9[4AW@3<@)<4.N$
M%N<=BH_70TY&3R_2VD=N@=7R&4#8`>R\6E]_>-GFG.9<.3F[::Z&WKHUJ;X6
M+!VCCIT6K7I@_^I%`$YSJR)8BLF!.:%*OIWLF>&TR<F32WE,G7PI+63G89XH
MXA5_+IB9%<?@H,U:XV8R1O/G3+I6^]6[J8;U/&$@,VRK.\?RH)!78QE2*S+9
MZ&SH-$JR>5CL]"MB[3ASC)M4[(8;;JAA)\9C#7!U3=K74@[`^<:V543UU5=?
MM0-\OOWM;\.?G*[,'F<^]MAC[E@,*EN+<45;3=!@4>&%L"(&!O8`M67/Z*\1
MT1%7G5[$OLU[.:UX2TA220MP`3?LL$R:JI27$<56/F0[U)R9T4PJ\R;\H=3^
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M=+!HX>]N&[1YZZVW(,]WOO,=^XY\[6M?B_P3PE0_-!J'%U]\T0E_^[=_"Y3`
MT2>WK61V]AB@J/B+3VTUBR,#.[YZ)&]772<3[6NOO59C%FO:<IL781Y4"1W>
MTG&H`CV*WH=+$>I&M%)L?SA#TPL/@QZ%T!1;$NE9M5%<WQRGVLU,M6+>'`]:
M(4929/I@2LO(N>...ZKE5P%N\%+$<M5YP*PC+)^6UX><IX3T0I=]Y@,O'R$G
M#_")5#^:HW+E"O$UI85XS6YVJI=&#^7XQ28I@S/]I5]7J`DTYE_K3WF69GZW
M3G!6JVF]?GK=C7JVECGRRG:D%*>8BINY5"!FSAE^K<';>=\?/7_[D<.V(M4\
MSXK572$P6?_8UGW#O0AV=JQZS:I*BLP7U#;:NM:\&^39)8$&/F%+?IN^_HN-
M]30\F<7T:"N&XS3D&=CII[5^<?#2UYWE`W.H%<"I5G51S6LJQ(\OA;1^8N-%
M;"7+09CC4H8_PVC<;D9JPED@7_3"QE/S%!>G(SD3HL@S%RO)9>3DV!*GX;(`
MBF'_S#//&.A?VC9F#^1YXXTW[(`7V-+XRRJ@&@;E0OW??/--R.-?,7G"0,>+
MDP<.T?O_ZJ_^JD<:T+MDJ1O58^A?37'\^/'KKKNN9#?]Q9PPZ`.Z>-&]HPN6
M1NVK6U#/*CH5WEP,3WZ>\A.U1E.;(H<CB&;21'E71"(@`MU`AHX[GCLKT@;F
MC>XXM@70>B0MS[S1F!42C<LW-OL">N,_#XML.=7+H`]Y<GW'!I,!%I]PR67>
M+E]9#]"ZGL[U)#!Y!O>='@TSPR#/;J)Q%*E6A'G[^35Y!Z]61VX@<W2"<Q0)
M1[5I;LZ<08]V4NK9[Z=`QK8B3W#4J^U<0!=#GET+S/D[>#FZK8!3V'^P4W#.
M$'M.-L0N%6L<.*.YF3KI]20F3(3,I1O%Z(H\^5M:',_RZ:=^'>19\[.*V,F'
M/+S*0P4V,3R3/0%M6MZRDU'DX"1JA3R34`;?"@_(Q/(,)T^>--3F3JGHGEE5
MM$X).2/'<.P6'_K0AW*/5&+/0[YC\[.E[#]TB#/7X&8WQEQ#_+///FM6Q<B!
M-L\___Q7OO(5GT\__72,-'][V)SVY)-/LG#\ZLSF8K;''W\<[`"?HE4IM8>)
M`@*&Z*!F[NMJ[,26&$1`DR<O`3.B#&]:@%]+L6`!;D`8+]ODR(-I"A8=?2\!
M<*IYY@XJ,VO\S(7N4&16V4<^\A'S-;`&=KQ(`8IE,0`EML>9,V<N.9\&A]1=
M?_WUP`?@1(@1&T]EN)M2,;U\=4+$RTVUJBAJI^6MMHR?F"(*J"[6)78U!JUI
M,ALLKQI9^H<+T^].LX[J8`HX.SO-'6C:V4+_\/QMM1E6H&O+,SS*OFY3OLU/
MQ;J$/#.92L&'I*[S'<D<"H7&.KH@4'P?Y)GGF8,K&]X_.K+MC!PX$ZG7L`A.
M&85=!M8`SF1][N)SULS*YE;9/#^YE`Q.KV<!*V!9;9M)2]_Y>8*7@&6=<,5Q
MNIXV<8.@YNIM*X$4!*W(L]IL>7MZ%Y=B$IPX<8)58)"=@9L`)_DV8AP1+KUH
M]=F9-]YXH[9ZVY+OG-V>A__!!Q^D@X"E+&DV#S5\[KGG8H2`,)`'I#C._F'\
M5$W>)\QA[0`<YI")F!V?K*;BGZNI1[]B^CU[]BRY.G8@TX-[AI+FDJ=.G:*_
MGM9?R@[S4H;[W_F=WP&J#?V5V(OIM_6@(O"KK>,(6X)>EQQ1>'!I.&5OE1;J
M"JX&L<LO\UGMXT]_^M-^`CM1:WKLRLNN'M3!'R*J=^ZYYY[J+,<B7L$"^\'L
M?[-M#A;/,QYFGU/J+C=4R!-]1^SB(8_G_-W?_=UXGJ$KD\_SO&VCKMW!R`5'
M\%5#CVKN+"3M9A_-B8Z"V\YR6#5]%/E'#RZ:MK2X7UM]#J9T>D9.L;Z35SAD
MQ647AD*Y=@<<UFW%C?75=@`XS_G.(]L@WFSN./R!%V3T&K*+8&==GYK,IG4E
M:$6>CD^F>?@3\JQNG&*)FU6]YU!QV$^7'PJ=!R;#_;5"T,0'QC0X::$_LVRA
M#>3)R6,;D)RLC<D;=5]'O+57\SS>D=KJ1Q!D/*T<`WN`Z%)>NL!TIT?,>.):
M#KB[O_V0=I?6__!A,?3..^\TGH*:',70IF7E&,!\`IR\S5"%J0.1S,*:CKWR
MRBNPZ+777F,%O?#""YW@.F"'-0(5/4/1++???KO>'.4E(=KDEW_YE\T-/7QT
MQQ__^,=A3JSR'_O8QSQ5[!RI(91@]GBCR'G"DSAYBNVIBDKIYRN)9<47FJR!
M%(8$"R="^\]__O/>T1TC$B\*VC4-#=IG33;<I5OV"DX#/JU81607Y7M>IO(H
M(UMH&MB6>SS*(%OI&\VYO)'G+`;/Z__>[_T>8#0!U*2ZJ66@G54SBGET$&\;
M%=O]M++#_<CBU-W]=$%\N]B<98R'*3755UK\(QL'G8,&()KE75J,CK\EMM[T
M/=LC1%H?>%*>)_%Y-6/F!>?!OD^##,X$-5-OM^TH?^GJS[D8\F3P#.;,^OBZ
MMC46SC"._L2AB-ZP7JSGK#Z?*H2N*UEV@,PL<LW:UE`1#M/[L(3Y:<<`[^N@
MY2ZXJ!=LG<Z+:X=20<D_8]@CD?SX9.@=+;OKKKM^[==^K<2EZC@`'S:/%GO'
M5G?^DH4)`2A1:M8.V6;24TD[$0+\^;:Q!P(?4,.P>6;;@$RP\^JKK[)S[(0\
MU:VNQKH_4AQF@&=@"7B7;NKY`2;U],#F$="&E@'/'$?9&\R8R%*\#MWT7LR;
M2`ZCULEU0U6=`V-CG*A:<?SP8&36L*AVI(C1+[LI$PY"PMB2,ORQ(G%..'WZ
M=(MN[]CB4F9FNOJC!H*<H_UOO?56$ZOF4)ZDI:L20H.=7#IMQ5<[$D%BF:TA
M3[3S^7GB7M`17_C"%SRGEB3M_VCC>]D-\4>-@57%CJKG'%_QYT?/]W(,C\IZ
MH_7DH[`S4Z2A/0]Y1L&;KU%G76]J3ZH[\_]C[,V#+BO+LU_X8F*<(F`0#`@(
M-',/[]`#(F,S=<O4T(!`,P\RHR)X3*Q4*J<J.77J9#CQ5(PI/9[X1;%B``<F
M191))I&I&1N:H1ED:!H0%#$HYU?K5\]5]_OLM\GW_+%K[;77\*RUUWVMZYX]
M5\1?GQ=K7`Y7J;1$I*I=#`)$&6Y9\:3"3GXR]J]VW0WLB#DIV"[F3*MGQ;9<
MZ<W:D$<FLU/KUVG5B]3;`6=&M2TYCSD1ID5H!;441D($*_X$CFHDSW@9!O,`
M/FR9J<88%1:GV\L*/*J<7/[[6NP3EP-Y,,=-W8HW+T^X=DZSIWG1L&\`1Y7A
MV&./Y95JM1FD'IS1:842!PWX3AN(,](*_D!I8#C`"QH9>IG]%Q`-?EJQ8@7J
MV*.//@KF\+(V2Q2I-W:7LZMA<0=`16B,3GG#$:V'8^DP,,<\`FW()G"A-B*D
M"J,5;,!5<[ALI&*-4X[&Y<"@^`E$LO`R1^,GUL"7P#IF]<8;;P">;`QD03"X
M6,OY<I>,;_RCDLY<$[IK!-TZI1([3S+_X)%''@G;M,FX'C2CF)*I"M2`,SK3
MK9AAXIBER6S,:DP4=X/;`A2CM,+*N/^HHC'#3OLJ'U4EW@9VJK0&3X(\M7!E
MMU?=O@.]*M&R!;W/@0@]7#S&O"@7+UYL:06D6U-/G$<A2^[[_J'I;069E%6O
MJ/*!,CJE*9;A"D058:Q*V@WM.97G=-5U*NPHIU7)J@&!)B"H6U5MJ[:-"`II
MU1$ZDARAGI7B@2*/Z!0=*FE9M;M6IVW%R6Y!,$T]>I`S[1KBJ/*H5\N;H*9L
ML($^E^.//YX'U3`>"$8:[-I6$OGE+;/5T+D@@9K`CIT4P`T$5GN"K;(00RL/
M.U!`3&6"GX`S$`80A@58C5'*H`WO9=`&1!)Y[KOO/H[#!"`M3(8YKS-TPY3J
M<%X0!D&SKB:P8*]ANZ68T9-N;M:ZM)&<"M<_#@/<T'3#&J-_;?8'-'$<BQ8J
MW48(`VM,[(DGGK!_EKD8]DYE+ZO?B">Q@TE[JH4GN9/_8VH=/U;R8'_L8Q\#
M(C1E&\UH^G;5^ZRWR1J9F(6/S#)@DJ;B0O!`?M15.PUQ&ZMZ-:HZ=:R@0YX.
MIM8OOIL.>=R@.T)H1K=+`">_*M%14DS6UE3KXVI+J6...8;G7^FVPYTQ,ZF<
MJ:KEFD!0P">HLN'4$53I`#`^\8W:^&`9GBBC.LJ[E@K!G!1"[V"G"T7>II7S
MJH&""4[>9BC%4Y''S1)R;'#RK-85U/(7LB/7B$)=9I9:50J\NR81@[ONNNMN
MN^UF]0RK%%HQ552,A2<=);K^H?Z;WOQW#F4*S"]`O^#I!6J6+5O&T;B!)YYX
M(L)U\,$'\Y4=51S^J%5XL]P6:&,+8U.D+;R#)"(.IFPC#EI76&\+!M@1%$B2
M<]===]E\%B`"=CB4U2S!'QO<@!@[[[PS9V3R<!C;O:%0<$`PP5HH8$6DS^99
MEEDPNY-Y\I9D7WZUA`538B]+""+%Z6)@%UV.R2ED1Y9S9V-@DQDR9S.A@#[F
M$!+%$4XYY13^=P0J5*>JI?\K0^67(^R___[,UA0))F^Q&D#&[H%@#A!D@T*;
MSK.-W::X^=Q;WB"VBN9/81OHHG7%J^X3O:9"31J+=$I3FEEW>HIB+I+$HKM!
M*6">G]8?'%+1IV(;<1M/'2M-)1L"0CQ$@@D/LX]Q?$9YGC<J(\@@$*5_4ZXZ
M^"8T!?>\#UY@`,K-*BHZ^/IG;725`UEC!E9MKU`-L-TP,CGEV5/FHGY-6*`)
MGK'MZ$/W)U:F-\VLUI4X!;XLPA/O.=#AKZI=,J59I8MQ6MLX8NT1><"BO?;:
M*_ZL<+DDU#NT\_A/<0]U7"Y<N!#YLNXH`GOXX8<C1*@G[,ME(O@''730'[:R
MD'F#\T2Q,43EWGOO1=OZ^<]_;AM-G6(V#F!9\4<N%&T]SG8!-M9%0Q`:`6K7
MFC5K5JU:98E(B`0R!21">,SJ11[-=V!8JD+HT)O#@NVQY`9)MC*_0*<5B@P`
M!738Y=PJ@C9LLJ^Q?;(X+^@$8;`#.W,&,&^^^68T+";)@I'5J#`@$OP0$.`F
M+%^^G,.BG.Z[[[XRM%&KSBC4=)9G$X)8X)'F%7/444=]^M.?MOR.B:Z6H6:>
M+/"I#@C[$G-L.`6,\\E*U&1>5?S7[QYZ.55C2X<\@D-L)ATHI<]:U3*D!(&.
MBCSK#04?0AX",I5R5&"I)"0X4TMB!GF4=*E[G-19/XH)84%"A^C1F7_K^MK*
M4S`,X-CHLQJ-*\_I8$><T8TEU:FEDK<9&7&:ZRM/78O1X:\)CW&E>"(O2GQR
MK>6E22=IGO*9N+'BS$J4LH`3(J2>U9EZ1!ZH_NZ[[YY*04$>P6?S-O*7^8^\
M;ZAAPA&@]!:"8RQ:M&CITJ7([]Y[[\V6AQUV&**T3JFI(O+P)","D'D8"\^Y
M?;*063"'0R$4:BAZ?(`@!$38X2=4(7ZUBPTO:*08L46+>?GEE^$\H)!I8H`#
MBA*$!V'DE@*&>J,L@<Y9T@[;YMI&W:A`V:HX500UU2+%[,C&EO.UZX1',"?+
MSMJLM&:(!868+20'S'GZZ:<1:BMP<A95,Y"9<W$'C"5`281LG';::7_2PAW?
M!GE&+3_=X-_A_^(M`_QR(<S<WA:FW@-$+#!)^*K%BNV<R/3X0WFA@`!F.+Z[
MY#1%TZEZ4#`A@!/KQ_I#;E$H1,0Y6%$5I2")&\<`.RKR08RJ]61?C23I/E`A
MHC;9%'S2_*[B0(YOGS@M0CF:FU4JU9TH!AS1+WI?SE6]Y(&=S49&+>2UQ=0>
M?%7)RC#'O#9QV*$UB9@V\2'EO%R>V<JY2X%JI5/6U!*F"5&.>:<:?&)#SDB<
MH>ZP.-89@$]2QFK;T-H_*T7=?7CX-,J4G]C7:GX^`%#T)4N6'''$$<<>>^RA
MAQZJ`ST%V5P^]]QS[4>LS3:M/;1V&LEO%R3%6?N)KVE[X=F7'#%':AY]]-'G
MGGL.50O]"_FU%]*99Y[))&$%$`!PP]:W$AB6;2IGG2Y+LG-,+39F?-A"A2V1
M1!W6IDJAL-B2QIJH0)QUC"THJA7(3AEVH46IE-)P%E@-]YPG#4)B]5%]W*@V
MQD#"M?B[D_W]WVM9PZC51$'U#HY`#/[6/??<\YACCN%TVK(LB&I9,WL.GGKJ
MJ?R#:.+\]9S=T!3]6283J?)4P\X'IHYJ@(VKJ%HV0@/"6SH=)'(J2:CTIAZD
M(D]5:H0(:_%5]*@T0TQ0ZMT@;>\Z0`@TC9I_^2DHUVT6D,DI1,(<N39G"?)4
M>J.LU5I>R89(E/*T^%/K:-6B%A5M4IM4S<C:R&*+6I)IYG%LI0A&I2L)5XY>
M%JH3D*D:5J=D:?;A4YO/=JUG>H<\'VZC]DG?<"AJRN,7#\LZ4VVAW,#33S_]
MS__\SX\__O@-AERM;*-<6&548XZ]D%+E3P@RQ=*H6G$&_H`L:]$UL5K%`:%^
M\,$'GW_^>=[=%O%#C^.%CJ*G>QHF9@N\SWSF,V:46QY95O._#T,#"(!C:0MA
MQS[7%N@V#9,!H(%%H*)*G^TP0!C4*YL)IM@X;`<,A)5!A[@;W'.S]=<9TF,1
M<\"''>VI:F>K!0L65%;S-I2F0YY4$W6-=1@Z[$)2N!5<,O-G@>>*?]-'FJ<=
MH%!9D^=LT'HR5B/P!E-']0X'?RI<*)X5%F(8J9A3"4-D.8I26$35IRIWJEI,
MS":C2HWJC$9=9=\3U19XH["0HW4C6EB'/`&]G$*+S;3M=Q.K8_$NA]M,"SC1
MMKI2I=L/W8>SIDLS[\`G]4NKAI7".[-'6A++;6I`<LW2BO4F.I=K@CG=B-E9
M\S*'C56G5O#HD,>_P"<'!6J]H<"@<:TIK?;>(>N6]<@:9.#HHX^6&JW36BEI
MFN#]JR5$DZ]YEP;]IHNTN@\,AT_$TP*AMC67KDA[.`X:UNK5J\T21?-"[>+-
MSIU<9W`Z(^,GGWPR2H>E)``?PPM-K;*QK,/\)GE(<IU,=])5=\XYYX"E<#D6
MS(S0107XH/K95$5_O=5-N0-<$?L>>."!-HX)/B/(7..SSSYKRANT[<477^04
MX'GPI`+[M"-5?VOAT&J=UOCC_0<]%B]>S'RX!/X[?N*/>T=KYJ*!10<6,E4#
M]K3K5H3I7,RQY`09-FXFV8QJDO4XG<<GC*CNJVS&]U1U+K]6IJ04!W:B53D4
M\)"<($`7IU<;<?I3J$MM7KEA26VH^*;YVH6Z7.LAFUJ>ZA:=8E7[827Q,R5K
MXL-*D<"XKK:=VB$K>E8=M9"R7R4V:EXS6U>^FN\9Y)'PQ,*C_A5]*B:=($P=
M29UP.>VW&*G7ZI7&[-,AST:#F])'SI(CJ185<>`KMQ0%!V!9N'!A9"3XP^=Q
MQQUG%64XC'6Q$FIB67)CX:QL8UWE__S/_T1!0\%QEZ\.P]YM2*Z5,5!MX#PK
M5ZX$K]8;LE-Y/A$W*]C8,-3B.?J=;<I@=KE`9*R=4<%I=<U*O@)!]CL&Q\!5
M>)0%D%7E+'IC6JC9$^>==QXJIQU[T=0`868B`^06\:^!J%`=H_70%H$@,"V]
M7?Y;PF-617+0@CFIB=>EIX$AN^ZZ*Q/F[UYG,`3YY`,L*=>F,4=/=`V2J:RC
M:EAA+QTGJ=;7J$B1W-">JJVX[$)X3E2ASFX3ZTJ%FMIQ*0;;<!L/U44"N\&'
M2OQ,19YZ]N"2A2E&+39U`WE4AT)UY!2;KV5L-;0;%GEFM$8,,UHGOIJ9%;2I
MM?OBQJKEE*O^-:MU_U1[4LF*;M5E9HD_8H@K`R-CK:A[2O18_FM:1`HITM6.
M:K_GGGM&?Q11MVZ=;BI%5$V.]Y,WLGY&7YH&J/]!:_IF7TANNS$J[VA-MZVW
MALYB(663E8`7^^*9PVA-4<M8_>,__B.J#<AC^S:V-VS&\H"VU09YH#U&!ZU:
MM0KP8;TVV`\-0<M+EBPQK1*%"V0PQ<`^:W9RM*6L.076E#`KP2+&8(MIF)95
M-TC2HG]<(R@*A0/<P!G;6%C"PK333WSB$X<??CAKP%60EM-QPW?991<.`C5Z
MZ:67WGSSS==??QVEC']!QNC-7*?$,/^O((_T)IS*LA(R(O\"!O\:_RQ2S_$W
M&M))V"51.ANT+$L3#20VT;FJ>M4A3W4VN2;*3K`B4IR544,V;6U9$C/&5UE-
MH*GRA(@\"[I<8SVNZZ40[%B1+8:4;.#NFXZ,&&%BBHDV5'$F,!(H&T4>T:_;
MRQ&>D^$:D4<FL$UI,MZI6J$Q^1J0"8>),;G:C6->%GEJ.=.4<]=T;.OSZCJW
MT956&M<G%4(;LE&"JE2U2H\K/0Y?/_:QCR&;&GD2/.`=SOW/7^#+*#Y3$U7>
MW6JXI8[3.LW4X+O87U,`D(<3N;,]ND7Y;-F`^,,<0`"I"$/GKU$WAC2CG5UT
MT45^`C@H7R`/1X`.W7___6O6K/GYSW^..+.!@8[,EC]E__WWAT[`/334G'76
M67:!D=B88F_TKT6;01N3NX47OEXP##4O$Z#4Q<`344B+$/AF)56K=?&53[`(
M(#(C%=V0"T<IN^...U"UF#"S??KII]E%M*E.P$ZE>D<K?MZMKX73_V!JEZC4
MH*A5K=XS=6@ZKD$X:EZ!G1I((^G5R.R:N+9]3E2(-FU!IWEL,H)1`:C.G!O-
M*(K)AX:HORQ7JVP@JWI@Z\HJ_ME^U/`RBB0>/\I:!:NZ$)*SZ8A_JB*,A4FC
M0PDLF>2HKK%-:?$II&B)316+^*T,5`ZJI(J.AAW3QL4E-::QUG0XU2VJ;RL6
MGJA=<6,E%2M^+G9/S^+JS-*&4Q6K;):8PRA<W@IO>U6O-IUJ]@_M232I%0]2
M:^5_M"Y%?]P:PE8)4K@82"*$![BX_/++P1,`1.NN#5Y5?T`#:XL!1_`<8,IN
M5M;K0X1!'GNL,RZYY!+3&Z$]SS___`]_^$.N3I;%/3SXX(,/&@;T`V0`*,06
MTRK_<ACF5PI$8([]JFR7PZ^6F)`+_6_#T%)D:UHC?T0D:_W9=0+4@B:)=3KE
M+9\(/-Y\\\VWWW[[BA4K@!W8FE:I($]NU]ITKEAU.N0)['1UM((\'>R8CUF=
M5O*?^A>'#HD5/@#54!.GDOJX?";.HZHB!61J9,O&)7>I6H,_7(RQ%1-&1Y"D
MXD:W)D`452O\IW*2JCUU`%+!K2)/=\8<O$:D!'8V:_UH4K,TP<GJ4`D+K-'(
M-2`PAIU:`:/ZS:M5.5[RE%,6542P.+-<5C.*WM1EFM>:&'-;G[Z8CFNL8.!%
MK4H*I/$GYATWXRP)6J[(OTGI45B11TZ>,(_WEAIT%JA\]U!C5@&1`HDYOB!0
M*[[QC6_<=MMM__9O_W;II9>:LPG"V)1*9Y.%9=(*')T+;<L>$,89HGE=<<45
MUUQS#9\<#2PR>OF))YYX[+''EB]?#M]02+DT>-VB18NTNO`).;$EMXU@,C0L
M6R!=\!%M9#7IG7?..>?84\;6NN[%>C0O@,M(`,#0+#!#J2U7"'^[^^Z[K0"&
MLGGEE5<RSQ=>>.&NN^[:;[_]$L.\SF`(JIB3GBE_U!KGC<).BJ57V*F$IY;!
MR>B2+I.8L$%)GJJ$I].J8M+1^A'\B>$EP!(C<$62"B:;K'UD^V@T4;Y&32C9
M,@OZ33JEID.><(^LSUXA.8GGWZP5'<T1.MBIX;ANN75KZRFFA?942_)H!L2V
M901_Q!!7NIR5H]I6="XPQUW,O:JZF.RHVHU'D2>6'`$JB>>QX5CO*\:?6@W,
M@ACN4CF2!]3.4V]UY:[5O>@KK^8:OW=JK5H++"LX/NJ2'Y9Y]2.G*$=(W\J5
M*X$=Q!,F`T5!8'5S"P*2#6W.4"#(#WL!,K`CTZMM17?++;?`(M!BM#/?=---
M'/G..^^$5_S3/_V38LL\N;>(]M*E2VVACN9UZJFGGGWVV4"*.E<XCP66C62.
M>\OZH@R[R6CVD34!7U8%!'G8'E1D,LS3/"_0$BX$A'(Y'!.H027DPA]ZZ"%H
MSW777<?"ZM6K`<PO?_G+L".T0A[1RA6Y>U%4*^'IDDDKYM3V!UW%XPYVWMNJ
MF-8TS([_),988E.-S!5\-AW:RWZP%<USN1I,`CMB4:>)1%1=$\`)_9@6+D2,
M3D4*0+F\1<MW-BRV>[RS;U2>+I)_E)/H8YH6RCS@9J5]>8`ER.,D=1]G_9:M
M!TVMSI?<!['(>./8C1.!'"]5HI&3A*X:I=YD'KI5ETTV[U2SVJHFR-.5%DQ`
MX$1KH14SLN`CF1EO_6XF6B_1C+I2IE1S0&K>1,>9/U@R4V('B,+UKM:GV$@2
M!(1G6Q;$$7;991=T(K#"-BZ\]V$L7_SB%VU9!6\QD#CU9"P4K*N(]6`4$LT1
M@!2CBU'![$6%Y@(B03-^]*,?<=B?#^/JJZ\V:8L)<%'JF`<<<`"8DP:=L!=-
M-'8_%VI$/(M(6$'+*"/.*!\SZ5)(%(OXBMYG_UG0!OQA>RL7F7_Q#__P#VG3
MC&X%X*!D<1/6K%GSRU_^TO!FP`HXY5!PIX4+%\X8.I0%;;3,:T-^1VD0/"WF
M=+#352)]^PS0+OV\YBR(/`D43)2.],;UL?:(/!\><5['4!R+38PJ8=UU%V79
MQ[+C&)'WCGC4]4&>JMUT>XEU59_*H2H*I1Y%$ALK7D7YJK2GAN5DKP`.F]6B
M--NT7GNB34A.19[0FV2`:N=)G=*D@IIUGCR(E-Q)8$\-[XGWO&).P@(]@AQ&
MU+);5CQ<XDG">.+>JBFEL?\$>61$E1_Z`&S6,M>Z:(H/M#ZJ+@1YY#PBCZ5X
M$DG"WR%OL?T6M`2=Z,8;;T0VT4>L;0C^F!]A*SKYCW9F@WSXU3XLD!_4%L.,
MO_K5KYI`RN>__NN_<A`(C[E@4`LKWJCW65.:JUZR9,FR9<N@/2>==)+M."WK
M!X;8(,8>58876COK*U_Y"BB'QB<$,6=+]U@,AWD"-5R+A>)UC?%I&+-M94QT
M!79N&P8+SSSSS'///<<GMP+-2UN6O=0!(@[%8:%GS)F;;R*#<3O>V&FM.F\/
M.^^96GL\"1&C4%-C!>-53^Q-#,5QEZMJR7/B\OY0RV((X>E$NU..IK7-1HIC
M>NUXQ>934PRJ<N2YMBCYW55C"OBXF?2I_NI(8%ND8_,2;[-%26K8LK42SG`R
M`9]:2$>'#L?I=*NXR.,?CTLKF)/$*U4J;3X)4>[`9$YK`+ICZ]`G1ZHHE(I>
M($.7[*EQQI`_@4+DB6,]G?N2&>$N1BF+2TF[Z,Q!#I^*P,ZF)3BA0Y[*>=9O
M%9S>5ZKN(PNL,<['9=@%;&3Y\N5(W!UWW.$"=`5I19Q!#-0NJ(+U)5(E&%*A
M[=?*QH@PVUQ^^>7@#P3)'L'P'_9]\,$'X5'`#I*.V#[RR"-@$1+-RF]^\YN+
M%R]F5ER"A).;<-AAAZ%V63M(HXW#(NI:CZUL9L8WIQ;H;)!G+QLV@"89%V3H
M$2!I@+0[&@9I,!*4##"YZ**+[-)NP"%W@,D#2M`Y+I`K`L%8(W>ZX88;N!:(
MD"''/($;#!WJ#5$8M>K4#@[3.K.F+5[Z-A[S&J*<H)T:>!/DX6FI20T)D(LU
M)NZJ2CFFM8=T1MKH+*,IS-&&ZC9ULPY&NA#92F;4@SI6DSB3&M@?]*M>[R!)
MD*J;9`T_KI5SMAA\6%UDH%ZM'5OKF?R4@!RQ(K5T9@UUDI/FF=CCV:T'7PJ9
MAN2DM'N%G9J0U66:2V-2RXNA52>^=0\B-$ELXL^J4<UN$&^[B*2JZS\2Y-FL
M!6)M7')D_K25J*U$/>]0'N\_'OJG\X)6"KA,A`LYXOW^LY_]3(<.P^1TTS\1
M3*328EE&,FOA,>I/U0;!UYACAJDYJD@W![GIIIO07V`.(!*T"G`#=OCD7*@V
MB/R!!Q[(E+@T_X4]]MCCT$,//?KHHT\[[32MS7:-L:RQ=F.1QS0*YL`$XK2J
MPXI_,!:+H/J5:4/PTE"&95&+X_`3:XP@LD(7UV)<`5<'3#%;6SP;-LD=XXJ^
M][WOL<ROIYQR"O\R@#\M\J3_2V=2'D6>KK[6!JV47ZS'-2:Y2YL26V)JUI,5
MJXZ_?J0E941[ZNS#B?CMP&?42)NJ=!W(5(1)?%VU%02:JL&GJDNQKC`D/!5J
MXO[N0MURA""/ZT6>;5IGJSJWY%6E'K((DWVC-Z7_@C5(HV<E`WW&4)VX%F-W
MRR[-*LMQBZ=@5RV\$VM,+#S"2$HN3[;*R=(;?F4]G[ONNNLNN^RBA=DCLV`>
MZ-RA1&J"#[O"RS6-2Q94%>=J6]ZLQ%%TS*<Z7F,B^(.A6_'Z0P/H=8:*#8@V
M[^Y;;[W5YN#WWGLOL(!.!("@AB!WEAL%?UB#5"J/RKMY52A!+*!M09#`*`D2
M7RT)"%ZAH7#DG_[TIZ9@H]<`1*M6K4)@.1'"RY;P'*7&MPE7O73I4J.:4;7T
M6%UXX84ZW$4\/?LZV5/9V/ADAM5'=7Y%[9*D:0YR7TW6T#,KJ0)0FH^$M739
M,^V=R^'J4@O:>C[,'Y8(A%H2F5^!W!-..('G4(8IP@#U)IBG%XS,QXB=T;XP
M,?BLW\J!;C#4X4F="F[7)B5]0%6KYA%4G_BHZB1ZC-ID8L:)SA+O4E5GMFAU
MAET3K(CBTQEI/6D<TWF-AI;$+%S1(!9C:<_FI8ZZ$]MF:MM?$<9M5*\V:\5S
MQ)9`XN8E2D=@<<<$)*<91`U.3O3.5D.[3_!DN]8J(I4#:V96PGC\E)"$#@$F
M%F]/N*#42.TIEIQ:@;!6^HJK*\`5IU4`1&`!A<P`G6QEP4)U8H@&=M@,R-)8
M)%+MMMMNHR;Z:NC[4$L-KA6<UANIX^TK->6_K*JWUUY[(4'0#Y/*[[OO/N0(
MA0)!,_<!S`$BOO[UKYOH!/A835399(`#B#QPA.+#>Q]XN?CBBU&C5*^^]*4O
ML;N)ZAP!^+(9#>`#XB&_,")`CXV/.>:8S8;,'4NK[;___D<>>>2R9<L2W@S$
MV9?3B&5=Y\80Q@0-X.CK__N__WOF:?"S!"D=]&QH%>0!:MC2NH664>6K53M$
M)!#8&FCP-^X#Z`JU`WQNOOEF:P,Z0%'NGHR1!6[=44<=92BR_G&#-@,OTAY_
MZM"F:EL;#,6O-FQE<#[0ZG<EK?O/2FI2E]H9N_&HW:::>4=M.)'*FB;0%8F*
M_:2C.H$=X2C6VLV'?HA*L0PG&VS7FJI4)E/I33C,1TIK/+[.*)T1ZE0[&-RJ
MY(_GO%DOVGC,&:7:N9`2\(D_B^=3;I-2[5T5T]$\K)AQ8DR.+E8#=:)&=;&"
M09LNTS.^[YAK8O])^GER16N$8:PZ71AS5;Z$K(K5U<17WVY)0$ZD1WQ;">GA
MG<O3JRW40#@NT!H7"!KB8R%!T,,*7;`19`T5P]:6#,L26I;<O'4DVHPJ4[K`
M*S,I-.JR,?@#-X#VP`<T]<`-;,O.N0`E6UH@UZ>>>NK'/O8Q&2QW8_'BQ4<<
M<81JEUW(36:W+$;@2$0*%V+8[)BI6O,G:5^&]VBG,@5,(+(F,YQ'A+&V#[?E
M7X?!`C#R/X?Q;\,`?"STRH4`VEP1*'3CC3=R+8\\\L@KK[SRVFNOO?CBBU=?
M??499YS!WR35-#<_(%-#E"O@='$[7=:YNE7U9U4_5'T>$O)7W=RCWNT.?V)U
MJ7:;BB>1Z\Z75$<D/<CC<;)+591FM%K$6[=6FQ4EG$8]Q58E-VJKH3N>BL\6
M+9)'1K3E5#^[$E0#<K8N8[M6"3DZEZ$U(DE7-C#=9[0&A]LD5C!C-$1PUM3&
M6#4)*]0EL<K^5&F,.E&%""&K4Y'RM=J(0G@JSXF2E?6>1?OSW*'E_;2.RRX2
MP^#Y5)]+K=TXUO_P#__P`T.I_P2_<;&(ZK'''FN_SCONN`.4`&U`%5[W2!GL
M1:&S)+)=KM1*5&VL)&.HL+5T$%4;!*.FL3$(`*T">:Z[[CH.>.655T(8H#I6
MB>>,-]QP`S_!?R!+0,$!!QPP<V@D#?=;.@S(P^FGGZZ3'07*!'932FW<:?2.
MD3G@$LLIA<J4[*Z>OJ(JB7X:)&`E=C`J380MMR[>`J1V5[<VH-TH3"UAVDR>
M:P&%N"@;<T`:@2`(Y%-//<5/*(QVR=E@:-3;-7OJK#JUB/'ZI>)Z@G:2_IF$
MK.A9FPP9CK'^59]X%Q`8\*E>I,Z`T]E^PST2WU(A8EKDB9(2W`@45%*D=5>X
MB&NI,]I42U'U<0M<*D>"FT?+!)+GN%6)/:[']Q0)LTD>!`NF1-4J@DG%"I_I
MZGK5DA=QHS/FE%$!)\I7\"<N<G6NJG;IGPK"),$A3J[*9RJ9J5\SYK>F?NDH
M6B-_`D=K0YXH]7&OQ\(S+?)\8.BFQ\O7H&7(_W[[[8=N<O;99R.SFGQ!"<3-
M\A?0'L-]68,@LXQ4HH\@H6".VHTM.Y%K9!DQASR`/&QF`I>=95A&&#FX+8/Y
M"BC!<UYZZ26S%6SCQ:\(-6`%U3$Y+G7,3CSQ1!@1%`)Z8VRAX"/RF#TJO*C]
M`2-<UY>&P558Z,/4#XNI`DVN,=7=8]K[CUT`6-L<`T%@+W>`A0H^7!HKK4+V
MPS8`3YOUP!Y1Q!Y\\,%?_.(78!3_+_=\@Z%1BQ2TMHI8;^A8-RWR1'&N)8ZM
M/A&B6_/-X]?NXFTZ]3Q`M$4)VZNP,Z,T&J@*2%55*IAT*DP$O\,-1UQ(U7XB
M=%3U)Z,BR=8MND:J,VJ.WJ:,`$ML03E.MV5\Y4$>$ZFJW:9F?78)Y@&?%-()
MI4GNPYR18>6NZJZ*)3GE<53*XG]/N/+$U&Y9V;$ZW"M'FE?RTR=:"V-A)^I5
MO%HUMV)MVE9".&)>3B[AM-J6Y67D_"QP,WGIHP1=<<452`T,!!"P;K/EQQ%/
M.<"EEUX*VB"/1N*AC)C)I<U$M<7FF.R%5%I8&+!*[W($$$T$Q<I&&!P*4L17
MF,^KK[Z*A-I,$)V%]>QXY)%'SAYZ!J%SZ637SVZ_5'4NDS@T,NMMUX`,*JH)
M6J*'R]$QYYQ5QW32Z:=+ZRO-1.:C6051XX_%0%C@PKTZ0,G&HU919H!(W,.;
MAV&[C7OOO9=;"J@R9]6K>!C?VYJ#CP8*UKB=NEQUKNA6`9_$*G>939N7",!1
MG:N+;ZGTINHU6XV,;!/<Z#:K"M%6S6<=Y*D!P/$E58/2*(8$N&:4&C@>_R.M
M!G*0*GZH[**N5"?6^<I=4V>58L@=X1%;M/!L7SK4I$YID*>"3/(@JH>K5O%*
ME&#GZJHKHU[%YY5HP,[(K#IF3E;X3(!KYS9"F<29V(N2J[XV"W.-7JZ1\VNS
M,*->Z=LR\H3C(V+H.P\__+#F98N]:U;5$L(&MJ.R^\-55UUUV667`1W6*47`
M+9IA`I?-RG4#67U4O0:11V91/:`!*",VM()"L,!Y7WOM-?`'=<R&@)`'U"[`
MZK###N.F[;[[[BR856&_'CLU&UAH5H59ZL*.32O25%3D%.M4O@SXZ8:1S\Y6
MJ+3]J,,2K'KG#0'ZVC`X)L?GL%Z.I:>ACMQ)8`>DM0$TD*6JE606E_,?=8&"
M"=?1DU7C)42>:MBI529J1D/G#]U\+2&"'>8X5-P$C8^T<M\QU(01;=E:*G2D
M*$.ZHC5FV]8]O()#1:'PF6HW#C^I;">8,ZWVU.T[H]0###0%N\)J9I3^PA42
M*^:(*GJT3<ZJ@#-KZJBX49$G'":EO=P@-4Z3KE[S(\)SJBTZX%.=7#4LL"+/
MW%8N(X%`E0MI4I[3"OBD%//:O.IY\*I+_6V\ZCSD!A`:4L(N)YQPPG777:=?
M!CW+_'1D#>31*@(!0+)XLR-WB#,O='B1S3JMQFQL'@ML`.Q`/*R;@3`BFRPC
MR*A7K$$WX5R`#")IZRAX`HP+++(M\LLOOVQ_3Y"'GT"5O?;:B_N@GXNIHG#!
M'\"92G)D7""&<"%=L?&$EF$51I9A)GKK=++KZM+R`_DQ.D@@LNF5#B\)#U__
MSV%8!M8+M`81VU@5!.K(!9IVROU$D42%7+UZ-6"^X="95^21<U;DJ6@32_*&
M0\/Q#5O7IPU;WX3DGM><S4VF*R\3"K3%="D)%7FJX85AUF3@(BZG&25K,I"B
M#%;P"8(%>6)#%CJJ@3I,(TI6S?X.&XF].H<2"9,P%?-1=@D+BK][U&(<5/&P
MR=],BD2LRK7H.E+O+JGB-;/T-(^2-6K`Z>PV2>HT]CA1.C5%M,.940=Z%*7.
M=<7899==-..$U:A_5<MSQ24FP+*88^1/=7INVLJXA5VG.(;OQXU;<\;W3QW2
M>V#'J!)3C1!JD[(1D]MNNPT<L*X.DFM#3QB"L;L:D!$QY$BSK7YGHV6T_``%
MKK<_#A*JC8@C?_O;W[8!A,J(GGK6&`^,2@+F_/K7OW[EE5=`(<"-.=B""L[#
M7R_^G'CBB:>==MHYYYSSV<]^]LPSS[2&H7'+#`@8\^'L"0MD/GS53B[^0%=`
M'D@(6W+P^-E3\UGE42\8&X`YNKJX0&O@6^N5@]AW@TNP]0_+W"6N!0[)!=Y_
M__T`+$3.1F,\*MSPJF=51IHDNPV&5E!Q4]8J@JF08WS.:"1/PGM2)B)?D]?Y
MD3;$HFU:B%TLR1]I*0_1I!+?(J1L4UIA;M-J@W<<(\2C6F:B<'F0V*6W:LF8
MVFUF3"U9O$V+UG.7&:64.L,HH\3RA<]DLU":6IBK<BU)2Z=PN4UE7[5XZ8XC
ME9/CY*JEDJL;2R93"P.ZK#VG)JV[05)$HR)5Q:H&'SI`&`\UWGH3JTQ57WFB
ME/5;U;&@#3WIZ%F&0'.*#GDJVTDD3[PA(3RCR&-!,&-+UAD*<QU^^.$6X;GQ
MQAMON>46E"F`PD82&FH01CYM%VAU940,<=8>ZP9*O9FD&EYJ_P@=ZUJ!T-I6
MK%@!^"#"[&[383[-9%^U:A7(`_X@L-;VX5PPG$6+%B$+W*)]]]T7S>ODDT^V
M4[!)6.>>>ZXE4E.BF5^-_-'GQ7J`A<F`$AK)TZG'Z!V8#'-C,PN+283D0CK<
M;>,NHGI%\#UM1XG_T17(S>2*0$[`Y\DGG^1"N%[@B&=OU)BS7AGY[VI.1)<?
M$7MR93MQH&]6ZFXE4#`)XYNU7*IJ,.R4K"@[-:*ODIG(9NH_"`A5A:FZ3$6`
MFFLP:N/-^FU:,F:<2MN6CGAUXVK[S<$-(8X'O+,/9^..\XP:<]9&C3K8J>!3
M6T)TAIU9I1]H0I=9EJB$#E4\&2OIY$&JR9$1LTRG.ME"HO-M)5`GB!3`J6:?
MJG]5DAP*G4)/25%?O[0[Z9#'URLD1Y)OAB/['GSPP1;/N6X8\!]0"'ZB#PMN
M8_=SX`C]R)HVQLF8`P6`F#UAS1S=W,H[DIN>$7J1D&)T'R@!R&/#4%22E2M7
M(J=0(-2K:Z^]]L$''WSAA1?6K%GSXQ__V'(6D!^@@/\4T5B\>/'QQQ]O+:\+
M+KB`]3(Q/5Q:?JS/+&ZX;)5F?F)C>X%%[0)&[%UN_BDS3-'71/L8FLA9P!E;
M!^K",\Y0^X]<B#L#8.KATL[#>.*))W[ZTY_RZ*8V^_HC(VSG@Z6'[\8C(^:=
MC4M-]9ATA!J?#6F,ZT-C*N$)'&W90HCC-Z_&WJVF1M=L,S6F+MR@JC;5EF*P
M7\PXGHNO'JKZDH)4VY3LRUK0)EA7=;0@4H!QNY8S7G<)@%3,Z4;(3`W\"VNJ
MV:`UK[P;7<1@##LS2T7!((S><ZE%'2%%U9(C:G5%+:JZ5+.NY@V-T7?;;;>W
M09X*/L*.#;;D3LFMZ*HSQ998O:M)ZDG>:/6;B#SK#_69U;;L3,$_>.&%%T)U
MP!SPQXYR,!!$_N^&H5X#2?CN=[^+M"*8MB^W'I?)%&8K6)XT9=M-54BVA3FD
M%AT%:FZ__79`!H;SXHLOLB#H<5[F`/7ZQ2]^`54`HSB7D<]H6#Q=7/*NN^ZZ
M;-DRU"XC`8PCTMS]=VT8Z*C%6-,-L//I3W\::.*K$9*V$0SMT?MO`H7@8P]B
M48CC:.^"*8$V=N+@%(9SUSP+</*::ZZ!O]EB5?LY"PA%C<]9KW3E"UGM>,Y&
MK1WG:%CRQE-[-,1BLUFK,YRO&HJ[O.S0GA";K4LV4[;LO.3*NYNI86U7\ILZ
M<19\$F`3?4UPB(%(&U'4J*K=A/8(+\+"]D,'&7=G33UOU?BJ?M1%XW0L*.B7
M/$V11Y:RX]01,W*.W.E?'?*$R5B'9TXI,.CRJ`Z5I*JPG6K8J2'-$Z4@88W#
MD;>()W.G9J#'VE.1IPZ$RU\3"]053JEA/#68)S&NH\B3,!)+QX@_5NEAA@@F
M$@>VP#K2/UTS"[B$C.L$M_F=C8/1JLX[[SRPA3>^(3T<A#5`@0YK#28&_.BJ
MUIW]K6]]"WWDX8<??O755U>O7JT9!%8`$;+X,YH=T,1/X`\GA9)==MEES.V0
M0PY99Z@4S0-F@V#+[Y@QJNU7_!$)5;[LH5-#@)BG(`.,&"L(P0.%@HTZY3V4
M!1ACOY+D&`O$5\%-<U":JP+=MPX#P'GNN>?>>NLM%I#!#GF$'5E0G`*QZGRP
M-8"8MMY.-*Q1-[HK-V^5*)3]S4M1B*I>Q5"\=8DNWKR5`]UR)&)0P\X6I?*Y
M:SI#;MA%E*E1P=^^%9&(JTLK<>?O=LAPW-YM-*IT&0IA.!WX5!.Q-IG,0<2(
MP:>VFT'`NYCDH$H7S[-C:T_399TG/VMMR!.MJO.MSQSJ@ZF+N0L+R&G\7!TC
MBI84/)G;JI[&I55UJ(I%E3CIU?K8,#1'=X;E#GPJY]FPM*:MN>HB#V)KQ+[@
M8WD]=E^R9,DIIYSRE:]\!>Z![&O68""G2O?7O_YU=1^A!B""#%A]754KZ9G:
M21!,[;&&.FL'9F-V![Y`F!MNN`'R@^!???75X,SRY<M_]K.?@3"L`9I8>.JI
MIV`+J"IP'L`'0086>.#7&=HZ<!7<D[WVV@O\X>#,)'6A33\W4$<%RK0L/EFI
M25EU#'@!*PP7A*L`;J`NO`YH%7;8P,ZGZFY<"]=N,7R^&DA@:3)MSMP6.PR:
MU?7``P^\]-)+K[_^.LM(M"[R:<M<)`0T48*LB3\]1IZ8FFLT8*VQLWFI]5=M
MQ1WRU+"6*%G;MC2$K4;2FA*25RV]VS4_]8R6_K!]&>$A`9.J6]4`X&H_&;44
M!<&JM4>*HK#'#Q6HX:>M2W9GY22S6]WC@(9PU,%7\JJJ)ST*E#`R<Z3,5Z*.
MNU(8II!/JVUEQQJ0,]YJ[,3G-6N((405&J4Z#EWGR>WRZU@K5!B+4(*?:_Y%
M#3*<'!)%83X@C[5]?'\%?+H\G:[N]]J0!VF%Y\3.H\X%_O#@H;\<>."!(`-H
M@-8#PL!YD%G`Y#/#^-K7OI8B?H@MG(<%UEME%$G4D92<<9.AM,KRJ9_(S"G6
M(^F<"'Q@1X048K!JU2K4$W0]Z^0@O_"$9YYYYHTWWF`!%O3C'_^8+8\\\D@+
M1]LLSZ94@//IIY_.!#B7+=&_]*4O_<LP['S!,>W4K*T8B(A72S(&_X'V`'&`
M!OC#V;E>34#_,`S=?&QLJ8V8@-2YY$)6>.9<MA0$;5:N7/G""R^\_/++0!!_
MJ%[RV.*F+7,1A/E@ZY17_^Y*;T28KL".R"-IV:KD=]?XP,ID1N,&!8H:$EP]
MYIV1)+#0`4Z^UL"_ZOFJIN/H.,&6:I"9UD03DXOZ5YQ9,2//:'W,.^196UY5
M19)J)4Z(H%]#BL9:79VJFB7&KX;K)`-T6@MSASR)0$Y,<I!*2%F;D2>X,7=J
M[N?;<Y[.L54-/FDS:D!7G!<U!GY:K_K:D(=AQ1@YC\5(.3Z$9[?==COZZ*.1
M.`0'\3%1RU1T:`]B!1^XY))+D%D`1S4$V#GKK+/80-7&6&++MJOC@#/P`8Z#
M8+(9VR.\XA*'0L8Y$=SF-[_YS:.//GK//??<?__]<"%H#[+_HQ_]Z*Z[[OK5
MKWX%_MQRRRW`PIUWW@D_02C2'4P/'1?%2N9_W'''??:SGP4-TO,490W,`7QT
MJ5LUR`A`6)"L1D.TD4N@#6?G#L#*@#OX#X?2I"Q?TN:3@$.U/(XCW0+HC%,R
M_?_QQQ\W5`#:8R:^21,I]E7)CY[QJF>ENE<JM^>]T[D;XC%/"0NQ14OR%JW"
M^58CJ9U;E&*A<80%B+8I=6FJ4SL:T(R6FS"M147M28U&FXS8Q?K,9[LAA$9O
M%.>M>5(5>4*6MFVN<(?X%M:A!69&22KOF)6H-;,55T_0H`S$C8,S6ICKFO"E
MQ/[%\JQ9.'8;D6=.J^NU-J_ZK-:>.#D1ZCL,F=+,H<>6J)+,T$I18G].?*!0
M`WI`7:K?*AD3\)G8>33[Z$E7PQ)S4C0C@1:;3NT/6TM?UACFFK$N\AC`)N=A
M&9E-CS]F?M)))P$(?%YPP040&V#'$GR:-=!EP`V30-'(SCWW7(0./$',[<^N
M&5DODAQ)NXK69GU`5CRV42!(A?A?>^VU<(R?_O2G4`)[=0$^]]UW'_H7Y`'Q
M5Q%#87GQQ1=A/M=??ST;(_7O']I`V("&R^0.;#=44@5\T+\6+UZ,F)]WWGG@
M"8C!A8@YYJX:@6-DT3>'H9,=A`&%+'3&KR:$0O-`2+[:+!Z0L5>%+3"L<VA%
M5ELY<R)K:("?<!Y@!SKW_///KUZ]&L+&4\3-!RB`2C,@[.@7`]U&&_7]QVN9
MP6KBVZ05+]44[(,A(L5NO-5(.>*/M';8"=V9T;(/$J4<S.DHA-L',;8=4KFU
MD"CI\@'IC<I%W$.Q1:NOF0^UW52?==2H#KMB=MZA-.54Y*-/[5@2-@6NJO)$
M\1E-1HC9IQ*;:%4S2V.LP(X7HOICK%W=8-9:VM/,+1F@B4SN8&>R%<%PN0O:
M83V/MVLX6L)UYI72[D[)KQJ(NLRLF(,\:1*[X@XSDJ>ZR>H#5A_":H&,NU9*
MGSS$P(XMMQR&,9LTBK3:Q>^,,\ZX\,(+%4](@B$K:"(P&40,";6+!$*-%H:H
M`C56[M+ZBJ2G0Y^]]NP6JKU%\XM<"!GG:-`#D0<R8\4_N,U##SUTZZVWHA`!
M1&P`]V#-+X>!%$.-H"(\#U(=TS"EQT#TOOONN\\^^^RYYYYVLK#'NN5]0%0Y
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M[[UU&2-QNI*!$22.E_A%%UVD20<I8\U55UV%X(,GR#*_(GTLH'`!7+:<,,:&
M@^CJ<IA+;K2A76;`);:WJP6R":NYYIIK$'_8@CUQOO6M;VFP-;?K%[_XQ5MO
MO:52=N.--YY\\LG65.2ZN"W^4\`.:'/HH8?">18M6G3((8<<>>21?#W\\,./
M.NHH4`AZ=O;99P.5MC8V\UT49<X`+V<$:@S>YM+XRC3@//`BTT7U7K'`Y-F&
MRS&P,.NM'`M:&IC]\,,//_+((ZM6K0)YH&WL$I4*VF9I+Q;X0VN-Y3^=VBHK
MGO1JX?FSH1&PP.(C$283M*G6F\V&TL0U#,^@G7B]XW@*R-2@OM'1V7EB)(F7
MW&..LI09I4%,!8V*&W7]]LVE'JN.P%+IRJCI9A1V`CX50+*O\)+99GU2(;)[
M/%;^%)X3U:G+_>R\Y"%"2KI@,MF*M(L`$ZUM\>PA8SJ9$6%3\I-P'A<F2]6=
MVK\O_G&11TB!/@7B1I'-6"`VL_?$YJUA8I<GV.5M=4FCG;;%9_JS:"H!B+C/
M(`-\!KE#RJRF;M8#KW)DD*^H2_:U00EB8T18B0.%D&B=\L`77T4>$\#M_OFI
M3WWJ<Y_[G(XDLRWX">#B:!:TL?(\F+-RY4KDU$H^BK-%QI8O7_[&&V\@O!`)
M)O"-;WSCH(,.8O)<K#=JX<*%@,P))YQPXHDG@BIH6\<==QS*(W,#85@XY913
MP)ESSCF'F;O2/EP,RQO:TMWBJ.")$3Z:G0$?HZF-X@:%["FF=1K:\\5AL,L_
M__,_`Y6@J+52;[OMML<??_SIIY]&X7KEE5=^]K.?'7'$$?Q?Z[<"I_QQ_#6J
M5/D':UJ6;JR:9O[AJ>5,JQM]RU)%4$]6,B",Z@GR;-\B`-T@C&+[DH!05:&8
M2F+LK?$Y:EYN+QJ(6I78[-@<Z/%`;3]=F(V&FNH^VZFU<E#VG4:09S26KQN5
MX60^U9OF093KBC"=CE:_)@_+C6>WKL15E9M3,LW#<P)0LX<*J/-:/2X=6+-;
M6=2QTN!&T,C7B=8J/2''8(5VFT3[S"W9$UU,<K#%729+ZF@LSW-;9T!5MIHE
M6A-V4B>JLAWC1J9%'C04J`Y?-3*GQ]]AAQUV\<47`S5F1AA[C+@9!*@?AY5H
M0(@AN($(PW"007Z"14![@"/+J@LLAL2PETV$SS__?/07I%@<TV_.&B-J(`GW
MW7>?W7#NO?=>M"JP"-CA^)IB;KKI)O-)K[_^>D0;_&%?B(VVG8,//AC8`7"`
M%W0K4.6T8?`5>&%NP`L3!@"9!NJD_4E9L+`JG\R0S8`F'P#4(CB;S2D`'Z`/
MA+1"$==EQJ@!WC;9,4F-7Z$];'SMM=>*/"RL6+'"+D),?LV:-3`B'GO^"_[-
MQ.W4B,'J-Y?;=#5VA!T=Y0D:W*(UW%P;\GRD%1%-NO=V4ZOP54OR-B5'NQL=
M%=F^A<','%*?HN9X6&%DQQ9F4[</AH1X!!#BJTH,#[_.*(76=RC=]*I!9A2(
M@A4!G^I)KVJ4@<0S1[+.9Y;L\CBG9K5T\IU::GE%E3BY9I4,T&KG"18E/K":
ME^>V=GL3K;3I9&E;$[1Q(>::%/+*7O%5U5"?ZD-WWZ21JFK-;WUPW(:9;#ZU
M-[WFQ,X#&_!Y>VU+([/=Z"S%S.`L"(Z6&7##5";DR(`Z`$05B9<^O(@U5A_U
MU8]$([-P!C"*-8*/433(*7LAVN`24@QK0F!!&^`+$+.B!4H<.M?]]]^/J"+%
M"#B<!VEE&[,R`4`$'^8`[;GKKKOT'.D"`UNX7=`;%*MCCST6+0S``4.@,<S*
M7CDV2C8'Q/;K)I<)0;8H94"6]MAC#WD@6,U+`6K$]'2'&?/#G%DVV\*:(7(>
M8,<X(JZ.S6!E$$A`DGE:8)8K`G8,3[(X\R9#HT_ST&M+FBY<>6W(HP+E9IN7
M9BYKT[8D)WJ[-"QO-UT^5"5%G6[E-M5;M&-)WZYL0>.,/"H.IJQ1EBOGJ7ZQ
MN*5VFNHTWW:(6`[QD%'L6)(=,J6LK-2E*EEQA$5=XB<M-G6#65,+)L=NXRYC
MK9!%M0:/CU1NKP[Q9$E4(*K`%18DU0E+F6S]B&.<B7U&G`EZ5*M.*IW6Z.7X
MN;P<M38DR".H7L7^X[ZQ\(1[6S9A6FW+[-%ID<<80GOR@CP`D<U9]MMO/U`"
M059#,4;.G@Y($_!B*(X%WOFT#002Q[*!?)`*MD_VI<9;*P&:WL4"&AF<*OYZ
MLSBUGT`/(#QP(1C.#W_X0R24KX"/"0N@#5SH5[_ZU;///@OF7'KII0BU38>9
ML,AS_/''P[X@.4S&["TCEE,9'D3U*HP#-,D+Y&$7T&GITJ7@-E30KL0L(*2@
MA*D9=BVT_995T2S48\"2-7R,H#:,F2U!'G@=D[SUUEN9/%@J^'`#^8M3USW&
MY`H[HVZLFK@GYZF)$K'PK,W"G$(3^9K(X2YL)N2GZEGQH5?O=KA'C,FJ12%+
MT;\D&]M-K5V\-M]6=6178\ZLUI2SBX?I;,)5$9O=4K^#,%69JEQ(BA)5+C[T
M`%U&@G`$&>4ZR5;5AAS:4"W,B?V+ZZIJ:H&L6'L$C7`;3^3!`Q%:C"O.Q`I=
M[3RQ_[A>,T5X3E(GU+QB1_(Q&T6>:6W+;Z-ML9E4!\RQKS$0Q#:(&'!Q]-%'
MH[DPPV...099YKQ@D8W\E%\`!.IB#"%08RHZZP$B\`KFHYIFTW/(#[*)V)KM
M#L*@N4`>=-8S6&,A((YSW77761`>?009?_#!!Q]__/%KKKG&['B(%O*+Y/[N
M=[^#'4&!#+FY\<8;P;%EPTB+"BB65<+4^TR7,'54&Y1)K,Q9\@/R@$*''WYX
M6A5S3XQ7Y#9R9[AD"XO9=<N"A,R*XX@V]C04?ZQE=,455S!Y-"^F??OMMXL_
M+[SPPF]_^UO`DZERS^,WK]&A7=Q.M?-T*5JUTE>,/&OSJ@=J4K!KVQ)=W!ES
M=ACB;;8IF9NQ/.]4`H;5FS3^<$R!J**-6VH)V:FUSM2!-7,MOBU5'H%(%Y*O
M^QBEH].%,,PI]7!B:9E5*FM%M"N3Z5`HG$>K<G;ICE]-/>*#HNI7Y==+X%/]
MA94Q5E=O>VC,SJW[WGAK#"K^>-(0(6<2T]#<EFH:%*K*5)Q9G0H6DXX!/+;E
M\EQL(/*HIGE='+\^13YO!O/XZ"97J^8A&L_LRG0Z8!GF`_@@7*P4?]9==UV.
M><@AA\C<V(:_@/.R#7?LU%-/A;V8.(#P\D[GJ\FA0!`""(6P`;'6$K8Q6Q,Q
MM%R\S:W8W785^H:0?2`(:+KXXHN14$C"`P\\\/SSS]NRZL<__O&33S[YU%-/
M`43(.[]>==550-/JU:M???75AQYZ2$/*'7?<@41S0+0J2S2S`)C8!<S"'18X
M-<'*I`FK";F-*:Y<#JPOH95Z`!FP06XR:`R^,4FFZA7]QW_\!_3,#!$NQ"!G
M0PJUB@,[W_G.=]"Y;KKI)K0M="X+/[[XXHMOOODFI&C+H>Y?P,>72`4?@_JZ
MH.48EK=H[3[C-!=\]&'-&*JIA]O$O-.E0FS=*I^'\VS3RN9L7](MJREXU/[3
M&7!FE=`75LZ:FB>U0TGW#A,0*$*91*JH;U*+ZC=WI4"AU(A:,TM`CJE2P:Z9
MI4ZIAU+KF5.2ISJFY-?Q5AMY=FL#T1E[G7F,S`&6<+-Y4PNJ)]]*?!".\E/N
M1M`F<"=2>1QY#F/^T!N+GQ+>G'/IS(K3*N&"NPRCAD//+Y7D=]MMMPH^;%^K
MR<7"C%!LTEIF&XTFSS%7U"A9Z^#96DZJDZ9ROM89IE$L7KQ87QO+/*A<)GMQ
MD#WVV`/P04*MG04A06Q14@097O'R!Y''R!GKX=C!TZJDMJ3ADUTLXL>G^>_6
M+K9&!["S8L4*/NTI\\@CCT`8_OW?_QV`0MB7+U\.;0!YGGGF&3:S71>*#!C%
MB6Q_#,0979PFH5J`K0-FFPDV,!N">6IV!GF6+%D"2AMI8&ATFO0APEP:X,/I
MF+"I^LP?\@.XI6BJOGB@R9`>)FQ#4MOB@)!<%U,U@12<-YZ'/XX_-/ZL1.QT
M&E;GV!I%'HT\:4&5*E[;E@3P:DF.FZFJ.>$V-4,SKO`H/CN6R+UH6U79"8>9
MU=KU5M.0XC^S1;\$9'9J]?U&%:(XN:H%N+*I6)`"!6X?BQ!C=FNB%R]2/$T=
M<<IYZ[(H,38DL%?8%'#B]9YHV>5S6F71>)3FEHY7KI]L3?<F2X>:BD4UJB>[
M!`_E/`E=#HQ$F5HP70OC+F,BMNAH6$[2H]4,P5H22N2)ET1MR[R)F'K25,XZ
MA.NW!J/(EU'-++#^@&&`<NSEVTH.P(GVW7??DT\^^<033URT:!&ZB<G@8!'*
MBPUQ>/MKK658)]FT`@-]$56V9V-V0<P-[`$3$%[T+Q@"$HVHPB704^S&!4E`
M?BU*#PK9M!V2\_333[_RRBLZJ4$AZ`00]/KKKR/+G(BYI1:]3C23JOZ?81B!
MS&"VNJA4&X$LU#&NCF<LZ6!6$7G?^]ZGY8>_!KSZSV%8+)%+`V0XIN8L,TR#
M/)===MDWO_E-K<VHA#"?VVZ[C>M"B_S-;W[STDLO<1/\RP"?35O3X2[K/"I5
M*L(E72O(D]P'(W,^TAK';-6:Z"7?:KLRPEA"?A+GDWB>[5JA&P^UW1![/.I"
MBK.[JDZC[NQNQXI4^4ED"/-1OF8.B15J;8&IF5/S-ZNM>W9+BXC>U*E1@9%P
MK:I)==!7W63J->RUPY#G%54N!N19I3?$V-B4UN<)V*O(HW-*J`E5B^H43E(M
MQF)7U1_'AR;IU2=5(P-K0D0]SLZMS'*%*8B'UN:JLE4'1TW=ZI!'DE,K,)NN
M]>XR6,DG.H6M=94U%@X__/#33CL-\.&IVWWWW??>>V^N"RA#]#CCPH4+F1)B
M`@72XZ/E!-C1VV6CJR]\X0OZE0R*-BX1/O"UKWT-:043K-`%_S&'5.7K.\.P
M0\WWO_]]1!7`,1[OL<<>@Q&Q'D'6VO/<<\_]XA>_6+-FC383-D`I`WS`)1U8
MIJ)K%A;ZK"*89AFL9VX:9RR"P?90M4]\XA-<(%`,^>'&\K3S=_#0:B[C5]NL
MFU)J91X[JS+4):-MH9=I&DKJ.LAS__WW@Y,HC(`/C$BB$JM.?;FDTM>TE9.E
M.D+3EJV)L)B3](<MIS8:WJ941Z_\I_JSJF,]%IYM6]EV7T:5\%3:4T=``.G>
M:6IL3."H"Z>)_VC.$`F\8RM280J`\]0./*>U^G4DWJ8S`D<IBS<J4PJ9&2OE
M)G8J3KKH=,&H:$]A2H$XYRE/F#D4,9XLQ4N3L%D1::P4&TQPH,>4(V6,DI.J
MP0F#(H]<:**4]$E@3Z4]X3;S2UE4)[#ST,O8+/64:V9\N#4H4?>O!LDT/:F<
M)^"C;ZMV6H')&+TFI4&G0-`^_O&/(X,`R/'''\^T]]IK+WC._OOOSZ>>=T[G
M50--;(E,(>!`#0*(,")Z%@H#CJ`0IE1HSC6>T/*JD!QSHW1S&_9CH@0\`8E&
M?S%XSV[(IG2Q`'F`./$3&T`;T%D@/R^^^"(+JU:M@@*]_/++0!`(P\$M[:7"
MQ179F]B(:T,<+:V3Q'9C`FU%"N0*/MPB_D'0AO^"^\8=X%$$49FJ615VG.?@
MB6<6>;[\Y2\#DL!.6B&;`G_]]=?__.<_?_311T'+-]YX@TOC@%NTSN;5=U!-
M.AWFU&(7/@]).8]Y)ZGH6Y;&-.$V769$]*`N4$=J,>KD6AOGV6EJ]&^,)QT0
MC7JC8I]16+K=LXO10<I42(B&W)JG4,$MFU5,R\;Q8OM^KYO-*FW0W44`%,JD
M*Y[."]'4+&^9*&.RC'K>P([KYY?D\>2)5ZRHT8!.6XHROS5`CXLJEQ,R%NC+
MH:)V38L\U4?F1=4:"*)-W*^Q3W;(TW7=2K\5ZY!+=;A7JE$(X+_\R[_8:(8)
M`"^6Z5BV;!E_.GOQ#+/^J*..6KIT*;L@5KSN00]T$*NI6X,+80>"0)[33S\=
M7+*GGEW7V<;N,]`#W=G@3_))60_)@2I8:P(XNN:::]"S$%CX#T#$!C;@8\T]
M]]P#[1%M'G[X83[9!BX!?'%D2X29*69E'CL4@Q*:RDWB8&ZZZH"+=+TYYYQS
M0%W$DYO)<P7Q8UEO%Q11OO>M88"!-M?@R%912W]5D`>L8X-++[T4S+EJ&%"R
MZZZ[#MA\YIEG7GOM-1;VW'-/4]0W&WK%CL8J)VJ](D]B=5+U:^M28KTNSVB-
M[<)M.F=6<*9S;;/-G*$T38)P!`II3Y2:^M[O'$:!FJA4H]L']'8JD7OZK6K,
MGDQ#!2?($#MVD*?:BV+>F=EJZ0A9HD0-)`Z`!"NJKB3@A!1I2IIH+68D/YY+
MZ0Z#FB@E<2H(9`0-YDQ-HW"A\U7-*TW2`PBQ`O&K1"71@#4F9^=6XU3;<M2K
MM6E;T<46M%XY)N9(O^4\NC_">=2Y4J(GG&?]UJ=2@X\QS!R*[?D$.JZ]]EI>
MS4CH^>>??^JIIYIK><HIIR"`X`]0PW4Q`<0$A0M<6KQX,<@##FB]T6*,:!O0
M:XDP^0^?J&":?'4P(8\77701"&#%":")3UMQP2(0TCB/+)C,>K22E2M7`BR7
M7'*)^9A0CBNOO/*AAQ[2U&-W0KWP8)<V9)U-S-"((S,Z82/!!W!2%Y@J85H>
M,QDF?/;99Q]ZZ*$''730/OOLPTU&,Y7X<3\///!`=F>>T##;;'EDYFP(@8T%
M.;5]<)C2U5=?;3X%`\R$K3%MF`_@G/9\2<Z**AW%JHZ.\Z0!5B*3*]HD?VJ'
M5JFO!@KNV&*#9[2RQG%O)6YGVU(,IVI&U:)2"49E&G$_=4%]%3>F-4K'3Q2:
M,=$J:U4X4NHK\LPL@7\A,+'PU*CC6<6--7,P7T>T.]"8:.4LW+%:E0,^8RTG
M*V')XRT(.62LPYP8?V:VVH-)GO(X<T>&NR]H%<"R<E[)-S>3HN:;[S(R`CAK
MLS`'IF0^R4WNZJC$SJ.K2S>ZY*?6V^03A0OQ,5@.&.'E?NRQQR)T/_G)3Q`0
M(`+8044Z^NBCCSON.#Z9`[K&"2><8$P"B,1\4+Z6+%D"3-EJTT0MF!(RJ$47
ML;6(!.(/\IQQQAEH*(JY-4BMNV[+!A4B]C++TC0Q?@('U(8,'K[QQAM1N-!9
M+K_\<E@$X`.=@$*L6+'BI9=>^M6O?F7%9L-F@$%VYY-S&5HCT;(9L?3,SJ<Z
MN:ST9>E"M3\;_=C/B\M'*C7(PQLU>4'5F`;$1J+XI38L>RCX.',-/I===AFS
M_<DP[K__?C`')1':P\;(!4`Q+?)(=<29V)F#/QWR),M)F\^60Y%DPVR$D4!*
M.(\BV<%+Q#_%>9(T(0A4XTQXSHXM@2*PDS%JSW'$KQ2@",Z$EE1UJ?*3+,<*
M'6>TJ(5(JA:Q?J<A"CH\2K=4XO&TP&@9'B_%<R9:Q77M)Z*HT3M\.K'Q%KW<
M\2B/G(.X/FLF6PEW\2=10(&1Q!!.RY&RF<5S8MZ)3U^&$^3IC$[S2B;[M%[U
M.--C:NZ>O0^W8G2@"D\:R`/(Z)R%V[#`&GX2A20\*ERL?.<[WWG666<A!68;
MH<C8;`)Y0=C!#0#GXQ__N`V%]Q^&UDN4,B-VX#;H2A8N_IMAL*`:99RP9F0&
M&Z-Y)8'=@NKZMJS*Q7HH$+*)/F)5=E/F00,A`NG^X0]_>/?==X,_S--J@0`4
MR_?>>R^T!Q%&\[KMMMMNOOEFY%I"9:2BQEYP%9IDC4'Q@7G::<(I.1D`1Q.0
MGB\#=;@;@##_`L!NY6I((ZS/[CE,SSI%]M%(,7GO##-G&P$3VH.J!>?YV<]^
MQB31$YDVR_RSO"SR-JG>*_]?$,`L";[Z+VA;K@;D1.G4:J7)F]BF54MVFTY[
MJL[T.+FROH;T)+1X9JG=%Y]UC<#QUVU;E53-Q:*<7V>7]BZA3$&8V27P>%;+
M'^]4IXDAC(>SQ!,]45SD8ZWB>B)DPDPZ[2Q(I0DE5NLH:]DQAF(A;J+5QU!=
M6M#RS2>;EWR\-:F)IREQ/D*$-&.B="*.H4;\6=!R-MUXP5`3(QBB,<1\!S9&
M45+=8UG2(K<Q/B=AR2YW6EO\_@Z!RXEQG&H!2+IZ(@E35T&##P^DQ0DA.7P%
MM1);R#,,@""#L`@4%K0`($B+*"L1O3///),7/;H2"WOLL0?XP_;H'2S`(A!Y
M4[G-JD`5`A_@!JRW4*H*%`(+1NE#/_?<<\$?*U%HX+5<CZ'1;,D!83N`#_J+
MZ&>%'/,O$&08#GSF@0<>0'Y!$C@,IT.H`2L[.\!\;)USWWWW\:L]1IDD*@^S
M0O8YOID.X`,+H$J:`]I:-,ZIOVG#-C>L1R&%N0F_-DGDJ6;:');CLZ7U>2Q=
MJ,U*%<P@`4"/>7*?T6I-S&>2JU>O_O6O?[UJU2JT5]T$G=/\PZWL=GWCQ&^U
M=>M0$^2IP!)K3Y<<6I$G\<#;3JW`TZ5-C5J#J^8U:PC2$P%"@4)LLE>.DZ]!
MF(HM.Y48GBK[09Y9)68OZM7L%F)7P23*4=A(1LU6V*G$'T9YB7Y446OV2!)Z
M/%QS6D+H9(LHED*,MQPNCQP2-6=J_[X`45C0@I;F&1W*Y1"Y\!8W\SB::,2]
MJD]52TXUX,2,7/6L!:7W*+L`.PL7+DP[DMK=V`=5PXX0I-T`D`&+>":U*J>>
M!LOH/CS\L@N+'E]YY95(AW6]SCOO/*0,L>)7Y.Z((XXX^>23D3X(@XD/H)/V
M$V#D]--/!Z\@2V95L($-*1!GUG`BP`>%RP(^YE*QE_E3?EHTE65T$P394LD(
MKVA@Q6;3,.$SSS___/+ER\%)&_0P<Q#IAAMN>.:99_@)VL.O#S[XX"677!+8
M`<VLP,RR.1W&&YM9)NP8FYV`0%WDZ;UEZ0^^@JXHISPVW&1HSZ&''LJ$N7PA
MRS18SVM+9<D;"]_[WO>XS[`=P`?R`_.!\X`Y:]:L`7P`:O!!FULU[`2(-FG]
MS<W)8NC@KD7::Z'CBCRU>&EU8$6KVJ%5O8@5*!MWQIS@QG:M5,ZL4O-<\V]V
M"6.9UOY333US1C*J.@OVS!*1&$2*A\C@G\J@1DW?W7RR>SUO5*?)D1SS>25S
M(?:<:CK.3*)>)=YO3BFYDS@<I=[,J0IQT:KBZ@HR:)]A>[F6N0\>(11(\E,]
M5M4I7P-X'%E3K3KL`MDPI4)"Q<)H=TB?5;.>D]*EDB46:84&?+B-J#_(T6FG
MG09GX+&'[1BM9XLKW4DF,2&DQ@\CX\BL!<'8[$<_^A&RAA(1V40-8<=++[W4
M8!A8!-P)T>-7R_)P4@C/V6>?;7@A*&2)>,O@<*[XUMD+&.%TD!,+`QII8Y(I
MRTSI\<<??^JIIQ!;V!JT`2Q"\^+L7,@33SSQZJNO/O+((RM6K/C!#WY@_SZ;
M07"];`9F0D@,/-8FXR5P?%,>S/HT]\JL<UO^F:IO>AI(=<XYYZ"'<I]Y;H$F
M;HC%Y*VK9O4P[J1UGH,\3(F[9V%GH)))@I#,^<TWW^2\P$AU7=4_5_Q)4>6X
MT9,0L65I0%SSS;OXP.U+X>+J!*_9G5T1C"XL<&;IU[!3"W29U=*FM+=T[*(J
M7Z.6Y`CR^$A2546>,***(54#FET22*.^A8QEDOD:[!I?RQB;VA*B(D_E`['8
M3+1DBOKKO)9=E3&OU<_16&1GARAQU;X]M]0)E,.PL?[N'"JU=V+_J20G[;3$
MG,"("*,).KCD9&+Y8<&K\*1\K>'T7354GL;X9-___O?SI,%&$!"8#T#$FCWW
MW/.FFVYZ^NFG>?@?>^RQYYY[[O777^<3$;[^^NM_,`SPQQ`[``>Y!I1^.@SK
MM!L(A_@@5F9#J'8A>HBV[6S0K=0O%$8@!6!!5$VDLA@.GR96@#;L`AU"'0.+
M#+"Q^C$D"DIFZ5%3,)!H9!GF`+:`/$`-R`G#8<Z<'0B"]KS\\LMH7J94V+%+
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M$WB)_RNAS@"4API`;5*Z1B:2,&P'_`DB06QXJGG5<AS(S[O>]2ZN&C&\\\X[
M>?X??OAAY/2WO_VM87C(*6)HWRNS*2$>:`0("#@#"`!*P@Z[HS)8&1[A@MY8
MHI"5]J\Y\\PSK9T.QT#,[?HGVFAA!HN,%M:+G3P+$,]8("0=)#$]00NMU6]8
M4,4#9$!%,.>>>^X!&R%"S!`6\<(++SPQ#(L9PKC`.K/@-06+ARI<K/_J,#AF
MD"?]2:WZ94T>YF`10B;&Q0(^W$8X$IKC88<=MN^^^W(T8!DTME"8Q9QM_>R^
M@)Z%-1C<)5`(J`<>`1_KN[(!.&"PA`GF:E5QH'<EW/V5_WIMVE9&C4R.<ZK:
MAZ-Y=8ZG;!#DJ;0A=N!4QO"GJB[-*96OHI=U"E%DN3*E^*>Z[:L*UFE;-9N@
M[A(J51%CK.555?TH43'C+:5KO!78R=PZ/6NL9$;,:W5*QUKNN=O(3&*'J0#K
MM.>WKECQL`=/DM29GP)*:$/^%.3Q%`F_B6UG0<LW7U"*8R34)Z;L!:W'A*2(
MIQJB8C"S`)4GT_8!-;7G3__T3U6LP)]%BQ;QAN617K-F#6+%(P3SX;6(R@.&
MW'[[[<\__SR$Y]>__C5//A"$%",:O(N1&MU22!_BCUPCW8@V@`/S06K8#*&^
M]MIKP2AQ@!<]E(!M@"F^HJS9.)C=$5*)$%!CQW,]1PF;B3IFJ4/[GH,,<@:.
MH`-+4ZV5N/B)>4)X+%T(!;(W%@AIT3]8'%<$M>#VKK?>>HC&WGOO;9EE3@$S
M,9W<WC1@$9-/.7?!1V>?38H=!@#8N5@JQ8URPI_\Y"=///%$8`><!$#T9UF-
MV1ZL3-@`9BX'R+*1&<C#/><25J]>_?O?_YX=P8=D8,ED!**464YU076NE'.?
MUL(</U>%G222=Q;=:@>N9,:(P>ABLUHT7:4-,UO6I]+:F9VS?>=C"GI$\:F&
M7_W7G394\6?4PAQ_^JR1^ET=$ZLT*0A042NGJ/RJ.K5C^]5$4W6EZM<.X7&S
ML2$XIWJOPK(0[<ZW-7]J1:^@AP=G2VTO71&P^:VZJ>IA$"D.K+FE.+-0&67-
MLZMS<?`:;L2)0*$T5.(A3"2AG!QBPTHC>8`.I._99Y_]U:]^A89UX($'&FH(
M5"*2R.8KK[SRF]_\AD^>?,M0H+D`)NH1%PX#"85(//[XXX@YD@+A`<V``N0.
M_H,HJ5#\]5__M5TG$#$DB)60&>F!-$##+/H4LU+J_X]AL*/\1],T:XQGUJYB
M]6/#?A1JRQW+6^0,7)K-90`?Q/F..^Y`EP1+N?!;;[T5W#8'WQIHW+>]]MKK
MU%-/-5_>UJ)<,N"@#<<2RLS<4$,]\FI,\B60"DH#^+`&Q(,6&AL)9^.BF(E1
MCMP'\<?J/>P%6)D28F=#0)*9,UN8FWVXN%)00E:SY=!KV-RK>++2IR^Y#S4S
M8M2KOC;DB5=K^])->/M6H7V'UO9EIU8#<$Z+839)?$Z+XI/D3+3:%%'$JJHU
M5OQ'%;AF3\T?#WL9:XD,YB6-E4B\:@B:UJL^UOID)011N0[[BM=^K&5(!0`G
M2I+4G.+,"O.)PVMBI+[-6$N,BH!'UQMO"1'C0S(($W"#`)?0-]X""&,'KM8A
M)V-D8$H()N2F;NPVN^^^^_R63)&:/]5\)#IIB)X<PGZ<26Y^[-Y2([&1P]:R
MEK7WC>0G;TD>^)>'`?Z@@R"&*%],X#.?^0QJ$<@#(KWQQAO_]5__]<M?_O*!
M!QZX]]Y[D0)DQ]914*,33CB!MSFRLW+E2G[5G(O$@0]0#@-C+,JGR7K9LF6+
M%R\VZL\4"7Y%;,,KD$W+.%>GDIS'7CE(L8''EA"TC!C'05I!.<36KL2J,$`-
MTX8S@(TLLP'X`QQQL8\.`ZIVQ!%'I`!(<L]!(03JW'//U>D/DDBHF.'_/0P6
M.+YN=VD/EV`=L(0X`BS<A*NOOEJSO*5^N%@V`'SX-)^"7=P7MG/I,(0@G5P,
M[JIMY3D@XL/_F#?+1UH_QV1OR76W;OU`Q9`*.&*1P3/;M':?M9QR#6.N`<S5
M8U[92TS-,?M4KWI\6[-*TH1X4EE$^$P%I;SBHW1,#H%\6IS&ACHS$JJH5R$2
MP0UGI6#.*=GK,3JQID;X=!I?I\2-M7+K09ZLGUORON>5%N=L',M,]"\!,/:B
MD*)JD>YTO0!78G@RO#I=3H+AY-#=N/K3Q1RWJ3ZL4*:8>BI!2FI8W3*FYGFE
M>Y=H64M<)IW'L?'&&XM%W&&D%52QCL2;;[X)O8&N`!&\IGG:5ZU:Q<K?_O:W
MP`YL!S4**4!L37X$'TXYY92CCS[Z^../9Q=$&Z6&7V^YY19]0[;$0M`L$X'<
M??:SGP5V(%U+ERY%5)5?\`<``9HX;+*B6"-U,3C93J/2#_,7#'YFI>YL(-2\
M)\ZEPUI#RC>_^4UF9<8$EZ9["R@`>>`\&IE//OEDD&?===>UJ*GX8^G%_?;;
MS_[+P"`HP2F0?>8C9@H^!N?8Z)!MC'_^]K>_;0,RNSRC=<)A1&`+#7&H;P\#
M_&%+=K%T,U^9,Q`$\EQSS34WWWPS^W)+N?^\!;B9B4N7]FC8Z1(EMFJCQ@>F
MJ$6(T(S2TC<I5RZO+1MBA](_J_JP.@=3M!4AJ[,`[UBR/L>F>K>S634=!ULB
M]5(4!7-6JW$1VW(TLK'BL8KCJ=I/)DK6537U9'14*@:<V:6B<JA+E*EYK<2Z
M^\Z;FJ)5\6?GJ64`*Y@$7JH#O<.<<+`0H6KDB3ML;FFA/K]%!G;@TZ%0K#K:
MJZNF%N01V;0R>2@X4GP<\:J[1MAA<*_@_P\^^.#O?O<[D`>$>>NMMZ`W``@B
M`,]'J[*L#<C#KR^]]-*--]Z(I/`Z-I<!`00*$D+#2_P'/_@!TF=W8-N%(T'&
M`ED3E3,><L@AS(&SFY!N@71+OILM!4;QDYJ.U`6H,528W:V3@^#;Y5S#B_4,
MS0]%\&U,K)V9E1IV[K__?J:7:O#`#I=F<RL(GH46!1Q;D;[SG>_D$XJ(BJ1Q
M":D'$SBX$8,R'X#(F$`Q%JBQ`Z"EE2$\;`_(H.)Q4FNW<G.^,@RV83YL8_=2
M-K-Q!NNYSS"TZZZ[#K0'?%"XUJQ9P[_`6?171KWJZK=GI*B@T!1W>:VHL_74
MCGCA-M69E96Q]B2@+M;C:"C5(J0D5AOR^-2B%K.+5ZMSC@=Y,JKJ-%ZJ=8E"
M-?XPYJD*96/-+S:WA?\%!P(IW9J<H@;8Y.NLJ;U!QTLGB-A)YI?&P<&WSMH3
M]W3UL+\-\E2O5JS-,>_$8Q[E*&A3G>F3+<AYVE$)3Q!F<G)*#GN%*9%':K3;
M;KM5UVI-WMEHHXUX%*'KBQ8M@@F`-@C@ZZ^_S@(/]N]__WLD$7H`[#SYY),0
M`WX"CN#Y+[[X(FJ4%:L086-=P`1D#6FRSPN_^LK6<<Q/ZAWH+*>>>JJ%PI@J
M4K#!!AMP%8"&9F$+:-A@"ZRPY3IP!/A`.4PCU>8,`NA1,DQ(!_?_-0PK>B'%
M>O9!/$",X[.,2@7&(L6:39#EQQY[[->__C6$Y]EGG^4LJ:AL$^>T0F89DF9O
M8DYM*T/#%Z-GF0&1/'=MQ8`/D&+'>2"%9>@BRBSXHQ-0@.)7N)#YI!S9LH3.
M_ZJKKOK)3WXBDT35>OKIIU][[378()!B4EY7O#U!R/&>2V.V;KU!N[[G\:IO
MWQIZ:L:I$8.5V^S4"B-7WU:H106E\)Q`Q.P6!!B8JKI5+#]SIN9>54"84Y(7
M)EK-85G3K%+^HEJ$JH]I;HL*[IQ0F</$U-2GRH4ZQ4?\"0&KAIV<I6,:"UKM
MK.X4:HNQP%0.LS9M*V[Q4?"IOB=92BQ(8I$^*7_:N66[CT)9A9U0FE'8J6J7
MD8I\[K[[[M6NF+>DY.>#'_P@#]7G/_]Y]"P`!S(CYH`P?&4!G$$J7QD&A(<'
M'O%\^>67V1+R@/PB,N>??[Z5(H"7[WSG.X@)R(.\^.ZV_801OT#*PH4+M2J\
M][WO929_\B=_8I=DU#1;VUBQV8ZE.HPXN.;K"RZX`.""`K$&@$I9&SF&C,A(
M'H-Y[+/S_>]_'UGF.);H06U!>;SWWGM!5'UP`!'*"Y<#KPOR:.1)-]5WO.,=
M*%]@]4DGG23N`3C"+`AIMU!]Z#K9K6YJMI<F=`@88,+]X<Z8AP[T@3^0'Q@1
MV"CMT=T/X%CQC#4H:,83WC(,NQD"/B><<$*<6?6%,HH\,UK#J>V&UC#5JU5S
MS&,Z3OF='5N+O6"1K&.G4AZYAA%6-:>C*[-'HHZKBZI3M>1%U54T5L:<%KH3
MXW-VJ>2DJD[C4X-PYDRMMS.G!-[,;NFBXV7$+EUUL<P\9J@*)I503;;PGOB/
MYI?4ITRU`EJD^VV0)VD+HW:>&*47C/32JBJ2*EA@)S^Y[RCR1*O*-JF>X1D3
MWA/D"=FN!:,T,X(;=]YYY^O#`&KX1.<"6`0<JZ;_\I>_Y"O+@`\;`%-\\ORC
M<R'.9FY^]:M?160N'P:*%;AAX2\M&&QSP`$',"6>4COS,KC;,@KH!.(`=@$^
MU@!D=T`&`4=#`6'0K6RJ#O[8]`KR(Z!9R@]J@;";Q?G7P[!4N[J>X85ZHU@#
M>5BY<N4SSSP#\@`"RY<OYWK1N4`>M*UTKA$2K7'QKG>]2_[#'0;Z+-#!884U
M:8\^<<W.&KKU=JGNR?J8C'%'(`P*%*3K@0<>N/WVV]&G-.EH>@)G=/TS6`:=
M5+7XA'#RCX"6>^VUEPZ"JD17P\YH!I:J4U?F*UFBL3#'SF/*0X)S1I&G1C@'
M>7:<6E`]U&AV\<LG"2N2&U2)BZH:F:-GA7352*&Q(:AF3@E"#ID9+\T:@@!.
M<KR$Y=3SCF)+("X,*G`70I6C!4\J@0G_J0[K3JOJ@.6_U;:2R+"@%./2D#ZO
MA07&OC2W):K/*^5W1)[.*6_TX!Y[[-%9C2I?<M^PH)U+59_HE:R,7]6(C@38
M\^2<>>:9//9:=0`<%GBJUZQ9@QC^YC>_`6<@`V`.(LE+%N1A`U:RC:(*3^"M
M;7`=!$/]R)>[Y85]E;/RF&..,5XQ"=$\M-PBFP9*,_;==U^P!=4#&63?3WWJ
M4Z`-?$99MBR/M<*,:@9GH!\6U&("5@B$[9C48!H4AS(>#WZ2@!PHQ".//`+R
MH#.JPCSUU%-<$6M./OGD/QB&/<7@/$*0;559@*1!VSB[79LYLL8N52W'%]N0
MLZF(Z;`#BM$HN2?@LS0&ZH6J"PT#9&Q185D,FXV"3MSAGP^#C8$I".=SSSW'
MI2$^EL*0^21BL/K0LQ"2DPS0:FVNQ9.#-EFNQ2Z"`/JJ*L+$KE+C#&O`3W"C
M8S([E0S-C"K^U<@SNT4FSRY='MA,7Y4_S2GAB.-#+M785+=X*%/@*">=;,F;
MXU.]\W4$E,9+J[Z*47%&=_QG<G!;SROE+.86S_C:X.AM+,R=RI-=JH4G,%A=
M\/*31"S7HWUT:-L'^'04*&?)8<6WQ#!G5K&EUZ".A+GRT/(7?.][WP-;T+#X
M!%50IH`@D8<U?&59/_L33SS!2GZ%"($\X`]K0)ASSCD'^#KCC#,01@O4`$'(
M(Z_XL\\^VVH\2-]YYYVW__[[[[///HL7+]YSSSV9-A,P.S7.:SZ7+EW*[N`5
M$&%//<!'2H,:93$N2Q>:3,%7A)I?34HU5,]Z8OQD!RN.!NPP50VY+%]YY95@
M#K0'SG/WW7<CT2M6K(#7<45'''&$G,>Z%F$^8N.&&VYHL1T`RL1YU#<4(L`$
M8(F2I=DG$,2LY'+FN#$']H((<?-A/D#*D\.`_^@WMPB\=0B9&XP47.(%P53Y
M+W@%0(<@/!MOO+&&8G!#T[&$ITN_TK93\[9JC?=M2U?TF&[\ZG+-S*K&VYV&
M+(G8AV>6\LC5%"Q$*#[5YE.=1)YK]M2PY&K5"4QYG*"$J*4W39=Z#$?CQ?TT
MLU70TMR10P5JQJ=&"(^W&.,%+8HF"!`,R;Z);*E*GR,T)HJ2*E*-J)E;0@&K
M+RDVGU'C4DC11/.M)\QX02F5,^J<FM^R+6+K%@:K4C99K,>5"$7#6M`JQH^U
M3CKF2@A!YED$H'C2-MED$[,+^6OXY'F#A/"$\Q@#.&A/@`^<!SSA4]\6[V+D
M$94*>O_,,&`%K(?_O/#""Q`A:,-QQQVG`@(.J,N`"9;=`WST.J7/PL$''ZPR
MR/18`/U4M3;::".=1^NNNRY`Q!%LV(?,`C(<&4V-K^"&57$@/V".1>/U2NMM
MUQ_--``?D(?-#+S1M8VP(_ZH+0@[[`)!1LGB$E!;$'D$GPM'M+E=T#"A1O+S
MCC+^L`TF?\())]B?PMY\DBY3(?P4?S3UV`N52P!YF,R_#P,P1%U%MP))5JU:
M!?3Q=SS[[+/,#?QAVB`/D[2@M"HAR,.]!;WC-=AL:)(5?Y91.KY?HD!9YLN,
M+3%DN]*\)BD2TR9^2GLZ>K-3:Q:ST]0R7VY3<RZJ>2?J57Q8FD<JW\A;>ZST
MGTHD3"1NK*1C!*,F6\1.C1&:G-KI.Y"5L,:JZ4R6.LES2B+GW%8J>;RDI4^4
M-(=Y4T/O''-:I5,A<4ZKB1&>$S003N>U^ET3+>6*3^89D%'?"?8&HW8N!4B#
M"0'/:L:9:)5STJ1OHA24[H:G^&@K-BBJ"#N0(M2QG8=2//.&1*W==]]=DW55
MV2S5PL-@_Q$^N0G("_J4;BRXS5O#$'9>?_UUI$`?"H(`M[<:%0M6$$4T4`<0
MM!-//-'B9E\8QNFGG_[I3W_ZFFNN85\V0*!,P@(BX#_("^<U=$07C-6!H!":
M<-5E0#--(@S-RQQ!SY0F7)B,W9,9=L5"R6+]_SL,A)V5)E4A^\;5*.^`(9+^
M_>]_WX@^Z,3#PT"=X4JY]MMNNXTG1*^ZA*>./VJ##6!KW'/`AQ.98X7.!8U1
MW]2W;C`SUV(T$3^!3H8+&FC]K6]]RY)?,A]@D'NK#Q%]$.8&I_K.=[X#\G##
M86AL":HO6K1(-[J%OVIR5A>](RB)`VJX"<[I1BA-0OX2L2RMJG`4X.HRMJ)&
M)6,KEMZ90ZN:ZB@/!$WKPYK=`F\Z!:W3PL:FQMZ$(,V>FF]5C4CC+00QVU1]
MJIJF0YDFI[JW<L:@Y41QQU>#><`DYN6Y+1(R)XT%)M,>:\V.1:'9K1"T:W8N
M/:W"9#H'TV1)V>C\XY7MS)T:V%.=4_%AU=!!N8V`&9?9Y."MB[7'H>,,++(P
M"U1']Q;\AZ^\<$4;M"=8#1P&($+#DO:P$K1A&?6*!<T[*",(+PBS[[[['G;8
M89_\Y"<_\YG/''#``8<??CA,X[333N.18Y[('7(-4`!!?)Y__OE''GDDJA:3
M&1M<KI9#M%`>4Q)Y-*3P]:BCCN(4R"G*B#%X)GU;+%UUQ@I=,"(13WJ36!HK
M=\&R3*0R-`A)UW@"\EQZZ:5(-,LB#X#SU%-/<9F@$RJ,]IQWO_O=?S1UO+,-
MN_B]YSWOX9[#OLS,`CU`$N%1DJ/:Q;2-<1)Y,H`@N\!+PRZ__'(6T`&9"3<?
M)&0;WAJH==QS4!1`YC[S1X/5*'U`B@6Q74CH8/!'HIOHG<ZP4Y,CPH)&8V:B
M0'7#]=5C51U8LTKTX&2K6F.8<9SF$ZWX<*A4E*!0FABB9TT-"(SX1P>94^IZ
MC4TU)L^:-25[?;S%$%9;4`=!G5X38W74GPX`.ZH3`\Y8R[H*A1,HNG.%C8RU
M@CQ>5W6RC[6N?%4=JP@3\Z_0-.KRGC<UO3UX5;WJU2T>C4DV59UE50F=UU(G
M-%;[-?4T>/=M/31$,$Z5)P?0X"$':GB]BCR0')8-%#2`6:\ZR./R_???#\YP
M9#`$A>ASG_O<LF7+3CKI)#X1*_#AV&./Y:E>N'"AU;K^[N_^#AH`4'SJ4Y\Z
MY)!#+`6?@G4FKB(C8T/O,\0<<4;M.NB@@\XXXXSCCS\>[H3H@1*`F!$O-E(W
M:4+M"3J!LH,N)O)82EWWNB%&NLDLMV6SO\LNNXP#@CDL`$2H6ES7/??<@RZ)
M7LEMT;"LA;GRG(H\K%<=X\;:.YYS:<<VJEELU+UE'U5+LQK;\_\-@P6ST;4D
MLP#/N?/..YD/_P7Z+[/R*KC`'8?L70:@K1DYGH)4PW!E"BSS1V<A;4.K,[TJ
M63*?JC%%6AG5L=7YFSKD<0/UFEFE_\MX"[S)FSWZB-1HO'B]8TOI?.X1V&Q3
M-Z[6H<GB/:]JSGA+3*C:7.<3#RD*A@2(*M^8+`5VJH92#;EC+8<B1I[H-=5Z
M'//R_*G%*W),<6FBI:>%G(3VA/G$U-/!3J[(E9.MBHX*2TQ/&=Z'D*5Z=9EP
M13"1:JS5^L@T>$1Y<J3HR#N_\K1'O7KII9=6K5KEJY;W/H3?I%%^!9$@_VP#
M^"#%/+0(($>V?I>YG,(.-`,6=.JIIZK4V-6%<<$%%Z"2?/SC'V<R/,`H4[RO
M)UKI$IY,7NM[[[TW\F)?F+.&L63)DJ5+EYYWWGF66>:`NH3L*P&%X/@6Q&"E
MO8:C;2'I,@H^36>P^,;WAL%>*%R6-4/>[[[[;BN[<NU\,AF5OO>^][V`S]MH
M6WX"F-S,<\\]EWF")-_][G=!'CUK.K:D/9JA1"%CBLP#M?X/M.?FFV]F,FA5
MRY<O1^W2W,W_8IEH2)V`8X$+Z:O$E5M:_5D:<U3$0FSB3!2%U+RF19ZZLE*=
MK5L3BIG39:Q7QY9?%?E$&\8^,[/T0Z]8$32;,V=*G:YYK?U356U4`>:76-_@
M3U5AXK$2ZWP7QT(RT1Q&$Z71>06TR1(0&!O.@E;W)KO'X-.QG="8F'&J;2?'
M'"_1SN.MT7#X24ZTH)5JSXXY14C.O%*>?5X)VJE'FQR2/6O]+I-`-<[,+89E
MYQ/7N6/^U`2N)$KXU5SUZC+C+#Q1/">VI.3ST$,/-?%'3Q8\9_7JU2M7KN2E
MSS./8#[ZZ*,H7R"/AAT6@*833SQ1.\SBQ8O-T[3\A1WZ3C_]]#///!,(XI7-
M>E.NH!`0I$6+%C$99.%][WN?/`'IX!&-(LFU;+KIIB`2;`>T0=MBAH`/>AS'
M1&"1:(X)_S$#%.1!S,W+L`2TB>I(/>M!&ZTH((_1-08;&PP,?4+,;[WU5K0;
MX/>..^X`>;AV^![*#F)B8SXN$ZBI)N6*/-`>/E&X8$=L#ZYR=E@9,U0W#.-*
MB3#3*\QA-](`,+3P*7LQ'RW>#SSP`,B#E@KR)&X3U$)F/_2A#X$)L>=8;:#K
MP5<=Z/FILAV]46O3MFK/OFKMT0240+N9+3^K2_^LVE9GNHF1>4ZK'3'6XG`F
M2MO-&#K<)2)0W4:^5>>7VC65<G2*3_Q?$X,79FYKK#FWU.ZKCJK@28Y0D6?N
MU)";:2=0.4_E(5*+J$([ET(3PM'X$&,</6O^2(Y#9X;BTPR%U..JMI<*(YE_
MU;#B$=.`XTH=5?%/)0_""CQN'+-/@@8%/8L0ICZJ%^A#:)CK[KOO#G/@%>];
M5831VL-#_O333P,=``YL7SW+9`H4$TZ-]/'$?O[SG[=G#4*$^"#U9HC;0!-=
MAC>[;4.9`'\Z3(;'1F,.HJJIGS5.CZ?7J$(F]N=__N<H64N'`?CLL\\^QQQS
M#&N06;62*ZZXPIA`RW:9$L[IF(RTQS9;_S8,%A1\D"<1PA=??/%--]UD-46%
MG>L%AZ$6?_$7?P'Z"8\VD5^;G0>TX2N$!YX&\^'VPM,LD@:^<2[NL&$\0I_E
M>JQ5Z%?;.C,EYLDN!NT(@\R*ST<>>80_B+^`_XA[&S,.-XJ_$D``JUE.,^*:
MGU4AJ/LIZ5K36IBC;=6`/4G+G.DB^H(\G1I5=;%J,:YZ4[78A`*MS=Y2-:F)
M8O+MOLXM4<%5"YO=RO($829+:^")TF!BLA48G)AJYQEO,<9B17?V>5-'ASP[
MEQZ@$J%YI0Q.E!T)B7.NMI?\&HB;:/$`"X8R@"921<T)O>EF,K^U%JWX$[19
MT()\M`S+A5Q?_>9&)N>*0GMB9`XZ"4&I@0!%9SULX>&''^:5:KH$F*.'R_AD
M\(=7+<OZT*V)@73SGD7H%BY<J!2;C("F@,C#/0`<9-D*6OJR/_6I3\&.N!Q[
MK"/4$`F.P%\,?=ISSSU%5X2(]<P0[O2YSWT.^H1VAN(&D8#SH+Z=<LHI!QUT
M$`S*`C5\PBN,G`%G=!69ZLY0J$VWM":/1AXF;'@PR(-2`X@!/IJ7D7$H'\+.
MQ)(N87SC.\OXXS+>\Y[WJ'"MM]YZ8!00M.^^^YHY8E<O0"\5F+D;P*/]^S2,
MF^I^\3!,"%7U8U80SEMNN86Y<6/7K%G#_0?\N<_\<=PH[A(\1P<ZG,=VX083
M:NU)'0R]A]NO?4SK5:]5W+M4B)VF9J9+9A*K'&28:!$F$ZVE;XT2G)C:V2I2
M'^=4=5=E5'M+[,:A0#':J.7E=>^+WM/-;78G`WOXJO$JN\<0/='"_R::K[\2
MMGFEOLU$J4Y3'5X5D3HKL:"1\`!7SFN9[.R+M#K/\18+Y`%W;L&'"UI20[B9
M`.7]%PTJ'L;R+-18R$)VI)E(HF6APHGFN!=,^!H&%<7->E]BG312+A3E;EZ+
M9-8+KYJOH8#M82,\Y^A6(`RP`[;\[G>_,V^+KZQ__OGGT<5>&L9EEUT&&G`<
MVX4O6[;,P'Z0QV;?EO=$^>+=C;`C4V`1O`@D.?C@@T$JYF/I(=NR\R<>>^RQ
M``N4QEY4T`SF;V=AB,=))YW$KW8C1?DZ_OCCV1)M#LX`N.D)`EB0=,@`IP-2
M.+6I3[JQ]((I]7R%BMAUPD(W$(S;A@';>?+))Y]XX@E@EMD"(T;O<*5,20NS
MS,<<"D!&\[*_,H`@08G;BU[)>3D+DP3Z=')95=627TR5&9KE`2B)F=810N'B
M$BR@<<,--Z!M<9.9F"DMP.,11QR!X/,/\EA"7$WUU:3C/UM#EY,6D53TI(+J
M*(]M9S0X4$H3IY+A@HE8#N8HC-NUPE]5_&,Q'ILZHC2-M00EO_KP3TQMWJ?\
MSAW2P#UIA2`VT'[+Q-19%%M_M<&T0.%;NUIX8FKV7)T[:6[S>E=#=`6ZL",Q
MIYIQ)HL[/K@ZO_G!Q<#QUM>F:CT>@</6>CC5QQU+2US>*DH3S5G_T586?G[I
M/9&C10V<:+TGTD@TD%+-PG&3A>K$L".R57J3<QGJD]KO0A:/)8^-CRC/(92#
M9_NAAQY"]'C=VVJ3)US:<_?==R,O0`I?40$@'B`&PK7!!AL@:URI[?.0)NN]
M\Q+GED)+_N9O_N9_#@,L.O/,,R$P?!YUU%%[#P/PL<*A'OD##SR0)V3>T(R#
M"7_B$Y_XPA>^`!E`X3KWW'-/&`8+9YQQ!@K7DB5+3COM-#:`ZD!@+(H.8;#5
MESXCY)>5T#G0CZ_ZM:T$R/:0)1/#609S'GWT450;"`8W`6H!0''W(#F&"\IV
M*N>1V`1\T+9<"01I[0&"H"5<!3?!]"MF`ACR:7TP"(_!A!;NL(&%'G_`1^0$
MM?1S02"U?EM^EO<"O(@;J*JEU@R8&+$3V*D53<->NE10L:A:E:MAI](;Y=TX
MG.U+KFC"DL>'HGGA/-6]%0[369Y#@<9:UXF$-%=-:KP5/)\WI&)5Z]!DJTJA
M-'6JTTY#&POMARP@`B+,O.G"_(2^\5)()\C3Q0YE8AT*1?FJ2EEGKXX*EJ_1
M:ZI76NQ=L&!*MOB\$D2]8&H@<12K&+ZJL;=SIL<&%>2)'69^28ZHOJI:["(3
M_FBKK5H!,&9G+R3]D:5#Z/C<+I]).#D"`G.X_?;;[[WW7C,C7GWU55.WK`8&
M)L`QH`=_^[=_R[_I^QWP0=PVW713$("?$!ETA)4K5_*^MFJ$B1((U-*E2Z%5
MB/-?_N5?@AA,B0D$\P\]]-!%BQ:!2(`/,P>(H$"`#(?]XA>_>.&%%P(^[(ZR
M!@^!\!QWW'%`Y0477,`&K@3KD&6D%5%%8+7SV%W=Y&Y^-4X8,=<6;?0@F,`&
M%II8L6*%R6B(.8^*N1M""LQ'&[)0PX6+/,"+:[3PB#S`LI$_0-;&&V\,4$-I
MC!>RG*#F+^T_VL`MRZ.UV?*G%FRT.JL9H[K^04A4774NZ)]IYD9G&99L)&%*
MF`9YXL/JJIN*/,).+?/N^D"-AN@YK5H[1]!(R]^7;(6)(2NA!O_$U36WA!G7
M6)W$_(R7!C&=8A5]BF,N&)K'54&>VT*"-8:HO.AU&ALJ:XD#)B:SDH/P,,?<
M.G=JK/)X"^3K#$3C4T.7YS9_=SA/D"<C8.)7;2,Q5L\MI8P7E'8/DZ4-30!J
MLABNLV7`(<895:&Y4R-J0C^J*RK@H]Y4D:=SOE?DT=13B9![Y6+KY42U_&CK
M;LSNZ#L\2-PQPYAYBA#G>^ZYAU<_3."!!QY`O3*`Y+GGGF/AKKON.OSPPV$X
M/'MH9W:FX&WK2W_##3<\Y)!#_NJO_@KZ`49Q'(@$(@/_078NNN@B0`"@X!/)
M`B5`.:0#P>2Q!'#0FW@2>!Y0IO;;;S^FAQYQUEEGL:7'A"_94<M&I4<???39
M9Y_-\E\.XYQSSH$+08189F-.!_L"?_0H&><,/="WA8`CT6I8*%S`SN677XXJ
MQ(4O7[[\\<<?YV+9%\V.ZUIWW74!$Q0N/M&GWM.&R*.VY9I`4*S--H!F&^M^
M''GDD4Q&[Y4EB>P6"JHP'VFA]4.T,&OZ9H:7#</J/4Z55\.SSSZKP0?LXNX)
M/C4^9_M6O#2&Y5B2:R^)(,QVK3%?94>NF=7Z"+-LX)_&G(H\,UOQ=E$H7O6@
MBD$LT5-JC$T(PT2KZ#6G!>M.MMB;V26T>/[4&+S(^/P6!CPV!(/-'6J;BP8[
M#A65A2!6<L`:?)*#Q.HR42)V,B*P63_9TCHF1_Q900\%TY7Z>NK&\TM:5EQ.
M,:WL7$H?QT1<;59!GKC#=IE:R'3!U,*D@;+Y)48H.W:5+C[:*I(%BX2.&E58
MLR=R10O*8!L#(=3FS';G0>+O$'EXWA#>_[^V,PVVK"[/_563BK=RU:`XW3*W
MXHU,3??I<\Z>SVGN!;J1,<A,2["9(6@((`)>1$$$&0S!%@49`@C$T#+)F"B"
MS'0C"(C(H*A,@D6$(B25JGS)?6K]ZGWJV6L?N)4/]_]AU]IKK^&_UE[OLYYW
M?KP9>KU22EWBJ<>;PE^_^]WOSCCCC/777Q\C!N(FF7K7N]Y%F+'4"@F7*(U>
MZP3)"*RDO$@TJ"BHXY,\+J(BQ8JL#<U']$8SU+,A<1:4:3[Z>M!!!QW5C%-.
M.46`H]TI[:4U^^^_OT#RN&:(%(F&"86T0(*JED\XX03)K[B!E$=-1@*.SYKB
MAY)NL1T!$4*MA3ONN$/B_,033P"S^O5C'_L8X=,8;80G+%,3PYS'M(?QCF9X
M8]T<U"[!LM;HTD3G="TZOC"9=ALTO]!734;3(VE=DZ1B(;>1['6&(Q[%*I][
M[CF!I*#RD$,.$40(R>&N1AXCC$N>HEYE'8QTHR?A<?0.>`+R$(9AG<@9G=-1
MO`L+3'JL6O:<=+6SWFL<S07G&9:_NQ5G:`6G$^VQ$)\E594=SB,IP&:E!;W1
MM%+RHG^!0#)>WV8(_0KCL8J4PV=O@6>GTAP2$WJ1MCDLY_A,M3[W7KWQ`"'K
M4"9(AI362&>9[2II=;$!V:J3,3"W=&^(%O*PN^F9SX+>U$(>?%Z&../YL-+;
MIZ,U/"O_Y$_^A'@P/5'"#?T=>LCON>>>SW_^\WJ`)2D[[KBC])%''GF$F%[)
MKVZ:MM1CK$])E@1*G[SZ=2CA%0W')4%WW767=A21N/ONNR59YYY[[F<_^UDZ
M=>I3_$=O:K$=737><SWPDG$\[+H6Z5``SA>_^$7W##WGG'-TB@,..$`X(W@1
MY]&R#B6-0\L2P`,//%#((RSZW.<^MWKU:E(O-0=ID1AIQ84$,M]OAGX2,.*M
M%HN0AB4M1FJ.8!DE2U?W7YN!4JGIX=YZ(VT+>B.>8PKTSF:@?`FBW__^]^O@
MFCEE!FFW@3=0](;BA((=7/_H@)0"$]H('L7$-&TM:Z4F_.JKKY+,=?KIIPL?
M](\(3XA+)VC0R/.1\:+*UKRRQ@X@X^30Y"WXLXC5H>GP="55V>&.)'KCJ2J&
MD\Z=I3&F)[*K;*I=6HW%+>DV]LY4BYP,,)ZMN#LM0[K@&/8]:=K2S46&]:F7
MHQX8/2H[[[QS-ME$+C#R=,?K8]@P[IEX(,*=<*;;<C(['NMK]0JML%L^]VX4
M2DWDZ56M5)^Q/S'2&C,7-7G2PI.;68?R@(28F[4*[`@T^N4ILZ9F]0UZ9BR"
M3&;03B+A(-+8M5+\W"Y4/;=:*07GF&..T3;O><][/O2A#^DIVF677:1&25C$
M6_2KUHCP2(@D5M(FI(;PHI=,Z3^5I`NX]%Z6C%!H0MJ6!%PD2KL+/:CY*>JB
M_UVP(VHA&9$LZUP0>"U+2*5,B0_0`4>PHP5*IYYUUEG''GNLT$;8*`B2DB60
M(<Y0A$=<Z."##Q8ITK(>+4&01%(2+<"A3+%FH@7)[,]__G,I5IH>C3`$35H6
M8.H2/O"!#U#X0E<GP-&EP?$24FS5T5<N'_U+FVFE-M.^ND5:K_LCPB-$H@>]
MUNC&ZC_2#(4YM,VB`X50"#>65@I\M/+RRR_7O5K3#/IJ:8C%T3Q:@"DZ*H;V
M[__^[\)2_;]Z60B]I=9A9,;.`X%)4P_ZE(M]I2>KY=M:7(TD<&.!*@8E;,A+
MJDFH8P475SL;1D*-1<RD`O*0O,76T6'CP)U$'A,GFY=G*\NI6WE,//F:B=:(
MX>@%JE<54>*Z[7H#BG*O6+%B-![S;#6J7UT^W\BP8S'G[6]>E!MCTQY%>(R1
MP="15AH?WPJ.5:$W`I]!Q!PZA*9;/KX6\L#$#!3]<L>C*+60QZ4MF!@J%7AN
M/F-#D^T\,*CLWC6LE%*L3]Q;'6JC:G0"`R<2'G,!J>L$ATBLM*,VED`15*R'
M7((&\@@KD$?]FT*>>^^]5T(MCB2:@457+VM]BH0(N.@^O,TVV^ATFI(6*-KI
M"*5WO_O=^NF((XX0$Q#M$;8(86@"2!<;/4)Z9TD%$\*(YPAV!$12S80SVDL'
MURXLH*G1]$&["_U$*FA!_HM?_.*VVVX3]1(8:DN]"@4%(EH8D#4'/%-<H^,#
M&8(4VW:$)/HJJ-$V6FD<UDK[N70$'1"LUH+NGG[2[:6C'^U6:9I,87S-4^LU
M9V&1-$&MH;6?0`G"(Q02A`KA=2'//_^\%&%]ZNV`HN0::WQF17=K4C;XF.0`
M)IM4VZR6A5D#5@,Z9:!@TAY;=<P9TA'OZ,'D.?C+3##L!IJM+$AK6X[209.:
MBJPKJUK#"H!A,YUW\\TWUT.B6Z=G;X\]]J`.I-YE"%<J1^8D@W)GIREF$`G=
M/E$O`I@[XT%ZI@J]\G`-(J/!]A/,/GKPX`SI4!M6ND$_PGY:EN%^)8OAMD8Y
M`O^Q&+>0I]L$)>J,!-[,5#K5_Q-Y"",$UM)PS8Y`6;=BH9E).OV]AK,3WI!U
MZG+0\L;1:'IE2VK>7T/BHZ\2M'?5$$F0Q(F*B$(\\\PS$@V)B=,>!3[B/.(G
M1Q]]M$B4#DBZ!("SPPX[K%RY4I]Z#B6J>EI./OED;?^%+WQ!Z($QY$M?^I*P
M2Q1(^I18F380O`ADJ#RF91U<7_68Z8U&XNH99YQ!,0I-0\\>'7:H("KM3SMJ
M_M*G<$BU+#9F-0PL6AHV+S-,>U"FM`;#EXZ<2I9XCFZ7/G7?6-:"(&+KK;?6
M'<-T@Y&'EA,T;=?,R=X2U,!_Q';T59>@[>DK*@U1.M<___,_"T7Q:I&BA9U'
MHN?Z[21'\"O!@;QK8"R\@YS^X"(8-KD80QS8HPWTD+L?\73U=_`NG0IXL_#.
M1L[F3)3,6CI>L]V!/:8T,^.QQ)W*D>3]GKYL+>,]WW[[[04UTNCU"%UTT47[
M[KLO?23UF`GSQ8):?",MR1987N5,:=!4&$O[3*\\4Y(F)I-J&F+>KVK)@\A*
M&)8#R*9R+A_/H'4N=G&/SM1QF)YO[S!RR>W1!M9LJVD9?JVCV2+=4L0\2=\E
M`XMVL9-1B&1]RLLM.[/K\YC1.;JL90W(^N$4*J3-\0=J@#PH%%`"2GCI/D@M
M^N4O?_GK7__Z[F8(<R0C>F6+78BN"!,$'9JV5`]=BQX#T1[!#E9B/2=ZC/65
MXNW4;*>4A"14^Z)>G7CBB43XZ*$2E`EJA$C:7>Q%$*3-M(980;)6);!77765
M\[PDO#J^SB[8$;$!<R9A!^W)WJM<WT(D(XQ9$$2(9:&0[I68#\BS_OKKZRO-
MHX7M>M+$%<7KA(J:IV:(QQ^KN$BC;J!H)&7SA5'2MO1U[=JUTA"ES^I6O_32
M2U*X1)RDNN8?FHW\@!%')A-&2`3[XJJ0O'&5.;6>U;(`VVYL*.B66ZI3[:6L
MH,U49+))3N)#=[S<G^G05+2<P/UD7T]:=,T-#%8<AZ=:HH%)6>#S\8]_G`)Q
M>IUMM]UV$@T=0;K\[KOO[K2F[D29':M"CE0!1F8C"#G-VHB;=:).9:>F:MF9
M\/M8/;2I',43M#%CZ8U[\WL1SV.B-8K$!(<.IA[4K=X6_?%81*J;SM<P.0'$
M-JO1LCQSZDX3S.RD"7UJ.<_NC><K\]1W+%VKZ7YU'*SKHTI&:'^L(>01"DF.
MT"DLF)A']MY[;P&.^/_CCS].&4]]E;R3)*Z7CMXX>@ST@.'5DAJN-8*+4T\]
M5:BR\\X["T^<4$FW&D&-($4LY>"##]8GK45%@;2E/H4SHCH"'R$/=B$1`&&=
M=!;M2X,;&E1)/+4L%>83G_@$]3=P5QE&[!^W81D:8TL.&_^W\0'R),D!>30,
M.RR\MQGP'U%';:]EW4P]?GHIZ^8(<\02Q7`(AI26BI)%YA?I;P\\\("T1;&=
MW_SF-[K/SS[[K!2N%U]\4;=EXZ:%!&H4M;^L.KGJ6BI3K=QSITNTM*<L$>80
MP9FHA&P#L@\U&X6(9ZJHCFVP%O:4T)EH9<[V_?'BGP:?E/'IJG<Q6_D%DA0F
MKWV7+U\NG5W8CH<._-13)Y3>8HLM;./MC'NR;.$95*@/6DF:<3H5_X,H]2HJ
MAF5C3C_B>3J1F65)=-@SJIEA9%25-]*RW:TQ"%]\?R(>,EU:_8H.@H"U7%T@
MS[(8&8=L@#+R&#FY+N>E#BHMPH9H(X\C>3*\,",Z$GS<(26[X9"6J"&1H68@
M9HU43`10!QUTT+GGGBO=X7O?^]X]]]Q#4H,P1R`@IB$`T?3T7+D.C^:SYYY[
M"D]..>44B9[`1%H2A@[PY[333A.QH:HS*A55ETG$P-0L_-&G#BZ,(I11\$*?
M0>INB3R0W"&=1?OJGQ)(0E%P6K6&PY*U#&\!?*Q;@3,>K+'NR;+V@NJ@EFI9
ML`-HPW]T)W57M08#F@16=T^3UZT32=.TI692,4/WDV!(_%R//?;8[W[WNW_]
MUW]][;777G[Y9<*N=&GZ3UT5$*"P&=G)%(DY+B2XR43AP=;P3^GY<NJ$'6'3
MU3.B6Z%WQBB\3N8,.7@:@8ZEU;(3_+'<35J;#3X67B`(FPD<3%>MQYZ0)*W?
M<LLM>?YY.]N`TX^`7KC';)1@3=NO-^Z.1]<8G>:BK8.IB`T[QI;4FVQ7&4;+
MT80:;]^R/J6J:!COCG?H&T1NNT$O%2X/;^")+:V":3Z408:O5NZ&D3TZ&G?E
MV[3UOYK!OY-EZ(P\&OADX>HN,X7!&<*C@<G"X*-_5@Q6L$!)KE6K5@D'I#*(
M\TAPI#118$?\1*Q&8HB.(T$6^&B&>@V)ST@C$_.1Q!$X1P:6U@A8,.:(U6A!
MQZ<"_#''''/""2?HI29THC(SL".QU8Y?^<I72-&2_-)=2W`D%J%Y:N9.<\!"
M;DN.C3F`3]IM^!4FD\3&`V[#3X8=#=8;>03:1A[=7NXDEC2)IT#XVFNO9:J:
M.=7IR;98LV8-0=K2MDBC>_WUUVD\_1__\1_B0KOMMIM`0+<4;'&*A/]<X8;$
M:J-J@TZW/LS1!"=/11*HR<]TC:FJP.."/%-1DP?]JU]>X[3;)*/HC/NFD124
M&@[8J=(TG"@#:2SI5HM2ZG&@6/'I--'46J^Y#9NPY_DFL1&)L%8U.6PK[D>H
M3PMS/&8KB]-S2)?3H%(A$,9NI9SSU:P`@>V.!RA:WKU!/\(FAY$7UHMD3+K2
M^,@MTXT!Q'-HV7]\U2"P:5LB%1I6SM/$QGS):*8UO(E2BW20:FLXY<<-*6C8
M1`4&8(=/[,QZ6D1(2+X6X?GRE[^\8L4*(8Q02%J#B`=-7L15!!I2K[2+I(]^
M@EJ0``K3-#>!CS:6<.FE+P"AWA?]TT5O_NJO_DKDA\IC_Z<94JST50LZ$;VT
MZ)ZL'2D(+WHC4,).*UG6D74T">!;W_I6LCOQF*<-&0Z3$)0_L9`(XY&*%<OO
MJ:%KI'(@:(/.Y6O7,JYP\M<D;H<<<HAN)K'-="L3;(H'BK_I$@3F3SSQA)"'
M@MC4JA7^//?<<P)AR9K^IFQDXQ11,K/T&&0PST;5O,_&'*=NM?)`TXUERS!P
MQ"Z`CTTZ,TT!'(*'+:2MN)?N>&$KCF8SSE34+4SLZE9U8J-0I]K2&3J8MM:(
MYX`);,]K-]4H4Q%/J5NAT?:X6;>:C=Q/6X?Z948>EG'8YA2?91@51+OCU4I'
M%<.SM)+BYZN:C4V[@ZA6:DE/@F$<T_INQ/[E*1)"6Z:8!$!3K+FHJ\.O\U5(
M>50Y([WRU+,9CG6CD,L;YF'UN?%X^VR_'ZUMN9`FUF8M2T80%I@/,B6<.>"`
M`X0`M*X3==%\M$8:EE8>>."!0@"Q#GV5?JWMI6?QNM?NF%/>\I:W2*)WV647
M\1P)%WW&J7`(F<$ZO7KU:C&!L\\^6R)&Z0QM(#CZ8C/$$.Z[[SYA'65YR!H3
M"DE)P=&FZ>VPPPZ<$:\WJ(*JF!8;:T]:B2Z9#G3#BP?`DB8=JB)C3]:-XB>0
M!W55)$<+0G(!CFX(ZJ>6A1OZ"_;>>V^Q'0$I]5I%`G4#<7M)VZ)DXKWWWOO0
M0P\)?%YYY17I7/H43$G2]3?I4W\?'BCCC#U6&4.8VA-`8<)C[SD6&+>\<4X6
MJ$(.5\*7PX"75OD=`X[%UK1DIDK*H&Y8QKL5(CAI%\*M,QT='.Q[FJU8H)DF
M8]W6['ZE9(ZJC1VR8]Q+5F/SM;4_FWG3"F24&U75=#.EP43]TI;4]\=]]%:C
M^N->^Z1P25$2$T;C&1:V)P_+W3:(1/5D+W/C&>[S,5@S:5ZFET3JC]Q2[$6&
M/KO4^:I=,`$9BW@:6QW?0!YWXJ:%`7)!<#ZT)Y&'%`S]'1)SB?]?_N5?ZD4O
MW4JL8YMMMM'Z???=5R]Q$1Z=5T>3&/Z7&/2NTA#R2*T`<\XZZRQI4F([`A#I
M:((7@8D`Y+'''OO'?_S',\\\4[\*E,2C($+:3"1!3$#8A2%(VTL2?_C#'XHD
MD#0JY8M`02H"83$VMJ1_G*&KT%=^U5?00]NTD,>PPP9V8_G^Z*3H7)`<!K=Q
M_69`C8AAT$_D?JY<N5+W4S,7\T'_$A#10X>@."I(/_[XX\\\\XSXSZNOOJHM
M(3:#*ON&FT#+K=(ZB3#^:29&)D0@JG`>;"^F.H!,>L9G*FVS'P92+Z1_W'9C
M?=6#L7SY<FD*PZIVE;!@L>(KK_79"A(V\9AK"D1H)E8HM$;SU)//'+`UX13.
M`[;4#02$JT9-</2=2=HPG,X.DS/"#,9C?0$Q.P=;^5-6RI#H7I-TCSJL'5G3
M7\BKGG1H%-D0W:K_P__2JT[K9B-SXR-1*,%G&,8EB"C.+&ZL*_"`//KO>N&\
MZT?'TD$YVJ3J;KWUUMMNNZT#,VSP26_LAV/P`%,N'H\P0;GZ1`PESCJ%7M!B
M)E(61''%=L0]=MUU5TH('G744=MMMYV.+\D5PZ&+%KVKW*Q3-(E:@AH"%NTB
M2!&&'''$$?JZ9LV:IY]^6O*E%[W>_J(]XCR")IB/=KG__OO%><`<4:"O?O6K
M@IT[[[R3-$S-33`H`<>VC)$'@T_+/CQIP.%70XK7&'FL84%U8#L:NEU6KSQ8
MJ5O'!@0J`$>N9:I/_=?2,2D1ID_1'J(*!3LXW`5$XC\//OC@CW_\XR>??/+Y
MYY_7E0I&^DT1`,(%70H#MQ>)5P[::9F:\2C9\N.?.M5'CZ\ST?'*`)4)$4N;
M^L9^>H=E")VJXAAXP$=5'@<,R:_=*@B<02\V-UE%LE&Z6[XG@\D@ZD)TPL?4
M&7<G#<>'9=!"U"VWM?F#Q<JCA0E&AC3:#**"*^CGW(TTRV#O@DE:\^I&\JE5
ML&X36IS9"HECH^IL;@1VIF>B"MN3>#47E0G1JKA\!QR"@9J87>=LQM^4;,=W
M$B0TI[)2EJJ6K0&V#SB\!]HCY0C?.D`DD<'NBJE$XJQ'%_>W4((`/^*6]]EG
M'RE<8B:ZDW`;8TY^E=Q)@9)DB1V)+!$-B/5&JI:6SS__?*D80IZGGGI*2@==
MU(4P0AX1'G$#:1]ZZ9]\\LE:*="[_?;;UZY=2\4>;2]$TB7`<X05Y)YCS,F8
MG#^:&(8CB`UV]>0Y.19$GO>-#V`'SJ.%_]X,U"[=80I<<*OU'^D>DCUQ33-$
M?@0O4AOU*2U2N"K.(Q[XZ*./2MO2Q4HP>6M8/T)%VK0J)#MRN(4\Z%R+JBOZ
MXO'FGN`,6[)^:=1&]IB-B+C^>"O,V<C;LB6G6[D\MHJD<=7BW!T?9A>=J--N
MK:2E-`TBA]HTS)8<C[0#ST5$KJ4^G4II5[&C9Y*;M=#,K*F5W3"LW`=?G=4K
M=C20SE>)8W`L;3AI/NI7.E5:BM+F/(S8GI8&9]M1KXDL2L0P7S+RI+DI=\\+
M]]LG_TT'$/JUV$*>5N<"]U*14%B(<!-+BK7E,<<<(_IQRBFG2#_:8X\]T#<7
M-XTDCCON.!$A.N4!-=J%!9:UF5[E$B4(CY!*&"(`T?)GFB$($F^YM1D77721
MUNLL4JRT7KMH1Q&`U:M7:[U62N<20!'`(VF5^B;&I=/]WN_]GG!&T$'Q'-0H
M.ZV`EQ:D&'\`')N.UX\!VK!RDM[D@.&`,\`.L>(,C/E9Z4LW39=YV667Z>KH
MQ7SII9=2S$<L2(KDCW[THY_^]*>B/2^]])*(D.XYOBV[#[#M4#0#:XQ#!]_(
MGYZP8Y"9KBQ19TXEVJ2OQYI7>L9G(U1O<J05=U3U&:PTM8PPDT@R&SU#_7A;
M7TNM+0&DY6XSE1I4/:[4='*;?AF'YZ..7R]B"-,RDWK9H`)[4AT;53*"S4<M
ME$C;$1C%<:S:O#GR^*=$%5_I8+P.1DX2-0UKSZC21?EJ9F6CM)6X22;9`C0=
M/`,V<$^T@@E=(=Q57XCJ(?A?"Y)$<0:)LP13!Q'#H7&YAA0Z;+D"%HGDWGOO
MK5.#,S1,I\H?:P1'NM(;;KA!NL,%%UP@#B,`$>S\S=_\C:!,A`>M2BOU$^UL
MM$P+=7T5)9">):U$H*?M]:L.]?.?__RFFVZ2GB(&M=MNNU'-@WQSDEZ%(:!-
M$IZ$'3(=K$P9=MZ[T`"!X3DX_ECY@?%ADS*1F=B6`1QWR!(6X9/B_NN_._SP
MPW5UV'S$WZ1P:8%:A=(QUZU;]XMF''GDD?R),)\LR^,4]8V;SGU9/WE1M4U?
M$F,JFOHAGE:LK/4LG:B0;)W(MAT'Y*2`ST98H`%JJNHA(VBSD>MM,+&=.:4F
M/5^]2/%.)YJQRYB0VEF+*7%,1,;ZE%E<RYXSC`HYAM]$GDFA]M<$%NME215L
MN$[[TJC2P5I']KGZ$[FHS"?-T<G*K*\E?`T:BWT_&H^"=<NJ)X[//B@S3BL*
MT7]?:F%,TO&K4''S'.-,JV<!?9U(II!T2!(ERY)BR<OVVV\O;!%$2-,12@@3
M<%X#+*(6.CCM&]RP^"W-\!I-0RCQ@Q_\@+1TP84`A&">3W_ZT\(9/.RXL4BF
M`(XDB8(=B>$YYYPC7,+"\[-F?.][WQ,=$N.2C-,Y0G.@9K)P1LA`\:XT%'O8
M2^YA9<K8DIP'Y,E?\62!-CE`'MU`0U`+?`BIHA,H:*]_[8`##A#/^8=_^`>I
M5$(A"JL*8`4^4K5>?OEE44']Q6`7.E2F7T%R[)P"53)0T&3&(&`NU(E:RBZD
M,]M4`%L236T<X3-=]2LL3387,&;&2^[,5/8H?OE>542?I#JF*):.242R92D5
MKJ1/@_'J#?FKU25PSQH0R`--0AZML`S+7;X@\4AM*VT@9CN>:K><98,PTIH@
M>6*)P[X6@]@D5B?28G+IA^W7/BR4IC3^#"-BV:=(TTW.?]BX)M."/8J1-YG;
MU2K#Z[AZE'V'][BTE(2(9:P0DBQMO//..TO\J:PNB9"D[[333CJ"G59P#,@/
MN9FL3SNS/B4OE!,4>L":\(SKX%(WQ&0$._Z)XH1:(\)#.4'I(/KU*\V05#[_
M_/,2R>NNNTX["C2,;Y302?4*7U52G40>?S7;L8X)\EC#PO9NY&F9=!9$'FZC
MO>IN88.I1U^!>OBG_I%5JU;IZK[[W>\*GX4S-`&4JJ6+E<XE*-9Q0!@J;+OV
M#C0&D#&E,;S8MY6PXQC"V:I0FGXQIZ[[4-YWJNJ:6O7H5X*5(2+M0E:4',R#
MR#@*J&6-25M*:Z0Y-ZT*?MOVPOB,#"8N]<;;`@ZK7V>G>G)!`V::\JKN,S4?
MN9"&R@6Q+J?1C4*IO8H#S&OQ02S@+?D=10'2EH*3&I-MZ?-5R#0!<RZR)/",
M&YTZ35K6L,Q$<Y$$@:O=AIU!Q3#C.I^+."(;A1*!M7O+L.S05OL^$GD(YL'G
MSIM:(K/%%EN(BHCYZ_VKA;///EM`H><'>XZD]6UO>YN$75^Q)\-V0!Y;F$6-
MM($D5,2&MJ3$`0I5A$4"&:W788\__G@MZ"=T,?$K+0BI[K[[;H&/3GW222=1
M3T.8(]7CQAMOU*_2L^@X#+&AY`YU,"A;@=DGX04EBS0KL,7*%]B"*VJ2\[#@
MB!V0YX,3P\A#00`LS+C4T7"U%_^%PQNP^>CXNN%'''&$+I:Z0VO7KI5^*BXD
MV)&HZN"]QB>;J:/XLS`I9P;Z=!4`-/@D%V(S*+UA![EC@XQMMNHT4ZUJ9JL.
M!L%FF%7-=I(4051ZD0>!<'4JDKF%/%::6IXC&S0Z$14#XLU%"%]NG[L;?$RN
M$!:[WMB`R]0!*6TQ**UM07*5()D_>1K6IP9-0D<_1O(-H\2PXI8QXTP:A<Q,
M3)E:6M6P>H:.HD1A0M-\M;:9;K+^6]1N%-YY9YLF\K1V\3'33*V115HREM7U
M>#/Q&>5+6[J+DP16NQQZZ*'77'/-]==?O^^^^^J9U'I)GR3=W6%()J7>(-J9
M\,?.="!(X",Y%;S\W=_]G;`%DX[4KJ]][6LB+=*J*%$H4/K2E[Y$WH1D3<O"
MG'OOO9=(:>TH/4N3$18]]MAC6G_555?I<G1\P<O2IAL+_G2!#.5TA"'4\DK7
ME?'$&6H&'S9P%@G@8R+T)LBSH)T',#?RZ*M+E+A<@'-8^)77A)ZH/??<\[##
M#CODD$.DY"Y?OES_D8X,JZ$.AI"!?S"1QQ4SIJK10Z9?@3Q.NR!<1X\0<,1R
MOTGG8?M4<]*RVHOZ@8[W`RBFHZ%Y/WQ;O0KYZX2?*R/6DO\,RHR3_O&YZIP[
M6\&$4!1-=51-'$RQ>A6":)A*G84MF0:LSR]QT!6?>+]JSOL26@AFKC*<\!RU
ML%$;`V63AF4K;L8$YI953+'ZI@>J19/Z51;,<&2`RGDFZ]/(5"PSEF55_HO*
M0LNJ?Y"U,$/KH!(Z6II7KYH6N814>D,RF0([CW-(W<);DB7IT%\C[K'77GMI
M)069<5)3.#2[X.FKN`U`]+9FX(XW%SKPP`-)OCCNN..$*E(K2)W`L'/:::<)
M6P@O//+((XD7DL;QP`,/G'_^^4*>LYJQ;MTZZ2!WW'&'U!`Q*-T<29"8CSB2
M%#1I@H(.G9JX/@$%90-;CBJT)&.(W5*@1`M&R'K07I,(`^SH",(99_U#8%A`
MPT*Q8HV9CXOM_$F-;"3!OY`I$AXD,N!51R%R-3!;]EQ7QW[PC:OQ#1O8GP4N
M`2"]:(TW555)EU:G3IMN7&'#,F[[9-(5(Q7'[T:SK7Y3N6Z__?9;L6+%=%7Q
MA5F-FCP(9U7PD%NM6'",&I\XE\#SWR\KD%_]S'#4)"4-(Q`NY3%QHQ=&9J_I
MA=O+.#:Y/LF;?S+&`ILD*>#?'XY[[<VO6BYL\YPW3SQO94/HZ^:;;]X"$!QV
M]C#:A3>JL,EA5`_+(H0<EKV\W,JG0"1;%AZ83ZLQ7.8;8O#D+?S!IL*,?M*A
M]/!0/A0NH4%6`B70J4>!>@7FV/ALWY:@26]P(8_01GJ3\.?**Z^4MD4U5($/
MN:B"'8$/E9F%3N3"8Y26#G+MM=?>?__]TCYNO?56,9^CCSY:W$"@=/GEE]]P
MPPV",AU0ET\VEJB.H::E-P$=:)0N#&*[<?*6W(9EAG\"J7"=F]Z`0J"*\<<1
MFPLBCQ8R+-`X`URD@Q+;CBNTL^#Z7=:PG(%E5Y<M.:[N-5M9G$[1PLC#:W>V
M(I#-9P`$)W89'-C`*I45-#O?[5B?J6I7>I*WW7;;4=.YH!.E"&W/F1QYG'05
M#2LNNE\1?;UR5R'(/H+5'&1G5%[CE/TTQ=BH,@C+DM<CS@EQ]B[E]CY1"\'Z
M%0:0U2<&59[+^0C&$)N(S7\2>4S;S#V,G"1$#"-7B\D(D9CMJ'SK'+9;[7N,
M.;Y1[K1N_[NQ'80$K[+I@-F.EGF?9M$P!DP>`P6:`J91LI,RH)>:$I35PJ1,
M<R[;=AQ#J)78>814AQ]^^,477XRJ)3XC`#GGG',^^]G/$JY\ZJFGZA/,(890
M4//HHX]>??75HCI4(!3;H<:[X.CK7_^Z-$%M^:UO?4MJEUC0TT\_K?6[[+(+
MP"CDL3''<3A6D001-A>;\\!A($5&%5N2B<FQZ=C@8\(#1F'2`4P@/U:U6&-B
M:?,R6&228RN<P[$R`S09K/]<D*=5SO2-+,Q.$I^)0LJ&+"-/MZJ76[VR1;H5
MZF/1[H0/W4#1LMM87^M$#9S9Z/[),]PRI/2JNH6-V+/5B#REK%<96*/*>;2N
MU*\HH#0KM2!ETA1C)I"O?N/#J*KNS$V$^*9"-"J+MUF6%4.M=("QM9BY:IPQ
M'!_<DS?*DLCSYJVSN680CG(=BKS^F2K;;A#F[E'U`F@:EFO>+,B5?X`C$QYT
M-+_FK'.9X5CS2B<[K0TD/A3-(/)$PVJ(!%"R#.Q090(6A"_[K<VP88=E"@.2
M2_47?_$7@@AJ8GSM:U^[XHHK1($$-0*?8XXY!MNR>(XP1VOTJ0VD4@EY!#)"
MH4LNN40\AZJA4LVVWW[[3W[RDR(\8DKGG7?>S3??_,PSS^A7W4_!SONJQ)#C
M<](RP^6D#<>PH_74]0)8T+.<^&#P2?X#5G.[M![<]E<[MAB)/*T(!VM8&6'N
MG#OCC$,$TW&)>8?72D93.'30W&9)%'4GG\+YYMUH]$E]]0619](L;`7!M,?<
MQH+<FQ@80(91M094L8"W\"HUHSSO*%K;]")Y/'>T%N;=N^.AB?AZ)N-5$#K*
M4Y@\#,/5WD(J*T=)I5@SR85\G`1GXV%:<A)Y6CPGJ4[+CL2.M@PG></TQ%WJ
M18:(-2G3FV'YK081:)UI'?.5X<XM,N=I$7573N#%ZEIVO)&1#M["N&;\BL>@
M\>ZHSXS^158FT3ND2DD8(1N8=Q@"JRVWW%+(([U)P"*L$)*(S`AP!#+47A:,
MZ%<AB380R?G[O_][8@4%4)===AEEBJ^[[KJ++KI(\*+I?>QC'Q/GP=U_RRVW
M//OLL\(H79%F150`]3I:'O!$#&/(!YH:L)B:M:76HQGAG+*C"DV*E2`5NV/`
M<9DUMD$+@__8SF-5R[9]8\YDW5H#42M0Q\!B>$$#VK2IS)QAA"[JM;0:764>
M%JF+VCC+YF#)T<IN-&CH1,2R24L+?%IVGF[Y=UJ1@5YO$T=GO.Z63:/F-DC'
M7!-R;+9CR)JOOL:>`_/I5"QQLI%A1><.RT<S*K-S\H?<."T><Q%][30-3[4;
M;:<LX+UP/QEM4G*3C>3936PL["W`:>&2#]XR&ML;/ASWW5N]LN4'`N-$+1NW
M$[A&T<O8A\*\0QL=W8<-H\MM0M`&U0;7X86L\=-NO:"%/'8W@S^B,:(WCE66
M<.GL*U:L0&<7SD@0*.X'^.B84)?5JU=?>.&%HCVGGWZZP$<$!INS%G"I"T]H
M4_6W?_NWEU]^^3>_^<T;;KAAW;IUM#8^\\PS=5Y!GZ[]J*..NO/..W_XPQ\^
M^."#4LUT'$U28*AY0GB8<PMS6N8:@P^F'DPZV&=`#/#$,8%6K``ED"HWIM*1
M!G9CW5*`2U]MS#?(6/.U#N5_#7=DDA:CBBW&F1"!V=GY67:..SDBG>.`";"3
MX<II2,F`G-2A%APF)$E4^DU*M472R&.B@C6IV^2,&Q_ZE3>1R-,MKSW*H#64
M^6JUT"L_3B^J4LQ5\I$)B3<#-CF=,U5;[,7#4F8U<#KZ+Z<G[HWLTBU`&%4*
M;:]RN%JNJ[GPI&>D8J)-SBT-629F\Y'UV0(K9@)=L?<\DRD`(O_J64W2(90L
M_@@>5%RH>#U2[<J:=88FOW:=S&X#J5_T<`-B@_&AX\P2O.R\\\YB+]*D>#L<
M>NBAN^ZZJZ1`-U8GE1CJ?Z$ODFB,P(2PP+_^Z[\6X`AVM"S8(3M#B"0F0[.&
M-6O6"'_NNNNNG_WL9]=>>^VMM]ZJC041FIXXSTDGG22V0Q,K[2O<@^=HB(F!
MEL:<M!ACS]%Q/E@Y#M:D[.<B+"?M.=AP0"%S(3@/V.)#V;S#+85#8KU'>]I@
MO"4ZRZV*7IAH-AYOU9>!6%D3U9IUELO(F.2L`S9=;8*U09J%TRIB)<B"YF32
MA"E@9T&S#\.&Z$G-*WW629^ZX=#W?*SK#<:'YSD<=R$922S%_$24<K^<YAS!
M^J9QPP<?1NUE<ZUNV:X[$Q'7>01;I.?&\RYSDM:P1N,6;]\*7[*/;U1)RW.>
MVN<=1;*&P7`0!A]#"NN717/V022-PL$,5HZT7#9>G\>,:[9I.9UL'$LR#^3B
MIA^*D]EM5<#F`RAA:@9VR"!P\4\I-5JCG][^]K=+]*0B"5($"WCQ!#)[[;67
M)KQJU:I/?>I3^^^__Y__^9_OOOON(C,"$'T*:D1^!%8"'#$?L2!]2N'2@G!)
M&A8>JZNOOEH0]-!##_WZU[\6[-QWWWWZZ?.?_[P.*X9S:C-$DY8V57DQ/5&#
M5&#(@C$'_F9?E4G+I/7&/YGY<`34)5<T\E>`FH/8SH,*YB)L+KG?0AXS'.UE
M>X[-.$"-0T`S(6+3IL#I3/6],MHL:BH3SHZ7#>1EE!9F[YM<Q;(PTQ3CXJNU
ML.GH)9&>HT0)R[NY03]2R`=5F\)I%+T*1&%B4]7/JQ/IF?W*,QI66?)A%+@P
M)LR-IR`-RDB.;619E";C5^@<\M*I0*,TT7`H:WF`V[(JYI-:'NK8J$IV#"8T
M(+S5%F0K@V@H+8,V\MNB3)[2(/Q?J4EYLV'DJB<O,M;Q$]U\T@Z&:N:3M@B2
MPY7A9E[VWS%H_&A;;;65/:K.T+'SPH443'B<!Y2<GX`W":DD0H(&YDAV*$`A
M,=]VVVVWWWY[<8\==MA!R$-5\\,..TR8HZ\"'/H1GWCBB4*)5<W88X\]I"Y]
MYSO?D>9USCGGB/#@,:<G.Y^"FF]_^]LWWWRSH.R**ZZ0AO7DDT^^\,(+#S_\
ML""(8$(-Z5FB.H*XY<N74\N47`FL.AB601B"<.SR9IC\M/"GY<!*\P[#!W%J
M/VC#-C:4H5O!85QXWSB/5KMATWY1=UM[&6H\`)GT2R;Y@;%L.MZ;F#6&(S.?
M?L7U\4B@G5F38GUKC3&D9=>U0ZH[7L0O]:S$'\M")[SJPR:*#UT#/<*FDIR&
M]3AK"KTH=3BHK(1.-+T:-1$U.HC-U.8)R%=W/$"H5]D-V)K88#8*?5A]LS<J
M!=P7:S'O56&Q-'T/(]/3,F[YM?YEEH6"TU\HCL@PXC!RN(KYACG/J/+7?%NZ
M4<\P+>J)9K;D<$#H3:_QD1G8/1^N:[YR-U#0>/TYC"?]("UO^X;5.<7OWXPP
M-%60[$A^_ZAI/*H'=<\]]W17"*E:FM+*E2N%&/2CH6@S48*"'0'.3COMI"WU
M*?)#5W21GZ]__>M"'NURY9577GSQQ80+TDM"@'/CC3>N7;N6MJ'WWGOO]==?
MKZ^B/53*$@L2^%QWW74ZB,`'[S_&;8<(@BJVY]A0,[DR>P`E0'DEMF*[J%B/
M_@6'0:5RK'*JKJA:`-%&49,?;[@^M7W^%YM4`^+%3;>:#..Q>=DE>K("#W9C
M@])TM9A9&L4&_0*:KLH\F0V*=<7V''NQ<W0B+-EZ5@NCK!0D_T]5R[)L.4(/
MLI;AT8FHX[1L\,!;0H>54CVHHCT+:FT)@,F[("2&)NN;@_$H:Y.!7M3-Z$4_
MOOY$)I=G;F5J5&4N!N,M`JW^6"_S]AXV@P_'._1-'L>F;$P]S(%;E#@V&@]@
M]GES#MQM:VWY1UC_,LX3H>IWI0V/MEZ:S#MU*ZND,E`!B'[1-D(>XF1VVVVW
MHYHA2K/OOOL*<U`N1'6D)5UTT46B,5H6%SKTT$._\(4O")I$PX1"@B!1,A&5
M;WSC&U===94`1]Q&Z$&19W&8FVZZB39>9"W]\I>_%,[<<<<=0B?I:"(\=]UU
ME];_YC>_>>ZYYR@F?\LMMPCB-`%!C?L^.%S0=JHD-O:2NP"^522W`<IJL=K%
MV[3PAUM$;5)'*>L38L,17'6_%3J^455.IE46V^O3=AL'"FY2_;#LX0)Y^'.=
M+HJ&Y0P(1,.N<XPY4]&5N(4P*:0MP,D$KMFHM.R]3&R2J,Q5YF::.SCX,%+.
M.Y'5-:I>5%::.A6.V.V.-=,<E;>7@UB*A]$'F?DP\\Y$M.$HJD!@KYBKKCHM
MY$D]Q4#:C6(=GD^BS2C<55ZP"87EEFG%6\['F`MWVZCBBS)X.,-[O*65NV55
MS,>0.(CJBX/Q\H-H83"995&?$%SB+AF@&$ZU8-H8%1W@2IP&_BRS(.>M.W4K
M:Q4ZS@2AIIT$EA,!"*YP$9O]]MM/\Q01DIA_YC.?$>$YXXPS2(40%1'X"'9(
M@=]RRRUYI\PW55LI!WKUU5??<,,-0B&Q(!K[WG[[[4*>6V^]5<"BE3H4!0Q%
MA[29,$I[_>0G/WGUU5?OO__^\\X[3[_NNNNN*(9"'DTR;3OV.AEY[`IW@+%!
MIK6F523?&A;PXN&$K`0Q_X31C)L,(F6M2/^$S<T)7!F3L\EXS?8EU>@S2V$`
M021*&*\`@:DJ\PYH3$>K8AMMDL-T*WFJ,S%FHYUH$A+[MF;'7>&VBW:K(1VB
M/=UTSFK9'WKA%D^])I4:6S`,09Y#GK$7?G83JNYX7;+YJ@&8$NK(Y&Z9NX?C
M$3A^U\]'G]!>V+TG+;09"3R,I$YFXHC$WGC]9X-,DHUD1/:%S877;&[<(Y:A
MSL/Q,5?.P5X3L>!Y2C"Y:80+<E)<5T8>7Y%IV[)(^()RMQP?]FIEM(\=7O:\
MV_@I<;`FHI4$$TIR5ZU:)2@X\\PSQ4#$</;::R_M]6=_]F>B.M*SA#SZ29CP
M\8]_7&C#9'2-.H(>]<TWWYS>ZQ(T:5[:G:[$PIP''GA`2M8%%UR@?74$J7(Z
MD2YVFVVV.?+(([_YS6^"2-IFW;IU+[[XHA0NJ5JZ`P(<`0LV<*<SH%)EM8I<
M;SPQ2M@"W*I3S9J$G40>L,7N<L`$"F2C,>H5R,,--_AG3*"#',QDTNR3=AL4
M*Y#'VA;$AN)@_-=3-?J-;VBF"N8X.8OW4:LL(=C2C\`\:T`F0C;_)OCD2@/7
M(-J+]\-59%%-#2MM*?[)IH])1C%JC+HMN#./\G&L0,U%M/`P`@('C<%Y6)G:
M_:9VF9$JM1)_=7A/@N&@W/V]\=CFN2HW,2@GE&T[\Q,YYO:YIPFH-8%4OB85
ML5%D<A%ILZP&Q\<G-8H"U*:+$E@0%2;#>:G>[VW\:AB-1TBB:F&`<C$6#QXP
M'G5;+&U)P#1DVH\<00:TP?N:^LQZ8D5LI/M(:<*D(_XCV*$5CKZ*DZQ9L^:0
M0PXAPUJ<Y[###I->)CC5)6R__?8Z,A'.TMTH]K5Z]6JAC5#HZ*./U@8[[KBC
M%O9O!CT$3SSQ1,&:T.F99YYY]MEGGW[ZZ:>>>DJZV+>__6T=<_WUU_]`4W0=
M2I86&R,/7Q-PO.S4SD2>S.YL4<',]`1\G/*&,F4X:D7L9'*$4[0VFNA6D^.-
MM*VLR<-*7,,XRC'OV`3M][[UILR;L";EM-#9ZG#7TJWLCF]%VJ0!UGC2K98T
M[&AR99#QLBTP@*3Y0#K%YB=J[MEP9*Q+4C1)NGH5K&OD\3'1SGKE!0.(_'5!
M\$G.DT@XBC#%W,4PR#0<CV?+3&[,]LEYK&1E<$X+;;R<!X2B6'TS5W&@3LLP
M!2(!K:B?Z%-S<PN48FZAXJ!J'#'`'R<@0[_3.&F2P\-/8#,"I?5$QM*<`CJA
M(P@'3COM-'&2@P\^6,1&&ZRWWGI:O^>>>^ZTTT["GYMNNFFKK;8B@%#7(E*T
M]]Y[;[OMMM*_=*42<"'8V]_^]K>][6T"F:...DH,Y])++[WDDDL$4#K"X8<?
M3I5FX=MWO_M=\9PKK[Q2OU*C3^#S^NNO2]MZY957[KGG'AT<JD,VJ`''.&.3
M3F9N6KVRM<<V'&..8:<58YQ`9+[$Z5A)!8Q,R(7)$)]C(P\8A6&'#9P$:IC*
MW"M[QNV@A/S,1&$<\(>@9>>00DA8SO!"O-BSD>)DNM*+_L6=R*WP@@-LTB;<
MBV%K<W>A",-$(7M_IIORZ0E<+0!)8@,N)=](M<B3Z8^/4:2NVT7>J_[I_>J-
MWJ]:?,NJ*GL_?-_#\=BAWGBQ+RN)O0@H2ND>C1=23@SQPF`\P7,0EN26YI50
M,#>1<6];#6=/78^1<3@M-C4?R>_>S(I5QCUJ@>P);>`'%89#/*%5_O2SHPB8
M`AF(,!!)FEQ,3)MI&S$9/2%"C--//UU`H3F0&0J2:.B_^/*7ORSJHNL5U.AB
MQ8C$?/;;;[^5*U?J[((=TDOI;:%C:KT(SX,//GCYY9=_^M.?/O[XX[5P[KGG
M"FUNO/%&:6$//?200.:))YZ0DO7XXX__]K>_%?*\]MIK3S[YY!%''"'D(=#:
M:1'8D,U/$D_L\O[P>&=Y,,1I#N8M@$G+]V>G(2O!,=0K;#Z`#\0CG>,.8,B0
M<FVC(Z`H\5[8J$HJV9\U%4624U$RJK`!?S$(@^@9)7@2'/"#OM:INCIV9\]&
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M"Z(ZO_K5KQYYY!&!#T3HW_[MWZ1S/??<<T(G1P`Z)MG:D(.-'4Z3-?`=XV?W
MDS&JE4YE#0L4LBNJ5<[::Q*=<F0T8"NK+K/.-XEZ;K8S;U*M;68CM9.2%YVH
M>(S,>AMSH>FH>F&E:=/JL67="NA@QV[XL'C,6K'$W>CHUZTJ/3X4"E0W0F6,
M)\DBV*5?25N&/F!S:?6S2UDV:AG-+/(VG%I21N7-L?39H.W#6DLRO*2BQ*$<
MLJN#="HO;&[<P3T:=RTAMK;,)W;-E1?>@30V`6D-],\6[V$XQ#T-FX^LCIFA
M#<K?W0_#?C<Z(_>:I%$[?4:5=2[J,M]$274C-,)`-*I"/?^[&<LJ[6LNK-RF
MY6D<X'UGWT=:GNU,,>>Q%ZSU=8,JUXSPVK3[KG>]BVZ>(C_2K3[WN<])(Y.6
M=-999TDOVV&''00(KJ3QCG>\0QO3,.(SG_F,M+-33CEEN^VV$X_ZR4]^(O7J
MIS_]Z5-//?6C'_U(('/555?=>>>=O_C%+T1UKKGFFJVWWIIT41W_KKON.OOL
ML_6?MI+',YQO$C:U65*@+%71,N\DU>$(MH"E8;EETLD[MB#X^%8[=#.MQ%EF
MQSJ7R8__T,R/F(G.H2YGX:\@@%.T4F<A[`?1F(IZ[VD%FJGJ?)-)%HE+:=TU
MY^E$=D`*IBTA-EKRZN]'IX9^9'"D/F4R,ZCN-NG:'D;88;]R0GMA\AU&:V#;
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M"369HIN)GUE@QVY$VW.R`MC&U3_"UF,M6^T%!Y94MQI#D$>"1GJO;`A*,#%T
M6)ER`"&XL:"V95*4JH?EJ!_U+NR%'T07JLVBNJ_M0NQHQ_=,)5&:11@$!M7'
M*OF,C4@M^W9"P:`RX@?E>YI4`V?&JYY:?^Q5X2_4P$Y3S09BD+81PU?+TFY=
MKQ\^($_,1,LTSZQO/E+%6P8?0W=>5&\\EGNNHA=2.4IFN+0I#FG]CICJP4)Q
MC&E,GF^BKZ%\LU5(W_>!C6U"]&/)TYA1K_D*-O(XO+!5$R\WV+C2J(F"@TA(
MTQ$"H$!)MY(2=,LMM]QXXXTT0__4ISZE];`=\1R*B0E_UEMO/1T-/[NP2-SI
MBU_\HA2NVVZ[[8X[[A#M$<]Y_OGG?]N,QQY[3*1(&U/OE+10'=`1.S;1V-^4
M50%-8["9IS'G(Y$PNZ`]>>/HS9IH8V"Q,7G!F'!;C%M1RF8^_CM8;[\5/]G(
M,Q6MLI9$U4$;\996$9Y%E>1NC]6"PT+J8!Z+>3?2U2VAK;?V(`)T?1`;ED$P
M"%6G*E`-J@*\D0>MRERN5W5[;/])XC0<STN:CX9WW0@`,.>QD-IJ9)B=B221
MP7A[+]./7A/NXB2"3I.]!15)2^^PF@7/5/6,?M2)G:O*8+8_CR);P?,?5EY8
MM\D7\W!T\:A,Q`FP<]4P(C'9"-.B7CZ[B183!NAL:C//\5F,2]`D_L$MMMBB
M']7@J=+3B3Y*?MEAO9RJ8IAV=K`^9<'OZ%;DB;6#U,7@/[B3J*FN]8<==MBQ
MQQY[\,$'?^,;W[C^^NO//?=<39A@/RE9`BA:G+N`_!_\P1_0PUV3.?300R^\
M\$(I5F(^+[[X(LU?1)^^^M6O?O2C'X568<+%EONG3;\PO$L.*@9YS$S2)VXZ
M9+UIDK=X^2.58V7#5^)P,L/,59ED01FW`Y,!$`CXS(PJNR,Q`B^I`J1+H[I.
MNKIXE4Q58]"EU=_*&T]'BKHQP;ZM7E0%M,G(2I8MQKWQ(GXM88?)S$;ZN>GW
M)!&::9K+V!QAH=98W!0E,_+,5U;7,"+ZDF8XKL8&GY3Z7OC%K([U*];:@&:;
MJB=LTXJ7A^,='ZQ?6,.R=F/.,(PVZ$GATA#D[8?A*$]P&%6+SUPS%[GJ=E'Y
MI$8D^(E=5*/(3W>J"/^LYP`1(IC'M4\!MT&5&N-=H.6MMMK*-]9S\-/5BMF`
MNO.(.N3,K^"IJ*+)^,AX?^0T7"#:"!$L0OJ.A%3@(ZU*\Q3S6;ERY5EGG245
M:<V:-:>==MH11QRAN5%)53@C`*&!CM;0M@:S\XX[[DC+FR>??/*^^^X3^9':
M=?OMM^^SSSZ"%R&/D]"U0$<,1^8DYS$*M?#'5IT$&7.5#6,8?#C4AM5(R/<A
M`Y]LDW'$5"L;BY'(PW^TI*H'6*LR=/C%D0K43.5X3D6YL*FHGY/0`=H`3;.1
M"PE&(;!VE!N7[+KJC9>[L5`;0Q@MB?9[WZI';SQ`R,K","+ZADTF:3=*;(VJ
MM82A)FVM<(/A0G$U1AZ_W'OEM!I%6J41P)PD[5%)+89AP4[4[4>L=<J@)V:&
MEF>W^6BV:7Y!QB5KAI&(8;-,/[SD**U.5/?11E$J>3!>*&RNO&E&'H_Y2.PR
M+4Q_^JB*8XPBG``V.]E[HAMN4&OZC$45A[\D*O9($(P\9N^+JI=E1CY;Q+0&
M7H$ZL&%3YX%(O/>][WT"%FE>VVRSS?'''W_RR2>+_^R]]][[[;??00<=I.D)
M.BC2+MHCF,+5);`2\A"9LVK5JIMNNNG11Q^]\\X[O_.=[^!/%W$ZY913=$.T
MBP#$F>80$N=2930.4\*QE29?0TW"B^WGZ3?W!O^S*GI]9+QFX$?&ZWIM5,V&
M?,=:ZS,^,!6B)>-U2A=50D3:<VQA3LA*O+(!V;XJ?^5$,]$,E",86V;&^V&9
M,*2]8EBV67,#`YU%*:TNHPJ,&4[4Z.M5:E@O4AY,5P9E%QU$6I;%/]$C!7DP
M;L>VO%LBC!Y&E3='GF'T#?>I45Y2J1G&:*FB_?+T^40)%^#_L/%NCR*BV'=L
M%":F;L4@901.(MXD8OA*AU'?HU_^/N9C+Y7O6(M;CBIBIT6].%1&1X\J+-,*
M5R)/.D%,;U(*$GD656V?I1479/4!T2;^;8.F8^__;'I?4HM/@B;VHNW)X?KD
M)S^IPXJB")3>V0PA#&WXM"R8$H"\Y2UO$:0,FIB*3WSB$Z))Z]:MN_;::R^[
M[+(''WSPUEMO%0OZV<]^=MQQQU%O4#OJ1%`L?%(9GYQ95Z8KQIST>B?RY`6F
M7KEA99<XQF"#B@S,))0-(FYY2>5[IL:*98R[BJ8&YMLH9X?XDBKGGF^*Q57S
M!)4$G2M#?=[$JSX[/OP86$&;JE99W:B?8XM'V@12KTG`Z86WJU-.9\MX0@=O
MYV&YM%*1L6)"?`B/\;"JIZ;]P;B1\NY9S86?=QC.K-Y$;.$P+*@M@F<OSR!2
M,`@`[D=DB\%G+O(IAN&_GFEJ65B+R7Z=*)*.&K+L,V'_U*T".),8SF5NL<46
MSMP?1;7V041,V</%3)B\8P*75<^+42329L2@-V9AU#C4_)_:H*1'&BX]T\25
MV8'>:RS>BZNM9"<2>6P(6E0%&195YR:B@$QRC$YI_.%MKO54[=/&'_K0APXX
MX(!++KEDQ8H5+N-,(0N^"CV$5'0,?.M;WZK321W3[=UZZZVON.**9Y]]]K''
M'EN[=NVO?O6KAQ]^^*Z[[A+S.?;88S%E"U+$CF`[F'H8'ZX"@#BDDI6EY;F%
M.58G`55V-T38#YAQ."R;_*1E3%\)E6%')S*8^=BJYJ'-@(@E5>!B)HI=S$0L
M.H!F3CL3Y0'YKV<J4IV_&`CJA*<[<6,V*AAGV$F^I]*3#@X@R];=.A/]L*R1
M#<?KV_A!30D:-9VP7%R+>5HY8F*]\`CWHMEQ?SSFQ/*HHW4JE\2V7(1N.!Y^
MTP_[<^IE,(U^>+?[827N53/09='^QKK,H/*SX`DM3F*2,#=>9KD?V;6I%LU5
M1>7--]]\$(;EN0KCT?I>#*,<X9%S5<@BDQU,8#BR,0?%EJ\\'OVH:::#;+GE
MELN7+W>`H@D8,*4S2@1XA=F,`%SX<4KVSJ_3T;`IR0\_V7;!6S7]7*EKF`4)
M`<1DQ%Y6KUZM&6;'*\;ZU=]3^*.OZZVWGNZ2.-())YQPZJFG2M5Z_OGG*<[S
MRBNOO/[ZZP*BVVZ[;====Q5\@3R"()V(S`[[QVU#_DB3H>#P;',5XI%2YTJ7
MMWU2B1*;1&W`Q5%B?5$%&[>VW+`I^67#CDD1<3L+^L2-Y%K0[=IJJZWT./%2
MF*VRR0[=61I9#$LKT\HT!JED>;;"DF<CV3-]0-/C]82-#RU74:_,JMT*E^U5
M5F:_'-#]")ZQ\395L$[$G%BL?!QS>*M^/F`_O.06?^L%AK)^)"S0U07!V:RZ
MM+3,+(DDIG;6`?M5&6RS:LPW".-)MX*3;9@=E`'9!&E8B:6&Z-2Y#$JI7@W"
MR)Q*S6"\-JE%G@-22S`9(-@KB$CD2?=6^NLWJZ[K6+Q[Y9*SPPOX90*;-V-9
M%/SQ7>5"[!!)KSI0,UUE+9U5,5/-:B>1QU8+O^MM0?4P^*"D+&[JK&[0M-&1
M!!URR"':WL757=*9*CJ.0A3^:-H77'#!W7??_>,?_QAGUGWWW?>#'_Q`:UY[
M[;477GA!H*0)O.,=[R""2(>"6<%M_C2ZR6"3P0X#:(`J&T?.IIF,KR*WMX-O
MD^HILR@:"7F#9"\MV\ZB:@/*[NDT;\'.5)7S8@/]CP27V@IMD]ULE#OF7_-;
MP^0$T`"($E5,8SJ13L6I.]&SKU_)32F8EHM4OM*'!<&>J_)WB#R>CK0+]<I$
MW*M\S'X3%^UTAN&X>]K:A$W*+1&S'I>$`26E7]EAMG6,*N)N,#Z&D4ME"F<$
M2&)CLF%U<GX\:Y+-N*5S3:SOJ&EHF%@Z'_4K6O$_AJ:6C=H_)<<P@#M6V=Y_
M;B^)YVE?\K^9D#X<MVYQ1IB/$TN717\*5XD?-#%:&<8\;'P$2R/`WN[7196V
M`_+H48>1OI&VY5=YXD^^RKT&B=-!-FJ"?)8V%1LD[+H*K?E0-/S]'^.]8S1H
MSZ>?CCKJJ'7KUKWTTDO"F9=??ED0=-III^VWWW[GG'/.Q1=?K$NC/8U-QYB:
M49&,-CGL$(?);%)5T]/EM&!T9<M$PY:+JV"7;XLY3()/RVZV)&JSIZKE.&1V
MG(XB@9!,,\S9R,PRL?'*J8G^$;-5#LM:4CJ\S$!FJS*\`<WTHQ.Q>=:,C!Z]
MRC?WCE--ZYP$I7[YPKJ5Z6EQMN(#/LQ$E>-A&9]GJX6ZO;IS48`B"8]A)^><
M0-2+$NX$$J2OA\T<N3<J1]*HO.'&0RM]PZAZVK(_^WI]@5"OV8B13N1)VTXB
M85J26PYTGVL462'#B%[V_+EI5NC2\FR-.QD7:U"I1!KG*WT,@L3</(=!V8+F
MHR'[9DU'>+\3;46T/]U1'YM6;;HW0AXCF-V[BZ,LC,5G<?1^0MZGFZ*([O:2
M`<`H1#1Z$.<!0$1C1&:TRTDGG73--=<\\L@C__1/_W3//??LO__^^DGKQ?$@
M2'_\QW^L`V+;T;GX:N1I&6VR,.D&30'\3%LP:3$<M<)RS(4VK(+5+4MO(G".
MI1%OG`PG.=*2&)H;KX!.]1^W3PKJ,AV)HCJ(#3O3X]4M6F;D!9$G[4*YQFPJ
M0<;(8\NS'UH+>Z\)!;0J9^T,\$D.P#/<C[P)VW[]&NU'N:U\1S,&D6A@$>B-
MN[E30_$9>]7UV.+C'5L$STAE%6E08<_^.IJHAV.MK3N>+]92$D?CT3C>-\F;
M;5SST6?0INS4[$SPEHV7(#-2+5MH&%%MB#8C0K&BH,VH7),)R,,HZXK6V:]@
M0EN>8:TFTCR'@PKS]NO2O&A!;<N.CWQ!+XH^W3X(/WVD$K0WB9I7$G_<1HXE
MIM3A!YMVP`(6BHX*6,1\=!!=`N[XE2M7:D>AC4#)_;#P6PFO0`-K579PM_Q0
MX`9J%"BQ4:0S))?CZ\;1N-,PE8I5HF[+F&-4,41O4AWW?$L3QCW,FC#L=*._
M7J>*5#B,V6;D!)_,?>A4860O&VH29";!RB/%G^>Y6RY@FR,&X:WVCIUP<L$E
M0!XS#5ZXB$8J1,"77_JIY5D#,@:FWZ<%((Q>N>:1V4$Y??SZ]HT:5L7U7@3G
M=,=3XX?CM01'XY5S$GFLJLQ74'$ODM^]I?'!IJ'!1$B`407']WQ%&TXBC]-2
MAM42RW&`29P29WI5)LC533TWWBF#LO/XL'EIO@F>C.%T6#T^N/:9ZI+6J^"-
M?.S?Q,(\%>'ZDYJ"Y<4H!*]`Y]+@1-9W;/YUDKA6TAA"\")P$+;\X1_^X>__
M_N_CI2+()QM#0)!</@A`R$P'X,5:3X9!`@)L;PUQDT@G`4-:VE.+G]C(LZ@2
M/UO>KI8-V3MRA]\(>5!8%D7)';B-[3;6M@"0J8@;G(YDS]F*(AY$3D0O8O_2
MR-.R/!N49JL152(/3Y%ET$P`$.A&_(\92.)`"Q;2V.L'>VG3,R*%M+_02(8S
M&@\+3`J4-FHCI+U4G<AR@@GTRX/?,B*9O0PCB#%A)^<\7QV0#:U6W$;CH4=S
M<V.ASL/Q$,2\_[;T#BJHV^(_B(!D8UJJ5[X_P_*2&WGRTI*/#:)PXF;5@72S
MZBX!L4FE;[Z&K7PVT\TV\2&+JS=!/O8V0KZ1MN4M';1FYZ_E+@5M:=/ZRE*Y
MI)(?;?O]<+51)AR(>!MM\.YWOUMKB/D1*+WSG>_4]C3T!'G2@:5=S'-P;6>@
MSJ)(!M\X*HMZ/NQEY&G1'G32Z2HWJJ_)-S`7FUFUE$WC#\;A;C7HA`5IN76[
MS!C-6_P?X9J<K70&*W$(T>+J7#-;(86^_^C7/+<<;7:\!V@B3\MO[FULV+%E
MP]J6>52WJE_VJM:6+9RVTM@VT@^O?;\_%JCF=RM<*(VKUH/L9$F;-M;XI`&C
M\*VW;.#]QN*=!,-"Q/$!_]FJU-JOT.O\.E<1Q4E@4OJLI!B%O.-PH?ZGYAOF
M45S"LLJI-W#Q4\;AS%<7"7V=C<@K7^#\>&D=GW%9%:!.C$6SFVL\97BO_(Y`
M^0+*<,'/381#YXWM5FOL5/EY_KG)?GKUE?<XZ#0=)7F-3L`7-L].-*9<6@5_
M6*^%F<I%0AXWKDZ[MJYL4"W%'6/32JK"@.PF>N[RX(U;P7Z.V,%5MTG31\8!
M.9P1$^Y4M6RPAVNC\2XS(+"U)/;%`K-I$Y`#`G"$U*$61<KG)"&T&60J_(Q+
M*Q1YTZA9:A>`;73\7P[\X]]9U+0^YW^T8PMQ,_ATH]X@9V<F5L3F(H;$1F,P
MQ,C3C3R(Y$4&L4%5N>F'\]<:#0H7<],:0@5F*B+1BE5_O.QS?\+H.FCBZ'P6
M)`5S\;"2+'H1RMAK4KK0LZQ;X6N;C^HZHR8&;S3N#9\-?U._R1%([4:7X&L<
MAIV*W4?EX;(XFP79)81CV@C6B:I?@)B.LUGT=TB+M#9V.I6^+E^^7#>!W/E!
M>.39GO>40=O<=5CYZ8,F8A,''&&*VIZCF1V1%@H8VED&4#,E\Z)154WD(>31
MM8[_)LBSJ#JGI&EZ<47=SU9@[533F/)-D`<!WZ1J05@8%T2>](.WP,?&87YJ
M97=F&L(FT:S0R(-QZ8V0)]W?27L65T.91!X<-_]?D6?3)LASMFE2,UW]B)=4
MM.<D\F@@+.DE]Y\^B3R`!E<W*,O)<#P@ULB3^G[+R&S,X8#=R,7^3R%/&G4'
M4>QT0>1A/B"/28C.@F2]"?+8><1LN3\+(H^U&R.JU</_%/(,PA7())D&%B=@
M04>0",]7?<*TE@,RGOPD\NC6&<J8O/Y3T,/4"_*I77@V_'?,E5>1R^&ZL!'Y
MZW\6>995MU-.K87_"T29C<<-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*.2`P
M(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0Q,#8-
M"CX^#0IS=')E86T-"GB<O1Q=C]O&\?V`^P_[Z!;V>;_)+8H"B1,G+5(@K0]-
M'O+"HU82&Y&42<I7^==W9LE=4I9$.A9I&/"1XG!G=F9VOG:6W_YZ?_?^_HX^
M:*,(Q7_N*GY0LOTOS>_OF'O""->$:?<+)R)Z,(;')*;PA`I!*GM_]PLIW%B1
M5#B0BF/\0ZK-_=WV_F[]9QP*_PU^H`]2"D#P((42\$<8SD^?&ZGPN1$1/H]C
M+2X/R,FK6+*(D9A1`F!2.YK6;H+M0QT>"MT3_.WC_=WKM\E3"M,3Y!%><(QP
M@_JI:YREA*<YDL24CLAC>G_W"NBF>/U\?_?B75:DEC!C)'FV9)M\L.3)VH+8
M8I-L[(ID!6FVEJSL![LK][DM&I(4*Y+L][LL39JL+$BY)@DI#OF3K?!Z?8!7
M=Z1NJB0K:@>]2ZJ-_1-Y_._]W?=`][_FF9TP_?0,ASE11AX_PIQ>S8X*L`PX
M20V3@9-:RY:3=9KL+/!K=8"I9\"!M:V07RV3YB:)<:`(=+NEB%.X#Q2!ZCF*
M]E69VKJV]0/YQ9)#D^VRCR#>LMF2=)?4-0APY^13V;3,G[(B`>D^965CTVU1
M[LK-D>2VV9:KFC0E665U6GZPU4NO#.[5/"D.ZR1M#I4EY:$"O?EXS"T!U*M#
MV@#FMV7E'BS"`&J\<FO1BX0KTS)@.*]6'X>*_#)H_+Z"59#MD]WN2-9E>JA!
M\5&Q@>SZ6#<VAU\KG%-C88AN;B!5&&&;I5L<IRB?";!SYU[:)PV,#X,@AP`<
MQK=-4AV78`(8M*`$7/1*(..6!V\8^3D03!Z#:)U.N-G7>US5>0D2;+9)`8MY
M9=-D%19]5FS<K(;<O#I#0/<6#,"A?DF275W"2[`,*@`$#5IB]I'R&A`-9B]$
MMP2:;54>-MORT,#<LAK&WY<5F+`:"?V-*EI;2]YF&U1?]@`_L)<H^5:L..EK
M[",PV%,"BO(29S9<!<[8D0_E[I#;&@WB#E6CK!NO0/4BC%"Q9P37QC-"1+I;
M"BBG=FW63IE7&2SEV@+EU>^V(>4>^7(HLB8#<W%"'PP.WHZ2R%#2>LR>`.?,
MP*_"2G3/^>7GG,9F[#FC47SU^?L.1&D'`J;WG#?@"5C@#3NW$RK8"=492K3B
M<;=$'I,GL-P@J3=E@6I=G\R_'>;?/^"0SRBK?R!!#PJ'C>!/ZWW"[>[^[IV?
M`K[DX",!<0DQ0K3P3(2[B^!N^![:C<[Y9P[>WC)^=70/P#]O>&&T&]Z#RW!W
MF79Q`HUWBM//'+R]59R-P[<#7AH>E47B`$3$H+>@%1<7DKZVD"0QK'6J+W[C
MDGZZ4&\<6TE^P]CQB`'`=WM+J/WZUWB)*AY,W)GM^9PI78V+XB%:T]M?#)4Z
MY]-Z@T^Q(CH<0T"TCA2`]<(0_?7?`2$WY+LR++T6HS"(BK<Z$J'(4>!X"7J/
MEZ#4_27^REN`V%_ZT#P,Z<%R?WD^3NP1(0"BOSQ."_8I:;%_X_SE]_US`5&L
M!*O_AU1)0IHPJJ?3HT?7I2I51&+36DRC'F(!`L&X&@3+F-2]9&V"#J\-\=^4
M^=XVX#X@H/AF]0%B!$@?SL5^ZZSCR-PRZQ%==J/K=GW"3*G3X5:=.5CV,&OP
M^PFIRVPW*W9%1<`^GLO<B"8*:'".:A`I8!R)<US9"H2X(NMLEV"87!YJG]/E
M65J59;5)BJS.SRS)393AR[$,MD31N`_FN(_ED@8B5N3_AP3CS2/Z;(A9WA\L
M(*MM4D'0ALH(<6INJQ23L/F)Y'%(`Z.X9Y_J%D::[),GR+0PD()L,-T=5AA`
M9PW0[7X_8L#X9,FF*I\+S*\=5V'I6(S*ZJT]CP]O)QK#HXZST2!,]IDB,@TH
M:4/7\Q2VK&K@,R@&@:#QZ`+:#Y@-UCB;%7!_=H(C(_N(;9#9>24%%B)'"TA(
M=YBZ[+==4O,3Y"Q5LD&6-\!*Z_4#5BXF@$WMLK[YZ8TBGX7I**3B2L:JI=<E
M6BXA<M65Y[+ZW9%8AF3Z+&^<GT9-0XJ`@N]XRG0<R@7#-.[';+,ECVW^M(?\
MZ5U:`>E(->9-/SZ^PVQIF!'-3W"HN'!-0TRCA%]JP+TJV6<KR-IK1YS+;%RY
MJJM5.`NQL47GI/#1U23L=G)#.89%@W*,--Y\V6-7.[`O,0-]MKL=_D5=7H'<
MLS5DE3E`H/7UQ0:T=.!,ER"W+Y[0@2$S0OGB27W8-2CO=57FL,A6V;HK^3F:
M83Y9U3+W`?3$DN^.R2I+YR=4APH'C8/M$IIV/OGG7=*`W/.A*GZ2V7.7V7=9
MO4_<,<]_`^G^_/3V-8EX6)#A89E]`'F#1045R!KP6.BO]CO;6%)C*KXF)SYD
M$5N@0[F`<Q&"`$6-]V(NG+-%BA2`L`][P+$Y`*NM8RXN+J_,CK=`Y6LL*Z!/
MFY]:R0*U44^L+W&=4%9O#\C#M5_LOG13KAV=^"OJ+(&YE<XSH\V8GV(N0R1)
M41\ZK>6JH]G78E#:?;22@?6'===\DJ8-<$"ZQ+O4%W-\3"K@:I`/A4M-%#/N
MN?179[F+A\J[RPO#1!X-`B#NR^.T8*=T20]__NK[\!@S06$N%75&4@$(83%B
M'LNE;QE;QK>,/9):X=BZ]1(F>L!`O,NK(MYG&-\T$'P]'1K0CG>'/`=W_)>Y
MYR?':QSC8R/`M0G&FLC.#;('VJ47?Z5@N/\VXQ2,"%C:L,!-9&YA,=:CP;*3
M0<EU\L+!VOVSQA4/0PCJ]E3R0P,^>TZA84W7T_+B4@WG-I'1KR(R^G5$1GT8
MUIK=%V)6#&`7/8;Q1/TV+#)@<647&GPT=\X054_^ZJ/$UYLJR7'G+D_J\TCQ
M-KU3@9#Y]4[$7T/O/):%]<ZC`<,N*$)VID)S7PS%J*[=:/B-1AJW+\GF]0["
MJP9L1B?*686'.S;Q8L+37T5X^NL(3X?%!N%:B-<8-H4XX?W'5C7D/B"^DVW]
MM"Q6F4N)9O71`E3#DS2SY!B^)1<7'8M-0+.@[#CMT:"/IIB]?NRJMEYVY*>3
M@M6L2RR.`OXE!+5\+.4$M7PPY035%TC<_D*7QVE?(2$_67!?D)Q5%ZI)MTFI
M9^424EH^?')26CY^<E(*\1/E.E3=>*2[T@!YMRTK+%:GQQ3,89/E9ZU=-YD^
MM,;+1!PH*[Y\R(&RXLO''"@KC\;(!Z.PB->:/AKK+D8DOV18MG^T>=NNM?^1
M5$EQWHQWD\3`7_)EP@PGL>7C#">QY0,-)S'=2TQ&O)>8+PPY9X7M0MB(-"MV
MT(^`?;',A0\D!I$P-5'8/!:,^5;)K+$G;72SJJ/NN?P%ZC@R-]!Q+DV($[D(
MM4C.=1?DIQ6$@U@#P+(B9&2M-YL[]N;<?(78VV-9./;V:(QZ,,RHOM<@ZM3E
MG^7.IH==4D&J5.YJOV5F5[/&"(H'2N9/ECC]*@*C7T=@-`A,N2:Z3F!^1^8'
M6Y0Y;F:\/]@BQ1;)I"@@R6UFEACHAR=E?HFA3UA>8A[+PA+S:"!%,ISWM8DN
M0?HN;)<VY7#/)"O`!UFR!6\T;W;;4_0E@AMIA$/!:;^ON9S@>,"RJ.!Z-.AO
ME.SK$D9UHKNZ2S]O%3`*E'R!P,8W(Y@<:>FZ=6Q^;>P>'+?KNCVUD]VNJ&_^
M.^T#;/?2W!;AE6TU#Y;[YK_S<6*/"`&N;:MYL$])B_T;YR^_[Y_CYN4?9AIN
M#8UNK7W6Z&--=C(.50`J^C8)ZMN\WJ'O2%9M60T"*9N6X$ZRE#Q!++7&KI]R
M'=HC9J4.7Y;!>C!-PWJ3DO5-,@/KB/T#.YNLNEZ>8:=_#X4M8)=;CFZC5(6#
M'U*$_@W%3>C?P,WYE:^G`!?K0[YW-&'+5MO!@21C6Y<OCEUNA[B-3A':(1P7
M?2N7/Z)1=^6$T[HJUA;:WH>$/+L<MH$<UE:NY=2GLO/3RL(I"C5HX>'^/!&F
MSNTAF1*85YVTRAV*3=8VPO3]:*BJR.4W;`%::=\4P4(U31K316$0,;>\VH&,
M:T?&H7:[#_Y)7[PFKK<RJ?`<4S,_J2(.W7PL-)X)XS=&BK+*W=FKI&F2K'";
M)*XSQO'4";MMW<&EYMJE"O!RKH=G?E)U%+251CVM/K;UAN>8V=VJ55!W<NK*
M]LU-]"@M`SW33<$WH!E.FV-TYH\/4-6):%UEML!&NX%E&QPOG%\,*O0JQJ;O
M512F,QJ/>)AKT$^+S;1=BVIQ7C:YD3TTD+.H%.1PUE+UK6.NLN?:=-,,.^S<
MD=J3+8TE/*$0X>2PX0-/R-6I?1E8D8&I.>F\(DCXK`1J8(\G<$&A:!4-^"!8
M;Q'BD.W6MJC;<P_7.O5N$P/3`7W;"`T>TR;5O'$9CP*B!=F)A^;[^7#'V2YL
M8>93;FX/>5+T[;K.0^7)L?6\SUF-!]5AR==M`\[L?.?&]&MQL!0[[6]M37/<
MM\6^]GS$E:WA+[2/8R$ZGSH'<U.(SL,1$7?>QQM?'P-_XYOJU^T)(!_E=`W`
MEQIRYQ=/?U9$BIY&=XTT9IW&9*W2=$VW$$S.:[0Y#Y2$2@`_:SBZ$<=PMI)V
MQ^Q>E,79+LYM>&2/9TD_I_A@.LKHL+ABJ;O%53?EGD!>L)_7F%-]05AR7ARL
MG]UYI>3&H=6`<5ST*U.'MFW<='#=S?T!B/E77C@`!:$BZPTX$_U9HN'>3O<%
MD3K)\916_PD!K"IBO@0K%0]US4]G.//$I9%]?AQQOPFU*=R)AF)X_/W8)O#N
MM$B6V^XN'&C$\QJ=29F=8-:?>9+#Y)/+84(_$"T2.?PPBR/XZ3CXE$.=_6\!
M.ONS3HJIGK%^]>9ET6S=J0%W2B`A1PA7NH^%'(EM\[O34SJ+1$YL<-ZI+Y!(
MZ@^]=8=N!I^Q"<%&FVYB/GSHR'5']OP;2R2>K/]0CSO:VU$;1?VR>EV&,Q?N
MN%XZ.'/[X^.[[ELE]4MB'S8/R/6S@P184>5X;/OJEQ3T\$L*GT0&5)$HK"G5
M%[XOH%#R"U%(HKQV=1A.#31^C4*-?4OBE0$:QYYS"I'[&("@$Q@DU7H40%')
M1P$@L1Y'$5$Q3F1,Y3B`H?'H-SE>,>H_J7$5@DU\M^,5XXR.3X0)&H\3BL;N
M^M<_'(1B<@)"LRE*(V8F(&+<_AV%,'C\:%RWN!ZGE#/<:!Z%$.BB1B$DC\4X
M!+BY"0@MZ`26"-.`48B8F8G9&C:A8Q!"3,A%..L]"L&Y&I^M$"P:UU,A0;KC
M$(I/<$QHSB=F&_$I?L00V8U#&*['5[:D?&*VDM%H8@Q.S3@=4M`I.B!9F:!#
M35D8J:=LJ8RH&M</&=,)^R'-%(2B-!ZG0S$ZH<F*@ZV;@(BC<:XK8>B$\Y%*
M3&!1?&HNFD](3D53:T[%3$[,!:S#!,>,G'!SH!YB?`P-9(SS0W,L>HQ""`C$
MQB%@B'$-T@J_KS,*H?&LZ2A$),0$1"PFXA]MQ(0-@N!#CTLN8F+"JT<<<YA1
M"#"Y$W3(*<E%2O()2C5^SF84(IJ27!3+"6L9F2D-PGAM?"ZP7"8T&5W#^*J,
M!38BCD)`B'V=#@BPO__U_N[^[O_%`GC,#0IE;F1S=')E86T-"@T*96YD;V)J
M#0H-"C$P(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3(@,"!2(%T-"B]-961I
M84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U
M<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R
M,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B
M8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^
M/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*
M+TEM86=E22!=#0HO6$]B:F5C="`\/`T*+TEA8F,S,R`Q,2`P(%(-"CX^#0H^
M/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,3$@,"!O8FH-"CP\#0HO
M0FET<U!E<D-O;7!O;F5N="`X#0HO0V]L;W)3<&%C92`O1&5V:6-E4D="#0HO
M1FEL=&5R("]&;&%T941E8V]D90T*+TAE:6=H="`S-3(-"B],96YG=&@@-C(R
M-C`-"B]3=6)T>7!E("]);6%G90T*+U1Y<&4@+UA/8FIE8W0-"B]7:61T:"`T
M-CD-"CX^#0IS=')E86T-"GB<[+T'>%S'=??]O[M[MS=T@"#8`!`="RQZ(4B1
ME"W+LOTZCI,XB9-\=IIEJUBR+*O8JNPD6%"(1H``P2J1$D5)5K/E(MFR'2=Q
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M9_3L0=EN2_,1D[=3K5ICKWL410=3WS`EEP,UW;;Z0Z@X`.^#J#V(B@=U58<-
M5PRC;:=$\M''LP$=/>CH0TT/JK>AN1.MV[%R2^H;IN2R8-C>,(JE6U&W%>W[
M[=Z'](7=EMK=^NIAB>0CC[M^G^+9KC0,JMZ#6:W/VCS[4?QM-&U/=:N47!YX
MAZS-O;JZ;5AV%[QW0%>M9`!6*'J=1/*11P]`!Z@F&/0*[`H,EC0CT)+ZABFY
M'*CMA&<;RH^B:LSEZ<Z99YH+IPEABB?T$LE''B%4JNW^H#LA((11"/NI:6,Z
M"7#*&Z;D<J!U,YK6J?6/PWO`631L!D1<$=-4%262CSXA/[T:@@%G7,`WC5B,
M_KG$`37U#5-R&:"VC>B;OX/:?C2N36\<5T`&0($(UD0%))*//&3ZTJL_8B:[
M5P@KV<"S0C5#E_*&*;DL6/J`V=L-S\.H[U(;QF'!FWXDA%[$S!+)1Y^`A<W@
M>%8\`.'/$Y%YDR%D2^>#Y))@J-F%QAZ==UBI&=(W;8%B$G&27UW*1X42R24@
M%%<$&1L1JO.F1()T&"$!O70^2"X)4GXEES-2?B4I1,JOY')&RJ\DA4CYE5S.
M2/F5I!`IOY++&2F_DA0BY5=R.2/E5Y)"I/Q*+F>D_$I2B)1?R>6,E%])"CE?
M^0T&J8I:A<@6PIG\)!'71P+.B,@.",-<E&NO$):8,(6H,@O#!6LI4<3CX)8B
MS,*GB@FSB-IYJ3SOTU?\44S'*-D.(5Q!/R7>?>Y+*9RJ**(^B+#V24(CXHK'
M[$'!>4_,@2\^3=_4Q1)J.`9?A+YIBPG$M=R%`^=.9QQ13JHI+LPQNA27I#D4
M5A-\9=YFE7QS]LNQ"Z@DQE`(T;-%9*2D!L-TZYR`4,+T7F`V#C_?VAH7!O^?
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MBVOR^/8D`F<;J7EZ`L$YS8CEA-G%'^L^]*2Q1(2LP1!"+`6DC::@T*0@RC%8
M)@.8C":504>7C001I[Z&HV,5D.TWP_&(SBE?++!4)B$:%*B<MJ@M'K1QLN-:
MKQ%C-!V[X/!#B480#AK8F!0DN?-$(C.I+8(LR8CV=(@$)2SC?*\_)TQS,34:
M,VN_G:<-?XS!\T\GU9]0$!_4'ULLJI^<3'8<E@!'OW'QX()[*+TOAA-S%Z.@
M_B](^96DD/-V/DP6:TV;1XZ:`>S4VJ,E+I2Y@"D86)@0)>&$DQHFC7"G(A>L
MF6@-5A>8Y082U%P!6K1`TPRWY71NMC-DX)6*>*Z/6_$YK5/-\K2QD";R0@&'
MIKW&8!`3/+C.%7,DL%61:$Y$+(HF7`F^5*F(FOCN\;-I"/'=SRE?";ZX6222
M)CHG@^PZ'D<G/B#^`6<S=:'*AWN$\-FA@1(/(Q'A^Y*4A=GID1X7^=1M101F
M(SCC.^_K:SV=@]_',7>*WNO)^@U$;>>=S@0)+.MMTI:.12RQD)NMW`3W<7X_
MNV[8P<7W,B='#1<5*;^2%'+^S@>]!FLOF2XBFAD+9?AG+)$88C%C4@DC9YV<
M^C]B)?Y)S5\O`M18YL7(MF3KU"2FV'S51L'FZ$S2/ZF;GJ'6[3K7=<*S8(\Q
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M)=+BH7G1<++I&41"[YO,C@1):4WA&`]UA<B9"5E/<FM-OU#-)$)F)#=5=Y#D
M7=BG1,8;LWIV0D9(![+>F8"/I6#^9$!E?3MWLXWSN-L<"6)BBAM^7!@GR&3E
M_!K>C1O.B(5SI`9LP:;/^C`EU-=.YI/"^\_:C04SIY-O_HA/.W.6;V%D'8ZK
M_J`S*C)GA'(R@9FS>JO\E_S&+YR,^.?22?9]-`1@Z]<T-4<RXIP2ND#83EV5
M=E]2R\5^?UZ0S?OSEDWAHPXW)R;2YH3Y7;)=1?)!_PE8PT%=:([D=[X021?$
MXJGW%R:$]6WN1C-C0HE$+=I?TY/CK(N*E%])"CE?^=7,72LK+;\QQX)9?7=G
M+@$,T!L-4!3HX-8IA?3OAL_BQU/9%ZZE&`1)RHONEGDPP@V#O?GS)&@9I&,G
M_E#I+<2?_2^<C'A#2=_(7,XYKY-`/)C?=;\I7P\7;&G(,_%!7YB/=&IS-7^'
MDS0$]NFFGBN9!_HO)\..W_W!$Q-ZS>5KC(?99H[$_T@Z]=I$I&ONW>)O?!$Y
MH+O`#KP1`RGPV;FJ^-D)N`LHO]'DF@U^+7EH5TZAG>_K5LRJW@EZ*`;*BPU(
MM[IQXP:\_B?(;Q#/'LQ*XP>=Y2[`KTXLF!6Z/\%Z#YT=H>@BD61=,O_\R>)R
M"TPHL9OQVHGZ&<W1I&F[&@Z<OY5^ONF1\BM)'1=JV\4WD46RJ/N4^8UH@9C"
MS[Y+<F:BUOK9?;S`0/.R9OR:OGG:JKDF<I)&L@BJ;]&;*1J/6Z,!34`B[&<0
MLQ"3F;Q0*F#QD1[2%>(ZS?UHF!:XF\\"!>ZG?WK(P'MO0"%EH0;\FL"D-H,6
M35J_4:>(Y9)HBU!F8,Z=](TD'<4B6BB"[J^"E?'/AQ&.9D:$>JTF458X]])O
MS^#E.W*,](D1OQ#.&;K@F^IID2TF,1>F%FJ-T'=\BT1"6_SLMTY'"OKNP&MA
M9XP3D/W&+`ZLLAF-YL]OP+_MI]X"?SFD3HKTT`0X&7&K\*=Q3J,+WHK2J,$<
M/[NNP^3W*V18BCE%6YJKBK!=L_DS>:%RPL5R[:.[+Q2G2*`4*KT9_EH!>Q7\
M"][E]Z;0:<L+P[GYG\.+4P747WQ3`50+2?$O>$6!LNDK^*M;Z/F:!5GF(DV\
MUTA%?8+,\D2FB*@GP_.HG"?IG]HBA'#<*"*:)W::^@M#5*3_Z`8@C77\IR$C
MI3`44/SLB<I(\+-S4!<CXDZV6CG-V5-!S8>3R)T)8HK-\NQ$5!O%G,B<UKST
M5)A!80V<,O_H?BKH`KT!AWG&5DT$,ZC\M:RQ9YBJTYOT.5WJ%'58YF`0QX75
MSXYT,Z4\'-4E#?[C$RJ/+$Y1!XI)NLLD+ZZ8]F>*,+2U.E)^)1\Z+I3\?B-Y
M8NPGE5=(3R)4GTUK[UA81!79@.]\ST[_?"]ITLQ2LRJ.:=-DL^^FA86+9])%
MWC0)R.02DM8)P>L_@['\?Q>&]S49#$7FL3=@>OYL8I$X88N*DMOAA#X3MY%,
M\3Q:Y%7S<E@6W8)?S&3RH'4*B;")F[\??*,H*W]0.-YCZ9L?C]D_F/,RW$#)
M0\YG^Z'-E#G%C^93:FU0/[:7I^1>[G09+>D.-!\[23*B"XN,T_PKJPBI8BZ-
MDD1B^":)3TC/G_^GBX3ZIVQ\+GR#.@L_/L\=`OYB9]V+>_C-74=P2IMIF@Y!
M6ZUAH28?Y6DF7NT6$([$:9S@+V2_'[:*0'$XF$>"-L5IUDVS&!9&17+N+'N&
MM=HPR8G11:<1FW-&Q!(1UI,Y2N(IXGFO/F/J_05)4#X5\BW<I[@=P)/<[QA^
M\U3.R%.V4`*^(!*<#'M,&(7/0P4URXF?+WR&,_Q-5S"A3+U+;])>YE0M8A$3
M^N>NHQZIV`[=<W[2]JRS/O9`KDB4O#^A92KI?!:9DQ.6./^UW#?CU)8"9FBV
MKBT2H:Y6T3PAQKAPO**M+9GNA!EL`?^`E9"^G*>)Y^+CIW`J,&].%'-WS!9[
MGH@:Q?0\>J;<C5+'&L\]$UT2GTS.NF;Q@IQX<BZU5-M[0B69QI,"TOJ5?"BY
M4/)[&ZNO`U?AUU3Y^0`7U_&WTMJA.I&GMI:^(S+CO!W#.J$);$P4G!!I\0BF
M>6Y(8;=MW#0M=-SP0QZ6N(0A(=0S)]F4G:/A//M:'6_-:3H0LOR9$0YU/KX&
M7O86M)S2%HN>F*/+I@O_PK>#FEW-@]S"*5%!MWOS;6JJ\T7"&(WEQN)D+R47
M:5B_2>JKZC^]D_+K$C/IX@?06^>3`!L^3T8:7AVU0&]!)OZ3;"J^]3PRL5Z?
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MWVEMR\F,;EHX>:=;()/O-8=(V/R37<A##@GPSTF69S#)SO/TF3/:2"%,!5C`
M'?&$,32CGF3[7_U@_09UFH;7^/HNK@EO8YKM7L=I83K-R3`&0FS8A[0U+5)^
M)1]"+I3\WJ.C2IN.J_%;:HDS*J]TC>+:3,Q7,I&%OI?S10Q_;T`&\C/)=C7B
M;_I<(EAQ\!/TCWS7I_&'*-X6.+RJS`J#E2I_/M)OXZ,/J3&^3RKW'L9NA\FL
MMR.W8R-&S'0=X)NY)TBX?D8"R3Z$;,P_)JSQ:5[1]-H1'B#/@\,$R\T##A_)
M5(341GT_Z?$0RIR?1_'L?-"E?69G<K.;;>(!D!&6X;;\Q3Y2CXS?=$-G-CI@
M.T9=QG'V.8RMIAP6Y)KICD[G#0N"I!(SZNFUE)L%2,N!JA:C(/.O\<:A16Q6
M.]*,!L!JQ]T.$AD:/D^_A$^CHXQR9U"!)4^_Q;/\9U[#/S@L9%-F?KU<'*,.
M#*@&2]:<\?L/U_&`PD'2Y/S)<UC(+I=\NO=3[^/M'1XS%I<`&?<A%LS1-KFH
M,[PJC&QI7N=`AA_)NP@:ODY74'2J@N^'DHN<U:@V=4B]$I7MRP];TZ@+0H<9
M>'L.4W'K;S45_5T/K`848+Y-I_^S7E7;R4B_-3SW=4Z/65_8]1(EQ5D"0_;'
M\6HHET8<O]WO7L+>\FJ]&;][W43E5@DLJ,`?A'N"?4=DCKK>?C_C&C/WTP:4
M9"H8>4F3S5G]&\.4-1YX/*NEBKXY\:YCWCS,1RT552'PG4EH2^F,PJ_[1[<[
M'78#51R=,9VN90=N<O\=W3DCTX@6%XTX'N$NK,^+W-S<S+)*\<['P^=>7RWE
M5Y)"+I3\WDU&(VSF3[M^QT:1@6=88O:159J>Y&#=DQ"1]$3<\44["^/"J_"X
M`+L-@_K[-UA.SF2*H/-:&"V?0"CF$J=QEWLQM8&/;58C,57X;4?N,).(.^Y'
MXMTT7Y_*GE^W6OY/;)&283Q\L[6$1_KVY\D^G&L\U<\"_\D',L69_.O2LH%%
MZU_2LZ`%C8DH9L_N;"4M,MS(ZHLO[.55RL&$^]-N%8XB(S(>?)\-MM>Z.4MF
MN^L7VEGD7\J$]:I"$;%-3QL^ET6?.UK7L5"\=3SMB:\AS<1=P*.4(UY0L5B\
M@[\C8T[MN.7>/%ZG1[GX@2V+Y.13^(W@@?_H)]UZ%%[[/)N.HU^C,EJ\L!D-
MW\:^OR'16WI$V$X)1";PJV_P#!K2D'<?R8+E6Q9=$674G;9Z#.'7\<D%EC1D
MW/TC^M,"&MTG$AS^0EOUH:,^2/-RJU\W<E=`VO93ZH.T/7ULIL8*Q-3"?[^)
M>AOGE6.()4P[/V%R6BU'V'XV_*PWA\S^^AXW=4FWLN<X<PT/0ZC/LK_TC188
MJ4CS:O_6_MI[6`D[]977'5;>$;8ID?7SVXSYK,!V]U\97CRI?)8>D[KXSS=S
M'@/'<?JY!4[J"CHJ3U#AAQT/7)$#-[[UK'+*C[?&LV$VV.!Y1BPEB_>]QTO3
MX4Z_.C_LYS.(QSY)!5!Q\R_Q7A1_8RR@*K6R3WLBW%,U;_GA0C)NIT3-5G"G
M[/H+]^LG>&^=3[CO^VK&I,`[-+8Z]_ID*;^2%'*AY/<69+.M=[7S/[CYZ[4Q
M;.ZNY9H#5,W]SD-+J.W[:,#X>WS"E$9*==L/Z6MIH1_AWF/V-X7A5-QV:]K\
M!62Z_(<Y)@Q_Q:W8]@\C])/\U]XR?@&&?!C^X7?6("\`=G^9)$GO+OCGG#=Y
M7*R;V+F(OFQTNQZ@0?2+^#N=7H_BV[5EKJ3_9+]UO9S-GL-);?3-:WW3?;,F
MLACO)#E`&:R+\E#H1'H5\$];Z#O>H+"1(,\--))^9"-C5!22S7P3VWTM-_Z4
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MYI<.<`4(^W3?_98!^1G4O[X@"F/"_:]D>%OP:99*1026;/M<I@G&CW=QUL+"
M\$J_B7H:PV<Q&Y\WT>.B'M,)$PTTIL(8_P>X2&./.B(S5#Z.7^Q1N0_Z:TP>
M*=7*&4__H7I*8-LG6>HMR\EFME-.3[XZO\G(=[SI:;K^PNG?6.[K42>Y*CJC
MYUXH*.57DD(NE/Q>#Y?1"'6Y[M>D&QP1RQ">Q$UI"C5\H'@_KV1`@`,%N';5
MT!B_,/<S^-X;>'(0;_'R>YV85=YE8]@5?9P5)A]V1<&7]IK"9W#J*12:7282
MBM^1]NK#T_B2'HM-1;C!P6LD`KJ7!\J08U@*RT\B:23O4"P6*-M?TD6HU8?M
M[_-L.\]ST:AV0IC";`@96!#"^!I_=_[?C)D3PL(.6Z&>$'IM3YQ"(_<7MR#=
M560VL:%^@F4M+2`0_0]2RG0VZ9'VQ>UXA7]E>^&?R6RVDC`<Y0A@F6?(\G\G
M]RK^3O$5/!`VGSB-SZ2S<I"IZ3_-GNK8]S-HW*RH:0._SGGA;C/W`S>;>!U7
M3!\0N=,)S6(,XJE;V'!UH?H!+7E[OP#%K.!.4@F]>`]_2VHSO[!NP"K\F`NH
MO&B!^SZ5LLQ+/H2#<G&SA7J-'![7TY]"QB#/@ADC(77V!Y0>&R4IR\!V>R;<
MI5"^T@/QO7DNNJ4%N]]!D/K06($VX6B;TQ:)_>ZF'![LH_`Y42""^#)=U^R^
M9@?\O!]0??Y;I,8Z4RZ>UV(X\&RLFG-UST*>>GM360WV[7S^`#T7/:]J>*'(
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MQS/USH`_N>9!X7%ZPG@#C\J-G^Y'((88S^+A#(=E,(J`*RKFO3C`J\ZH]WA*
MN,24-?(.VDV*X6K#?R:RUO&:8=V5`_E^3=M_^95,-O)1_!NA34CQUHR<:TW0
MV7%UEY/T//[RXB8:&MMP_4\_+L[P-/W$3KM9I<MGC9W`Z/6J`>[\M3@5<XL)
M#F2A[;FCI%J>NYW3D`7+,9%!1;2CC=WF^$:NF':)EQS7*&2RVAL/YFHK:0W4
MOP2U_<[LXO89R.0CE?N&2>="(97)#^G#J&&28W0H['_X:2:HG')SG_@5SK##
MQ.$3>9S]1[5ERL[YVPZK'`Z.]^O9!9>;.R:4Y_\//<P&2L,/N!C-M^E9,_]B
M@)TPI%V_OIX*H<*`C!_'>.W'>A)XE_ZJ`1.O\GT%GT4YE,RO/0->*3=K>J4;
M5E/N?+AVO(=3`]2]NLWZPL?H>;V$3^M<)K/N7]DS8TH(UTP_H,N&R;WW]Y8[
MS30>R5XYR@;_EWEL@AM^J;)$^W$J[A"/:=,`9MW=H[AO"T[Y];R6PV]-G'N3
MM91?20HY?_DUQ..(QQ1M(9")WFLA$7"M19^%>:9E>%5D::%TC8_NUUOU9.(M
MO/68YG_S*R2&`5%'C7&@387.ACP\QX[B[$@`@7=QC3Z'+-[!U^C*CKNI6;M!
M9A4O>?T]5I+\*K;[GR6C3IF.>K^A1SZ6X&9E3C@GA/[17E0J6=3H7IB!>!&K
M28K-;N/M^,.T(QE75KSGB`K+&VSW9L6HN<TJ8=[:MNB;I&WFK*+^',H+3ZG'
M,H7/%8Q8`E$VJG]UR&2#3K'@WWR8.66\CIVNQO%W,!'/O(.L0R7]KW<K?F%X
M/8Q?WF%+QP(2X*>%S4\6/IGZ?S"2V0ECYC7]96*.([!U?RR;++V_'C*^H,5D
M^^UX.B]=7IGY>@Q/_HNAD"26>Y/\-WFF7B^F5)%PDZK\^'KJ6"I([HYIB^5&
MKG!DT(C^*QQM+/Q6R5^"]T&L>C`S$LO0GH(I$<D2$5+C=%(2+:*"[9]M6(AB
M$L(?BT6\5HU]&@4^>D`OXXITNI;KJG[XA4>\S\KS'LG4R_A4'@WP[;FWZ"9$
M`W<6POB>,/.:MZ#MV5OIH2V"PTXC@E`"][)#Q?&9P<5B#HE(^JFOL9_#@NKG
M^;%:[J$2@.6+/7A3&`(S>4<;=&8=/M.7P0ODIO'LGODPV!QM.!7,.+6?^I$&
M9."A,)65;??'83'!NR9CFLSO,-X9;#'!;KT&OZ=:-)O5^>?L#"?#6H'CX&O0
M?$I6$7131TS=S<X_RX>BH[\_R8%'=,*7IRU:,TGYE7P(.>^(9X%D93:Q!X\7
M=^5H02!UUZ&0AN26E?AW7GCOG#Y64,VC[:Q/]FO?G\1D)),^/QW@J%;BERA3
MK%=N6,ISV2$]#>W]OT`9-7I=^C^]BIE1;E\N.);U.,*)_-<%=GQB@8W4[SJV
MN,C"6:!-<Y/UYAWDQ9]/;3384()LRV/:,/G834ORR`0R8?W/;&363AS&FE=<
M$U&C"*K:YF(;_81LU-AT^KTE=*%%F5_E+6-L,4:2BX07\`I8'_;<HYFT&7C!
M5R@.J<@W0E%O>!KB1_EF,CM=Z9_X#MV.Q$1Y;_=":N\DKX?.Z+;NY_:;.(&_
MSF43GR>VA/H.W>Y[U)^X<CZ'7[+.Z^YII0RZKW\!<T)YX5ZS";S.X,D$K[,*
M4Y'&]=2%)83ZU,T6AS7+E([')LQ^8=_QEVR-9]S*@_<SOU96V])(*>MZ##%V
MIY@^"/FK_R`8'?>,GW7QRA!]'IXY51,7KMD)^$Y8A2BGT?H3URYT4"]F1=<?
M2('UXMG,>W[.+IJ';JW*0JEBQ*V_H7X3XAG=K3_GU7I"S'O@1CA(FG)LO^3H
MRO;KS)S'W.OYN9P1>.[Z/"QF[^NQ&$)!?('-^_E_N]'X-A>[*K[?1H:SLEK;
M5G,<O==FT*V_]0-#0!B>O5;S4;GQ3-@3C"/XM)H.2]$G\>(9&A&4[_T\#P'^
M^;?4I\\71[&B/Y^W@7`E5*<YDGS:#*])-L[&*!<%<T<LV07X['UD&Z1/!WB#
MC!!IL7,'KI3R*TDAYVW]QLTBD1,-6;30*Y;I4^[UURXIP`*=:1Y/TJ>98$DC
M+8&^Q%U#Y@IOSIJ:6Z0M>;(EIDB9ZT6`C"7EYJOQY._G'8\EA^KN6,+S]^#)
M+1><%1MR[FET*MI:@F\]6ZPMT3=M_<S"/*N:1=_Y%FXD`2;IB^A%/%,\CRK8
MW;HFI".GV39Q>JF8PM'[H'>C",X,*.6W(7@\:T)HJ[G.N(*\HB"]9Z-SH8Z^
MP"E%6GHZLK;OI;3ED.B]%^39L9>>TQ?2$!Q7.)%7^AG\2+1^D;YI38?54OQ7
MV/!94N8E^3JL_W&!>-/P6B#SJXMH@&S+-.$INLNS+>S+17H!SZB5JRV(Q#`M
MC%,GT(JB8E[213<V_>($[QF9.NTH!W+-Q72!W"_3(-HM$HH6WFWA3X=`]C<)
M43;L"SY7<&OCHFQ>Q)M+KW]_6/?E7%Z*EE;@HKZ@^U#>C+:M3`A^PZMJ1?XO
M'EU=#/,2Z@)A,,)@M6%3EY4#!]&007/5SO@P])=:$;`OQ;#H'](3O$G<%`]9
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M3XNCRR;0<0==\+T8DG-G81Z#5R9\)A%U!(3>+ZQOQW%*I`G>!^>(")VV38#>
M+YF+6F/L*U"T"`/Y9X1UUI_,5^UQ-I;T9#H>%[PT-R[<H9,D7/;@-'CS"!\D
M1&W6>68&K[/E;R,S59S"A,CV1U4^:VD.TUQ*&63E:D'8YOMG..!8+)06X2RS
M+U0$C+Z@FS=NL'>Z1LSJ$X)NYY[E6;/BDR(CPD'5W-,A5=O`99Y@Y[F.[,;W
M./VY_TZ7G2Z@')T4",3SIS6KWN^CU+I(A<CT]?FT4S\BX`5L_->\B=GTL$@G
M6UV+89[_)MW:G\4C]PA=?.$KPA4[B9-"_[IPB'>-8I;S&Q7.5T1F>)87"?MX
M4UM]7)L\/17FO3-\8@7=G:?D&CDR)#W$^$)*ZLLQ1*,+Q4SV)!^W1+^E\EDL
M_(Y9S0;FR'7TC.:<O)N/TS9/"V?D.!TOX+3QKIP"'F$E]Z=$%D=$R2S=-(#C
M`4P*9:VVNYSTT0K;$LQS\.(*QZ>V4?&J,\+,*[&%Y;%K#2\*WH$NXKDBJCOC
M3_\C(9*D_$I2R/G[?@NHEL[-<>P4+7B@+GEBEQ8"MY*W,VB;L^;X0_NI$^"0
M#M.\\#(B\J)/&\B8N?'YA>)E];$?XIU$<K^#58OQR/M\YP)(1.TT].;8ACY=
M@+</&+2([@8^5BS.NT?IDT0DF<(2P7&_=2>U>XF$%II`X"0'^-)V17&(&X[7
MS?$9Z)LA^%CZ"GBAA8]/NSC)*FJA3N',)(]>DV=;<!L,<Z?`$1AX%UYNE&TJ
M9RR8)TYG<#<1X0]CT_23+&VCKAJ9T>)8BEQ>-<&K/C)Y%6[R'`W-IYH(V3E$
M/,G.%.^)""0P%=.RP)OO3-S73%-2U<0L#<P74$;>XBW83MXX%E?HAV2FB@@/
MM$-1IW99A2S_&!_$8V8[>3HSJ!VBQ#-E+'U)CU`AAUQ+)'LE;6;3S\N;DT,)
M$7.\GPP*RI'D]2^=L/!F#6UKH3_(.\5$4*4G\BMZ"B$+_83[K%C63-P4.8VS
M&WBCII/)*)<Q76(*4^]KD2W/1J6S"M\"$<QY/>G/$>E39UA.9^B^,QQC68MR
MEN'G:/F*MA_-.1TR<)JCR5CQKFF>.N1(#M3G4GK8`?(.BW]$I//DFI[L[SQD
MD-FN@\GA)IO[7U3QZQ(:J]SS`XB?9*WYOM;W"3-UT)S:V.(_$MI(RJ\DA9RO
M_'+D6U[>;SX;NE;[9BRJGR)5)(,J8M;,.<N+PG`ZN?J7=SPM>EL8)TD`#_-X
MMG4(A[[A?OYDL8A;WQ>FF3C/]4]]<`9$A,T\EPC9Z;>GJ7F>1$"89K6M"A/"
MXGN/[S@C%&I9<^PFK:??!B(.]DR&$9U,3@B2@>J*4=<0RQ4G>06O)LN%(D"W
M8_.5`T&PHC;/D&1%SX8+H'Y$B*4DOUKTFWF:C!BUZ$!*C'<':T[CJ#(]G0P%
M8]0VFME9E[1-&8)/U>00Z^$`!^R:8/>RD@AQ_)DWN$":D^+FT_9$\'A!TYFP
MX'T0H;"J#1/T0CML3@NMUL(B=G:+1"Y[U\.8\B?M=K>6-C5([]_7I(F#*MNT
M48GN@XCN)GI,L]I`@SNXF#[.MJN+I-OGU\="6N_&!:5_)WGJY4P6_807_DU0
M'VHG44T&E!"!`C[(B=Y/N,\>2TI?I@O.D5[E^+1!#1^Q-PMM5_A\LLSCTY1]
M`\><#VC>'I+64UIQB>Q7>`A`1O6"T`Q\/%;*"(GDP:PN5NE9S9ODS^#]'<+-
M,9P#2^CGR;--0UJO*IXU+`3VS:1KR2NA*U`OW[5<&7D[]\7A`O8/C^<_?;_^
MJ)_Z8IY.U0('Z44X+29WO4D^E)RO_/(YE9K/@42)!\A\=@R?^$82-\<[[O6\
MPU1;%#$S;0V31,P5!N,Y$9%%INSL::Q0LA<!:Q_-"-"(GD5,?R:D8_LV9#P1
M7BR""X*:H)T,%YRB(6?"12V1OR-X.W]`5&E./-.I,]IZ!C'_E3GX62WS-)O0
M'HSE^<,N31]P/#1?!!1MF5EV.)%/K?LX&UU&S<JUBQ!O28CP\7!9L81*@A9+
M'E>7C-8>I&PZHF&G"-JT0([.WPO-=HTK$=(3,5^<06(&IV/S1+3<1]_W9;U,
MIB!=+5PB`K8_L(>A.'@*KPH^\8>*2U-OW=R<988/P>232>D6P1E3(*ERPCD5
M<XEW%K/"QT!#`*$=L9$L"A%*/T%2'*:ANF;>!S59\VE&IK:)."1,,5979W*N
MC0@%]$%>;J%HYBA):*XV<:;%R>?P"*3G6?ZYY#$<9LKCK*:38H)DRGIZUJ#U
M!<;).1K:V+4C4S75C=J/:QU9,#Q?B`HRT5D#P\:YA%W+A?HN/:`0&=C4%[BX
M5PJZ^>YQA?1_.@HV@#D$4$8LH?E>N%@RM<[(%)S1[%ZN5$6)&8.8S-<<1/EB
M`M.S9C'I^F4R+'"L[IV3&4<WFQ1HL4#U^8H5T.6^]U+]6Z<1.HU5UH)L9/4>
M9&&GI_D6]^9DY^M.G>VVI/Q*/G3\2>M^#2)<D(BDQ^-G#^U*1-TB:DYN=Q7!
MDI@O)Y)TL4ZP6<COM2!@L:@U+G+"/$/-G[-'E-<@Y8?Y#'=>[!ID&7=&6*.H
MX6OS^',6?S#I6^#H9R*8K>W?3^-E;*0Y$4^$%#4"CGDEC/X(/CB4S1A(:+U`
M&&<B.*VIM_#K$K&TTVRU*C&17!M@)/OS!!M(#HX_$\<LOTD/:>M@I_FX9$-<
MY&J^:WV4K41[,*P%F8F[M94&^IBFA"&.\6X*G;VUE7<HG-5#B_`9IJB'FL,4
M9]FBK?3`;%SO3_Z59&<R]Y30L8+-.$/"I3EMRH3FLQ7^K'?I.W$S&>V_31ZK
MYZ>[6WDW@=!V-\>54^Q,2)IV.C9WHWE"+$RZ@^AK<_]U`!,9Y#&+YD:VS_IH
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MQMOEHB>5N0#2C9DI;YB2RP'5<T`I&]2W[,4G.^$9UF=8)F,<$C"YH5ARP1"&
MTS-)T]<1"$`+;LD1>U*?L,N;4Z<@(@M%P**=N&36@GZ8]%B2\H8IN1Q0:T8-
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MG)(+B%4[5"V2$#`:I\4)>R8?+NF&+.<4`R,]`N@L4!P6>F^BA^),`Z3S07(I
M,'2,V1KVHF0]ZA^`]ZBU;HMA:;=:\6^HZY1<0,+"-RU$9N4V<^FHNV[KNT+X
M!?T73WG"+GOVF.L>4QH&4?D`FC:XJ@]C82]6K$MYPY1()&I[+[P[4+W36+\'
MU;N4F@%[^V[%NS6WYI!:O5/7NA--.]&V`RNWH&:-M687:D=0WZ]O.X3&;C0]
MI%1LG6:5G3K7]44L'A6^22'L%=]!>9>Z?`/:[T?3L,F[S5+7@Z)M[H[=J.Y&
M\W8L&T93OVOI(5=-O^)9@_KM:!Y%Y4Y4[3+4/Y+R@I)())(+3,TV5&W3-^VR
MM.Y1&T9)(;&81@H#:%J/E@=1>1`EV]3JOASO8UCX`&H>4-MZT+B%OI93UI.(
M!!,)WX+V(V@;/>?U&^Y'T2%CX;J30IP68E'-J#[_F*6F!W6/H>4AK-X!>M^V
M,Z/A:5WFMD5%!]&ZP4B?+]SO;#Z`\G7I*\;@[8%W0^H+2B*12"XLM0.DO?JF
M(11O@+?7NGP_:H:M'4>4MH.H7N?HV)*[?-CAW8O%V_6?&$7KG:B[LZAV5(AH
M0`A;PQXT#Z/DGGF>?>>ZON+9;_OX%BS?CL6/8,G0[X68$3-1(=!Q*RIN-Q4>
M<Y;L<I8^C.);K%<>Q,HAM*['ZEZEN4M?UFTH[K/5DBG>CY:AU!>41"*17%BJ
MAO3UN]!`.KP-#;UH&J;!/I8.Y15WF;W=*-V*JD,H/8#V0V2FVBMZQ*1XG\2S
M9A-JAHRKUMHJAC+K'T)UY[FN;VP?1N%VE&Y?\+%!8^4]F:W[323F%3O$E(C%
M!)G$J+@)JS<95_\")6M0WXFJ851O99=(?;>A81"U.^'I1G5?Z@M*(I%(+BCL
M\BWO1<56RZIQ-.Y$\493VP%3TSZT;2A8^1@*CZ'Q(;3=,"LB0IR@5S*`W:V=
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MB_:J-?VFCNUHV(FF@X;J`;5ZIZU^&TH'E/HU:-F(VEV&EGZUXIES7=]1NU4E
M4WE9/UK7H'FMKF,W&D91TXOJ<=2/HFDC&C:@93UJN[!L#'6C:!W651S,*+PW
M($1(G#@E!,IN1?NNE!>41"*1_'_0UHNZ;3R55K<+U8-*TS@:=J-QU%J^1ZDE
MDW4$K=OYKY5[3=YMAK(AE.[37=F-IDY3Y</NBNZ30DP(L;CHGE2EWUC?:VP8
M,=3M16&7M:';67/K2SYQ1HA(5"RJZ''6/(;*$7B^K52,HGH`RW:X2\>=WL.H
M'47CM[%RFXZ$NGR`.XN./M1M55L'4+S!UCIFZ3B`\CZTG=-'+9%()/]=/'U*
MPZ"A>9>^?L#0V(_R+3IZK>]%VSWFYGVYM;WV!0?,52/*BBTHVZ]>,^YLW^`N
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MM-X.SUY=2R\\`VA?8VM^TMZTVTF6<\D-AHK'47G0U+H'9??85NXPMVYUM/09
MJ`12_8`D$LE'EK(A7<V(XJ6A]W;S\@&.M%G>A9(>-.]&RRY+PQ'+"OIP2%??
M,R&$"`C5N]]6-VZKZ$NK&L@E^[#P#GC6H25U,N4=()E5EHV@90!57?KV_:C>
MD[GR&2Q;JY;NL\T[:J_K9%=PQ8Z%S9M%G&3XC=RRZQTM0R@[C+K;D-^;>\U1
M>/>@_)OYGQE#V5K6\,H1%`\KY0?LWH=2_X`D$LE'E7/(EY&]HUVH66=8<C^-
MWX-"V!9NU3??#[(5276]0X::PUB\U]%\T-P\CK+AE*7_'-U';NU^?4,WAZ>X
M<AA%P^ZF!PW%!]2J@_:F0\?C(A8@'19NSQZT;T/Y%KWW;G?[8\A:3]G7K=AC
M6#7&^^;J!U"],_4/2"*1?$0YU^`]I[PK)V]CD`,OS&#IM_4K'T#=>I/W&;>W
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MY_F&R=-IJ3A*%J^Q:3=J-J/DNYH.WVNZ<@!%FU`^D-_^L'7)[I1EX5P+YSP#
M.N\P:C>@?I?CJB-8O,?F&4GS#J)Z&`U[T/:`N>%QM;33WK`.C>NQ[$A6V?CB
MN@TGPV)66TI7L/)KJ.R$Y_&4/R")1/(_!5WU?E0-65H&L?1>4_-./7U8VD/#
M<Z5I$+7=)L^PH_2@O7S<O*P?'9M`XB.W+6A8F\C6W61L'T+5.&K6O"H$&<.+
M&V]`ZSXT=UM6[T#UW6KE]O36!W6>,50-L(V]:*VE<3!WY3A*[W&T[+`V]YH:
M=J+Y3K2M0?L.U.S@*Y=N45L'],UR!85$<AE0OUY7WX7*/E0.LTWKZ3,V[U3J
MM\"ST]WX/90]@O8QM&]%\19;T5Y;Q2-RT^Y9"N^WMS^#BCZTW8KZN[!P=[:W
MYRU!?5(\%A1*[KT9GWP&+9VHN46_:@#5(Y::_5FK'H&G'XNWHO$@[]VHZ68_
M3/D>M?:0N>%!?<U>U(S8EQ_@#7IEZU.?08E$<I%1F_:A8HVQ8X.N=2MJ1\RM
MQU#9"\]]%N\0VK^#E5]"^W4<KJ'JR:QE.WP</4R&K&$<R[NQM`NU^XS+1E&Q
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MJO^Q??DAU'\-+5\UMXRA\`7[DJWVQH?L];=/B*DIX4?E+>:69^RE^V2X\K,L
M[D7%#LORG:C=C)I=YK:CEHYQ>.\B125=975=>C,I+>DMJ2YI+RDPZ3"'?Z^_
MD96Y_`E2:=;JRHU8T8_FK:A9BSK2WJ[TCH,H377N)!+)):!VO['I,,IVHFAM
MUJI^?<T:HV>3KG33^V+"+Z;>$4+?O@4U1ZTE^_.\_>;FS?*PGB2N*\8,WD,H
MIU'`&EWK%I3VHF2K8?E]CN:GL72/I?F(TK!7U[X?*_:QSZ%^.Y:Q%R)KR<9H
M@/T2,T)DMW\%-3LL[4\;VY_`TF&T'289US>.Z&MZC%4[4IY!B41RT6GZCJ%E
M`RJZ,QJ>1MY!9]G`VT*0ZA:5[<?B->D?WX_2$4/]PZC<85S>;UBZ7AY5>9;R
M^]66$53OTWL/&%NZU67KX-V,ZOT\FU;3S3-KC0=YELW3G[7J$4O-?E2/\!Q<
MS2UHZ<SXY#-*[KVQ(,_3I9?=ILR_);=M!"4[4+O;V+(/GEY[>^IV!4HDDDN%
MH87&T4,9;=\U>6Y]0PC2WMRZ+V4MZL:R36C>@^)!4WT_JM:EK]Z/)5NPZH@\
MJ/TL-</F98.HOE=?UX/*4;WG`*I&#?5CIH:=UN9>1\L.E-Z3NW+<TCB(16MY
MU5G5@,XSEM[ZH%JY'=5W\\JTYFZT[DN(P(G9Z&DA<EKNY@4/-8.ZYKTHEYN7
M)9+_@33UH+;+W-*'RG7IR_>A=!@50UC6AX9A4_TQ5_T3*.W6-??!TZ-O.X#F
M,5):TEM27=)>4F#285)CUN249^0RP?,X*CL+5GYM0O`.CI-AL;AN0U;9.)8?
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M]#^A+/]'>,;0<L!<>``=ASD64-/VM!6=2LF8ON4N7<L1%#ZJ-O4Z5@QQ!*'E
M?2A?A\HN2_VXZMF;^@Q*))<-YM8N0]-N%*Y#ZSJTW8?\>UQ-3YLK'\^H&H+W
M9V@]PF%XQ8NO^X6EH1.%VU'X`J\T:_DJZK]F7W[(5/]C%(WS:K149^1RH7HG
M1ZIL&3*L&M.MV,,!/+/6N]L?,U:L1>,`JK^=7K<M'!>1<&)AS7JTWZ)6'304
M'W`W/8BB88Z-Z=VA;^C.I>ZR1(N<V=##433KMBO>/EW-",HNNQ4I$DDJ*5^K
M:Q@VM1WD^??&;;9EO6K5%G/%5GB^<UJ(F:G9(L]Z9]73:37C:M4:W;(]^K8A
M"XUP*WIXST7M*(HZ>1=&K=ST>HFP>Q]2R@^@>)ACME?UH6PM1W$O_R9:!XWT
M7,H/\9%&Y6-I#7O>"@2%-F!9V+P9%3O0OLM>UVF;=U0MW8=E:SEB?+6FWE5=
M:!G@@,SU6G#F5&=0(KF,\'29FYXT>1^Q->S4E6TSEXX8/=>]*J)B5KBJ;\#*
M?K1WH78KROOU-8<S*P_`<Q\J>WFO<>V(KG6KL6,#*M;P3N249^3RP%#5ZVCI
M,[=NM:W<@;)[^/2BRH-\DE'-7:@>3KMZIZ%E#SS[U,:NO!5/&DJVH/5VCBP1
M%M,!8?;TZ:\9))GEDY**.CGP<OTP:WCC"`=DKMG&P9E3G4&)Y#+"\P.TWH;B
M&RWY3RYJ>/!M(5X6PE*Q$VU#F-_G6#SL7CZ(NCO-JP?,R\=1NE&IWV)LW@E/
M'\?;J20;K(\C\-1+Z_=24=W)9W0NWHBR'CZULXI/\-2U=!N:'E7:MF#^`6?%
M,5/)G5BZ&9YMN'JG8^%>4_U^_<KM^>T/^7BQQ&LO"Q\:=J=YKJO^W``*[[0L
MVV-HW<\+(6C(X]V:^@Q*))</;8.H&G/6WW%<B+<3(J-XG;OTX;2F`7B'L'H(
M+3TH[+=X'^'``M5KL;*7CWXH[='7]9M(A)?>RY$GJX8X"F7*,W*9T'80Y7V6
MC@.VUC$4;^"3Z^NVHJ//5#>,P@'3BNUHO4>W:C_J^](['C`L&<>R':@>4"I&
MX?DV*D><-8\MJNB)1#GD\DL^X:RYU=K0C<(NZDR-#2/&>KGP3"+YT]$UDMFS
MWMP\I*L8L7B.H&Q,:1M&RQK4;#8V[39X=ELJCIH\G?!\@Z.=KURSN/&&UX1X
M50C4K$'5N!:0=A,'ITUU1B07EX:1[+8;)^.\>#BO\7I]59?)L]M!MG3=*):-
M<1#+EO5HV("FC:@?1?4X6OM0M1UU`TI=KZ%NJX5$NZS7Z'D@]1F12#X\5`Q9
M/OXHBC?S:@22W/IN:\,PBGKA[>53)(HV\\D^GN>-E8]-"!$/\?'HV=X>+-S-
M06C;;D5%'X>E+;P_]1F17$RL1;<9F[^'YM^BI,O/BUOFWJ4N^(HN5`^K=7L,
M5>OTB_N7K#IB*#]H;.]%TSICV0/NYH,9*_:B9A<J#Z+Y(0[[TWY3RC,BD7R(
M:-BN;]EGJ-RK:QA6KB35O1>UN[,]SYJ\SZ!N/9]HN?3;I\5,4(B<O(TYY5V.
MFDYS55_FBL.HV,2A:&OW86D7!Z=->48D%Y75SR#O;K=GLZED(Q]FNF*7U?//
M)\+"Y_\]UXVRK::J/BQ]&HV[4;374O=`=E,OYF]!X2Y<\1"J[D7-/6E7/82*
MRR]LOD1R;LKK!E#\;2S?CN9^5!_`HC%=ZT$T=>J;[[<MW!KDA?G"L.1^U*Q#
M8Y>Q=M16^QQ*OL7A9ZL/HNBHOF60P])ZY0SX1YTK[M,MV^1<,8*J`=3M1_E`
M6N/N/,^.G/:CQN);3XCXM'8F77KE;:B\U=@Z@L8=N&K4O6H(B^\MZ7C8434.
MSVXT7':'1DDD?XRJPX;J\?3VW;Q"K/X^='3:.[KTI?>(`+<F77T/&H8L*P8L
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MUXRC;+^R8HNY:L2^X$!N;:^Y>1_:[N&0L][-ZK)UQI9NO?<`JO=Q6-IR.?7V
M4:>V$T5KC(T#.D\W2K;8EQ^R=AQ!Z?"BHH.ZS&T<3*EM)VIZL'H'6AY"W6/F
M%:,H_\?30LSY13@BLLOOXR,VZ@^E/B,2R8<&>\WMQT-")")A(6SEUZ%^''4'
MT=!O*!LR>;>A<B^'%FS=#N^(4MMC+=]CJ!]#E19^MG*40]%6W\MA:6MD^.Z/
M.O5;3!\?1?4.:]U>E^>0J7B74K$%=?>CJ1_+AM&\'=7=[H[=*-IFJ>OAFD,2
MW7X(WC&UJ==8>>V)&-6QN(A.I3XCDO\&2F,O6KK@[475N*5FK\FS%9Y.I?&`
MKFY`0J!FEZYIA$^(:.I&QR!JNT&CQ>I=ILJ=\-Z/]NW\>6,WZL><2^\60?%*
MB`-QZSUKU<9=*.LU+]N#PKNL[=M3GI&+A*UI`$N/FMK64<GHZO=RE,7J+E/C
M@Q>]ZM:,H7:OKN5A7A9;LP4U`X:.!U&])N4%<HD1\9F$$._$A>+Y*L_V>O>8
MEAU":2=JMJ%^)VB018.IRBY'79]NR;KTZATI3_"'!*HJ7&%J!KCRU(]R1:K=
MRY7J$BMP;2\:NU#?I]2-6^K'#=X=J-X.SRCJ>B6$LWY$*>\VUO:C="NJNBWU
M0]G+#SCJAO&)?J5\R-$XAN8QM72MB`D:&%)'EM71BP7?YB6^#0=1M==XQ7=1
MOX?/<TQU1BX6E1M0,JZN[$(5]>"CUBM'S,L?YUA>%[G>IK7T8>F]*%[GJ.]G
MX[!\O>K=FKFZ/_4%<HGQ'L;2@8*2M2(@HCXQEQ#FDG]Q+=^+IMU*PQB?A;1D
M*QI'E:L?!C7M+SR6^@1_.*"J0A6&J@U5'JI"5)&H.G&ENL3RRQ&>^WA$W#"H
M-`XI#0.H'8!GV$3=J,2[!V4[E/K1]-6/H6J/6G\`E8,H6&/U=J-@!RH?L9;V
M\;:ED-![OXG2(4=9KUJ^)G-9OUJ_#36=7.$KMZAU/8ZFP91GY"*1>>4HBKK-
MS0.NUL,HWH4E0UATT-'>>;'KK:'ROHQE7:[V?I0-H_B`J>5!5`UAR=Z4%\BE
MIFZCI:,3GKM0U>E:<5"_\":.+#'W%MJVHVJ]L7)[5NU(6O4>Y&Q26@ZAN"?U
M"?YP0%6%*@Q7F^(#5(6H(E%UHDIUJ>6W;EBIW:5X282W\'$G3=1CCINH@Z@=
MD!#Z3XQ@Z1K4[$3S/M0/I_VOHZA?KV_?H&_M]@L1C0DL7(NJ,5?=`TN:'Z8*
MKS8^:*1G6K0-#4/F*^C)=J%T0/7N3WE&+A:-&]@`KNNA*F1L[L]:_3CUW?#^
MX\4W&_;!NQ?U/:CN1<MA/M"YY69E]4CJ"^32HG@?0.$N\Y5/<;#*YA[V&U?L
M=K4\*R9/B8@XGA`HN1M->PTK'K$TC*5[^U.>X`\)7%5:;M:JS6&N0E21J#IY
M+G7D0*5I$#4CVCK_]:C=A,9]YH8A??$-:-X@82J_F;YJ!SP;+$T]6'R7KN+;
M66WW_CH@8M$`BO\&J^[&59O4EH>0OT-=WF5NW(S*;:CKPK)NM%%AKD7K9ET+
MC<2WISXC%XF:8779$4/C491UL\^A?!"5V_E4RHM==6O'E/IC5&-UC?=F+'M`
MJ=R$RKMT)0=37R"7F+)>%`VZ"G>7U!W49=V9Q@H\@,I.M#V)FBT9WK\+\X[F
MZ'&?L%9_2=]T7^H3_.&`JTKE751MJ/)0%:**I%6G2^[[;=Q&W:79.X9FLGX[
MT7#06+X1U@;`)B$L9B=@,:H91C5+![>(4UT6+M7@@L&E+@*RH!@L:0:H@(Z^
M7V*TI4%159L%>OH$9U\5I#PC%PL#99`RJ1J,L#ET5`[6>939]HM=;VG0G58Q
M#J4"#BYC2H7=3B4]+_4%<FDQPIDS+PT6JJ10,UWT?V9@OA59AAPCE0K5/2-@
M@N)P1!/"-RU2GN`/"515J,(8M`9*50A*!54GJE276GY;J0,=MGGVZYJWH7Z'
MTOR0O?1.Z)PB`@D1#D,(LS^$B,!,D-ZK/A^_3HLL0?\\`_&>(\[?29\[1:\&
M$7=&3D/,F83(%")'B#01U(NP/N49N5B$;"*R6,SEQ4]"!)>(A'IF`KE4I2]V
MO?5NR%BZSY&%Z<`2$<L6<\[)2<2$DOH"N;3,",P)JIRN.;\MQ/70RLPZYJ)(
M"'U(T">9OCEP)?0;1,"4\@1_2*"J0A6&J@U5'JI"5)&H.E&ENM3RNWPMR:^E
M8I^N81N\W::VQW*J[U0,K#820L15(?2)!%5CQ`55:7KC3,1(7:G:VR;XGT81
M17R6M3<BK"'^IHE>@W'ZOMX7@T_0LS:D/",7B:C0S7&KIU(RQ(1SEHO(;4+&
MQ:^W]]N\1V'ETA9S+#*10/(1I+Y,+B4BEBG\6K]/%2_!DDO"&Q&Z2(RJ+G\>
MFZ;7_\W>>X#755UIP^_MO:C+DBQ;5N^Z15V6*P22S$R222:99))\DQXR"4QB
M<"@&;(.[9;FI2Y8L=US`@`DA"1`20CHI0`(84UQE6?7VMK^USG7F^_]O'G\3
M0"#9G"=O>*ZOSCUGG[W7?O=::Z^UMH$^D.8[0=]/=X-G"%A46&"2)>'1D2"Q
M."UXW].=JCLUY7V*NFVHZM8[NN'J4=&7"F8;&3+^1P2B"EJ>2)V("1TO4E&0
MQJ6"YKV66Y6S"XY.*)4BJ@A':4)91(3:H)SV#I%Q58!%)<)B0\)#(D2"1.*D
M>O_/VI/I5\:[@$R_,JY&R/0KXQJ`3+\RKD;(]"OC&H!,OS*N1LCT*^,:@$R_
M,JY&R/0KXQJ`3+\RKD;(]"OC&H!,OS*N1LCT*^,:@$R_,JY&R/0[1=`&)S-C
MH20.OP]@.`2?4`O_;"*$LR+;-V04PA()6J70=*4(I8]&]2*@C-(U/K6(9M(=
M1L/T)W78GQ4,T8?4P"5$!"+A).DG"A%31OV:87J03R>$)A;&F#`(ORHV20_2
M",Z`T_H""A%4A>G^]!.^;3P[PT#4Y..;:.FRR"1'Q=/GJ%\E)2G0Y^Q(#"%^
M*/U$+81=!,W!";6(V6)A<TQ*\0A+_XW]U\M&IKVW_V_,//J]@CR,8UAH/?3Y
M38B0\;QT/8U1,*RF3A8AW05.JU'X`N!0_*A&<&:-B@4@8(QQH+X^)!+BPRU&
M:2AI'//Y`A*>L',BQ,DU0B20Y(S0AZA61*DE*F\P2P0-DV\9PX(E,.B#%.0_
MFQ\=L=`%/@%_F"ZV\D]".I8ZH??2'?Q\PPGJS[!BDO[)K4H](R2!#.K.TW\G
MC9.2O(W&!V*4.81^*_ST7X5?*`/4MB%JMGI")(JP.BAXF#Q!3OCR"K5'E(CS
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M'</(F$&(>9-^BPC3AZ(Q_I.):"<8GW$B2T132`#",83#\%_F6V,HK`M'TH4H
M#`<0XQRZG&!`1Z+H\5%KS4(D$0E/>N$/QM](_3=R9E&)_I]4NQF*F4:_5Y('
M(=(F/''VJSS+Q**+7(ISET:$$NB_9WBAS!8A"WWO(0F)&B(\NVDLE!X_O'P'
M!;T@C35_3\P9X<^<A'Z.KDF*?Y9F=Y[/PTPX291(?,A#;!D+*D4XX4U:N*6\
MX)-^5@!(2$1\\15JHHCX;2,38/J-$(=H^)X>^J="6IWIGEJ2&9*BL'`0U9_B
MOQ*'YXE`@L0D6E(2@BR'"?0*IV,&UB4"F&0I-4P2:TGI\U)7&,_1RUZ@^YBH
M'RZ0''K3_[:RT\\M,6I;E-/M0SP7B'OMXF(&O>,;$?AY@<MA3@XD,=?%%$$O
M]T.(A=;D&<65^DUZ3:.8Y/4E)%*)S'E9H36(B/=R)Q"[TE]GA:*L_P0F4GF=
M$C:>N4(3XL;;/>-*J2OT4C)UBM1C5OH@7:.F!E/G1"+\<S^UGQ^MDEZ*KM'3
MI/--VL,A8WR*R?0[-0A(4XFH4B@GZ'.TD`4IQL,A?'-(L1D3-)N*/1'2?_1_
MH'&AGYPS!X6!M!UI-J6-#<>ECL2`EU<Q:8WZ3><B],-$SB\6:>,B5?JG6<2L
MPC^'^)FHFSB6I@SI2R1@$9KU0G7)R\QSD<68?I@IO&DBG"["YI$@?6^5U"K.
MS!T91XBGOT%:D;427=#W)-[))-LD-GZ_E"X:!ZM)B*<\STS,-/J]HCSXYGKY
M3[8SK'KI1,0ZQG/3*CS)9VD(QG6G1;Z(&$60%#R\*MD=(J868\:8/X%I621%
M`WJ?2!_G%'+ZH7["9Y8&SAR9M$K:6EZ4[N_)"GDJ:#V5%O'\,U[S<!0L8"&U
M""J?CHOK&Z0,Y$J,8651"2O\'D0CDL22VA!01$G]#I#YD\A+\XC&1Z\6LX@)
MZYO\N#RZ,RO8HTQ?L5#A68E=Z6[$O<-"$6;U+YF8\*+TK"@KP[-)BWYC@C7/
MD">+U..HA][([N7EQB1.6<?I_D%.%0^1SAP&9ROSDD$*PRQJ@)@H&:?9,:2F
M^4(8%ZK`*"\0DY.:`*UNP63ILA0O&6[2`G2E?O-%\3(U=4)[GE<-*R\TQ+>1
M!!'.C7J8=:,QU:B7=?YQ'DWJ(O5DD+56/Z^AN#@2?TT325IP/''"9Z*)/#$A
M#64,W.P@C;@M%M.&:#[&5'RE2/2%=*0%T2(2I;G&7Q*?)XQ+6=@R_4X-O)E$
M8@$O=;Z:E9D`=;)Q?!B!$[`I#2:NP`6]`V^$L&99HF2;L+*Z[N/(NB'ECR/,
MAT.TFH]7^L=3(CQEBN[YE]0Z*(S@*EKIR$J'/0%<2*OK=P;)?4'7I+\:39<4
M@]DL:4)Y\1+]U^KC"662I%?+JJ]D/85#<6%FW4"RYHQ1,NM$`JDEX8!!4FE8
M2:/U>C(L+0UT940E8K9X"K^(_7^HF/^JF/X.G^'T>P5Y&#J+FY#&E<&LT$&Y
MYF&)(<=GA=DU0=Q+"[%:O`9O%+<:RK_P0ZYE(4UA+>E=1(^DK44\9%+1,DV*
M*ZFF2A8`6I29_3+91**U6U@"ES5>YU([BI&6H`<,%:DZY$*=@NS*Y;K7N=.,
MKTB*F==[V67!5K\'E[5W)ADRR>/FMI+4RRCK$@FL[TVD\Z^HAX<TGTB>M?8G
M^+=9V/$S$ILL$=,%F56T1+FDY`>XG7.%5.%!7-).2$+[0GN6!GJ-EEY?G4B]
MD`"5)B,368L&<8FT%#_K$LQFI!F&0&TCWF,N#3+57V"-UR`FBR_%<)-.>?<S
M&1(9D@YIHVM&+_);3TK%$Z[8;U')'42_"M6_>1Y?S$#+T:Q`0/JA%SY?7)S4
M\=OZ)+]$,!C7A^E%TL*244.:[:A0K$G`O8^JXK-)\B^1"9`:]4FOSPIYJHBF
M2FW03?*OBD18QQ,G&I\^R@#W1I),OU.#\31:N"7F5/BI\ZEO1[#A_AR::+O]
MTH".6L5;MG].,FB!XSY,3.+?,@V%T&B6X*U`2H"$7S*R)+,Q\<(E9I*A9Z%5
MX.!K-9)`DCCI?W($/[JHB4S"<X8FFH:]<%[]!?H3JU))+"WCK#]XA\C.C5.T
MGB<CL1,)F%\?.6L0T02:I#%J4BR+9";`CK)</ZWI_E32B_X/K\;,PFL1'M/?
MR%9Y67*B_W\G\(S!C*/?*\B#PH[>U^/.!ZOX:>)B*.:N2/JK4(Z,:7E]Y)EH
M)NMC.9`(T^KGTL+#]3Z^F/7;&"F*K)W.'J87'$H(>^.#142A&_(0A=*?4H(L
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M,D)6$IDYVO,>ONQ;LTR_\-M$<"Y9;<^O`3Z'\V3?74)86D-%-$NB3:,8@^?'
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M]I80@9]A5<TH49E!XG!+-&P<&\58]+)_F`Q_X4ORQEU5IQ*70OO]/R(2-8VP
MO:^4UAKBX;@];B":BN]834A;4:0;B$G'2S^P'QM-]M$8O8$ET/0-2V(Y.7?[
MT026NJ#^;^Y?R0U"]I<W08R:V-$Q+*G!(I&7E9-8I-$L>P[L0XA*!5<O%0M1
M^.*H)+>3"5?L-^FEF(=I,IY!(PRW/I5)HC+L407#R8$)HR3Y.B92NC*0+IF6
MYKCS+:Z$C(]2J^9*JPR)7-)X5#7)M)QTV:$=B#?2(OEP%/QJ$?;/1.-%\)B*
M\T4D3?+U:3T!E4R_4X,8<2Q9(BHQJ691.6>[.=>`*IR,T4!D2V:7EG?9A/&E
M+L5OQDHBT@"=VP<L59ST*ECI#:I$>`$9.*1[L`5*MLPSJ2I@TVL6$;,&!1X<
M((4DB^XP(M*'!2[$V"(C`0M,JGP2Y?J&:)1-I%F%A?:"4,>$U7MY@R9-Q!(F
MPJ0.:0)"->Q)(?$8\L6=#$:N11G!ZUR7U1@,2Y$/0C,\2AI+XAN^)'K*^&6^
M5?P7_4:GO;=G/OU>01Y.T<BR:I1$_,-^45&V\1_4:LPY-9;\FDA8KU)^_G%F
MF/&SF`=T_':^\&O>$-K?2]XA$=5[A+29Z\\->3)>CBK>XCMHA=]^P9O"#$`V
MD:AZ@;^TB8"=GSN!5P=3%3#]/,";!6RV3%(OJ??<SO7/'WXQ[=)IHNXY06$<
MDP)OZ(*)((VOE<5O0G^*M]XRQH7Q-;YGRJ5)!+S:B0#8#4N2=A*?Q-R;]J@O
M"=,;T<0(:1$1HT1$:=+>+H?6O,R>59QE-B9[2G(L\.N;^*\OX?,*]#POV0(1
MC?`6T)+!7IJPUB/T%R4W<D!2)*1E)4MBMEE#(N%E$NG7-4N!FQ]+B;$T5@9$
M5EC8I.@=8S1J8/?O%?HM$,:HT$P(PUNQ6>(EO5-G__:C-&J*N+)!*U&`U1O2
M1HRT-H7H7>(KB#`-\3)A(R*]%._>F"(<8^\WKP4T9?RL68D)GCYO!ND:W6D/
M)#^,S>LG^K6>O)!)3.Z]O`TW>_QB_(-:IM\I@FZ(1HWL.'\N#]#K&4MA^N@>
M7@W?I'\&4D3,$(ZFTIH[QN$0RJ#D8AW:#'PRY35ODF0<F8(1^,(F$;6R+VYB
MEC@.C1;;+B20?'I$ROW?)I)133Q%O:*C_W7^T#3^3#K,-*?+5_\D+S",3Y=B
MU:&JK?\(/9R%7\!KHE22#?U+QV:5*&"$#2J#%7JS&H<?+LY,@!6S>OMU?W@#
M25"J](JV/0D3?+UU[S;-;#5L*CZ_X52$>=X??\?HY0TXF7[_9_J]@CSX([,\
M=(WDGQP.)HE1S:O[M*E`^RDL8S\HTI$&A?W7?[!\7(_O/X&^ZV9#8:[Y'B8B
MK./YA8Y6P\ZEL^UT81*^UDKW2;[P^_22/#S07?+OYH04X)<ADT>*D[DH57T_
M-9"E4.-Q[J6T@$?2Z***Y]M@-.&;3\X]]K](+-*0IGG.;Q"^U*\I,!=X)$JZ
M@?ZI7=#.D@Y(4:#V7Q'U.GUTP[#Q-W<ITFEQT"8BD_Z6MOIG6$M*PI/@]_)+
M6N50PKHO<:U[/8HL7S.*4$V\#G!TPNR1-I?%6?OYJ%F<2:W1H.--EU_8N8L"
M-"^28I-8^1\*$S+52OOW-D`*<K-$+EE;;Z1VTCJE3KF%'F02?[+<",VW?XWV
MC]$RHL[\7WB%1C^@$'^N^G@%;CMFO%*_*4&=;4];@#<BF>(%+-!IO_NL)$)^
MB6:CZF5?0#),>F05-.$W\;#`6/;S/UV0PB?*F$Q(LB@L6N"E$>-M.OMMCTN!
M#9$Y+'C!O,T?RS`C2Z''\C;0,D%+QO$.38:*Y#`SR8P77JF,")7D\M5&@QR`
M$8K*@6=3@S'Z;UA/R_<HZ0`TE#\%5+.;^NE/BJB/M$>2;:-@O4(="1F"(6TL
MIO4&S9>V`1\G`XIWXH8GP+O,/EL@-I?U%I\R\$PF']&26&R"+@DP?AOLCXVQ
M."V`[=:?DU!IQ$GEQX'/_E[7H@,+**S[7]*-_(RGS*%72(^=0S/]VSF*C?M,
MI'B<W&%(O1'/>_$&W?\TJF%:]2-ZJ.'"J.WS4'_]6:T(*Z.O)7[#C9,DX9?T
MK_3K7XQRS*JD#Q@",3U'=?KC%MS,PLRC7TTLH"3E\Q([3@WB&8T!<Q;NX2T;
M<9[:9AOE[XM\7OR^E<8M<=GC.#^,SP,KGII%:E7D`KZ*V;3([GX#XF@BD'7'
MR6Q)#5/MJ=<,_D4AHH;0&5P'RYK_2`-OT-IMD#@VC(G0;%)9R;2/B332`\_W
MDS#HGN"RY\5L/@>UO!'V=+(56-27(&(YG1_&JJ=(")D'CJS$'YY-);7<=P%?
M0=)-C[+C=_PQ(-G8?@YB-.$WW\HS?BKY*=+Z@NH'5]BA2R292X3I6\^!=5?)
MP]GU#REE#TO;9X\K28`[CJH\0CW"4I1,=Y.V@W,X'OZTYJ.T[I`>.)%T*;XA
M%<"^CRM6_X6H.%&<PC\"ZWYI$>.XX_/X>+N"V?4Q,U1)W_N568RBP8Q92#K^
M5W/@&,V-G,=_5WA>8`6LYD16[/?]%>+1;!K_3KI_)/-<#(.+<Z[K)_U9%PY@
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M/0B>>N=U#2;LN:"Y.(S`:[9Z2+.8+*97L_\1BP[P(S3B><U'%.[O_<(B/"KQ
M+.KL^/J/,!K+]/\QYQ,TD[^AX.O#I&DDLL=LC*=52!@CDB/"_[>0X)F#F4:_
MDB%LXF4KJ&+;X2UE&70?[9M[B;=X;.SZ&U:S-S6`<\]85#1`+QL"YZO^%8:;
M'N.(LHG?J[^$S.__V,B)-J\@3X^#HS2+2P(_A%:53J]E)<Y+R(`%_[(-8W]*
M^XC2<,O3&4*4T$/9RF;OI6(DG.(-&-[HU"F0_'-JR2B'O_K%`N'#T'K,UL[[
MM^<DN^8H9BW"D*]D)(R[%ZO."8F+@IIPP$2&VYF^1!.Q.[(/OZD5?S54`)M?
MMHH)$@#CZ%E\&EC?4[S4BF6/49\G^D(:WX]4I/7^XNP<,L;I/JR6"-O0B.0%
MI;6`W2-S6!D.6@-_,7Q*:U[)W]@C4CCNY),&8LZ4Y`(M:?86(!\?V62,'85&
M[QI@_T#"&"T!HD),JMYZ/F.A!FM^IN/^&46M%EUO2M;9RWEUP/<?*SHMK.(5
M38TU]>#/2(4N%T_R-LIQZH0AWN`>]B;^&VGL'5FS+?C^0W3/NG#8(DX4P9CV
M0V%G'XX'/_/H/P%\[_$FFATU*>@YG2QB"G$VX<MZ[(WJS[R*3QGRUSW*8C9.
M$^19';1*#FBQ*>=P=^F^W3GWS)NX'AFXKRP>MB'&RX,<<F8=B6B')#GQ163G
MPU0A-1SWV;)FJ/<-Z;^0B(Q_2.&XG8DL,3KK]U'=FZ*88\4C2I)_*4`E[=D-
MH#7^97^.;RR5_LD1,D3"?%B;GNW3WY`@8\M)FL4)P0@V=4LS.JKQOI#]*>!;
MOY>TT#=PHSGS_B=4XJ^%2U-L-ST-,6(\]R)N0N:W>'^9MX/7?C+I(SOHL_5W
MOP46LXIREK[_2_U-R/KBPS1!$L1HQH<T6/E(IK12F,1?+`OU21HEL!*GH]GL
M=@O'77"F2(Q/IQJ2`\_^)_J5D@M,WIB-QDC*=\.M23#4)_PIG,,ST8.7>:]-
M)R[,WG4GZ5'XG5<]\B+^"9KESR63I2PNX2/`5W[/DN!_,^7#"GW'"8G*CMC1
MH/T=?0A5#-%_Q[1!88J=Q7>`NQ_@N)>(SWK1&P]-,8^S)]9^:I#H%X]%4L6I
M7/J2]\ZBQB=O3:6^Z:&576BBE[+Z/IOPY9]DAA_"NI^EB:!BG(1Y0O6[0Z26
MHYDDYQ7]5S%WVUG\[C"4-CPJM*-!C?"G3KZ.:KWEBWVD2.*^'Q:=C=/^8\FZ
MI1*KCV9.,N56C%^TQ:,?I4!T/2GD(QQ2KA0OE"\%-IQ/$:^R%_0M,A(?XYWH
MYWG[C/<X+D9).<\0/P`:RUX5&&*GL>2FH#GR5O:B5'SO"$MU["^Z&[58]2!I
MMNGB!1)P]>V_3>.?OXY_!7;])N&"'Z,[V!5R@A=$"S=C",NA=6_`)RQ8\02&
M>.],]XMV:$SHDN8R;[T%YMQGL'[V`3)84A]HUB[HX7CCD9]#V:R,!(WBCUDW
M6/#M'Z8*;PJWYU@"_H5L1EY/_1R5G3\2-7/4Q!D5=0ZL>JRUBO$DFJVL5D55
M;`(0%?A-,OU.$1)\$Y`VU_2L6P9T3]RGI='<-BQMYM*@3[!GZ=*8Y<_]N/M)
M%0ND3_'J\;DTS4X*=50H):7%&`\)'@D7>@(FHM\$*/=YE$')52@NS@O%DN@^
MX?.V+P!?^!69166!OV8OLN$+)Q!Z$U\BX?T=AOT:<2;C<Z1'_:B8=(/8I$(\
M1[*7F4X6I!(GB)HF6,<._QI-&MS_*@=$B==0JL7ZQ]-&/4K>N+E$\I`B'E<G
M(>/V1T&*!!.+'Y<]#\(8\JJFN[=G//UR&B/&(EHI5,\8'</)[7:%#CO&E=$A
MO>0+3?(.P7/&22MITY$4]KJ?PL=0>-=S]E^?Y6E[`Q*_^8*4'7`*_X`Y=SR*
M":&(_((TK'F/TI>\=V,7%PV<.#94M%2#9;^L.\5.CXP(V_B\G\7)PD+SA_WT
M$_7#$@%*\;W6/_U4J3)CSM?83*,VQZ)I+^U%;K'MZY_$$T0"'@U?]E.RZ*U_
MXD1=TV_>PD+@B-]\^FG627_R9T=H7,E!$:/X(G*^V(TOH.C+[,7*&!_'^#,H
M`%:_H&/O2E@_XHNO!2EACV:"<Q;4'#W+%*3VOXA%:D6;%*PK10+HQ2^24Y#R
MDBCD&(D@OT*0WO&%)+KAUO-DJMM\GESI!,]T\1:::7EZKI`Y^6+B9Z'^VE,<
M,A$XI?]WD_G3#T-XYY!4?]2&M<>)/W.BOX9=E;;IF/$<S<TS-$R&ST*Q<8]Q
M/I+__2EZ=)F(I(QP*)WUMD=,4EJ$X;P?WU#AM@=HU3.)'[-B"TTZO?^3H]+N
MVU]12WW.&HX[*DP3/\+L),/#1-I1_5@\I_L2_2DS$H]5^S'R5;CI,9L0U5)P
MFI$7QR#O!LKT.S6X7#;!,B:20I.LWHQX=6N^"C,LG_U!/&`RB>S-X]LUG^Y1
M#4FG,8I+JK;EJED?X;VYJ%`/C\T6P[,F>8,UZ0*'X\Y]\1F=FL3^9/XYH1B7
M?%-GI4PTKQ_?,<]:U,64^,M!#E^_[7=&4EF;U`E?_XV6ACYR2E-IPBV/Y`9H
MZ`.&VZ'^<V3.6:&F==DK%&_RK2PQ8;I-AP^U)[\E<'K[W!(8E_V2Q$`9?`G'
M3W`;?A'"[V[6W'H89R)F(C2.H(A(&RO"$/&II[_#9SC]^A7Q_4J?,(1IRE^@
MS[,[5K`^V7>:OV=5]K7R!ACG?#=58D65_X]8I,6:I\F^2/*_BGH5OOYH'A%7
M]-2<&]3X]O-)L?'4F+!T_[,ANPS'Z"<D14_@ZVT%+YS&)PWX5S;_U7R:,,]N
MU05^"EDNAA_T,6?^6H`&>E3@5^TPP0J+^1EBZ8MSO%Y(!V3;O@*DW,,<Z!?*
M21KNG[H2H-[U:U+YS&\<U21I;9O_3']U_;L)LU3X(3T]J`R_E%2DQNT/SOD0
M\+6?D^*7$Q;&B`>M+J2M1#PA^N7QV6T'(%574,0"<X68,SPLM7`"9X8,"Q/P
MX&L%?PGK/'[.,@Z>S.BZ`;A>>9(=<0G$6G/;,"SL+1]#T6?G</C-<.9OSN/V
MS?;@)5NY&=L?F<-![R_B'XUI=[T,SB[\:W:!#IO_@*`7D==GU^I47W^Z+.:;
M]48,]RPT92CP%'>U[OEC90GU.;^[@!68_9U?*CF[D)>&S`/792,93WA-?E$V
MM#U1=SVD,)*YWP0>XBF<*?X$]GYXX3]94&&UW?$<+N\V"NVF2EAOP-.<Y0K_
M'W.:]E!KT_?^6'=J0D7",+C*U;P)?V#';P)O@/($M_EE^ITR*#G'4YA>]25(
MX;OZ<_3EJ7F_/9R0I=)!8[=P(+WYEBX6,^'GX*XOS,N80Q:1%BE0_N(G.5%V
M%&0*CW:$IT_6IAMIM06TF<GZ;-,_TRPVTI!)&G):3&@>N$F+C)0,&+YY<UH#
M9\:ES(,B'1H5RAY^&K4ZF(FY%?:?_H'=MK<DD<FHU*I)LN;JD?*/+<H1H1`C
M]B,K`(-UKM7]Z2^A'G8]##\5'!C_GTB%FA=[[=W*MRYQ)J:45<>QH-X`9]:/
M"IE^_R?Z#>@#U$L14ED3HV&C\-F#G!V3()XM4B$39IN*52T<.J4?(\(<3Y`X
MT'[?9S)U(+9,*E721;-TQ$[[\$]Z&F=U+A('QSC>U2?4GTNFP4DBB<+W3:,B
M\V9E"DF148F.$WF<3NY)%:$2$K-+%U(_-TN5A:2Y!NB4]#2[&;-SD;2B-6/"
MAU,!,H2-(EP4$PFCK^/,OOS-8_`1&X]P7&(D@&/_3DU)LD+YK[?@P^"HC-L?
M5WE"N-F<0Z(,_3R%!K,,*"8Z-Q:GZRQM/U.03OXJ#T?I_^+MP)0T9%>4II^.
MS.-"$*-F(2I)R^5@X)CVY_W920;DLDL`=W3-D8KMI+)A)<QW(8E^3:*,[]"M
M%A+/TXIP)PFD5HELM>U3]:]<TMS&IIQ5I4#_4W,^`_;>4(^<^(/QF^H*(%-G
MP"]_99D/WH,#TG:S-\]$<KOVPSH+4JAEQG\QO1(@U9UGCA'61WXAA>F>LIT2
MV/,OZ72W`N1C$5XE01I7>T7*UPW29.1$Q2R:DHL&C"OIIYGJ%.CO?1$CTL;T
MD,!]R*5FSJ9Y]BVV>2^>1F,RO<H\V+3X+K6A4$2T\3V^,"DP@70QH9?I=VH0
M4\1ST[S#"?$8PF$IM?^MH$**5T\;C?WM./B`A3YXI+CN,3]9.G,EWM:?#[+!
M-4PZ@%"=&S-)!0$4DY-2^"@'L<R34G(,9R_,)8..UM_S7&!$X;OLADWVC;(6
M'6`CSN6+Z,_S;J".\S(N9FSH(Q)(XC/0HQC_J^YSYH3?3*2P#Y!=<]8+'JDE
M_$_S28&S4?C9Y,SV"$FNHDFL98TA%,:DT/EB4AVV>/C03,*,H]^PB0:.Y]1D
MLF1QV\:9!-1,ME+5FE&1RL$`;`?91EA45%$OYU6%?*RCGN<J'SG2!H%M7!`O
M)5PD#<U#T[R`XTO].LGYD"<N)7/&`>FQO"=EF_2K([Z"L%3:;ICY/$MPW1[]
M>-!ZEBR74-$E20$^0\_E@F#EO)I[<9&O+/K&9_"'F"7&?M>*X1%ZA23_B('U
MYPL<W?J64(="6O::LI:83\V6:I>I(VQB6_TA2)6"=)+(&?FV_+WEI/2X89]"
M.E'=&@U(Q=:$)2"1,&^4>+-\7`S-Q*XYH1KW@!W:_&HN$3"*D2+VIOKU=!-V
M+$=P82(>LZ?BT*!0=H0C>/FYL6#I*,?BQC,]/WS.B]/4GBCG]5\05EZ/8E*U
MDR#72/$+S1"_$35UUD6N1S%;2N)6<,Z@L%)_TM2@F7)!J+P\:W03,>R]U\36
MZVDI\N<2/@K\7B3$Z[^Q9N*3BIMQ[<'T$6$+!4I$-)?-F=%$$=-$A>85OYK5
MW?"\H8#&3W,M:AL1J=*"FR+3[]1`LB:X>I(GBX;R%&<IIDE\:Y(R?%6A>(1V
M3!DGAQC)\"AUNY2AYH??KXIROB>11J*X'&I.`TI:@6E\TDR,%QJW<W!X2#T>
MKZ5S,8]E2=@B$\E,^SPIDC@_W:_F@!8>66+OY.`H7CH"U<>,;W"Z)=NDXSO@
M.J*6RIIIQ7G$)DDKT%T2LSF0WF<FE5B$<TDX`Q$;+R)GJ#T:$2\?0;_E6'HE
M6UN3T]W;,Y]^>2/`S.463Z?2!#Q-C8QF,[=$[&]P+05U*%Y>P&LZ)^PQH:7Y
M&PPG2.]B'H\1VQC9ZWO)=)J90>MA-C.$0F8A5:H<$WDC]&&$TZE(J0YR+H!1
M>%)(2PQ%I%(\7J*"5,YR'>%:BS'V^BHY#X[+*F;$I)*,?^'*/%KA-]'USW?C
MUJ,)(L3ARI*`V9G3)DVLP(?4DR)%!*5R7B.<F?N;B"1L882&,KD"9!B>*-?R
MXJ!*NO-8J@C/'6-5(4&<3Q(1$Z_ROKB%SD4/O,2]M#!QM@C-FBP/^\0@+F1S
M#(-P23J&+>!EM=`;E:247F?<QC4HV'*?.\H$RW&VQ-(AWA26ZJ5$.#J(P]'C
M=:*$@8.01^.):3IQ2@KCB>DG>`9E\_IUEGX[*S01KW*6$:9?!>T1WNSCWT9]
M]FB\V!%UNU_]QV-(6327MSO'$X>$XLU.7#\P3RKI`Y^4/1>,F2]RNI\FOJE*
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MR!,_2B!EE'T.],$:"BIB<0>%4`7#\2(A5S=D^GV'D/;BJ=.\DUQ4)Q*$9YP,
M^<SI;]C,0$AH^/@#UF344:%E?S7-FI$IN[],O]<DI*Q_Y=^.H8&T&T@JKCH4
MD8J:7L[)XG),-.XSL(;#VX5,O^\0H13OB%E,9O*&FDB03HO0"-]TMVK&8#)B
M"_HERA660$#MYZ*L4]D_,OU>DXC%,UXOEX[D'.&0#^%XK0;>.E'Q/K4G?HR+
M\F^'H5S%D.GWG4+-]1(C1A%3GKN$L[P=8(M=G/96S1RDBXB*)H['`Q_SI"+"
M86;)4W5_F7ZO27!9R"B"EX]ULXJP*<I!;NE_*_/+M=.E/!&"%!\UW0U^EY#I
M]YU"%8T7<V8C2.45VJ@4Q3K=K9HQ8!\=B98FPL?&I0AA/^.)G^0U-9#I]]J%
M1II'')`3",4]#%JBW*"4:OJW"_ALP5!PVIOZ;B'3[SM$:(XWIN%H+JZRGDQ"
M,NI%-##=K9HQB(7B9V6J_2%(9R(KI=K7]BF[OTR_UR2B?,QQ-*HC948Z@I//
M*@H$N5!55*B#EP\,4H4B\0K\ENEO\+N#3+_O$`%=4"C#TN%QG,'!Q&N=@6?Y
M31^T$^SIS1*Q66)"*R+:RP=A3-']9PK]5G:@JE/EZ-?4;47M:C0=MU3M8/KE
M8]8_2!#V8%`3D,[J"@>DXX:EP[S\K*_.B@F%=!I@OA"F2=ZS-H>E0P^)>:3S
MQ/F,OV$O_%S0<KI?Y'V&3[*7HRF<*>:=)4(9(P&D:O&>RVW]EJ3"]D2-C:W4
M\8K+A[CQG)KN#I%Q52!^TO2D)#Q!D""1.)%0O<_TJW(3X7>@HD_AW`KG?:@_
M8G=NAXK697R@P%$*K(XF20<CZJ0#K)6^2W$+R"J"V60-^2;B1P\GB/@^]>7Z
MYYE<(>HBXN?,3ON+O-_]QH?;PAO22RDD1CXT1VCT4+[GHEN[T]S0`QTX^Y4C
M9L$5=X/3WR$RK@KXXM6_)>$A$2)!8G&JW?E^TV]U&VJVHZ)75=D#YR;4'#!7
MK(-JQI7U?J]QT8^(4`]S,7S%I.!249RX*AT3</$BO*SBVN(GR09\UD`,GD#F
M>-`:$OK3TMF.G,DHN"[*M+_(^XP`KU9JO\\:%?",Q4^5G6=Y[YT/:'K6X#H,
M+:1C=*2CWL-6X9?3%F3\?2!1"5NE#/1,$B$2)!:GIF??9_I%U3;4MJ"J3^\\
MH*KN@*M?77`/5/9H3/6!`D>+<;:X)>I7Q`)J(=)C7G5PC.N,3?J)=7,"(9R_
MB*BP3T1L7J&0E.0LOY^+A(0B*J[$&[;P'LITO\C[WF^T4NN\?KODT^9#VX?&
MM(GO@_.AJ,V<?X\M&>>]1+E9X3#BI^).>X?(N"H0EQ86&Y%%(D2"1.)$0O5^
MTV_Y#C1LA*-'[SABK.U35'>K2NZ'S:50*3]0X'J#:HT*2@4T:8FSU%":E2J[
M4JE%ME%)(W7)!DU>HM8$&&#4*?4VC94N5FFA-$)M`=10**`"IOU%WF=P_48E
MH-%!K5+`K(#:D$#D6_]>RVWRHOOL)<N!,H6)S]<CJ-790.:T=XB,JP)<MI($
M1I(<%B&4D3B14+W/]*NNZ$/S9CAV*,H/&-Q=BNH.376GIN@_5!5]'RB@AJ,^
MX.S5+SV.BDYE3:>^=BOROG]13,[-;?-X15B$QL9$0$QZQ%L9LUM5U?O@V*^I
M?1!E^U"U%Y6=BB4#:-X^[2_R/L/NWJ>HW$JKML9Y,*7A25/E?N2O`'7=>RVZ
MCCY5Y:%$]S$4KJ$&:!N[V8U6L6;:.T3&50$6E>HV$AL2'A(A$B02)Q*J]YE^
M=:7[%`NWP-V*\KTZ%^G>VU"[3^WN0&/[!PK:^ITH7`N:PM7MFMI6%-Z:Z%YV
MFNQJ5W]";8\J]SOGA!@2PI1R(#7_J5/"]Z(8/BE$8ODMA;4/)N4_AJ1=R=<_
MCI(-T_XB[S<JUZ-Y)YH[4+43%:VH:T'#5BS>_)Z+KKL%I9O@[$#U'BP>1%T_
M?58T]DQ_A\BX&L"B0L)#8D/"0R)$GTF<2*C>7_I5YQ]B^JUM553MTU5O1]4F
M.%B=4U7V?*``=S<</<JF`RC=H:K>8:E9<RHFDLJ^A.J#<&PPUG79'+VZLB\3
MY:H<W]:4'D\N[IGKNO=\4$R(Z+`0V8N_@O(UJ'IHVE_D?8:EJD-;.8CB?D/=
M49VS15-^O]GU"/(.OO>BVV=MW(WB+<JRW7!O@ZM?4[G+7-8[[1TBXZH`B0H)
M#(D-"0^+4/$6%B?7^ZW]?M"@:6J#<QLJVK7N053T*JJZS$W]"N<65/097.M1
MN=)2<0SE#\6B0N^X%TU][)&HZM4T$BWOU%7OM%6O>4.(U/(OH[H3=8,FQQT&
M9X]V?NM;@GC8YQ?G7Q<"A;<IG6VZ^@XX5I@6KD'Y1M0>@6.KTM6CJAA`?HNQ
MNE?M;%74KD3M!C1TH)Q,]2Z%JTWMVF*HWH'B-FWE`]0D;EA5%S52:FH[-9L;
M/]T=*$.&#!GO$%6M*&]5U?8:&@8UU0,HV8Z<=7!WF=Q]6+BKH/H$KN^/BK,H
M?]*4TP+G2G5=+_+)E*:%LE==TXF"NQ)<=Q+9ECD>4KCN0M5C<'?H,U?I2P>4
MSAUS\UKGE7Z%J%L(SZ6PL-5V(O=PZD>>0-XW4'($]+BF35BP#XOW$-\J'4^B
M;)NV^`%[W<&DA7N)Y%%V$'7'4+<%3=^E)G'#2K93(ZFIU&!J-C=^VCM0A@P9
M,MX9'%U$9:K:'N2OA[/-N&`_JOJ,S4?3KSL$^QZ4+9\(750X2-%=C>NZ4HM^
MH*GM8$77V6E=>A05.[2U.ZQU+<B_S1=X/K%JM[KX275C!SZZ#T4/)A0=0GTK
M'.O@W(>JAZVUVR],".$;$2$A@@+S[U;4M]KK#BD*;]$6WZ^NZ$'=6E3_.;6V
M#5F;D=N+1:1UKT+5RH0;CJ'T"#6)&T;-<[914ZG!S,".]STI4H8,&3*F"N4]
M*G<O,ZJCE3?::OM0WHN"'N1V9"WJLKB6C0FAJ+D/;C+S>TRY`RC;J*[K1L5V
M9-]ON_X(\C:HJCNTM6W:BD>(5\?$2?9.S%NMON%V-*Q6U7?;:Q_4%>_,F-]M
MJ2$JWJ18U`'W7:C^3^$1=#WQ<5)5A]HY`'</RAY'W9=1LPTW#-B7]"!G56'S
M@Y;R/:CL1[74)&H8-8\:R4WMY&:7]TQ_!\J0(4/&.P+[44O:4+K%L&0/:MJ1
MOT'7>$!7NT_=V(*\^Z,Q@;(CR%^'CW38RHZB>HNQJ5=9TVE<N`?.=KBZ6`>N
MZD+I3E/E+E1O3RM\4,2$MNH^?&@+2*.N^!'J!]"TFZ.I2]L-UST&HM/BW<FU
MQ[#D$#L?,E>/"'&1_A\6$1'.S[XSM?80BC9H&M:A]EXX[K<N&43.>D-5.S6)
M&D;-HT9R4TNW4+.Y\=/=@3)DR)#QSJ"O'5`XNU&V`\Y.5.Z`J\TV?Q>*-\(Q
M>$%<G%W[H"+W`.9WV*L&='5]J+P'A9O9_5N\65';#4<;\C8J:@?MUS\,YR93
MW1$TK5?F#WH]8NZ<G\.U'^5;4ZNVH'BE8DDGRC9K"[NS:T\H2@[`L=]6V8/"
MNV=_KH.UY87M<-^-E!6O"S'A&1V/"<6<>RP+3Z"\&U4M^@4]6E<'-8D;YFKC
M1E)3RW90LZGQT]Z!,F3(D/$.4;X5C@YC\V$4=\+9:ZCM1-;WTALWG10BK>91
MS.U$T^W&A:0`'T;^G;H;=W$D=E5'XO4/H&R+KK%/T[B+/0/SMB@:=A`/(V>M
M9NER=4VG5T13+-\US"?5^OZ,N@,IN?VFXDX+_;SD>RA9E=:T'XVMJ.S"[`&M
M<Y?:N1O5NW#=&C0.ZA<.H.0K%X68](I@2*26K$91)]R'J$G4,&Z>D\B_DQOL
MB,=(3'<'RI`A0\8[@JFI$[GK>6.KI$];LU=3N36U?L,K`3&[\&9%<S?J6^`X
MD.3L0=FMJL4#*.Y5U>X'*:X5._0-W:AL07F+KK%?X>[5E0ZBK"7A^@>1W:.L
MWX&*+:>%$.%)-#P`TI8=+8HE>Y"WU=YX6%_?CXH-^O+=24T'%)6;=:1%5VW3
M5'48'8=4Q6VD79N;#L&Y6U/;IBV[Z7Q$B%A4A$>I2=0P:AXUDIK*#<Y=SXV?
M[@Z4(4.&C/\WKAC?2^9\>1<<AY6U[;JR]CAMZDKNG*KGBK#@-(3J5M2L-"V\
M;U;Y/F7Y3BP^\';C>)WS-OM](BB&)H1(+MB@R'K4-/\$ZF_'_`=8'Z[OY)W!
MACTHVX.B/FW#<4US!U>NJ^I$R8"V\AB*#ACJCG)4N7,3J],EAS7TSXKUJ%D+
MYPZ%^]"T#Y`,&3*N65PAOA?.7<8;GU"4KK0Y'T'9/2-"P'4PL7+CE#VW?HM?
M^`S%;9J*0Z:2GZ+^%C0<-.:WO>TXWN8[\0\/(;]35?&]BYS3\8(0D\(K5`7+
M9S6W(:<=KLUP[M3.O]O:M!7Y=R"O6UVQ3UVW3[VP'^Y5JB4;5<TMR%]I;-RM
MKFFWDR9?2JI[N[GAH-+1B^+WNZRT#!DR/D"X0GPOYG39&UJ5I0.HN'-,A%'6
M/BNO']7;INRY17=B?H>(B5FS>E';#L>OX-B14+S^;<?QUI$VVT.*NKWIH+*T
M/:GQ$'+;M54'14!<.!T>$\+NOEM9NU99^S2<W6C<C05'T-"'BM5H6*>IWX3<
ME=JJ'EO=8>3>F[1T$+.^KW9W6.IW*RLZ4=QF;S@P_0,D0X:,:Q57B.]-NN&`
MKN0PRFX?$4,H;"NI>A9%]QH6=D_5<_77'TR<UX."ME/B[.R2=?0AU=6IJ.E_
MNW&\FLI'D=N=<>.C*.Y&T5ZX'L#BW7#<#L>RQ$]LL>3?<VY8Q/QB."CT.2N2
M&H]HJ@>1MS:ML3/9W6TIWT-$C;H!U+<J70=1W&*[;A>J=]+[HFRW>?X^%*V>
M_@&2(4/&-8HKQ?=BS@8TMDAZ;W=*U@%U;;]Y42\JUTS9<^?UHFR]L8D,_*,7
MA(?48-0<0?'ZMQW'V[`<3:M1O`(EZ_0-W6IZA8H-^OF=R<Y'4'H$CC58]%,T
M;DVO[@Q&A1A]+3)\*A(42%F%BF.<O]S<@8+U:L<^E#YN6WH4A;>B?AO<AU'U
M,&JZT+QRV@=(A@P9URJN%-]+/'9>1.'>55C^#(?@UJU$02>:INR,)VU-EZ)^
MGVKI@93R^Y&_W;1XE4<(-&YYNW&\MO*'#66[]8Y><^T!VX(G4+@'C7OA6&=P
M#6A*V])<3R2XUV'N/>J%R]#8`U)HK]L'QV?.BO"D\`7"(KMHO:F\`W4[47JO
MK6D090.H[%8V;-4L;$'!2KC[IWV`9,B0<<WB"O&]KPFA7?18RMP>-&R#8XNR
M<C>:5RNKIBX2H*0C>4$?TF]!4[?9=<+DZ$/AFA$AWG8<;]E=^L7[X#R`W%8X
MUBJJ5AF<W7;G8Z@_@,IV5-^MJ>[6N[>KRX^@JH>#DQT;4#:(FB?88US]Q=-"
MQ&*\6?<FD7_&Y^<LZK:Z6K3N>T`HW*!O>&SZ!TB&#!G7**X4WVMSKM;FWH/&
M#H["6DQ7;C+4/H3R[5/U7%MS%W(WJQJ.:>L>0-4&N#HR7.V&DNUO-XY7U[@5
M^1NU#8=4];UPW8/:>SGC(V^/JK)%7]<%YVZX^U"[!\7KS$N(D+>J2G;9W'VV
MJJWFPM84]P&M8S<J-F'^NHS\6R\*<5J,$`^;\GN4LW]FJWY$6;ULV@=(A@P9
MURS<ZY7N8US<IFB=N6X0]7?]2HB*[*].5WO4!2LF8D)1\Q]HV&IQW8=R:N%^
M<_4NN-8J7+M5U4?A:(=CJZIFJZFA#853IXW7M:-LO;ZQ):7YMM=BXH(07A$*
MB@`Q,_$SL31Q-3$V\3:Q-W$X,3GS>?$ZYG9B>.=N8GOB?%5%NV'!`,HVP=FM
M<AY05`RB8@<:Y`*8,F3(^&]P;.3D`F>OKKY#V]"/\O\488'RAZ:K/?-<N[!X
M\)S@RF<H.V&KWI-8MA'N;41E<*_E[;#*0?W"=E01]QXTU.V8JN<JJO>JJP^C
M>#>RMLYJVF-W;#/DK[?D;Q63[)TX38VI_B+[*VJ>8-^%8X.49-VC+C^B=V_7
M5'>C^F[V==0?@&N[JFZWI;+76M^.NGM1MS;S^L?UZ8>G?Z!ER)`QP\`6>DDG
M'^%4LP-EF[GB;OER8_T3T]:D^@VI\UH-#0_KBK\7$1X4MK)Z6=.NJ]N%M#[+
MC6NUB[8@J4]5<]"Z^``J-TS5<Y45FQ7E;2C;99W_$(HZ5'6'4'L<-3]"W4Y3
M>4=VT?I`F)C8=U:$X?@,[]_-WX?&'M[1FWM/@GM=FNL)36F;P3504/L`9F^!
M<Y^J_F%-\1Y#*>GJ*[#PMFD?:!DR9,PXE.W4U^_B(-OR%N$7<*[0-&Y%P>YI
M:T_M&C3OLLTY;G`\8"^[]8)X&1]JUV0?U3N.V#^T%J5]J-RD;>Y&SF'STFY4
M3EE6FGU^!\HV*5QMG%I2O0:U*]&\$>6K.":M8+UT1&8OQZJEK(H$163XE!A]
M+1@5Z=6=H.Y:]%..<"L]DNQ\1-NX%WGKLY8.(G\U1U/7#*)\MWW1#Z=_H&7(
MD#'#H''TZ>;OA+-%^`0JUF%^"PK66NNGS5@VQQ.?&[?.<3T()WWHG!CU)9.J
M6;!,4;X)!9O@/*!I[E`U;T)N.V<H3]6C*W:A=+>FY@B*V@V-?2A?IZG;SF>R
MU[>B;D!;==!2OB?9W9W6V(F\M9KJP:3&(_J<%<-!SNDX-RPL^?<D?F(+',M0
MNYO:C+*[K4M[4-.MJMV?6'\4:6NG?:!ER)`QTZ"NV8NJ.XA[-?,/8][=AH5=
MIN:#*)JVK2*C<P<GILUIP0T;47O8DC^@:WKN+<_PJT*H\_?9FELY^J*\'XVW
MLVY9-74G!3NW:!KZX>A':;?>/:"M[%84=)O+C]KJ#FNK>I"[DC.4&]9)V<I]
MG+G<N!O.;F7MT\K:M7;WW6."<YQ%0%R*BF3W/2C9AWE]1M=F8\-=*+L7'_WQ
MM`^T#!DR9AR*VGBOK7H3*7XI'SJ`G)4H;+<LG;YRY65;337;-!_>CZ(!76TO
M2O9F+MJDJ+P?V;?]68A$UR,:1ZMV_@K,V:=?L`V54W?@=?4JN-:C9!TJ6U7N
MK:;Z3F5%N[I\%_)7JII;5$LVPKU*O;"?:_54[$->-_+OL#9MU<Z_&\Z=7-4G
MIWU6<YNJ8'E*P?>],1$4GB$A=+7K4784KD,:Q[KI'V@9,F3,,+#/P?T=]O?F
M[4;)IH1%>SGSJV'Z*GW5D<V^4^ND]JPWNO;JW%OY0*+JO5F-RQ*KUKW*X1!W
MH&!WXI)#R.U4UDS9UIO&-8B2?F/=@TKW7KAVHG*]JKD+[G:X^KDB9=$!KDY9
M,L"5*FNV:YH[M`W'4=2'LCU<S=+5PY4MG;U<Y;)V`VC5*.VT5=P[R46)`R)P
M280#TS[0,F3(F#80HY8-,+N6;"*F9;YU?X>Y=]H;]G>B:J?&W6^I:GE3"&O)
M1@,Q9&D/%F]7$%WG;=&[]JA=*W5-=Z.J`\Z]<$]W:_\;1'A4Q*+G(T);=I.F
MM@W.W5P]OG`S7`.8OQN.[:A?A^KUS-[N`53L27!V\S%Y.8.6&X["W0O'>J6S
MSUC9A;J[T'@_FK:A2JH^5[19T]"EJKMB/609,F1,.]B?4-B.G)4I'SK`&TS5
MF]CG4'053=N=VOK=ZHI[;?DG7A:3:37;D^O:%)4KT+P5M7W:Q@'D/ZBN^`DJ
MUJH:-I@7S;RSWMR'4-296K(Z&.+SDBZ2&E_R%3Y!J:*/%&]U^5I53N>\)4?5
M)0>U36VH78N:K:@?4"_9@(R-5M<F:]4/X%Z'Q6M0,JAQ'-)7'U95[475+O."
M`TS=Q;)S0X:,&8RB5E/S0</"+LR[6S/_,.N]57?POMNT-^SO@Z+F*;A6H_)6
M>^VV].)73HOPGX*GL_(>0_%Q.#>@9HUN_B'D[%8[]B7-WX7L&5>I3.OJT"_H
M054+RKLM"T\HYMPS'N/S0SW>%_U"I!5OT95WH.`)U/0C;Z_!]0":CZ!I!6JW
M)BQL413N5M7?HZP_BMQ'$MW',:\713THWHF*=D5-'RIV*AOW3/L+RI`AXTK@
M6+*"M1Q75K&.N=?9HIN_4^.8NJVK]QH5>Y3U;4K7PW"NTC<N4^9NR"A_\)P0
M)F>WN7$C*OK1N-%\XP;D#J!@C\D]X][+4$6FQWKKDD$X[N?"%`WK4+0AM?90
M6M-#VOSEYT5T3(A+0B26W8ZRY=J&79KR@^K\`_;:P\CKPW5]<&Y35>](=^Q7
MU[7`>;]A\7;4K3<L[F17$N??7;D@IPP9,J8=!9*_U[F"<RO*6U#=QMD695-6
M0/*]AJ)JDZ+L<10L0\-NS9(.S'E87;<2);><%AY[P3%-V7IC0P^*B(3OU"[8
MA])=T][@_QO5O:CLMY3O*6Q^$#FK[$MZ<,,`:K;!W8+"^[5+?XVE&U'ZW0M"
M1")"C`H1%7/J-J%T&YIZS:X64\9#FJ)]F+\&91NPL!-U6U"U!B[BWNV)'"@X
MW6\G0X:,*X/SB,N7<TYQV6;.+W9VH$3*.)[NAOV=T-5N-/(A03_0+MZ#BD$X
M5^NN>P15O?:\G6^*,5OE&N3=G_:1^U#Q@'+1;E3/O/<J/9)PPS%4K43Y*BPZ
MAMQ>9&U.K6W#XA[C=0>1?ZNUZ$%K8:\N]V&4WH'FY6BXXPTA:+S&?$)?V:'Z
M:#?<G8F.E8:F)[1-/T!!'QJ/T.NK:G:IJG9JRZ?N$"@9,F1,.<H?DFKI_*>V
MH5]7WP%G+U?:<4S=T9GO.5I0OM[8>!PYW2C?J&S<Q@<QUQW65.PVEAX])4(G
MA;`4[#75KT7F2LW"1Z:[M?\-3=]EE;7N&,H.$FTF+=QKKSNH+7Y@;MY!97)K
M4O43:&Q'U4XLW8;Z8W`]:IFS5^?>KUJ\-;/IF(>/$#WY5^%!=7]B\>V*K%O3
M&W>A<!L<_=KZ?:AL,S?-.&>+#!DR_@L5V5_]E1"HOXNK2A:M4SL'E.YC<*^?
M]H;]O:@8,"S9A[+EYMJVI-J#IJI!%-^OK6OG@I#5&Y"^?T[-CM-"Z`N79RS=
MAX(9IPUJ*Q]`<9NA>H?:M84K2[BZN(9\0P=J.S&_#W5;4;'#WMR/O%:#:Z?.
MV8KYVU#1I2@=0.4*+@14]>C<TIVAL(@)W_F)\$4ATNKOY8"'JFYEW5Z4M$_[
M"\J0(0/EV[DNNFL3UTBO6(_&#FWN/3;GZK=;QOQJ`6=>Y'9R%D;!;I3=\:H0
MB57KLAJ7Z=S=*!K4DB99TXN2-O72%O/\3KIRVAO\;E%Y`F4MLQ?_QR56B<6%
MH,AQK4\IWH.&?:C;82#EN>)>3=G6Q(;#?$!)>9>]:(_5>02.`=2LP.)691/U
M1A>JV^'<ALIMYKH!%&Q5N_M1U\\+0=.4':4J0\8'$'P>4/-JGGJ.+6C8EC*W
M1[OHL=?>P2$^5PLJ^SC[>,X^[?P5&D=KHNN1/Y.2GWV;P7%$6[$&KCOH`^:O
M5U3L1.5!??U5%.=\!92O3;[A!%)[$@L?*6@XDEAURTDA7A071"`:\0M%^JJD
MC_P(]2VHNE6UI(OK""WI1,,Z7=U:<_ZCJGGMFLIN5&TRUSZ-&S:C:2,<+?K&
M`^KR`5W9@#*W+=$]?97N9,BX!M"TD\_$K%L)5P^?DNG>=5Y$^?S?MWF$Y56#
MJH-<>Z?Q=J[#4[[=UMRJSM]'.K#)_4E][=;$O!-8NMY2T8ZFQY!["YQ7?X!6
MXRK5PE:4KP,M*,4[]>Y=RLHVC6LGJK:E-GUS7(BQL4C8)U+F;3#6=&+^!E3N
M5=*B4]F%IOM-=8^;:_NMKKTHO%F9>T!?MA^%K;J&G7"M,2QJX]2YO"E+XI8A
MXX.(RC7F1;WJVOZ4K`,HZ^:3XAM;,&?#VS[`_6J!NPNY[:KF39KF#CYPLV"3
M5)=R&>F$YX30U1\PI.V`^XBVL)7L:U7SU4\O%5*9S?H>]9+=RH6#JJ;]2%EG
M;WI4ZUH'QP&4_$"W]'&X;[D@1#3,!R8%Q:GTXN]8ZGM0?`2NVY'9EO[1AV@9
MFE6V/=71@\+M"=<]S,F/CD[4]VJNVS?]+RA#QE4+P\)N%-U;4O4L"MM&Q!#*
M;M>5'$ZZ@7BI!^6]J.WCRNJ.5M(85>Y>E/=,>X/?+2JW<-WUG,-<@[UR$TK[
M[!]:JW<<,>1N5;B^>T:\C-+#MLQ!1?-#JK(^--X]_0U^=S`[CRE*:!GM0]DN
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M*77N^T;%L!`!+C?A[$7%K=K:^]2NC;P=4++=V+@'12W&A7+RL@P9[QR)E1OA
M.CC"A1GOL3D?492N--[X!)R[V&+-64<335,]8&@89.XM;T7557\"+Y^V67@0
M56U\_B:I<S5=<*_E<SF+6G3-@YK,(RBXY9PXE=ST)++O5%4?G_8&OUM4M*CK
M2-O?@.*=:=<?YVJ<Y9N5]3OXM*.J'1S50"M1SA94=J8L.6ZHVH\/=R-ON;E\
MD[+V3M3_$*4/6G)6B4CTK#@S),2%B)A5N$V?O5=9<E2Y\"%47O7R($/&-$)7
M<B<?RUNQ15?6KJQMA^,PIR>XVA3.+>:F?D45F9F][/*MX-`C3=/5'PE0>,C4
MT*:JV0H'H5U5?53AV@W76BP@7MJM<K>F5SZDS=ES4@A-]4J=Z^I/3V@\B)(.
M0_,!4\-NLF(T#32X6]#<H:MN-]:18KP-12O3%^\QU'1C[AIE#=%U'ZH'T?B`
MOOJ$IJC%7+T6->LP_ZBNZ.>&O)W9[B^/BMB$I!*KYGTUN>;JWXJ5(>-]0'&O
M:O$`RFY-<O;PGDM]BZ*Y>W;AS==J?._;A=;=IJW>I7;M1>YV8_4.:]7ROWC8
M]E8T[$W+7V<KV87FS6C<@(:M*-]KK/S`T<Z5^D=$PI,^,:MBA::2[*,!S#_,
MISNY.TQ5QU45`W#L4+O;S+6[4-!JK.M`^1K09T<;JMJUE0,6UU',ZYVUX"CR
MUH"8O+I?4;L'%=UP]7)TBJL5C5?_<B]#!FFY-^Y"_IW(/VQ<>`1-MV-N9UK-
MHR>OX?C>MPOG%H[NJ!E0-^PWS!]$[ET5_]R54/GM0%!@_AY4W3ZW[BGD=6%N
MCV'I#NZB:6_PS.@?+-ZCO_[VLT($1"`<%9G%R[0E78K:1U&]#NX>%-&:?@CN
MO<H/'49MK\:UVU:_T5C=C;QV+9^4=S>:5J-@A7KQ,;C;6/<NV:RNZ52YN]1U
MO0JZK/*#U\\RKDE4WJ.KZ[-7D7[2H<@],+OVP0OB(AR#UVQ\[]N$JKF'/=NU
M/:B1(@3<?2C9B;P6A>N."2&4']J-O,US\Q[/6'),Z>Q#Y0?N).(K]0_F;4).
M'RI.H'X_JK[QAA!^$8J%1E/JUJ/\7MLG!FCELM2O4A>L0,X.-#ZCR-ZG=77H
M;MB`^N5HWH&%#R@:#\+5H:EMLRSL0>4&RX(.E*Q%V7:#>X^F\JJI+RU#QO\+
MU5ML94?QD0[DKT/9D6A,(.]^=6/+-1O?^W;A[(*[4T$K47T7F<\<'ULQF+SX
M1\K&G2A:'PL+6]UWX%B94MZ)O%[[=<>FO\$SHW^RFG>IR^XS-;;"M<58OU=7
MM<=0VFDH:/$%A`B+V%C4&R)):T/#3_C$9\?-^'`GFG:A9']"Z<.&[#Y57@<;
M7*6=*-R)DNVHWJE?T`775H6S0UFU"\57?>2)#!D$4^X`G_#H;E/4W#<FA,6U
M+&M1%W([KMGXWK>+XAZ:[S3K:>XS`U1+;$"<D+<]>_&/4+J!Z.0M(5#=HR]=
M3[;S]#=XAO1/*3NLB$6)2XE1B5>973_<:6GN0LT@RCKL\^\=BP@1"I%:7)I_
M,S$S\3.Q-'$U,3;Q-K$W<3@Q.?$YLWKY=F)XYGFWQ/G3_N(R9+QKI!;]`-=U
MZ:I7*QP[)T(74;8<]CWIUQVZ9N-[WR;(SB5KEVQ>LGS9_B4K>&$/6<1\?F75
M)J[Z6-MMGW?3.#'PT@%K9<NT-WB&]`]<'>P]6/@`>Q+JE^MNV*"E;[+WP;U-
MZ6J=LW!`7;H#CA[,[T;9S2>%B(5&_2+T!G5CU3?87U%Q@GT7\S:Q'Z-D)_LT
MRCO8OU'+O@[V>$SWB\N0,05PKC3EM*#\R:@XB^O["ZI/8.$N/F3G&HWO?=NH
M[%!4=ZOK>GG?1]H#XIT@=YN%U+"\#6C8B=S']-<?T<Z]2<0$7#.N0.5T]0_O
MFA6LX!TTQ]V\FY;7;JSNMM5OU%0^2LLZJM8IK^\V+!A`SF;MHH.HWJ&H?51;
MTI59O"P<Y=VZLT+HK[\=B_<D5'Z[XI_)'+O+,']0W;"?`R%*M_!^W[2_N`P9
M[QY-??^;O?>.DJ,Z]H"K>WJF)\>=S:N,<LXBF0P&FVB#_?S\<'HV8&R,3<8V
MQH`!DY,!2PB!0(ADT@,33`:3@R2RLK1:;9B=W#/=TZ&^JCO+^?[XO/K.<K3:
M77L.=?8,HYZ9[KIU?[=R>>?\P;$19CP6FOD(S+K8-^]*F+G\WS:_=Z#$.4[7
MBWRG.V#F4LZ`6K""06#N;>Y]5[I)'YMWB3KW;FG^8S#Q:C*FA_Z&APE_)OR)
M,\?&W1&:]S?/K+M@]JV<5[;H3IAQ<>+`E<KTI3#I)IAYO7^_V^79UWO)JII_
M&[L7.#_M+O>L.YIF_JY0XNRU%.)G10S//M>_X&88?Y,R[U[/@CL]\__SY+!&
M`R%EKP>D`ZZ#1==+LU>I"VYB0W7.*IA]KVO6LB$AF'L-S+K.L^0>F++,O_"1
MT()'U&DK_=/N3$S_T68'0PO_Y"+QGG:SO.]J-@GG+QWL^PE.O\--]ON\%6R-
M3K\;IEP7WN=N^`KE#$MN=L\E'>Q2^-IE<,"%,.V2V#Y/P*S+AXK/'=C;/._R
MP)B'0S.6P^3+N8)C\=V$2T.V[GM?K,Q<'B1;?MJ],/O&AGF/RN,N#^X]<"?2
MK#M(T?7O>PL'`N:LAMFK8>;-'!$8Y/NO6WB/:^RIO8A%-#.(H^;_U#?A=M_$
M-V')<H;]?6^2EOR%H%M9M$*>?ZLT]]JAXG-H]FV>62MAR@K?XK^I<Z]US[@L
M..__8,+]0PY$_YFD3EO%\#O_>IAQK\I3"6Z$1:L4.N+WN75H:+\;89\;8-];
M8?$M/'!GVA_E_:Z!)9>T(\;GGP63SG8ONIZ[9R_X"TRZW+/DEL&^'VF?93PG
M;O$*.&@E++B'7T^[FN=%#I35LV\.S'\`IJV&N0_!G/MAVD/RC(>5`Y</%9_=
M#7=M1'TSFL%9MX;F/..>=XNR^%II\9^';-V7K(#9RY3][X0#KX-]K@8N>;B;
MG:@#E>=]5L#4VV#RC9Z%M\GS"83_$MCG/M_"!P?]_N=<XSG@(?>T!P)C5K1,
MOC;E8`]B)V[V3+RU:=][U!G7JW-N#2U9!6.N]^YS#\R[:<CX/.M*V/\6V/\V
MGO0T\WI8?"U7XAQTS9`#T7\FD<K!]5!S;I9FK/;-_ZNTX#;W@MO=DT]WS5P^
M)*3,N`LF_=4U\Z[PDON56;?&][L=IERX@8SE">=Y%]T@JDIO]Q[R.!=9S%L&
M"Y<.]OW`3-*W_^+99ZDTZP:8]*?X_$=<LQZ`KS*P?GEPP5TP\3JNF=WWON#<
M1USC;_;-63%4?/8OO":V^!F8=2J/9%I\F3KW$QAW%^Q_R5#=CVOA=3#A(O>L
MRUR+KE'GWAV8>;=WR:.P_U?0?J]6%]WKF7V_9^$RF'J!:][ER<4W!\:?/]CW
M[SY@%4R^P;W/?3#C5F7Q'7Q`+[X<9I]?0J.(N%5SNA##4RYH6G2_/'Z59]JC
M0\7GZ/Q5),G2@J7NN?<G]WXQ,.L^V.MWL.@_KTQIF-",FV'OJ\B0]\YYV+]H
M.:V+:^IE$)DGN>2A(7"'_#&WX@.000*7!(B]J@1160[*+@7DAG@37>,".:2X
M58#!OA^`%D4917=")`4`8'ITZKEU!UXZ8#[/7>9?_!>9[-#]+H*Y%X(\4TH`
M^`?]_OLC+_@"$H05(!X2/*@N\``$8>Q0W0_]N`JQ@"\,"K/:S>L_SK7D^P,7
MZ>O(NI>GKG3/6^E:<D-PX=4@S07OH/,Y#!!72#[!'U+`!:!X^8F\K?4P)@#A
MMGBS6Y)-='0TB<L0&K)UIUNCC06T=13:6T$)%%^,5G[)T`/1?R;-OA$670NS
MEWOGKG8MN`WFK5`F7@2NJ.VXAH30<MD&V)9BVRIB#-&/NHR.S\B"HRF(C8ZN
MV&4),417(GH'_WZ`R#0)HUH[M4BD#H)[7<3]N@?*YSG7<G^MJ8_!C+LCLVYN
M:%8+!CV=.F1\QC9$5Z:#GFL*EH`)6_4T#-W]N+"B:!I82'<21*NAN6Y4:/P=
M`^;SXN4PYS+?O#OEV:MAVFTPX6IO0UVV<N#@WW](1R5KR*D<W7^;DP:LN+`(
M)0<J6"7)1+FK0/^J9JTAY+.;;D`K1QWFLX=8W9WUQ`F`AQR(_B.)+&M8>!/,
MO(/#'W.OAH6K@S.O`!>M$0P)63HPY"*8-F1SC,.(2:-`>%NGHZNC"`4$':64
M3OM4Z2D/_BV5(VB&*XQ.+47TD([HF_<0[/O/`;-Z[ZMAT>7N^4_!W-7A"<M)
M-T);PNS0,)FHHTR<##OHZS6)D^.+Z"5^IO0ANQ^S1`L]AE:9,,$H\CL`:G#V
M*P/EL[3?@S#[M]+T&V':/;#/PY'YJVC)]L#]=Y5)+`G<`CD$&SU9$QQ4C9*/
MQ!A1I@N<"KT(8,F/=@AMWU#Q6=?HKU(NA6V$8A8LTBYP7`C<0PY$_YGDFO]7
MF'>;R."Z`>9>"DL>CLZ]"5QD*,&0$,E#D;'.H[.TA+/\FM1@N=0+Z,CBM8HL
M0@DT@"RYP;Z?DB%V#=V,[<T3)J@0W'L9++IEH'QV[W.G:_'O><;-PC_%%]XC
M@8?US_+LH>(S&0Y(@."$T2"N^I!0HA2F-X=LW07E;$(M#^H)NB6@(VKO@0]+
MFK["M^\UT<7W<3/D>=?&]KV7;&T"G$'GIZ,B:;QDJ57H'/%7*E4F$\PJC+TD
MJ*PJ^+&L\)7EH6&RN"65_FH5+YL8Z"<=.(]N+_%HJ('H/Y1FW0:S;W?-6>%>
M?`,LN@3V?3PT^V:0R.+V#@TA:9MNM!6M"([#$MO;#<)*(N#UE4EN64-3]#(8
M!JGHT<&_'T*G,)+-F)M)@!]W1Q*3;H4E`T^GG_B@=^[-,.M1F'^3>\$]X(,M
M&D&-:ZCX7"G7:240%JA<*,JV$S0=4MN4H5OWJ%51<XQ1;DQ/I*-!4A,BP#I`
M/L^^Q[WH>O>T52Y2@Y><KRZX28(`YIH'^_Y3J*91K3"F!<OL?PA5#*BPSRJ0
MS_!?8K7.AH:K@E()AVY_E83B;2=M4FRT)JPTIW6HKSD?AHH6W.Z>L5Q:?"/,
M7NJ=LQ3F+7/1F]+06$;#D!R"7PLJ&&(KTI9`EDF#=0V\EE^9?0<LO$6>NUR:
MO<RUZ!H"%[3%EP_U`PXCL@G_":!4Y&,7``*N.0./R"^\%F:O@ODWRW/_`@MX
M+#*X)32'^M&&#>FV)-SL[!MA]<8&,C-=->?#4%$-?G=)-?C=<U2#W\&G&OP.
M+ZK![RZI!K][CFKP._A4@]_A137XW275X'?/40U^!Y]J\#N\J`:_NZ0:_.XY
MJL'OX%,-?H<7U>!WEU2#WSU'-?@=?*K![_"B&OSNDFKPN^>H!K^#3S7X'5Y4
M@]]=4@U^]QS5X'?PJ0:_PXMJ\+M+JL'OGJ,:_`X^U>!W>%$-?G=)-?C=<U2#
MW\&G&OP.+ZK![RZI!K][CFKP._A4@]_A137XW275X'?/40U^!Y]J\#N\J`:_
MNZ0:_.XYJL'OX%,-?H<7U>!WEU2#WSU'-?@=?*K![_"B&OSNDFKPN^>H!K^#
M3S7X'5Y4@]]=4@U^]QS5X'?PJ0:_PXN&#'X5U*0RPA:>)3%5C-UQ%;&M9/$,
MBP)?$-E!?WOI151'"3.0QA;1=-V-EH+%.L0IN<$7UY$/O_^:SVA)6&C:PA?X
M<O1H!D^UZ\9`2LP6<1#H([E2M<N]I[('ACKA2('?8"I%]RD[1A-6IA!V:3J@
M'D<[S.-7[+T0ZSORU=EYGA+ZL0"=V%3&)(HI;_2,5H&><?*>X.>_HAK\#B\:
M(O@M&"U8!#%#S9?)\2Q+FZ2"MXG7YND`]?1^%XF'Z2GRWB>8"EJH6`84=@(6
M5<T"W>$AF(-]GR,=?OOC<P=S-9*B:RI0Q!!/$DGS](U\L0&MF-&CF*:;`,1B
M)'0[=L-@WR?32(!?*T]L:;#Y=;"7SS)"LX19)`2&O#6:!%4<5:UYGLGBR='[
MEI)%CUD,LZP6%0<;T5$V%0:?F?U0#7Z'%PT1_);Y[U@>.)4&$R.((9Y^8H`8
M-]/4D0.-9PSYQ<;Q63H8='TI@>82=.*(X;28"R;F50WN?8YT^.V/SP5L)DTX
M19A0BO0B(;"+CSP>;!?J;:>_C42%DO@&WJJ)P;Y/II$`OQ46@Q@IMQ4^L_RL
MY?)@4$F,X59,'&>4&(HMHYYU71+F0I!03AQVD\F:LW@.45B,&QY\?OXKJL'O
M\*(A@M\*R@73R[Z%(O30'B_%,7U$$2'+_QJP&2A4$O4N2[9,0@:_:7L(0+8B
MSWHKE@A)W!9!2F]RL.]SI,-O?WSN1CK1W%F<@#C5,OT9NI@A0D+;U5YI(0PI
MINA_0P1<M`K6'D&&$0&_/'8PW\@#W6S(:(#Y"!;VI==90E1=VJ1!CL=KMI*H
MM-/%O?,18SS@LK)?ON0JH)O8CHS`WCW!SW]%-?@=7C1DOE^9W9+Y.8@M>7J=
MA^*[`(H[JD(3P.3)D.F&V__0^J8P?O4**6S3KS@61AT_=DN:QWEC)M);2+`@
M#?)]CG3X[8_/TV!\`*#E"-B0@Y4_!RTMHY8D?#CKZ-&COA'.81-!<3>C5L2B
M#6OO$6UM),!OSA`CX\N+$>MX/#3Z]8(T68VK`/4`<\%S_8LMZ2*!<$RX?]W,
M<W:FJ2>ZI;->2*#6AD*B]@0__Q75X'=XT5!IOWGZJY3+4-0#V3S\<VET#`0>
M[?9F,&8@K"O``9'D1(`7<'_"`;,TYJA(P_ZT(_?W=/$^E0A&3$S:@Z]%C'3X
M[8_/:_E?$^8:^'Z"<>,!;*5M^',(CR$F+XI^3@B#JHZJN=U=YM>^P;Y/II$`
MO^C0H1_?T4D*[00G`]=<"6$(K/V4@\6DV6XOMQX!KI93O.+(\^1UZ.!/*4?X
M"9GE/SX+O?2_EH36M#W!SW]%-?@=7C1DVJ^/8V=DII5@\Z,S0Z"<<X>20=FP
M0FC/RIO[D['\=1<\)*07=0_9:YMO`OA6?`>)$`&"*7/:@S'H]SG2X;<_/J/I
M*R.D"E.(O:?4-S_="49!)<A=MUJ!XX#/N(JT@_BL3[#IXL'G,].(@-]>**$W
M[31@#K8^LE"!^,IWO.R1,#Q;4"UM)W0=/]\+QU]/%\?^='C+)2_4858M]L"1
M`&>OC6"I-:N3_CSH3K/^J`:_PXN&"GZ+KJ(YJT@O"J'_4B!Y$#R+,[%2151/
M3X$$P]=^YYC5A+UI>L?=71YOW@-P*'0458V$'X,]]%DM--CW.>+AMW\^"UB>
MBEGWN[?`6WRQC`5O^QUN.,S;P2'[A@JZ,1_7!]_#TT<C`GY+X0Z,[:079O2$
M(+3-@K4XIDC\S+CI_KMP'^R$I4?[`28\;"M7`?ST:?I4T-XP^FCPG/X2L-\,
M%=.)["&6_G^H!K_#BX8(?ATSK"'D26WH@1^":^JC9)%)A@5$&E]0CT;29-^"
M;)&V@"'"P,TK(7*4]$^,HN,BW4,D_=:<#U^1SZEJH`U![$3AVB6,TOUK;X.&
M(V&=`1D<C3J!-JG$KNP@WV0?C0CXS28M).;$[1UP%+CVOLO/:0QIMVW&$:=W
MT`]5QK]S'X0A7`<!\/A`#H3B\&`W'."""_XY>=6!`#&(GQSBW!(#LH8_C8E[
M#P*?'U1)VN^.!BR-*V^&PP'.>BEY)?$@!.\@&-G`[KK_&OP.+QHRYX,7S2D]
M.P&?`U`._?&-\33'(T*<8.9XC!SL=#A&;%>SR_)@&.[U?P78!]YER"5,&&=A
M4!O\<H"1#K_]\;DO6]4<IYN-E10G2(@X9GW/?8I\('R*8&(,38G#3"@YZ!_\
M^QP9\*OS?;I2&<!W("*/.?:FJ--#[X<KEF"U#264-EP/35+XFP_"0H#3GJKG
ME)+WHS^2@A&05VZ!TDOU80A>VTG7-Z`C/S075F.\HZ-.VPG_#?"[WX%+@3C4
M@RP]C/1M;C1\%M;@]]^4A@A^-Y.X9B<@QK/O@23!0?<2%(QV.$;L3G/U4`"M
M.JV*3H;$VB_6;5D*L!\8V)#>"65#1B?BU#(?OC*?\RHGK!(R.+*%(0V5C"/E
M+6_O'7Z8)F<QE.D&4:CE(^SJ+0ZZ/#"-!/CM107-%BQX<2N,`3CA@9"C>[(5
MQF1VE3L!K'C>N[_!%X*K7IW^8Z]ZZ=O>CA1@QZP38=KOV?G@V[8-CFR&QSZ'
M/`GYZU`'HT"%UL#B.#VQVW?,4LAHXX\*PO\\2M\Y#NV6RC;/^MW'Y!K\#B\:
M(OC-T"Y+\][O0?@=^*0+R$#F,BNLS!2%QJ1NN5+L@80B@EV"[BSLO-<#A[A>
M[:!_]1BT"YRI1M5\'DP:Z?#;'Y\[T:UCDM-]L]%.C(LLJ3#]W7XKP''1M:ST
MME;2T,U*G<)ZVB#?)]-(@-\>DLR=8194])\/C=[CX3U^?TR!*X#B[!#+M_SY
M3$[M>[8=O@^1RPA%,;X^"],`KGB-#3JC"Y9X&G[R\MRMCF*^JTP\(?J1J"':
M:$,9$P3FQGHX%."Z#VG58L+#%D6<M+ONOP:_PXN&"'[S0JX*'%8+O/1?<3KZ
M;_IL%NE@^2()1A-F82W"1X][E_UM%!K3A'-2^?"61/2@6!%'Y[F82\:RG*L5
M'7]5/IM8Q_T?RK`%@Y^LA%L>`H9B`S8O'2,=.*H#ZW4Z^XI13NTSY8J^1Z)O
M(P%^+4R04;#%GF(38%[5%H?P_5LGDMY;PJD%LBD*T[=EDXOV@E-6`GX"AX#_
M\B?!,"*X?MQA`)<\`UA)XB8X$7QG/R_\&,\!>*&]NPY%>PW=#A$^FUOA.X%9
MOUM-:\?9*?1.>?<QN0:_PXN&"'XUA)+A9Q6+76?)6XZ7ZD$]Y[D$66>$&.T8
M?_(2^,XMH.T(9BTPL9G@]X'+8.Q^L*UWKPV,NBI=Z3B#[I,<Z?#;+Y\U^M_%
MJ8KR\(GP/ZOI==0V$SL1EIX++8="H3*&Z[.X\X:D%5U[H+B;:23`K\E]'D:)
MG@\Q.JT>^`-,`G7Y9I+;P#;2"G;`,0#!\V7<";@1#@S67?PR@:<+/X(EKM@E
MKP:*J%8VM'Y+4?^XQL-Q#4>YX@?-<!2=?:V<%+$:OKY<QLU-TR37&6^2(DT7
MC*U@<Z&RV^Z_!K_#BX8(?HMY$H-Q),`5MFU]:0-R=XZ#",0`ZB`\&N#<QT@V
MO)U\,9O&!\LP4YX8`(A)\-+&:9B:ACC:R0YZ.<!(A]_^^`PA4!1B=?#:=P[`
M'G\G>X,GG>>%"3Z9F-P&\/`7+5ALPZQ20<G4!UT>F$8"_&)>ZB7XZH&WN';8
MQ\G2KP,DH1%`@?%+P/U()Q2SA,9C,!.]X%@`%0*0:(.HQ.4MT?/>A!]!@MXD
MP'OB[0G8%<0B_*0EZ:''I?=_/W8KPO="`!X(1O8^E;3E3EJX49C=;4ZV&OP.
M+QJJS(>2A^LQT]"+<IG[#[3QFV4PK*8*JA:&K;*ZC3W`/JL`:/I1D]*VWT;)
MQG$;Z,H4=S!`NQ9Z^XI\1FS.EF01QY<V,>@1.+LL([BQ$D=NN#'[!?ZX"PW%
MPKBU9XID1P3\:@V<)5(*DRG!]VE-,"PHED$HJ+$O$.P\,5GE+AFD`'.KHE'M
M!GMU'*UY"QD1&7K`>)Y3&K@11Q$3EE-'.K!([5/X^XON0BZ!]D1=9[=#"4,%
MME-V6]%W#7Z'%PT0?LL8TC51.&D&<^6J:]'+:?S(A3P5CI4'T(R:7.LJ.TZ_
MWU,L>UBM+8+#6D1]KP8%OGC`S@3+(!%52%!))[&-B6C)94Z<V&W;;:3`K^@4
M%T<K:?/.DBMD)FL^M.L9`6PHL0/'C94PV@'V\:+'1E]9=*!UG'A)=$>D79GA
M:I?1^0PO:P6]A#/"RG:)%`@W&<LBO<HCVAU$!9-WZ_$QK."7[\%58#'V64[U
MP5VB72>]&$,<-LM-XK)&Q+#N<%<BATNS20A)6VC#//>)*CD!SIKF7R=H;2RQ
M!][+6&HHNX]OH5)>K!%&\Z(](+=<L_O5EFOP.[QHP-JOAT/D3M3(D2#--BM!
MDDFG`I8M&[SZ?@(KO>02F:5^R]Q%HT)5RX&(.'A*'':/639D>@<N?B9!C0MU
M24=/IJB0(B'N,+:[Q'NDP"]I6=DLF`S"B7(%=+'EG3*D60<+HD'J4Y/&@,D^
M\V*Y>LPUY;-N1@-^7RKR*K1T"BT.;0_I9I9`74UL:HWL7]LC>"N1,BS\EM)N
M;ATSK."W+SNZD;@JM(@06BY.P[/5<E_!H$+7E%)AC;53GUXDYG.;/H=^RPB;
MS#I7D4LX6UA+X<R]"#V7B3*W`L[O-J:9_&ANM#P9[E#G2[,RD\3^]UT-?H<7
M#11^2TJ)8S%NVBEVL=H];P+B9)LU*)40V&)#*4YKFF89F[E+X0F2WDNX36+@
M5!@?A-D[T#T;(E1Q>`O$12*$EWXZLW.WB?=(@=\"[W?>62;GH`9%U,PM]F8$
MBSZT$IQ:9@FW0T$X;7(-B)-(9S-8):MSR,@U(-<AFK%7JOA`:Q$DC:Y"7\(E
M7?58"?)0#+YGYHE-%M#N34@;5O!KMQ`SRPR;X[%<1^=:GAA5:7#H`"+-7X?J
M:`!NIE%-[4-ZLQF=>M(E3)9#T:R>N-1#&#Z=<9M%E&M;>)[+5Y#S?LG-9ZZ5
MY$/3$;>!K5HVVM_U-?@=7C10^&68G5)$Q<"JC`4+W9`5';QY=SNA8MDK_DEU
M:"OI_8<,G*38:Y*%/H$2X=3FJD]RH!03EIV*5K1DL,+&.6D\EFCWB/=(@5\!
M!5&"RBKDFKGZ',?HHW0(]J(GS5:S9Y-#?P-E&[2JC=SWZQ)9UI6RER-TS#>%
MPT:%&!^L!B<,%[@W>Q#%C`Q'E_]?GX/C(K39??<_S.`7I51*<-42QYFM<N=>
M$G[+6\K0.^%BKX^4#;U2U8VGEWJAR(5LQ$!W113'B8)-LC+47`ZZ^3CST`DH
MK!*_M?M"F44^=IN[^*>]3H&[.K/3N/\JN1K\#B\:*/Q6@'9NVN!5TPL*ZB[L
M\]DV;]D(HC-A8Y9]"`HK8T[_\%N)DHULHDLW&WE$"W^DU>K?5]POZ9`K0MZN
M0G>@).8[6.9NBQ2/&/C5HID,E'G+1[!0QZ/',-R>]5@\6Z&.+&*'3RAWL<-G
MD,IJT;85F4YD,F/+SHK,KS7H(;S5I)Y.;E?KX$S;;!9ZG;]LB=;B*#HM&RZG
MKU^$++Q&NX^&%_R.S7`-IH>12@P!R1?I]H*B>6]SF>>M1-!J02X"JMO.B"=F
M6.C@L`$H55`J$\<J@:H=00_%LFW%'3-J.ARPV'U\:Q2N>[_!QX2'%\BJAE'^
M-=7@=WC10.'7'"L";7&T]R.#-&W+Y?)XTK(V\BD<X]9/?/(FRZPYN/N"N?^2
M6&;<-K86>EL8,4PRG\=W_?\X*_XE>4M5D*3?_6CQ-E:&/97_O-`;XBB!`%[>
M7%J5O:X\^KB]H4B1XB*+-/U<*%MQ9[.M?&+R-4UIH][$:%[,$!%&L:>"JH$1
M#66NO'#X(]RE%NMTE+GWK^,6ZZ7N_G2(X02_`GNGFYJKS/C9F.XEGD@:@F:.
M)B88)2!32S-;3%Y!TCV\:XK-Q!9=JT:?.0!A5534`EB1>M(DV`DQ&ZL1C7H1
M(ME]>=1\>^$,^O/85-;\:$F6&-?5W_4U^!U>-$#XU<TZ4IFN.AG&0TP%",8A
M#/)X@$4_@&UX0!I=61$L1I'JWY/9A>1P'V_=BJ$5PAXP-W^SM1G^_/3`Q8];
MGY&:'4P7X>K1<.Y3X&1WIWB/&/@M0[GD3A4(/_U.9^#&T[@C@1<"$5_BIQ]R
M_]Z/[YT"/C>H4*]`TSGPWOU0)T<],&4"P&B@!9=5R3T)1N]W)VQ@+Z(/-\-3
MOVF>!*-H:_[\%GC^K6EO?NS;P;QU,\Y7PAQCXDC<;KI_'%[P2S)<RGHMS4.?
MW?IY79)SH??S@[S@<%B_'>Z[F/20QAYLV2YTC.L/"#1]$]YC`T$5T.<M&&#3
M454)%]<=MF`6_.EN8(W%E'6>U>(K:;N/:6DHMA\7;H1K5X%PQ?M0#Y;[UZYK
M\#N\:(#PRYUC,8H[8--K\UQ1N.-CN8*1S:^,@DA]T^'P&4\83)1YDRKI$GL:
M^_L>*U]G(5W`T?/BQQ(!>$!J.N\?7P%V/"DVHNLKZ#X+8G]XE^SNAMQ_H/;+
M=H?+0)%_8KO0:+KWYG$1C_22*6%F+Y$0XL:/VO8"N.7E(S;;D0U+X:HGW._3
M!W<F]@6XYXO]UR*D7X3_O6ZL)C;UBNLF-1P(S_(=AC=<4U_7##<L@S(OJ+O$
MP3O"^9B^>\LQAA/\VJ9?1!@3]UXQO0G@C7?JZ`CK0->.=9,6C)U.I]C;'6ZV
M-71I,<`4+T@'J)_A&/X(5Q!7$V\DO1.6^,`/RO4/C><"(GXN'UD-CAG>74PS
M/H!6`!D:ECX]]7,.%+JY[4__<E6#W^%%`X1?D7'D)GL?7PFZ)+CS4X_.W6_@
MO9^"HL+-&\86+!$<+T6$,[:%%CJ-DSJ=!K*(\ZRFMF$'F.C)ZW',31!IPQY=
M:RUN@A\"G/6JUR+5BQ,JU`()"9O#)"H>"R6"?<N6D8L"O#TL]F1VS;CAR.#I
MKY.A'2P6@`<:HMIC3D$ME!:->K`D)F*@G$?QK^E6M@H+HWN%U"%GM_IT*T)0
MLPMGQ8B!WVI2F05&=928`]N7!F@=W[$%#TL@G);Q7P+\_I4`+<T[S\.F[6!9
M'FSW'`WJ/=M%"K>M++V/]#J.NUW@#OS7:]4QOG[4$IDML&QM:R4M"YSW(\=Z
MVO#?%WY[A*-[ZQ5QXN%O7J%WZLLYCJD1Z[9A\%P"9`1-IT5LW(&0NAG@<'I?
M%>G!/BM-YD-3403LG)1R.,"5?Z=':RSF@A;GG]0AQR;\6L7/4T5P$A>_:$FL
MM&VN@,G+%#6RM(XD]GXT)"S[N_FW0!1Q>#$EBQQC%R]-111!;XWL&X`+GW-5
MAZ6:N*N\]QK\#B\:J/.!Q2!HH=?Z>\Q%6M/GR3*Z]1QL638Z*,&%;W!W=,Y*
MXE".I%4_99(LA?)BT7M-+V<G$@[K`=('2'2[.;@3Q(\6[Q^#G[P*%8ZV*\*!
M[!99/77\)?2='&0?]1$)F.GZE%&+[;O_!OC).X!;@#O#..$4[U^?S5\8$TF;
MBI[WLM&'/HT#(BTB#D6?G63B6.RE_0([29,W%(T=I_^>\/MB96+:218Y).JQ
M4?XNP&ET8*''2/EY5#31=N4H4.[>6H5?=[%4+[C7>/,WN5[V`QQ'VYS7BZN2
M.9QGHESDMLR2\([VF^`TTN$W3_>@2[\!B)TPB^P",?"N@=&O1$O6L.'BQC<8
MBIM[#`[UYE8UP+&PN1*RC#"C'X.P5*FFYWT")ZOPO<>\PC,?%AK%O+5&<+L&
M&K^3(/9FN1H1RFDHL:PJG_$-Q+%S5"?[$"34XCQ=JRBE<.\,N_'])L;M2D#3
M$P5LY)*E5Q*+ZM6S7@RB*8M=(V'_/2)J\#N\Z*N47;A(MRS\'X0CL/Q38.T7
M`X\^3D90\K17$^8:WV$P[8=/P8_4IH8@?(`1@KZ_S8,$C`O1ECI6^A0Y!I3!
M9#$-K_]QWE080XO/O1X`?G/QU`!`&."7S\.Z]^?ZW1"`41>^E>`L8H3KOAZ>
M"*`0Z)_EQKS[%Z-@`GTF.+4)VM;K'/+X81Q^]4S<)@G,<K'\W[XS&N+@@3&-
M"^$3V@NBO>TOW/#K9^'BX^B3+2VG-",VM1-P=??[O",=?C\F)-&KH7"I4(%?
M!_V_?D$1\9JX..-D<P,<0<?H-LY&$ZY+_]8,%$PHO:&.`K\*</+%T2P#M8>.
M1;.K*8/>G0[=^611>J#^N\(O8K+G73C2"P<O3V@8V,X!M;A=)*M*(NFRG68T
MO!E.,B&^*1]?+<%AT(MM>C&TM:_6&'94*T`W-$V+*)<\%;GL8/;%2S+<_QZM
MD5<WZWI6T".2A(ZB?5'WOWNS:99J_G@9/?BX&#2H?DAA4Y']>`M6+O*`S$Z&
M8U9S-6)A.V%^\W,_]]/&\4!P`F^9O<]YAZ`8#`.,L@>-137X'1DT0/@5.D_8
MP5#O:G<L&%^V)M;KR-F=,)L@]!OJEJ>"4R4?06F3`J_1/MJI8G'TG_:+?_\.
M6(O-M`N>_IH?ODE8VI8KP%N_A]8%L`ZAV`4/7`;SP7?<\VY]1^C@:)+0&U/U
MY7Q\20A^\CP=_<FEWX8C_DH:VHG9]TCDE*L_4SH_8MSX^9L\_;`31W\G",W@
MN_G_2(6HQU+#JF/513=SA#J%\O*]Z\<>-N'E3.)7$Z`%E`@T/K3>U;V.@U`7
M?9K`2J`;1_^[PB\$(1ET!WVM"H3KFF$N'/Z+=<U<GU+B?<<9O^OA*)!7M1.P
MR*3]5EB_XM4A/:JG6Y[**!B@,_&L)T;12O'8$:?%X0.TK4C84MA]V#O<X->2
M]6=CWF3XN*M!**X)[J9>5H3_(8*FE"E7YQ*&\QIL7"G!-V!#21*)ERH6FO1B
MQ"2AJC3U;G0=ZR/<56_?,8;LBW=_.SZL'/@B\7]]["`I>=:3B0[TXYL@N>&J
MK5#N:/W124UO(0_2>O<!6-,;)(7AGGW5&[OE'"8+!74?<)U&YA[ZWCJ;MAML
M1:D+X;%;H=4#ISSGLZT`FR?VKJKJ:O`[O&C`VF]+,</=H?'=@(O`;!3KK7O!
M^,5[PR92B5$V/H7#XG#R"R!20QNZGH#DN,F?B<:S9*;IZY.'N8)_?!+2>>^1
M87CLW;VZ.0`7<+I(FN#\M6"OXRZIO]L$N!V<#M@/Y-]]E-"?@9!+>A*E/(>,
M8VA-W&C+N`F.=<VYZ5GHPE%=I)NEQ_T7J<WOC]M.V^29A`=\8DHRVV(]"#^C
M+W\*M(V!Q5'OV8^S`)?7P>'AMGL_2&13=-O]3IX=Z?"[@S2H7IZ@1^IK5PK.
M5.'<OP.:(8(.X2V7<!NP[W<;9&V>;ES$$&HN-$:72+5+JV7T%-^<%T^0YC;Y
M)[<#YU:9XH?RP+$DK=\$IQ$/OR5P/@Q$P'WBG2IWR3`E?MYRU*F`9C6C[2N0
M'/9R%8:-ZL:[V?>[PXDX>K4"B+Y!23FB(N.SR>X$W/=2<#L==I6I6@I^[H+S
M7N:'30F'_&NKQBF@>B>.NG8+X(?JMP&DT^H-K..R%Y+VMQ.\P=Q^LAY'07T+
M!$Z^<KRSC?:%\M?M(`83>"NO)V:YX3?/2.4\213P`5$KNQ@I-$#X9=^L75?!
M2/%O8:_BNO4#X3-T^+S>;C3;I.)NA"4PYMQM'BS+Z4+SIJ?8F7`_J0H54@S:
MLB4XSP??OPVZ;P=06E[G?9'(:>-PD^<D:#[M&<#-<X^3)A_]E)"K[=*1WOC)
MKRG&:XJTB/;F=(T0/EL]W'T[.N%[,OR,KPRGZ!Y>A\4J7/80B9^T<7E;O7?T
MHWHXQ1NYY?,4_-`?/?TJP!VD,$=.?9HC^YAKGB_#%0_1!5&G_^TYTN'W=;N^
M@'Z;G;1!6J,S&@*_>D,M]N6F<I<SW$H'GWK79@&_G"JLB)F;L.Q2VI@BQSO'
M<SG_<(C7`X$ORE`JPTX,%?KJYG;1TV.$PR^&BO349&C]TM]!C]G%S>+T0C7#
M9(*IPW8MR:SFIF3NSV_PP3?<6YB!@:YM<&P;M$%+'32T`+S^<?004.YXC#:(
M.\.E<Y$[(7#X=6Z.OBT?YP4X9+6**=HR<.T&6K4@[F@XTNVMIZ?_)4E=*SX:
MKC_8NY7N1_>EBN!4$IB=\.9=X/'[5O--AOG1VJ<O<</%KWB$+\A5<&`7*=DU
M^!U>-$#X%266JHUNY^E&!4(K/QE;H9/:\&*FN9=TR"[9Z6XZV@MG/M!6XNWI
MUY_S*BK<^F"`_8=FHH+^4^7D&7\/X0O@]\?O7^LMBLIE7"L?(S7]DG3F#^$7
M?OC]Z\#^V\\BAP.<_70;ON21Y/I5GT!W=?!-V54PVHI9.!(4NK*DAPT[@3M;
MOBN%?O:<9**JOP@@^\Y_PH=Z'7*;\="OP7/Y&GG3)CBT`7[Q-F!/"#N4HP`N
M8OCU[^Q_&XYT^%V'BF&(,RO+T/$+L@)>4D2%.,?Q30N<302__I5;R01@3";U
MJ<3U6?#`M\C<\-))ER/KN.3&I[W@;GZY-`8K;1T(6?XMN;@;L7>8P:\M"H@^
M/-4/47CYW8D6>OB(-]NX#L68M_H1N(&3).E0DW/MT'%?,\GBYI)?I+NK(KXF
MY:M)".M@GS;W=]]N%#R7M"_4@\%[0P=H3[70-Z=+[KSMPYSO^Q"X^PL@QN8K
M7"2.S[=X_?5G/@#Y1Z:W1N&^$J_L3J'3F@[TK/7,`67YAY%B"CC2O;%YM@QG
ML1[BJU2J1DV_C5AK\#N\:,!5;PDT0AP7?@-<'EBYB4Y_V=%DS$?7L]0%\MO@
M)/">_:+`7H>-N,N_X9$A_@S!;![R=P)\';;;WC+&3P4(*;XWN-X-M+1_@1=^
M^\\(R</1+CAJ>7P[!M]_`B8!G/G!6%+&KCW>'SD]QGD+FKMGN^<']TBX'HY3
M/:?]LPF+DD'[Y5.8[8%+7H&\-AF+\-=#`.+P!<8M7>JY'N`8^"(W`S?!\83G
M['R8LWT;+'9+YZ^99),1UW^9QDB'WR=X/])Q&;(S4:O80+;MF6^2,BRCS:TY
MN#G,9N4XB*QJ[[-B1&>8NK(1?9!.OH#Z''^Y%ZWH(_L#_!K6TR)VNUAM+GJP
MZH7X-X5?U,;;?,K`;=]J:`(X]?$`9T)67(1^+_\*3KS+AT;]AW09)XHT/WT^
MP+&!S25/7Q<XO<DRPAJ&>$A0)QP&#6=\")UI3GZX\T`)+G0S;K^H>B3O11G.
M>=AYI=OCAJL_#N*VB3>])IHC56#%Z9Y3[X)/45JU;]QWB&QH$^C-W#_@OV_Q
MVX[_Y\#QMH\QQN,./P[.C\&OGJ5U26C5U-\:_(X4&FCBF0-.S_CK?N)IX52%
M%@C`/C^`#=A<(01S5&R?>/0$J`._!V#%@[&R:*J#I6GG'<_C`%PRS#T"/DN/
MMJJ;NCA]_S:HAT`,)JJ0Y.]3X):_PTV7`K\-8XX_#69ZU,G0^B8=\47YH`B$
MZ&L"T+(`MFF3Z*R_]@A9A5$-`=BT<_+B<9!TD4(QX?$7ZG@>0=KSF\,AX@Z!
M&HWL`U_H!+!S?^`FF1T;=\'J1V+CDE#GH2]L>>6=,?G^87"DP*]IJE]F'/E*
M.ULO_`ES,$Y<]<#EC[5IN?J/[@Z,E>EY]PH'H>44P?]\Z-D5R=$R!&G%%#CK
M.M@@UD7$W4)_NP.<;0<>W@I[23P48_;9\'Y^%)<;BUS?`B<'^OZ-\W[-:DM)
M_COID3L:Q@=Y0DA4\H(*-]XYHX136(;I7WNG?6LR*PDJC&N(P^//M!70DV7;
M/U#F#,QF-*77'DO29UW@"\;AW$O4CD*4YV09\,<?3TU"8$P]G'2"?W2HK4F%
M/U\#AWEA,HQQ07+6"=#.!?42;IWPRS!9<Z/K:$N<"1D1PLZ9TTX.00S<`?!%
M($';+=D(-ZWPYG"LA=Y=Y+'7X'=XT4#A%X6](T+>60QOQOH>3F&*]II]13VD
M>99Y'G=(QT:M'-(X%3R"%NW6<`Z]FQG00DX)LEWT?G-/)UB.R^3F_SR5K(QJ
MCBPO!EMO!I4TNIPBV.F&7H(I$\KI!&)3)T*W$Z%OX]JK,JMV'7SBAPV]KI>S
M="(F*J206^6DP[F7]+625IY<J=Z_HY@H=PIX*5GU*;ZWL38JNS"B1PK\5JJZ
M:*7:[8'3FW/L_`FD+4BCFW,54.VQZ4'\&@8V8"R?%PB,:F^&0*\Y98W)<8_*
M<$E3*J9?T[F',RMIADNL8//:TCANG&A46QL%2Z)O\.Z<(C',X%<KQ(EIQ9S@
M*JJ9`DE^.(,RZ<`BTU(IET'T.0]VMC-_.#6"K;\Z[JI!G[(BIL9=B2JB#5IG
M+UD<HS(HE44U1TFKSHQS&T8HI7./5A+:+`^$@BR/P_`74-W&032?Z'34A#UR
M"=VI+EC#:?!^X=R(X0[.'.8"**Q/6XG-64D7J8,57KA^IV/4X'=XT8`S'T*L
M'?'6]A8T4H8];+EG@9/,:3_VMJ`SCK-&L>H83+#TDC1F);O@S55\&<>M&P*E
MN5%)0*2R^RLET3VU[,9\JTX?R9,,>U@@+8(^_MI,N5DS8\*II0@K6[$KT-/K
M$<XWB<M@TP(-<"*WDBCZC(JO@$D#7=R1F&4U1)_J*4..+Z!O$"&G/NCSYK@[
MT+21#K]B"H,?[:C9&W5R]8X9U4A'$JUE+3M0+A)_@AKQ#:ME:U%=/'NE`%89
MC+(BVM56H=7'NIGX-KV7K.`0=USGE>)"&*N]RD^5F&ES!OAN&X(SW.#78=&*
MF#J0<-HZV,R'QC2]L'U9SKVLCA^5&8=1U;E01>[I@5*)^P&BSCQD+X19'3P1
M0#-0,0)YK=K72.:XFSD92P()L=[IJV:B;35#YU:NDM@=02PGL1PG-8.7HUSM
M,)S@;]"KAZQ4Q#JS6%5[(N)^N#VFZ$?GK<'OR*"!YOU6_'UK[9#R$[3**FO"
MU4BZ+:,=0X>487_1$N'7ZE_A$T;+8XN>M$ZUXS=IH9T<`"J1]M77S-!#UPNC
MC^LF\KD0*Q5%<%)53`APRE.Q'O.3S'2UL&AV5G?KN8B`';G"75@G&*Q4$'JK
MA"IF7YUF<V^JV@4WA*5&JV>*2&UUL]QBG&Y&S\$N$G5&"OPZMFB[79&J.JV@
M$*]43T`40_FYLSK9"$5NBHA<<B6>VJ%KXJ)OI'B_Q+T0"R6!Y*)0#FWV6&9-
MX.E19C7N[[/0Q8:#X_I*_9E'!OR*SE'5U>%2%$?WB(BSD"(^=U22'$.KYAA$
M<J;H!,@U:*(1!+&NXG7*3#;GFPD\U*M<I6^3A8?6;Y;`*"JFX2GWL=%+_+3(
M8,GZ*KU)U"*"VZ&R06]&":LM0LX>T0]?M%?5T&>S]J)B2;&UH-AW'E)+>#<5
M:ST?1@@--/%,C_"F-J#8U_Q*M;F.N(GGK>B\FGFA&PB1(X21C.HN1A=)D6A'
MR0H#"0P:(;2B0OME14+T_A6)P7H0^^;(1X4.1HI94\D`[G'-YWL4[='\UQ&#
M;[@8.2EL9-H4LIA-P'8W=WSBOHB*[D#6#ID\7S+^I79'=ZM8.JDK7I/C)L%2
M02D6^X>U$0*_B*.,L@BZ,68"/5%)YU)9;GW/79?#&C&0F[&HS"(Q78C;IVN\
M9#G.`19#FIQ&\4_5`4.*)8[%DBC0J-H+`AY=)7XA<.;?N.R"Y1;$W#3F%>FT
M3H5G.7$K]6I/>W:VUQMY<8%>/>L5V@*&P8Z@/*NL)*(A':,%T7>=K[3X=+-9
MJ/RYOMR_%H?QW"OT!+<XX.+HL(C2921RC,S<Q9?C<=S9KY=680J*OBA=U=8E
MEM"WQ0*176G;;J%^]#N%I`:_PXL&ZGRPJIIG=9I;V&'OD[NKQ%*'U:PPAN($
M)_:3"590-=-E\R`;M\TZ<[A<YA&$/*=&#`9R3!"#7#U=[%L+6OQQ1>,>$6`Y
MK(&(_N$!;E5=H.T0S!8@I9/D1,3NX"(CV@OTIE!+`L+WZZD.%!#JKH]4`J/`
MX[<JI*N45&Y:RXW'P6:M3]FZI=ILQ[N+"/Y(@5_..#+A2Z,X+&J*ZRT]FNK+
M%?0*]P[H&2[?+HO62=Q%W"*&-U<PGL5`#D,]!7^U>7Y.S)/",K=BKG`3RV8=
M?:3Q]I0A;[MH49QJ9*K_"/O(AU^9V]=4A&?&"@G!;D:',]XM#.N6V^0>]=Q(
M"@T2GKAENKY4CV71,YEAC=/4,5$PB(&M1HELC9BN*]R5CB]3:/6KHL[C.`N0
MS@J)[143#<0:,;S;?@9;5L7K<X2K92E+^\)B^]$0_'?L8'7%'71799O>U/I_
MWAK\#B\:L.]7)I7`%*-=<SEQ.C-\>45'%^@I0)84@+Y.L&ZT8V04TY6E+Z=?
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MJ+5^OR.&!@R_1`'#C*/=R&9.16+7+N]''C3F<,A,C-C.5V6R6EHE<\J!5LTI
M9006'C.YT-=T6E0!5*`O:E^JANEEU.5J?(&)+2^114D?SX?%^\F*U4I6L)B6
M[G'*2;M/C(5>S2+*L^2$JX3#(KHN&UIC53BYWY<F\C=$9A';;O;(]_V*#6Y7
M/>?HLRW%X&$W@OD5.AFY9M;1>*MJW&Y.+0D,$6$:NA/A)2X(+[W%N]+&.'W$
M8(M#9AW,$ITGJSNWT.?#H87."`O]WQ)^V8S2&7*K40E"N;(AU%U+$<$"UB7$
M?'F7P:$WGFHA?#4B-&P(KIH2VE6FN?MNP/&4-?G+'O6>:HMF?F%4YQG)!*$Z
M>@I5KP*'0F*TRS0CK(LX(/OPA1I3UA4;Z_-%$MIFVXRR'>JX.$AM>K'L(0VY
MEODP8FB@\)L?1S+6V8=RC9N1A8T5*B[SH0L:4RQ^9*^Y4Z0FI9M8#G?&K.H<
M0$Z'X*,\7YEGE8*<&RE"]N42ZQ6&R"G-B0@[8VDONR-VT'?V0`E].F<R^*M)
M-1ETYQAP_+811R-*R&#A*(TE<[Q9Y/(!TVC,HDO,26_@,7#LV?":XE;9C9F5
M17`YDA(9:)AUY=@;#)QC65`MUBMD=FY7]\50P:_CVB!L@4T83S&7?&8WL2B`
MAH_43K(TN1`5O\T8*\8\]8KM7,)6H;6Z:3/R::6W<1IP=W4[RU:%Y[LYA)F,
MGRZN-W24'O3U<"A'$IT-V+@0=2BR\/<2,X/T_17V)[O21E/1BNF5-C$QV8\Y
MV"P4YDU5S+=5[HMHR.T835>[@NBD>[?0FJ[':D^Y>KJE;C[UIM)!3`I;5N<B
M60&V@<&&7[+7S"JF.=SBB5:_:"L[2<O5ZT0OT_`F?GS1\E'S.(Z'3RXGNC-/
M`A.P'9?#V64)NPC;B'LETFG]S"[NN)OHYDT1T='%SM@<3WI-.V,):0V4G1+T
M5'M-VU`RZO6JGJS/XM0UCCL$K+[9<+&<$$L!U'6.X^4H*KH+Z!5625"OQ`JD
MTB#T39(2(_8L;&8SD^ZS0HJQM+T40[.-GC&/0D[ROA[BI.85N?=!CK9DZ5FB
M-?@=7C1`^*757+\L0LO5"HGQP+G]P)UW?"#'?G"EZK!@C.-6ZIALIQVG>TE4
M"B*X4,8%[,+B;>@I(A"`7P1MO[B7_K>I@-.$0KN(!2/KW:Q5M8LDIZZE2,@3
M),.<O2;LKTWHQ9T>,>">%(\`&6A_'@TG/$.`(&-1ZN5L23<:,5-/5CM,\H1T
MJSXO3#9;KR>SFC[+%="ZP%[+S2-@A!+.:9-9KB9@WYHC=_#\;FFHX/?3NQ5P
MJ4W0-,G+PX!`AHDPC7A^\NUJ07C1:3=ULMWA9:^CX2+-QZ('9[:T$I^WYEF#
MS1>YE/AWJNO7K[#9R]NM`-TYXJT_RU#@S1/>DK)D>T4Y[5@+`YW5&"79-4[3
MUH**/4G>X';R&TG1JP<397$@=G"O=971C!=T/'WA)[2F!=;E1))`4H0&ZKG.
MD6T?F<<H\RUY;53$,)1X57ND-26H,<S!UWY++1K=3W5Z)HY[_OJ69`3B$&OC
MIJ8`28A)X<D0/>@Z2>,$1?A$-$YG.>QN;.<5">,7OEXV[CRX70"@S?VBSP,X
M_RW2/]TB>MOD]#6%@%2Y+LV<$9D)W?&R"/BB-5,CON5$+1)=GY:V((ET]"*`
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M4Z)7S`XP@=0AM/STNHK5&9$O-%3PN_4VN/(Y>1LJSN>>DT+A*]X"TH%[/X3#
MKH?MK+H'24W"W"BV)O)\V/&.+GM2>=[4)=IK3@,9%&4,G>TG<!FU[#GH+L%6
M3FVBB\>GZ2=*$J:"8F0JW4:X@_9X3U6=@WRE"8M1@DV3;%Z1</)3;E6K_N4I
M7J92R;M>[-]JK8I=-;>WD<8UCO>^[<&='-WK[4QP/@`[BX!MC6[E2R=\BTA0
M:;/M:G9QR*HV%1]L^'7D$@E/.W0S4H4^6`&7/PQE<]R63]S'C?)=N2:@Z9!?
M`]]:YL=RF\9H.2^'8]I1+M&)7$JB[GF;[M`*\&AO>@2'VVA<'CTB"=/.?SHB
M>K"[L9<@<8[9(0YZ>O"BFB'.I,8*,.0TGNV]Q)`(:GM51(%&8:L;2YZSZGB!
M+GV>A2WK]"57<-@4^QI:\J+P=">%7W!W=S);A$_)D.AD_`O`CUYEO9V5\.XX
MIN0TNG9B8Z$2)H6$#3H-\I;*'3^X-D2IP>_PH@'";P^VI6^%U[F6BK6@&0#W
MEI?0@4YZZ5__KX7`S>ZF313F:C*ND&IQ<"8+H1%#Q\V=;3+-;*MJ7NR"@R!Z
MZ7W"%8F!'22]Q:K213K5M-).+K<G"[$+FTK<O]K+@)/R:-6!O*(H/LUUQ`I^
MFMP[`C]XT",$S+.S*-0_DDS+M[6O/"28+E5?!`S1#D6,1W2G*B)]PG87&<E;
M"5HK%L>JN'T$^E&,3*J4A\SYL.,>>"W;UDT/O@F.@KWN+Y#>[L=,[-I5?JOL
MMEC+E;.DT-)F%`E1:0Z->2I</<$HUT/;O)V+7_`CV-\/?WRQM0=;Z;+-/'BH
M1335\?,LFZ)/ZZ0-V"20D$W=SC)]*HA9#Z9<0K,-=[/-4K<$VL[]H-K@=RJA
MI8$*CS\V)4Y5=0A@DUAJW)&K\ID49IGG3&$B0XNBQ_KRW.A]4G1Y%HDO;\JB
M3(\NBU?Z8DF##+]%.K\D9+NLQ2J/WOH4K$GQ2&Z].W0T2$]^UBPB"^ZK[_1B
M5N(._"G(Y*MI"5[-A"\8M&>B'LSHG+PG!E(DRFMY^N:-K_CMC,="I9TCF`%^
M<%%&9&8BU3J@/(+#>FE8++=/Z**A0CJ8I7_-@;81ONNN^\WCW*^5S@@R0#`;
MKL9'=-$],EWV$LSJ^F0^W4Q)R]`"Q=@/7*9-IY3HYVQ)M$L*V3J/CV&#$;UZ
M-=)MTU/7$P+WTD[1$MO-FN]WF-$`X;<C5S4VDYU&`R'#P?'`BHV\B!HV<A4P
M;STV/$O:V&TIKJKHU4B&W;0K^7368:V0DQVT$=;[?@+-QS_/TV"S=D,7I_=+
M%8Q4TN$N,;**+&(R^@K6K';NJ.;1A7EE"F]M)X;:>9NWD9%H?NXY)IB\]'7:
MMIS)@-FI65%MH9MDO@4PO^`C^L6*JY*?(:J'7&A-[2#UP(!.;$*[;3.R\VV#
M\(72KN<>K:@6<T&TZ02I*VJN(?/]%J#`B-J&G\+79;AZ'>@Y%]J!',-:4QY%
MR)L>L*-:`A.I\%2+<7V98(Z<1XD80@JSOJGQ)(!3WW*)C/UH+S9UI7A@4P?_
M2FNZBZP5;R^J7XC!?*+S6TQ#6:N&A'`OL5[^0CN<&HL>O9IO+$=G%L%R1=7H
M12[>A5/8_TSZMB%TW<(4W>$6]P0RI,NQ_[S8F,,Z`K<O4."MXQ8M$<0PRF+4
ML'BR1E^!P^"&WN1R7QM&[HQ18CR,])1AQ\>N0^/PT'H>!DTG?DH;Q464C*(*
M>VB-I,GV4:R(,^BIRWR(>+OSDHVC.RU"SJ8#%?C6.W3/2>04FO$;V4M&:J>:
MPUC&D;:QDRVR'4=I]%"]/,LIDV'/!LEABCDYKDQ;8^W>)_'4@*2HAJMZYYK3
M;.(E4AAA<P9;MW&DP[M%!U$@T[*-4]I\:+I39$NBZW.6%C<)S`;>'20/D_4.
M]@;CUAEBEARM%(<(N=\:^FOP.[QHP)D/G"&6ZX9<.8)?P*'1J<M>IC?W8NDJ
M>32<6=)9*[[P?R$4`!\T_VPE6)E9V!FY[4"`NBB]U?"M,.F6/>UP#,"9[\-S
M)\9;`:*_!YYC54YVH>=<;_C"9V#I-UUALLK.AJX2)TMHZ.Y`WQT'0HS=SA`]
M$3JWTRYHJ+3#`1"X^%GHMANPZ$UA\\W?97=T`*(+9^W5A<H'AMCLGP%X8!Q$
MIPAGM:H$OC`\UQS`/M7)*GR&<;L7CJG_6@RFKMO`'K]R!?0=+F/H,A^L]+2^
MS)"-TGXP^GY6&@/<6(-PHSTI)EWZ+CT:PI#T!F#?&R*8DWIQ7$_!>\/WZ3$;
M1DD`/UU(&XWTY!]"PX]>AUN_D6@$I>VGM$QUQ,_CZ^#4IV'ID8&`KSYV4A/A
M)VUV,="M]=[%`#&70HPZ&C9EN2+`^K!A$<#*=^=FL9I#-?'*0WC"0A+F1.<E
ML]@B+!0U\Q0W5IH(#>!U!X",$EAC3;SQ`(]+!K*P/Q&^H&-@1JL"SWWJ$65E
MW)R\3-"=G3W8\"N2;5Q&7TJ`QZG0BS`?V=ND_1)PYYKHEU[6D%$AI5%^[#!H
M9A$.SWN0CA59M`>9L.PP%AX()F(_%>=U;_#[`']ZO>XO^ZI>NM\SZ<24TJ+#
M_QF06/8/6'XT/WCRU\+5(TH^EY+0-P,)8=.2<02810+2SV&1`N?>7Y?'.&[T
M%-";MOWW+X0H<),?^"YL[N#J#/--\!`;?>XDM(`7PG60W0)V$<X%./?5%BRZ
MM[%O9.K%)P`DH%Y1OG$EB-'VROJKD]#$SB-:FG)G3?L=9C1`^#5USBP5VDO$
M[H1#)'B@$S(:*;<2.A*W>3'=E_U8_MM'7+N::^<^TC_:(:T\$19>09\:A2\J
M$(<;[O-@9_Q@R>4'WY_7>8T7:<\&KRTDR$HZ#X*@PEX^[Q4?3<>799*9U9^R
M6D)(M6P.'+V25#5%+\+#AX/[.-BD@9:"[T'LG$>!QQ\7X<&CI0,?(!.XP<'P
M;[\'$\:'MZ)2L+VG@NNG+_"4Y,VW3_$=!H6\M*/03/*Y['CX[J/"@8F)Y;^'
M56]Q19*M>YR^<*$Z=(EG(<?P<T/(WMA<@.O6@PC9>'NP3?0-&'WFX?#Q=HZR
MM6=@5C.<]3J@YG]X?YBQG%@Q#M]L#4#+;U^%]'MP1,2CBFEN^$*XD?G<=CIP
M^ZQ0O/[9=X[")WEC_G5+F#TVYKQ;OP''KX(=5I3N[;6#9\)!PBC>$CO%YSKS
M;=C*7;Q"=QTX[;M7D3W+W4%O/!*F'B"_*J8SG!J&<UXZF,R<[;>ZERR$%^B#
MV5F$,/=\I_5W;P8_RW'#GW_\$1Y\FM3(49PE6&;KGKU,U=&0@ZO]!@T,E0O5
MTDO.5._)BSR]?\*1`*MV-@@/;1/GB6U/7OTM]7=;A4Z>:YXDPS5/UI$)</.Q
M</0R,/(*V2-M,/Z/C\?P$YB?X+C=7W?(A9?'T#(M>X^1]CL1#YWU*D3N7!?\
MZ)V9;0`/=I&".NOG"SS?NYX>EGX]<,=\4'_<O)94CIVQDWUPWM.R$$).JUZY
M6#[JH1`G#I65YPZ#T`FPJ0)GNMVWO`1K'7CO_V#T-%A'^GD)?E`?4$&YZO&F
M$H;3A?B]Q\&*SQH*'!2`0Y31/WP>>KIA[V^#J?G21>A8-NL1]-3@=WC10(N.
MK='HU&?,)*9!ZX9C(71[9XSC`KEZ6LI>,M_>@WK23Q4ZY&>2<A:56Q9\C;8Z
M=/2.M^@XWLGY72DRUCZ#(\/1TY\7F6`;8XO=_@M(T3*XW?IAB0FGO\B[4O\"
MCO;#RC5[EVB_/!;Q-_K6[H3VJG'=&3P`HN>^#9G/X23P_^H=/_>YO5]-@/P4
MMUPC.T[)=\`W`W#*:X!KIQ[J@IMRHEY^"TP,PY-DU%N!5`IZU\)>^T[>3(!6
M"%]P$JRIC*FFSV4YJ4!-#Z'VZT!9:^",K'_"=Y/>JW;XT91Z=9%'G8/N5^)!
M-4`['-R)""A)"$]^P(]/AD!1&/20LXQ$?IH'MR6(_6>_7)]Q0K@Q<D0(KB!-
M=;/O>]!T]LO"%[31/2/NNZ%;Z(=/)$'QO%T2YDP:MFUO^E80KGD">C8WS'='
M+GV0OG!):@VI7_`.M_^2>"_OK)OC\ESZ(MCK&Q8EX>DU'L[_WU3?HM2_Q`$^
M,K'CSG,`7V/9<!S_)5\CE6_\>R8?A?03-L9$G^'!#[WI(F2IAVWTYDB5U:+;
M1#%@/AW]C@1G;6"-8FMO&WN`/_!X@96$L23`'GJ5^,%*,)[P`,1?Q@9'5`1W
ML^M`S?;"+R!^P:NL'EL;H"T*SZT?QUKT!ICIWWOYW_F1R4(\6(4'OH#UZPBT
MX3D^UN-.#YCMS7/]<.D3KIV?3ODF*.>]+HXY#:Q'W5*#3'+.LXW0I^VH.PCB
MYST"QX-_Q4[H(DMA'1P86?!*IU!NM\-\?_B\USAO4'M^/OAIG]&^`]:`O?"]
M%:K^=O)G7O"?$A=>B$"IEO<[W&B`\+N5PVI^TC-S=%)O(,UA[/(=/()09-)R
ME+;R),!WX"/1?,`D):<"^7^"Y[#I!>X<4E?40V@D.[$9-P>_#7#6^YP=VKV!
M;"PX]WV13M;/^U_<13>5?(4UI:HL)7X*T1__A<2[\6L0/>-Q[B?C+`.0DX_9
M8.D)_JJB]W]]<.B]G`GYCT,G?7VIZ"C^@@_V`78(Y\=O$@.4KS@&KGLMCD^-
M_L-+M%_J.(2G<5)6#L&V@D,%OQQH*]`>;,/WX*3PE*LW2"([2\[@:$X,>Q[&
M'.Y]BZ[LY0!BT:G#2JSP`KB^H:YA-%.PE,C9":RX:(U.]'J__YH;TP&MBXY+
M./59#VXBQD[X[AOB2;]H^1[9N"_2TWG7WT7[5[T-6U'SL*,#`Z?`K/]>!L5N
M.!S@_!=(XVK`503ZD\2DFT814?*>K$@'_I4W\EU'!X^^3?B!7P(X4LZAA[N#
MBI#6+0?![]_V9%\,7?LN;+%\U28&G`M733^K##K\\CRIOAH*3C:N6*!71";P
M1W1\M]W=R58;HK25Q/AI&+WOF"T$;H;,D:QT:Q?Z"Z]`\IBZSXK<\`&-9@Y8
MT%&XQ;6?7'?.$R*S]PO_B0&XY'6AR7^F'*F*@6ZD3NR$(T"Y]#/(7Y^DX_()
MG,QA:"XRDDX#..'.)K.#+HC?^#3;.ZD\K'L$`M#T&/N00=0.)\Z`^/?N@H>.
M5:??%N-SZF6`1;&M[/YMPX_K%T?#E]U'*[X`WP=8"&NX=T0P:P8JZ$I5>&`H
M;I8.=<7H[(B>3NR5:_`[O&B`\,O%$7D)<RK[?GO513*L;`?NJU-NWBX\P]I:
M4AF2:W!_4B`Y#[_DTE_E/NIO?]KXG@G<HTD,:[.W-!\(WE\\2R`YP<R2C3OV
MC!="W`ZBG_?Q(3?$X)*_0WN.N_H[77"J*WK&QZW&=C@J#E<]%^GIA>*;O&=O
M>24B<IF^7K#A?!E.^4=K@93V5WQ)`!_,\X+Z!I?BNI#=E0$L^%Z^O0UFP0G?
M@5=[PIR^Q9LT6M%$'9DU9-JO:7(_,9YWV0%S`)9O)/LW:18]?,RE57QYFB+#
M*P0C7`_ER=(^U4*XIAE<\95OR1P$+T?6LX&OX&8X`."G_V!T);8?`G#!2U'L
M=!T*TFEKZ(?&X/;X-Z'QUQ_3%F[9]'<Y!+X?/BLX8[?D+#@C#C][%++;7`?[
MO!<^0Z>5C'_G-NY7T5'%(#D9L?DL@#]L2)(RMIVA(P'Q1!,$W\J)5G@\7HJ6
MSY4^'WQ+W!><E'@Y0X=@F-OEE:K.6*G:HV/PG0^JX"HWQQ#5Q-7J,[]-YCG`
M/5WTTQ$S*W?:,KX;(4WW;W3X]G+O&A'M\MLO>A6`&^T8CPBAPQW#=*R4UP&Q
MY:*WA2*ZM74?\)S]=X+<O;";3OBQ9SU/BHHWU>$_&0*_>`+T9R>I0;CP><A@
M$'N;T?(<.S%TSL.`[>X#0#KU#3`MX1^^G_VT?WP;#&,2?6TQ!V>`^\A7`!\D
M+18@"N-`65.:GM=$0O4F."H$OWH%.N@!GPW&I<0CJ')"(%?/T29-\IGB<-M`
M?`P4_]1SGYQ8@]_A10,-O96$Z\S@KG<=GXV>DX![WP_SE`1-8>=_GE/(EA\1
MJ-O77\FT\.Z^)S+K4;AYO]'P>Q"MTI0WTG#=C:.US?(W&^#*YV%K+R<%+0[#
M.4]SC4!_[Q,@W')0&"+P%IWO.=?F6^:JWX;72<7=Q+,&SON4+IC7G8*KCH&$
M6_[8BG3K\,[#`-^,;TW584D^!\;\@S=X^`OV6GM%3_@FW.*OH+>4:[F](1G_
M#7":01HTA\SA9)%Q6,6A2SS#/HB0,NO@@%:X[\V&;I2<LH_UL8*2RP8O),-@
M;^4CKE-SX]/33KR=.W@_NS`"UTF8J4><@&OA-+(.-O@/3<`5KT(NZ[>WP]YA
MXFUB^[NPOQ?.>1VZ#/;PS%+AMZ_495C]DY\X(@KUL!RYV^&ZZP".6-*-T_!=
M>6\Z^]Z`=N[T!9?\CQM@[L?M;#M\<C6,/@S>%Q&!J]U?>YSU=O@<18,"K"-U
M;C,]13:`6/\KR>\^A8RF,%9K7D0KCU)?J]O0H&N_XL;X^T4M(1?WE:5,%[2G
MX&MU@9O>`VZ.P9FQ;I+PTXX&]Z&^7HWN,YI_$(YXB'!8^<<L@-,YP>8C1RFG
MX.Q;P,G&CH0YQS_!WYQO=Q_NAXO><)5RD"O"05ZXX!654\>WMLT$^/[;7`UT
MP0G1<0#OZJ$2^MY<#LU'TFLP=R1/!._/7N5[Z]82^/^T=Z:Q<5W7'3_SYLV\
MV<@9#DD-24D4Q4WB)LX,5YF2;=D.DM9IFQ1)@*#+AWXHD'YQ4C1%U*";6MN2
M+5NR-FNC-DJR%,6.V\9P&S1P4J,MF@3NDCJ-+<N22=KBSIGA[//FW9YS'^5/
M-8$I.IS7Z!`_&"9I<]Z[[[[_/7<Y_U-T3CP:@'KX6[R8!/SLS$#@\_">\.P'
M]37A7UR@;)H8#:Q.FLK]>,MN@'WO[)J4*TZ'?P7\CS7-%GIPU(A]K^F1<ZUB
M$D[]"$-B[2X^J:_Z6J[QXH/%*%5^8[5%T2"6O6_=T.IHC:G/#]K7#[7?I4SS
M8/Q>PL5O:4&W*O.)_L1.)X1U93\H+AM^W^D;@_\2C8\WXCB.X>B&O_L7[9>K
M7!B:*E7N'_Q3])-^_GZ&#IR_OKNS'M]*)_CW*#^1:W>_XW17^S`N[CC_5@OE
MO(O.9QZE&LK=H+;TN^X(3T*>RL`(3?-@6`$;;+1BNNL<=N-&N0O3L*##&^?@
M]V?::71(T/;0$GV62^;15TY^%S8O&8Z?7G^T%0)-H/@!GGBZRK3ZE`8XM':Z
M%[;[?#Z<6'J?D%JM*P6CYM,*:':,3ZF\'7[$K[FU+>!U*C6OOMS[*:C>Y@H`
M-/9[9".'7#>^ZWX$6C92:D;]&V_+SUV"IQ_%]U$!Z/8]#HDD97]_N9;2&U6(
M7KNS68Z_RC=^W=W0',2K:AYS_*?P9?4VD==^$[0=9B)DP(>-O',<1XK`+9KO
M=[PM8/:<>I7VL\CQ@)Q\Y./#8#)/-L7.<LOO"N7VFHL/IB6"EIR'6_^!#:4U
MPB9_`_S>-[?0^8V\(EUN?'NKJ)_481S\S3K=H`V[M&C]PP!4P\/=V%A=VW!J
M\'D_-M/6K3`\\2H\'J+@M!,:QZ?\3V!'<\%FN^_U-WJP,W:ZJ.C3/_^L42S`
M]2\WJ8J&\\.>7?!NMAI'_S^@&ELTLWMESB>*GJ1,>7OML2@]03>MF?\[%7^!
MWZ7O0@WX!OGHM?K2"PXQX_Q:;0V^@W4P-/'N)J'[<,C[#7^-S4ZUQ:OW@I%2
M9B;ATZ"I`25DJX*OJ((/GEF-D@^>.6E#`75@!D6IAGRTBGXZ[HCSQ]L@$XJW
MTXHB.39XTY3,CAU^"P4\Z=8/!)!7CVBEPXUT1J([1[Y\6GX2"J*=4J7$)_\<
M8["<.T9;'K33(>(.?*-%9FM:!.5\G!3^;2'/R5-8U183&V9BTI]*'C]^]J\V
M+Y&EL#*O0R(5_&(5_+7<Z1!9_Y)P/?.8\RW\]B-%OIX>_&LR>+/)9*5*G7QP
MST@QQ*:>H?APPS1=C[*@MXAB\`[^:IK<Z6>%7=HLAV]1=%='\_WD*)V_+=K(
M:2'I$?E:#-C(C@!_^R',Z2`=)#"<:[PY+Q<9$I"BNDZH3J%"*F(8=;0PFU$^
MH,1A-:W3;%U:OJ@?"5>,RD(Y\>^D5X)QN=.*@=^;=++4*V;AV&EL_V'*H)D+
MY3/-'0#?EVOU.$/!A[+W\49*;\Q*VW;=M+V5QZKSL&K;7D[YS<I=5*HKD3>K
M&+M$P2-S0!Q"WQJG-6J_-`FIR8IN?;;[EG3&D,6&@CCB2.\%K3AMSPBXF\(_
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MM^H<3(MZF2_L+"1=\S)-`Z^*S/=.V>"S\`'UTDX1K_G'XQ':(4JTD;%,$FY>
MA/TO^ZGKY@(TH:.S55HL316X<H6:BLEOTC1T]2=E5J"(P5W3UBR_4>1,V\,6
MO-0YTD/W.SJU0/'G#;0L+]SS5`*O_D,!2:-&7R#;BNRJ?^Q&BC:%DLE+#_Q\
M+9U2,$*QCU=?I1V'B-L_H,RICGFJFX,M0,6&BA3T-MVFB4PUU1S1M9S8FLW;
M:3"E[,*:VQ<`?AMNTO&M7ARYI@ZK7]B_2>3[9:CI6S@9_,*;TJIBU7+?CNVY
M:O4@U'4X>&8:11K22?)>-32O,$P%QHYANQV7C5"@D9>>2\*[++9@H]$MW\)&
MZQ>F19[,)IO&9ESRR1HBGNRR'*GC571R+&MN-;937F'"G*2H9L*12/AUL<T<
M[_`Y_MA4Q30^A>A*&M(Y%QW+U!UZ%B8+E`R>$`[I&D$'`G]ZW@NC5(9>3&/3
MN?[MD.VA"_5YX9REC^Z0F2`@G>O:Q"QYZ<]2M:,0[<6LP.Q'V&?:\TO.#RG\
M:&#YM18ERF\BOA'?XEF9S(M]X\X"QF#.!5E((I]_6*984G24)$]^34Y4;?+%
M;UX6S0:91CI2-(B;95FD44G!)_\#\O%+KKX7_^//*9=V-M,NS?Q=J058=7?/
MVM."(CKLX9.4!;8%HVY==KQ)^4\4KG\5\-VQ;KPI)\[;''6_>H$.KQ9%_YNG
M07/4:E^KNDGF9JA1&EY;D7JR7P9(6B%=N<4''=^:_F+<L6C`2@X'%P^U0%'F
M"^=6A6)*C.DIV3@+@65ADQ::D93ITADG<S/:@I3>LXMDC-9*Z;VY.FG\597,
MR7ID15M,^`Q\WU-!453)IFRIS4SWGA1NDN*9#70:EHHLF`5)I6T7/N6TZ5GD
MFBY*CX*L1RQTO_(9JGZNPG:<)W_E1:K(L"+<=_^BC=8V]@5%:O.'IM@*Z>5N
MV,CN4F9#%.XM=Y=Q[==8]>3\&%TW==B^,E]-.=?TVXX8SA?H<7MB>)$?02[3
M*!#1<A<[DHX3L2#VJ#3=@IO^WWR#*+@-T21R03.%9)$*.7G)OJR@QF)`[G/4
MG1["(6\F"4:Z2F3<,F5FF[QQ#'W=[^(8M"@7[MZCF9W\N3>^W"PR'II:SCC-
M.E`G]\!63Q"J*(7B<U<4NHQE:0*?Q/&"?%\7BAOQ0Z=-5S>Q64_+K'"A+(KN
M]_-D=ITJ.`K"Q?)K+4I>?+#3Z3)I=X-=)8-]CR:G333AC5%:99S6!ZI($])N
M*M184$1*R:?DZ*S#=()B(9%HDN>:'-+KQK'J'D`V"\Y/^CF9H,ZC("ODCAB'
MA&A-%&TDL\N>.X9'&-H\N563&T_"D/I3I-.D2P6SG]?/TZ%?E%Q4&[<@O\%J
MZ<[:M"0V4GBL.T4\*A-LL>OVO;]:C@>OO&+R:]8F+F2":>F-20-93-HSIM08
MO6X*G;ZCTZK=R65\`1W4/L*)L]TD[2UJM#YS"Y^.5T9]:DH/B*)3.FK*RC6&
M::E1A8]L%M4U*X]+Z?88':4@1]]L+D2&.3$I$;J,G)/5<C5&%>GMT@&,COWK
M!;EEIH>6I5TM?E8NWR;BS2MT0!$_2)VE8JD8)WL*\NG+108G&8-(VWQR]\I]
M/$"7^^2#@ZP=<Z8(V^ZUL(UTJ8AAH1>[[D(&>W*=2(12<N"F4W]XG9ENNDB9
M-2]G9`&Q6$\+`D7R=J!EMQC.4Y1\42Y0%#'\\!8RLL6*GC3-.WQTUIT\>;KQ
M,I;DLE(^'A`KS7G:HT3]].&[$TOB:-B5H4(8F\6*(@SYUV15TQF:Q)F3%X<\
M7`3I;*/,>ZK%ET6G]#T'K3LMAF[*/D.&KF1A72O-F2-4-E%(PT",DY.\]68Q
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MY7=-6'[7#Y;?\L/R:RF4Z$5`U8W^J3;T(@R?AI$KKFUGP*ZD!4-@7RT6G$)H
M^8PO)ZA6J+?E.`P\6W)31PY4/?(\1+X%PT=KHJ\!!(O"D<Y"Q6_0*AB0,%!^
M?=,%R.6\@IHZI(Z]6G([CUZ'\!'/]E>@YSQ\ZBCTG`:/)R>XG5?!7K=8(//V
MY0P4#%M!-"P*!5A^*T7X+`R>@\&GG-$S$$$%ONCM/@&:K(?(%*"0<QJY4(;*
MF87B1?!4U?E[KL/(Y=*;^@9T/6D;FH#>K[K#SRI.[/Q@5E!BB(Q/&#TB%A)Y
MNS`B&)Y17>RN;Y3<SD.'["-_YHN.0]])&#L!72_A@$F%@2I^@Q8A$:0:<Z*)
MRG84%)&@`M!45;GB0G1_$CX!PY>4H<-:_T7HPW\?]_<>(?DM^AB"ZLO8#:I,
MY,4@2G&!HPLG"Y=*;6?/KN_8P@?=#[X*0P>]X9,H+4;:3U6`*WZ#UF"!2E[:
MJ/0G-K@>6%D!<()]UT3)_7GH!$3_V!$Y#(-G8/2LI_<EAP.HOE6E;]`J"']!
MAVS.I6<<LN:IEA5V%\MOI0@?MHU<5@9?U'JN0.\)&#E3W7,(YR(IP1!&(9!>
M]E(I-,.=UE4<F#SA/X>'2V_GMGU*^"GHN@0[7_9%SX,=_Z!?Z$K%;]`B8#R6
MSGD,PYE9+86L@1L@<J74=M:&OP?;#T/O41B["#LO^'8<L3DIZJOX#5J$.)7)
M=NC"LY)UQ58@2RL2'0&OJ_)"=)^"<<)E6_BDJ_<J]!^'G:?=O<?`88Z,C)*1
ME=FILJ2HFEIN\VQ0ZD:.0N]XJ>WLVW6MYL%3L/TH#)WSCCVMAF`NV2@K_%;^
M'JU`I@CI1:#BR\(ETL'$W$:/%P)=);<S]+VB1B]JJ+VCIZ'SD&_'X6"S9V:Y
MK^(W:!EL5/29.MXF66I9O3/I:'!S]%LAAH[05'K'"4__91AX`<;../I?`F\'
M\->]+TWS8["*<V'PXG>[O'VG8+CDQ0?HO@'M3VJCQV#D$O0\!TJ/MP'`5>E[
ML\Z730VX[1J`W::"`CX_@-+B'SY>:CLKH\_#T"'H/P`[]KMV7=_TT-^`;0`"
ME;X[RWQY'+1]3/T9JE45[';8U(&M\V#EA>C^9/`(1"Y"^)AWX!(,/HLQ@SK\
M?=CR)>?`:0;QMAROCWS'V7VV[H'G/'T'_)%QW\BWH.OY4MO9OO-UVXX#VM`S
M$+GA&/C[ZM[+KI9S:N>W*WZ#%L$^<C;PP%.TUQ8];Q^>4/N?A\A3,'RMY/X<
MWJOM'J_:<QEZGX;.YYR1R[9M!S?O>:[B-V@1:@=_"*U7;8/CCKY_\(]>LO><
MAO`+T%-Z.,'\GS!T',(7;)&COI'S,/0DC)Q2QW[B"_\11,\RB/K`$3J8-WH-
MQHY!=`+Z3ME&QV'WL9+;N>^\?_<1V/9UV/$21*^H0_M@\"]AS_Z*WZ!5Z/\1
M;#^H/?0,#)^#D0E'](IS8#\,E+[X,'H2>F]`WU5EX(AO[$7;P`EZ?#T3E;]!
M:T`-$CV@_M(^Z+P$D6..P:L0/@@/EWZ^FF$8AF$8AF$8AF$8AF$8AF$8AF$8
MAF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8
MAF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF$8AF&8^Y7_!L#=7\(-"F5N
M9'-T<F5A;0T*#0IE;F1O8FH-"@T*,3(@,"!O8FH-"CP\#0HO1FEL=&5R("]&
M;&%T941E8V]D90T*+TQE;F=T:"`R.#<W#0H^/@T*<W1R96%M#0IXG+U:V8[C
MQA5];T#_4$^&$W3+M7*)WR8>QPY@Q/%T8#_XA:)*$FV*)7/IMOSU.;>*B]K3
M308#*1AX1A*+Q;N<>^ZY1;_[:77WV^J.KZ/4,$Y__*=D;73X*S^N[H2_(IB,
MF(C\+Y(9O4Y3F;"$XPK'S[5=W?W(*K]7K`UM9)*$_F'U?G5W6-WM_DI;T9^+
M'_A::X4'K+4R"O^H5,J7UU-MZ'JJ8KJ>))%Z?4/)'A(E%$P2G&&9#C;MO(/A
MHAPOJ@N#WSVN[K[X.MOD"1.*/>(&'PB_Z>"ZXHI%L./Q2":).&*/^>KN@7S%
MQ^?5W>=?%_NNMDRNV5_8XR^KN_?8]=__^[.CF6>;^.+9/$8<^H<K29_IZ5^=
MLVV1L^_+K-VY^L@>;7ZH7.GVYT^R)G[;&B%9)+0W)E7KA"?P_X]@P8M'A3M_
M^`?=^4R/_2<^R;7!W?0W;E?3MW)U]^$JUBDU61>M%=<J6(?@+%JGU*5U.KF^
M=3H=K=,^AY__+*5<-$RGEX:9&X3-3&$#K+@VZ0`QR;4($&O8A[;.6KL_LZS:
MLN^R^E?;-HO&FQ=1%0G_1.MG"D0D8C3_\ZN77\292>.Q\H?`@+72$)AOBJ9U
M=9%G97F^9TVW:=JL:@OZRO`7<SOFNAH/?;)59QMVR)XLVUA;L:VMBR>[9;O:
M'?V:]]4?YZ-E[[JFJ&S3W+/G0Y$?V+-EN<.6N)VUCA75DVU:_'//-JX]T$]-
M=SJYNKVZ\ZAVD_#!>:GE2#TQ?2;W"0S'K*A:_.>=.'IDL)-KBK9P%>QDK?V]
M+4K+K/>O\0""U2=;68\I5MEGEIU.):)(]S041SB>->S4E2?V&3ME)UO?^QNS
MJCAF)=M9NUVS?^&!I:OVUW8\EO'H>2K7FG,1F.3AZD]"^YMBS!,^UI[QGRG&
MK06GG\JL:FZ28;34/L.ITB/`C>F;2X:^MG-YUP"J+N3X7>'>5[8&%PQ8I7S:
M*ML@R^W!LE/MMEWN\P_\Y[8LNQ*`R)EM#QDZ4TAEO]7WAZP^9A>PG]OK%@&`
M5N@#D`@S!6"`.(RH@;^NA?U'5[D<B`,"J<HW;EL`T#]SP[U#M)1=KH?QK2VJ
M!BL$HEBSDW<V]U>QR;9H<O=DZ\"JDZO7UQ%$9`0H[Z@4Z:AA=()-O:,_6E1K
M:T-U9GGNCBC)YD`.-9:YS2\6MH%\V.;,*%E[;W3/3?05M^VZV@=A"[XKW<EG
M\&UYXC?`;B56U]F>]KA!@G4JAP1'B;F@\(G"-EU1;NGQ/<+M[Z!U^KZ94$E6
M4](">`//T9*BVM59T];('#1@LV:(8U8V`/'O)T2,HO*"O[<67W9GSWH]6SK/
MWUT%RNSY\19AB,V0_DB,+"/$B/+@(B6&K&B]`Z4KX,'!$0`NC>R;3Q\N]UP%
M5C_4KML?6!.T`I(^Q`\A*,MLX^K`\.RYH+L)*LWZ4WV-WH)ZS$=G;Z((-.:,
M'E`\%5-3E'(LI"GW>[0YW^5&">`;?B@JNT-%M%11?_,L4GBBH%A1K0%</WSV
MU4<W%C6H(JLI#5^&N\)MP!4DA4>DQ]P8<"B.6^!)CA-1JJ?&T4]$8^*SNLZJ
MO3W".J#F%P?C&/SQM7)/E+<#PAK0HB>4%XN)+^$GXM<<BM,`&N`-W:AU1_P\
M^-\'(*LKST,7!)/G9`3D`O:[11"X'IN'3L8@:(S1/@Q'"!_86J&/9>?>+:J4
MVIVS\B*#3]Z!!IV2'.@;@9>`]I)/T8.)HNO*Z\NAW(821#=IZV+3^6:9H]-6
MMFQ\V_'%FG=U#0MN$0:5#!J9*S6-#XGJ)4S@N>:".1O2M1M;%G`,B8521M;K
MO?6"$5RTZP@A!`&R?TCXU:?K5(VVWU;H*4P14Y2$;[I#(QH:\%2R;H!VCXM3
M41&RKVV407[^/^X;/06:ADPAQW,,&:>]U'2[G>^*4![(=8XABC@M-$6`NBS^
M\-4]28I;(#D>!YYH0K(6`Y)?43%?$JR_`$I]P@(5N0U-1&3N'HS63J3/_H,&
MBC+^T*(G-&Q/ZJ\B8K@GH-MB7UW\UA#^@ZK,T$=R!.+ZW3*9G/[$;IG.1U0-
M`X9,IVYI=-HKCU>FB<6SANOT<9E&X^!EIN%6F[Z'?5LQR7ET3U1%C:3TC3P,
M+M28A^X]4%9ARRT-*9O"V>`1Z!LD1K?CGPN5>T2J&<U"+`.UY]G6TGVT)S&W
MGY>RYG92$"4W@%Q<3/71,/(<[+&XL,+5!:SV+6?J0T3+_61_'^9T/\*$27WG
MW-9_ISG=?V@00&KRNW[(?S'P?QJH9XZT(LY')T%LBL=Q(+:?I>;71Y*ZC&@L
MIQDCZ67`(PVR77WR.GKWIR'Z%@F.QI$GE=.H9P86&RNM\$(?>N,)<TD8NPF?
MC2N[(-1Q]06VH5I(?GA1V8,<Z;T/B`Y:UY^$7>R:0>UT;7]X1<*X:NCNIMMG
M]>5X?XLX:#/)L^GT;A"IGI3IE"[;UT7>E9`<Z#DHWV,61.,6LB/_M1G/HX+-
M>08]M\GV6`3LD^J"?B&15A=`.PB_J()TRUJVJ;,P&]%,]'S/GE`#KJ-YJ.Y_
M=V=$=P,QBUNH;&X1!CD.+(F2%V'0?1S\\T,!4R7#5IL=85"?X;QVIW`Y-*,2
M;<I-QSJ8>3]0@#[.;@.D0X!#\YTA]I@_1,*\#W:IG:OW654T1X^QG:V/-]*F
M4DQO3])X>GM"G\GYEP=,XPD59'3XD'LVQ$0_?0PB_&BW!35QT)\KS\<A@B%$
M!"*'*:XKB4!WEYK&WXRIX/JM/%*CMS<9?$4\3#MR0E$B>A1]YYJ67"6^R,$=
M'1R&F'';YO)TJPDHZ'OFLZM+.F_:`B#4(X=#\:<B"]$&%,^3>,JS>D.]`\/`
M=&:S*7V-[EQWFVXIS"C;4ZXF,AUD.UPYV;9&MKOCFCT>.D)*G>6_^@,E%`08
M<(/)UH:W`47)SL2F=*;4#W"CI_03V`'A\J!Y&3*2#V<$:LV^<<_T!:R;5><^
MY,U-AGRA!SDLN9SD<*35,+*\F>=[(LQG2^S:L`J:%NY75"TY,2(=D&U>YMNS
MPJ;PI_N>#8)0&$Y7$>8&,R!N;VR@UYI>'=!\GX7(V9OT$#^J!/XPZ01[-8BE
M':8VY,,3VYA(/P1<O;[I;7LPYF,A$TZR%8M3SI3?=]K`ORN7#%-,N"Y?OP[;
MY-QU<(N8NRYXG+QY_;=^"<0U+0%IO#I(B-%W\5$BN!E%EA$A$TA*FO1U^.C?
M&:`:_N[H&/N5UY/BM5?2V#8.[R?3BZ_C^TD=I=X$A0F!CLVC)/Q_$5]\"X,1
MSZ_<D%Z8!+WWIG/1I7-_>C7,#4N&%MW+QU>E*AX1BT]\A&8C>_=/,'\&4#2;
M_H<4&\Q=EUS,;Z#X/``?-.?I[`+#YR'Z`.4_;V3,Q?R"A$,ISH:!RWDO!!]0
M_N8*E,J\'T)R,V^G4#PU\RNT$`LKC%BR-!+1PHJ8RF)V12+2!5]2J>8M1?L1
M\]"04JJ%%4H:/K]"H^CF5Q@9+3PEDG)A12RB!6\3L8`QF2[E17%`:'X%^'[>
M6R7I?&!VA1)FWENEQ4+$E!'IO+<*,5U8$8-]YE<D4LX7MDKE@K?@)S6_AQ8\
MFK=#`\H+>RB^P,1:+S&,-DM4JB,NY_&AP94+*Y+%%2G72Y3.%Y!L0)=O"XNP
M(M'S48=:C^<19)1.%YX"=ECPQ<B%S)EHJ>9,O""S'@S882%B",<\XYI4\_D]
M(JX7HAZAP<S'-)):S]L1*;W`_)@U9F2E7V%4/%]1443C_NR*6*F%IR1J@8.B
M%&RX(#[40E>/A8KG,19+E<S;$:NES,5:I0N6$MCG5T1+F8OQF/FHQ\D2@N)4
M+^0%>FT!R8E0"\(4K4'-5V6B^$Q,(9_?_[2Z6]W]%U*<N20-"F5N9'-T<F5A
M;0T*#0IE;F1O8FH-"@T*,3,@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q-"`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2
M#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y
M,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y
M(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"
M#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N
M9&]B:@T*#0HQ-"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO
M3&5N9W1H(#0X-C0-"CX^#0IS=')E86T-"GB<O5S;CN-(<GTOH/XA'Q9VVU#+
MO%\>^S:+62QFUMVUGH4Q+Q29DCA#D1I>JEKS]3X1>2%5747::W'00'=U,<7,
MB(PX<2(R4N__<7_WV_V=LXW24#CTAW]*MF&@_LI/]W<N/W&%%PDWXM]XP@^V
M:>HE(G'PQ/$CT<K[NY]$S>^*@Y!>%"8)_2/:P_W=\?YN_^_T*OHS^86S#0(?
M$VP#/_3QCY]ZWO7S-`CI>>K']#Q)(O_E%WKB;>*Y^'3B.@+#`K6F/0NH'KKV
MX73![Q_N[_[CNVR7LW@/^``K@E]J1,<G72=PQ0.$?_.S%SC_)AY^N;_[A(_^
MY_]I`G]N`B_D"9RM&_KX,;^_>PO%N$$@'IXP;[,7_5&*/&MW32VROCF)W5!6
M15D?Q*YJ\E\[L6^&NA!E+;KAD+7BU%0R'RK9B9^=T)';PU8<JB%O.BDRC/MZ
MJ?`C'KD;O#GK1=9*02^2A1C.XVO.374YR7;REEQ6U5"9]ZRB#'Q4*\-W$ZL,
M)TJ4,H[R5-I5D`CBW,I.UCTM.]M!#5F=2_[/H2VAA'YHLTKLRN:4=4J2JCS4
MC7E'F7?TEJUX.):='98W]2,$+Z'O6PL91M$H9<0"PK(\_^;SQ%?:]#PO4),-
M-=O,K>>+W.`EN8*;S^,YXSQO;KX]D>=?J2T`[F@C#`G8V`C)'=E%NHW(6YGU
MY(KTRW/3PQ1+&-P*OI&F%B>2V+6NX=//M*I]T_(BV(+/;5,,>4\6#/PH:_GU
M+.NN?#0+%_L6.$+#M=/TXC%K2]F70`U\PG@"C7AJVJJXN7UZKI4H]>#A#L3X
M'6*\O?U,X41W7I"F=D=]5^NN@;MK#,BS6NR@ECQO3N>J[(Y`Q?[8-L/AR-H8
M@'Y0T!H;G!BS<V)?F=T;6?\.#.YN;^>NG6Y=[4?AE5R1T;T/6L&J%Q\O65'F
M-]>G$]F)`PM'WLVGP<=&^8`<UKC\*-(24CQ!A"5[DL"'_+(5[^6EJ0N%&5>>
M:O:;G+F0;?E(T+*7[0FXDNVJ:_?53KH13W#2LJI$5G6-@*M7--\:%AI9"')"
M"XQ^[*1*4LAY;MJLAU19V]=8/U;?G/&[?JA+QA823-8'())ZVO5M5M8`F@;`
M]:MD%&H&%8J_I3$YQW^(R03$_`_XUI.*BA)3<SR_TL\JF@C-GON1I\#XC=J:
M[<T]"!:&X/J2A7F:(GY?"X(NSW%B\:4G_6O2^/>:["HK"I`DV,G?\$]9$%MZ
M/W1'0%U5`=U,X/C[]LN6]D%9I!0@HSM8%;WA@)%-S9%!@C+6#6RMK@?\]B)V
M%TSLQEOQI23JM8*RDS0VXD>3R.>9R'?*Z@OQ8[*B(KLPA+<#_*D62?BS@[3$
M+)H,Z1/]#B9"%J0_R8A_R@I)XA>-@!<]E?T1"ZT0W!\EI)R&T)$>$H&6\#7B
MC@T^D+$]]_)0YJLH8D2:U`FL(D+ZS!-'"]D>+J*#V[1E?U%^(;M^([(.($$(
M09X#!WPLVZ9F4*GL*&;^4I)78B?!:SI*"%2XL[N.SPN(6'?DU!G#UGZ0U59\
MSW96]A.M4%Z1K:('8F4Z2PCC,66"^;,>#FWS1&+4PVDG6UH_;%R"]V/KAKIO
M"8A*`B1+W4J,>JHG<AN!82$%H<KV]B$8GZ(@J")CFB83O_:M7\.GH\WHG@.M
M+=LU0R_<P'G)/P]9UU2P5O%T+/.C>,*.(6[4!3['-JT^/.O:-Y<T\:RH*[.-
M))HJ%1`Q!BG#-SBL$NQ1B$#$NGV.1Y^DD*CB@Z>SH:[/6FS(K2<+$CO9VCQZ
M(A7>,U*Y6)NKB1Q:M\2-$();N2^)"K#/"82OCB(4<"1O&YUAL&DS^VZESN<)
M9X!B+04K?HPW$=!T\,CV5]FKR@4^`>`J3WAA0=@-&"<J+_X$,5?8U3CUC/Q!
M.N*O:_#7^-092[C(S*04E40(F3K8A/-9@<FOQ6-3#2=I88@^H_S54W&,A0,D
MA%OQ#@E*RT4@"MG#KBISA"E$92`<;<&Y`DAO5M%"/!:LQO0X<"G'(BV8,(#0
MPNZ%];T@>)Z=LYR#5*=EY/T#2T;0>,S*BNDN&Q+L:_+.:Y-"\@J5("(C\.HW
M4V!/B`9#`?C_2DH($PO=KN4D?F@HF49?9N4%MO8,T;^RH6*7HI?0MY9/FE1-
M=%./_L$\RTDWG)K:G:?'GQ'WGUA=W[&'O.NZ)B\Y.),%<NJZA@IT9930(!U5
M$*>I*9-@:TDJ*PZKPUH\L27$Y'(/#L\%/&WT$'JT$Q7[\(&A4K&Z(<H"=4'I
MSY7XVCQ-#9TGRH$4+UY#&Y[BZ&FX=1,B9P3"M'&WGLL/[%PK)K9^8F>A@E,X
MUF+],#%Y[0M$$+/\-I2M)&X)TO0]8_2!B"DG"Q.T)OR>%%JQ,XP6.DQ.0`.<
MK2K()!Z1NU"%&L]<9[J=4/.MY8\C]X]0<XR,>M1S&NBRSRHY:^S8-&K,W?5>
M:N!Y:4.1J1<J!4<6^LSE5.W\SPV?19B:AHUX3[QQVB#@[38.ZJ2"]OOVK#JU
M@J[,-?%D5*GG>]9%PBCRE%H-US2FK(V>U++"!D>I30\G=>O`B75:9,O3<,2B
M[-KAW+/[[)NFX*BYQU8K+U0DJZ/P,723+!?)XR24F7AUR,ZTG]ZWD#R2GJWX
M@%_`%K"$ZL(UJS54$-O,,)F<'P6:FNQD5<((U3Y,@X]E"U.:9N,)^`D^)+^6
M'<<@MF,*;;GLNE*QV4EI^.KDB2LN@R8RI-^N;_)?6=LZ6U]#"V%D#6'DZ8&C
M:2J(]YFW5C.+CY+*=2<.E7OQ22V+'/[CCY^X5'+,NN?(;6D)/ZN98YAZ&]?X
M+'A;A`=L(R9762[%B0J4-$+X%LC+?A74B_QTK)FXDYI)^+]#/J4G:,)JH'M=
M`_IE]O1D+*;IG'WK6Q?IR3],IK#1Z?H:"O`\6WY/1N#WT]@4;0F.+J7$W^.^
MN,Z+U05+Y&V&\Z$YG62;*U0YMQE86\Y<E.O0I=8G!VHHS6A&!X4KOU%GLMEZ
MI\N18Q,7?V(*4,OSPV5:Q+04SP?P5US%"%+6V.1O"_2KE(O"*!G!+1T)F:L)
M]T]2C``G14$PU9R-7V=5+]N:ZYE"9=+=`(N#\8Z'X1/HH]24+7>](T"(8T1:
MD6+12?BH.2]Q;4THY&,V164+>:8B&56P:8/+ZEF&O5+6$(8VAV)$,KETJ--(
MX,[&;HJJ6-D>#`TMG4A"\L><]GDOG^"9AU;*&GD?!AT(G$YEQYFP<FU3(=P*
M&,PQ>[260D2%C5Z<RJ\(7P;IUI#;-YP7.>U(52+/Y!9#3L%U/Q"J*,^C?'$L
MZ+[8WF'C:S<-L!SNE*,:YX3@685LL[@(X#D%M1'Y`@?D:`^7)GVN>(04NI8[
M!O'('<V1]#-9>)]VV%8QJH8RY1=:5EX!I)]401X#.;6&65-ZS,D633!%"[D'
MZ/4<OW9\2K>&^(XEJWQ^:,','YLL\J;KIZ>B%'54,)K&(F!>\R3^1(=C&]C(
M#DY\)/XZAND2(G=]R[4F752$62'1/$A2A&&Y"@/XS++6K11<:NR.?)*Q3E`*
M$G\D[9X-SZE)(4;.6-:/385L@KGS%9.][CU11ZS/@I=!C9N7G[W0BK!NOA5X
MZ419@4F5^^;F$P$!_B"1@F"Z_]YXN`EVIH/Z>!#%MEAVIBAX'.JBI=0<KG!2
M3(U_+IJJXM8D('_9K16X@F@\N@K'(^D@-*T`NG:OETUVF)TN1*RL`&ND_QZ2
M/K.T=?<.3&6BA!7-T0-)^8-$\N.)2"`DXQ&'YT37YCB)-VJ+M^*OP*,V.S!^
M#BVRY*S`B&/)+:6:6!PO1=M4EZY472N$J_LF'[H)Z*YAK$%JRS23<YLD#4R9
MYHHI4]BY_2I<NXQU=]$E1+8"NZ'OC;MH3B<0X&7.F<!SPD=1CML>))=<N<*!
MO='-$L,>^=W`E*"7^1&&T!SH%$:G<WP&)V$:#??E<$)HTE_=9;C&[OKV5"Z<
M-D8&&HJ('3"3>*V/ZJ6"S;<,<I64SA^;.BF2VI34-'\_-*J@"EYB'4;6A^P@
MN=\[4YM8E!U\2%%\=<@_8<K(9397(F[&QBF241^L<G]:5M-N4A.,\HAU.UK]
MV.:SKF.%]SE-5Y4)1+(=-921D+JEC`!%2PFT.-%BP7]+;._`D86@1_/7K?B.
MJ-#7['2NY(8>_ICWS4X=H4:L3\F]+X7*#C)Q->-&U,WMZ]-I9.5>%P=B$&PS
M$]3JT*M43^G7O!JXD6F-/8U<RPO&8E.@2;UJJ(*94E3@/7P'NGYH,O&^;+2S
M??Z7CQOQ?9UON01Y\Q@7AW:-*[;?>XD[447@)WHN+>[-3^M\]P6I;MY\[X,@
MF&E@O,I3R7C599+;GW3&$R7B32-`)J;5*P.2[X#898;T#FAG[.G+]MU6G1UW
M%)`*45&V!Y2X;D4`%F@VRB6N#1/5-=PB,/4.)_:#L0@;3*X4G(?VW*A2Z*0Y
M+:O)(VBYAS8[*;8$P*(.BF_*=MR%1SA)6$]%9=4=P1%D\I))P_#Y3(DP%;BY
M"UO\#?X)%9Q6T8%G"AZ0V\;I,`ETQ>/!,(K+-`*M0L8BWZYF93(6Q1.YG<0?
MN_S"(%J'C)$)Y[8JSWN,8,]E^'*59C??WI=9'>BB<;852\;(@4:9W'C"H/W4
M-C^`-TW;BK_U1GT]S78\Z1U4K&32T%36Y'%J@P!5P*3:Y%"OQLN-`*6A4XI.
MKA+&O=1?.T0B4S>S4&/W>)\@<$--%PR8$W:]HZ(VT??;NZCS@K@WCYTNC,I,
M<_M[:VZ43K7I>Y.*JI>:D\Y"_``^+Q"J?VP/X/J_9[9A[L>S;)6IW3Z,)^/:
MUD5;'[/\/W6<SKT]FNAXVN]A#A`_9.>2VM,^9R4#]3N"=;[W<O-#+3"QR7ZG
MX9CW\L^TF@V%44(1ZHYLJK+@.+(OZZSFP,!]N-RGM0J"Q+:0Y(<CXTG,R599
M(PNAKG19=?))]9?4BJJTD@[BU[A(XXW-`$$R.6YS;;_]>(<!J_D+@BSQ2KI8
MH])OVUZKZ^[\E[H<J!G4#Q*4JR*7>O]?&U;_A*#BG?\M2[J004T%/TCJJZ&Q
MJAK&9SQK;(7M`'`GY#/P3:WVEZ:LS?6`IF8"^FEHF[/\UXZK>&3*ABZ;VZ$Z
MQFW$Y^8"6X+4694W&\:2AL2R^3H)K<GG+^`YX"<#WT;8*>(Y4<(JLCOCS<^Q
MQA`ZYICI0"W5?!-F2CJO^-2DB^/J)%;=DM])V8.Z5V<6'89,70YM5O.!&]T9
MRGME!7R(1%=1!G7&I(]F$,/[RUG=NEWC1GUB:RR^.[;L)V[T4HUEU,;-EX),
MQZQE9<H=3J4&<1DMGJV?V=N9()$*/_8,U)HGMAN`V;?E;J"+=-0[?&H*I([5
MQ0`J:2E#^D1FO1N*@_SGP>JUKYZ(G%&*%:ZYXZ^Q\R`:&]@#S_1%O<]TFJGZ
MK[F[@/,1Q+CBJEF;,^>K6V13?"C5'29U9@G2H:XK7'7?L8;-20"W7XPU/+'"
M=S"06]C^`Y=J)_;4S7[I!E;POFQT+]Q[.J``=6<%*(%B6X[-<E!_)D^6M+]R
MK,YW5L?$S$@((`36,N<?%(H@,N_WG.EQ__P:\MOF@ZOCN]`TA9%EYUP<)7D_
M9H]T8/,AJTHLN2Z1?NR'EE&>&R<+(_K'H8?<DX"G@N)FC(H;A$75T%!RYCK)
M@\!`NZ:NI3K!WAF=K_(U(\Y+S,G$PV_WK,;F#KH3B+]\15`W'TF,Y*W-U-V3
MH>7[H_S-`4`,OH:+$3#P,B_/3+ZN3,-*.,%@XM^ZB#V:WQKWT^PYNJO;;]Z8
MY5Q#&;7-!7$JXM01/D\SOH^_B8<:60+UW'OY>>#298+7G_NN%\\]]YPTF'ON
M4@/?:\]_TT/"B(>XP<N<W[6J<K\UEG`\3-,U='(;\VT@#WR>A.C]`69";/I*
M?^HUG_],KWRBK?L++6@;TFMC_*/"H?UO=7_WQ2R:K@:\MN1HNN1G306@.6.[
M6V@RVF^_O(BW[I^<(A"A`5`]0_3<;`)O;M/>IFDT^YSNE,\/2)'_S`T(*.S,
M#J`]G!L0TJW<N0&QX[NS`Q*ZDC^K!B=P9@<`J\)Y,5RX\/PR7<^)9UWTK>L[
MZ<*(P%U::>B&"R,B-UD8$;LSSLPC`'T+*TT]9]XRZ`O#%D8P;YP=X=-I^NR(
MP`L79@D]=V%$M`"N;[W873`Q+UG:%R]UD_E9?,=SYJ7U^4KP[`C/#>:E!15;
MT)@?N/&\M'[H+>C#AQ6&\R-BA-?Y$8FW)&WJ>//O`#X%\^M`<%Y81X!M60`Y
M?PEA`G\124/'F;</<*<%_`BBQ1&)XR^L(W46+)D6.A]W0B?QYK4>PCSF+2CT
M@F1A%M];D"4,O(6="\,EGPLCL/?Y$3'=PI\?X2\$N3"!+2_$27]!ZY%#]TUF
M1[B!-[^.R`L6D#_R_6AA'0$=*,^.".GL?G9$!.B?'Q'["Q@4)8"Z^1&IOQ#5
M03ZB>1N+73^:7T?L+>U<[/OQ_$KC('`65AHN[5P<!0MH&<=+%A0GP<*^Q.F2
M)2>.M\!+$Q=A;&%$.J-3D.-/_[B_N[_['\YXOO<-"F5N9'-T<F5A;0T*#0IE
M;F1O8FH-"@T*,34@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q-B`P(%(@70T*
M+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO
M4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B
M8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-
M"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P
M(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA
M9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*
M#0HQ-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H
M(#,X-#@-"CX^#0IS=')E86T-"GB<M5O;DMLV$GV?JOD'/+BVO%MCA0`(7I*G
MV,YN[=9>LLFDDH>\4!0D<4V1"B\SEK]^3P/@968DTI:E<B72#$$`W7VZ^W0#
M\_:WVYL_;F^\11`KYM$_\RU:*-_^+]W=WG#SA#,1,!Z8WP@FQ2*.1<0B#T\\
M&;%*W][\R@HS5^@KFDA%$7VP:G-[L[V]6?^%IJ)_HU]X"]^76&#A2R7Q(6,A
MGCZ/?47/8QG2\R@*Y/$)!7L3<2\*&/[/,,P/S)[61D#[,.P?RF#8\-O[VYMO
M_IHLTYAQR>[Q@E&$F;03G0M(Z>/ICK8D0G:?WMZ\\19*L/O'VYO7/Q2?#CO-
MWK9U5NBZ9C\W5=+HS8$EQ8K]*ZD^Z*;^,[O_W^W-#UCMOY^_)Z/RB3T)W^SI
M]>_"]\Y=X)30`9G6"YW0G,/<3FP9PEA&\%\@\(8U6\W>'Y)5EK(?\Z19E]6.
MW>MT6Y1YN3G<L4?-MLF#9DNM"[:ORE6;TFO::*UFCUFS9>\X2_!5Y[GYI%^5
M;<72<K?359HE>7YPKS89IJJAX:RHC8(O+3@T&\=>9VSN\][<4<RMW&M=[731
M)$U6&HE26!V2E.OS-C,%/:AZM!M"'#;S^OMZKZM-EN?MV<`ZM:+@:K2B[\6R
MDS\VWTG^\_4^(:J`IH>%.84"(^M]E:7;<@65)Y>65?+QDI['_4Y6$816U#N6
M%4QY=QY"'4G-W?<\:W3%'!#*JF:`/=N5E88[)`5+V$JGR4HOV*^:I6U5810@
M7!/`AU'7@&[8Q2DO[J612L56'*6P\S_:;&6$654'YX:=<]6L*4<;%)`T*U8M
M_`T^"$'JIH1#UJ249(]W/F8[A#I(ICPX:UM@G+9N":_?Z$)3)%RQ.LFM?SQ]
MZ1KRJZ!#D!PI((XCJX!77"TDV\%UR'<S(V+`UE6Y,W$L+0M2`VV5?GP6V1?L
M/Q24.BT8;#1M5=RQMM8F8/5J1!3[H`]=<*!XEV0KHUU=0+.I-O-?0P$R[@$@
M>M^5OG"^NVZ+E.)6`@0?&$"[:JMDF=F?C-39(,8=;3C;X<>''B*DMT.F\Y6U
MLUZOLS3316K2W3>8$*]4&M-_TI#U(:O*P@3+'`F@T.NL@1K_BF'Z8[+;Y_K;
M2V?&$!RA4\+KLS4\D7>C0%TU[89^'P3]N,^Z/A?.A__>L*PV:&L+A,6Z@=YM
M'DX:"V(;;]B^;/!!CKLS),3$J&5&:3E+\=L>K`1CO#=X^AU+MWIG!I&-DPUB
M<)L#ZOA%K5,3\/3'5&N`X`H8#D4?Q`*OS[]2>*IS8L2EI?-A9$)VT$FU8._U
M7EM5E%:@&DI*]1W3=6-"3MWY=4W@=-]'\<W%0J>M*BDVQ%J:1R(NK\3"9H!7
M$JSVY>(7AW'D]7HX'\83,`NBH%>R'"DYC+Z$W)%&TF2?->3P3O4$3?T1JJ&P
MH#MT-?ICD^6==N_,J$T)K1,JSPZ&X82,ZHF0,HK[[!Y%\5'J?FDUAZA#ABU(
M*I7<%H(P<GHF9T;(O((;!4'<T]BHSX5^0-]IY:4&O];@*DVYO_3RD>R7CP5H
M)+GQ)ZSYYN(+A2,YN1<$/9*#CJXWF38I[2%#N"2W[TH/J'V=U$3D-E7Y:)(T
MX&SH#X8C527+'K`FVZ=Y:^++OLWW9NP^`<S)"Q!?@&0$Q#L4)TF5;JUKK,MR
MM6#WUS$O50..ZHA>;-]\)[&3%.;=YUF]A7L!9.1LIAK+"N2%%:3_]O+UBF`R
M[%$7#<6#DEWQ\#8K?]PF8//7*9@G(AY(4*>P*(B&*MYS.+E'$#(1"1"AZ'3I
M@,1]-=Z#)]5`T*4ZI9V+%W@!'^W"Y%2'G-`+GX0D[,.89SH'F)$:_E"7^8.E
MM7">1B/LK[(Z!7.L#`^&*^UZJG$%=Y!"=9I5JN_1^,)ST6Y-G)5,NRN+,LV)
M`0-O3;8L5UW-4F)K)A=5<.NV@;Q.$CC_J#W1B3<BQ+U\*"!03&!:ESLW>;DD
MZIN5>V/6U,R+WUQ#`U[4:2`8Q7L1.[,ZIG.P_-L8"M$/9.BCX3#ULU;-2C_H
MO-S/LP"7P0$:E'<YI".5V%II7R$P5C0"51/FKNW4U\EW@@*^0_7`FT/N<CTH
M"1F99!GMT])``OP@SU(?2H(#!'C>VS,%G$D+S^Q)4\/*HUDH^B(QV#Q3E"@J
MB^O4O"+T^[BF!G=6W/4GZS:E(G3=4A<M32K8HVQMJ3!XJ.D'6(M3N49J>0%:
M(&2)%_&E-'V"I&C728JR@-R^1`G\\@V&F@0THRA--7$E^578\YQX2(1![!+A
M0V8,EI8UU9[_+@L-T7-H!"G=U%)D'`OOBP=;O-!MSWHDJD8A+KX,2L:1%JBE
M,<#?Q;_:=$U-FH7M>N[W#,86M`=K:`2^1B>@-,VV*MO-%D_S/%F6E?4<5^_#
MDW1ABH5KV'94#(^X71QT)*<R91I!UO6-CPH$+[SK'!?&WY$*.NQ;(F=BN69Y
M^6B`<@3*BRM0$N$-[3IYI%_W/3A<9:O[DKU/F@3)*T/YS7[\Y[L[X\&CTOY8
MXG*,]EC&>T0T[BKCE<4$@W%A]U>!Z"M<VR)3U[`M[RLCKF1?G/F>=,+3UK/:
ME)*IVR+Q=/IT^P3?[S>Z/&"CW%NPR?Z(P3'"$(+`I252>-*)=-V:1_'PB?+X
M0/X#5U4BI56KKL51(+N;'JUW'"-&3U>Q\%"91>%@8;^K!1)[G#/..VG9@J8!
MBJBB-J@##+(!@8K:J!:/":M;5YMMR55'/*RL-G#V>F=J+I/64>D,O*:M]6IH
M3S19;;H3%<7"95;`-ZZBA*%.&\BV-$6KHR4CV=YQ(_!P3(:\"6XY=*>L1QL"
M`UF0OU89]D^'"W"+X;5MB^QL.O!/VGSO.+7)ZGW6&*V7C6W9X.T\VV7D9-=0
M@.R9N0SB(89'CI_\]*?WME@F$]!A'U:PK;OGE'1@,BP;GR4FS)*;H;F)'QRX
MK"9>AL"#4S>"PG#@@;!P%0WP@9GS$3/O(MVF2G:FEVB.E<RAT5+#P*:>P@8)
MLB-F^8B01RX".),J!D[ZNZ>\+E>[;$]^GE1-@4"XS?88P$]F2)JH.P`ID!FO
M4J1PKR?I=*C?J2(*74@PD'U*2_N</';T^3JN"V]/\S:UEQ57+(P])LWNAVV:
M.P6"!:#1YKDX_ASAUY]Z[O-`3CV77'I3SP7GD_/#`M')YW^X(2HP0S#3T08.
M[RW$7UI(Q4-JL:>PQ$^ZAN6]@1H,\*ZD1M*S5HV=YJ>_T92/A)A_T(86BJ8-
M\6&38_]C?GOS<[?I*.+,CY@\MF7@[22J\$[L4"46,G(L42Z"COK^3L>Y+\`<
M>&;%T!?'EYQF;K$WM%"X;3?PA>I:J^.&=U=VD[O6X]YC7:ZA/QOZDA4%Y"+;
M/>DTF*,TPTOWQ')<@[([D*MW)9!>F$*&YC(%JFG((TR\S.=?)V\4=4%<"-43
M<;B""^++*MML[18`C;1L&ELA.&=,(5&;ES7"T3K!V+3^[IP-GCHMD4+T.WQY
M6D+8`H"`$T2_+\96Y(=G88M[1I2C2\[HVA^E"S&D"^4:E4_;S^,ZO`(`*DH>
MFZPH7-E`9],U*#02:W,8XV^'B+D^]*;12,!+,P-F=K#KCP&1%^IVMZ?8:QKA
ME4[JEZGR*\660VIP69(ND@6=U#D1M/X64-;8XR<J0=UNZ;[!QO@9.4^""N<P
M/L`N]W0=P=P]Z@ZMNXS1'<H_TRS>,SP1HT`]MC3KA47F7>M&1@,Y#'E'#!`W
M=+%!56O:2[V+?7?T!LYG;.64_P@0E&XO1_TG1'X&*A'IOMA_PC`XQW]H11+E
MZ)(S)^AA?V]-Q`/A#..^L.R/:[K"'[!O;0/KQ>GX"$&FF&J;*K,W*-A#DK<F
M%8YFM(`Z?F]BN"SQHIGP&1*?OO'`>Y&/&B_@_%SC!0X47V@\6O%,XP6\KQ;\
M<'2#)W1K_MR8ZRJ?M+M5]%#F[<Z>,MN$6U,K8-2\-BFS:/IBH="/O7&_.V/O
MI\S@PP3=YH^:@8XESN0W*CPK!]&*9^9[%?8Y2"G+TWWJJ;JSA'?FC`/@)Z!W
MZ<`<*>B*C@=,-"7-NZM"[DA-?\SJ9KC]><K),DIJU:;K7W71^=BAW%=*&?"!
MU=A(\9KJ(=UD5#S:6'O&DB>O#RF_7_,X1CQY-D;<;9$OQ8@GS]:>Z`\>8E\X
M#BQCZ4JY]^,&JW-(\KZ[SJ"K8S"H-!(])?,.*L.=.M?X.-@6+O5)R)<-K8;[
M]R_0.'IP86'[R]">B&RJ?NVN!AR'R,Q2)R'B1?U:1R%"??`SH[GO^G%?"!%:
M\<QH[H?#5>H@')7[[KS[%VH]-LD'C9G_:#,0.;;5(*J6\=3)6H.S5J"SIIWQ
M]+XU`>#)I<M'5!K#1"=)TIPXIRRCHD&>XY:A_\YS7E^*LRQ#U.P\//NR_XL&
MS[.A#W6YWUV:>=<?]6A[KI+KQ+31AW:1L9#.;7-^N!M,1RO.V6T/ER[%H!PI
M'Q+3D!LULFB&#T7Y>$')0M#H3K3I+OQ7+1*/]"=YH)S^/-XUX+=T4$&]NS0I
MJ%=W8>/QH#>>&AJ*2CG`Y#!`E6Q@ER2MRIK:#@U\HK_LJ%^>9GW&ADY6#[[H
M=W2<@,K3S:A@W(QZYA>P9=`+JKKSTY>W;LGOXC.70$+N.CENA?!YP]"?;->]
MB:EI,?&<Q\06)@:(.)Q>0<;8X]0`/PZF!Z@XGNQIO@&SFY8B\KS)KN2;V!/3
M4G#/\Z9WR<W?64V.$-YT<_4-EWQFH]R?:;"^X8K[,R,0FV=D"7DTL].(4N(D
M,#P>S8S@/#[=##8C4-O/C)""SZSB\W!FA.)\6EH1>#,($^&<741$?Q`U[4H4
M@2=]"=ENQML`PVEIH;`9C4E)?SDV.0(ZG1D!%,;3(P(>3KNU#/F<M&$\?=R!
MZ$,$87I$/+,/GWM\>A^^F`LPOI@+I+ZDOW^:'(%(.3-"S8X((.[TB,B;0;(?
M=R<TIT>$T;36E1>):011&)M>10D^(XL"V*<MI_PYGU.*SI0F1R`Z3&M,!7(N
MQX52S<P1R1FMJU@&TSH-/!E/[R/@<B;R!X)N:4^.D'2?=7*$+_R9$4I$,ZL$
M8B8&!:$(IRT71'(FJP>Q%-,8"SW$R^D1?,YRH9!R>J>AE.'T3D-_SG*ADC/1
M,@SF$!2&<L8N832'Y#`6P;17(@1-'!/;$?&$3D%]?_CM]N;VYO\G0%H8#0IE
M;F1S=')E86T-"@T*96YD;V)J#0H-"C$W(#`@;V)J#0H\/`T*+T-O;G1E;G1S
M(%L@,3@@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E
M;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@
M,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&
M86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-
M"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*
M+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-
M"CX^#0IE;F1O8FH-"@T*,3@@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E
M8V]D90T*+TQE;F=T:"`T-S$X#0H^/@T*<W1R96%M#0IXG+U<66_<N)9^-^#_
M0%P,+C*#LIOBHN4QG>Y,<@<SW9-XT/?AOJ@DEHL=E5318L?Y]7,.29$J+Q*0
M+AF-CNT22SS+=U8>Z>=_7EY\O;R@UW$F"<7_S&_IM13VG^)P>1&9*Q%A,8EB
M\PDC(KO.,I:2E,(5RB+2JLN+/TAM[I4(B3>2:8H_2'M[>;&_O-C]!]X*_YM\
M0*^%X+#!M>"2PP^>,79Z/1,2KV<\P>MI&O/G;\C(%1`C@*2($E@F8D/3SC!H
M+W)_D<>!X)]O+B]^>I]O"V"/DQOX@A&$N>G(>HQ<"KAZ0)(B`0S>%)<75T`W
M31)R<W]Y\>9M1_;#(:_)H:F;HFKJO")YW>MM4VK5P7['5G6J[DF_5["FZXGZ
M5NA>U[>PK"15WMXJ^#!O54Z:'<'%>5OLR:YIS5>.^[P]Y(4:>EW`K8OF<,QK
MN/.&W.M^#W=L%:R#_?^=W/QY>?$KL/6_9V$^8JCB>&2>4<\\3_!W9)Y+2KH!
MJ$6RFJ$N.Z)K)%NW@9.C/JI*UTAR,[2P`+@'3NZ;]@O9YQUP6@R=*DE3@VA0
M6IT1#JF'PU:U*)1[557G9D^F(O"7,=`HC<C-=V#JZOQ;I2>BI(#I@"-N1?FE
M;N[K#2GV>56I^M;BP\,(I(JR>Q>MHV::C;0E2*:CC0NGYM_;IAR*7H.&;E2Q
MKYNJN7W8$-`=:@9_[H86M-Z2N[S296[0[>C]</-Y\B6R?9@J&0%^JP`:(]P[
M->4:#>38-KW2M1'!01?PE^YAHQ7$`)[-28'%(ANED)C?40K'*N\1Q$C5N;<'
M%$RVIS(`1$H'$)!.3;JB5:I&T:'`D)*=KLM1E#TZDQY\0J6*H0(!#MVHB;V^
MW9^;:,&DIWI="Q(LF\@GRGB03P(>W\BG.RIP(FVS!804I'OH>G4@]WL-'DAW
MI!C:%KQP]4#`2P%^2G6GJN9X@,^NR<=5O&>62.\\@U7Q5+K(<<Q;H'2`"`"^
M7*%9J`+#1-Z/MO.LW8'?!YO;Y86N=`^(M%$BK`1_N=7-:=CH[&T/``*X.5KJ
MO093VRK2[55UI\IU4(U"D*D7@I@((4FM$`PSJLZWE9KJ!+G8#;7A"!SB`]$'
M8!$()64[W([`=D#/6Z+NFFHP[/<H*/UUL$ZS:.H_W6ULO$1A/?5*('X(P*OP
M+R+O6K/4\/_&\0D<7)]]2TA9,BK<EC2+O,1EY-S8N]$2-C8=F<M>4"@66B!Y
M=,#YX0`>'M87X/@Q!S'VU>=?0(#D`>(]`;=D<Y*&H"_J>J-:7$Y,$F"`AO>M
MFWX-@:=I,@J<9TD`7.:L+C\XM`&!:SC%B')/P[I.$?*(";<,0G=PBB.WUBF&
MJ`$ZS(./!/T,1Q-)QBA2JWM4T$_PD;>X.]5V8#\=VN2CX&RQ,X;H:_('^I1*
M`[ZMPUE#OPD=.68RY..0^5N.GT\[BF:H2J!IZ-#I`665RC'KKD$BD$X<5*G1
ME4+,."(PC-A0'B`>]!@[W<)J\*G@-$$*^-$3LREU5X"\VH>U7&DJN><\2@+G
M@EG.I^X35%)`CK4!QZB01]+I?LA[H\9[</]HKD^BA"LN'L`1%[H$%8,D!LS(
MT(W"?:PSGL::/3B0C:T`(`E\]^$WZQ<,$-:0`/<Y=!S`SKCS;&,2>@)!;=45
MM./T!TC_R4/<*A,$@M_/CT8>$!103,4>[U6ZNN8IM#;6+X+4"D!'YY+8-9B/
MLJ#^"?`=[GUA:/,#U-ML%@&Z!2\`>KMK-$155>4/UJ;']+PQA@V>\H"6WP.,
M5`UFA.8"XKC';/11YH%HP%QK#>8I\S%M4HB*L1#M(+@7^S&/`1:J1MN2NVKN
MSTY/''N"5G;QX.P"ZU'JP[F(XW34>]=/E5#DQWR+J2%"`;`^!X(?3S_BETI=
M&D3SYL?NGLT"(8E]4HU%@<FG/NBN;]J'%5*IA/GLE:.AC<G$:'2_/.0E>@K3
MQ<#"POB)*$LR@\-^WS;#[;X9+!2C+*7G)I(+X:FT!+[Y%V/L_-ND$V$PEDUS
M#1=_.B,'8W,J-]$3O:LN;0_G.$#UCA&VJ6UD,5X9LI(#B*P<NAY<,V8B9L'9
MRVL9=+FNQ2923`7%4QNHWX!H]BB2%7QC$MD2`Y1!(^Y1RGCL*N-M-2CRI\HQ
M0_MHO?8!?/X:<(QDH&=%.$8R]ML`IS+8IJ2C;7;$H='#"S0`<:P<P3?89$[5
MWQ\.MEH\5I`+/0M6EP:8[W500A"UVT&UWF'3$C\STCT_EI+7$&821WZ;'_39
MLW<7)PA-J?/:NWS;ZF*SAD7$F?!NFT_<-A>^E4;>N5PW+_/C!!0&(\9YNSYU
M]0#Y9($JSS&)[%N]'2#:($I,WNO@LR&F/X<MPG8S)HM1EIW=PF22>/Y6!(6$
M7&,BQI2%U"/AZ6AA03*V]E!M.-2`JC.O5LF$XR0).4`:6NG"%;W.X/&0`1+S
M89<7_=#:*#0:NVTW0ZZ:'X\5U#Z8&!GGJ,&FP;:;MC=V/Y8-P"($LTKO(-HW
M[2TDVMT!K[OFB+^O*3FV;?,%8EMSC_VG'GS(*D*(J;<IEOAR$*#@^L7_HI(:
MMP2_1!Z2*F\!T6L`,Q+4$[6FZX>$9]P&@2D",$7B,Q%(_D?5H6W;PFU4W#6Y
MF3@`/(+J=%U@Z\(4.;?YK<WCH.KM=3U@V/[T]U^FL!@K30`\AH&U*OXXG#WR
MT#O-4E?TN/(56#.)TP#4:.SE8#^C[@VF#65XPH(%+:R&);T]/#2-.]L*,^)Z
M!LSXW<;R.1["8.?$&/?$QHR=7Y/W5B;K./1P>,9I%B3QC#\WZAP*['[L!O3>
MHX.W4LK)7=YJU9L^0%Z6VC4U[-$)+)LXA`ZMIJ@&D\MN=0-B;+'@[]6W7E?V
M*$@?X,L[A97G<:B.Y._DF!_7DH(_IN.,>CS(A+H\S^NKNUZA%I*)+\'3`$:1
M.!V\;YL#89A8NTCJSKTWY+%VVEQW5M!M\PWDURO0TK_!#@==5>X$0WT==(\M
ME:/N43MH<AB3P?QNV^8>^Q:VS@?_AE_1-2S!YN4*8I?2EYQT8H9QXLSPD+=?
M5`^Y]2]#:T_B(*[T^J!V+03'4_[SJFN<Q[FM,9KDYDP*+`G\#F80RC()<0N\
MD&GE]2H_;,C/3=Z6*)E?=`L>IVFM>7XN-/;E,"R]+>]T!V7P*B+@8T5#PTD6
M2QSN+&TV9T((R!.>STX.)/@C/6O&F32=L!W)1$P:CF.8*9K#`=`'=4+Q!<('
MA!?2M[;V=87!VP,X9=`R^6S6_/JMV.?U+;C+FZ;,'YX:1TYNJV8+D-<UP`=P
M,9CD916E,G\T)5EH*&)MY3N*K3%5D^MN.UUJ])U0]("'LX?\H/`/#?S\+_AG
M`ZC5=84X>`>U;KXAOS?F+_P?(^[_*'1.^)$[!7+=]SIW3AC"E)D*@?V*IJKR
M;0/;(-3!N-<0@#\HBY(XC#U(X?2;=YW&CJ;5Y"0;>'10B5==)^AW*``@S!S^
M>I-MO@TF8I\"QZD[5OQOB$Y_83+BI98>[B;L;F!HXNQY(SA^P<=\CL:AQ\GY
M.'V"60U`X#?P>S@1!"Y&G%K.O;&<X["%T(TC5Y"GH9[&\PPS6V-.*-[]3OYH
MVJJ\UR5XYH]U89+^EV^L7+M[!?2)R"=W3&:ABN'Q6,5@WZ$F;V];I4:H.1VC
M]0#43*C\I&Q>^]TF?)CV(P?G[P!23W+LW2X__S;Q5#(\U)W<U*#W`>A>,&>?
M-@&X/V55G'T;R?TV)TU)+-C.KC\1TXE@J>#>X[.,RW$8`Q(KY\D^GGAF1-7_
M?7YK2TDTFXVIB/6=R=[.WC-B]'G)G+]=R\14*E2RT$B4KIK<JZHD[ZNFU66^
MAB/@6>RU$D9D6"9\'&Z/&`A'Z\;XHK"*+W!4L'Q6859)J"[\QM_LDO/;:N:)
M7U=-."4\$5,<JA\>C=6/T]#?C/68]`**7,@BSHY.D42OQ+:`$B.P'4W:W(+'
M#IT0V7#"8TS/_/GV&,$,6DJ<NX0B?QPJ7@/%29@AE9/#^=&*C@.@V';<M\H,
M;Z$7+^U4EJT=(-ZM`U2,KR-]ZVJ,Q=SOA)TY04-G+HG2$Z1NGDU'UHK?0@A/
MV8KQ6T@ZA0)S8<;%[+/OEF;/,'7^2)W)*7YXC&,'8Z0^_PP?A)ZI#'D:>MS1
M>*;W%A/>5G5#Y4L0*V*+JK?%UT%WIKD%GJ`]7IL4>0VSC_UT`F7AJ$4RUQ9Z
M12N/8NG)67DL(\XFC--,L-`/&Z>QO)%#D!XU9/H$$)-*U9K9C)7"<OI:<N#I
M5`[3,H8G,CN1`]RX4-I,&FM\SL.V0;">A)B$/R9B:H:^ZW,[D-CM\U:M**P$
M@_GK@`:,1?A.XO3<@HOH$68"U]-0CNU\LL)T!&.))VWE\,@COQ.&1\G<>`2`
MX.Q[0?[\2EQAS`NJC29F$(]F`&HCV[S3'7;)OB"RUS+^U^*:9_1$ESP*M4LT
M#F&,UK]>+BY?B5T!`3DHF44\3.!FXSG40BY^VEJR'G"5UA(/8VM1F!3F<30>
MD/<=J?'@WL?BYZI'.TNY4D:.>GN5@2R&>@ORD%'PNU'Z*$:-*IG*QPP$?-.=
M:2CBA]?DO1V8S^L"CS_SPDS%FGDW6^-TDW1LI7E8'H:?.`WI84I=B=&W*C>G
MF=AI!Q)#-@B%X$HJI=23M;)*J?`[F2B2A:$WR4]C*9K@<V76N;OD/`E*.?\0
M54P!QY/#BM`N9G'F"P)\H`SXM7:K#^ZAANH!&W6V@SXM$Z:^J-0=`M><]"#@
MS2Q34\-7PU'/Q*WE?B]P[)^/E3Y["S9ATG.\=@<P"SL)<.S"[?3;;K>&Y3(Y
M&5X2D[:_.^T([?ZMZN]Q(F42/?)^034;U_FR/4)R4.,CU*CM9\Z03P/4-7E4
M5J[!O_"S.W$2<!PE69CE>-S@=\/4:AVL,<H]56L[KF3"/TWYY/$\ZOA'V'G&
MK94:;6_QD4?5^<-7]T#67/CVC>)G'.!FK0<>S?R9BTR3,_,TF<SJG+(0CD_/
M7Z<+3\_:'8%TPCD@.YX@.WZ4"[M!ENF1^L9#?*6I"1%%GL`5IR9$)*=R$+'/
M37@6^[%12$XJHCKS]#*V0Q[[,`?J3[CL5[OL@UW66?2>.WKC4R4CV3\>O5^Z
M.T9ORO_B"7HR_PJ'=#PE@`S(/AS_YI/J3EL%]IN?_A._>8_;_@-^8]<21VK@
M7_@Z3_U?U>7%Y[-0QS-/'<37U)SH?G>SX*Y79EX38HJ-,%BQ2#G/II1',OE!
MTA?>_R)\'S9.V:1T8"=/``V8]6,+RTR*5#@Y4J`C#D^H(WOVI00=SA*Z9_":
MRKC`0U."^YX.5>*SB.%A/3]4??;$4G+/XKH>,H:\)PB3)BP(,\SMFHGQZ?SJ
MABAM)E#7>.T)9Z&$<'TH79^_N>8W6OOHR6^$_<5)52BD.]_?-^:9EW9\,,T\
M'#B91)P=P!KGJ3?C^)-!Y63`WDS#J=84Q5\'?%)\?`:QAN_YYX97J8>C:/*N
MC<E3__[T<7R)`92_YBTRXRQX9P[<U/7M]3CV;,]T/M9^.MB\G6.?WRE\+!RY
MT]_A1CA35*G2C$(;J\<W.'7VX:$P!TSZR8/"DQ%B-SB\Q@LGTO!80,;#N<3X
MUA$[J^Q&F/%]0^J@S=-1)[28Q\W!-R38Y#,TA,W,"[@8%$[,7F?/7X\9+GKY
MNF1@"C/7!>94,]>Y>=;LY>LL@H`\<SVBR<OW_^J62'N+2#P_H1=Y/41/7ZHD
ML]!TLLX.SXI2EP7=F)=08'>B@=R][KLG`2]Z-E13$^BL-_%_^HAG'I5^F>1X
M2O*CS(U*DOK478XIXM-LQ3Q[\H-;"!*/0G$[I(]AA\^\O:RTJRS*9J]'&9]%
MQ17+@.RY!3QC\PM$MD"CQ/<3S2V(LW@6FE=)ELYSD6;Q/)$1I:#0V14190LK
M&%V@,^(T65@A<$!G=H6,Z`(O<206*$TBMH0+3#YF@4&CF,ZO@"BSL()A'V-V
M!8_XP@I!DWENF:0+`&/QDEY8@B%S=D4*VETP)3KO@J\XI?$\MQS<\,(*AJ_4
MF5T!,EU8`>7O;+"YXA)/=&97Q`L!!U9D8N$>298LT)%F2W1D63)/AZ!+_D5$
M2WY4F*G0V17@*!=6B,45,I,+=,39`I)%2J/91`%6)')>ZB)+TGD$22KH_"[2
M'/S.KC#O:)I=P9=L3@I\[>KL"HDCY/,K^$*(DS&?3YZN9,(7I"ZAU%^0*4!L
MGHZ8\@7/'T<LG:<C9BR=MZB88V-V=H5@8F$7R9:"?LS$O.;BA"U$]3AEZ3S&
MX@RS_MG<@BYI+@$0SE.:,'RN?G8%7])<(OB"MTSD$H*2F"_H)4F6D)RDC,U;
M99+AL\WS*[(9F4)B^^L_+R\N+_X?ET_/_@T*96YD<W1R96%M#0H-"F5N9&]B
M:@T*#0HQ.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#(P(#`@4B!=#0HO365D
M:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O
M=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@
M,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A
M8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*
M/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-
M"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C(P
M(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@-#$W
M-PT*/CX-"G-T<F5A;0T*>)R]6UN3V[85?M^9_0]XZKB=]88`"%[J)U_B-)G&
M3NSM)-/)"T5!$KH4(?.R&^77]QS<R/5JR69'['C&ED60/-?O?.<`>O/KY<67
MRXOH.LD%B?"/^91=B]C^5>XO+ZBY0@E+"$W,-XSD\76>LXQD443R-"&-O+SX
MA=3F46DL\#DBR_`?TFPO+W:7%YN_X9/PS^B+Z#J..3S_.N:"PS\\9^SA]3P6
M>#WG*5[/LH2??B`C+],\8BG):$1@66QEVAC][$4:+O*1P&]N+B^^>5^L2M".
MDQNXP=C!/-1K3AFA40Q7]RA2E/.<W)27%R]!8)'$Y.;^\N)%4:_)E[ZH5'<D
MI:Z[1E?7Y&/?D*I8Z:;H=*-D2XI&DDJ712?71-7DA_Z@.ME<D?<57%\7K\AW
MC91U"W?H*_)!-]V.O"W@4:J&:_^6JNVNR,U.D@^RV\FF@I>VK\B^4#5^)&]W
ML.Z*X,=[:=[U5W+SG\N+;T''G\]G"0@$9XDD'BS!DLQ:`O0"X<BAT:5L6Z(W
MI%BO5;TEQ6"+(]D4I3+&@N7OBCO57H&FE=KHIE:%M9R^K_TR;[NV/QPJN9<U
M&G"%EM[O95.JHB*?_O(._ENY5RA=M^1>@?W07(N8(<J]&3(6K,"9-<+GLE&'
M0TL^R5863;DCW]=MI[J^DZBP<_<5>:/TN65C+!^$R]EU'$64W/P!,KT\^ZLX
M']N!QE$P1!QEU%KB1I:[6I7H(=GJOH&@0!/\HEI(DU;5$-`?/I*?7>I`M/Q3
M;>05+G'Q/HIU$]I%1W[4</,]^=Q!(BWA7,`VKU.4QT&G+';)_J]:W<FF=>'[
MJ6];C-EG"9)/"R*$$X0!1`9!<OR,@KP[%FM5FMA_77;JSF3*N0V2`,;3S!N$
MT2`'SX0S"*;K6TI^:O2Z+S'YB'&[KO063-225=%"PL+7!=GT]1:"8:_*1NMF
M6]2JW1,(CPH6O*57-FDASV6C=$.VLI8=:(B.W\@&,]\D-REW15.4`)X0(ZH$
MF`&'+!(*F#U6<Q[TSGV::PQ-B(%UWW8-HA!JIZX-Z(`]X,L"(QRR?0O07%5H
M#%T9^-\T>D]:K:HKLBM:TM=KV6QU+4E9%1!/F##[OBO0`"U8L)%M7W4(HPJM
MV';%JI)DKYO##JULUH--ZNTB"9%E<:A^63Q4OYQ;._P6B0BE1=?`9PH5`-+4
MRFS2O=V#]F1_+&5ES-046_2EN5:I+[U:DQ+6]HT$[`<C``Y@$9&`$1I"A:S`
M#!O5M?8"V..DYO"]>;'JB*S10"U4V_M%#)*D/BQ$3@?4RQWJW2&\&8#8-OH>
M(AKT-"'?8<$G:]7N))2\=E?<RK/#,E`5+]_"!2!.QY;@23)``WY&2VP@G&\M
M<E=%LSV[MIQ'_R=M.8\?^)UGP>^<.FU;B$;Y$*DP-PX#,)H5F"/7Y!<)J7\'
MR_O&X,A:WLE*'P`<]KJ2D`]%`,!VD2`642C=="C=-,NM,IW6E<LHFTYDI[8[
M4J&8\#(@7RM`M;HS0A+Y^P$2OD4=(=@!_<YN?XPV)_+"G@8$&QF'B:'DY8F#
M/`O@*Z@`1OT6O-<`*W#`#NJCWW=ZCQBE^W9D'@.0F`\G[EO"R]QW+HRG(62%
MX6U##?.EN+5R2T"ITY*;XM;*4R%JXZ6H6FWC&A&\6%F:WVE0M(+'0J6[+PQ_
M-^H#!O9`CZ$"0HYT$G@"8/PBE3RC24A=B*00[8*.[2#K/XY[D,%XH[-E?%64
MMP#C4**OR7N;JU?881DE6_FEEW4)^N!JT$GO3?DR7&:G0+<MN!<*/%B&K*I>
M'AH%*>,*G#>[`8,5%$=I[`89MX`%TCQ0]8@/;":)'9LQA575T(/M+73=*RC:
M*VFCO&_EIJ_0D2O981';@^2''MD,&@GN,B0,Z_RVD06N".5[A'^@N/&TJFU1
ML&9?*>T""D,"HN%>PG,*^+Q9)AK2S%-\QK)@"V$^6UM(K-(EJF3:D@/(7'?*
MD+A:WGN5VF?R_FF^C3,4YZED%*O,%]5)OFT2$)W8FA`#[@UN->ZQ=_WCYO-X
M.5YYI&VM$>/!/]_`U;U>JXWR&6M"=0F/,-]C,#HJK:EPT?D@.TRH/M8%F72Q
MO@-\`>+LF@(;8&V)DQ7DS^VQ[>3>,$\DE!#6/ADQBE558.E&W'L/7+Z'",3[
MY>I(H"79J\YP\&Z9H4)*Z6""H=U+D72@">1FHTH%XHV++2;1H!VH(OO;HCEJ
M;)L<Q.(2%+F5L*[S-VVK(W#48U7XO(0EJO'9&0+<P]A3=ES`#DGNVPU*TP&G
MG!4&F@12'J%D=$:=E6T'"S,HZBU?`;`*-JN,!S$O0G]V(GKZSM8K6/?W!1([
M'DT6LI%JF=/M^YK\6!P)BR)A2HQ>==!!@JJ%Y5Y^Q/CNP^M0>7SX0M+\^(:X
M\1MH9VN125>U1NPR.0R-D\FAFE!ZE4218R&FP<82MX0_(8F]UKD8NB61.C@;
MR<0B4A;-2N^.ZP9JB*.?>[`)U*$&&`0FMZ,+&)Y$'PZZZ?K:#@F=]ONBN95=
M:\:@ZS5FRC7Y'D@'?,+\K8Y7:*#B<)!%@[S%EO(E-!=9F!+F@[^%<&4&1&CT
M[PKJK83X[.XUZ132#V,1:)8KJ*\`4.B=G81*&KZQ7D.N!J5STP-8FV\LMVQQ
M,'J`/%BC;J>'%.9>>;T]_]PJ2>A(;R9L9_'B=0OIMP5&T9]]0I4R/GHC=.&A
MH.>1'U$8&RXPHHOC,"#"W0NCZDT#@*F!V.^+<ZN:/7PC'\B!\`-XR](!27#N
M;K`=@B#0ER<2Q_%=J*J.PGITN7*5PV$-W'T':'*2S.YE5ZQTA0,]^&:);&*A
M+K!T&+JGJ:,(;ZDM50XN^M8F@.^O90T04R(VGG\0D@3A['CLQ6^,L;._!GK2
MP08L%L$&`LJ)FT",7`VZ[XM;&4HYSLYQ(`9EOS-U`7>J5-V;0EG4M38#]:_*
M!]9*?VV9ZA"E0ULR=-J)'RZ[@#3-"-!OD-^7LS)0EUMY#.%7(L"5=@O(C@/K
M366C=T2;X*81._(A8E[B-IV\+1Q#-+RR="P8R=4"IN!Y&#J(2(QZ5-^A>;*B
M4'"#WF:J6#1-<42J"@[7D-%`VE$K($IUUYN6Q7#XH_D6/MJNK3.-_&`LTR,<
MH`"I/Y#@[2!*W`C;CZ:0&C\?2&=T3_V<@J:"#YLNJ0OLL>^LD-;[IN1K4`3E
M7:8=XSR,#D;C[SCQ4[^;7:-[8&?88.%>S+V)-`D@B\AK$1,HJ0(,#0,&N&**
M=.UHRUW1*.PZ?)VV2W!?Y$ZALT8MM-]:A;:\JR`82S=?7<(I-(P,1!J/1H2.
MKQI2NB_J'G*FZQL,&P07TWEB(PE(A.DDQSV]8>66GS^\$Y(,OC@.<&79G+)&
M/:@#=(#(>C!.+=#7FK2]LGLA2V@?L6%D-+2DU'<BCWT"TADJ>90=5"!4WHZ-
M`&M-6^[#(O2P7U7;Q^,7BWANHP\LI_884!:9W+<_03;C74N8@&6!NL?9,-[/
MLV2TO6O;)VB1D5,JPT$;":+A?I>%ZJ,Y```Q:O>_\'^6P3J`!FJ^`79N=_\P
MJ,ZM2LSSH,NRP^,XYB.K17D\*FFYV[>U(_2'U>C!5.RVUN6MFS0`F^HMZAKS
M6ON:L,`%2_@\";N]V6AS2XATF(U]58*-:VUDFAKAJZNY$#0SSC;Y40!+:8%Y
MPD>XK4`Z6G^]C?!\*$\F=(NM;L#/XNCLST^&YR]1AQ@/S#\:T)AGD:,''VOR
ML>ST"H@,2ZYPBI"8*8(TK2_.2["DX!@(`-?0_D/?E#O386X;:5V'0;;$?`OB
M)RB0!([,S_Z:A([LQ*)Q`/O=V=<K66]U03X/AOC)&^*U-\39_9=%)_2/S_^:
M)+SF`=`9V#C[VZ"]'EG;,")K[83[8;7!=&?RI8;'C(:N*,VRT3C?D4=;?!^F
M0:WKLTO"XR#*LE4&1^2#TC09MBAC3JEGS&75MXBQX1@:PO&[$9</T4[&7L)!
M*<X=30'2AFI`IVBG!M`(U9:/-7K;%'N[(;3($;O<]X4`$Z,-`>Y\BO09=Q37
M=LYOI%9ZC2+V!RLW*&<WF>KSG[(`G/$2+GS*(A$C6SPX=\`BUR/OBFJ#L_`&
MFD!SE,@1Y'O7-[=2WII^XG``4H9]"KCO`%U&5S1',FXKO</''=\RTQR:^697
MT-@V?"^P>3C_;GYXU<+'!O*13E"A1_/>=-C!D:6A/;8/A/;]=SSU9(E2(^W9
M,-=,>,[\L$MZX"QLA4:'8-&]GI)!\^32^?PE9G#>@M,NK&2#/5F:AL/&J?EL
MIUTKI25N'>AJD1A-PE`"S[N'PQ-^?H]DR0[E@<Z6Q$EB2NV)AGTI:H7GL+RD
M"U(K!EH/!HDB$0S"A'"@;(ZB+D6A>,Q.Z'EV"L6!P_O7`&+P!$=QGD)=G[MI
MX%"Z_=N>WS5,M#S4_71AJ98G//^A\.;X,G0I\'C"S4.'N\V/-QC)6&ROL]/7
M4SQA/G$]`=29NB[P*-O$]9BFD\_GE*=3UZ&[F'P^U(#LR>M?W!*1F"7`Y4YN
M/=%@>/KX-PABF,ZY`WSFA*[+Q1LS%\.S2+K&+8&'^V[V,9^^PT?>8R#\@`)=
M"WQL"O_8X`__K2XO/GNA$P""'!R?GA`9PNC)Q()[$F%'J0R/B%KXX-<)=33F
M-Y:DY%$.X-X&OA*/!9Q\YQ2&FWL#D32_U_$@[G^[\^[QR1<SO'CU'$&>2A06
MYT&0QVF.P0JQ!`;BI^)@SJAN2OMGC8JO1%U.OG/.J"PP'1=Z[#IB])1)PU%!
MH)[R3E=W_BC1PU/M9OP39K]A>]H-S*_</K8?)ID::YH6-W=:CXG0V;6-PB%*
MFMF)`DY_L4]23P3*W.N>1M0DO.YTH"3LN=DG$O&\0$G8L[-/)$EHXT9GV=+8
M4>)O'^_)01)VX&AYASLB&#1VB3WQX\YI#G>Y@TBOD"L_1_BG'"%X%(0_[0@F
MGNT(=]CM3SL"7OEL1[!0+084C&._MW@"!?>ZUF6E:^PLZDZM]%K)\:G-PZYH
M]D4I^\[\"L.GYN/![?\B^I-N8'$0_:0;*#SXR0J:C"OH5Y-"H'5T.'0H/*%\
M3)+P)?"8Y[T$-`YS&O>._&NB1*-)'O,R=V]_ZCKPG$DB\Y+ET?0"GO-D<D&<
MTVD9!>YT3"U(\F1:BS2/IX7,</=UT@Y1%,VLH-&,F)1%8F8%C[*9%7&43:N"
MA&U&T@2S9MKK&+Z3*W+*)QGJ2Q91-K."4C']%@9+9E;P2$QK"UDW$U],S/F%
M)?AKS<D5*8UFM,TB/AVED$KQM+;<M,:3*RC^:'AR!:,S]N`\@JN3*V)*IY.:
M"SJC+1<YFWE&DHL9.=)\3HX,SX5.X],<O$#*Y=-6CR$=IN,C1N=.K^"S*^*<
MS\@A\IE(CI,\G^P\7\9IRJ>M'F=I,AU!*.CT6T1$9W01E,YX3K"YG`.B%4WK
M(@`=IBTF8CY3X020B)EG)&S&ZB+E,Y5:9'QZ9@%UDL\@?Q(A_YM<0?&G(),K
MH$^96<$9FWE+S&8P*!&,37LN2=A,44]2/&\PN2+#TY[3U&+.<VD$R#Z]`J!P
M6M*4S7DNY7P&+=-X+H)2P6?\`GD]$\EI"G5]>D5&Z716IEDV85/@K=_^>GEQ
M>?%?SFJY9@T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HR,2`P(&]B:@T*/#P-
M"B]#;VYT96YT<R!;(#(R(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y
M,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\
M#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R
M,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C
M."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$
M1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4
M>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C(R(#`@;V)J#0H\/`T*+T9I;'1E
M<B`O1FQA=&5$96-O9&4-"B],96YG=&@@-#$T-PT*/CX-"G-T<F5A;0T*>)R]
M7%N/VS86?A]@_@.?NMV%QRM2HB[[EJ3MHD&:MIGIMECTA99I6XTLNKJ,X_SZ
M/8<729X+M9A818#$,Z0IGOMW+LKKWZZO_KR^"I9QQDF`?_2G=,DC\U>^O[ZB
M>H42%A,:Z]\PPI-EEK&4I`&L!#0DM;R^^I54^JPDXG@03U/\A]3;ZZO=]=7F
M'W@4_AG](EA&40@/6$8A#^&?,&/L?#V+.*YG88+K:1J'3Q_(R$V2!K`WI0&!
M;5&L[[31!)K%J%\,X^'"K^^NK_[YG5CE0%Y([N`+FA'Z4$=ZC%1&L+K'*P5I
MEI&[_/KJ!B[,643NCM=77]_M)/GPU3?DU;:6<B^KEN2J:N7^4(I6-J3=B98<
M)3D694D.LMZH>D]6JMV1WP,>%+_CU6O92%'G.Z(V9"LK68N2B,.A+'+1%JHB
MK8)C),EE67:E:HJ<2#BV4B79%+)<DTU7PWI=5%NBNIK\G=S]<7WU+=#W\T6X
M0!EP`;3`<('R(')<B(+`<D%^:F75%/=R(.8KLI;WLE0'S111K4DIZJV\].U8
ME`S7RQC>B9*[SW"GFXL_"F0UYD0<]?H`>IP:3C2Y*"79BZK;B+SMM%1:F>]`
M7&I;@$:`!I!#K=9=CDN:)^1>E=T>UD`!2G4$#6I:*V[1R&9!/IU*4>%'S<=9
M!!QDO8`9'P2,GY$LA1I&=G)?#/?2E]%J_%B/FX/,BPVHZDB1#>VHRB+?%:`<
M6C-@,_YJJT2I&?!J)2OXX=)$\H0/5!H-_OIWQMCEGY.=<9."\W3<U)^UDFB7
M\5.MMK78HWU;4P&.SB%=\-G.AR4\Z7U8F&;6>L%E*9"L*,L3N2_$"C0X5_N]
MK/,"?!%H:RZ;07I&>[5K0H5]J,%RLY&P>B\7@S++ZO-I#V91?`*3D&=''>I"
MMJ(^D56A]@(>,P<#0/A6'DDZR`,$8N71K9JVU@Y[K+L%.'*X;8L2LFJY)-]7
MSDDOR#<GL<9]#0%!PN8UD9_RLM..4!UA4[,K#G@D<%:?5I;`FL[P%*)!>R)%
MZX3?P`X,'I4TO)V##^BEC")@Q'6*D"16$8X%!*:B;5RD$E4.A*S*8FLB45>M
MI1'<6<A;OOBNL>>NH;DK6&D47/S\>#C_XHP&V)`Q:AG-(A8Z1C,>,<-HJTVH
M.2#QI@"V@O*`FJVD9F^#)FDC)IJ/C??&\D`$H"FX[:AJB/_HA@4II5@/*QH9
M:&W68"-7=75Q,E/:TSEOX(U3/N(HY5DX!"C\C!P%VL'J##,<4KHXV$BR]"\B
M&0T`P96A.*7&6(,EC]/TG.!SW4`S75J_=''\`Q=REYHQ@K(@'=,>!YFE/8I2
M[N(GP@74=716N2I+L5+@OPT`+0W:0->K'=K(V,#"2O"VM=@:.[,._"?XBD;F
M=PZIG7"KK'0HG$&V:9H,CMA$9+H,74XQBKUC#(W&;&/D`^$OR9T.IL4>`ZGF
MC855CO8QWD`^P-*#HV=!YPD0YVB=UV`2R"='7.5AKS3)&)A;(#*'2)/`N?R`
M#2D2C6QL':&FYM1`AFCP\WFF8*&614A=(YT_/\=<8@61&`#'`+`VLD9!:GUM
MNJVHX81:[9W"+(PE%%71HE9M5-[-`K12'@YV&SJ]3A/KI.'V3V2Q8\_U7E7P
M:UE*?6>`H0()!NI(I0@0TM4:D^BTNMT5YT!:)]DK9$".7-QTVD689$/G8?@%
MM(XE^4[-DBBGX9`=!K%5P3!(;=@7ZW6!=&K?I0&6EBC$>@CJE4O@G_5@"W*`
M*-\@/+B\"D=8U['7CWOO'E[\,6%TQB4^Q'+*PW-T=`8R+Y^HQ4_0&UW\,>F@
M%9>'FAPBXHB;(1M5))AU/.AEWJM6$KH@/]9;416?C=KAPH^`]&UR/H<YT.RO
MP$IQ_Z`7<CCS')[UAX,E@XU8_O+$XK`WXE"T8-`?1-&@!;_"W!>L7#:7IS,8
MW87&Z2C*I!8Z+!"WH!/!M$*5Q5I@5KHI*G";Z/F;%GZ!YH39)J2J:P0192./
M.\A`3+`!'UG+@ZK;Y:6S+@[IYQ=*RI\S)EGVY3FC)ZW3B;)S7'TA)6*)K>M\
M7Y&W$,\1A+$@2'0$$U6E.O#O:Q>T3$%X)P"K_J&*"A:TCX?`AZ']VPXK`W]K
M=#YG(8'.^1J+_VS47)`/Z@0"?2_7HLS50ENSJ=+-8,A)["I(C,6#VJ6I]=@'
M4;=8[D`-0J\-E_Y#YJ!D&RP9K,GJI%',>XSM=0E7Q3@,.+S2Z'-4`#LKE<+O
M+?5#Q1M!C08X$.AE2PY=>="D@P(#8U<`#UY>C?`Q(.(]8$^&R@G/;`7))A(@
M#4,?>?V?A;9#+"T5ZP)5`GCS7UDT[4*C]1$O%@:Y&%2FJJ?0N3JT`.Y+AU\/
M8*&B?E!5E9_:6O08<0XF,%<^8CSNU9\'L8/8(^`)%P*@LI%RW;0J_]B\S)DD
MWOO$F4W%^1*@/S?AQ?K?L\>9;W_X-W[[B(]^"Y_8DI,XS>!OS&>3_J?R^NKV
M(C>,TN&&"08,$P!OL`I)K>$4IN1HU0=-YTV?S:JZF:0B2L=4@'&^D`R_WXMY
MGXZ/\5IBY8Y@&JV9"%#;7*SEHO=P37<`S(I:#%X`[4'75!$`(ZVY.(A54>IH
M:;R@M@'8:LJQ6UV$77?PTVF<YJ/6Z^W.2<Z@['&8]+"*]RXO3'GD\LD"J-)U
M8C5"50UF'SM(5<@/JLDA/;O%B$M^J2!?KYNB/2U,_;1KF@)RFU?(KOT)=>`6
M#\RQW7/W_D?R<R>`+WKA7;&1NL_RP&WHIHOV-86Z>#J-4@__BL0=6<V"/JQ2
M-H35R/58,2A@>X)\D`TH$3!)\^.7VU?(`Q/[]I@&US('H90GXV)O\[HX'!K\
MEFE,?5\U;=%V+2@H".@(J2C^J[K6G+K62ODX*Q\G9`TV2.;JL^J<V3:;^="G
MX:[)ZGH+PB5%IH;PE&7\I,J-('=(MMICH:RRT`)L<U<`+R"RWA=KX&2ICA=/
M2X*DIV5>[>&4CKA&.9SDU$=_-N4TT(QSB:+CR;4Q(O]^`/0B/Z(9.1N<0[@\
M[?,TFJ:#0PEL<<!6>GY9WB[)KSN)98']:H0/Q\X38/QF@[Z!1L0ZHJ:U%9.N
MKK4-&`<L#B#H3X`=6@F_XL%H.[8//B(WX,E]R$%/+/):-:9(.`<?XNP))8]2
M*ZUMJ58249`@]P)[@]H'6E")91Y7&S-%SPWHOCIJ*N#BX'SWN@8*BHW&[\`0
M,F\O@,Z1U\['@?9?<Z0C//K2=,27F,+Y88_*XZ'DR.EX-L7G`]]VD+K*>D&^
M*T'P:Z&-X9T@;Y$S"_(&(A"PNBHNWHR'X!)E0TN6IT/5PO6D(97Z0=\7$JGX
M42*%A=RMV/83!'Y*,9%`73>&9+'6R`Y,GH'>$#1H!HV/DK2/;\FH0D-[![4'
M0+^S$S1(9RN<YB*M;RBVG-5>@F-`F'^`U,IEDV?[S921):55JC2V`C^ASI_0
M2G2\*`6@#_,S]K(;C4F*64):%/>=4#:8.W"$.]K!734'5;EDMY5%U=B0+ELP
MT!*$=1#M[BA..K\$(]?RU;5NW`:`L;YXF1)BBKOZO!$L@E@Y,(D&"1U"@^L=
M;,`/5FOPWZ9FK#U?XR1\5!TV@=$-`BM0F9V\R:C>/(=H(Y<5!/$((;,T?M3&
MZM-67>G7L!UD;"I0VG?O46OEFCR8+GHP<#1NBD"V6Y3@Q'0%X"O0D`-ZLHU2
MMB%>Z7P9$]!9:&=#=L#HJ!WMBJZCL2>CS$]/SYS5-<IB6ZE1@\0V;RY?T(@`
M<`\4L&04/*+$!@_G3G<"X^H.,13<=ZW3&(E7.RO5Z!*,U+./1=5ICSL'UVG0
M:QP=(!2EJ4/(!XADTM;!1"V%T9E]IX=NSG#RRPH2_H",TZJV4DPCDRA__=+D
MS/.DD/9/NH!O\CV(CTAB89_Z\SA^/C5;0."NBE8=5;X@OQ:-'G!Y^3C3<_B*
M021UEYNEF!S:7N9<Q>30]FVP>L6H%>$<J7PZ/&K62):R_D%HH/$H(G!_(O_Z
M[H--Y-'!%(UUCJ\@/8%/NO[19V;OWKU9&*R/S@8+GJ/!TW%[2X,]!$LUH#P=
M,XQ#P`D_^-X7J*3/`PS]F7`HE869ZQ:AGW3SE.,2+WHIU\-WL0%"7ZU6=@(3
M8T:C\9].ZQ#.NLP0N.<<K^H:0`E@;KDD-`.(_3"/&C]S#O*#?M(T8X,"<)[T
M0Q!#"O<X&C9Z-J<DSR('<"ZZSH.(=P64OJ&+_JC1E\RLQ_G9E>Q:?;:#$W/0
MKS7=Y;:#^*/,YOB&&I`CRDR4C=+AU0KSB<J_J>XXNIQF`S6U--4!'`(9*,+M
M;E;\(>=(!WBI^&SF(.8A/NZG2^-H*..%COCGAZUF&2!ET9<.D/J#/0M[T*Z3
MV7ZHV)+[1!5W\4P#:!;R*9TU?-$L<JV-D*';_VQIOC2KTZQ_%K":)4/-*$EL
M7'G`YLLWWN/1%8#8`2X'0>@:[^"&@/S_+S9APMNH>NB,?M.UL&?4$T53+AK7
M%<8M?3ECENJD;N98SS74X,,H3$8U"C/A\+"3>S94@M[X%28_0-OM4&QS19DE
MN77!*>V;1.-@9CS>D$4,=1O4K797JVZ[FX4!<=^$R$:3%7K\5,^N=34Y[A2^
M(H&C_6LKLE%_U_6`WSW3PWWT&A#67A"A@(XT;B!'_VZ-J!E4X61JG$CYJ%PU
M!_']6VZ4I<-;;JF;KG:58BV(KD$D!9_76%+&2+0%\>/L=6.GT!LWMHB("TG?
M=-468B\2UQ:YG7Q4I<PA;M683)HH<+?K3!$;"]W5^N&X;E&/\-P\&28=7N_J
MN1`[+HSU4C?D@6I=6GY#<0;1@8WS(>*]^"CQ+8\])J9R`\90./MV`.5>/@B`
M^HTLS@.29)`G:"*&V^H7(!G)&#/K[.GUE('F>M834'/?>DQC[EOG.-GJ68\H
M\-FS'@:)]WP6\,BW3H/D^?O_Z7@8ZRTT>CKDT%X1Z.,WXOCP1EP_?A]D;OS^
M3I<?0;7?X.N>5?NX54^?&CB`8Q/3J\]&/_:]>CT:_OR5X_&5'Y81.<GZ4BMW
M`XV/0[\>9GGA(R"9=%'"/H$&#Q77KS4W&4V\ZQ3GX7T;6!9[]?XFS,+8NR'*
M8J_FWO`L]1,19['_DFD0>(WK)@N8?P,-@HE;4K"`B1V,^GW`#0WA$/^.B$83
M-^4T9/X=">43.U(:>[T%Z`6.GG@5(Z"I_RD`B:.)'<SG5?2.,)A0+["Y";DP
MCA5+[XZ8AA/4)A`@_#O2()F@-@LF.!8&-/!3&X*;G]B!;/?O"&DT8=,1G:`6
M<FP^<0;/DHE[Q-G4/9+,'[5N`#--V&V8X;N77@<5X,N)WATTF_`?$9O<$6;Q
MQ#VB;$*3`1XS.K$C\<?QFRC!=W*].U)\4]?OTND$+3R@$Y(#HYRP.:[?[/'N
M`.\P$5O"<"+`\0B+B-X=/)S@.H]#YN<I3T(^<8\TG/#\/&.9_QZ@'IG?HF(,
M4OX=#/_C!>\.78#P[M##9-X=G$W$]#@&D_+O2`"<^'>D4Y*#9"/PWS0)PM!_
MTX1.22YAX82W3,(I#4JB<$(N"9_2Y`2%Z]^18&[JWY%Y>`J@]-O?KJ^NK_X'
M9ML3HPT*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HR,R`P(&]B:@T*/#P-"B]#
M;VYT96YT<R!;(#(T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=
M#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO
M1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@
M,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q
M.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*
M+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E
M("]086=E#0H^/@T*96YD;V)J#0H-"C(T(#`@;V)J#0H\/`T*+T9I;'1E<B`O
M1FQA=&5$96-O9&4-"B],96YG=&@@,S4P-@T*/CX-"G-T<F5A;0T*>)RU6UES
MX[@1?G>5_P.>4I.4K`#@G3S-E522VF2R]M3NP[Q0%"1AER*U/.SQ_/I\#8"'
M?)`;CUFS9<D&"/3=7W=SW_U\>?';Y05?ATG`./TSW^)UX-L?V?'R0I@5P63(
M1&C^(ED<KY-$QBSFG"6Q9)6ZO/B)%>:HR`_HG"".Z8-5^\N+P^7%[D]T$OT;
M_8&O?=_#^6O?"SQ\>(F4Y^N)']!ZXD6T'L>A]_2!DEU%$?=`D>"@+O1#0]/.
M\&<79;_HA0/![VXN+_[\MW23)4QX[`8/&#F80SO.A62"^U@]$DE2Q@F[R2XO
MKCA$)'QV<W=Y\>:'LL[*.W;=I(UBGPM]JZI:-_<K9A=6[,>VKG7*_LAN?KF\
M^(A;__O[:3.2GZ!-6MK>?)$^?^D%SS$?X@?GH6->^$'/O,\389G_2;%#>DL_
MMJQL*Y:7Q5[5#2ZJ55IE!Y:5>9YNRBIM=%FP.]T<F/IZ4E53,UW@OVU;-Y5.
M<Z:*;_?',B_W]RQMV#-"95]XP'^X_HP/L:(#FH-B'_2MKNGTUQ8`))R0Q@W_
M/,#CCG]/A([_<L?>']119^#@X\"!HZQ?^J!.:=4<5=&L6%JS.Y7G]#D23K&W
MPL'^JMQH>TPG*0B$CK.&5+"W6;I5QWN&RZ\SK8I,U6OVCV7XCV3//^G<\2\=
M^P*Q8`5VP+!N-'2U-81NU:W*RQ/Q2T228>QT!;,P2E;L5)7;-B-9%"S-])9E
M$$B;I[7"80<-L[DSTCD>597!./0W'`R9XCI_S6X.,*Z1[,JJMD:X46H9(01!
MYP1A+P-?>H$5@BY@PBTQ"TT[S6\U[!=&:Y14J+L'G-=L5U:LA6:+;?^(:E*=
M@]'LD%9IUJA*?[->0YO2(LWO:UW3>>JKKHW%/#AT_>HQ)@IXS_V;142+P-V)
M-AQ$&R56M#=D]7_XP-0.\FK()`KBU%K#$Z$%H8&1V(U`84\-I$K.PFI5P4!@
M5"FK];[0.[@EC'-7ML76/D\*(4.UIEC6.F.J.:1%F8.IW)CV$OR3)SG^>6P$
M\*:+G2]49S1Y81S[YL)$K$6$#'SS#3=^N$^W9W?91W_\.SUZ1_?^$]_D&@`A
MII]XWHO[W_++B^M7(<]+>O(08WADQ:&S6=*\9$R:OP!I_D":;\GZ(J6<)<P_
M(RR0KT\8T%-'&#R'B]#OO$AZE+#(BVKVJ0L[%$JNX0L:.6.6^L`;4R_BEY(_
M!6+B@?Z7!Y@)B!2'_G<BI&EX&/M1CPZ37O9^E#AT^$Z7'PM5(9F_:VM=J+I>
M`*;1DWT4&5":]`>4ME&Y1E9&8'1@@GP>,>X30AM"WY'=J.Q06-AQIW/"8^DF
M5Y2CFA))9X>@VB<O<TBZW2)2U=AHV,,B]A]K=BPK10%;90U@6WYO;&Z!T!DE
M'2X7(NJ9]F+N)*^0+$H#O_+[->N`*N)_8QA#'C4P;)1M$>)W;;%'%D="3Y'6
M#>DVR=8.F*05)?<*S!%GIU.."^@X"(FDBCL-5$5"P07IOM)9FS=MA3.7$$'4
MH7,X>Z_V))16`E"/WK8#/EAUN@+$/%GFH'K`]>J^0^+WS#U4&ZB=(U>6HXQ8
MMQL23:-J0N!X"&S#,@SV(2G4[3ZMZ@[$$;!I*R1JP+P-F1+!PW(1000=3!=)
M,$C"Q3_+O^KS.3%>0EM(]@Z@UX0J`:Z:P0F,R1->J""T.\,=U%V5*1@#$_9,
M`F$`ZT#]"GI6SC-L102,5E;6_!9#II'?PW-/N'QY4DT%>MKCJP>:H+\OD:@!
MN4,/5Z]^43)F+`E<QMW"1V_5=OWJ66(DR!?FH&G,%?&@U]*H@V"^DWU^M#"^
M2Q!+I,$P#A9M%(1AW.LK[!W0"[D+1?\!LG[(IDL@\)IC^@O0=Z'4UG0%MJ;<
M5X^Z`PH;JU\5!3)=9'F[)?=KU-<&95--Q:0^8NL.QZS8J<U/QM%/*6KH%45]
M0.K5$DX8!CV&ES(:$E$7?G9E"8(VR+Y5NE>&J$VE[HCX(1(YSLQ?#J9.R<![
MB0*8;5`7FVQ"X><K>&PHJTK.^RU&:N?+*-PR%#>0GCH7%Y+4$C+P.MP.F#C4
MR+[+Q9\+3064:>?4)AG7E'NIWGI8&'?)=052J[+='\RN\JY@=4H1%ADK4RM7
M./>9N-N+NALL;UIJ"IB>"(Q,4WUGNA3FTOZF)<0@>C3(1_6L\3Z2PYBEMZ:7
M0QE5;W5:C3#*5IWR\E[9CMJ(:\H[8V`%D]XKB^:.@"MG-C281E?8#BA@L(8E
M1,![+"J'AED<.4O(R\S4V\9D/[8`(E#FOU'<']A;D(M\N6+798M?B8OW`!:$
MG?HE^J/=;2H9LY$$:82GCB2W,QL@D?6FYD+%BI%'+@5+@[B'I5$T0!$OBJT`
M1E&J@Y:6+4.F#5,V<)U%L!Z&;A`O1@BTV/:V3WV#/%>5=3"`FM)!7HM2K=3S
M=%-W':?/Z^OU8F((>V@J!W3N1UUGY_U!%REIQ[5T>H-]=5J"L"=F6=B"VFO,
MMN#1B&UG_O5)9=1\@J+A@<JJPF6PI[1.YMN>3K#X43#HNF%&C67=I\77[__1
M-*5CZ870:+I\#F32:<;C460ULTBI'O1W47`6<:>;R'PWS<9.#__H:J$%@%C`
MDT6!F)]TP!F&[XTZJD,KP!;S*<K\K6)56NP-NNA;\$^VJL]B2-U2B*K_LH1\
M?#=P^"[Y3)TOXD7E[PW](*J0>P00A><#,\B^:!`)"*MF>5DHFY#4UY/!Q%NV
M1]GI9.\@#+*&"Q4/.S$5865VFU:Z;&O*(7ME!@6C.<S*(<M;EQD6"/F>UV=^
M[OE##4`%^9VIWPPUBE(=8>%\/!BA'A3,SQJ8X6K<-2`Q0&#Z2(,A9(Z]P78_
MF%P)/H&%HQ5K(1K]C6`-A<KWHNMZ4C-FZ&X9(+@$]Z+/^^%X2A1W3=@VRZ#9
M74O]@#I+:=+3VE!_3(MVEV9-6U&#Y*XT<GG>']V$3)GQ(#*G:=>1N5!C9FPM
M)EL8,/"P^U<O(@*9],-B'L:#`20NYY^Q55NZP=4MQ2$S>NDQJQGF;%334-=1
M560<:0$`/#3KZD9G9C":EW?4R"GKQCVFCW0F)(F/G6XH.>ZIET<VY)J>Z2+@
MW^`<-RL?9L4^#QSXS\KC*:UL#XS@5S_&&S1+U2$8TR?29(4R(,V,L3^M0B-`
M@/E*D9G8]N/QI!I-]8$IL=WP]4'88#D*<+9MJX5*`!GV.4B*H3,;"6<'Y*ZV
M#%;W0'\O:^A,XPHINY:+3(9Z-)2!PV&?.ICUR<"L[\[X4^]0Q/V(,^!#8##5
M4=<:,8-^,\D?QI<G&E_NX#+W*C43;M3&ZE@6M@&[M8;0504VIV>J:DPA",.P
MWN"0_@-4V3=[Q[/0!0Q!1,-T,QB&(QX7?6.68F+7"5'%K:[*PDW2-S!A^&_7
M+JB,[>O:@5VVN>_2&QY?C?JQ72U%WX<@:K(?-7L?A%67;)9@/NA;(H$_E`)F
MSFU>&[!QRH:"'91`^M<V<:>L:(\;:`K?G9#4F4)+DT#SAXH=,HF+*_1D]\:$
M+?OMA9M<I=G!Y,H=^U>5[I81@=>!(1X%HUZ`"XA$?+TR]%2P[%LH'=1\556Y
MK](3LMPY372@`;51`IQEB!EN-2^%V3>B[`;Y](9$2CFU'DLAIM8C@4)^8CT4
MX>3Y`?G]Q+K/X\GS/1Y&4^N27LV:6$=5^OSYO[DM@251^$_'7=%K7#Q^(VV8
MQ(!5HW/J"<==C=7-WMZ710,_?SR$%D^]=H!C(SN%3D:_]E-HDAL0)TH'[RF2
M8;_/6BF>\9VCH@2-7=KVUF'W>M\7"8$_<H[8MS>BFGCRR@F_H$>'%XK\T"9(
ML992!!U0)J2[TX4V6!>`3P'ACY`3`?YNFE:7.PC2#O-2Y]WN@'13Z6S<[ONQ
MS'ZE_>SM^X\44K5K.B#8P.E0.MA>]"LSV[_B(^4`C$,N7!+HB;($_?7)CM3O
M(.'9H@^HM*/A<0^#7"KF+S8=U^S\/TW'W/A":?(AI8H>9'*ORRH;70Z&0V5]
MV33N%;)ACENSUB3==[H<+*&?VM+PX>P8ET?(V@!?:9)ZTC:_FBZ\RV/UL83Y
M$.Q\/&7Y/IZ]_J4@&85])@W,=U-:P7KL1(FX1)57,5C^_M!88@S2U.6IS+6K
M'5]`WG/6Y?E!3]^3UB6`>I\-IN$XF#YXXX@CSLD.2,N@>^OH<=?"AMT77@+_
MX)U_NCN$>)AVD\F4=97@VJEUD?B3.>L*&'TR:5]Y23!-@D\OJDYM"&B,/+4!
M56HPN2'F8GI#PF>(I+>I9W8(/B-K@00_(VU/>-.$"K\SRF=WA,*;V1&AFIG>
M$0M_9D<BPNE;)!=R9H?@X32W4O(9ZY+>G%ZDWWG8LSN`=J:YE2'WIVU41H2>
M)G?$?$YB"4]F?`DRG=D!,YP$D5>>%'+:I3U/S'#K>8DW<X:?A#-T!,D<'6$R
M#<BOO&@NN'@QA#H3GQ(Y;1_TOTS,[!"S.V3B3]/A>\F,)?L!YY,%!G9$_K34
M_9`FFY,[(B^9N07188:79*:4N@KXG,\%@D^7<U<!HL.TQ`+IS>2WP$,`F=[A
M>S-2#P)J($_N"#U_AH[(FXG\02RGR]<K<JAICP)R3V9V(,!,WQ*B"I_F-O0@
M]ND=OIQ+Z0&U9"=WA#*>H2.:TUP8R^F2&]#"D].41GQ.<Y'P9J)E).<L".8Q
MHY?(G[/D*)!BVBLC8(=IKXS"9$*F@)P??[Z\N+SX'Y@2D.P-"F5N9'-T<F5A
M;0T*#0IE;F1O8FH-"@T*,C4@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`R-B`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2
M#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y
M,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y
M(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"
M#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N
M9&]B:@T*#0HR-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO
M3&5N9W1H(#0Q,S,-"CX^#0IS=')E86T-"GB<O5M;;]S&%7X7H/\P3ZU;K!3>
M+^A3'"=I"@1)'0$.BKYPN;/:L;GDFA>M-[^^WSES(27+)."(C8%HM1R2Y_J=
M[YP9O?[]^NKC]95WF^2Q\.@??\INXTC_KSQ>7_E\Q1=!(OR$OPE$XMWF>9")
MS,,5S_=$*Z^OWHF:GY5&,3THSC+Z(=K[ZZO#]=7^[_0H^C?YPKN-HA`ON(W"
M.,2/,`^"Q]?S**;K>9C2]2Q+PN<?&(B;-/'B1&20!LNBA&7:LX+Z8N0NALDH
M\.N[ZZMO?BBV)=0+Q1UN8$/P0ZWJ?@`MHTC<'4FDP(-E[LKKJQO(G=#G\_75
M*U5_Z,2^;8[B7'2]%*?B)%NQ&UI5WPO5=Z)LZ@?9=JJI1=_@_>6EK.1.K]N(
MHMZ)_B#Q_6XH>UJD:OZB.#9#W8MF+V0MV_N+&#K<Q4_8JUKRC;OV(DY#=1)[
MM<4K^+N_B;OWUU??0[M_OYP-@MS:`+]:$Z1AKDW`JMR*.TA=%7T/]54'_=I>
ME4-5M-5%J..I:?NB[J%P)\Y2'(H'*;I#<R9EBUZK#_V,KK!9-QQ/4WM`5[+H
MJ6U*V<&J!;YNB[K#&R691=5E*PNRT2H6\%T4A+[O3("DT19H&^N^%O)TM^*G
M6A2[G:*O-J(96F&6:,F+JFN@ZZ&H2YA!(CZ*:C22]BDY4P<3;L6/7LEN0VI6
MPXXLT?6MK._[PT9L6W5_Z&N89;-6".2YBP`OB<<L,!&`B"[J2I$(M^*7I]IN
MI0M>R`QOE[*JAJKI5"DZ:',OC;(4,97L;/;HA#H7%%%\XU%2!"$:6KF]B(.L
M3K2,<X+"A^-D#>4SZWP_23*G?)"E6GM9/ZBVJ4DZ[<:BY,0E<;0'CT4][/&M
MULO$,`<)POQ8M)<-)<565@JQH#/B4<PT^SW9@)[W66B0YI3[HI;G5;1/G.NC
MT"H?>Y%Q?:.S="LO#4%96^B@AR'*@SPJ1"GB%FJ6!TK][E)#"[A9G)KJ<K2@
MU0TMF0>QWVGMBQ;FX&S&LT^R;YM*#D=>R[E3RT+;0^(;;6K5KJ)]//K>=^I'
M/GTF]5O9G20R'VXSWA*5VDO!*-_=OK1$B2=R/[,2.2`*T\`@T9L+'%"*<FB!
M#CV@ET,'5CW+:I2Q(U3=4XC]H+:M_`\\,1$?:8R++5#X"`^5"KY$_M(M3Z+O
MJ*JJ8^#OGMZ_ABL\GQ6'OIX7IU;W((I"6XH)&Z5XK9J7?GTZOCX/;B.//O^!
M5]Z\^(L2]R(X./5'N`GCU(8<"`!P9"->`W:15Z^;INOYBS<2=(0@AGSTCN'S
M'</GG87/6_&=#8V-!A0;$9QRDO%I:,L#)Q]0MARZOM&)2I6[JNCG"M[-1I"-
M1IR)/*NU%@UH4E1:,(*[43@$YTX1SY+B7C;W;7$ZJ!*!6Q`IV"!^V2KBH0`<
M]9053S`9C$,#EP:D(UD-K^JHNAR+#ZA0XJP06Z`<*%>X?0T3)*DU03;Z/<HL
MS7H.^OON]K]!Y+V;5@^I12U.IPHVV*I*:8T?E93^,"#+"^9J!;$LP$;!4.[*
M3]D@)'I9'NJF:L#*%/,/V+<FOK(1!]`.(,P:EH@]:PDB'L82<6XX=S>HOMA6
MDE'JF:H(91`8[>56_+,Y$[N"W#TX9Z>+QU;*FA64G[!:R;K4-7<#XL%<DAYI
ME*.`X5?5!2)%VK*^EW*'T"L_P"1$S@K*OU4L$88C]4XFW-O@_1BWFOL!&A#U
MSLO0C=H($*:=)=)?L-5&=.J^5GM$`1CHV[^\01`AV6NIB1LX'+T*#]5/:MH=
M,9)&[&#?JCGQH\DOJS"P#!VHI9_I&`\&&N`3IW`MB5J!49%L^Z&""T^(U[[E
M-@$R@FU]D/W7%>9\5L@T=40IR!V"X:&F/'U;JR-\\P-9]"=C]:\V5C(C1ZSE
M>$7`L`(!2:-@KA<P#`0>>0`*@?*!'P%)`4&R_@-$PW`+A]SG0^.Z.N"VJD>V
MN$7S*(D;'ZAKH)AM+YR@AO;B*S8I9:.E(>81*P0A<RQ3E],Q%4/Z3(I3`:V;
M'O*A#4#<[=2]['I=K$[-4)&[H7F%,L70(;8#(`<7J5$$>ECS&``BI3:&V.I'
M*0/EIJ="HP$;D^;?$OT'$\4[=+-)][KGK6$*SW'0T'<`'=)H2*/2XZX/YFC.
M6JBQ8<'WW8`2)8F6:$`%Y/0'@;62BD_7H]J>)Z78L7]J][7RN@?8`[4(QKG*
MR4^*V1"%V7&HN*:!I*Y@A21W1"T,XHD53";<,=PH,D4-SL9]W$1GEI%LPEH;
M;_&`I`6F6IK#*WIM@+)H4:[0\`P]0R\LLV'>MB>JUR+VFS,>96J43@Y$F.29
M##]H#2ND(W$+)AV2%V@K##VB]H_"3$*,').A&-7.9B..1#8&%"!X38SS%"<^
M(*"";EV/.JQ#89P93=MO'AI\O;MG<#4QK>!:N)J$CO[Y031I[4Q2O9.&B5+#
M3$2\4Y^F"/BHN2,4^)&@\$<*0.K)Q+1,NB:[+U35$#L@4*8NCX.1,1M))?K+
M27+8\@MV$K5TMQ+320+/E<]H'+1F;M"@Z4M%?(-%XJJP<47"E@<"G5OQ5M[3
M[$$S6IT0W>/VEYA=,]!\%@2)AQ2JLQQ)\M02L0;8Y0</)SP&_3!25T>E6@57
M$R]T)289;1#:%H`(*S,P9#^-O]S44X](>=J"JF)TGO)]%(F=G<Q0Z[>]6#Y'
M[M1T#XZGQY@"_BN@DY/Q;NP`"'145P)XV[4FC7&6.%#-QBKKT;!C'+5*C1<6
M^7N"QFUSN.R8Y^WD/<VAQIK*XS4%'ESOIIRUH5'B\RE$Z>"R8(>>D6/CC*;R
M8%L#O-Q,?M8P@YNZ>8GGFL$P]!,[<]3%G7)X'/;44K%*X^0&7Q8/R''=PS2M
MY67<\QD"H6LMV[)`#>6D^4H$3>>5"BUS]+TP'AFR;69>J^;70]$>"_&:&G9B
MA"O@>.P'J^(X[PJ8EBT<DSA-$H?C.H\Y09_1&1&J>VR$\G[@MI,803W`W]N+
MF64L9ZJLV>G$.[;VT31CKXE]K1"R4>I(812.7;N7FOHU!0\:W@!`OD%`NB@D
MG>TXN*1V0+=O7/.ZP67ZQP$-JJ+=$%/1CLH:I$5'._2Z^>@EM0%[CGA9H@#J
M<1">[GY9PP:)HX39N%,6V1:AEV909_<PM/)F4X`GR5KF0NS:X9Z8_DX1S?LK
M#+-[H.TBS99IO]$:$\X^M,UP?["XIK=)"MBPLI.)R171JZ-<"[TCMUOJ9V-C
M$,>V.63.9BL.P<XZS#P*4I>"\1B*:6Y"\:TT?<%!G4S7\7F*\/SC@3=G:.K'
M=)WL?J*$1/$$NRAIY[(#6R@/&TJYLJF`M(VF'1U_Q20$9*3\_`W\<MOKKF$%
MWS&J/'+1&$>18>;O&Y1$`6`AB-&99X?XY8M/T/W4<P*M.T+WT9!,5`_3"9E,
MS01QF@^,"2^N;Y`%_R=]`]"D45^?Y\46>#Q36?74BT(8U+`@-[^G`D23"?NQ
MZ-2?2,8OU=L(*6>%>[5&-0]S[T]6\WG.0@=0V(<A95&F??AS40^/WJ5O??LC
MW7JF]_X+GX+;&+?[^#_NC\;?JNNKWUY$O"ATXM&F6.CI)'_EMC4698S"J8QY
M^)4R+K@H#E<E7&'H6H8D'2<0H0U^$*Y=PZ,Y.F^BF?.3[1]\HMD:'[%``P6N
MW_6RV.ES*A)M7W.AKNO<C,`_/L!.,7FQZ4]H4E79)FP%;.>QFZ'2([:'2?*H
M33)L8C"G,C[(R_/R4SO[:U/M"W%'M0R4"BWN;]_RO(:_WXBJ*0LS^W]7M%UQ
MWM`58.?&=D4TL*6=%?UJO:GF-I#7,('GNHEHTB+E7O:X1=(68,55/:#EK\RT
M@.I^P\[N9=L.)]W9HTBCO0P(KX>:-CD*X;]XU$:![^1?MSI$03RU5!"ED[U5
MP\HN=)K"!H;UI^+#.W14A]L(;8M2MCT-E$K5EL.QZVD!==?$H%9P<9#95LH+
M/%?&@]2S&X'FZ-3+.RB)W<O7]0^8\43+/)G,D9-XXAYT^/(,5?5YFPXM)&56
MIUN\>A68"="YC;(%?C(>?,MBLZE%34C+,S$-,9VDL=+S*+,1/X/YR@_4\_[&
M`WN*'8<;@SEQ@%QEDK)&/"79V)Z-B4!G4>UN*F$$S,QTR&"!G^<1`P:EA)NU
M/!*7#MJ0S)4Z*M[RH=O_(0YV^_GIZ:XS=1!#M1MWLMQT[DF#NX858M>DQA.?
M>K9V\-:XKI+CZ9!^XKS..4_M>8=8[M8XZ12X0Y?^9'LERX)Q>T47K6>BC8][
MW+=2]\MN,U+WUCW:-+/[8DZ9\7R7-TUP,YUW&C<M]/2[Y>T%?3X"_?-FW(Q:
MX[AI/NX$A.,AK\2&:2L_#HI:-CT`>FD)\L1)L'*G1L?()[IZ\637PT#\#U73
MJEW!N[[%!<[;JT]PV!$NIR$LN9`;[^-)UAU-S'1(D*/Y]'5Q4GPJLZ9=5PX&
M,^,_-BAH]<3)?#BB*DQ'2"8^Z1-3:W@X<_V:EXP;J$F:CK&M:H``1'\L*"G,
MDXFMM.<;"L6T#)0ENQ7O:%CX<=`[SXPUVB#RT\F<-5?M9'^-#`3NVT\GAD,W
MW6.G:;=<A</Z23ARV$F8QZ;N/335<-0HZ#9U20<:'H[[&N]X&,,G_W8TU1ZS
M'C9Y(TMYW$)\&"?2-$6;0RMH)^$3](T]8/Q6E>(H>R+VZT"P'[F6)1T1.+23
MF4=XXSS$D--U#0@U.;>59OSG%K@MG&/Q'EFC3WW1[S8+QM,Q^N24ZG1<\$:L
ML0<7-3:2/M*_AO;!N+DQGI0)H]1WVUQ&IG/1V6TW]BZ$DV5QM*%OCEZQX^#M
M7\J^,<Y.GJ0MOS6.8I'F:!A9XE$T_I,2+/`#7R\(OK"`6>C,@MR'.C/7,Y_.
MSWSY>NI'L\]/?#0W,]=C+YU]?D3'MF>NAUXZ*W_@S<OOT[#_2]<_FB5QPDM0
MW)\]8>6[N/$__S.,V'6]L?E+%"+-F>GX[AB^$//?-;37UW>?S3_\YV8T>&QJ
M!B"37]T$A/WZ99&3J<A/>B\4M-S]X8@N;L\.0?CTV%>^PA>NEI@W^,'3T$]F
MH^:&.HVYZWX>^;,+@CR=C=N;,,]G`^<FRM-@=D'B^;.A>9-ZX?R"S%L0,O>R
M^06^Y_L+*_#?O!Z$,?-R@O*%Z?R*V(\75B3^@L]1=^*%%9F?+;PE]Z/Y%<1)
MYK4-N/;/K@B6_!*$?K#PEL@/Y[4-X@5LNPD2+UW0-O46+!9D")"%5/(7[!$B
M"F=1_"9$F,YG=!@L5"*LR..%9X1YNB!'E"_)$>?9@AS)(K:D>3!O]3#+H_GX
M`#XMH$?D+:[P\V1>CBC(%R(YBKP@65A!YWMG5\1I/A]!41+Y"V])_25=,G_!
M<U&^E'.Q1W]9.KN"__YV?D48SB-N'(3!PC/PB'E[Q%$8SMLTCL-D08XD7$#^
M.`WR!3DRI.7\BGR!Q**2!O'\6Q(_6,"@)`CFF>1-$@9+%1WI,!]C20RLFU^1
M+'DN24-O0=*,^J[9%?F2YT`^%M`R]9<B*`W"!;^DX5(DIU$0SF=E&OO1?%8"
M7V9L"D+Y_>_75]=7_P.&``4!#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C(W
M(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,C@@,"!2(%T-"B]-961I84)O>"!;
M(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\
M/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2
M#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS
M(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R
M;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E
M22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,C@@,"!O8FH-
M"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S.30S#0H^/@T*
M<W1R96%M#0IXG+U;WW/;-A)^]XS_!SQT[G(WLHX$"(+LF^TDO7:NUUSM3OO0
M%XJ")"04H?*''.6OOUT`).C8)CNIF,E,+)D@L+O8_?;;!7SSV^7%'Y<7P3).
M.0GPG_F4+'ED_\OWEQ>A>1(2&I,P-K^AA(EEFM*$)`$\"1@CE;R\^)649BX1
M<9R()PG^(-7V\F)W>;'Y)TZ%_P:_")91Q&"!9<0X@Q\LI?3Q\S3B^#QE`I\G
M2<R>GY"2*\&#*"9)&!`8!I]0IHU1T#YD_4,6>X%O[B\O_O4V6^6@'B/W\((Q
MA)FT4SU&+2-XND>1PBA,R7U^>7$%<@<\(?</EQ>O?MW)DN1ZOU*E7),'U>R(
M;BNBRD9695:0NLDV&Z(W9(._WF=EN\GRIJU4N24'6=6Z+&6Q(`^2Y&U5R;(I
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MJ+U20<W\*5OR)(C(_2=8ZU;O'RUEW_SY.WSS`9?]`3[1)8>W`_@?7F=Q_ZVX
MO+@[BW1,>.EBV$W*K70'V2C<F4D1`?8&(@KQA2).;!"G?W&#TO$-8KSS9YI&
MO4,+_(P.?:/TFU)6VQ.Y01>5=7WNJ`*H2-*D@Q0.T-`)$<9.B/N=)"NEI15D
MHV2Q)K\'/+!!`T_V65TC&F9D(^6Z;G3^`9Z'&'\9*>6#":QMI1]P/$!F6S?5
M:4F^+TGSS-2`NBM9*'F4\#AK<`P`%X0I*%9DC3I*0.,9P"5)PAY9@]`C:^3`
M90.*0$XY9*4R$`CX:5#1`N;NM*YT<:I!YUH7+;IP#>FEZNT#Z<%@D2Z-.0"E
M0<.2U/NL*`"3RW:_@A^`.GX-"[BXR*8MMY"WYM`:=]EJS>)>:Y:FS&KML9+4
MI[J1>T@)A?H@R>M3ME:YVT74^B!SE17J$V3</&OD5D,V\7O7/&A29-467@3E
M(&LX/X!7O,8+\E]]U&C/FES_Z\X8R@S/M?&XAYW*=[-8(1*=%0+>QR'C/.H2
M2VY9P*&M\EU6@X[?@=.6.6SP]Y95H(FRPOB]V=]^9V^S$BR5E4[-$_E>;V6Y
M)->E1O/TXYPC=:/`I+\L[Y9GCW<A>FU3"NZ-KH[`>W7VE2">O%UID/1LA2?,
M>=?*F/*UPLC(#'N897=9X*1@0$6=$,A*C0QM+8>4@`"#:2"^S=X8-H7!I[XP
M_X_#OT@]CQ6IEPP_HVAOK$MTV']VVP#X"][Q2?#<?H=8Z(QSG8.+&_8'1+(/
MSH4![@==%>L'M4:^5WV0C8&[05A;AZ[1D[^ARP"0L"@LY]JI`E#!^;\C6NCW
MF/L-?78>,8<S");V"E/A%>;.YK>Z.N@JL^P00IW4!M)0X;ZB&"AI.*.%ON;4
MJ^P,`MDK.X!K?51[0$2`CV\8%&'.#DOR$ZC]^18#48?W:\@-%<R^S]Z#3>>P
M`J4]X,7>"G%*K14&NP':$M74?>)>D)7&@@KR&-D6>N6,4,FM04`",:V`+K^#
M[)BK`_S"#1I.B1G!0SU"N\T*WQ+`0F>]&K%T\0C_NT%S&"2P3`RL$(2\1PD:
MQ0ZJG@IV]Z,5JFURD&FC]=IE=MCMPE`A._#ZQNVRU?2F`H+[K*KX]LWUW5LS
M[#M90>'V[>?3+<D]I`\,'!.$4&QMNNBQI&$&V\1)1Q"#.$AZ9Z$T[)P%*E]=
MV*+70*8(?@\BCJ&-<?,$$YS:"UN:>T=828,T\(JA"G7CQW\`I-AE1WQ.@P!U
M`/;4(DFJ&Q-=:XPV4]Y^$R[I+&80/4$T%G$$D07.#'U<7Z_7RM*!)TXOD2QT
M2CZUR\K!P`**:F`Z@#Y];D3G,(`)5!(LO(*Y/@+NH.(`S69>,ZF#'F7)]1QF
MX!UC#(3PWL`2X7ARBYT&0+='[*:'!YMI):)\H7.S<8<*=K!2@(\@]0\9./("
M6!5P)J/T[4Z5J#\2R:+6Y)!5C4)D*0TH6?;9@1.^L2";2N\)N(5$T^#/A;'9
M',9@/7&DD4^?II9`8ZP54$<DCM81I/7XU@F.O1)K&`#,-QGLN(L8B_N/4J)5
MNX7`@-E\R`PH\F+8K2K?ZU/=SP!.-(OVM"-68>*S2,1IAYGK(^Q2MD4YZUI#
MDFRZ?AQHJ2JR1R\WL5Z9//LM64-<%_J`7BWS7:D+O36%@<&62M8`=CE^A\W6
M$$9KA0&T:H<%BNUEZ3VX3=ET\3"']D''WJAPQ?NK@ZY-Z,_3+^()F[4=P>.X
MI^O(!.Q^BJ!C!3=*O]MED)?^.B4=TS**_Z*6XY27TYX!IH-2+^Z[':YDW6,9
M-JA->TB^^Q'QZ:C`!:&26_CX&Q#D_^CR$YA)&0?.:XO?MQ4@7U&XO`=(",@G
MFPQ@"SXW<IZF*0^I;^_XM!4FZ4L5ONV[/$(LY!BW(9"Z?NQ]%YZG)?G5MVS&
M!L)40'DP1\/<SKX.\&;0.TIYGZY]31^%74U?J+UJ,MNH<5)`1@6(J8>FL)2D
MQ3)U=?J\4#&;:I0"(QZQ$L)9UE6[[7!LCRWV/CD94V;@2`<@`;K"#/AP;LT%
M9*1.]7D+?!&%`R/ST.4_H(/U+'@;B;Y/F08^VXB8/W%D*,9L3^8H356Z:\'9
M3#<J.TA(%KFG4UWHS8/8$4]FQ;(HZCEIR#P9$]SQCY]L./[[_NY)'&*EZ0D"
M&,VPILQUZ7P_<IB'D;9`+!CKM>4:!@S]'"UM`@#1$*+<1#?V?^=P!NK[EA[%
M.TP#6):UZ4UFCHN[@[#3(X%KY"9#B!_&MNM+/+6>/1%S^/4`>'[V?65>OYE[
M=/""MR3%\]^N1R>Z]O^'4C^4S^7!.78U\'U8&ONV1.1"?)!@'Q5&/V8?3Z:I
MZK.WJ15>3.'=R^[%!;G5:_E1U:8YA6-PAMS@AZND[.$$.(6E])`/9M"?I9Y0
M^\/=KELJC^YDP58YIKD.,2>Q3W7$H+0GW%@W*]>V/+>,5/!>R'E=$SCUP!R4
M1ST?Y4%$A^WC.J^D+#%-=TD;<,ABNVP_`+O2"/BVK9M#=;DJI#G[;TN3+.RA
M%`#?3FUW9\^1E'XE>PF(%V\OEG;9N-E5NMWN#NTL.1FO@O3'1_[L,$[=H=D>
MPLK2GL%6.'2>X<";,5LZI,#MD=RCI;^#5/3G#KP9B]R!M^B_G>_`.^FEN\)L
M[;L%(>.N=5*5)BW]++=MD?VY4_!D*'<8!5\H^#B+,<<!,[(8FJ:>V?E['1U3
M]_9`#HY@O$5Z88R%W>>VV6ELJLJZ`^M?2H4(?0?\WO5(+![DNBV;2ME#"2#B
M:ENJC<JQ3[`Q5W>Z"08L83$\')HAA&C2UV?QH(DBNJ(;I;=-C/-=2QEO`]"H
MOY601)X1L,B12E?<U5#O-I`XRQHJGPK,;7L#N2'8D'[G<)3`EP#^B)XSWO<G
M3+F=%042O0K2][HWE;M"8%S)G.$\XRG@7D=`*7/D+M?F"`888IF#QZ#KVWRC
M[9O9X5#`4L8MP'&0%KLRTJVXQ%=FN0:5]J0_C09MM\C!R'4G`?C-"1P;R+XE
MZRC<^[92]5I9=T9O*B6*;YC2YSH3>_V"U!FV4DT?U=YW,YY8=LH>-)KE)0/<
MSU/>AZ(O`,+`=UY-4\Y>U["ZO.W.95YC67Z]WJL2>X9VW_"@Y>S$A7KA+(4%
MV*3L_,LD_3*OWKZ^/OO\@+Y/U8C.O@S>YQ3/U#KF)L7Y5Q,#QX%=\21;="Q;
M'\!O$`Q\S'09YD2V%>0*VPO"!V^'3F8<S+3Y=+V72'2N(03G<#$1)%_#Q43H
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M+U7U7$=Z8=#_\4O`?'ST]9_-#+;?]#B*C_T%V[-3RC#HY9JY(XITS%L@CCU[
MB+MFO:U05WT=[*M?8Y3AQ45?OLYP](5_5O!2SP@WDN%?&@C(;/;/U?P$YB_)
M$`F!89H!](4!(9IC;$!`H10<&9"&(AA[GN!)\<AS$0)^C#R/@V1T?A[P=.QY
MA#>F1YZS8%Q^H)>C\H6!>/GY'VX(L'QA^,?S3:2PW_[P::SROJEGKB#D]L9%
MXCK#]UT?_E9#105<]4FO,WRN1PO3"MOL3`=?^V:GN:WXLLCQ4.3/:!9`9W_!
MC_(.LY]"J+FA\H5+`!7IV+];(62?QT8TZO=7*5"GL>=A&H^Z[15-Q_WRBJ4Q
M'1W`@_'(NHH#.CY`!!-")H$8'Y"&P?B`,``$&!]AFO"C(VA(Q?B(*(PF1O"0
MC\;A51B'T<0($8J)51)@C!-^$8AQ;2ELZ[AO0:Z;V!9*PW!B%1;2<6TAYOBX
MAU*.E]9'1\3!A,6H``\9'P$VG1@!7CB*X5<L@%0W/B(,)[1E83J!"8RF\80<
M+)V2(TK'\\D5XU/0PF)(JN,C1,K&_8,EZ01XL'1J1!2D?%R.*$PG/!GO=<<3
M(T0T;O4H$LFX!T4\"B96B<,I7<0$D[F*DJF8B](@'-<%07_<8L`7Z43B@(":
MF(.R":MSQNBX37G$^(0<G$T@/X]I,B&'H,EX1/&$!A,C4AJ-KX*9=%S;&,JQ
M\9V+*9U(Z#&CR;B/Q1%@W?@(/K5S<8SGO*,C!&SN^(AD:N?BE$V@I0BF/$B$
M;&)?!)WR9`'!,!Z5(L(K>^,CTA&;`EU\\]OEQ>7%_P$%"R*G#0IE;F1S=')E
M86T-"@T*96YD;V)J#0H-"C(Y(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,S`@
M,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T
M(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@
M4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q
M.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C
M.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E
M0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE
M;F1O8FH-"@T*,S`@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*
M+TQE;F=T:"`T,C$Y#0H^/@T*<W1R96%M#0IXG,5<6W?;R)%^USGZ#_V4=7(H
MIF^X].Z3,[:3["89[UBSR4->(+))(@8!#BZB.;\^57T#:$G`1`LXQ\>V"#31
M=:^OJ@OZW=]N;WZZO:'K6$6$XA_S4[J.I/UG<[R]8>8.(SPF+#97.%%RK11/
M24HI44E,:GU[\U=2FD<E,L+G1&F*_Y%Z?WMSN+W9_0:?A'\&%^A:2@'/7TL1
M"?A/*,ZO[RL9X7TE$KR?IK%X_H&<W"62,D%21@DLDY:FG>'/WJ3AIA@0_+O[
MVYO??L@>-L"=(/?P!2,'\U#/>0S_4`EWCT@2DU*1^\WMS1T2C#^?;V_>_+%L
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MU;I!W6RJ@VZ`6B^BJKZ04U7DFQP8`(+WNM0MZ+8``1RK+>@9C"*8P@IXS(_@
M.#L-EZV?P$7W`^G0I#(0!-K51C<->E.6;[U]+"`#"&]>!`EC000"C=_8A35P
MU$6U(Z>N.!DUG;*3KH&;8P445D!;#6P<JK.&&("D.OWF9=-F)7`"BM0E?-SF
MC_FV`P&$$%)D9V,GC=9'%#6:59UM\TW[E74X#:!(EI!#$@5OC](@A\B%O8&V
M#UV]+733^RQ8*U!L1(2B:;)"HZS>79"+_VA"C##&CW_?Z9,&2:#D[#-`[_@-
M_-$M-D_27^#)N*SH/6+E?<HMQ(_'[+*(2%`.5B2Q#"%#\IAYF8"G@Y*+O&V+
M*X?`3`!1[M"NP/3!F@M=[MO#Q3$%S'L/ZB7G#/[K`&%,RZS$4.1D=*[J8DO.
M>7N`L+O)MWH+S@8J:4B=[ZNZZII%Q"&9$P=GK+>0Q'O*@/]:/^;Z['G2S7^9
ML%";H)!M-OIDM(JL_/AI*#=PEK8S;&9>OU8@?]7D01<Y>!=\*VOQJXT14!;\
MPMF;%<LQ*Y<Q"2Y]%DEHTF<1ZI)B=3I5==N5>8OA$--%?CSJ;9ZUFNSKZMP>
MUJ^E*AZABEJJWJ"L7O5\-<IUFB9>\[+/G3$7W'+]AP[D;8P6HF('T9]\]+!@
M`6[3./E_<CL.`=.(!K<?V#F/++,(#SZ\>^O#WX^@:TA:G\!R709O\F->9#4Y
MZ*P`4\RZ]E#5UB#@.V`3&O`/A/D.XCQ>;+J'?T",A[B*4FP'4@S@"C.P]VPP
M]TV1EYABE[#P5`34EPY@7R12RSYR&/8'EHTGXT4;J;(3$/T(MXSO;SOPS37Y
MOZS.D?2=WF(0L&[NQ36$6EG15`Y'8^#,RUW1:4B?1M)NLQ4Z=[?+-FU7FX]+
M"('%H0CH34`HYH3P$V3PO+W87%T5*\AY.]U>5I#,,4PA50T$M&P/,!'45=7;
MV1%Z+`*5"]<"X&Z]/#AG(>Q)Y7WBL]8G;P?'K/ZLC55`&'_9IM<&9[L,@4NK
MAS;+2Y<7,+@[2UHDER5*]0Q%@:$42N%@Y6ASX)L-9'D+?`'VYPCF;(HQ])UJ
M$]J]8>/7O(._:.0>-N#S#1C8YF#*!@#A=H`7V]R4EDW5U1OTG[?+)+,D#=`W
M5KU6!7/X9I?E!1+V<"&8E&L"](`8"C!RL&VP;W,1H#_@&:U-E+)*M*@'B-[J
M`J`91+V@W-4PW8=@`<$0`$VV1=BD$2/L=A@144*].:$<EY!"'(!O*H(09`_R
M'C46>1;`&$).5:NMCM!L02:]30-.,<5NJ7,?#@LL@!`)E%5M"EQ3)C\G!9"?
MY=;([JGK+,&\]!!7"&JC_9N>FU=MF(QOR"R(5&*=TC2V,0M[*E=[V:_^\'O\
MZAGW_6_XB:\CDE`%_\+W1?^IN+WY-`MYD/D\>7<(\-+@$U`:.I!;%&"86+]]
MQ(Y`W5XFZ19B2#?C\I6$CX.B6+%%05&<R""8*+@)YRGW;3'R_::M'L#F.:7Q
MBIPA3&(1LZ\AGH'!_[C^M(:J&3V')"O&^0HL;O[D+:(XT&H;&B`1+F;?)N9A
MFS=_@$IO]@W2-&RP;'X7JF<%E&O0M<,[(DX\Y@7HN3^<NI9\VM1:ERZ]O_^"
MQ1<V;=[]Y2WY4_Y09[7#N1\``Q]!V8C[/G3E/E_-33BFKZ>JEO-OTVOBS1(Q
M.(Y\=<68[(6?^`P$Z=<4&NA`'ZT#82J\K[.MQGQ!OM_M(`<CH,H;[V+&[0"H
M%`5B#`]GW$V(\*VV/2U,3'C'%<\?(2?!I2.YUYM#6175WC8M'NHJ0]R?Y<=%
M\%@L0\TE:#0`W`Z/;;`F,""`E-T1HPRF7I-B\W+;-5!)F>9"K0O]B)SOT.0,
M=R8%;_I>[D8715=4#7"KVT,&3`[*E\_ZXG*P3>;5N222Y$W378>P9D5XNH@@
MN.A[3H.6DP/:CA(DF$.U5%1G^'1]).$(-&LB;HG&GZ]7[?+"/<>WXIQM7(G+
M=I_/??,%D4J^U<X>EN"?ALJ+][4WI6GHQOZ+E@M+\AZAF4N`Y(^ZWB"`&W+[
M2KPSGI>C-%XT+T=Q*&3DH$>II,O+W[M^-+GHK#;V'W1J@.J#-FUI\M`U>0FA
M?!7NF%I\"THO`.B`'#'<D$9#^'=B_%Q6Y[DY0G%YEI9->Y$:"H\JT5>!U!T)
M':HSB`9/=DRZZX:QQAU9+.$"4=2?2/`^!B"R&9Y(@+U^#R1IJ$JKR]%G!=>%
MV4.2/IHP8&K5*BS$.@V[%E"-66=NC*.;IJIS+E>PVB(5UN[`X6VYT]8Z:\U6
M.U<-6JM80@C"5V7"V(!K.0KA`N'0$'LC!6TAJ:]WYO'B12I;+:7I6J61*U[>
M@UQ_6?$B5>R*ES1\FJ]X48$\K%V4#9YOC,:G:Q0U)"]^+7GCH5`FZ:*AT)3L
MMD1A-`ZQD$G?NGQK^DSOH`0W"$*P55^K'""=F4+\2WZ$1`A0@O$(4$11S%^A
MB$#JPL@>@*7?"8-)/.AN.)&T.<2P$!G6Y"]X/N^Z&GW`P(.H<`(,;@:(U/2`
M2%?:8REL"T&BT8M``BE]<<)I/#AW\F<N#Q?3E++'I.0AJ_>NC]A'P4%CIFI-
MTPW*E')C$-`%C],^8[_V=,KVVD.$LH&P5U\)`M&E`T9M!9F3[*MJ.S]J2)@*
M/+^RX)@(8S1YVH-Y^_`+6S"21H,6C/TT9PO&4V?<.(I[-Y:N%BCW549^^-4[
M\M;K]Y?U8`+A+)*OI'P\`(DD%#%]3UEXZ/X6.[]X.FCRE#&L[[JZQFSZ@[F.
MA^$?$,&F2XSS>.(6#CET*`8J0J=(F%$3E,/_D&V&,@CMHMB'X:QQ98G!+`A:
M/^E-YX[.S&S,%S<N]!T@>"B%S%!&"4'KT4;T!8(/1FL/$55_$F12+7(3<@CJ
M\\HH+1?@5L9>$7-A'#&GA+:/7IJY$HA3^+4,HY?E%-N*_B2D,F+8Y;K88EA^
MIG;].XUF3Z8XX^497[")ED"MZ[>!6)2D6.W_;'N,9O8"!?S=>R.?)50K^D,^
M:0WUS=N@AMD!B@P;+MFLHF&7*T<'*V&SRS!)!C+DL1S`=.6/D``:>!=`2UUD
MB"OASXAV=FME`%][=FD<][&-Q>YTP+.*%ONQKO9U=IP_PD;?PI#P$'!@22+&
MKIRWI`7:]IP-_9'%??Y,N;,E2`]GB'^8)FR5VQ]%F@&JK&Y+,X:',T$9YE.+
M8X_=YF`;5MJ&:+W;8;IU`QPVN"X17UCH+J1L.$GL<,S+\;R'L\5EM<C@(X<[
MGKX%?8;#%GX;C.J4A_XVEXESFC]G3>LTLY3/"/D,M_/[C*1AFR<^\_HZX>7R
MC@YM3/7'E2+U-G9O1BE<#NV3FQTMW)'V#`#C<M+-?\Y.792R;V%A$7!]Y6C]
MX94+&Q^JKMSZMC>(8?;$GJ;?PKABU=OP_,=0./_1BU%2Y?#0$C,7":??PC(2
M'@]8XF:FW4"\X0''$F&?VO:MBM8R25P$`+M[]>#G2WO)?J\9[.ZE;H1,PRX+
MF!TEO!^_0805(ACUD*HD>,)L&]`X@U656%RY2>CKBBNWI14N;@M["2HH'"[_
M.@A@D86G13J\6O`T"]G7/1:P$!Z&;EC$^C,;)OP0\2BZ<?0^`S57IDA^S#>:
MX"!59I"0ATQ79G\M`3O?-8#J\^<JY%JPQ2%Z&G;Y]^0"!O'F*9^SYP)L3?MM
MEAA)&(H1K+*7HW(]'(.F\04?G9FI79P$#J>N_7&,&QSL`A1W30_\^`23&,MV
M8W/&/KU1ZR_XPH#OA2QAF2PTF%420%1D?D9N]9<P=/$5']@FAEACQCSGQ\Y1
MH&Q)B,[90`!TH&Q?=WT=.69/9(*+9SB='YYS]=4V=_':3S"31:;$1#J4K>I/
M<X7D\GGISHX2(*M\`^%B!\UO,W](DC*^\E(:LF84<^5'8R#R[/(29Q4J$YG^
MQ:"TQ`N6*NDS??]RH3D><"V`I[59F-$83+<,.,G=:Y)5/UT,_#8GO<%W:NT9
MO;V-+YC8#P]Y=<P:F^/QQ&O3-6UUM%-4=@<[CK^$"%)_&L`C&4YS(BK=-$-E
M7G[!DSN@Q>&/)3*:IT,&'^"S;R.&[#*A>G=/E7/W9@C84)>H9&><1P=L\;2@
M:6</1G$OA(4/@9*A'*A*^V:>3)WE:S/ACVIW@S2#]VR;"T#QHS'6YT>UT$46
M,I5D0/N"II(D\4!$RA\_+%*0FNZT>\%A\.Z.<IJ`V'#5>WS2DC1G!P/U^#=5
M9S_XQE^_X'[GP-,9$61$XN^:2!0EPCRX?X+Y'1$<'3"R"_@+"R#S):,+&`>J
MQQ90#@R.+%`HY)'[*62"L?L)8Z//CP%&C-V'/#/*@&3C]`O&1^GCC(W>9S1Y
M604_N261)1$R^K.OHK)@(.SIKRR(U-?%LXDQ[KCP/GNP;Y]_AP>N9?MT]HD]
M-]0`CTWL<(`:?`S#`<9THI=ICH<T?P5=:&3RC\^!/J8\'8$RYL=>N0G6GAX?
MN3V8?.)`=-1T[I085>T=4^/><\<5H+&Q!4(E='0!Q*7Q!3&=(#*A<GQ!BD7.
MJ!AH/,X%HXR-4PGW(>./KA"HL-$5TMO<BRLB1)*C*V(F)W9)&)U8D5(YP6V*
MLQ&CAD&GM,(93<=WX9RJ<6ZYH&S"0"45X]QR@*83*V(<0QM=D=`I>8`1CH9I
M<*4I;P5F)[@55+&)9S`UGN_NA*FV1E<()2;HD%.114!F'Y>ZB!4=MP^1I!.Q
M0Z23*Q06Z:,!BJH)2Y9,I:,I]D[R9#Q)WT'5+L<M"`KN9&(7R(\3O,1L0G,R
MF?(YF:AT@A>%I<;X"IZ.1]R(\G3\&<#LA-0CSM-QF48"#XQ&5T@Q$?FCB$<3
M=,0\&O>H*,&9EM$5*1^'B7>18A,Q*`8H.ZZY&/#RN#QB#E7]^(HI3'X7RRG-
MQ1&/)RB-N9J@-)G27)R*B6@9JRD+2@"=C/.2L"E+3OA$"7&'K(Q[90*A[F4Z
M``V^_]OMS>W-/P&W-6_/#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C,Q(#`@
M;V)J#0H\/`T*+T-O;G1E;G1S(%L@,S(@,"!2(%T-"B]-961I84)O>"!;(#`@
M,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*
M+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO
M1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@
M4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3
M970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=
M#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,S(@,"!O8FH-"CP\
M#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`T-C@Q#0H^/@T*<W1R
M96%M#0IXG+U<W8_C-I)_;Z#_!SX<%K,'M\,/B1)WG[*3F44.F,W<SARR!^1%
MEFFW$EER)+E[G+_^JDB18G>[Y;LY<1"DQ]VB2%:Q/G]5]-_^=7OS^^T-74N5
M$HK_F4_Y.DWLC_)P>\/,$T:X)$R:OW`BLK52/"<YA2=4"-+IVYN?26/FRI(4
M)TKS'/\AW?[VYO[V9O?O.!7^%_R!KI-$P`+K1*0"_A&*\Z?/59+B<R4R?)[G
M4ER>D).[3%"1D9Q1`L,2:?:T,P3:A]P_%'+:\-\^W]Y\][[8E$">()_A!<,(
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M2+S4\N77D2&Y"C_A6OWB`LR0('`-HVF4//$2Q1-E^7KJ-6EWD[73Y7W3UNV^
MTD[*BDZ#@+7'KM)#T9W1/(XG`&K`UN2G4T?:S:^Z'*H'34[>U#K;BB;W8]?N
MN^)@[>Q&XQQEVVQ/Y>!7CD(\58[X-.$O_<+[%K9;#%7;%+799]%LR??'8UV5
MYJ^]^>-C-=P;BB8J@6-;_:#K]E@U>[)K.T\M?M8%L`V&#/<M<'>RLS`]T<T?
MYX,FA^K+<`+&XH*=KJ-X&.``!`+.GHQB!O2#7<LL_7"LI>Y[I,$?_-GLZ5`T
MIUU1PAZ?/433!Z>'[-!?!G"BI"C+]@`LZ^_U=D7`),%CPX'^!#\\]2O8_$YW
M'1`*`W`83+&X*5'"TQS1ITJE_#+`4)KG0=#!1LUZ>^J']D#>V0./<;A9:JUS
MAAZ"6^O\P0K6:G'W)/UZ$3VZY,]6N9-KGEI^DA@GF3&_(/K<=#(2.7X.SO'C
MI"N?O3HLO1V>/&=`%#;S)/?++!\W\31D:D+5Z.#0KBR^5I9<8-CB8L)S&I#$
M5)9[.4GP<R`G'YY8SDE4%M?(!/;S#60ER5E$64GR)&0L2T9*.MT?K:^MSS;,
M^-J5Y6L&+54+T/7:[)"5JG2<_!>>+)XMX/PB=VPS#MW*H\C2,5?`N.SM.YOQ
M(B>K`6.Z^?@,8SWPSA"A=7I_JEW$72Q_[I`B.@(BZBUFB&X9=-02S\0RBN7)
MZ%@^#5H;97W;'@[5`+\M?UK9!6J7]Y[PQ"VSO*I*$/9`YM)LRD_-9V0E1H)=
MU8/40/C[FSX3#9%A>]8@>/"'4Y041W$V[HEFTF<X0JAQ3R:FM[)NPE,(;;=.
ML#&:K="^7`*'S,.G3X\UA/!HF:I=!3-@PO3\/1,^VU?MN\N?@_(TQXQQ(>Z:
M6`O'/86X-&-.<X"12+0YWI_;[K?%XS/!+A"[N.9D(O/++*\Y64(#5B94>".D
MS&>#;QBK&T,]P`2Z,V1!#BS&'+`X0A;X`,)<-,VIJ.LSZ@5*]4NSB#E[7_4F
MZ_-)L7$?H!9K\OE>0[K[TN5,3F7,^=$\/(`7*I;/^C,T@2/%$94C0QWTC*4!
MZ)R:S\A8Y,*GHXX0],(QYGGF3C5(6H1/6C[HHH<TT!BDCW",[7;Y34R[B*B9
M#"L9XS++:R8#\S*QDDHV^0^&GPWFJO=5TZ`B&)G_J1S:#0@OERO"*946$0%%
M0*=B49_GGL2X`70+(`PXCR!G770]V;5UW3X:@.6BOBTNM7+B952`,Y3/N/AF
MGE$?!$]F5<@D":U;4;N#J1JP2?"K]US.<1G@#D=L"C!FI05%BQI.K.C,<>%A
M9VCDJGYFED<(,+Q%?6Y(8]"?C@B]7$MC>?X8@UN?E7KC#<$*D`'VW1(2(2/)
MF<>:N53^,!0=+>*/#=GK1G=%O2*/FMP7#]K6+R#W:-`KZ"]E?>H-P/H(X_K[
MZHB<!:\$NQ]T74-*"#[*P-&Z&\XXRXC#(GG@7AI,&MO&JFH+&1",@Y,]N".-
M<`29\B!S,H7$/!/_!XQY3=Z?.I"5;O7"QR(12^]:J-1O.V;I$0X^X$Y*@Q#2
MR<3;MCNVB`^3CT4W-%91?@*W"1$$XFWD8PN<6AX]D5Q>8,'R*9F8!"1"2B;2
M@,$TL'\.-+5:@4$7\K6=(($8BI"[8@,S>:)+#L5HBJ:0T*@_AH5%CU&*R18W
M&G<(8E\-]5@C('#RNNE-]%@TYU=L`+SKH(SAOAA(-9!#M;\?GM7S7[$/,?@@
M/9XEN9HL@A`N2;:5K]$E7<1AP$;8ZMLC0C%%#]9C`Z9;(_5(4-647G&`+98_
M,"&2=)%-*V1`VUGP9^12<8Z4<V2)@PFXD!Z:2LUGY,`.(B.@9CQ><]@M6K\>
M7>:IC^*<,N9S60.1C:<B\E$Z?]PYH6Q:2.(WM1&[_F2LT.Z$B9%S-6&]#_G^
MM-+SX4)I;ZZ&0&+@XG`(4KG\A#,5]!+P['^%5QLJD3I?P7,*90_LU`>U^"NP
M(H;(96MDTB"Z3\J$,4C/7/3)9>:M8F8^/X:M+ZLH5<A<^1U$]*[@PP,ZD\G@
M*F=OPR`C8LU*\`OD+E^S`C?BEE$<7!RZN[$9AZV6+RPE^1/V!B9#.80=9*=Y
MVD(&YM3%L@68VZ/Q-6B=R]]/%=H$,"[-XB!WHD+.1.S422';F)C"9#YYM]RE
MRU,,'WAOXW*>R&,,K9<^%U1T0KI2-FI]:-LZL'RGWMHXS!&JU@0AD.;KP<+"
MBIJT?5N<GR?JIMU!FZ,-+""\_0#S[$8*R:![$W-YY`O8LGW2P!2%!U,G))^R
M$9'+D0<8]T`@@*%2U8V4"D^IX\13>@VP\>C-_^3Z'"<F!S?C`K^M[_-=3YP'
MM=K,9<6S3@]I+JRL8A3@G85#.".HL,BF/<=589')@#LLG2HF"96OJK"S9+H[
M]!A2/E1;'89!B\=K*?6[C(A4R30)127E4X^4^?QH8*MC<388CPUZ@F:Y&(+K
M.]:XZ=QS+B<9<5UW(#N-6530EP42VO0[B,'PB56\]ES4F&U%":?3S"=[<FHM
M2[C,?8CUZYBKC*7DMCL;V+\WR=FK188)&L+D\(#!Y@BH&C#=P`.;NMH7SK?V
M!F-'0P;RN$%`2!^P$\V&I!'.*$V#?H4),,Y<2^6%4B)LTY"$>QV,M<4DHT9\
M`UQC0_Z-0?H.:6M=(U&F.&(]S:GKGX#*MJ#P$MUWI<AG<!<D^S$8$%34:>)!
M'0B2U%3Z"`I`,=JE&5C(-'X#`:.97P8+S$&!@+N(Y_O)5_@CBA%DOR0W2I#M
MEGG>\;Y\)1L$)F`NFR0)[RS8<,5@(%5/MA6ZG*W%.H;'ED"4I?=M!^+UE\6;
M=Q(P:&F\/@IJNE_&SDW*PTL%IJ5Z:7*RQ"\8I1<)@BHW/SK1W+NME+/7&JTQ
M=CCUJP!&V?["1#)"#@8,0EO68ZJ`C-F<!F,R7S1GVXG(^*)]97S?6-:@57WY
M)!%L(;;'>5@I"V"ET13JRNQE'A]INQ&>_/74!/AD,9G0J7)N$+)@O@]%#V%9
M.-U?_U]1]:L=;6HB-HY2),Q[E92/EY3,V4=1BM0O&$<IE)\?P^PI'77PVT5)
M-@5(W>A=-82X]NGR_;7EFR*3D"U1#GGJ1N'YY$L5%;Y$N-689E2-2S^+`QB/
MP8';EYSMRE0(=\"EGN@O^!>O)Q=0_^>V"`+.>VV4%)A>14$FQ-2MD4V0B5!/
MZ@&(&6&RT<U6!D!(GF[7UDVF.2:#.&<C5@;IKAPH,4:/,4B?"O0&:G>Y)G\]
M=EJ1?DP>VJ8^D_&V2:<-A&8S,823S/62%XYEM@#ODXR@WAHGCQ.IPV&H%#X]
M$L+5Y<JB+C$I<D)^F0^0"3E8L>STML+S-3+<NU2H(+OJ"_SU&"'5223S=,2L
M$LO,+X.VG^6>7UPP5S$Z`1N&ZJ`)BL$#-F8,RU]QR2_0N_RM58C'W#(1+JUF
M$S?CWUG-OXF$I'E`4[IF.3H1I.G]YW?+^RCU+81`LO358XK0,LR?6"1&?8C.
M)1V+&7U98?&]'\BVK>NB([;DAX$UJ%X$3F>!\,3L1LO3@/:XW6CFSO;8BZ$F
MJV]N0)G[EA:=,:[H19NLSW4/P/BN,JVX>W/K>4QE,/PIX(C*ZF@0]<)6^-O3
MXI8PR:FG)2X<C?=_`J[EX_V,-^UN^1LGZ;>B2:F`)LXFS"B1#C,ZMN5O>H"P
MK;>]\_:>A(T&\-)P#,L&.;K;5DQ]HZ$>B$2.)]JO%T_A&/,K14E6^-2[QM74
M7*6FUKX.BV(V&&\,[FK2C$[OBV[K&JY,`0RS/.QF--&;OXURK'4!A]UK3?[1
M@K7%V_3=OFBJ/^Q$F,?_!$8C4LU42NYIC/T5#]*O])5'I>9F5\%9B:"])_>W
MX=X6QVK`'*&H^J_NQ9W9`UA_[OO?N&LD#WK>EN_]"Q9D:=#AD]`QL31U!Q1!
M["EMZ\I>>]I53=&4V+[<3]=W?":HZUY#@@G)(?ZHFJ_$&+)Y3B6V@I*K-<1V
M8Q_'C\W#TXYW^^H__XZO/N*Z_P&?^#J%UP7\A/>%\+_5MS>?%MF>2/SVE%S3
MA'/?5.T1_WX`S?]QTOBKVQ9)N&W&^5?N^XJ]HAY+#W`&D8\@['^W)U)"'`%&
MIVO(H<4"_0:B!Y.`0FI\1`054N8'T!#?+OJH-_`;C!S(X^/C^H=SL:W*==D>
MUB$#2&L!!#<:HIAF1#Z#3L4HI7ZF/,HFP_[K1+H.V*%=D<8V>GAP!3;8:=C5
ML"8_0T[98*6MV&MR!AZ9DF6QM:/0!%LXV8[O07_J"5IP;//7H3[I\M2-]Y[@
MU7=?2@C=]MI"#WT/O%J^'(M<R*9;7ND$,3%W'\B>FT437/T>:;4X,QB(HVD?
M->"[C?@M!M5K3S<FD/I+J8\#T5_NJTTU]/9B"R+S!,CL]GI-4,BPL=1P$#E@
MIL9YQWE6H=EIHQ1H6>IO]/#I4@C/W%V[]H7'-H`2MKC`V2)!YB3?O5V\X,6%
MWUS$$(S#JVX91%0$]1&H;04=^QI.FQIDPGPMB\:"\:XHJ[H:SL@!1BEY3SX-
MG=;#BOQC_6Z](C\7$,,T^Z%M5N2']=LU&)PT46ORT88Q)8K-R#DSQ>*A)5>>
MKKCQ2B9$N)(P%^QQI9PN7RD`'?I&5$%V%:S$LV1<*8*H9UGVC:A"A4\<R$RS
M"=L0PMT\H$)0`V7,1^NF@>(5I3!]-)]'X3X4X%7@?[#QZ/((^KP5N1^&XU^^
M^P[=9*_+];Y]6*^L98'XRP[W-A!L\)=S%-O'IP9`.D$0N6L@"HPO6N>0$<\>
MO;22$Z?@4X5-<3C64&@,I[F=T+5-51KP8O*)[]ZNQ@C3L7GTFY:E,=A`/:;@
M\/<WXYH1`G&W6LQ6M2RDB:NIZR93S%ETE$TX"6"RO75=U'U+BH>BJMU]AD#$
M30\L!'('W9EL8-N6)U-=Z?3051HO3?:Z>ZA*O7SJG@KER7F6#QK_C6V)F:+$
M?GGI]+[Y7E'4=R[L`/[*`(&N=FX`Y^;JWNL#3`@]-X`R.;N$8L"?F><YS6<7
M`$N6SSV75,U2D-)Y`B!-G-V?H/GL<W3^\PS*7M__[^.05)HAD%A=S+:9EQ_V
M4L/3Z6;A^,4&H!G*W>?Y;$0>>^#`^*)1>Y&DL4NY)4R;V2Q-!;_Z+`WYGK^^
M91EN^?EER!2_;<QUR3A+\;+S`(\N^<HEL/XS+C&NP-+GVI6D<Z=VIS(V^YRI
M=%;L[[A2LW)Q!]N<'Y#2='Z/DLKY`1E5\P-RQ.1GV<#F+<P=Z#^;U<\[QIFX
M,D*P9%9'[UC"Q)41*9NW$W=,XI<HS([(J+Q";4[YK+4!N;AV*)PR.K\*9_CM
MB;,C.#:<SHX0-)VG%G3N"L=X>L6VWG')KO"#9YA"S8[(&9=75(E=HU8I,3^'
MH$K.[T,P=64?@BLYOP\AU!6=%8FB\UP7J>+S\B&DNF(Z1'9U1*Z2*_M0ZHHD
M)W"TL[X11N"7_LR.X/@]&;,C@*E75DG8%5J2E%TYN41>T[DD`\6='P'6X0K'
M<L'F#6ZB!)V?`V\JS?,C!8,ZS],4`L?Y?:20-EYQ3WAT\R-2GLUK5"H1B)D=
MD7%Q996<7[%!H%!B_N0D'-P\/\#0S<1Q9@3'0L3L"''MY&3"U96=IF(^I+^3
M\MK)R4Q<L98ROR9!4HDKYY+1:Y*<,>R,GAT!Z<F\5F;`L-?W`:'>NW_=WMS>
M_`^"E4O"#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C,S(#`@;V)J#0H\/`T*
M+T-O;G1E;G1S(%L@,S0@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR
M(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-
M"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P
M-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X
M(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&
M#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y
M<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,S0@,"!O8FH-"CP\#0HO1FEL=&5R
M("]&;&%T941E8V]D90T*+TQE;F=T:"`T,#4U#0H^/@T*<W1R96%M#0IXG,5<
M6W/CMA5^]XS_`QXZG;1CJ[@1))LG[\;;IDF;K>U,DIE]H2C(8I8BM;S8\?[Z
MG@.`(&5+9.*(Z>S,KFR"P#D'Y_*=#]"^^?'\[-/Y&5VH."`4_YA/T2*0]J]T
M>W[&S!-&N"),F=]P$LA%'/.(1!2>4/AUI<_/?B"%F2N4`4X41!'^0ZK[\[/-
M^=GZKS@5_AG\@BZD%+#`0HI`P#\BYGS_>2P#?!Z+$)]'D1*')^3D,N24@MR,
M$A@FK4QKHR`^9''L'XJ!P&_NSL_^]BY9IB%A@MS!"\809E*ONH2'5,)CT#[F
MBX`&Y.[S^=DE75"J)+E[/#_[XN;KVV_(NZNW=]_=W)*[?U[=D7]?_42NWKV[
M?GM'WGU_]_W--;FYOOW^V[O;OY"[G\_/KF'E__YZ^8SY#\O'.(C'K7A??."2
MGGP!-5B`O';V8^95Z$14F=GI@C$&UDV-=87"SVC=G\J6U)NRS5<D32J];O/\
MB:1E46<K79%FH\FZS//R,2ONR39I=)4E.:FR^F-]09KR7L.(BCQFS<:,+<V/
M,`X&UF2EZ[3*EGI%L@(>9S6Y*HH6WK_1N[)J2%F0=V6U!2%/K7D8#E0'QY*4
M,N-97UR>?BDY6`KBEX6Q7>J;VS<GWU+PR#B*W8YR!E'M=E2&DMD=!5OKAR1O
MDP;WK&PKLFSKK-!U39)B17956>]TVM0+\O4:?O-$RO6S?3;;2Y*T@;T";RC3
MM*TN]F:Z`*GK-F]J?+G<Z0H6`Y\Q"ZRS(BE2=!-PHU6&#V8Q0\@[QU;2.[;D
M06S-D!J?7FKOM:!)LGH`O]3X:;T&&^@5&*$@=9MN2)I5:;NM&Y!=HV^#19HJ
M6:$]=E66:J,IF"`MMUO0J&[*]".QBZQTFH-9+HSZ8/ZZW&J(IAKG,7.[`?4L
M=@B"SAT4I'QGA]!\WK/#R;,+&ZS-8J@CW1X$,;=KU]E]D:VS-"F:!;D#BUK/
MZO/"4H/+$<@[I"@;FT$*]#BTU2.X9)+J!;E:62_J$H\Q<PO;5#5)5C09FCDK
MTKPUF]5LRAJV;I,T?MXGW<QB>1%UVE,H9#ZUADY[R*`@W3H#/<O*2@0Z02Q5
M\'O0$I3/](,V8F;;SDTOP&'!/_.Z?.&NST+P4*#!0@<C<T'>6G/-8@C..D.$
MLG<#CI^-&S2@VQ:4KE%2E.+_4!($I.A.T'DK@H#7>I/0L*^ZW!5=K`P?:$![
MKW7.?#@78QPT957#*\S4YB9KV@9'58])M3IY8$?R#[*4`BB[YSR^G"GS&6V5
ME^5'-$3O1(M9?!@@;B=&7TU"MV'O<PWI'"9=(R@JS1[5$)$8<ACD30X>?7*I
MH&7HQ%)&),"@7)QZ&0[;VVM/0Q7U_HJ?4?]WUM/(MVXS;OUFG#QXH#MZJ;0\
M^3*`C;ME3@^\!713`X>2B-B<20UZ0Y,FNYU.*@/1"K)+[C41-OK_P)RH@M[Q
M9X[T0/F5L+M3JB^8-!)]6H2<!L40]0;0,$>@1U'HJS;M4[-I/4V^R;99X^!L
MB35*U[-E6J:HEV=>^P-&'FH^>Z8]UO#RD'DY7A]W(_UZI,+?V:Z/\!4X?T`[
MN$T9ZR$O<W#[QB#4?^@"D%>.I>([P&QO'&;3^^G2+G#S#US@$:7[%WSBBX!$
M,H*_D2.*E?\Q/S^[/9F5!)V5U/#SOVZ+)[:`.<)(+11B%<<8,<E"NP<_Z([2
M@+;G(=./4)P3;!L(9-S\Z>0B14$OT^^/XM&5XJ'V(N+*:R^X]&@;B@FTJ3MH
M[A>S!##[O8S5B&N&\;Q\FY]_#KHM##W;%O=LFPRXPU'8`\/.+*%SL^V:A?L5
M=(+(.Y`E=GYY1S5XWJ8M,NB=VIVM1T3_`EM;#]Y/DUVRS/(,>^'NY;>,O*_*
M56M!ZIU.-T69E_=/IGN>H:Z&0>SQ#AW@'>KPCA'\U>$WLG80^;5GQC![2@:Q
MQ\F@;S2(O0NR@K8^+W=80Z$(P%ZWE>>/WF3E^TU2;1-?%<R.N$?74#=@C_RC
M2G]J,^CH+7WPU5.RRE+,:BE,`4VAKK+/)TAN$_3F'V->]"'I.3TNI/>A*!"'
M4ILIK4A]M$B-V$@8L2X2=[I"OB3[[*/OL-F13P),7C59VN9)=6$HFKI=_HPD
MC&O_+!4UAQ%X3ZK%/I"DC#MBLZV;<@NM`_)"3:,+1WOI(1%;6FIW%I?@Z!).
MR'E=@H?1T!P1BP:`ZX!+[/.`W1Z!+=9)EF,,)G5=@@<T$#/^S&(0K#BTT(^D
MZ;)E-@]G&]*..>1,]64BHJZ$.YX>'=M1T76;IN"8ZS9''?1VF=M$_DSX79_Q
M\>G-G[_:JPUV+FW(Q.Q!6RZI<B_`ZY!5BD+GQF2K#!YERW8N_E[%/>_3GV)(
M&?4F0&&W20$;W.EW7Y6/S>8"$Q[(!Y%0=TSB,<[L]"T,RAZR63&*GW\.^*P"
MV0'(2(8#^-R170"?-PGRTF0#/E!63S8L&I*7M3G3P+U!DAJY]23=&!*[Q&._
MS)"[Z(5KZ*&-UYT>@:(*0LYK?S$7,P084;&N#:>4>L_G2HAGYH<83M-V"Q4(
M\]5*K[,T,U&0[,#"OV1X8@!IX$]2+B*RS?+<A#V@!)U"@M`5$>R"<$K5@KS1
M:=+6&L\?8$Z=8YW0MBQBCD@P'5CT.!,Z5+1OFZ.^;78-FP&T*SP/*B$IHU1U
MDCMAH-)]U.8HTZ0$S,Q9"JBJ;G>&'8,"L%Z#4SXZL\%<@(HTH&G,#&F%Q.V*
MY)@GZWU'-A,6^CZQN3"I-V0-&606>CF(A$<V<<\Z19'+^#]LW$FZ]A&U%T4V
MZ$PE`,37(9>!+KLJ*QTU#2[09%N`H8_@$^`W.X`(!M$`E(%:B;CFPE%;!/U@
MF%@S@QLNN@7FL(3R+5(X(%!$QT)=%Y^?MGH`Q1Z=:8Z`YPSV<9EK5/W>L"Z-
MJ6L-PF/G1F`8>S'!_/ABQN>8.TUF*7B!]+T#WNSQQX4BZ`YJ>WP*;FS,4%L^
M%)H_&P9FWU!LYQ:H-91&T`52+QX8]B>EN@;PEVY0^7YF[#0M0MQDN]H>3B>U
M.S/=?];%TQR6$/W1O>J/"Y5+!JB/"5[0R*"TJZ4N[LO$0IKR"=3XCUXE>5I:
M;&\]V41XY[>8!`H(BP6Y*\D*7*+/#RO(#@_8,^7;LF[PZL8'*H/N1>LPZZK<
MFDGG4)YY/"N"G@2/E5-_'\2C3,\B8D&@0JQ*6WT+:%&R'?J\OYSS3`4_WTB+
M5)=E86[[@.=#P8C0:;#J5&:M&8P@8W]T+@8VB(,._'FU*MC6HNT4.M:N`4PE
MF_*1;-&A!VFOVV4\HZNTN5GP/'QJG6)GD`)Z3)9E9WKC=S9IS*%^Y+&O$+S7
M/_!W-K"=P7(,63NIJJ2X=^?G>?91FUW<^^UXE-A&^9D7>0"WU#Y_@L5T8Q(H
M-D$VX\S2_TCES\98.+PYX?``N)\N?BZ?C*;9%BHA1JPMB"C7?5:8!-7["2;U
M#&_Q&-KWX)4?F`=+@JF/';-V<BXJ[)63_O22GWX9-;2AN5?0U='NCD'M:CK9
ME0VZ/_B#:RL'V)S<FF0QQQ9+?]@D!^)UIVS#:'Y!V$`X^NL]X)\6NAX.VW7;
MO(A>DMQ7VD=&GPL\?]I-XQ+B'-H+ZK4/ACRAU?Z`TB;\*G/+!V5R3-][R,)K
M//L=\+>VSE?FI0V&JE[5G2H[,VNJH6M/W88OLQ)!,V2258L=/1;%VPS:!:2&
M+F8S`/-X5\9]>\^Z(YK!%AQ!8;C'GO0P=U(]B+'8R#,D"`&]OYB*A>7?,G6U
MV?G!/322;,L6/0,>KEO'D<Q@`"CHGK:*!R<!5/3\ABXVAO6W["2X\1[OU#IN
M`P\$F@UX].`8<4&N($[<52^#;3J5,;OA?*[L0]O482$;"UU+-+0))L=B+D\0
MH8>]K+\<)L+`>4(!,!44!Q]/L$U!2DI_:LT-N0M_:<Z(CIZ^!_/WMK6'OA8`
M89@<ZJ06Y!H0!38ZCP9&'6FW'N<QAO+(-Q(]MRN$2PP'BG(-46MNAE7]WNW)
MBI@F(9]::.MTA1`'\J2]/[),ZJR>@W\1CJ>?BW_Q\\_!?XF.N@X7-`ABSW\%
MLB=@+(Q`UABWP'*0)JRZ/MFBC4<S#(%%5NV=V,UB=!K,:_1N_CE(+QYYP!]%
MPT,-9_/OAL>=NQSZ$.SA]7:';4B]GP=P#Y#G@OR7[+*5X3`6Y.L&Z\`J6Z_Q
MT*89[)LGC=U!D,,,KKHX=%!WK<$,4<\=G6N^UA+UE)]DT7XUQ&X>Y<_L!6%3
M(SJRWB+8W.":O\_@7CR8E]/V\\]!R',V+R'LYY]#>-,"S?D-HW#&^U9,SGN3
MR,\_B_!T[N]V';QK@BNK(`Y)&%,BS*S]Z^;K=S`@X,H.X$<&0%NE1@<(+H/1
M`9R;^S;'!S`6CR]!\0;CR(`8OZ$T\AQ,R\:>AXR/JJ#8N`8!$Z/R2<9'GPL:
MC6X"!Q.-&PA/L(\\_^2&N&V$%//2OV*"'+GS+_;2?P?W49@M+%!CXJB[;F1`
M)/18;[&8/K^M;:<Y</T0I@WM_<-X\*._?XAZHUDQ<QT0&:+E^&T2?-7&!%^(
MR)&_8J&8.P?Y@%[_(M0C:5>$>GEPR9'R:U[MF!+.X\'94^S8-D^5#X[=]P[6
MX7?W5;*M'>HK'Z`/Q:]XU:908P>")^=YKHM[=ZKDWC8\FF]3W?2IZ>"^?(6.
MQS)-&'"OY,L\B7X",.N5V\5<'_L;M\NL^+KM8K%GC@9?:).L^T*;.\3QYX(7
MPT-!73W@=_70U/:>#)[ZN)/";AL/F7Y*WF.FEY)Y@0^;'J/[E:9WP?U;38\K
MOM+TRM-6,1N@=!8_.YMPW-+>-]":JH0->*H!M==?XN-7R';,S`(BHQ/NL)E!
MQ->:F?-7F1E7?*69>4>.T5CUE(A4HDM(:=5F_9EW!?V__1ZJ=>`7W>6O$.?H
M?=X@\O(<M&P4'*].:EB=G@4&=).^YW,$\$&89:K\*Y>`][K4[E9@ZCG24J,`
MX3(>!P"7D/]&*_PECZ/Q`9*.8Z#+@(KQ`8I.*!'2<1AV.86S+F,:C0*M2P`Z
M=&($@*%1M'@)*9Q.C(`T/[%*0..)$8J*<669PF]AC8Z(IO:$Q32<<`SH]<>U
MY0S/6D='<#H.@"\!,TQ8#&(N&->6!W3"'AQ<<!0(7_*08@D=&P%..*%M%-.)
M.>*8C\L!B'U"#L'P?U@9'<'CB9`5(@K'K2YD%(_[APBBB<PAU.2($+]F,#H"
MS#&A2QSCA=[1#!;2<:M+%HIQ#Y)<J(E5!)O0!8#(Q,[)8"KF)/3=$[HH<++Q
M$2&/QO.MC'@X,4?,)ZP>4!Z.VS3`A#H^`M+#N`<%@LL).<P7^4='!(#4QT<H
M3B=6"=E$#@HB%H_O7`!A.VX/12<XD4O%N!R70_&IG5."!^.2*LGC"4F#J9U3
M2DQD2Q5.>9"*Q,2^J'C*DT/*1D@.,X+1<1X)1D0C-@4@=_WC^=GYV?\`HG*P
M0`T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HS-2`P(&]B:@T*/#P-"B]#;VYT
M96YT<R!;(#,V(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO
M4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B
M8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2
M#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@
M,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E
M>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]0
M86=E#0H^/@T*96YD;V)J#0H-"C,V(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA
M=&5$96-O9&4-"B],96YG=&@@,S<P-PT*/CX-"G-T<F5A;0T*>)RU6TMSX[@1
MOKO*_P&GU"0E:0F`!,GDM,]4<LEFQU6[A[U0%&1AAR(U?-BK^?7IQHN4;8%9
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M18Y%^TGVP,_G0;6P^5_)PV_W=]\#5_]]%]XI`]Y!]99W#NJRO/,\$89W"<R6
MO7J2FMX:J%O!(:>F[9%0Y/!8U,6CX0]D@MS+;D-^ED3^?H)727\H>O(LR;.J
M*E)+J652-C5L,$@KG[:!`U`Z>U47=:F`^7'K%G_%%]JFZE;+2"'*K108I:FW
M@#1F1@HCQ]VYZ^71:%VSNQM0-5;5P#)^TK^U!2@7>7INVD_[IBTE?JIVSVHG
MM7R*JFO>%`BP/>R+LH>=]0;>U!9@'5S=Z5]`4/"V+S*O?U4J4.YHSU85I`&O
MV/TV=*ABH^T:5`\45$5OF/KI+]^MK!5KP^F*RLKJ4=:RM5HN=D=5JPX$INVL
M0'-3O8*5($`0[JF!??7!AZ)^-%\O(8DT<9+($^8EX1Q!T[XA_]JC+1>@F;KI
M)^Z.1$UE->H0K>9"BR`W;=C:G(;RX$6W0D'"SF4S5#NRA6,@.NR>9`OL@Y/`
M;J0Q)@52&:J%#"+)1C&,P3!.K$$T>]*<).H*U+)ZX;1@&CN%3XRM'*2WZQUY
M4BZ&XA:32+BYE0L1X((;+C[\RN+HIOW3L)08M5**<J3#ALV86FOY276?.O(1
M`J`"FT#CQ23R??WE?)3D&\OX!5WFF)_^B<<\(XW_AD]LDY"<YO`_IF:6^U^K
M^[N/[R:KB/Y)687V%^/^MYEK6!%9%NO-<P&H!?#-PQ>M"9JP9$S>-I%V!_3;
MQ[9Y[@]D)\'I=AUZ5-ETZ+*U?'9."M[<FT]HY387Z3T*</A3#^8NES!;`#>+
MJL+O_^Z1`W!4%J<N<F1B$CER"Z,>(!SL!YW5;-QTD>"%7QBH8!0$ZI(%:L=&
MO@D.LZ&E&3J7F]11PL>=?))5<])?.3U*K=T%PF7&(X<<(C8R+6(;+GW4US"H
MV.U:9-`CO4N(AR#*6!L::M%#2C38"[F%1-L<(1<8[`#/(=&>=7(QDOF6DA^]
MS9('61[JIFH>C6AP08/991$94(^?4Y%X&?`T]S(XM4KV10MZ<W1A?A\1$Z8*
MYWL5&,$UR]`ZG>!%<&;X%J0(V53[<G]H.K^5S]?[0E5XV@+,I[GP!C#)ET+8
M3'!I@<8FZ^;)8!U'YPJ)-&G?D=IL>P20&@*`=0"D`M+`>6JG;P!7L-63[/K1
M;,P6%8K@(N;A?L,BND]3AYQIG(VHB4:I8;]LCB=`?WW3(I,'!7#GJ!X//<*;
MG4+`!$`&(1%H%52IMI6FMI6/P/V&?%V?@4GK]"L",'IB066A0:BQ:P@3G48D
M\+:+`*^JL5$92XA"."C-.!^+B(Q;44SR2V<UU4I-C+5D3$LM*MHQ]:Q`D;OB
M"$70XHA)USH+IAZ__Q*I)V4>N_-D+&(QVZ'D?QA:%.<*0;J.-$6G2])#\60*
M%XA.D-%W*VTD%M]7ZA-F$_N*35PF8MGU*S"TJCAW;HTU.UT*3ZU-!V0(:$O8
M7)2-T8=/T@^[3#\Z:1R+LZY:L+*P?O9)RA.(`VM3!=:'7.ANA+7#O:VYB"UE
M35#1)<S$S2X,NVG'-H"M_3&;'Z4T=>("0A"Y`^.4T=RK/Z6YJ]XGV15X0C(,
M)Z<*6<="MCPHX.8-E$<^0M9U;V%%!Y&,%*8K,B;P\067N;Q`5%U6PT[^_;U]
M*N74<WZ[4P4B@DB7K0O\_HL0SY=%TG[_)8A/\G11XOW^BQ`OHF6)=_LO0CSC
MRQ+O]E^"^#@3BQ+O]U\BB,?"MV`9$R-Z<GVGAVF/$2(V@%S\5'1=4RK=<-09
M;*@G/3E745PDYK&]B+L4Y2>,V%?#^!N@;0GF$]^%S7/^NG3N`'&8.A?@_/$"
M"ZZNMM]<D_"B8[<$=(SYLM#1[[]$`RFF!CKFZ29-:>8;2&DJQ@:2Z45(;1>U
M:8!C-W;2J&^==;Q2T!(2YWFRJ,3]_DN`=9XZS!KAG9^#:TG$1H&_K/O+H6U-
M8[V5E?;=JVK`&K$`Q`EFK_KNLA'O^@$6$6(_1ON+OFR;-NS+`D`Q]ID6<'8N
M/%R]N'))J.'?]7^&VJ%TVPM0V)>$HM9=,Y#/0U'WNC!^?A/=`_3$LM@4C_H"
M8V5N'\ZXR@IA9ZZ</DGR)-LS;+_M>MP6XPF4`CW\7$((<>S#?4+'&S<GA&EG
M`^C;#JK:F7+"J681OV++HD:__R)^%?G^Z\2LJ+AHA+\T<MU946@8YN+R[%P-
M#<46O47;8A%HE&'K1-7NH&YL=1[579F#[*9W=ZL+>W0=++MR"8-BN6O$4IJ/
M-S(9M>Q/8$'9'(^RQ8RIOA2N.$<74?5NZ'I]WRQ-`)HT$DV-[S.I*PE?1*J5
MBSUO[M>9ED,#GK:8'%+?C,W8Z%@Q<\U8['WL9`DZ6?E6L[FJAU#@*0--@4*E
MCB1C[V,+[QB1P-JBMY7TU*;@D[4H+81:5]?'II57PO6&?`T@;A%!)"*(J0P\
M6KEVCTOQ/1E.C6T3R1;$<-1P4-_W5Q`7Q]2@#0#\X+UICZ/$$Y^S31SA_1F@
MD@_K]S\IGXI)I&/7,N&QLY>V/[_4V<.A&1X/NK,.`I(MY.6APTSRW(QZ7D*G
MW'>;*8W'3@^S.KT@4ZNVDF;LIGALI1E2T0&LJ6U/!UOE5X`$.(7&"*#YNGF&
M5PR7F(8189.#>CS`5Y4Z*G2=;=$I$,T$O2PA`.8+A3@:V^T1LVES#$-ZE`"]
M>(4^B7,9^DH:F/9M=W12E,;*=2MEVPXG<^6IZM6%_6_/)OS55\3EW&@$:DC)
MHT-A2X@B\CU?,<8YYCJ?EV')CI&H,=UI;DI#KBGWS.V$0?%V[`+[OV;P`I<7
M3X6J_%U$50PUK`?1?=58=/5&[V_2/-XL,KJ4>3#-Q^LGYLOFGP^J<E-$``?5
MR<U2O53@BOS85/N"/!1M>6B.J/^/FZ\WY-<HN1D)7:.;`^QWA)M4#8"+\?<_
M)O?'K+':R.QAFM-W/PU0QVNFXO>/V:/2(3MP$9FAAP^@*/K^TW'QA8W1+!]=
M3;C^NG&<0]$!/I"UM7X]'DCJX;B%X/#2+R`T@,\QS&P8@)IAD6Q!4U]HQ2,D
M!(Y\C3%&O!6BPA-D"[ESXVP%Q`N#\S""^;2O\X>^EO6U8Q)!W-NJDASA_5:'
M@;UL,=L8J.C?U7AK[%BULFQTT>47+#/:INL!FS;'WAI/N2L-RKY!-8%"A!]"
M`Q:W..6&!`^M3@*Z_C)A0E_J3$K-(Q2HMDB=R`J1MAJKN._.Q0ZD='FEY@Q@
M(L\E1,!3'P=HYN$@RUV^L+1-FVD7M&NV7X1P;6,"CDVA^.":IO%P/<0,"P3+
MS`)V94'"4A9<$#-(<*$%G+$LN(`Q&CZ"`A_!!1'EP2-RG)L-/,]H'.0AI6$6
M!(V#!":4!Y_'-`IJ@5,6I)]%>1P64'J=_L]V26)(!.3ZVGPA55%OOO3UA'+B
MD6]"#?##V</,=<>U'T+<^19R.YKLJ]E"^M9L(6R;FN'"?/*K'RY$N2=XNPYF
M_@;)X(Q772[%5TTE"DG*)MXUWPAJZXI?F4C)*T_/8G,BS=X^,N#D^M4QSJ5C
MG!.NE7L)X#X/A?GPJLYK%7[J=$HH6C>@;099IF,[_[B!_&O=(3!@3__K]I#V
M`'ZS)JBX21-XXHV:H+X7-9F/C?U\K(G_=6D"OJVFW8"4_%UU^G(]*.<9XJ[)
MF7/NJ7M3S@E&PMODG-AAJ#\H9WWB;7).LG'\D.>3ZCT?Y=Q#@6HKL1<#*1>8
M[$9[GR/^NKU'GOJW]0`\W*H'.VOT1_6`)]ZH!_\G1)PSHX</G6[2@REW[W@6
MSC>YPV)?9;!W/2'W)[Q6S)_9.&83.;%\')<%?67CW8>?='W'LQF+%A8;E'K+
MB(T!,)F*;>QE)KZ7V9Q4K=LV+YSZ'<F`0G-A"7*QD`0!`$PD2,<A72N]H3<S
MY6Y0>C)C#G5JTYX:/0T'L52U4-C)W1:G!B"8FJE:6\?X((G[W$#]U3FOG`7$
M@H$R8C<'2MM#^Z.!$D^\,5!&?ER:B1$8I&Y<&LK&B^N5:2OM-&PKU1UTX=Q)
M[%.]N@/\/XB["@P@;COJWI0SI?EU^"ZF\/UU/Y_ZOBU+G/.\OF$T0/_&0R#`
M^F%0>P9-7Y:K>;!(6N=Q$GQ.<Q%>P*,H?`+0&5Z01.%";RVB.%B)K=,H"Q.9
M12(/LQE%V<P*"FO"*Z!BG%G!G45=71%'Z<R*)*(S*DOR-%CYKFDZIQ.:1<F<
M843I#+<Y_JEI:`73?X8;7,&B&8DQCG_,'5P!,IU9`5$QV*M8,Q&EP6[!FJ71
M'+=IELWLD>5TAHX\FZ&#1WFX\[/FH+JP]CG+DK#4.<_2F;@09W.1(YE=(;)\
MAHXTG[%DGN$?M097Y#A4'0YA>-\87$&!W_`*B`YA7F*(#F'-Q?&<S\5Q'NX<
MKF.(#C,!6S`1CK=QRI*9/3(V(_4X9R(L4TCKX0[<.J%L)O`G;*91NDXX"_<!
MUTE,XYD5"5Z8!%<(.A.#$D`P8<TE&8MFY)$S%K8Q$3$>ID/0.<T)*'S"E`K.
MTC"E(I[3G$C83+048LZ"1,IF]"*R.4N&V"#"7ID"=@A[)>*3ZW0`3OO^E_N[
M^[O_`3KQC.(-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,S<@,"!O8FH-"CP\
M#0HO0V]N=&5N=',@6R`S."`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W
M.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\
M/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@
M,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B
M8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]0
M1$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO
M5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HS."`P(&]B:@T*/#P-"B]&:6QT
M97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0T,#$-"CX^#0IS=')E86T-"GB<
MS5Q9D]LXDGZOB/H/>)O9C2H-"(#7H]UMS\Y&3(RW71TS#_,"49"$-@\UCZJ6
M?_UFXB)55I'3'G%CH\/M*A$"\LXO$TF__\?]W:_W=W23Y#&A^)_Y*=O$POZO
MJ.[O(O,D(BPA46(^883EFSQG&<DH/*$B(JVZO_L[J<U>J8AQHSC+\"_2'N[O
MCO=W^__$K?"_R0=T(P2'`S:"QQS^XCECE\]S$>/SG*?X/,L2?GU#1AY32FE"
MLH@26"820]/>,`@/DSS/PT.>C`2_?[J_^]-'N2T,>T_P!2,(LZEG/3%<4O($
MS/_QGTS0_R!/O]S??8"O_L_O.H#/'<"X.8!N&(T$>2KN[QY!,`F(^>D%SOU\
M;(9R1UX4;/WKH%M%Y&ZG>]W4LB2%/,E"]V>B:](?%=D/_="J!R+K'=%[\JDI
M]Q(6U773DV;;R["LWNGZ0&I5J*Z3[9GT#3FUS;/>*;.@5FJG=KB][N$8>'IL
MZJ8EMQ9`Q$``H#TK@"CEHP!XG%L!Z+X#VDM]D,@TTC)T!!A0+<%'?Y7UL)<%
M\(T<O3NT2E6J[LF+[H^P\H$T0TOD5I<H)OARI51O/@-^=T-A]G22Q>]UY,7(
M>XM"P".?57DF<K]71:]V#VM((,_R8`')Q`(R;@4`"FG5]OPM/<@P<K+7M:P+
M#8HZ-9TQC0<@HAM*E-R>-"?5&MEUQBX*V1W)OFQ>N@WY2TVZH3C"YT0]`_</
M1OL_--5)UF<GB:-\5BBXLBEDKU810,J\!8@D#0*(T#!0`-<,WJA7:90-F$#;
MJR_DO6ZZ0JL:;)J`K4HP>GQ:-'7?@H&0ZL)2X"=C$QOR-&%YJTH-DNC`M(#Q
M#L71H>=U(&?<5SY+7<IMN8X<XC@8`HM'0^`N%(!'6\=\0'UTP^G4M#U!LB<2
MFI@U+@8EORM[B"&'(\:0O5(E,09%)/RQ$I)EK]K:V%9G+0#%!#_(WOQ6R5^:
M%H6.QG3I.6M(`=FUUL`A"3@I\#RU0KCT55V6Z*H=$-_M-80L\!,DN0,5E^H-
ME3N/L*N1(8B3&ISBBJ6`='8-Z+U4Z`40>)Z'LH8OHP6`#B3LJ4M8MHH@6.0$
M0>,X"X+(\LA*`K0!?.R;%L@M%/*B^\WW$9+.YJ@L$X80.)VF@GE*HC1VAOF3
M.@RE"S&5/)-25^`_X(,:O$JWKT-PIT!K!U6K7A>RA'"FZH,&8VU!(\ZVNLN,
MMOE>\;Z5VD&\62+^_<S^YO[)N/_-;0-5(E)G&YQB^K`:`3-Q2?/OBNP@CI7-
M"83[]5RI4;`#^@;9@NN3NJEO31NG(A"7LXV@%*SU*U#T>/N3LHD8HHP',8@@
MAC>,K-)%VS3M0=:ZJ[H'-`"(]2]HEB;F-YVRT<_D/H,U#DT-4:6I4*Z(,=9P
M^(S3X/`TN!FG^+-U>*34\42J9J?WP!NZW08?X)]/7LM`,H3S'=FW377A:_9K
M\"3P3_X)Q]V:'0%?\/PDAA7P,\9O?HP8Q8;A*4]LWOSCG__ZM^[FAZ7I%9[$
MS8\!X.>/`1?B"8VM"X&>HMLC4)'SB>5%R9AS14Q=@$>LT`W;7Q3"@@;V]_$>
ML@Z:W1Y022O+!]+UD%<?#%8L#=I<PTTB'N!B%/*BH*AZ)!8RHM*'FAR:9X`U
MIAB0X`$`#3OC)T\&T_F/`#M5&OP`(!#&1?4;_&B`=>MR#Y&G4PG.@RE_PC@\
M+]5!=^Y73'M898&/-2]X"F`%6U2!/ZJU1)'FOG:B8UYFN8L7E6R_J!Z)F:"V
M5Z$!_01SK22]KK"T`#`!``?9LS56KXIC[6)'@VBZJE2+Q0;\OE>RTR@70$X6
M@'9K9.HT35;-U&'_-3)U&OOJ+HH9&XN;Q*4H*,$\>G_P]M5`12X+;V8G4!=6
M7@"??!%<F,K,UGBH/?7;2=4=HO>=*N79U#\6VP,"4SMMT7+?O+(%CQ&,CZQA
MGB(4=C0:H7PBG($"&8=65H9<!'NC<>FOSLOVCDMT26_!QHM-V?;SYO.&?&R:
MG7&P']OA0-XY=[8E[P-N_?''=P^D&-H6V,3B&?U9=;9.D)6:2GT-(;!0U<4I
M#U"-"2L#B)CU3K:[2;CH$46;3DQKZC:?\3V"05D$G&*YV5U\VZD5/W5;@#A"
MA5@I^.:N*9N#CX@_*C`?TQ%:@W\:ZKDT&\.U"*BF-OC+4_^'S@=<8P"H5]`/
M"*A4G6EG8-,'HI9)-=C?T;T)OMN+#%6"K/KC&54/7W_6ZL4V/X9Z+Y\;6[_A
MLYV"N`\&XXH7J+!M<;R"')(\"CEVA.R"7^18N5=0(T$X+2!U&;^P)!EBBZ.L
M#Z8WT7ESGM@N2O$$A6QQ'OWCP]""&<B:_%Q[9\#-/OS\8+H;[:1NLT)&&\`5
MD\"P2L\K285/7!D=:UL1QR$R^!8#JLUF,I.6]Z.9AP2&_+X<-3:R0(CH+BWF
M)_RX`C"`(:1O=8$-#L3U-6P!$`"D9^+'1`I6<A]!3.HW69U*;*56#1YK@ND:
M@HA]!4,Y#X)@F>_Y3-L=#Z`X$(>NP(GW2AG'")'.-S$QF]^:3@;VZ@E=MZAC
M`$9'D41L=!2>YTXDS_K9)#*UQ_*G.`-$,9#M@4R+N.8W79@8ATC4K4#K`<-X
M71)##*F+<MA-<\PJNA:AON,L&77-7)_3V/,*-3F@$'_TNMI+Q(3'B$^B'.6.
M1XS<E^7W&*VFZ.<Z.K?M6(P(#INWKSI/1VU`ZZN&TQ2%;]N5\EP2+G)H,@$[
M4>3:=19]V4AF.PFNG?JZ0?/_'(TGE*^*QL/^WZ>D?%9)<>8+)L;B\:HAC5UW
M^2?=?>G(YY,JL+>"MO,WT-![W7PZRK:2Y#UVSP"(K"#7.%FWR@G[W[Q%C,0+
M6^7DZ28346[B"[:(<Y:&AB3Z)[;+4:I3I&^O''\\`T(MR"?P9FQIDR>T=`S@
M\"4'6Z#*@?S6N;H`,[(\J0&1,?A.KS38^W<[]IQB6+ZN8OS^:Y2?<>1+,";8
MV"BFB4NFX7(((]$'&XF\D1N,.-82&#V[!NI.B+$#`BKY328U:_!;0X<=1MCR
MAXA\&K'<1*E@!"L$89''H=J.QO03.5CI>^+FTG-,_\U5'S>,8$_G#`$;#!;@
M(-X972U29UF];K]K<)^&4HO1,06E-!IODK]UF;_LWQ(`>JNI2W<-,*!!4B_*
M%UO`5&'+3E]!63^^7:Q\&V6,G(K0AF6W/R:9"C3G8[H0W$6U[O7E>JD!A.]0
M%KJ_>?)-\S10]/W!8B;2B3A;-=*%_=>(=$*$^CI+QD8;3UR?X7HB)Q6$,K1G
M]2S+P5P*2_3\9U\)VPZ1@06AYZ)K;!+4MO4FV_)\:W9B(-KSLRYD1U0P2H[E
M6:A+$LY"A^J@R%8W_1C2"C,O@0!]JPH)T7Z5<,9$Z!REXV`,2T4(9Q>]HJ4X
MC+'JFS`,/]_\1@6TY6E?5WN"QA,IT7S22DDRE_.*4IN*P0[_^%]^'63=0Y&@
MNK>P%-$=@:H9RF6]RIR'H+[,9U$Z]@53?WLQ:4%MB(./F(W!5_WX!:1Q'&#;
M#UC^@%\;AS833#,F((LCCO@X5VY,RQ`G7S;DX]"B($*6FYZV@@!X'DKEE(^7
M;CQ.?,&(IHI:,[UQ>;(5[:BR639]S3O"%?+<E$,UHW")[439-;6T5637F^FA
MKC$264,":;C)R\7HX'',_06650*HJWU3[QZ975QFN%"P'^H#,'[4V`*WK?#3
M`-7WN>M5!;S5NP<S^.:[K%?R`WB!/W8-"<1C/2K&D:_,#S]Z8\4A+Z,VT_(O
M#,^Z.[JVX!5[?2TECWR=V?S7T^=7]M*I]EGYZ=#"(AHX$9NIJS#.P[58FD<3
M9.6<7W<%7M^>?<OZE7)K]8+Q[$]VQJAMGNWH$-HQV;7#`0SW<V#_]9?_M7)S
MG9S&6;@22V,^YC1O\J>A/8&.W6B;'_GM]*$VPQ[UY9V=F?.M(7CUME,_]C%#
M3]1-]BIS:Q!:IB87@(/?'$[`5SV+*_<:*9T(D[$LQ(\XB1P\5W9,%AP<#&%#
MGJ"0,>,):"&K*)?ZZI-F^9B*N>]<CZC)#!9=EM87+1$HGFN\JB1=A0WK>JBV
MV`:T_GAS%`'EL2=]9;P"-?DH)$:ST?,S[HK4K>Q>S0$:L0$$M]/?Z+U]@V/I
MHU2,0JNF5,50JE5Z]RP+E:`8,3(W>-D$ZC`8[`87;:/W5,I"F3EKK)_=)9L)
MV'A3=5109YC@C/>OZ-##"5$I9"Z$U"94Z7:WQL2/YV=E?4/%.DJ.I31(+HX3
M'_%DVY_QB@XJJ>+HQM*^NIH:\1I`=2C1AC`2NH9VTU`[YO%DCM!WR7Y7`C'J
M=I>0MK>$XQFMF4PW/:6M4K6=+U20WP%DJY/G#<R^\*VG7GZ!=653'W!&VP5L
M8BXTUQ!!'(HM/ADVS@(6'5$'4EJC#1\ECA'J@Z[-!000_XM[30+)12.'&J/0
M)]L;,M/DVB"J4G_!VPTS2E;YMU(*<'P[UP_&<'(7^=<[4[?F/P5C]`)8L:64
M)FDXYO8]$%0B#U>GJ1AC*Q.13T"@D'I`@#`U:<B33=NO<EO$HG35EE+8?XU;
M#4:IO]40,0Z)?74)73B`\<.U7O#-">$32I(-!*CQ?L6T]WTO9!G3?EOSV=0#
M4!_3;`D9K''MS#6,(<IN\#+=C#&$_=?H+T9)N-_-Q_?4N)GI>M,6%M3BWC^Y
M4G:^J1<;(>T\"J9.G.'"%KZ#%&N\H2?""WKQI+$*]8MEW(R]NIISKTV>\@0W
M;??ZU<0WRNPK]>NT9/T=IKV&!%@H5O-HE$#L(:NO/,.`XMA*0O5N`Y/-3F%1
M9\8/<;0)9]-4/4"!U[=*5I>CN1=Z]\G50**MO>,?,-<Z>X!CBJ'K&S#!;J5>
M112N$B_NUFCD>A6NKTJ"[F_>%H_@:YZ*=8%K%(D)ORQBDP9EYMO/;JAHN96Z
M(>]`*NT!\!WDV4EH&/'1;O(69ZM>H$J8A@#_2LJJ5CZ].AV;<5%R:>0=,5.[
MV$`W-R1VOM048-]V)BYN^@'P=9.>C.W2O,,89NW=7K*`=T@C5OCNRU&9.'<9
M(]>84<W&5O38E$E\:`]1JI`U-F+-Z)&Y0PX^9V8K_2,@ND*UV=<296%&FO":
MU/;J3&O'=`#JQKYTV)0$NUWX_N[-6S+8*$G_+XJ]A(I1D)$8VYD0+?Q=Q+60
M]N^U8]Z\+(7SK]^5&B`2`TEI3@DWNXY?-_^\`"Q(66(7L#<6)`CDYQ;$3/#9
M!8(!9W,+>)3/'\&B.)M=`"%L_@A*`4S.+(!T-\M$%LWSD&+DG'F>1-'L\YAF
MLVH0$9VEGU.`[3//&4T6!)2^3=^O;DELCX"@>74<+0H6&GW[CQ],W@YQR`+Q
MI2^[GPP6@F3Q`T0)[/5?&++=YJ<_XY8OZ#'_C01M8MPVA;^LQX=?R_N[SYYH
MQ_55DI,IR=_>-P88[%Y1OPKF434S4ID]`MM&[@AW0I2]=F"H<V>T]IAGLU;[
MR"B;]:Q'3OG\`H'_5,/<@I@F;'9!$M%Y(E.:+7`)UCF[`-^ZF76O1X@0=&$%
MBQ:$'7&:+ZP0E,_S&HD\C^97)$LJB5*:+IR2T6R!VYS.!S0P'<KFN86POB`Q
M!F%GGEL&,EU8`18X&_H>64SSV>#YR)*%\`TK<KJP1YJS!3JR;(F./.?S=(`X
MECPVRM)YJ7.6Y?/VP7FV$#BX6%P1Y]$"'4F^8,D\S>?3UB//TOG$]\AS[`#.
MAS">S)\B(#S,\P(89D%S^(+3O,\)('6>%P'182$<QRR;#[<BP;FAV14I6Y"Z
MR%BV(-.<1_-TQ)0OQ'T``F*>CM@,"\RNX-$\?GV,!02A^16`V^>YC9-H'CX^
MQBEC"_+(F)BWL3AG\3P="5W27!*Q>)[2A.%[T[,K^)+F$L$7HF42+UE0DO`%
MO23IDB4G&79"9U?D`#(75F0S,@44]N$?]W?W=_\+)EXQ5PT*96YD<W1R96%M
M#0H-"F5N9&]B:@T*#0HS.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#0P(#`@
M4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P
M(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-
M"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR
M(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@
M,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C0P(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],
M96YG=&@@,S<V-0T*/CX-"G-T<F5A;0T*>)RU6TMSX[@1OKO*_P''24IR2)#@
MXSBSCSPNF62<VCWD`I.0A%V*U("DO=I?GVX`!"A9!E.S9DW56#::(+K1_?77
M#>C3S_=W7^_OHH>L9"3"?_I3\<!2\U]UO+^+]4A,:$;B3/^%$A8]E"4M2!'!
M2$0CHL3]W4^DU7/E*<.)6%'@#Z+V]W>'^[O=GW$J_#?[0_20I@F\X"%-6`(_
MDI+2R_$R93A>)CF.%T66W)Z0DFU6E!DL/HX(B*697M-.*V@&F1M,,K_@3X_W
M=W_YD3]5H%Y"'N$!;0@]Z:1Z3$'+-"6/1UQ2G,+DC]7]W1;6'>4Y>7RYO_M0
MBV?1=*>C:`?"VYI4W?$H5"5Y(W_G@^S:!_+CJ(:#4!L8:W>-K(8>/HU-3;B2
MO2!/8G@1HB5CKR?H1D6JL1\ZF*8GG2+\V+5[`C,<]?APD*HF)ZX&*7KXC0]V
MMC^1QU_N[WX`O?[U?MK3<M*>4J=]DN-GK;WLX>6*[P6N5!Y/HA:X5,*K03Y+
MO<1NIW7Z)+O/!ZZ.G'P:>]F*OG_XUA5G;ZPX0Z^$1W'%'_Y+T^B]30(O*,O$
M6H1&:>G\(2N,0;[(MA+D19"Z(VT'6S,J!:[1G,FIZWM06EMG)UO>HH_`ZWLP
M3@5F:@7\WW-U)D-'K%>]\B@!TPPP'SY:JW%/3JJK1_0H[0A'?L89QV98PQO*
M/)N<`;W?:IX4I5%]I[JCUN[[,Z]E13XW?-AUZD@>175HNZ;;GS?H)2CBU09E
M0<%3(P9PFO9,^`E4>@;UX`<:!$1>#K(Z:-V>\,FOHU2B)CLS%0309(,-VOT(
MH;.*\LQ%0@S0Y2*!&>5A3P0$0*O5:1K^U"F(_F?022G>[@7B0Q_>V8O]?"!_
M'XCLB?CM)*I!U&9_C;X74[[(ID&[H#EV\C>4%.IHH&0-,Z34FB'*`'4G,U!F
M[:"7`XN&+2)\AS;A=EDGH617(QH,\BA`OQVJ`QL.DA@I$";B!>001W:S")I9
M%@2NK;M7PAABHT&FYXWP-@$W&2N8<BU;4.9LX9`@B6TXX')<=*+SHC*PJ(M-
MK]\=`W%=$?N#$)@']2X@P^/\9?:082C\KA6/T\CZP$^"'#AL3B./<C`[VF)8
MM(/J&M(]BU<8@+Z-P>\W%YY!FT&T`-YAW%AS[A4_OG_B0*6RXH_GC3?GS_S\
M[^Z)D)0*($M34BI\4LHCNOZ.6+CZ",(VT^_&853BXE$3`2O$8)$X>I;$J0O"
M,DF,YAAT@#PZ#X&*4I'NJ9%[S<P`)#W`/I!'#:ZO5_VD!(?\@^D&D!4R]R#L
M5`Y]`'&&`Q(X$.J0Z[T@L=MQV9C\UJ*1[$-K&"'.)R.PW!DAC4L+15>8Z:E9
M/U:88W=C`P0%45*V@->(S_#[D;>M4#/ZJIGI*_.(!NRGP6V6W1SP(<650%^[
M<9C<8PT#1-%D@-)S=%:PF_K/TR=LF/7H?MSM9"5Q-R_8"0;&C.1OT"[C#HP(
M/HZ_J%_%@--@ZM'9[8*3Z#S'36R8$9@*7[R"%?(B<;&0^]Q<3!REJX"-&I+D
MTQ%_:L1\YW"'AHFP:?JNKGC*1=RO@,1YEJR*Q&[^-9`X3R>.3&GN7;&,;'WP
MV=%WC"E^$N,`5-F%B]T%@.BGL\43#2VOBL++.$0.U8]/OV`DPEYRTHAV/QQ,
M3(]0D:B!0V@KL1\;?&(5*,Y]K9@6OCZ(2ELK6D(_,;]>7)M@$+#&&7(87F@*
M`E%KQT5\#9M"<[\KW[[T7ZRD-]HR,.$:=H@GBDPS1B<[,#IU#*;@4U#P(1XA
MP!PE\-:A:X5>E^K.O!F@9.1G2_)U!806>>(].,=XZEK]G`=PPNMGJ"E-.GH%
M0_"KZL;]P:`9%AHK*(X])*MX.BN-R[2\W2JY+O76`),L_Z-<.`PF;OXUP"1C
MQ1116>QJSI1.)08P%O+C]Q]-S6OC1">;&]@"\0`D2!`YD(JW&!TF=0F=]-$M
M_M-J;OAE`((#4?K)R+].^OCX#OP58`8+LM6\*8U=ZZF@GMG%EMF!OHVL-)%#
M%'B2.F%5P'$KT6*5/!O7&#H8:VWTA\DJH$PM:Z1TVHAC6PNU[X`5`DSW.CHA
M+H'`;,!*53/6R&5X*X_@M>C"AQ'8`*D:V<*KFE7,0!W!+5+/[=(IJ0\*8`U;
M'QHB<&\&_BMN+KC!67!E.@&V:X))HA^X24#(?$%YY#&PW=_S@0,WQCR!S17L
MY0"X'";];8KI*W$:I(759Z[.."2Q0C\I,5A6O885(L]P,Q\)L<VJ5GG=!JU%
MP\\;4^J@8\#"G@VI<\EO`AY(1<!W:[`!K'M#J@/RPIY<9LI3!VYTUOV5R6D<
M<-6CDJ8W.VMO3%(KF(&5CN?J;#L!`GT#8><Z[T5;87?P64+0PC)U40/^`&;"
ML,=0O@JI29%;$85)K.)C+XR]=2)6`@D(NL"[(WG.<J?\MT-M($^P_!W:QH$\
MX>9?(T\PYGK2F#$FPH$I`[WBDS`[=44)9/O<-99_7.S\3CO#11&`SF0;L#,&
MHL5FJ4;'!;B5Z#>FMV<?62,2$M>++F8E+[/)84:&YY!GO1^X]1Z;'NWQ&AC&
MX=`I4QN#RIO_0PQ5W$-!>1-@8!ASZ!KZQXYLE_%,?9L5^J9[:<XW>N38V6GG
M8-:341?H>J%5UR)6@A=@@3)S@`?RTP%3_@OR"]AJ>3)=$#QSZ'I7VM^@XKKO
MM(8!(NJYD:\V:&*='K.;@FJ^$A/(F=1]X>JVO$<.A0=M6*:C/]_:Z[.N/[0V
M;6=2HW^%*2=:(?73+RBB7K?/5K!"6C!?;CHC%+G-!P?>`PD89C!_98`Y,5HV
M@?8;%'G-GB"[``Z8@PI?:2#J6-?X+EY%_ZSP)8>#`19-[.BS62BJ.C^%PNU!
MVTR:M\NJ3V7HF_S:V\(7\:/M?:VF/O,<V5=<B4;$-]77N_CJF/IF%8`N(9I>
MO("^XH'\\V8#\%6Q;;J=CA1/#'*E"'`-8!IA8\>=QUIJ:"BM5LV?L'I\=H>6
M-@#>]`#$^IUM/_CFWJ/NFE^2+'OFC=63W+>S%-*O=CB9N@8P+7S7B26Y;;V`
MIITK$'6'[U;SR5:(L_*HGVK%OFMLG=AA2&LC`=UNH?H0J]3M29FORL?<_&OP
ML:1P-'W>")EZ@#]`CK6'H\#!;'3TX"MR!P$#3`(;\#JCS$NTM_KO&'[6R6\P
MD(D"R+G7Z@5(>_ZZ@CLFF6]$T\*7[JGM@$V=KQOK1>(H>[]\?<+0#GB2HBLZ
M6V+:]I<$XU0ZZXR]C4]3"D(*1L^UW7D^Z3X_S$!FL&Y#-'&]X#CS'8PTB7+7
MP3!*@L)3Y0U,PC=F7+V))S/Z%-F=/*CKGB\>YLEV="374!)]/P?PYVP*4QCI
MQAZ(X=C^VG8ONML*L'WL#1%8PP:S"T1E.3N?LS3-;0W1YXLS_69W6;1K]X`U
MU<7NVR<W5W;1I<KT!PPM^"0;S>!\#P?UK15_`7N99NF:97OB.L)Q.N]>9-<W
M9\S.Z[;$U+-W*+NYF6@TLO?F!&H"^!,8"BG["K!,2[HJ++OYOVWQX7L+U/9J
MRQQOLR7NX@+++%O\F^#-@$TTA="@SXS1"VTKR23^'6#0DW8G<Y>)^^)G.I18
M(Q_J"S9K&IZMV,>FB>MCEXD'0I;'OH_]]J4QA,<G@4'KB34><O6][(>EXR!+
M_>:-,>1FYH;"G`6M$/:4>G;NPSXIX]P=B-E[:QZ73OJ*9*779$Y&9DS3.=ZM
M:OO5.=<;4\VLZ*H_:_PU;!#Y^QE)[FW`[-;?VF]SS029#VX?WG2=$%^WY76Z
M,VD>&/;Q:52].?6R5`?,T-LCL&[>^9ANA?%G8!.Z6M&X.VOQK'&#MO"-ZX1Y
M*C@U:@X&<GA]A&H)4IRIQ69%QP;A_!G+2BLJVQ[SG+TLK)EXI_:\M76<=A6I
MZO?6)<T3ITQ)08/(W/SZL'W_-^5SL]'((T;$;,9$I]#GH\*>?D,$*<&QW`9V
M4QUX@R?@.J!T,D1W.(IZK4.:.(]<&Z;T?9@RSBXC7>]9+]2S2=!?9IS?G=*#
M7N(W<`5].\DVJ"[]O`<6//:V3]O,6A.'6?[RX&(NC0LEIF*N[5:Q@6M"Q_@5
M`'\)::I!>_!;/*&VE\MJ\74T3<3I/CNVRR`6\3+YC5B]:CV!942K1T9MIB.:
MCNL+!&!<TB#(]?-+/2`#'J*1T33!5`>BN((UC.':TS2FOCU=)JX"@@34(JPA
MD)LJ4.^MH;J"*SSO;WT),$M@JQ"[.,Y6Y1=N_C6(75DZ7I=@.\CQ.EMP?ZS!
MK?S5*\L)=E(TM67_KYLAF(2X>0Y#;+?#.LO>\+O.O9>$#ZU9HAIY&9%$*^-7
MK;^]@FDAB8P`?4,@IR4+"F2T2(,"C$*2#0FD-`F_(L$;A"$!&F?A5\1Q&@4%
MHC@+:E'&824*+*("XWG,@N,94+/0.(M94($T!C87&$]`P]`XC>.PB:.\>'/\
MJQ5A1H4XO1$Y)<%C0!LY\>LO^/BO-;#8)-KH(2JG[NFC1EB(D>^Z%JE7?^'I
M9II__Q6G?,%(_@<NZ('AM#G\,%3!_=K<WWV9%EW$;R\YFR_YBAM$@!.NX6OX
MU$W(TE=_OO$5L+0IG=LWQ.5UA+.W=P5&MV61!,=C_!I12""):%@@C6C0L;8L
MRFA0((O2H.MOBR@+"Y3X+;B@FE&4+4C$>#\P*$$G_WY;HBS#JL90<`3#>!NG
M2SL29U&R\)8\2A>TS<LP7&WCHBP6M"W+!8M1_=7,H`38=$$"'##LXA!T+`C=
M6\JB!6TI*\+POZ49?MLD*)$72^N`*1;6`8"W%(]%$K9Z$A<L[!\)9.P%B611
M(L4#GJ`$*Y:P)2O#B7^;Y%D6MGI2Y%'8@Y(RH>&W0`VYH$L:1PL[E]*EF$MI
MF81U20$=%L`VI6D8;5-&DX4YL@6ZM4US&F9+V[2@^<(Z2KH`^PS`(;P.(`)1
M.**8KFJ"$DF<+;PE7:!66P;D*[QS+(N+A2R8TS#1WK("\#(L42[M7`;).+Q2
MX)EA(KO-Z-+.90E=0,LL7?*@C-&%?<FR)4_.<LBG88D"&-^"1!&P*7"L'WZ^
MO[N_^Q_2MV\4#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C0Q(#`@;V)J#0H\
M/`T*+T-O;G1E;G1S(%L@-#(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@
M-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@
M/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X
M(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A
M8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O
M4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*
M+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-#(@,"!O8FH-"CP\#0HO1FEL
M=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`T,C$Q#0H^/@T*<W1R96%M#0IX
MG+U<6Y/;MA5^WYG]#WAJTXY6)0@")!]MQTG:AR:UW4D>^@*1D(28(F5>=B/_
M^IZ#&ZE=F4I=,>.Q5RN"(,[].Q?Z]2_W=Y_N[Z*UR#F)\(_YE*UY8O\I#O=W
MU%RA)!:$"O--3.)\G>=Q1K((KD0)):VZO_N9U&:O-.&X$<\R_$':W?W=_OYN
M^U?<"O],OHC62<+@`>N$<08_6!['Y]?SA./UG*5X/<L$N[QA3!Y$"HM)1B,"
MRQ)ASK0U!-J++%QD8CSPZP_W=W_[3FX*((^1#W"#8839U),N#)5P]8!'BBF-
MR8?B_NX!SIWBUT_W=]^\&=I6U7UU6I$G162K2-WT1-4[N5,ET34IU:.JFJ.N
M=Z3?JU8>U=#K@AS;IAR*OB/;IB7-`'^?:B*+HAGJ?D4V0P_W=KV2N$>OZI+T
M#2F:JI*;II6](D^ZWY.R'7;D+^3#K_=W;X&>?]V$:J"21B!U3W4N`M593"W5
M17,XREJK#H^E?CNVJNLND]>J3X,"0DJR.>&*@R$8/I"AZO4!23D.[;'I%&FV
M^+UN/<L."EG1P]W(/%D;5MA]=0/,ZDBMG@P/NO4R7(ARQP6:9SQP@>>YY<+/
MBAPD"'[?/,&)VY43.TH="`&*))ST4??()_L=V0[]`#IR0>AK\O<MJI"[,LJZ
M:3O/D8LL7KF'+<`!,':O!N@@'`,X8XEE0)`RL`&(-W2HEG3#INMEW6M9P<DK
M>>HFAH!2-<*41[C]$9<,"M4(V;-K@(^U6=*JW5!)*^GI:OA1@+:MR:L2U@+=
ML&T-1UB"_)1[^<<Y\^2SG&:6_%8=F[:W9KY3M7+B.9&BTK4NX+!]"SRP[*G0
MEH',0].>T=D5+8BS/J'Z`VUH">6+#:QI7!!]!PL*Y#DHBZK03I;@`\^"';#1
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M0@RN%:A5A6%)_::['J.3[(WNG7-[`=*S+`W!DZ>CR/$SDCX1\).N*B<[=3E^
M(LF6.$?"7CZJB_S070>1%B3<-6`PR#^#$3#FWMQND$J1_O]V\\7]Q;C_S44$
M1IGQR&MGPH-G3R(A0F1'=PJAQ03C4H&+/>C:AB/KC%%/FP.(`@%.71CX`JH%
M,;`"/59@G>CL(?CO$./@+D8SO1JV%BP.-:`G5:"T+LET">UD'M#2+,\"Z2QW
M0>T+:M3,^2D\\U86NM*])U9N\+<3,F&K,7ZC'CN@B+`-K=SX^XUN;BY@0*^>
MS#P&L:+C_0RT/=S\22R:,#3F4<@01,QCR]"I62,7;+Q;0K)4!+B2B1&N1#R`
M=A],(10,X"U_\,#5*F0A:U![<)XH_:&5M7%*$N$:)#5!^=]0X[8VB&8QC(`+
MEB58`8@>?L/4H`)[*:U'!T2H*Z(AG0&'/Q0(W>Q="S`@S?,0:N-LXGC9F+6X
MH[E<#6DCI<8,H^C-T54/)@MF#U_*\A%`+`)Z4.(.;1W1BL'F=AT@<XRVF+O`
M/STP8@=)47?HK),VD=O`O7[?M,VPVYN8VRG9%OMEHFZ:!<">QD$%N/#9*DK$
M'MAZK^E)K5B<J%7Y]2G53-!(1;QHT`C[?]WA\WGF)CQD0U%0+TXCYSG?@7_O
MR'MPYWH+MNY2&@1XKW7S%D`->$KG/[LE>!OS97GK]_\ZWJ;SO(TL"L_%.N-X
MBL^&N51,,VV(,>!+@*\^'1X]&FCNHY:;2HU@">LE-7@W2+$&P+E8/&@(H$()
M06L1Y1;9#3*)&0&$_9=`1"(-:0J`]*#<4>*BV*L*G!BX,/2<QF<X&:@1G@X&
MJL\"!1--RF:%&0P`AGX59`0PX`!1QTK)"LPLQI@$9F0"TP(.4W"?ID3Y"`09
M3YU-;P'W05IK<OQ1?4+\@,`!D?"I:3\:TI]5^]#/>N:8VR_IZUF^BP[#/0,4
MOOVH^F,E"V5J0\C8)3C`?+9"F4@"!S+A:CRC[WJ-`D;\AF9H#*Q$%Z<[PPZT
MSXVI;!7*%#H\9#:)#7FYS:UI27(>B+%T@"'&\>T?DY_Q+`T\2ZB'?`!LCYC#
M@O;;#*[2D(R7R`O=KXG+^7_X\'YJ&WJ1&I:(0Z;#^(@)A0,$5H&'NE3MBP*=
MWB*TVS=/6',`=(`HSB,_;>J6D&`CE;:T?78_("5=P@>]/<'E%5&(.&4HY$[,
M!),!_&JC^GX97"RB`-`9'6%AYLMX9^FUP\`N)R]_CU/#$H3!]%B^:[7J90N>
MSE\WQ=^.G%2/1F&W?E3U$BDYS]BB`2CLOT0`XD*,=;+1ICA-QD+9!5]T&`!X
M;Y17,)"8-*#6*V4G`;>W!IG)SOED76.Z4V.+A0`8KTZW)H<+&NA9-@'E@D\Y
MEX]YGV#>&9D4!N)K/ZKLV+_9J$(.RW0/>!+:)RRG8V3)71,)C<K;G@U^8"?R
M>*QTX>K^(<(^:Q^`(<EB;\HSKLQ9`DE=?W-?S_)`Q;)R3"!#&_D53WSU6"I6
M6T@KM*KA;[<F#A)CMQ'4WT`)@YPF*?8(DV_/FA3PXA_#&M0DYM-:VYETFO2"
M,[W7IS7Y;FC1)T^AB>?1[\D>;%T9OO=YO^E:5!"AL`@(>A?Z%0ZXVFJ';7S@
M\Y;@`@WY9Q1-ZLK>T)TJX$D;+*[Y\B_9M4IB!\%!2G($5V"Z<VOR/NC+\_"-
M-WY[DB5DLC]5L@>&',Z0?(,EDJ(QY2//4=./<-7L!1B0Y+X/%:5B5(/D98'K
MLD"1),`LU5`U'9!U#K0MM''NA'1Z5V,6+X$9+W`19"Q=;[O3NBZJH33!QO:I
M5\@9$^(!+BV"Z`"X>#6(L[%VG69L8@RRL%79)4R?`I[RAUC8]$'-)^12,6F@
M"1K(5=AFQWHRV/W?:QM';&\K)&I[!9#`N,2CJA&8DN&(U<S!-M2,ONNVO'EX
MIG\4JS@]8U4:C=4_[L'^4;;]6(%TY<K/+DWI3=57@Y<80IMV">T5H2^8\[$O
MR(4#X_^3%S+B=OW,E1$F=E-:;?HQ8_,4<;T"P`!@0AT];6Z.P"SKY4=85S7U
M#E"\-QM;NEV"!4G('I,T'7.RU/4'#;HQM6K=[6WQPQ1=2I"8WD%*C>X-CO^K
MZ1O9P(-J#BZ]T$>;<)LFDS:91Z4_8ET>=FW503KJ"]FY&2)0!VQ`X?7F(L2^
M.7(0(PL6S-,Q0OC'W#YA03&RD%FGR>B8XB3,2(%`Z@%CPU2IP5\U;=\MD?\E
M-%HT_PO[+U$!9CGS%6`1Y;8"_,T;&]%O_3A(FL+CTC45^-D5G+EO@\K*N49T
M0R\+^"Z2=%CT&V>U$!FBEX6UW5X?%Y$RCD0N*>6P_Q)9/N.A1YFS=#)*Y'S?
M:Y>.@C\K&Y/<F&(SNJR#K`>L&0\MFI2NMZWL^G8HS$"=Z4"#:ZQ->Q-\&OBR
MPG8!/#BM9`MY<%?(2MV<,#I2MG##F293'F:3)A]/Q;2>-1D),MQ9P`,R%A+\
MB$W2LM3A\7.)N8`[Q>(!KT],[3P(C9-NSX8*IO<J5]<)I70#Y:V!$H?REB`_
M#EDISR8C3E&H*T*Z:'7U;'CWN9,P$=I.B*C"X)[:Q>97&U7O&HG\4)8?[_[T
M[0I`3[$V,GW7G$#;_ZE*616-*0D@UL5B":1F`Z`Y!'9FIZ4T(`H3DF/E*4DR
MIP!X&@B#G2XM(V19:I0S'/K+[,!I!--ILD,)@&!>#B0\*2MCG]+[SC[0>9H^
MQ>3!36UZ$8LD8W&6C;8XF9-V]$-R?>S](0%7XZ@$))'5,@W(6"S;@`S[+Q'_
M8TY]0&8X0.?BL1FF>QJAP+FS>#-F\V]#-A^*8ELE.PW,7X;9C"[+;+__$F$X
MICX+BUDZNJXLS9]U>R^42[J]&7%KE1]:)/^N-1;>W^/<2/?GR9"3&0B'=&R!
M7A\--"S:Z^/A,;>7`Y:S1D'0?#(>G/*0#MMZ!<X7UD0?W,!YHRM3>VH5YG%8
M:'+QH5,%1-ME)@=I'O+6:%+/3\?1(J<3>)Z^E26V!+$P:]K\%ZSW@G*Y]/1,
MH]!KJJI33R8>7+!O`R@D>938?#.#],@7B#MKM,U%6)%%H2@5CS`V31P$>W5H
ML&N(1M"9BF#I^N#MI"XA`9(6'_&XTVKCL=6/LK>(=O*:P':H39D120T5G$DK
M]>#Z67:>HEL0]5$1!DA-]`MCAG%X*01QGJV)CDW0%?;?GE1E9M`]`GQ6[=GH
MI@6-J;&$,];PL0ZS>LX\SU,@]@0`JN\K6*.W"`!6]C&E;NU@[7'85*!B2[`B
M&2<NDWS2X7)J<&PJ[$N`=1Z.<'+]V:)!7S[V]?)'7=H+B/X`#LTA9--E`"34
M&8ACL,\+*UJ3#WBO?3/MF2TMP84XI`$I'0O2C#D?]A/HJQT&P!<0RH.N-21N
MEAR4IT6]U<D*UDK+L@I9`!`85*+O+CN,`!9U[\I;G6NS=[@9N`P3B("=Z#.Z
M`8QF"0Y0GPF`8QQG:+@?/'4T]6[@'T"],A,74[N_8.MF9AH,NCD`P1/MF`Z6
M3_M3H#5JU^"=&]F"";7=\TPIN-Y%WA(*54TQ0N$H]\.W+]74>.<?Q[SGBSG!
M5V1#)DYTPVZ'?2\_=`^Q,G!&+E/<3<=\(*.3C,@5!2&+.2`HPIQ@A0W%::IC
MWQX=<QU7AP_=#-]B=$O/(YX9<3"$3B*D]8%V1EO7X3<[[V-'F?&5RN?I",+;
M2'!!TCPBS/!@)-:\@(MH@,5V0?R%!1FC?'9!RJ)D=H&(4SJ[@,=\_A%)3//9
M!8QF\X^(*>#EN0649O-41'2>BIQFLV?,:#I[/<4P-'-=T'26`DX!P\U<3X`'
M<]<99;/GBR,`NK,,2K]\_9-;XI01O.O%L6T:+)*^?(V7A_C$W2O<Z*@S%YX^
MF/P<D\D&W[1^-IMMMWGW/6[YA![B'WB@-<=M4_AA*W[AU^K^[KT_M-.;BT<6
MTR,_2PLBG&,,KY3X[.9EDFFZ:5_Y",P^W"/<$^+HN0N8UXJ'/&6SU^,HFE_`
ML$PZMR#!Z>.Y!3R:=T$/:31O&@\9B&V>RBB97T"C*)U_!C75T?D5>3I/*;Z`
M/&O$#V"$5P1">42O/$5$\15J19[,&OL#."MQA=HLO\(Q4)UHGMH8>'IE!6PR
MZW8>8A:Q6<_]`$9WA=HXR9(K>_!,7#F'R*Z=(\W$E7.8_R)C=D6.[X?-VV/&
MYO4#@F5\945\=07+^)5S)-D5368\GX<6#TR(9)[K+!79O`:Q#,O;LRORZ`HM
M211=D5Q"K]E<0O%_')A=`=YAGF,)B^>#^$,"4.G*'CR^PG4`_O$\3Y,4Z[RS
M*[+XBM=/@!WSYP!'-X_)'C@XY2LK8II<>0H`GWEJ>4+9O.0XQZ&FV14"6RNS
M*U*:7SE'=DUR8%#S(.T!0@.;/ZF@UR0'ZG'%6PIV38-$$E^1B^#7-%D(.I\6
M0!H878$_(LUF>`H(ZNTO]W?W=_\%F4T9Q0T*96YD<W1R96%M#0H-"F5N9&]B
M:@T*#0HT,R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#0T(#`@4B!=#0HO365D
M:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O
M=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@
M,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A
M8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*
M/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-
M"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C0T
M(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,SDQ
M,`T*/CX-"G-T<F5A;0T*>)S%6TMSX[@1OKO*_P'')"4I($B0Q-&3G4EF4TDV
M8V]V#WNA*%#"#D5J^+#7\^O3C0=)R3:X\9J;FJJQ)8)`]X=^?-V`W_UX??7E
M^HIN8L$)Q7_ZMW3#(_-??KR^"O23@+"8!+'^AI&8;H1@*4DI/*$!)8V\OOJ!
M5'JN).(X$4]3_$&:_?75X?JJ^!-.A?\F7]!-%(6PP"8*>0@_0L'8^7,1<7PN
MP@2?IVD</C\A(^LX%A3D!FE@6!1KF0JMH'Z8BN%A&(\"O[N[OOKSAVR;:_7N
MX`4-A)[4J1ZCEA$E=Z#\'WYB$?TCN?OY^NH]O/KO_VF!T+<`"_4"=!.D:4+N
M\NNK-0##`T;N'F#=#WW3'62S(FV_;;NLZE16DIV\EV5].LJJ(W5!5%4T6=LU
M?=[UC20/JBS)5H(L7WK5R!W9/I*3;-JZ:DG=$'A)=4K"[WW7JIW$&>J^(7E=
M=4U=D@+&X.<:WLDZ!6^M2%;M"(A!WAH!T#*@-'8(T"1V"(0)#0P"LCMD%<BE
MJET/2CZ2O:Q`LK)\7)&N)ONF?MB0FT9FK=5857LB?SEE50O"PVMYV>_DBFS[
MCF0`3U5WI%1'U0$R70VZ[78*U01<FTR5),].6:ZZQ[,G;5<WV5Z2`AZ5!C[$
M:0$\1"H<'`%8OX,C!2.?PK%"Q5!ID$15!#?_,RE**;M6:[`M]<9V#<!PJIM.
M@V*1?%#=`=XIZSPKU5>`X9@UG^'%U00V>+>1A:KP/=Q]F*_:X8<)`H`^3+@K
M%[$+D3"'`P_2P3&",+G``:5#(^@.&@BP4@T#:G`O#RHOY1DB?8M:O$\Y^8ER
MFO*?*`0N.QE\$Y"BE^6&W$[<357WLNW0V]K1J7#[+QPOATGVL!I*M`0BG#M$
M('X.B-!06$3<YK6PH8_:SB$*'#-T\>;I5Q7)2*>.LGPDVZQ5+3A1]0BAI82!
M,+X`7T"E`--C]ADQ0VB=BK#U&$JFYG(!QA(`A*D#(.%#I(C"V$:*O.[+'9AD
M<P0UCK@+(..I4;GU5HQJLOKZ>)3P;;T#0<'DU?%4MW+JZWG=PD:#4KV.ES7&
MWP<%8P[9/0P$.#K9H%UDNWL(JY+(HI!YAV\@1(UL^Q(G*!;!@`6#6TQMP"!P
M'K=1!'#AK,I16E!3:[AYK50OY4F4B@:_/4V^.'\\SO\Z2!,OI&D:Z<E%`EF'
M07CYJD$-$L8-JA\+O;%@[;#-X/HN\J)ON)AJ#6Y7@ZVAF]5YWD/6QB!1/!DD
M;>1>X;R-U+ZYQ07`4MLA`<'T""<,P1]/TN`22,2)0T($F'`L$BFS'O8`\?1`
M'K2?E>HSQ`X4;0?9M%+MP>F'OM;*YEX['G[AO(T437W4;OA.U>\AB^\?R3L,
MR*#VJ\W2PZ[2D%IGH6(D5V'LJ,4W]1$"N\J'#;*"8D0;=N&0M<..[X`(R&RG
M(&9J53((HE75VS0*;J=33+!)R!9(&$ZS!Z*"K@A.21YEACF#?)O!*["#.%0(
M@<&4;_@2T2(-!G;)1BH1V&CAD_$;F<OC%KY@R,^R/*\;G?Y!5O2%3\#!'G1*
M_0#ILB4W;5M#E-'QA7RLAG#J+%R!(9!6[2M5J!S2*LF.=6_8ZP#T5N(""Z"0
MB(%A\FA")1*+`PBKN:#U-G+I:AM\0#YVJ,56E@K8-]+A#+0X@<7\HC`C@$E$
M4/>\B"EH^IQUP900*!K@%C!!7^VD)N(FC6HPE\`C&2BF]FR+!U1C!H^[@VK/
M)#0[XV#"7QH,5$B/<G7*IC%1LU$3!PQL?ZL?`"\(A9/@X`!VG&0(J.!J0*_R
MSX`%_.H"K@ZC2^`03R@F&^TBLE0;-[@$+HAZ?&.D-Q0#8C70ADSSP%TO-2:D
MZK6_8,[-<B@7VI6M/0`[G*&1^[[,X,'CM'XS`1(FZG.8[/M*ER6W'6#:@@VU
M=0G!45M$?SPM9Q#1P"P%GQ2A6(XA$)^L>,\)9"'1^0XW+;,$R%!"%S:'-Y%0
MJ=*RL@WYH%ED=CR54*'I+R>69&;.LQXL8VO3Q'+T.F&.7=(TX$.TC'CDV"7J
M#(0/M]ML&-DUZAY=`[3(<ET8C#4'5EGD6#=8--Y#]8C!<H#AJ$J)]:0N3&P]
M9?SE=A(D76)%,WOB/:NE*M`D&"AF!!,-;N%H=@9E`NX0[/T#!,&V-OX]906#
MY#I9_"9:\&H-/70U%@O2R3@9Z"3C,=<DBFY$G#(77>6%G[^WX?"CHW80<@]J
M?T`<Y0GJ;NSS]"==L1T?H?38Z2@C=]@&T4BV.!$IY5ZUI4["-JKHB*-+`?R,
M&^<*.(C2;0]<;@D`N&&1R!PI&PP([,?FEZF<8!.CF-;C78&%60#%-F46?C*%
MUH5-X<?;J5U]Y^S*=K9^#ZO"Z.$4?Z59S=AL^%LG]Q#EF-$A`0A36=--$K#_
MI\F^<H\\MID@C%93P38A34RQMTAS-P%K'V$-4^Y@9:&P&>7FW!\7".4Q'?@_
MI=P*$+L6F@X`;^R,Y_[F//$BT1N>BV^Z<9`5\U>6M'X$>.JX/TT"AP`3H<UE
M-[DF*E#D<%VJD.\WMQLH?DY9T[GVNI$1V9SA/65G\-$)?GCG%HOZSI9U-WN@
M,C`0&V&N=_YTE)L8:?!#IN[E4CUV'H\]9<8L"&'"0T?OSHLY\/%JES6&=W_Z
M<(L2PA>=-"H#OSOIG:]);1B=9CFMB0S*-$MN=IH`=`TR7C`0,*(CAEY3-RFT
M`\37]15M6]4PXB40X([J,VK-(`!*D]J,9+A+BT0&35NW$'4E"!M>'W4_5'^L
M[E535\XP,J/S2G/>O76@[C)6KLRW63>6PJK*=J`P(MKVIQ.L"%@>L6F]E`&$
M`\'G?*CX@I!;-YC`;]K`VAQU,:.K_0^WOV;KX>/E*-T],.B.D:,NBA9T?:8@
MA,_HACV`M@0*P=`_CJ.Q[@V%1>&Y/A;&L^=)*X2#WXM<1*"5$WX1SAJE@>.L
M22+XV/B+PY$!F%,B6Z758U<3#/J^QIQ1FF#7]MN?[?9/.SY%B2<#[D31=!(Q
M\IGZ#J$$:`O5F7K(-MC0^B9M$VP7R;+LR[I5^2)`Q)'CKC2A0X.=.1R<SJ";
MTT=.M2P?W[Y`CU(2L63HV.!QC^O81,FOVIX+2G;$0N!ID\*";5]WI:K;*F7.
M&?NFNISN[+4%W#8*!G(:CNV[4,16^9/$<VO9'S?D._>K._;!`U_+2\]L=*>*
M0F=HO9,0P_*L[5POI\!PB.I-R-F^K+?Z$`5K];P=LOI#W4!LLWEB0^Z6B=^A
M&'A<%//QV$>XP`6)5FU[YR,#(B!B4_?[0]UW$VFQ&:O)F[D;``:@=CKQ@IY]
M!<$<J8#5%'2>9+UV9:K&K"4?F^S+"O^O5N3O/>2+;D5N,S`D<M.`"V>+1/`P
M&=E<,C;T(VH+E7^J/9+5%?D/4)JO0&8RP^I@AX^0SI""W6X^;?3NZ7,])+D5
M8"=='VYO2@_<1]O^5;:[;[`SMM^2O#'H8-<6G0";6BYB82,3&R2KI5I5(1=C
MN38F,B[XV*$!FVCZDZ/U1EG=M>K,K0@ML64?$+EL&'XI8+NC=>M66%@K4\>Y
M.+$A/V`[J\)^[@D64K8V*'K-@DV`6`*+:&SBQM-N56J/1(VH@,'0?$.Q,?-(
M;>J8\/O*Y9Y23D^,48$V*\_BJ0T2/J2FH;C5YR$08#"@X$F`.?5;!`HVN2`P
MGH_3V)K%N'EC<!]#!:+B=#0GW66)?;X<VX\'A3=@G,$#6J`/Q@S]:(]5Y#U4
M#J!J<6$F9Z"/B^UD;I/+,DC0@>F=W92PA;<]Q!E8^93P&8YWD4/M`>UE\2MW
M4-@^XR4OI6(?W0&36@`()EPOEXIT\`ZN?T<DWI;$"+\L/'+=$)8.28PGK@C[
MI-K/+;F!B*3RMUX^I9/E&1MS1Z3SB`Z:Z/NP"_^"K7EO;HDX1K]"EO\=5H79
M\)TVE*>=C@4Z?RR,%KU<,<R_!*%FP7"E($"Z@NVVF[*3304N<_]*Y_?U^.+I
MDBS&@5]=_]EL="?S`WACO<>LCRYY=EA127NYRY0=R(O;^BCMQ:'6T"ALV$#4
MJ)>X2Q.(9-'M'N9?HI$<I`-73]-)H2)L_?0/I":V+7]Q%4MS=?-!GR>30C;(
M.2'B;L@M;D%=3.M!*,OWIE\$6W&H3R8K0ZDNAW/E`B@<41U>T%*YP@0,0S#\
M+G&/-784G?)HB+0A=8?)F@LYC5"'W)QF@O#R>"KKQXL>Z5;5;RTE)@,GIF"0
M#_$>##KD^NU7XA-`&$\&DLII<G&O=^3B"ZB,)=+OHS+V:$:5`Q&-*6:XNUOH
M]NJDG]%(8%*MN0:@F\L*#T@P$5D*49_P\FY?Z8;(,L>]033<C@G3"6L,7<O#
M!KZ\/@*AT;=GGVOP#_<\4*&L@2+1W!H!K7`$%E#FVC$Z`G"@DV.(Q^QG?3`L
M76]-(D76W7)W7K2O86;3=ET"`#964WP2L[APU13>^V@J?<L8S_^S\;*3#C6Z
MBL(ZX"Q_.-R>#VF3MHKI+$]C(4YL(P3&A\D%H5:^><K1?\UA(5CDY%+G_243
M&GU6>$T^8DAVB:`DU+..K^L_(X$!-(S-`/;\@$"$//8.2,.(>P<DH;Z"]O*`
MF`G_$IQ!9O4-B!CS+Q$RB'N^`3"!7XN`S6A!6>@54C#F?9X&J7<G$A9X58B#
M)/4]YX"S[WF$U,7S/`Q"X7L.XGF?!]0CWQ<[Q-I:$#U?W02#$P1/G6SL";G+
M;+KHLVV0._?W#W^I(?Y4%X6*F>;37W'*!W3*;U&@#<=I$_AALN?PL;R^NG5"
MB^!ED>.IR)>)F1,Q%&2F&GPV0.C[BJ]<0M=]9@F[`@LN8T3LM9JU\%O-.A!^
MWUR'U.]ZZU"D7M=;QWAT[QN0T,`;0-8IGL)YM:2A?PDAA'\`!.'0KV>@*P+O
M"";"&;1#D<RL$HG4KVO`!?7O.60-?S1<!XF8`2Q(D4OX+4?,X,&H\&>G-8-)
M0O\(L#^_MBQ,Z<P<4<IFY.#)G!QQRF;D2%)_%ENS-$G\J#.1B!EO@S`\,R*8
M'<'P@JAW1)C.6'(8I4GD'\%CZD<]C&-_3EJ'"8MG5DGIG"Z"SNQ<*.9\+J)I
MXM<%TJ_P(Q:QF0R]CF#K9N:(@AG4(PZ^[1\1LV!&CF2&;JVC%"^9>T<([%S[
M1G`(ZC,C`OPC'N\(1F=B$`^I\.\<CP(_LUMS'O@Y\IK'$+?](Y*YG>/@E#.2
MBD#X)8WIW,[%H*P?=3"/&0N*@8[[=8FC.4N.N8]/FA'"7U=`X95X,`5Z]/['
MZZOKJ_\"0C4@@PT*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HT-2`P(&]B:@T*
M/#P-"B]#;VYT96YT<R!;(#0V(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R
M(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT
M(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q
M."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&
M86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@
M+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-
M"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C0V(#`@;V)J#0H\/`T*+T9I
M;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S0V.0T*/CX-"G-T<F5A;0T*
M>)R]6UMO[+81?C?@_\"G(BV\&U'4C8\YR4G0`FU.3UPD#WVAM=Q=)EIIHXN=
M/;^^,[Q)>VQ3@1,6`6+'HBC.QYEOOADR[WZZO?GU]B;9%CPG"?ZC?ZNV>6;^
M59]N;ZA^0DE:$%KHOZ0D2[:<IQ6I$GB2L(3T\O;F1]+JN<HLQXGRJL(?I#_<
MWAQO;_9_PZGPG\4?DFV6,?C`-F,Y@Q^,I^GU<Y[E^)RS$I]75<%>GC`E&_@B
MAW73A,"PK-!KVFL#S</*/V3%O.!W][<W7WXK'NJ24$;NX04-A)[4F4Y3L#*#
MIV#\)MDF*<W)?:U_3],*?G^ZO?GBH]Q-]:BZ=B"J)1__\@UYF'8'.0[D)"Y$
M[/>R'LEXE&00C1Q(MR?=U)-WTZ!:.0QRV/Z5W/]\>_,>UO/OW[]JO2F!5:=F
MU5_\-\V2/_T#Q>(#Y*VSOP9Z@:Z5%'KV9$N++'.89RFG!O/O`<%Z&L;N)'N$
MO6ZFG83/#%+T]1'_)L;%`(OY^_;3Y20]]'?DW(VR'95HR*Z?#J3N3F?17IZ_
M^$YU'XZB/PG_[I]N-6P:K[@SFF>E-SHON3%:M+O%BF4K^\/%KEF!8^V[WBWV
MO7GVH>_0-8<M^;:!GY/P7HKNN/14L!/^-'P&(7P/_JI@VOX`W_ADWZ^[J=E%
M`:!,+0!I.MM?<1MH1_$HB2"#.K1JKVK1CD2:Z.J,13MYPC4[(,[>_(_6*FW2
M3C[*ICN?`$=O_][B`W-,DHP=J8^B/4B-E7@4JA$/C08'YJTE>$X,Z_/<;S_W
MUB.A:>MK@+YKU$YO@MO#L_;*6DXCX-%H\ZQ?J'8'7MPK7.QPENU.M0=`1'6]
M&M%;<*AJAU&-$TX(+QLL1'\!)VM4#8.VY/LKIK([_R"CF,\J'_*<>?M9:G=_
MD+#X:6@N9"=.XB!A'<"N$*U+?]C)NI<"_!CP:=0>.!?L:&MC[Y?@%SW`\Z0W
M<S_)9M!!('_3^(P3["].:B)!_J8`'0#M.NP\-\3Q@93.(%`/`G6\)VH!3J[J
MY=;!2@[=H^Q;[='@J5TOQ@YW'N(6M_P1_7K?3:WQG2@)AR?I'\PWX30,;[DL
M#!G9(T.SW)+CUUV[!Z^%6'Y2XU''?]TU'@WGNQ@O^N&#]>H88%1%&37Y^OEC
MY-XJ3QP))\7L@@6W0'\%Y',Z=_V(\786_>B2)+`-.)JFGL>N>=1TT6III)FG
M`T\T].)R#/[QT(L3\,R/4HNE\]0/P+_=&>>?6L-4$,I[)9O=`(&)63U6]JD8
M<[%7YNE,0!7S!*P]S#C8>.R`)*SI5YZV)?_L>HD1>4=V:A"'7DH,S17/M&F)
MX(ND5X<CO`")"(>K=I1-(S%#-1I)V8^7+?D*R"\&#M1KKY07#@=0Z.5+.+QF
M3H^J6.K'XD$U:KQH:QY&@?LY(=DNWL.4M@`**;>5!_@[8')!?Q.8Y2?D[\:0
MV%&=S0(\3T>`HN1>D97I0H;B[P:*A>%WY.FHP*N?V:]U?PR>*4L>E6?\_#%X
MIBQ2CRV=L<5ZT!`Z.#GZRDLA9C$6S="!&@$)++4.EI`2N]X+7.-E1L2$(LZ^
M:EA**T:H#'II:HHIBM3'4MD8GVAY:V,L=S&V[[L3*+D1-`\L"^*_NPZ6P9$0
MJO.%Z7=D#V)U$6FC.F$$]?(P-6@[2*8S6/D(T-T1F/ZD6E0'9J+/J0IL!QQ.
M`F&$24!-Q(`B];JOY+/JS_#/&@IK$.P6B#`R3/L]BE-(/EZ.XV.C_V=ECQ0"
MP(!2JT&VV=H%G6FN"I`_?>&S>/>95K"O1+&>>L&7)70FV\0*OJ5)4.Q`6HS"
M)%IL1F02/W\,)BG*S`43GSV(X50:0Q`73ZJ!BAE\6O977B&].Z`W38UF`1U\
M=M^]:'%:!5(Z4,-HPF$\]MUT.$*I4<MVP'<Q\MQ73%VNQ8TN72.X3Y&7<Z[.
M9O=AED0;=5(CE$I8XO2Z$D)RA"IYVD-&G7I7WYQ$_\LU!>HJ^GF)>4<>%(1A
M?6R[ICM<7JXXM^3O$&K]#F#`628=H#&LSYQ4I3DMYFHIJUQZ7NZTB7-OG]M'
M2-O@'SK@6PE0&:K!H+O#+78\:G>ZFT9-.AJXOL<F@::,.XU5+<X+L6-`U1`-
MH-^B()`ZS9JRF3XRGEBQ?FVS=L5=1]IN-!YI'OM5ZV8!+O?)R'$<!\6^+I=G
M6#0JZ.-/"A6PPP?;([].:@!_6[B3-E[W/6-8/W<)$S;'?6X[!DN[P"7W:)8`
MV3FUSJ)AJB%]#/NI:2YOY`5?S%AV-NZ$=`,Z&5XS[235UO!>T^E^[YNA>(U@
M2UYY+-[.L('TD-OJ.U9Z\/._;?'AUD%><-_`9W/[WOC(A^D!R)L\*ODT8!M1
MCD??21LZ=`:B!JA)33-?TRGPF2_\/!.ZEMK_0_;G65S9[^>/D:QSYF5_M9#]
MF9/]*-9M6)HPVDGLSF':TLV&Z8PR[KJJ=,2TX/:AQCH:Z=P2-Q+4-Q>Q@\W^
M`$H88O5$[GT>VY+O?`M-1&'JG.9SKLKG7.5DKIC&H^O-:OEYIW.G]4%'N=@A
M.7<#\K3Q133+^N,!\C#D:$2A-NU:W?[KCNK!#CSWD/15+:WJ#>+QW@9"!"@R
M7LTN4"U<8#[F<!H*!$L/Q0[4/=.XLN0[[1^JACJG;RZ?`S,8]FYU+:.1G>E^
M`:KN]3HOBF%ZY>5^4LR]E<H=\<S)!@&0>M%WKMK=@8<.6(C-9XI0M#F5`2%S
M'@4`]N?G%UQX$;=`\//'R`!99@H$7FP+AJGFDVT>)S;X_F[BX6R2P:X#=T'M
M8S!U@250),CVH$`F(K/,S8)EC6C/H%R'H6Y@>(PDD*59W`UQ\\=(`EGBRY9%
MR9^[@[[[HUR&ITL'-N?.9S$^4E]*%)`F['[.H>&([YHQ7]O8&`0`E;T_XBSX
MXHS3=A3-4382`)Y(8R.J$:XCJG]=B/FO&Z%.MBN^9HK1O8/8._)KA^ET-CT1
MA'3`D]4=EC.]ZZ;$L+[T+?9\<<;GVJFR?51]9\ZQ4&ZI=M],NFAU.SGBH=?.
MG4RN&>UJF`-6*,^=P98MCT(?+/KZ%8O<&+;GOEC)JX7M5O>$RVS8HQ>J['_9
M%KFSK9="7T3!'5QB<^IV:J\`&7../YR&ZT3G.M:8>Q"5`TPTRBC=/L;F.P[%
M?,B25[;QN3C)M#U+V[9SZJ9?'N6;)2^CXH[,$80PU6A'(QYD@W]IQ)-61?/4
M-N<;!&HQF3A8G"+'BH347W5(BMD;\H*YOM_+5QDB9!+VAX]NPYG$SQ\CD^A;
M6+9[S.94PLIB3B7#]/"SOB6R7XN*H\!ZOY804_,!E(TNK#7`']Y/>/Y&EB)U
M:NT]"W/^@Y,(*#H&I"(3F!$<*"V\B,X6]43",N=`#Q##6X(`6.7XHB'&\QLI
M=.?+1?XB]O0MH%Z8ZU4ZHO3Y0^>.@8?/<17->$7#NO4R0+4"PCP*$CGU/;"Y
M`T;=I:DKVV>*[.IZFH^*_M/J-ND/(UB/]RE^']G,]V&<BRT@W'4GP$M/<H6E
MB((!<RWPE%:+0_O*'R-<,]HK]'*5"6)P34KCJE8__]M`YN&KH-RKUHHO+@AP
MVTOZ7O.!OR'X40V_#!!_H,Y^E.1;R.TQ+GJ6<:^:^/ECU&6T,&*8E]M2GS7;
MNJPL*W]R<P*UXUJIFEXZ*'Y[(.>GA;A%BEITXJ+<J+5G#=&`=O-'N4_KCPFH
MOJCEU(8[)L(D,<M?D)IX3];@>JU#9_6I*XH:1*M`B:4^F?MXO3BKY5Y@!\E<
MI;QSUTGQ1>%RQLRP:HC#C'0^(\@H7^1)ZV)ZQ5@_X)TEW>7'NT:FOK#75%YJ
M1SYO0IZ@R-!'(<(?R&OQT`U*<[\^40=SSS9/7(,$:0IK$KRKJB&,<:^'^\J3
MS8FR=#YPO9ZK2[(7(W5,0367"5>9X_,8-/<R$-#N8>@:.7[6!<%DD)9)24JH
MB)DV9EZUON*/V8*59D#ZRH"$%45H`.4LSX,#*E3BH0$E2\*?*,",X(`\9>%/
M9"FEP0$L96$KTG3%"@JL%1R0I"PX@&/V"SROTC1H0TFK*O2\H&70@AR8*_0\
MHQD//6<T#3Y/D_#Z:%*^_OQ7.R0WG@(BY$5M07UPTN<TE?/Y?,!0--YGJ"Q-
MW>LC2V#-KR$5XH'S53"9:3Y^AU,^(5G\`Q>TS7':$GY@CEW\9W-[\X-;=$E?
M7W*Q7/(UGV0).*37G*;^>#$UXM:5;_R$SEWF$_8+:?HYB63!7=OP/.@U&\IY
MT&TW*2^#H;?).`\/*)(P@6P*SL,#JB0-?Z+B57@`Y^'HW-`$SR""(R@/<\P&
MKXNN?(7Q,FPJS<"6\(B<T["QM.`K>-&2A]EB`PI_#0_8]R`C;E((7Q8>`9.$
MK84<R5?F8!5=64=6KJTCQX.XX`@H)<.[GY9E$48]K<IJ-=C*\`B6K(Z@51)>
M!TNK%4]FK"JR\(@L#^?##<N+<,;9L"+-5[Y2)FNV5,G*SK%J+>88Q_^A(,AQ
MD!S#B&64AE70!D1.L3('HRNH9QG$=GA$GB8KZRCH"N5G)64KZZ@H"T=4QI,\
M/")/$A[^2@Z:(VPM&%N%=RYGE(;QR#,:%I>;/`?>#H\HUG8N+VFVLE*@H)65
M\K6=*Q*ZPI8%7?.@`D@Y;$O!UCRYR)(B')5%!D$7'I&7`4Q!_+S_Z?;F]N9_
MQGE.IPT*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HT-R`P(&]B:@T*/#P-"B]#
M;VYT96YT<R!;(#0X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=
M#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO
M1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@
M,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q
M.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*
M+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E
M("]086=E#0H^/@T*96YD;V)J#0H-"C0X(#`@;V)J#0H\/`T*+T9I;'1E<B`O
M1FQA=&5$96-O9&4-"B],96YG=&@@,S@Q,`T*/CX-"G-T<F5A;0T*>)S=6UF/
MX\81?A]@_D,_!4X@*>QNGH]>>Y,X0&+''F#]X)<6U9+HI4B9QXQG?WVJ^J1F
MI&:R'B9(L,".)#:;5=5U?'7PW8_W=[_<WT6;M$A(A/_4IWR3Q/J_\G1_1]45
M2EA*:*I^821CFZ)@.<FCB!1%3CIY?_>!-&JK+$YPGR3/\0_I#O=WQ_N[_1]P
M)_PW^2':Q#&'_3<Q3SC\X05CE]>+.,'K!<_P>IZG_/J&C*S3.$^!;!H16!:G
MBJ:]XD]?3-Q%GGJ"WSW<W_WQ3V);`G></,`-2@YJ4\MY"O]%,5P](4DT3\E#
M>7^W1NJ+@CP\W=]]\67S3,Y=NQO+H2?#40SD29*=?)1U>X;O73L>CO!7DJ^?
MQ:XJR7>U&/9M=R(/LCPV;=T>GHEH=J0=.]+"N@YW.W>5'$3W3`:[J)(]>:KJ
MFI3MZ2P'2:J&'*O#L7XFOR<//]_?O0=V_O$F3%,&3,.9&Z9!\)9IEB2::4U$
M-52/DIQ$]U$._8;\38`HVKUBMNT.HJD^B:%JF][07#4'8&$XDK%'ZG&9N9>`
M0$@_ED<OR:.`K0^=%`-(I!3G:A`UL-&#F$K9K\CWO_M:B6T1YJ/",D^+V'+/
M<U!(Q;VF&MGI!['?]XJ0O2BK&B0B]5<@66S-#ROUBV5&_GJ6<+Q-J<ZPW0ZB
M:G"O3AY&T(T63EV<00Z/HH8[3Z(98>MA['"-$P]NZ,C8+"$%L'(C!$:3W*E`
MEG.C]V79=CMX>OV\4LIK=:+M>B#MF6PE$=M:DJ'UYC#59F3!\7-J.TFDZ"O0
MYZ=C!9KPU([U#JAN=B`SW/_VS0OI09$E5@(L85X"^!DE,!S;7J+":^[K6FS;
M3BC^VVW?UFBE2%K3-A-[V9!O]D1,I&6ETX,%H&:T$U;!GG#K?GAK]A+0:\M?
MP39Q%(%N?P*FUF__I'PJ29I1*\F$%:F6I-SO9:F<B:C!1!J!GWO4'!2M.^<E
MSAA56YMZD67NC-/(G'&K'@\>IT<S1FJV8U\U\!V^P6F)09MN/]9&$?=5(YJR
M$NBIFUV%#A`^H2Z#0?1XOF,/2GX4W4GN0!D:(G9ZV0HTX:2V:+M+QM&<GJ3X
M*)M%9!!3%^`*+P..GU$&NU$9<2>1&&0'W!:ZW^VX.Z#S!FKKMN_1$G95/W35
M=D0C0*^GXH&VYQ,$JT&[=8$\/\H.K$>?/(%-D>$KLMM\+L/IK9">>XZ_^&QQ
MWMH=Q<G,YC^Q.'KS_5.__YOK`J"=(HJ-+D3>'#@SFO#P(F3CF;UO/CV?)'EG
MS.*M:6(3HG0H!KDR]O:/B2>\TP2PL`,]6:RY[R<1IY,K-(,3JG@IE',`A7XF
M4V"D8U15HMDWO7'^W[X6&2G'#N+<L`R4R_/,<L6Y!S-%G$^AG$*7`,WV"M$A
M$JM%=Y`747T%`1H#,Z[;M2>TU<&H`SFW?:6Q'DBEEX<3\*,^FV`N'6Y%J3P=
M6_`.($8`1>UX7I%C6R\2PO,LLNI<..S.T\CPKG#6K]4)<!D(/XM^BB"#,1SU
MX*&EQ:EG\/#`$7S=C>CAP$-)=8B]67ZN10FG^QX%I"%P+R\0T5%@?-\"8&P&
MN!T>9_&@<WJK1220N.PE8Q/GGICTQ02QML'G]Z*6+["EQ]R8W#0JN6G5$J7O
M?75HJGU5HBI<`EN($!ORI['#E&9U12`8TT!K>C0`G?<LP3UW:4SD=3^UN`/I
MJ27JZLM<:Z73$=%?9&.[JH-H)4$\@.Y*0.N`YA_;>E11T8.VE0UY&@5K;.LA
M#JB1?2P*&'BOEF&>NC2&4V_XJ6'^`D]/0#H(Y20[%86G>6WC0/YUB7FF9K+=
M#?FR[L'^^_:DT/,2G$?,>?+,(_<H<\C]M7G"R0#M$E`.:"^(PP-ZY=:4UZNE
MP(Q'W0GIK7&:5?.?"(0)Y.&6KP4#89)F4_$A6K+B2VS)`_0!@\/@L`"(2ZN*
M=&X1X<$")YOE-I.(4NI(XY0R9]%.><<._(OLWQQ!(AEILBC&<_LO@?&R6.<\
M:Q2BSNR_^"#K^JT?!4=E'[5LBID7[D&J6N&<79Q'!KE^;-JG1M=AMG+P85?N
M5F1;M9.$V]MV"RZ[F]2N+KP=ZC?ZN5Z<Y&4E`G*\QPKC)00/]`M+6`%W&1O+
M)YB.F=K,NZK]#A-,X3$F`)1&9]2**_SY,.NHOP*P`U[:1NM.[E7]"I(\ZP6O
M2*8%8##=>0G^J4/J-$U\@2XR2/TJ,XB\KPA&0##"XITMTYDB*\9FG??B-03[
M`X!X'S0PXN^[]O2BTFE1@T+/2[">%IE3],)79G/#^0U=5FC["6Q<H>Y2[.0)
M3@;916`K.B"Z:N!4AU&SH>J5>)"-"NCB`*BNDJ:^C;@8G&L_!I0`Y+8$\[F%
M\RSVO!=&ZV6CZHW&&/&`-!+OQ%D"7YI?5V(?9&48!9F]-:V<1X[897T?YG1>
M+%$13=*<Q"`]@U:52YO"NTKAG7Y`2"I!Y2&G*U5J\E@I26+AL=^0!X66+O4<
M_<$2!YRZ;"7VCBVFUK%=+20[I73UTY=5Q#D_]P'34M"0Z@P9F=ZOO>XME'=`
MC[`(]['+5G+J2^Z<FG2U:DK(&7M`J%,O!!;=R*=)W%(P5C%@\1EJ.2PSTE,F
M#9H`>H\2+*=`'].9QV4P4VI:2DMA)K?_$I@I-2VA@F^HZHQ\TOB)&4C\0W6J
MP.=C+^1I`2A%.?,D+.I/*-R0NOX7HW'A8PQ-_JM@:@&+2PJ?*!8>-D)>9:HC
MV@N\;V0'W/P6,/4O]G@A.3:Y)F[G'=`2O+NF#$W3J;<QI_S.-3J`V/YLJA>E
M@X2FTWM%/+\!+-Z2W!+\^]9/DA>3LZ?^[.<.Z]OK^K$,IEQ"!J[UPVCDJX-9
M;)"#AK'_WZ`R82Z9R./)@$>>!&!E"6R/==L#PQ*+8VW]F2#J,Q'-$G*(7*,@
M3KP]1$7NBF9OX=]N8ZV75N2QUG7@LX`,XL(B:4BN?(81<X,__U>P5FSZ'DMA
M+;?_YQU"%CX$T[(H4DCS<*'&6C1.C6?^()7I-!(4PC;/L6=LIH1,SV8_#F,G
M/W\V)B1>SI<5K]U_"2@;4Y=E*/=O<ZS,Z#C&-"V[R=S5+V/52=W4,UV-23,+
M$(+HP*1'A8!U5+@(=WX<[M]P(0N8-R]<1R0J?/78<GYS\$ZU`VS:7'V:@I[O
MIFBUVIL&R:3Z\-(3((-?47L?KIM(P#;5E^`]=U`W2[U[YWE^LV8XB(_`?-TV
MV`@&RHP:]*YU^;HW>!0[U0?$+MD*Y1'0A)M26":^\=3AW<CC/9[99C"0K<YP
MZ*>Q?CK'AX3Y>3PY+:5@%_`D^Y<5)UMG"HE"H"#^\O##1`(KE':U2&N,^T(Y
MBR:%\LN$YZ4FN!$U09KQM$5U>,6H,@-L[@U'-?,*[&YE7<&=;BQ6==GZ<;^'
M\(_F4(K^B+,_1Q0\PN+1>(`E&/<U\XCY=F@:O^B#F_ZWE!J7M-NZ.I@+=IKW
M:UE*)01.5X1%4:XGPU0\0@N^$I,4EMG)LT0&S=P(JI$:JP!X4X\[FT/Z(:@E
MI.`KYVGB9URXG7>#7*.4>I;K2D\3&]M2.6<X3(U/U?+]6%_.LI[%LPX6*IVY
MHE`^C1S5@.>DV_JX2&V-N;KY9<LDLL@.?)H.<'-,@EAP^DWNX:@'DZQ_N97-
MH17(J=1Q`9:LR#=-N5'J]'W[#.?Y=[D3==E>/*`$OZE!I.HZ+\&YJP[39()I
M;5%QJJP7AX`Q'7CIC]595VBF(5#8"'>)W6TT7)FIF1:DVIM*3@DF]GI:U@Y*
M58VV#G0+2PC!%Y;SV">Z#E+BB0*Y/TL,Y>`*$)J`-6^?-;E.6]5H]W0RP(E)
MLVSG&?=J^%&4$##M8!2RKD[=3I!*_[X`8JH31%N+79>0@"\NQU$R,0"3YFK(
MI^L5V@W58,FZ^"-+/>*"UV0#LBFEA3.8Q:$GKT5U6B2580N7C=F296/FWR3@
M\43H-NI\8\SAY?L-1,^>34(E0@\;DZ[!<JP[ZRBC@BS.ZXJJE]-8A-'58%F+
M0E[`TR5>IO`5UGA298P<X-A?'^XW.%K3>-7SG)VOJ92UK<P8-L8?745[L:^:
MO#>9C1*.LDDME5U+VK(<]:3:,J_4^!EX]7*-G32WK2UT`:48X<AVE9THT_/O
MKH8*3JC\B*.2X&Y4(45EP>TP?=7BQJFK^;3N-"DM"0AJY\'>-JHQ;F7BSV;E
M$C+P)==)`Y<KCXPR>`+B^A84LE,(V#A&X&YL+OF;&,9KL*7.&>[=BZJ^>HL2
MR<JEFR_'<:M^\KPEI.#G[7DR&<S+3-'U@!`"BV,3DFNTTMZH_1ZX5#F)ZC8I
M&5FC!Q4>D&T,UU@Q4W+<5?U9OZH"7QNL0NJ91&-['OJ^?;$DC3V_BTS;TX6G
M[>GU:7L,3#SC&<F*B'"UJ[]=O:"(D2N.]`)V8P&%2!!<$'$<HKJ]@!8\8<$%
M.>?!1]",1U%P0<K2\",2!@<<6A"S-,P%9S-<,):%B:3XGD!H001;A!84+`DR
MD3,`S('K&7CUT/44TNW0]81F1>AZ3)/@=4[#]#$:!:_3*+M]_1>S)-&J!#GD
M:S,JX!"<&='7[U0F#@DE9G`3QU5L]>E!^5MP2%^UV!0;+L=G]3;?_QFW?$*S
M_BL2M$EPVPS^Z*ZX^UK?W_W@B>:W:4ZG-%^:/F)D&EG(S!([<?O:R:!R%)_Y
M#$H</#)/8/REG\F#>K,NTJ#>KFD1!XUO#3XHO"#&R!1:D.!,>6A!6A3A1V1%
M$EZ0YT68S2*/@_:QQJ)?T$+7%+SIC"Q9$8<YI3Q/@W:VIG$>]NEK;$?/K$@+
M.L-M5LS)`\01](B@.47"@RL@O9GAEM$LG=F#97F8#@BT<W3$63Y#1Y+EX=-G
M:<;#4F=9%HX1:Y9GX5"X9L7<"A[!8\(KX'##O'"6\SB\@N.@?W"%FO</KD@`
MX<RL*.9X28N9D^/9G,WQ/.<SO!1Y&&"LP17'83\;4QS""JX`/!>61\P!\857
MQ#2,=-9Q0F<\?ISBRT[!%9D-BS=7Y!&;65%$:?@I213-^*`$`W9X!8MFXE_"
M89/PBIA&,W0D<R>7I)3.4)K19(;2?.[DDH+.>,LTFM,@('3F7%(VI\DIA\1C
M9D61S,3\.`O(%*#-^Q_O[^[O_@GL8-ET#0IE;F1S=')E86T-"@T*96YD;V)J
M#0H-"C0Y(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@-3`@,"!2(%T-"B]-961I
M84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U
M<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R
M,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B
M8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^
M/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*
M+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-3`@
M,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`T,38S
M#0H^/@T*<W1R96%M#0IXG+U;67/CQA%^5Y7^`YY2FY2H8&9P/F:]:\>I.':\
M2MD/>0&!(0DO#AJ'9/G7I[OG`B5J6+4A7'N(`H:#Z6_Z^+I[\/[GVYM?;V_"
M^R2/@Q#_T*?L/H[4?V5[>\/H#@MX$K"$KO"`Y_=YSK,@"^%.&+%@D+<W/P4=
MS95&,4X49QG^"(;][<WA]F;W%YP*_RPNA/=1).`!]Y&(!?P0.>>G]_,HQONY
M2/%^EB7B_(0\V"0B2Y(@8V$`PZ*$UK0C`=7-V-X4B5OP^X?;F[]^76S+-&`B
M>(`O$!`TJ1&=<902[H+P>7H?BX@'#[_?WFS">Y;D>?#P='OS[B<9/-5-$W12
M5L'4!_*W8]%503\/\+$>I[K;_SEX^.7VYB,\\=]761</([>P\#[,8EA+2>L2
M(M;K"MIB^"SQ\0&N9RP:.<)C1EA8*<?[+UH3J8('*ZZ6].Z_/`JO_H!D\8#@
M2V=_"]($%3I,-**,YY%%-!="[_2A;F"S97`H'B5,7\IN:I[UADNUY>=`W\U=
M.=5]-]X%LB@/0;^CH1^[WY];&;R?Q[J3(]Q\7_<_'(JA+>PUF@0N?^SDL'^^
MNM"P9WF6&YF3*#,R1SSA2F:[DA,=+_L.9)SE0M^G@VSQ5Q"PE@`/2HC#9'ML
MB@F^5G3=7#3!`+^,",%^Z)^F`TD(7QOG$K1RW,T-(*I`Q"F##\]%59?!#S#'
MKA_:52!(N8$@BF,+09C&"H('61ZZONGWS_?!5_,PT*[?H1X,$A9['&I8;PV?
M^HZDKFI0C<GL?0_6AO^3-/_I:H3BTT0@:#$1`41J*.!;3S5@<ASZ'8`!*@.`
MJ7F*/3Q6Z<,:$*#<"@+!%YH/DQ($%?BQH=[.4S^,5I@:-G?HBDDM4PES!U?+
M9J[0`*8GI2A#WS0@-'Q-UOL.=GH[UE4-D($7"CXLP#K*_@@&5@Q*>U!S^F<I
ME=1X]5C4\`$'%\,ZUB`R@T/N/$"4,.U3C\T\@DQM6]/NC+CE:G\`$-3;SY)V
ML.[P0CT$!8S;=V@T<AAJ@(^$_DKOMJQ>[*Z3<5N,DFP%306>>)3=2%`'M(8U
M9.=,R\Y#X3Q!DFCO]_^+_6&I14<(0P<4$I2]FDN0?C?T;3"KW89I.@Q6$IP.
MZH(=1%Y5#H\U>(M54(#0:IQ!E#I+P,^(`K@JD'.H8)^&B:3Z'I;7[W:PH$$M
MS^EM!8ZPZ8]TM8:KLH5M?A$F`!+8Y3TXE**9#OV\/Z!GJ?K@*(>Z!]]7H$>4
MW1YT).CZ[MHRIXQ9H7,.;B]DQ''>;:[_I'@!;Q@K=-\9N-;8S2Q+]>,$<WXM
M3O"STNENG)NI`.,#_$L5MT?P894$@ZMPMXQG!IV]H_@&JCU.J*=*VT&#Y0Y\
MV[0*I<J2=%5&9>=?@U!E<6B]*3!TYTVU1_E.Q3\*D0`N4("#0K\<9#'B7I#C
MFVKT>W>GUV$+CN`?QGF0HPF\Y3Q.?6O,$%RJ'"`P2=C!O@4.`3^K6O.PMG@&
M<7Z=(?JLHG?"<',NF*,4N=$[T!Y0)7`//3CX%@*C(^9X`X71@0$$<;Y"*QJH
M7=&AER@-&UDR+0<D^-=N3Y$8HC5"V8\DOR&@[A%K0,`<F0Z=(\V$)I9+#UCL
M=HH%F06?NLA6@F.LP-4^D+G1**)/N(=HOVB*1:4V%W?\-XR6Z)N_==>)L!&)
M!3V"Z1?CU^,3:6[8-6<9LWJ0A9I7F94&6UD6\TC)!=(JQ8FUPLLW6.5]`*EG
MT8P](7%`53X9-$BT$-`/X`V/2K'@4E.4\L3!J<%K")]97BW$,I1JX5^NKT<A
M%PP!M'Q"0`"7^^!3W=:P2TB\ZYV":0$.$/&ZZ$`P4&ZG-POO?N*Y7ZK"'B8"
MHD)>!95FMPH:B:78E,5J-!+!%!H8]&595_+5SA?5HP2N@8[/K9SV72W_4.\/
M\KS#T!(A1:&QX"U*8I3F`94:HN8D'E=/RB&M`4&4G6.8,7Y660;2*+1G3#&4
MC^R!!B$+QI2HGHHM*@#*"#B@UG?]I++Q<<;OUJC0D&Y7H\HICT?PEX!5@S*K
M8*T@62%4ISQ;-53;^=<(U<@"#>WEW.7`7-OJMV1SB]+6,KLE>KO4V$41!#C5
M8XU$F52W+##X[$!;.[+'>4"KU:8.3MZ1*:61SKV33JJ'@FZLH)Q);HE_[NP3
ME%/'*VUE`U#Z;@:']#<PP#N=![^P):D-<VMJ0R:DG3-1%_B-/CNAC6.R<L,U
MO8XU$$@-669Q;@N*$3.%3BOZU_,`<@]W`5XXYXY'C"TD='=.YKNE]6Y!?[8-
M>;VV@-@'_S29(VX3-)A#H?FZB>Q"KFUE:19;%+[<S#P^(HG7I?-V_B];O+\4
MGD2*SH-2A"RU)L*33+/:?_8C5?8^RV?,7L>^ZV#KRGYNJN``.D/[NM4%Q>OO
M'BZ1A^OB:^9?PP<GH4D:6,H=612&+_VD2F/H`(#Q.P+74QZ*=<BNK(]8BI/M
M%K,@3?/;HBOVJO1`U1.*DC5$2\6\E1-K]-X]D1.V%986'C8I!C)BL7,%MQ-G
M)E$(TS!S?0Q3=:_;(Q9&<9&ZMJRJ*$JX?ON++(D_OF#[0(2'N;:5^$&B9\'?
M?IV+!J27)T@X=9VH\D*UYMT\07H9_/BG#\%3/WQ6(6F["C6*$UN&SURA(HHB
M4WP;0)2R:&QVJ,KEE`*X++#JSQ(B^9LL9\1HJ0HG$JNRNQHG3\PT@(2APVCG
M:E-;(-M8X5\#AMBF#"%S')GGEB.;/7#]`DK^)JK1^#;[;2NP2+C,F91-JY+1
MM*]`]W;!)_>][U71[VX5((3)%L(\3Q;9@NY)?-/(K@O^):LGD![^?E<,L'(>
MALG=LFA"1!J3S*%&YF_%'DVYM9M;.?2JJ`U,I3;%]K*H)-9,B.Y-BOB,DAY2
M=R-,/E,AA:+X&N(S6X>/Q(*.1EK\!K)!%4Z*;=W4TS.54X#Q]^@-"U"-XZ18
MA1Q:L)*OB[I!4\8L4*G*0D_.^X$G"EM'XAI4[B.\CO,PSBJS:IIBVP^%PF$=
M3AJ'MB0?.4)F^)BN+AMR:4OD/6:R**SI6]7KM'NCC*T:;.W\:P3;*+%T/TY<
ML-5D'Q-F='S8PG`IC,E)5-GP1<$),W2DP4A^2]*ENJMF+&>X!A9XEN)X;,"1
M:\:KXK;>-[V?V#4Y#.1L<5M74"MJ;.C"C.OYBCPS/8ZEXNBBVULHO/24G7Q:
M.E37#73^]\YT>(S$)IZ?172[BH.)A"U-N_(L,X5I<V[C;+PD1$"PA><I2@O&
MDCQAG[2W3:#I4(\+N10M1G)3JW:JZH=3>:OHGN],V%F/+Z>0\1H<5LEV(K8N
M&[?SK^$@1&[9.$M<O2[-,N<B5+FU'TQ;LJO[12_0F8BJ8]KT]O1K=CP$5E4/
M@1BETEX=E@?G+I"<8RZLJJ'P\W>Y2O5>I(:4\]AZ1PI'U`:?MPTU5#1G(!I*
MK--T=2M%I:RDUUXBSU.[1D670<DXO_9C!$AL'G-]+1-AM`":B6S1)C&^>*DA
M5W]^\L>`F*X*8KH$,<R8I8LB%KFAB\996QM317';4.M-OK@,0LY.E;.&M`/\
MM<2C7O4J/0(ZNZ</8RVJL-ST""C8MOVLPJ7S%V4/^3F>#X`(\UC+)W5("Y?;
MN31P4;=3)3LL)LR=\2U`0QZQ^P#$'Y*F29X>.@&_=CK<.K,U8(AL%L@3=[(Q
M3?1V+E+;U1P,6ZQC1=N`V&(?<WW;8"Q?@OF'.QB6_3$@9JN"F)V`F''7N1)<
MDX'7IOA6C=NDG_U@LL^3:NG5\[0X"Z^`C8?D"<Y7)7EV_E5(7FB;LEFT*+NE
MNN3Z@ZMB+PX=5/4XS$=5?U#]2:P!W`=_KP=3@8)-5@6HDWQ(I4[8\:X;W2Q2
MC1&<$YN\NIEM.D(K'<W@F:VNQ-&RNJ*S7]!1K(=@^0AK'KK=<O6%"&%7LN[!
M,R;2A<P<:8]EM.8DACHMM#QE`_$2I9_J5G%O^$E&39UW?1[OK1,&@6YB;9?G
MN)>JHI+J-?8VM24C$;LS5WG"7IUXHT15>L^[J4X[=0@&B0=X[TYJS/#5%FF^
M/N4;H.\S)T!=O:`8]8E&<WMY4V>Y:R`1VPI/$KDDGR>Z6V6/:2HJN`0&#1)]
M-H1%H(YX3)>.9??V3'*%90E5%]7G0!568]\JKT_PZ"FI0#?HX47U6(_]\`QT
M:D"/TM+!7YI^#0R$J?1PSES<RH0._FI-:.RT&92IXO)AY3O(\"952\1RLCK@
MJS>WA_1OKRN?H/8S]5X>E<^@L@>02:S.XQ'8>J20J"!3!1+E#\TK!:!,G<31
MZA#]&BAP6^Q)W$&D6!@*M)4E[ILNHF*!YGF5[B0/UZV'V/G7Z/ZR3+\'E=S'
M^+:`?@V**O5T0F19$`,8)SR(AI`NJXFF&5P,[<OJO5:S58"G`LZ:[R69^5=Y
M+2FR%8(L7QQ,,9'K>]<.5!:E?#F&(/1-YG#L`NI^2\3S6$SVG1*;SMGT3V_A
MH@&FG`4>3VP:N(,O\QASH3[32GZ<<7>&TIW(!XJ6O*Y6DRRVH*X.:+]XZ<9U
MM$I,I-6;">IXDPYM!@)ZM\?I\5G!7;<-RP0Z;JP!`N,6A'`!@F%L-HG'T%K*
MUX9'+R8`,.;%+-TBQ"!>/4+0`S:C"MM-\411F4*9>6?'0F4P,L`@#G!]PO.S
M`YX5&$U;8Y6WE*P;SQUM%4Q3F[%H\8C:1"U>U<,UPKQ2@SNM]=WSHO-)05MV
M)"Q%+'R)!5LY14>2`L@M:96Q#76TNA[.P;!.:21US'W![D+SGI:*KZ]VS?!-
M*P.>P]OB<;QYI,!\IQO%!;ZD`M@`<.5G!&Z8[>DM=0B;!E9RIP]XG?<&"H*K
MY[)IP@P`+SPM!M<H%7&0YI#4T:SNZ_3",'(AP(D&\#<&<)%'W@%,0!#T#0A%
M'/H&L%P([R-8QO/,.R#EB?\1"8CA'1#SQ"L%B_@%*01/_(OD//8/P!'>`2%V
MO#T#<HY'8M^^GR$9\MQ/D0][[B<L37WW8Q9[[T?,OS[!0N]]'J;>^Q`%WE[_
MKWI(K*9@T1D[RP/TF]K.V.M7N5TI.M8E=3R+8KI?#Q1QP$'@JXS((D[,44WS
MXS<XY1/:_3]P0?<Q3IO"#Y7QVU^;VYM/9M%:N<\N.5DN^=0UH&DG]IV;V-0:
M7[,]W!H/*MY'P#\#BGX"CUZZ(>'5B@V^1^B[S_/$/T#DGGW'`9#J^P?$>>Y_
M1)+[57N3(@_U#<BRF/EAR/R>=L-"?.O>.X+ED5]0QK/4ZP,VC,K@WA%1=@$M
M%N.+L]X1`.B%$6G.O=YN`]0_]CK,#8-M]4N++L4_!V>PM?X1/+VP#B[PKG=$
ME&;^W>=Q>L&.>)+&?OW@:1I=&)%=')&G_BBP$6%Z09,%),Y>3[X1'$]_>D>(
M)/1KD(@XO_"4*+\D"W@&_\Z)Y)+-B33SLX\-F%Q\`;$<&(C?QX7,3Z,V>);'
MCT<$V:0?4\@LT@OKB)B?2FVB^$*<WT0)\]/2392&?K*TP1<*+SPE#R_XH#C$
MD.\=P<+,CT=,R:EW!&1K%]817=JY.,:^IG=$`B37/R*]M'-QQBYXRSB_I$%@
MM1?V)6&7-#GA8>2WRH3G?K8-65?JP12(R\>?;V]N;_X'](M><PT*96YD<W1R
M96%M#0H-"F5N9&]B:@T*#0HU,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#4R
M(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X
M-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P
M(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@
M,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B
M8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G
M94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*
M96YD;V)J#0H-"C4R(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-
M"B],96YG=&@@,SDY-0T*/CX-"G-T<F5A;0T*>)RU6UF3X[81?I^J^0\H/SDI
M22$(GH]V;%=2E7B=\J3LA[Q`%"3!2Y%:'C,K__IT-PY2<T#Q9E@^5CN$P.ZO
MKZ\;F&]_O;_[='\7;;(R91'^0Y^*39J8_U6G^SM.3SB+,\8S^DG,BFQ3EG'!
MBBAB99&P3MW?_<(:VBI/4MPG+0K\@W6'^[OC_=W^S[@3_C/[0;1)$@'[;Q*1
M"OA#E'%\_;Q,4GQ>BAR?%T4F7M\P9NLL+F*0G4<,EB49R;0G_<Q#[A^*;!+X
MVX?[N[_\(+<5:?<`7R`<:%.G>0;_BP"-!]#]Z__$2?0G]O#;_=WW\-5__:$7
MB-`+1$XO6$>;2`"$#Q5]CGD*GY_@Q7]OV(=J:+>J8W$492OVI.#?3K%#)YM!
M[=B_-S]OV%D.JAE8ON)QO!(B6K&O_J8/Q_>66(!UO<AEO$FBB+.'WT',];N_
MJHRG5P$X9>;!$7E>&'`>CET['H[G<6`_5YU2C6X.K-VS[S^?.]7W@,YW/W[#
M_J&WG>RTZIENV`^ZEB?`JAU[]L/8'/3J*_;>LG,4/8ZLZ)PG^21ZQHWHVPL;
MCLI8[R=C/=GLV$,G=^HDNX_LPWZO*[5A#T?=._N2S=F3KFNF/I]Q/>YA'YZ[
M=E#5H-N&[=N.GGQWD3M=L9]J.<"/3NQ!5<>FK=O#A5ZV[5JY8U4M]:E?!H1(
M.!!2SAT("3PB#*KV475H,LF:\80N#K9K0?`.++4;^Z'3LJXO\-Y:/:+F>S08
M:2?/YUI7$K4ELU:JKL>Z[4%;-1PE*$D:FLT^J@M#3-70;]@OBAW;>L<2IOM^
MO`Z@GKZT`!)ED7EOP(3CO$'8*(>D:J5!`6(&:K=/\#<-(=XUI*:LG9`K^'%5
MCSM$SAH/5!X8P?F_V#V-C=+X^?H->UU;&98`(2N]-Y0^))(8MB(0SJHAG:P_
M7YGXZ:BK(^:^K:JU>E3H[8]ZIZP/_W'?UV!L^-9NK*S5J_9T4ET%'K>([H"Y
MU3TKIT@0PF:RN;(;]C<P/MAR=17>X-P&"PB2K49]G3X@.B0#2'!SSVC'[OE7
M5TQBX5"-ZBBNQJ92W2`A?(PG/+8U((N[U>KS(BB@OQL4\E),**`W(`JU.D@3
MN'M9#2-\_C2JWH("@4N9;ZN8W-:*#:TSN]&U:\^0Y`?90<*`V@=FW7?M"924
MXW!L._T[>/;8@\=@YM4=.(WL!JP*;0-8P&X(MOI,B%$\X:Y+@,`+"T(<93X7
M)%EA<\%<$6]DE!.-1S$.BH`2C[+6)E95`QY>*4+%)3+,D;!>[?<8%X^JQA0(
MP0[_881#RL!*PWH%==.F14P%6%):"KT+19+;;@D<D#L89RA%XG%(T_)9==A"
M%B=C7*/1[&8!W&-NV"EU0MD)0!!\%DCJLP8_PE*#SC4.8Z=>S3,G>4$'JXX0
M(*HYV&2(/UT`@:)(G"?$T904"DL1FG:`+?NQ'K#"V?I@#;)A'P`0K]6\?,GF
M<JTA8=-N*=!1$]P7=.Q'9!@:%H"M31JED`+``!6JG#:$SAU$(RR%%RV!0I;[
MLC!1A-2FA!=V!Z<DH78@9]V>J0A"QE(&!^L0&^!V'6IP:CNU<LJ@\D`L%!8:
MH[;=A/7Z!+RPHZBI;4&$5/C\Q4MHGSJ>&',^%<4\MD5QIWI]@`0-1!?YC$_J
MX`ISZ38,&@6YV]D\/U/8NS(J`#D>LP;L,-L*R@8\FOV=OK>7NK8YE@HM\.4G
M#8&([K4$#D+XK#@K#2E^-MF`;$QFD3MD@_(`:G^I)&\U?2@)%_]_S_?F_MFT
M_[O#"`UE7GJBF<W"*4ZL._T(L0_^0$3[6=&<$0KH.(!F'306E*D*S%C6AGU3
M56V'1*.^K*B<M`P=54-*D40Y.D]6\$6/T(!ARS5_X0)>E.>>8A83STZ2Q*;4
M><A0*]UA81S/P!OG]?`YGT0-JK;9:TP;VE*4N2H:*_!)&FBPPY"8/>1'U>".
M8Z<'*+]*]I"4^^?$90D8LHEM9L7D!67YDF)<B?YP5,"0O*2N6K@<``A]&C%Y
MO(+/%9^@A$*]5PBE7JF/B,82""2>:69(O3W?]@"\2AQG$B+%PCQ+%`2H47OE
M`6A0>>B`<)@"BYE1`6]N+PH]JVKK6F[;3@YMY]J+!BNYI-K](Y(2@*=6/2Q>
M0OW8<4P.5O?JTS@+]7]3U+:;2TH.``P#$L9.]Q7TURH$V8HTA:B:L0Q'U<&G
M<#JS'['QF,-O_&8)##CW%66:K"59::</GOJ^53G?H`KCMD=PS&@"XD%#2;79
M\54_:BV!T=C+^,!XTH#E@7JOJ@(W6"@.LM)3S%3X3`"[%C-Z==T)+%!2L_P=
MQJB!DNKW_S+A\S"$J1_1\FB:0O(BY6Y$.RB@6*9A12^`V+XP2!'Z8#R@:L=Z
M!S6A.Y'';\<>FK!^(:CMR'0QJ-W^2["7;!J:SH8DJ9N2?:`R[,<T_6@BQT0I
MC0&QI8=^GC5*VS'B'O/W\Q;IE5D!\)2KJ<`*$AB8JE.R.IJ^$4U:J:97=MRV
M1+1.\])<S.8CPC9#3Y994%TRX\'6U)Y.'61'#5RP48:VT>0WVH:F?2L[_*'Q
MA^T;<7)0ZX_*S$5PV>K5;MFWZ`M@D18S)CMA$<<VZG",1>D4/T!+*`^F%)-M
M;`V")'M$#48H8?IW9:"Z,1QLNVFL`)_[2S\H-V%%7%RK:%B<6;>$^GY8&HL9
MD2]YZOI"*D?@!%XI'&Z!&^L!2AIZ,U*YUZSVUDS!56^/&GP?]Z49\[S?O)A3
M*,IJC5*[A6I7.LU,XUDT.`3L1$.ZL#1C`11X"N3+(CDV%?&B.=;OOT2.3;EG
MQDDTM4A$D<R9VGPVBE$D^QXJF@\L&BL2?\3(![SUFWTDNF8[@OO9":RE_E>$
M:WCQ/FO8!3PJ*?WH-8F][FED6;&+@V?)L+%G9`8!&V4OTJPM-50=IL@SDU5#
M`'0#G>"</\+/>QMV.PV9M">ZN`<0&GF@SF(1$`K/BWDR]09Y;E&@8T4BK!7R
M&1"K;1I5(RH[M;=G-*!^K^I'+"](8ON!"F3KTHX]EH+\:6;3UP<2L_90O\J=
M;$UV6R\!0N9X,8^XY\4B<^<QI@UX-D:<G/3C[.S-23GZZ;'K>:PCZ^:WL:$A
M_*0W]@T#K>OP0&MO#[B,H\R']MNZK3XN-2=($C]ZG8YG1<[MF$!N-36ZR`$,
M#JX+6LUX&!96]!GPA]J7Q)5M>E&=J=Y@5,DG)"K@*?-`V,D3CO-F6%(-DS;P
ML*K9\%HL*D0TS1^+6;=HZ<;,RKIWU!.ZV97C&ELT)5BU,_7P##_R6N'DUOA"
MVY`3H#]-=-(6KED>I*SQ2A=M=S%!M@0*W!-0D4X>4=KIH9<8N1!L+B$UD&B8
MR%9,[^E!75.*IVQ)APF$D77M!OY$]@J>5,N+(>W&9ZY<RC1.$!2UHIHS``D[
M#PB!Z\/G<_H%D!#3(#6-I@%2%-GIP4E!2=OU<[JX8=]A?C3U@?H%^=1#F-.1
MA=0U%I/)AE?YT@-K4'*',*/UC3DRU(P\PG;FN,^]^[UI"-ZQ<1A\.0\)D"B1
M9XN2*+__$B1*I(Z=1WGDSRY]GV:KACF_'^3GMFE/T&Y`,NM[FI`/MM+_E;,G
MB1TL^/*)3F9Q-G"P*['^0J8X'XECT-^,UVT0,_9/3"*G=@=A\/9+E@B-Q//R
M(ID-V=W!K0L-#52APFFQ/TT'=8^0*2`@#K+1_<D?Z'?*B6T.IR40(BB"'5UZ
M4LUH<FA_5I5)CJ[E@6>D=`^9%U*+*43FTD0W+'250\2>0!?Q5"F2V/,G2-K>
MPB@,J$V"4OCCX=O*\6A;$R&*:9(!ZYTKH!=09W<$+@3ITM[4&,RUL1.B:#OT
M%_C,7DMH+X%!Y(ETG$QG]T5B,7`&WK"?46TKT+D%$V/6<H*28\Q%->GO%8?P
M#W`U,(??:'R\=_VM&^(\->9NA*5O%":_^$M#BXS:X]+3:;S\ZGH*[NZT;"7>
M0T1GP`/[1UF/5[XQW6W3JC:\",_DK2OC=W#R/O:]N0:E[54(.Z2W9]Y[1<]E
MW:_LH`**"W"4XS-\GAR*2^"0>T8MIMM=HG`XV*-G=T9`_,=/2/W--9I(8)A`
M.1Q-G+@;7_"Q/_KR"`70F!=H(E[]T#M[4D6/5G0>J8:A5A,6\_=AU5;OC4(.
MW8.#8=G;L7DR!SR*;`Q^/5-Q"1.GTTV-B1TFD1N$FX9HQO:><6(:6YJA)3#[
M#K+!>PL9Y]Q+N:P%XCR=XQ$EL_[)G3(:5D>$K>ND;5Y6U!IT[04(K+U6LJ53
M]LJ`U`]`;E]284P,-I4NU`QB,#E.8^]C?8WW?AZUZ4@6X("QG?<OQ0']_DMP
MP'@VK)_=XX-P,-:'NK-K*2F90\]3V^C!7DX]CUMP#G>H2F?M_NJSO\W)<!HB
M!W/^3%:WMZ(O=MP_S=^F212R1-LB+=4J\VDRG\^NK0EW94GMP9L'T\';U&SK
MG@HH;P='7GF\U(V#)W/+P`VY@[K:%YN!VD2IESJMX=-]9LP&OEF.+`X@[H4]
MZK:6>%O+V.^U:9<?"IDJ/1NNXW2DTF<"SLR<9K<;F:S,!'4^.C+W?^>U=78)
M<J&K6WR:TQ?32462N2F2M:"Y$/-B)O3'YJ%O#">?#>K0R]IQJ&S"1+TG*99`
M8':O.4Y>GMN1XL^N_5A*-AOR`"9X`7OGHGTO'UNZDOC:&OHE"(87^X;C!8'0
M+;''09_4LUQM*C>TPWD)G2LI-VE!OU"%R1\,1@OB-Q:(!)0,+8BQ`PHM`%[(
M@PLBD0=?P4LARN""0D3!5X!YBBBX(!-14`MP]K`6/!%16$B!][!""^(X"]J"
M\[@,:Q$A-0DL*.,DJ$01IT$1\Y@7H><9+X//4QZ6+\'?F0H\%WA7-NAK/`QQ
ME+\MWR<+LGD#3UY/!_R-=(#UG_M[#+%)B*\2'))#?.%+(.]$K@S;=\3I\[`O
M@ZZ\YF4<]+-U7(H@S&M1QN$%29F&7Y&6/+P@*Z"\A!;DF+=#"XHB%<$%95&&
M7\&C,@KKR7D1!SUNS>,BG&'77!0WP.))$4Y?:PYXWEB1%44P-M<\+_D-QP'`
M;FA;YN%JL(ZC/`G+$?/\AAPQ],!A.6*1)V'CQT!4;D1!FO.P?\19'MU8D=]<
M4>3B5C3F-QQ91'D9K*!K`?4KC+J(TRSL04(@SPNO*&_H(I+RAN5$>BOF1):'
MJ\Q:Y'C9/K@"DD>P$D**P]]'".:X*+J!>L)Y%,8T`784EB,1P`O"*Q*\GAA<
MD499.**2%'^Q/[@"'/G&6XKH1@Y*RBC,']9I%(49RCKE49@EK5-(,6$Y4G'+
M<FD28@JT(L6S\^"*[);E,,&$44^+6QX$B?^&7;+HEB=G41FFIFL@=F'F!;U4
M%L`4>,GWO][?W=_]%UZF!=(-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*-3,@
M,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`U-"`P(%(@70T*+TUE9&EA0F]X(%L@
M,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\
M#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-
M"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@
M,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O
M8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)
M(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HU-"`P(&]B:@T*
M/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#,Y,38-"CX^#0IS
M=')E86T-"GB<M5M+D^.V$;Y/U?P''GS8I"2%`,%7<O(Z=N*D$B>[D[(/OE`D
M-(*'(F0^1BO_^G0W")"CU4"NK6%MV4.)((AN='_]=3?T_J?[NU_O[\)-DL=!
MB/_H*MO$PORO/-S?,;K#`IX$+*%O>""R39[S+,A"N!-R'K3R_N['H*&Y4A'C
M1'&6X9^@?;R_V]_?[?Z(4^&_V1?A1H@(7K`141S!GRC'N>;W<Q'C_3Q*\7Z6
M)='U"7FP3E@F6)"Q,(!A(J$U[4A`<S-R-Z-D6O#[A_N[/WU7;,LT8%'P``^0
M(FA2*SKC(*6`NR!\GFQ"$<;!PV_W=^MPPP2#Z]/]W;L?97`HSL%6!MT@JV"G
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MLJAA?QY;50XU"%/4L%E5<-P7[:$HY=#C`"M]MPE^W"M0R@GM1S4]_/>Y1X)\
M'4S4E'(5J)X,K=%]L!OJ^AR4^EFV9`A'W8/D"F:W3X)%?+DW^S01Q]8B,D!8
M:Q$"\)%4\7UC5][K0&])JF[8[52IS':-XIC%%X\R*'K04E"4I3P:*REUU^/.
M3R8$4X%FP-IAZ"/,"/<GB3_765D7ZM#!/`/XX[$%TUC(*J+,ZD)DDW>$63J:
M!;KO7FUAX]!&2WTXR+:$-:O?K#L[:[`6#-"\/8/SDP)@9TM=U\46_5^WL*/?
M[]!>T`,<BB,>C`Y([D@3D%&,4Z_HTZ2>)33!V:@)'H6YTT2&UX03M!7R4REA
M>81<ND?OZ#H)CK!`T,E#MFC,<?-_F3;]P3S+!$V^1KA)8JM.F#6V3M;+MB$;
M`BT.32N-QX`Y2/78!.70`CB6YV!7@P$,--#Z0U&!WW42X*/8[="C<#M@`D"L
M178"N,ZB.^'F7R+X9R*UN)]RY^%1)+)K&X&AJD,D@PC86^\\@AM^4H>B1Y7G
MX<\AT$^,"CFCRS&2-[(?'P>\Y$@Y<`Q<Q"O<G"-LE`)\`(;V`XQ^DNCR\U>;
MD-DMX=M9%#J42YTQVM"'4(3@]NW0`G@!D/^O@16M@K]K"-__U!C.\?9_I#ZB
M=!_D<=C6JD2YO]FKIB`YOV\J51C1U#6-MM*0HW[?ZN%Q?S&H4EW?JNV`"+F(
M`EAD%9#/0QX?C0`E`!E5"U1.8US6IP9VOQNVG0*Y6B)GP./JH2).`U)^W:FB
MF4:<5Z2&2K7HD!#M9%.]M2`B94Z2G$.40@2#).'=^NW?%,]TQB.66IW%82Z,
MSB!.08"JBP9LEBCOL3@C>>M0^H'TA:P00UJ'ZJMDHP]@+NA6"VQQFCN.GTT4
M7XP,7SE$A:TTM`0V'&U]\W$35!BA*38W8YAOB(^,GKT=.M7(SHA4!,UPV")I
MVR$5ZI$)P9TQI+?RUP%,H"*^4Y@@KL%;'D<`?[F.)=20.KJ?17Q&[BS/?4WT
MKP'S6K3N^NRDD9^.NC/"E/#$HYP+<$8R0-\&0&WD:`0CTA%U?`T+D%`;6UE$
M`XDC^A%S@,_SF(\:F+8#^#OF(210-<E%_!3W]RN>K=)0T(J_8LDJS6**"&@C
M9PEJ0R^')_\J2TDV$;&5'_K?.GHF&7,"?WGX],3^5/!%8[^;?XG8G_)XROO9
ME/N.EO#=G%IY#'M?/$N;I1Z+KJ?=Q3QN_&XW0*8H@0"@63U?\+)9+G6$K))R
MB".DQG;DF`PMX0BARVTR-@MZ8LSS9GG+A,P@4JTQQYU@"K"A[O1J#@&?L=0+
MC:%R2&N8%AJV&LA1)PVI90?O:TI*_G2G*)5:0`5);I,:%O/)`)B8PO[(FPGK
MC[(=K:'H$/S@7F=T\A(KD>5`:(/4ET#LH!M%S.6*6D`ZL(W.FLS*V@QA;8$)
M'V@#ZT2[1>1/A8WA?,)"D5DLG"*;1*!&N-974A#=GHJVPK#8MP5:#&:V1YN2
MV"];69,)P10(>6H''/&SN6!LT\%P>I92WUZ5ZD@/`E'8+Z*%.'5,)INL(!\S
MVUVM3R845)I*,WM9/4K#Y\B(&SVNOR>^0P2'QKP$`$.32<#:%0<F.P>JT$M#
MD+#8!/+K6E4D^)QG(@,%>UA"#<)E`3Q/)V>P&;[Q^ZW63\9<@<F"E5KN;LI;
MQALN=W61HG/"PT4CCYM_B<B3A-'5BG,TTK`'L!1U<-`'!E$-/5'3UK+3%M.E
M;=&"4;3@H.8ST(RB?=3(.(TC[@+PVU:WJCL`;4-*4MC2;4!5,Q@S]&!=<JQ%
M@;?JF@!Z`1.+,T?"6>Q"3I3$-L^ZK%R\Y(=C>4V2#*`>A1%E#!BS.#K5FN7*
M^-M1MU0]@:GK%X4SM-:K:?:;UTE2\"XK_B),+$Z21?W!S;]$/2P6N:N'"0Q*
M(ROGT1B*WX^1R.Q6.QSG!:\G*8]84-VU^F"KK#8/=SM--M.4K2PZ>X_RC47`
M*>;YLIMAYU\"G&+&W6:PQ+DICRPQ_G=A6A^::,Z;XT24N24L6\9@D%S8-[V,
M>A&UQ5!6JDI5J@->3SC;#>4>Z=\.TGCD147;[W\=BB?\L(=XI\JBP>NC/@'$
MUKJCXD8O:XGH-31PWYCNKE#UT)J;!J$A<>C[HGR"KPX(9DC_%@!AD<>.](ED
M1OI&5YO3W,M8L95GW52?A0KGE*:@X29XP9J([X-[`D^H9>5T2CP"8/],Y(EJ
M+$554=Q;F<[9,EI(;?;#8^ZT$#-;@,<EEQ!=S_/>UO8:"LTZ7E@(P?0-*&PO
M"9&TM0&LJ9CNGBY+C%>@1JQ^C7=A7%4<"LR?3F/-802W46]+J""96CK9E`!F
M669-'X1$:GH]12,Z3N28A`''*%$U!7X,J/4'P=9J;(F^@Q#+=H#<_$M$/,&G
M#E`>N88:BQ/F#AT@LZ[D$8M(#:F]DZ16Z@Z40]=KH$/+J#9<MJ7CYE\B?D59
MZECFE,]%:>YZ:U2$HWP,-'P"B]6-=`HUGNKK\;#0-G:FILZ).OVFM1/;F?%_
M_4E/>W4Y]P)>':4NC0M9,G'LL:KSJC2R@,`V%XF.9%R7PG:P3"YJ4@^`<:F>
MJ;V_+6HJ>P<2(B-B/;S3=(;A.K:Z,PWB)300N^1J<BP1VF-2TT([++]B%0?/
M&0`GO-!+BBLU>7YB+N?%VM4DP[B?W4P'I#P"=QSFX@8Q5#0VW`6,%5O5N%K`
M$JJ(7,(5QU-.'\;C^06L2'P#$0LBT5N_/8O<VPV?!RSA_,W?DLYDY.'42A=Q
M,NYW%W3JL<%R4P$H.AGQ*\URA2GQQ&#>&OP$/&97_(7HEWNWG.>VPQ.QJ:@=
M)^$85S[0":L/4S$.JY5@`P<PPH^]+I\6""<\738=<O,O$:EY,J5#T]$P'H6C
M#WV40-:4J<[L@O=*NS-[9V*#1:/&#K?>];()GC66_Q`BEM#TPOT8OF0_AD_]
MF%A,A)39TU8/IGY:F1.&JC0:WU[1.+!V-&6*5(^R(=($NB=[EY_`NX'.E]C`
M[%MYD&/G97Z4QN#W<U';_@^\B+K5"X`T=XT8+O)H2D7$F()>$U"-#54]]%0K
MANR1ZL_C2;FIDPH):@/ZZL:&+:AO;"TH@+R]>MQ#M,8F!G@_S(-9GJF#.=&Q
M,-U4!59Z*?==0`',M6%``<FL`#]VYX&@F1W"W7/R8)O8?FOD)<SN[%'2"TO!
M\;/]M.<LZ;1T9VK7F^!KV&';IQL;6JZS1Z=:WEKZ%#;9BK]@F$R!$DU:SL>#
MON\6.6+`YDVEV4E!,=87CEC"/5K20ZIM-?&J5]T9K=V$ZXKX6F?*=^CBHPVT
ML&EM54O#MV8'WEXV[C;!#U3.V+:ZJ,9:[R(Z<"TE%L\X*(MG!XI44X'AM><`
M:]78'D23K"15**7M%4T6;.4J3:@FX5=7Y`99@>,?D(!O@G\9">?(ML(,_82%
M</AKL7$)%4SMI'1VJ"RRU86CQC/,Y7B"6@+XZ(,JZ6R-,BYJ2VVGHET1M>XZ
M,IKQV`B>B,1V,G[A^H?TQ86X=:=_IVZ74`-WR4@\01MSQ^MGNWE1^[HT<>,`
MA%?;7\8S-"=LW.PNSBE@E@*7!(S6MMSAM!4D(STA7ZT.RE!`TYG<Z;K6)QCR
MYS<G)FF6.T4LTOQ@X=(_0%EP\4GZRMJ)?*9X4"6'I('FG2:@7Q_!@%A$9@!_
M98`0@,*^`9$``N(;P"-P8-\`%L7^5X01[+YG`!Z[]+Z"93P1W@$IS[Q2L(3[
MI6`QS_V+%#SS#XAX[-T+QGGJEX+A+TY\`T(DR9X!.1?>-68\Y+[[*6C:=S]A
M_@7&+/+>%YB4>NY'Z&I>4TJ\ZV-A^KH9_#H.`23&(4Q<SZZ9\U7V.=#$[@`E
MM8Y*.DF8VZCV0`4P//JL&V3DW0N'-M-\^!M.>4+L^`<N:!/CM"G\,1TO][&^
MO_MH%XV[@E9^9<4`/*\3/WC2)%5\$]F#K]$FL4><?@:`"3X#M4S0^UAV_86^
M>@P\F4QDWG5R8S2[D?HT>@!RXHZZ-/(T^YD;$@(%0YX+=P8(![@V[L5/9\Q9
M.8AP?_D"(5[#Y#ACP:NM>NJ@O6X^R=Q\+DH_8/FQ[38:1O2.)Y>(O\Z%U\#7
M+(^]'K+FN1\"UA'^V,TW`-)0_X`X2[Q@NTX`K[T#TBSQAHQUEONCTCK/_3%E
MS<),>+%RS5CF1Y,UX]D-7;$HR_VB0B)_0QDLSD-O7%BS)/>'^35+\UO29G@(
MQ6]:J3_*KGF8WE@'9VGB7P<$03]=6`/A8'ZM<P'QWC\B1M?WCDANCH#,Y<8Z
MLO2&'?,\8]Z(MX["6/BU'D$^Z;>@B'-_7(41^0U9HBB_L7.1N.5S$6#G#5D`
M&OP:@\T'Q/:.R/!4HA_BV`VM`QHSOTX%8\*_#L'QL(IW1!1F-]8![-OO42(.
MPQLCDM#/RM8B#6]@D,C"R+]S(L>^D3<LA*&?/:YC`&7_.F)^:^?B"']DY!TA
M&+^QTOC6SL4)NX&6`#`W+`B=X88L^2U+3D+L7/I'Y)'?*Q.6>G0*O./;G^[O
M[N_^#Y'S;ED-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*-34@,"!O8FH-"CP\
M#0HO0V]N=&5N=',@6R`U-B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W
M.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\
M/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@
M,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B
M8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]0
M1$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO
M5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HU-B`P(&]B:@T*/#P-"B]&:6QT
M97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#,Q-3(-"CX^#0IS=')E86T-"GB<
MM5M+<^2V$;ZK2O\!IY23VIG@21#Q;>--Q:<XL:KB@R\4!S.BS2%G28X4^=>G
M&R3!T8H#KN%A;=4N)8+]^AK]`O;C3_=WG^_OZ#8QBE#\XY[2K9+]7_GQ_HZY
M-XSPA+#$_883S;?&\)2DE!)C4M+8^[O_DLJ1TE(A'96F^`]I#O=W3_=W^[\@
M)?QS\0NZE5(`_:T42L`_PG#^]KV1"M\;H?%]FB9BGB`GFX2FS)"440++9.)D
MVCO]^I?4OQ3))/#'A_N[O_XC>\R==@_P@;.#(SIJSCAA%*SQ`+I_\S.7],_D
MX9?[NT_PZ;]OPR"Y8$!N3AW%9WIE\4<&:XAO4KJJ])[^*L)+L:[P(_U5A*?)
MNL*/]-<0/DW,JL)[^JL(+_BZPH_TUQ!>0Q994WA/?Q7A5;JN\"/]583G;%WA
M1_IK")^DZR993W\5X>6Z*=;3CQ9>!(07?0:D6Y9H"`SY_=T&RC*&SR_`\_N*
M=$^6G+*V^T#:KLY_?:K+G6U:\I0]6U+O.UN1HFJ[HCMW=D=:FY^;HBML2_(R
M:UN2Y5U15Z2$WQTR]YC!-PTYV::H=RU0(,]U"6]@Q2M0<NR.6?.K[<BI*7+D
M03*2U\=35KW>V@)::&\"Z;0'%#F_.1O)+BSM$C>R:E=!E(D149THCRC'9T1T
M0FA+OD?37J!*]D4)R&5786S/14>R0X:(DW/[@;Q8\E*?RQT@!U_`^\>VRZJN
MR$I2V@/\O;=(L-J1&EX?LRH[V*.MNIM;F`JO^9I`4GUA8*&,&`VL!:+J#$RR
M#G9%[^N@^`H8*Y,,(G`NO`A2BT&$QK9@[APLWX/S:,FN>+8-[M!]4Q])#=L/
M]EQU<+`\GMNBLH!R5X,H[:D&J>$1=^*T;[<KA$ZEUZTR/?TX$'08!-57@6!Y
MZ(+2$06F@:I#X5]@VLG08-ASV?5[82[&N6T(<6[`:PB*=KM&RE)BW0+9T[^Y
M\R>4*,Z]\ROIG1]'!-[LG\\9.'M3OLX`X!+7OCSGW3G##5%,*<Z!DS7H]K]:
M^!@VP:XF;3VNV9^[<P.0/#S9=J(!FZ,=@,NS,[S`/=7#N<;>IVJ,[THF4\9.
MA_C>.Q1([E4D;7&HBGV10V!&BS1D9_,2=OR6_%@?G?,YY2#&UY#87YZ*_.F=
M/N_M^(8%A/_RO+-_N[FW)@#KJ/(JY9M,UVU9//U5A)?KMBR>_BK"LW5;%D]_
M#>&%7K=E\?17$5ZLV[)X^JL(3]<="GKZ:PC/Y;H5CZ>_RC39K#N:\O17$5ZM
M&^<]_;?"(^9:IS@:HT0XJM/G[BP#%B12]0OXE05*0@<96B`EM)>A!4(8'5S`
M11IFP814P054T"`+@#=-@@M2P8):,,W#6K!$L*"03`D:7B"Y#F+!!#=A+3B'
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M_H+`UXR/"7>4>-[VG$?;GJLHVR/'2-OSQ,\$M/:V%\,@:F>?;5F?<.[J[+^#
MKA\"2^[&'475V:9R&$#`.=3/\!.NA!].=5GD;F#0V,.Y['&:AV%!]FLP*&?I
M:R4K9C+HGB-A2-,T!@;',0Z&-#4C#*F:1N]N8(4\LZJJSU5N>R`@HI]=Y,'Q
M"GJY[0HW@,%AX#2Q(5G^^5RT?:#",Y@&\L$!P#ME35?9IGTJ3O#[7VH`DCP#
MY7-C'=D\.Q6((I`^%IWC.8O=DL+7L(.JUFL\CYU,H[%3+`H[Y!B)G?)3173*
M,5>,T'VYA4X9CO@=>BYFG9KZU!2VRYI7TA2')YPS6ISDCB##@UMY!8,%P:^&
ML0O)YS%@+!H#)J,P0(Z1&#`_VN07^X>Q8;);UJVSI?W?J6CZPT1,&K!],(B5
MI<5A9.FPL$TW`C%O\`4I0TE[%'/6X%K+6(-KK6,,[CC&&1RW\#A*GU*V'CB6
MV0N>]Z&_0_1QL_)'EPVF`\!O(^2Y9EK4;Q1HWK10F<::5M(HTR+'2--*-OHR
M=#O]B61_YGU#/@R^&1D9OI64PO-OP&ES2R:8V[TV<CR\[NI;\L".975%\#NO
M"*?:AQCEGE\\1&^/=B#<SYZ`S`:6)>&N!A8]67G>^[$ECO1^*J*\'SE&>C^5
MOA)*IX+4\^P/TDA3OV:E:VC=J30$[AW8G;19::&D*?90H+Y^<$''G:A]6?E\
M.WN^_A627TVGFGK19T'`TZA($)(D:N;@.,:!D"3:=P4RG6Z"C+[NS#QF4*P2
M\8*'.[;T9<W%R&'HVV`75$/S]OYH^BODO6IZP;W`LZ:7271BE4E48G4<XTPO
MD]1'?S&9GN)T'GF^K6`@GMBL<8>N%3AY#BGWI>CPQ[+,'FM8"&W!A^%@]IB]
MDJKN\(Y`8RO[`EG9-6BG,LOM;C8F+2ERM3L#PXR:S&/"HS.R%%$9V7&,Q$3X
MT"^2:0!'S5!=HG>WYSS'BS`8:<:=L2O:'+OB5V+W^[H!<$J;[3`/=#4YXH6I
MKJZ&2TX^H,WCL"#\U;UA)NEG<1`F.C<($Y4;',<X'(09<P,UJ:\Z`1(^X=`5
M1S0PFO2E*$MX=O>3`)$W>P(1P,!E&YR6%K_U5Q6&-#+>9.BO0/4Y&Z-8&*,E
MQ:[>4Y#*:S:/D8I.'4)%I0[',1(CY5.'"P`#1@:?D><!(D\#K58_0.J'HZ0]
MV1R'%L1"'*N/\#!-6"^C5[;?0Z<V9)T+-&^H@I+<ZQ"X#OB'."2>PWN\_Q!A
M<V%^*@T;S<\-/J/Y__.G[[`)MFA='/?,M6%+_*\ZLF(!Q="16?09@&!19P".
M8Z0C<W\$()BWI,3VWP>;;%>?_&W-#!+`J<NJW$ZS!>??[CBF^NWU.-YG'><^
M?:R!(C6'9?71-KZF^N26DX_#]<I9E!94NXH2GB;SP-D!3]S\6LC?CQ)/H\X.
M'$=0999E&"6>^CO+)NW##=U"-6B^"B1\_=TKI.2<_%!F'>3H(WF8#A``F<>B
MQH!UP&;BS>$"$CL]9<T1:J=S5^3]N+0_;X`*"W/0C35-QDD]329_!-<<_+&O
MK(=)"[C0QZ+^-$@^>!.*#+_]P4GM?6L^!BP)>K7@@$)EE'3>NV@:[5T\:BSO
M.$;:G/NQ_'AA&_^[@]&3=Q50=[N-C!XVF/Z+D3R4VN]#P;3_H08OZQ<7$8J\
M;ZOL_XK6S0O\(BA79N+"#;75AGMUPWDOGD-R8=#`?V7X@Y@Q/XY/=+]/OO'Q
M==;5%WA=O;D#&HS,9EV=Z>@).M-1$W3',?+(6_L)NI33!!VO6UQ$TKXFZUVV
MKZJA@<$?CW5C+VJRXMGZ6<M\J>TN3OLML'\;LJ;$%Z/EU6,GSKR:\X`Q'1N;
MF(@:%#B.<7[.A!\4X-P<6?)MDO+?'9J@'(1"L,5%/K^Y_[XS+$4LW5`!O_\[
M(S],1!_>YD.D=F,EN9^%)_SB7(>/@ZB\L;9R'?77B/[/AQ\O9'9#P`AYK]\,
M,%[@>?^B_=TG=H4PNT:8*OC6_\<=-8;G][<1\=S.1/)@Q(R1<^#`]9<7$M/@
M);N-$<&+@!MF>'@!-RK,09CP/;^-3&7PCMU&I>$;;ILD#=^QV^@T?!EQDQH:
M5M.DX5MP&P9Q-ZPG8^F"J1A/=5A3)LR"+9A,T^"=Q@T41I@_0RL2LZ2MQNT6
M7`&J+,AA]((<G&H9EH,S=P836L&Q?0JN$)J&O8/+)'P-=,/5XHI$AV_M;C@D
MA05=4CW$BL!NY&&K"ZI4V(.@0=%A+M#:+^@BN%E`3HBE+2<D5KC!%1`9PA83
M"37!VZD;`#]=H)'2!:N#*B9L4XC5X5NR&PEM8=B#)*<J+(<$<,,[2@JC%U8H
MRA:X)'0A!DE-61@YF5*Q8`]#D["/*4J3L!R*+2&G(,2$)56"A2^1;Y1<0DXI
MMA`M5;+D04JS!5Q@,RQXLDJ-">]*90P+[\J$)@&;0LWQZ:?[N_N[_P.P%PWI
M#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C4W(#`@;V)J#0H\/`T*+T-O;G1E
M;G1S(%L@-3@@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]0
M87)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C
M,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-
M"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P
M(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X
M=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A
M9V4-"CX^#0IE;F1O8FH-"@T*-3@@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T
M941E8V]D90T*+TQE;F=T:"`S-S(V#0H^/@T*<W1R96%M#0IXG+U;6X_KMA%^
M7V#_`Q_38NV*I*A+^Y232Y$"1=!F@>0A+[1,KYDC2SZBM#[.K^\,25'>72_=
MXUC!`;*.19%SGV]FZ`^_W-]]NK]+EEDI2(+_[*=B*5+WGVIW?T?M$TI81FAF
MOV%$E,NR9`4I$GB24$HZ=7_W,VGL7GDJ<"-1%/B'=$_W=]O[N\U?<2O\=_)%
MLDQ3#@<L4RXX_.$E8R^?EZG`YR7/\7E19/S\AHPL1%DP2@J:$%B69I:FC670
M/:3A(<\F@C\\WM_][7NYJBQ[C_""%83==&2=,N`R3<@C,/_5KRQ-_D(>?[N_
M^PY>_<]M#LA.#B`WWYV1LLAFI3[L?S7Q_)W-LX2466DW3Y9)61;DL;J_6X"M
M9`R^/L"97Y-:=D^*[-NNUVU#V@UIAXZHSWO5&&6([!2<6<M>/ZOZ2#;ZLUH_
M$-U4];#6S=.T<--V9",K7>M>*_-`U*=![W>JZ8ELUF2O.M,VC:J7Y.NJ:CM\
MMS["1AMB9`VOKU55ZT;=7`2H/\&\"&@)GN)%D`J1.Q$`X>N6-&U/GKKV0"0P
MW?2ZTGO9JS59#XKT+?*I.SF*J%-&R:[:DJIM^DY6O2&PRU/[K+K&\AP6/'6P
MF;&,R@88WDA=#YW=LEWU4C>D48>7V[3]5G6S"(*+41`YQ(I1$#SU@@#U]6T'
MQ!X4V<FC%<E*$;FJ+;V@-F!KWS9.>7#\>JB4-9<6]`O".;&')?E^XE166ZV>
MU0NYUO!%;5"8S@"J=JC!LI!W!;:D'F:1`"U&;RA.G$$43@!&/S5ZHRN@$_C;
MRF[WBCO@?ZA[9^R2["7X3#6``X%?F$K6:.:Z72_GB$)%6<P:A<+^<T2AHJ!>
M[BPI3UP0/Z/@OW5.!LJ'0&2,7F$8.:)Q;.JAZ@?K>`;"CM5'!Z;3#!B<(+*,
M!F>M=J5J:VC]5O;DTP#Z4=VMV1%I&O@IV3)-$OC\.S"QN/U)Q8GD(-M;P7W5
MMS<_2)1_%DN`04Z,@88H)/`CFH+7&L2#'?B7-JAWGY3>^N$,(0+@SQ@DLRP/
MILKRS-&'"1$#HX1PWZ[!)-<0+TY3YV;H,>P!K1`E=K*IU)+\>)9Z,&?3[M1H
MJ"8$W9U2O74&-.ZJ]]:/H;)OJX^PK/NH,*_*^FAFD@+F!.^P?))"7OA4@9ZG
MFV=E,&$LR0^-<[E*&@C<*`5'Z;[3D"$.&-KA<[N"5'(<4_T\49+E\T;)<?_K
MB,_C0J<.Q9;Y,F=)85UP@:B%>K#V\]F\O`,489$$ROWK':0@2&#D)ZN`[SY7
M6]D`OJNUL;8W@\SS<EYT'_:?(S/E4!MY=Z?P^@@)\M1)'!T7(M$.W-M9]!;@
MX4JIQ@H48$S;6$=]3^P&D+(B_P:EL?R!L"012Y02>4280[0!70+@-$.'<<+Y
M$*2Q@Z[K4PW/X."YR$)=,"&A=`1"$'+,YAAC[=8T`3`(1*4NT?W*&+OY,?!D
MXIT*EH;@EC"O=&/QN`:(L0Y^8WH(>;);(\[8:@#VK@2":"?!.)X<:(>'.]WH
MW;!SUK)MZS5\>W.S%>S/$%4&1XS'S.![HCPU0DK%!`7P,RH":\@>BB:?\.9P
M`Q[*XT0$/V!BK`@JN=>]K/7O-@<_0!*[N>'31`0RY@5?%%TL,$R38/I<>,OO
MY6<T;`0EOFHG9HN(Q]5H-IV[`/:#`SLO8J/&,O[61*?IGR6>-#T5#YA#L$C.
MN;=('_4W7;N+!4=;C#C8`V$<<&`%+\T4R%GH;E`Z1?*<91/%;U7ET]:/C]^0
M#T-=*XAQY$,+\0T;$!:4NB[$IZ%U\!,PZ5H/NP?0,-1;MO73.L0A?;&&2&3$
MK09@*Q;2P`VX<*>P)V(![!P"2$)7(TNG:,XR7UOVV]:H$T8,8&:U,\Z,?U)U
M;7EY+:"@O%T+YK_6FPU6^HB[*CG`?F8G06PH(&QJ8,O+XG-T%N-?KO5';)G!
M'JMV>-JZ1IB!E#"'%+*B"(`]"S@FS;)L`NP]H`PC*U=-5".#:U7+HUHO$9,`
M8[X)Y)^[4@4KE;H]`+LV`KC"V_8-P5@@),JU+690\RN]MD^E^3@NQF:)%TS[
M(FK,(89\K"UIFD_^6^;>?ZUREQB]^BV$JZW<8_?@(8"NK7Q6Y`DXPA(T:/U(
M9`6<&+049-)G!9^7#)I^)[7!H`E+UVN-(H;GC<*W9'<<WUC>&AZC?D>>9VE^
M9X+."N[#_G,45!EWM7PIEI1Q'@JJA.:AH/*M7U=IHR;W`-;7^EFO(<P%LW9%
M_2PE:T;3>24\[C]'^23*T"?(6<@^@O-)P-:E&O6,T4-"=*BDV9X(V&<1%W4Q
M<GB%3+UBU`AZ7NS%44TM-MZ5K9M&E4%8FR/2B"(Y.U7(/.=`M)T$0,A[2[.-
MAG8H@')Y<+''9=9QC9)=`US#JHUNH#K4$$\J[+W;)(:"<AEZ-4!8@BCCFJ&P
MHMU!WAVCN-QLP*Q1>L,L?2+LYXU2R-F)%'S'`NI9,T"UU&N$E,8JR>.,#?D6
MD($C$[L:0+H!,6%[MU;/H'X;I@_!0U_XY6F3"5^&/%:C$)YE/5CMCWE:PG9@
M!PV9)]^(-)226<[?@@_7([.&8'7<-H`(VJH"XNU$:#VVO=7G'A?9#L#K_ADD
M*1"4!E<`OFWG;>-:Y?:ISZGNA76KC'.?\(Z=J31NL!(Z"\TL6%2P4%R4C(9H
M8!,42F-2Q22766*J2,I98VK8?XZLE98.T6.FHI,8*<_+J2F%X?'69T-%/IY]
M@THK<A!XQPLF,5J,3'(ZEJ(?%<Y3(2QN<,"#_>-G;2QV18]?*X1H^Q;=!F.C
MK&RET;E`"+&TPWCPRI5NCK\$D#NR,@O^2G,VJR6'_>=`!ZD(I5F2Y-.\E?M9
MSS>JLXWK$]6.%0(\L9/8W@8X[$ET^[;S79C5L98'I^AOH7HY8(<"_CQ@ACE`
M18=_*[^W!#3OZ\^#!R,'W6_]+0=5#7BSP<PR;4YY$9+#Y,<I&^]>A!(,$A7\
M/5J:@-5AM\)<L).-?+*DNR[_1T4TIM,5]B+1YB&5O*I.W5P:2AM(L#B=/KKI
MN_4,=\F@K5&>@QG+O1/1SR$!-I9C"9^ZZZS@V9@>;1/58[<::DR`*G^?PXV2
M><N8L/\<,8!G\U8(8?]9B)]Y(L?_V$0N3CR;>;3%_O!H*T:\X/,2/^X_"_%T
MWDMW8?\YB*?YO/`S[#]'S(9<-95TQ=1)3'Q)\R9O6#2F#62S#O)52+S]<>\Z
M?B_:C@#\V_H9"U()N1FO]M38<IYPG!^<P@8^7YW)5'BBK$U+:KW3L\R%:#HB
M%RCE\FDR-?8U`JZ<:<1'DXF&&4=\-,G",3,8$U1))X+D^23()!D;!-/T`$O6
M%B]OG=J++8@!'AP]Z%<[7+I2ON.C._ALL$$-U8#"RS`6_4_6^,KX_/`6U3>'
MU;``^)*)62[R_*3[["V&[#3.!&P3YX"]8RC7E<9+DCADW.EA9]&<XW%LGV,]
MA%C)5O35T'4.)]KIZ#P%CKV^/>_-P[#_2Y5@$BCR(K'W/[C==7K=7F"'!7DJ
MW`+VSH(LY65T@4A!:;$%L(&(+N!8F,<6,)[RZ`+*D_@1"2O2V`):\B3*!2U8
MG`N:<QHEDF8\B2\0+(_J@J:LC'/!64:C"QA+XUQ0[+S%%B0016,+2I!U['E!
MXR3F5$2?9]C1B3P7E$492),B2A_'ZSQ1`>3O/__DEPAWZ8JF9WP90CH-ODS?
MQ@H16H#"W^ZT5XS\?8I'VYP%4/`-)'<LRE^XO-OFO__$+0\86_Z%!"T%;IO#
M']>8"O];W]_]-!&->@/^S]$,H>G=L)T[H[!$LR4O?)7*EW9N<K!A+\O)FW0!
M#NG.I,7Y0R.IPK[+0N><9]0+*L_&\0&DL&[8VUZ_O]FWD\V`;?VA<\.0O:SL
M'>G.W3J=;MNO.C^=/YE$OO.R'\^OP_`>MX(L_)NJ\)K#S7E.0K><4R?HK_`W
M%_WV3=[Z?XYZ/V>)Z:RWL`:]!-,*!KTO-Q9>\&MLQ9X(O)P],BXV7H0;R06=
M+CCP\4S_:PUMS(`H66U4ARKU]QBPU]4AU##$J$8CI,")`]Z):-_>X?G'%:2_
MVQM-DD#[>2U@6KQ2"W[N\J5:P!.OU$*X$0U)IIQZF6,S;VPN2E+5TAB]T:"#
MMZ.NLP*^0-5[`L:4/I)U7L#@`]<*V$\XOE3`>.*5`J;C0/7D3N98)5@`CRW2
M0Z?[7MGBT"#XA:]>H&KMQE][U>UPX?JLO"\0^9Z\>5D&*L_*FV7EM?)F^54I
MR)YXG;S9=/-9G(259#P30\.94>W63W'5YZH>#!8L-KI@5-G@</%95CBM]I>$
MC+\0UF!/NW/#\(@G7&+GW5!SPL]YS7!VM6;\K^:^5#.<7:T9/J9)EIS\!"5<
M+:B&W>!^D4F>6SO<][.#<YX@L:L.?H#JN(+,]WUAHO.LQ"G6&]=)G/J?HGTI
M',,3KY,X+:?!-9TDGH[WA`YJA$H`JI[M77V0+4[?L4;'*Q=-^`U0,/"S6D&G
ML!?BIB\1<.U;(VMS%@5=X.K=FV'IQ-99!97)^R`_.P7YKV[)0JE:CI&#B;$W
M];8S@,50I(Z('H$EDC_"G\"*U\T!L()(G;,HXW74@N+/@F,+6$GC"P#;1$NM
M15HD670!A*UHYV"1%47\"'@69[,H6+1B7I1%&F>3)L4%25%:Y'%&`3%=$`7E
M1;S%L:!I2:/]A045Y05F:9:S"WOD>7J!CB*_1$>9Q]L4"Y;D\;;4@M&LO&"?
M+(_W?!80G^/-@`5++ZX0.;]`1Y9?L&*6YV6TZ;%@!?X0)^Z-0L0MB"=0'EU8
M45[@A=/R@N8XN^1QV`Z,\\(A,,0EQD52QL,;SY+BPAYY<D'J4-B5%V0*,3!.
M!\1J>B$*TB3>,END`'/B'I6RLKBP(DWBC;5%*I(+,2C-$/Q&5^3X:]A+,3]N
M8VF)%_2C:2&YI#E!DSQ.J6"P)+Z"7]*<2.F%:"G$)0L2EQJ>"Y%?LF21E_'F
M-232,MZ]7H@RB\@4$,5WO]S?W=_]#_=];3T-"F5N9'-T<F5A;0T*#0IE;F1O
M8FH-"@T*-3D@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`V,"`P(%(@70T*+TUE
M9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S
M;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T
M(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&
M86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HV
M,"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#,X
M-#0-"CX^#0IS=')E86T-"GB<O5M+D]LV$KY/U?P''O;@W1II`9`@P:.3V%O>
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MX)NW_QRH*7QA+*79V9+SW&.J1&XP_3"T4;/=EFO`[R;:E*U>]TW;146]B8YM
M6:_+8U&=H!SUS4[W>]TZ/43%\=@V7\I#T>OJ(8KE,OF%@8$VVZC!V8>^ZV$Z
MU-:Z.1R:VDP7%1T.>5^TZWTDU,V+2P_*RU5NA6<I.(&37L16>L%8MHP0@VTS
MU"`=R;W>EWH;Z2]Z/?0EV)O%YP;W^CEZ<RBJ;=&N;J)^WS;#;A\54=\.78_2
MW.]+D&:OHQ)P@F_T0&N:=J5K#1.51?MP0P]Q.C2JUTL_:72++\R#12:<(8A,
MC9:09P:+YK[NSE3)\Z7\)E4:7-\.+=J)$?9M6X`Q=>O&B7B_;SH]`:74L'RK
M:7!W;`9X.`<*4CJ+4(GP*"0R-2B@HC:Z6^MZ4]2]$VNJ]:=PDLO\FW%"),I*
M1UM`H-X8SVMU5:#IT?`Y4(B50X',PJ(@<VY0>-\N)Q*#ID@S==,_%2L`DO:9
M6$%HG8%5P!\VF[(OFQI&_Q'[F@,(P7UT5(D'(L.?"8@SDWX-^H%%NJ'JR:S!
M2$_E+;?X9Y!RW?M`"0B6506F'A4K4'3?8&QI>YBI*W=U"8""J8'5[5J-P28J
MZVTUZ'H-O]SIEI`Y%'6QTP<-X]`^YD"")0Z)=$P4B9#*.L9V6Y0V,="V0)T]
MIH-6_S:4[5DN-CJ_*RI`I%Y7`ZD4/5M78#2@>I3S--NX-_#)%)=UTQZ;%FP'
M@FE1=P6]#KG^73T'#$IE#@;%?)1,$N9@L*:+VH<8#RD00@5LS,D$]@Z@[,LC
MX/,`.JW@*[F'OB/E07(IZAWDA]JG3WAK,!`<RMT>QFRW&JT'T#I`Z-$].M=:
M.R?I]N"+8&DX(;BFG@>&C%D8!$M]XDS2U"9.+P=*N2)Q<+\K#6FPK,$NX`?R
MV:*JSCC:^Z;5:$`F+9P,_AI(,0@5U7WQ@",QYFPTN%>_GP4%&3L4XM1'AR3/
MK#&@.B8"M(\E:H@HG88(T#1\68-=HU=4A@P\@#1#!=RCP,0W=!0E<":<KSDQ
M?5RHP%B!X:"SE.,>4*`)YH`A=A12\#2=&(/-F9074-#[LB-VWH%2VN4,9%SQ
M=%8N[N?_-AC#]4V6Y[Z\@1K+PLA5YJL;3+(ET-!5KS=H`&A?5='NT*M.G&@&
M:+,LGQ5:/_\<54Z6.F[+N*<S(HMM%G]-OOB#7NO#"CPJYI3.TQOTFN8>L0ZQ
M<:^26G<FIIWPF;^(90*1&\I1"%>VB(A6;;F!Z%@U10VDH:I<\)[!.[$78#.6
M'/,V=X&ZZW1OB/6A:?L=L(@-):1*;W;&RCJH<RSOGFS;`M.$L8$TO*78`R$/
MA'?\9@>LGE)V-R!?+#'UK8MN'VVKYAZ7GP,'X3BMD".!D5S8[L$8H9I57T#"
MV@Y(MVNPBJZ#F@SW?80$0TGH1.649#>#OAFCK$EY&[TMB`EB\J;W\*W(4B`S
MDCH6B&%+R1T6V4("7%?-//5-QAVA%2E6=A:%F-E8#39:@CU4H!+#.4C[9?\P
MR5O]ONBG5F'%U!L2;U+74>"OP0>HVCV'3=]!&H!<#F@!'P82TQS*KFM:RN':
MK`+OS`!"FGLN*\68MWEBG8*RZ18L%,T5-H>(&*7=1*NA1S6;;+S1Q"]`:2U4
MJ76!G/RQH*X/T)40!HK60@=B-VW;W$..[Z"X:P[1JJ@_4_9N;/OD<-`ME+[5
M+!ADGLB.U7X2YS8D5KHV=.QU_1`Y/+#\:,$C[B/S&#4,P0!X'C5[.AA7UD:?
M5*5/^/X9CPLV-QR-\Z[1%8=9G"%-'8OE<396=RJS($`%4_;#!NLR*#W!'1XB
M*'(JM'NDGA"OCT5+/GO00,/Q#ZO2E*>MAEA!]5BSJLI=89A9T5U()<3PYTC?
M:<)F3=]^_CF842I\XY<SY:,63X4XX4;ZRQ'")F6E(X20ND??:<ON<V=K<M0,
MN1K:L"E,+4NF:`-^K:'"'#`SO;082:JF<C`Q%@Q"YC8'F1A"N]90U/:FT4%E
M8&>YPR=;'R=0CUM7F@-QVQ7&G<;2</I7G\!."XAH+[T>D%VW7@YDB3%(4;_#
M>HL77R@[$8PEH\\+Y1K>7RHHMEZOJ5T++%#,<&J0<;^/;Z>[`6>7:MXRR,\_
M!U>7:>Z#LAS[T'EV6@=91T4/\64V-@R]NP#_@@H:/`:B05$AKYPTR2ACHX>Y
M0/[X?6IB/>&0-QC%;>R8I9R6TC?BY=B"!G^WP0ZRZQ-!X$\Y9VA#6>IW]`+>
M&5I)L8GL;-)WCET-_(1S_F1Z3$`DFX'Z(4,-:0#P(3I:81\(+*$\0$&#FG=]
MQI/@;]KI^*09#6$.S<:^%$M&OI$P%_Z_PO:0&6JL$*C86!<U$B6H-M:ZI:+%
M,!4Z6@*VB<ZQ12()TOMV&5B[<Q[J4P(KPX'F7.&@-Z7IK$VZ27-`P7TU-BG)
MDU38$P;JE!V.U";'U&QZZ;BGN[+'HR!JF1-#M![<''5K:597&B*.12>0<2"I
M1RBI](8ZK'?`X!RQ-[TQXF]%Y\J98@.V4:P?9JS))>-CC!O/'97DSA!`8R66
M$V3@1=7AF<"1VKYHHE`_3`])\%'=:5.P;4HPGLXJ>PQY+RU%`DG,B6%,&;*-
M$"^_C)R@)=BDA:&83=D=VKK&L.S.7E!T,`?PDX-S^.ZAZ_7!GELW6-//H=A$
MN<J2*9&.QX?8@\&M?HWC^=PRS6!D$0^FDVTZ_SZ7H>O38<CT;0ILKOOB#N=<
M^P7AJA[<G'/`D/KB,H_'CK"T*'@I3J)P!R44:`P>@>"3#$>1SAQ]K+!CM/K5
M^D$'#N)C5%G?(9ZFTD+?;O5N@+"._81BZ/=-2W'#%+3=`&YO`IRMY.<`0?KJ
M4O+QC(1Q[HZ*T%'IR-.<Z%#].$#P0N-$JYAF`#1KV/WM*6KGIO%_)`8I+.%$
MG)<8I$R-*V5+D2%#_-V4@'12_20U<(>J`,\LS8,DCGU/F?EVO7"7D33I%*^'
M0/K115N5Z,C[HD8;)U5ORVX-JGV`AT!?J&MPWH+.9KFRE/!Y;RSY^><H#^+<
MWU=*XHE7Q3:VO!NO#]Q0!,4C41/[Z>C\G.;?&_[8HA\V]7A"=UH+T-ECNZ%^
M#T61=_49D7)LX='+LUS6B3-_<2D?&R*QS&V-@(UH-']WV!99/E6Y-&%W"V(3
MS?@CHO\'6'2%N-G+=D0N\=3@C%C:Q#-V_>?`P1_L""X]#HFK%3>P,:0`AMCI
M+STUY)X2O>GT1&.3T1B'ZZ*GGI\)J"YOTZ^G[SW'H<=#A#DP\`<\(DF\1T@A
M;1?SGG@PL6@O\U@X&+9+)U6N][4QYQ4@IM[,$H!B(6<-0'[^.5IC,5.^@Y0I
M3VYXQBW>;P>REJZHS/TL<R'#F=W)O27J=.L=W>4ZY0'F.5WLF*,=+)2:50-^
M_CE2@,A</<#DI$/$7>I]_>0M.E,.TD&DR&_R.+^)H;8(*&=RVPQ8X[-W6.TM
M+S,/!CQ_9;&:AUR38]L[:6(L'C-W@G=OCV`H'I]?4OW*2[P@\/0"RB-L]K;8
MJISI=@>\R7,<5I!A\!2WZ%\^<F3`]9SPL_1-19S,ZQ7QG]U\R"OXY$!/CB=Z
MKK']^K0\MBGP>?W=3"+8L$)/H..4XH!]M@N!C:Y\T@4T3)CC60Q27ZJ]YG`+
MQCPEFMS<E:ZG0M*8PT7TXM;X)]TL/"_$\#9>4=+G!Z8W[#I/W:>R$A<<*2<>
M$MH)(VWC>?WL9;T9<*`P:.]Q)R,U5(EO,D[\V!2_A^(S4+\>(@,&"300%-1<
M,FL+O!(Q:3:MBV/9PW=_JNVL!*O2_L%=&*#KVGBAT?1F$.:>3OG+M?:G;1L-
MM'P.#%)?)`C3,'I%EW)@=5#]BR=4_!Q%\F>/7%18(N$(/T1`WSJ6=(1%9<_M
MF_?1:??-S//Q'SC//6[BG_"36$J8*X6O,)F4_K?J^NK3B^Q5IGZON5C&#*DX
M=@66%_<FTY.]J1GVEON]T<%F[IN)(G?U8_3#FT_??WSWX^V[#_^*/KR-?OSX
MX<<W'V__>Y;.GA0@GPH@$O&-$@0L320CO&=9!$-@GN60)G.HDFG:\7WZI!;2
MOB0U`\0S`S)LM(0&I$F<!P?(A*7!`3!!>(DXAB0?&B!B'EX"()+!`2SF02EX
M'H>E@"@K@IOD6<S#`U*A@KK@,F9!*7@B,A$<`(506`H!"@\.X*"-X``F>'!`
MSL-[5(!#Z'D&0H2>ISP.2B#Q="WP/.$L;,],A2T%BL!GG_]FAU@M@$$\]G:(
M2=Q[.W_\\4*9CUUD0VNHZ6/;GK?47('L^WU3(\OJ'D4I_F0*8#(S82J?_.K#
M%&F>/[_G=+KGLP,;L%G.$Y^LW-'0XZQ(GSG[QC4X?G#1KF&7$/EY.%3/*P:>
M+O(DZ'X+GK/P`*'B+#@@SL)A:)&H.+Q'J;+P$JG*@^ZQR%0X#"V4BL-BYNH2
M4$RE83DY5Q>0X$)E03]=<*AD@IZXX$E^058NL["W+WB:A0/>@F?II7VH+!R3
MP+3P-G+0ME@:S@X+P=,\;!M"I.K"B/CBB"03%_8ALPM&+-),!3/^0F0RG$7`
MUV02MB`!F>;"*GE^0988DD58<S&_Y'"QR%18EACB0ABQ.`&7"H^0H;Q#(U)V
M`?4X8RJ,::QXF&DMXAP28#C&,1:FE`M(P4G8HQ*>IQ=&Q(Q?6`7H_H5H+!D+
M:RY)F0CCD61,AFTL44Q>V$=^27.PT32\4PFT)KQ3*2YI3L87N-$"N/X%"Y*2
M7]"+3"]9LDPA!85'P,.P5TJ5!C`%OO#FY^NKZZO_`6_5:=$-"F5N9'-T<F5A
M;0T*#0IE;F1O8FH-"@T*-C$@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`V,B`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2
M#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y
M,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y
M(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"
M#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N
M9&]B:@T*#0HV,B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO
M3&5N9W1H(#4S,S8-"CX^#0IS=')E86T-"GB<Q5U;D]LVLGZ?JOD/J%3J;,XI
MC18``9#8M[$]3B9K9Q+/9"]5^\*1*(N))"JDY,GLK]]N7$A*HBB1*^94*K8$
M@D3?T%]WHRF_^<?UU6_75W2LM"04_S.?HK$4]H_)\OJ*F2N,<$68,B.<"#;6
MFD<DHG"%<DWRY/KJ[V1EGA4*B0^2481_D?SS]=7\^FKV?_@H_*\V0,="!+#`
M6`0R@+\"S?GN=2TD7M=!B->C2`7-#^3D1H81IR1B\'^DA#(TS0R#]B(K+P:J
M(OC-T_75G]_'SQ-@+R!/<(,1A'FH9UTAEP*N+I$DQH'SI\GUU0T0'.+GE^NK
M;Y[F"7F;+=?QZO5_R=,OUU=W\."?+K(\"V2UOC!+?_,OSOGEU]%U/FE0L4GA
M68;-@DRR?)WE\28A\R2>_K:-\TV2%R3.$[+()C`^)?&&,$')_6J3QY,L+C;Q
M@OR8I2NXYUV>?DE&Y'&;PA=!Q8A\OUW#YWQ$WB^R/)W&(Y*N2+Q>Y]GOZ1(>
MMW@ET4B"H5V<78ZVJ[Q6*5B89U<I[=A%_A(R2Y(-R6:D6,>3A&23"=`,?&Y7
MTR0G,5DD<9&0EW0SAR_+;+69`]%YLD*^C:3@UJ^9'$E)R68.TDE^7Z=Y4I!L
M1=XEDV3Y#(\)V(AP2L,Q05.RCTQ7D\5V"A/C%<G6FQ3F;[)A!$&U5WM(>2D(
MCI]1$,GOFV0U);,,^=V\9)>F08<5#9J/!:6,//T;%KZY.+>4[;#+A?#L\A`_
M([NO29R3=9*GV71$7N;I9$Z6VV)#GA/079)/T@+4__P*Q@N:]HKK2ZDZ0FD0
MT8K2;RZN=O!J.N3>_`-6:AV$+ZT8[E?D8_R*W,D16&[IX<AZFT_F,0H!+!.W
MP9=DD:WA*X,GD7@">V8=YY-D@::_B,%R_D4EQ2=<F@L)%NK94*5O#"Z_3%0N
M`R*B,K1K/8+ONOA:/&I@25Q\F4"4R^QL.5`5N[R>!*N9&U=:>W.34CIP`:LJ
MMO%J@TXNAL>#^TP`/,"!>GL#]#&@LK'>=@!/J*6T$@G'02"M1(!(I@+G&M[_
MSUOR7;:8IJO/Q8A\^/#6F/;E*1$E*0.:-0MHN0PRJ9A=RS-X\?5"W<#6Q4V;
M1;)2Y."FS71E-N@;F`A+1-&ABP^G)C(R>.&07@SF$P/6).6+&T_`9<UXJ*!1
MQ39U;`-@+!$O82M_0!CXT6_D6_CR&"_@P^<\2980+%W<XT3\C[`US'.:;`TM
M@096"L;LAG`34NN:"CC7JO2JYK.)89.$_)"!$X4EP+%FVQR]:)$M4FN30SA1
M3!U<-!FQ*IK$STC2+%W%*V,4QKVC]@N4D8U]?9`!P>82Z'OW&D_3"?F$<'!G
MX:#RO_>KR7@$8.&2AS([P5`9[>UEGBT6%\_(%"C6\SALM*IH6),F"\H<103.
MMK*7%0BIV#X7Z32-\U=,GVI!VR#I@N:L3(9I">1!Q-RNMQ%SNB&PU4E<%.EG
MI-$%D,W^(#[P!V8([\$8RUH&?O+Q>%J81)&L(;S$IT_@R=M5NGDEOZY`)K#L
M()R#V_9@&57*$,I9]E>WSYCR?H7D^708R$0VGI`J"(?W$]X!88"6]`X)`Y#`
MU,426ACX!OF]^%H`K8<L7=RG8S7*+P/[.U"8$/GX87QY1:F@+L&PRDB%D/R@
MOF1V5?:\B5.T>_2E"ULP^0(?9GFV;#(W]`3H]C?Y%J+G`79&%(5E)%#!$-<>
MAN+]JHZ@(THI\266+-N8/>R\0S:;I9.$/*>`7+#;\Z2`E!P^H%-PZ:9Q$L_;
MU&!![^R[)3V.)"UAK*J)F*R@II*S_5GVO$@_`^^%AS2C$KA_!8S6>0*M>;]G
M\AQT("^9\1/<A!)8GBA`9(M%]@*\#Z+.H*QWZC"L[!$_(_-(X&21%;@\QA%C
M\FZ;XQ<@MQBB0L0B51(U<(5(TQK[5-40CE'=4"!RZ@2^P;[GZ7.*7M]LQ/SB
MQ0$!?N*/$0/&\W4KD&5X+Y3R5I#'JV*6Y$[SSF8Q?0<WE<&`$5(!P9C]LIF#
M&T`[3HT=@V&#3UHE$Q.O#9721TR5VUBH:A\+YUIC4N!&A5UG%3FR%%H2#2\D
M!F^T2$TI-W=7[65#,S)>.N#R,7\JR)LLSJ=F),V!R0PV+=X<DV7\"V`_Q"IP
M+=U@)#--U@G\`;M_ZN?B`B:"P^>_SS%B+B:#Q'.AKJJ_M3(X'KI83Y=OBXVM
M`'Z,\U_)[9C<+>/%+,Z?B;F&[N[/6!L&M0,/R)DI=*>%K=B`ITI@HUC6P/?#
M5&#9?1MA)?7@N>Z)Z$UF\3*%FY:F4%Z,R;UY\"H;!,?"J*R)2EDY/E/Q\XYO
MH(,>""C]Z@,>\P!.5SQRR<I@0S(>^%,>/*Q9^0.'+1Y%@)5B1#';KJ8%#CK`
MLO[>!N:XQ1/(VI*=6K&U`<A.$N,EBBV@N#W,P-P`(OA?\&B(?('UMKG98-97
M#*%;59:Z0B:K5,H?XL4Y[++/%JUQXT\`GM>+M+!;_`A$F]0$")^`GWA.P"PQ
MX]GB=@61S+,7N"L?V>V`XCC";6WI`KS*8F&.F8:1@BBS<\I9+:YQ%4X?<@!_
M:XB[)GGZC-E;NDQF>;Q,^L>_QPXZD"9N:0*+%Q>ODD`H%S*?L=*H"F?`P[E=
M?3\#'V_"9.!ZB.@%<GA/P\#1"\!:Q2T+6,6M5O7C+1]Z&GO>"V4PPUCY@!SF
M3(\9O]GT*SSQQ9%DX:`<9E0U&K"E`:Q8Z3)A,J>X_N@V\`>6$(?#AG)'EH`T
MV>I+\HJ[DKQ+$(S2C3W36\>ON-D=YS'YZE-];AG0_YA#/O(522!=67A0AM`^
M1J-Q`BD#\K_48IROV9@2P*^%D<L@&UJ%80E9JG)KS,-W/9P!,K]"K$TVY&_Q
M8@L<.>*+>6R.I&=UY_VGPI@`4%YLLLFO(W38TV2&B2>@>0*\+TT2&I<W3MUY
M-W[>$3J8$R9T)BP>0@:*5OES%:D&PKEV;XZVD-2B8N_'UW%J2C<QN.))7,Q'
MJ+P\`:]MS!N'SQ6;-Q>/B,4@09RJ.E0"):I-[T_7%AF@+RC*1W'>`KH8`(*Y
M-WH3RX-,RAU1MW0C+0CKX.;G=!5[I["[QA!"*!LZ.%6J2E@T*\\CFMC";-TJ
MV1AX:=<.!HML83/Z^!D^;L'"IQ"*@S'L^;K=^C4&/ML<^T`@>(68("E,MHR1
MU!"<ERT-C*O*YX<^58L7P!5JXDM2&*=X+)P9`-UE]%\U,42MC,NJB2&D9?*B
M0G_X<O]T]Y$$>U&+?=*G;_%)+TC&]_")CR612L.?6%YDY;?%]=7C1:A5%;7F
MH#"J'%7$7#;ZX>[;VP_DQT\/;^_NWMW_\.WC&92K'<HYY3U);]$B;*>2]OZ]
M*&TV(O_;A[?92%`&_K7B9%`6)_>V+88^,7:P;%Y],0.+ECF6^1;)9_@3DOT)
M1!%FTP]@TT)'#38M^(Y-B_%Y)BVTM(8AH_+;Q4Q:ZI)88]*Z.@0.?//8X\]O
M/MX_/MX__$`>WI./MT]/=Y\>R=,#N25_>WBZP\''N[<_?[I_^B?Y[N'#.[AZ
MFC6IZZP)$?;DK=TJ17B!O.3H\U7U_"&LWIQ*V:1'1I75T\A9_0]HYFM(<"?Q
M\^+RCE]7%/1D+VPY,XD$$<(=NP=C+3$=<,?N,G"8]^/MIR=R?^FE!9?ETJ$>
M4XT'@9C+]5OIA">H8/TXNLEST4U054,W^^V2Z%912T7(JD.@T(5?'V\__?7N
MB;Q_^$3>/GS\"`[A[J>?<=O?_O".?+K[</MT]XX\/CV\_:OU`]Y9G'8':H<]
MR?ORU]J75S&(IX(4TZY_-_F&1G_%]R@4EZ<0<J"@C(:H<*T7=*PC[3+_6Q-\
M?S1':3RRC:NN<$=>\`^N1SJ(1A!#UH)UEQOOA,S9=E-L(";&D-8DF*97&;])
M.J*"^MOGR<+$T5A(REYL37NH2G]0=2,%875J(ZGC?O<`D@EA>9E#^(X][,`I
MIJSY]/(E+@XW>.H&:>4-6!DQ_'^\G^"7'_CUA(I+L&YQ>"RWE]:]8+J;QU/(
MY#*;R3T\O25OMHL%I&XK=SSS^%ILDJ6Q8;CZYHVIDV""9`J@IBY&'B:;#)OT
M87?8UKW-/,^VG^>VTT:-!C%FRLJP2E?O8C"I7%B%'3YCR-FPAF'H"$>'K=J7
M)HQS5E(VH+(Y8*Q?!GBNFLB$4*I1UUBR?$Z2E5$XNB&G\=LEJ!!K.H]FVIVO
M"]J7-TQV_[I\SA;DW?T'D[\7"?EMFVUB>T(Q@&)Y)$K%UDJ77(3.3>7)#`NI
MYA`FOS0!847`L(7H4.UR6C7%"A>[3)-X@2?$6'8K+"H`JF"1+4X7D''EOU[<
MK$3X!W'/P8F4*X7C4);A*?-G#MOU:!@FM?J#F`PH+5?"BIO453W#AWQ3TX=D
MCQO2HL!--3*UM"6X+$RT\P1/F4S#WV1C2HG85!";@X3B\DBL:HH9!(G1QGRM
M002U`^1:)U?5NK/!U(L4R<84Y5PSP3S];#N=8!)Y3J>V8-<4A7F<<N_A051C
M$:LHK]A>(>PMF.Z^;#:$9PO*ABFIJY-%4^=RB*4,7PA36&H%W0/3]ETJ!\]O
MWNR#[_?Q:HN-K;9M7AY@KWW8:MKTP&/>?S;,20QGM'1X(2]W`VQY5G4/.+;,
M24@=MTO&]M\)5'\9HOJ`;PEX>@]3&!.`8/-VJ"&X-$^N'F'>O05NS=NY.($?
MF1`)2`3:)H0"I-0V007@S=HF2'Q-KFV"""#.;YL0!+1]"0BH9>L$%M!V+BAO
MYX+I@+42R:*`MD\(>=BJ"Z:X;N6"2:YXZP3!13L7`5?M1((H@]8)#$N<;1,H
M:R=2`QMMUR.@H>UZB&]>M5Q7-&HE4%+=:@JPJ4Z8BHK:!1`>O_Z;FR*MFL"D
M#CV")M@<X#P".WP16);U)NE>"<7\PWOP)P-7D"B_S4R'4'%0]V!-=2=X;&CK
M'KKVU=8]JI?XL;,67]U:.I,W,\PGC9_L9?-QOL,OC`7X[GK8K8YG]YT-D\0X
M,(F%JR`JWT;PD\55<H?XN>L@*[+A1D>VYZ"D-C0?S81PEW!_G8$X=$?/C;=J
M=L1S5_/QO,83YFC<I<9.V"?,7<<3GZXB%9R7E&'AI4S1E2_!F!``&Z,+>]Q^
M1*;X5I4CW7.Q2Z^=L$>ZOPZ2ZRI3<^L9,@VU*`ES-.Y28R?L$^:N]Y&I`O@Z
M*5-YADPC6IJ#YV*77CMACW1_/>HL4G/G49'N;7OPZDN/4W[;@R'ZC60_[FY[
M&#/;OB-9!BR/ACV[N]I2Y0DLB1'E/K(?]W8U#,*NYK3'KE;ZI`7BF8HGS-&X
M2XV=L$^8NPXQ0.=-C;_RHLHS/N8Z1K_Y#K*4(\+#UP0<C9[<7<+LA#T:_?4>
MV]?>>NRL;L\E.L(<C;O4V`G[A+GK/80GX8HG+-)C&87N5:(/V4N;[[,T>G)W
M";,31(/OZR<\>^MIX>$;;YXP1^,N-7;"/F'N>@_A*<Z[6A[^L("CT9.[2YB=
ML$>CO]Y#>/;6T\(SWM`1YFC<I<9.V"?,7>\AO!!_-JB;Y1D`L#1Z<G<)LQ-$
M`T+`8$^$."Z[<61^^BD(?)R*.4A0=_JS$@S\>).03OSV35FOH=6)I:LQVX.R
M@+7393PW$%"%<K,*#';&NX&!(^P,R1CO#BM%>P14PQWE8N\,#\\ZOSY!2"CL
MBN$>);7QCJ1@":&1%#EF)\1B4`$5H':I.1SO!C3G*\8@QZ%B:L-=I6'N[*X8
M`=%>DV+JXQU)D34;W2&%C6703HU!G`;%'(YW`['S%6-0Z5`QM>&NTC!W=E>,
MU*I1,?7QCJ0HQ9M)46-Y0BP&S1H4<SC>#2#/5XQ!O$/%U(:[2L/<V5TQ(0T;
M%5,?[T@*OES72`H?A_($-5HTB>5@N!OV'E5+%1.8LIUH!ET_W@-T>7F0C\75
M\@?8(O?+8]]O5PD)6C-&+IH!=V>\&^`>?0EI+RWDHA%I[7`?I.71*?.L48!0
MBDLU0:P;[P.Q333H,57'4CSE9-V$K;Q_$G>&#@P&'NJ@-MP'5+OHP*!F@P[J
MXWW0M(F&8!SI8YEBR!MU<#C>#4;/T(&!NT,=U(;[X&<7'1B`;-!!?;P/<#;K
M@,IC"2?"6X,.#L>[(>89.C#(=JB#VG`?J.RB`X.%#3JHC_?!R"8:^)@?TX'!
MLD-!'`QW`\>C&FA,3*ELQD@_W@,C7:^I:6FN?KB`:?^B[F.RWKB#XE/Y(3H7
MH*01,'?&NP$F/5JN;,Q08:4FW+3#?7"SJ1OWG`P55VR"3S?>!SZ;2`G/RU!1
M`4THNC/>#47/5XS!OD/%U(;[@&D/Q1CL;%!,?;P/IC:1(O;]>7.&VJ"8P_%N
MT'J^8@P@'BJF-MP'87LHQ@!J@V+JXWV`MHD4/H[.R5`;%',XW@UOSU>,0<E#
MQ=2&^\!N#\48E&U03'V\#_HVD<+&47A&AGHHEH/A;B!\5"T[&6JD&L'7#W?'
M7DU]YV:DE"Q;-R/J>C=K+5HM.2JLWX2X.\.=`%>?=VZ)/Y5UB+-VM`?,>F&<
MFYWB0@WHZH9[@&L3`0ILKR4UC50CINX,=X+4,T2/R'<H^FJT!Y!V$3T"98/H
M:\,]X+.)@&"LCD7BB'$-HC\8[@2:9X@>L>U0]-5H#ZCL(GJ$P@;1UX9[`&2S
MZ/DQJT<4:Q#]P7`G6#Q#](A>AZ*O1GN`81?1(]@UB+XVW`,"FPA@^\7SW?SS
M4`3[HYV`[ZC@+;*%_'B'GZIW^.VW<D@2EC\7+?W[.XU+R*CG$J!#WZWD5M@O
MY.(+[FU-CC>:M?:RWK!(A*T3>$1;FUUO@DBT]EG>"/Q!T[8)4M/63M(;%;6W
MDMZ$D6AG,XK:^ZMO-![JMPJ*ZA."8"QJ[VB]85RWMS??L$"?8)6)D)UXA@S%
M"3I4>(J.,&SO]0;#"8-VO3.-/Q;3:EL4G4OK#*;TB1G\Y(P@#$[0(<(3-LPE
M7FV=H61[1_8-#Z5LMR`>L?86?)BA3_&B]0G-!?34?@M8J-MY"<`MM$LL@&5:
M>]QO`D&C$\^0](34`T7;>_%O@A#?P&YW8(RU6U"@J6JG`_^EG_8=):AN[U>_
M$9SR$ZL$](0/@AB?M6M.2/PGR%IG**K:;4R$5)V@(SJE.:'QWPEKA07*VE\G
MN9'LE.8D9R>\I0Q.69`4[(1>I#QER5+"MFR?`<ZR?5?*4+7(%**!NW]<7UU?
M_0<AAP!5#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C8S(#`@;V)J#0H\/`T*
M+T-O;G1E;G1S(%L@-C0@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR
M(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-
M"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P
M-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X
M(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&
M#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y
M<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-C0@,"!O8FH-"CP\#0HO1FEL=&5R
M("]&;&%T941E8V]D90T*+TQE;F=T:"`T-C(X#0H^/@T*<W1R96%M#0IXG+T\
MVW+CMI+OKO(_X.$\S&Y)6H"XD-CSY,PXV3F;>&9CIW*V*B^T1-O<0XL*28W'
M^?KMQH4490FT*<F5F@E':`)][T:CP1_^>7[VY_D9G2DM"<7_S%,RD\+^-7\\
M/V-FA)%($:;,+Q%AC,ZTCA*24$JTHJ3*SL]^)TLS5RPD3B23!/]'JOOSLX?S
ML[M_QZGPOXT?Z$P(#@O,!)<<_L=U%/7'M9`XKGF,XTFB^.X)(S*5*M:,)(P2
M`!/*X'1G"+2#23O(58?P#S?G9__Q8WH[-^3=P`N&$6923SH#BBFPXP:(__!'
M).B_D9O_.S^[A%?_Y_4+:,)X:`$>FP7H+-(B(3?S\[,IG<7F^0G6_91_RQ?9
M<D&^ED4^?R:C<!@BDL4'$JF"1&IMY]?1C-,8GO\Z<*V]Q,AVK=/0HMOY05Y,
M2B\O$8.&&GG]_I`7&6D>LBHC*?Q9EK!$W53YO,G+94W*)0Z25?K\F"T;4MZ1
MA9-P/2&?GM-%/B</:0WO-621S0N88T'*"E[(%R1=/I-Y6C]T[^!\]0,`U3B5
M>W]>/C["[Z>09$);ZFG44J_P&:FOFW+^+Y);&HNT;DCS5)*[O)ZG!7G.T@J(
M3$&9GX`#@#-PH'@&<K\9/N7+!GX`+B$IP*!\>?^28C_Y78GO9^DM</MNW:RK
M;$9NX/>/Y>,*7CHV[;$0+?'"T`T*%D7'7R;9Y+&2NO4(YMGPF,S7587*<PH!
MHQZ;Q1EX52]?<,9FZ97U07E-&E3K)@5A@%"7("D0;'Z'XIK@V%V^3)=S8P<D
M^PX"J9U8\X;<KNM\F=6UE9>5W4Y[($]Y48`1K%#LSFY`Z.NB,<I>KK(J-48U
M.0DG()8X3G`F/"L@5#E#MR3FH-?S<KG($9$)J.HJ;^`GH#G#'PUI!9!OM+Y$
MMT#NTGE35L#"A[1!0UADV2-@5V3?4F"`L0ZD^Q;\1V-HKDO0\078$'#<L1%_
M_J%,JX6Q^KS*S)2SHT>'&+RU9\2'<;.'XY^FVBM[TNJ;8L(Q^?+/==X\&Z/.
MEK61-OD*_"2?E^``'NT/)PB)2:)/&A$3I=\M(OJU3A41_?Q@*%+$K<^@^(PR
M-%9>%D7YA`Z],1Y[595HY#5X\TZ.578/&FV`4.N;M%G77ME/Y-8%%RW^)W3K
M@B<;;*)*M:&3BUAZMYY]S^L&R<^LUL\WM=YYD89\RN;9XRWX$<XF)*)4G<#J
MY8;6G,2\Q&G-2\$>Q:DDE1VO5>SBV!]44@9_,=`K"$UULYD]?88TI%H:KJ?%
M!/XYGY$+"$Z+;&&\\Z\9JB;\`YC/R%X/A:"HN2@B<FWRHB^K=GA";B$:X*I/
M#_G\X>@!#.`58]ZU0M1J[3+1+E>S&O5D$M5%N4**;I]/:6P1[/D\4B<TMHC+
M#=J9H+KS2:HUMI?1$S/+BU65%U9D*+]TA8[*,L:DM@]EL<BJVD=F`WBQ7*XA
MY/^29<9X8<H3"%-JX;U'EXO$X+T,.=>;N`$9_U@OLQ/Y!K`N&1^Z)TZ"UBNE
MIY7%E+?"BZA+"C[?7/Y"U*RWLIWHUY]PHB?$XA_P%,TD3,;@;YA-)NV_BO.S
MZZ,P`U)R>7"!(,`,2,8WF`'[=&LUOUQ<7?QT^<OEU<T@#Q3?Y`&3\4@FA"0F
MDQ;+?6:]4SP;$D'<%#L!;JI3)ZUFB9#*YEK79!@_U=,?%I\"O[C##W2<:MJ6
M@)CTCOK3Y^N/OUU??_YR12ZN/L&?BY__]_KS-?GR(_GQ\]7%U<?/%S^3CU^N
M/GV^\3"_7E[_]O.-`?GR]?+7"QRX'J8X[E$<TP-,9N\.EW8V<_+L-][P)B,3
MF3CLJESE;&K,T_JJ#S]E2]B9%B?PO.*4Q2U%B6A+#RP277%+:Q<V+V!?6F5W
MD#+`YMX4`8Z>O$%.YK%0K3/AQU\FWB16RHU]BW3[EE-F0I"?OJ12'#\3$NTR
M/5L[?L$$]/$]Y!8)M2$W&KNE;.9^],42\2Y2TO3=I*35>TB)TZA=!J-:;#/P
M#T_9T5=B\7N(B$?\O43$(_TN(H)-4F=(<<2LM_^PKH^^DG@77\=E9ZSC:Q;[
M9]^,%S1Q)S\?RNKX2\7O$@%YO$D1+!`[BM;5T9?2\CTT0%!V0@T05&QF##'K
M,@89N9,9DQJ9M"A02L*Z0M[4>&I0ET6^,*6D>GU;YXL\K?+L-*<9HCW7B:CN
M,COI,[OULLCJVA0U`+$F^][8TXJGO,Y(O@1B`,]Z=HJ<5O`3B0P3VJ@[Q-DX
MPG%$[Y?2A-RF=;:PM915#N,3\F-15B"N"7G*L7+7GC[Y$\G?ECF*\AJ+@R#$
M_RJ7]^2_2W.&N2"/:;XL\.'C0[Z$.;Z6YE_X!^OCIY!X=[)B:LR6>,F42V^O
M,I0O8H%'=S5)R7U1WJ8%N<W+)IL_+,NBO+=%:#R$-:=5ZQI+]J"\JQ2/:EU!
M=%65*U#<)JT`S+\)BDRPS-J<@#H9=^2=T$7*.-G@(L3\3H6BF/=4Z&N1-GB0
M06Y:SAW]:)BS'40?W8O&$`C\,I#J"*QQV_TYELM/<:S>L5@PT=:IM7DV^[#2
MG+"NYR<Y\#:E<=?1T*TNXJ3UZ7665O,'H^F+[%M6E"MS4IW.F_Q;WJ">@^2-
M!\`SVO);5CU/-B$GS@$LUWCRBR?"V-Y0E4B1/1?.ENEM@;5C"`AKZU.`:)P1
M;!&+"??/)PD*'/V".R;9..*6S)65P>^OL74%#[27?ST_9M;<']+J,9UG@"EV
M=7B@S![H0[C800[XAT<(;L4S@,^+]2+[SV-'$H!G<M^I$M+*<.(8]EK<3-S-
M8#K*`(!B>$>`:#=`I(7208!$R"0($`L(/2$`A<80`I#8$1<"$)C9AP`X=C.$
M```B3`7C`U10+H)(,LUY&"#A-"@+%O,H2`53D69!`!G%02K`&^@PDL"&*`@`
MK`P#,#:`)`6M#0%HK)<%QA,F@S3$C`4Q5"P*ZH)@-#C.J8[#ND2#XS"\?_[N
M7T(!%T`A'BU1\%2X)X5/=M@\N@[2/]MA(30$^K?Y&JRKQ2I0BCUT;G'`W*&"
M-0J#NS)&/-,);ES^LM7K1#BG;PZO/T)^=U]6_22F:[L5L'ET_/:L[[/9`FQQ
MW(\#[>!(W\05\ZK?V[W@2@>/F:%'S.'8Q\8";"/FQF$S!!;Y-IX*K4C";0ZA
MQ4PI<)Z>IY*[?H.KM>G8V'$T?-#2"4<#;XL20FWLZY0[Z,[FZ\IF*9!2W+[,
MQ0^C'9U'TIV`=#E$XM;/ZWH-VX3U:D>?UF%+@_-.VD/^;F7EDY?L>U;-<?=Z
M;*XCT4IX(^+F".@O4SEIZ@82),Q\CKH@ONL\@E8SZ1<$8B&$N32U7+E.R*>T
MJM(E));'I5FUC@,+NI*VU0^FM=L*86Y8Y?</3;W':^#5`&><WD[[%FD!MHS3
MCX-OV(EVZ'@>7^7#7D.!(7G$'(Y];"S`-F)N'!E*H[<Q5`$#O>D:ADIW<OY[
MAAS,%MO2.V@Q1=O%>ENZZ3%7D9JVS@"[5'A7<S#/1D5@<Y3>8TNPL\VCDLDZ
MEP"&*50BO)UPK`[;IJ<JG^]T"8=)D[_=)1S$:WSW<)=PJ`8?[A*4UM[RO!'V
MS<T";%F>'Q_A$LRKKW`)L18M8@['/C868!LQ-VX8*M_8JP`)F+?2G8G?X.0!
M:<4L:8US1)9RV-)Z(U)SZ@JQFYG)T2E574<-56Z]*L,:["Y+/&PYWEFBF"6X
M7_.,53SR;B_-"WM39<>!T4'+4]&JLSEH55V)TJ>`[H8%9F)X)V./)2:TS9R]
M[O>UW`)L*;P?3]YLB.;-O8;H]CG`#MSGL#U[J$!I*^ZJW]TU%NU;.R[W-UAO
M=GQ:#7TFOK.R:QM^D5SA_@2P'>&1[*N!?FB3N,'<;^>Q?3,T=2+MU/&;>2RQ
M_D)WW&*()EJQB6;L1;2)H[$\LJ\&"#&1S/+HK728-W?0\;<7:V`2/(Y9V/"_
M<Q$Q8R_ZGTV(&L<G^VJ`3\;7C-(E^V9@ZIC&8]D3"[6'/1.FXXD6](7!&?<Q
MBA#[YMY*<5?C4,A/7U/"I\(]);[8X1Y[-27\;:3/4MU1A-1MT[JD6@]Y+;PL
M&O)<@3*.(]%3VU+6EG'<8[^,@S^.]'5*#V=?Z)<\8@['/C868$<9!W\<YRA?
M@Q?Z(8^70[&/C`78QLN-C_&RD,EXQ/I;MQ=[MU>L$G*O+?DDL'MWM'LV]`FV
M`#MV[R.5I8=52"C@ESUB#L<^-A9@Q^Y]G+*8-U^!%SICCY=#L8^,!=C&RXV/
MB3*Q?*VRO&*54(P95!:,%HYVSX8^P19@Q[YNI++TL`KMZVCK\CR.?6PLP(Y]
MW3AE,6^^!B^(2@XOCV(?&0NPG7Z[\3$Q-U&O5997K!(*MH/*@CL+3[MC0Y]@
M"[!CZS%.)CVDAC(`^.,R`'AR&8"2;9RTC_T,0(W>M:CN*JTO:7^X*9NMNP1;
M`=QBZ)%M$>-MR+2/6P$<?@0&171$`%?)ZP*X0\SAV,?&`FPBMOUR%_U5%_T=
MYPW`%N?]^,CHO_>2]%;T=T0Y^OJ46(#=1-FQ+G508HL2"[!-E!L?N4%3NZZ9
M[]Z@;05Z2Z:GN(^>!=C"U(^/#?2OX3\&+8>8P['%AK>Q=1__S5B7)2BQ18H%
MV*;*C8_;5^YD_]]"Z8*CSA':)\D"[*;.CG6YAA);)%F`;>K<^,@=[4[R7NQH
MMY("2Z$GMH^9!=A"TH^/30I>H5@FP#G$'(XM-KR-PWM8;\>ZC$*)+5(LP#95
M;GQD1O$:HC#*6:(\?7U*+,`>HLQ8EXXHL46)!=@BRH^/+`'LUJ?=)8"M[,'1
MZ4CNXV<!ME%UXR.SA]`G-4PG&-X7`?W;,36CH1-]PMWWP")[AHXU`-X=:O\1
MJ9B\K"!3LV(LHMU+AGNDL=WKY75K&G%WB'-5?LN*"9F7=4.RN[M\GF/[HVM@
MQ!I$W51IC@=-KDGP,?^>V<;&*BM,>SL`S[.Z=K]VK9#F6Q^;'</NRT:F3]!_
M[Z=KOSPRW5';/J"[#W)0[4Y#-GL]ZP9/+;%X;\DV7Z:Z72\7^,6>HGRRS+G+
M*H0VA?YZ?9]6-;FKRD>2WE?Y?%T`O2E>GZSSQ3KSC9_8VTGF5;FJW8<@'M-G
M;--8N^[S(Y-,VZ\(J+B]:<RYD-V5Q[YTRCLRSXIB791U/B=9\Y""K";D=MW8
MA_E#]HAMH'7W:+[C!9Q8Y+81?E46H!75YB>0;O/RL2PR8(K];AE^L`Q/A/W+
M6=V\;'@]C/0H\=]M8ZJ["R`BY<1=WGX#?/W'9Y89L-_(.VLJP'0-4L06^3OX
MW7P(8N+T&V2.C37ENMIL"#;*F]?`R^I?68.O(L!;"0H=`(/KVJ`([Y.V'X6(
MW)<#?\C+2ZM?/[@O;AV3H^"?.P2\J_KP]Q%+[(_>K%WBY>40TZFJC<<4;_>R
MD?L`S5N]+*R(I.Q<<D#_9'MWB');W*4SF2AW2'=I7.>6C:!31(-JF\51(U/R
M#:\)-<_F<VI=AS:^N6%'Z6I5X*4=VP+P-F4],N6\O7JT><OLS:L$S`$UI5V%
M\J0MGD>)[^.W#`Z:PD@2&9I"N[J@7>.+IK[QY>][X]?`HGO;1&FWZ$[C8+$<
M:QQ,RS'&@2N.5!&F5=O+$KDZU,_ETQ$7`1_4+A)L@3IDC;A=`QMJ(V?DG#.G
M@R9+V$B<'LJZ:6^/5.G*7*E`@"8#H]P`]!=,P"?LOGWQ_"83/[+P8E^TXJ;E
MRNI^8IY-]\/>Z!=<-&#NP.1N4;9A<%QZ@X/@]]5P*F3Q8XF.C'WMV*R\N!_Y
MBD7V6CB3[2*[+5S8UG^V9V*V]R8K3"Q\(AA)?Y=LYTZ&1?'(1<`QMHTI;@V^
M57+"&Q#!ZP/39&`<?*\*`D0)"UZHF?(D?&=G*I+PC9NIC'7P(LD4$IG@)8MI
MG$1A@`1[NT,`.AG@`Z.)#%Z8F8(HPO>?IBQ*!BAE7.F!.40<OGXT95(-X:%B
M-H!''(?O44U98GHR0A!:!>Z>&-VB6`H/0K!!B"BF83P@9QI0X4C$*G@+:!I)
MH<-<CY2,!BPI'KAK!!!ZB)9$#T@NTD/F!MY6A6GA(/X!HP?1!>\=33FG<F`.
M00>XSB4H2!A"#=R/FO*8)F$-X@GE`WA`'AJV**ZU#$,(JL-7U::"Z0$?)$"X
M8<D)2,S"_!"2AN_4386B?`"/>$AR(J%B`%.-03\8%NB0Y"2C`]Y21D,:)#D=
MD(L40YH,SD&%K5+*)!D(@DH%>`K!_O*?YV?G9_\/92W4(PT*96YD<W1R96%M
M#0H-"F5N9&]B:@T*#0HV-2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#8V(#`@
M4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P
M(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-
M"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR
M(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@
M,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C8V(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],
M96YG=&@@-S0P,@T*/CX-"G-T<F5A;0T*>)R]75US[+:1?5>5_@,?4BGOEJR`
M`/CE/*UC)YNM39RU[U:R57D9C2B)V=&,,C.ZU\JOW^X&0!+#)D@@TI;+-M73
M)$XWFJ>[`0[GV[]<7_W]^DK<EDV1"?R'CNK;0IO_;)^OKW+Z),]DF>4E2626
M*WW;-++.:B&R1I79L;V^^G.VIVM5NL`+%76-_\N.C]=73]=7#_^*E\)_1@)Q
MJ[6"`6ZU*A3\3S52^I\WNL#/&U7AYW5=*OZ",ONZ*&JX5IV+#-2TP?1`!IH/
M9?_A&/"WGZZO?O7;S=T6S%/9)SB!'$$7=::7\!^AX=-GA)2759E]VEY??8VX
M)8B_7%]]]6^G[/EP;+/-_MX<=/O[U]/YV+6G;'MX;K/S(=N\O!S;;;<YPU]/
M;?;0[3=[^'-WD[T<#]OV=,K:AX=NV[7[[=M-UNX_=\?#_KG=GS<[NNX!SCIF
MF_O/&Q`]PH4/#WC-W5NW?\S^)?OTM^NK[\&<_WH7HW.89@&3WALM>Z-E71BC
M[[K#[O#8;0'?Z;![/7>'_2D[O6Z?L@W8LO_'VS.`!,,!=W?,GC?[UX?-]OQZ
M1+S69%#H]MFN:U_1FNU3^XR7.XWLW;6/F^U;=FZW3WL:KCW=9%_:K/WYI=V>
MLTWV>0->/K_A^?OVR\<X0C3.$7G9.$>H$H_1$<^;X_^VY^SP\G(XGE_WW;DS
MAK?/[?$19OIPS+X\=>"7+Q@A9YCC%XP"^.M+M]ME=R"]V[D8V8$IKT=TT`L:
MMCGZQH]<L]V\;.ZZ'0UWFVIW.6-W)8K!\*_2W%H%W=I@3,'%&WU;5WF=??H'
M#/3=V^:^VWJCF9-__!V>_`5'_@\XDK<%7$#`?^$*NN[_VEU?_?0N`'73`]0T
MXU_]54JY"$PW8V"%?']@0)4.&,:C+(=XQ&.,QU/VT_D($?;XMHBW4&.\N4CU
M9""2<C&X,C&0PNS<J,*YH]8#.>LJ-^[X]^YT/AR16'9`K*?7N],9[T+\$\CZ
M=*;[[=A^;O>O<'\];3ZW<$NV^^R^/7:?V_OLX7AX)IWOB=.R;U]/W1[(ZV:X
MJ[<'N""<CO=PM__<PD6[_4UV!S<JBDZO1`T?04X-WCG&>*E[DE85'J/QE)$V
M':0,(%HTPI+5R^'4(6,C_Y[;G\\=$)#C;#P'4+^T^Y;BB(@5J0E\2"Q_T]/\
MR^ON)?ME]K)Y:8\W=.)FWSU#1GAHV_O;[`<8<'?8/[ZWX96L>LL;>:N%R`U_
M?/WN(T%5,?A8U*+G_X*.T<?G]OB<O>PVD/X^8H;1-C/#C=)]>!>%K3TV1TPQ
MV]<3A.K!S/&WW>'[/>2>MSY6*1WM39J!X@.RR_WKEN8?\VZ[V[WN(""V67M^
MVD"J,5-I+_6GI\WQ>3,*^]"U/L`!=:W[^SLO!@>X$,=D"/$'!<@6[N?]80L1
M1S73N;L[W&/._*LHQ)`WQ_H`_MQV^Q-HY)2H7\C8+7T*%[GO3MO#YQ:2,)X_
MF'K[$416Z\H:*O-F(+(:2FTR],]85YY;<W=NME!8PBUY>D*#3FUVN/L;5$3`
M6*?L[BW#R7HDT):;\$\X[>'U2$ZX![[;'5YH!DW2S?ZTVYS!!<_9)U=O&*OA
M:CO0/FX>/ZC2K)7H"\UZF&"5#Q1V]]KM[G%X&^'MST#J^/?=$)6(&B?-!*_A
M.53I]@_'#13CKUA\0JF4@1^AR#RX&A*\XO'W/=3<W<,;L1Y;VN'E/\(-N6LR
M9)GW+)/G?93[A>"9#-@=.K#@Z8`!,`9IDX]UU^'+WK#ZT_'P^OB4G4Q]`)/N
M_`<NV.TV=X>C87BH3/%L#)7WKRW+2O3&?DA%4%5]YR*:?$B*4O8WTC#WCY#F
M*,OU)0`E?'-304L&/L4[ZAMBD8Z(`GV%]QH$UX^__&YR8G<$JM@<<1I^;<XR
MIT%<M4<3D11SO<.AXOB`>*J*OFVIFGJHB[0M$_NIWQR/F_UCB[TFQ,W?#@`O
M`XOH;J'N]`%B[`3$2)3B*1^.O+W6X,UQ3[PS(I0MM;I0'L#9SU!U0&VVAR2R
M>;-7_*";BPHBXXRB&36S4AMG'`]OF]W(@L]DP`DRHVU7D?BIY&O'_`DY%RGY
MN*=JTMU>[I:#['$^=G?4&D-WN]GO6VAN,<W0S;E]/1[!:$LRIQ%MG;"HO&NA
M,?Z@T)"N9!:CJE'V52/UI;9]Q0(1URM>,1YPPA$_E!OG`WS^WMBD5#VXCRWL
M))20@QMR2K+]LHY-N,,M>CC:P+!Q\=+M,;+?&Y0JF_\G\W%);10%2@XT*5SC
M='@P:RI0:,!4XUH54IC)@1#3N^X?=','*XA?8U3_"B*&G&=HX2,"6O1M4%U7
M_4R6N;V]#W?8`"'<1Z"O\\#QV7]#OH2[^*<SI(!3]HC%'JVZW6"<M]WC?B0[
M8?C;=3A(&UM<>'EW:PI1C<P1Q5`+*#I&<WY[P)7`>^K@8%:@P@&O4^:&L1XW
MQWLW,4,G\`%.+YN^,U%YWYFHVCE]Z!@N.F=B.JZS.+5M]OM/W_\ARV^S[]K3
M]MB]N,;"*;U_-2*@(#&&?/57J472]>NPHXJ^@RD&NBUD8^GVQ_;TNCO3BNX/
M+ZTKP=X=B%(]DG<@E^!(U<AFF8]6CVDE&6W._@>J`PB,>[CYOFNW[?,=W%4J
MO\FD$&7V&^AMH+&E3B>@6+QW,!2E[I&GEZ:S2V$0"DK_DZ$6+GW+O!KJG*&7
M$HU=M/^$J1S2VN$+401U\2<L.+#.I5;2^'[_]NX)%]C"H9M;4GV788J1$\2(
MF&1/3'"GF=O,=(<]=SY0.=MF;Q!QN(7!QR:2%\;>-^_?%S4]](O@@\A1LH*^
MJ6I$INBRP_FT&08*N=9&0<XH""V;D()L=%X'%6H%#7I(H:(2)J!0*J"AD$*!
M,QA2T%"G!A64;,)62+E@1:Y$&*2035`A;V09G`LL.(-6`&E"J112**4*6I$7
ML@B#U!)+IX""`CN""C)?`)GG.JP@0"6DT.1YT(A:5$&(4$H%@Z$09?!S+8HJ
M?%.5P<^E4,'KYZ*:__SO5J4H207X:THH389+1)90\NGFY;`*4.0F#P,M-K5M
M<3Y1!H#"XS<'7%H\GR9;1CFW]P:7K<R>43/ZT^P9#?OR4']G1571UI*DHYTY
MJG,\HH_-X=/87I1IW8#K(C<5FQ+.M=T3X"ET007.U[@"(FP"I.X>6]K#ZPF8
MG%9^+XE\"4.`PX$`>PS3'#]R#3C#NL9YR7D$LL#.*32^<]SG,#RTKU'`Z-1F
MKLX=](M*]L`L1A^-4;@$9C\'ZLXY8*$-34B61>V6/DW)\A4FVAG/X:,E%J##
MZJ,R"A<`W>?@G[R)K`GQ5`LPY+D2=!PPB]%'8Q0N@=G/$SQ7RISU7#'CN;)I
M'$"'U4=E%"X`NL\3/$>GKO!<U>@>F,7HHS$*E\#LY^`YQ1%CP'.5A%9(N%T'
M@2F"G/?[_?;8;D[3-;=_9BR8UF&61*$:6_P"$4%Q2>--2&B8M%KT]Z-SD^\0
MHW#A&_=Y'3UG=.;\G-W6]$`6U'`VU<#@14U4:4=ZZ"G4R6>8*M`P%Z5;K95:
M#UU,HRV)_[$]9Z?-KCV%P1'G`8HA=!\&&O7D<31JT:UP#_$BC%1?`!C$D<ZA
M,^WXD'J5@+^IB?_%`A#(231B=8%D)(^$@I',0LF+&U7K,!XB569JIO(XGEX_
M-42\TZD9B6/]@6<F3$V!90LS-6-Y))2R$+-34]<JC(=8FYF:J3PN$:R?&F+;
MZ=2,Q+'^:&9"=6%J*E&Q4S.61T*I1E&*4*0M4BD?Z*99`(3L//7,2!P+!\\<
MX`R+@H&41!RH^K)>]66]'LIZ/2[KAU.MUB@M#.G"ET>E"^TV,E0U/"(#_;%=
M[_D-/>7UD#T>#O<G?%CU/E25JZ$J5T-5KH:J7#6L;4Z-S38JJ8`RKEPNH(C%
MU5"TJ^H"K%&8P6W5N!RE4DH(.G,%:B)LB]H:X$,U"C.HK1J;T*P\):%9W#YK
MYC=*SU751/MJZ$=4=0'=*/!6.#4V#:;%#)VZQON87M30KJCJ`JQ1F,%MU;CD
MF10S=.8*U)1)+&IK@`_5*,R@MFILIDV+&<JT;,S(F[JH0IV8&CHQ55U`-PJ\
M%4Z-S<]I,4.GKO`^Y3TU-&JJN@!K%&9P6S4NJR?%#)VY!C7F.(/:&>!#-0H\
M:J?&E@!I,5.5RHL9>MC/E0#Y39'+4"^HAEY051?HC<*,(5:-*QV,.*5T&,P(
ME`Y\8P;S:BL(.+(5A!1]PC6'_7>!F+X3--A"PI='%1+2;5J*:K2C+=W&T>^.
MA]/)/A&UHO$S%CICG6%YW2=G<SAGH]-F"XH\O7V5LX6X7U!8^-82'[-1",.W
MVEQ=,1;'U14KP%,&M."M'3YBHQ`&;[79\B)/ZY>A2G7PO52A;X1:J/LI/1J3
MG'6^'48A:)+39FN-M'"B4]?,""98"]]:XF,V"F'X5ILK.9+"B<Y<`9Z2HP5O
M[?`1&X4P>*O-5AYIX506)1].ZD;(<D6#;4QRUOEV&(6@24Z;+4/2PHE.73$C
ME'LM?&N)C]DHA.%;;:X:20HG.G,->$R;!KRSPT=L%(+@G39;E*2%4U56?#CE
M-R)?6#&BLL.:9*WS[3`*89.L-E>>),T'G3D_'TQ!H9N*7<CNY0D%Q?#E'34\
M!:5J]Q34#_US*/A`^O[4GKY9KIP0#U<3^/*XFD#,[@QR:1U'8M*Z)XY+ZQ'C
M0P:F@9C,[,LCGOJJ8Q!@UN/F8"J/2Z01""!U,7,P$<?EPHCQ(6UQ<S"51SW\
M%($`4P4W!U-Y7/:)0`!\S\S!1!R70-:/CUS/S<%4'D&9(@H!,"SC@8DXCK)G
MQ_=6D77%;SKV\GBNUG7_%9%2#9N.N7)/C@`@_#?[L3VUFR-^`79_[[X(@H^'
M!Y;+$19+V55R&^?@+CUE@D-P7%VEMF"K!D8RKOCVR<D3VB<W]$7[)-7<0AM1
M,N/[J3R*JM>X@,AXZON).(JC5PV,),SX?BQ/Z#5F?%\6LX^;(!4SOI_*HRAZ
MC0N(A*>^GXBCN'G-P$2^C._'\H0-P['O_0W#O)Y#@BP\=<%(G+#<-\(1L]R'
MY%HT/%\[>0)?E_U#-6IXQON"JW_"IT3\+P2O*+`+?A?/E\>Q=;GZD1KBV(+=
MC_/$<:0=,3YR=,'OK#EY"G>7S"Z)NM%YM:+:9B9D*H^C\/4.(>*=3LA$',?D
M$>,C<3,3,I:G$#HW(?*F%@MKD43"S(1,Y7&\OMXAQ,;3"9F(X^A]_?C$YLR$
MC.71+#\S(:6H5U3A4V=,Q%%5^+PS_"I<"Y[5=?(6C-;]%HP87K4FBZJ\8/;?
MT??VS;O1-O?/W;ZCMQITG]M0'0XGLLSNR>.87<]]H^NB#H<A.$H?B^,H?<W`
MR-DX`L?E5I["Y5I/([6ZR743JL,9WT_E<22^P@5$ME/?3\1Q[+UF8*1GQO=C
M>0IM<[XO;HHR6(<SOI_*X_AZA0N(5Z>^GXCCB'K%P,3$C._'\H0%<M;W^4UQ
M\;3K114^=<!$'$?.LP[@JUD8PVRTXY'9:-=2N?UH>QC8:$<-;J/]0A[%\K+_
MFJH4PT9[)?0%R__6?@G?O"MC^Y:U/^.+-![;['&#KUC;MRLVXJT'G#-ZPW.W
MJ6T/0QOQJ,)F#D\>ESGDW/>$!GTB:@O?6N)C)H4%^%:;RSYC<5SV60&>*-J"
MMW;XB$EA`;S59C.8E<=F,&31X2T;2HEZZ*CEBIUX:Y,SSS>$%,(V.6TV&UIY
MK$UT*O/FD&EW/DP/)B)KBK7*QT\*"Z98;2Z[)L66.7,YMB@%6?#6#A\Q*2R`
MM]ILADZ+K;*LYF-KJ=6E[&9L<N;YAI!"V":GS6;[M-@RI\;%%B5::XJURL=/
M"@NF6&VN>DB*+7/F<FQ1DC7@G1T^8E((@W?:;`62%EM550=B2X9C"[?@G4W6
M/-\04EBPR6ISU8P1IZPIKHHLO^T4,VVG2&\[1?^Z$OS"]_"6S<I^3_J`[^$^
M3+;K0[VFF.DU17JO*5;VFH+O-45RK[EF8,S(8J;7%&F]IFKZH?V:6]]4U5S1
M3;F0<?Y4'M=LKO`!9:^I\R?BN'2X9F!,68SSQ_*$1]MYYZN;2[JYZ#89YT_E
M<=WF"A\0O4^=/Q''Y8L5`Q.G,\X?RU.Z3=;Y-U4YYWNBTZD#)N*X;G/6`5RO
MJ.Q[$RZI^4(>\\HD-?LZ!;91PY$XVO7E4;0;@P#F"4=BV-<31[%OS/B@2@,Q
M).S+HYZ.BD"`5,G-P50>Q;XQ".J:FX.).(J$8\8'SN7F8"J/>CHJ`@$R)C<'
M4WD4"<<@:!IN#B;B*"Z.&!^IEYN#J3SJZ:@8!,"=C`<FXB@RGA_?KSU5*>R:
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M4^-"B+*?M<&:XP,W"C,V6#4NI2>%D#ES.80H\1G4S@`?JE'@43LUMA!("Z'*
MOWG])_*JV3UP7&!S9EB+?.Q&8<8,J\95$T:<L/2V+GS\\D#/]'?I;^]0]NT=
M7^,C'\/OZTC=V+==_T!OW.[V]$MZZ&.[^(9(OPD507JF$_3D<;E>KWNU'P[!
MI6N=W`*N&1@SJY[I_71Z[[=B:,IGC+NG\KBF;\W0F(BF[IZ(XS+;FH$Q"3'N
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M<"P_%L>Q_)J!D<9Q!([>K3R:WG4_M/]<[^S+G(F`&<]/Y7$5]PH'$-]./3\1
MQQ'XFH&1H1G/C^71S%WPGI>S?3QQ*^/YJ3RN^%[A`*+2J><GXCAN7C$PD2_C
M^;$\A919SQ=S2W!$GE/S)^(X-IXUGZO#\5<[.%+NY?&D+.M^>P1_"Z/_V5?W
M8U\]*?^AVQ^.W?G-_.0@%N3+E3CBXLC9ET>1L\.[LA+'D1B.]L11'!TS/E`R
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MHZ9T8E%;`WRH1F$&M55CLVU:O)2C./=+^$#_8@UPMOBHC0)O@%-C\W-:N)A3
MEQU/2<_BMB;X8(W"#&ZKQF7RI'`Q9ZY`C2G.H'8&^%"-`H_:J;'Y/RU<JEKR
MX9+/O;X)=\2=!=88'[91F+'`JG$E0Y+?S9FS?F?;+RU=M:"EJQ9T_RYH>QCX
M[BUJL$6#+X\J&@KWPU=YI?LW+&B\XOBK+E0QK-OQ01HPACJ;>_MTGX>U#IGJ
MM-G:0:?WJGJVX/5K!PO?6N)C-@IA^%:;*R%T<J.[`CPE/`O>VN$C-@IA\%:;
MK21T>I>L9[KDQ=^&PG1H;'+F^888A:!-3INM+71ZIZU7-7-^G6%-L5;Y^(U"
MV!2KS94;2;%ESER.+<J.%KRUPT=L%,+@K39;=:3%5CFZKZ<O1"N7NGQ,GL8H
M9Y]OB5$(&N6TV4HD+;C,J7'!1:G8FF*M\O$;A;`I5ILK3I*"RYRY'%R43`UX
M9X>/V"@$P3MMMD9)"RY<E1X'U_"FLGIAP89*$6N0M<VWPBB$#;+:7,F2-!OF
MS+G9\)<G)+_=*-/?\B&'MWR(JG_"1!65&CWX?]<^'(ZM>[SOO/DY^*5:1,/6
M"#)IX\6<NFZS$8?@\KM,W6Q<-3#F8,EO-CIYPE/T;FCN*?IZOMNO)#L!8WE*
M4AW`K%J&H_PUG8R)."XAKI@,2EK,9(SEL;ROR^!DZ%DO4,9@)F,L3TE"D9-!
M?#^=C(DX+H&LF`PB>68RQO(4\I?,EJ0J0Z]99<R?B.,8>]9\OF\2?9,I^B93
M#$VF6&PRQ4R3*=*;S+S_=67=?^5+-O8;7W\Z'CYWI^ZPSX#[YZF?;[/$T&F*
MH=,40Z<IECM-,=-IBO1.4ZSL-,70:0IY@=DH+'>:@N\T17*GN0(\,;48.DTA
M+Q`;A>5.4\QTFB*MT\0U:\$4;.7"CY80Z8NARQ3RP@BCL-QE,K$TE<>M8*^9
M#LPY8N@LA;S`;!26.\MI+$W$<8ET!7A*-&+H+(6\0&P4ECM+)I;&\NCU['PF
MEA96+"AGB:&I%/+""*.PW%0RL325QRUOKY@.2IEB:"2%O,!L%)8;R6DL3<1Q
M=<`:\)@PQ=!("GF!V"@L-Y),+(WE*9O=8F:S>TTK*8964L@+.XS"<BLYG8^1
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MYG)GNW6#;S`IS-AN/NOK+6?[8+!1F+'=JG&%5F(8XZI'*(R+?/9EUDWCW.`\
MXL,GA1E+G!I78B6&L3DU+HRQJG`V6'-ZX/V[,>>FTGS6UVIV*D=6&X49!U@U
MIDA+"V-S9D088Q5A;7=N\`TFA3G;Z;.^U+.VCPPV"KSM3HVK\1+#&->+6.M5
M&7JBP=EO7>'C)H4Y$ZP:4]-YXJC%)F?`M'ZPU599T!=E<\U?.Y]+U`(?R7&/
MMDOS@VJS@Q1YXB#@F\*]NM..H2YR(%Q>2[J\I*L/ER'WRNSK&CP4^CROBR:H
M(.NF#BJH!J(HI*!K5005BKH(&U'695BAJNNPF76SX(>FAH`).DHT4,,&-?)F
MP=!<5FKA&JHJ%G#H:@E'414+.,I*AV<=TI8(NQQNKCP<&'E3B;"&%(L:>;40
MX%)62Q&L:I&'-72APEZ715&&`TB6>;,P2MDLV5(U"S,'=^/"W2:;6H1M4:+.
MPQY3>0ZI(Z@A1;-P#94O>%WI7(1]J@JX'\(:92X7Z`FRX`*.&L)P0:-IPAI0
M':GP*&#L`@5I*61XYK02.NP/K445CC%=X(\/!37*I9G3<-LN(*WS?`%ILS1S
M4"\OL&61+T50(?.%>2G44B07,+D+"4PW,GQ7%D45\"FD\N__<GUU??5_"JD=
M]PT*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HV-R`P(&]B:@T*/#P-"B]#;VYT
M96YT<R!;(#8X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO
M4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B
M8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2
M#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@
M,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E
M>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]0
M86=E#0H^/@T*96YD;V)J#0H-"C8X(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA
M=&5$96-O9&4-"B],96YG=&@@-S`Y,PT*/CX-"G-T<F5A;0T*>)R]75MSZS:2
M?G>5_P,?4JGLE.P!0)`@]BV9)+N9VMK))F=KYF%>:)FVN9%$C2['Q_GUVXT[
M*?`ZTM2IBA6P2?0=7S<@\;N_W=_]X_Z./.8R2PC^4Y^*QXSK_ZRW]W=47:$)
MRQ.:JQ&64,H>I61%4A"2R*Q(#M7]W5^3G7J6X!D^*"L*_),<7N_OWN[O7OZ`
MC\)_P0!YY#R%"1YYFJ7P)Y6,M:]+GN%UF0J\7A1Y&G\@2QXR7B#SE"1`QG/%
MTXL24%\LW,4T]PQ_]^G^[H\_ED]KF=`T^00W*$6HAUK1*4A,.%S=(DLI95GR
M:7U_]P`,J<_O]W??_'=U2GXM-]4Q^;?DT__=W_T`S_V?Z;,KY0[,SO3LW_R=
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M!A7:@!IOH8@L,_Y/1<JM'GB*48]ZZ%AMW>R>S^N39:ACQ)626`EQ>CO#;>`O
M7BO-#FRY:[;UKMR$WH`/ZCSW4KN/R5^KF\B?%C;^):1B(W^:">,'Y>Y4K^L]
M"``BE2<TTGL-%GFJ7L&@AVK=O.[JW^O=*WS^7.W.E9<)A/@!9'_]\"Y2*U\2
MR=])1HY5!4_9-.\JOC!ZCNM#O3_5S0[5@-K^]JG:O39E\LO7W]]$=D:M[#EA
M2O9OOGT]5-6VVIV`1?IX]5ESO(N[C.L]#C*NU!K_]%;Y3`(*J[2/]654$Z?H
M0<?Z>-(DK0><JB^G>M/_!+KB)B4W+R]'R%28@':W4'B1BZ["T=D8V@%%KW>>
M:\TM+`PJ_L$;#C#Z?#Z>#G6/%)29C(4:M$*;>SZ2^IC\XUR?,(2WV^:Y/M6_
M8XZ!>-T?P,/!@4%L7)"J4WUJ#LI7T0=OH8:,&#6P3!96#1FC3@V>Y_(5'/)X
MA(2HY?H3+IF[CT0''_BI6I6.D'0@FS3K,RP@.@O5NQ,L54J#X!JG&D,3/BN:
M55*#HU0O$'@G)ZCQLR<;JZ?FO3P\+X<U0PI(+::B.<!`FW19EK<4@(9^!\,[
MWL[H&L#XYV;S&2SVF/QG\PY9YZ"7I&UY^*TZ'54ZP?P#[H$YU0IXK$('`MAA
M4O,&O&<-R;9<GV#A^5TOP)MF]PH>=_RG@-V0!FCNEIT\]<L.8&>E@?7'6JT/
M(`I&!,0V_-V4)_13L.+G\E`W:H%9HZ^NDN-Y_8:(ZE"!DR.B>FU`+SM,9+#8
M'"!9@]RERJV@EC78%YZ.6;AZ!#6^-(T.A7('\;1)7BIX@M:YTMX/YT.SKS`C
MWD(70DH;#@$4X1E^UDO0LY?+&#4!*Y8;,.,I`7\^-=OJ<+PV:XQQQYO.TX#"
M&;O^-(6;YINKZY=!?-FG2P%)!I><WY6&*=9\2L/@1O4&,J).K-OSYE1?FX^4
M>BDE>^2$4,7'-P]7GXF%+D5SYO-+83QJ"PGQ+7D^ZX@`H0\VX%U([,^;??)U
MLB_WU0$=7R=50#_K<J?2S:&"X`34"FLFW+=KDM=S_5SNUA6&X2VBI&`^9THO
MDP6JD!4@5P)O($S]LC(9;U>]^SRH@-L>DAZF@@H)R_5;72G(?=19X]"\@V94
MPFR.+J7"TM/"$)@\Z^T>5@^`AR@O3/:1O%6@LB-$8PGWWPBNB]S!]9SZ7,&,
M$MZ;P^;YO7Y&P4_P/[^A/VN>]U6SWRCCO%>@!OA[!HGJW\L0<((I5<I48R#<
M;RK#&(!^PB4"5+([8]H]'W!]:)1+!.OK\;Q'O<#3ZMNX`2]<LN3>M?/<X'6W
M?./2\?Y6P[)@ZRJ-%S:('4[*)<#@1UP^(>.'?J*`1M=WT.35%RS;=+FNC7TJ
MGU"'UB^4W]2*N%R.G?OZ(0*6'RO^]1,EZI84-C^E1`B=G_Z9QDMO9R=S<]VD
ML4.E>S[6=;ZLL\D"D>1+LX'B2P&*\FF#[O&RJ=#4)P\SK[\:%8ZS6RZIG`4*
MH#1U(#LM;%T?]&2>/GR9$/9ZCGT-+]<+^?>K.WG.<N\;MV@IYL4-(X@+"^Q9
M7KCTG%&[\/XA^2]56KQ!?4G_3GAV;0$E=SQ<7T`HWGGJ<'OJN\&I3$WQ;IIE
MJIGU5+V"F+;F2H[UZZY^J=>X9-K2J]GU=$I46TSE4G#!%2;6OP#21Q_4C__^
MHWRNUW`1:I9*%7M0*$,V7Y\/&L?=PKC4X71*74[)L#6O9-^?#U!'P<)1VAZ*
M@E,W*:)Y[MC)71Y)KSY-UI*:2%^K9M(4Z[9']:O7_<]6$:Z9='6,*VA$?G[]
M:82;I@7:;U(*I@4/M`TYPVL;Y76UH/;]:\_.>1:7]>H%"N<RE#,7+H]P*DQ%
M]N.F.4`YT0WP7;.[-C<0O_\BN3-)0KDI\54,YP:^5E_6FS-VNY)?`(*6!^QJ
MH,D!IFZ:O<HIM\ALA#FP1'Q6Y\18P\4QE%!0'MF0A[1=Z;3]R]??KY*?=NM'
ME?&N#F<PV@V+-\QV#*/=:8*GA9G+B'O].EU$I+I^#DM3-PT"^QR-:G/8ZOI)
MC*>!$AD718""3'L3%NKST[%^KDL`G%!YNB7D\=O'%12J!ZR@3:>OL^E4XN:9
MCXL;Q$):N`J;Y2X#IR(W&?@Y",5;.#O`4\O"#7T=<**=16:/!4^9=@H(Y.OK
ME$8DNKJ?4P@G)]+-UVJ:\L!3&,E\*R++3"[?'YK70[E%+WY2VR[[3:7V03]7
MN-\'?EXWS^C4Y[WV=$BRRJN;777U-1>P>U0[UU_=\U`SE!8LJ!*,9M[*S8NN
M,%?)&4I,VZD)*F_=K#M6U6]J#VR_Q[[-Z2:X/LU=2RG-/!8ILLS9<7^HJQ-F
MJU.U?MLUF^:UUIMS)[59Z3,"6'/='*^.=UDA'9NW-1^3::`02($>I!!NJEBH
MWO3Q!;LOM:V_8#_PF.BMBHW:[C?[+)C'<=CW#55F#_6(/8=;V#4+MK?=1G-*
MB3G:@QNAU6%=EQOE7U"9JK8GU)HW6O&IE(ZI6W9_2!K(#K6J6\4RP@K;_GD"
M\(9]B&:CEK%UM=F<-\T1BVH]K/*FZ7\&^V8WJVDS(AS;-USY,AIJAY#,`126
M948[>-[B9K4K[OQ?RGGU]3`GA9OF`O==OSF=4S_=33I/*77'1@HJ?8UBDO3_
MJF7DI$X^'+;'[@F:P>[$RI'MR_JYM0I]1=7A+7<,3J]3-11"Y3&IC\<S)#JV
MHFF^$K#LWR"),>F.C!1I4)J9''9\*P]ZU])TQ/Z$ISMVR:^G9OT;[MU\Q1\A
MF^]QKP9)7?2N,=8A$>M1/`)283?.==DR>[11;:KCEHXZP:65"FD3^WAFEA^^
M@#YWKY5VK$^W.3/""GMFA&;!@0&:FS6I!1OPG`0RJE)6]>S.K]6P9A_*W;'4
M&0U;DP`_-&EU`/MNU08F:!.A!F:!YFE3OYI=TK-SL59^L'C.X[?R)@K(W9D1
M$F"JW/;A'*8RP+*-K-!CXX!J)KH!;(H;I]OF,+SZWT(#/'=E)7-9FTN[IDT'
M'/K(A#KK`E+>JKX7N6/YAJM]"H$1:(8*?XA3VDJD;658^;<E+.18A*N=<+WC
MV?%JW-2MH&3!Z_KHXXU.@S%F6V)$<+]5YS;V6Y%MPC1Y:DYO*I?5"J:XI@!X
MJ#G5U,)TMI%P`7*2E[K:/$,:.."1!N4HM]O]RYF7]H8>@5MH7JFT('ZO@J:Y
M]8CJRZG:J4ZC4][7-S$O]><V6)"X[9&%,+]@V&[*P^O5RU^:IHZ1V]9/-!6A
MR/AE$'^\SV"5X[K<5&,%D4;>>$EI)/G<;,Y;O=3CF6&L,HT_`Y:!.OK+QZ;<
MX4?=0E`'1M^J;>UI;M4QHS+SXOIJT61E%:2748HGX'$W,`S3H]M]-N=R[**#
M0Y"A-\>@6WC]70GJ)+EA<.(VBU<8E!\N)%B1N^#$5/RS;Q^9&,%3R17D95BZ
MUNK8YN=:G5P("ME;F%>X;D`F@@"6K+7L.ML%)2/Z:M=Y7?-@Y?VX"R2"1PVL
M6BTWJM5&$3P+U'4+)>2V8J22>"=W7FZ<\C'Y=KUN#L\0MIN/5:N2T(>'+LXC
MUSLH3%I[XVA[U,I1`TM\Q@Z2M3NJI/IFCRT9L=F1"I(G0D*AI(3S4JCOBP$!
M0T""!*R'`!:';)"`I!D?(F`R9720H$C)X!1,8,-IB"#7!SK["3(&1AXBX'@$
M=(A`G<<?(F`L'6:2XO([1$"H'+0%!!<;E((6>*9DB$#`OT$"J-@'F:09Y<4@
M`2SBPP0I&6&2X3&S(0**3<<A`D+XH!22D$$>"\(&O2&'"8:N<RG3P>N$#%Z'
M^G[8&PD=O$Z)Z)?O'X8DT\X&3XI^_9.ZO$<OOX"9.2"945UVXBZQ/:?_22U`
MD(C_A.7"[M0^A*X?\\M_X"/?,0__&1EZS/"Q`OYH-.;^=W-_]VOKNZW`60Z)
M=ZLM`9\VYI.BU9?5Q[=07AS#5BN5\P^'Y;+G5&+`%7-<608=,ZGZR-Q'SY>]
M#LD)(GL67_K6ON.2GAZ6.,<8\XQY;C1!ES%SG>5BML;TO6)491EAEC/+9)L=
M3=#AS%X'MYW+F+ZUCS%/CZ628<SRV.9&$W08L]<IF\^9OG=<93GGEC/+9)L=
M3=#AS%ZGQ6S&]*WCC"EO9)D-2I;9H(0ES\:!_M@.2B9U4(K9V"MWWY9*N7"=
MKTS:KVABA?&3.K%_/D*)<\1:8RAV-?-6#L>S<-&B/W9B%P8Q=GO8'XS=M"^I
M>'I6<,<8\XQY;C1!ES%S'2T^4Z_`2J*^>]8][XU=WS[M8509)@V_;<XT09=)
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M`8BDQ)YV)"E^'PJ7!?.MSF%^%(3#B4F;G\OQ>:C0,#1!(PKFP4P=A03#<\$?
M\_-??-GOJQ%F4J)FS7B'FV!\+CN9B+,C5U*,Z08Q(DS;Y:8[/`]TSK`-+ANQ
M^8O%\Q>SYI<Z++*LPT`P/A=%I5G<''DVS(O"A1@1'66$XW-YX=XU\+>:4IGY
M!(?:2498RJ.A$PS/92A?'CJI(%%;A>-SV9$LS@ZE*Y[Q87X4%+WTW8OA>=AV
MNN\J&!F;7RZ>7\Z:'S[%[!&.S[0'%WG<'H*-\&(21C=VPO&YO`299$GL*.2(
MX+/-43`\DR%U9TPY(W&3D2)JIW!\+BMIFQ7<C[&G(XGZ0:@1EO(TYKK!\%R&
M\$[/4/OK"V.\B#@O8F$8J3NGAY&"H#'S!.,SM8&SA^9)21&8)QWF1^%-#)FB
MS4\X/I<?%H2U>!1%ZMV%QL/)`VY`GUDAHH#6C<\'M.H+N":RF6^+,F:/PWVK
M?\OHQZIZ'FCE*@XBR+8]/@O96L[&-E%PB@BD;0W/VHJ8-#'`5)PA!E_M^`+X
M:J=NK\$K0`N]O52NYHO@UM;P+-PZ20&P*D0G+A9/7$R;6&I_CR%5.SX;'=*X
MYF5?JQ3@I/+L"$*UXPL0JN5A6@&.$#+B^Q?#T_NQ^33?1YP9LT`X/AM_%GV^
M3U+1VW+-8BYX,3P+=TY1`.+#Z,1R\<1RVL2P.,4T'X[/1G<LKOE>K9L(CR',
MA;[/@]"?YOL(`7&R"*9L#<_:3YUB`<2*,0N$XW,A&\_B%D@[W^8)6Z)IS`$O
MAF?U/">)GXOXQ&+QQ&+:Q(+&]1Z,SP:'O$?O?8LMPC?EXA%$:,<7(,(IKA]K
M;V9Y$4>#=GP!&A3N%QRX/T3/I#U$_[/^.;^?\>?\QMN=BI$8*&R-SP.%AL&)
M[4Z<*88-P^%YV'#&_`@%8:(H1#3C2R"B8)<NRU8YIR-UN$)V,&\,*H;#\Z#B
M#'U@EH_-7RR>OY@UO]2A$06.9GQ!BS-J#RJ&>5%H#Z,@!B#-^!(`Z<)W1B91
ML.\R3BZ&Y^'(Z791L#%BEW!\"9R,VF55Y'(D3A0*O/33B^%YL'*Z/A08C,TO
M%\\O9\V/8#)BCW!\03LS;H\)[<Q8G(3C2\#FDCA1$!'FC&'.<'@>YIQN%P4Q
M(W8)QY=`SYA=Q%B?60'&2R>]&)Z'0&<H(Q?Q^<7B^<6L^06-&R,87X)'8\;@
M(XU;A2$Q&&*PU(PO@:43@J33!(0E2)_GQ$_Z/&>6N7/-YN/%NX<,50!9/91M
MC\^"LOZ-).K72NT/E]I?+OT+?K5-_PQ%%ORB_<BI3R.BE=9*QJ4]9VD^7KY@
MR9!%\7!K?!X>SM+Q0Z$(.`W?S//MF=4$/7P;LAB*#H?GH>@I7".Z-%P;`=JL
M:H(>K@U9%'N;\278V_#=;<]*V=>T5QC52&$$:K.N"7JD,&0QQ!X.ST/L4W0O
MF>>Z\%P[5C5!']=%G.MB,=?%)*X5`C9<2Y>#`E8U00_7ABQ:'9CQ)6WEF,?T
MMI5SEV"L+&VN-4%<`$L6+2G,^)*2(DO'H9(W@7"IQ@K39EL3]$B01U/-Q?"\
M0F2"XRB`;K@6+M4$K&J"'JX-6;1\6>@XLNA--2+M2S4*YFLIK$!MUC5!7`I+
M%BMZ%@6MNG.*[K&JL%Q+S[5C51/T<2WC7,O%7,MI7/NT;@5HL\H'TKHEBQ98
MRSQ&=?'GI!I5>Q@!?(8/N-8$/0(8LFA5MBS5\"#'3TLUJNS1$EAAVFQK@K@$
MEBQ6RX7#\VJY"8ZCRAS+=>&Y]GK/^]W=DD4KP&6.@P`[ZCBL[]L[JE`R$N3.
M]0.V-4&/!(8L5C8N"EAUYQ2]"^JY%IYKQZHFZ.-:Q+D6B[D6D[A699CA6KCE
M-&!5$_1P;<BB)>HR;\D9Z?&6@4/B1@`K2YMK31`7P))%ZUHSOJ2NG9)F8MLM
MK&>[A2W?;DG]=HOYF6BUW6)_X?A3@Z\=^\D4I_!1ORCS.,RKJ@M9S]8+6[[U
MDL[;>F'QK1<]//ND.7?SSSGRI^H]UK,'PQ;NP=`X*_A.7C'2JE$%&(OOP;#%
M>S`S#(/+;&S^8O'\Q:SYI8Z7:)7%EO7Z$;)%[4'&-AZPO&$]FS!L^29,NG03
MYC)B@N'9!\R718PJ6R(6"L<7'"[OBQB1CIS"5'7$I<=>#,\K3*9[K*H(8O/+
MQ?/+6?-C41"Q1S@^>S>&+(P8;O)$%/@OBQ@>))#YVS$LOAVCAQ<<*U\2,0I]
M1RP4CL_>EVFO,8S[']TE:3YE;^;298/A!8?*`W;F'BJ/\B(6AH^Z<WKX*+`;
M,TXP/GN?)F\9A_/@S/^(:13^9#U;-6SY5DWJ7T,OI/MZ[>6KP=J;+D3&`:T=
M7P!H:6H/M_,4?_(']>+>PCZT=41ZMD;(\JT1VE=@=78W2'QW@RS>W9@R,0)0
MTK-!099M4(A`_ZVTWMLR5.B1Q#<8R.(-ABGB8]:/35PLGKB8-K'4_AT%H&1A
MFY^XJ<FC^6[4'X9.CI.>+CU9WJ6GXS5MI]%^Z?47P_,:[1.TKT!D1/OA^%S\
M0$2/UV>]WZ11$/#2^RZ&YV'*"?(K[!>;6"Z>6$Z;&-%B1/'A^&S@1J>[/3>!
M'06.R]R>!Q$_X]`XB3=]R>*F[P3M*R08T7XXO@0A!F[?0HBT]RL3"LE=.F`P
MO`0:>CX&H&&GG1IC0BR,`G7G%#L(&K=#,+[@&X:A'5K?,)2#!\E)3V>3+.]L
M&D9&86"T98@=2'UZ!S_ITSM<$GO&Q7PT7=I8@Q0I8GBR,S[9K.I6/J?G:$2P
MTEC.(5-L+$$Q)(2EQE]HHQTD:L?)?"3*Y;1#.I9]YMGW/&N"%ON=FZ6_V1U'
ML@9$@F$#6NH(%#;#"WJVUGY#];27`E]<:E1@M-&66Q/TJ$!=D_YFV9%;$8RH
MP%#'0+D=7]`MCBH!N\5CWPY'4&L58G33%D01C,ADJ",0OS4\"^(/A*4WB&2>
M^<(S7SAK*H(>:ZIKTM\L.^(J@C')B[CDQ6+)BTF2(R"WDDN730-Q-4%<<GU-
M^IME1UQ%,"*YH8X5.79\09<][L>C7?;<Y66KF+84BF!8($L=JYKL^(*JR0HT
M_6R3%21W&5I_+.R!H5ZS"I>A]1VR([HB&-%"'LW0P?""/8)9&1KK'*L"X3)T
M(+<FB*M`7Y/^9MF16Q&,J,!0QPK(I9XM66^&+HK1W0EI%6)UTQ9$$0S+9*DC
MU>BR/*7O',]36/PYYJ5G7CIK*H(>:ZIKTM\L.^(J@C')95QRN5AR.4URO[!:
M);3%Y7Z9NI3<+$A;KX2VN'Q\5;;4L7I\H1]S%0)+,C26L58;?J4.I%`$(P(9
MZEB!OS!#\V"YG7XDS`AB9;+<:UMJ@KA9]37I;Y8=T17!L!8L=:3#8(87[$G-
MRM!8CSL5%%X%3FY-T*."//4J*+P*O"/DHS%MJ6.]CH6>C;V.4`FM7@>7<L2[
M<X?&K'+:DBB"$:$,=:1M8H87M$T"D89VU+QU!/6"""^(PY*:H,>T@CK3YL*9
MUHNN",:T(.):$`O3M;YS/%UC;\-*+ASR"L35!'')]37I;Y8=<17!B.2&.M8X
M6NC4N(L8.G5K%W'LEZFX*Y2M:MIR*()AD2QUK`5EQQ>TH*Q(HRTHW1JB/.U_
MI4@>OE*DV_4'C?NW%=H?I(O\)JYZ/8Q<.`D%85F[P]TYKZ+?/C/T9I4'R0;?
MW/)`9<X&"9@<?KO-0UK(P9?7/'!)!]\3])!)-DR0RVQ82B&+88)"9H-OT'F0
MLAA\1<T#)7)$3DJ%''D&*^@P&S058WQP?'/P($56T!&CYR(?UC@5HACV"UH(
M,4(AQR@8*<@P'XP6(P[,6#'\QJ\'EF9R6.N,Y^FP_[`,7WPX2)&3,5D$&;$<
M$V/!QHHB'Y%%XI=,!P.6C+Q5ZR&E-!]Y!J,C6D]3*H9UFG)&1OC(\`5]@Q0Y
M34?X$'3X56F0P,CP*^$>4DGD\"R`H48R$*>D&+8<5V^Y'Z3`U]L-4W#*1_C(
MQBS'\Y%WICUP08L13HLQR\&J,)(M,S+F01FE(W;)V)@G9RD9?EL?4,CA-\`]
M9%P,Z!06ZA_^=G]W?_?_64+6I0T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HV
M.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#<P(#`@4B!=#0HO365D:6%";W@@
M6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@
M/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@
M4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y
M,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0
M<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G
M94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C<P(#`@;V)J
M#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S@Q,PT*/CX-
M"G-T<F5A;0T*>)R]6]^/VS82?E]@_P<^%$7N8/OX6]1CFK3!'7!M+@FN?>B+
M+-->767)E>3=;/_ZFR%%2>MU:'1K!4%VO19-S@QGOIEO2'_WR^W-[[<W=*53
M12C^<Z_,2DG_(]_?WC#WA!&N"=/N'4YXLDI3;HBA\(1*01I[>_,SJ=Q<B50X
MD3(&?Y%F=WMS=WNS_3M.A?\F;]"5E`(66$FA!/P2*>=/GZ=2X?-4)/C<&"W.
M3\C)4@D810RC!(9)[63:.@7]0SX\%'H4^+M/MS?_^"%;YZ">()_@`\X0;M*@
MNNZU_+1'D5B2,/(IO[U9HO@PZZ>'VYM7/]0-R?*\/E9=4>W(X=@<ZM:V"]+=
M6?(-HPM*W7]8.;?%O=V08[6QC7O\>FVK79V1CS8_-D57V):\/S;Y7=;"LUUC
M[=Y6'8$_R=K:"F>HFPW,`&]L[-8V#;S^&_GTO]N;[T&;_UQ%9\9!9]CS7F>N
MDJ"S,(9[G1O;V@SD)%FU`4GN;5D?G*CUNBQV65?4U<(]>RC*$F0GV;YNNN(/
M$+>K29N5H"CH@";X\.U;8C\?;`4V@ZG:O"G6J.&ZOH>/-984%=@&%%T1M/3V
MV,"G&GAW6S=[M](\%J!IL("F:MAUAJ^]!799L\$-1R4F^]\U-NO0%@O26DM^
MK#M+V(+\U.RRJOC#"XR6^>E@&_=7^R+QDR^++SD=Y7_U,NM$IQ?C]"E?24HA
M*OZ`I9;77RKYRYJDD>D%G6ZT`%SK]UDEQF_SF^Q0=%E)/F1%B[O[.N^*>Q>H
MUW8Z!=@R];H40[#W.H,0A.(LP.])?6Q(!6[58BSEX$!U66RR#H)F6U19E1<@
M[PPA`;C?R\8UE4ZV5VT'ZZ*SMZMK;PZNJ-2PHAKW)DU9OSEU"XBS)>_J>M.2
MCW7Y<C#4$2F$E^+5KUS2:]L5$DS*3*\EE9#D`M;2@+6(>H@QCX"XQ%8(_V\A
MD^S7@(("D(53JA?@!]X6.V>+%FWQ``B;'0Y-_;D`H+3E(V0CMA!2N8Q$8-I$
MK))?*61M^&!E.P_,"T3FO-X?LL;#]1R^A)"Q=XI2G@SPRH5(O=*G<O.%4<D@
MMX&ZX(S<V\N64J`=9)D<0!I2+'S\=*&%@K5@G17Y=%>TXU"(.V?B&8QAC`Q!
M;TPZ%ABF=_/GNWIH0."F`(%174C&Q])M/O[5WA7;#K?MKMAAHH2!.Q`>M-P<
M\V[,O0\6,G.?@Z=:=C7BW<2J#W<%)'I\@HENM\/,U]G%+);02;`$58-7""@L
M>Z_P:1:1#HNNTZUCTA=:O26"5KB5KHP8=/1&@&%G;03F*<OZP9OF#09"]>C*
M%K38UC[`!X:1<QA!T6`$P4<\<&"(1G@HNKNG@K>NH,"RR()=T"%`..OE#[B`
MKP>IT9%6Y/5F4V`!`MH^8K4&EKD'**^;1W0IV]Q/C/8\4H22SMAS6$`,%;<$
M6A`"@K+>#:`^;G8>FX)Z?D=A#S'&G3F>AGD?)[U2#C//Z*0<-+H0@P!`/\MV
M&=BW>[I.CPT^4D"8:N<FG<,2;*C#TV3(@%(K/=;AH%(;"M#6!<8WDJ;G`F$`
ML:>(XN`2JNW&O5I=/8="CDM2_1=S:+Q22))0-U$EA[I)N==HIW=-W0*U:NIM
M\7((C]0(B4IGK1$2&6HO2H4<TJ56Z9^I$7;."@=OA3/5`02T2(<DR_5*7"X.
MGDXQ0P@D7`VEP@0/.0]5X#=B`71U$)NE*_;BVJ"Q!PPIS^0<(D8J!<I$J!0L
M$6*EW++3/#.'.6BH%CDW(S8:TW<CGNPQXN"3-X!SYJ!=AH`%Q<W1XA;Z-+%?
M`WEP[+1'C:DB@R%C2=/G()(?]\<29@*D]=@X2Y;4*1NZ,NG@%9*G/5/JZY5G
M*2W4,]A9..DVK,@_.S3+).U?6W`!VQ0D[RG4KYSSJR\#2TP,I(Q\;J`64@"D
M+]C_OG\S[*0+(U?LV,]%ZYM:PR.,(]CYWVSGTJTWYAS[F\C!S\?^B^*A_S)U
M:T`DB-4U[/8>WKC'5M'/]OI"I>E$*D8GM9GBO5'7MBS`FE!<.P?;9[^A]=IB
M5Q7;`H3L4&*HH-LV$'F[!8MVGLICYP@^2,JBLI-`\TI>/:NH49TK='%B*P&K
MG1@N5:,W2M67=!Y,(!*#IUU;B.2)$+U#]1F$K&?)7%H%-L-3-32.E2,YN&P?
M=^@A:ZPV)[3BZ)I-Z!^=S>^JNJQWV!M&B+TZ5M!T(JDWS*L9#"*XGJS#I!(3
M+Q`#ZR\?4?-GP(/Q4=F'`#TO+U*_V'X#T4;Q!),^M[[ZL8;<=V<A]5W=)367
MTR6Y&!KMFH6X6'A:%P"N@H*K;8]-5N60NN^R6?H16@X$5+%)YI"A'S&!+=??
M;X\YT,UV>P0B24J;N<(P8#%YBM1]7MX>NV-CK\\U4'Q.9^4:F@9VRD,M_NK[
M<(`Q@S[*B/FX!<ZO=4@"@B:)3P*SV$X-:X'M%!OXK.:Z;[=_F)XKO9V<*\UA
M5_E7.6F<LRD^<%+*DPEG^U-]W2^>M(4S,U>M??CV+12V"!3/*!W`RDCIDIZD
M/.5&<S@5&P@KIP,A!\;2EV]1%@E2:S5VJ7EZAHB^B-!%.K\SV$"FX?B"IHJ/
MQ6+2Y_]O)#,C@0R-QKQ&88^@#L*E.QWML;;O6\%&UXVK*X&K`?3>(;;^SSH*
MYLE+5E5UY[F<.SJM.E!P;5T^M0V>F^+LV`LJ2V`^S6RGJ#(9CC;,6,0+0:>M
MS(_`P0Z'ZQ=\9EA^WO+63/5DPHS'=C1X^P]EW12;#-@2A"C45F\?LTV1PQ9T
MX+BNMAF.M7W6))[4'+)U4?IK`>CN?3$T<O0F.]AC5^2^,JS=#-@!!KZ!@SN+
MO6'8Z#=LA2"';C;'+NO`-*FDDP,L;D*=^\4F2A\!)X<:V<F1QK1_N<&`S@OO
MLCT&GNM.)WT'U)<;P/.MK1P7>VP[NY_%#%(.D#<6MSP)Q:W]_5@<_,4`SYI1
M:5\S#4KYN$3H>MEY:CSC23[C22;.3\U7JR3DT`>3=#P;3@SMG>ZC/^>"L/BW
MHPRX]S.85!@S:Q$ADB&VJ&&C4U']9XJ(=C#&?C#&<.?F7-D@%I)-R@:^XF?*
MAIG/B(620^-7LO&,F+/D[!DQ7Q@Z=J]9TA]M7[WQJZF9'!"/7=)9VIQ"#(QY
MO`\B3!*.R;NN*=;'+EN7UA]1WD-2*,DVR[NZ:?&Z2%X>-Z=*^2-0`-O>*QZR
MG6_MGO:XM3L+GS:*L_[0T/D"]JF\;]G]H:P?[3R]7L$#(:5J=`1AI`F]WD%)
M\M\"F/%[V,MB\U=XPY>11PSBS%M6,)5,%&=\C'Z1AN@G[X_EP>W@>Z@$FD5@
MUV7FVDEW6;G%?7+YQ+LK7B7TR=6GFN`2&XSF?=&V[N9>UV1`--S$8$3;=%E1
M.=*!IX?.4>;8Y8%7,VK&,D*'<YY3WTR&>QH0N(-?MJ[QFA%`IFX\R;BWK;N3
MUY(U5$FH.)BKK:NJU[+N[Q3"%.[D`E'1]S9".8[^O\]^<[\!.MV'CLT<=N!F
MO'MI1F]/>=\2ZM%W1'*4)5SO>,(0/6\XO?Z`UQM:H%RGT)%!"/=XT!X/AQ+!
M84@2S[$A2>8Z_N=Z/,S5(^A1K8=P=Q="';1C4]!M1K6K_?5;B(AO8?L/>,6V
M*4#79S<=3O#<A+/RJJZNWE8$JA/TF1<O%$TGEA-F[+)K$;J)>=;>D?8.(N3J
MJ\/F?"4]$SK1D^O)I<U4]U"Q#HB&WON4*F#1/8?/*CZ`ES0CUP\I"F]N[RIW
M`1J]MNWJ_#=2'SQB[9JL&DM_/;D?CF2P:-T@\,\?7G\D/]8K6$_\2A7]`#_8
M'#R!"SXK3^!,?36>$-9"5Y%B#(EP#/K.5JYB0@QYO=E#"FB[QI]>SV!9ELY[
MEY2-#1<J1KJ`)W!_YI[(Q";94YM$64.R8'*LP*4^VVP<6,,<M_;UY%JI'O47
M@8,_;S6JA=)CJU$\EWB.FR/*2%^[_(0%RCS,@4W:$7S"'#D;LJ@7\-D=.'^O
M#^N$DQ)AAOS((2""I//F#9ZF$YM\[?PHE/Y*>@J$@4%/*"&3L1^9IA?SXR11
M^31T-NF0UWG>'&<*8CX>$H^GCU3WO=3`-*&2KXYM7[".-.8,KT6Q1XH("C;'
MPK$!L@7"BOK`FWAC";^]\YSEOFU6Y%UIJXK\:#</!="CD5[V!&,.*["!\P(+
M'\,WY*WOBOH]..H^(]_A90';`K2^N2OLEGS,"X2A;9$#O,!/V$/7^?&(U4N\
MKK-FLR#1"]5:L>DMTF!CSR<:NP=2B"8;@&2.[PE,+@*/7\(*QP?C%;9Q__&<
MV3H:BVT0>Y:Z`.CT7\@K7<L5L\+P!:X%*>TNF])"O#>&784P?/RVFE_\'ARN
M/LX"XDF@@E2.UUJ%#-=:L_`5P=9?!G!)V7ZV^7%23IX<LB/3EEI+DJ24^.]O
MCDN[KU9BUTD(/X!_80#'JYBQ`4R@^)$!%'PY-H"G7$>7X(:#;6,#$F;B2VBF
M372`8FE4"R[9!2T$2^-"<F;B`QA>!HD-H%CU10:PE$%-$QM@&(]JP1(FHT)"
MX06\)39`41,?(.D%(045\0'NZG]L`*,TJD6:ZJB,)C51;]"ICCY7>`TL\EPB
M@8W%3"KBWI@F\>=4Q/>`1ASI]WZ(\E,P>9Z*L0',V//OU*KAVXWN?D#NS\9-
MSY$_N3H3X/I-C0>C)W<`_30?WN&4#PBN_T*!5@JG3>"7+ZR&/\O;FX]!:&6^
M++*>BGSR]5!PI^%HLT\_9XF;._Q[X1+P_^3NG9#/\#KJUDMPZRA`+`$AHN&]
MY*F,.MY2I"H*,4MPW?@`E<:1=)D`38D.,)BR8P-2_-;Z)4/%]<3.\X4YF-%Q
M,:#DOB2',/%`7S)IU(5-5WC4&1VA#8_[!>0-=F&$N3@BQ6.8N/<9'=>%LS0.
MS$O.\5)B=(30<?!;<LGCJ7C)%;VDBZ87=HXG%X,M2=D%74S*+U@LY2Q:'"VA
MOHIGPR44:!>L+J`XB=M4""XOR"%YO)1<"L62"W)HEL0C2B0TO3#",'%AE91=
M0"!`:Q'?.<GP@#`Z@E^HUI92L'B9L93RTLY)*%PO2*IYO()?RN32SDG#+Z"E
M3"]YD*+\PKY`J7#!DQ74R/&H5!`.\:A4PD1L"GGX^U]N;VYO_@^K0<\%#0IE
M;F1S=')E86T-"@T*96YD;V)J#0H-"C<Q(#`@;V)J#0H\/`T*+T-O;G1E;G1S
M(%L@-S(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E
M;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@
M,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&
M86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-
M"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*
M+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-
M"CX^#0IE;F1O8FH-"@T*-S(@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E
M8V]D90T*+TQE;F=T:"`S-S$U#0H^/@T*<W1R96%M#0IXG+U;6W?;-A)^]SG^
M#WCH0W:/I"5NO#S&6:>;;C;U-NZV#WVA*5AB2Y$*2=EQ?OW.X$;:EJ'6%GUZ
MFB@B!&`^#&:^^0">_7IZ\N7T)%K$F201_J<_I0LIS!_%YO2$ZB>4L)C06'_#
M"*>++&,I22-X$O&,M.KTY!=2Z[X2(;$CF:;X%VE7IR?KTY/KOV-7^-_HBV@A
M!(<!%H)+#G_QC+'[SS,A\7G&$WR>IC'?WR$C<\G2#.9-(P+-1*SG=*T--`]3
M_Y#'PX3/+D]/_O$^ORHR0CFYA!]H('2GSG3*P$H!3S<X)98P22Z+TY-YM)`I
M?+P]/7GSOFE5N:K)NUW;JKJX(^=?BW5>KQ3Y/B_K&?FD>O(W<OG[Z<DY#/C?
M/S\MC7I@6LQ,Z\UO3$3/'>`INV-<W2BV=D>".;-Y)`:[2;]6Y$[E;4=4O51+
M\D]5J,V5:L%-9H1A!WF]Q`]RIMN^:S;;O+XC95T@6DM2`SC7%L#"`:@<@"L`
ML"/--<FWV[;Y6F[R7E5WY#N6S2+P/^S[V(8#LEF:>;O!P;WAX*?:\.]H@L//
MH.-NJXJ^O(%)X;^V\(6J^[)>P=30QE;EG=HS?\JP@P6Y!$A\L[(CVQ::M"4T
MR;'S7=7CCQ&X3O5]I3;0N^Z.;)NV+YO:/?[?V\M)D$B818(R)CP2*35`M+#:
MY4U^5:D9N5V7Q9HTA5W7LM;SJO*^!V]8Y]4U3M5[A#'.M,NU$^!2D^5.D;[1
MOQQ@,3W=Y-5..7,OFJKLUN3BXZ<%>0N#M.`K(T2F0$)*%P,BOQ=$'"<&B6;7
MDJM=5]:JZW`A^S:ON[Q`"V_+?CUR\:YO-@KV"Z)P`YNF@<]@XJ,]L%1ULRGK
M'&WJP,JB:-HE>!9ZVG6U*_J=>;3WQU,`P%.W*;*4>U>0F47`[]D6?+R;C5RY
M5>`%N"?LRI[OVD:;#\LW(P7LE!6L=`\M2P@.1:\;Y9MF9WS]D7$F*/P6R:AJ
MNDYU\(F26QA8%<VJ+K]IE[G>];M630($H\X3)$U]-HCP,P*Q56W9++N'9H,G
M.Z<P*_J+(LN&U$T_TV"L\QL%_[)F]F1;06/X[0PBZRI?J;WK[$%?J^5*CS4>
MXMA))X$`Z*Q_\SQHPYD6?VVA9=0'7IG%F8'V1\"Q)1_J`K:0=H#SKUM5=TI[
MP`0I%KC$=!D6^Q>)[C]CD%T2^/SM)6.%L)5^+`CE6>*QC?5GQ/9##8%:=3VQ
MF$Z")TLF92QI9/H'PR*:^"#%A$P?4Y:G&,L,=IJ%0EDH;O/N80:7F3`4I",%
M<AK,>;#1'[1**-6MKL?C3N!(21:YX"RYCTF<2A><]YHJ'W(62#I/4Q9#>@QG
M\>WN<1:T<&`MR&"6.QV*7`[WP$X!0>)(.O!UCT`LK7MO\SOD*28JF[7"&15-
M?:.`-^`CR,S%'^NF6F)ZAKBLP#;[J\=PQ-Q00$-[;L$LUY?I')QB`X;K/@E\
M^$]^1ZR#+2""38*`]'0]'1`0PB*0+Y<E+L9LW\I`N@44ON5C3GFE:G5=%F5>
M6=,Z?'@-J1HSZV-(1*Q]_0'"9VVYA`3UL8$\C]OH`:^=`@?NZ7L,>6'8#):U
MUNKVOKTF8Y/KMMGH.:FO/6S[$1(X^6-/%.HH/U.S6A`5&3O^,.D($`H]^+2J
M4RP"TI$-KFG9WVD"OH3E6QP]_`MXXB;R3/(0Z!V"?T*S%R:7,#E)(E\+2>I1
MC/5GDT!O(+3I"LTRE`DR:)RR23-H'$N?08?\R3E[5OXL#0[[TB<DG\/IDXGL
M5=)G+'QM(^F@=%#^U])GL.1G,C;Y\\,#=-QOEA!P@</7V)6-RM=05D+Q^&67
MMUA%NP(:-^D4*'#J\T<DAP1B50\;S\&H0BFH;WRXS*%\,\J$+G7?0MY8-?D^
M"A'IG.F4F_V]`9VX@?98_Q1.[[B&``VHH*=4RJH&4P!`#=W/8N#%Z/+?-`(T
ML8D#O`_,\&Z@UV*OMD.-E<\/HH%)RN3U:@8W%F`0CU2/C%L%\*)M;DK#"AI?
MEUWF7X$Y31#[I)RV>I#"D6A8<4^B!7=1``IV5Z1O[QG^\^+SPNWF7EL/8>W6
MMO9*9P,TPP@"1K;0TE=5$:<7V$@"+7%SZ!&6$`)VT`2U+T-5IG`HYHASI(4]
M&_.S3%C>6%7-;5X7:):67OH1T=>:0_[5<L6^6Y`_ER(T.F"IES0&^$;@/D6[
M)X%A$+NS9&"-7N4/I*E8/,Y23Z2,!?EQUY*W70G)HMM==>6RS-L[ZQO&)_[5
M`*;_AC^T1)1776,<R?J/E?PF0$!XV9O&W"=_P83U_XNF0L_$_[$&_*10C<&O
MNB>L@D<S#1>I%'A\:XAU/R.HEEH)=]1\!3[4ZM#?-NA+`&;>$\`<O4*7828M
MEBWLH`*JDBDP&`3O2!B2]^9WH,;=LG2ZW0213<B7LKHP=15<>NHZR"*Q_HPK
MBR=4'R$H36(;E9-&;9YY[L8'[L92^I<HZ^ALZN@5&$_])*<L]`2[AT4TQ+`H
M\H4>GK1@^MG'R8&>I2DSLL:]:#?\ZE%`GF`+ZB1DR7@<#V3<"94X3TGE7PBY
ME^NRNW>>=`\%9-,C#:OQ+76<';*V%0.[&:)@9)\IK+>2,Q9@49H.$J;SYX<*
M8YIJ),#"O._;\FK7ZU#9X]'"T44+!H62FR$04!&AER$!G1]])#E@@2>.TBM:
M,9>6F10Y)I`U^.GQ59/LE>R$(G-D)XN&4U:1N*K[2E>'N"7!`0T/=,JT3I'H
MQ?[P:ZDWA=4=MX8OK-J\MF63+EIVL%,F*:3YZ)!!^+TKI+"6V)+/T#L=3MZ_
M_4P^-0OX,<<#G9_T48ZFS\![<7<J5QUW>86;#[\KNV+7X7?Y57.C-$^Z4E6I
M;AP@"DK12LN6L'7-F;+FX7[GF\V-TZDGTA0X]]7$Z,28ZR,0#85J-^Z4<@@_
M5ZK(=T8_0)*$AX`UV%F!:97&"XN$O(78@S1LB5\W6UTE:VIF)5[@1H9,5?;K
M35F778^![$89WX&&,++E6!JLJTE$!?1O"X.X1RJE$V.AL.B0_L$:K=KFUHC&
M98/S7]W-R'G][0X*`[0#OKV`W;[)R9D]:E?3\#&6'>%FS9/]QT/_SYM\$D2<
M)::0R>2"IG@4@G'KTS-S06`H+H:A7AXB0P.E?B!,BL/A)9..$[R#3#`CGY^=
M"D*(1O*5[*20=-Q(*#M%Z6!I'%L-ZDS'PG?C7/!NC?=?CD_>63)8?GS%'CW5
M'EA-MLWD2R<?J#O8<*C"AT,5K@]8S'$`^2&O=QC9=,Z%G)0O(2'#ZKTOZ[S6
MYVIXJV=GU.///82XO%UVY*R!O_#?O=$_,2\>VP`!)-M9$/NBA!]_F,0/@R[-
M4I,)WT#:/SOV8))F>VP21Q^&23\,BK`Q:N5:A`7J,CNZJTDNQ[Z6^9C@#W8'
M3P%^L,>C)G&@A"6OX4`)<(:1`T4T,0<3;SZ#!QU],.#AK^!`21*-'6C(*"^Z
MQA1B!(SY<XT8)0)[KB'<E34@X!B"QQS\)=DT-!L@)'XZDQ96D#[]2)A,1WJ(
MC.XETXO\;J-E25/4M^K+KD1JC.+\--4EHZ\$`L=8Y4'@-//5I8R=OF^JRZT!
M`6\<$K795LV=4N:2Z@0R@L1=_2H`2)Z,O4#&H[N[J3O=M>9"70E5=-^T'1YA
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M#H7AD,MR_8(`GM/::QC#A&#)H=S85LK5%C]NRUK?!(05?GMQ-B.6`##Y3/X:
M.'[B&1_-G:7#M2*I/^/<1W-%I_NL0^Z'KMN9`XASGX^.OE_8>'+1<.K/>60%
M*F1$@!$4DX8684K$PTEWS7&*I:;#M0LJ1IJ9+2WU_2H(S+U[.>1GK><^%E?-
MO&?ZM8)]ZO$#X?AVK>H'RK&^V.KD8^U7ZJMJB[+3HF4QP9+H-]N\=)H.[U\)
MSFU.!((&M3,X!OB*?G5$&P^)89.W?ZC>O2ID$B1F1L1"&W'T5R+TI?,GD@6J
MGS*)$GT[F^M^AP[T*XPHF//$-&!/-.`\CH,-&)<RV(!RQH(-(AX%AV`9@Y(E
MU"!E/#@$2QBEP0:P$X-6,,G"5C#8'^%)`E+A!HQFP;5@%)H$&T3(8P(-:$:3
MH!4TI5EPDC2A0`U##6+*P@UD=&"2(DK"#7@DP@V`U(:MH'@F'6H003(*-4BC
M*/@\QOM+H>=1%'PNLB38/Y"F\*Y#G3KL2T%7HJ$U^&*;2+-M(4?L3<G4!RWZ
M.,1*+RFY*Z_ZS3ZK"%RZUQ[>-37>V>GN13;3S4_?8Y>W&$1_P`DM)':;P%^&
MU_E_5J<GG]VD8_;TE./QE!\(B;#:L7\#4SIQYC$]U_>8GCD$2HAV"#L"EX\B
M>G!5YUD2C*1SFF;!G3-G6=BOYCP+;XRYR,(!8BZSL&O.XTP&X^`\P3=`0PW2
M[("9,(5P#S1*:7@2P)(.S(*RE(:G07E*@_%X3D42A_&F,DF#6WE.XR0YT"(Y
MV")-PP%O3K,TG"'G+,*B)]B"RG`*G#/(U&'O@3PK#XPB#@3O.=.OTX9;'-IJ
M+$[C`[8D:7H`,7#"8"+#_1J'^^`1/8`ZIS0.8PH,+@K/@W/@%N$6`BN=8`M)
M>7A'X6''@19)%$Z\<YX>2(T0XJ(TO'(0JVD8#T%IF%#.!:,'@KG@AU9."(@/
MX1:2I@=F&A]:.9'0`]%2I(<\2&3TP+K`ECO@R9)&<7A72@A"X5TI61+`%'+L
M^:^G)Z<G_P=>LTKQ#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C<S(#`@;V)J
M#0H\/`T*+T-O;G1E;G1S(%L@-S0@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V
M,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O
M;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B
M8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*
M+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@
M6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^
M/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-S0@,"!O8FH-"CP\#0HO
M1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`T-C0T#0H^/@T*<W1R96%M
M#0IXG+U<6W/CQI5^5Y7^`Q[F(4E1"OJ"[L:^S3B35%SKM=<S*6>K\@*!H(2$
M!&B`'%GSZ_><OH(DV!!I8<JN$=0X`,[U.Q<T].&?MS>_WMZD]R+/DA3_TT?J
M/N/FGW)S>T/T&9)0D1"A5VB29?=Y3E6B4CB3DBSIJMN;7Y)&WTOR#&^4*84_
MDN[Q]N;I]F;U)[P5_C=82.\Y9_"`>\XR!C]83NGA^9QG>#YG$L\K)=CX#6ER
MEQ&5`?,D38","\W32@MH3G)_DHG`\(?/MS=__FOQ4()X+/D,%VA%Z)LZT05*
MR>'L!EFB5,%A>7MS!WQ+/'Z^O?G#+Q7<LVP?F_IKM4R:MOEC\OG?MS<?X?;_
M^R9,$,$#%SF]YVE*DL]?X=%W;_\H-128*7`%*[!@>(P"ET7_E/1/15>]]>,I
MS;Z5I)3F!Z9EN?*F57B,DCX4/9BT;#?;JNF+7=TV2?4;'E?)JNV2=M_-HP>>
MB6^E!SYT<1`>#KV/4W:@A^*YZ)9]TJZ28KOMVM_J3;&KUB_).ZG4(@5`*)HE
M_"+U,>IG]U0E;^ZA%-@%1#)F(T1X;ID0-B)?JJ+KDZI9`M-_J<IJ\U!U"2.+
MA*:IT%S"0;:`!_?;JMS57T"*^^3S4P5V+<&>CU6?/!48RTF]V1;E+@'#HS#?
M@2<4S<M;RY1E`Z%,P/WA7Y32MW^.&"H/S#OP>65MW<,]MVVW0\?'0%^MV^<>
MM-/NBO4<Z":I"DS-Z^N2'3C/MT8WJ?)O):F.DC1W42()\88&=)L$M^>B3XKU
MNBT+=(-BTS:/VO]7+2P^U_";HT2*Q[:KJ_Z_K@YU<5Z(/$^U#!`./)WA_@H2
MSGSW%^'^;XZ#`-LJ50$&,P^#TMKW'X!_!H,W[;)>U6!)0&V'>,FFVCVU2T3S
M75<T?:T=8*^O^?37]Y]`.^Q?:9;^#/\`<CY7"40$Q/\.V/QU7W=PMUV+"+H#
M#]"9<-O5@/G;"GXLDU7=%$U9`V1H@DW5[/HY<H',B=-!-BC.4E><:1Y7:Y#9
MNBPZ+\@\1YD&".+8F3FZ,S40_)L7:5#U?QLY*<F'!A8I]0:FV?D2;>\=OZF>
MT?^:)10N.L&#+[1=M=`GP7?W:_!*5ZE@U7"^:.AF*66DY$XZ)KT5N3Y&Z3#>
M4+:B*Q[6%48<<FHB#?F]GP-7)),^IM(04X1:E?_8!`61;&&+*82`#RTH&L/K
M+P`0Y:Z%*DR7BE\0+8#QHBRK==49,P'9%X`/#$AG@GV#*PA44(!8&LA#<.^=
M-B/2]KNV_,\LMJ"I*XPRY>$T2_$8Q6ZWR%)ORF`#?]5FNVY?JDK7E#-`"H44
MXMB:NQU*!PH`@TK?!,C4.J.7=NFMB]DCU,7)JFLWR0_%"[H$006=^,D@.#7-
M1\@ENY?DIW71+))BGA21AB9O4`?EU-JUV.B@OT]^>:HAQB#3[5ZV=0E^]Y+4
M?;^'[&8MOWLJ=MIG$TB!^CQX=@?>NS?1V&L1"HLL1CEU[[U\Z/T+Z\?^UFVR
MW7?0?/2SX(Q0PC=X:6B9*,=0UTHXZ.C(`HR#;1R613J):%.CG(!&4`X:[A>X
M^/Q4ET]'':$P5X,N`3;!UDWR5*V7R</+G%V4@,;5R3EC$R5`9>XQ6%H'@*3,
M=5#5;U6YUU56NUK5984X.`]"2.#$<3-[2R&$ZRA207SKR"AGYP!BD3Q4)008
M]-&;:ED;[P#M=&7=8T;32=DMZ,165AY5BM4*[@)(>Q@J4*T^PJ+&FG?D'CH$
M")YWV7W.M)+QRG+=ZD)O#AU`K^XB*1,>)4G.K!*T#&/1@D.$D;R)O1:((;/[
M&5*Y()G#/BD]]F44CY%9U#[@SK;M*Z]UAU*@8X=<R",B%&3R>@DD<W@R@Y+=
ML3NO)S,EAXHAV##9$!:N>=+E\T/55*MZIQ/92[&LRS<?R*2!DSGG/I#V@L!$
MT%!'9\R/?5ST&JS"ZF9=;Z"-@_9NM=_M`<D/JNP98BO+5<C4(5$SFZC]=`+^
M;_>03UKPU^X9@<,/X).ZL8'7].VZ7A8&/WP+BG&YM3FX3Y[KW9.;`MKBNC^,
M``<Z^ZT=`19+LX1WFD,%BH2A3?!+YMJ=D];<(BC$Z48S/&8JI[BB[]NRUF1:
M\O/BZDK'*/FI@#3V4$$.'[SEL%J>0P'"=42I#!T1X]"#F<!\E6&UN6IP:'W6
M]QLGVH,"[WB831;,5"_WR7ML/8RU'R'KP%,V!<`?_(H14JQV`.3?%\V^Z%YF
M4067@Z)-#HHVFVJ&S2E8L=TWV@.@F0+[X$*W+!I(1MK8IYXSPSP-,LOOF7>I
MN#Z(;]!T)6*3&1$6L_^[AF9BB>T$FN>[8EOCR/KGJ@=7A;+BS<7-B6?I^OE>
M1)D\_UTWSZ/*Y-*_Y*.^E-.M$JK2*Z^H=2'U'F>&]:ZNKN_08H)F[/=/82-5
M$&>^7&>#]T5Y;AO;3S5&"?ZS-;W9L*>%ELQ.,S4^>HB!.F]3=#5`A@XOP)"R
MJI:]J4OQ!GVQ#K4LG%[NRYT]7</!Q^;K"Q3&'_:@X*J'2GD&!.'$OP)@W$<,
M4SQW&14@K`$[/[1=IP?[6+'[X\"L+F"?VO72M3)>N&U7K:H.Q\&X;.O=RG3U
M/71!G?::.;`&[#>KUS!%0R8*W0[+;<O\]R;Y?K_6LPZN!^28<]>5?F."WO%%
M#\:AA^GLS'G0$*"N@N9.U+70!!T$'YQ][-J^#_X%-WK'%]+EJ,_SO&-E(I2+
M4H865]G&X81ET^MK<5$!Z"7)W_4X#S-P\H^FWBU,I%1%^93LX7==I-6FP\`P
M>6Z3,&LXZ)Q0&VU3F=,ZD5?XRBGYD/SDE3B'$KBK1U,5NB?&A2O&S!`$2J4B
M\6W?.W@<H(26\#[YI4KV:$0H*S([%`F(<``8=1^<1;^U6%;5YG3ZZ15D5?`^
MJ``*%EV2S*$)YLO2=!`+PKUF>83L@&\%=<?NQM3%?M="5567:.@O@!RV"L-S
M(P9TVH3+,?4`(5EP2A<IQ/D9O]`^IV=TNB2%QS3X=@O.:T^;0Q$D#.R#1_@6
M!45S5@1S]$>P`(&_7.HW;2#@!$18D:$[[_=0>SJE_F2O^M%=]4.U::$X7>XW
MR;+JRZY^@"<]5.OV>9:40O/P<H#(P<L!6Y^#P+I6MA-_-]3TLV)H.(Y@`914
M=*:\!AF+4K]='+J!)&0!16MR?A")(?@NN\],Y&FZZ]^,G$LYN+O-23_+^UPJ
M_/Q=B>!<6:I\POF?]HN9'YFD,U;F[Q_0"4S7\OZQJVQ_I#N6J/=@8X`F^['<
MM?@(1Z/[)--ON5-S^)7?BI6*G(9L2VS"\5D6NK]E(A>"Y@N:\A-GPET]Q;K^
MBL*-9$Z:+7B:+2C/(3Q/,I3+2,;)A@GGQ./F4$'8F4-YF'](;E7@LN"J_C+#
MWA3_^'F';VHH)Q&$#\;G>=B^E>#[%_W.TX+#P1N2N&E.P4#WQ!6DH!==99P`
MD+OQ\NW?IZ)=_48<2&6#[6KN!=1['<+@L.N71<(6BO`%ONH>HF*0_%C880H<
M$`+>UF9@=1S.]]#9-%"U=2`^/O#97TZY7$B6SK)E+W>U-*%AMP)3;JSU.EE'
M#(LQP7,(:L#.U]^$`;"$FV#+@],PN&I=E!HO9]&!]"4UYR),8-TLOGC40'W6
M;&^=SW#C9_8&VY]B>Z>9WZ'$!Q/=5%"_=;HVO@@5,EU(*A>99*;,0Q3NJK7.
M.[;V.=:)?]_S0]4]5AWFPW*]UW6R;L`A%4*?@N;LJD>`=;OQP,T^H0CUW<L<
M]J:^9E9IJ)18*@.<?_P-O+1YU-.&#82AK9#]QN)^4-T&0;W<ITYB-[%J[6%\
M&(W8C@R;BGWI-U8,2M&B7LZRVY%^D^U0N-F1AU'IX/5&+BW`8'=@9EI'@:1[
M70GQ*'-H^?6#PQ/TEP9`D'%B".@9`@Y%192`L9Q'"2B#DB]&0!B//R)E:1XC
MH#F^]HL1*`K8&B.``(U*006-2T$S*N-,<BKB!*BI*`'%.CI&0"B548*4DJ@4
MD,UHE$FBB%)1`HE?6L0(!(DS"=T7B1/P5,4)6*KB4D!]'6>2I"+J#WG*H^=5
M"GDX<E[BAPF1\R(ET?MG:18]SPF)"LC(E"M-V`"')>?._VI),N/.(,GH#)]X
MU".GJ)?EH1DWJ(=%IMO*_UD7T`#U4/'ML+@X0#YSFY__AK=\1A3^'AFZQR]P
M,@D_#&[[7]>W-Y\<T[F0"0??(/GE.[HE.5]R8!6']P:HO_36^M+HO:&PT/<6
M()(<N;F,?"0#D>1NGD,%JK",_VHV?N@W<ZCM_\.VY>/Q_M%C-@241,B&N%A"
M?>59"<,'<5H3$'<;8RHX6MLCA4?FM#Y\&CHBKEUK4[LG)LH5JM]PY1CTS`A]
MJ`G$(5_N/%B&IE<X1'9.78$^X[EGS/)XR(TA.&;,GI?B<F?*P9DR-^HQ&TUQ
MO"'.:"X3U#'H>#WDRA`<,>C.7Q%*^M+LW(<7@5X[I&5,>$\;<&,(CAFSYZ_0
M7*;$J.:R,YH3P)%ET/%ZR)4A.&+0G;\R0L\K[E[I[UDAY5DD!T70;!AT*Q^,
M;GU,0_%2.*=^VD#]*S_J]C7]K6JJ#BI^/0Y<;NK&MD5'$Z437G4TX=>9[)#7
MT_7+`I2>>X=WR@%&'#Q)'#$0EB_4E;DR=PT*]&72-"COIAC)]1-E>LQ)6+^0
M%=Q&,,I*EE-\9Q1G2,?KB&U.UR^#@-?;1L?TJ6T&RY<J1-"K;)-!53UFF^'Z
MA:P(Z.S&;:.F3:,1X50Q)\N70<Q9PP3HT\6W&,<6MWX%MH0=..E@*WWFAO0_
M5ST40;@='.!E67VIUNT6QVFQ2B45XZ"27I6[]*7D'`0?E2.I&$63]!KLUU>^
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MYP0]%,H0C,OGR$;!\&#],C"4YX8W@5ZCC?`S$L>W/K3#F]P=GO)MR41"R3&$
MBFM++26GYQ,:6!S7>>#:LVH(SG%MSL%SCMCVZU<!KQRI%&06J10T/`D__K%2
MF$/E!B[G?,:1C<+U=3ZC+WV%SVBD$GXZY/C6AW9LI<YJWY$=^4Q8O@KD7^$S
M&J<<URIP[5DU!.>X5J,^,UB_*C7(L2_`QU-#_"E1=):C7QL<3M.L:IR6O#Z4
MFZ:=<T1'-I90ALL7LGS6#4<K24Y<7H$CFU=XYB'8'/H_0#=2,?/Q:=W1^D5_
M@(9?-`"S(CAI/.?,X[$Y/">$H\9Y.CG.(7;]BCF[LANE)W.(9=]*<LBS(3A@
M_^CBD(#"D-X94!-$#>BHQTIY?NT`T=DO-J0Z3$A.!7E0@9?;$(RKP)P+V8SS
M([D-P80*#,EH-\&O'EV.*L'^4;A7%/-&(TXYAY(8@JA0CGHTQ_&KQY^1R#S,
M<99]X6'%'#*?.,X95)\+"3*\/O&RJTG9+?58,W253YLK+_!IC<-.!2JHP,MM
M",958,Z%;,OYD=R&8$(%:M2GA^M7C'3&?5J^8N2+6=`HQ.GF4!!#$)7)48]E
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MWQUZQ[*)G6YW#)+6Q%-D.@$_3$UL^`.(2^-[2.^@0\WC/L8)22=PDDY9CC.2
MQCGEG/`)3K,IRW%!)L"2RRD/XHI,V(7G4YZ<I6E\ORE0Y#P>E1F1$9U"!OWX
MS]N;VYO_!S0MN&$-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*-S4@,"!O8FH-
M"CP\#0HO0V]N=&5N=',@6R`W-B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q
M,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N
M="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C
M,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO
M1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;
M("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^
M#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HW-B`P(&]B:@T*/#P-"B]&
M:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#,V,#4-"CX^#0IS=')E86T-
M"GB<O5M+D]LV$KY/U?P''%Q;WBU)BR<!'ATGWDHJE623V4H.N6`H:,0-12HD
M-8_\^NT&29#RS(!>1TP<S\@B!*!?7W_=@+[XY?KJ]^LKNDE212C^\:_,1LGN
M1W:XOF+^"2,\(2SQ[W#"I-FD*3?$4$I2SDGMKJ]^)J6?2TN%$REC\!>I[ZZO
M]M=7NW_@5/AG\@;=2"E@@8T42L`OX>>:/D^EPN>IT/C<F$2\/"$G:T6-I,0P
M^&L2F?@][;R`W4,1'HIDW/`7-]=7__Q@;S,03Y`;^(!7A)]T$#V!'U3"TP-N
MB:94D9OL^FH-&Y;X^N'ZZNWW)?D^:ZM;5X.F5H13"C\?''%EZVJW)7G95J3=
M._+NUI5WE24_N>Q4YVWN&O+#J<[VMH%G=[5S!_C(AKPKFHI4+TWZY9/=YMG?
MR<U_KZ^^@MW_^S(R&C8*F?*-I)21FS]`LO7EEU)3?3)J]*!/:83N]/FAJ.I\
M:\_U=^F=,'!E"H[=;813R<)&%+[&C:#-?OS;EZ-MR$/>[H,9CZYN;5[FY1WI
M#9Q5Y?:4M:3:$0O;:9P%ZQ);;LG6W;NB.OI)?J6*7EH<Q=@H3^)%>?LKY^+R
MZ^AQG51MC!2\\Q50U,47D_(EH>3%UU%T(M0T`,!4[.*NIY2>^AY38PP((SK7
M.];576T/Z%BWZ%>'8^%:B(7J'@#!NUY>;='/3L=E0H.F_?:$")"G3(]XWMTA
M)KQK5Z6[]`[2=-S!LH#$J)@*RSA/`L!K?(WB[FVQ(T\0S,V*G,HM6.!AGT-@
M+P/'/#%_E?1<GYF:)1C,O2LR?#V%XX>\*$CCW&_HE/9X+)Y(WC8$//58YZZU
M]1-I7;8OJZ*ZP]368^(4^<!?LZII+RV&IO2OTIBF<JHQR,HR1(=_C1ISNYW+
MVOP>*<`?3P>W1(0"!PL^*\WHL_@:]W#(']L3I"`?HK4K+*('V"IS38,9"]\^
MV/*TLQF,\SEL:KQ=52/J'%R=Y;;PYLXSV^9`2_)RR(`7!T:@>(-<,L`]O_PR
M>JH^+4>G-TG/01IRFU>NW5O0B$_8F2N*4U$U>4;ZMWUN`(UBQD>]+&%DK084
M!E;2::2WX>;BZP'5384)S(R-3'?PZ_]X[,.@!F)V:#"</YG6KD;:9/,M.37D
M#:,K2KN_WM\Z4,V!9=F&Y$US`H_E*R:2E5:<-'N+[@QK+J%HSD;!]2@X[YE@
M=>K"`<S<M%7V&[$M>2,W@-20B;NM>2_Q)!"]!.*I>Q>P,7-G;%X-;!ZDK-VQ
MJGU>+SM50L!!G)7D)[_*5X^@Q?+.;<C/4Q+0[O-F$2T`N`V<A":33##PX=J6
MC>V\'?[_#LC(`44RG40;TCE(UO%BDN5U=CHTK2W!8;VX6]=D=7X+(MQ"3GCP
M5=+!/I&]!:R$?.&-3NQVF^,:@#M=AH6L$SP+1O6.=/D(`!48+$@Z:$]H*`D$
M%STO>^<]\$N7=9(+-ABS=&T'KV[KAP!BUM5C?@#<A43Y)EVEJ4%7)^@4M<NJ
M>@MJ\#K9N1K+G%?KA>JVR.\"]J*;+"&XIH$%\!#ZDLL^]FV&_F?+)W1MJ'.:
MJ@!2@-ZXRTNP,&8),'7K@[W+.IXP`'NU!_#Q_`]T7#!Q"?.XCL=Z))GR2!*8
M%BX![@:Y">;MV*[W(/R(>SRZLG&+A(!18LP+(RT/6FB:"D1%L7TI.%2(`UT?
M'=S>@HC>V"#Q"0WL@]CKY-2@W&#N<Z\![>R`7O:5I`]V'VF[L$SCZGN`DP;C
M!J=>0@$BU"4I<.-!`]@C\!JHW>^GO.YLN3O59=Z,!7''C1$K7Z^:%\E;.ATI
M[$C()-=]U'Z]\WN`Z&GR1P(HWNZ1XA2`09[Y($T%HWI^VJ/W@^M0J:S:\T:$
M)<W19?DN1QT\'?V'IL"8E_=5<3],V]C"CT"E+&`M;0*-41/N3@?N?@:<K2T\
M\VM)X6P#"8R'!(S`<E=731.\<87;#TP/D!FUD+=%9WD`,(?\UD?OQ?F9&`5;
MELTK^,!4A3H-*I2B+_X\&CW8&DS<^A@]#MP&_&LE@`/VS`3T:A=A@3H96"!5
M*GBW8'TQ[AZ1I#>!:NS(&[4Q:D.^WIVYX*?[0B=+/Q_$B(=JD.TCQK-ZS3M\
MX"RA"&E"O\Y,^G4#-DV(0V^3GD5VI>B!-/@;9(-_Y#5&JFM:CU"=R)VV#KTF
M8PH$3"].6P3BWC%62]5$29H$N1>LB;"$'M7+DI$$RU0-)1%@`ZEM:P>I%[&Q
M&)@X%V;D(69H/67('.Q=3QG`/"$X^Z($\V+7-0OF]+RA:MQ`GZ:1,$%N$&T_
MN#H..Y]WFS?9J6F&U+[Y7-F3URP@TB#\VR629)(.[)Z:-)W4.$DXQ@B,GNG7
MSC'L5'L!"FW(]4,5=&D!)%3F@P0+]K<E4(9144RF8SLP37M%1>O<BQL.W.*Y
MW!=O@2=2A666[X`G4,^/6N9T+#B44&FG94\:AU*R@^JJ]@EX`=1)M`[UOYXT
M/G2?68*CPUY\8KQ'NG@L;-9Y/5]IHWWR'-L4+_4,["1)?]0^\!732S3C=,1_
M*J57\FS^)=20T,`TM!B9AN&OMT$`+%]@(,D&*N91.&SOG/-+/XJ)%95BQ1+Z
M4H?CN9IAW5!Z0^6]A`;&LTG@&$$#AO4:Z/H<[X$3E=YB[[NB>$6^_?8]@3S2
MU?1=E0H4H4&2/.X?\A;\1&7@B.?RC5TP@-V1N_B6V,N>L80*QI,I^&_L+%,=
M#G^,6"5LSM>!A7+YZ0[.DI7F?&[.<[_Z_&+RU2R<)$$!BV1A9<+9@9E>)A@Z
M#!_U"+`K="I:Y.HS'2;&5ZPG\*!-;)_DY>G9\0M.V3?5?BAL"PYW(#=#X__)
M.^`"+J5TJ+&,')FEU'U438X7FH&D'6S]FT-/L?6=QX3;)^\2MQ!4I0,B!IP[
M]&"`>!>>HK<UL'"L7%%C.+QOT)-C?G10\G1N:+/,%4`CVZ%,GQQU%/940@`N
MH06E`J\8.RMTL#QLOW0/PX:]'HZGXN@W?+3@\RMX">8NR,XAS`3^"X%@L;\*
M;[A'0*,M2H4=F+S<U5#<U2<\XO$T^,&!:\%O+&F:_@P(U8R?<#NP?OLG#A9>
MC2G)@NR?&5-I7+%L*%P$"YAM6'\2]MXV>_(!RMB+"P9+R[1;&DB9_+Q+'7'1
MI`GE$$^#;`D=COD^U-6!?'\<?/D='CMVU'0)81/V)X6-8Z,'P;[W:,8V7D+'
MYGOM=H7S:1;"H\L0,ZWH56CE#8U84E0('V2'NJLZW2'P;+MS4&<A_'NH++`W
MTCY4W>G_AGP'&)RA/RT`#Y*'HP?&0WW&M9+A2LA]ONV!,%C<CA;'8[./DH).
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MN22+$!(5UD(#TS%'X[VHD9!\[=LUYT&_`%\0E(=V13(Y&#$]`GWH"VU_A.-*
MC(L73NZ113S+B7F0()X33=*57/#$.W)_,GH^:@&3<]/QZ37*+H/LG"9]G_R-
ME,KO;#>O!$CD-]AP`8*$I81[(0%*IH:L>;!Y"6]M3VZXXO=&Z.[IT3YY8.G?
MQ^H25CGD904I:AD]).8E=PSDW[<)]E6Q=75H*KQK<EN2YG3;Y-L<KRV"\<!R
M_;7ML:<-:-FXMBV&WLW'2?6[J@6GT'Z@&63^E'L22^A!A0M,TWL+@S>,=!B3
M%)K;C=;V;HW?.;!M6^>WI];>%L&V01V@G//[@G@1H,LC195Y"6T[4')_=6,R
MWN%I&_FA*GSUW=>A2ZA!A`K":#/J09OA_@:L#D8-=XR:J1_[ZKF9W+GXY@04
M!@OOX0YLM=OAR>"E<P1@&6=RN4(2O\62#M4%UR)T'Q(Y7#CWN/VA<]%((>E3
MO(8Z4*>`OWX7XW+^>SDP(,%O]N``_LH`)3F-#I"2IM$!`K-W;``727P))KB,
M#J#<1)?@*8?PB@TPW$2EX)K'I>`)3Z.;Y(J;^`")R!`;(*#"C`[@,$=T@+\T
M'QM`\1999`!+.93XL0&`Y_$!FL4WR1*\SQX;H!B-#X#"-"Z%H$E\DQR+V-@`
M2,71`2GV?2+/#571YYKRZ/P)3:+/%1-1"26+^Y*8,0*G:5R#5+\NW^_]$-4Y
M(^#IBQC)`D:RY]]Z4>$>F>I+2/S2G^FSQXU/C)`;WD.&PV1Z!HW=-#_^"Z=\
M0,S^!C>TP2^\*0V_.H(>_EE<7_T4-MW[Q8M[3J9[_KCLA>G"_24^U*$O9!`?
M`NHS%P'E!)K5KR'TQVF!J2@(K$T2Q:$U).SX``#3J'.M1<KC`V0:AYFU2N/Q
ML4[2.)*MM;_&$5.#CH/$.M4S>X`@2.*;8!"&41Q8,Z[9C#D$)*?X"*G9S`@U
M.R+1\?2T9L`V9F0QR(JB(U(EXTKG$)-QWX$L1^.K<%AFQH-Y.F,Y[K\&'1T!
MM<V,+`IX1WQ$PE@\6,$]Z,P<ALUHG:>,S00L93*^#\'`#^,C.#7Q?0@QDW9A
M1)K.C%!4SJR2T!GT$9K&L^=:&#H#HB+%BX]1C*/4S*`@F[.<G,O#:R#X<<ZW
MEG+.<A+81%SK,IGS(("@&;M`N,QX,F0%%H]*F:9QW@+5F8[H%!+D5[]<7UU?
M_0_RNG?^#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C<W(#`@;V)J#0H\/`T*
M+T-O;G1E;G1S(%L@-S@@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR
M(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-
M"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P
M-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X
M(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&
M#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y
M<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*-S@@,"!O8FH-"CP\#0HO1FEL=&5R
M("]&;&%T941E8V]D90T*+TQE;F=T:"`U.3$Y#0H^/@T*<W1R96%M#0IXG+5=
M2W/D-I*^*T+_@8>.7>]&24L"(`G,GNRV/;L;,^->6Q&>@R]4B9)J7"K*K*IN
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MRR6+[K[`M-]7=71Z+J.WLJBC\O!0/D3?EMORY;ZL(YYL(A;'V28ZE*=H6QR?
MH]>Z^KQ#H?NWZ'%W*`[;W>$I*K:GW>?=:5<>HR_%,2I>0>SWW4MQ*O=OT8=$
M;F"%-W$<WT9WSSLX_E*=#Z<(?KW6(%7O0.J]34\8F`Y^9DT7HK$]4]KVAW,9
MG2IM6`U&[SZ#88]U]1(5J-EGT#]ZW1>`1@GJUN7QO#^AN;L#`0)&;LORX1A5
MCP.3P5PIT>2H.#STCV8;%2=T$*[DKD(37P2&6%D8))QO8."("**`JU_^7M;;
MW;$D6W#@L=KOJR_:V..I/B,"QS]%O\1IO(/_)+#.=5W`&`+X>JZWS\6Q!%NC
MXNFI+I\0.;B24.E&@,<?GXM:7[LZU]&V>GFI#M'Q5&U_W43%"4^S"B#N6SKW
M`[_E_!)X@"]:.%2B'!PI[@[$XQ4\GQ3>:',7V)O':I-E(F`O`%N/V)O>IG$T
MF%S/KL^M7D^[ZD`J7`*7/+6XY!ESN/`\,[B,6<URL5%I>)6?$#S876>(,#K@
MH`P$E^2[W\Z[TUOT:5\<-M&7W>FYA\TQ@E.?T!-I@WQ@X,670B"5!H$D29N-
MDJ<&@0^BMT2XMVF9/OM7:12R+*7MWR#F1PL`P/!<.;"B(5IPZ4M`(1*"`NR/
M.7/>P+)<:BP\#MQ%YW:U6MEXZE1,JW69;`G7CX6+#;EH8H/BVNIOSS5ZXD3"
M3#>T8"YIGH\@!*%^;L)4.G-@J-@=CV<XIP0'.4+PJ<M]@8YQ&?^7,K?6<]Y$
M1I&U,L4/VU.%IH*9PB7)ZO&Q1&#>?\U1JRR_W)KC]<%KWX^-J<!<J9L+XZK%
M-\NX\:Z/SQ#IP"7`53ZBWWRJCCL=2RX!*X\ONI5DXG@G`WIO`XC,39K]&5D'
M1(M=">[]0)ME=]C697'4"-#.P0!+/TJ(>Y^+/;(0']T"ALFX951(65O,DM*&
M=^M=P)ERY2BG3'FSA5(3-A_*X[;>W8/!Q7WU&1+#$4/_*\1+VM1%]%!J#"BB
MR@W/DI99:60H*^[$+3C&^862#0Q37"(1P^`\K-9D$:C%BM?=J=A?!(!<N1S*
MFABBI,FA=;$[]I:A62JP['A^?:WJ$^E:@7L4IZ[TRA`3VI:@M+"4$%BQ*Y(R
M'MLB27L/(/:Q.CS0GB37_,L.W/(!$S*PV$'9].[PPJ[*XX:DI7E#TFPY]X->
MXI34(R5P8^VK(^PJ(`S/Y0'][7YW`)\@^J`/X=8[U^2$SW5U?GH>6",VI@#2
MJ0P)S79[?CGK?/10/NZVNQ/ZW@5\*I/2DI$$>9:Q.LEB$TMZX4"(C52Q+CB_
MIGCA*6F):CU7>^"CQW^G^`++Z$G&3&X2J?!BR/=<C/(7?2K):;M>`H0\<1LK
M:9%3L_`03.HA$<&"NVQT[E3<K5#B6,98Q8)"PXH8?0R/F-J(_E^?<PG[4]%4
ML:W(Z@#0D;"I9'NA-N`*YP,QM$`]KS;*DC(,I&CTU_?EX:DJHI]*V#DZD'VR
M=/\2YG/+S9),N+@JF#)Q]6NH+LRJU"7&_:I&:EH@#D#.<&O#_@7.NM59]:'\
M7.ZK5SJCNM_OH#)!^&!KHW&PMS$K'=XP^&*BJ?:[!]KICRX4'D\P0'T!NN"7
MW7X?W5_&=F994Y(GCDH(SLW2%R^0,79_Z!0*SEZ]@"=_-G4F!+2R)`VK0QD]
M%_M'3=W!JE,->>4,IB`-J1XVB);NAKR6!W2AXGBLP-:3#99X\,=_^Q8]!4JT
ME[Z+$?27L#_F;NW3QGZ&9!7MM\%;[W9=*;B`CE2J.AS*+:VO,R/DOEU?@BOM
MSP_Z2A6<6B,L):ZZ+^<AT!>`()69BWZJH169,JT\ZWV-*X"V5"VAU2;,U>#S
MA[/>'4\'DFKZ$4NVR>T%,GLJE*NXJ6=K"'-J^R\_H_>"IX$UR-V&00K6(,X=
M"Q[GSX4_#NI=7-6_TIXW#!$3X@>>;;+,Y-/WKD20+UK3O[J(YR2NW2=:#7!E
MVWUWG6[GJ;C?ET!"7S!)_H&]&4B'^^KP]-Z:,98[U:#R%-C<H<KSYMUGXDD;
MA%@UR1/GI,*^K%\Z`;%Q];Z[8+5H/>9/[^X-*1RQNKZ_-\`NXPX(EDH'1,IB
M4Y]]4R`3.+]6.@]2#(6MC[GN[%J;HQ&"LHPK6@Y()H!TEQ"8]CL0@TL6NK(I
M?]\=3WJ?M7?I!=R?J=3ECB1O<@<W2]\.#"Z(/L`H4CVLQ\"6X^.;:6C1?0KL
M8$--`8SR1"`=RM]/,!5Z!K#&T[/F`_?E&]1*M]'_5%_`]%JWQ(Q[V>A2X^RU
M(1$T^T,)J?<B&83EKKDKF8L#(DW,RL.*OP#AB1Y!QZJ&==-Y3[?[*LB*YD#T
M6IU`7V!`$'-W0)*VM)!H7<.-MDV9"`1L=]R>CZ8'^-Z6I2EWINFJX*M?&./O
M/XUJ(Y@IUQP5]!L1_'%W_#7ZWJ!TAZ[^U^(M^OKQ$;A']/WY=+X,.V*9+8R8
MJ=V_^I$JU>.[@]!,UD`MWGT6Z6;IM"0OT%`7;J:+!%L`QW73,SGLIF.SXB.4
MFEBQP:;Y"X:-3\TMDX?H)PA,+39JLA)DY3/=7L$R%;N'79:FVU][79R"$W[!
M<H;BC&;Q6.)\J>B^#:/;-I?PR=A5:[RI6+BTP08K$'>O=;NOJ"5&=Y(.M&D@
MN^:HVW]'SS9\[NB&^:'2,?>C+L_>6W6>94YWX5R<O?LT>=R"B*5<-IG8^`96
M,!1G-7T_8_<">[]?#M$CD'9:?[/L``@U-C#SGMXVB$]=0I8JVTA=Y,ZZ<G6I
M4ED3$$UJW1VI=-X]T+T1()7`&.S-0>PS1?^HP,8(:A(*C9!637F%W90G[?+8
M$Z9:?+\[/ILZ9>#K/^U.I:[]K+$P=0E9_:R)",I<POS<EJ6,'C&P&34V-5GQ
M\+DXG`J\HT%$:7=LC8#JJ';''%VO?;9MJ5UM\BM4[M&W;\7#;OO>5@CP=VO&
M!?U=@+^WT!*RY>])9AW^4:?(ZO$1[Z@B9-AKT*3+443@GD`UMMC-Q3%\FF9_
MO,C=0+H%KKT[;36<;*>Y[=K&;_=01QQH!6E[HJ^_0!&E.TK8,XC0)\NVVR*3
MI.T+HO_"+>/0TU9)<T,BYJV^J6R5U>!S)>RQZDW3>)MQCKI?<L0(3"4WKDRM
M5^/7\LV<4S:/S9C]1S$HPKJ\QL2&Y16)?'G>8=50EZW.T04XH7[VR7$UUG`U
MGANN]C<@L2!DGRV8;O&UNT"T8'6)]VEZ2P8S<YE!895#:.2D=:,>/64'`CD^
MH(<";$0@XX(%!5(.Y4M(0#`E@P(<_3@D`-PE"PHD6#.&!.)$YB$!IE@2M(+)
M)&P%RS%ZA`0R%H<%4@Q+(0&1J+`5/`$:&1)@B0A;D2196,DX@8(M()"H)`X+
MR#BL9)+':5@@BUE8(,6G#4,"7,FPDAQ[0"&!6,F@@%*09P+'I9+!X[E*@]?/
ME`H?C].@A<`,@KXD)A:!XQ.L04>)@_8E<3[NB;\9D52O8B+\=Y$3%W.38<Q-
M7:JA)M96ES[29)H[ZBU"&OA8$;7MUJ?Z,C_^&2_Y!7/`_Z%"MRE>-H>_=#GH
M_G=_??53YZ%E<'"1Y2B&2,*OO?Z5)_B+#NN?SVU[<8REN`$6IQCAGA?4-^$,
MH5'VAAR6,_^+R:(Z'R%A'K&>Z2:+1GGP2Z.\M</JG"GZ20*JJ[X]#C$0<ORB
MRE?#P4<>@&GD<^50M3IVM=$"?<7,\12<R`ML'F*DRFF&][A;#V)!G#25Q:?B
M36?E;X%-??,6?:+[5R/@RIA9&ZPY7<6U0,\&>UPNQI;.',6VY[&09(W'PB_C
ML6GL5E__['HLC(UZ;`!8.E4X7%OWT!,N#2OZV&J!_]"TP$->JPVPMEB](>-9
M/]$_>UX+@VN]-F637LLA#EG%C(Y=;;1`7S%S/%>+L>60?JUB2MRF`F_+8<_J
M#F]5C<#'P1&-EE;AKFI:H*>E/;[<+^G,&>BA(E8OHV)7&2W0U\L<7X.>8DXQ
M"*"Z#,4.T`APZ,9&0:MK5RLMT%/0'E\.')TY`SA@Y4ZOU.V'EC):H*^7.;X"
M.)$K+W!R!+A4)%9!JVM7*RW04]`>7PX<G3D#.'R^P>IE5.PJHP7Z>IGC*X!+
ML\P+G!H!+H-BV2AH=>UJI05Z"MKCRX&C,V<`E\=YHY=L]'+*:(&!7G(M<%G*
M?<`E8SDN!\)J%+2Z=K72`CT%[?$5N1?/G`.<<B'$JMA51@OT]3+'5P"7LR9#
MW-";-_I>)-Y^K\OB\536(?IB5%4NJK3TTP)]5<WQE?1E',);2:\0PLXV_!\F
M9[EF)*KUGF![?`6WYNYA/Y4WS3<,>/K.B;O)O*<'IL,Z$F\`91K*\=A0D<[X
M,BK"QU[&&&J`W`)FDCT%FN&%&-&9W'.7[,.4(I)FA+*GITDSOE`5CG'8IXJ,
ML[`RQ$B&J`R&EU&<^:M"G,4S?S.\%`H\<\6J<"@E?:O2'E^HBL`@[U.%RS2L
M#-&=(2J#X67\:?ZJ$"'RS-\,+X4B%:M6163,NRKM\86JI&QLKR1A78A*#4$9
M#"_C9O,7A<B69_YF>"D28U%C8E'P63G?HK3'%ZJ2Q2-;)9_8*433AJ`,AI?Q
MOOF+0D3.-[]<N2C96-"86!2\0^-;E/;X4E54ZE<EFT@J1`&'H`R&EW'*^8M"
M)-$S?S.\$`DZ<\6BY(Q[%Z4]OE25//.KDB@UH8SR!O7!\#*:.KHJ#7VFMKKT
M\U,[OH*?)LWM1=X\3)=P\U#M7XO#&9^7TZ^EN?NIH4Y@+/W\-%[?*DO&6'RO
MAQ=++S&-UY0/=.:LB27-X"6B9GP-$6T>*6Z\4XBQPIX(X]#\P?`R!CK#?&**
MGHG[P_,GQC/G3(R4TH-[>WP-U?3ASOEH"P\IX=#\P?`RCCG#?.*"GHG[P_,G
M3N=M-"*-'MS;XTLI%"8&'^Y)PD:T(-8W-'\PO(Q&SC"?Z)YGXO[P_(E;FST\
ML?+BWAY?2DU:":#[ZL+@W85_91;6"J2#1V1F7'B<9/*Q"[<[GMZ\,!A>1FUG
MK!=14-_$<O7$<M[$//,Z2GM\,8=5<QUEQBQ!?CJUGB0TA'4PO&[6`*S$7CT3
M]X?G3]R*>L&)&?>N9WM\*?V5V=SUG#%+D-E.KJ?RYK'!\+I99[5]N51>6NW&
ME]-JKMPSHCQSSRH*_%*=?LGW0;]54NSQ'=7B<,2GH^E]S^D&,*KE(]C=\44$
MVZH[LP&,,WEX=F=X$<]>-+^DB7QTVXZOH-M6@P[]4'RB;X(DV0/&8'@1ZUX`
M!G)EW_S]X47D>\G\P+5]B]$>7\'!O8O!,Q%6!IFS!XS!\"(JO@`,)-"^^?O#
MBQCYDODSYEV,]O@*8NY=C(1/M$F03GO`&`POXN<+P$!6[9N_/[R(IB^:7WD7
MHSV^N+O+5BX&4E8/&(/A11QX`1C(7+WSR]7SRT7S\\R[&.WQI8LAU<K%0+[I
M`6,PO(C`+@`#::=O_O[P(AZ[9'[&O8O1'E_1S?4O1CJ1,Y`L^L#H#R]BG^-@
M=#NE/)/FF4G\I9^9Q,\`F6</S<_!5XV-5(N9-HRU.[Z(L>:98ZQQ\VD2:=^G
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M`HT5\Q5@JQ:THW)H085+1-:`KJHD,*:U$?.5;>NTIC.GM::*QFJM&JV=JB0P
MJK7RNF%[?*D;*AXM3I]4%FDCK#U=S4E@Q`@KYBL25T&OSYP!/<\:K66CM5.5
M!$:UEGZMY6JMY2RMJ>HR6G.7(UJJDL"8UD;,6Y"N<QB\13,S;LV8)5AK3L4M
M*@@U-!:E+AXD,`*-%?.5QZL6M*-R:$&92T36@*ZJ)#"FM1'S%=7KM$[2>5HK
M1U6L`5U526!,:R/F+<77N2'>69KIAC-F"5;94VZ(KQ-8:)3C0RT\2&`,&N7E
M0X/A=2K/N,V!Q:I(;7]`I+8_()2KHD7[34_OC2TQ<F-+K+^QE;HOF,KFL]5I
M%ILOF-)[@J-?()QQ:TG;;,UWIKK7=<W/,:NM-*P#2_I]`S,>K^@;S'@5AXIE
MH[ZQI*NS%NBHWSNY:3HT[YW:%2>!X(I;:5_O00^O>#?#+GCH@<UN$\)"(!L(
MG-U:P`^!/M9T,(3LV:T%)B#0TMY&AEAW=Y`S/PABDZ83O5ZJQ34>%IJN'5H@
M:)*5]K4UQ.I[C.GT*_-491OEC1U.X]SU"L86DXXU/9'F16!K.0F$+3?2OM;(
M*G^F,Y?X,Y7>!@*#1M=N+>"'0!]K&BQ"]NS6`F$(C+2WS[+.GT6B_"`DFUA.
M/)).1;W&PT+3M4,+!$VRTK[^R"I_IC-G^#.5ZT;YU*47_3-W38>QQ:1C37.E
M>3_;6IZQ2<N-M*_'LLJ?Z<PE_DPUO($@<[2B9;<6\$.@CS6=&B%[=FN!,`1&
MVMNP6>?/=(_:!P($[AGWB#4:%IBN%5H@:)"5]K595GDSG3G#FZFW8)0W=CB-
M<]>[&%M*X5*M/D/VS-4"8<N-M*]5L\J;Z<PEWDP-!@N!:B!P=FL!/P3Z6-/P
M$;)GMQ:8@$!YO;D]OJ;OXP.!;>#0C-OL&@\+3=<.+1`TR4K[ND"K_)G.G.'/
MU)2PRLM&>4<=M<#(8G*7:O49LF>N%IBP7/HMERO]F<Y<XL_4J3`0<)==6W9K
M`3\$^EC3CQ*R9[<6"$-@I+UMJ77^3,])>/TYGGBVCCH@&@T+3-<*+1`TR$K[
MFDFKO)G.G.'-U-LPRB>...J?N>O0C"TE<XE6GR%[YFJ!L.5&VM>06N7-^5B:
M'?5FY;BB1:-KMQ88@4`)!X%!HVNW%@A#8*2]W:UUWDP/FGBY1CH1FZG79-!0
MCGRVK-`"88.4ES\.AI?UI$:]6?>*I!C_BE[6_HI>CYK&:>3^$4KSE?ZQ*<RW
M#I=/`1;8;I29@?>^&,2B+/BAPQN%CA`XGJCP9S5O>!Q/"$Q\Z_$FC>/@QQ1O
MLI@%/W%ZD\DD?(5<BK`.4D[HH&3X2ZXW"?V3U$&)))<38#,9_OSG3<)S-2$A
M)B52R2;TR&3XF[$W8(H,?@OU)I$9"V.>J"S\^=P;%K/`=RY)(HDG;&$LGE@Y
MQB>^M@D2,OR]T!LF5/C[M#<L353PFZ`W+`/,PA)Y,H$Z?FEW`E/%PM]_A1W-
MPE\GO>$)^%!8`BX1WE"<DD=00B3)Q"QI,A5\LB3\:>(;GB=\`@^)GPT/A[@D
M"^L!L7IBY<#8/*RI0%<.2_"IE1."381*D4YYD("-/6%+/N7)0L8JO"MA0R7A
M72E4'L`4LM]W?[^^NK[Z)_:CPHP-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*
M-SD@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`X,"`P(%(@70T*+TUE9&EA0F]X
M(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S
M(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P
M(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q
M.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO
M4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA
M9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HX,"`P(&]B
M:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0T-#`-"CX^
M#0IS=')E86T-"GB<O5Q+<]Q&DKXS@O\!!Q^T&\W>>N%UI&QIQC.Q(^]0&YZ#
M+R"ZF@T)C6KC09K^]9M93S1%%C<X@$(.L]DH5%6^O\S*XOM_75[\?GE!MEF9
M)@3_Z4_%-A7F?_7Q\H+J)S1A64(S_0U+,K(M2U8D!8$GA)*DEY<7OR:=GBL7
M*4Z4%@7^2/J[RXO#Y<7^/W$J_#?[@FR%X+#`5O"4PP]>,G;^O!0I/B]YCL^+
M(N//3\B2*U&4A"8%[`:&B4SO::\)U`^+TC_D6=CP^\^7%__UL;JMRX3RY#.\
MH!FA)W6D4P94"GAZQ"VQ/,^3S_7EQ1601RE-/C]<7KS[.'6[IKM+U#[Y.(U3
M+Y-/)]E78Z.Z(?F/Y/.7RXL/L-3__/\WI/D=V1`S&WKW&Q/DK0N\1'&&<B69
MI9CF^-%0#/(J#<6_RN16MHV\E\EXJ,9$37VB#,W`AU8-@QR2AZ9MDUIU\-TD
MDZ9+&"'Y-OFY2ZK=KD'N;/2+=34<DD[*W9",*MD#,_77>\/*LVG=K+?RS7R-
M"+HL2D=UP82G6O#"4#U,M\-8`3U5NTV>LN!!FJT=*OAFF/;[IFYD-P)UIV:L
MVC/25%"/"KXZ2FE9>-LV=_;!>.C5='=('F75)Q)&(??T\%OYJ+K==A4.Y,QS
M@.>!`QDS'/CIL=HU-=`X)!)8`=L=#G*75$DW'6]ECQ:P;^4?S6TKDU/5CYWL
MAT-S&E#ZXT$F52_A51AUK+II7]4@890L4M7+`2BM#_J7';"U5:<C,'`#Q.-"
M,&S2"E+MODS#N`KU:>KL/$N]_%.6.?F?I#%T30UHHZ4'_NMD+8>AZA\W>HOU
MP2H&Z._M%UF/S;W4=*.4;Z>AZ6!T<FHK,`&M`557W8%"J?&@AP`SX`=,J9]J
M`YG&IFW^U,J1@/+(=>2/JF[DS_/"RY\0;CCP5_4`=/6;I!F3!@@`0]>R=A9P
MK!Z30<JOWL)!\?=-5W4UL$W;#([HJP9Y-QL"AA$T_C2!N.M$]<FI;^Z!U##%
ML`&'TK;5K4+[N5_'"S#J>5!F,QY8W]?+UI@H*O8F@:W*;M#NOP?:V]9&@EKV
M8X6*(NM#IUIUUZ`&@(F`4O2@.'W5W4E4\&&;7)^S`F8`#N^3`=D!!H`\Z]2(
M7J^ZKQH@'U@.#*_:=H-3NN=K,(,(QPP&$UEF\)*DAAEG6U)(;7\<DGUU#P+2
MBJ'`:K<0%GLD&Y7]<2YX^?O4C(]!OIH4F'/7M).6+[P_C*K^>E#M#GS)QGJ'
MVS&\HUGE-V&XM0(GBB)WG$@#)P2SEM%T]ZJ%#8/ECGVC#1Y4]1Y\EY;P)PQH
ML$6,:$"3L0`7&AX.LM,!4.[T[@]5?SSS%)M9%(0%IG8TCL'RH-)AUC#U[6[A
M)<"1PPN.^'=OF[V(<S8E>O)2;!D5P-H_8:%/^_W22[$R+,70H.U25TLOQ+E?
M"+4EFSD1_(SJ\KX"WU_+Y.:`L?]ZY@T6QXMEV,T;Q1='HP4GJX+1@CKTS47*
M?%0N4^:QZ$YI_Z>A%WH8]4;EB7D`L`"WDP6T)[:2?M5G'!P_6O717VNW:]5G
MT.I3+:`^+^MR.:>;$TR`D.[E'0V(UR^UBJ/)\\SG<9GAZKL?>W";]=*+"3%?
MC!=I$&%A(R<X[>NZ5E.GO?HOJL5\P;CU#\/8'`'W+"Y,L";TYM8Q$0_PN/X6
M=_49$.NIEX#=#=)$0.^##"#^T6@9(F`(.7O5'S%^/S2`6_]W>[--[B1`?L`E
M$.7K6IY&3`X"E8#G8*93"W3V&/HAEEGHB[-B8#Q67U<!=3DMO31$2&S*PM(M
M'<NU`*IAF(ZGD*`!K`,,?T:)DY=&OM5^C\]UAG/$(4C?2?5(/G!*)[DP%[RS
MJ_"[9UF*"^$,:U!/?%HGLM)3KS5`ZR(0=CR!YT32P)-*Q*20G,$&'=P`REM@
M1'/7-9#9`J@!$>\:H!MP3:^.-A_R;-187_OC9@?4P3O24+<'^*X>SEAHLK]6
M<R;(804V9(7/[WB>SI3`(GO(XVKM#DRZ?I:K/4G9D11`Z@!)Q\H7?VSFIOF%
MO_I7@)L`6@>8_.2L"B9`!.B6>TZUM":NPH?,97F,9H$/>2$,'W;-4$^0V?F=
MSN6>G)O*EVEW9_5W&!3H-$I1^P-#8:`&D.\`P0I\!CR\A?3^89N@NVE`\\!X
M8"5-,"8(8::^&;ZNHPNIR_)86094(4HVR_)09]530E3WLF8`C54[J,1R4.N\
M3FK5-";_[3W=TO2D+/4$F;H%@#'&EE^FG/.-ICX-2HES)4/R4]`>%.@UY'F/
M0Z-SWU\`M:"@?7ETA6RE*/P>WPYW8XK#Z;=@Z-^!OB]"Z]2OM0JTAHBX."TO
MIE[?D6]L9;ZQ%?CV(B0.?'NC,L>/-C(J/"*FON*9Z\_Z9$/U$ES_RN<9:2E6
MS2#3W)=N,A+@#TLSGT&:JOTLRCV)]T.%H-6@6XOJ]I8W.G#W#6*>&ST*4$%S
MCR@/<9$?-0VC.@)><*$>!X!+K$ZG7OVA`VJ[2MTJS7PE@F<B5/!<4;LDOQ%(
MO)#(DNJ/%LF,:M3X[UYVDQSL^4VF!\*'=(-0YV1*V^VCJ7!=#PTX>#PF:79-
MU3]BC;A5M>/87Q7`F[\K+-GA+`^6[>.#LE71-<CW9W<@^W"FPP0/9SIZLR#`
M#<1V.=\P9&4&D^R>/D'@\@^)F\81('J?LQDHBT#.0LBF`PZ."KAQ7[539<Z]
M>EG+YMX4<A$08S8/ZZ_!`.83/I&F0?ZIS4-]#1]Q6-,;+`=;OU-JIP^T?B,I
M>3@T]<&"],$1]E3:,)`:R;8@XZ5)$2GQM*Q;@!&IF',M*T,!QC&MU08..%7Z
MU.A6/LF.#*Z%8;?P&>R][RI;]5Y#RL3EMSQC!I:]0\O%VO,*'EO8D]*W>^QX
M7!+^'))S8=#YNYL#P.NEUQ+"K[6`4L46*N9$L9"%%_JS*>IAPO`C9.*R&TSY
M97'10;KGMK%*,5A7:%<,Y8*[%)ZRX,QR:Y8?=!T&CU[^5G43NB38!?@D#%P;
MC#?53NF:U*C+7.J^&72$AXAWXPHQNHO#UV=F);H;S/2K?C=HC[@\;:DG+O,I
M'%]\&4K],L`Y0FT=Y-W-Q^N;Q1<#T_V6)K'\,H5?YLR(,2`M[FRS-`BJS+:,
M$8/_@9LL=:@"N9G\0VVU_C&."O-/$QZ7]BMY2F=&L;*WS`O^/*<7=Y?H2JBO
M4K$BY";,5:G>:W?Y2_6HK79I,9>%W\!3G5H^$R>!VA5M'\N]GJ9TFW/$PT9S
M*:5LIKESE5U\%WGV#+&+.P5:L+D`.?I7[Q16`-KE7&$)R4.F14L;WQV(AJ@#
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M*[BV/9TW[?`PK[]O:MW8+?^H#]B!HFT5I^SE`WB2+;B0Q=4^!]H=_>NJ?9[3
M&:=MNOGN1U3T-63J.\:XK<2_&]Z,X6/5+>J76KN,-J.)9L&1"L[F!8]GG8:U
MI'YG[.BEYG`W?F,+]*:7NO\J1]T8"MIH&U+,V?+N")$-K-ST#J_IH+COWQ*A
M^Z^TP6TG72.Y,B["F=KB.\F(W\J*Y\(T$S.*:<G#&4N:"7<N_$7=8G=S;<Y]
MOPVBU>G4-J:Z7+6M=]/[T;HIZ8L[Z-=,%X:RC1CW<D!7ARTWMFMA[O)7`5.<
M^@KQ+"`**JR0U33ZWA!SY^%;(DP#!#A4=)S'2K<-M&J8$$J<,%%0T]`^HH,^
M-B,2J%M./.]TOT&G=+D=>\H[8)RM,YO6Z1"R5F``*_UMF8P&):?4,B#$'1L3
MC>!_U;<FDDFWS"-+CFJGVX,6/Z>%',SM<5U/Q_)BSHV"AIX:3MTQ2Z_<:5ER
ME.-![7P?T?NV>F/B%?6^Y7>B'E.\&?5I$:R?N,ZJF_J@T#_[$S"4NFPU7L#O
MG"ZL$O'P!MOW844.KP56<%)D(0=UG88FZ)U,V6J%_`4ML_#M?C-/3,+=O?.;
M>?K"DDZW#'X#QSM4M7&<$'L-(+1HS_0XF=-+$YK/L-\S4-K0:P/=OFJ,P*7V
MT5.]"I1BF3\D$&)VY"FL+7I:/!WZJ'Z%'(VFJ=_-REWC:.^>;@BJ@6[B+NOX
ME&:#@D.9]SO=1JZ3I!!5L`7YY\\?3;[MRMAEMKCC*(OOQ)R4L/E*H6>'%LN7
M-U)&9I)@KB*O;Q*Z!/5)>>.#,9N?YQDHYI778&NVZ+%"@9T)7Z9R9\:X2<KL
MM6;P"Y]T@@Q[Z4+)1>_XNL:$T(%LT*8?5??%@CNK3N8JW";YBU([W?UW8\UN
MN[QXJ2=F]58V@-2,NEH(YZ'0FQ:Y..\G:HSH'O3]#%=RL(@4F*MO>X8R@P6T
M*W@A`;FKV_/*6("5,^ZP61E<Z!O59UY(*U*(*]W.WBKHY$R-U"W>HD1#T;?^
MUJNIT-+?=*3AVB<OG#6<JF&$W=[K;!(O9<]ZW&=%G[-.:9M@SCN"</>H%]KO
M^C[P;^.FOB?/"!&;)RUB/Q1EOB&$@%JMDM?06;-<&O(:EKN^:)N5GS=(6Q1?
M^ULC7NFM$3PC6A3HQL(+R/=OI4Z5CIC#_1DZI_7L6O;`@*E'-NG\#]:PA_RK
M<,%WS1$APCT9=Y!@>@K*;?())0B;-]<^OI$59ZF6%2KW#SRG7G`SC:D&TQX$
M*6PH?]CK\O-[&2\7]=:@W[?-$1'2>4ZL%LS*B*[DY_Y.`6SN)X!5^L\!<-M[
M\6+3X+61=G6>M3];$<+[`>?,S8O",W<-%H06,!XZW7F9633U0Q[L4#?]GY=^
M(W1OYL9S7JAH_!$'BGMJ\<]-`%S3?TB@;^Z:3M_U';38GUC.&BSP764TE+&X
M*V,%4_6EY$"E+P^;ZO*3H(_UDS('YN4E2;C>5]B`_NLN6.3GN1G`7AB0<\!3
ML0$9'H/&!J28G\<&"$SG8@,X@_0W-H`Q%E^",B*B`PAC42I8R>)40#[(HYMD
M.6/Q`1DMH[)@*:-1*IB@!8T.X-B<%AO`:!'?)*6`M6,#"&71`4!D?).T('E\
M0$Y$?$"&?TTH-B`E)+Y)06A4'P"_E/$!I"SRV("R+*//"^P>CSW'$_?(\QR/
M52//,QI7IO05*0C"H_-S0J/T,5)&59&2_&7Z?K=#TDP/`4J>3<RH=[OT6[>;
MAG(:->DC!.*RL.CCL_EK&WM,NL9O+GV;:?[Y%YSR`</`WW!#VQ2GS>&'20+\
MK^WEQ8W;=$E?WG(VW_(3U$_2Q*-G=T[V7.ZE[V"_<0F(8PZ2V15X^32FQ+7R
MJK0B>>DYQ>O`L0&LS*)Z><7+N)N\2K$8$QU0D/@,&292L0%Y_LH>BB(>D:[*
M@D:#WA7H?]R`KRC%BWC1$2R/&)$>P5\=(0KZRC[2@KU"2U;$G<D5S;-XA+ZB
M&EW%50M":%RW("N/T\(H>45P##0X&ERN`$KD<5H8!]`8'R%H'G6?5RREV2MS
M9/05KK,<.P6C(PKLO8W;*XU'PBN(!/%X?<4A%L7MB3.2O3*"4_+**H*\XGMX
M2LI7G`^$S3@_(`.-(Z0K7B#2C[NXUR0'OCJ-[U10&@<@5X*])CD!;(]S78C7
M-$BD[!6YB.PU318`9N)6*?*RC%NE*/((3R&V??C7Y<7EQ?\!J[V8R`T*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HX,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#@R(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y
M-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B
M8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO
M1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B])
M;6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^
M/@T*96YD;V)J#0H-"C@R(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O
M9&4-"B],96YG=&@@-#(Q,PT*/CX-"G-T<F5A;0T*>)R]7$N/X\81O@\P_Z$/
M`>($&H7]X.NXB=?&!D:<9"?8''RA1$JB39$RF]S9\:]/5?6#U(RF%6S$P,".
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M5A&7JPAT"`\.W5`T;&S[:MOMV_JWJF1MU_Z!/?Y\?_<>UOB/FT@2@WZ]*+E8
MJPA%^0V6_W#[5R73J\"T&?B355HB\3,J;5OH`].'HJ]N_OI,_M\DS=*YI$*F
MWCUBE2=&TDVAP:3;[GBJ6ET,==>RZ@M^KN!E#7A$"2[`;KTTCN86TJZ,QYFW
M@>)Y9E8&;O:YTK@`/73;7UAWPM5IMN^+%J^.;0G^W(T]^C-G[W\=Z^&9?6BW
M53O4GROV]Z9H6=&6;DC"/M(\/](\='O-'@^U]@+;CULK]`95X+U^$17`HJP*
M,HQ7JP+I8K?[#!(6[*FJ]P=8U*V7D*?3$I9U11[Q,VDC<$TKK40W)6D+D+;8
M5^Q4]757(OB(=<Z>JZ+7ZZ]=4/+&@H2:R?[-UQDW#QHW3W(',3PC8;_YH6OW
MMWX3A+=[TPU,&'J1FHG$5>(-F-!G-.`/$'8E>Z=U->BOCI>W+,9A96X!7VFP
MT.Q@,&4G_TFHZ-8!`*DZE\)K3TSNGPNKO4\(-Y_KZHD`J_E:7PE%81+[52P<
M[V"HF;S9#-]C(%8D;T/>4I"WK%C=;INQK-L]V]5?_'4@*<7`(`VS0]64A.8C
MYJM=9Y"_`ZR@I`4SX+7Z>"KJ_@@90+.G0]56"*#P#WZ'VPM@>,YC)V6>34(Z
M!-\>BG9?:1"/;>M^.Q[U4$"&P@MEO87T:B0$+L:V1=\_HP**8S>V`Y$ON$R*
M8,?B&7C7X'(2(N6FJ59P%[Y#YNM!*9MGR'`P)8J/3W]7M_"N&NC;N^T6I\3)
M%U!!AH(;I(NDH1C?P$+:LNA+??-`2OS[P(5EE*;&A1<)VGQZ5[Q6.7!]?!?2
MZP@_HX'_UJT95VIU^Q0"CC5I5@@U>5>J+$6:V16]']WE@X\`=/AO:WWJ-'@`
MN,,2V4=B93.98\'T(_.Y.A;,/V_FOT3-%P"/>\9J`>VG*(X^?O?N(_H#?.9K
M]F'']+@]`&X9$$*3&$2X``BW7S+&)CSMX$FF$S[%9LFGOM*PKA503/94-PT#
MPDUU(/D2,.Q:DX<AY([#V"-*066T:[HG0-RFTIH&VGO=.-`=UD*UJ771/R.-
M[C9#`=+".*38K7UV3K1A$6,SL%W?'6FZ)?0`UK.1E$S)*!8VD""IG.,M9IH:
MO(C,-D(`E11)->8:LBL.U>/1/156%1K7*JMH0V#O2BZ7%9?0!#!?HXDH3[*)
MA:?"J,)Y@B]]T'NGO`K$!.7H:+G5EP$OG0GTN6A&O+.MJM)Z!SQJ+J_9CY"T
M?Q[+O4G1LPK33&=]`LRQ&QN&#(&Z%TNH0?JZ6&`*QZ2U!.>"\>Y5RU(N*`1F
M,LDI6^19_)IP^<*XV-0-ULT4AD6#]C[SY;D3MV16K9VWOG!B?19"FFA;L=L9
MDP(YV17;H>NUA<1EX(Y+KX&)8ZL\L=T.7!T8N<-%'P&5P'T1?4VX'T\]$"OC
MF6>2K-B,QI7=$4%R2\]`UH7:'/2R[=KN"!?A;UF;/@7>GSUGJ>HR%"S-?6DM
M,NF#.LTL2X%WPU*/*.N:?3K4386(?X"*FU@E&+]$T-]453OQ27*)RR#0M8L4
M*"K+O2@+1TLN9TH3L8I]3@`HO%2@@,."RH[%+S[=X1VMS_QE"=.FKN@6G$]E
M5,)MJ]*YLP?/6<22"UX(TJ4*3`G$U*UW6?O)>*X9+M-XHF.1N&0_PS\<!@&\
M-:@;3/RCGJ,?LI\>BZ:9NT,8]Q#&ZYNW'5`$)\8B38TT7K"I@?,K<<-:+%0.
MQ?Y=$`F9\O0[SE/+O]\CQS`M;/#QOW?(3="0WW==291F5ALMH6HA%NT?I9'K
M-$1BHO*2/J/X'UI60#W8EY31GNKAP*@:,16JN'V%*I2:+4J0JUF;4,,'%^5U
MCU#T(VXYL0\M5#S[>@,Y:*E2#<'!+@SWQ53DO06T)5Y5:P*K-5,#X9;8/`':
MQ,EH*Z$=SV%A@7A*,E]A)K-^DG28YCJ$)MWLG7:?#C5P*J@R`.VZ;4VDFCP`
MD?Z=KF'Y>MSHNJRA*+.['@/0&"`FG[L&89**&%,%N1J08+&L``Z/=6LJ0G>K
MG)'ZA0AZDO*I?>@IC5*Y=?=+DI&7$3/MP$I]K0T44(OMXM)MX?&B>/'%V*GK
MB;&-;3V@UM`[D-5JX'SUKMX6X`2@\?%HMZ:64$.L?`&?RUGZ%[YR+1F5UV#2
MF6^B=5>>:D_"S^MW1_-93]8&L?L*F(W9-3-F!X<GG4#N^XC-5/CN4RBHWC8S
M3&Y=0GJ9>B>(IG!0KF<^4_Y,V`MD''O#K1Y<M0,*<]1]C\W4EEC<"CD2F+LC
MG`*-MGMM2M8I)*QOS'S(=7)+XV?U,K@@7&G'.8\G@B\LP3?UMHWC_\Z=WU&R
M@._-\PJJ@`E,7A$?.B2`I4`/;_#=#]\J>JV2Y=AP$OE-8SG5.;E2#A[G,@;:
M+F:=N+?0/CL^?ZP*#7])<"R'],HP_F?3=3^OBGI@E@&5+4`55>JE7V3#,DYF
M->1T)D*X5/ZA!52MV&/QI5I@=P_>KY)%^5,L?+DPHX]*I=/^&Q7$SM$A]>VJ
MGDQ>?'$]#>I8H0.!&[35,*OJJ2]&_H70\H1[']24_Q<X(LQ!.S-P!8(4012G
M/(W]J=,5;7YAF['KZVJ9GE_,_5:<$%/89*X-7%8GD+HVW!G!'W`0PN@WNK`R
M5\Q6`^%`57_&W2=6-)!'D&V>`R?(>P3<_%1-@3(Q<_\,@X!"172X#_]3!`7X
M<JBA<K])ER3"FU[$W!WW>0F8R"[0OI=\@!"@'+<5C7IC!'6/3&_7I`7-0*<5
M:^I?\)`5(9)MO1"Z4/%9OFS.+*&+U#/,+)_M"#A50+:LP4>G-C;(1=:N3?Q3
MX]#V',B+&R#&^$4/2"/VM6EWF>8(#0)-M)7=M,4O%YQA92A,9;=)'!-?YN01
MD"=_\(AGLVT<Y:)AHKR%60QU"\!.I(A9L^`M![#26`V^;)S6QK<\T-C.#$21
MW0I!M9&+N6)VJ;A0CEQ&*O60*".[>7TI:HTJP!=`!=HHP#J&E=F>WB$RYC1I
M)D$6<2Q*R(UOGDDDOR_9[WB\DIE:12K':?<]8NL2\@M/+WD\R9]'B?.$5Z9=
MV5J+_',W-A#+W6Z'6T:;Y\M`=WLJ@"N/TD63)>C`>48:3WQ39N>Y\JT4Z#,@
MF/GEZ=)D+=@12!,JZ>T$:9UJGB=M."+?V@#.M`O!`Q[IM:(GTXE)*=PV2O7E
M5)N@%I'@5!;.>ZN(CYNJK7:X?4A;FJ^55!DUU08445..9AHB"==!,4U]),W@
M5G'5TR;JV9;QFKTW)UN64$(\D<&IVG"'1DT(X))-!Y56:L[A.!B8]C4OBN^0
M%><8AYK`%+,&L/$.@!</_=DC09`;-J,Y`X3YTBEEZ!`N01DC$K)E4J64GC$F
MV6R_/[-JZ)[:JM>'^N3J8)"6DCQE]]BR&G.&<SCTU<T/$XMT6N2R_78!Z6&F
MCFA"RX0^HSK(:`;^;X]Y4DVB+M(IE_Q_[92'RRMJX=G=)C$U2MV)\W<^PR(F
M?MN-FP&WP-\YVKV`Q");MF$M$L^ZY<0NP$FG)$)[L`4%_HQCH`9*IP%?>.#5
MJ8]E<63B2_[T"-`-V^6Q/'X[Z@%R24^\G#;P?#&_`&C002UC9Q7Y6BN.E&W8
MG8IG:C:9QE)Q?H+KM=3`QU%!FHVM30(#)@J#N\>B+?:F87$$(:F!ZTY7H+"&
MA-N.:--4P"<GU2S6M!/2\6LA?/Y4F;*LTHF&M4[5,J@\L55K"@4]M96`:<W$
M<V6)!BAM1V*-(()M1<Y/CU+NV>,GS,7>]K_73J4K=BKT(CTZP7VK-N63X#*Q
M_@[U4:N+K4F3U)WWGKEBP*?+>GB"LOL`E8<I%?0)BO(=-C*G<8=:8Z-@BZ5S
M7[6E/<EA"N^6-OG-&:7SX\27RO<E?M&0.T(MYB?DTC1V_3E=]9"L3UU3;Y]M
MLD!AL`=I?HH"K'`[`NG&MG2M?\&=VTG.V7F*NBU!*_WSK,MKN=@5''E:YN@)
MSSQC%L)7E8*.6Y';OZ#!*J*?6`$->E4'08'4#(=NW&.9`<'>U%`6FP[_)%R-
M!VEVX!TU'>"K;1/6G_GU:GD-@PO6UCR9R//TBQ8I;9MZ;-TQ!=`!58=UAUV#
MU0S(33:8'S9Q1?/LK!+!N(-28(*ED17D]AK2KUNW2#K-SK_;Y8=E+*$%Y=FS
MG'7K<YOK4;;M8(P";@NQ4)J-*6\\[<YQ@T__I:.?--ES[J@-@Q44'K0+8^<C
M!S$7+5I"F#^OV8?VU2_^D&,[?S!J64(+4\.5&G`N_^?Q62*PG2'NFX!8,.BB
MJ4RMW=A2*XK=^LE[G[IY7J=?"5R:KBJ@4)G/Z;;Q+LRRD!9\[S5*XEDY:;/A
MI2;(`:I=0+VBK.9PO2D:X];4.#4EHM_VB7T'E7ZO.3VF,;3L,5\Z!70&0SRE
MYQ!:$_RT2/=Y:KYF:3[;R,U\3D!(@!H.DX`7X4+&,OA.7088MAFUR93$_-"C
M.RRTMMUQXSI.%OGFV[63N0T0%"749QIU88XJT@,WW[N!BM%JX47M8EHY,&N:
M1TS2K-/C]%-BJ!QRF9D!XHT!F4SRX(!4QEEP0")%'!P08U<P-$")5`8'2"'#
MKQ!(H$(#.!YK#0V`S!M\A<B%"BX22B(9'I!"C`8')$($I1`QSWEP@.)I6`HH
M5<.+%!Q/P`0&<"[#`Z(HO$B>1UEX0!;%X0%I%`>EX$G$@XOD<22"_L`EUIJA
M`3P'PAH<$$7!`?!\\`UYQ(/WLR@+RICRL#<E5\Q`=6?@OHI$4#[)H[`O1EE8
MPU%`/[_:(7%"0_CL_]<P;ZIPCZK\]2^HXWS:RS%M%?QA0V9SRR-E3D@#0*+P
M..#YS]',-/_\'J=\0I3_*RYH'>.T*?PQ737_M;F_^^@6G:9O+SF9+_GE(?V8
M^3I!V)\=7&J_T-F7KWP%_4C.O,*^X<7\M-D>LMI#GB;!^SR_,H'(PRGK0>9Y
MT+$@X>;A&>(LG"X>DO3*&M*,A]>09>&DAWH*AM<#^'\8(!XX3Y,K(\35$4`0
MKJQ#93PL"H^S)`@E#SR)\[#&011QQ7$R$4X+X%K1%5GP?_<0MIN(\C`9>1`<
M?Q$6'"&0K09'2)X$P?,!4GE\98Z87]&Z2'@2UJE(>3B+/8B,AV$:XA4JU7#`
M1I!.PR,`)Z^,$%=HQ8.4T17HD2K*PI:3,0\G[0>97.$_#S+%_E5P1';-<C+G
M*KQ2P.HTO%+%KUE."7X%*)6\YD%*7>&D#RJ^YLDJ@?KVRH@\"T>E2M.`3B%S
MO?_W_=W]W7\`^3H@Z`T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HX,R`P(&]B
M:@T*/#P-"B]#;VYT96YT<R!;(#@T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@
M-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&
M;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A
M8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-
M"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T
M(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*
M/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C@T(#`@;V)J#0H\/`T*
M+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@-#0P-0T*/CX-"G-T<F5A
M;0T*>)R]7%USVSB6?7>5_P,>MG:S4Y86``E^;#\YCI/V5*_3:WNVYZ%?:`F2
MV"V1:I*RX_SZ.1<D0,IVH%Y'['(EED@0N-_WW`O0[_]Y>O+'Z0F?1JEBG'[,
MIV2JPO:_V>;T1)@[@LF(B<A<D2SDTS25"4LX[O"`LTJ?GOS""C-7'"J:2"4)
M_6+5\O1D=7JR^!M-13^#"WP:A@$6F(:!"O`K2*7<OY^&BNZG04SWDR0*7I]0
MLDD8)5',$L$9AH61H6EA&&QO*G<SB'J"W]^=GOS7Q^Q^!O8"=H<'C"#,I)9U
M(<%EB+L;(DD*/'\W.SV9@&Z:Z^[Q].1=N=55UN1E44_9>SW+=K5FCYKAZJ*L
M-JS<52PKLO53G=?X,&>Z;K+[=5ZO0$JMJP==L[)@&9OMZJ;<Z.H_V=UOIR>7
MH.Y_C\)#J'C/1"JG(>>"W7T%Y9/C+Q4.Y:6,L-[=/QU]G2CYRUB*]TQ`1&'J
M3""4<6L"5G7L/H.6STC]\Y(598.U9F4UAW:7NH"9K*W.I^S'\E$_Z.J,'9MB
M8[/PV8[@.%*.X"!*6X+S!='XJ"O-FI)EV^WZZ26-K%PP\2N'4V,,F?&NZ.Z`
MH=FLW!5-30SJ_`$&K<'\.BMF^HSE#7LL=^LYRXM9I3/X@W&"];I\I`$,?@'Y
M[.Z;Q6[=SY35XXB"IYTH>)C&5A0R33O=@<D/X&%S#_4%XHQ)SB/CIT3S?39G
M<WW?,/UEJXNZ);U9:?:D,_.A8+J80Q[W3R3%JOR2;[)&0YK_)I,SSOGTK2Q%
MWV8I35J.WOTJ0_ZF^5.OR%*8?"NQ0,9.8HGY3!*[*AYTT935$_N_;+TSH6\,
MS:5*6O\..*W]]7M8]HE4N;7&F3_MYS^ZH"+.TD!99Q>DNE9?02+29_HZP]1;
M<N&BR8OE,X,5@7%UN`,9_@SIK%SG<]R#L]>U)@=M7GK*&=M6F*'*,0,]D]<8
MB#D6>8$,AV>793FO*1"L=W-:=`Q#$8GE7X7"!3NHM8UUQ1SAN<H1V'3Q]6F#
M?(L43<')>')_^XS-5GJ3SS"0_#];5OELMVYV%!+!XN]&!KB!/(X4;@33F"D0
MUR`2<#TKZX8A0K2CL0QQ3",R1/ILJ=L!8XB`\E\7[U7<Q_ND,X&-;E;E?,H^
M[JNETQB17F6/C"R!!-&RN<F*W2*;@7_B@BA'9JMW]^`=]H-H_D0AG9Y]7.6S
M%<LJ$N9L5U68?[NKZAW&F?2RK+3>:(KQCWFS&H/_)`DM1I.\SW<Q[VU`;RE2
M@Z*>+UT!LIW7;)M51@:DJ0<7TN`<,UV#9_VE_5U#ST>'%SQQQ(\,9/;$)!(L
M;,6DDDY,F_+!!`9H?YYM8+#D)6WPR.$VI&$H=S?#=>@5XLHK@K,FA,Q9H4>Q
M;<+V70*/8H>_`Q%W^!L(8YU_-0B$E`=H]9G01@LKB!W*V6/J4`)562+'U:%$
M+=2+0\JP-W63M`_HT(3H)LL+1$#@L(H^-D_LOBM:X!@8OC$^@I!(49+]MILO
MS17H>PS=HC;I##(5?6VE1*=;:UP(,=J&:\O+8X[H<Z\9\M3<L$NW_Z"@DS?&
M6G$)R6FF3>9J8Y1GABX=%*C9$.]A/%5M$/`]17'8SI3]HD<10>!JBS"0O0A4
M;,W[(=>/)BGWE%N$OD6.GCT=G2S)PR%=:1KT96_8I134MWDYIVRY!K!`X0-#
M0]0T\1_V4N7U[_"W!E_FK2YFJZQ8:L("-N<:>YSG7>T,\2+UE###W!@I"A*$
MX(>\IF!,/CR&\$7D:GO4KI;)A#QX:']#'ZI72(B_4S8W7(&#W:QA5AQLNT*E
M3QAB&#GA/;@$-$&V3+D']_?GZ><'MY`4DO4O9//`:TA/(R&G.$U=+`EZY)0D
MG>W!(>`$5@A0YR!$&.PP1PIE*T`(L#EK*T<@)@SLV5FCRNT0A;6-KF-"V,B8
MA]']"ABI[XU`XGTF=GV2,4202)<2DV2`G))6!,"^Y2PW)F#`RYB)1$2AHV?<
M1"*B9,`Y#T3RLC#V)I*ND=4Y1V_*?4MK\;P@1N2@BOC5,F(ZBFHC5Q?%26_=
M(>^2R]V^=<-#"\H&V6*A9TU7T[-B9PBED@9^6U;&MFTQ8QLF&LY0HG(8Q+.V
MA0`'JNR#W<3TW%QOZ#8%-8KK8_`>NIIH4,,'L:WAG2:G[*I-?/K!N.:N&DAD
MGH-D,%"5&QNUG(>;LF:OI3.F:R@HS?(TKFLH/-9+3PK>Y^14I7\*)V^R)V-(
M\]^0Y70+3L;0<6"+/IXJU=?]<9>\9J8'9XLZN&"^V4*++^M[%.M0(A7(IJXU
MI=H;/=+?68I26W\$H7`>J5+147Q#1KC3[`8.M2R,(XW0+XF41="")VGO&Z':
MIR(WW4TBY"M%?]/LRZI"(S5_>,HHU[O;--(\9.`-U1[5W/B%R1FW#5R?G?<5
MR?O=>JWQB?W*%;\]?X]?@EV7U&A^8S_8(W<RDYYEF8@6S#DVQ]!SR)V>4Z?G
M*)&AE;#3+\GKH[._6V=_Q\>T0@WHXE%?_P92=9KOU$%Z()5,6?>%F?X78AR4
MN6C[PC5%^RHWOH58F'4U$]Q^H^D7!FMV>WD!(I?`1U5&/%&&<38S1DB(I`/M
M2=H7AXHGKI@@G4]9F_L<`ZCL_YL@;+T#8X3#'@#MR'XIC<.@JXJP>U\:ZB_@
MZ0?DL35&`PZL,M,1,!BNR7XGW+K.Z/&*$1XP1=APS+W6H_2,(^[V/:*DQ_,R
M=?P7@*QZ_H-)7[6&&U;_4;=E8M?20,'WA)Q7KTSTA#X7^1<J;2IP"V%M8*OW
M:_U#!_XQ`5+Z?;[.44AW+:3!ED@_"^V#E/3H$[53=Q5%D=ML#;G0-M$(HE!)
MZM#/H".8VE:/UFT3N'!T9V2SI&.X)3@>&@=X!Q"HO*&OJ]'S!GQOJ65<6XG:
M[3%;)NZV98LYZJV>Y8M<CY(>E=O&$+'L;2&@O3R2P*+2^7+5,%)J[39V@&^V
MI%(8:0WU6"61#&;E!H9BZMP%6U9E/8CZ&%/WY6K=X:%M"R3=]F"EFUU5$(0D
MMP+VNK%P>:3Z5BD+@24?R,`5\3V$[TA[5HO.H/*\:=D?UF:`QB2L"T@$?!A^
M"DWH+Z-=!H"+KM1;/[49L',+%_2IX3P(12S;M'N`N#Z&%`('YZ0:M,PL['!%
MRPLV>W.UY6YFZ<]0H`+MM6[_2FW0HVC7&]DKE(VXWU[W?&NS*0)&M?R.LMND
M^JV&8)!#$YMB;JQ+["C4&LW?_/N'?A.@-8CS>UTLRZQK*3N0]1IXZE(P&>8E
MG&A)PKU"",42=UG]._M85AA+J?O8W,9P$\MNVYQ\]ZN4P=&7@4W:9=)P&H=4
MC5-M<WEU]_'HBR7B%9["XR\3]SP-ZS4#=4?P\=!M;?!$]`5O(.RF-5D,,/:4
M=GC3]/C\.@K&+4\3.5RHWQ@7Z?$K!\'Y0*ZR/TBBA"N5M@#%Y)&?3#ZT-46&
M6,I^KA`-\RVBW0,"W35@,5TNV/D28>#HVUM(;SVM(I!!'YIDE_&GI@:K3'BV
MT,2"G&?9C5R/C6TS0?H7&4T,S&-7FI"')'U30X@N<),%=>!N#/]TVU8B3L-!
M,\XVI&JCC_8T`7(J=+$L*P=-7?:PFU5YT];G]982,V%MB^"`Z@G`E<49,,FR
M;/*L_4)[7U4V:VSG9IL]F1F[)9I57LW-5O`3JW?;[3HWV\-CB*+?]`IX'ZK2
M0-KS&BR;MVW$,X//UWEF*HS<@&WJOYEM3>K*[0N'LJD%L48LKBYI%=L"SJRB
MW7KJ75%KOMR:1QV2W<_(9^W9Q#&DX/:7>!"_TGYN`79WH(X"!X'R;F>O<L<K
M"9XYG-$B>5>%K=LS&E8Z9JM_<-J+G+H_QO*H38'ZK&>=GJ6I.<=%R&0,(;C]
M)Q&$81^QPJY18LLNTU=_56_&45I0VFYQ/F:UX[T+<GOXZVTGTA(O&T'LSMBE
M`XMVSGUU=_D_+)ZRCU?7Y]<75^<_L=N[<UR[O+Z[W2.GG?WF$\W^2*3]'9_D
M5&&%"/_3$639?UV?GMP>A06`.L?#7E9]YO^OD8=G]^E3;Z3/`^JE3!U];P?U
MGB.%@?K>R7W6$;I"/!TTI:)0NGT8EJ%H,J7RH;ZT<0!KWXNR;(JR:;>;NMQU
M52`,%,8CZ$C758&HU^WL+%!D4C,&)41!$=25IM_/M-C/MUP-N.9A[Q.J]PF$
MK2\OCE6TS^];&&8CDPIY:V%Q&+NO_V\+^Q;%I";IMLMD?XQ0<=FIZ6*HFL,M
MV]<X:5W9.`R]7Y`F[NMW,/+\L&4ZY(3W_7V[>;,H:=>*]/\SG?NZNKIJ4P;@
MQ'E1T!Y7BVHI\VUI3_/H-5@8!8[&D0]]`74-5AJ4"T<_F!S&D5MJG!C%U7>>
MT?4G,9FX+I'J<['B-A>;));\N70E$]7:N%+NV]&RE8H<K03F0^%*'<GMR8TI
MN_CQ_/K3Y2V[NF;GUQ_8AZO;\T\WEVW.9;]<W?W(SB\N/O_C^NZ<+GR^ME^O
MKC^9!_I<C4<O?OI\^X^;RX/,JVC(?"R2XW,?B]2QGRHZJ=$YS^WT('EX=H\^
M^5;Z_`E/*M<B$]TNQ+OKLM!OK"8.F*UPC0\Y.,81V[*N-=MS&,3GZ[N;SS_=
M&NW^?//YXO(#5/HG\9<4HL,W*G%?CX>_$)LM'_OXZS#\4ND>>9%X(WD>E6*\
MV4-I+4ZI*'*]+)Y10XLB$OT[.GJ"7.S*E,QX?_Q5V5,LYP3W_]CE5=NXN-FA
M%!9!=G0<A\CBA##NV:14#)F.^A0>RJ"+Q4(-RKY;/=M5;65X^:4]9<C.9Z:P
M%VD0FNJQ*PIU,;<?VP-[`)P/NK([&L\AP-F1T.&+)CJX<ONTLN_%!#W6,ALK
M`*Y51=MCY:ZASIGNS\3U[->[+6VQFF.2!(X=JJ5>1DX-.+ME,=BR.;ZA!HZI
MT+65Y?&7B8>R&[Z.F79-OGIP2'&X'S.6)MVK@3P*NI,5(\E8".&6&U'&`LXU
MX"H)^KY$8/VO9A>K7"_@;_`]LUGZ>;'(9[HR%MC>ZTN$[MZ9\\+V(-R#IG/5
M]N)<U_FRM6#W1NW(1AL'R5\AT!B58"_0-.RLY/A'7,@<^Q<_@T%GL2M]YGD]
M6Y=T^J#MAI9K>TR^G.DY+M>FU<W>#[?ILV80=]J(^`;EFTUAN")UI5;=>U-C
M\-^_[?F7N&.WW-CNZ+C"HOT;?I&0UAT/:[9]V]>Y7I<47Y[$/7;EIJ1T]!^_
M+L3X;[X-:_JK,4)6G'(6F'G["<P?$:"_9X`?,T"^/H"<)_`.2()$>@>`A-0[
M`);J7T))Y#W?@)`0M&]`(!'K?`.DC/Q<"'F`"RXC+Y$RE<H_`%#(JPL9R]#+
M!7B`M_@&*.H/^0:$4OB)-"^>^0:`!/\`(0X0R07W#A`IC_T#$JJ@?`-B'GB)
M!,A27GL0(0_\`V`0PCM`\L`_``6/?PG.0^^`5'`OEXGPVU-\0!$1C[SS*SKL
MX+D?"NGW*2&\_)G3Z5X!Q=_F[X]N2&>M*+]?/1P@OMTQQK,N+ZDN+]$6D'UW
MYLZ<@426N4!*H@[QGVL08]JXK>;3P5=7S1N]?)OD:$CR\Y=MH4UWG$'9G/VR
MFVA.#[YQ"0-#]O[^22A>I"6OU4W2@'OOB]0?829(%UZ[FP2QWW`G(=WT#5#Q
M`1JB./73$,>)U[DF2>S/69,T5MY\,8']AP=&B(,C9.QQ(C,BB%,_)P@S@3<>
M3X12\0&E1Y'?V2<BEO+`*G%ZB)<D/:`V)%`_$)A(GH1^7J1(E%]BR**A%Q--
MD(B#`W.$XH#4`0?\"60B(R!(_XC8O+;G&P%L>X".0XEJ$G#ZDS[>$9C"OTH@
M#^3T21#PR*^Y(.2)7QZ!$MQO8ZA;_&D-X>F0YH($\,$_(A7*3REB]0'-A4(<
MBI/RD`6%@3B@ES`\9,FAXJ'?*T.5^BL`E%FQ1Z;(2Y?_/#TY/?D75T=)]0T*
M96YD<W1R96%M#0H-"F5N9&]B:@T*#0HX-2`P(&]B:@T*/#P-"B]#;VYT96YT
M<R!;(#@V(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R
M96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P
M(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO
M1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2
M#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-
M"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E
M#0H^/@T*96YD;V)J#0H-"C@V(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$
M96-O9&4-"B],96YG=&@@-3,W,PT*/CX-"G-T<F5A;0T*>)R]/=ERZS:6[Z[R
M/^!A*G-[RE(#(`"2F2=O-W&G;=^VG66Z^H66:(N)1"JD9,?Y^CD'W"40%!7I
M5JI]*0#$67!V`.R+7TY/?C\]H6/E2T+Q/_WDC:7(_TP6IR=,]S#"%6%*MW#B
M\['O<X]XE!+?]4@:GI[\3&(]E2LDSB,]#_\AZ>OIR>STY.5_<";\K]%`QT(X
M,/]8.-*!?QR?\W:_+R3V^XZ+_9ZG'/.$G(R$]!R7>(P2&":4QNE%TY=W\JK3
M437"%T^G)W__'#Q/@#J'/,$+F@]ZTI)R&,^H@-X%HL0$9^1I<GHR`KPI`'IZ
M/SWY]!\JZ3/\@:Y9F(;D'?_$"9G,@O@US$@4D]4L))?)8AG$'_^-#:LPC8,Y
MF23Q*DWF)'D+4_(2Q4$\B:`Y#9=)NHKB5Q)-PW@5O43A%&>!X7$X645)3-ZC
MU4S/&KX%\W6@V]+P]W64PM#G#_(W\O3KZ<DU4/BO@_!!P1\*8I#S@;H@*@4?
M'([/R(=ED`:O:;"<$>3(5',D>2'7?^2,(.>3%7E8SX$CS`D.C2!WW1I#D%%!
M*:S'GX#6Z."@/%:#`@Y01Y3,X*R0"29)$$\)D]-#0W<<[VL1Z@C>6G4%O\M5
M=QQ94;J:!2N23";K%*5ONDY1=%$X7Z)L`O+\^SI(0>))&$^A_RJ<A(MG^.FP
M,\(I5?G[L^`M)(L`QH$*S(\DP=2O:`'35=+"\!EI"5Y>0+_"Z1E)4A*`%J=A
MD"5Q\`SXS*/?0OAGE321S%\XVU>_QWL1Z743R<`^N[R@D2M5T2B9*FB\>;J^
M)=Y%"W(^T<-W.-$[8O$/>.)C27SEPU^838GJU_STY/$@R"I9(8M:Q,$/E&K$
MA9MC.R;W3]]?/Y";N\_W#[?G3S?W=^->U)5LHL[9OKAKK]?-:)GC_ND_7-!#
M2RO.CQJ6NQWFY1;FTUT2A_L)C=L-2X@*%M@3AX(EU?9D;[HLL!P/"&->#@R<
M.[AK#0S67W`_7_,OYP]/Y.;FY@C*X8'I+I1#BLIJ2XK/E7+XN^F&YWJY@$E9
M_3J8;DA5X=I:DS'I14ZJ)G**'1XYU60D%=2M+:E7>(6KFX?KRZ?[A\<S<OW+
M]>6/3S<_79/[SY]O+J^Q[<O#_>W]DWZ\O+][>KC_)_D"O^[O'LGYW16T/7RY
M?SA_NB;?W?]T_7!W?G=Y_;_0>OOEGS?XW,\$U5HAU_</SP44)Y3>PI]X32X4
MUNOGFZ?OR2,P`LP6V!(,BP(=%MU_)F#6@#67WY_??7=-SB^?^LU:+G5Z0=&L
M^:KZ>4BSY@EQ/+,&3AC?+LR:1#R*:)KQ0G*>,&Y(YO/D74<1X'M#DH6K#!K3
M(N:-@T5X1@((*3'&6B99I.-?B#7#8#+#?Y,U1!M_A)/U*H*H(GEYB29AFIV1
M*<3'DU629OK-W\(/$BZ6\^0CA*`TR/#-VR"%*;AW=O``!'D+;VZI-(1`[G@_
M:#8=I40X9=["N5OG+2X^(Z>!U-_(^9A<+X+Y2Y`^']K6,[`3)0Z'<2PV[D(T
M41-,7:\.5772A@3/8(F?PQ`D)=82<I$$Z107_:HE%OD0Z+^<!5&Z"&*P5VF8
MZ5Q,#[B<12'F-:5\W>?R1;(HGL`OF`G#6UA7<0PA$JQ.PYPZB.5.&<0"AA6E
MJ"X5\F>=F.=4Y=0B0_`U`W<*S7J?@7Y^')HT"1%J2=MQ\QKI-KG(7.'4D8!;
M)'#)>PRY2K9^!M9%0?I!KCZ":30A-WELCP8'(ODC+*_C5SD*JP-BY=2UAA\?
MS]&)G`$NDS'80?)YGJ31-(!T(X7$(B\&X,"#8^>K"KW<<H,J<^?@^35M<<$M
M0.4+<'!@@E;`CEPV`,=:0AKI&DI!6+%\QRA3;*^6.#P8M\E`1U%96'DMHP<'
MY[L-X6"*^74(P8H$(K?#T0HS\4FX1'T8DT?=^)*LXRD&%L>1)LGY5Y(FR55+
MFFB=SL#"%]:B-`Q1#+KK^F?D-JW=O782V7HR";/L98W5C#E8O&-8-*^L2``2
M5=U0"%?6#@O\#L1STZ*DF<S7941W)*UOH'5DK0<_4T+Z*EHOG0I>X3]0[=V#
MPU&JN;">6X?R3NE#7])DH=40*'V-8AUB!V0)*QL6,<<\#*;P"/*Y3).W2&LF
M_"\-IQ'$*QE99WGE.UO!.P=/1B`>_3I"H#S68I97&2VIG,)HO0?9#,D'F7^>
MK\.C***25?4CSU8__1H&<79H4.A2"U#'%$&4](HB!F)7;\WX13UGE6B+,HVR
M"=9@/R`##-_">;)<Z'`8K,[Z)9BL\HHU"N0D62S"%*NTT9]!:8.R98@M*\@6
MXS\_%F$MEV]!&B5K]#/3=;;"HC`)ELMY--'OYND$(G",Q11>51ZD=1K@\J+V
MT""TC.B+$/;+/%A!,KT@3^%D%B?SY/5#(XJA?0+C4E3&91J%*XQ[5^6@*,S&
M;0<2(8%`^QO`2%*='6"A&S+Y'\>/8STGP`FCU_@H#'"J6AZK?)]0Q<H_1\FJ
M)F\9K+0]T?4"_=Q>)\B0UG.]XZ9M5BDO0#)T`;O0,R5'\D4"HVJ'?8V8@=(*
MTM?P11)4LH0G*CO`#PY&L)8PL#K&P(WJ/"0DEPS<T&L01]GBC&SER%CUB4!@
M5M`$9O@X<1`KJX4,XO!*8SW<`T$<H[S(M:CM#JAP"B8%+`N(X"NH+LAIJ`M4
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M=YV=D:NT7":(3P[N?D`B2N2/ZWZP#ENSB;G<D`OJ_!SU'I8L"],W?,S:BW>7
MO"4Z"LL+8`4+F>^S,3E?'65M&V<]L*A=+JY3EEPW4,*:W%7P%L'/2P@D83WC
MZ/")'A458D=.82&\Y/4I$*%J)6:E$C\'&!%7[NF;IG-J5E&;ZT?.__ZHZY27
MC]??WOW[_VZ?QY?W>=7H*HS1?2$C7^?),WBF.E,\Q@+7YT($KVRE0V6AO&78
MK]UJ-$F3,I(HO*D.>_^+D>=H/D??#5B^)^D<-':*9T@@/EZ';3V&;`^YM02G
M'.$.UPL>.)F#JZ],VUGCP`C"#:8+L`@Z%$`3=P0N,+_*4(5RZF3**S<6)@`Y
M6D5("F+TKM/Y17Z89VMABW5[^.:J*.YH45B%P2*/.R#8@1@]*TH]61GD?)#7
M-%DO:PB07B3SMSS=.@;1;IE!4NG[]6Z*+`Q2G43\';*BZ1HB1$@;0EBV^'5,
M/F-`PGSP<I`>H`EJ+7)MP#8<$C#KLJC50U;6#.-^2<`[7#;J^,<@69:9(U6B
M<0I*>/4>P]WYX]7YO[[]Y?ZVV&L(2#NCFN2GG4BN^$#L10CAYCS\:-H\R!6#
M=!Z%Z1F!H.U]BQ%GM2-L<*%(Q`]-.1Y.+4D_KL%TA=]@,N?%_E+AW-*CK*FH
MSF/X=6I1'FO!&'D:@C0U).N,/("4)LF47$(8W5RU7/<>PS@"H_10FO0BZ,J.
MM3Q"J8J*(\<A+FWPZW#+TQ7I2TA(2W@;H3YNYW)7">+ZD)KK:>OW]3%GW*D4
M3CZ`=PS03LLRP/$%_+4-\!S7MPYP'64'H1Q@D&V`Y)X=A(`LT#K`@6C:.H#S
M'BH8II^V`11WLRP#``-I70L.<F*E@KL<[)!M@.+<2@67>#K2-D!PJJP#'.;9
M!W#6@R1CCGT`9=0Z@/F,6JE@'E56))D+^:1U@*3*/D#@62S;`(<J^P!.'3L(
MH-(^@#+'2J;/[`+E]:R$2WWK_(IZ5A+!>EG%$<R372N9G4,<J]=6!EGH_[T8
M(G,2F3!89O#%K++,;,MQ0MA7GT?+<SMTHF70^Z0/H.F`+=8UY*UC>LQT3`^F
M=?-S>G[C9WY.KR8!JS$N*/,B7REXFA=//C[EW?IQUJ07VSBHE^,.+#GANR[M
MKFGUS6TY[`6QLRN+*H(<"XZ%5_3>=\$BW&)90;U'2^I+1K2)S@=LT%_V@S\:
M2C\7RDY_W]P6^CF\4#(`MV2*>O?Y:Q?UJECQ1<V(-LFJ%H0&]44_.,/!Y`L(
M!^WD]TUN.T2.(4A%/^4JSZ4^?2E.9W9PP:65!JA:!1JDYP,VN%#V^\/E%`^,
MN&Z]3G6V7QZQ*JN.Y'(>9-OJGD_GT6KU2A+:R.8#-O`N^_?`VV6BPMM78RI$
M?IARA+L)K#P[&Z8+<OW',L)-`)-R@U:B<@,/AIWDA%>=?//"=\<>ZE$)V_7+
MROWFH<+L6Z-Z`0K`:2,&-M7%5QW;A0N479@;97?PY/BN;7)5\,[O8)UE;OVJ
M;6XM$_O-K5_MG)N./7U]TG%*KP>8,)8+0"Y]+Y5@M-N'9)XNDZ5@2.770KG3
M*>,M'/4Z`S(H(DT<M]L'G+MK(-D\ABQ9#RXH%HSE(M5"9KMCP'$Y6F&CZ\FL
M+B<7)T&,!W%W/(-LIT@52^UO2,!V^^Y'6Z1L<K=.VS?N[VSAHH77@,MV^X"Z
M2\=*XQ'[=MY=W1[&"-@5S9"G4HJ-]B%*H7RO4@K?:5A+YEFVWSI01-E'7.JH
MI-:)=OL@G:APM.A$`PF06P36B`UJ9=CH&*0,)1JH#$K5.V>\W%K8:\_/</#T
MK^)9WWCRZWN5CBCO53:+FMO[?+J"7VUH=O!8%4+G;\CB=OON[D>"C/C2[MIZ
MYK:IOKY&VZ/Z-8&HVR8"M]MW]X&2VPG<86Z;/6D0:+$G)E^+K#?YVHWV069%
ME3+H-%1%L?+0T\_!1QR2VR3I\0/:<J!D&+QLNWV815&&&XM2]GM9A&GTLAL=
MPQ16U2>=&G<4.?5;AN5SM<O6M"MM:]+O51%1DU=MMP]3+64JAF]5PW>`TFD<
M8)U+*!N%::.[-A&YW;Z[>DFZ*Y$[0.DV$%X7D>TH0%"SNK;;!ZFKJ`Y\-3;:
M1+71]@,&<[=C\KA,DV!E\_Z`@U%76^W#=+7`K:6KBMJ\/Q[K-2IINV.8DHKZ
M!FU]-\!AY7F0;O]^NW7@[3$_I@N#DE_!S68V+PLH&]6UU3Y,76N&]JJK'8I5
M7<O;N5V2K#7%0-UV^S`]W8VZ':!8]=1,G=&[<L>LKNWV0>I:W4RFC;-)#B]O
M)I_/PS\"O4.(.^2/03;++W-?)/$TV,7C`FI&+6ZU#]/B`N66%CN[>%R`:5;F
M=L<P96XPL/%Y%5Y^7F53A1_+(Q_?F(]#[.!V`5NC'K?:A^EQS=)>/;9#L>HQ
M-Q[]-+M=`Y';[</4>3<B=X!B56<SD6VW2T6S)%GK<;M]2*E2E;?LU5@Z?IU\
M.Z53N0$E7N+'B,#]5F=,O[7Y7RH:1<N&YK;:!Q4S%?4Z<I8-KTM%LZ;94-1V
MQZ!BYR[`5;$(_L;:;+</JH7N`EJ+G0'T=ON@4FDW:).#D9XY?=MH'^)@I%]E
M)(S6'RA@HJP*/423&9Y]_@<>`\828+]3071,3J7=/LBIE&BV0T/1[U00IM&I
M;'0,<BH-IE&G^.S<)V,AQ>@A$+3)0[3;!W@(M\F?1LVCWXZ;4-EN'U2=,"X5
MI]3K-KC2-><Y&^V#Y-JM@GBFZD1;J>*NP0-^#V-%+B#3F07+*$TLIA;1,,JS
MNW>J4Z+7EN<N%FF9<SM2G8V.88)<H-$OR&TCC#"-$NSNF:NX38YT27#;&IMP
MV&X?)KJF5=D27:-EEN;0?Z-]D`3+ZJ-$C<NYPO&*+9G'5;B<A3$:YI_Q8M(.
MT3YB8Q1DN7>T7V+9%N2>2J06/=D1[6]T#)/G`ANC//>$M:I8+J-<R[UC]P:#
MAFU$F7#9;A\FWZ;%`OGV+:;946;!;K</$FQ17KYB]4ZCHXJ]V>^#-/T@_QZ3
MAR0+X]<@M16A$`NC0+?:APFT,'P/2W9MU6FA<U2')+<[ADFRH/M99H!IE.!6
M^S`)KCFRXWZ*"8GM]F&B:UJ6'M%EKC&-VV@?DL9)7IQV$6/%A5>F<=0M-P9_
M"#_(=?GY-EOZADB8TK=V^Z#T37*V4_J&((SIVT;'H/1M%^"J8+XI?6NW#TK?
M=@&MI<\`>KM]4/K6#=H8)-".,)?N'^;2^OYVXZJ0ZQ=!PD.PBL,L__KU0_"A
M:X.7LR">IL$.X0+MB'OI_G$O-418TM\A7*!=X2_]"^%OQ3W*Z\T0[I:;(<5]
MD^TR?W&+W;2?OR\^0HHF=VQW3?X2%*]!-=<?B,^I=O4S4GW1NE3U^)&MPD5F
M/+O0AT7G[1.OQJ*OVJ@*!3$Z-;KWUHB9U<:2:@\46TEU5R*U+3$0N=T^J*2Z
M(Y$[0+&55#N(;/EBX9GSHXWV(:9/>(U;DG4<2?U"C*^".`KGY!;K5_-DF:SG
M2=;Q28$=$*&=GTR01/AE0"O++XH8S['WP>C^+(-74=O)9#3,",!DL-OM@PRV
M\`PI@Q26\`*!&2WU1L<@2UVBH3\KYU:.CE??4>VTT6?D.K\I;0E*$#.3?6FW
M#[(O#;[UV9<>*#;[4D*Q;KV:J-MN'V18=J1N!R@VP])!G2FTPIN:1ONB]DY3
MA5MG8'XM<DR6(@=Q5(K_SR$_C\D/<]SPO_FI/Z9"A(PJJO;.6$M$VRK:$XYJ
MI5(=B>M&QS!-;;"-^8T/D#MNQXYK,,?;^X66[A`-('9&;55[I[@-%O9JJQV*
M55O+BRX[1`,F(K?;ARGM;D3N`,6JM&8B<W5DQ:5@XZ4XU;P4MQ&VH@I7G_O@
M=C?+J+\GD/PZ6LN5B_:GP?3TU'8W<.1SZ]W&$?.%]7+CB+OVVY<CQU5V%(3;
M@X-T[7=(1\J5UAN<(]>U7Y$<>2ZWWDH>^?KZD(U1M'<$PU3-.H*[RDX(<SS[
MI=\1$UA\LHZ0TGZC=H0?!>Z!HOP^6ER_9]68YS/KQ5@0/OQ@@%7ZJ,?M'.,,
MKZA91_">F]8C[O1<M1YQH:^&VD9()GKP4,S^F0+0-?28UA$>?NW;/L*W7V<>
M.90Z=BC`#FZGUN'4L:^<XU!IYX<C;!>7]0C9<X%]Y*B^E7-<ZO=@ZC'[UR%&
MCM^W<J+ODOH(!*A'@B![Z%D7X?1)LA!X7\H^PK=_/6$DI&OA*;B=ZU].3TY/
M_A_IQO9G#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C@W(#`@;V)J#0H\/`T*
M+T-O;G1E;G1S(%L@.#@@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR
M(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-
M"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P
M-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X
M(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&
M#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y
M<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*.#@@,"!O8FH-"CP\#0HO1FEL=&5R
M("]&;&%T941E8V]D90T*+TQE;F=T:"`U,3$S#0H^/@T*<W1R96%M#0IXG+U<
M69/;.))^KXCZ#WC8Z)C=4&E(@N"Q?JK#YW2YO59Y>SIB7B`2DMBF2)E'E>5?
MOYDXJ3JH&+>X[8BN*A$$D(D\OCR@JW^>GWT[/_/F4<J(A__D;\F<A>I_V?;\
MS)=/?!)$Q(_D)P$)PWF:!@E)/'CBP9-&G)_]3BHY5QPRG(@E"?X@S?K\;'-^
MMOHOG`K_#3[PYF%(88%Y2!F%'S0-@L/G:<CP>4IC?)XD$7U^PH!<A&'"4I+X
M'H%AH=K32A*H'H;V(1UL^.KN_.SO;_@R`_(HN8,7)"/DI(9T/P`J0WBZQ2UY
M24SNLO.S"]@O\^'WA_.SO]4K<EN7(NM+WI"[C6CX3O1=D<W(^RJ;DW]YS*OJ
M!W+%]Z(AGS:\V?),#N!E2Z[K9E<WO"OJ"@;Z,_*[:#ORCM^+:@8/JTID,++O
MYN2FF9./(G\H*J`@$\6]R,FF:&'>;"/*NB&PCT56B"H3Y#_)W9_G9Z^!OO\Y
M'1?@K#47@".&#4'L)XH-N5@W0A#8WE51PY:V1=LU>[)JZBWI-H(L.MX)\J6"
MC3=MT>UQOQ_%`_FC;KX2WI&K?K7B94UXI>CZM)G?S%^>[G"B:UX6J[JI"CXC
MG]6#7,RGX8.7:C[X'K72$,&DD@V#8\H+1<FN;KN\SCHXYY*L1%G6#^VFV"%M
M6RLXRZ(NZ_4>.?%65*+J1+;1$C28$D2F)INZS%O@$[F=+R2'D!^WO.)KL847
MD1\3$`Y:K^D.(I\9PIF/OR/A=[#A2M%@#^F6MRV(9]^*KFN!F+8KNAZD`'8X
M&(XG#FS*^J:![9?P`4C^J2D(F2,A#>:AY_GD[@?L^^+T*T4#9OE^Y#LIP=^1
M6:_SHE,JBVQZ7^4]2'<!X@'"WCG.?*C[IN+E_&>W&+VPQ1@DUVSQ;S\M+"_-
MCL(2Z\G_%83>3\V?O,S@R",I8T88D]#R-Y:_(W]_Y_L*Q*\&'I]<%2@;+.\'
MGG,)"0W4\AO>DJ40%8'S(]>;0JS(FZ+B589'_-MJ563@"E#L_Q=^(Y\:@>8*
M-+<MT'I_X%7/P=8%GL=`^_NFJ-923G8<?,,*S!O9"]ZTY!8,@Z01UVM%@RYA
M"LVGB:46G*NE-E+$PMK\12)!PEL!]A@^VO7+LLA(5F]WO"I$.U.F'EZO80`)
MF*9*?-^)1ODQZ>O@5?")Z#SD>-"/DM0P1#I-G*4%\T*VUO[-)N%!X!L>A,[[
MA>"RC?=;=C`I:'&?=?+$8&?@I_FNZ,`W_5";E13DP(^RWN&APG"@:PU<Z5#1
MF[J'Y[N25^V<O$$C^AMXC24RQ_,"$`$8L-Z0&W#_6_UI.'-2H"4`&#H%`Y!J
MY?XI=>X_!?`F&2!=O*@*V,>A4,_('9QAVS=:Y$<DY:K../DLVKKI6NG[X'#A
MP%O%0_#T2G;V3YGCDZX^8-8D0I`@_%,\8,[J4%\K`AP$FCMY%@]P"L^R8Y0'
M`&'(Y<?KF=9V=(>&9N3/9<FW"B!]E/($;^(0^)$!@K"*-0?634)^[!GR0_C3
MD&]UX"/HL9%+0+*K&I&.L5V=:)JZ`1`'"*?CV==6XE6QZ^0KR#<?WE%O`@L4
M*`#0\`4QCE9WU)A^"7PL.!B(EMS790_D-P5@AE51@NSO!"`,J6FK*4P_\(!1
MAX*90\%4RT`CZF8-IZ`4GH`^"_0`'.C41!JG+PF[XM77IM]UV1X@3RX-WN]%
MN05*NQH"@!M1\@<0`RWPEEW()^^1R/O2$CPG@%.P@=I@P/.M`PPBJD7AWY3Y
MM^@@<@@1P#162O7GJ/NK4F+F75/G8%9;,/+-5]%I0]*(CL.A-U+<+W<@!9H-
MS\TFWYB"$7YJ34*46)V0J``9`13"+JN?E>"_+DZW!=\6,_(&.%GD7`O2%(SP
M`NL?8M_Y!QT6?>@!C_EI&J/4#@".]U1J7W^'D*A#E/-O2M&7!;DI^+J"<,M$
MWX@Q-.\5W*[[;@>\Q.DF8$*<,,L$+W),\#47MB+'L!\B0[--4FSY&L5"270)
M<"`G*YX5X.^D*?_4H`H#T[H-[PZ9!6%_KCQ%W4J9D9'P2^ZU>9FQR#P^"3\B
MBQQ9D#K4%&A^5+VT9K!M4-][H+U4T:""BO"')'%EB2ET!&FQU!`=.A4;>,)W
M`H`X:)`,Q,%+"E@.M$)C49YE`+GPG=.'6"&UY$\28L5A\A=#K+'Y(S?_SVU^
M/'Z+J8'3@9=::Q&R5/N/?Z!8WL[)`DP_[TXNF6$XV`$$-0[,)*E.9Y&#&.XE
MU9EAWJ4'?5687\KD8B>DL'YJZC\%>BT8O`.!+9:E4*I6EABN#%Y;]56FA'J:
MW$WL6_`>1Q:U4)J$.H4))(KJQWX++FG90Q0J6M`OV-*]M$)/X]+XD6$"11V$
M'^,<>RT7(E=F'9DMLOZ;34%_E%K@'H4N:>>'-GAY&EE%<QE9*0E\1-RX$$B"
ME*_3\][R)MOH>'XPZ9\U<"`G-WL.;N'49,<0JANZITUXQ<RS*UV@B+DD01@P
M+6(:@*#QG>*`$\\N[UEM#EBJ5Y>G(<]%)E<SD-SW%6"H2L=1,_*P$8W0@@ZC
MHT.)QDCD=?EUPYN.+(K.I%L;C:?@!0G'\<79\(01SSP6EBG(CVQ40MD@.(^U
M?!_(YTQ&7G5YS_=:%PU&UK0DJ:8%P!EP`6FX*1J1:0AUP+A'HJ_!J%;Q&[`?
MK<8EMX!NS3I3<""T`4G"7&A.36QZ);H'-.9`G2^MM"7/'?*GDJ/742=K]WSJ
MS5)XP>Q6'15X\"`X^3*A9Y?Y>?SQ\NQTR/)A"*@#'ZTM>.*`=BNNT'M9K&1@
MBX6?#Z)IQ?[4.V.,V9U-:_882X<\H(.42!!H%+'D+<B6<JTRL=<!)G6R"/JI
M9#'QI[$+@:U5)<SZ_9`R9C-60TO%$;-@I(TZN^@Q#0NZ7JG@JYM&'8*4V6U.
MJ`X8B)IE)E`';\AK+V*N)N`SK1#71==`R'&9%;DUC*^P*@HNY<MN<K/#6/3_
MP6<&X'XZ/C/P<V9V=/4^I2X%9\!LIAC-D=$ZDM[+.G+#?Q3E*ZEQ`SF?0NU\
M6_UCODT*A7Z@RT-2M4`"ZL9L!@,%\)IKP(,(*@9Z"6$K>E1PO\6NT-5=3G80
M\.K`'0/;',#%NC*EX!WX8@CZ5<H(9LD09>-KVWT)]JA]//\DH3]+;2HD<(`L
MUAR0!7W,A`A-,WDHN@WLY`K36+J50.*U3WV3]\-R_\DC==QLS":-I>W\4\32
MC`V2+!9YLR#6*>G+4GSG,G&(K2@+WFXXMIJ0J[K*N<PBGOS\`WCBMN6EU%4-
MHY`]4R-]C)$7JC"V)[_8#AF`DZIPIFI\4EX@:-QB1&HC;*7L4^3^XR`<D!3X
M@3:BF=W>%$H4VB2%LW0TH:;F..#'09X8D48EH?Y6-.A5?@%S^*TO3)IP!UON
M^DH&]S/,/N0G;X(`232[G[C=@GI#/L4T<,&GJ<<W'$C'](Q+:<CZ4G4OVDY;
M89T2E#E83,6<>I_87C?<9VCSH2PT67)5$F]%)E6S*/>3H$(6F&Q00!UR#Q/3
MT`:A,-;=O_7`')'/5,ZJ;8M6)E?!R=@4T4`"Y2CT/M>J7GERB`4!O-GXA/@E
M!#EU_/&]0;N#CB1;[-%1;7SRM#2X-SQ!A5)9!)?24@Y7V=L)^S28Y\K3=%"?
M-5KP)#-GHOJ92\;=#$\4_>\MEPD_^F(N2Y,U:2XK\GU+W;36!%O;S$J(,)/(
MI5-\4^0=Y+(L>R2S[C:3N($P]9P;<!*9&E=ZV3?@@L@;L./8#T/NX?3Z1A#=
M?4)61;,E*A2%+7\6K9!G>-=`8+XNP?'RYBO$Y.`3-N2:-W595-QDQ'0":%5G
M/;Y?5]IJ:E,`,Y5[TG80NQ`([@5I50OJ)#TH86S37`.D0WWM#UW91X*:1Y4S
MDY6-\"-;+W^DE=AB2>ZQ-JOZ2EU7$0&VH-OH,(6U!W?_5E0U8%A@.';WZ@\'
M[;PSG.P3=K1.P0EF\PZA'PY4/368KZMG!UVQ:*H,"U+#`LQZ7;9MG1427UES
MX##7<X9!L?>-RW++9&'Z*)NF`]I)/%A(75XCHBZO$6E)T%W6]5J?T;-D*)ZH
MO,>6_UEC!TT%H>.R[XS<`#U]AN'3JB])R?L*M$9F0/&P3Q[<QJDE;,H('>"C
M64;&T(EK8S'I\I;L'G,0HL5UP[<NX1U-<K"!C9R3U%41F*<MG1*U^)&HR5YB
M&4Y>YBJLUJ>'Z:NR!*'N51<)A-V@UVMP9#NGR3-W[K)92;V:-8*;FCK^77(`
MTFU'$#FOP$+6^`"X,XW!]UQ_:3`$_MH!J?"_-0'_0]V4N=+*@4G3;>('(;5J
MIQ]T&`_:QI6[%Q58K.L:N+96#9>RS_QJ?BD[S9UA4!T&8JJ^&IK8Z#&FKF(9
M4"T([P0OP5LM5%7B,14W_==ARN#DX6T<V@U.F;.,DP$?@LBEDIAO;EVTX/6_
M]9PLLDU=E[*)4INZD^=),-`RVYFDHX%&TW8TT+_6CC&>A9&5)ATTA,XCLU";
MU,]%!B8U)Q\P_P^FM3JYT@!2=9L(/->-%LK.M$=-#2KO<E7CGD!JC.\WM7[0
M]6$;NO*5'+L9=!31GOR&!@-T9PB8N'(3QW8E63&.J4[F\+*<(#;#\,6L%UE[
M04^_S"%98>`\NQ=KP_FKX+D][9^V$2\G.8)G*`U/OTQBESE]E2'V_`--LBD2
MENA(^GVENEX@P.(9.)A)0*YLL]<695#2CB)M41#?/&TNV@HA84PCUGBO#((S
MF2E%E04#5*#E,9!F*94?%3N338/")@9JW30(6*@1]X5X(%N`2!O9I*I[\3#0
M!/B3JR3(MJCZ;IJ@3Z:H3,YL6,,TO4LK[/?;%ET'^$93K])[B/8*O$JGS5S1
MMCVF9W8RSRS3H\7*);K(<N_8@M=*#ABF6_`E-#3+M4\Y.04#/!/]![$#@TP"
M0PD&#3D(:7&;E@EZ=T65BYTIX\(>J_KDS@?W:/8YK>VF7CC@R$%;J6VZ%MM=
M6>]!''+CU62/N(+Q!U>H=`Y`.N3A+2H9%$+`L`(@I?I<S%13G'"0V+Q&-,AK
M6+`+A_9WV7MC;\KP9=W#89*\_B%<-RO*O.JC?=0">W"[\OKU;^KN[?<M9G<Y
M:;?8D:@G6:KPP%P[>87=YE8)[+63*9@01>Y0!T534]9]+]-.$N/KU(+,=1W<
M*I-U7A!UV73$<[!*A;QB)?^T"7\YA\OL'))X#>.*'%F(%Y'Z)A-J&<W7*0@/
M;3+#CZPTTSA)AFFM/81P)08TJ.CO/DM!+3#/)B_/R2A0+&>Z1]Z1\P;"U083
M'X/[MHL]F+MM*\N!FWHK2EUTZ!MP95@:G`^U0A:(\T'_ERC6FTFZYV6YQERO
M<A`Z\'7F_?$%PO_6V>;'K7RJ\?^JJ7F>@;IC#DI]I,:)#FL46P%'>YBONQ5Y
MP:_XW@P'#;E%#=%_&=D?".(43/!=Z._NV='$W+-SLG^9W_/OA;LM@]?"1+V`
MH]5M=G<R27*/:!_DHWER`5-AF+&CYHT8Y>,4]^M3&_B[6^9!8N[8G>KD'!L/
M>89</&"LS7<E$^!,9LF=N$/72^U*LD.7NH8]EFK6ZNLX.N$_Q=$FOCO:P3=(
MF(O$VFU+(#:JJNB>K9%SMX)<84M?>L$F=8"O==]B)74@Z`]U\Q6]?$?>UF6.
MGRQXMFE?37QK#D-T`V4C5WBE:?#LK3E,YO#J*T@IN6OZMC.EU4%IIL7V,:%N
M`=W^<BF9\:N\;[V&3Z_Z/<*$&[&#42CV0*',:^HW3$YSR0'--ONA$YV"^M"5
MU88=HRR-W15BF<I$`<#&!71UR(ZN+@O,TV+O-MX'O-+[16I??P=F8:`"P<]6
M_X6.[>,?B]?HRU[A':(=$*P(!]:IIB<LVBSJ3:T'7\N6F.5^>#M;PL0I&$$M
M?(U<\CT,3'2Y[(L2\7RK>M4XYK15Z4WZ^O\(`:25I>FKAE,'B%.U7-T@,7B/
MJV\+&#9NJV]A`;5Z)ELHT=T?7YQDU4N\MZB_8V8*)OCTV>A6RX),6B/U.O<,
M1*GO/@$%_;)0U:RZ$=CU5O('G=[6=TFN:I"8ZB")C:[P'5_W@EQF/!?;_=-&
M]E_YPTQ&T_B-.R`#^Y_O4W_Q3ACS+-W3?.T&G32!FCZ[=5F/B\.`Q"D$@7)2
M][;\JB:LZ^"-<1P0O##`Q\Z+L0$>A8<C`VA*63PZ(*'AZ!(TIN"1QP9$V-X^
M-H#A%V2,#0B#>)P*&ARA(@CB\4WZ030^P$.@/3(@2`,V2@58JH".#H@Q%A\;
M$`7!Z"8#AH'?V(`0O>G8`&#$^"8#U,6Q`;Z7C`_PO&24"C_%6L#8@,2+1N7!
MC[QP?`##V[1C`U!S1@=0SQ]?(@`7.3H`_ALG$P#?J$2E1XXB\>+1!0!*C](8
M^714'AG0.&Z>QEE$O61<8[QQ^GTO3EY\_DT/T5,`JY\:;L#WOC7<_A-GB^RQ
M'>FJ-0S[<DV*X8YC^ABS'W4E*\L'!EY-\_DM3OF`CN0#;FC.<-H8?JCPQ?Y9
MGI\MS*:UJ7IVR]%PRX^[\.`]6_ADII#PU*G)H_W))7QBX;A>(:2/'1L;-907
M:30JM1=^S%X^5AP`P<_X"A2O88\-".-Q&W7!XGA4]"\B<'NC`^)XW*E=)/CU
M)Z-\.C8`Y'_<+U[X?IR,T^&#6QHU`A<^9=$XN_T0KXR.CF"!?V05"&B.T!*E
M1P[-C]-QK'+A)\FX%[^`@#\<YUC@X9>9C8[P_>#('(%_A.O@B.DX3]&7']D'
M.^)`+H+(2X_L(P:#-SXB\?PC(](CCN:">D=<_@4%.WE$Z66Y=G0$3#(N8X!U
MO2/[8,=.CD;^.&H'\P0:,SXB.79R-/6/6$FPU4<D"/SSD7,)@V.2'%*/CFME
M2%,VKI5A&(_P%'S*ZW^>GYV?_1^.VS0E#0IE;F1S=')E86T-"@T*96YD;V)J
M#0H-"C@Y(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@.3`@,"!2(%T-"B]-961I
M84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U
M<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R
M,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B
M8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^
M/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*
M+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*.3`@
M,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`T-CDP
M#0H^/@T*<W1R96%M#0IXG+U<67?CQK%^USGZ#_V0D_CF4`RZ&VORI&46.R./
M,AI[DGO\`H)-$AX0H+%(H_GUMZI74$LS'A/7]K$6-!NUUU=5W;KX]^G);Z<G
MP3S.(A+@O_*[=!Z%ZG_%]O2$RB>4L)C06/Z&D2B:9QE+21K`DX!&I!6G)Y](
M+?=*P@@WBM(4OY!V?7JR.3U9_16WPG]'OPCF8<CA!?.01QR^\(RQ_>=9&.'S
MC"?X/$UC_OR&C)R%/.6<I#0@L"R,)4TKR:!ZR.Q#'CN"+SZ>GOSM=;XH4D(Y
M^0@?D(*0FQK68^0RA*=;)(DQ%I&/Q>G)&="=X/?WIR???6@6HNW)Q9S<;O)=
MV3;_0S[^>GKR"K;_UW]/1/PR$72?"AK&J:4B2!)%!=GD'5D(49,&_AM:<M'D
M[9(T*W)5MJ+HF[8C75D7@ESG;;$A+`BB.;D:VK)>DWXCR"[O>ECQA3R('-9>
MMY8?N74GVCNQ)/!=3K9B"RSCWD=GE0&G8&^*TR`,#:,\`#.1C"*MS_`&/^"3
M'\4]^4_3?B:W?5-\)J^^%)N\7@OR2Q`%()C[30F\P[JN+ZM*,=7!,SHCEV5?
MKMMFV,W(]W4Q)WF])!]@CWL!"[^O>]'6>5\V=5[-4`J7F[QLMWD]F12"S$B!
MAID1`XOQ>Q3#S2:'UQ=E3BZ;=M>TDK:C$P)N92E1NOCN%_""X[\GV>,X8M;"
M.36*[YY3.VAI1G9MV;2D;TC9=V"<[1J,\[[L-P2$I&3T9_+3[M=F4^^K#E5\
MN2G%"NQ$%$-?W@GR?K4J"V7<UTW=Y35L.X%^(8@:9F$G9^6!=N?+9KO+ZP=I
MMS2#T-QOP#;7TF\I&NR<W!BN%Z)HML:-?R]SLSU/UUY>UN0NA^V'C@C[X2FD
MD$1&"G&86"FP.%92*/(=J*\O1:?T:36R:ILMH5D:S22?\N&;^14P`L&K$J!O
M+4!X3G;*502P4>25_,!&Y%6_*?)6D,(L7)4M1$"P#[2BM:A%"XN+9J@[46D]
M)-DD4HA2%_"<X0?XO8IX2O7`+U.Q"ED`9==([4TKNG(IZAZUBJ37XKYZ(*NF
MW8(F?QSZ-K^]%Z(G;S"X:4;`Y$"**$!E2V,;*#'$TRS*R+K-ET/>"]SY;=[>
MH?==-E4E(*`B"?DDT@BIE`:(`$S=N@8+4RT.FL5LCS0@:=@NP,M_JL%.VZ[L
M'\AML6F:"I^^R^_GWTIF_#(LR)@B$^)A&'S3_G[8D06A-8J,6BED^#U*X;87
M.[2`'^;D4]Z"L1X?==`Q$5D66\L,L_CW@H[W\`-B!@A?X4P;SU*OD>L?\F59
M[.=9::L_W9XKF\>D/),ON=^`#3X<F]\DC2V_&0-D%8"DOP*39Q,8>9HF%E-R
MZC`EU]IM[FMPWFY8@&N7>:ORP-'IH*$E)+;)G1^?W6#$;Y#H5RF-'_UE$$O-
MRR;68NS4B+$JT0[RW>NJ:<ME?O3W9=DSV@J/_1H61&,!\AA^E@)47GCTU]%H
M;!S2`764B2+M#"J"G`_KH>LQVE+(^AA'5-I2T4]#>4R(Q0B97^=?RBWY^.K&
M@'K$BG>8-S"_KQ],]B>+O%.X9PIG3P)3NB6QA?(AST+%WUO`67T#V/2C^))W
M*CHBCH%*Y96B\A8R',;$SH1!QX=AH%FMA*SE-&-=?@<_J;H-,%^'@(!4>8NI
MNVSA8_6RQ"WQ(]U#UXMM-ZT0(E._!JE#>F%BRIF\VI(+D0//;R"%"&15.]*<
MO`6:JZX9Z7@_>?QT^1%``&0-9/B1@&90$/202U9E778;B9)%L:F;JAEI'UB^
M[8>\[>U+E1:FD`-WU2T?@ST-_,_??T^NQ1*1ZE-E;]4#LA2HTS'Y[]L*"&Y&
M0AOY!F;IY@ZS;Z2K>Q#:'4#&`?$OH#X4D/BR`P,2X&IS>"]B0ZIJ@RF$0#-7
M_=B6"DM3W5+1=*\`?"_!(J]%VV*Y_NZA!OOX61-^J0DW0IH&%G`>6G*G32@<
MS,$)A@;,A<(X>PD78(S;DPY6/G,5[,`L;#L$K=FU<+!,<'7#%`H.F$V,L4.O
M0:!#GJ\X-;4=525*%LP!V"_1C*$RJ40.WX(C[V8'S`(R0+X&=J7A_XE%`=G"
M8HAX4A9;V$8]@@<3""!)(ZM([E*:;F4\]KVRAKC6;^&WG7:^+)N-/;@X>E.1
M010V1$YKURRC8W&PQ#H\SR)M#]K35=1=B"+?/NYDO'H_D[5>VW3=HKDWZGX2
M[XGX;<`"<#7(&CF?Q+R3V%3L=-2+Y8$.7TJ='3H@MB,>)`<07_.Z0_OK>C#,
MIVD(NQS`Q#8'HWX@55,`-S(;ZY!NJGY``P-\R3O(5K+QH4)[\"2BCZQJ$B%$
MU`@AS5Q?/`HR(X5GDY'`+UC^7<QOYY#)UJT0RN>1M^N\ZP`$#)WH>]1MUY?]
MH,K\CTY@LGZLR?7%N?ODIPWD;Y"NJ_PO!D".HNN.CUJ1>VY*8QJ.&GC869'<
MCWH10,J-J.ONH;H#+>='[T8@-33\@]T(W_ZQV__;1.EO=<29P?\T"IPA!<:=
MWN8M9+K_G9,/32?J-:CY^+5<,J8B=0@UC"C[O;V.<_#BZH4!2P^?EQ!,A7?+
MT7C&@K7^1.@S3FTI,FJQIYG.2\70MA`N(/RXR0CB!23?X84#G>6W_P00<MYU
M35%"!)/US"@4R4]#]=$-%>)U[+IN]5AFUS9W\`9`]TL);R']=]L<$OP4@HBY
M!2@A<_.5(*$.H2#<'K9';S3%]NW3)E[0M7D15EW,1:DPMJ7U5S"XJEP)TA42
M_'<N&\T?F:AL#*M,+17=B3O9(]>9%ZQF(ZJE^_P,U%Y4PQ+4_'?RKEPWEQNQ
M=47-U8_GOU`>?OCQ?!(%A[;.BD:<4QZ/])L7D#V:"HRX$F11`J>[7$W2.EM<
MF2*DE+`LDBC$CA&U2-HM2.2_<Q#5^M2.-NTD-6:NF.#)"(3J4A.K@*=![!_D
M=JCE='$\690(JZD>\BVD5-THR.N^/'H1E#JZ)RZWTG@LH1&""2,S?:I18\MV
M6&/%+:IFAQ'LV(1$C/X_L1Q!_3]B.0Q<FJ.F]%;@]'GCI\\8_Q1V2^ULE-'4
M=0>,W6I_4Q[V?B=:V?DQ'C;3#UZ7->BOA/@T=CWG<"]9O^R^044)L/)F;W"H
MFF_H")"^^C8O>M+EE>JL%9.,1Z/,CD<S.G)@J@71M&L(M%^E@_I5A>ABDV/D
MP;FN4*"TQ&%+N06_[DH5\T9=`MCQ>0G-R87H[Q$'R1H=/X)%^F2]HB@QM18D
M9UM*AW'&S/$;DY^ZG0R^U;8!H`7O4ZTNV2U<Y/5G;0$C**)_*XLH/3OOL`2I
MH6SL`;5<P/,9@?RT:HJA4T*12.[I0'D*QF-;7\DS$%K[B6&\@&PJWU_6RZ'K
M6YFQ[:&`7YM2]G:?YVD_L2O!R3+2BDT*Q6;XIPQO)7XSD[HIV`_M[''4,3"'
MKBSSKG8>'5I0O9\6G=\:]V,TLVFJ96?*4/CLI=GQ5;V&'*>:Z8\+S0]##_MV
MHTGST:NY!(S<\/Z-Y9:_5HS8M+6BW7^*6C$*;)7&,S:J8$PTR'LH^3>RAOJ0
M/\@"!ER@7K83#.3VR,')H^W71NF3HA$JQEM1HW?^C,6-18LS/)#W66`*.S:%
M(<\LA=,BBS#D(UDPZGK7D6GY7I3-J.5UJT9.,WA-MP/O+!>`P'%$M=!-FS'B
MD@\F"#%A9JOA*')8*(@2=]10GR,Z>FW&[=LG/%>7)B,>@\S5N3P.4GNJKFP4
MT'&R!VQ3WLES5[-G>AH81[5/C68*:.`O6O;1M1=SQ]JTIAV'U+[I3$K1YF+&
M`M,<<D*4>0($%=@C>U-8;F+K>NI:9BPV+;/Q&5]0%T9ZHS$$!J"Q:8Y?,'!\
M0]O$4P66CJ60!"[Z\D2''-,XERIY(VH!J+Y]=,8(,C\J2PZ9$2$;@^[=!W0#
MS"#@F9RJF>;R)-J-7.^"AJ/>A>;K:A0:E7L"`N=S\EI/SA(].>,SQ/[WN3D]
M*=KBLQX0(OJQC4F+_T<X?V8Y_)OR8BFWJBK7V"62P,@MG4(&W(V(8^=Q>`U`
MI1,C?YU)4)'`3-F2MP,.C=[*$YZC"'0%$0W'+U9,2:S/0";[8KH%;-E.D(VC
M*+1<35SG`_QP\J-\5#8Q<]ZBDJ$).SQS+;KG[6`2W3);X&?<@3A[X.<5%-@-
M@'%R#A[ZT)78+%>(WDYW;ZJ\K@U"U[A*MP*0`?7!?C]7(19#,#^_F)_/55"P
M\_'1N,9@?ET73,%_$(V.N+KF<YAJ`8A1"2+I?.:(ZQ1C)*['M%.5!G;_*4H#
M[H:RD1-J*`4LHR:6B16Y+HM-#M&S&:H&#.MF,[_Z)F(2WZ&VQ%*#9^CD)1WT
M]&_6V<M9<(_OP&$!'H?\N1KD18@V@\+WZ\-6F"G6#WD]X`D3R([)J*\@1^IX
M@>8I\)O`4[B=,0=9[`X@&X`^XN-FJ':0VV[RG3E"\EHL6L.!NS]Q)0K5`H3?
MQJHAU(W[.^NVN4>W0ZYVN"<NV<E=Q0KJD/Z9'LO0R0PR!?]NRLQ<%.?8(U#H
MW6I!Q\";MEFW^=;&2ZR<WD+>'RK1'=WX0".&P`F+&)8$]C7?WA!Y>7<^DG(0
MCL:B@;F&<F/L0%F701+FI%*6HC%(*[L'Z"#0%LSIHQQ/>ZQ6F%'#@.Q$LX,Z
M5\(,>;`%7&R2YAFGKB\1CNS&.,YB6*Z%O#'RIQ1CO3X:]<C/9_N._D%TZE2J
MQ080"BY$__4*?KUHVIJ\)"AUY:8"!P.<T6+-KS920SB4U':B@V@\L"5^FE@H
M'=H28=3[5KPHTK$9."=7`![VTH4\-CL4>"X'#Z/!AX\^#>(`2PW14P_`@I%X
M@M$]!(:7?Z1XE@WJ&6ST7AXB[,D'#/0.A&#_IA#EG18()E/73.UZ"+X&OL`N
MRTENTK'4%H&R;K(LQ.:B#)X*>X3OD-B]QJ^C]5TC;WS:TT:R)VP/(DV!NI@>
MTD^%NNS^4Z`N9N?L-'5#9CNB`NS=XHSLTYS\L\)<^?W/QS>")!J3$;CK4CRA
MV@J\&.@6QWA_'/_LW<23>TYB[VZ`F[CKZ+&]CH[F/5W?+>.6@&FC4Y:,.`W8
MZ`IT8JY`6X5)O_UAJ'Q0[P78AO6A,DRG4'51TB`H/-&D`90ZNW+T\T!A:%F=
M$$8E83JVG3BTMA/QS`S_#8R>PFZI.Q+NBGYLX^D+((@8EAHQZ).MJP$B\<V?
MW[DI05F9$#["#7@6R:`L.<6,#=2:/<5H(T-P>C6K`MTY2R<;9U,WTV<.F;$T
MUIWD)\98-0M(0*[7)A.33$K.RQ'E[P$QM-._=/M%T?)Q`RR-S0E[VP"SB$U;
M_R2M/6HG^G0TC]"`[!81Q*<<CT=9BF4\+9J^5YSX42I40`C11DPH\0S%9_$@
MR"4D=X1R8B8O$;D7P.<4I@7;>I-O%V@\\AK%5(80NWO.HSL"C&?)V!+V\-7X
MR#0B%R!_?UXM[7C_Z/%YE2_R[22GCFGX1^]`^X&+W?_;Y._IT"#Q>DPM[VZZ
M@$3EV7YIB4)9$8WE@5PY2KX0M5B5ZE31?:TNHD!=M&M:Z8<X+*Q*/#8VA;2#
M:>?V=O]]:6._,D2A)!`=N=S5?5S^*1YLUN-=-ES`7EC`0I9X%X"N8^^"@`/0
M]RS@&8^]K\`_$D2]"Q*6^5\1LX1Y%T0L\W+!0W:`"\X#/Y%,WJ?Q+*`L\NJ"
M!RSU<L$RA%N^!6!H7BY`3)&72!8SL%/?@@B/5_@6A/0`D9QR_P(@P;^`PC_>
M!5`:>(D$'E*O/=`$FTR^!7$01=X%41#[%X#G^%_!\4Z^;P&#/;P+*/5;%`T.
MZ"*C@?<-:9!ZF80ZSVN0,0V]+$;4+Z.04K_C!P=<"H.K5T#)RS[[FUX2*1)I
M^$QHST`)-K33IZDCRMQL1.4Z;*F;/ZGR,<?C-_)/J=0]WA?;RP!JFP]O<,M[
M3#4_($'S"+=-X(NJ!>V/U>G)K2$Z]9`<CTE^=)P(_PB!H5@7N<^F/=0*^\97
M@&L;**[?$(:/,Y_?JLX0-_B>TR3RFM49!$K_#K)EZUL0)OY(>Q8E?M,[BQ/F
M];VS)/''ZK/TT((,:UROH"`$^=F`$!/XE0%YS^_$9Y1'L3<UG@$*\4,`6)$=
MXB7*#NB,QAGUAC,PG#0XP$N:L@,2RP[DMS,&A8=_#TB!!Z2.6=0OTX.)^`QR
M.?<;$(OP[+=W11SXL1FLP#^ZYET!)G;@+5E`_=SR`/]^H7<%Y`*_/#@+$K^-
M`4KT)`RY(CRD.1X=`"=G/*;T`*7)(<WQE!X(DCP[9$$0JP_H!?+S`4L.$:P=
M6)$QOU>&//'(%#+&JW^?GIR>_!\)_3/P#0IE;F1S=')E86T-"@T*96YD;V)J
M#0H-"CDQ(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@.3(@,"!2(%T-"B]-961I
M84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U
M<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R
M,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B
M8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^
M/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*
M+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*.3(@
M,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`S,38U
M#0H^/@T*<W1R96%M#0IXG+U;WW/;N!%^]XS^!SRF'4O%;Q*/ML]WS;6Y7&U?
M<^W<"TU"%GL4J9!4%/>O[RY(@G)B0S<.V?&,+(D@L/MA\>VW`'7YZ^+LX^*,
MKK11A.*?>Q>OE.Q>TNWBC+DKC'!-F';?<,(CM3*&QR2FE$1P2VT79Q](Z?J*
MI,*.5!SC/U(_+,XVB[/UG[$K_#OZ@JZD%##`2@HEX)\PG#^];J3"ZT9$>#V.
MM7B^0TZ6DL<,+&*40#.IG4UKYV!WD?J+0H\&7]XMSO[R?7*?@GN"W,$-#@C7
MZ>"ZAA<JX>H63>)**7*7+LZ6=*68EN3NL#A[<U>1:E^3W\OJ4-CLP9Z3^Z2Q
M&6FJPA:/I"I)`H-^RNV!5&O2;BQ)JUUN&_S4[-,-7-Q5==N0];XN\V8#M[85
MV3<D*3.\5MO&EFW2YE79P.U)2TH8$?JI_9T'6UOR)W+WG\79-7CUCTE\9QQ\
MA[GO?*=*>]\%BWO?:_MQG]<V.P<3R+TM<OO)=C8F14%N;8I68_2L\R(O'TC?
M?@L.@7^[79&GR7UAT6'$L%JO\]36S3G)H%7:5G6'`CBPLW4*=\$@I85&>5*0
MZE!"V\[YM-I"9P#=(6\W\T!!C8="&0\%CZ,.BFQ?HX<XOX\VJ8DM,S#G.YO:
M[3U,E6#GA%.JS_NI`Y`P,(JDM0,X4ULM(%J/S&9">*MCT1D-(9A,/FQT-*R)
M5M1$\/Z_;F"F5`\7^;ZJMT20O"07NSHO'#CD_G%J:Q1EQR!P+J(!!1F)P1@(
MOLD'YOP)#)Q&>H3!\'[DJTUNU^0VS2&X<PAL\KY;`U.;HZ4<S0$3*)=L``)(
MW73FG),?"EN6Y'I%?K+9`28'5F;',G,L*H,P=&O*F#$ZI>G#<Y,W$"!YBZL=
MV*+*RQ:I@R1("\1^MNF^S8%Q>MYP7#$P!T;6NZ0&?G61A9=P;3[4"70`7FWR
M+3(P$E([?=1!F`_.&;Z2%*(0Y_[-<O*1-#N"D?/8C.$=][/:Y:/DD-09X@ED
M698]-2,76>3,J>V*(%\?(2!H%'4(K%X[DGYQ).U'>O/J*'VI=U``)NH[_XU+
M^JK^H_`J0%6!,.F5X3(>2()S$$!N_JZJK),+U^TF3YO)?40;A/I&'T/]Z['_
MR6D$)PC47Y_C(N-934JJ.OS>@[2XK"#Z$</OO++8((UDU:[%Q4$09+Q^N6_R
MTC8-?%%F^[1US-$#WRD;E"TP'\`A*'+@%I0N7K"<>Q7C[K2@2ZI':^'[.0@4
M>:4C4(Z:K.=S(_O(R<NTV&<H+M!&R+-EFN^`3+^BSO.CB^N\3,I.87U],4G3
M:@^I"KOL61>X%ABEK:NBZ#D8Q%J#:A7^KR'-8^,FW^8%R*(90(C1\V[ZE?:S
M#YSO(%CO2T=US8K<`?__D6F&K)-\2L!<E*8PXXC=P=XW>>L^'@Z'5?:89'FZ
M`MDY.9]!0,=:?OMJ#"R86$8#8DR/6E;K/F%\L)`F6ENZ2J2!TJ-9/[KLF>5-
M6E3-'A3W$RF_![%;D[>MW1(%^A@!=OHNGMIX"3,\6#]O8I5/<*+Z2/.+N(^M
MOT&7#\`K&.`HYP&,S`F4MCK'99&00P*+K";KNMJ>P\==77W*&TR\@-`<2T%0
M+ZB87PM"#7R`D?P:HIN7/>8`@@U%.^-\G+F(]Q%^1%A@0("O/'U`;4)V5>-L
M=V5[7F);5Y=CD?__)0EP,3)BUI3M^W_=_(0U3Q3IH1)AS/B2C`G:2_^?ZRJU
M4%-#_`',Y+:MTM\W59%A7KW=WV_SULW$D,W)%41OGF$U?6,!<%R)W9;)',@K
M/2_R0_]SB*5(^`V!&,7F():B'O@[K`A`&WW"#1U;XF83!+FM<46GFZ1\Z!@!
ML\%NG"-8'`=@C@UICB=JFSR"??UT0$^PLNQ(*,](LN3UXC84;)R/-!Z-NUC#
M7@2HZ[3.[T$&YMTZSNS:E9V``<3AYT<(/X#`,3N&6#9L6<3=G@X85"0N''M@
M^HJSW`-FQX!,7_P)[URG_B`D.9]^F,@/,WU,JHCZWG%C@G4S]&9K+6*ZFKZD
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M-P!9"<48U"VU=3ANW<E+,\#?A=P,&"CCJT0EN<>`2CY@T$?YBKRKO?&-K3]9
MIWC<D>`FR=W73XP=[YR!9544S<JROO\YLI32=,A2T@$]9*EAV^>++$6^][%W
M_1G*O'8.0"6=%]"A_SG2EN*^8*;1T4$A'\N"E_90,POE`4K[K-LW.`KRW!W4
M3'["&&MOK_:R5TP^C.%^&'=B-M:IG`]UZI>);.0X^TUQ]O+)DGG&=SF]Y%=^
MF!DDOXZ?(,MBGU*Y&'*JBZRU"RO(]6YO45*753.?:(?T>F,?]D6W%7,[^4D6
M3/M@[,QB"N*-ZG$9CJ6JXU($Y?(9,3%J"-'M<3]76!=-]0<6:UYF=H=/+I3M
M.3F:`)!D-_O"$D8O)H>7,>_UO/!&3!WC*ZC?_4#)U@NY`=\9YE;&XZ,8;'R8
MQL2]3CBE#X<C;!"]H/9PJ^L!]6'I!#!HYVYK$A6V.^CM';G8VCI/87K=%IKO
M>?JR&CW49M8,Z/M_G?%Q>'J4/T4W2HR%F^J9_NW=]3M8`$]&[CJZ^0$[.J`5
M/\([OE)$2@.OR-'CIV)Q=CN)L5H<&4N%]/O;/);]_O:*7/]Z??7+W=M_7I.K
M]^]^OO[I]N+N[?N?5B?-U^+8?*[$*^T_$2EBWBT2W__DXE-P223K]TC$2FOE
MU2>5PSG+[2_OWEW<_.L)].3NXO+OUS.L.F'FW2[Q_<^A.T7D-P_$T=ZLB=BH
M.]=5450'M[_JCF0;V[I3`2CYD>':JL6]Z6H+F:OI1(#%FC$[QX*YWD/^PC.>
M),^&G>?NH:MK?XSU_NCY(9NDFZ%@;@\5V5;-+%6CT&QT_&@;7@V//CULBL?1
M*W#BJV.WAAPVU>2V<:F>&#=:)V+16^>>N<0*%B9E<MD-5\;QJ1SWZ_GPN![H
M07<$ER:[).TR9N(2WC./6Z9XRI<B;`4>1JQM77=/V$X>S)"<1KOE&,QF.&?H
M:_W)=0U@-`P\8SD4P6U'\R(BK]F5>X\>ELGV2:#.L6ZD'$WHTO2;83U,_PRG
M'VZ:9]A>KNK\0!,4=2\??/A19CGWP-0X:R+BSQKOM%L4"ZC4($)=K^/M[L<"
MT$"BCL,&_(4&@`P/-N#X@X50`P92/MB`BC@XA`"5KX,-8BQ:0@TB?!X]U$`+
M%O1"*![V0@`,82.%H.$&G$?!N0"F-V$O*-<RU("[!RE##6*N@T;RB',5;*`Y
M#3=P/Q$)-0`9&6X`0(0;<,;#7C`:AXVDC`;C@<&2#3>(*![@!AIH&H<;*-S%
M"360U(0;0#T==)-Q%HXHQD[,!<#$@D,81H->QBP*1F3$=-!'S<(@*91'0?8Y
ML:88,^%(,<%%RVC`OX]]$]5%*Y//<+\A>&#8<S_[^O<WRN^>@*LN2>)3;G&_
M<7/G*@.0@%<5/KG8-E\5NNRY.AVZC;I*UQQ]])6NXYJ`S?K8YB^>'P1V$./O
M3M20UK_.C!U?O7(0T.M]>08ZK!M#JB_3(X^#4[>,9#"TEKC&@PUX%$Z>2Y!J
M0:):2AT'PV^IHC#=+C7^@C'HY:D&,3X>&&I@HG!^7N(B"*[R);`(/P$V5V&I
ML@2Z"W,)M#`G7&'2G)@RIDR8T99,1V%>AL")PUI@"?G%!(EWR0R-PWU`H7<"
M=<B#8?9:8BH-VP'9.)P!EK"VU0D[(-6=6$G*1*?6&F4G1HDI/>&MH6$9N!30
M11@/X2@YV()3';8#I.*)F1.21B<L58R>L%2?FCD1,19&7<2G(D@8=F)>)#T5
MR9"D37A52@9"(]R"ZP"FD!"N?UV<+<[^![(LQ;,-"F5N9'-T<F5A;0T*#0IE
M;F1O8FH-"@T*.3,@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Y-"`P(%(@70T*
M+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO
M4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B
M8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-
M"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P
M(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA
M9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*
M#0HY-"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H
M(#@R-#`-"CX^#0IS=')E86T-"GB<O5U9DQLWDGY7A/Y#/?A!.]'FXC[VS8<\
ML;-AC]92[,Q&S$N)7:VN-9ML\Y"L^?6+1!U`$6`1`*LG'+;9R6)]B4P@D5\B
M6?S^[Z]?_?[Z%5H)S2L$_]A7:L59]Y_UT^M7V+Z#*R(J+*R$5$RLM":J4LB\
M@PBK]LWK5W^KMO9>DG&X$5<*_E?M/[U^]?CZU<.?X%;PCR=`*\:H`5@QRJGY
M']6$3-_7C,/[FDIX7RE!XS<DU;>,($(KA5%E+F/"ZO1@!]B]B<<WJ7`*?__A
M]:M__ZG^N#;#H]4'\P%K"'O38>B85$+)ZL,3:,2K#^O7K][\`U.9^^^_51_^
M[_6KMP;QO[/T$C-Z"67U>O,/PM`+W)\K](+W%^[^U4LH;^;LBRH_W'^J/(8%
MPJ6JI$85M7=U'[?3UES`">LN(!<N8(3*V0LH,?!S%Q"LZ>P%&,MY"(09GKN`
M:HQF(:A"BLQ>(#&:'045:'X4E&,\KR3#:/X"BL2L+RA!>GX4&'$]>P%";'84
M1",QJR11B*#9"R1"\Q=P/:\D89K-7V#\/7\!T61^%%BI>261TK/SP=Q`SE\@
ME>"S%YA8/G\!5VP>@IEX,7L!U7QVF)CH^1F%\15?8&36WMP%6NG942HM9V>D
MU'QVC$+/&XG#7CX77-25-:4QFU\0:G;18C4_/HSDY<__WE_2FP![&<ZX-VCC
MI'%OP.=[CXT(7<:`N?D;D@:T0MHH_>&+V3(^U!\W3;5[J'[8;8_-]GB8;"'=
M;7[],]SR"^Q5?P&%3.YA;BO-_\Q]M??GYO6K]_X0B`DV&BNX#&:">;7I7ID0
MLNG?[EX^^N,%&3'Y&):1X<K+^9&9Z]HD@3!:+4WFA\SK?[Y^]:T9NC3;JAWO
M+_534]7;^^K=OMVNV^=Z4[W;'=ICN]M.-T^7TC$Y#&(8SU1W>\'Y,(;WS=Q1
M>1NZ_:2B%S(&S[B*.[VDTVM4QEX0ZM6]3U6V>0FGSKYL9>*;M/9]\[]-O;]D
M/*5')7M]IYK9"P(E^_=99>)\GO'L)]E5XU%*G%[:Z34J8R\(]>K>-QZBL:4X
M9SP39;3)8D`Q,R&1&9C-W]_7FWK_-4@*RX&H23)&+Y$51;+W4C3YO`6'C3@P
M($YDST@01]^8_^`+4X*:I=B;?O#"U-[V@G/3#^_G3XGNDPE30E*GEW!ZC<K8
M"T*]NO=-DIQM0?.984H8`PK:1><WW^^VIT/`0VX!LFN^Q%5J#'V#=:9VL!<$
M)NG?QP6^DC3)5\#6!\74&/L\;>P%@6+]^XQ5ALWGF=`D_YJK82>%O*M;OL?=
M^K?`53?@*#<GKJ[>F\:#'`Y;"6"!%N>[+_7^/C+[RJ'8-"`Q9/[NAF1FWZ(X
M+O2/Y9%OE@3`Y.)`+JT@QL9->IBST]EI+SB?J,/[!2NH^VC""C()X*`8&S=F
M3QM[0:!8_[[9+[*M9V;8L(+,C%,,D<YZ?WV&Y"N8<3=!B:S)?0L4SPJM"6`S
M]3\F)Q-P)CBX"<C1F.@,+I\ZUUX0^+E_OV0"VH]>GX!<CIGAH.-4&WO!N6+#
M^V;D(I97S[$#PU.U8=S6>MS$\)X>O/GE+/6_$0;2C0'&CQ+?+@HB'`A:,3W,
MA+>_G]KCUV"&WP(%'QW6K5@),7`JHHCN.-5_;M>&.;:?F^K=I@Y7\JW@PTH6
M*\18/\X?=D_/S?901T/'38:E.>O96V=JS!Z'F3V=P_:"8#KW[^<OL^Z3UY>9
M$&C42XTIG*>,O2#0JW]?@JEB!>DY$YI4"4.9<;1A9\)O[2E+-V-^>*RWGYJJ
MC?CN)F0-QT!BR*@UZWSWSLR4Z#RY"<OX#"$]A!,&-9IA92`3-^TX_Z?>G+IR
MPZ+8D,,8/ME#<[C!$,E^/]6;]J%M%D;4<HPW4$Y!J#?MC\U#L]\OC::H'W)2
M5_U-XQ,3=B[[2MF;M_5^VVX_'98$$[B0.0O!AK4\+.OI`K87G*_EX?W\&--]
M\GJ,D0P[O9C3:U3&7A#JQ083YF9=0BJ?C1'5&_"[S2:8%K?`:"]EE2LM=#\/
M=\?'9K\D$'STVC:WZ,!XV0R4?*0S@].G[K47G'MZ>+\@F^P^FC`%]4AG!AVG
MVM@+`L7XF(OGUE2D(#['X,SL/=9E'W;'>G/NJYN`W$9_E3[?@N.57B[3YUL`
M%+HXD$OS33GV,GAXZDL58R_#^P733<^1E]_[`RO=G4YDWANJ!^A26;\_,8![
M%Q2]X<1@_M;2WAJ*_MGWEE?NK7BIVE"KG[^U[FY-"^ZMY^\-5>$RM6T]>?[6
MHK.V++BWN')OV4V2TMKJ[+U5-TM8P;W5E5D"9:E"O6U%:_;>C)=.$UN,F;VW
M4L5Z0R%D[MY`4^'>,G^>6(8[>V^I"Z>W)9:SMU:T6&UU90I"QEFFMLU5YV_-
M2M6VF=;<O2%+*9PE-L&9O3<OGMUVLYZ]MU:%YK8;Y<5;HY6RS9*4#@T)9J8K
MY&^;#^-VJF8.^^>;(94:#_OYD)L#_>:"=_3[YWK_6_7=JGK[5&\>ZOW':EY+
MNP,K+V]X<!NS*CJ-MI^\F+V&^#*.+XOQ91:^X1$`1,\5\.297B(".S?Y)6N"
MD+BB#206$6N<B[/RC1QK0/81P]?%^#H+7W?3CNHS!3QYKC<TC7N#(G2'T!6%
M;,H4&B009V52&0:Q>54,7Q3CBRQ\ACK#TS,%/'FF0[J/1APB>8(_9#<1\+E!
M/'FN/G(Z003BCFSB@*B%*JDN5,DSC<[%68EECHLTZUQQKH`GSS0)(Q.3>.<Y
MP8%.`LI<DCN.\\HVU5T;^CV4E\%?-[/-N,.5&(BS\O`L?!T-C;X\U\T*I;HY
M`66.$R2[V5X;<7,@+X._;F9+4`#I+."%\BSBDJ,![F:4.+.!+\]T-)<XU=$)
M*',L*M71W;7!:@K$9>`)1E8T[N9`GD7T<C30(NYF3Y[I9L%)LINOH\RQSE0W
M=]<&;@[$9>#7C6P)<,3-H3R+&.=H(&74S;X\T\T2J2K.+^B=%'Q>'TO;(Q'6
ME^?JPZ9\9Y)`D>L)E&7[X20)Q%DU@`P721[?67UYKDFXCKN(:I7@(ZVB!CD7
M9U4N+AO$'3U`?8$)6YKH3SI<R6(J3\^N39P1P_<W$19C7P3E8UM$NW^JMW?5
MNWUS:.^;[=$V#_SPV#8/P<GFC9IP-!1/L))D_*8$5_TW)=[^T:Q/MJOGKP\/
M[;JYV.(/10ZC!YO:R8E)9E"UG^27OD\Z_6)&%'@0%Y5+^*4OFGK`4`\Q"/0<
MV<GS:P,X#1IJ&)$QC^*BHD@2L(X#ZV)@G0:LNWED(L\4V<FS225\93P!VM8G
MPC$[<5'!(PE8Q(%%,;!(`X9Z!!B5GB$[>3:T2/.S+3T8"'P^:"<O.?%*@E9=
MQ)!GR*.XJ&J1`@P%`S#K.;*39U,\D@9M&7_$W)Z\J(B0`LVB,<R)BZH'2<`Z
M&DH\>3ZC9FG0P+QCYG;R(C*?`&TI-[/)P`3:DQ>Q^!1HW+E4G(W:D^=SVS1?
M6PX<3C(G+B+5*<"*QLWMY$5L.@5:B[BYG3R;X?&TC<-RT=#<3EQ$;I.`6=3<
MGKR(U:9`2QDUMR?/)B<T+7I;FAD))YZ\Y"`Z"9I'H[<3%S'4).!X]/;D^5PP
MS=.6,T;&/(J+2&@",%`\LZ%'S\VG\IPV-$5Q`KFB%B)V%NZ+\UA=$K",`\MB
M8)D&#.R-R/CI]T2>Q^I2H(&$1<9\+LYC=4G`.@ZLBX%U&K#NYE'T<'LBSV-U
M"="6A(5C#L1YK"X)6,2!13&P2`,&]@9&C1U<3^1YK"X%6G;^C)Y13^1YK"X%
M6G41(W86[8OS6%T*,.PJ8-;8(?1$GL?J$J`M!8N8.Y3GL;H4:!:-88$XC]4E
M`>MH*`GE>:PN!1HH6,S<@3R/U25`6PI&9/QL=B+/8W4IT+AS:?10=B+/8W4I
MT#*Z7P7B/%:7`JQHW-R!/(_5I4!K$3=W(,]C=0G0EH2%Y@[$>:PN"9A%S1W*
M\UA="K2447.'\CQ6EP!M*5@DG(3R/%:7`LVCT3L0Y[&Z).!X]`[E>:PN!5JK
MZ)C/Q7FL[B)PM"D:J3BY&^0%3=&8]">,%*9\?\*H[&LXUOM;_77;5#_O=ON4
M;FBC1XP!^N(\!MAKE]H-'<.7Q?@R"Q]XGP&*\L%>7M(-W6M0T@T=L<:Y.(\B
M9E@#B%T,7Q?CZRQ\W4V[*&'LY27=T%%O4'PG^16%+.L+#1*(\VADND$L^8OA
MBV)\D84/Y!$,'R.5O;RD&SKF$)K:#6UPHTQS(L]CFAD645UDBA%.7YQ'.#/P
M8=\#R\=X9R\O:7YV'KG:_#R/,DLQAW&F-#]'W!S*R^`3FY_#A1>(\XAN#KZ.
M1D)?GNMFSN,+#XL[B:^TK%G&&O.()\]NQE83?29==/1Z%YUEL@`=(\<3>1XY
M3G>2Y<(&*<J1>WE)XW+:6DQ`F27$B6O17ANNA$!<!I[8N!QS<R#/(^49&F@1
M=[,G+VE<3G3S=919(I[H9GMMZ.9`7`:>V+@<<7,HSRL&9&@@9=3-OCRW*Y8F
M[ZP)*+/T/]'-]MI('`_E9?`IS<?1G340YQ4A<O#C.ZLO+VE^CG(,1>^8N-8-
MKE74(.?BO`K%18-,SIVETM'2Q"C/+TU(34-#7'C*2C$,'V'0"BEX-'[?8TWA
MM7TH6[MNI@W62^+;7PN@X_?2N1H?0D^([/N\^X;NG]IMO5VW]6;HL*XNN`,J
M)Z!0I!0S$6>58@8MKQW&1X%E,;!,`^;8(L2*+U-YUF%\$K3BT3&?B[,J+6G`
M.@ZLBX%U&K#NYE&LMC*59QW&IT!#T2,RYD"<545)`Q9Q8%$,+-*`&>J,&JF;
M3.59A_%)T++S9ZQ$,I5GE4B2H%47,2*UD8DXJS:2!*Q99]9(460JSSJ,3X&&
MND+,W*$\JU21!,VB,2P09]4HTH!U-)2$\JS#^"1H^!V>F+D#>=9A?`HT%`<L
M1*3>,)5GU1N2H''GTEBA82K/.HQ/@I;1_2H09]'_)&!%X^8.Y%F\/PE:B[BY
M`WG687P*-+#FB+D#<18-3P-F47.'\BS^G00M9=3<H3SK,#X%&KAK+)R$\BPZ
MG`3-H]$[$&?QX#3@>/0.Y5F'\4G06D7'?"[.HKHIP,#U9/S19&?RG!9K*:]_
MP]B2,!E]W-A$G,?JDH!E'%@6`\LT8&!O,OZ`L:D\C]6E0`,)BXSY7)S'ZI*`
M=1Q8%P/K-&#=S:,HJYO(\UA=`K0E8>&8`W$>JTL"%G%@40PLTH"!O<GXL\&F
M\CQ6EP(M.W]&6=U$GL?J4J!5%S%BK$Z6/NXK"1AV%1E_SM=4GL?J$J`M!8N8
M.Y3GL;H4:!:-88$XC]4E`>MH*`GE>:PN!1HH6,S<@3R/U25`6PH&$#%6-Y'G
ML;H4:-RY-,KJ)O(\5I<"+:/[52#.8W4IP(K&S1W(\UA="K06<7,'\CQ6EP!M
M25AH[D"<Q^J2@%G4W*$\C]6E0$L9-7<HSV-U"="6@D7"22C/8W4IT#P:O0-Q
M'JM+`HY'[U">Q^I2H+6*COE<G,?J+@+'6JREX191<C?("\XQ.1_.]Q@3[KG3
M:/A1[3]OFNVV>KNJ?FGNO[3P.*?'5?7C*J'A&K2*\4%?G,<'>UT3&ZZC^+(8
M7V;A`POD.,X.>WE!P_7HK?R&ZY@USL5YA#'#&D#S8OBZ&%]GX>MNVD7I8R\O
M:+B.>X.R.[,6KS=<1PP2B/-(9;I!+!6,X8MB?)&%#U02#!^CF+V\H.$ZZA"=
MV'`-N%'>.9'G\<X,BZ@N,L7HIR_.HY\9^+`+@N5C++27YWH$]K>81WC"`]HM
MCXQXQ)?G=N+2:0"==.+RZYVXEF&&BR80YU'6=!=9AAJ)8KX\UR1,QUU$F;XC
M0E_OEH[ZR),7=$M?]!%+ZY:VT#&>.Y'G\=QT+UE::Y"B=+>7%W1+>T:YUBU]
M!666VP[C3.B6CBR%0%P&GM8M'75S(,_CUQD::!%WLR<OZ)9.=?-UE%E.G>CF
M[MK`S8&X##RM6SKFYE">Q^LS-)`RZF9?7M`MG>CF!)19)I_HYN[:,(Z'\C+X
MM&[IR$0+Q'GUA!S\^-;JRPNZI:-;JR3JCE]+?VQM(&*0<W%>L>&B0:9'R*@[
M*NY_B=55&:;R]#S0Q"HZ_@*R)GSL(L9*BN%IT=!$_'[=PH^O/[3KH8OXKG*/
M;K:]SK'VYAOT(KAOK\;</<*:(7@-:HV=U=Y3K!?4`#,RJC"9(W=G*]9>_^N?
MX9-&+5+]Q;QB9&7F..'FOT_PIQS_W+Q^]?YVU9133:X8Y?UOPG[?[MX]UONG
M>D$[$,1'L#=+NQ@-OP-+.:&#BR61_<^W?W\ZM-OF<+`/)Z^7!,?P@\8C.I*X
M0W]SW^Z;]7$W]PQR@&33!>C$E!>4SDC"TZFAQ!4#'L1%-3.4V$J!;,O$%-G)
MBUHI4J"AD!49\R@NJHPE`>LXL"X&UFG`NIM'9DN;(CMY42M%`K0M4H5C=N*B
MJE<2L(@#BV)@D08,12ED6R:FR$Y>U$J1`BT[?^+S03MY44DK!5IU$4.>(8_B
MHEI6"C`4JY!MF9@B.WE1*T4"M"TN1<SMR8M:*5*@632&.7%172H)6$=#B2<O
M:J5(@88Z4<S<3E[42I$`;>M!R!XJ3Z`]>5&)*04:=RX59Z/VY$6M%"G0,KI?
M.7%1Q2<%6-&XN9V\J-23`JU%W-Q.7M1*D0!M"R6AN9VXJ/*2!,RBYO;D1267
M%&@IH^;VY$6M%`G0MEP1"2>>O*@"D@+-H]';B8M*'TG`\>CMR8M:*5*@M8J.
M>10753<N`G<T#E:M(;5"9?=(".XH>O@KL@%E-"O-1@A#[G/!S$=',+$BBO*Q
M5$(TZ7\(?.]^!'Q!:&R2^`&[>]2>,20A2R)09TJTTJRGPX<E#8@9]C"X@A\`
M`Y"/N^WIL"2.V39'3[&5Y.8&O:>0U'U1JWK8[:N@.^,V8$*0-T!"L:M:Z>&Q
MB-5C?:@^-LVVJM?K_:FYO[/%C>-C4SW77Y_@00&[A^K+8[M^=)?>-P_-?M_<
M5Z?ML=U4AY-Y\]@^-96Y`#ZYWCT]-]M#?6QWVZ6G/!V+)$"?^_%P^QK&8Z"?
MVN.Q:>PP%ITM/C@AM#/FF]UIOR0*5QX*%D2/+L/PVKIL9VR\K]KM?6.L;)_E
M,)2)#L8US5/5'JOZ_G-[J#]NFNJXJY[JWYH%E63,5Y(B*48_*#+,9SLI^BFT
MJG[<-8=JNSL:K=>;TWUS/L'6]>&QL@NO672-PXS!XT\/"NH>BT%8OP*>]\WG
M=G<Z;+Y6]9=Z?V^FM3&9'SF-TE;?^FEWZM3]ION=\JJIUX]W=ND>FOWG=FV4
MWX-+8&V8#ZWKC?FKWE=?F]KXQBQO9J>E><'OQD5UWRVJA4>-T.`?S,9)Q`7K
M)U&_VF'%UMNJ^0/6:U-]_%J=#G8\Q\>=^=OJO61$TGS4;%+$7L6*J=P@,)7]
M(X_P24'CNW#X4Z3]@*"Z;O[-Q8*/BO&Q*X*-#YXU5N_GUP<W<PZ/NR];:][)
M]-HW9@X>S$HX5"::^,OB&WVGC+G@$T$-_0:MF8DROMKPHY-]E&&H[^6L-NU#
M8R;QX;2OMY'#E!O@N4E5!GC8!#$=`SF!!'Y8ED_MZ:F?C&9J-MOFH;56F1@/
MUA-8;6&G,C'$8,G[%*?WRX)`&(D1R>1P#!&7PU&*AW!OY@&F=UKP\\"TH"I0
M?W>#1MS]1BN27H9B8D5].NZ>=A];L[74F\WN"\R.!16A6CN;7`T1S&S##'Y3
M*#]$(!T/$>%S%KL!`10,*!<+;-%C&;<B1$;+"M2GZ=]5A^-N_5NU>[89TR>S
MXH[6W-1VO_7R0_7%1.NG^KX9YH%]FK7YP'?/>Y.&L3N;0%;UL0OIS7[=FAAN
MWC/+%R816QE=GDWJ<'BL]UV"]+DY'*,;;NEH)17^<"D><P-A7\-P'V"]-K^?
MZLV2R/!13=P$]F=P/X7K[19`35`[FJG[9"/NQ^93N]VVVT_GAI0+ZD:-6YQR
MACZY2:!UO\Y75;!3@+]-#K$^;>HC9-LFV6[_":K:[&F_,RF>G1?&N>^/YI)A
MVW`/V%K8OI*/CD5C*L5L+FCG\7H-VH.&1A_(?.X/U2^[E5EO]->[)94A5(W:
MB)&!TB41S/[MQHN@:F!AWL/:61)'.IQIB\^B(,H;#$%\W'`9YSUS^KX^F#GV
MKMOD8DE?\>07(N(KMB2")"-"V!-PTXUYW#FP42R*HU]X.E/EC42L");8E8MD
M'X+>__3=>[M6%P2&`Z*7]3Z#)B?GI,ENCL.LX18D@?T8R)F+@13WQ.I]TYB0
M=VPJ#9$8=KJU"=&[37MO8_C#&)H/0\0^#*38<L:%(W;_>_+P3$CD/1,2]1X'
M_;[K=L5?F^?=_@B[X$^[_9/)39>,/X2,JKQ<D"/"&R^FS+$:A/L=ZK_>?S\R
M"B"W%;#U^^K'9MT\?329$<5]$K5O/IG=:]AKZ\/A]-0G82?@]YNOPUN?Z\VI
M*W09=QO!(4J5;G$A&_O.,'9#@DZ=SH5>TMAK5XT+.9HT8V%Y->'Y63/K"^?Q
M?OO8R`$,1IZ-!D,?.Z(PUBYE4L,337]UQ!E<\;`#/F(=\V4W2:D/G7FZTLZ/
M^^$+BC#9?Z[WZT>C9>_WSGYP-_/O%F2X>OO[J3U^K7[PJYKO-B;'CB_76T8,
MW0O]B"&LC?-7#M7-[;996P6^M,?'ZK&%X-$>(9[4S\^[=GNT.>!0U1G:(7?]
M<U:?3_O#"<B%,8,=8[-_LNDCW*AY>M[LNM)#_6G?V-CT'Q4XM[7.-7?LYYKY
MM+G3^K&.3_:;#""1"UACED+90)7,=G*'3#2Q%.;@0NS3D]&K<_E%_D-66CC^
M<]?-F;K=&TZU_ZTYVJ7<P)P(;KGK"H`0PN%.'4%;>N1\*,A@+?KS#C`^`"\)
MI=@(-9]J%"-H-QC-5UBAKHGW#1P1+(F#34`:@:[M*C>@",\W="`"P&B)[HME
M0*--<.F6QZ+@GBWGLZ<;($3<BHM'=(*H9TFDO&HI$T-=>GO?A9RYF".$O..4
M%@4!OC([B1\$S%:Q]$JF8_$0<I*1Z:.>:<$Z.%R*/I&Q1*//2X0&.-@9E'^A
MV,`X\^R#B.HCG?&(R<N>+A03B^$X<>YXN1#!B3^H?W&(X#KFM$5#A$#,MV("
MPRJ'PKXINR]]]$G0^`60M[7)V"85TS%?J5J;^2R]H/%8T.2(N:P,]:S"\#?X
M+HI)M"9:]4E6\\<1-#,SW)Y,W\,IVR3Y@C]F$\V[_@L'VV5G#M3MAJ&]W.(0
M5'D&))C[I_:=_:`4W#ZTQC13KQ[`A$O[$@UE6$(Q=9,+]W3*GC75&WOFU?NF
MWV:.CV93>:J_5A^;<2NRG1+[QK*&KH"[=)+#J-/YY9S$8"J,EL$"N581/)"/
M200S1C![E+%*O\5"J\$=E#KN6W@;JM7/YBK'M9;45II=8]!VOO_H!@CI&62^
M`>F6Z6@;5_J#1N38/1V.88U%C^T63NK[#H.!VUFRU@P)P^&N7RV$_P,Q/LQ<
MKU8QY$I;V[0P7+`UP:FRYS'U=FL"V/Y0[]LNI9H2X[M+_30W#5Z,U1KDG=?P
MX;RF^>.Y[97VM<'XKOIX.G8G(/?-8:SH0-_1IC%94KU>-YMF/]9E8.K:(YZ'
M;A7W<]A.T=H&XG8[7OQ"<Y:Y\;[4G#4)M3/I"\[9L:<,0^8S'@,-O25>(:%I
M;:]2UU<")8O=:5GB#`=!@SXOE++"29`;,B-#/\"Z/AT6#?7P.SGA6!;-Y."[
M;@-$]*3DACL[*T%3!Q)CUQ%%O,_<=G8J>`6XA_.?8[Y1"VK([`M/!RA%N>E`
MF1R3"*Z'+XI^VNWNS5WKPVZ[6A1;DI>>(4RJ%YHAS)M[<**J1L-12P.'9JF7
MHH+2P;\@%?36,/`7X;)=K'5B(K5XP'9-LY*XHBHA?.0O>TN?ZLWFZ[\LBX-F
MP$&S%]H1B=;>X`E6+JU5O)]RARH]Q_IH4WYK$\@W;-ZT?FR;SQWYO#_MAV.A
MH2J_M"?'9E9,7=<>U7KHFFOVK0D]844?DB"3VNW,-GQX;M8=V_)6&O37K1^A
M%'6PI:5F]6G55<@W]<F\TV=/V^8+I%WWI_7QT+W=;!_A\P-(\T?;I5I+#WSL
M9\74';N:<"^&=L%!*=M<M#WNOQH?F(1XO=L_[_90.H,$]G"$EY_:-?2NM:#X
M`6H8779[,=W,;<U9>.Q8C2<#2+E=E2L]CMWO!')G?[>>16>>#I<GKL@-\N5"
M,WSIQYD2$>*94M`+Y\-+NU*,I2WFNEX9&IK`7N(X.O^`6,-F7?`,B\I^1R&E
M5Z8<1/@@E$&GJ'U.X(6N38VMKW)AP%5DJ%DA[*8*$</7,+S#9T-(M8ZMB$)T
MS(4'C[5+I3G2PQ=WW.''Y+!@.2V(QKX1M+=YTOXT-GZJOIP*S)M3MJ=^C/S*
MO@8=W(G]@KC"=P!#_5*%XF`L!2I%T9-9AJ@+2'C\?M9\!\*",QZ^,NOFG))C
MOP4G:,P3JU@'PK++#H]52.HQ!#4PA*7:'19T(_6U1A2YJC(:DLQH<T7TY*10
M"6XV):<$H=35$A55CESU4>-+$VUB+74;TSZX=E^SXFS\&L/#R9"+JN<^-H7N
M#C(COT-<K@E\6V;0),I>RR>F'GN!F7:URO&WC>WQ[3V<.W_3/;.V)PL]58B>
M]"ZG'Z6>@M>^G%B*8;9K#\/]Q#230T/6]7/K!6<\%9Y/D+=%\_&;DJW]6NMN
M?V\IC@U8<SVNA9I(1`9-KG]C!1Y0`''_PM=B\,6J$_P8_&!\/M#EZ+?7!2V$
M@%U@^#ITA\"FWT>V7\JS-R?VWNXF#W^R[WZK[>^=7WX?:R9G+R#:_EK@Y0NH
MTO,J,(W1[`5<H_D+Q+4+I*;S.BC-YT>AM:;SAD*2B/DKL.1J_@I"U144BJ^,
MQ.195SR&.89G\LU>H?65L4A#LZ]<`<6<V2L49*SSDX]<L3I!1,_;E&!*YO4P
MX9?,3Q]S@;BB!R-B?B$1;L8[?X4PFLQ?(0FZ,EI%\+SGB"9TWAX4$3$_QRB&
M8ZO9*\@USU&S%<]K2DVB=D53?LUS5!A-YJ^0UV:069-7_$+UM9EL8K6>7Y4,
M8SR_*AE6,S8UT?[MWU^_>OWJ_P&Z.'S^#0IE;F1S=')E86T-"@T*96YD;V)J
M#0H-"CDU(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@.38@,"!2(%T-"B]-961I
M84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U
M<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R
M,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B
M8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^
M/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*
M+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*.38@
M,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`U-S$T
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M9KNBW$0/^ZK8/$6,$`E/6>8ON^BQK**7O/IS7VR+7;Z%.Q_LG4#=EIML%=WG
MF_RQV&VC_XSN_G5]]0D4^]LLZE-T.+C?J$]X+&OU68J_47W0_/6Y`!.@_KMR
M!_)\S5;[O%$9]0"CO*/DAA"RF"JC#,E(C(SO_\D$F9V!=!A,,W%RW,1,T`AO
MQZ<KOD@4@Y;_UC8F$B,/;?SS;W=?[CY\_OCCYQ^B3W_[[<>[?T0??O_PZ\<O
MT8>[V242T-,:B=B"DR31$KW__L<OWWWXW^@?GS[\.C?/6`B7IR"$&IZW\W-*
M6TYT052B#*=/GS_.'3EQTEIR8N2$<Y.*69V:.&1`[)N0F5)(G#IL[J!'/I:K
M5?F*2667W:_R:)M#GH"<LGN.(#'MLF(3%1OX]]HDH"I_RJH';%[N=]L=)!O\
MG4/VV;U%V2M<VT;/^>HANG\+)[QL%WV$7+>^AT1U@;2D>-P/4$YO=.I<3.9X
MS)-H:\MQNB,#&4RRY(()C$6Q(A=-D,WS+V&<F%\VNS?/OX3P0L87%;YY_NSC
M``H/R5+W,@DX#7^;@8ER83/,I_7+JGQ;YYM=].&IRG/\M9U=$.#<2!(OTECP
M5I+4#I$:%_U2[D"``B#(+YF6:AO]]@)9[2ZOUL7&9+A+^)BEY_LXD.8!:QKE
MQ2*E+&F4E\Q"T!\WF/<@^\V>:8EHN",B2<P@\_XUGYT350TG4(V2!FH*PFH?
M@T?S"L:;8K,KP>%1WH9?5H=?]%K`V#:W>#Q..H8@\&\K'Y?*RG=D,)Q=&!CA
MVYA(%K%4;4PDMF?^E%5_1!\6T:=UMGK,JONY98B3M)7!'82G#[Y'6:7"#0V&
M46]#(Y8.U&E#`.94\/<2G'%&AP_D1:Y$+0UA3B!P.R?Z\%(5J\B@$?@34]/.
MIB`C$W@'9DR<Z!;B)KK?X]1PD[_"99SP06QG#P\%)BQ(9KO7,GK+,T!5]_DR
MVV\!=N6%F0)F%>"RIPR"[;4J=I#]<,H%08=IXR%[N\B4D"=),R,DC2\XH59[
M4!Y4@![:T9(OHA]KQ1&DW6C\Z'3;#$`C_'H`$_R3Q`2OSMZ+`237TIO\`BF;
M\=G[)XE=(TG>5`TXY397?%]46Q@T46%4?W81("7T-16S=TW"&S:=>1MXD,Z?
M"."VFALF8:;BIA[!P.;:L!!W^5_0$1Y,00*Z'19G?JHNEPJE:L42C:W9_&R$
M$U5*F*!Z?YDN+DD=O2E33?0*;@&',_#"1+#<Y#H_W42/5;GN=GO92P2)38@E
MICB=Z?:[$J>?2Y,"(>&]5.778HMH#9/A=K_$"I*>E%I.VJ^7T;RI]C&9-OTV
MIC7.W&]6^78;=?,O#/9;'6ZF,)?521@";U-NYI:201#48LY0+`EQ2JEC$"J<
MD9<HV]]JGV&I3YMF]PP^57;X:<8"M$[^UTM1&11NZZ7P_T;[<A%U1_!+>+8I
M9%+.6!/3*?Y&19HPS%:KMV8T!EG=T1R#=WLP_.IHQ6&KC0!SX<)Q$+-6J<O&
M00Q<6O,1Y6">1'3#(,,HR&!HZT5`FP0NX5RB:ND$;Q,6CVV4HNM,C!T,O-$Z
M^P,Z[Z:TGIN]"XG8%2Z)V\ACL8V\)?28)\P@Y47'*9ZTHEQPG.(P26PUIE*T
M24,PZXZM=^IVF`1LQ]HVD'BSV>/KCFP[/S2$&&*JKJ8R?"E5"ZW26NALE55O
MV)G?<:)?9IB!#&1^,>4&O.;(66[V6XUE46*=2I[*;&5?X=S_*U_NS,!1`JXW
M:C]$>ZQ7P)@Z>Q>&2:JC(..F"[\O]]7L0`7F:BTK(IRW1JI^:Q1]6V;5P^R<
MA70Y)RQN.UL=>NBCCT4%QB^K::6J@`!))XS@44T8*5)7";3[+Q&^2=Q.D=L$
MG=:U.C>U:'B.O2K'EY>/Q18&/0.L\&UC6=5C=.9>NXF*S7*UUT`,)ZQZQ"_6
M!<YI(8:K?)OK%-^^H;S?;XL-8H)U`=!@!^AM>Q-!-\*_+F&!.&U0JS,(*"GJ
MB6GY6.RR^V*%;S-`TV6V!>U7Y:OIF/.7+FA*'*E@]M=(%4O\C5+]GD?/.($W
M"6#V\4<FC@14MIU1\!KYH/=,70%S6>>%-%92L*Z`KW:CIRJ#'.?&452^8+-M
MC?"V,(,WTZ\=XJ1+^%C4A2">4#L%NDBIP&7%.*.&5<<X\]=`B<.4<DJ;:"%U
MH:MUB/:&MOSL,4-35WEWK)B?%W0#1^>DK94(5M=*3#+9YAM$DDUY=?;DS67K
M\TY)LU?6-_?^^@/>^XJ,_^?Z"NY>Q`CWX,\U_E,T_UQ=7WV92<*XXYBV"!WK
MW]I8F[8GFEDRYN-EN3'EQ`LD.0E12YJ":.Q,$FDJ?.592+5E%]P9#`7#SK)X
M,7VK`!BU:I:V1"^K;`.#QDN5+7%&A3_+%;2V"V+@8=`=UMMV+G8!""435]&$
M48,NWN]GCT2L/+2<&!5-TL;E"R9G;_<XU!I\V8S+%QE6:=J4,A47;;6;VN$#
M7[B4>XL%M/=N@$>QOM]7V[R&Q0T4J/*5KH+G?V$B14]^S9;VKG7^@--O]'.^
M75;%BR$_P#.0^E!L[>"-#'8`XO#I&E$@,(<8WQ6`O#?+_#)V2$A3"4F3-LB9
M=(MBD)E7Q6,.`;S=5T:6IZK<O_2H&+?9<ED8[4#);&>PTZX".+!JKK7WF%[0
M"7@-Y)Z@DU2Z:I%]S8J57N=Q@6$A@<ET:X/+#@MH[IC_?Q@5*(]=4;`DUM0^
M4CLH&V=B(C-"-9%@T]?L(Q7D!M<\2=R:)ZEGJRY<SV8O/O'4]1`AJC$+BQ5M
M9CIZ(JPK:R7TW!QS>OFJ8UG/Z5\@CO\JUI`0('C?S3\=Y(V,G0&=BOY21'R/
MGTC"H@3+^9I1^T2]Y!07<[#$-&!'&L0,@%JH@6`Q"38`J)D$&S!&PBPHH/Q@
M`X*+"`(-N,+7[Z$&*>5!+0";A[6`T8,'A>0Q9>$&$!I!7W#`SV$M&$P3@PW`
M#&$M"$F#0C)%A`@V2`D+-Y`J+"1TMR3<0."[HE`#KD18"U0CV(`J%HP'JA0)
M-TA3Z.>A!DFJP@UDFH190%X*-Q`J":I)!0E'%&4G?$$I(JA0`TBD03654L&0
M3%4:5#)182M))8(J@A&#UX7BZ8G<$NRU+`WKQR@)WD])<IS_G[9);%2@PC.>
MJ`BGW78\H?VEYG%3V8XILTMN89"RL/Q.@R_`N]\!&.TMAC./Z<X;*4X;X;&)
MF3<JYY_-O%'[%3,:"*=&+T]+56#]).19_6R8S(Q]M+DU]&PI];/QO2$,!^/6
M:8.N]<.5@-F65,VZ^"2UB/MG/4&(/NAUR8?<$R4T]W2T8N;.8XJU[=$`":#@
MM>E9\&ME?RG\92[KG\]N_"%-NW*D22B8,ZG?^\8`]9A9D?G^,\SUNUBF^3H&
M76!%K*7M2F8:'`A97X>@2$<NA]1!08^M-F[;"QR3K&!6QJXTIL&A8/8Z`#G,
M`Z/,QQ.(1KM2$R)*2IZV$25M1'W>ZQ7KY:,OEL_BW"Q@8ZDP>>/]%YBS5,6N
MZ$]:SN,F=`3;U8%$IC9,?ML\Y-7J#>8#\[*#6'$6Y6C62\T.)F75LL!77[/K
M9]>G@'X**]S6CUS6KU1_MG5IK([\AW<QTGDB\*8GXJ)+:JOJ[S\9C7$0.-(A
M12SJN*^[0#?838.#N*^O0Q"-36;Z5BMKJ$/&G#6"61F[TI@&AX+9ZS#HCK:B
MD.*,#GDVYU$=\CQN;&R'/(M=K,9WR+/U.[]#GJ>S<#LD26)UH'.@2\;M4%1W
M@FZXQ[ZAJ+X^H4OJ6P=T28F3*BM8FRL<:4R#0\'L=4QL,1^)NK!C)/;K.%S[
M4%=,/IDOP`Y]=A8ON#>5K/[`!#O\O^VWI4S5WS4L\7N.KWGTRRKKOV\[BSM$
M2"KB.OFT8,J`R?^>F1D_ENG@6?0@T\W/.ICJ9F9'3^6ZF8,H'9_LSE,P;I,=
MS$L$;13,LVHS-S?@U$!^F!(FS#"SV?1(0I.\F9?4*:2;+$R#@[Q17Y^0T/2M
M`Q):0M)&,-[,1AQI3(-#P>QU,*!,Q]E/NN$H%JD@'0/V?'4.*ZR;M(O^29IV
M(&%_A<)9:K406+\'MD'_2U4L>U]FG<-'LLZP&MMU1;B\G[S#4?Q(!"8P<[2.
MKGW>]:YI<.#H^GHR?L:.=PX)0-6@[UK$KC"FP:%<]CH,C!!/HRR8\#8JA@3@
M.:R8;#,37PA29Z9/[;+K.=F)-C9@^&:$V@_I/V:[8T@K)<T<H_9$U^:FP:'Y
M[?5IA9Q`6"Q2O<$(YW6=#YB#T9PRVV-3LZGIOII-^#UFPMCT+_5Z,NK2#`C3
MUNL>VY)-ASZJ9%,+.<!*>N(,G)(#`0[)P_GCG2/XX^0;&9$#`1SZ2"\)?!=5
MNZFSDKZWE'X`E^!,O-8S"BNIVZ([:5?)/GT:^]-FUE,JX)0>"'!('LX?[QS!
M7S*OFUWZ2#?'3`QU\P`NP=G=0#?KMAXW]^G3V)\V<VP#ZJ`W]\C#^8\+LQA?
MAWO<[-)'NEFZ23?LY@%<@IAWH)MU6X^;^_1I[$^;68/`OIM[Y.'\^:A!`V>\
M/C>[])%N3@@9ZN8!7(+(<J";==N^D7OD:<Q/&UFCN7[*[I&'\Z?Q*/[,)HV#
M,'?I8YV<RJ%.'L`EB!.'.EEYQ\4>>1KS02!5*N4%J0U]`D@E]5(N0&/-&D])
MZT\G?L_>-GGT4UE6I^$IBN&#IUWZ.'A*!H-X1)/(R0-/.^1Q\'0$?P"(FI$'
MGM;TL?`45]\0SSHVEB0W::I.0TEM>@^4[-+'0<GA)D'DAYP\4+)#'@<E1_"7
MS.L2ESX%2K8N.04E3W`)8KE:SP%0TN?F/GT:^V%0TM/S>N1Q4'($?P!S/C>[
M]"E0<IB;!W`)8KF!;L:V/C?WZ=/8#X.2'C<[Y+%&YLR?WMZ=QI0^?[OTL:*D
MB5\4OI#I:?#G,4N//`[\#7<+8C5/DNV1QX&_$?R9[>8>\%?3QX(_WEI`B44L
ME"TQ$OH-)]\P0D_)I+P#3X\\#JL=M4E;Z$0PEI(#D.:LRD(T!->]**E#'X62
M9"I.2J9Q$"X1]<`CESP*'@UBC/@'.?APD:6/Q45,-:Q['^SU%_R<P8C'+J-3
M]<$37$*HJK%D=,2,IA'QH[D.?1K?@`<U7@,6/ACGDD?!N$&,)?.&CDL?ZU%U
M)'2XWMCAV$H1SKS&=^F^-[RX@W0`8^F-ADR.@XPAFQVT".V]8AO&+`2H9)*&
M(RRVD>2#<9,R1#PPOC2"\KC9I4_`;P,[[@`N(0!ULN.:1OW8Z=.G\0T85D.S
MOD<=\@3$YNT][XY*D'I=Z](G0#6O#&(ACQE"@[&^(7KD41AMB`<T"NNGSAYY
M%#@;Q)C97NM#998^`94UAN^@,O$-X8C*Y#%AE'<`Z9%'P;'C5O"6SB3UE\YJ
M^OC2F;0[,*MD(42[])%*^T'^#ZM\LXD^+:+/^<-KL;F)?GE>?%R$)=5H#D3R
M`L0.?1Q`/+H9M;^,AM\R>G"B2QZ'$T?P1QR%C'QPT=)'HSC'6<']'<[E$[M\
M3J+%,)<@:O-O_NTO`6+8^$!CASZ-_<`2('#R84>7/`X[CN`OF3><7/IH",G]
MX21$?$,.]E7SE^L\+G'I4Z"D%'XHR8Y"R3"S(*B+O6=;^`N#_5S2(X]C/MSY
M&MIYG._2IP#+87U\`)<@P!O8QTW;?D#UZ=/8#RP,]MWLD*?`3%\/&U(8]/C;
MI4]!FSY1V$+)L#0:(_;-TB./`YW#W:*A8C_U]LCCL.<(_LQV<Q\$M?0I$%3&
M'@C*OZ$Q0E!Z0B;E'8YZY'%(]*A-NH5!P?P05$S^PA?7'I^LOR'^$\P/*<7D
M#X`'L4;HA\M%/5C2)8_#DD,8([Q"#CX0:>EC1WT8?FO6W<(1O^%)$JK:H9%]
M`,S21X[VYM;8/]ISWV@_@%D0;0GO&3\']4'!O!A/3/D.V]QYVLT:Q'G<[-(G
MO-]UW'SR_6Z82^@%:Z/@T7H<9][8Z=.G\0U5Y&S$^(#;I(YK[AS`&#&3QZ,N
M?:Q'4^KON)*+&QH?JUEH#.2QODL?V7/-K6-Z[@!FH75Z)WNN:=3SLT.>@MQ\
MQ@X6"#T.=^E3()M/AGBAV!$Q-+3J&Z)''H?5!@2\QE3]W-DCCP-I0Q@SVY=]
MZ,S2IZ"SVO`#T-E!@=!CA4/R.%AVU`H6=Q$9B2,;E`079<$DD#31)<3A>QMD
MYV,IB6:)W\^,#NF6)^XZ(%1_*SK<:=-LRFN.:S3;Q)H=FG'G7ES"AYMKZJ,Y
MON;;W1;_]8A[^.5_ZLW:S)YMQ6:[RU8K<XC:??Y4;#;F``Y['((PQR'T=Q,=
MH-[17"5%HU__/#O<?"AFZ"KNV[<G["H\BM/K*G;"5<@2=1G+4[8\\90HNU<B
M3$2(8*<]];&JR\7G^<J<N4"E<=:,ZB6$=6P:./[K+"[*L2*+$UJ?<8H[(&HK
M?LESW(@\CT2]!_7,3HSK8R_TSE7ZZ\?LOOPZ*Q\``#6?P+%49S#`#15:30@G
MS7Z:+"5V/\TO^_4:MU']SMWB^JZW;\)Y@C#HXGU5>^=2G<,A:9W63R)G/9B[
M-E3".4,FMAL6Z$TMVX/;_"?K[IZ+;:?G3^HS1R&V8V%O$A4IGB#H_][S1!*E
MRI]$^8DDBBQ1E[$\9<L3+$Y%L^DNX\3N#_.Q/3']QDV;>)Q<G5"E3&YBSO'`
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MFWR;*AG<O/56)>'=2V\I2<(;Q-Y2B*<P$XB%$XI03D\Y3)`TN,OT+>Z6>T*7
M6*5A>U&)VY4'6R0LO`7S+4W9":-3<%O8I@PR=%@.1ID*1P]CC(?E8)R%]\:]
M98+&)UH`'CK!1>*I&\$6"0WOG`V]$0^W"+90N,0ZV&$)"V]]?0M!>,)S>&I7
M6%+.67@'[ELN3GF.QTR%K<[EJ0CB"3OA%YZ>BF288(9WC[X5>I_]<(LT8%-(
MYI_^?GUU??5_I*R<4`T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HY-R`P(&]B
M:@T*/#P-"B]#;VYT96YT<R!;(#DX(#`@4B!=#0HO365D:6%";W@@6R`P(#`@
M-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&
M;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A
M8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-
M"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T
M(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*
M/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"CDX(#`@;V)J#0H\/`T*
M+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@.#@Q,@T*/CX-"G-T<F5A
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M-(%1A'FH';J`43)]]0`B(4&*3YOW[_ZDY86Q?OKR_MV''Q_OBNWK>7?\7%R?
MZJ(^/.]/7P_U\5H\U^?=:7M7_/?BT_]Y_^ZC9O>_%A&*L(Y46A;]*&[E(D2T
M<GVIBVM]/NR.U;5>6@**RE`OS.F%(M'P+_YZOB\^'JK]8W5^^&^7CF+NBI/6
MU%FKJSH6CZ=SL:E>+W6A#[:[2_6PV^^N7^'LX:N6JKJ<CL7I,7[:TB/"1`](
M+_1F0!0I;$<D"&Y'M*VKZU-/L.4E45U1"*&E$>7#Z?6\."]6=GDA)H6;2'-L
M)O*QVNU?SWHYG?33C_67>)TOOKHT:5<JZN:"(NU:C%#5YW-=MXOI7.S"]>$7
M?G?9F:7V^73:MI.WO&$*);S@8)BE:J;NR^(66&+<U1%FS@(Y5NV\79ZJ_;YX
M/I]^VVWK=2P&*3M)BGK?R`EN1`@FY<M.6T]U/+Y6^^*AT@9_J?;5^:O^T[8`
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MV+%2Y3WG4MO#/]N<JVQSKN*[IUW]6/R@C?ZXV6D_]U,S`ZMX'"I=@&0^_Y,V
M+S5NM?@/S;[X^5Q?=`@X7N^+3]H-[HZ[*P@'[LFF5C!109)6["X%,?[S8CRT
MCC>'T_'Z="G^@3BJCUM(>+_7GOKPH,='\1UX@%)?TT>-IW^]G@[:]VW`$2\>
M_G0*;!6@B#91A,UL?/C3\IQ81]68"]DL,1-9UIA6L*!F.5/I7)!->TS^5>TO
MQ>MQ7U_T?.U,)OU<G77*_/AZ/NXN3SKI@6#7Y-A5<3Q=80WH>3Z>CHNG:DPZ
MB=>=!YU4='2#F73AB&$>*`=&7!CMF`V&0CKN?[WH/&C7^"*3O?[^O#LW:4.;
M4>A_C\8B[KOVL,8$(V8G&$F7V3)1EM9N?8:DG>9S?;PT@H)!$GZ'$+HS%@F6
MK%?`?O=Y][`WV;E>DCH0%0^GXZN^4&V>FOQ'C_#U&:XS]`^DW8,^?]I=BIN,
MX"];37*"AZV@`2E+JP',_1I7K0(:\9_W$%2WI^>KE@6&>ZATU-7_-GDA3%D@
MM#XY[*[7>OD@0TO9$1F;3*\5F<$QR`RYY^6U5?C]TJF>3L6D*%=-]21'=H"=
M:**S#M8,\%.XY?/9CEY(;9H+BQ"6S&9S>M47PL#B]LY^BW_7;J473T\X[0RG
M)+@9SH?7R^*<A.AP(D2ZE<$9:E>S"8:GUZLO<GP#BV7Y](1W1&&$-^[Q@^&Z
M_.:S.VYJG'Y;+"EYFP#>?V-RC>>G,_B7-;P(I?&*_;"*:O7]GM?*FM56WAT7
M4F[/I<IVS_4-F-Q6[Y3!$VJGOCMN]J]Z?U]I#ZDM$1*[A[-Q_FUD&S);'4$V
M5[.;UO:HKU9[G3_HARUOB[@SH*XM+L\JU!UX`>>F15L2:70%F>N#MDB3)^QT
MU&@4:36RQEK%KIQ'&?:5&MRF=7H2GG26?&GJGEN]=SM?VMQD<SH_G\ZF</&L
M#ZZOD+S7ESLSM:]'G64_G<Z[?^HAZ(=L]J<+5.I6&`4#KXK_D*HD*W&'%48^
MX%)IO>KF='PT6QI8[[NCMON#R0-,4#$SN:V;N&2VZTW=[[&"C<D*(4=/<:EL
M*8R6F+;UGZ<5LI$N*V2225NP16VL'LZ+UBB8>$FT#V9]>VNV_C`5YQVX'=AT
M+N]D2$D[DJRZ-(G"759^R';`.U,ANERU@;:%URUL0ZXN%RH.KY<K**5ZU(MV
M:Y+;CFD;+_Q4_0;^_+':+!^ZB7`#6'GC3%%'5:9&96SBM/P.'?]10])Y1L?X
MI&QK`3!1J_@422RO3I&-$M6F`H>ZOD(P,_46[6P6%P$A)X/6+$6P1_WG2IL0
MC&AWP/^%G@W@5"\)UN[,EQKL?DA;L#9?;:7'KR[2N&WZH=+YF`XSNVMD^U^J
M2_'Y=0?)E@[1ZVP$L.H(OW:ZRE&'&<'([1RYK9E_`Z%Z^[JYWA<_/JY<6BD%
M=_;B-^F(MZ*$Q4V'$6Y7R0B$[(BSYB842]SA1$0'"52VIM0%W%=9=43OA+T0
M*Z\ZHLKNB*7/]+D=\-TW3?VJ*1,=MSMCFL88]5_:0NGR.;+B?]"D<]1=7DCZ
M=@4J'/[;E.'U:/?[XG-]K,\Z_3K7^UIOR.]L]5`GT-=]L_]I8==U:GXE<R5T
MZ;T$8ZBMW5YJO>>ICCJ.MC`P.$@#..RU'SU>=.JX!\N]0#(/LUH=;)4)_RLF
MUR=;U31UW)NE35C[0`WEX=I41B^[WRVPH:_I1^[VH)NG:AT/13L5;.HW][)U
M4:>'ML39&*R9NE-3WU\>6I5.G'73)LR[`T>\$]FYC>Q7O3\(*A50GV[_4)NR
MV?+0!>M(15$+^.H<XWAYW5^KXS6[CGL;Q&5=E:^;3T$%LJ/U4I4^BVE7V[\?
MM_5YI$:TN-=2?B$8$-OWTQ%&I>M;J\[+9RJP[_'&!\FFTP:R\'ZUOYR*T\-^
M][FZVN+:MCX<=X]-(\H:#@$SE_%BG^(+U=J%!="O)FSMM=^Z%O7OU[:]T.2_
M)G^IGI_WNXVIP>^K+_?%#Z]G\"#+SR'5V;`7FA#LRUE*8#>%S186EM)V^3!+
MNWK3\=])X.(_E/.VOYEX4O\.[K^^@%<_5%^+BS[=&O^BN8*E0Q2`-%[OUS=:
M7-A0K3#10CD$"4L_SZZ=K8(@IR/8`433XG]YVFV>"I.^O.ZW4#"P:W%7;Q?W
M3`(50B!GF-(7*8E"RC7[_+4Z:Z&(-MPU6GU((,.*K3Z\=)R@>];[`J(P&6KU
MZ??W?*_=P;_MZ^.Q^'A?_*W>?H&TQ/6Y0(O$#GHAEG>A>C:\[*O6NJ#-Q[)2
MXKY4'-N.%RR$W5DT'2^_;G:02C[N-K;EY:Y10J,%K;^/KBO)M*2L86&N'QD+
MXJ94"+L3=5TP:Y3']6KU_-?,_%4P4()+GT0JVX4$<'FC_4;]$#R"T<,?OMV=
M?GZJSH>J>'B]Z)SSL@KX04O4D7?5]4JE=*Q,&Z8#SPBU76E?GD[[_=?%`Q)8
M2LMYW50:WIGPZD2^"88*6^4X?8']P^7U04_WKCI_O2N^_UIMM6'^"!ZM*5+I
MO1&LCW__]<]-P]:/Q\W]G0Z(/^Q/Y]VV:MK$UC#1MF%9E?=,P$L+UIU8<#-N
M30,WVWC7Y<,-<^*TQ8I_$$+6V&4)W\I.B`^LI>V5#-KN=')RZ?75R3^BIXYQ
MY2=HW54L:$<IVH=UFH!(FQ&9SJ59[6YKK%_7[][Z]S5:ZJACLW)'7=D9#U*=
M$A)3>*RC#I/DEKKU[)A!@&F'L:(=LY)UM265[\P0MM7G,O1VP^Y2_`M%:$+;
MW@KKE2OBZAM^G^8RHIN-@H1W&P5[);5V:$&?X.2NO<6W+JP[3E223G71]F7?
MZ!1<HQ(.6B]];=J_NU1*FX7X1L'ETU#DN`<%IL5;$F&8;3?\K.K5S><+__SE
MEXS6DN^>+WV?-26V"I75[[BBE]-YOA5Y32^G4Y*.9E1G=U&6S'JYP5Y.;=U^
M^*M8EJ!^VH33`5V>C>CHP/1QMCM)WOKYSCN$R]LO'1@C6YZ-<FP"/[%\6:?4
M6V$^]*8&;$"69Z8Z<T=@7^832]M?[[HG%^>N3<1RAPVH?T7+O:$%Z-4:$8?X
M.C_VL!*QA?Y;)7[8_2U?75,=>;!DOBF:VW;YM5J_L1(=WFN680CJCI)P7X.6
M%LOK=WXO_QH^<T*LZ!&I)K-LS+INS>K#*MW6>@/H%;MR)P'MK-45W2T5W+%9
M/IL!$($/O8.UAH>E9=?;_-$>%MAU?)WP6U:,O8/]([T=5]XV5`G;:.6J6MPF
M#*;U:;WD$(KQ5H85DT-1XJ[R5:=J4]JJ3?P&Z1JQSKT_A[%PB*DPQU\Z+]VO
MT]<E94>`5=NZ$.YPHIW"H5"E7>R=MJ[E&]B\JE>,+=`G9]FL'ENP%!V=KMVE
M!ENVEEF88R_.B:"!J5H\BA'BM;=\%"-$=>:&R,Y'!:3M=_ZO:.F#[<L?8O",
M=%T+]F4LJE@WH\SJZ.NWUZW@F9E_2990OPLIJ46F%NKH:\N/MI>OWGU^NM;Z
M'LAWL#2(I^%COP7S>-KO3U^:#W3IU=)IUE[^!0'5U8(2'H8VQV820<PU"J$P
M`Z7K#(#4UGT]@*NXR[)1S1H]_%:&%3T1UILORR;.>)??SV+:9;9FK01CU9W"
M[@<@2EN8#-\J"NT&K*5GZ1=HI]-R;%\WT%<*M?JM-HAJ^7X1S(9G97'DBF/I
M.,5)P^*\*/VC1D7+SNSCTN]NF'`OBIJ9`S>HI[H%5/S\0Q?;N3Z\0F`PT7$-
M%\-=\XGJ;/XX;R5LN^P,IM7Y+&+L>9SWUJ?FY<UC`]I>ZO-ONTU]B1J`FZ^\
M';<U-._!WD)G`-=SM;GJ/\,+GY_-QVT6_^Y"J=QX\S.>$0B%M>\KKP6AN.>O
M`:$P]XHN,NVJ]N-@]OV#M[J+FT;?T:;;#J+P_U,/K)XYZM]\E;[9C#%;`XE:
M8(?Z43N#F]J7FMHFNOB:+?66R0X]<U&58[4_K5C1OF]([Y5RG]A"G+7^Y?L?
M?_GXW:>??BF^^^FO/W_\VZ]__O3C3W];8753XKX%)_QG&'0<[GP0I9-8FE5W
MJ76TU=YLA>^_P1[/B\2H?X="2/<.!2R#ZO*T_,M=O,.;F/>.W-;,?B.TKIOO
MA)V>3>2IOE3G[?+U'ZJZHNC]O'_-SRP<\YJ?#CWU]JYXKG9;$QQ`E,8&[6<Q
MUNB6U5;173/^TT["'!LM;7=Z2Z9CUO**$9QTV9>M8CXT(7AQ;GJ/X[G1SG>L
M!,/V#5E8CJ:M!$+V\F\!@!-&TG8G(X9\=[)L5T+<1B=6>(5#NTHK!NB]\W$H
M8M&N'\R'2;?U97/>/7<;I-QR6/X-2>2D6K$B3+2#MFQ6J`BILJO:#JYIM]+.
MZ33>YDX[8--U5ARK,V3`O]6!UG>'@PZC.LO8?PUJ`E!C`/^]>),,O*1R0S^F
M7`(?$RQAJLQC/;WYP#GLYF$'"#>0&S<(HO.-L1LX?+QZ[`:&)1V]@6(QSH)@
MBD=OT+OU<18(WM8>N8$JI$9'024:'P4MH9P^=H-`:OP&COCH7%"&Y/@H=,Q6
MHS<0^(K]V`T82EMC-^C-*1J[@4BEQF\HU;B01"@Z?@.'%X;&;F`*CXY"+_IR
M7$BB;7'T!B3%Z`U82<Y';]`<QF\H)1UGH6/D^`U<L=%A8J;&5Q2F;\P%UG%@
MG(4>Y_@P$=0M1V[0.?KH**4:5U.I\.@8A1S7`8?OA(PY%UF.FZT<'Q]%8I2>
M(#;*'Z,1_B_M+;Q1D8X6_?"BX,N[-KS@.`/2M&X?RG&3>P`V:[\7^ZGI4GPL
MOCL=8<,<9AK-8W[Y-WCD%PAW?P&![CD\MM3_:4I>[G3__MVO\'@%[2[Z/YB6
M\,L<\+DN>(8A%XSJ.XFD#3GV9U.H#7-/#&<2=6CC7QBYQ;8YE7@ZJ6$SB:>9
M`:;MFS8#+.!S[WMSI/F;(YCN]E!OD."SD'M#TQ[YGSCIJ\(\O24ZV,/>4V&Q
MM%SU#2!*Y[$^#6EO"\5D]OX^Z8N[C$L]ZV7:[EU")M1@'XKK]!=Z`J!0^K?J
M$(*K-W2JL%-J9WS=40M_R)U:-=E4O;94!WO8?ZSP?'FD'/^+,_:V6%+L--LC
M?O'762%48B%/-6CR<*7PEC9+K\W.J-Q8X4T\=RB\-LNIVK14!WO8?VQI^<(-
MMU:IO2V6M+04?>(7?YV:'TM)6ZC:9^LTQ7W?";<[I!]@-Q%O`>;P,<JDKAN?
MJ-8@/IH"Q?*LL+3&)SE`QNW7Z:G]QHK>AOX,-9$E&</[_P1UOC+1Z'*@S77>
MC$%*YKM$;-O9A^\&REUO,AK]]!=RC/H[VEE/1LJ[1P)O#7'?I?<O/>!RV*IA
M/]A:=6!=WN88]8?$FC*03;7JENI@#_N/=:$$;KCE(^UML:32676/^,5?UT$H
MT4<VE&D^DC`7QH-1^;%*[]>DBSA`-E6;TD6<YK#_6.?QX(:;/E*ZB!-(ZF)Y
MG_C%7V>`F"8:'),=LX;=4&-OOUY/F__;K_3,8<2<P2EV+X"Q,8L_WR@@SV#%
M2[=$`M0XR0*EBZO!W/D95=YJ?&H"9%/73$MUL(?]QQ+'U^<<?0ML;XLE]7&U
M1_SBKV=8H"S3+5!1I\WNJ-Q8*>7^T)D=D$W4IJ4ZV,/^8[GE"S?<LD![6RPI
MM11]XA=_/6>U0H;:6J`V#`D_`&0,XZ?G86A_#BN:9H-S6*D4&YS`;/2]!78[
MY.*)!D_;[/,0+16_@!CVA\BN2^ISZC>7:$MUL(?]QV+'%W[Z\8;!V]MB25WV
MW"=^\=?3#;ZA3#-XVD;]0S0J-U9&G`88=GMGZG.9M[1IJ0[VL/=8XK9L<,,M
M@[>WQ9*ZK*5/_.*OEV4A9"+XS5$WA<<&UC7[YWZ?XAPV)?%L1ON99C$1GHGY
M:9>V9^[CRRM\XWI)5K`TK)\4]_`60+OOD<1]N&H#7;&_U<7/^X%.^9G,G><$
M$)*UX_RN^\+YHHJE\W,8>,NW-<*N,71-1/A#E_<"V50C)"[O;0[[CQ6>[^U*
MB[TMEM0E+GWB%W\]W:4UE&DN#?:B3IN=4;FQ<L3](?/:G)P16JJ#/>P_UKE[
MN.&62[.WQ9*ZC+!/_.*OZ]6*!_4YLEP9[$R%&GLC]KNGZOBY'GHO=A9CV,1Q
M_S'QML3SL[;)(8N<-T;IJSP</C?M71"RS1#_4>U?:P-5+\L:=T,&QU2XD/'R
M6NU-$]C">O7E'NBT0&T?TH?OZ\?Z?%Z:&]`FN]=YXT.!?RU;3,74[';'SY<)
M#H$CES$&ANG-%6-_Z#)&()OJ$+#+&)O#_F-=Q@(WW'*O]K984I<Q]HE?_/5T
M]]I0IKE7CEW&&(S*C]4C!-RC+1Q/SABYAUNXAUNZC_5%?CX"MW`/MP22NHRQ
M3_SBK^O5FKJ9XH1U:Z\$^R^_$^MX_KS?%S^9MP1C,YG#&.>D/7,8L@72'NX!
MINZ,=N?9QVP/,/'I`!/W`!/W`%/P6.'YWDY[N`>8`DE=VM,G?O'7,^Q2I:<]
MW`-,P:C<6(6O2@N_&>;3`2;A`29!AQ_K"LMB!&`2'F`*)'5I3Y_XQ5^G2F?Y
M::M5=-`*Q>XY:]\)__#I!+^`U+.+.9R2RBG#,RD\J!!HU.O95\2%WXB+Z:""
M\*""\*!"\%A7U!8CH(+PH$(@J0,5^L0O_GJZ78A$4"'JI)`*>B>$[2Q@[FS_
M5D^":9OPE.:,X:E-%!'?YK1#WL+\4-6X!?./?M%2_X_[#-#_Z*5^8MMV\LMN
M\U2=M\5?[HMO:WBY)TUQD,MV!J!P@N84"FE1FNYBUGQ`=^`MM?+2UU-#>>NK
M:6^I18?Z4+8R12TBI!5):HE8MZ>Q6LILM91SU$)%*!N=KA:"2$A+TM02L::Q
M5E^,/$8ME"9;6D,Z\#4_2N\$2M02"T=*98*6:!G2EFE:BEBS6,D6^,U:/`UE
M]N)A*I0MP4D31D/:-#?=8SW@I@W:"<A'NEH8FZ,6&;A!PA,\,.$HI$WSP#%K
M.>"!M3R-3;%TFRK+KDUURM_]]WG?YG(;"^5>^T6:ZE7H:F6"ER<R]$<RT<M'
MK-6`ES<H;YZAREE>7LE0MA0OKT('I!*]?,Q:#JA%T5Q#572&6BAE7=DH0BEJ
M"1V0BAW0N%IBULUIJ!8M3ZZAP@>+!X,?9G=4OK6OB;3$4"BJF*XE2GE(&_NC
M-[04L6:Q-[00;)9--939BX?34#:2H!:&0]K85[RAEH@UCV.GA<E@DX+3]6)(
M<_7"L`J%XPEZX:%5\-@JQO42L6Y/([UP\Z="I!L5PWAJ])O`Y2:*!LAX7O1C
M)+`V1A(2#T902)N6>/18#R0>!A_,LM2&,GM%4AG*EI`4,")"VK2D(&9-!Z*?
M05SR++4AS=4+1X&U,980_A@-38VFA;^(=7L:Z86A;$M58JJE3N!R&Y!AN9;*
M,0K'GQ!3.>(A;5I,C5GC@9AJH*8L2VTHLU<DH:%L"3&58QS2IL74F#49B*D&
M@\FSU(8T6R]A49*3A)C*26AJ)"VFQJR'ZJ&<9,=4+B?'U`E<;FI?9L=4'M8T
M>4HYE8?E5)Y83NVQ'HBI/+N<RF>54T58T^0IY50>EE-Y8CDU8BV&RJD\NYS*
M9Y5315C3%"GE5!&64T5B.35F/51.%?GE5'&KG,K*.Y6XHQ1A35.DE%-%6$X5
MB>74F/50.55DEU/%K'*JQ9H"R(LE0%Z.TIR11,C+43>G)-`)X%8D'_)R7[M!
M!A%L?\/-_0[F+Z>'^GPMOKTO?GVJGG?G4P[BY>1O*V\IB)>G16FJBUGS`=6!
MHR79B!>9B7AYV<H4M8B05B2I)6+=GL9J*;/54LY1"Q6A;'2Z6BS$%2)>T]42
ML::Q5BWB1?(1+S+@H@F#'U#+0;R\J#)!2[0,:<LT+46L6:QDBWAE+9Z&<B;B
MY65+\-$6X@H1KP2U1*P'O+3!K4@VXI6O%AFXP1;QFJ@6CD+:-`\<LY8#'MA@
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MA*3`0EPAXC5=+1%K.A#]#&R59ZD-Z4S$RPG'$L*?A;A"Q&NR7B+6[6FD%X:R
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M6Z9I*6+-8B5;2"UK\324,R$U+UM"$+`86@BI):@E8CT0!@PPAK(AM7RUR,`-
MMI#:1+5P%-*F>>"8M1SPP`;L0OF0&IH.J8US&874T!Q(S8\_P<M;#"V$U*:K
M/F*M!KR\`<;R#%7.\O)*AK*E>'D5.B"5Z.5CUG)`+8KF&JJB,]1B@:P04INJ
MEM`!J=@!38+4'.OF-%2+@=3R#-5`:D/!+_\E,B^JF*XEBZ&%D-IT+46L6>P-
M+:2695,-Y4Q(S<M&$M3"<$@;^XI)D)HCYW'LM)`:RH?4LO5B@:P04INH%QY:
M!8^M8A*D9LG;TT@OW/PI&U*;%OTF<!F%U/*BGP6R0DAMFNHMAA9":M-5'[,>
M2#P,,)9EJ0WE3$C-RY:0%%@,+834IJLE8DT'HI_!Q?(LM2&=":DYX5A"^+,8
M6@BI3=9+Q+H]C?3"4+:E*C'54B=P&874\BS5`EDAI#9-]19#"R&UZ:J/6..!
MF&J`L2Q+;2AG0FI>MH28:C&T$%*;KI:(-1F(J087R[/4AG0FI.:%2XBI%D,+
M(;7I>HE8#]5;#=B59ZD&4IMFJ1.XC$)JF98:UC1Y2CF5A^54GEA.[;$>B*D\
MNYS*9Y53+9`50FI3U2)"VK28&K$60^54GEU.Y;/*J2*L:8J4<JH(RZDBL9P:
MLQXJIXK\<JJX54ZE,GE'*<*:ID@IIXJPG"H2RZDQZZ%RJL@NIXI9Y52+9060
M&DJ`U!QE[T<@)R!JCMB<RD`CF!4R&T^3[L?9,?:_9-W^,OS_K,[GK\7_OB]^
M.5WJX^?J?,T!NYSL;=$M!>SRM"A):S%GWM>:]K`R%^F2,X$N+UB9HA(1THH4
ME42<F]-8)66N2LH9*J$B%(Q.5XE%M0*0:[I*(LY4]%0".)7,1KCDH@"7EU,F
M:(B6(6V9I*&(,R-]#6FOFK5H#.%,<,L+EN".+9H5@%L)*HDX]QTR`%0R%]G*
M5XD,?%X+;$U4"4<A;9*WC3G+OK<%P$EFHUIR,J@USF,,TY)S("T_]`1_;C&L
M`-*:KO2(L^K[<X"E\DQ3SO'G2H:"I?AS%?H;E>;/8\ZRKQ)%,TU3T7R56``I
MA+*FJB3T-TJEJ"3F;$Y#E0"0E6>:.J@-ACAUIT>1@V)Y,<5T!5G8*D"QIBLH
MXLQ07T%4Y)F1(9R)8'G!2()*&`YI<9)*(LZ<]E7"B-ESY,%7V3JQF%&(7DW4
M"0\M@;,4G42<F]-()QS^D@M=30MQ;_,8`Z[R0IQ%BT+<:IK2+5`5X%;3E1YS
M[N<5@#UEV:8AG(E9><$2HKX%J0+,:KI*(LZT'^(`=LJS34,Y$Z]RDK&$&&<!
MJ@"OFJR3B'-S&NF$H5S;5&*B;;[-8PRJRK--BP^%2-4TI5MH*D"JIBL]XHS[
M<1/0IBS;-(0S42HO6$+<M+!4@%)-5TG$F?3C)@!->;9I*&<B5%ZRA+AI(:D`
MH9JNDXCS0/D2D*,\VP1X:IIMOLUC#)S*M,VP!LE3JI\\K'[RM.IGCW,_;O+<
MZB>?4_T480V2IU0_>5C]Y&G5SXBS&*A^\MSJ)Y]3_11A#5*D5#]%6/T4:=7/
MF/-`]5-D5S_%C>HGI<E[0Q'6($5*]5.$U4^15OV,.0]4/T5N]5.,53^A%D\*
M(8H2?F=OZ-?7!,20&QD+XD7[X[;H'MX@V]QFP4DF"[WJ+7#4<F#AK.J',VH>
M3LRS_4/,CZ>1XD^*X]'K6.FT:.P&H@@:O8$J/'X#>^L&KMBX#$*)\5%(A,;5
M($LJQO54"CFN*$35.`^,\1OCP`3S<OP.BC$?OT-'X/&A8([(&Y/.*5+C=PAH
MGQZ]HZ1OZ!Q+BM[0J:)T7`Z"*!U?/`23<EP.0DA)QN^@6+UQ!R/T#2X<?HUY
M]`Y!R/C,:3G9&_J0I'S37LMQ.?2\O3%S%!,Y+BD%E8W?0=^:.<HH'=<ZY6^M
M("KH&_-"R[=6,I4$C5NE=G%DW"JI4B,ZU9[ZXW^^?_?^W?\#F$Y@,@T*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HY.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#$P,"`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N
M="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q
M.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A
M8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*
M+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO
M26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*
M/CX-"F5N9&]B:@T*#0HQ,#`@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E
M8V]D90T*+TQE;F=T:"`S-S@U#0H^/@T*<W1R96%M#0IXG+5;6W/;-A9^]XS_
M`Q[ZT-V15-P($-LG)U%:IXW3M=5I=R8OE$A9;"52(2F[[J_?<T`2I&T):FQQ
M.M-()@2<^^7#X9O?S\^^G)_1B3(!H?B?_11.`EG_;[$Y/V/V"2-<$:;L7SC1
M:F(,#TE(*3%&DB(Y/_N-9'8K+0/<)PA#_(<4M^=GJ_.SY;]Q)_RO]P<ZD5+`
M_A,I`@'_",/YX^=&!OC<"(W/PU")_1MR,A:A,4`1HP26265I6EK^ZH>A>RA4
M1_";V?G9=^^C^<)R-X,?6#G835O.&2>,2DIFP/NWG[FD_R*S/\[/IO#3_Y[J
M`"."`?=7W?[DI9N+`YLK,`$6VLWIA,E0D]GB_&P,2J4&"+J',R\S\B'*=E'Q
M0#BEP8CDNX+,\ZB(2;XD<5HDBRHO2A+%^;9*8A*YOY%%OMDF61E5:9Z1;;Y.
M%P\3\L[]XGZ5DZA(2+0N<Y)LMNO\(4E*`C_,E\MTD<`2.&%G_Q)E#_CEU/RC
M\BAK^.?<<,>_QL_(/[);[N9E&J=1D0)]<4ZRO()S%DEZEUC*RF0;%5&5/.8X
M*GO"F)"K/#LU^9)W]!L.2L//?P/1X].?I'J2HEH'K:1$`.YO)=6JL&<43DCD
M&SZB$'"V24$V>5:MR"(J5_"\BM(L*48@QG@([8:A;*U;R]!I%T-2K=TMJJHD
M54ZVNV*QBLJ$E"NP2FM[J'M0*1!,RBI?_$EV60P,5*N$O'N(XG1!+K,J*3*K
M[V@]@J^+";G8)+`LMBQ=)V45H5MPU,WTRRZM'LC;OI7\LHZR"9G!ED.PK[13
MF6%.91P_(_O`<%ILH@R91:ZB79Q6EN6TJD"3C?[`D,&<8WAF^23?A(=5"?RO
MU^`A)S?V``38\C.LL0<TZ$LNU,I)3IO#QF[C&`:T(DDW\UU1@MJ7N367M!A$
MNP%M0Q?EQAEW@)^1QB*)2M#7?)V0JHCNDC5HMJS0*]?6)L'H(U!S%D?9`G1?
M-6$=[/:[.GHW5K!)DBK-;LL)^74+%OM'GF;PM4L$X+U#*%SASQH6AU6X8K(G
M3*94EP=,FP>?*;QSCC:(#*%B(5QVQG5M=J9-=NK'+4%MB/6$+U`Q.'+R5U(L
M4OC!MH`L2Y(O.W!IV`@#P!+B`=E$Q9])1>ZB]2YI(T.]`>R$7V+,=?#@MHBR
M:H]5#"$(+)`:07#6"8(WD:PQ1*1NG42Q1TM]D06/179R>0T@"&U,*PA#.Z>7
MM''Z_2J"*BZ"L`R1.BE'A`>?*53Z-:G`6"L:$%-%=JA-^[,1E&@I!H\5QK1-
M5"MXFQ<V<=G%:=;((\T@T:W7D/H@P.1WD!LB"'Z[XM02T,(X$0P;%+04?6$'
MJBX?OGU(HD$L7(>\C>:,N_)**OR,BH5\F^8QUJ)_@&6W!MC:^<D)4LI1)&O&
M/W/.3WZ,ICW&6:`[BV;0$5K&2W#*#!+0#E)6F11WX(1UP=2:[6T"=0<8WP.X
MZA;D0998<Z*>2K(L\LUSA\"6`AZO4[#3M':8Y`Y,M]V_KMV'4+(*6B5+T<5S
M(YJRHNN=$G15**8J2]T\N4VS.KXN@?+%RK(W&B+M<BB96S*']3`./^T$0DWH
ME"^4T0?KK/L4(IGK++JJ=%^`Y\'AG#B$>F78J=>U&P$5C0_;K#"R#2UDDYQ`
MTQBY@#J/L&)LXG>VV\P3[(3K&ANX6D75(X^WMMK]H*[=XEV!1H)_V**(8OQ6
MF\J3P%%&FT%:#BW:+E%0)IT(0MU4+)@V;!HI\KNTM`K#1BD'FE`S6:W.$CTP
M3LI%D<ZQE9I#2IF\F%P/=J,9&Q2[<?N_C/C0*VMEVNZ6F\!%DT"V'?GE;/J1
M,/;HY'JCZQ]PHWNDX@-\XI,`-F/P?]A-==_6YV<W)R%6B1ZQ5&A78'-G&!-R
M,WW[Z_7E['_DTV]7T^N;'R]_(9_>D[?3Z]G%Y15Y,[V:OK]\>WGQ<_.<7%R]
M(Q\OKBY^F'Z<7LWLU^OISQ>SZ3MR,_OT]J<?/_W\;GI]E'LE^MSK0)^>?=25
M;AM*)IK(_^W'B]D,&)G\0P5IV9"HW+>OH]#O"BK0@[J"V_]EKJ#]XFTP7C`I
MQIC#,9D(&U^X2180&ZL'\ND>JH5RE6XQN+Y-"H0MR!LH(9;I(H4T4C^W0>EC
ME$6W"=:T`T0>Q8=$I56W_Q"HL:+"I>T>/!*8)M%A>599Y&&>K/-[R%70%BPA
MT:V@WH)_-S7X522WD+7:C#7OE)#WE?2\+[.I_&,$21Z*B!&":WI$Y@]U2Y:O
MX43<<X#L%H2N#56F%W%E8V4IY*^[-(:.R,+6MT6^VY;_&2)Q!4H-:CYN_T&(
MYV98XMO]AR!>&CXH\6[_08@7X;#$M_L/0CP=MEAS^P\1,H6[BJ#:J!X6WP",
M;_9%OQ2KX"HI-FD&93`DJFBQR(L:L+U/(9I:;&:WKIL;_-+DN32I4]CT+VB$
MLML$+QTV:8D%-_E,@Q=+[W"!%SH.E<,+Q,F/D=(=`\TIU[)I3J%V//E9$`&?
MLR1/?@P4P#V6NGX;U,1.;XC:]"R1:=4EL8`U20SMIL-4TFRQWD$K-D0Z%>Z6
MA;,NG<JPA;?O<MLKYHC28..(I1CTR_?0*EKKAZ9^V_2TI;-[:"0.0^"VC<9+
MFEX[C(M:\`!YOX\*!(G*;C'TTB4<#=(80@C=S8.076`P00-M-_BSK:80M^I]
M12%`4(#H$D</>XHB2WR<0`EK;WOFL,&N*BM@$L6*O'8U%S"'<2=NZZ@MA"`0
MVRI?-XOM#7RY@^V'$(*[Z."VB&QLDK>P]B('`RBJ%+GN5-W>KR'@L\U+"_#A
M'?RN<B@("`LT!V6\-8=^66FU6W,)Q>.NUC1>[5=%8N_'L,SLB>OI64-(P=UR
M<*EE!P_B9PON^]FS.K)`2LW69(`<;//5@#G8[3]$#N;:X?G"]&Z1FL#W:P:)
MM"18Q"^L!5AAWN/=CVUCZONE*(X+7-:$E]X%,/@3>.<"U'.7=$,LD,,7W^6>
MB8$18="]PH,B6N01WJ,,85M<M3`[[0&MTC0.]DN>`F7D70&TC\C-+H4ODLH1
M^;#;PN=B1-ZO\R*-(W!5J?4$*XMD6Z&3=/+J2:FVP))DT::N7"K7$JXB$$^9
MPZ<FOJ/@]@?X(>0@'>(<LFZ,1;"@O35W.06OS#KH^%$>.1@W-Q-RL;<]O4?&
MXT<1A9N1$68D=+`O5YW<>S5DVY;[T]?GZ%Y\P$$XW)\.NS\+!]Y?#;R_''C_
M@_JU;3&"0MI`IV,W[G:PXYZP(.2Z7L`/+-`8HWP+%(>BR+<@X"ST+I"<^H\0
M]N;3LX`S[C^",2B\?`LH$UXN(#7YN1`A$UXBA6;<OT!1X]6%"!!%]2V0%"\*
M/0L$57XN.`W]1#*<4O`MH)1[%W`P>"^14!!H_P)EI']!8*27"RX-]1,I#/?:
M`_1&U+\`,CKU+6#&4/^",-3>(Y@&H_0N4$9[V62*^BV*R2.Z@)I-^(_@AOO9
M9#AG[EM`3>AETQB_G$(CO4R"&+W/E;$#+@>?!X;Y8VCH9U`RZO=[JKWG<^8_
M'V+?X?._-$N"VF%8[^4#EX$,P1O3)@.QY[/\03>1P^I;1#LZT,R*S.HN>4G>
MYE#-0@__[&J-[;M:@VUU?;=F>E_=Y1KJ'1*/A-P9?'6]R2@7+;@#83=PX`YE
MB/`\3=,XDH])3O*O/@PS='L8"$6Q;N*7L09,N-CD.X0VRA44K5"30LN[B-:+
M73T1"IW+.OV[FR!P5_0@T9OW%S?`C[B>D$\9>9_,"_M2`*.VP%5[9U%>P4P`
M?M@7G6<.Y56G!'V9,<8[%$H&AV=0/D(#6)03\B;!\>G1LV+ZM5JD+0Y`9?=2
M@F"\P0&N\S+);J.B&B'6M4V+W/90OT5%EKB1Q[@=VK305CWX5",F]50,M)UJ
MI!2T)BP<Z8#:+1X-S(Q:@`UV6S^,]L]#GI9U.P34=&="=FVJZ!"0;]"/[/BY
MI=*2'77F6<]DNF',)ZOKR;'Z:>T#*;Z)`IRES01W@W?:GK5NR3+H5=/8.L@R
MS:+,8O0G9EN[&;ANS%<HT8X-P>'U:"4RTO/$&[#*JQQ:==-UD'O)[6WQE,&+
M+,,)SNL$!Y%PG.A]7FS`!D_(H8:*N&5Q,%_&49M.CI1W(_$B:"7YT\T;A^/M
M'>1\I1J#%EM@4G0SG+1]WZ)^,>0=^*>=[A*LCIU/[L&CLMQM&CS:OG&R?F@?
MH>'65^=/AG=;]Z[?4.E9R%,&L8:`JII!H025R',&H3GT9#,*/ZXO^,"MP@:L
M%A,<H+<,?N9*D^=GBOI0I0\<ZLN@]K<NZ6O638ARUF!7=B"RP:L1(<\J'/3`
M]\O`J?_,T,OG#_@F&8+]^*4/WFSR`D><(;"YJ>BG2,SW+V'H8!\=2,?0<Q0&
MU4/#5ZBGF3?[:O7`H2]6#W.3RU2Y"PQI)PB<>IZBI?ME>H2*0S+ET(*U5.R5
MJ02AHWC$OI+SF$PM%/\"F>*AR,W>0X_(5&J'4@:F-GD&9SZR^$:D-<*Z!WA^
M%.@.A1XL1!'#C=%KEFF'U9Z2([Q*;3GRW`Z_Z@C]2&A,BZ8Y0-BI&0';;398
MLCYZ_^[DB@O:$6#HI)I7!FQ7<M*#5'>0YVKZ=4>$[H@]+O6:G:&#[DDI#+L"
M5X3-Q6^95,VXF!W]19N\A/H%JA*\>&@MO:]([*6^QUKP):0>BBOH^1XA8#NM
M7QZK93.A]]5Q!4Y[::RV+T_5J91W+UL(K9O`@E<>__1BR[XD84?<GEU5_!,R
M#PJ=44?F7J&W^.I>_$#U\8,G&T/SS9A[9S)H'><Y5FY?ZG_A&5"$MLU;<X(T
M3[%R/R@Y#I47@QFS,/3B8&,>^K&XL3BV0.++9;X%@?$CS&-E_/#O6&L_JCD.
MM?!B36,C`O\1C+(C;#!H^;T7`F/PU-`+*L**(Z#@F`GCA[K'3'(_^#EF`???
M3(PA*QP1.=-'KF#`M`0]0H?AYHCU42[\='#H3;PPZ)AS%AQ9(9@?ZAQS"=SX
M5P3,^#7'%6=^>7#-_9`M>".71^@PQS0GZ)&KK[%@_$A8$?R8YH0`4_:OD,<L
M2`3\B%Z$.F;)0H.E'@E@U'_E`2M"CTPA#D]_/S\[/_L_W88PA@T*96YD<W1R
M96%M#0H-"F5N9&]B:@T*#0HQ,#$@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q
M,#(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@
M,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV
M(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C
M-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&
M86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM
M86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^
M#0IE;F1O8FH-"@T*,3`R(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O
M9&4-"B],96YG=&@@-#(X,PT*/CX-"G-T<F5A;0T*>)S-75MSV[@5?O>,_P.>
M.FU'XN(.\#'9S6YWN\FF<3K;Z?2%EFA;K2QZ*=G9]-?W`"1!D00A@19G.IG8
MRA&(<\$Y'SZ0`//V']=7OUU?X42F`F'SQW[2B>#5C]7C]16QWQ!$)2+22B@B
M1"5I2C72&*-4,%3FUU>_HIWM2W%A.A):FU^HO+^^>KB^NONSZ<K\.1+@A',&
M"A+.H!.<L)32[O<I%^;[E"GSO=:2^3ND:,G`&+";8`3-N+0VW5D'S9<J3=V7
M3+8&O_U\??7-]]GMRKKW&2ZP@;"=-JY+^($Y1I_!^3_^BW+\)_3YW]=7[^#2
MOUU$`:%(@8.O[I^-]2]=_S@1Z//*Z"%,7?+OQ6,B6J/_B.:(N+A`Q$?[EVW_
MDXT?'4XPGO6&\\\7]R!U2F;)2<J.G&"8I]:/)3@DS.<OH/:[?%<<\CW:YOL]
M.CQD.T3^A;FXN*?LR-59,HW,G&EDQDR3:=5Y2A,F,63;?XTC6&`8"T$N[0W,
M,HW"6;*.8=<_3C#AM,DZJB2ILN['W6K[O(:T$PM-Z8)0@?8/60F"AWR[1K=?
MT?NL_`]ZDZ!WC]GV+BMOT6V^R^\VJTVVW7Z%1"V+Y_L'^)T/6WXNG_<']/=O
MWGSS'?IE=2AN\Q*1!12;5@M4W*$O#YO5`WI?)A<?2JZ15++V',"5-)YSHF7E
MN;-RL[?6[XMMWOI6?D79;HWV>?D"L<CVU=<'XU">)^C-=E^@31,[LH"`+CCC
M3>PV^_US=@L7/#\5.]M[_GM>KC;[W+J=E66V.^S1$[3-=P<(XQS^B]3Z#TYC
MB5D%G+49QK;I00\4OV3IK,7O^I^E^$GJ+WXZ5_&3"T0K5/QU_U`"2DI7`DR)
MJ@0^/[B4-GEI\O1[R$Q(D%71*=[O\]ORV=0$U:9\4VF*YI.IYP.Z2=#/^<MF
MMT#O]K\EMFI,1VTE;7);8&4.*J`ZJF)[*IZA&$QC**!5OEO;@IBC##!U98"5
M`T`!Q6IC`$;U<2M!)C#9>EV:J3@^,*MO"G]PH(G&Z`/(LAM`SWR!;IXWAQPQ
MBO%B#N>%%E5&JX2QE-B,!N^)9'4&?`L(G-T7"_3C=KO9%6"\!+`@R0S0(*28
M%1I<_W-`@^#"#PUL)FAH%,X%#4W_4!6T9:-4-6STQ]U=43YFAPW,7Y`5M]D^
M7R/X_.81:A7^'M"'(D$4'0ITLWK(U\\PV1'V`UIG!VCHRH+P!:*F[NXV6Y!_
MV1PJJG#S[EO#+4R=?=SL=MD*+O_^>;=>H)^3CPDRD;VTTPHX>..UK%>%E+++
MJTD[P=7UDJ5Q\^+Z%/>XQ2^N1N/C(N`8$U<$9!;HHKJ9N[!VQ)7)AKZ9J>,M
M$"D@J`GZZ^9P2"R1-)_08_85YA^86?+'O#<;;5'Q90<TM$;UFJ]!*KYLRL.S
MG09O\\WNOJ6$C_GC;75!)U-G\9F0)F\D=D7):#-7O<]VV7UNJ@_JY.=O%S6!
MK@GL/?A8@H-/67G8]2Q^LWX!\EGNJ_HZ_\*CH*YA\MMFF\=99FD.5S=DG;9,
MA0A5>=X?O_W#YJD>PWTSB@FJ%S-(ZH7"^#PRGC5T_(B-=UARCPO,X;Q2+5/G
MSGNB13WN;AA-TKL!@='C*4QZ'\&T`WCVT="8M]N7==+P"I@Z%NCC-MO!!/\Y
M_QU6,4K@E,TQNW.A9IW=7?]SS.[`B/VS.Y]I=F\4SC6[-_U#$C%(L`9(TJ:<
MWD`]W1<9>KLI3.W??T6?_O#=PM1/@AX@3;+[,C?(6:!=82O_J=CG_7J#]2_@
MB('(HC2?#7R@Y]UALP5N\%*AIJZF_PI&?LI>-B`#ZGN?K8M9""^GN'&<IZ+%
M$5K/&J96-FM#7TPI`?O-[]"[W_/5\V'SDJ-?[@!C*@`,1&AA0_12',PT8;K9
M[%Z@`BTI>BJ^F.M?X,?1]&(@R]Y+F<-C[&[PZ';*$)2<'ND>L@5=SM![P-'B
MN=R@55$^%:6EA@L#0@3(`'JWO2TWZWN@<]G7G5O84$)G&6:FI4-,JAUB,BYY
MLZZ!$<G+NTV^!4[I3)<,$S7+C0\FY:SXY_J?`_\8EW[\$S/A7Z-P+OQK^C=T
M@J0M#*2Z=]>3JP71^CRFX.4'J'@RA7!TNQ2`[M>LA`*Z?)X)E;:AFR6+Z<Q9
M3.?,8CR2Q7*N+,8S9S%NLI@2XF9Q+DF=Q9_R.B7WYR5PDZI^HGOI`'%^%*$Y
MDI7J>9/5]3]'LE(YDJQJIF2EEYB@`LG:]&^85TLX>W!+.%](QOXOTU7Q-D:S
MI.LEYKQ0NKYZ8@BE*QU)5SU7NEYB)@JE*W7I*A5M&8+YW#P:V67F]M%37NZK
MFZ`9K(3*?'4HRLNOH%/5NCQ+]EUBK@IEWZN1/I!]1(]D7SI3]I%+3"V![&OZ
MA^5+RMKU.6<ZE'V5)'?+U:):KEX\&:DF;03F2$8R\V*)^''</,?!`BI-I4"N
M;*_MY7:''44\I;)J0$<::&KV:@4:*,I%L(&D9IM,H`&L6<(J.)$XV(`1&E9!
M"2;!!L1L!0DUP"3L!4L)"QK)-*'A!@KKX%@P24C0"P9\2@<;<"S#7C"LPT92
M;'94!1I`I(,-:)J&C:0ZE>$&RJ!(J(%,>=`+*G0:-I*G))@/%*P,-X"%-@\V
MP#H--H#ENPRJ(#K%X08JE4$WB<+AC"+BQ%@00)"P"BB,L)N0$,&<),`6PF[B
M-!PH@->@ESH-1P'RC86^ERD.%BYD6]!#F-G#((Q54#_47/!ZBE4XPB'8^*UN
M4D\#,)C#^2E%YE%>/3^1P?R'1=K>GZK8IZ$"NIG^JSM+=^C;8G<PZ_O.-%9U
M\^D'T^47,U_^9`Q*A.E6P:^**+E_;J^O;HY=X':#-\:FG;4%/FZ;C]1\K%O8
MSP]=G[&9?#24B<=G%>)PJ;FX9G$BX=0\W34L[@-PF@'%>)4JR8Y4J235;M>+
MYJQ]=ORFO?']MGVX^(MYN-@E#6[7/4SL+G`NB+UPU6UZH7,M+%9'KDOMM82/
M$*;V`@'K/V>>:@?VV*2Z3=^\I@4L@9DOFP/AYMJ81^M=LSR1DK4!%ZQ^"O'A
MN7F&WA_JU^D^RBJ<0&CJO18W]O;"R#`*H5V<7,QZL:G;].+D6MBY*/+6;77M
M&.]M+S"W1YQYC:D]D^HV??.:%C`YQ(922-X.HWT,7>]:R<L5`%!V/RS2UZD3
MG2)5E-2KNE^:I_LCHR<Y=^%QH>J%I&[3"X]K04CTZ-77CHY>HNVQ'=.JN@ZF
M6$TJ_*I4W37`YN0C.!!8!J?-;CZ1P-J(N3(CS;)QL`';[5QWMVK\J^:!`P9U
MC*5MIM\Y).O*HX"L\>",$!I@,)I$SX"^..(&'XW3KZPBX(L]`UIYY!!RF(O<
M&-*$8;/OPR2]6L#<OQ`B#9MD,,0W*$-Y%"Q%!,74O&=0!N+S]0L=I1\F=Z-(
MX9X!1_+(09''A74\*)0F*FR-004;=]*UYE@>:XV]M-D]2!2I=_3U#P*U@&C,
ME]0/-3)`H4Y`C;N;CRDF[?903-H;5.?NB'8[Z),Q8F6005(_V,A)TVUUZ1A>
M=SF=4>%#F6-Q',J<I5A9#5YXJ>53X.7HL9++9+Y0,ET(I<<8D0$!3_R'\CA<
M.2,,MOZ'\1^(XP#E',4&,<RM'Q^2U/(I2.*+/Q%).D9G6*7."R&U?`J$M`_C
M1B'$2UIXA1@4]Y"D*X]"$K<5`V/!V_,7S=[&D2W@OCO#KS&$$V=)9VPFZAF]
M^0S4,PT]Z'N5#[KU`3BS(,I10"CP*IR=+=%H](3"*URD3+0NHC-H)*_6O;B/
M[!UY'++SL>V3?AK)#9)T#7#B20`_.L)^&LDMGO<,</)).._+9;K@*5#)WID&
M/XWT#,J1?!+<GQ\4"]+#06G%DU`_0K\!>6Y!OFM`*X\'_Y%!T<F)X;!XS2W4
M=XPYDD^:`OCI*:#+(F'U[V61C7P"BZ3--F0LVD-&U?'W4YM3_=NO>Z013/.2
MQHX\#EKH&+3T2*,Y3>0AC<?B.$PY2[&R&KRDL99/`1.J?&!"F%PH04.DT1/_
MH3P.1<X(@ZWV8?P'XCCX.$>QP0?S*@<?::SE4W##%W^5C&6^K6X381]GK.53
M`,,5:R1GQ-R/&XU\`FY@[5:?[7D8JGB]B__FD#\]Y#OT4[/5%KG-ROX]27YB
M`@9ZT:,CCT./VO!SB0EH\H'(L3@.1&+T*ZO(BR6U/'+D!%;.@BZ6:%A^:GT&
M+?$,R5`>!RCGA\3"P'!(!N(X7(G0;V`$%'GAI99/@1??D)#DA#$6$DS8?2A3
MRZ>@C"OM,VF)UL(++TX>#R]:MV_&2+5;DQ)!:GRI#^^_3=#-0_:T*0ODMI'[
M\:5+2XQI/F#IRJ.`I3'Y%"TQ*CR(TA%'(<IYBI75X(.21AX+)?!-H[I[+XLO
MN.`!3N(+_E`>!2'GQ,"4NB?X`W$4=IRE6#*KP0<:C3RV3FGK\\@KM[ILQ,;6
M@Q-=>=33MG'7?1Q$2^D'B48^`214=9(PE8GB[;,VSNL[X)\VJX>L7!L.\C8O
M'[/=*8SP<A!CH!<J.O(XJ%!C[^[S<A"CR8<8Q^(XQ(C1KZPB+W#4\BG`T0S=
M,7!(>]+K-`7QC<A0'H<?YT?$5OUP1`;B.!B)T&]0`Q1YT:263T$3A4-HXB4?
M-N`^4.G(XT!E-!!=RL&5'TT:^00T$:0]L,K=P61*1?TBGK_8^[;_3-"G8I_O
M[LU1ZCC.`;9Y@:0CCP.2VN:3G`-4^!#D6!R'(&<I5E:#%SIJ^13HJ%5W.0=;
M"!ZZ#^(+_E`>AQEGQ,#6]C#X`W$<6)RCV*`!:/"B1"V?@A*"1'`.$UL?/'3D
M<?`PZKJ7<U#M1XE&/@$E&&TXA]V+57,.BNO7-ORPS7<[]"Y!'_+U%_-2L8\/
MR7?5K5(U=9>/,=<+'!UY''#4;IS+0$"3#S^.Q7'X$:-?645>&*GE$^Z"N('L
M/@:6"WG.PQG?D`SE<7!R?D@L"`R'9"".0Y4(_09$0)$77&KY%'"I+8BB(";@
M/HSIR.,P9C0070J"4S^X-/()X$+:W9W",1!&&@;RJWEQ!WI?%&67>0QQI,<\
MP"0O@'3D<0`R^@KA'O,`%3[D.!;'(<=9BI75X(6,6CX%,@@;0@;58L'TV.81
M6]B>Z`_E<5AQ1A!L30^C/Q#'@<0YB@T*@`8O.M3R*>C@BN,<ZH%3/RQTY'&P
M,.JZCWHHG7JWZ?3D,>B@W'NB.V]+QLU[HM]LM^[T\]Z^]6AP#M6^)CE#]V7Q
M_%1QDOKTZGYD!\HI<\<"QNQYNL![LU_3MWF,U_1]QNX6H\>WNZ4KCT(_E8X>
M]O#1)Z/)L[NE$D\!P?'0>NF34>3;W5++XQ](MQ9TZ1-=*,$7*3U!:@V$^4;E
M2#X%%2.B8K#,,RJM>`HXQN@'+#2*?-M;:OF4O8W>4>'XG`=)-NZ>_2VU?,J#
MI"/`&GV05$&!V3<W>E!/'A_4ZV4BAI%R2U+:_$\B?KPAC$]4`NZ[M_75.GHO
MO[5G0H/G.9<Z#9[77!*MPPWHJ0;LQ/G?)4]9\$SE4J0J>.YU*57XU.92J?!1
MZZ5F,JPB)2>\()C0X/G>)2%8!T_G+\WYW+`C)X_X+@FCX7/G2\)I^!#KD@AZ
M(N)$4A6.*%&,G+!#L_"K!)8DI3QL!\64!P_T+BDQ!SN#+2C%)[0PHL/>4D["
M!X^75-#P2PN65)YX_\,2QHV?L$.?&CF:4A&VE&&:ABUEY-3(`1O"X:@S=BJ#
M&&<GQH6)4YG,)`F_(F')%`Z_,P-:Z$!,`6;?_>/ZZOKJ?QFH(1D-"F5N9'-T
M<F5A;0T*#0IE;F1O8FH-"@T*,3`S(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@
M,3`T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y
M-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B
M8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO
M1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B])
M;6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^
M/@T*96YD;V)J#0H-"C$P-"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C
M;V1E#0HO3&5N9W1H(#0S-3,-"CX^#0IS=')E86T-"GB<O5Q;<]LZDGYWE?\#
M'O*0G9*TN).8?7(<GYE,S4G.)IXZ\Y`76J9MSDBB#RG%\?SZ;5PI4A1D4=16
MJA)&:`+]-1I]`=#\\,_+BS\N+_!,*H&P_F.>TIG@]J_Y\O*"F!:"J$1$FE\H
M$GRF%$U1BJ$%P\]5?GGQ.UJ9OA(N=$<B3?4_J'J\O'BZO'CXD^Y*_]GZ`<\X
M9S#`C#/!X!^F*&VW*RYTNV*);D]3R?H[I&C*$@RT*<$(R+CEZ<$`M(T\-+(M
MAC_<7E[\]R_9W=S`NX47C"!,IQXZH8"28W0+X-]_IQS_%[K]U^7%#;SZO^,,
M(+<&0(-Z3Q!A,?8I,[VK9)9H6=_^Y_)BBF=43][M"XSZ+9]OJF)=Y#6ZVJR?
MRJKX3WZ/?BDK]*FN-]EJGJ-_K.[S"MW\L2G6K^BZ7#[GJSI;%^4*_;;(5O4P
MO@^)';,SB]T/,)C]B-A5ZJ1.9PPGB9'Z>9"(,-9)_>_%HD+_>$:P?IP;!=+K
MTNC/[5..'LK%HGPI5H]HG=TM<O1<E3^*>]"H8O505DNK*U7^F%7WA@A>J=?9
M>E.C\@&5FPKE/XMZK9MRJV3S;25[-DJ6K=''?)XO[T`5&9D@BK&<C:YZ4C63
M-UPS(HJMY#GUFJ*$BC-J`_2/TZ`-@@9MD`FQZO`="TR^:X-\7:YJF%4SQQ]?
ML_MBCCZMUGFU,K.:+2;PW_D,72US,"_W*%O=HZ^Y5@OX#TPNV6MP#*G6(:T"
MZ-NZG/\;?7D.S1-T5ZZ?]*@O3\7\:?3E#?12$2<$"I[+"X&G^ED+P6KL2U[E
M*+LOGS6BNU?#L@:3K5['YHDR$ICBAA^8?TK''T9L82<</+U7`*6?-?8:?2AA
MG9M9+ZI\OBXK;0?0U7-5+.R4Z?G+GK61L(*I]10^E0OP,F:=A[G-5JM-MFBU
MCPTIX>K_0W()N%X_S/@>)Q';.@FNW9KI]\L\-U;U'$L@X6:XJ7$+PNL!E5)8
M/8`I_]MFE9_)3H,EDHR?-4((_0]C/HV:44D2;T&4"$Y5<.&\ZJ?;FU^!KC6R
M[>CK7W1'+YJ+O\$3G<&2)!S^AMYD\[_%Y<6W49@%76J8Q1BK,-5"/VMF9^CZ
MYNOMU:?/Z.O-WZ]N/WWY_.VOGW[[AJX^?[2_W'Q$MU^O/G^[NC:-$]/R\=/7
MF^O;+U_1I\\?;WZ[@;\^7]_,#B*6K(68J3-`AHC<8SY_!`=9E4K.JLFA_W.$
MNB+%WA_()&@R)SX^O,ZK=0;&X&N^,"Z\?BJ>:^?M%\;9WU;@+;.Y:3R'=.5Y
M$[C0_^C2A8X%]\$W9BQ$&A2R8RO=+Q`\_U;E-43;J[61ZO53D3^@FY^0UJV+
M'SGZ\O!0S/-J@G[-JG^CJQFZ66:+AZRZFZ"B-JYV76WJ=9Z;M^_R50[T15:]
M:@^NF[OOP7P!_<1%5]"'#N#/H5A4>L52C=4!"\DM]$56/4*\N!T=S-#M7H8-
M/,UJG<]+>.QY?6)>_P74<5[4\[(!6M:0L)20V#3BT?ER!O&=R66>RPU0G$,&
M&KA;7"QI%I=^UC+0F"#/FD,(G:ULJ/UKM3W%3QFHP#*[S]&BU#'ING2Q^.@A
M`4L#MV`SN0[@C<V<CCX2;\E%-#DI9\P9G5\6957<9UY)7T"YZWJS!&,#E@BF
M?Y4;<X->"L@4C)+GH`V5D655W`'=QNQYG&%*N4X2M.<*P28;?90TC*)W>G@(
M+Q+GL#\:F#9E`I7YL*F+55X/W\C9RP@$UYZ3\RH%@<#)CW0&-P?Q=2-1HM,@
M,WE6:\;?<Q$]6L)'3^9@,LXG,JUV6R)CP8`+PD."L'X"]U'ESV6U'C]%H$DZ
M`KY(8,$3>M;`(O1_CL"""Q'2>)4VGH4XSW)E]VTZ.VYB8JQE]OBH=_/6\+0L
M-Q!XN&V\`HSF'81TQIB`J]D?/AAOW.-MT4MV!C,$<\6:;2L2LE4FB(NCS';$
MSV()F!:OZ!V?8;0L%@LPD,&'`&/E"W@&BVN)GC>5WA]?>Z#KO%K6-FBJ()JJ
M\^>LTB+2(@')U!!F+2%(J_]\#E4DZ7E5T?=_CG7$V'D#]-#_.9BG8^RW1I@/
M_9_GE.7<ARR].^DZL"5"8)0HC)CIM7G='._I"(]22T#["<"T0Q`8(T@)&+88
M04*DB!)('<#$"`0!HQ,CX#B)#\&PX%$"BI,X"H(/H,#ZV"9"P!1.X@2I/J.,
M$2181E$PB1F)$@AMEF,$'!+@*`%5X.QC!$0E<0*LXDSJ$>($::KB!$FJHBBH
M3$6422I2&=4'RE(>)Z`II(\Q`I+R.`%.270(6'@B3I#J`_\80:+B&D7D@;F`
MQ#"-#\%3&84)02N/ZB2A^BY$C("H`X+"J8K"5&E<#"D8YEA[DLKHRI5I'*+$
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M/O=TTLA@F(^V8"=#/<J"G09/G&C!3L/*C[5@0E)O*+S-:%L'2]`Q%+Y]@`4S
MK[[!@NF0R3,F0_B^Q8TEZ#+FVK7T*#V2,Y6&Y=X;9!_L/&:Q=*SJEO>`B/"T
MH6E8[+"^,7&WV[;BP-&1NA6N'0'VM^FJ?)D5J[[U?=)P,FG6-Y_!(B-!L)*Y
MD#?[D14+DVL^E+NGTB<-G[*PX,U=/F6O&;Q_V*PWU:[5/DVR<GMY4W<0\[YP
MA09[EKCD(2_SBZJ]?"Q!9R7Y=GGT"C=O[EWA?[A]%6&25;(G$8[=H$Y]<D-)
MB/&5<.=N-_LOP&_?F+6J_XK\K=GFVO5.1`GJK+D=8.KLJVJ_('2TJOL^7L;V
MS5C7X/9TUPD^6L9\2\BMZWMT`B'01!&RX[,D'BHC^VH$B/:'3D;'XC!O]N!X
MMSN&&BHLH7<P^P;A,[)S"UK[OH%RLJ]&Y*0-RS!=LF]&NTX'BT?A/>*9$)5,
M%,<["TZ;CV%`[)O[@&QM5.EU*?W&H'Y:N*?4[UBYQ];&H/YMJ,U*PG4BH9JK
M'%BI0U9K5:ZCEBNR%^<@>K0!6=B+<X_MO3C]XU!;EQP.ZXQ=DF$OSC/6<&,)
M>O;B](\##>4;^#)VR/'E6&PS8PFZ?+GV(596GU,YQMHI[$X.^X91HN8UZ3V_
M;^]B..Q>#&W`EJ!G%V.@LK2XBDV*MLLR[&)XQAIN+$'/+L8P93%OOH$O8XP]
M7ZKA*S!C"7;X4D.517#R5F5YPRA1'W-(68RWD"%A=-BW`%N"GH1QH+*TN(I-
MBO92,B2,GK&&&TO0DS`.4Q;SYAOX,E[)\Y4V?`5F+,$.7^E099$,OU59WC!*
MU-D>4A:=63CL7@QMP):@)_48-B<MI@Y%`+"F7`0`3RX"X"+X2?O8C@#X\*R%
MAR,90MS.Z&VYSA8Q!VXY],P&QEAPF?:QX\#A1^"$X@$.G.^[!M=QX(XQQV.;
M&TNPS5CWY<;[\\;[.\D;@H[D??M`[\_W180=[^]`.7QM)):@'Y1M:T('SCM(
M+$$7E&L?FJ#Q-R=H'4=O87K$;?8L08=3WS[4T;]%_MII.<8<CX$;%GSK/OF;
MMB9*X+P#Q1)T4;GV@7EEG_C?Q<(%CTXUZ`(D2]"/SK8UL0;G'4B68`>=&JI=
M)J/M@[>3T7:"`HO0@VUS9@DZ3/KVH4'!&Q3+.#C'F`R6WCZRX(?WB=ZT-1$%
MYQTHEJ"+RK4/C"C>`,IX.0\J;4`%)):@'Y1M:\(1SCM(+,$.J'2P/BF\1Y_Z
MMP`ZT8/%Z2&W^;,$'59]^\#H8:_\;0C`N$0*0I.TIVN"]TL!WH%`S'0-,DAM
M7<J4S:0OY_A.98)V-D,(3LV04O'^,6-1![RKS^_]O7U7!*C+I-VV^+N4R4E*
M>>LN?J8_/[(LZKJL7O7V@ZM_>\Y>S09ZO"SAWE2D_IJ](H9-Q0.9H+L\J_2N
M?Z&_7J%+!MTG"L;&JIV]KS#"H22#<N&.W4PU0?F`Y'<,ZO&<5^;["$M;V%@5
MC\4J6RST)LSJ1UZM"PT66"Y1_90!VUN?X9B7RV6YLI6/YD!!HUGD=6W/;M[Q
MF<#(_6Q[J\V&CCE/'1VU],7EA"4R5&:DB?L^D:M"_9:;DLNK%KSG*G_(JPIF
MS&()$,=D4E](\DS&S^I/&D71+5%@I9HBE8325E6CEL<*;9TW;Y4Y&H&856!K
M>X-Z7V^)[3,LBMUZJY,G4N#`?2A59=R=:WR*U5U.XKR:VIO,?2<&L#T4/_MU
M$Q;F.S9CS"P.H_;_,P3E/ON:"!)0[M9CZ-NJW!C*5!QO7)D[N#W6N.HA-9;>
M,0_-&`E?=F+-MWRHQ-Z\@L>:8,BICC>OW;*N8^QJV\Z-#9HJV=@;YU"4P.YV
MW]%6=5QK.SK8I+F^3"U:.A/*?YMA9P&-9FR',BU@F7BF#QO;X:/P;='HB@HG
M&D;48%L[^N3)4#[+A5=5B'8\AV&)[=KV-UC;_:^_P=R.#I7[BV,X)8WS8+X:
M=:]YU\MT"#-[BX:%#,STFGBBOXBG*]OZ[CX<L/$4)X-LO!Y3@^D?])!HPP?;
ML.(A@$Z=$KVC$TXY)#&D8^2K_$>Y^*'-\_`0FBICZIG[LLBNM1\=+&D^3B:(
M7S*ZX,FBW?8N:3N*GMB327M("1;?ES1G8*?7=635?P`S\9BCOY?9*K[X'.'X
MF).0-NAZ1HL95HY;.H$QP.#N[;T1S>\-N?Z2G;OU#K2@*?.GK,X1F0B,)QCR
MPJ[7&Q5E(DE`>=@IG#",",/HBU^)<E]?\+Y@_*D3(?>A?FU"2BN\=SXA31O-
MDP\7)QAJ#_"<LP917"-'K-R]8PP#LCY?/OXD\O`!+"'#W0C[_-*^&'SDPNLU
M)=L^O.\E]]E)Y[['1^N^)ZP7"&^*<RCVEX.;@*&HFF*5?0Y\-HC!O<<E6N7H
MOJ^WZAHSL;\24&Y7`O945G@WZJ\E[[L92`8.H8^OW!!N!-$Y!Z%(1BM:IP?*
M4:?D$`$D1_$1F$JB%?%3@>-EN5.1Q`O>IS*)E[1.(2N-#Y&20W(B\:K\*<$D
M7FT^):"<<1R$:@,4IV`T6H$\!2[(@3XX.R!P(EB\1G=*)!,'^$A8O*A\2E(:
M+WW7RJ>BM<!3"KIS@()0$1^%4LKB:$'H/#YSE--X9?B4"AK_V,`4DC=U@(_D
MT,Q!W(H/<*I8O)9_RO"AF6.$Q6N\IXP>TB`PO`?FA?%#FLP$C=>"3QGD2O%5
MR:)?!0`;>O//RXO+B_\#>L67S0T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HQ
M,#4@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q,#8@,"!2(%T-"B]-961I84)O
M>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E
M<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@
M,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@
M,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*
M+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM
M86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,3`V(#`@
M;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,S0T,`T*
M/CX-"G-T<F5A;0T*>)RU6UMSVS86?O>,_P,>,K/='4G%C2"P?;(3=YO,ILG&
MWFEGIR\414EL*%(A13ONK]]S`%YD2X)D66JFMFR"P/G._0)?_WYY\>WR@HZ4
M"0C%?_:3'@72?8D7EQ?,/F&$*\*4_0TGFHZ,X1J^4V(,)65R>?$;R>U6H0QP
MGT!K_$;*V>7%_/)B^@_<"?^M_8*.I!2P_TB*0,`W83A_^MS(`)\;$>)SK978
MOB$G0Z&H`-H9);!,*DO3U.)S#WGW4*B>X.N[RXL??X[&,:`3Y`Y>L'RPF[;(
M%7RA$IXND"0F#2-W\>7%$.AF\/'A\N*'JRPC41R7=3(A43XA=;Z,T@E)\U52
M)M6*3.H$?C=)2K*:)^1F$673J!R3MT5^GY2K=)PEY-=BE0SLXY_+*(_3*BXV
MGMN]<<EUF4YF"?EW$>7N09';W_^=W/UY>7$#H/YS$NB,`W20O(/.J9$=])`*
MAWT2X?E3$A=Y52\6T2H%8N!GI.=C4LX`]`-P@423"7!G5=@'RS(%C,L(V+8H
MZOPIAXHJ(3F@JD;D?<O!GGOVB>-VFL](-(45Y%.\*L;PG9O!>9A`3<,$&@:F
M98+@^!F9P"F5`Y)69!D]1B@NX$%$OM51"=1ECV0<5?`0@*;9,_S`,_>>U1<R
MK;-L=&H$H,$FY"T`T=,/5#OZ/^7D8_1(V(``$N7T\&-4?B57HUY=[\H:)%$F
M<9+>@RAYP`;<:%+-(Q"14X'%`H!7JR+^2NIEHY2QU>(*U:(!V*I'M_,91&:"
MH`5L-.\0!T8YQ!NV]3!/XSF91Q.$,4YS0+BFI6!XK8%W5@THWFBA!II+$E4.
M5`2J#`8Q(MLXVEOV,U:>`[_0K<<2N*[!;WC8:"SG@T"$KY">QT\=Q<MS,(&S
M5@DH!*2&"1R#DV7"FU"R`95Z0WS'TJ(\%D@=+3_\P24]@X5K+>W^P^=@J>YL
M_`JDD!%!UY42_L\)N.VZ3%>/I/7FSZ/,`W`H^;Y*<G3BT[)8D`]1#NZMU?`0
M/?O37^G&"$I0!=ZL&IPK3&D5=OZ-J@Z\H=R!/PC@M"[AUZ47J-X$:D;DRNK/
M.[#G!88AT9G]0^*B7PK[C5=]`#P'"P+:*8#J/!YGK?QW^/-I49)HN2R+[RDP
M*8%@]8:/)%FD689&WP?>-6Z-CJ9_EX$@_8*^WD!V[J_Z_8\C/O0SG[D$T:B1
M8@HX_I?E/FOBZ[L4?/T*./T>V+E$Y<KCY`P\#(TX*P^[_4^NP.#!PK#--%D0
M=B%+<AHX)K[/,6X4Y03B#IA5NII;O;Q:)&4:@PG?VLAU\SV>1_D,(U>Y+$HT
M]UD!X2FW;V5IM<*TL5I!&(K*2059VPH3L*(NR;+(TOC1A0&K\06LL(;=B*\Z
MA]W:A-+!UJ+SVQ)+'PL;$VN@VGJ8"#SUGX5U9/!3VBD3A*V61/"Z`&4+Z65R
MGR8/E456)IE-U*MYNJP<X"0"/]WN`K&[<ARN*QNP"^L8EY#/IIB7GX,-LLU0
MP67QOLYH$Y9/>?;8%`<=5D@T"C(IL"8`BN^Q0'ILG7L,DI\5J!G9-KA+V"*K
M)S;^+9RC'R>H&>M,10ZD+@]*UPSW+/!YFZ\R#D5XEZ^)ILPJDV\UP%X`654+
M\76:;^6*#-RAZM%TFI98S]UC4)@DD*DM()6K'*?/P0+:I:R*]44VYXT3S8MM
M@GPHZJQ))*<8:3N_D'Q/2LA/D^>6\F<]F2$;,9^-H[)\1*X4]:HQC&J)]C9.
MLQ15W1E=JW`#`LFRK713B(HNFH_/P@ME6.<4E.F=@F[488?IWVT7)5JS,W]L
M4)"\MED*+)E&;@'@2.ZCK$:=V=!V6&>=`_(1E&]A<QQW&'"WW>(<3`AEIQ"Z
M5PA;SS@F.!->H^IO)*[+$KF"VCT'G4<7\$QOGC@V<)95/0:!IE$)`O\)\:?E
MMC<641[-K`6NN<2.^3^=*Z]309O:,J.[U%:J-BP^MPFD?IT)D.`M,*E=++/B
M,2D;^_7SH&TT/=U[G*P>$J@6GL0$J/"64=Z8BBO\SL$$23OW&/3EK%9-.8\0
MQE;Q&T6PEMH'B@*S^B2NT9L!H=,TMBI\9;M'C>JC'UBMZ_1@EVM$>^H<XL3Y
MH2F2T)A(E7X_"Q.XZ#+\0/0&(573AEK'?NKSP0#;\YT20H[)Q<E/";M30+Q,
MND1@W=V=G*^!W`),GOP82'#;8TZ?/3,EUOC&`K8E?=Z5S)P^LX`PF65G,0#:
M50BT:T4+)9L$`<I82.!M_[6LL\1YJ3*9U8T3:]'=WKP=M*Z1+&N`5#GW]07>
M`E[R/VA`%_"%M6_8/G0.F>27Y#[)ZX2\+28V,*)+'F#[*%K8ED$7%=$;3,Y9
M-@2Z:TG+(.@['D$C;O`!_R1?P!VC]_HP(M?@K:)\0+Y@HWQ%KD?D=AXMT[(8
M@)"3)7:!8-5O49F#1T3F_(*Y$?G?"-ZHDGP&J?_)&]-2R0Z'X2-!P]!6SN<I
M7X%GRIRU/.[V/T[@VB_PH"N03!\"`QDTV=#[NYN/L,&3D]U&7_Z%&ST@%1_@
M$Q\%))`&OJ++ZW_*+B]N3T(L.*.>6"K"+FD)[&<D=D1N?O_E_?7[NUNREV`E
MU@EF@AY)L4]V0G8D/Q,><IX'"GL?E`B[;?^^'4/"`L:%6\!W+*`<B/,LD(8S
MZ5V@&41@WX*0*?\1"BI+[X*`&O\1DH;4NT#@B-"W@-,]*!@U?B(IU=X%PM#`
M*PNAJ?:B$"&5H7>!HL*+0@14^HE$&-X%W&C_`F;V$$F-\"[@QE#_`FVH%P4/
MM?(2R15.)7P+I%;^!4*#?_,MX'@KP+>`:>$_@NK0NX`9'*;Y%FCCUR@6[I$%
MU+?&?T2@M1<FDT9Y=9()(_TPN?$SBC'#_#"I]O/!X#S&\USKT&NZH&]>C"%5
MWO<5E=[S`^H_7U+IM_L]CH/O<8^,AKNUX%NSI/%N$"XV0YPAV#AK0AS;O,;0
MMYHA9-FH;.?CS83HSEU=F.)`=X7EP$9H9MMR"=@V=+'9K/W8Q68;'R'7@X0A
M?-E<!9@=,-<6-6)D-,[N,3N\PM0<4[AM:1S467@<MI-?>IY]M3L/0I%JYSA4
M!+H=0DR2[]@ON_D^3\?I,QX=<+XO"X&@T1+PP[:\R"Y6&.NY387<IZSY).TG
MU7V<K^L-_HX%],4\L:^ZOJP)0&U$DZ%OA=^_KFE/I>K)[(ES"Y[3V3S';L^+
M"54]I3AYH[1KD`!?FP;)NZ2*RW39WE%Z5\3U8D/1&X919AD6LA>7&3)0N\N,
M`[;VR4)LJ9;XB&V<HMPQR,D7(U#[(!RPN5=,HBM=C>[+^';2<S4K$]=F!1$U
M5\BP(/V<159J7Y*BG$5Y^I>[:X83_4ES@^,V6:[<")YK.X*79/SH;IPLBGQ&
MWCU&DS1NRWE\/=IL5+P:'N]J'Q[T@WC#&B7$[L)_;ZT3&P`I\8C@;Z8_?OTQ
MVDJ@6^26[WZ^MLG;MY_);T6931[22=*_;?F`SZ[B;W5:I99[)P=/@W80KCG>
M%VP'X6%[[ZI<.EH9TK3%.@0L1>L(M@4XO^%!LN@UO'U;>PQ/*+W-\/@V_N$Q
MR+\7(U#[(!RPN4\X'8API#3Z1P1QN\S2C:[JJT[2:IU=DK8G#4]Z"I;C2G==
MAOYN*LBGN?7S:3HEO3=QCF+310P.\!$'V.S)A15TE]>8[OH]4%*U_9[S^8BZ
M6A4+\K:,IBOR.8J_1K,TGZUMP7>9+M0':%_BI8D/O"H\U^,.V-IGNDQNFJX8
ML>T2@W-08B^&H/9A.&!SKSJP=AA*0]9'3<Z:Q/3*-:"M`+\DU<HJ^UN\ECE-
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MR7#C@H`]0O&C9>B'<,#F/AFV(/!^!>]OF5`NGHIP_>)X([+-%L(K:!%<;F?H
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MYP>7W#]`&_*`^T>$0Z[V28Z'?(\Y<PUU\1Y[W2<YT##_.'0HV#X-$ESLD8L0
M^S192.Z?P@]%P+C?*D5@/#P%#WGS^^7%Y<7_`5,4EG<-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,3`W(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3`X(#`@
M4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P
M(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-
M"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR
M(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@
M,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C$P."`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO
M3&5N9W1H(#(W,S,-"CX^#0IS=')E86T-"GB<Q5M;4^-&%GYWE?]#/V5GM["G
M[Y='YI;-9$(28'?RD!=A9*,=(Q%9,$M^_9Z6=3&A?5K(WJ2H`H,.I_OT]YU;
MM_K-+]/);],)G6NG"/5?]2<[5W+[;7$[G;#Z"2-<$Z;KOW!BZ-PY;HFE\(3"
MMS*=3CZ3O-9EI/**E+7^!RE7T\G-=++\AU?EOW;^0.=2"AA@+H42\$,XSI\^
M=U+YYTX8_]Q:+<(*.9D)16%DRR@!,:GK.2U!AA,EE-+$.$I$_=?:U/K?:B4@
MP#G?"O`]`HPSA0I03B4F(!TS#!6P3*%#2,.80P4TM?@0BFJ*"DAJ<2L$C5C!
MJ<4GR:C!!2B5*!;"48-:(2P5!A4PE*-6"$T%.DDAG;.H@'`&%^`N,DGF."X`
M*XT*<&<=:@6W5J&3Y,8:E`]<684+2"L%*B"LP@6XY?@0#-P=%:`^5B$"S#F<
M4<Q&L&#&6GP(;0UJ)E-.H9QDT@G43`;1$Q?@CN)F,AM9!Z`<QP2<U:CO`N%0
M(RU5Z/\;*M#Q-<7'5U3@X2L6.2+QD5.-TX`B4>&W1J19`B;[M/KF<CIY_2&Y
M6C@`B5PNM_^Z37UM@M[^KR.7MSYQ,DA9Y'+A/U('W+S\.IV\NDRNUBDIEN1M
MD5=I7FW^3B[_,YV\!^T_MRK/O_4JO_J4^M%/:*Z\6@,_0*_;^74]G5STDZ:>
MPI2HT*3KRJ&=-'T^:4GK2;_ZE4OZ9$8#E0M,.1>U<I@YY"Y#+G^'@21,_]E`
MNAE)RQ%FZ*@=0]3O-43O6.*QI:;&=@:5$X.2J`;W(EW<EUF5I1ORTWVYN$DV
M*3E=E6EZ"TB3ZZ1*KTFR\>C_N*B*J[2$DNX$&$LUN7HD20Y/;XM\1=X])M?9
M@GP'#"GSI,J*/%F?P*^+>2UT>I7FJR(9MWZX@3`3;^#,4];)UD*P5F\M?),5
M:9Z6JT=R_LV[9DJ_4D69AN\LP!PG[5A60B1#21E3C7#2:1>BI`ZMJ!]F+"%Q
M$P8HQ]!JC0!\I-YA(Z2@E[#QK'A(;ST7F1G!Q>HFA5\>TDU5E)L@(P\R4?'6
M1,$[.@K;FKC)5C"GHO0VPDS*M"JV=%3[Z`BQVW,&<LR+Z2@X3L>(:HR.T-D$
MZ&B"RPG#^.5\L04Z9L(`Y2A6C1$0.J1F+5;<^<\>JP]%>>M#7\L6\CDIRP28
MB`+FJ]^1@%FG4,!BJA'`+-00`<!L:$W],&,!PTT8H!P#K#4"`.-0L[6`&:V?
M`O;3.EEL8\;IRG]_@MN^N&\Y'1OW?4>$XA91C>$FV7/<&$27^7,;]':DL:$?
MMV*`<A2ZQ@Z8.95=Z!>&-]"]+8J[M*RC=1VE/V6+-`^$_]/[U?VF@I6I([\@
M5VGU-4WS8-"O\?[7Q:D'?"?S+U]_>9VT_W!T.WV@W]K)_'HV=FK55-.!K.2G
M5]M\>?8C.;NO?`9L5N%#45R3\W23)I`-07A39=5]E=9F\#T\-M+59#/LY3RF
M$N5Q3#7"8V/-'A[S$`1^)`_!BXW0,2L&*,?P;>V`$$2YZ4,0<TVWE):W61[G
M\;MTT=0PKF:R.B'I<IDNJNPA[0L<+K8/_TCSHUME:%=%,ZXZLY3D>VE[,M#G
M.KFSU!<\:UB5$_)F_F]XT)+^Y_MDG56//G1_RI9;>B\AEH/T(_F2%U_SXUNL
MNL9(>.S:.JW%$<K,P>Y8.["?L]GCDGZ#?&1J,4*@+AE3C;DDTT&7##JD'V=L
M8L%M&*`<!;*Q`IBK1,=<P5G3X;Y+'])U<==4`T^=\.,]\$O0VL?DP:ED7V@_
MML7:M5T4-:)/,5PT*<8S%;K>8P[+(=.VPP)=)*5L2Y?9<4<QN\;Y?8$N$%'>
MQM?%39XM`!'PPP*:1.BCWF4/V<;[*,2/T_*+_U2'D8M%EN9>X-.GMTC*/(#=
MGG'MC%\]!]KO:["QGJ^-PST_HAKQ?*UYT/-%<&TD&^WYN`T#E*-^H-M6&]C9
M-V^F+2AO(7\L,F#*)^\1W8:"_^4B63]/R=MHP`Z-!D<W4ZH^-YLN57$(<4V$
MP\-/G;B^>4O^6:ROLWRU.8FX`R?*T+$5I.9X!QM3C9&6!CI8(*T,+;@?9VS]
MB-LP0#F*)K5=']3';B-T6V<U&U-_(^?9ZJ;:/&/I#W7MP65#T^V6E]_3@@=?
MR.F<O+]-ULNDO"*7)71*)_6S#]#^+K+-HFC_B-21AUBG7-?E*<;Z#3X7J"(/
M2:F>TX6O)LGF)BG3&Z!V6@*SH6I+8*VN_3ZAWP_<;.YOX?/5X_$M-;(+/OW&
M.K>T"3_GZ2K;5-VNPUY7`R:.S`]*X<U:3#7B:DJ$FS45WG3P(XW-$+@5`Y2C
M((F^6=O9X#.\J93>W]ZMB\=@:7AZ5V9KLDT&K$L&SWS,L^PH&>(@,SEMO8YS
MM[.WXH8DB*W7])XRD+E2CSZ\4Q0_NXNI1I@K;>#DKF9NL*N1>OS1'6[%`.48
MI*T=?FMZISVEMMWIS,H-D-;'NIJT54$0,F]S!NM.[E[*YI,@90^R3S>]IYFS
MNJCYO3FV:P\F.Y=Q^_C'U=AM=BGQ8[J8:HQ_/'!,!_S3X<CI1QJ[TXY;,4`Y
MB@_OVC`M>OXQX:*1<TNVIJON=Z[.DRI/-S<UIN?)8YW&W]X`X\H$X5U'`[F'
M!L+:T32@>(,54XW00+AP@Z7#8<B/-)H&J!4#E&,T:.T`&MB=W6RAX@GT8Y+?
M)V774/5$^)P\YE"M%D4Y!/=]IS5"C3X6A<2(XQY1C>&N`L>B->[!UMJ/-!9W
MW(H!RE'<57<RJOI=;E'O>(]S_]-U^E^`&RIVC^I%`G5['0+>%/EU,H@)>R,`
M&WW>*@3>K<948TQ@X6Y5A_M5/])H)J!6#%".,H%U1ZZ:ZSX1M.=V+V?"]U[B
MXJXLDNH0V#DLZDC8N<./:V.J$=BY#1_7ZKD*(>-'&@L[;L4`Y1CLK1W^I-WU
MYT'&?QX$^[-B\]MUFN?D++W^FN5#<-]7]W$NQO8=7#,<]XAJ#'<I@[B;<-WG
M1QK;=^!6#%".XBZ[XVOI^H3O7UQO=E7S978-8/M]U>]R?TA70W=2OR23^X\;
M<KKQ;SG5E/!`GQ7Y,:<IC=A=[LA9Q/A1S,YB4,WZV.<GT&XQWZ75\XWD'Y)'
MPH-;!T>'BYN^3-^)SJ*+SH?L4_Q?]@V8=J/]EQK\G=^(:NR57T?W^&^P8/<C
MC?9?U(H!RM'W81W]L_QW[#2]^^PL=\1_QX]B=A:#:ML=$0DEV0C_A9XU_/KR
M(6B9;I?'N7Z"TK4!)M(?_P7>RT:_R<`4_B9#3#7FO2+\)H,)MUU^I-$O[*-6
M#%".\D'H/\U[1TZS]MY^N6/>.WH4L[,8U.[TH-K*$=Y;-QU'AXMUK[-3UK]Z
MHEA3)$>:G+_`>RG;?TM([]X2^@,<U%_@:8NAYOVP_2\ICQR#D2Y>-R.HI^Y;
MOT:(W92:.?PFV(PY_$+=3%#\RNY,&(E/01J+7H>;*;^:F(!F$2N,SSF8@&7X
MS<.9HPRW@E$J\)5B5.#W86>,02&*2W`166XF!,>7DTF!7P^<0<B6Z`7`&3BS
MC<S#</P2WXS9R&5N(!^7^"B<<H%;RYE_S0N5X+Y!1"4$MSC!N.0N,@\50XYK
MCM]VGG$C\(N5,VYCR'$G)+[J@L88!"R-X")XC,E`4_R>_4Q(AE\3!0F'K"G$
MO_>_3"?3R?\`,VDK4`T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HQ,#D@,"!O
M8FH-"CP\#0HO0V]N=&5N=',@6R`Q,3`@,"!2(%T-"B]-961I84)O>"!;(#`@
M,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*
M+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO
M1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@
M4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3
M970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=
M#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,3$P(#`@;V)J#0H\
M/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,C8T.0T*/CX-"G-T
M<F5A;0T*>)S57$MS&[D1OK.*_P&'')R42./].,JQO5E7[<:QF.P>]C(B1]+$
MY%`>4G:TOWX;X+PDS31&H_%6Q9+-%]B-#U]W`]T`_.;7^>S+?$:7VBE"_4]X
M9I=*GOY9[^8S%CYAA&O"='B'$Z&7SG%++(5/J)"D2.>S7T@>9!FIO"!EK7\@
MQ?5\=C.?7?W-B_(_K3?H4DH!"I92*`$/PG'^\',GE?_<">,_MU:+;H&<+(2D
MH-DR2J"9U*%/5]"&$R65TL0X2D1X-T`-7PM"H('@_-2`]S3@G"FT`>-4H@TH
M,PQK(!U3J`II&7-H`T,MKD)33=$&BEH4A90T@D)0BW>24X,W8%2B7$A*#8I"
M."H,VL!2CJ(0A@JTDT(Y9]$&TAF\@7"13G+'\0;,.KP!4(&BX,XJM)/<6H/:
M`]=6X0V4E0)M(*W"&PC+<14<W!UMP'RLPAI0AUL4<Q$NF(4_:`-C#0J30>1%
M;9(I)U"83#I\H!@X!@Z3V\@X@,EQM`&U&G5>L#@4I:,*_;ZE`NV`H;A^306J
M7T5"AXP$2$%UQ-3PL,"PS[^43<HA8JUY]\UJ/GO]/KE<.R")K*Y.7SW-C=4,
M?OJN(ZN=GUD93%EDM?9/J0/C77V;SUZMDLMM2O97Y._[_)CFQ\-?R>J_\]D[
MD/ZO2N2G'[S(;W[._>`[M%1>K($'D.M:+[?SV475:>`=+!B,BW7T.:PLJC[3
MIWV6-/3YU6]<T@<=&B9;8+*Y"+*AWX(:0U:_@QY&EV8IGVC2)U5:CH"AHS@&
M2.\%HEM(@%D)<Y-G=N%75*ZD%AB]RC;`:99LR8_YU;[8)<=LGY_!BZ_^[7U^
M(.>'0W:=[^`E2?(-^7F?3]E/"2&P/>(PD[/3B"^F56/:PP'&J.KA@!A9#<?N
M-CVFY/RZ2-,`>),<TPVY2&^/Z>XR+8@\`V^%#EZFQV]IFI/I&:.ZZ:*KNPA3
MYJF+G[+U35)LR)N[8IOEU\DN/2,?;Y9OEX&;M_?))EL#><>TR`.3P.MO5-%_
M7YS#`_.\KI?AG:O7GU\GG5\X-3HU3P[P>[C;P2!<WD^.UMDJ\%!PM`HLM_YY
M`)M>9X=CD0`1OLO<]ZG+UR%\>U]77;$/CR-..SR,1$0C8<0IWA-%5.<X@B8_
MCL\&H6,H!@A'22IQ_!DQ9&0W?0QI#7<LA(S68EJ#014L4>L(PO``\E-R#RO.
M1['C?)O^#P8#HLKDE`E544;+"=WW,DSNOIO>F2Z2PTWB'8J\V>>;I/@SXL=`
M?[8^5H_T9Z90?XZ)1OS9>H/O\&>[?(I!GS2-]F<4Q0#AF'%4.+P)4UD;!RMC
M[H]@D;L\N\K6@<XGIGQ^=WUW.$+V\\B:?TJ*S^1\2=[MDNU54ER.LZ?)P5I6
M>0+GS71J_'./]OO8+RPS1MJOU0RWWXAHS'ZE[+%?WCGJH&FL_>(H!@A'*2UQ
M^."F34.IU"\SX(MC>GL#CQ^6Y)>DR--G1<3)07+3@&SL5FG71/#O&(&-U<',
M(.]]M@53@UIP3#1BP3Z_[;9@T37^7I,?_V>#T#$4`X1CY%8X(`+7\;<*2#'K
M_9#D=TEQ#PE],%]5FV^_'00[KO.&%)9G>2!?])$OW5CRC<&S\IAHC'S5G93;
M[J3<:QI+/HYB@'"4?%7GH)HWX8OQ@?,OS+/K&\+=,^G?0_9Z)!<WR6U6[`/]
MLH_^4%<<1[\0./T1T1C]3/?0WYE->4VCZ4=1#!".TL^:_%XV"03USP?-7K=%
MMB5</X_^?R0%Q(Q/^T.:7R?%*?;;'OZU46/YUTZC_,=$(_QKXSKY=]VK;Z]I
M+/\XB@'",?XK',!_L+.JOB-$;$%*SL$,-F`"P9_3PS'80UC"O/MREQWO2<@^
M\\/)<#YNRS#/^B9YS4>73;3"RR8QT1C1LKMLXKJ7J5[3V&4JCF*`<)1HR9L<
MG-5$5PNXBV/BL^X-\?427US_Y^TC?X</,+=^GC5,CHZ?,E2G80W#>6!IX9,L
M)D_X&O/KFV>4'IWE:XIG^3'1B/GY$PK=YM>YQO2:1IL?BF*`<(R@"L?"UU;+
M0O*KCVD1RG/Y.IU2'^>V/6Z1\MMH+:)!Y9U*ME*_LA3Y'_`#7ZX_[M>?IW>H
MR2DRK%X)ZJ9*YS]JBHD/POFU3]R@5\<]^6&;YCGY.=U\RTY^YOK<3-"QT[E2
M>#$B)AIS,]%=C/"_G>,,JL;.YSB,`<)1$DL@WL\8KUGDPMCHA,[]9L\#8XU/
MVM*)T70RB=(9$XW0*9WIH[-SUO:J1M.)PA@@'*.S`@)L4E7O$'+EGWLVWX^<
MK3&J^R9(J4878?Q6!4IU1#1&M>XNPL!OYPSI58VE&H<Q0#A*=0G$>ZYL:L/<
M'V9[P'7/9M58W;X.W1K$R&PY6@LD%)46;\RR9<RR-.9WN]OM_CY-R=NL2-='
ML.#O;]8OL`@C;`WIU=/9V!_A&WV>1$:.D\1$8P[3<YJ$=0Z.>,%A$AS$`.&H
MNS1G)XQBK9W/<IZ[N+O<%YLL#\NFC\5^EQT.^^(>O.>8MG9!!2W+[KMDD_J*
M]$1;CI/#;9W#\(->+<ZJG=Z'!?;3TO&,W";WX;`4+-".-RF!`4D+'T+\BR<;
M9*O"[T/`\NW4-+O.//3;(LO7V2T\2W;[.W!!^/I?C*)G1NN@;&JDHCZ$P;2L
MPZ!DLLQ4G[][`*,TU@]%Y#Q&3#3BAZ+G/`;K7*%X16/]$`<Q0#A*5W,"X?_&
M#U\"MW64P;'6!JX8ZX?OP7[7V6&]?XX#:BW/K+`/MM,FA\KJC7G7*@W*JC0X
MW`&Y%&,=D)>G`_H<,"8:<4!>[L4_<4#1G?-Y56-=$(<Q0#A&%*\/%5#E3.N,
MGJB.K7W=;[]F^?5CIRMW;<343O?`"29'JV6-5K7*%+:L]$6=;O7"R4^<44K#
MWYCWO0BF-!-Y'[-N;&&3<SQOBXG&O(_UY&VB.T7WJL96-G$8`X2C1+$ZJ[&B
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M,RXXQ2],+[C?RL,:"&/1RX@+&<8*::`8?IEPH9E&+\@N#,/O?2XL93@*1P4^
M4$[@=Y$7C$)XQ5N`+^,CP;C@^&`RR+XC_9!"HG<O%TQQ&^F'YOC]R04SD8OT
M"V:YC&AQ7.!H.>4"YXTSKO'QX/[B,=Y"<!?IAXPQQQ7';YHON!;XG59PM1AS
MW(J(OW,7LR!!1807L..()0O.\?_C8`%8\1NZT,(A8PK![=VO\]E\]@?29(PD
M#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C$Q,2`P(&]B:@T*/#P-"B]#;VYT
M96YT<R!;(#$Q,B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*
M+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A
M8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@
M4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT
M(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]4
M97AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O
M4&%G90T*/CX-"F5N9&]B:@T*#0HQ,3(@,"!O8FH-"CP\#0HO1FEL=&5R("]&
M;&%T941E8V]D90T*+TQE;F=T:"`S,C@P#0H^/@T*<W1R96%M#0IXG+U<67/;
M1A)^5Y7^PSREO+L2,_?Q*#MV-K?75(ZMR@M$01(V%*"`E!WEUV_WX)0%-$B(
M=KD24>*PN[_I_KI[#O#E;\='?QX?\84-AG'\%U_YA='5_U:WQT<BOB.8M$S8
M^!?)C%J$(#WS'-[APK$R/3[ZE>51EM,&!1GO\0<KKX^/;HZ/KOZ)HO!?[P]\
MH;4"!0NMC((?*DCY^/V@#;X?E,/WO;=J6*!DITIQ(9@7G,$P;:--5Q%@]29O
MWU2V,_CE^?'1EV^2BU6$=PX?B!,1A3;08;P`_>>`_07[!SO_W_'1:_C8?V`$
MS(4Q@3,'_ZDHM?MXM!`&:&FK`7)D@)(ZD`.D5)X<("0WY``N/*E"!P$>H`9X
M(4@5VO&@R0%6"!(%N)I&H;60M)%*"'J`Y)[TA1:"TR@X=X(:H`(W)`KEN2.-
M5(XK20ZP7-`#=)@P4@5+#Y!!T0-$4#0*[@-II`R!D_$@G??T`.N=(P=`$J('
M:&]H%<H'>H`,EH8I.1U1DD_X0@1,B]0`'S@)4[C@R9@4-E@2IC"!GBBA@R)A
M"B`&/4`&J#'4`!$X25[!_01,S@,I(7!+F@`%A/R\XY8TP$XD#S.5(@6GB2_H
MQ"`GWA?<C>O_LQYBJBD2>J"*!O!26T7%HRI:?3;$,LH7`FH6.U_A2QZ`YN<?
MH+B>)Q?KE!57[%61;]-\NWE4;"LQ[[Y&D1^PJG^+!BT,BG7P`^2&WJ_KXZ-E
M8S2&OS#@.K%?Y8\V:UZ5_M^EYH\,VDVVHF3+JJT`NQ6'7';^-^@1,#OVB2);
M:;)Z!@H["6,'Z:,X;`\(F,YYY=A3Z.<LM`31L^C0,EEMV0])?G\%+^[+++]F
M9]=EFMZ"I]EELDTOV4^K;7&1EI#Z3S#M!7:1;C^D:<[>%NNKA)TGY>JFN,WR
M$[8\8TE^R;YZ2"ZS%?L&PJ7,DVU6Y,F:'1X=MS4Z?%%CDRI4V'[GAO^\/(,?
MX@0L62T8_N7JRS^^3`;MJP95PY,-2P#_)6"_>&!G^!*G8U//QP_)`_,G4"(@
M[2#<-^E%>9^4#V!2_*N.?STTWN`KE@)*SO%UA5AJY#8B7J=;P-,8V1DE:J,0
MOT2`0W2!O@+I8H;2!TW%8`/-Q`G1!!.#D<-$=(.3"XIP<O?&8*=`[""<]%P-
M`QRGH`MM0I5#JQ8=]PU$VFV>766K&(LQ>EYO5F7QX0D5E^G=-KV-9/1-K-T6
MP-E?LFVZ9K_`R/LRW9Q`C)9_L//B]NZ/+(=?WZ77V0:X#H)&8_,Y")5I$$K=
MDE$Z?(T(!Q/"?(:2H>PANV&\*;=_*`M#AO*4:"*4L6$=#&4_Y`M4A+[8&X.=
M`K&#<,K1#0P,Y<[/OG;SFZ*\Q49A>7\!X9O=Q6CN0OBJ+&Y9EK]/-]L"\E26
ML[LR>P]QS>[6R:H:4UQ=I;$(K2!V(:-!S,.X-"G7#^S'XGT=^U/IS$/AF]E9
M>.?I&)@03<4`K"@&8R`,N@D4S>TK:!`[""=CH(8!,>"E;M.9=K**@B7P=8/=
M1)/+WMY#@Y!LTB?9[`S\OVXRF64?LNT-?("E$`/PZ?=I'(8!]2WT)[&6U2.;
M!J1.$P='J'6#T-A>;V%\D["?I*7QIDG$ILG7>?KK-$_?)_`19$$<_N]B?0D!
MOV'?9[>0Q"]/<+ZRRW0;(_QLDR4QY1T<HW0MDYWNJ.SJWK"UYAW"V+*S=?RQ
MO$V3;>W7=\D#8+IDYYL$D*&U0HT0TADYFY#<D82<$DT0$A=,0X24@YQ!1;,)
M28+803CER@8&NC)T[84-P^W%QY$*W2[F[+'.8F[M/CA*URQFN!;=8H:[,$K*
MRKSQ7J)G]*M7;]FO1;F^_`#4ZW\:>BBVO+G?ILB$!_:VA"*4KVY@GN)*)WF?
M`1$6AT=K;-OM:ZU:?L(JNH)[MEYG&_`F0C`CK+.0=F9V]4Y9DG53HBG6B3#,
M.K%X"L)6JN;V]32,'823/A+=O@GRNW*1%K;NZY?I"C+Y-DLWXR6P(E];+&Q3
MX!YB>(TSL`Y@''1VD>;713(8@L^"QV4;@B&T)0*PUNW>RZR`:E9>/[!W7WS5
M8Y2P8_&H]=QXM%[2\3@AFHA':\U8/,K!.=5Z=CS2,'803CFL`0(^$J)K6UP3
MC^"E@\7?0`7HQV(7&@<'J>N%E%G`JM-';V%4NJ;<?12+#BW\UU,S),,3PKG1
M*.E%PI1H*AK%\")!#L8B*IH=BR2('823;A+-(D%HV\N-4N^5&]LEGW`S,N/V
M)JT[;5QO'AJB"<TJ0:C>.L@W$#?9-=A4E(@1+"G3;5&%Y%BY-D;-W;DP3M,!
M.2&:"$ACW'!`JL$)-6KVS@4-8@?AI+=,N]XQ0G7MHU#C6U1U*"VW$([U[@3[
M*BMA<5J4[%5Q>Y?FFZJG?ENLL]5#=._8$L@`]KG>5?02:$HTY5TYM`32PYT8
MZIGM7!+##L))Y]8HL%61MML;ETHT)QV7<2/A]?8F6VTJ&O(11VE84<QU%*=/
MI:9$$X[2?N!02@ZZ";7,=A.)8`?AE)L:#+ASI-NBH)2NUS2X;YA=9DE,F>`M
MS-^]G>NNG@]-+?=S=QBT5;37)D137M-VP&N#F1.US-U>H!'L()STFF[/V7SO
MI$TURX!71;ZID^/K,M]LV1?LO\4]5.?OOW\+VM:0(>$7*'[C*?:0)ANI6I.K
MJ@RS,MP]S5?A>K,BA.]BV?HZEC=MY,8"T=80".R<X48YNFIY2*L<),%>O&F\
M6Q?C[?2P6G0_(G2WXV1T<_;J(U4?X3]X4,K0+`-TP)TA!/ICL<!956H6P<;4
M2=Y3]\GF50*=&BU8QEP0[8K;\7IB!50TF.2X^=J?W4\#'%:.GP&X\KS5@N5;
MNN[\4-9D$LI:%W<5GF)_RBQV4%I9Q3_#+%BE'[G?B,[]\>0?IT$]Y15XGAW8
M[<Z8SP#8F=#7TFL^I7#*'SYAB/807H=N/S6$NO\?XM2A9U:"LL:.3YA)@NMK
M41)DU;LD'*^HUHP*1LOV,+UJJV9-^OC][`[LBZ']%^7$W#Y;!7HW<$HTT;$I
M-[`;J$:VIE'/W$Z;QK"#<"K:&Q3Q2*AW4!^:GBTMM]V)$-[MN\E2Z-_^2E?W
M\>3UIRMX-RW9W7VYN<?F&_JW91K/=&.E@9I8-^C+I+Q(\G1S2`C&\[XC)H@R
M7XONM%AP-Z:C>CM1AOJL]Z>_UND#.UO%_E;B-3IB&?*,D'!<M,8,TT7-OM<2
M;QU1=)D03=%%#=QK42,[YZAG-EU(##L()^FBVFLMVLNN.'A)TN5-EB?Y*DO6
MAZ++3`@&)K[GB"FZS-7B1:?E8'29&1)XL-48,T@7Z6?O[BM![^Y/B:;HP@=V
M]Y4<KBZH9^[F/HUA!^$D77A[`TART547[?>L+F7ZYWU65M=LP>"?%\O%JT5#
M'+`!)AG#!^_C7A9W>"8P0K``JZ>:8(<&"[!JL/C@2K6A0)%XKBX)'7^C:YK$
M\[683HM="*.Z(S1I1CC\49MXR%A5RK;V#/-85GO;>L_'`^.#1O0=ABG1!(_C
M-?,!'@^6/=0SE\?23IR)3`DG0UNW9R+2=CS&)\#V*WN?C<?/`:OX?CR>J2OR
M6/%=>3Q;B^FT')+',V,U\KBV9Y#'^*@KU`>Q9],!IHC0G7S$G<>_Z\<[!(+`
MJ!GBAN51I=-R;YVVTXFS*;O+9D[*YK+9JBCOBC*>4T/0E^E56J;Y*JTN.6/\
MXOE@DC\<T"X90FL8L;/]#`V*JU9#C*3NI%3(;F<[;K(]N;C^'+T8&9V;"<X\
M1PE>%.W`<2V[E-?>(OSNA%UEZT=/6JCFJ9YX/SGV\-WEA?BLQE^KFR2_CBZ_
MS38;R&5/3C1VL'MT9:@[IPQ32QFDEMHSA2"UC!VFEIRB%JA$+/OJM)W.'K74
MPDKG#\&LF68I$5J[)I@U5T-\;,`^899:>-=<0:"(-5>MLWTG3Q!KKA+?]RH7
MO/&J,LI\1*OV0H^N2/7H8;M)@ATX$E6WWQ[J=<R+"0Y/:!OO1GVK;I##L)R=
M61VY'*:PFJ`P/D$_LSAR^>F*XTRS8FVL[:(9/%-!+(W=C=B]2^-<M1@5?)<C
M@V?H,+(/C7>7V:01'_&W?1*GXJ_9JR@.\7?"YM&BJ#J;!PGE]?CS\+;_//S'
MC#+,NW:AT$32\),G?*8*-+]646LPYI'\>`^4^DJ`T^#I]X43Y/<ZG,:',ZD!
M2M'?BG"J!?T%&*<F9DMB@.6!_+:24QL\C<+AX^C4`"_I[QHY#=+1$B#*IN9:
MX!.0Y`BI!&V&4(K^WI53H9&-Y`@C#?E%&*?""C<QPN'ZE1SA19A`&R3]I2*G
M,A[SDR-@%4M'%V1W0]LAU93GI,;]%7*$P>-4<H2=\IQT2M"S+OU4!.$W_]!8
M%)^*9)!`?Q/+J9*"TXR$*27F%%+7Z]^.CXZ/_@\WXD1+#0IE;F1S=')E86T-
M"@T*96YD;V)J#0H-"C$Q,R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$Q-"`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2
M#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y
M,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y
M(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"
M#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N
M9&]B:@T*#0HQ,30@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*
M+TQE;F=T:"`S-#`T#0H^/@T*<W1R96%M#0IXG.5<6W/;N!5^]XS_`QXZG70;
MJ[@3>$R\3B=[\2:QVVYG\B++M*VN3#F4E,3]]3T'!$':)D$'(MN=:9*)9!/"
M=VX?SL%-KW\]//AT>$!GVBI"\:][9V9*5O\M;@\/F'O""->$:?<;3KB96<L-
M,12>4,E)F1\>_(,4KJ],*NQ(&8,OI+P^/+@Y/+CZ#KO"OZU?T)F4`@!F4B@!
M+\)R_O"YE0J?6Y'A<V.TZ.Z0DR/!K`6Y&2703&HGTY53L'IHPD.A&X%?GQ\>
M_.7-_&+AU#N'#SA#N$YKU1D'+:DDYZ#\BX]<TC^1\W\='IS`1]^/!6`5K?HG
M4W3.Q'2=FTQ/V+FP$W9.^72=9]),V#ECTW6N5391Y]!>TPE#46D](4EUT_\4
MEE%\JE"']M).%>K8N5)[=BXBG8N*1W3&#,3EXO#@"/,%O/T"B'\FQ^OB:GF9
M%]OE?$6V93[?WL(/Y&:^(1=Y7@#>IUV^V>:7Y&I=DKMUN5VNBPU97Y'MS7)#
M+M>+'7Y@-K9=I!!!]DF"7;)].X]9G;+:Z@(*`30[G7%N667VD_GBAMS.B_EU
M[JR]6!?;<K[8$C#Q8GU[EQ>;.=J9W*WF!?YR7I;SPC=&CRQ+<,AV#2XB5\L5
MO`=W0<O\Z\WR8KG%)\X[98X.(W>[<K.;%^[W;[?Y+8H.3U=+Y]=E,84%A*D2
MOA4S;C7H_6\7>51P;P,OZP9J@YF:L9?5*W>OVO^LP\_"OTK_JMRK]>VL;V=]
M._Q7O^'U&P$6NL3W7(P>K9HU&D\R1@BY5^>FWU=`!<$S'ZW<0B'I!PDE\3VZ
MZNWYR<^$R0?(54<?_HH=?4$I?H!W?*:@,PG_0V^Z^6EU>'`VBK!0OS;"4LED
M+2Q02U;"SLB[#V]/C]^^>_43>75\_,O?3L]?G9Z3-R<G9^35Z??D[.3#W]\>
MGYS-!M71HJV.T#I1GRQJ?&YI311EK0Y$@6F!T^?5[A(8C:%[NBZ2G!_!-[;!
MYS-):474%T=C`UG1`&4S+6E0E&5"M#5]D^>;T8=[F`75\),D$Y[122NGT'^:
M\#;"*$JX$C7]%<X7//TIOI_8+V`Y(::UG-BW8(Y9CNEZ+%(R5%<"?XN&>P.9
M>WN3D_M\7I*\N(1D^WV^R&\O\I((2%"<4OV2G)3%9DO^2/ZYWA77Y*>?WI&+
MY0IS^FY#_B`M>\E@0@%)&GN:7U^7^?5\FU?56+F^RC<;*!2@=MODY>?E(L>D
M#TBE+]CP0V,KCO-Y:^OZ1FH3%+?X'C6?NY"!(G&]PXJFV*Q7R\LY5AN;+;Q@
M';-Y":B?E_D77TQB)5/,BP76H4TC4'RQVEU690IV]GXW+[=YN;HG'UQQ`Y\N
M"!@:BIKD\.GUL*1!TQ&&QRB2?&C3D-BD,IZ&[X-#/P4;W.7E<GVYF<3%AM>Q
M;7"T]BX6U`=W%<\_STLH93&8?]@5.1'49:JS_&[KPYQ68>Y^C;)7/J]#`X(9
MBM"R*G:#UX-+S\;62T$!42LVK4>5SMHFE%DS/'#O4.%K]R_+[8VSS=G),88Y
M\*7(%\XDX=$4#M:JEBZ3LI%.^D+JKEQ^QI$&YB`+3T:<FZQR/VEPE`4G@H0^
M(-&KP=D/'3V-.R6,C+4:T[I3:M8VF!$M1@C/"./]V>%"-(&SS&:[7OQ&UG=A
M=C?Z5"23C6LGJ7685)-F[-#_%!F;<;-GQE8#&1N2X$N=V=]=QF;L_R5C>TW_
M"QF[;=/_?<:V<KR$K7Y'"=OK-7V^;@PH6V.#T*+.UQ^IHN#26^?)^9`Q)G!Q
M5JU]6#D34E53Z!=GK\<&XED`FM3F@M4XN#`80I8;'['\&PJDG_/R.B\?5BB_
M++9KC&F(9SEZ02!YRTA"`V.<D2!$V/B+X=+68(^R8K5K0\%AEA+A>FT^[O9X
MH8'B6=6`]S207.MH`\&5BC;@\"?:@'$:AZ`LH[$&,!,640AI<#R.-<B8B&H!
M15Y<"ZF8C`LIF8@W$-1&?2$YXW$M&#4FVH#2+*J%L-1&A12&8L!%&F24QQLH
M&Q=22)O%&P@KXPTX[OG'&C#0,]J`6AZ-!VXLC3?(#.2,6`-M:;R!,ED<`N(^
MWD#8+*HF%S0>49P-^()3*Z(0S%H>51-<0:,QR3)KHFHR;>.&8LJJJ)I,VK@=
M&(2<B#;@ED7)RT#/N)J,T7@/%.:6L0:6Q44PU$0ER`9&#STP1BK0,3X\#8P,
M`\\AUN)NII%8_>2;J"K5,-F]%LY"FF5/#RJIL`H'.<OOW%(<S5Q)<CZ_6.58
M#!^OBRU.=Y[L(K&N33'H-JNVD6SKQ["-Y(#!KC#B@7>_K0[!(V1<A$)$2AT*
M$2JQ&L%I>M=4'6?#".H6#+X15;=0P5*8_.MR.>-^X^IML5B7,.%SD\B+>P"X
M@DENL8!I8[F^=47;,51K\^)^3,FXM8UHU9SLQ4>0;TP,046#@5M8G(5=4\:-
M/UNQJ68!9E1DC)"6NR/%^5XPBC]0$*(H+!E`'>L=_.-+7Y^_NBN7*^*71UK5
M>K[8E<OM,M^XR>3)U\4-'F)`K]\NW2+(DT+Y.4+W+GS1EFV>+A[AV`E5+AA0
M=`T+<8I9DW4S3`TP#"%1F6_%U`UFBU]LIJ'D&(%>J6)!R13DBI,K&0&>!&MG
M8&U169O-3)B(;_J6C_;!U:;MY3BQDD&@,&_<"F01WJW2'3!S:T9GKY^LF/4N
M(_DERB>K-[)FYL@1Z7>A<43@.@SYG`L?DZ?KSY4<3%5R[#L8#`G;.V'&..W=
M,\>A@*=F6RMZDJT>&@IX<JZM,2=)M:ER8::M!1L8"Q(1,,_6""EI-AD7(J/E
MYH&Q(!4$<FQ+.<J;LTR*/4JP;_*+$JA_GY1C.P>!`:%[<ZQHA.[DE;$\D5?&
MZFY>90.\0LA$7M68D_`J52[D52U8G%>I",BK&B&%5\FX$!DM-\=YE0RB>%LY
MF`LVB8K5T[C`K+"[Q\>BUI#<_?NVC5.ZJ:54*K64[::6&:(6KOHF4JN91T]`
MK42Y'+6\8`/42D1PU/((2=1*Q45JJ><<5=H'!*G5*$>550VU\!)#QZR0F[%X
M-2!T+Z_@`[70W;R"N6TBKSCOYI4=XA5`IO**\PEYE2B7XY47;(!7B0B.5QXA
MB5>IN,@K_IP#8_N`(*\:Y:@032THZZ,I@5?5#K[/5WI_7@T(W<LKKH+0G;S*
MM$Q9;8'VF0E'NH3P=T<<KQ@=(!9B)DYN:]`6L>A8RRVI8@G:&"/.JW0$TYB[
MM=Q"G[G<DHP+;FVY.<ZK=!`50)!76JGZ*I;-_)CQX]GKL+P2.?4E'ZUUJDA6
M&SDNM0D*H)'J`=^?TOP6J@])T4=UCD&B^Z[+(=5YEI)"D>J"]5"=#5$=3ZFD
MY=`:=)(<FBH7YM!:L`&N)R)@#JT14G)H,BYNY(OG',K;!P1R:$LYRJ5HUB=5
M]B2'WA.1D$`3!.[?KM!!X$Y2Z4PDYD_=G)A[1"H^0"K$3!RG=#@]%T@E9F:<
M_)DJEN"-7'%.I2,TYL:P8S[LQ`SF\ZJFU&5^M2P@LC[GY%VY_GI/SNK#@IV3
MI6?$Y,B^:X[A&=4,B,@IIT'#`#P"O)IOE\5U=<DXKP_\%SMW"GB]^.UFO;K,
MRR=WQ?8Q,ABU%G$B-\HL(#PEXSX=J\:Z+CZJ<Z4O;O,<C=@UH`Q!]=X2AMEX
MOP[N:(=-'5`D[1E0Q-"`XC=S4X+2@TZQ_YDJ%NY_UG(-1&(J`CP)YGZP_RF>
M59`GX^JL[>9XDDX&R5@`<6P0]7<C9+)>/WK?*LA[]CN;,^S5#<HFI_NZ7/=?
MG-HS)L.9%\IY*,9Y5G^I05H),210;UW>DJB3\<HD[<:`',KH'L8/G2E"S,2Z
MO`:=I"Y/E0OK\EJP..53$;`N;U2G6H3*%0:#0'E_%*"^7-!5H*<*(.D#A\>Y
MGPYB`H@KT$VSR,7#(I?GLKN;\I3,:?0:DKBW0M<J2-Q-+YFT(X/TDK:'7D,'
MBA`SE5XR;,F(9O`2IAZ\>NEU^2Q^)0J&]Y-JR0;XE8K`&MU3YKW)N)#26HX>
MH%4RB&TK1V76;'=2_GB[,QS025H^3A"[?[>S$;N;6S1I5P:YQ7@/MX9.Z"!F
M*K?8A-LRJ7*YU,6>LRV3BN!25Z,Z;3*7:B6NUBVY,/'MOS*XASC2TK;[!QB7
M#-+$6'4V-HRES)IPMQ\C[H'JI^L9$4*,&7=,3:\N%J=M2C&<A2`(@PFGY)WW
MW9X!U_M-6IH'N,Z!0<(<(FU@D%G?MM+0$2/$3!P8:M!J7Z]U%*6^>/W&#<PW
M,!K@4-QERB'TWKOTP@3X[C'6]E^3T.UK$H\K.45TS7FNZH'EJ>7<C;E$".?D
M"L(C*/WXYJ.(WB@\TO&;=D<LBU]%.>+XW7VQ!E!91"^K'$G&HK=MCA3-XDHH
MJ^-::!N_\'.4\?C%RB.#9WEC#2S7<3LPRG7<E(P)&I>"N:]'C+807`S((?'K
MGJ(M%%,#+6#`&T#)6/S&W1$S^&6;T1:6L[@]H'J+W\0ZXHS'K^4=0;(?\!P7
M7,8EY9*;`4G5D.<@P&S<ZCP;BB!N^(!?N!T*9$%QV!U@M(D34C`3L2D,3">_
M'AX<'OP';>J-Q`T*96YD<W1R96%M#0H-"F5N9&]B:@T*#0HQ,34@,"!O8FH-
M"CP\#0HO0V]N=&5N=',@6R`Q,38@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V
M,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O
M;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B
M8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*
M+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@
M6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^
M/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-"@T*,3$V(#`@;V)J#0H\/`T*
M+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG=&@@,C,Y,0T*/CX-"G-T<F5A
M;0T*>)S%6EEOX\@1?A>@_]`/0;`))*7OXW%V=B9(L,`ZNP:R`?)"4VV)B41J
M2&H\SJ]/%8\FM>-I(1[U!`9LRBQ6U_G507W_ZW+Q8;F@&^T4H?C37=F-DOVO
M_+A<L.X.(UP3IKO_<"*$V3C'+;&4$B,$J?UR\7=2=KR,5,A(68M_2+U;+O;+
MQ>,?D17^S/Y!-U(*.&`CA1+P1SC.+^\[J?"^$P;O6ZO%RPPY60OJ%">640)D
M4G<R/78*]C=EN"GT)/#W]\O%G]YG#[DC3)![>*`S1,=T5%W#+RKA[A%%$J`:
MN<^7B^_>G+=%^P=R_Z_EXAVP^=M-#G.SPQS?2$H9N?\/G+:^^4ERKA:7CG=J
MK<$=#J^?X-"?_2%K_9:\][YYU?E=U+Q\/M,S`;XC-V?/@3L?N/^32WI[^6<'
MO%K\:-!1/7B'<B3LO<,-7J-WWE<U:?>>//NL;H@OM^"I'WSNCP^^)H*M"$<.
M6;G%"[4B[^JR:<GOR3^J<[DC/_YX1[;%EI152QZ*PX&<&_(('+-7AW5$'05Y
M'/2Y05Q'CU)STW$>XEI18WK+U4-</T)<KTC6@!%(!::L2>/KCT7N&_+D:T\>
MGF_N6(A+9]T@'#,R^%5VURC=R=?@B"/(!^>#5$>R/=<%N*PYY_O>VYL4^>*T
M2YHN@?_KA(]#-*+_8%2A]6A48?$:C7J??4H#8V`WP=/:;>2?`F4<4R/(2.J"
MW;K\3`<R+7ACGGSX^3+U/D^"!)EHG1UAPDZ9J)4;,O';Y)TU-FG\!/XI\LYJ
M-N:=GK!L+%%OP.4_=<":*/>L9&EM-_)/D7N6RS'WA)6AP#OHG6^4>YAS\!!D
MW>_82D&[[K,AE+LTO*QY&W(/AW7UG^35\5BTK?=D#QF:(O6H&5./T8#74M,!
MK[>^]?6Q*$'Z=I^UG1U.=?6Q:(JJ)-7C!!<]/O1R5V"GVI^J&JL[Z.;/8+0:
M=$`((L7QE.4M@>=]T6D.;.!O49,"R$YHX#+WFUN'D8:Z-ZJ;I-$UUB1-@L#_
M=<*;:"`80_NN4,',Z5S7%4(D,`H3:(\A74"^'0/RYB)0&63H<Q#,R/GMC['A
M&)PB0[IK-NC9D+OZ]MH),UGXZ_ONV$F`E.$D`[Y$RL&79NPFWIPPA[,#N:L.
M15Y`]B)ZW=55[J'6WKY""#XY-TWJ*9HV]=37"A^I/[B[&6OWU#-+P8?J_;8J
MFZ)I?=F2)P!,\LN[M^0T.J[VNZS>8GLT(.\%B*XF3)[5D@(?:T[(]N'@^W'S
M=*J*L@4^*X#T%B_P`>#39"U"/09(@OICF`ZZN[GN0Z16'WW=>(_BH"9/5?WO
MH5S,]&S1"FBA&LK-Z?P`IB%9GD/Y[?1X+.KCAORE!*J\VI5%.Y2N=C\W1'$H
MVN>7[86UUS=M!HR;/1R1I;"$=F$<U7S6PHU1T'D<:FP%]?=U^!0YW[AP?MJU
M@!5S195005&*UZAHUH$3>`&:UMX3&'LG;$.:/F#+JKRU7-SR;V0!;O7<!([9
M8`+)AHZS5SNT5EW#M0TSV/\8^3?OH]P4+$G`7)NT"Y#`/P68:QT6()*&Z!:.
M#M%]5Q<X3E0P1^RRG3^B#U\#:/W\#D^5_E/;C1(WW^`)&[3YVHXL=@P\.AF-
M.BNFK5%HR;J$6)%C5HXV>\(U1G-^`(A&:TZPG0*:I0K0;*=TY6[88TZ58BBE
M?7.%,H4<]I]./L=Q"(1]\"`"3D3P<=AM=,-5&`B[\7"(BL?J7),\:_VNJK'@
MSV:N#7DAFOH2EL(*W(8QF89M+K>4ST%KLD6",L4P>P<QTJ(TXW2F,)<J]":*
M47%1J!HT>.,O)N'!7\\S;_5C/6[;2(8[[?-V![/U=M55MY>ZCMI_.!=US_X"
M&U+XEH7UD7-R6@,P-V[JK\$1:C%+3PC)?@$`A.T9DJ%3')NY<Z]0KS^6]:+:
M%CD4>ZQM=77>[:MS&_8M7S1F`B,H)T-C,NV!)*>#$7X84[47;47RHL[/1V@,
M2W3[,7L&SQ80"4][7Q+P)?[G`7K.(Z(TD#19_3PEZRLQ/]MNNPX6;)K"!L8$
MJ)-FZD+E`'4AR'&5G%=EZX^G_B5.478*`4CM"A0N0?IS:8.`B9LT=6D*XR93
M&#=/_^S0C1;MOFK0FT,PO#Q'A(QNH!84C^#@!$;"X>';&$ES,S,2%S3$B]+R
MTD:0!A"[OH_\,8E2A*^FH?L24R/AQ`#9_]_.&064:1<5@7^*WE;Q<5%!K0C.
M%D(,X/#2WAHQ<.L/?@<@D003-`MR)<8$K6868-#^3;.K5;^)]^P,B%`7;8?W
M58FX2(Z8`5##BA:*1??V8-CU]Q^0\FE?'?OW7!.#H@D&3+*"4>$E/>C$IYSA
M0U]W/#?M4,Q7704J2GPEF`U%Z'2N3X!]T)B6AV?L9IZ3N-F)(&AB-T-7/S/)
MB[N8X.8MX#B^"6DN9Y`I_*&K1W=W0UJ3[_WVC"^"CMXCRMQ^-(?:-,J>9#27
M5B>%K\#_4OBN,='2$>,HZ;_H-CW>?0<-H5^PGH!_@4`)7/Y'"+J)+D8@.!2V
M&`''%B5&P#@N/2,$E)GH$=(Q):($EIFH%M*PN!;0]MNHD%(Q$R>03$1](06^
MIHX1<"9HE(`Q%M>",A$54CCJ6)3`4A,G,#0NI-"4QPFD<W$"@=\"C!%PI^)"
M,J>C\<!AXHL36`>I'",P3L8)M&/Q(Y135P@HCZH)>!2/*.A/X[[@S-GX$=3I
MN)J4RFA,,D=Y5$UF:=Q03#L759,I%[<#DPZZE1B!<"J:O(R[*VIR)N,<&.-Q
M&2B+R^`8CXI@K\"'N0*2FNEH+``"1N_+*_=%]T8X%HSQ8&74?+G0?!A(5!^M
M@),O?IV(A3K,/O_.KII>TK"^*>R6LW;\&A^^AX%>]BVN`,KV\HUQS^;G/R/+
M)^P+_HH";?`+H<K`G[Z'"Q\/R\4OH]!"VR_+K.<R7_8.N&L79EQB<37NJS_O
M4O`0)5]Y"(-GQX%W.$.9W[8J0D9C>ZUMU/5K)N(]PII?@3IHPTP4J-:2BFCZ
MK*6+)^A:.1D-T+7F/-H*K0V/A_C:XI>&8P0PHERQ).4J+@0`41RJU@!F\0J,
M_HHW$FN&W4J<0C%UY11]!3+6`#E7(H]9IJ_8P[%X?8'@8_$N>0W8=<5Q<)_&
M)>6"B[BD7%[S'%<\WAJMN;X60=SP*W[A]EH<<RA6\704UQH'H+`1FP+NO/MU
MN5@N_@M6:W^N#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C$Q-R`P(&]B:@T*
M/#P-"B]#;VYT96YT<R!;(#$Q."`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q
M,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N
M="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C
M,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO
M1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;
M("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^
M#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HQ,3@@,"!O8FH-"CP\#0HO
M1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`R-S,T#0H^/@T*<W1R96%M
M#0IXG,U;67/;R!%^9Q7_PSPZ*9*>^]@WR2L[WJVU'4F)-U7[`I&@B(0$N"!H
M+?WKTST`!K1D#1TOP$JI).$83G=/]]?7#"]_'8]^'X_H3#M%*/[X*SM3LOXS
MWXQ'S+]AA&O"M'_"B;`SY[@EEL(;*C@IT_'H(\G]7$8JG$A9B_](>3\>K<:C
MY5]Q*OPY>D!G4@H@,)-""?@G'.=?OG=2X7LG#+ZW5HNO3\C)5%#.'+&,$A@F
MM>=IZ06L7]+P4NB.X<O;\>CEZ^1N#N()<@L?\`OA)VU%%]J"F!)>@_2.SP3.
M=?MY/'IQ\_;-N[^0VW^/1U<PS]_[H>;T$34]<YR*FMK%[3^NKV[ZIL<XD*/:
MDZ,SYA0GMW-X/3.,,7+[`(3?YB29SXMRD>3SE#QDU8K<I/,J*W*<MB@)4[]1
M11?PAY%B2:I52J[^F*^2_#XE%_-JXI^4Z7VVJ\HDK\@\V>_2!3S-=O!X6Y05
MJ0IREY)==I_#"Y@XJW;P8)6LE^3NX#^_SQ=I60^8D`%6P5D7%@&7'Q9ABA:*
MU[@*P$.9[G-@=+%?'TBRKU9%F7U.%[/O948_QPR@H>7F1>^B"D"MU[*7E5K*
M6UF%P&N4]<=#LLCFY&U>I66>H*:3]01NY]\M:Y0;H5INC'2>FQ=H4-?!8M"R
M>E]E4#FK";_XC4LZ@$E9IUH8"\&,AS&L,Q/4-NN<5.D/Y&);9FO")X13:GH7
M$S_JAI03WK0$S,RH1G]`J?WMG2*X]["TX(^IJ9=V&/&D.[=XEI]1/*O.+!YG
M]GSB<<[.+1YF3V<33YESB^?H&<5SG6M13\3K/12QSE;`22O5QD6-E^BN+P\_
MD)>[E_V'Y",?X\Q,:=?%"M,D8;\DY7_(Q8Q<;2`G2LJ[+WBHI[Q^@U,^(#\_
MC4<PZ0RQS>$OS"LE"[?K\>BFE^`B)>\GN#Q/H'/U`Z1"$ER1^1/KWHN$+/`P
MD(0J2,@X9.BMA$KK6L17JRQ=0L:>SO=5]BDE[Y?+;)Z6O4NJ7>#E.R4U$4F%
M)<;96E(Q,U!*-H)2V<CYX?W'JVOR_C6YN+U]?_WNZE\#I'Q&L\:!<,E<J"(<
M7B,/5\E\1;90R$"-\[`J=G7-DU3[,B7)=ILF)=8]Z^*!8+D!I<^\R'=55NVK
M=$>2?(&#BBR'ZNBQ8?JW'Y-#GI)?"BC*\#9%:G5%MID0++>2JBK*/#WL^I;=
M0,'2"@].1E):6]J+Z1"K+*4GA-J%$.C#0I;WGSP$0L-*Q'4@!+C4MJL^N6E"
MSS+!.MKKTQ?@6!%OBX>T1/7N]G>UC4"A-B%+4/XJVW@#R'*O]3S9I!.R72=0
MO^/C794F4$7#VR0_U&:U7D-9ODWF696ENPG6XVB87[R'2?(%_(+QP>LAU,I-
M6P@JI4-92I5N2_"N80#X>5V4&ZAO^F?$!4X&MF0ACF1F5'0R:VUJF7^^N9QX
M#<"2+[-UZC6_\_KTAH"*2?]897?8,?$]"AC8:FQ1S/>UPD#5X$GRIFWCQ^''
M)YTUW8#[+[WV_<>'4"]\LDVNN`PV3O':^\:V9_2JV&RRW<Y;\SW6_UE^3WSK
M99=DB^%\&$<?UC`Y,.(ALVTI#>O$!!5GD@EJ@2,5<VIL4+'A1VZLMLY[-,O)
MDRA%EGNPV]JS^7%UFZTZH/TO:LN&\+E$Z/O/^0D^I>5A"(O53K3B<.R&MN*T
MG=$@#?`,0=DCS7.X+[<0V^%F!W&<;++[586-TGFQ7R]0#(!CG01,VCA?)E6V
M/*"AXP2`U656;OPMS%VMD@J\/(H[E.UKY8*XP]J)UB)0&M;VM1'GD@G*X,Y8
M!'>AJ:HE,U^U?>)SM&',UNB`0M>A4+FF[=ABS2<*GA&XS<HNCTCQ67<'.-TD
M![).'A"=!S1@-&;LXC>-^T4!:2=8\:>LK/:IM^EBV7NS&$53;9>>8V<318-+
M89[=J?C:9D271:P23+?3O-UYJ%/O9L=A6:SA#C%88W6'24>S*=%L<QQM:C3I
M%C[M$JE!M"O;YCW7/#0I%&M]+#)2QWBR2$"56;[(YG`QQ$8%#=ST7[NBJ/3_
MH('.B;+#[A,HW8BI9M;'F<]ULZEO400-I`811<@P/SIVKD,^R[EHDCS?0/N.
M9M9,P=Q-+XM)'6Y[ZV4Q:;K5Z=V8I25*VK-TFF(LB+8[06GG.KAJ7<>',LOG
MV399/^T&3<BK50(I29*WON^R2,H%WOR8E5!7%&6=^WPHTUVV@`C7>_\(^&=L
M4"!*Q\X%Q);44$!LY_=`['K9G$MU!,0WZS3/R=6,O$L7#X\2L&=Q**UM<<C"
M;8\X[/0P"`ZED2T.I=&BQ2%7S>;WHS49A`5ENO37A78/<]0\!N+-/`,L98#!
M#HD=./\)#SK$>?RU:!P"'LR<#1X-J<'@P=JV"UR%%%EK8X_0T753OQ$83#;`
MX"K<_L_`>%X!NM-`7UMOSV<]KM/!(!"@;:=`:!V:0=9?HP*..MD#4!>VK=6H
M['RC>Q(&7V<YE!(97"&T+J"VV-?=J#^Y1Q(!F6C/?@T/LI;44"!KY_?.U81*
MA7)S!+*;*MVNH`+[:09X*_/T&[$F)&VPIEBX[2\(J4X1@YB_X.'(G;5AGTAI
MT>P3/5F509B@+H0AX9KM]0'C!]?N7*;=DAK*M(,H0Y^!$";0PDQ.!EOA_JP<
MV@JBZ#J;KS`=OTPQ13\-(:A!8%[=0.CHMK]P)6S_J_1\TL@ZE0\!%=Z<F,0L
MC;+0W6.0_-9*B"B@)PZ$.BM8F3M;4X(->3X1P,JZ4SV6=AM/@A[W)*Z+N[2L
MR,TJV69E\6U!B+6G:Y@0X;9'!'6L#X\@<#1LL),V8+\^S:Z]F*-A+P7B=M/^
MB*Q_3PQH=EX`\:\W$_H_Y","+6R+ZY!IR;"+C`;^MZ0L#V#FNS2_3\KJM(5[
MDV;V.$;4M[W&B+!,YX@1+;&!"*B.P"`0HN&0B*2ZVV&BS?F(1QH>@@5KOA%#
MOFTN+"?&0:'AZ703^F_OP`!#53V`/S-`4U!:;("B$#]B`X1S)CJ`.QLGP1SH
M-3:`8MLF,D`Z6.OH`.M85`II;%P*J?&[#+$!RM'X`&E-5!=26!>7@N/WLV(#
MF)5Q*:C542:%LUQ&!U@,\+$!QL29%-JH^`!E>'R`/^X0&R"TC3/)#8W:@Z#:
M1@=PIR$;C@VPVL0'&*WB)(!"?(`R*BHFER9N45R<T`7GAL5),.WB8D+(B=HD
M<T9'Q636Q!>*&<.C8C)8R?@`99B-#@#\1\'+A#XA)K<V/@.S*LX#M7$>G%51
M%NP)]V%..$EM7=06P`-&W\L3[X4U<7NW<6-EED4##<,34\^]_[T9HFI#`:M_
M&KD=P2RSB=SL23I*P]$)IIH*%G/QMH"]3>[6*6[GO2KJDTQ/$D3V*$%D6.W`
MM*;.$-W1;<@0_2&JYUG6QRP_2C8P7H63#D??_7B<U?@TX#M),$A2&A(-!64?
MIS$RBLVIBOO1*92&4;.9<FPTQ@;`!%'#F4H61]Y4\7B&,E7214/65$-Z$!U@
MI(VO@Y5Q>$Z=BH?-*=@6B^N"00I^0AM<QMT8ZBN"0S]"XM'^Z`@EX[YDRK1D
M<9TQ(\6)];`R'IJFD+KJ.!^<GM(;9S*>&$XY5_'<$DS\E.9`+?$0-^7JE`%Q
MK4[HA9M39LRM<'$T<B?B?AQJ+!I94W`J5[^.1^/1?P$S):4?#0IE;F1S=')E
M86T-"@T*96YD;V)J#0H-"C$Q.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$R
M,"`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q
M.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@
M,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V
M(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A
M8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA
M9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-
M"F5N9&]B:@T*#0HQ,C`@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D
M90T*+TQE;F=T:"`Q.3<Q#0H^/@T*<W1R96%M#0IXG+5:VVX;-Q!]%Z!_X*-;
M5"HOPUO?G-@N7*1V&@MH"O1%EC>V6D5*9`5!^O4=<J^RM4.)5F#8UFIG9\YP
M9LZ07+YZ/QQ\'@[XV'C->/B)G]Q80_EG]G$X$/&.8-(P8>(WD@'HL??2,<<Y
M,U*S=3$<_,F649<%'11IY\(_MKX?#AZ&@P\_!E7AI_,%'P,H-#`&I17^4U[*
M[?L>=+COE0WWG3-JMT+)1M(+9YD3G*$8F(CI0W2PO&F;F\JT@%]-AH.?+Z:W
M,\N$8A-\(`Y$5%J[KI1C@DN\C=Y[/0:#(S'Y;S@8\3%^K]GDZW!P<O9M>C>?
ML<OEIE@OIYOY:CE=_(27L_$/;/+/<'".EOXX"AX)EGEG2CAJ#`('KX+#45=$
M<WEU=OZ>3:[9Z^NKF^LWEV>GD_,S=G%Y=7KU^O+T#;N9X!>_GU]-;K+0Q638
MC4Y(9I2,X$[^EL"_AW[Q??5KVZ<_W/0@@%G/F8J*6PTQ)5'`<5<*R!X!RS&=
M*0'#C20%-)>>%``N:!/2XQ!1`L(KV@3'@J,$P'L@O0#G:2_`>B!!@D%F(`6T
MYV0L``*/40+*(2=2`M)9V@OA/`V2.VTH`>6=H@40`@E26>MH`6,U+:"M)KU0
M8`4-$DF<S`<EK*`%N.6"$L"D%K2`,XXT(:V5M("QCG13:D=G%-(W'0NI+-`F
MI%6TF\)Q,B<EMYYT4WA+#Q0V6TVZB11,CX/`E..D`/(P6;P"+.VF4%[0&J3S
M-`;A$QBX<R0&G^`/EV!)#!29#$B!Y'V=N`^>TT7G$MGJ@.PT4@AZA+GM3Y//
ME4C%CQC,Y[W<8Y":7BZ>]G)\UL=FCG,U'>8-L_"1>YR>QHG29'J[*-CJ`WN]
MPIG;<O.XU>]+->]^#2J_AKG%;P'06`>U%O^%&5CG<C$<W-2@/0Z+1MS"'SS_
M"%UO]_RC%3<`T02*:>/BQT7],0(I!>+'AV8PZ_L6`=C=N/IFG9A'^&@SEJX<
MRI.WT_OBZ10LN(!5D^L]TD;O["XZ$"KR<-7EHX3N8)O;$G9R<)XEF@]96(Z-
MPHP.@X,3<NS,5:*]*SZMUIN0:9?+N^)3@7^6&_:NN)\_XHJAN&-OO]PN<`%Q
M.INMOBPW\^4]NYBO/^Z7CI[[,AN5%,UEDXW1<_0L*^JV\<R;L0-=+GU.+G9&
M)L^(P3E:8T2.@6.7CT9&1S7BND9P+F%+(R+#2%^.&=%Z<L)V))A#WLFL"YPM
MTW41=&?6!:D[V#:>A-TWZ.%1J^NZP#!798$S^[(JD'4?5XOYW72#%7`Q7TZ7
ML_ETP6XV^,7'0,>_/!O%B!?QY+IJ%>TJE*Y*?GB$-*$ZVH8(^U#5\5$--&PE
M<YDK+"Z:#BGJ$&EIQ(X8O9HN,$8%NWDHB@W;CYV<@I*=A%'-9;=79H,WT*`G
MB&,G,`/;R.R1D;D6F1D+@PE;;QG)$,HPL.RLF!4?;XLU+GU^PJS@9@_8K@M;
M=BX/@=V7:1)AUK"?\U?,P["&R^LCG?%(])%,(Z&/[)$.+S7BND;:/B(SC%!]
MI#\.(<`B>W;I1-_LLL8<MHXRR972'1<S)INE.&_FGMZW+!7V&I^Q5-L_PH3K
M^E.QCCNRCWL2EO6NJB^IFLMN?>7Z(7'J6CMR(&'AH]O([)&1N099V$B.;;L<
M8^%=-<;LKV*Z?F1A[GKWG+S8='D7/NCT**.UKC,`><[TI6)X:U`[LYO&@N9<
M&JOCEZ2Q3".1QM))\E(CKFNDI3&5882DL=XXA`!;FTMCU@F:QH+N3!HC=0?;
MAN?2F#50TYAOI\,`21)[_3!=WA>/;+[$&ZO9OP^KQ5VQWG.[PAI9T8:'YG*K
MTC(]DF%SJW*I=`?'3,HT`7B]#<L=&99O8)WL04?>=]$H+HZ*1O%NW+F&<GO@
MY/SSE_GF6QH>/K\%3_GCP@/>P#NP*>&C6\A`'1D9'!)&%-]&8XZ,QG;#:*QO
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MQ'E:>;GUDLI4;S`R2J%V)ET*F49"*31&DJ60;<1UC;2E8#.,4*50&]E9"F#+
M-_Y"[58L^K@.TQQLW1JEKM>#.Q,7JB-NAQO!7U._4ZIL:/_TF!YH\E3""%><
MY'VAZ)-$(QGVRBD!)0QY\&$$PI(G*T8`AG9"`WUH:V2`/K0ULD"?-!PY\#0&
M#_1IQY'@(&D00@!]QF4DI**/1&&\E$M8`65I7X56C@Z9,,#IX1`6Z&-/(^&`
M/@<W$CX5-LD!:*12`'W(%!,X%3D<=/JLVPB9/)$_4D,B+M*DLEA:91+%Z"1]
M"!/KG1-CBIQQ_GXX&`[^!X;F,Z,-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*
M,3(Q(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3(R(#`@4B!=#0HO365D:6%"
M;W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C
M97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P
M(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W
M(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-
M"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B])
M;6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C$R,B`P
M(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#(S.38-
M"CX^#0IS=')E86T-"GB<M5I;;]LX%GXWX/_`IT5W$:F\DWIL.^VB@[ETFPQF
M%N@++=.Q=F7)E>1DL[]^SZ$N=M*$QG0M!(@=D2;/]3O?.<[;/Y:+K\L%376F
M",6?\,ZF2O:_\MURP<(*(UP3IL,33@3+TBSCEEA*B5&,-'ZY^)U4X2PC%1ZD
MK,47TMPN%]OE8O,W/`I_3A[05$H!%Z12*`$O(N/\\7HF%:YGPN"ZM5H\?R`G
M";=*<V(9);!-ZB#3)BC8+ZII4>BCP&]OEHO7']PJ-X0)<@,?"(8(ATZJRXPP
M*B6Y`>TSD5IJ-;GY[W+QZK/?_Y7<_&NY>`_'_.,REQEZ<IE)N=0L7);0E%G#
MR<T]7%PW':DWY&.U]GL/OZJ.?/:W1=OYQJ_)I\.J+'+R)L_K0]45U2WY4#0[
M\EVBZI=%99QDU@1!03;%,G*3!SEE>(]RWFP]>5N[9HW2_E`T/N_JIB6N6I/K
MK6O\MB[7'A[,(1H8LA>-6LI'T82@@PE_>'!K,-+'"FQ6N:ZH*U=>P9]Y>FEA
M-"69$(,PG$(,HS`\E8S)7I;?/=FZ.T_<85UTX,`.S.;`>[N]JQ[0?WE=M759
MK!VNKESIJMR3=NM]"(.750F6;@^KME@7KBE\2[Y01?'X=_WA\"<CKL53YO`!
M0,84'KW:+%4A:((+?.YW*]\`H%P13JF^"O*B>(TO@ZZ/%&\[>-E!L`=YZ[UO
M@K+M%:S4^;^'8+JT'C(SDR(RZ/#J"^?\TM<HRJ9K7EW<&8KJ$V]PH7I-(%>S
M,5?]UT/1/00/Y*[=DDU9W[=D4S?$NWR+%D?'=/<U>?`.<K:HPH,9PL9FV1@V
M5*@Q=;G1NI<4'%_4:X+`MR;?!%%*`'5:3S9%!6E2N/(T;@!SAOAJ]Q`YQ:HH
M4>E!N2$I+FY\4&+4:<X($MFIZ:1E$R`+87O3M63G*G<;K)&27P_-4TL4+>EJ
MXO^SA^<(U+/XU_(Q$)6=JH:B=HC$>E]4D->D#A'VDBM7K@7WXS;0(B!G^]W0
MK5\05G`Q27OYI(3"8($M33EI!H040IBI,``"K@\YPM]13\P]K`_-.A2"^Z+;
MAO@%ZU1KJ+;M&-`#$QCBFOQZ!_A8W&Z[H2AC,?BM"B7G&@W;8CG`_*G;T\/F
M"`%@CV-ED&;`(HX8&/1N$(Q"JKJ.W'NRAXH7D`E2'Q!IUU=(M`5&:[WJ'%BD
M\:Z%TK<J8:EM#TVPC5O5!SABZ^$33?C8B[BP:;Q'P^W@:8/KNZ*=MJ2S6(&Q
MT0J!V@4K:,WMY/U[('2DJCL`NUM(VS6J.]H`31),,"]Z"7$4=$;T$O"!$WNP
M3(_VH,:,X%7T%*?$K.B:NB0U1/2)1QN_!VH,C*G'MMX\1967A_5`)HKUP!K0
M:M-Q,_C69'+,;#908\AL*0>,.Z<`DC*'&%?T-7CM(7&KL!"4VC=U[M<'0.D^
M23"`W1Z>[B%T.S]6Y[QH\L,.4SGWP)-6D`L837@B+N\/S1YS?1[Z9XQY:H($
MZ;@>&4=?98)2X(]'J$_\9@/=0G'G*RQ$<X<XFX2=-<35B4V84GHJT%RK[XCQ
M-Z$&P-ORX0IA<BS;50VD'SE;;U+8.$L=-YI.Q<MD0U>C%!M4Z0/5E6T]IF`+
M$KI=@6%\A7YV!&I.UT?Y%?%WD)RAL3GLQRP(.+_#-K;O&M=%FY=U&^)^"/'G
M\/P**\`06C.15"/'EHYI.V(W^'1HZ=RQ^8:,!/GV)8A\0,H2>C),YDV1.^C<
MP00%UASD9FM/5@\G'*WOB/R=*P]N,@@&A"O+YS0G&`#P&B`N)5!!5KXL_-T\
M)N#'AH)-/!UXYQ```9A.6`N@$[H8W'Y2JH\0ASO'B+T\D6.3N+,0.6TGXBWH
M"/>&L6':\+$Z5>_J92+2^(UOFK[0`W<!QPT>)1M7-)CGR/W`^1-+00(/2-GV
MASYJF(\W`,H78]6;(1*TX<>V(SMV;)DX-VSY=D(!,1,9##S2#U0_E-U8'8KF
M9"8P?@`>1KK9.4RA1D9/C3K.G;@:(N&;!CK>S09_@]+(^+`_"US_M_0Z);=0
M&1$&'K`5\'NTQ[.@<_%<TM`4C5K.DTO,/N4--#72#NW_FS:4@4.+8`K6^:4&
MOL,Q82()<%H;(M&8;UV%-!OA:@<]0QTFER=VQ0AJ<71Y:;U-9B?%,YY*2ONY
M[ZMDCB"E;!J.ZI/AJ!Z"M.^M]^ZA!Z5GVLWKJ>*`?3Y,9CZ9.5]/_>,O=0J7
M"NPV/X>!([YKH-SC)1#D,CP$</K150?7/)!QDG/QR+5F4GV&R+62*#FR?BJL
MF8#0CB//U^UK\KZI@/3\Y9]@J%ORTT^?+BZ'M$1Q.94C(R8'6S,`\CL/_&I3
M?/-E`?"1BP]0(=X4'5DO9?PXT=-<C9TN6.23*W?D+<+S%?E0U@WD\`RBR(R.
MWZTP`1X;OUM1@X=^=@W4!VY#")I'`H3$H2*#7*5$A)N/5X0OI$!3:VB_@;^P
MP6C(]-@&C6$:VZ`TL,S8!JE%_`JA*8]NX$K'KV`*^&]L`U4ZJH7,5%P+:96)
M"BD-?N,7VZ`5C_I"*J6B6DBI.(UN$(K&M8#"'Q<R#&IC&RA^!1C9(#(9%Q+"
MG,4W&&'C&R"@HEH()61<2(GSS=@&CE//V`8F@,#'-E"<(44V\$S0Z!7<"AG?
M8"2+JLFUC$<45V=\P:4P\2N$4'$UX8AH3'(F65Q-*N.&8IFP4369%7$[,".,
MBF[00D:3ERD15Y-))>(G")Q5Q#:`M^(G,,7B,M`S`)*=@4FH=M%H``R,KNLS
MZU!,XS"MSD"'U-%2PXV(F]C0>)Q0\_+Y7T<;]RHP\0P;R`@.E0<VP)ZR`4:G
M&1:X<ASCT,P.(_B;,*,`BONNAF[A*3GJC_G\=SSR'MG)CRA0JE`D"R\]E9_^
M+)>+ZU%HH8<<IG^.PDJJ`*Y[F5]]X9(^I4@]&+]L#WUJCV?.5M-,1XV3T.<O
M&;`6D.3/#4&!_0@Y<#"=6JF&?Z;Y<,%+@B;C)=%FZO^Z)#N]1(3O*?`2]I0U
MBGB.)=I&`3UA6D91)N$JGF6)4"J:Q@G@>32/$VE%_`1E190B@);Q`I\8&\>2
MQ%H5A>,DLW%>FS!J:10/$\8,/[.#FSCO3*#GBO.(A`%YC7L,&I((\O518>/8
MF3!CXW4\8?:<UUAFXT4RX=3*N*2<G7,<YS9>IQ(NSH4/E_:,7[@Z%\1<FSB'
M3,#Y\;X%.E09L2D@POL_EHOEXG_"`853#0IE;F1S=')E86T-"@T*96YD;V)J
M#0H-"C$R,R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$R-"`P(%(@70T*+TUE
M9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S
M;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T
M(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&
M86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-
M"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5#
M#0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HQ
M,C0@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`U
M-C@V#0H^/@T*<W1R96%M#0IXG+5=2Y/<-I*^=T3_!QY\T&Z4>_%^[)YL[WC"
M$Q/[LB)V#G,I5Y>LVBU5R=TEVYI?OT@0`(EB`B0PVG#(HI))9B;P90())%'?
M_N7QX9?'!_*DK!P(_.>OS),4X_\.'QX?J+]#!Z8&JCR%#5(_6<O,8(B[0R@?
M7HZ/#_\]7/R[M)#P(FD,_#6\_/SX\/[QX=T_PJO@OQF!/`G!G8`GP25W?W'+
M6'[?"@GW+==PWQC%\1>RX6NF#:6#H61P;$)YG=YY`\>;)-WD:E+XV[>/#__T
M_?ZG@QZ<'6_=`[XA_$NCZ9P;9R83PUMGO95/0KF6>/NWQX>OR9.CR^'M;X\/
M;_[U\_[Y=!A^N-R.+Y?][72][,\[]\_#TS\,;__G\>$/3M)_?B%]Z&"-CNI8
M89A7Y\UWU\OK]7QZWM^.S\.7EBJ(2%+)$]'471Z<T&_WYR\NBO&Y*`<2+\HU
M-[-P#<V]OQR.PX_OC\?;%V]>AWPK291NE8S2N5"QLX^'XX>?CB\#I[N!$:*Z
ME/`N56IM.5@^*O'FKTR0+@&V;"5E#M,F&,F)CC9*J4<3?SP>A_WA</WP<7_Y
M?+K\/%RNM^-K#F;W$D6T)0/\&</`),E[J`L65JB1@148C!"VRJ"%\\`:@X+F
MJC%(;NHB?`2J,3BGJXM@#IM5!LIIW0K"ZU8(RUE526$XK3-H9JI](10G52N$
M9)I6&023=2LXTW4E&>.LRD`9K3,06E>26ZKJ#,;U5I5!4UZU@BMBJTIR"?Y7
M8^#$U!D8T;K*X"34&0B151',$EMG,%15S62:U1'%U$I?,$E9782@I&HF<YY7
MQ21C5-7-I'2EH=PTJ&HFM;3>#M10-\>J,6A*JLY+%:F;226S]3<(INHZ.%#6
MW\"8JNM`5P(()2MQT@V+53BX(%B]KU?N*S>NUB-]':^"T>I8PX6IMC$3<@4H
MK/I^YPQE_7\)+')TF/G<?3YKH&G60)>S!A7G1M1YII\WP#3)Q2H_;WB[_^E\
M'*[O!C<;O1TOM]=LQC"^YK_^"*_\#68Q?P*%GB2HY'*.`::TLW^>'Q]^C$I;
MY^3*8<=-/)OF<_`H&#3.="P9)Y-OOGE]/=XIY^0HP[T@-S%SO=@T9?./!D'H
ME$U9Z]_M<JSF=\.CM7=K-_F`=YOF5_LGBZ]V29?/O]Q@%Y#@',QUM>\(.TNR
MYG2L@U2U@XP;*\<.8MRDN:@P)DQ&O_OT\N*P-.Q]I_US747H"-!EZL-WJ6]S
M>E/?1ATW-!)T%TB:>OI=0D!.;T)`@P;0JR#)Y`HLR$TP*<N?,G'H3&5Q?$1Z
M(SY<:F/<E#$XL!NC4JZBX-KC8__Z?MA?GH<#7!Q_^73Z=7]>!)])2]^?3AT4
M(AF]#2)!S5H#^8YT(@P"C9'<V#S^R2#8Q4X.DT*_'/!500,-<0)$Z3MPS.B-
M.FA!<!U<?DPTVQDF2LH`KI;-L2"W`;78#V@\<\D^BM=([\"K%-/ZP6SY8$3K
M-RZM_N3`Z5Y[.#JDN@%S-UR.-Q@U]^?S]3>_N/'N^C)\NARNY_/Q<#O!H+J/
MSSF^KYQE.V'7`A&`TIF!XCRCM^$\F+<U%#I)&-SGY+9`N%V^!S4(PL`>Z,U@
MGSHX`SO;:6-VTI@-L7G9)`MR&^2+39+'9I?6HEB/]`ZL<QG';NUFIGYR]</E
M5Q=]KR^?:_'7B41QF=';<!E468V_3@0&R#FY#9`;!'O$@00,B8'>@\0@.D.B
MVA%N=\04=0'$+!MA06Z#8+$1\+A$"4SW`7SNZARN!%R-M_UEV@I`XK;CF&%V
MPG).;\(R-0G+A*9Y!H-KB-S_\7+\N#\]#\??/QXOK\=7/^>XWMX?7X9#-D7=
M$!1'\V-+)*N9O_0,K-8`D1MUH8S>YD)P%^_$Q.\1&]0/EN0ZCPQU]0,WYH9S
M<IL;;E$>D#HJ'^W(-1X9JLI';M25`[W'E8/ZF2O3'=5D)]G*H&((2V8%"W-;
M1H:Z68$;BPI=?3(^6>J3?#C0QH9P`%=C.-"61\<(EXN=O\"%Q8$[>DL^JJU.
M6R/SO1$2\M&WU]O^7'/Y?+P)MD4SDTDT^DVX7%@7V3`GS^E-3JYM,5)G3A[U
M#B;DRGJ&DMZ!#?'NC-SDW9NTADV84>MH0*ZJ9RAH'=DPMX[TCL0HZIVYM8#$
MR/UA)9\`?XV6!*-R]3U#R9+`AGAR7_N/3VX>W\&%-)Y5W=$W:^`?W9YV`,HU
MGOCD]#;':=``$*O1Q"<CM[G`=OD>M!I/?')Z`PA(DP:`F64++,AM("S*S\<$
MB><YB=XQ)LB8YU`KIC5*(<*8\/WI]^-S&`M\.E\;[&0AILO^F"ZWY3X@`L.D
M[`[+&P1[T,E"9)7=N4\4?3=A,I3OA#*5W`=IA`6Y#9;%1D!C(V<X.B.]`YU<
MQ<S%3HF+"'G+#Y?;_O+SN(A4`"@>0CF>8.3T-ISRXAP=#:$<S1$R<AM<M\OW
MZ.3X-#_26U$+>X<<F>9;E[(+O2&@+MMC06Y#;K$]\H!*.0Y9VC_)IJF&35D9
MVN&/U^OS;Z?SN18\W4M14&;T-E`&55:#IQ.!H7%.;D/C!L$>;B`!@V&@]P3/
MV/QWP9.8G9#5X+ELA`6Y#8+%1D"#DK(L9(IP=0Y7*J95X;*R<`0<6,)X1V_"
M,HF;XCQ-#538G/IWOSZT=5TH6!<-34:)F'Z%R]JZ$+!@'I+3FSQ$6;,I98SJ
M!TMRG4>&NOJ!&_&RC-SD99N4=V\/RD<[<HU'AJKRD1OSU$AO]50WL8CJYSMK
MPNRX61DQ($>,1@7[<DM&AKI1@1MQ^;X>&9\L]4@>ZY6*JT)P%7Q=IU6A<(FM
M"L$M;,!*]'8G5SJM"ADADIMSN)Y6A597@X)-T;QD2EH-"I?H:I!770V,WKMV
MH),.U];;EGRCWL&$7%D=JG-F0,H?UE-<T%-<&/MO9,"[,K)A`6$D=^R7QYZL
M[)??10:5UI2"[3.#/4/)=G]O"BN:W1D\,N"V1S8TGNC.D9_@U@NYHUR[D%);
MD(K-$%HD5]\SE"P);%@0T;WSAFC'MJ1+%;;Y[^@M"U*J81\<'*VP$Z_Z=^);
M-`#<XSOQJGLGOD&^!VUA)SZG-RU(M6@`F,$WWOM:8'QRTX*4*FR\J]K&>[VJ
M487]5C<&$292F0EC,HQ'?S[M?SJ=3[=3V*A\O5T/__O^>GX^OBP*'_\>591(
MNHRCHFL+QKZH!),DO%E\V?3WO-@]$U_LTE!JB!BC(920W3XWBZI@A0',<1ON
M1OA"783JKXM0&^LB%%X7H;KK(K8(]OY?J(O(Z6UQ88MH\%^\#*+/YO')EJ5`
M1?&EP$3OF*:&'5>("Y;8&!>HM#2OICU/\6%#2:TJ%!OD]#9<EO?KT=$+KQ?(
MR&WPW"[?H[&PY9_3VU#:H`%@"]^=[VN!\<E-JW_2XLF4[-QBY\H]FI(I-0U>
MBBZ*)#_N/T.%9"5B@A88,G-Z$S*C=FL1$T0@D`SDCLPD"MY<R>M%(:",](Z5
M050'MF,<BAME)98BK;$@-\&SW`U8+)5:X"C5W05A4J>",&739\B26IY0^O+I
M.!6$K8=14`8%J^Y>FXM*;@RC(`G#K.Y=7FN0[Y&I\16R2.]!K$96R.C.$ND2
M6K8>5Y$F69#;@%MLDCRNPNH>AMA([T"LM`FQ;/I4`KZAS!![@H,*CJ^W&%^'
MV[6<(-S%6Z<="N&,W@;AH/5JO'4B,.S.R6W8W2#8@Q,D8*`-](Y]P"@Z7X8Q
M.V-U+<8N6V!!;H-JL070&,L5CEC>MW<"B!7I@\+980LB';;PX_OKRVUP:/TP
MGD&`S@CP6,L5#M2,W@9443J4`8^U4%2,X'5.;L/K=OD>GO[C*02V@=ZQ&Q$U
MR&.MI3O*Y(9(NVR0!;D-OL4&N0M:5(:=!+@ZAZNT_!XNL9T$N(5M%][1FR#/
MXO=LE'"3/A"2W,1ZC</U@PO)^]\+<+^+BJ-MT<QDDH[K[.$2W5&`>ZB39/0V
M)V'%[TD3OT=AT#N8D"L[,A3T#FR8:]&>KV#]DUNT!L2-6D<#<E5'!ESKR(8Z
M9*#WC"-![WRZKG::UY;RHQ7!H%SUD:%@16##O+BK[?V3Y;;'`KMPCXS.+,;-
M2W]E(O+#9:4$`#@PG[ZCMRR[2!*_8294I%47IN!Z63,^6WM9'T6"N='R9*6*
M+B/J-0^1&W/SG-[FYJ0X%F5N'M4/EN0ZCPQU]0,WXNT9N<W;MRCOM`W*1SMR
MC4>&JO*1&W/Z2._)>`@R"HN=H&2GJ5VO"HAF!0MS6T:&NEF!&XD"?7WBHT"Q
M3[(!66@\:[JCM^SD";TA_P!OT7CJD].;O&B3:("Z1E.?C-SD`5L$>Y1J//7)
MZ4W+GIM$`Y26-B_(30@K"T9'"8DG.XG>/DJ(Z?04'A:4WOSY>OD9V6GJE>(F
MQ%&*BPZ"P,>+$!V^_I(RQ"1#/3')=#H1D9FPTN`SMN(>PS;Y99>=C+S;3<-'
M/UD8_63WZ)?$;\L$01+FOK)W`&N0[[U5%L:@C-[FQ0T:@.\M6V!!;G/FHOQ\
MN.`:]V)>.5"HGK\)$0\48ISPZ;P:$I:%_^UZ.Q86UFJ#"\<SL9S>!E)1FE??
M#2X<3:8R<ALZ-PCV\.-X/A3I'5.C*/IN^X)KLS.<U4:;92,LR&T`+38".MI0
M_%RE1._`*6-I*UBQM+9&C9;SVN3MR0A`BN)'*^7T-I2RIJ.50!(&5MISL)%_
M<KM\CTT0A&$VT#L6U:(&^:*:(E".OR&R+AMD06X#;K%!\HC%K0YY.%R%/)S0
ME*$2O)`U<*$).*F7U]3`3M('>D*EH,RMXO'0WG='EWP_NQ>_'O<OA_'$J.?C
MK\?S]>,'2,JO/YU//_NSFRNA,M@<S3_'RU01&R[1Q3:XASE/3F]S'E(\["C+
MPJ/>P81<V9&AH'=@0UPN([>YW!:M'1*#UM&`7-61`=<ZLF&.&ND]@PM!3KFR
M.VOUSBA>66^+A@2;<NU'AH(A@0UQ\+[F]PY>;GXLYG.MHI]K%?R<FW1J2;BL
MK+<!!^;N=_263(J;>,:6BY/3'(S&.=BXWG;&<ZM>N4HGN:NY5:\,]TB2H9XL
ME3SE5L)J/+?J$%],K5QN%^6OIE80`T9L1)A$2&B30HRNKL9&;C0LZNXY!3?%
M,3T/BT']8$FN\\A05S]P8]%1]TY(-BD/`6!4/MJ1:SPR5)6/W&B0U'VS&4&2
M^OELANTDUSOGJ^NKD]&N8&)NS,A0MRMP8S&SJU/\D\5.N1OC9=QIA*L0+&7:
M:0R7V*0(;J%14O;M-,*CBJ<,0+)49T>MSCY:*H62NUF`3/N,P;3Q<II-R/(^
M(]Q#?5QV9[=<;=MGC'H'$W)E1X;R/B/<PYQ;]J;&F[0&O,FTSQBTGJDZ,I3W
M&;UZF%?+SKR:)+WO<I2=%69W7^]_-_>1::\Q6C*I/S*4]QJ1]E^0V_RXW/[8
MS*50\')';]ELX`TU)(#R0A4+[Z]B:=$`$(M7L?#N*I8&^1ZTA2J6G-ZT=MFB
M`6`&+UOI:P'_Y(:R%8`*Q=<N$[UC1&!Q[9)J-18(OOFQ_F50KS0S2:M_&-0M
M0"4!Z'=!W>^U\V:"'T7PVH]?!6'[&&N"RM&@:,'=Z%FHTLGI;4&@6'-Q-P#B
MA389N<W[-PCV[EVHE<GI;6Z_132X)U[@TF>S?W)[@0N%WUW!EX)99WF*"U.<
M3$O!W*;"8.9_!2J<;1K6Q_QNQ6[XZHE`?OMQ_S+\NC]_.F[X1@CTPU":T]M0
M2IK6AD$2`M:,W`;6[?(!FUX0@MF<WH;9!@T<TI`66)#;H%N4GPU53./'_B=Z
MZU(+&9B)99),TI2[:'_M:]D_W=Y?7TY_`\R^W[\<7[$QH%<^_"Q15&!UK:=?
MB)Q920V=ZI_A!\>\E8/<.4>$/_\R7*Z7XW!Z?84*?G_V\*?;Z\U=G-!5KC6M
M2KW.W7-1J^JH!`)0?]?=R]E)[LJH!"(P1]>]*]);!'M/UOBB<J2W9E9N#H/#
M;(&S#5)J?KS:HYYIV:P+<I_4;0.?P@]I2/3V@8\I,5L!F19`PK#WW?7#A^ME
M/N;-AKS=AB%/X8<ZY/0V%U!-ASJ`),P35.^A#@WR/205?JA#3F\:\EHT`(PM
M6V!!;@-M47X^Y`G\4(=$[QCRA/P"0UZG?#_D";EQR.L6(F=64J*3E2*=LS_0
M<<`;!SU\O/N2AG/7W__OAG-EYD*F-30W-]MIRW;68KGQFK@2C@6;VKD^B`N*
M1[",WA;!Q+8#)T`$%KI$[X$36P3[V"3P`R<BO>,S#+1K?<^6MH5]I%FVP(+<
M%KJ*+8".MPP_?B+1.\9;%D^BI8+9J0R#A>\@OGE^/HT_CSW`;VE@B.\43IT5
M4?JZ%_<*87QF(F%R^G%J+</6\^DR'/8?3[?E3V-O$%Q<*G+/1,%;2EY!#NK6
MK/N\CB1^X\2$H>=U9.0V[]XNWSLSP\_KB/2./9`9O"8GUWS'%-UI+39,599M
MLB"W^7NQ3?*I"L%/\$CT#D<G\00/2J=O&)692F#GOW`VO'NY?AB.OQ]?#J=7
M_P.A?LH]7#]",*A];@XJHD#.Z&U`)MN.]P`1&())[WF_6P1[B!+\5(](;RXQ
MI$DT0)>JL:;DS5^))`QVYDEM-11IAAFY51?_I%Y&::<+71VPJ,'/^$CT=AQ3
M$\_X(&::<G.>IMR'PZ</G\[[VQ&J!=^=#J<-)Z>#/AAH<WH3:*.>&Z,O2$*P
MFY&;L-L@'Z#J!2$0CO16V,QZRD-83+`A0NR,L3M+5KY\`^PA[3(C=X!YIE4%
MS'E,`P<<:T3@ZARN4C5IN,1J1.`65B-R1V_9$8291<@YIPH1H=6\0&3E[,!N
MZ3/Q]2W"?@DJ24#W"/M?;.<M)^=;A#URBO,^630@'ZP"IB*\$I12P4NX1*MS
MX!X:KU3WAXU4%;^U2_P^(`2]@PFYLB-#0>_`AD4YU?M5Y":MP>M'K:,!N:HC
M`ZYU9$-CH^H[34:0I'>>?IH==7&1%L_SA^*;:$DP*E=_9"A8$MBP:-K5_N.3
MF[_0]"`3\5<DX2H$4I&^D0^7E<IDX$`G%*)O0N$?-=/$6,QFQJ62NRVGLW;K
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M509!=/T-DAA:95#$J"J#IK2N@X%ZOAJ#);*N`R5$DA4.JU<X&*$K4IBU=5/=
M($3J/48E8?76H`I*/NJP(')%#[/6:]02M8(MXIJLSD'7.HX!2YV#K\&'";K2
M+TRN@9A):^JNR)0E=6=D6E7:U/G['_[R^/#X\'].4-?I#0IE;F1S=')E86T-
M"@T*96YD;V)J#0H-"C$R-2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$R-B`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2
M#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y
M,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y
M(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"
M#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N
M9&]B:@T*#0HQ,C8@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*
M+TQE;F=T:"`W,C`V#0H^/@T*<W1R96%M#0IXG+5=68\<-Y)^;Z#_0S[XP;LH
M:WF3.8\>VX-=[#D6,+/`O)1;*:EW6U6:KI;&FE^_O)G,##))K@S!5BHR6/$%
MCXA@\,CO_WQ_]]?[._1*S'Q"YH]]4J\X<_][^'!_A^T;/!$Q86$I9,*8O)IG
MHB:%T#1S-3TO]W=_FB[VMR3CYH>X4N:OZ?G=_=W[^[NW_VA^ROQ9$=`KQJ@6
M\(I13O5?="8D?S\S;M[/5)KW2@D*_R"9OB-"SAH11I-F8\)B>FL5="]5?$E%
M`OS]Z_N[?_KI_,N#G#"=7NL"MB+LCP;5*5431H1-K[7V,W_%A*Z)UW^_O_L.
MO=)T/KW^V_W=MS]\.;]Y?)C^^?*R/%_.+X_7R_GII/_Y\.H?IM?_<W_WHY;T
M7U\'#\+3K&2`,S-%+)QO?W^]W*Y/CV_.+\N;Z:M+E2Q*U8HC/$^O'[30GU_.
M7UW43-:B,%9.EGFF&+OZ?ED^+)>7VW1]._W'Q^79UOAM"(GMV3`2K#N[0A;(
MMW\A#`W]_ES6U/R^[M/F]W7W1S*HR;ET6OZ\+-/YX>'ZX>/Y\N7Q\FZZ7%^6
M6]ZE](\(C9).<D83M0"2)#M.-`-BTC$0F('/3)`J@S)CL<8@&595!L%0702G
M0E09&"5U$=148HV!4%K70O>PN@A$:14DFRFI,R@R5]M"-Q6N:J&;2K$J`R>B
MJ@5C1-5!4J(->8V!$%)GT..V#A)A666@,V9U!H5950LJ,:J"I`*3:G^@#*,Z
M`T7Z98V!8%1GP$C612",JPQDQK*J)E&DWJ.(/&@+(C"MB^"85-4D#,_5/DGT
MR*NKJ96H,V#,ZFKJFJPRX!G3N<J@,*X.7BQ174UM\%']%SB1=0PZ:JK_`B6R
MCH$<&!"M9-U.8D1QM3]H*UA]KP[>2]VI:^\%J7=8;>FKSH:QN5K)E(EZ5U*L
M^OL$U?'K05]NHK]Z%NX@8`J'%3B&%7@75B"!?%R!]<BT@86.VF8=J]C`XO7Y
MEZ?%!$\Z:'PQ@5064KB?^>,?S$_^S80Y_V(`O>(&DIX:3";R7/WSZ?[NYP!Z
MUH$RU[)U?-@;:IDI13'4XM+]MOZ!WI]V16N_K6O%_#9!^E=D7[`J"(T_KJ-Q
MKK1OCY,#X<.X_U[.S]./ES<Z+O]A>5@^_+(\:[._A2%G9F&H;@U=R9*&:9YD
M:T+[LP^NJ?33DW^RC>A>V\?WZXYH:*-MBN9C5*;Z':H`,(*A]M$RT!Q7>*^E
M:\?3WR%0J;H2OU`T`O,8<S2.80O,O]=SZ?[.I*=V2/J!R]T,BR`D"C4GM`WS
M``/6')5CV``,[P>&DBLJ#VO.=D@/S&/,T3B&+3#_?J#F)"5@S?%"S2D41T+`
MFJ-R#!N`X?W@""U6G!MF2I'18:;GGG73:7Y[T'36?]M,?O5OFR;K_6U;M/+;
MIK,-XG9%:[^MN]H@;E>T\MNFK<UOC_62\D^C5\HFPR@-_E[+$'3=9][&OA3H
MT#@2U8R$$F$8$<9X2$FPF?E,U[\O+]/M_+3<ZN!LUQ%K*_,V]48Q9'U<T:+U
MV2$P'4RL1NO;U&4=N;-R7$F?>2,F82-=YNV;`R"S<!+E!LF*W@E%D!F&@OF)
M*GJ2G-4QV1$"-,^>WC?HVIO'CJ-]\ZS(O74R%^KDH'FDMLM0\ZSIG5`D0\7F
MT:;A-(OY`).Q!/O*V9'[3$NQ<9)C-`:`.=OAPZID4W)ZEW]BQY+MZ&;K@&YE
M,-APH*=80UQL!C8SU9I+CN0AW]:BL[$`S':Q7'*B=X]".3>)MJ,5J.X5?<@`
MM(@V`W5?W8D\Y)(;!-L1#53WBMX_KE";:#/^]CHG\M"`+@J&W3$A?NIGGI[\
MDPBS+?\85]^`:$-SK***9!ER>E>T04.>@DK*0K2A9]7,11N_O]Y>3)[BW?7Z
MYC;=KD]OH,AY5#YF*P"$"A7#'25\IF3Z"^+H\?+P].G-<ILNU\O7E&\ZCY>O
MW01#>AIBW<1W7U7(6DFJ>*IERGTM/YQO[Z?;^_/S\A4%$XY_>^T(YU&(69>D
M9L`X]8A9@+#J_7*^+6\FLXRV7&YVJ=!TJ?/'C\_77Q\_G%^6IR_3-Y2<$$+3
MV^OS9*;<NMEW&9H&G$6/H(=JP/GMU!"XNK$:AFT<HBRD(/QC:;0&;C#\'L^C
MJ6*6*?%;Y^7A>TURS(ZA#M]S0['[4(K,E6S+^03P7H\<L6.H@_?<8+SOZ2/Q
M?D@S9@$E/E'&3Y@=Q?O&13J]@HJY,HZAJE?@!N<,8WW*%3UN%NNA/7RO28[9
M,=3A>VYHPC'4IUS)!O#&`COP08\<L6.H@@_<X"1EK$_920K8I\A)<7$22-;[
ME,F1!;V\BKDRCJ&NE^>&)CK#N?!RHVRF&S$7KF(N7*5<N,IRX?D<*:3$MY%0
M3N^*A'RJ7#LQB:./I@1[)_:'Y^OM-FF7]?;QI3:/29ETE3+I*F7259;5W%9(
M(6$SEBYV18_3Q=8PID2[2HGV@-LR%'![-LA5#.5J7<ECU-9V>=1>@1RJ8RB@
M]FR@CT!C.2'*(^YL/+,3HNHD<'4^EI815%I&4&D9H:1(8`.=PO@J0TL#6-N7
M5AE46F7P8!U#`;=G@[S!4+=Q)=O61CSJH$`.U3'`J`,;Z`;&NHUD`NXV](2(
M.%%!*FLH*JVAJ+2&HM(:2E$1SP;9_>$5EDKU`[-9F:^W1!LNQ]=A9'ORWMA&
MF:UN)',KQU=K>A!H.R?7ZQ3)<,JAY0M7LEV^-G56$&`"<WI7\JL#@3$T4!OL
MZ5VVJP>!V86R;X,=N<L*=<@W=@-J@SV]*R/6@T"/6Z`&=N0N0U"6GT5QLK!Z
M)L=7SV1</4.2X!3%$;]OV6]6OKR;?OS59".6V^\J`:HL+*#)\04TV;`(8`<R
MO'(FAU8?7,FV?+C<+L7DL094)7MZWWAM0&;'%;Q:-58EKF1;SKI2);:WPPM%
M8[A<R2X_2F8[6BC;C**<WCR*S/YJ'I.R",=1Q'C8_?_'Y;:<GQ_>3^?+F^G-
M\GEYNGXTYP&`A-TH"K/Q?P5C.#<\*I_P5`V'V=-A(6*MY$!N>+B-S3[<WUH[
M:O9V1^T0X?&`!:7FT$QS:EC--C7\-:'IQJ4T9JV5BIT<"W.TQD`S??L;/&=9
M:=OAS;ZFDY9W^[@\O#SJSO]EEZR&PTT-5H_[;)RNZ*0WI6V*,MP5;IHTY@9`
M)`\Y%5^)K>&F$20W`!)]9,8=$&QFW-I@G!A3#?$GT"@K^I`_:Z\4ZX7VC9+(
M0VZM7;[U;D"CK.@C\]E"HPC.3]IZ-P2D^RI)Y"&/6JR2+"`U!S`A5[JA=YD9
M+((!-(L(P8=1Z:W,SV8KES4K'\[/_[O8T!0P=*,(L#E&%"'`;K3!BXZ*)^8T
MEQ=_Z&>&A1"RTG'`BPX+-M/=WUP[8U%2)R)H-:M!N,.+2AY=V5>$I[NXL3EA
MM!.31?^[WS:]<XOY[,J(A/RAIP_YPV(&*I]=V9/6>T?HR"..,-3!T>S*2@`\
MH*>/>,!U]:^2APS+$\*TLOT(JO\5?<3UM52#X0'J/Y%'?%Z+8-,YH/I?T4><
M'5C_Y*20.LU4EK!HIP140B*/>+ER)4#S1B$P[.QR>I<E,&&]MU/)UZ&P@K9<
MEN?SDW5VYS<?'B^/MQ>3C/F\@`9I$(:9."8<XQYO4#SA-(H_]@G#0N1*QQ&/
M-]K&F/WVVIDCX*N>A(E('H_W>#P^D]+$\?_3R05OF#AR]?4FC@8LZ"@=?<11
M"MD^<3/N34N"_*4E#_E+7XF-$T<K"'*;CC[D-CV"S&S+$V9FQL^/)XY0HZSH
M0]ZSO5*LS]LW2B(/.=%V^=9G`HVRH@_Y4JA1^(D+/7G$#7OV@2I)Y"&76JR2
M32Q+E=_*8I[<5A;!XL9!_PAM93&OH$602.^L1F.A6)@N8&'.PWKWA\VS,5`_
M79^7QW>7Z>'3\_-R>?@R+;\^O#]?WBW3N_/CY7::+DMMBXO7-:B=JV@9"MH&
M-FA)):?WV3)67.V*_-98>-Q>A0@6A7TC_A'<XF+>*3V?W5I`2QZR@(PU;7$)
MJ+T".53+4$+MV<QN>[RUFX[>;3?-$/6XS1#%88B:@(JHDT2L%O0[38)2$7[<
M2UCJ-X$-6G<*]%Y-;%%@ZK[WR+&LM6U>!Z].!([")I)2:P2V31]*Y"&#W="'
MK!5SJ(,".53+4$`=V+9]:$7O-O,F=BWU(2Q.4M4.#0=-O%(1/@D;7DI]*+`!
M"W6>W*N'+=G4@\"83LOS#D,_>8=!XH9!_U@Y#&(XH"V0&WK/XKD@/"[[I<4:
M%J_#>GU]T=.W:UQ"7_P2>D/\Z+0-B@<E=5,$*^P>:]OI#0OH.?!0IM[5<C$*
MSCV'A^\UR3$[ACI\SPTLZ&?D/@?2`-Z:.0_>ZY$C=@QU\)X;VB<4Z`/;Z0/\
M?.LS.TE)3W*SZ0T.?YU>0<5<&<=0U2MP@UYEK$_9H@W-8LVGA^\UR3$[ACI\
MSPWLB!CK4[9D"WAC^!SXH$>.V#%4P0=N:-_38)\RV^GA/D5/"),3X0W;Z8->
M7L5<&<=0U\MS0UYFJ%%LR6*C9!,)/BMP(K&A]^RG%(@TS7Z,",@TY_0^T]PB
M6EM!(P(PJQFYSZRV"-:FSTH`3&).[]HZV2+:F!BHNO?T/JO5(EH;"*"Z=^0^
MB],@V%@%J+KW]*Y=DDVB]?@#=-Z1^P9T43`8^'`90D7SY$)%KF*HZ!\KH:+A
M@$+%#;TG5.2*QQ2#9"G%('WV^5_-89FWS]</(5S<7@\+QDA>TZ!T4%#&,-$_
MUL)$PP+:(CD<)G+5%B8&^%Z3'+-C.`P3#0MDS^1HF-@"WAH/&</$`#XA=@R'
M8:)%"=E$.1@F\@C?3A497DT5T4E2?L*\(53TN@4U<X4<PV&H"/6K-7T@`;'2
MK3D!$53Q6N7X'<-AV`CTL1VYRXBW]#%K,F4,&SWX%6+'<!@V0GUL3>\.&\FF
MCZG4Q^;3K/A)S0?+`28P#*IY+7-]',-AY`BTRXH\D)]HZV!Y%,D+420?CB*Y
M:(PB>2&*Y,-19)-H8R0Y'$7RT2BR2;"QC+P01?+A*+)%M+4^0'7OZ5U19)-H
M8R_VU;TC]QF@!L'62`#5O:=W19%-HLU8W.N\(W=%D67!8`Q(9WA<!_I`#,C2
M#FJ$XGX/PN9PV.;E_?(\/5X>KA\6NU??)PR-!?I=0]Q+"Y$<'8_D6->RMY$$
MF04Z'(QUR#=6@!;BJ8S>9QW:$=@1#;3!GMYG)#H0F*&];X,=N<]6M,NWI@%H
M@SV]SV1T(#`#?5\#.W*?Y2C*ST,!@F"3$>C]*]/<?\?%K#"L5J9Y6)FVWV]9
M;B]A::$6+6@4H'7(Z'W6@926TS;1`D&@62"C:\%-@LVX)PBV!V1P.1=%T3;V
M%33%OGQF)TVH!1!`"ZSI(S.BA*8I8+7C>=\:.W*?@6AH#6L!@-98T[L71G&Y
M-:2>[O+J;E*@&E;DD<E#4UN`L0;"L.%`8_DF8SA0S#<1$@T'E20:CL_:;)@S
MB#[>:`@O$(8-2$;O,R"H?5>;&?8(@W8$C>ZJZY%OS`;"L#E!8[OJ&(L(\@U<
MB.E)=,.-N%"3[.E]T49[E=BQOV^2';G/F+3+M[8#:)(UO=NF<+A)=)!^(JHE
M^-A7R([<%WP4*R0+/ECA=I!([[<A3,5M<5RDX`,);T/^[?%R?7Y\^:(MB(M"
M*M$'*UP=PL:O#F$-ER:80<[@.T/8\)TA38)GX20`YB+0!S:3!='[C4#T1'EI
M(Y`9UU`#K.D#P<<*3'/P`33&CMQE+UH:PQ@$J#'6]%Y#(6C>&+I=8V.PDR2E
MMC!#&JB$%7D@]&AK"="K,Q'NE#-/3_XIWBGG'RN+988#6BS;T+L,CXA7RYF=
MR"%XP0+(D^PWWX*A@U<S:!RUB]?,^<?:2ADKW&["QF\W8>6;*R*_-1DBWC87
MX"?,CJ$.WW-#=G#XAI06\-9.B'CI7`"?$#N&.GC/#=K2P>\1<!3AYYM?U$G,
M!R>NK=D1\?XYK]-*$<=0U2EP@R9Y_&J8EB:Q5D_$:^@"_(39,=3A>V[(E`]?
M+],$WE@[$6^C\^!7B!U#%7S@!MW!X`<4A"ST)ST+;5@-"RIY[7(]'$-=)<\-
M>97A:W7*[;&)[1@*+L1MB[9/+!I9MKY1-0]:&8-]1T[O2;(S__T$';2:`S(A
M:"7F>;4GUWJ0@Z29,7%.M:!EU"@>W6"5HQNL<'2#C1_=8(U'-P)NKT(.UC$4
M<'LVR%&PX8"Y`;6U7AZU5R"'ZA@*J#T;Z"'8>+3-"M&VHJ>9J%J8ZS0)2N7P
M'4/YZ`;4;];TD5!]X.A&T,&KDP-W#`4=/!OD'(;ZD"MYW(>LT7*H@P(Y5,=0
M./#@V4"O,-:'3(8RZT/K#"43[,18*4-I;;Y7Q6N5XW<,Y;,;0`.LR"-SC+&S
M&\8D$SB]N:'W;)%@I#UQ)YTDT!)G]#Y+W('`F$`"IBXS<I]-[9!OK""!4Y<Y
MO6MEM`.!-4%`&^SI?=%N!P)C0O9ML"/WV:1V^=:*`&VPIW>MC/8@,&-X7P,[
M<E^(6)2?QWFHD)Q$8\E)6S0F)Y%,"QQ<TM6&VE^6M]?G)>RH>#G_NCE[M8G7
M4"%>0^/Q&FK,42(XY$+#(5>+8#/^42%J0F-1D^X/032T`U69^P%5"9`=TT`C
MK.DCP0]J\5R;^&7?(#MRGZUH:!!K#(`&6=-[/;=)IU4:A'%THJQT9;H=XON:
M6)%'`HFFYH`"":K@^X\W])Y`@JJN3Y(929")R.E=)J('@1[81A)@*3)REZ7H
MD:\-@Q4$&(R<WA5(="`PPQEJ@SV]*Y#H03#/4!OLR%W&H4.^L050&^SI78%$
M#P(]AH$:V)&[`HFR_-Q'4Q&^"6B>GOQ3_":@?X1R3>85E&O:T'MB$"KC9;TL
MGNDALS_2\Y_/U\^/-W/3DKG4J"4&,:-1Q.^H>07=8_R.FG\$$T[F'6B=Q/`'
MU.QU8`T)IX#;JY"#=0P%W)X-LFEB],MI+:CMN!?QRVD!=8+J&`JH/1MH"<78
M)],XBKBS%+*@)XQ+'MI:#Q&_D^:U6$%W#+`6@0VTIF-]QA5M^T!:P.U5R,$Z
MA@)NSP;9X*$^XTJV?1G-HPX*Y%`=`XPZL(&6>ZS/2($+?8:=2#%!:5)'00NO
M4`[=,12T\&R0]1^J>U>R6/=@%,;"FK5Y\DZ`Q35K_UA9LS8<H"]@PY]#HRRL
M61.5[@+A--P%8CY#_Z3GI`T1'HM+U5X]]QB7JOUC;:F:LD*<.O:E9%>T;:DZ
MP/>:Y)@=0P9_4YBEPLGG^;:U#-6V#=PJ;]H=N;EE74G@PM)O:FZ%Q07O4`5)
M;\<`5X%[QU)AMM';,=2KP',G<[)R36SLUEP]JU]7PFY6K\@)SPWG2GW%A#K*
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MZ?#W>GOD&PM0^/)N3N^S#.T([&@N?#)WL`U<T;ZD*_SQV[$V<"7[DJZ%S]@.
MMH$U%QT(S""'OS\[5@.N9%O2E:B0=#5/3_XI)EW](Y1T-:^@B?:&WF-IR)R^
MD$:<I?GV^_/M\6&J^'2O05`F`H]33/\(IE7-.\C^Y/0N^T-46UHUX/8JY&`=
M`P-#;/>.I\(\%1:I,-QP@0V816?DKEET:+?F6730W5=#KK!C@'5W[W@JS#<*
M.X:"[IX-FC[G]([,;JX],9LFPKS"G.:N1$>^$D)]Y.`=`ZQ'8(.FRCF]:ZJ\
MTJ-YJAQT\.I$X''65VI(]XZGPGRCM6,H5(!G`^;(8YW8ENSIQ,;$>MU#->0*
M.X:"[O8=3X7Y1F''`.L>V*#)\6`GEF*N=N):LCE4@J^/'+QC*.CAV8")\%@;
MVI)M71B*1$D\+$7B82F2#DN1P\-2I'!8B@P>EK)%_4>,?GA\^O2RO#F.9DDZ
M"T7262B2SD*1X[-0I'`6BHR?A2*-9Z%(.@M%TEDHDLY";>!O"K-4.'E_D5Q$
MO0T#-^0:Q6B".31ANVM,)ZI(.E%%THFJ4A6X=RP59AN]'<-A@MGJ"GE(,99@
MYGDEU#TD.#T@Z4`620>R@E:6X3"U;%A`?RF&4\LKK=K]93J<1=+A+)(.9Y5:
MU[UCJ3#;*.\8#E/+0`??D?O<9D\'MS8Z'?$BZ8@724>\BE5@W[%4F&WT=@R'
MJ66H@^_I?=ZSTL$//KQK?60Z(D;2$3&OBF,X3"H##;LC]_G2INZ=3PD+W^^)
M]`$7&+_?0Y&Y9]>OO<[,?S3[3\OCN_?:-4[GS\OS^=WB,D_N*[++7S\]?CX_
MF8M0//63^5+:XP7Z"MHH1JK?))!X)A$DLSNHW??GGAX^/;D/15S6V3(@3;:9
MGQ;.F9'Q<V:D>-IF,TN$CXJ1X:-B38*-H]F>U-G,?`I'J`:KQ!5MRV<#5;(C
M=^6I6@1;TU2N$CM4X0-!8[A<R>:<L^U26H:/G?$<8F="8_A)JC&G9P8-!QG.
M6A,BX5Q20Q#MU`F:12U20%K_(DW@UE6<?VUJ14<#`[>\$)#'P1Z^UR3';!ER
M^'EADK)2)&6E2(K`ZXT9N"'+0493ZJ$MC_;\!<U])>3J6H:"YNY=RDD1LE'7
M,1Q>96!5!)+Y@3[P;9B@^^;*HA,SQRWF@^]X6!OC*B743ZZ,9:CK%;A!FTN&
MEPA:VM2:/@_?:Q(QI\BQT*;N74I/$;)1V#$<WH4`].8=N<_HMVANC+#3/%1"
MKJYE*&ENWZ7D%"$;=1W#X44*4&]>TP>^2@/W9G+"5/_'6T)E7RF^?G)E+,.!
M7IX;<I=#+>I*MBVVF)N$G)\T3]Y/HGCW@'\$%UL0?/]HI`\X2,3*R:4\%/2X
M@PI/X3%^.-(_@DLLV'V)9><)`WW$$Z*VCU`$W%Z%'*QC4.`(<N_F5#BY410O
M+R@U5V"#7"`:O18UMM:!"PPJ>^US/1T#K+)[-Z?"\T9/:[1+*GLVT/>AL0M9
MC>]#K-GWY9&ZKX90(SE\:X0+F@0VT-ME]#YOU]!\QK0&W%Z%I_`8/U19:C[W
M;DZ%YXVFUG"7E/9LD)L;ZK&N9-L'.;W*0?M<3\=04-F^FU/A>:.G-<T%E0,;
MZ-_&>JSU;V"/A?U;OI`2JL'72`[?.K:2)IX-\FA#C>=*EAK/^1VL)XAFFX.N
M#/"W<>&W&>*Z;-Q.[W(E12':!%@AO2D9XUFH_]R'>*48]Q?X_?05A5A-@I!U
MBNR[KRID7@M)76IS%[61@*P$8@6D7[)]A4S?28FK[[%4HLI`D&15!HI$_1<8
M$JK*P,UI_QJ#P*B.0:*95QD4HG4,,Z*RSC#S.@-&\UR7@;5%JRNJ^\M\T%X,
MX7I=8([H7.<0B!W@D$=MAA7B!TAGI.I(M9DZ:#:B*[5>ZX0<=1Y"T4&[:"MT
MT(4)FW7X6>7@:JZ/1")$I4[U:/[QS_=W]W?_!Q)<B'X-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,3(W(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3(X(#`@
M4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P
M(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-
M"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR
M(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@
M,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C$R."`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO
M3&5N9W1H(#@U-#(-"CX^#0IS=')E86T-"GB<K5W+DN6VD=UW1/_#77BAF:!J
M\":PM"QYPK.P9ZR.&"^\N:J^K:YQ/=JWJF7+7S]X`R23()!5H6CU[<,D,_,D
M"!Z`(/G=7]Z_^_O[=^1&&7DB[C__2]]($?YW^_#^'?5;Z(FI$U4>82<ZFQMC
MF#YI0D[:T-/U\O[=_YX>_;%F(=V!I-;NK]/UY_?O/K]_]^G?W:'<?Q5`;H3@
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MB.+GFS<ODN15D8P]V4TZ?7[X^]>[EU]Q#GUWM.-P?GT^C</;YF]T/#BZ`S#[
M?-GC,TEB*^,NC7"R2=O8_;GVX^5R.M_>/CU\.3_^>O?X\^GQZ>7RO#SQ[4$4
MFQ4]S8:<N`^@>/)]IS6@KO=U!FS'P)Y0I&4@C2"F::#YK)H&,U=M%XK;OK!E
M()ENNQ!,R:8!9[J=!6,'65!FVD$2IIL&PC#9K(70;&YF(6;74[<,%&/-+(1D
MHAVD;0Z\:<"I;ALP>A`DI;QM0.Q%L&7`#27-++@FJADDG\G<;`]<$MDV$$3H
MI@$GLFW`"&N[H$2U#>RUN9DF,[3=HI@^J`6;B6F[4&1NIFD;O6RV228H;Z;)
M.&T3Q1@E[30I.>"!$#.W#*@A<_/DI9JTTZ0S4^TC*,;;,4AV$(-@O!T#/^A`
M*#OH)ZTRG)OMP9ZZ[?[!'&S73#0CF%F[Q2I;JO:U0C99MCU@LZEP-R)JGI3M
M^&W_VJY1ZWSZ>S2)*5`.ZPZ:=0==ZP[;IR3A0664^5;I&CN6\\KCP_FG^XO7
M]$]VX&'U_4)SA,/\^3_=(?_A=-!_N8!NI`O)CB=/8?24_WG__MV/BS&<$B>K
M)YR9:PGVUWW\)=ROL-G__%SGZS`FW4DX+N-L)PW+N"HJ35)4*<!E,,%@%5?:
M;KV/QA5V/0Z,VTM0"BS&N(PF&*P#B]OM!6XX,+]K1V!J3H&E&)?1!(-58&F[
M'HXK['D<EQ`JQQ5#7`83#-9QQ>T(PL*N'8')W/!3C,MH@L$JL+1]G+"PYW%<
MTNJ'%)?,3;\*)ABLXXK;$82%73L"$S0%EF)<1A,,5H&E[>.$A3WWXBKVRHZ6
MM-(^+AN!^QF#T;,/T1N$GU5<<;LE3,O!H;7U8.Q%VX^LE9N.,6%D_4<[(MP,
M?%_CR`Y.C)M["H[FV80YJ6_^?+F]W/WB+@MOZ<V5CP2^S7PCE!T[Q1DPSFT;
M\=>BWU^?'DX__/-RO;U[?N-<E9_43-,\5.01N/_MG/_IT\E-,?WM;?W:?6:1
MLI8S"Q3_Z8N;WGO>.1<4T^E<<*TKG@OAIP@_]?9<2-O'SX6PY_&Y8,=0Z5QP
M$<1SP?\,)X`W6)\+:;L;?XG!P.P@W\U)[\[+O/;8Y!7';I1=6<6:FIL]M>SP
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MBB6.C>//Q4#=8<@&J&?5-5"/4:4`<S!Y:+RY%*3MUCN']-I!Z]6&'%ZCW/@T
M!19C7$;C#3:!Q>VNB8RV?'=7/E_B;6`R=N^?S]?+GHYT@]4890IX&9HW6$>9
MMN-&[2G(%GON7$IQQ1"7P7B#35QQ.X8]+4N7;Z_"1,JHQQZ>OC[N"21W6L8P
M4\3+V+S!.LRT'=?%]-#GSND4E\QG116,-]C$%;=;^N3@%5-44MG1QPR-]'W\
M>!?6*6PNT*]Q-XNBGL6-H7/43/]]OMO(YM?X,;KX83>"D)C6MV_H1!*V&'F:
M<-X""R=>RUAIWS-3D;'?G;_<K77F<LXES6W$-K5L/=4TQW+.!=?`PYZ[#?Q&
M^V5!UBA.8EOF[,BFNKY\RM>=A$,=06/9C]M5\KSLA5&3Y@$H2_KAN_/]^?'V
M<CJ_G+Z_W%X>?KI<3YQ.[I:1:`?LKQXVLB*;/I4+T@(?NR#%B#LH\U<8-QI<
M!;"&AR:(A_QK[\AJ\E4`!1\L&;>7NA3!8J$6HY/A9-)V>SLH?UG:DK*!QZYS
M_:3X"Q?@O\`[*F67$K>G9%M*?G,0R"S!ZM3X8'6$W;)?'=J.QU_PML1LX+$K
M:']A?(\+^"_P8&'\GHC"",7`PM3X:&%F`Q=&Z$D0-LV<M6/RG?66G`T\UOOW
M%\=?>P#_!1XLCM\341PI#%B<&A\LCISG17&HF['SBT^))+;HDR0'[/B[#EMV
M*G@P)+]G":F((1O2P6GL9RZA6#2R4GY/1*7<LCRH4C4^2HM8GD94%%H(XY,P
M?*)B;L?EI\6W!%7P8%1^3URQ_,09$$N!!XOE]T04:V8<+%:-C](BR,[%2$Q"
MF8E0=1"3`2\(&WAH$F^_SRM*W.E2RZ.3M%RLI.X2'Y*Z7*65'XS0I'0%9RHH
M73OZO;[<_<LO-7<K0#Y>/EVNU\O'DUN'>GE\CANV0Y57AN54=YC'F(G.-^(8
MB2M2'I\>+P]?[I]^O5Q.S_Z.W%/S=IG7R#8<-]]3DU?A;*<E-64WVUL0O)J@
M<B?`RG.&47H[\M-VK+V'F:X]9WQ8:$N973>&P\O5*D#R!4;IZH[DO?X%'&<8
MLZJCR[$3R@#K%3ZLTP0;8]UKW&WR!4:)YH[DO;@%'&<8,^W=Y5@QD/4*'Q9@
MA-2LERO%K"8U\\;B&8"!`J,D<0<#7KH"CC,\[-COV>/8@-17^+"BHFJLP7ME
MNDV^P)CE#CW)>QD*.=9HQ[K/,5<@ZQ4^KACY&.M>8FZ3+S#F]G]/\EY/`HXS
M/.R8RC['C(.L5_@PZXHBNADO&@$&#+:C#7ON,0#-N\Z:@F)TA0^I/L*2ZLM2
M5,8IUS\\/W_U<ZY6A-Z&V[=!^'UZNEK@\?GK_8M[*`K0H=B(W)IL+5-$2L9Y
M^>?+]9>[V]4=-7"BUSF&%&?$,8K3+7D8F.AUG@#A&6",\$R$=$[T.D>0_HSX
ML/YDI23+T=L\2<;;\3CI"/!18(P6'>##*4C(?X8QDG3$OWO<!:A'A0\K4R[V
MZG$\K0MP46",0AW@PNE*R'^&,4)UQ+]B8"TJ'*-7P5H8:L^-@]M23F4"?!08
M(UL'^'!B$_*?88QZ'?)OP'I4.$;$5O78DU/@M"U`18$Q6G:`"J=`0?\:[5\/
M^><*+$6%8Y1M1RE>ZZ3JC3<RI./`^^*4[!T8G$8&BE=@C"0?*)X3TI#_#&.4
M^8A_QL'&4^$8@;[;KQY.I1OP.E-@C$[?YV,Q6SR+&1;H2WQ$H,]*Y]EBD:=E
MA?]]*-)?+M>'N_#2$E"E(\-R)Y;,BV=,7/1V_OEZ\>\B:4P(.X^@/`\X2I[+
MGGE9XEU`NMS#*%T>*3B:$'8>0$$>\'%!7EPO3@ZJ[-FA6@\Q`A04&"7%.RCP
MDAEPG&&4!N]Q[$0VP'V%#XMO=UV%N6<[47B5O$V_P"C9W9&^E\>`XPRC]':/
M8\5`WBM\F'<C8-Z9GB=!96-F&*"@P"B)W4&!E\*`XPRCM'678P-R7^$H42T/
MUV,N9X:!Y`N,4M,=R7O5"SG6:,>ZSS%7(.L5CM+/QZR_UDG5D\+ZN7W@IGZ&
M#[R<RP;*56"4<.XHEQ>X@.,,HQ1SCV/&P792X<,EE'*_9Y3SO!>)`2\.!4:)
MY%T*P,EL>W)!BX@S/KZ(>.9E,EO(K)65D!U:^?[\^/'TY>OU]O/Y^=*.WLM.
M&R:THGB)CRG9&'[O1+.[;[5=4;R`QP3MB'_M'4$KBA..T;4<6+'$"9GXT<H[
MKT:WA&S@,7G;3X@7I8#_-3RF<@?\.U$+%*3&,6)WIR`=4\U;,C;PF.;M)\,K
M5<#_&AZ3O@/^%0.+4>,8!0P50_M1W\&<B->M6T(V\)@0[B?$RU?`_QH>T\,C
M_@U8D!K'R.)2D+&YYBT5&WA,'?=3X34MY%^C_>LA_UR!I:AQC%9&E,+KQ2T5
M&WA,@/93X64CX'\-C^G0`?^,@Z6H<8P<W>NF]%$WY44D0,@:'E.ENX2LIB9M
M\<)SUNY7>,[:/<D>'VV./S?OPXY6E6(M2G:)#RE9FA=!:%G>2\O3BVG_>'DY
MW3\][ZZ]=6HNY)-22VD0DYZ)CC^W;_B.9J"Z)>CGY6:ZNXPBVWOY&...*2R#
M#08[<4<S2!,3S#)QOV='U%XJIJAUB3J'&@SVH@YFH)(FN&?SW$E(@><0=I<,
M.ZT9$DBY+*,.!G`"R0Q2WBC:_9X]M#MI&Z.."2Q##08[44<S2*_CHG9[=D3M
MI6R,.B:P##48[$0=S4"5CVLL;J7S4&/Q6C@DD')91AT,X`22&30R0-'N]^RA
M7;$<M<P]8A5J,-B).II!XPE<U+*O/_0R.T:M\H6I"C48[$0=S<!1"*ZQ2&;&
M&HO7Z2&!E,LRZF``)Y#,H%$+BG:_9P_M(G?H*8%EJ,%@)^IH!HUU<%&[/3NB
M]@.!%+4I4>=0@\%>U`9L+#6.&2&--!8_D@@)I%R640<#.(%D!HVK4+3[/7MH
MYZI$K4O4.=1@L!>UAJ/6Z*AU5]1^J!*CYKD7KT(-!CM11S-P#(=L+&+1LRR?
MZ*1DDE1,<F[.Z(=L4F++%((!G$TR@X:!!/L<*-CPM\^!EGJPW-.G9)9A!X.=
M#*(9-)!$M2*_9T\K,ED+I`26H0:#G:BC&3C\Q+6BF:M7M"*W%CYE8[)&J%((
M!CO9&%`C5/!H+D;TMB+@[HK2\-V5C(^/295AZ%>TR';`;GSH(H.&G$M\:,B9
M(NZ\H>(\`8/'!3PT>!SRK[TC:!B8<,0K6E($RUN#;!*,3%3KXWLJ`"<;>&AD
M-\")&U)!_@L\RHC;$V*DXPTM4'%J'/&&ED9QCN^O`,1LX*%1U$!AW/`%\E_@
M43:D0!7&#66@PM0XX@TM8"C"3#,UDSGJR]P@`R!G`P^-6@:*XX8+D/\"CP[Z
MW)Z(XKBA`U2<&D>\H:4.!?>&%H"="D:\H:4*:?0-+6`L&AV+1E7*Z7:H4C6.
MT/.+2M5*C(N)D-F>3AUO:`$(JF"$,D<6RTEB*)8"C\9"=R[/'6]H@8I5XX@W
MM("A4#FQF4V4'"@%IU4A<M;PT(V;_3YO<?=%\;"(/;Z=L2C=)3ZD=.=T]X7*
M:LV]>^%F>QW1RY.%/MW=6N'[Q?X!EMR_)BH97SL=7L/B5MJ_M0>1%O53GEZ)
M^=N.5?W.I2WEH@(5CGG=KY)]KWEQ+O3*<X91FEWTK>IW'NRIMO*<<<QCMLGU
M\A2DDS&M1?T``P5&*?0.!KR2!AQG&'/[I,NQD]P`]16.>:(6IKZUIA_(OL`H
M_=V1O=?)@.,,8VY$=#E6#*2]PC$/SX*T6Z%M5D/3Y3T!@($"H]1U!P->!0..
M,XR9UN]S;$#J*QPS,U]1W[>D'TB^P)C)]9[DO:*%'&NT8]WGF"N0]0K'+%,:
M8MVKU6WR!<:L3^I)WDM3P'&&,?/)78X9!UFO<,RSI&`W(XD=A.P&8L".ML`H
M0;O+`#B#:YL+]"SI"A_2=TQD?5>^M24LN<?+XQ_N'I^N[D,L=X\OE^OE&=:>
MR-AL7"I_[IV[-\![[9E6XQ\\@>WUHO4,/5@:<<R#I8H.O'>%>$_`\Z4!1BE1
MLB>!X=ECMPH2>,PTXICE^"F"U2NDW33+P6C9Z\@M(05&"=-^0KR<!/QG&*5/
M!_P[.0H4I,(QR_'W"M(Q7;PEH\`HN=I/AA>9@/\,HU3K@'_%P&)4^'`QM(2+
M02?.YLG8C#IFB;><%!BE8_LY\>H3\)]AE)P=\6_`FE0X2M66F@RMR`>H*#!*
MW/93X24IY%^C_>LA_UR!I:APE-1%E,(+U"T5!48IWGXJO$X%_&<8)7P'_#,.
MEJ+"Q^=VU7Y/I2=Z]#4(+UP!2@RV\PY['L_NN6_$*P-*X!4^(H&ER9]=YZ9Z
MG8KL>43TDKZ!:S<^@Q^E?65P,T\:6*?YU^.7;#N'D/2-.$;Z^J_V=<R^.A>`
MY@TP1O,F!HYF7YT'2.Q&'"-VD^OEHX[<3$:VIE\!"@J,4;D]%#@U"CG.,$;>
M=CFV^A7BOL(QNA;FOOE]>2#]`F,$;4_Z3GA"CC.,4;)=CA4#>:]PC(0%>;<7
M!J$GLOM&&Z<T`1(*C)&N/20XB0DYSC!&L_8Y-B#[%8X1JQ7[?5.P0/(%QJC4
MGN2=F@0=:[1CW>>8*Y#U"L?HTB'6G7X$DB\P1I#V).^$(^0XPQ@EVN68<9#U
M"L=(T$9/(\A>3^.D(D2"P7:W?L]=$J!96,GA[[^L\"&5)_/W7^JWE-@.=U""
M0N+S%6'Q]/T7*F5X%_@W_SA?K^?'EX[W;CO'H`CEZ"^]2#$P_TF\)TB+<NP'
M7Q(AG?.OSA$H23GNNR^4Y@A6)PTC<J)'KQ?V4G)+28%1VK2?$J\H`?\91DG4
M`?].D0(EJ?#Q-;NF49+C.5B`C@*C)&L_'5YH`OXSC%*N`_X5`\M1X2@!"Y5#
MNI?$3IJ9XRE8@)("HW1L/R5>?0+^,XR2LR/^#5B2"D>I6G[X/1-P"A:@HL`H
M<=M/A9>DD'^-]J^'_',%EJ+"45(740HO4+=4%!BE>/NI\#H5\)]AE/`=\,\X
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MW"9?8)0\[4C>RTC`<891NK3',>,@ZQ6.>4L?HI_QLA&@P&"[VMFTNEIH.E8H
M^`,K*WQ$]PF=/K#RIE]`Q$9DSR4QI\>P,%]`=(XAS1EQC.9TST0/S,0Z3X#T
M##!&>B9".F=BA8(_N!)QS.*`%,%RX261DY('BR^=>@0(*3!&C@X0XD0DY#_#
M&%4ZXM^*4*@@%8Y9,;!3$'6P[-*I2H"-`F-DZ@`;3EQ"_C.,4:LC_A4#JU'A
MF&E8L!IT(HI/3'9\!Q&@I,`8]3I`B=.<D/\,8T3LD'\#EJ3",5JV*LG0-"Q`
M18$QDG:`"B=$0?\:[5\/^><*+$6%8P1N1RE>ZZ3JDL'ON!P<N/4=EYT#@Q/'
M0/$*C%'F`\5S>AKRGV&,0!_QSSC8>"H<,W'<Z%J%.@K)@%>;`F,$^SXEBXEC
MP>''UU;XD%*7Z?$UQBTS>8:V:^'$\^?S]7*"GRA[763N].+IX;6AKR$ZCZ!4
MY^B'UH3HF:4EW@6DT3GV:;5$P='TL.#P8VH1QRR32*Z76G"B7$VSW%M;Y&7T
MEH0"HW1Y!PE>/P..,XP2Y#V.G>(&V*]PS(J(7?;GO0]_><V\9:#`*!'>P8`7
MRX#C#*/4=X]CQ4#J*QSS*N:*^HY7,3M9O$V^P"B=W9&\U\.`XPRC!':78P.R
M7N$H93W"NE?`V^0+C)+4'<E[Z0LYUFC'NL\Q5R#K%8X2T<>LO]9)U8W"(KI]
MX*:(A@^\G-<&RE5@E'KN*)=7N8#C#*-D<X]CQL%V4N'C[WJ83_N7H\:L-D2`
MP5X4PI[=:U>M\N2:@:\P6^%#6IFEY]P8H661L9Z/M++["F):]GNZ>SR=(:F,
M#<R=1"0]XT:%YN7=:CJ^A.++]>Z7\XM5ZO?G6Z^?I]/CY<6%>?FG6_UQ>=Y9
M^OR*F+A6VS;S&R/%I/3!]*[3W,XS]/JSB&->?R;(T)N+G2?@+6@!QJCYQ$CG
MC+MS!+T,+>(840_6A$WN#M7ZM2W@G#M`28$QVGZ`$J?((?\9QDC\$?]6T4,E
MJ7",TM\OR?&D.T!'@3%Z?X`.I](A_QG&R/X1_XJ!Y:APS%N*P7)0-A$M)V4Z
MO@@)<%)@S&A@@!.GX2'_&<8,"H;\&[`F%8X9&U0U&9IU!Z@H,&:(,$"%$_:@
M?XWVKX?\<P66HL(Q`X:.4KS62=4I@P.&@P.W!@P[!P9GW8'B%1@S;A@HGE/[
MD/\,8X8/(_X9!QM/A6/>AKS?M^I)S!UO0X8X,=CK3=ASCY/%M#L7&IQV7^$C
M0PFNTH.!9#9Y*,'=URV]8O_SY>/7V[18^_'IQ2KTZ^7V8F7\3_>7TZ?KT\/1
M4XO8X-PI)O,GWV=EJGL")@17K]0^??QZ<:]H=C&Z>P*7V_NGYZ_7RPZ;7L(+
M#<[01QPS0\\5Z9JA=RZ`&?H`HS2][/@0JA/M0H,S]!''+.!.KKL7<`/)%QBE
MWCN2]RH;<)QAE&SO<>QT.<!ZA6,6<`^Q[C7U-OD"HT1Z1_)>3`..,XQ2YSV.
M%0-9K_#Q!=RD9GWY?0K6?..HU\];&@H\?(/`[0FU@,VW#I93]5`0&4:I\HY:
M>-D-U*+"A_/7=%&+,F)MUL&+YRT%!4:I\0X*O&J&'&NT8]WGF"N0^PI'Z>_C
MWN>U3JK>%=;?[0,W]3=\X.6$/5"N`J.$=T>YO$`&'&<8I;A['#,.MI,*'__&
M'1F[2GDE#"1OL!<+O^=N\N!D/3/@E_4R/OYE/7?\M+"%EZ^],[?>Y7!ABU>S
MMT^/OURNSW?KIR+A^6H&?]Q]B8^)6M[]4A4O11GXF?8%/*9M1_QK[\@UUV4`
M!4>L$$\1+#]E,/-)\X-70WAYNB5D`X_IW7Y"O$H%_*_A,=D[X-^I7*`@-8Y8
M(;Y3D(/5R%ZU;LG8P&,RN)\,+UX!_VMX3`T/^%<,+$:-(Q:(@\6@DYSGB9N#
MZ10O9+>4;."QJ>I^2KR&!?ROX3%1/.+?@"6I<<Q4=2G)V%3UEHH-/":.^ZGP
MDA;RK]'^]9!_KL!2U#A&*B-*X>7BEHH-/*8_^ZGPJA'POX;'9.B`?\;!4M0X
M8KEUHZ/2\\%:`*\E`4K6\)@XW:5D-5-)E/MPM5.3]M=]^&4',O=Q<_BY^6QU
MM`(%;<(1@I;FE=I:%D'+W6\G:/]X>3G=/SWOOCK#*;J03TIMF88WV,DHF8$*
M=X&/*=R8$M`TL[V7D#'NF$(*ENCP4Z>?V[BCF3ZQS3H.@I[SI;M#FVSOY6**
M6I>H<ZC!8"_J8&9/MU78&4=-&-.1"6.G-T,"*9<4=6@CWF"GN20S2'W7\)CZ
M[F@L7M[&J&,"*=1(NS>`:4]FJ\928)1F[V@L7L[&J&,"RU"#P4[4T6S=6"H<
M-<\]TEB\'@X)I%Q2U*&%>(.=QI+,H-$!JK&$/8\;BY??,6J9>\3P,]#N#6#:
MD]FJL108-:;H:"Q>:,>H5;XP5:$&@YVHH]FZL50X9LW\4&/Q2CTDD'))48<6
MX@UV&DLR@\8MJ,82]CQN+'Y@$*..":10(^UBOT-/9JO&4F#4:*>CL?BA0(K:
ME*ASJ,%@+VH#-I8*1XV11AJ+'TN$!%(N*>K00KS!3F-)9M#("M58PI['C<4/
M75+4ND2=K_[!`*8]F:T:2X%1X[&.QN('*S%JGGOQ*M1@L!-U-%LWE@K'?.Z\
M:BS+SYU3,FG-)FIVWW--LQ1(B:440G/Q!CLM)YE!`\$`8^ZKQ)9S\)'T4@^6
M>_J43`H[UH/M]_3);-6*"HP:2O:T(I.U0$I@&6HPV(DZFJU;484/,\_5*UJ1
M)EDCI,12"J'I>(.]5A3-H+$KKA49T=N*H'L43/,XG'6_[N.O.8T#X\^8!G2;
MQEE`H]J,CX]JF0E//G_KWEQ)\V(CRG1<"?7=^=[?ICF_G+Z_W%X>?KI<+0?3
MB1&BCF^*Q)13]CE3F0:1\>=>TLG:K4M:/XJ0<#(^\&5F;[W2<N";PH^9+&,.
M!HOP5SNKLK,J.\]EYV;!DS5P4VD!#PV>4[V/!L\Y<UTRS^D&`SCSL$V5G=4J
MW6!PD'FPAFYG)7QT`$YDSGVY<L),LV&3,4?O/'+OO@JD)'Z6R02#9E[)&AB7
MXRKJ]^RIJ!V,IN!C'CEBF0:[NQ7UVU396:W2#0;MS*,U<#\NPJ/U='M"]?Q-
M8Y"?*(AL+/,.!C`%89LJ.ZM5WL&@34&TAFX)(ANUL%OV&S4_OBL7"4G<+!,)
M!LV<DC4P=X!KT'[/C@;M!LPI>)FO+>&G3`/RW6KZ;:KLK%;I!H-VYM$:N*>)
M:]!^SY$&[4;.B0*5)465=S"`*0C;5-E9K?(.!FT*HC5T6Q7;H&<#DS#SB2DZ
MS4>WNMW`/)*2^%DF$PR:>25K8(X#UZC]GAV-V@WL4_`QCQRQ3!,'NQ45^;H;
M]E"K=(-!._-H#=P5QC5JO^=(HW8C_$R!*13DO(,!3$'8ILK.:I5W,#B@P("-
MNL9'29B7EZKE`EK_Y?&.6\21E430,IM@T$PL60.3,;C:^CU+6EU#:C<;D1/1
M)9&L+(/!3GEYO@B'/=0J]6!PP(*&6=!H%O18"W<S$8D"GB^[5=[!`*8@;%-E
M9[7*.QBT*8C6T/U^9`MW,T6+%EZ/\86P8WPS&7+PZ1HWP1&)21PM$PH&S=R2
M-3!OA"NOWW.PD;O)DI0(S4HS_)1I,F:WPBQ?F,,>:I5Z,&BS$*V!90Q(%NC.
MX&FWD9NL+1,;R[R#P0X%1F0*(AO+O(-!FX)H#:VD0#9R]P@=++;U1&T#I_)@
MS9>;JDJDF*Q9JV2"03LO`\K.#3RT'&-?F\3I)<N)6]5L_P*/3??4G!MS4Y56
M3<27R.TXH48%)Z,#0:/=7%0HB[K1PGV)T)7E]V_HQ&>2G#37_K_*B:F=5`L\
MEY.CUH-KP=8#\P[*D?ST)SM]J^U%J;6=4JJ:!HR2]A$XI:1I(*CM,UH&DHIV
M#,J];:UE,!/=CD$3.YQH&AC3-J"$B+8/RP-K)TH9X;QMP8EL<T$%T;1M(8D^
MB$,=U8S.Q!Q$JBD[B-0<E8T1RMNL,WK4>!BC!W5A_*@)VVZ(B@,+PUG;0LX-
M3NW)^L-?WK][_^[_`<9TO=<-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,3(Y
M(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3,P(#`@4B!=#0HO365D:6%";W@@
M6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@
M/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@
M4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y
M,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0
M<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G
M94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C$S,"`P(&]B
M:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#<U,#,-"CX^
M#0IS=')E86T-"GB<K5U;C^2X=7YOH/^#'OS@!-H.[Y+R%GN]@0,G<;P3Q`'\
M4E.MGBFGIVI<U3.[XU\?'HJDR.(111*+!79KOS[2N5$?#R\2?_/GQX>_/3Z0
M)S7)CL`_YM?X),7RK^.GQP=J_D([ICJJ#,(Z*9^FB8W=2/1?")7==7Y\^)_N
M;.XU"`DWDN,(_^FN'QX?/CX^O/PCW`K^"0#R)`37"IX$EUS_AT^,Q7^?A(2_
M3WR`OX^CXO@-6?<=$Y.8NI&23HL)96QZ,0XN?^3^CURM!O_FW>/#/_UP>'\<
M.LJ[=_H"$PAS4^<ZYZ-VDXGNG?9^DD]"Z4B\^_OCPW?D2>.R>_?3X\.OO_]V
M>#X=N]^?W^;K^?!VNIP/K[W^W^/3/W3O_OKX\#NMZ;]^&7L([:9Q6,P9GBB7
MTIG#N$Z;,>>WE_/M\GIZ/KS-S]V/;_H_G^;SVZV[O'2_M#V0(V</>2)TZMX=
MP8+#[1?7-+#5<ZD;&1%K(D:U>/ZQ^^'U\E.LF[).*Y.L&R;2<:-TO;MI2EJ`
M<;8(L`T!RBG-"A"NGXB,@)R8&K("(Y-9%7)@^GG+"2@ZY%5(*E560-`Q[P6G
M.UXP.N:-I'3("Q`JLKD0$U59+\1(.<\*#-J(K(#.=]9((<DDL@*"#'D!3G:,
M9(3E!<@T907X-$U9+_@XR:R1?)B&;'O@<I)Y`?/,YP0X<'=.@$TLKX).:D<`
M&#PG0$B^1;%I)Q=LF,:L"J8FE763*2*R;9))33%9`4'R@6)LFO)NZDCF!<BD
M^_:,`-4:L@\O':>\FW2D,G^'@;*\#;J/SM]!4I:W0>P0B.X-\CQ)&579]D`U
M`^4%R([`1$76A)'FF^Q`QGR/QD4VS-`5Y#ETRMY?/_?YUCKM)&GG@:)DV+;_
M;U9$+BHH1XJ122?)%R,T*D;,M9ITEK('VI.I>W0%!,^'*47>'=Z_SE!RZ6KL
M#<JOJ"A9;O.G?X5;_@3%T;^!04\23-+U=P=%3O"_KX\//SJC)R%T3Z\OGQ";
M3:6.%U#FTM&8_.N_:*ZX+]#DL-Q;WZ#VULNEN7OKJ,"]&=%W&>H*/UV;^9OK
MPD^.NM/SA9\N1DRT_W<^7+O?G9]UP?O]?)P_O9^OFO;OS1ATGPUFC-4>+E=N
M>;@.1DPD&(7\T>77J_UEDKC\V?S\&#9$P%ISRJ9]JR#\BU7.0&\,-S^-`(_M
M<G_7VG6_4M\@V%:X5GDU<F^8M3&V9A&X-\S^71<W]8U)CU>8&Z_(9;3"=/>_
M$3DU3<Y`9VMLU2)P9Z#[>\.CM%PZ[$;.-$AKF+4QMF81N#?,_KTA<@-G:.3D
M1N1&XI\$9VMLU2)P9Z#[>^,3NADX^Y@1MCQFE;Z;2Y6YM68=3?S+,!<8:-2=
MG&&@__P\7_70__RA.QS?3E]/;Z<Y&0.;QX*P9HJU-FQ3+(14UM_;7)JYMVF4
M;78OE^;N#4VRS>[ETLR]39O0]VYL39NW)D^CF9G21:*M"[0.[6A`X2^NS7D<
M:W,JV^9&/['"1EVHV"8GN;2=WG_,;]WKY7;+VP8M!XQ8D_?B&V.,5S5&9UQ!
M=*!]@:;QSH`5KHS-<J6="V)/G`R#*0E^_:L=0_3PQV@<[BP)\$I3E.ZY0U/T
MT&$QY2]$$DKZ<60]G5C>+GA(L!2%>*U=YE)OER!DM8ON6*,?*R1=`5QKB[FR
M/ET#&=!TA7BE*0-7V71)*GHY[+1G(`<D0`%<:Y6YLB19:_\*_*`$3CD.;Z`<
M-3K*$9([RA$3_`;*^9?GOWZYO2W3R6\7??OCY7P\Z8'.V7(1H/#[>+A][+[<
M=#U^.G<7I&_\YTP%#0Z@=*6:AR?.L;TR&51@/*5:1@W+E06*@7]``\9+$5[>
M-PY3D6K#$TBX4[RJRR]2#;20ACN!J^J!$L6&/Y!PIWA%O4#*5,.3GOJ<P%6%
MRK9BM%`1$F<-AU>R!C"JF-P*T#@(QQJ<#W9!ZOOYLV:*DUD9ZP[GY^[PZ7)]
M._U]`2XOW<OI9\T4A]MMOI\G0:L9;2E*#Q%>1P]B:Q2-5S-:$\82(5S'$A7Z
M@11`$486%J_MH&%.Q%H0==!,DIZ.>_4"/.](2E*\CD+*0V(>_#0E"5S').7Z
M#7$@*0GQVI)`2CPEDNL*91(%%4H:D`2NHYG-@,15"5,XOSB\@5^XGVHU1MBJ
MA,-O4Y7<T<GI_'8X?SC!!"RPS>7MXWS%V.6NZECV.:2T$N%UM&(-WZTZM`J,
M3T*XCD]*%`-A@`:,2"Q>2R22>-5QJ]6C(#;F:A`D^"E>1R`%,3`/>AK\!*YC
MC@+%AAJ0X(=X+64HB@=?C3WE6S.<YLE.(Y#`=52Q&0&T(M$^HXSA\`;&@*6;
MA3$@HHXQ&!EPQCA>;GI$<YU?S9X9/8;Y='D^O9R.7N!\>9MOW>?#-[.LHP5N
M;Y?C_WV\O#[/UX**1>M%J27"ZZC%>EA:L4"[0A@FA.L8ID(_$`HHPHC&XBT5
MB[4@:NN<R9ZPH:!B05*2XG6$4QX20Q-I2A*XCG?*]1N:05(2XBT5"YJ2@2;\
M@U<L:4`2N(Z&-@,252R#;LX8_WB\GG^&B?G%8;7.HQ!EYU'^_72^7$]OWZ!4
MF:_S[2U3EX`9&'G$>!5Y.//VZA)0@;!&!%>Q1I%BV*0"&A"Z<'A#7>)41VV3
M\I[+K24L>*:QX*=X%4V4Q``>9R3X"5S%#R6*@0"PX(=X=5TRX,$7_<"V8@^/
M+Q*`!*[B@^T`8&7)H":<%AS>0`L#]P.9=:)$^(F2/UXO7T\W*#E>+M<.YJ1A
MAO7K?/VF:Q"8#.Z>+U_>O[U\>>T.Q^/E2[*M!"L^P%Z4/R*\CC^L'X7%!VC"
M:"2$ZVBD0C^P!BC"V,3BU<4'\1:8103%UT4$0:"W*Y@RP=(2X@T+/H%1M0L^
M2(H2N(YLRE-DN`5)48@W%"-ABE;"%Z2?V,YZG.&*-"`)7$<^FP&)BQ'=5:&L
MX_`&UI%B+49$4(Q8UOD1AC+=Z7;[LHQ]+B]ZY',WK+DK2;0Q**5$>!VE6"-W
M2Q*88D"X)(3KN*1$,9`%:,!(Q.(M)8E5'4^5D)Z0W'(-%OP4KRM)"F)@'NHT
M^`E<QQ(%B@T-(,$/\5IZ&%48_)4LO_LNV4.RKR7[U#L'NURADX8U@=NTEA4Z
MG.*4X_`&RN'2KR-#;-TZ,J$(Y4"M<[R<;U]>S1KQ;;Y^U?Q34MEH`U$:BO`Z
M&K*&EU8V6A/&1B%<QT85^H%\0!%&2A:O)25XZ\5:$'>;O1ZZ]D+M36L`ER!)
M2?$Z>BH/BB&5-"D)7,=2Y?H-72!)"?&&>5TT*1/MY5YM9]@@C4<"U]'+9CSB
M4H8RG%=H9AOF#J]0Y7A%TM%OB2-T=*\^?OH\GV_+M.W\,_R>._W3S-9VE\\&
M_W`]W`^<[LH;RG!>H<U[-YWAN^4-92BAT)9=C,N5!8J!,4`#QB06;YB@=:JC
M1CN,@Q[VYY:"L.BG>!V!%`3!/.AI]!.XCCD*%!MJ0*(?XBV4@49?]6K@N5(D
MC4`"UW'%9@2P4D1-^"Y:C]=3AIK<+EH*@S>_%*3LXO%O/Q[.'^;;W3XULUAL
M5H]?3X?WIU=DSQI:DH"A&'7$>!5U.`<*2Q+0A#!(!%<Q2(W^22V*$"*)\:J-
M;!46P-..Y2#%JPBDQH)IPG*0P%4\4J$?:`/+08I7[6ZKL4`_]D@$$KB*1[;U
M1S6'&O`]L1ZO[<>TY\.Z)W;EC\GM/;'SL/JVQ_GT%9:',Y4%F('2P]"\L]69
MMU=9@`J,%X;6G:U%BN'!'_"=K0YOJ"R<ZG@Y8:3]0+?V2YNG&(E^BM<10T$0
MS`.<1C^!ZQBA0+%YY)'HAWA#98%&7PW]-.4J"R0""5S'")L10"L+B6][]7@#
M,4BW[94-S'[YY/?GK_/Y[7+]5E`J2'P;:XS7<8&LVL8*FC!*D*W;6&OT`P-(
M?!NKPQO699P%R;J,8K*7C!=4#TA:0KQA728PJG9=!DE1`M?Q1GF*#$T@*0KQ
M6OH0*DI1,,'$V-B+01:4%FE($KB.2#9#$I<6'-_8ZO$&!A'$,\@Z32J9FR;]
MXW7^?#@]NYF,6["=]?CE>M5,L[^M%<Q#:2;"ZVA&E&UK!148O_#6;:U%BH%`
M.+ZMU>$MQ"((3BQ<R7[*+MA@&0CQ%D99K2EZ6\P\^6DV$KB.2@JR8;@"R4:(
MMY0@`MGGRJAF^*T(F`<]C4`"US''9@30$H3B^UP]WD`@S.USY7Z7JV+VC?2M
M;>]X-4+Q+:HQ7D<3K&J+*FC"V(*V;E&MT0_D0/$MJ@YO(0U&<=)@5/64C`75
M")*6$&_ACM6HZFHD35$"UU%(>8H,8R`I"O$6)F'(EE4Q])P7O&.#Q".!ZPAE
M,QY1*2(G?,>JQQN8A+@=JQP^H>FXA`IU-\]A]\!G*@ZP`J.2&*^C$E*V8154
M(!P2P74<4J)8DX31@)"'PUO(@["-BD.J?A"Y7:M8!D*\A356:XHK#B0;"5Q'
M%P79`#[`LA'BU;O):"8;BO>*Y_:Q(F$(X(9O!93E`BM!Y(#O:?5X/7'(T>UI
M93"[Z\8P=.*>.*ZPR\.-8?9+$3`&Y8^A><.J,[*P%`%-&(T,K1M6:_0#:PSX
MAE6'-TR9.@ONW@R;>C'NO)IAB`-)28I7S9Q6A,201IJ2!*[BD@K]ACJ0E(1X
M0^F!IV3H)U:PJ0.)1P)7E1[;\8A+#X7O3_5X`X,HX1F$L95!&(L9Q+TKL_$:
M7FX2Q%B&44J$UU&**MNP"BHP+E&M&U:+%$_+G!1*(JIMPZI07K7I!%V+->,9
MTHLA-P>")2#$&RJ2P)CRBB1-1@+7L4A!,@;['BM*'VW),/2AD-W#7&CZR!8C
M:002N(XW-B.`%B`"WVOJ\0;Z$&ZOJ1ZL^`*$3^Y=N^_GE_EZU?RAN6,^7(\?
MS2SJ\_QU?KU\AD\9=9?WKZ</9L]807$B\#VG,5[')*)JSREHP@A%M.XYK=$/
M_"'P/:<.;]ASZBR(MS?VTS3THRI8L\&2DN)UY4EY4`P/I$E)X#IB*==O>`1)
M2HA7CWB&*"D1V0\R>4,!+U'2F`1PP[@GL*CT&VF2X7M0/=[`-\SM0:63DGY#
MB%#V-)`?/UZN;YTN53[%7PW(E2<,WW`:XW6DPLHVG((*C$U8ZX;3(L5`%PS?
M<.KPEO*$J8T6JWJ=GEQY@B0@Q%O*D]68\O(D348"U[%(03(,32#)"/&&U^_"
M9*Q+-'IX(Z?<U]&0$"1P77VR&0*T/B'X!E2/-_`%\1M0"?=[UKGD=L_Z[\_'
MRR<]F#G\O,$5>!U"\(VF,5Y'&:1JHREHPIB#M&XTK=$/1$'PC:8.;R$0,FR,
M;X:>#R7S)$A60KR%1U:;:I=KD`PE<!V=E&?(L`>2H1!O&?0$&5J7:VC/IIUO
MOA@J2..1P'7<LAF/N'\7([%'`L"O5_M+N*_PVY_)T696"N,CC]?SD1B7?7/F
M4^9,KI\R'V2X<!SL>\^4#]8SYV3LT"*`^^;$,`Z+\2H.<\[EOIT/).'LMBYX
M8YGY:008;K<5&SM&[YAO@5N83XR;?927!RYP5EL'8E,7@0VKK9A^ZF*S5[SE
M!69G=_P",^VU<9DJQWKA'/*F"W>$P5:;<6(8PS:VF>72_38#M.7LMBYX8TW(
M%P$\^D[LKLVL<`L7E[09X"AKM7,@-G41P*UV8O=M)L!;&!QM,P/IQX%MM!DX
M*<)Y81WRI@MWE,16FW%B".]'<!7O9UH,5JL).3GZU[\L_2ONV5*%IV!@52E(
M!&R_]@*J^7`!H?SA`I3X]7ZAB%H/%S`?\?X,WZ2!@W7>?S-?I+$?]39?H\$^
M[+U?.-IPN,CX*/C#7^S/K8`X:;3KB/"ZKD-MSKC$78<UWWH2VVP$=LRWTDCM
M',%U/4B!\8;KK/'6C]AB([!CO)7&"F^'-ZQ..O-C4IA(+\FT7^=:IYQ_L2=&
M(.^4DT;[E;8&M5RZGQ-#IM9\ZTELLQ'8,=]*(Z5^6X-:KBPP'JAP,=[Y$5ML
M!/+&.VELG-#8H`;!H@9%X>`N/Q74CW3HY1YMFR[%NF:]C/TQ`CNN66FLZU&M
M<Z"!8Z5SH$+@2[8>KS\.20CAQQ#NW1<80PP#=9,:7^=;KF>X&PD(?'TVQNOH
M7)2MSX(*C(I%Z_ILD6*@2X&OS\9XU8NR):H-,R'A3O$ZLBM1#;R2ACN!ZXBJ
M0+$A$R3<*5[U3FR1:GAF4Y\3N*[^W%2,5H\,7W/U>$/UR/SW??AZ&IJNS.U;
ML7_\<CU^/,`;*W>G._1P.DQ!Q<PVRCO67MZQJE56T(31`FNNT"KT`PNPC2*+
M-199Q%N0;&&4=.K%4/#-0BPM(=XPO1D853N]B:0H@>NHI#Q%ACF0%(5XPR[3
MS10).$NLY,5[)"@!W%)P%"4H+C@(ON@J<N<O[A`."19=UQ?E)OL)PS_I8N-Z
M.L+'V\V@]3J_SII^S(#U>?Y\N9W>S(`U5X(0?`U6M!_8*#9/$+PK00BZ!BN:
MCBY<KBQ;@S4:,)(A[5."!)G>X:(?QR%7D"#!3_&Z@J0@!N:A3X.?P'4L4J#8
MT`02_!!OV+(1!C]:O]()4'+KHTOF*4^C$,`MM+&:4L/K\-CPP4V7P:]ENHR/
M?KK,_LQ,E_&-LS@]7L\_W)_%2=FZ9L(')N."!^J=3]F/NZ/5AG79>1][:@3R
M3CMIC,!BO(K`G-=[4V+.?.N)M]E/B=F?N2DQ$$$651:XA03Y6#8EYHRW?L06
M&X$=XZTTMK9B\99JS9F?OG!2LO\*B,@ZYGSTWOB#JW<:E9/&B-GA#16?:U0[
MS."O!4YTKEBOO/U^BFPG1TX:68%I:V#+E6539-9XYT=LL1'(&^^DL868Q@8&
M'\`-&MC>!W!WM.2&JCY(7;[!PGR:"Y2-F8^./R]\I\$Z::0CB^!*!\K6^+D<
M7:^E?]E>2S'/Y0I?9;-2V.K.'5[572G_G4SSTXW/U?WJCCNB]50Q7P?<NCCK
M_/8^^I5T^Q-=]N<;+V/$>%U'M;T)/>ZHK-W6A=A8([!EMQ5#RG3>M'5^N7+?
M:L.8UFKK0&RJ$=BRVHIA-;[#6[JF\#60L&L:Y=3+462J;>N*\RJVWPALN.+$
MT,ZH_2427O02R5UG9'VP[L2&&X$M'ZP8,MQH:T3+E?N-R/#88K5S(#;5"&Q8
M[<2PL4IC(X*ICLU&)(3LQ;0U6#'=@'7%>A7;;P2V7+%B6`>QP`TCG<(FA(U3
M./XVKL?K%V:XX'YA!OH\R_R,4GORW0^G\^%\K%JR'Q:+4,KFS:_D.DL+YV-!
M$T:^O/65W!K]0)<<?R4WQJM6:RHL,%2%Y"#%J^9(:BP`JDESD,!UW%6NW[`-
MDH,4KUK"J;$`GO4T`@E<5UUNZH]+1(8OX7J\H41D_JU;(OQ;MT(*YL^B.L[S
M\ZU[N5X^=;?#Z[P<E/GID_N>NEG+,>?MWFY?-*G,RS&:N1J9;51^K+WR8V7+
MO*`"XP_67+R5*`:"8!OU%VNKO]CD5<=?T&,]&>$3>KEOJV,)2/$Z#BF(@WG6
MTP0D<!UY%"@V[(`D(,1;ALX,Z?(WALYY+5EN<`[FSHY!PIK`;5J+UI8YP=>6
M/=Y`3$2NQ"0"8G*'Y!V^+6_MWA-/%YS?^_EZ^JI_=Y]?#\<9Q`MJ'(*O.<=X
M'3F1JC5GT(1Q%&F>`JW0#Y1$\#5GA]=2U2"]!3M/2H&6+`>1LDFF119?PVY,
M<Z2^L(Q*TYS`=4Q8KM]0$I+F$&]8>`K2'"\\34,_J((OJ2$Q">"641G6\/++
MUFS$EZT]7L]E;'3S<&2BOLCB@N)%ECFEYJ?#%0ZHZ>:?Y^OQ=/_%I+B@`M,P
MSHKQ*LYBF^\5Q`45&]%%:];\$DR18LT3;,07K5GC>RQ<>M7Q>RR]E+PG?',Z
M2S_Y6/Q3O(I,2L(`#ST2_P2N8I$2Q4`36/Q#O*&>"N*_5T_M:,E5-M[!7#V%
MA#6!V[06U5-,X4O7K/U-#^;?]*#!67S<G\6'<9`]*0NG(+1Z`@-1)E+-J\_.
M\,+J"31AA*1:WT>NT0_\H_#WD1W>PDL*>=N5]ESH<1[9.<36<`F2E!2OHZ?R
MH!A229.2P'4L5:[?T`62E!!O(2N%K%]OD%5>2Y8VG)\[)>TBBZYYM@4Y4IZ?
ME6("?SG9XPUD)=;#=M0Z*S6I^X))C_YN_A!1,P:$8T1O'P]7/>ASFW$.'ZYS
M.OJ[*Z$$_A)RC-<1ER@[D@=48(PE6H_D*5(,E"3P(WD<7KWO3WG5\><^>LIS
MV_ZPV*=X'3\5A,#P2!K[!*XCI@+%AA.0V(=X"R.ML=]EI+R6+"DX![/E4QK6
M!&[36E8^,?R4'X\W,!)SI_S0<5A?=8`-*O%6BON78\,79U^:5MW`:I2:6/,)
M0<Z;TIJ*H2<$17`=0U7H!T)B^`E!#F^8/'<6Q#75V$\3Z_=?.P"&0;*2XG6D
M51X50S5I5A*XCKO*]1L20;(2X@T32&%6FB:0D)@$<,,$4F!1\002P4\(\G@#
M^U!_0I#@:SG$5^XYG8_7X%V'Y7\,`9W."S'!YR[-C_EO7TY?#Z]S_O1CL!9E
MG0BO8QU:=F`0J,#HAK0>&%2D&/B$X`<&.;R%9RAR1`WP#&/]=/<MJ;NJ"$E`
MBM<13$$<#!&D"4C@.F8I4&RH`TE`B#>\`AXF('H%?.RY(OU(MKXW8I[^-!`!
MW$(GM.3$)K0,H*.T.TOAUZO]Y=\2L#\S[T.`!+;!]`ZOX27S>?^%EY08UF]V
M"[O-Z+=;Q-,=WKKW\X?3^0S5D![%?9L/U_U"Q,;`A<.[/K@]G/9G[@4)$,&(
M+<:KB(U.F^?7>'G@$6>^]22V>1'(FV^E$7*,X"IR+#$>R,,9;_V(+5X$\L9;
M:8Q@'=Y`L,[\^UT05$S]*/;.5M+<9/UR+L;.+`)9OYPTQM6-;<I<6I`6H$9G
MOO4DMGD1R)MOI1&^;VM3YLH2XS4=6N.='['%BT#6>">-]1F-;6J`CQ]@;8J1
M7E+2*UGPS1#GEW4Q=F81R/MEI9&^IRTIYLK-I$3E*U5X^>KQAFYB\.7K./G7
MYB2?9$$W,<-AET@'$9>K8!W*ZJJI6C*7#F7E*JC`&%FU%`GFR@&I&7^5J5N-
M*HQ657/=BMK`:4\&UH\LMQB*92+%Z[BP(!.&=M),!'!M%*:-*&QEPI`.DHD0
M;R$CS`;HX$;12[(U@C`/?!J.!*YCD,T\X)66\!6K\!6K6"M6L5NQBHV*5;17
MK'*M6-=/EFABM_-X?YAOL(,L^HY`05TJUKI4K'6I6.M2L5^7BHVZ5+37I;*P
M+A5K72KDG<V+P'Y=*O"Z5#37I07&&W(0:UTJY)W%B\!^72HVZE+15I<.TIM?
ML.5M1TN6&5V0]K:\`9F)M=`5\BXZB\!^H8LTTA1O<V&OT!5KH2ODG<V+P'ZA
MFS;2!*XK=$N,!^84:Z$KY)W%B\!^H8LTTA!OF&\-&NGNER+P0E>LA:Z0=\XL
M`ON%;IJ4`&Z89$$?O<R<K:%*QEQ?Q9CKJYCR5+[\Q-[;A3^A]3)KKY?Y6B\'
MG11WG=1_G^]ZJ*K)7>#6Q5OGN'?2?Z_;_D1?W(6_Z8<B_LI!@).&CFI[Y2'N
MJ*S=UH78V$4@M/O^XK678VLO9Y-L!/`D.S&L>V/-13[?+2WO^CGKNPU#[/`B
M@/N^_&WM))F\<W@1V/#=BJ&](VL?7F#>[P\O@'&7,+B(Q.8O`K@G3@SMOB*\
MKOOBFS5QW'U9NZT+WECA.X.-]"U_6_L^)N\\700VG+9B6*?7U'3-E35-UQ#R
MXKL+0^SP(K#AN_G;VG4R>>?P(H#[[L30/K.MZ9KQ&.;]QH1C_,*R"X.-2&S^
M(K#AB17#>DG6/)C;;+A+_S5.YM5('0OTUG3CUH+(;G*'B-MO)&VIT,QO5%1F
M@4]C-]BMPNII%%(M2?CAEU,!7C@540'_2ZJ8`A7!AO.X!;%.<7-_9FZ_WL<T
M$=9]!VO;N;]3IBW+WX!.60'.]..9$Q!,YFV03*BL@*)CWH:!ZCXS)S!2DA>8
M8-8@&RA">=Y/2JE@>\%6.^G@5/\U*R'HM&.'W$L958SL6#HPOF/IN)<U.L&^
MK&S;(GMMAVGNS_O"V&X+YI3M/"2""+HC,69BJI_$W_WY\>'QX?\!0&K?JPT*
M96YD<W1R96%M#0H-"F5N9&]B:@T*#0HQ,S$@,"!O8FH-"CP\#0HO0V]N=&5N
M=',@6R`Q,S(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]0
M87)E;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C
M,3`@,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-
M"B]&86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P
M(%(-"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X
M=`T*+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A
M9V4-"CX^#0IE;F1O8FH-"@T*,3,R(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA
M=&5$96-O9&4-"B],96YG=&@@,CDV.0T*/CX-"G-T<F5A;0T*>)RM7$V3V[@1
MO:M*_X&'/3BIT00-$%][7-<Z53FD*MFIRAYRD66-K61&FI5D>YU?'WPT")(#
M-$6NR[6[-/``]&LT\9I-<7_Z=;WZ;;UB]\K*AOD_X<K<RS;^:_>\7D'H@8:K
M!E1HX8TV_-Y:;AK#6,.-:<[[]>I?S3',I5OI)Y*NV?VG.7]<KSZM5X]_]E/Y
M/[T&=M^VPBUPWPHIW'^$Y7S8;UOI^ZW0OM\8)<H3\F;#A17.;F"-@[4JV/08
M",9.WG4*E0W^Z6&]^LN[[?N=;4`T#VY`<$28-%$'WAAGW\.SMT@PW3SLUJL-
MNY?277Y=K][\LM\WV]WN]/RR/7X['#\VQ]-U?[G_4_/PG_7J9[?"/VZW([BY
M;$?+W.:(:,B;?_.6#19P5CK:2C?:LD:$F?,4P5L.((2(`%X!<.$VF@*``$D"
M&#><`DC+%;F$-%PP$J#!TDLHT$`")%B2A6QA@H7@C#:2@Z4!`)+<"\G`D"Q:
M"ZTA`08$R:+5($DC6P7,D@#)#`UHV821@@D:X#Q-`X`!R4)8JT@CA;&&C`>A
MK*(!TKH#DP*T5M$`=W[12W"K)P!,T#2!T1$EV,1><&,MN037UI`TN6:*C$FN
M6$O2Y)+1CG(G(Y`T.;>T'[@+.4$"F-7DS0LNY$B:8$'1,QAH21O<&3=A@X*6
MMD%.'"#03IR33@TT&0_`@3X?`*8`#"1I@P4Z9@VSI-YHH4@_.]&DQ<1%-'U,
MT_8+2^\2G[JCF*7CA.FZ?WY#"$H1B')J!%U*`N/4")ABF!NY>.(A.6+WS+K\
M+R1'#]OW3_OF]-B\/1VO^^/U,LA:XC3__*N?\JM/D?[F#;J7WB27@S9N7MO[
MZ]-Z]4LVVNV[=(N#+ABMR7P.F/.Y-]JJ>ZE<RO/POY#2N5`2F--]?GEYVC\[
M@[=/S6Y[^=0\/IV^-H?CX^G\O+T>3L<?Q_F=U&B4R^#`SLOMXE@TZG5RYV=W
M#@VSNSMR]NQA+#6[<KR7VA['DK,[T5AJ>QQ+S:YM&V<WLR>/0ZN3NT>.\/3A
MDNX8]W&;(,0EGDT^)N.E]9>("-?=8\QHE@0/P6M[3RJ#CE)4JXFHYNDQQ8F+
MZIY3F,OA0E"_]7'\LCU\:%P4NUB^[L_[R[69X!R")W+N^&>F.EQ'C*98=WBW
M&QQZK`<=;,E]PZL;V`V03@0Z%HG1R'+$#%B,)S"]"4QO`MN;@-S\#F^&>]]O
MG[GU<2CNO3LNW3.J#B?:FQ\JWHBW+'HC>6;D`<24O8&=IC>!&7L`,;0W$M[H
MD3OZ'3/]H=JVX@^N[!T(20=\/'&B<SI'C?@@AN36X?.9^M@[;`<=,P];7JL"
MY`&:Z<PB,<J6AVU%3'F+L=/T)C!CZHBAW9#PHX#OM\_=X#!T3L#'@SYZH_/,
MR`.(J7@C=IK>!&;L`<20WNCPXX`?=,STAY:R%O#6W'%HZ8`W+*M:YZ@1'\30
MW!)^M-.OVV<*=#7<<P70"X&U'(797SWAE4IBA9>OBH>(*JEQU[Y$C%G*BYE2
M)HFQ`&7*8KP[/>^;Z_;W_:5&T1WS2#&Q'3*+@#+)!!N?1:_;9VHOLIS2WF0X
M<NBL;9-JX&51=ZV5>;`<48V`"FN$%;06FQ=)+7*^66H3>?3#D'$$E,G'/ID'
MRQ'C"*B01UA)6E/[(F4MT0>K[MRDE=#U!S8Z(?EC:'P$E'DD6$E&%X9N5-$;
M0M>?RLEPY-!9VZ;SO[9[L4_FP7)$-0(JK!%64,UEH1M%<T[H^L,7R2<_#!E'
M0(5\Z)-YL!PQCH`R^00KB>3"T-4**O0%N]-0TQ6O>\D'Z(ZA[1%0H8&P@AX.
MFF?*83UN"T^:5HNRM*7V^=437_OT!FR\M&')QQ=/3*KY_/UT#"63[>YZ^'*X
M'O:7'Z>?J[U!174:M,]2IV3H+4_V7A+<2B6EZ#?/JKG,6=\?RGZATF$]:+_]
MD--VC@7A."WLP>OV6<?L'`O\V?9Z#UXUSZH=S5@_G"Z%/7C=/N.&9;,L\"?#
M:P^\:IYU8-37'Z6'DJ7TV5UA^BS;+LF4;?&00U3QC$GM\]-G*TTJ90E??L;L
MV?AK?\2\VQ[.S9?MT^=06W:Y\_/IV%RNI]U_F\/E\GD?L^KGP_%T/ER_Y5K7
MR^?S[M/VLJ=R[.B'Y)*.?LY:XV4YQY:\6.!*[0OJ6U96XV>8):/=2&%H;`3P
MHE3'/I$'BSPXY^>5[4^PTL$9FQ>DV&GW;\^PD3NZ84@X`LK<8Y_(@\6(<`14
MN".L>&AC^]PL3<@R>[@3W-RYFX%*L:,7DD.&UD=`F4B"%<_^0?N\LQ^)3&;8
M:#=2Z(S-^69E]V*?R(/%B&D$5$@CK"0WBR(WCIP1N>%TCMR3&X:$(Z#"/?2)
M/%B,"$=`F7N"%:5N6>1JH_KL6\8@LM]L7KVQF5Z%%+045@V5M*-?T<5#?T1`
MQ34(*VEPOWF9R;>]8[+05;*@JV1!KF1!_WFCF/5#+%R)=J3(P_99BBPT*C+W
M/RM"16XM"O+;B@3O3L<O^_/EX/J"4/N_70_^G7#XE5SSLOT6WA!?3\TX3/Z`
MO<+T#0:ALL'AVEL<3/UT>OK@S&NVUV9[;/:_[\^[PV7?O)P/NY!9?$>;_%!>
M>OP6]T+<\'0"N?0'N?0';2?6T%)1D=#.>J'&V4ELYV9!=L)OS$X@%P"!CVR.
M`*(`F%_<V?S>+MT1`4#>$0EMAC=$;EZ4I!0WDTI2()<!@8]X1P!1!LQOZVQ^
M68>\(X!V`:+=F3OT06Y?E*N4G`!W4NL[H_D-SWN0JX+`1UPB@*25T#ZJVW'F
M`HN+@XG69.8"N38(N38(.?FH;&GLR[7!_'(."4<`S1W1HZC.S8L2F#E1':0-
M<H40^(AW!!`5POQ*SN8W<LD%`4"Z(*''4=UK7Y3'9"=,YC'T*F12D()LXA<8
M(5N!7(,$/O).!-".0O0H5G+SHJRF>I<,'XJ-L9C.^*N8SA@KDH;A9:FRX+M*
ME86N?7YEP=@N+>A^(M/.JBH\;8\?;BDD(.WD@8XM)`'#RV(AP?>5"@FI?4$A
MP;BC_A:I3G8CA:&Q`3"P>S0XO^@S^45?VNT`*.]V@A4*"=B\0*/39M^LT8D[
MNF%(.``JW&-?)_`FO^=#PA%0X8ZP4B$AM<\]R[7LLZ>.L1M6H;0RK5)]'/.R
M@GY-+A[Z(P`JKDFP4FEBV+[,Z`F!3W8CA<Y82%I5BX?8UV4')K\Y1*814"&-
ML$)I8MF]$$?.N!?\\8[<DQN&A`.@QCWT=6F!R2\.$_<`*'-/L%)I8N&]X'\?
M4V1O%-RY?X@R0O(!NF-H>P#4:""L4$88-,\27")J2X][1JFDNTHEW=5=21LO
MB3*"1Q3E-[4OD%_=II_%Z.Y3.L$U746X[*_7^'-L+\Q/A^W[PY.OZWLEON[/
MSX=C^$VV[]Q^/.\#<OJ1&OV37)7<HKH?=N(E]4CM(46=QO8E.JVG?]X7SFPT
M'YD,;8X`4[P_8U\6>95%7G?%\XGH2.B27,?F)7*-P7&[7*,+T!M#WA%0=D'L
MRUJO[(AW`$RX`-%%U<;V):J=G3"IVO0JI`#B*E,/'T$YHI>3PX?>"0#:40E=
MU/!!^S(*4QJ.YB.39+/J?L!9"Y+8EQ,`94>$`V"".Z)+4K[H/HDC9]PG03BB
M"Y(WAKPCH.*"T)?S`&5'O`.`=D%"%Q5]V7T2%+WD!&ZT+SY-/U`GCZ!SADP"
M8((4HDOZWF^>I^_5B$;=!57_3DOUO],:SAT^'7<&8?U>!MVM+:+Q$\^Y>R*L
M_S\"B/1=E6EE_*[JS;OON$A@DA89')#?=1';7R1'U^CWC?&[/>+;NPUGY+=]
M&^",_+AOPSG]`?9&N$TD`2VGOU_<2-"T#0HT^87A1D]\@K@Q(.@E+`!-$QAP
M\FO7#<#$Q^S.V4!_0;V9_)YU`^W4CH$$,V&I<KM*(_34IH'A@O8YV*G0<<$Y
ML2T<I@*8<Z"_SM]PP>C_IX1#&,*G[D;[^=?U:KWZ/_H91M8-"F5N9'-T<F5A
M;0T*#0IE;F1O8FH-"@T*,3,S(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3,T
M(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X
M-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P
M(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@
M,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B
M8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G
M94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*
M96YD;V)J#0H-"C$S-"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E
M#0HO3&5N9W1H(#,U-3D-"CX^#0IS=')E86T-"GB<O5M;D]NV%7[?F?T/>/"T
M;D=2<2,!UD^.$R=Q72>-MVT>_$)16`D)12J\['K]ZWL.P)N\6FRS%C,>>ZDE
M!)SK=RXX_NKGRXO?+B_H*DXB0O&/>]*K2/I_LOWE!7-O&.$Q8;'[#2=*KY*$
M:Z(I)?!`*G-Y\5]2N*V4C'"?2&O\0:KMY<7N\N+ZK[@3_IG\@JZD%+#_2HI(
MP`^1<'[\/I$1OD^$PO=:Q^+TAIPLN8AE3#2C!);!$])T[?CS+\7P4L0CP5]=
M75[\[76ZSA1A@ES!%YP<W*8]YT)HPJB4Y`J83Z*5C$$05Y\N+Y9TQ2)X>75[
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MR.N\K,#X%^36-CM2#NK%1<W.D'\7%AW#N4.](-^5Q9;\`_]!:]BGMLCQX=4.
M'&=!?BS=)_Q[!=^=@W7).]:Y5(/C1"SNW=H`T152`<3:FJ1DFY=K\.>U!8?/
M=D69E]L[DI7[0UK<`8=I0]H:D,`V-3D`CP5RBPP<JO)06=.D%2SKOVEAY0<:
MT68&[B(ULA=[X__`N3C_,7HB1:K4:$(<GR<F]&.>-M=EM2=7@^3.38V""'>?
M:7G^8]1P3,)7DE+F\.XY*).=79,*HN$H8LGPT8LX<<\H8H@\65ELVJR9Q4T0
M#+R;3$Z72G?07IG:I%6V<Y:^,3<F+P\8[$B:-?;&-FCGH'F'`!M;9^6-J>X6
MTY6+#@"*]AJ^TU:&E-?H,\A1[=Z9(EWG%I`"PFOK,068QAW!%Q'5M[#C'+Q3
MW:,C97(P[@B?D7<+4J^;"H.\*3[=[8UW]UU:[=/,`*49O.D7F7J%4%:;4^P`
M/NS3RN9WL#S+VXWY^PSLQ'0`^PBLN%<EPP"#[+RLR;ZL/!/N820=8<Z@T-/#
MH3*0UC3&R?^ZSW(6J+',U#4QU]<VLZ;(0">FN+%56:"601*X;XF@2M+-30J_
MVL+&H&O8,[]#>8`V$1E1:C.P'R6]'[&$Q0/[D>BBW:B-ND5[KCNE]L9FJXF1
M(KD=Q\9%N-R:%IG)=F:/'-03=G.S3;-C[%\X\;WJ@H?Y>##.V,E-BI'B#G>:
M0P0J&M(BK<9D47<QKS"WP&/UJVD@?A_*JFD+[\$@`4AAJZUQOGR[LR`@Z[P3
MC-QBM,.X!Y$_A_@(%K3.>VO)[QRG#\>!U1Q\BMYQ.4W8"%K,LWEU0O1`+;A>
M"\HJG4H1IQSEA?G8D!K@"G)'<@=85Z-I`+,`NHTM6B^=#L^<4(YBO,.OND&/
MKW=N0W`E$*4K#>9@G;/!RBF?6'D7D/-T74)B5E8]<=Y$*_-;:RN7T5U7*3A]
MZZ$8%?_QD)?`;^/`:\K<"I*X6Y2,LV98G:4%JK\`S==U6P$T&)\838S]SPXB
MP+9JGRC.(0,J>QFH>%1_K'0?L[9IM>G<&GC:IPUDL/5@ON#_Z-C7;?[$FC)<
MG,A8#=:I)D#4X_"T5`(C^<[6H*XGYTN!TD)*3P@D2I+.H`<IZ!`_^1@_8]G9
MXO<%>0F1+\>ZE!TC(H($6..I"H2\/ZS()U*N2BA#4JP4T+.RLCJ4ON)8#`G'
MH85?UBZA`.A.M[:K-K*RK#86-X1?S)&!(_-,],QK-CHB-EH<\Z,[()!4$%4^
M"R]`]+T$PX4:7QOYM*EQK@86TE=9'KY[1B'C@J^O75S##9L=BJ-/KIYHW0&C
M4H`^/>.S5,,B$;.:K.BJ;5`5Y6/.Q[F.!YM]`VK"6@ZL5H:L]IW9^`*2?+7Z
MS\I5>^>F6(`K]23/6.D)F4PEPR9!E4F:')5Z[]Z>^W1)XQ-,GKVRDQ/U0V4G
M8AJ-E=WYZPO)Q^.P_3()5(QU&)&2K]LF>P#<CDJHMN[R]L']P=N_NWH_![*)
MH6E$5334_)+V+O+^KF[,OB:`.KG]A+1<M\46,*QT@:W>?P'PA,CB0W[/>3)$
M&]TWCL%S_YDZKXV.O=9"K@)>*RA=P%]20_WF"Q/,U``W(?QFOV(LJ5O(=QWD
M`G&(R37VLO!-MDMK,P*Y2VQ>_^D5Y$<YQ)DMI/MOW[XBOC/\IH6<>`[^J4_N
MDWA%70+<=V%YIY>N`RQGZSMI-A`Q(QA!L=*?`A8HL4;O0#JA>HBM?8K]%KWB
MQUY#+^'#^Q2*DY?;RKBF_/FA4IX0PMG!2D1T5/C\8`7[3X3.J&*C?W'6=T.@
M5``Q%UV5"+5`6W0@!6;/L,6<9E`E'-(J,SDZF`N.<UEC_,>88SRQ1\P:(E]7
M/W]O&W/V=B!5?X1Q*7CSH'&='[L5%U/C@ERK-Z[8/7]>LL^`G5SW#0.JHS%V
M2-7U6(\3NY\0_+_QX#\BO+\72?M[D&G0=J'Y=E?F@/SE;0$[U>VZMAN+::0]
MBDOET%TA@%@NN=_B%[J`-6/G@*NA<Q!/^F.,=>'C&$G3>TCJZQ$@$RU_CJX.
M%T-9SQ4?`4AW`/3#4$YJ?]5Y'.;[,.V)K`Q>.6%RPM0J^D!EA(#4Q?Z=R3=D
M[3M7\!<JJ]N2[&T!BFWN_")0Y@9[!EBE-35Y65O`NU&K"[*U-[C['')@:C16
M/>GB=8GXE&E&J><-K*ZJ=_;@J\"TF=#J^M*^=JD>X+(RF;$W(+IG0D4+"ED2
M6&V6UK[MSQE?1)1-,J>VJ,P6:D^#+:4Y1$"'SD(RZ:#HXXO+H_P-"2X+8+F[
MET2&P5WW>`/I>V#-SCNR:])A[RK/T[%PQK;0NFL;`%.%N_7'`-?W0Z=B+V\[
M,YN!=Z;[Q@)E8X>/Q[3#JM,:?,846R20HKO+%5M@U]:WY)_%R4+'VG7BLZQJ
M71,0-5<W+X"XW)KK7@(=>V>_2.1JX$H.88V?_1C!AF,P4C,^2D_WO<%Z](!>
M"B2WZ1I*&=^6QQN0\J/=@Q7,D\>S.#X5BUS5A10^8TRA"[YPVL-2)#>I;W)]
MUHN`EX<2+Z(Q8CR3U'NN[UMO$;'+=6ZWWL:["[6A3;:QX/,-[(&FLC&^[IG1
M!O#ZMN=\1AM0(IH(6+)HN`5)6#_04X\5W1SJE4/U+*0:#5!VIW<!Q>+-"ZAM
MG_[RF35VC3X?<=X?Y1$L2?23(V^@Z\9X<JJEAW>*,HDBHA(H#]RNX]?=X!@L
M$#'W"_@#"WC,9'`!BZD(+H"<FX861$!C\`@('$P'%RBIPT?$$OPSM""2.LA%
M).4C7$"$#Q/)I0HO8%(&=1%1&0>YD(D$\PDMT)('N9!*BB"1,A:)"BZ(A`HO
MD.(1(H7@X06<)^$%X!%A+BB/@D2*!&=D0@L4C\(+8BYY<$'$H_`"X#-\!,@I
MO(`+'F:3B;!%"?J(+G@"P3FX0&,U$%J@L%L26A`+$603-!$6%&@B";()<@K+
M`6)=PH(+&(^#SLO!Y()LLD1&P1V8QC'AT`(EPS2P&._\0@NB1P`$("J,DTS@
M_6EH`<!@>`%[;`$%"`DM2&389K70P7BCXB@HYSAFX6"2).%XQL/T2Q[6DGC,
MHX0.VXF(PTJF@4#U6[>DPT\F3J0K"<$KDBY=8??2%1H/Y6'4W;VZD9>^F>3F
M4R#1>@6I\+W!;+_-3]_BEK>8/KU!@E81DJ3AAV^*#1_SRXOW/=$*DBBI"113
M]TEF-'`7!-+HYKCY2NBNHA6KN)\T^\#!YN]EH\`EGJ@@#)P\,M2UA*^._1Y%
MAVL<ROM)D7?EC<D74"Y`SMD/=37]W;%U=765VJ)>],-O>_NQFRF!DL05R>.$
MU/&(G[MVGT[)9&U5P>YN_JUKSTS&"L_,=R3'WL%0`;HK361[.L-8XXR:JZ0\
MV^Y:?0U%/]X#Y>6M%\ZUJ=R$&QI5W6YQ0NBZ*O<DW58V:W/@%_)X8,ANVGX@
MR,TLDJPJ#W77/=BG=SAZTG93U6=F60P=(S<$TY>4,AH[1O>&#[#_T>9E;3-B
MFET*NEJ0==OXAV',;7ST%<K>;*P?\#Z4.5A%-9TR6MMR7^8&A#)>L'4-S;Z\
MN7]W\86L\QX*.-735E'7U2S7-W:<`RD,B-_IVS054-KN<=@K!16;C6LCO7@"
M=0\55H*I@;S[PQ(8!E2"T`#+?C><Q)H_!4[P1&3EY)%A0<=#6PKCZ^3ZM6M;
M?-,-L!Q90S_N.8S[^J[%9`IR,@+C)W<&B\'A0OBR&]E\\1!./,;0@_^K`P)X
MS]%IW4C^9-W(Z$FZP6S_B;J1<7\U[.8#\2[G;7E[QD-`5,,ATZGXY3G/4,,9
M.(V>C*,'<=+%+(?'DQ"U@\_#_'F5'MQ0-BYH#(#L9&$_5`$V>7I^^_Z<ZO_!
MR8/6I?3`RDGK8HP_G/S$T^3G\U$9R$O8,+$?]8VT^[-2F,7Z5/[WJD%`Y9LD
MO3UI&?G_I/?\]?F.0#;Z(X+6]"5')),C!(6*P!VA/N]PZ6`FN\11\M![EO!@
MJKSD2;A(7XHDG,POI7Z$QDCK8-6VC#4-+U!:AH_0.EPY+A,,!$%!07@."X(Q
M'>X$+!G7X2)ZR<2C"I,Z7,HO692(1RB-'],94TFX%;=D^C'+85`%AGG!Z?=@
MH;CD3(?[=4O.5;AAM^0B"L@4O.B;GR\O+B_^!X_A)GT-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,3,U(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3,V(#`@
M4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P
M(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-
M"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR
M(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@
M,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C$S-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO
M3&5N9W1H(#0U.3,-"CX^#0IS=')E86T-"GB<O3S;<MO(E>^JTC^@4JYDLD4Q
M?0?P:'L\6:=J=QS;J>1A7D"P)2%#`AJ`E"Q__9[3Z!LINN7,LE4N2Q310)_[
MO?'F7Y<7OUU>D*6J94'PG_E4+:68?[3;RPMJKM""J8(J\PTK5+6L:U85%8$K
MA+!BU)<7_RQZ\ZQ22'R0K"K\58PWEQ>WEQ?7_X6/PG_1%V0I!(<-EH)+#K]X
MS=CA]5I(O%[S$J]7E>*G'\B**\84PDU)`<N$,C!=&P3GB\)?Y"H`_.;SY<5?
M?FI6;5U07GR&&PPAS$,=ZI0!EG#[YRV"1!5@]KF]O/CA?_1XH\?BS\7G?U]>
MO(,'_?W[MS/43&S'YNU^^(4)\GLW2.)#2HL/*4MI\+D"!O`*]GV`?3^,W3`6
MNZ'XN=T-*\"2$2(6Q>Y6%V^'[5W3/Q8/S50TQ=U^M>E:`.!N&'==?U.T]O*O
M_?#0%[#F[=L/Q3^'<;-^Z-9Z4;SOVR7\2#Q8]SL]ZG71];!_T_]N`B?PKVOB
MV$FJVJ-?@]P8]%_?C%IO`9!BN"XLGYM^77S8`#SPU4<]C#=-WWUM=MW0%[\0
M21"#<T/*0<$<J&H6NE\8X^??1L44X8QZBE3X^2$(NR?,N6$0()!/415GWP:N
MN&UJMA2$`'Y?<3,"EN;LNS$2$9:`F7.$935^1L(^=+O;XL?'9@U:]!XEOS<R
MU6R,5/WCTVN$;%:;!>K;V-TW.[UY/#>LJB*G*7-U_IU$3!4BF:.*-)^1*K=Z
MLRY^V@QCMVZR&`!P*(XK0@6N.`/0#B,8M*#=U\.XU>/FL6B;S09LTRF&S4Q"
M=N$=?YB7G%U71>V!S\LF],D1F13Q9.*46#)9#OW!:`\:R*9XN!TVYY=.4=(7
M0EN`.PQH4XD><49;<&6E$SP;R,"T7TW=NFO&1W0)L0<STK(N5H]%M\,_BAS.
M`:58*@=G&;1(,*=%=WN0XDDC>"N-SGF+5GQ=&)N#[#(N-H^@,EE[^/)RC$%4
MZ':Z0H7&V,8J=$FK`TE=G`Q'<OEO`;<ZR#+Z;R%)+`K,NAGKL\^^6U6?0.K\
MGAI2D4A^N"(R>.KEV5D%KB>F(;=!/JH352XJQ(!WU--^LW,:/Y-XEJK7[6_[
M;NJ,SW@+_F-I0N0<:L]K'[TR;YZX9#9X?T$MITIZ</)J.55UA#BIA;=W7`AV
MI.3@I!V'IMW0_@H^::W'";_+Y):KEZ(#KV(Z4#2SC@XE?H[H``]N=7>OUPL0
M@4)_:6^;_D9C2@D^"7]%9!KVNVD'PH)>8KIM0,KS$:M$9_XR0@/*PIBC525H
M\.6"'LE,P#IVY:#+#?S09W=:K/2@97:/G/J=T#U*-KO''T`(SKX7Q,\OA!7Z
MO,!:&JF!<FH`;"M6S=1-BV+;_(J2G4OY7PIK7I,#7G(:<A?J:C=.^_/%XO*%
MT!5E'3&94>X#.U'7XKMB\</2TFP!UUF<,L8G5AAI&801/R.<W6XJ^F:K"^^+
M3V6/"^.P,T7DR#<+96;E1+X%>D@:["ZMCGR48TE,'_RLOW23*2CBE\OB)\BB
MKKN^Z=NNV11-VP[[WERV.<X4A6-%ER7LJC`FG"61DQ`>5L2F&+M1-SO`!.NB
MX#6B:!`2P4PL)<2#E9FE1/B=C!>I?>#))#_TI:B"I]*L<U?*>1F8\D,6CDOJ
M\VM5A_Q:U3XAN&M&3`9FO>VVD/9WICR'A;JY@AZG";$M6G<3"NX:J84"#]=Z
MB#3@UN%.8^D)([%@UAJ_%QCV3W>;[NPE6%66'N/<%4`:T990Y65)FL](VY^O
MKT.U.0MSN6_IB#(X%E)985[IW8/6?>Q(FMTS7%K8(MA<+BRV>HLM#NN1W@S-
M:+C]8P>!^6X8CX/-9?'-##,+`6CI+32)"$#*XR8((H6P9!$["I&X`R5S-B!D
MA#2I0P8IJ_*$U,WZ:IB]VD]=KZ?)<7WHH_SHM"/W)>,3IA#D9-2YJH+8EG41
M4Q6J@JIRU<L#%!"(3+4!O)6\1$>!BBK"FJI2A7BC5$=1<3_'&EYI.STMO(1;
M33Q_W$X]@,+7S-CYMY$Q'8#EH;6I;)0RP2,A@M*0[>]T@8618Q-FA?HC+GLW
M+_OO>=DT2^^Y_3B.##BP?Z<?3[?O2^7J^9QYDLC24N1M<]?M`->/#<1K0(O7
M[:Z[A\!-3QE:^Z7@63O[)7,U3%*%D(6+BL_(ON^+O^W!*#UMNV/C?J--`.NZ
MC&`?KO6(-+$Q"JS98D4$M.5NU'`-^_0:`MW=8S'I=C\:LLWJ-`(YX>K-.(#9
MO!N'5NNUL3BOQ*(D9$$(61:?\YC`DM3!&`37QIQO?P)R\:!'BZZ/X-_W]Z`E
MQ@'^H^_`&YB"JF[:VV(/?P,Q^LGF*&A''X:HA&0)98J/AAI8BS"7\>HGC5:G
M>%-\\$3,0`15,^_JPHB'M'WG3P@:<&HWL[LU@+V"S<`[&/QFYCCIV",O7]&%
MG#GG/(?GZ_4X;.&;;@HR`[$O8`:N="['GBPP6DJ\SH)_*;TJA,H?%T*Z&1=+
M?(B[KL&!%S>@]@"=!@3:G0O=F_UNV(*[;)'?]WJ<,*&SV)_@HR,KW(XV!1;2
MA6!L0>KZ6^)A1*^;IKV9><E""5F%7#SD,>B@;;>[[P%EQ,S(N`E[+!M-4/H-
M.P&68+WN[+C",S;#(@_I^K1O>D_>#_:NG]U=.=`7/HV3*I0BF)MLV0XC".9^
M6ZSUU([="ENW>C,\'-K'&UB$6!NQWX_M;3-I'\)/^MA<@$EI1KQE0E1--0#8
M',E%2>F"2')VA$M&(HRYD-QA#%>L%SBL=><@.7/)%5$AMP@M*DO4/TU'EG)7
MO))+.1LA`^3Y.WT`G0GW[?0;#5D`%\%)_N]P/R=OLZ/L>E-S&M=-#Y;2*,DG
M")E`6NZ,VOB<8;(9X!.YCL3,M9O=")Q;8Z8HUJ:&]'0Z+@<92C^$4Y=1R9+4
M!TPJ)HC^BG*A6+W`,M"QH"],1-E]12Q/>'LF%X+(!1,UF)(G7M5Y4;/VP$E&
MNO>G+/4\*<.41Y3^ELXFGO#@U]W]V3M!%(RS`R5W"_4`:1&5M&Q<]*B;T8PX
M-:N-=@8,[9<S>"D6/:/)9A!&@P=]-+%2)`<Y>,M]*S\R@,+D_(CH;*$=5A@!
M&.T&$=Y`!L07%14+1=B!#?<T2*`=^_+H%O`38$%.Z7P>^T9]^$M#[9V77#G%
M[B'P'8'VFZ,&B06=B7)1<O(?HW^"ZZ@ZH@8;H+[QN!SX$]\8Y(1%.;`U;,]@
MP,$5!`P6Q6K`F`A`WC2M+8C=&%-_=IXF$D=1L:R)HU"^7\-#D,3KRLI,G`QT
ML_A`0L`6)2L7LN1S5(MV?-0;X\)L@'=,'%]J<35Q>-AF;](",ZX!7A6R,R3R
MJ&_`,=@A3!^7?@HY6PXJB-#B(-%@J)`V<$'HW]E)"J3'%C3&#8F>WUY3#U#&
M\3%(D?TVX(!8*:P#^O3N[=GWJNH3*)U]>(Q"PANAE'G,FY$@."`KK`Y^M>:V
MR/3$6]H0/.1]4;'?J<A3P_+9I!JSHJ%UG97'EBPPW=[/:5P.U>`T.)4P"ZRH
M\AC&V6#3K<\.!)$>BLR1$H3`;B=C"EBHH]>N;@@\:^?280:#K[@'($MKD]>^
M^T7K$/N;KKUIA$0G=-0"\Q"5.J43E]*\9V]\`RG;@"V0R6&2<\`6`H=`,$;J
M4$20M0V=7Z]T?S,TL7_ZX`B1[=0,GD5[BO_9S:F"+=PV^<UI26A,;55Y\2R5
MZ].9<,"1/(=ZE&68)P_*SXA3_C?=H'NPUH_%QS_^&(V1GQT6B,(=,#EC`+C!
M;8/3D97=RY+X_&&`.H%5AC`@</+)#/DB2QP0B$AI-))H$X_F:%#-&XWEZR7D
MH)MIP('3IX8W3X-6PJT1>3+Z4PG14409%8Z<"EK*PP;MD6/IA_[\5E.^$-X*
MPMV`-S%#S[;[:#Z;7M07".&F[E[CX(=NP&5D,6@J#`5$[7'EVN,8<J[UO=X,
M=S;#=;[[P-1"5KQKNMZV=]"EMT./0><\E^0Q.'Y<#M,H94`KHVF4LO+;U')9
M"<YF:0'#?_:]4#*?H'1VNXA!BT<INS^7=16)'Q4A>1#")0]WXW`S-EL4JI6.
M6DS#/:9#611"N$(H)+QA_HRYGAA(>C>8<:W]W2SKH!"N$)PC!7<`9<YL2AJA
M3AD+F9P9'3"';YO-=8&EX&E1[/LU<.#AMFMO<TW/8^CQ(KAS06+<%0])'>6'
M1XC`ZFTVD-3H7TWW[NYN\VB:F2"G=V.G=^B_=[J][8?-<(.QOK6&L<VS%;&S
MA\>J>BE9`2WQXR241"TB6=HX?.Z5H_/2_=?'K2ZVW9?='@L;9@3$E@)-/VB:
M7/5OV_3[ZZ:%=<:/Q&3$'@'68_4XSWD#X;MVK@!"NITI&E52>D0S3F?AN92(
MGIR&4202IK-6D%CL;AN@B'&:K=YL]IMAZMHL1M#/R;"2^C:)(NX8O(7$N`5@
MHJLN67YF2^MI33QH.9.>6D44($1ZAC!T^H8"X.3SI>\,W?T3/,_N[AFZ>U*?
M3H,RC.63L%V6VA4KPV!3<%\8.]G>'KHLE$M()+9^RN&["C2+$.DVW<%(*,Y&
MX>23^6_LU.P4NYTYYNL:9PO(I!=X&-_6=W.@+WVG)@0NW)^'.B@TGWO[NO3;
M9[24E-`(2U)'08IT:=.)OIU8@AD-G4=GG5HTGV[JS,VZ15FV=%EV@\TK?(\1
M!IYS0?XU>")P0/T\U^4[/[/B9!I>9-Q/:[$J*LW2H[&,$"6;N;O=V/13,QOH
M(1I@J6;TEL6L%^V<P15M-[;[+8[DM69B<WHZ_60'@;?-8W';W,\GLU#,XSI_
M#OR9;S00$@1<N3?F1*5F@,CJJQE3PXE\W<YH<^K8NN_-\&(\E`)QQ3A\Z;;S
M49U7]:*N*S/6B!(R:AP%F'LJ:S?7]\W,-@<!B*_-5SQ*EI0-NH;5IKOQ09$9
M4FSM:[?F-W#UT[#IYD&B<&;.3'*'$243X*YF;&_Z[NN,[PB8]<CA>>9/?[G3
M/1ZN:Z9I:#OS1-^)1=>8`7M:A6,I88!=^!#)I8I!7)L5R+IKA^WGB<[WH;@V
M00@US3.HF$N:%Y7-,YP8T5LA_];HKAD,S7("7(G:XYJY"B5Y3%4>SDI+ZF:]
MS.3/J,V4XMH?"\C!WC*<T^#1N5!WAG#.N^=>DSEL->JMK3@]KXR19JR:C9W5
M<W(.T>O\4IY,:82LI<<NHW.4=1T3L52AEJK<?+M)5*_QY4/S6+8NIF9C1[:&
M/#,W-`R654'`A'`-DP.ULMIV;(><U1T`XA&5><"COY]O7<?;SYV@_SHQL_Q=
M(9XQ%#D($$;.*(N'KH1K%]M6/0`_(PA&5:,UWCWU6@>D:;9HLK[.MYJ<&K&V
M%0=GL2,[OO<!\&F-R8%\F#B+)ZXJ8LLJIY7T\"21&52O15F4F/X9$,)>YGV?
M.,J-!^IQ`?O&`HXO*DLM8*BGJ07@=EAR`9$BN05L`(1,+:A$F=Q"EOCBT]0"
MA6]A2"T`&--;"%&E@>2B3"]@@B=Y(2EP*[F`"%:E%HA:T"06HA(\":0H\84Y
MJ04*NW.I!9(_`Z3`4DYJ`3P@O8"Q.HT%92(-)&$J*0^\8B*]H&1@J5(+%-;&
M4PLDH^DM!"9UJ06<TR2:G/&T1''Z#"_`.I7)+1ADFTDT605X)!>4G"719!#X
MI!=(+-FD%@B6I@,#D>/)!8S)I/(R$+DTFD2(Y!-H+5@2!EJ)-`RTQ-F+U`+U
MC`&A\AD[286027F@7*3M`]#IF0447_R:6D!$6FAK7B8=3J5$DM"EHDEI43CE
MF_29:00D2[-)/*-2'-_OG91FF:0/(VE/17%LYUO7?[-+K"A2?B+X@8B;^N"'
M/@E^2.AN2GN>",M6E0U]/YO3%/A2E*'?80)^$/;,C_GX5WSD`P9C?T.`EA)!
MJN#7G![Z/S>7%Y\"T.S;,*L8YJ-Y-F(>YTK_TB4K3P?+S4M0YCW*_[#95E=%
M96O.:@F:KN;L]J?S;8%H5-_S&KG_SQ9UM`4W/3#<HCJ.7-,*>E6SI(FXHK5*
M2O`5J],!X16$.4D=NQ)5G52R*UG1]`)5R?069<73:%95VF5<U55:DZ_P?>U)
M6W1%:54_0VSP\6E$**])&E`*H>DSD,KG6$95+=,4I^6S@@/D>`:7NDY;YRM&
MJK07O6+@B=,"#N%$@J:@(^_^=7EQ>?%_1&EYE0T*96YD<W1R96%M#0H-"F5N
M9&]B:@T*#0HQ,S<@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q,S@@,"!2(%T-
M"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*
M+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A
M8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2
M#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@
M,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM
M86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-
M"@T*,3,X(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG
M=&@@-#,W-PT*/CX-"G-T<F5A;0T*>)R]7%F3X[81?I^J^0]XV$HY*8U"'+P>
M-SZ2N.+8\4XJ?O`+14$2LQ0I\YA9Y=>G&[?FP-@;,;5EZR`$=#?Z^+K1F#_]
M='OSR^U-LL[*E"3X3[TKUJG0_ZN/MS=4/:&$981FZAM&LG1=EJP@10)/DB0E
M@[R]^1?IU%RY2'&BM"CPA0S[VYO#[<WN#S@5_@N^2-9"<%A@+7C*X867C%T^
M+T6*STN>X_.BR/C+$S)RQVB6,E+0A,`PD2F:=HI!_5"XASSS!/_I_O;FC]]4
MFQK8X^0>?J`$H2:UK%,&7`I![H]($LUA\OOZ]N8.Z<;WC[<W7_QU1QZ;Z=!T
M9&P^D6/?38>1[/JV[1^;;D^F@R3;:I*DWY&Z[4?[W9?]\51U9W*H1M+U$Y'=
M)`>Y)4TW]:0BXTG6S:Z!+Z;S2?UX&JINK.JIZ3L8]-"W#W:JL6K5B&8:R2CK
M>6BF1H[D]^3^W[<W7P.;_[B>,%ANA2$*887!2WR/PICZJ6J1KFHBK:S&B;QC
MR2I)U']`-MD/_3B2T]#74F['%=+?D?<;V>W[BC0CBJ&96F2[!^IJV3Q(&#-(
M>6UN1%YX=DJV%DE"R?U_@(>[JR]57$J.%JF77)EKR9UE-9#':H!=AFT$[D_S
M4(-R2")8ON)@#..A&F!;0;)51^0G.=0-/%UDE^&GFM8DRZFCE66%IO4T-+72
MN'?INDC7!$P@U,-`!]_0!\T-T?.!P<@!)@+NWHDUK'6"CXKIU6L:<JA`/:KM
MMD&KJ-HEA%&6W,B"T:)TYI_A>Y2%V95F'&=-$TCB2$9\!=[@0S.@N<IQ.@+E
MAF4MK:/4G,<$V'1U.V_AC54-)XMK\YJ)Q#&K+?N+GQECUU]&!#*EI?.H:8)F
MH42*_H$,U519KDG=/\BAVB^B[F6>V1WFF=_A(C,[7'5;TL/V./,DX*F/L(^#
MQ/W>2+^=X,NG0P]6"9Y.?1E80N"^@;6#574<=CGOMAGK>1Q!FZH-L+W^7):S
MUW:@R!W/7RPB4%ZZ(,&]0)/,!(EOY@'Y7Y&YVRHQ2&??'[S`?K#^[_T>W#\:
MS^I9X*SPD;*Z>=3;\(YZ]P)?[V`)%1?!E^SZX5AUVG'5<I@JV*0EN`<DXT(D
M<]Q3;ISGK@>:*N.P4+>JTZEM:O7-"*N-$`CJ@]6@6K;MC+"A)A+UI6\)H()V
MJWX)#`).@#<((%HYCL9[!C+X.4D3G.?J9IR4CM/,>0M^]65H&@@T29G''`DS
MZO3C[[XB'U`,&&>^W[3-7LGRVJ3D:?H"Q^+JRV34+7,!2V`GZ=6W,8<PZ^4+
M[!2:,W2WBQ@'I`QZ+4Y+9QP`WXWK5RK?S\.H(>\"BDN!`DO%@HI+*0V8I;AW
M5G%3?'^AN.0[@$;SH)P<^4$.3;^]-CT,DK+G;%]=>UDIW#+7CRT,P+*=_:EM
M)-=>C"<7.YA2'\D8*[RZGM1^@=8>8?MJ]$&]=MTN;I&O,/]#AVV<E$IH""+^
M,%/\,$F8"MXL8'<%;+_UH:7WH2PQC$!0/383$(#1:.@?(#09^VLZ",?P\<,$
M3"ANX,&_^N$C4#Z0&A`K1+-!,4-8DN3HIAR@M;%Z,\BJ/B"<A5#\BK]>8<BS
M6!Y#VQ)BP&Q&[R<+TM?<IJ\6%@S]N6JG\[4I@)S!4K!LQ@GX.F"5>]]3&->S
M`P5<`6RX>I2DD$7\?WBDD$@$3)9IX>Q3I$:MY2?(GD:L(0#"DITJO@S-_@!:
M^'AH`&4]]C-@*8#P>P3@&DH:+'J)-B%OZ[6JRNT*4[BELC``YY:K);.PDH;"
M2[/<"<_FM42VLM:&"4*1C4I9EK#)U-77$NYM,N/&)M&W?U+@1^78Y+U/]S_H
MW!O\$`XZJT$019LIV$92@9,:#V2<C\K#&$::;IQ4,G"H5!VM(EMPQ.##P/7!
M(O*7&>;7V3RIC@#9)[(Y&Z4)\?42`N&N4I1GW!<<<^:4&FMGNK(8$FT\]GN=
M3VQ:Z5VMRP,,+R/LZ"=\`"H/?'UUKK:086#52>=)("Y@U"4C6SG60[.Q*2D*
M>J4"6K.S9:DE!,%L&8IF!?71-S."P`0<\KZMLM2SRL>5(+:VQ`(!&.QU0,%X
M+7I26[K4'H4_395VA-0+7UVU2V7T1N5,B/_NZY_L^Q:K6Y#EJ["VK<XV@UM"
M,`GW@A$^Q2R>9D0O`,LUN7\UB=[/E7*#TBC$U0NAPM.^<,E59&XE$$V2FSK3
M%]^T_=!LK^ZV1<'=>@NZ;8'1P6T^2S(?\XK"%<_FKI[0?9VJL]IX--0G]0_$
M8;V#7N-"<"LO,A>>N:_SI2;9LQ[:EX%0<1UL7B]"DBA=LLM3+[W2`*-[;^.^
MI.M"R>2<PZ,$UX%EET'NFU$?W7@^@C+6^UHA9A``7ZP8D\(/+&,+YK2I".5'
MT\3+#X\"E?PN.;]^.2A_@=&K9[$9XVX9\%,\0^YL#>;Z:IEQ'L@5LA$GUYQ2
M8]8_S,,XJQIQ?U$P7<)$N"M@JKK,TP+F;ZC1[AH\J*F,D0S*V9#199)X;JKM
MY>LO=8G?'FF"_9FSD.F907HK7&'!_1'"]")BH#;W3XK,9U#"G-=AX/1(5%.X
M0CP$?*\4J0J!53L$((;>R]BKA:.Y?5L\\.0K6<OC!J9C@+X@U\YT$=@,6$`$
M65GX=-EE"+RD!H!M90WH,\Z$W.TPC8`4#+[^MNH`8IP)S14#^:5`&BQ__S(W
M@_:Z'Z4\_;J9`=$V[5)@2T%/`\>9C[?<EBP!(;>-!IG^K+\SJ4*@O>JL<B,E
ML-!#SJF*)QVFGNKC:89H7+=G$T1^G$%W(,/%B/%1(5,S_:5_O93?$4#G..L3
M@24$D;E$K0CR19[EOA@V^\+M*[N&5:,*-O_JM4%`?);"9;$E2Y-0%H+2P#(,
MC$#\;W,!4R!4C(^P2;!3>$[X"(Z\.:HC7O09(.'KPP+^?Q))"BEK()(R./<J
M2E-04)TQ1AAK\E>=',D'U(EGZK*$]@J;5;-4.#-.:6JTUVMH#3F3:EU`X_1.
M9CL'T2F@U6SO=E:GP;:"J!@;8R>6)U01CRVQ2*'B6=N`"T0OLHP1\\3C7]_-
M5-B*]K8Z5GN,9*X"0G].1'J90B-3W:Q"4>\*``<\E=R<0[",^JU&8#%!;W5E
M:A$^W79]+CK//E7-Q31H-NKW2PB#OIA*9;;/Q7"F>I20O14V)CPT6Q7Q3(U!
M=;C8L@KP6K6V=(XLZ0P,H8M*%D!75)E=*8"NXQ":6`&K^LP>%`2KC*_)90$Q
MI*5K@&"E/^5P8=YLQ=KM"<@%N$2&T$*"?IQ`=XTB:41D-K^NYE'+\[7HH"P(
MF=Y(-#9O?1L)BJ"/^'?-,$Z+R"'WN6&0V^0VMZFZ#D@91D0P9KML.H@\?W:C
M1HPDX;!X'A2X>6Z\UC]_:P>%'1;X(AV1C1L#OOI.GTT]:6(,6<5].H*;TZ[.
M%=F7$`!S)W#8H>IJ@*79$V!'[IH:3ZCZQPXVY]"<@`F?&2"?(8TGD$_7X!8V
MJN,25*GI5H'9NCX[U_;CNWA>`/@@B69"8[U(SY:01%+XM,R7A:DH+JLI4058
M$]-\<^S#MKJ(-B!.>7I2^9(Z#'(WH#;LAOZX!/NBM#`\*8/#=&$/T[>0-M03
M`.@>B_ON4]/5`S@4I!1K7B^IRPI_\EPMU&G!43L=T"":AF[:A/3K=]44CM$E
M3W\NY`FXT'F6,DE<'5';P>>7.U[M/\O\ZHOTGXGP1,G%,Y[;U/W[COR]?]"I
MM,E$LTND]K09VYN4B\J5.]U?JJHG\M2QLF!53T!^&TA,^(Y,7I;9KRCY7+]#
M-'^![^L7^5+NEEF^T2K+DD#*+/&%M92G)D-2]1Z;0.B>X7Y8JC8O_"ECDGLC
MR7(36)VB8WJ*&/1!@=*VJK76LU5>Y.H(U!Z)Z5,%[(-1D*ZO/X;=W=@M_N3D
M#2/LBQWO\PD_IFF^$A?S+R$&=\:8Y(D7`\<(BV)XD:6@_=XSE\&O`N8PCEY>
M=E"C*%\E@J]HEES6;F"-4RM59G!HQA?DO4Q6+-QA4H+]C8Y]VZKK2HZFXK@&
M@A]EI[;.D+XB?_O;EZ2JD?9*@_L`;3GZ(1DPU1^5]#WC#Y_HFIDYC/;'+X"O
MG)HL(`/N3ZFXX-[Y<6;OM#S5S(*O,OJ6XK]+UTS\>FVGV2IG[*TYG9(M(8?,
MIS_:[2IB%CF&X_Z,`?OL7'M2$AS#.6%=W*T('.-&@GRDM46%QD%8WU5GPK6Z
M0FR7GT[-("\Z[A#^2E677X&`=0ZCS;C:_GLV]S14MQX\[8^@BD!%<_7.V])+
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MQ+*LN>5Y$6P`34U=5=]O7&*S_;$##Q!,89M,\$[5Q4Y4R]PGA=4=+0L[-,AI
M`ZZ9"&Z3VOBII*U8]XH6:)HI8ROEGCNL].N[QE'W%0KQU_B[18`#<]=H$]1I
M5P:R-=H04S\V$+_LQ3`@:&XGK`-U<KK`Y*KC_5-S!#P*?NL=92OJ+Y"A@V^Z
M69(MN/RV/]D.>)S2`-4?VFI2/9/WLCYT?=OOSTJP2W#O+N9"5`O[G6U30GB5
MS/0?'JOAHT3(60U[E6!`"%"E,$#H'6P=!GO7:;#O=>?_.`VRV^/!AZV<@8RV
M<PV2:TZRA1_J:%;7LI58Q;=50;P%,:CZ6EO-':#Y9=(VZF^0"N%;0Q-3K^CD
MHR58R>$TMR?=!E>=$/95'6QW"VA';H,Z;X650MW7"K"QTA<4L"6MZ79#!2*!
MZ>9!AM`(NU1T8-=B-H<6_3`M4#C+0?<MXY]9.,OC4DTSUS&9A-=$#'CX2X-A
M4P7U'Y4Y*?OY_B0'HW+7YAAIXN:FZL],?';30&Q^^MK\JN6A%"5`]81P-;&?
M0?T1"OQ[&!G5`]@K`P36=&,#>%KFT0$L!6<?&T#Q0#LV`/P^BPU(2Y%'ET@+
MD?+H@%SD42Z`AS@7:8JW96,#A,CC`SC>-HX-8"*+<T$%3Z(#$D&C7(A2\"B1
MHN`EC0[(>1X?D/$XD;!5+#Y`L#(^`*!RG`O&TCB1E&51?>`E$_$!!?8GQ`;D
MV/(3&Y`Q&E\B96E\``@BRB;G/*Y1G+VQ%YPB6(X-2%@699.57$1UDA6<1=ED
M.8\+BF6P2'1`RN)R8((5:70`9VG4>!EC;[`)2"`^0R)8E`9:BC@-M!`L2@/-
MWW`@$*SB?A)\>1;5!^`R[A\H?VL`P]I_;``5<:6E"<^C$:?,1%32!7;>1)[G
M91&=/V=Q#C(6WZ?T#9L"`47I![./6W42#U4L*=X0<$2^OY@AQG=1_@+F*0EV
M(AK,0Y]AGB1S>01"`\1Y>*YN[Y#<ZUKJ#C*I;L)"UP4NTM/\^&><\A$QV+=(
MT#I%D@IXT0FP^]C>WGRP1)?EZR1G(<E/CB@3G,W]E8+4'@H^!X3JUIA>(_]M
M204O"V(.`LIL#7@GT^G[-]=;`MFP2T0K!/_+$F6P!*AAKI<HGR+;/&I_=WB;
M-O:<EG%?>\>*.(*XXT4<!]V)@L8'I$4:7R(KXE[B+B_B;NH.4HJX',HB'ACO
M:%+$X?T=I?@'.*(C&/X=@N@(7O(W-DR\M6,T+>.8[HYF91Q(W-&\?&-/*.A%
MU/7=8?=PU#G?L22/0P%("M.(3,$"OO[I]N;VYK^VF6%N#0IE;F1S=')E86T-
M"@T*96YD;V)J#0H-"C$S.2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$T,"`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2
M#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y
M,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y
M(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"
M#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N
M9&]B:@T*#0HQ-#`@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*
M+TQE;F=T:"`S.3(Y#0H^/@T*<W1R96%M#0IXG+5;27/;1A:^JTK_`8=436:*
M8H#NQC8W9_%4YA)/XJK)82X@V"21@`"#1;3\Z^=[O0&4R)8EB[;+HAH/C;=^
M;VGP^]]O;_ZZO0F721X'(?U5G[)E+/1_Y?[V)E)7HH`E092H%1;P?)GG+`NR
M$%="'@6=O+WY;]"HO5(1TT9QEM&/H-O>WNQN;S;_H*WH[VPA7`J!N_&#QQP_
M>,[8Z?5<Q'0]YRE=S[*$G]^0!7<L3$0:9%$8@$PDBJ>-$E!?Y.XB3R:&O_]X
M>_/=^V)50CP>?,0-2A%J4RMZQ""E$,''/;$4"4CVL;R]N0/?$=UTO+WY]N-.
M!C^T^T/1/`2[H@^JIAR[3JZ#NNU[V0>;KMT'[4%VQ5"U31^LQZYJML&`V^JB
M'X)>WN-:'3S(HNL7P7%7E3ML="_!:C_6`W:JFJ#`O[(<]V-=T,I:;JJR&H)V
M$Q2'0]=^JO98KQ^"OP<?_[B]^0FR_>?M-,!2JX$0]QL-\"2-M0:^$6*1Y>$B
MA%-``>#I1UG*_4IV`8\6`0O#9!G,U50,0U>MQ@':@1IZ:=4#M6B9L=X&ZZHO
M.TE**[H'N@`%035%0^+?R[H][&4S!/+303;K:A@[J6Z[B@9PJ]%`'CD-B-BX
M0+6'"6`PLNF/#\6Z*H,/L-.F[?;!1UGNFK9NMP_&M/OB09MW'*JZ&J"-LH.G
M!*NN+=9*.JW#!SDL@K$98%\8?%]T?\JA7P:_.%49_U)[%77?!BLI&\7#%520
MY]QJ(,FC*0KH,ZE`VXWX)@9@DZ+I83F[8"S_UHPQ%CG.A&+JV_\QQM[^,?%,
M`2P2DPMDT(U20#^/<67%];YJJGZ@-5BH'P^'MD.X#\5F0R8N@L.XJN$JI8D*
MV6R+K8YVV7Q^V,M@5;4#W,?Y_D)M?`WKIHD5CN43QN5A:AQ\4+C6R:('@WU1
M2RVC]DIRQEX%(>%:2]9O$=2-/`:(B_58ZG@F/]`W'.JBE,O@9[A'MP9*X&*Q
MOB^:4@;TI+ZL)'VF)Q`.Z&`_V6]Q%2W$N?7Q5'"G!9YK)0R/@+YL&X@^2L6D
M0OU709;)!T]1<B7K"C=9C#S=^QKB"V;%9VGN8#Y-<Q?B7R#.L:IKIQKR90B6
MJEM6\J%MULMK<([XM(:+Q62X.'N:HF=:+092;2<USRN*T0VE59*I+`[5@*P,
MTVY&,$]^^2C`]U(.>AUAO#47@/G*T1OY";L?98W0WT,;NWZF`V7F:^@AS*P>
MXG@&TA3=I(>Y]TH`$?CN=_#?(FA&E:Z!UIM:?JI6M50V[(IR&*&%3M9:OEUU
M("10(A8$!W3+OFC&#5$J1R8Q+[G*`LA&3P49BI?K).N,4I+&LB1S;APK7",E
M%.L_1BJ[+&`I:0BOM#SXUZ!ZZ7M$V4(A4[DCAU$BMZL_9$EPKN0FVZ_&OFI`
M'0#3FH4!Q08X'JS:8:=(H(QV[$H#F671[W3J_ZQ4&L"E@(774$3J"E>4U\X;
M0G$F*L@C=DA6;5>518TZDIS^<@U[K"`;L+B4<FVNPM]EU\!75FW7M4=H%B`]
M?=9$"MV'MOQSU]8`_NO`>!:[<C7)IDS-F2E7R[:N"W`VEV785=TZ.!3=4$EP
M)3_)KJQZ:[*V08G>*VJ87?XU4ME6-<CM(WEUK^VNTR((#IW<2-4"Z+OW``![
M5R^1)RIZRC)XMP9H$I[75U&#<#5KED^@*&P<D(5[58VN"*[DVO#;%14E^6'7
MM>-V9XL4P-JAJ^[AJXCGU4"4WV'-2+6I&F1O96<L%B3S"DO#K`($,,IM"Y(%
MD6!+B0(1X8=?>EDK2`#E-?3`7.4:1S-0C$Q:*V4W%`0"ME"OI)*BI=P`4.B*
M9BN5F4\L1NI3TE2;H"=-`=Q(F4T[D$*+^Z*"EP%'D64044KJL]=;>G2W[ZF_
MDX=!K5T)&4-;Y4'XV"7XC*5/"IQE\'[L2`'DVFA1)KD?6]QZT+JJ1U7H@O?3
M$-<Y`#[C[E%*<QK0>JN:^[;632^:0P6RU]!!FN43**:3#O+4@L,]4I0R]GOP
MAY*&!%(QX6J"XPY]EHD8W<VAS[MBET/H;?F^8I?#\V2NGFQ6`ML"8EX#+:P]
M"U7O:0>94MRF;H_]Z_-:<H')))Z8_/9UNZ=^!XEM%1R&W,$FB^DSJ8`M@]_&
M_9YJ<.#5;]6VJ5`SPF."=V79CHWJACZT-=61_5M+3_QQS1]<0(2OVC_WRQ_9
M6II'H9,_3D(C_P<4>65U,*GN!S@"9%TKEWAS:1/NV'FEK?VZI)GGUVWN4622
MNF(\XU,HS:LO(+Y&#/*9TJD2L#*%%LKT0:<?ZC'K<:TKT4([6_]HP*+BCZJL
M(^`795Q[;*AA'U=]M:Z*3I<=:';ZF=]>0_8D<O.R64.6)G:>T"#EV;D'NHRF
M1_O@&JM54=,LP(RVU%0+3=N>"@H]'BGG7O?V&$,"B.@KH\SKU]/^KV/>'\()
MLX4_%YFK>.(\,[.Z'PB?2='JPT](Z/<H7>%,5_"$.$O=9&D:*@@W5)@W(636
MBFH&:L)4$I$3;U1$!<IO4""\>>I#XVPYS1EZI!"J^@SV[M[\22<Z.6U0<M.@
MK-`[$R*LY:'MU8"AH_((<FL<4!T+.K5M1079OAA,1Z&QH)-NXD"%-O6FJF"Y
MAG%3VV)PU55297)`J[NC,>%5XC*.PZMFOYB[*6\^35!B.HM2IGEG8?=764JX
M)LK7*^A5Y*Y03V)7J`N6/6*B<TS0\()^I7GJ.M"#K:I#D3I@M:!9`Q$AE$;=
M<"#J*-'@(LI=FM.IS5HDA<]DN7E4TM$&HE(%8'O4P$Q3KG4[KH;->)7>5:2N
M#(W9E#LC88;M+OL1(X@+=?KEIA7Z+((B2`T=2%A$RDJ?MIBY33FB2=D3UE!Y
M+P\HX[7*IF'>,OC9M*YGZMS3M/NW_BI:2%PIFL\&LK'MX"<9CE+W*6L)?*QH
MM(&N:E*#/C^LP&K5J8FMYA[26JU8)2SFK=[,X*;)ZPB0NXL>0M:XAAZ$&^]&
MV=2R<=.4'-H!,I%YQH9F.S2A4R%Q)DQ6Z@`#]NL/LJ0"R#E"``FP"]5$KI&9
M)F*!W9@F.9_0`YD3"C5+I'J-_/`3R'5'3(<<5]$$<S4EGZDB%W:68?VS5\YK
M&)E6X2!E735P#C/8/2^6G5.H"3>ME\-\[ET\&-\BQ\*.YEAH:ONN=4PE(C?:
MY=,97)QDMJJTK*P*,W)01Q/]5\Q7/;F(YU]5P_E%Y=/P-C&I%8;F,9O*I@,U
MF0\:BRGNZ;@1WG>@EPK6P'3J',:>H-UY/4'6?*Z/B%=XH`=0--LLRIT+"?LR
M`N66K6SH+06T%)13>+@(DI#JBSQ$(GGXBD;?IX-ID,L9FWF[Z2)^(5^=>_`&
MNJ"9_,/9EFA&64`<J(X$DY]VA8KAA<Z*1I,:!$BWJ&:ZK1Y/;AXAS`0L2LW[
M8OU:3_-7)9S9.HL)IH=6W_Z,@K`!.KWYM`G/8YD;F?*I@4!5;!#7/5N7[+UN
M0[OB2,4H0*2H-01LZ`"<#IBV;;ON%Z:!U1EI/=*<CP:*ZJR[#\9>-W<Z7=O+
M"^A?[A4$JT/U+>`8R#-VJO)5[T3H"6-UE13,$E>)I6+2!!>F5%?=N2VX4'\<
M]2%:V2(&U<!7`?#8VS=^"GK79RLUP5X.N];D4E.:;1[IC,2B/KE3,_FS2CX]
M?;N&#H0MQE@83L58PMUY2D]&H"'#4*A$#)2@;@WL3@#B7HM"@]"/-'>@L[4M
MNI594P.[2SJ7(TR:Y$*%LPP^4)&ASV"FL0!%G*Y=UF-)L4P'=U?1`7=GXW$T
MM;&A/42@\X)5W]9`#]6JZ>@`9^<J\%<?@7N2$8O8E9(1<#[*;0$6QJGS`!ZF
MYOVG=\/3-[X63@_4F1J<T#ZLCX.HN(3'_O,*RLC#<[I0,SD:1Z6XSM6FT]WJ
MI4(:7-'PA`C8!8(X@:9\!"()F9>`QTGN)6!Q['\$?##U$H340'D(XES$F9<@
M$YE7BC@5?BEBE"U>)N-8I'X"@3]>`A2!?BF8`$CY""(1^:4(!?<R*7)U;.(A
MR'CJ)TBYGTD@+?,3Q"SW$PB6^Z7`$_Q,,I9Z_4&$+/82\)PA@?H(,A;["5+&
M_(](6.(GB#GSBLD%]WL4Y\_8`H5JYG]$Q%*_F"$77I]D.9CP$F3<KRC8,O>*
M"3WZ]0!CXZ*/0+#$&[S(J,^(R43LWR$2W,]#*/P\1#D"PTN0/0,@J`K].(GN
M+?'Z0Q0+/SY$XCD"COCV$L`8?BE0YGLS3A0FL5?5>1)Y_26CUV=]UYE?!(3^
M,SG3'U0QS[S\(^[]"!KZ<Q4/,^_]+'Q.P>EE_?UE2&+-0L3/-Y"1*XBBIR^P
M)^%4OS(S3@CSS!Y&ZC=1U'GN\.0D2&_SZ[]HRR,5:/\FAI8QL93AASXT<;_6
MMS>_T?:9^OH&YY8=\G4JP<!1'DS?T9BOIR\NS*,X<<?5TYO+J+",9.]/VJE3
ML1YSF,!&Q`I*RQ,.GZY_^>L*ZM;DPIG%4P[R7#TI>\3`M/Q"#>D[$WNPQ<F-
MU<'6-WY&TC#53TQ/.9FOOY`5%(SG61&+-(H6/$J>82D7YW3S9/F+;:/OO&2;
MZ1M&RH:`G[T!TYP\7.$NIT_JLO[XY,M)ANJLS]OU5_@\-R>5Z3*/8&#2XAV]
M9L#,.QJ_SH<$EZ0BS]!260%/A5$$%^2R9&<CY63]99%B!#L3*8Y>>:#AVXC@
MF(WHHR+0'Y_R;<@R%`^/XTLMORJ^>/QL?$WLD]-I]JTDISPK@@OL6S)$WPG_
ML_571>4Y`1"1+%VDB;C@/UG(G"!&)L>]<AI%<,%_+-FY6)XOORR6+WO/6:0/
M$QO2^&1".@I=%.B/[ON(9[(9*,Y&]NGZ2P87421>E"JT"%8:RWF8N9#0'R\)
M8:G!TFD\S-;#5X1QQ+\LC`W[1I)3GC7!"?N/;IXP()PP0%M-$?@-:*G/I5J]
M_!HH,/;[<BC0*K#:.)5;$UQ0@;HVX4B8/Y);$?A58*G/)GFS_AHX.:>$9!'R
M?!%FSWBU`@VC$Z.>4UD4P3-B&>ISX#)??AFX7(Q,'?0IOUR;)_/:_'1K$:)M
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M6R`Q-#(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E
M;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@
M,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&
M86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-
M"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*
M+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-
M"CX^#0IE;F1O8FH-"@T*,30R(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$
M96-O9&4-"B],96YG=&@@-#`P-`T*/CX-"G-T<F5A;0T*>)R]7%MSV\85?M>,
M_L,^>"9NAU+W"BR2)R>-T[1IT\;*)`]Y`<DEB00$&`"TK/SZGK,W@)2\:FW"
M8X]%`4OLN>TYW[G`7_Y\??7[]16]S0I%*/ZQG_2MDNZ?U?[ZBMD[C/",L,Q>
MX20O;HN":Z(I)47!2&>NKWXBC7U4+A4^1VF-/TBWO;[:75]M_HQ/PC^3"_16
M2@'/OY5""?@A"LY/[Q=2X?U"Y'A?ZTP\_4!.;EB1`7V:40++9&9IVEC^W$T:
M;XIL)/C+N^NKO[PNEZN",$'NX`M6#O:A@7/&":-2DKL]DL1RD,3=ZOKJ!NCF
M^/G^^NKEZ^J=69-7?6^&_D_D[M?KJZ_AR?_YW_>WTDWLS]W^+\F'/CW)'<T]
M=YQQ%;G+\//(76FY(V5G8(=5VZWQVD!6;3^0LEF3M3G`]:H<\#K\7N[;;JC^
M@-^.?=5LR;`SI!^ZLMKNADMS(64^LE'P6TDI(W=_`.TW%]\*3'(B,9KK:`]"
M9=))K*X:0_9FV+5KTKXU'3)?=<3T0[6W`CKV9G.L25V]-?V"W.^JU8YT9;,U
M9-.U^SFT7!0TF+`LBJADBI^1Y&'7&4.&E@RF(0^F[/I;\ITI>[-KZS6I]H<.
M&-F;QIO`J-W`'ZD-6$A'VHWG=LHC:<,:>")LT>WA\3\>VH;T96WP;F>&JK,;
M+.S*:%=SR`+\B9>%R'147U$()XO.U,Z,5ZOC_N@^1_.N@.B)??L+(!)35_NJ
ML8NM$IT4.M,?S&H`(>#CVB,(<&&_CTS"S6,]X.G8EE6#8JC;OB<5_&U6]1&/
M&%QVJ_I9)*&R</0Y%]$J<NXE`<IL#Z:S3(+&?C"'LNIZ2_\>*`9;*9L5*&M7
M=MO1DM<M:=H!>>B<OH'54VNP-N)=RL)*SSUBC18X[@@K\"G'KC/KVTL[UER-
M_'^@8TV'C8(50;A*1"^AJ/!1X]MF@"-?+>$`S!0ZJ(I$?'CH2`0F77SLPQ/B
MTYH'\4U.J=3X^4Q\/C;Y0T,.<`@;YST&L]HU;=UN'^#X_7ZL^LJ>5_0NO;=6
MM+ZEP4/X*4-6!A$J<#AOQ,K`"D99,BY9]'@Y?GY?P"+#O:G?FDN3@\?NTS">
MP^&>,*Z\$;W$Z#:+P68JAI4)*H@1%J-><'W.1,&E_JLEY7IMK;*LO5V&^(/1
M>%Q[;L_W!@PW>$=[<U4>JJ&LK05#W.`4V(&8`C_5+;G;89RMMA7N\[:LCP9I
MF4,,4ELQ`.^4RB`&KG(OA^K1N04Z7BC)%D)IC'T0:'M@&)AHS(`WIW'X).SB
M%Z54"\$8A@KX]:]F9?9+,&#!%E8`B\?!VKP[F`;"TCU\Y87B"P:YS!QR@.0F
MR"'/(JYF6GI!;$`WI@0/Y&W"HBYB&@S[C_BP;#A-OGJ2F:JNP8V1\@!([9V%
MF?6#98]"FN:L(7>R.%TA95@QAPQ82)RHT*/?884'RD"41M0`F!,DT*,]GQN'
M9VS5[@$<'VL@.;KIVSEB6EY\5*Z5A@1Y'A('P963Q\MOVG:-3%Z:%\B6PW:S
M!/]<?>S#4X*2,5T1:LQ)*;IS-)R[%NT8C,$Z2,A-(+(C8(2C]&8`R\9$`G]Y
M72%"K<#EO7+H&^,ZK&C69;?NR2]4T3>O7[V!GPQ<,>1&?'%QO4N=3_CAN8KI
ME]+:'X1@!/:$?@],=>01/+RXG+'<$P@K,H!96MA0C%Z*H^D@94%$!&2#8KJT
M='(U(8+?"HH;(QY87!X/Z(D>1,YBPJ/M9^36VM,<]LQ#RLFI&A.M+/?V_%6[
M/Y3-`X:_S@!.[5SXK]9@Q]4&KEM8<$#'!P9\;"K$#E]"<@5X#?-1^%O6#WUE
M3P`XRZ;=5RN;5)4K`!Y5/U0KAR!V[;UE,NSHLBU(RG"+)0)?R.,_\!`\(P,:
MDTV:3V10Z%""&*G:06Q>F[[:NH0::=N:=MN5!\#LD"6O)@GB8]%\;CG\$3["
M=ZT_<$?=`7Z?)O13,7S6D_ZX[*MU578/&`S_W=8@+33X6621Z2*68]"G!:P8
M_1N0]B^#?@#)`'W\K07F_H'_A.0;;Y"O=N#@`!*`Y]@&%U*A6/K6U^+NJV%G
M.1V?<"JM#TZL4^RI,=]@T7T+S;VJOV_(JT-7U83K`-.FVD?.4*T#`@/-;]4O
M5"I@^E<`L`.8['UCRZT5V/V;46N(&3L+?>'DE*0'$^DW8/ZA8G,X=G`@`&24
MV\ZX"!&%,X<,A(KF+L;\50DO@W/Z+TX"@.]`@X/A+W_AG%]^&SUAE8F,3:S9
M<>H5.=RW9%\U3H<]N"9;6S0=6#<J>P\N;(M&N0;OMQH`'*/2VL;F*;B@M6'Q
M-P.:WA_J]L%@Q<EL-J&\9GW?W\OFB,;@8;/+>^;0+M,!V6HZLBQ#2^!)1K%R
M;H#6-7DA<A5P]ZKL=P[>,[Y0\##[%<O-L>G,%IRWM6N`P'NLF`[MZK>0,\2X
M@36-!BS)E\X()!>?6Y]766PSEXU3%A2?L>C&)&/>C0U=V?0;K">TIT$'DCKP
M5)Z)N4\"AQ0\4#KC21!43`3"V>30:YF'H^"5BZKIC$]UT>I9[MU<L/;CT"-.
MQ7ON.U:1.U.OR=+AWO<<IAGTK+0<2QO%Z,^U3V67'9`92F9>R1<G`_+I0,><
M_@Q\V81=)<=^'Y59T"*&H*[?50<\>4_9,%H\H]1J%,]V9^K*O)U91(K33R$B
MQ67<!JL;C,>CSW4>G7XTS\H&YGX@=54NJ]J&\,U9'6(.H\TF7;H18XG"]S5?
M,):C#_["^4GG*$O4E.U:G'E8<*@++#V`!ET@&@!Z;;%[00XM%N@PR7PAJ7/K
MX(SQ5-LL=%E76^>4O1=\'.D`DEJH'U;,(0T5,A^:"8>^7\YDAIF(N\UHA:#=
MD2?&QZQ*Z"R>TXCYO%>M`/"BHB*6C+;YOG,,UUE1Z"_L*7:&,H;4%;:_ZCI6
M(S&H5<W:+`%Y8QYU&N'FT*H04:N3PCY7WL8GC+3W8TGY:73B10!&?G35D[-2
M(<M=-1'N`'@'DSV4KF#Q(J?A1KE:=4<'PJU<%QZ7X8-'K#:')%@V^NQ\XK-]
MY%T#$PX-SA6?@(!`Q)SQ"7U\Y)6J20.;9OH,9=@>@2WVVV&-<WTN!.1?J+AE
MJ"2@FC9EU<$!Z7XSP]@HF#%J99`5?@+!98*?"*Z(O0FA0CVZ/P/9TS1U!IN5
M13$F$2,Y.&,2RN,^,]Y#2#JZ^0B"EHSA*`P48"0!/W=H>].?6/AD4.>1XB4+
M)S;6#<[:3A:[N_1Y'N9C:XY*.F)*&GJ2)Y@2.T&1T&59V[$#L.C'?9*A?<RM
MIM;,PWR"+;)M:O!%KE%FG1[(T@H-=\14JJVKM15'V&T.$<2.(>A_[!@*&N+7
MSICAEGP=_>8_RYC9GE9,+$NH;)M*>-SYB=(KY")P,N/YE5DQ$1B7>0QW"A*1
M",S=\(BM<KFQF6<5/(=B9:@.0"2.]:],4!^6^]"CL+%Q.F(S!S$L)NEL=#)Y
M:$-^VUC9=&MKY;$B=M94\1V`4ZL#NL$/[6W[&6?$('!8#]5!IF/N`^8*YQ9]
M$]CIX-#6V[;&0HB?#;)E:S\>-\NDDRC&E&XL44F6>6\#;F-ML$6/DQ`Q"CX5
M_C[K_8DZ+:/&H2YK9EW5.T0X>8SWJZNRZZP1GCS\K"8[5]E*^(Z@2]LB9.:Y
M\!'PL1;=.7*>LFDG9>9QI1O>FJ4=*SZNRYANQXJQ&\3\<,AWD.!=O`%(XTX7
MF'A);20G+#&9Y6,I-O,P^#M;?IQIWHR-C,[2%<8*6V".329L6#9V34;L@];K
MVD/UARHU14XN(SWSSC&Q7$\YUR(Z<0@S<8#K;9S17O@.%SJ3S71V>]AA#@`9
M@2TBHK\Z]NY<VX)CC$(+BRXGYQL'-`R.A<$_-F;-,C_%=<S@BDF/5"EONN!E
MFJVQ`7U5=:OC'NNC*WMA7:T0%%L&3WSLF,O&@5-(;1[L?.K23;(#7^6R-C91
MC;W7Y4,(>?*6?+LA_1$G!1LG@+GXS^*\*,LFP[@!W#C^GV`_CDR=1F?KI4-0
M=8$6!-7;G`&'E(_#$0=OL?NPJ=M[4#N.<+O@Y^ZUQ\'>`?@-&_6^K-DNAW*>
M<2$>VX9<\G%*@H8W$89=:V>$/+DX^[3R&8N+4G'R.F"*4>NAIV@U>"QK`J*`
ME,E.WED5VVG/XSY\*RTK%+J7UCR%'3ZVU*Q40FDK'(:$E<?Q=>\-'MD$6OVV
MJ?XP9[#-#I][E&+>V1G:)P"+>;<R9MV?@:39$`N/C39F!_3#U``[FYQPZ4]_
MSH_I)U/VUCK*)9A"V]@58,:6:7MC"L/]Q`T(`[R$LQ0LD&S"^R\U"+?:5%;*
MP;U:K[J9R3>,C38Y:3<6U/M_^QJ%=WY@G]/W,!Y923<%I=:(W=@I,-L;A.D_
M==5P\;E?R4<N9GY%AV<3>7'!)IZ$>7FMV_O&<IP4A=<V(G/4]!)BA9=PL)DY
MWL<:FT_9"'*D$M[@)Z]'V+'M$D=C&KCF:K'E&E*8"L?6;<7`SX=^1&:9>C$M
M\[.2OW!)YQ"%C&^FB7QL+^N</\9[ZQ:.N@OKV&F;@`'LUAA7"L6%(X9Y+Z"P
M7WT65?0AP9T#7N;9R/[,8_)9%G?R.'(.58K8?BK$&,]DL&KO0Y_&9N\;[CX=
M77)C55J1O(`\Q%(XDF+?&(4%>:;<`OZ>!5D&651J@<+V66J!S"A-+A#8/$TM
MX$KJY`*F6'H+*G616J`*Q9)<**W27*A<L221*E,TO4#)/*D+);%`GEH@)!AO
M:@&7*LT%9,EI(JGD>6J!+"1-+]`B3:3,A4HOR`1/+X#@D.1"2J[31`K,,%,+
M&-?I!93G/+5`%%RG%VALXJ86Y+Q(+\BP7)1:H$3:HL`AI74AA&#I+;B@:3:9
MT$F;!$UD239!"FE!@:IXDDU055H.'$R.)1<H7B0/+V1P:3:YD#K]!`XH/[F`
MR6=HH."+4PM8\8P#8?H9/\ER623M@8$;3"]0SRV0X"&2"X1,&RV^])>,.(QE
M.BEJ1C.9-!A&\3\I2"PH>)H)S=.JRI\Y5AFV.9*QHDB'"I:.5A+[^\ECG18Q
M9_09`>;OW_]WO\1[-R:>K@NSB+_8(_Q%LU@85GY4$[%8*"[=69P%(.NKMK&O
M&YY`*_>8'[[!1]XC'OP[$G2KD"0-/QQ(C;_6UU=O(M'^_#Q)<S:E^;QHKNQ(
M16BCA<;BXT0#C<NI!CSS_S>Q62#)\048C<?(@NS7E]L#XN*X1Q+(?\P>V72/
M\1T:QLX1<AH&W.BT([D!?YCTN#<\3V.Z&Z'3Y^A&XCQU:H'2Z9-TDT'X2R[(
M=1HFW$".DZ8!SLTS@J(Z2U/)6)'V:#>,%^G@<\-$P=+B9I`(I%EAJGA&(Q`<
MT@G+#<OQ;MIP\K1_A0Q3)F0*UOOUS]=7UU?_!0'2364-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,30S(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,30T(#`@
M4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P
M(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-
M"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR
M(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@
M,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-
M"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD
M;V)J#0H-"C$T-"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO
M3&5N9W1H(#0R,3,-"CX^#0IS=')E86T-"GB<S5S=C^.V$7]?8/\'/1S::^'=
MBN*'R+Q=[G)%BZ!-+ULT#WW1VMI=)5[+\<=M+G]]9_@IV11MZ=9`<4!6(4?B
M;X;#WPRID;_]Z?KJU^NK_%8HGN7X3U_)6\[,?^;/UU=$]Y"L$!D1NJ7(2%'>
M*E7(3.9YIAC--O7UU7^RE7Y6R3@^B$N)?[+-X_75T_75PY_Q4?BOTY#?,D9A
M@%M&.84_5!5%OU\QCOV*EM@OI:#Q!Q;9#9&B`/`DST","8WI02MH.HGOI"(`
M_O;N^NHO'ZO[N<H(S>[@!FT(_5"G.@&-<\:RNV>$5'"ELKOY]=5-?LMSO'ZY
MOGK[;O&YWNR:;;-ZS-ZWV]WV3]G=S]=7W\'C_W4^"&WC`1"Y#"C>9J_^>-2Q
M^-JG)RV8E]:"A'-O049*>6S!.5HPJS9U5O^VKE?;>I%5VZQ9S?>;3;VXS3[L
M-RBV>ZJS+W6UV6;U:@$R'^IY_7Q?;S)*9EF1YR*K5@N\X+.L.GJ\>UQV_T4_
MZ7W[O*Y6<-WNJB4T7\`(2N76!KEBS@24E]:)JO5ZT_[6/%>[>ODE>T/D+(<%
MACJ\(12O9S#B=EW/=\UGD)CI+K02J++<HP6:5;8%\%O=\UQM?JEWJ+"U(NJL
M5:WF<Z.LL<9JVRZ;!8RZR+8[^/-<K\`^[<-%3``KV2XDRH6VP=MV76^J70,X
M;B>-F%Z["NYQ2Y?(L'2)=;Q/]19\:/ZD;?:A!LNV:[3`!9272!=6>44#%""N
M8RB+`,5Z[*9>ZDG:M=E]NWO*UN`-V(O2#_O='CP!'&BQG]O%,W^J-H]&/I@X
M>WFJ5YVU]`F&6>UK>/B\!K>")[6;2TR\E(5;_V70G;&R,+IOAG1O4/%Y^[AJ
M?C<\T%VLSW6-2QG=]7[9/%H5]T`'&RWG3%8];FKMU[<7T0UBGM6M*(E?V"5>
MGS&O/2;ZLJYQZ<%$_@P+/5N,I;KLI8:I!S,]M,ME^[+]YK5#A5#2*WR14%'F
MWE,$"YY"\/H,:]Y7&"_VZW;EC8D=P<K_?R8M*?5:7R2V<V*(Y^U_"Y9?8,JX
MG[*<2NX70&[]_ZZS8CMK^0TI9MQ'.)[K<`<A:I`*-I:KD*+&!/]^U+R`_DQZ
M`E"\#.2&UVB`EZ<&U&FVO4B]JG<V6I\?EM&;.^$R^V@M8:W[VJIQ2;QN)F$!
M#RJ*UQ^&=TQ8E-2;D.MK-*&/`J@YFL$Z0Y?M+S&S0OJTE0D_L\)3^Q\^9.]<
M<,E>&@C+[^[KU6-;S;)M_?J0"DBC'2;A9X2^=MY40$]0G3+BHQI7Q$<ULQH_
MA7EY;6UIH2+:LE<?AG(_S.N'-$JE?SH8,,^M>[^]!V)[F9;R)N@>]\I?KTPB
MF#`FOS*8I!-V/!-PV90,VZ02K]'O_K8"FJRSN^JW^M6WV4A$=OB+Y#94N7,$
MTEE33&^]#R,EAH,][L0PW#5&Z1TJG>VW+H%9-M5]LVQVF`GOGEK(Y_]MV1""
MC6F:00A]J'7F`W=#&K/%E!F#H[NYJ<U^85'OZLUSL\),5"=1[>I2M`JYL<_Q
MO!6*W&Z$%\T#(*Y7\SJ[KW<O=6UP/#2K:C5OJF4G'J(>J!8"UGO6N'XS:[-Z
M5<UWUA(01$WLK6$T2+6[604VFZ!]*0.(<!0@BG`6(,2A"<)!R-QN_C#R;;;U
M;?:N/[6?J^5>)P99A7EJA?8#-ZC!6K`YVCYAVO$P0]6>JU7UJ`WX1S#:NEG!
M3="A-UO/[0;]ZA<\@]@]59"GM#N\V.%3L\ML#BESIP(D9[*S@;+6J+)UNW&!
MOY/O`/J8<[\T@!1AW^,.L%IBMCEQXY>F*IK[LP7OQ78O_P_([KYOM]OL!UB.
M/\).O+Z`W0KA#Q2X+,*!@K2;ZF^K;3,W:72SW*/[8-*Y1%B01&9;A)4]59]Q
MG<$BP_132P6">:F;QR=H>FWPL-@]>E4``^)>X7>`?//Z([&NG8J2!3MQ:R>P
MP`861+;:ZRT$.)DVS=9L'I^?P?&VNW;^2];N=[":5@LT3V<?>8FIY87/AYF?
MVE)?(V28OZ9=;-TAT&0'/X&"\)#^AE/;G*D0K\RN&$VQ;G<`!0@:J$,['.RX
M(`N&?;<),GH?C>NRNPU"^\VKY7R_K-P*3SBK.?_Y8K?D,-AK*RU*Y;6^K&,*
M23OVS649-HZB*%T8L%9TP>D21_/*Y?D%"^<M@BCJ3^;L[CD[<KIO+O(FHAQ*
M,*%3*`51H51Y9MX[A2?H5T(@H%__H$`Q(%`*R/=3`D(`9Z0$..R"D@*P\T\/
M03E528&"Y^DA")-Y4B#G>5(+KEA:"]B6YTF0O&0J+0!3D9P+#JR2U(+K0Y24
M`&4LK47!>!HDI.(R*9!3E11@BJ9!,DE96J"D)"T@*$EJP7A1ID&R0B7]@>G8
MF!(@A:!)@;PHDP)4`<4D!21N^5(")65)-:F@:8^"E9>>"TA&\_00M%!I-0M:
M)GV2$LK3:N8T;2A`4"35+&21M@-,%1ZV)P1$(9.+%U*4M)HPV67Z"13<-BE0
ML!,8")8(I`3R$P1"U`F>))+)I#\0H,&T@#@EP)E(8V`L[;2$LCP9<6#MEDE3
M$T"9=!A"<I(>(B_26J@B/5?RQ+HJ@6#2454FC23R$^&*Y&D2)FD;4Y*GEUPN
MDN/#\,-N\JL5L=Y,.F4WW=TJ\7D5.:[!\(<.A!.SI\#S!VG?A-]5]TO]ONQ]
MN\)$OG^Z9A[SZ:_XR!?,\_Z.@&XY0I+PQ^3+_G^7UU<_=DMTF$#32!33M"-1
M`N<<IG1INNWE4U=?;,,#1PA^8]-(:3?GD30RH-+Q2J-R`#V87%^"@+T,N%P_
MS`&0\"A<YE8^`"S(XV[+`;,8^VA0X!B8[0?6A73B&%B9V":K$FYUIY/F'=Y;
M?(\V8#DN"@?08>VC0H$C@*X?8(R=47,K.VDY(`$/3'A/ZZ!!@6-@MG^"Y3A$
MJ)CE^(#EA([L&J##VD>%`D<`7;\8;3ASYZ#A;J6NL*/4$0;8#/;`G47WX!:C
M;X]9Z,1+?>E/^/1AC#OA$\H=ZN_JS:I:=M_WIG'J]5JJCBL]^,79;Q^U.!W0
M,RRE%R:,)`X`A.:1=M)WVO&!2VF.1P)X]O#F%!"E1RSS0R2A?204O?N,02$S
M6H@9Y*=I2)H3(K-SW#Z*`$;,CE[\Q[/3:1YK$E%,FATN9'1VNNUCH:A\:'9@
M4S\K29&&I'GGV#9'S:,X9GAN#K(`[K,`[K*`4O@LP%X>U?A:J0[_!%[JMX_B
M)2'\FP=J7LB]?=\NE]5]:XLL4ID##YD#ET$!GSG8RR-=G%B4N\2D\&AN/1T>
M-2?PD%AP>0!6"PSAMF(QQA-38I.Y\S1JO?8=:A50>ZA:8!"UZ8O2HVV?0H\6
M=V\!%C-%\AEL2E-I$P]I$Y<'Z+7`@").+$JJT]S&W'K&!"!9\9!5<7D`5@L,
MX;9B,2J>Y#;FSC-S08=:!M0>JA881"VC;M-MG\+;<;<I<SXK2Y;*&7G(&;D\
M0*\%!A1Q8C&VGV1^<^?9&:6F)LH=Z5/N2)\JSYGFTG_X$<E)Z4!.VF\?LT$L
MV;A4SZC@M/'(2T^@YG)("2>-NT9R2/JV?<)N4K\1/(?T+7RK21^S$>C!/[@Y
M1`P:(H:=0"V0G$`G'0L<='*JS$XG8_T(XDR@@@F\WD8@;@+3%\(/E0=Z&X$3
M)C`BT2A$IR?I,2.P64'%#);%&2FRL8DS3U\7(Y!4RTE'8Q*=GN@/K\U^3++P
MA2<6<UEZHA^:4MT7`AJ5!PH;@;3N5CH6UR9YM;YSC%=K)G8FD,$$7F\C$#>!
MZ0O1D<H#O8W`"1/(J%=WVZ<$R;A7"\YG3(H3FQL,A<8FSCQ]78Q`4BTG'0N9
M=/(&:="G^SL#T-+&2KQ:VBL?*^UE[Y@4VR9&02'.0`5L:U$Y@!Z,#W_VLG],
MBHT3`YL0IP,;4H4#9C'VT1B!0V"V?^(QJ1!DU#&I!>BP]E$9@0.`KG\B>3J`
MIU)C!TQX3^N@,0*'P&S_Q&/2F.52QZ06H,/:1V4$#@"Z_FDK-&&X2$J*M2VQ
ME-2WCS^.P%=PKCZX#&6ARGTE]T.]V;:K5;W,[)=MIS-O1!,[9^BWCUN9%N69
MB3..%$G\;/.$Q,^-/_:,%$>,I5^N?6R@(GD<BLS+65Z2TR>DL;DY;A^W]L^?
M&[V8C^>FTSPA?9DR-Y@LQ.:FVSXAB8A"(3`S;$;EB?-KS0;'MCEJ'D<O@W/3
M.^84H&R45US[!%XI'/$6E(1:94DLKWQOSCO;S1==+;S=K]?+IAX\^T0.(&6<
M5LBDL*5O+8;8]R`3(6643\@4VM=WGC6PTB-$^<.V3^$/.W3?1VDQR\$5AW(*
MIJ+F/VX?QQQG6$&O\&/S'S6/.LD[;V`9-7^W?31%J+CYBYS-%&RMAQ(3*F,V
M.&H>1PV#-HAE'ES)*$/X]@D,X3_A+1@/W^0H;C_!^.=^MVT66,Z]^=S,#Z@A
MFG@@F!A#]-O',40^N"6()1XX4H0H>LWCB&+,^$H/%.,+US[AN,<AB+]TR$ZG
M'+%9.6X?1QSG6P67>V16CIK'\<>8\65T5KKM4S*-^*S8,_T3LX++/V*3H^9Q
M?#)HDUZJP0<J/7S[>"+AG4H/0D.E![&?$WSWZ[Y9^V_W%O5Z4\^;ZNCKX7ZV
MP0<*/?BT4@)]ZSFOJY$MXA4>?-)[<GWG60,K/4*4/2;6#``H'JL9*-2,YGDJ
MV8A9_[A]%&><8P3-"O$*CFG6UW>>-;",6K_;/B'9B%J?43+#J4DD&Q$;'#6/
M(H=A&\0#N2_8X+Y@@X>"#=XKV(BF*P-U&P?MHU@FU&VPSO>S^EM:9)F/U=Q_
M^MM^KC=/=;70A-/NGNK-&:E#*.W@H;2#A](.WGO9&K?;0(5'OWT<:9U9X<%#
MA0</%1X>OCH)WTK'B&]RH<<YX#4WA$(/'@H]>"CT.`G>B$3)<^*+>Q)LWUN^
ME)<S_%FO,]*>4/7!0]6'TPH%TEHYZ2@13R_^.&M2D/="\0</Q1\>OCP)WTK'
MR'QR#<@YX#7AA1H0'FI`>*@!.0E>1CVJVSXE($1+0:B$=)Z>2AH9<UHY!?NJ
M:(&T5DXZ%ELFUX4,3\E!1N<+0K@O".&A((3WWL_U<]:!2A`^O1*$G_-F#ADL
ME(#P4`+"0PD([[UJ/=0X7OO!I]=^\#-K/WBH_>"A]H.'V@^>J/W@H?:#A]H/
M'FH_AN;*B<6"R.2B#SZVZ(.'H@\>BCYX*/H8TMWTA5`4BCYX*/H8UMWT16/0
M]&J/J/;Q:H^#/#J4>?!0YL%#F<>0(DXL&G:FUW<,K[B#L!/J.WBH[^"AOF-P
M]G1?B%FAOH.'^HY!I:U8+%A-+NP8Y;F:2D-A!P^%'3P4=@SI;OI"R`N%'3P4
M=@SK+J.>VVV?<$0RX+FQBH[^.V`>2CEX*.7@H91C2!$G%@MODVLXAOW6!"$B
MR/#G>:+[>=X!M>4</Q/UO^;B?NPL/HC]-GCL/%`%@]A?[U+B5NJ#7IR'CZ\X
M"'ZCZ0=)_H#&5PTBNH-T7IWTOWS07\8FO]F\D>EO5F](F?XB_::017H$BC^%
MD1)@,OT#!#=<IG_CX$;(].\LW)2R3&.04J6U4#+]^P(W),>?!DQ*$/R%]Z1$
MH=(_O7%#J$I_9'M#F#HQ(83+](?&-T24Z4^%P2W*]"\VW!#)$B8%Y_SNI^NK
MZZO_`2IHGZ<-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,30U(#`@;V)J#0H\
M/`T*+T-O;G1E;G1S(%L@,30V(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R
M(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT
M(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q
M."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&
M86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@
M+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-
M"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C$T-B`P(&]B:@T*/#P-"B]&
M:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#4R,S$-"CX^#0IS=')E86T-
M"GB<S5Q;DZ/(E7ZOB/H//&RL>S=4M9`7(#U/W3/=CO&#[>VN#7LCYH5"J(0'
M@090=9=__9Z35Y`@2ZA+$QL3=E.I`WGNYSN9"1_^<7OSV^U->!\+'H3XG[Q*
M[SE3_Y?O;F\B^4L4D#B(8CE"@B2Z%X*D01J&@1`B:(O;F[\'M7Q4PC@^AZ<I
M_A.T3[<WV]N;S7_BD_"_P4!XSQB%Y]\SRBG\0P4AX]\%X_B[H`G^GJ8QG7X@
M">ZB)$Y)D$9A`&0LECQMI'SJQ\3^2&/'\(>'VYO_^I0]YE*Z![A!ZD$^U$@>
MP9V$!@\@^KM?"`O_(WCXY^W-1[CSOQ<]GWJ>'\;R^>$]H2P*'O+;FSM0BXAA
M^"M,^[`MVB+(X']Y4_=E_534??42E%UWR!ZK(NBV\%L7'.IUT099'61/;5'L
M@"CH&[QE?<A[8*HKLC;?`L$Z6!?/1=7L)4V6]^5SV9?PA*8.'HMM5FV"9A/T
MVR+XL=GML_HEV!]:F$L]\`H*2%*A%1!1,*-6`$WQ&A6`K&1MFX'DDN5UT>5M
M^5BL@[(._M+T19`&7U`);\T;H8EE3I![%H9@GG\!1W=O/A,8?J"&E%HUQ/(:
MU?`AZT!DM$E1=UE?@KG>F@W*?R^!:>P$!BE#*R_A8:KD#7Y&#Z]S],P-RKT#
MB;_T3?[K"O[^NBW!F]-D%1$NG9H(LDJ21`9*5G5-4'S+J\,:5+9IF]U5_!;N
MU@8CH#CKMS%W?IMG57ZHE+6`ZW59'7I@J2[ZH&JZ+MA#S,H`#C9-*X/N!>*T
M"XH:.?^IR(O=(Y#0:!60$!*%E#0,^0HC>E]@\!;5RWWPY0#:T)D`YLF5MCK4
MEM3(-<3GW(@/B=_F+0(U08I_J$&2NEBO@KJIGXNNQTO@KV_+''6@N>VW61]\
M+:L*D@^FJZZ$/`8_-X>^ZT%<2'B0F?(B4$_3>4[F!)/H[H/W4FJ?NJZA`)H:
M!401M_87)%$*(!%=18GRSF3%H8QHD;]B0M?BX(\#48_M>BG;GGJ61(KM=Y<]
M7/AU@AE#Z@1JF2UF7.`UZN0SE)[Z4`2?B[QYJDN,B[<7,;5L7"BC7X%Q^KT/
M]R@PCIE68)B*U#I5'#HT8.MRJY3X+W"I5NFUPY*8Y7G3KC%S0ESU6\B9V683
MO(?1@\0/P8=#515P%?P2\O#+^P_P3P2%]#Z(0G9AI'B\@@-Z=%)1&@M;VYA@
MLVZ!DGPJ:Q"CS"J4H9>QWEU%Z2RQ2D]<)F=">ZW6$^H'=07I5OT1=`4P!)D;
MM+QI#FWPF'5E'@`ZZ8NVS%1NVQVZ'G/;KL!_@+@(OGS\$7A\*B$79BA2#K#-
M&M/8\CX`6W>%>QKDCC]BP8"JV$%ZN(HB:&BP:!39FLR22&.0XAFR,SH69%N$
MF@-4)L4LOH%,/P!"JX#!]B789FL$C=L,V.VS7XLZV%<9W@Y5KVB?2RSN0YK'
MHD!-U+($_""S?%>`L[9_@%()=:-`2AQ]/+S(RMD<JO55%!%16]NI<+6=:W`"
M]MR4W[!,M2`MV&<'K@IH_`>9T/,&>(8<_EA69?]BX#18N"B?-6:7C#_B8-8U
M>.M+D`'>`;'!N[(*]%(WH-2BD!&+T:Z?DJ$'H<8A1F#^H7=<0Q%<F.XD$L1U
M)UP'[KK8%*UDVI^8`*^!9?NR!^'W("@6?F7)'/RFV17M"H,'Z_L>8E\:'LI@
MN2DE@"O*IRVT'Z#FS@(E5RB##A1FU'8-'206F8O$.@.+0ZT$U9OMP$%1`+#3
M4XO8SN9D8`O=MWDN.S":DJ#XALRC`;7\0-X?VKI;!27&%M3^SP7&2*'IN[[<
M97B#II..5@*PJOL&(BT'(Y202J[E!C&Q32H=-JDF,0"`>:S*;@L,/KX,NT<I
M3PVNWW59"W\!Q,L/X#*RB97U2<>&3?R@P&$*#+(=%JY.C6N5H)BC.9WO7$-Z
MQEUKEK@@,$C?P%:+\[/@.6O+0L7^!GKLID7#UMB18#P;:W::<;AK"YFS@10'
MQ4Y;^"KHCQ-^/?`B>S?=R;/894T6C\I\-P#QG__]I^"]7;&0_O#^L:B?&I71
M;"993R(;788Q%#Y"##VA;K%MA"D>LN[7X%/3`BV6[[>6-@FY%5=)^NX70NB;
M3P/`V4PCV'W"$+QC1_[QYX=/;SX9^/:I3.S-IV'4R31<99`X],UGX^'`+YEN
MU-])+[E&#$C0B)+%`"9Q[08E`W"-JX="O/6$$%EVPJLNV(`6S400W8RY=E<7
MP4BLH&+M`0MC$/Y)5D`#ZS-(V,'?6LA_Y1[RVS.DMK\`&L;A&J)?M?`RMO%>
M`PP,LCFJ+>CY*LB#JZDU"<GOI-<DC`>*#0EU:5.DL5/M<#WV&EZ;F`8M2H1;
MS&&A7LLH.\D!0)P=5/&@`7L\`2HQF-0F\,<BSP[0M)1]4'82HF%I1,AK8!O@
M>41M3;T"5/#4]&6F_L#%[197HR7<70-*?)%/U%/TV[+%P19J:G?8[ZL2&J'+
M*Z1/%3RQT#\=6"/2T/]GJ$/K=:FX1G-492:!?BGA;G>HI`QRU7&L'"QH!KE*
MM8S:`VU=A?LFU^HMH!Q7QJLL;H'IC19"MY!#8Z(A#R"63.-<;'H!W6`TN\T$
M9!%Z5;#Z;K1HIS"\[8@J"6EG5_(PNLUBWC@&L&O,]@"JOTD@55TG*@AU*WPN
MY254+W'^FU@)D:[",$1T8GJA^<T6&38*)*KUZZ]99Y6@TYY%/TXG#X`--0JV
M*Z4#8)2Y+NL:.K#;4U'"76:@B=9!IC(#]C,UMG70W#5Y*26RZ!Y!'ICJJ<UV
M,LZ+W5[)K%N%,0A\+/JON`Y@-0%:')H>7:M4303TG3]OKB$U'6S&.)F5Q(8O
M7)D`><$>D-JR0)8^!?^Q$?OI)5N7^>R:_*;'W3H`_F^^:X7;JO1WV<1AE`\5
M181KC<QZ+^YFP$-_.Y08&-NFDA4>$D/9K%<ZL<LEGUU6UOC3:1!=P[INYR85
MKJ&G9NO"$[>/6:7[#Q.'ZT.N/%G[Q=MORJ668691.7G[';F17N3FED$!5)<^
MN8JQ@=INBQNNO*ALWG3%V,6UYZ,NATFK7:N4U<#M[56,J_>E<%LQT5WH.\@7
MS:ZX2D=-Z14[:AJ9SH5PI`-9(FBNS;++>[TT`DBB4B7$+"?)G8!.KHCA(G.7
M2<PUJC;=MMSO#=S:PO]5>@-JC[$WQ!MZK\I`N*>F6>L%K;7>PKK2LA.UVTF$
M$9>(\?R)@J6UWN,%87%/50I\#Y6B4^M%DR*:`F+OS($<J4$B/"S1!1WDJ?NW
M=A4F8BO/5?:ER/?M2_DW]HC=P8%I;,KD--(I\U.#B[1U\*-<V\M?@@?T.K7S
M?07'(,2"=,YC5W;2R&V3;>SN4>=VC\9@^P]R<54RWAT>NW)=XK)=-]B,Z+48
MTE,@:/ZG+O%:[D=UP;JIJJR=WG7[]/Z+W%3CY.WWU%`#4?C_QR!),N`G2EP3
MRV1#B_P@M)?;91B*PY;I/(O(WLG9(NLUB'AK46*`_$:4ZZ*GF`R51DAJT1.W
MJ^J@JN);OL5-MJ!%CUM)]5TAH")A6YTT3$Y+O^L])4\&[)]8!0*GS0RWD%&+
MYZR427=]:.7BSK;0EH,T7;1]ID-'EK'!#IE$&*Z8J2T6N:NF*\XU=)#8DW@D
M<9L<J=`NG!_SN\]>)+.0%T`[ZT8S:H:QM*CHDWXN`4\/QI1*V!QJ69(A/0V)
MQB?OY!X/%J1!*)A]X6LH@+NNQYW$8]2<Q#,[,?*,U?J?ATXCB;;8H&6N%)($
M?C&<7?D87I0,=$#"`>3`P[$S,:D6,WN77K5N5,%!$[9%5LE6W=[X!'ZD4V'3
MF4BRF$2NEU[#OLSNXH6QZ^43;AP<W`XZ4K7J9M)P;@K(F'E<ONMQ3TLM<N6Y
M<EF,<=P.:ZIR+7/"N/8V>[U+=IW=K8B0F;.Z\FR2@.*8B#"@\L'N"?)`,0G`
MQJDB(#,$*4]2+P&H,O$2Q)PR+P'GD7\*QB`<?024,?\4!->U?`018WXI0N:7
M@@O&O4SRE#$_0<)"KRUXS*A7"LXA4W@)(+'YI:`L]#-)Y#E6#T&$1[I]!"'U
M,PF]CO`3I"3V$R0D]DK!8D*\3((MJ=<?&,7,Z2,@D'"\!!&)_`1AE'JGP!<(
M_`0I$5XQ:4+]'@5MM]\6E$.7[B60>-A'0&GD]4E*<)G-1Q"15Q05DM@K)A'$
MKP>2$LZ]!`EPZ26(B5],PEGD?P*CPL\#Z-K_!()[ESZ"Z)4$0L)7\F0D<#'6
M1P!IT$^0O$80XQZ=CX!3O]-&D,N]%2>").=5=41XZG68*(+*ZB<@KT@11GYC
MB5<"*Z7,*P/$OE=+2>BO5W'(_<4F]"N904GU1VWDG1_`JM]/0@]R^4V3<&6#
MB$ZO1D06>$4GP"N,;?O/]<G1\#X4J6X?'V1#)-_CJ'L$@R-PIA[S^4_XR*\(
M!/^,#-US9"F%?Q3PMW]6MS=?;@=O@/$$&8"<M=-RP&5E+A.\U!3R>CN6&<^\
M`.\D7`XV0Q;-H4W'&VC`\&;Y=!Q)830-'W-G*8`'L.TB[M2]L^RY&W"SW[)G
M6#UB2=,<LV<HL+)#]3_E+_&OLL#-NJ?C]X"[J>SI[G"_.=:'#OX7-X\^'K\)
M,Z/H-'1.8*4ZXE[3'$EB*4`@L4S/^E;QNAM(@T!?8UP4+HV+0B6T#J&NCUP4
M!M%%ES*G[DW/=%'%F^73<42</ZCK8Q>556AQ`.E[DU==-$ZI8\^P>L22ICEF
MSU``4ECNH1'>:Q:$U.L][_`<PHP68R$LFY;E(]8TS1&;E@)F6VIC?6]\9J!K
M]@RK1RQIFF/V#,4%6DPHF=8B]T:Q8M.R?,2:IB%348R5_L(HGE6B"D,!S8.,
MPBD5^)==A.!VV871P1EZ:DX4=7U[4&LD?8.OV^;;[&@[]8_'+&'\($\7.(VZ
ME<^+BX&#ST:++WVVO-7S;/38"_E6M_J>#:YZ(=_J5L^ST4GPV9>YU_RCP_M4
MON4.U4JC*HPT!4HHDS-MK`^.QQ?Y8&(WDN/4+OUQ9K8:Y(NU0;-7N\3#ER^'
M;W_+`TH[]7(J+EY^+N3RGGS)\O3H[G=P3*')=2S+93T3-5Q'S<??#GAZ;O1"
M]-^J3+W5UA6G"^3?J<`XLL<*HM@M#-OWL^6;Z.+T#/.)@67X`2/@,",##\;)
M3)+Q1G0\!T-..<`@A9G2(P;L\$51'\_"S9/Y1:PF2HX8<.-+TVP,^,UP`+T"
M#?$]/MPD("O!XY6((C]+,K=,&&4P?E&Z.E\I,@.=&L4-7Y32SI\_@0Y\RBB#
M\:5&P>,WDT:)5EPDJQB`\RL\8>H\U8D;OB@7S^K$X1`,>)H.8;=+PF;\`B#@
M]E\B-CS.$B]-PO+M=D7^U[U+?5,I[T)V*>0XQV\HW&N[+#%G#$RFG4M]X_X'
M.7%A-,AYH_%E.8_-[O>,VAN<(CV:^7AX6;([9V+,9CA#<C3S8'QIEN.QG7H4
M4!P/(<]U)IB')G1_.KXLM9VA`IF"3G5_,KPLIYTQL4Q:$[H?CB]-9NE(]X-M
MZ)-]Z#-F\28H(^!<-$FB4[6>#%\VZWD0%::8S(YF_(+L:$_;D\1EQY@)O8;X
M5WF`HAOER#.0%C`TF75&X\NRSNP7H::1%LPQE7R&P\N2SX+Y,=?@1%,Y2(\O
MS4$)MQR\$@??,PMF&"/G25T[X\'SJ2N>>_`T*)SPG]/Q99GS?/O)?'?J/R?#
MRQ+H^?/+3#;A/\/QI7D4X-?`?UP-BV41.P<1GBKD9'A9ZIM5R!@1`G>3.<^,
M7Y#S0GNL-G;?F>!)K-^J_+O\Q$8_!H,CV)6^"KN`N\D$.!I?E@`UUZ_"+IAB
M*O,-AY=EOG,FQMR`,TRE/#U^27.IIQZ[[(J%?(7'2'S8:\(`I^/+,L@9>I"1
M?FJ`D^%EJ>.,B65NF##`</R21G+:`(+C=]]B+U0ZU<+)\+)\,:N%20B2QD3O
M^^!5I:]BL\>B+^V'+T_!%E),K0<>C2_ZZF1J#M`3QNW'RWADCGK^.'R5QWYK
M<MB&YOA5MQ:_:!)LBJP_M,7X[9+#HWR?6_ZM:'OY(G#=]!.?:?E.:1)WCEJO
ML+_3IW!?QV?:/,92UBK,[#+IRSD#&6I<.HJ/DJP>)^GR)"N_1/7*K@[F-,.^
MEF3,LR+PLZ^ITR/N[?`EB3J-Y_8='3TF,L.\EF/,L2+P,Z^I<=$J/DKV>OP2
M?&O8/P/?OC*++XM;);T&0R'Q:D49G8VUHPB\BC+4QTXZ&+^D$)UC9\S[AGTM
MR9AG1>!G7U,?.:D;OJ28G<4\I'O-O)%CS+$B\#)OJ(^==#"^N"#RD9.Z@L@2
MNDHI]SL4[J`:H;1\8TD4@5\H37UD$3=\26&=M\@8TZ:`E75%A2M=49D]6*,O
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M6&8C6R)GK*=^<XB`D2-)%<&,T)ILHJ^]S&'5G6>(C`5*B6RD'\LI">9$EK\Y
M','(D9R*8%ID0S;545_HL-A1SSALF(H5X7/E5T(#K06MD#'WDF!.$$TVT8U?
M9CMUYYSM?M,'*/G\L>9X>*QY_&P6XHEC]_T%\^V-R4E2=;IZ\2ZKP,5T\\&X
ME.&;>&B%DV_[73X%OL,DIK:MWG**>##%8)M__#U$>8+==TC]+O6_['`G7TOU
M$9#4__[='4T3[WL`=PP_N^TCX,+_]MQ=+/PO(MTEPO]RW%TJJ)])(6(_DU$H
M7E%U%(GT%643P?V"1%2\8H^("?][$7<13[GWS8V[*$X2[[L?=Q&T0_-\@.=]
M_,?MS>W-_P%CR;%^#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C$T-R`P(&]B
M:@T*/#P-"B]#;VYT96YT<R!;(#$T."`P(%(@70T*+TUE9&EA0F]X(%L@,"`P
M(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO
M1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&
M86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2
M#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E
M="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-
M"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HQ-#@@,"!O8FH-"CP\
M#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`T,C(R#0H^/@T*<W1R
M96%M#0IXG+U<6W/;1I9^5Y7^0S_D(;LE<?L.8-_LK)W-5.W&$VLJ><@+!$(B
M9DB`!DC)FE\_YW2C+Z2H5D9AVZZR*;&!/M?O7/H`[W^[O/AR>4$7NE*$XE_S
MJ5PH:?]I-I<7S'S#"->$:?,;3IBBBZKB)2DI)16G9&PO+WXEO;E7(17>2)4E
M_D?&^\N+U>7%W7_BK?!O]`NZD%+`!@LIE(#_1,7YX?>55/A])0K\OBRU.'U#
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MGPBG5%\9AT1QUOT3J9?#%BWY\\=WG^%FXG>JZ"_P#[MZ&ZD)5?-*1[1F-F`!
MP<EMEM>"A8A5`,%!.A44YC.JX+TQX4_UTP9!\-PV(-D+O*(RS[X9#^S.8?!W
MSL7YMXEX4HM"4&EX`K$RQF9(?F:T9Z<B,MG`K#SW-HKR6(%"4^45^%9'3&UW
M"!JTBD"#S4'_<=4U*])!L"48]R9`73+<>9@X/SKH,D8'7I3>B_`CDO2N:3#K
MZ/I[`JG%V0E`H;#JVX77>:_\X34PE3F\OBA9'8N65BK8F\3/2,7B>00BTQYR
M*B"NG4BD^T]CUS?==@V_?3_4XY+\O.UZ-,\<:*?@,D=Z1K13D#RX;:Z-B.Q>
M[SZ]/_M6DIW@Z/R0)HO3)FXT>_;=5.10>D%+B,ESM.!2S4'X_X<%X>K\R*4J
M&3L9X]Z\-0=>3V'7Y]W0_(/\-$U[6RWEP#*(*7,Y4Q;,*OK#9KL>GMKV_/43
M7.DVA&A=:EJ%:*V4E0'Z)Q@TZ.#-H3K),@LD0`RE16$-[NK\*;>,I$M5!&?*
MP1FI^R54R6V_G"RPH?%5&8R/ZS(BABO%/,)39WR?H=1N3>8)$?R'>EJ1C^OA
M\<W-BA=C#8VMCO+@![QR/K@@/[9].];K]9.M0^KM=AQJ3#7Z$Q$`\H^IVW3K
M>G2-!+\^0R%5ELHC,`O$NSH*XE`S=K?@L1&M"_*_PV/[T(Y7)\@?VR_[;@1W
M`WYM4^#<5&/;S)%]ADPBN5/A=T*4JWR9HW0EXU1B:\N<"576>L1!A^C/GULH
MK;Z1`(#-2`!,"M\B4@[A'+=D"5IO=L,X78&M-.O]$H'_?JQ1*N"#.6P7<,!U
MK[0*I+D*U),VF=`#13\VV:Y01[>F^S;<]]T_K6V;AAU\.ZR[98W-@<D!B*%^
M@*QL[M%9A0_FDFXD=S7\\U"O]^VT@#QMP%BWJ4$:4[,>IOW87A%;5ZSRM/!*
M1#P+A"SJ9)9E]:R%9YJ6>Z3^]BENB%PAYO0#60_]?3N"U8+O[MJQ!X8?VD46
MHIGT-L6]4TGJC.KF1+<&"0["=NI#G1"`1UNN37&]%K5U]A,:(]YA,RQMOQ:N
MF;9@L,`BV8&53O96FW:W&I8+\K=^":+8K4`RT;<91%%4OA-MZGVG/SH;L27H
M"MNLOE@A[5?\W,Z.!D@SVS9Y:">?<.4!7RT]R9G!%[P["(>5^-%[>'42?`W:
M&-UBUWXW7)';_0XL>V?D`E_4QD#^IVW:S2VH5X!I<$HA1;$WRJ'>TG?8L>/A
M+9W.[1R+(Y9R@L@3VS@J<V/0"!"JAG1Z7-9]TY+';K<REPUC=]_U]?H%#S`!
M*(L9*%5YUG*'(!$+4;)@!N9SP@SJ.T"Q0VWGT+`6`<L"`%,Y=Y5B`_MSVGX%
MYA;D?=O4@._/8,MB"'D$\Y_:-8!>N\PC"ND;;`7US2P!?ZPH("W<KVU`M2X*
M4;4;EO.9&OKI?*YF@B^@\$=T8^#<'*%!80&R<>K$D\'9?X_:^Q@91EQJ\N:O
M1J80_;XKRO**4HJ[^\P@AQ"X*XOGAD:&#!`$ZK;)#,)%Q(\HE0]06KCRIL'B
M*@O(0(K];;BLRHA+IF24D<B#-/]4$%Z0=[9CC+:-QF42%@S")Q*1R$[/#I2"
M>2ZD;W+Q\V^C#H058AJOYJ;U='A`;&P#4Y6Q-4+\#N4!$"%,O7@7NW@.=V2^
M.@\]"\Y<B?`BIIA#>H\IF+S7AJVY$@#U&@:;>AR?@(='[,H>IA?QW4PD!C;'
M%M9"28"'_%^;%FZPJ[\"ZO7M70?`:(0!O\@@!QQRF77&J:_C1$&%J_27^\8F
MD6.[-F%H;C\<5$_D$7B(:B=C_2\P#7EW7V^&<6>*K!R%L`Q\9<Y"(+(%"7YK
M(-2@I&_#IZ9%Q"<O?%6M:2E>0\)<=;XNRM!@\Z;+"SY3=!3G.49Y$^G'=H-#
M/,_J_>$!RUPPY>Y^91)%^+F^;^=TQ&#XP2UWJ[&U"#6];<+E%?ZD*^%I%4[2
MA71]C$]S.>-'&DZF/;5MMP,[^8H_SCRQF?,.KB*Q<"9TJ(SU04CVJ=R!16[7
MD/Q&97_7[\8.TN%FSK7GC!@U'4XINBP%ON:^UZ'*T$#C=(Z6QYF^/2XP`0-#
M@@-CX*`=MV-K1\BFT*$XK@OL]2;$G.P98!40^<+C"C)N"_$YF/=S=DRSB/GY
MR.`@J+BRS4BA_=J.33<A<QW$2=)^V4.9"SX`MGT/B<3.\%Y#;5./_X"P;-4Z
MUU>FL@)1F#MF:6"I(I3U(O#%Y%S6_]R'NI,IUV5`VNSY+49,UR_%'PX<&;'G
M8>YX@75`Q69[C[@P;O#@]_M^;FW@=-Z\!COOPWX'151OFK#9M*N4*WVY*E4X
MA"G5H7IKS(YL0N'=-5-OG#/MR<H+49Q3OQ.>GE`9CD\T9R]UQX^U?3<.&_)_
MM9E38RBA9W8#.G:>;M9\^++O=D]9].EG49@*AT'2`+&9BHWQY!-`[!6FO.;(
M#[2+:3T2>7Z5,D]9QGD$S@J_354L2I,&S>>YI0/K6`$H@+/'/5#W<U[//JD@
M(I$^&[XZ/V!BWA!LBPL:>GA5.8>"7U?=NCWPC-W3MFOPU)1T.#00FMR`^[:C
M:Z,"+#`)W=VPMZ/:DS5+5Y+G<!0_^L"$]#T_4<JY+VU\O`OM^!C%KXX**G#Y
M[7YLH,)LC]).=L7G1-9D<\?0<?Z>KO*,Y6P@J"J2'Q2+4:.0^0Z"FRI'45TA
MX_80[5!`.30;#O,E\[T-7KGQ2SUKQ&0L.\R=5NWZ^$#M_*%&>,(R:H;S(N*?
M%5&^)IQ>("]K]N;0;+B[@\QLS';*+0KMJ<E<;)0TUCL/\R2"\NKE8^[;MH'8
M1[K-IEUVUB+GM+6^7;>V@72<Q\XNG,%R93BGI]H#K%!Z/B2IS4,EYF0[AA](
MD>^Q9L0TY#NVJ"@"TG=J40G7LR)XD(TH9EC(#$*RD)Z3C*8NB])O@\F;#IT.
M5G)U"H6PN#B1TV,Y!7(KU)L[`R\]0U'(H-0L#U%(6?I&3Q%FJ'C!PBD\A*;M
M,'FM^T`&)N."&TH`@QA6H<L6VZ0Y#CR4)S<S&(@J%@POPI%>4511IV]NVKHN
M:2Y_J(*><OI#I2.NF8X>!E/"!^7#R2:LYM;=INO-.>9^MQ^/FC`Y3%:PH)D0
MGRKJII'F)D><1SX.>XC0`W;?'[LI:@1BPP=;+']L[L>T)2`+PZ&16>G3H4,X
M2-UOYSY$#@&$R9DBZB9)=Z!A#Y\.'UR(3HA-2/+GS*>4YB183]/0=+5OR+S,
MKDG'K9`/GHV,IJLR"$*$T1"E0CU!U1SN,OHDR-WMGM$ERR+BD>HRE!E"Z!"@
M_HCI&H/LP'G-M_6+]F&>?3ELIK,K83/>!7F';25K7/-8WZ9>FIY;#O7ZD0\J
M>92'NR=3S:RQF>\X:HH3/&P\[(6?&*=X[AHY>)#A(<_PO)$J*NUFE.-$##EZ
MK$<KV<Z/R:.&H8HUO\4E!L>RA%@E/<6YQVK+2#8\?D*'LJ-\VSSY?`!0YG2C
M'1],.CTG'<NC*'QD!#ETRWVKK))EP&$Y!TND\F#F!P=]SDX'2,L1<C#_G^>Q
M^0.N*0M5DG:`-'?A;:[X7$ESSSH*0#C]=-C!M]>Z(#8ZEYBG:''J'%%J,YA3
MZ'4'E=83V;3UM!^QZ,JB:AH>4F)!UURH&8L2^&)<]L-/-Q])I<]>K@OI:<O<
MZH84,-HIV!DK,SS=H;3?S$G9H8,X_6C1W)#]R9R%V`!X@TD)HD!XX.AG@YPW
M>&@4'@K"R]\U^,@"WLP&BPQ/)D'@<@Q5(I1:4OC.>O_W?6_F+V8#:M=KI.C'
M`>?C\/&IV9O._F@/5R(BCZFHZ^.";330[XXC3=/?BMJ<5!Z?3F*BZ=;Z:>6#
M@T?3LS7'E_;4/8/GFOD%=X(<*AHM>,@1/4JAL3BD.GLMC\0H]>??:?+RVQS"
M_;-(4OC:4+'PJ`5ET<#^W;!>#X_FQ-U`\=3:B:8PO?KLV8C,S20!2;.C/&.F
M+BIQ("!512[D4_7P*A?LESX?D',GNM$K9PZGT_RX>A8%<U=8,VPYN,A>52[?
M!AC=N&F*HP!^(G+/1_I-O6[V%@2V^W':X]@S(/'SPL,^.NA&Q;"S,&.&1PE[
MW[,_PPF7.=;SQM`"*O1(R&5HT>K2M6A=1\TBXG^?_:TL^#B%HR'+.U\X97DQ
MCIXDWHQY5@R?%Z%$F+N&R\T[LV`!Q9=SX0)^>H&N%*0UJ06ETCJYH,!9D-0"
MK5AZ"R5+EEP`%49Z"X'E<FH!ES+-!9.O<$'Q_62)!:J2,KV@E#2I"U5(D>1"
M:8"FY`(ERB072D+T2BX00M/D`DC`TPL8?X5(RLOD`H!BE5Y0<IWD0A8XIY):
MH+E(VH.4.%.36B`XQ*34`L"<]`(&>)A<8)ZL3BP0%:^2;((UI"U*%*_H0FBN
MTEN`0239%)#N)VU2F#Y1:H%Y#U]J`>,ZS2;E:3E`*:!D<D$)1"07%#S-)M>2
MI>^@1)6F0<I7:!"8E*46\%<`A+-7<))3*9+VP``&TPO*UQ84DB9I8%JDC1;*
M.9F,.$P"WB<7"%4F#09`3J6W``1*<\%86EF,ON)9E9!))DIPK.3W-!VP"BJ3
MUT-(3(I`49F4H<1N6MIKDX;":3IU8;1XV5V^S$MF+3)QNKO!?%K&CM,^1G48
MAYVG9LPP^]P,O3'U(+Z(8^AWV#,XR-[L;7[Y$6_YB&GB7Y"@A4*22OC/IN;^
MQ_7EQ6=/="E?IEG'-!\==T+`8J5_\%JYVO!YTFJ<;!9,\>^6A;!)P=P+>DKS
MWB>L+3Z><1-\`8G?)%G`_*E-=+Q)U/^3QWDX4TE<OB[36=DU*W7Z!KPLDF!R
M#8B8]-5K2*J28'&MJG1PN=;X;LO4@J)*YU379:731%95F?3X:P;NE<24:T#5
M5Y0!T/V:.L"(D\ATS629AO]K!G55$KVA+%0)@8)A??CM\N+RXE\Z_F*Q#0IE
M;F1S=')E86T-"@T*96YD;V)J#0H-"C$T.2`P(&]B:@T*/#P-"B]#;VYT96YT
M<R!;(#$U,"`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A
M<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q
M,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*
M+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@
M4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT
M#0HO26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G
M90T*/CX-"F5N9&]B:@T*#0HQ-3`@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T
M941E8V]D90T*+TQE;F=T:"`T,C@P#0H^/@T*<W1R96%M#0IXG+5<VX[CQA%]
M'V#^H1\"9!.,%/:59-Y\V\!!D(MWG,1`7C@49X>Q),JDM./-UZ>JKZ1$-47M
M"(9M3K/8755]JDYULZFO_WU_]\O]7;)4N20)_J.OLJ44YC_EYOZ.ZCN4,$6H
MTBV,L'R9YRPC60)W$D%)6]W?_8ML=5^ID-B1S#+\'VD_WM^]W-\]_QZ[PG]Z
M#<E2"`X#+`67'/['<\:&]W,A\7[.4[R?98J/=\C(@LH4[F8T(2`FE-;I61MH
M;DI_DZN@\->/]W=_>%\\E=J\1WA`.T)WZDRG#"S-R"/8_NX_3"2_(X__O;_[
M#I[\QUOUGV9OT#^/])]2W7^RI"P#N?+^;I$L&8.Y>GR%81]?*O)<U"WY5*P/
M<-FT9/]2=15I=ONZV7;D/XE,7E_J\H44;44^ML5V7ZW(:[V'ABVI?JW:L@;Q
M75N7%:E^.11KLF],EYNB_;G:VYZ;+79L.B"K8E]!QY2\%AVINGV]*;#70U=O
M/VJQK]=%^?-;NR/-,^^/G"U%DL#U_\`)BULX'L+(.E[*W#E>)'B-CO]0OC3K
MJK-^UDXJ]-6F655KXV#TQ'.S7C>OZ)?7JO[X@FXJ/E5M\;$B1=<=-F::_OC6
MT!0R\2:\([<`/K]AYQ*A?GWG>71FI5)V9CG/E)M92'O*S.PW;;6J]^2'NGMS
M!./H++>C,\J$QQ6F0#WZ^WI;;,L:PK#>=OOVL*FV^XZ8"-XU>_@+[JT_D^[P
M]-^JW&N,?=-L=L7V,P9NV6Q+D&D+$_W-,RF-.2V8`UV6Z\.J(F718?BOS`5$
M?0WXU0-A8U&6S0'_N(7Y\*_+9\J'%<]2:WY;E14H\[2N=.;JJHK\%:PF'-/-
MDCSVK*VWGR#U=*2&?ZM?RZKKC#DUQN"V^NSRU_-AN^K,HZ?M8,"NA7P)20W2
M80W)$?[:8Q\0M<9I/RX_+&_A"@&4;5VA>.J1P#)A7/&G!O+$%N>?-$_K^J.9
MTH$/?MM9+QB48(;?-JA]=X!9)T`&'P^%3OGPU]-G#19M3NC[03>^KU:0D];D
MVVK7=("6[[$'P&%U$\/3S(5`PCRG27VM`[!I=XU!,)J`<]V`DF!,\`CDSVWY
M^<IYB><'(1SE)FGN\P-GN<T//R*[/I/O+.UU;Y[_H#AS.MPDNPKVI9W'O)=X
MWA0VP*'^4VDH5R#>=H6;WF?R[!->MP=W&B1#_$$F@VIF4^\_VVK%9"5D4BA6
MX(D=TB_``($+"1'N5SNDU]I4*C]N:_SK`W:*80Y)#D(;@G\+V-$8@G1Y`P=`
M+G,.R')J'9!J1D,/;(J?*U\RV7P;Z@#0O`!P/S^[U%YL3"H&GS5MSSKP3M>L
MZY6NN\9<N"1?E7NLYL#HPQIZ`.^M5V150]\M>6Z;#?33=#<)<)XFS@5<&8Y[
MYTU>OC6BE?0#WJ1>X)R[="5HR-,YM9C^04\-XA*S<EN]5-NN_E21OS3=U;DA
MHH[.0U:=E(;LF;ODV==A#3J0NB.K"C""I6=GT/-2;*$`!2QA6$"$01P6Y`GK
M=Z31"FD0@@S0L3JT:%E!=E5;-RL+'*"&KB@-8A'!)CU7GWP)<0N[4U\X);UI
M4-*FY;)NR\,&`@!8JWO0%<%N;Q=$B',3!VB,MJ'/F\",S2OD$:/[JH:ZJWXZ
MV(!L[#U#O+98\-FK/'6W336W<8(RY=,"R8E+OQZ4L#327@!3/KS_Z@,434OH
M*'EX^X``H#DM$(*2AXB0/!X1WV_!7=5;NX7EO*\130(XTLPNDQ\P"+`T\I-C
M\RBRBBZE4-O)I.KBQY6@+P7V>I.)%KXXE+B%80T23#H:@1!%Y5!]J&I1.0SB
M$F+@L-8&F*`\!>CUQ6RDIF!,?N$^2#P)LR0+23CO)6&;]M[CAL4_S4[%,PF+
MJ._#(NJMK68`-*?63>HT^A9[2V?[5Z'_6P"8AHVK/),!P%EOX\J%T:&#2NA3
M`01S@`*M@GR]&JF,&E\VF8V5L.L%,UX5L#XNU_#`L*8,B^@E^19$H1=X&)[L
M7B!%O?D.%<N\X;?=H4IYW\6)ROQ6@E1N`0D98D.VQ1[6@C>9X;!#EJ=AAE5B
M"1DG<%,5N!0-"\VR:%N=:_W,G=V+>`@;$6%7H->X*S[K?0)\%E)[U6O9[=KF
M5P.5`).;+.(I]]4^YR+L9W!Q`G-8K)N4/(;.L'COZH_;^KDN8=5^7:D<3Z2X
MNK2[7PD-BV])/7?C_A$L'OQJZ^]MLX7KLCK-HK@/R#*>D31/"->ZA$'U1C\(
M:`)#`79&(!%Y&A-0N<A45"##,B0FD`H>'T*)A$8%)%?Q(007+"K`N8I;P?B$
M%0"VN)()5U$!F7,6G0M8ILJH%3+E0+DQ`<63J!52<A974K`LB0IPIN("C$TH
M25D2%X`E1E0`*H\L:H7(J(@J"8LW&<6#@)B,"P@*55=,@%,>%X!J.3X$I2(N
MD$`7,0&>LSBB>#8Q%P#Z-#Z$HC)J)F":1S$)H4NC9G+.XHX"3&=Q,RF=\`-`
M3L0$6$Y%-'A91N-FLI3S>`^*T[@.DD_H@)B+"O")!,+81)YD`.HH'ABDP:@`
MS:<$,D@Q48&4QT%+%5-1Q@'(\JBKJ9!)%#"49VE\"$XGK&`T/EF43D0639B*
M6I$S$?53EL<9*\U5]'F5Q]TL<Q5UHLAY='R>Q[,XR^.U"\WS:+S0)#U__Q<K
M(LT0E(]7>]17>_2TVE-^*U:_>M.[T4F>V>VB1UTO0Q7^3;/=GY1WIIL?_H1=
MOF+U^6=4:"E1I0S^9U8Y_L_U_=V'H#047)+C"GG^NC=Q;S_&%KX2`*5[!W?,
M[=P\*UBD=V5U3Z$;.=)[>KZZEDKW;AR>TR63^-KC?W:!9NOKGZJB)=]M5R/[
M@PJ2LQX;ALYG[H'K1\^Z+9RW,1Z`6G=CIPDNU^Y23Z&5T-<O0QQ"(T[I7.7,
ML_FT;HIYW;R>02.NKXT,'VKG)1`3Z368H.>VK\(#QL=6/15\UU?)RARKYR0`
M5)#T9X)*9UGAMWUE$G9<<>&D4?4MK-HV3["VY/1TR_>+AH>5%SSK%KEFF?^.
M`13.3*(2PGO)>^S(,U;FR$M>XEKX6RU'YG"9Z;-H4!W9#`G$E+$^F)\=RGW[
M&1A%EM9YYM[,T+3W/M].T5^KO7D_4.QV:UC>8^+=-^2E6:_PS8-YE[!IMJ3;
M-^7/#[C5[%_ZX5N,IZ*K2_N"8GW`UK)8E[C7B]MC<7L1XV@8:#^P][1]5M@X
M@R_P.&(01U)'"H3FF?XV3RJWU<:3U.3:=[^94B33(\*2XDB3T#Y7%5BN]E6A
MPN[ZX0D6FCQ(*AYD.N$@A/"(@WK-,[4R3ZK3O4@\21-AAQR"TY`#7JWM5>82
ML;T\.<AII3!T;(X)(35LGQ52*O<A)52(*:%<WEL=ROT?R6.SQQ<U+T5[\GKI
M2Q0`GSL-XMNY7V0E'9@93GD*F=O-<HA]B/=JLULWGZM*O].IMIUY"5G]BM<5
M656XWZO?\AZ@O&C[&^3F^3=4FBN22_?*#4H>_X:*Y8DM+<T^ODY=Q7I-BM>B
M775D@OXM^!P./>:4(UI[>0(_)P8:<W6<X4P[RZ[(</)<V1+D=>:P>BL?-3UE
MC<`9O:V8.E+;-\_.R_BD3"ZJ9KS66=#:JVH$SFEM[D&R/%+;M\]/HLKK;9)H
MUDNB#S+/'R@7D:+#&N/L&EI@!,:-<6)'4Q":K\J\P91(YATG:L9=`F;<)6"H
M(EPPF$M_TGZDM&%IOX0)>7C8/BL/<_\V3^3A]2O-F0GVO[<-1OJF(-N994Z\
MK"$75!7&7<YSWDO21R&3,8<YZ='::-`^+W.P"S.'55_YZ>[I;`0&ZA\]K,+#
M(4=:L&B!*%B<M!IBY:1Y7E7&Z615-DQ#S@59<(&WVPB,N\#<4^%A=62W$9AP
M@1$)*:N7R@;M\^K!GA.&]2![H)0_I(F8J`<Q8QG'.!\-#3("4=N<]-'TGC3/
MRVQ\Y/UVI*;$[)&(\;76L'W.AD)^]KN>HYH`AAB-[$'[O,B^9&AEK!M;[O2;
MY]'Z10-G>H31Y<V@?<;B6EPTM`;'J<TGS;-6]><''DWD6>:X$Z_6]LISI[V,
M<"=*C''G4?L<[M2G@.TY"=D["2-M<?_U"0-Z#MV9`UR:+G%M,]@5F*9&ZPWG
M&.\$3XWV,D:-*#(60,/V60&499=1HU-?^=GLZ6P$SE,C?L[C'U;AX30\/$F-
M*#)"C8/F6=3HH'`Q-7H79,$%WFXC<)X:O0NRX`)OMQ&8I$84&:/&8?OE!`)W
M^D[0QP8=-4)09-.D:%WBO#,TQ0A,DN+(Q)XTSR+%GDV7DF*FQDGQJ'W6QZ[J
M,E+$(49C6EU-BA<-K8QU(Z0X:)Y%BI<-G.D1QDAQV#Z+%"\96H/CU.:3YEFD
M>'[@\10N/"D*3XHBD**8)$5QAA3%]:0HPX*2^J\8>([7XZ2X.UUB'M/C!8PH
M`B.*P(@B,**89D1QAA'%]8PH+F1$$1A1\".=C4"$$45@Q+"AYH"@!:8948PS
MHKB:$>5<1A2!$04_LML(1!A1!$8,>W/6;B,PS8CB#".*ZQE1GF5$*2]@1!$8
M4?`C4XS`-".>3NQ)\SQ&E/,9D9UA1'8]([(+&9&=841V/2->,K0RUHTQ(KN:
M$2\:.-,CC#(BNYX1+QA:@^/4YI/F>8QX=F`#H11X17)Y#832LT<#-$92W;<^
MZ3,7(^E$WS+7?:=B/`"CAP:D[_OH(`J>4CXZB')Z#H4;H^@5<\$C1O5C#O)*
M*FU9@E=K>Y4;4D[=Y>`("K9=.8W*_:1$3"OPN-7**>B5,2RI!=*A7NZ^/F`Y
M'P/J@M4PNM4I9G4<:F,$CA6S]P%`\T^=9$3E)J;R=*DR::G9'S090^NU@Z4X
M/:X>Y'KGW-2#2C#[?1>>:YDX=6(=Y'PU](H1.'*0NW\ET)W.EQTXP0]5>]CU
M[.;;YQ?1*ASN2YC?6>+2?23XE?VAF;&?,OF"D3/A1YY\*W[U&%G?.IZP\&E-
M8A/8^[;"3TKM+W;\4.S'7OU/C7\V8V3!O>^FWD)A%,,X@02>0V(8M,]+#.KL
M6]P3#3#XT-(C!8Z;+Q\?GYPQ/BYE82`\`#DL)T+[[+J8]5$6%@=BF4P>I>'&
M[_2XQ`CMLRM:WL>C_>X>ZEEQ+B/I+W[2\8AW[5=$O#WBB0<!\]2?NJ"2V:#X
MMOY4KRI8-O]45^M5C'UY.@[80?L\P%YR_A2!A?:/(+7?/`^IEPR,4,2SM6,0
MM>US0<&"S0.(GB]]N?'O&#!M^S7`]#]8<QZ8HXQ$LW%\NO8K\,G\H2">^S.0
M+'/G5!TC_;/!%_QK_.F)]T6Y;]H+,BQH-0K80?L\P+)S)\'',RSZ902W_>9Y
MN)TQ/L*49N/PM>VSX4N]!@/XRDOR*WI]#,:V_1H8>^Q<F%]EGH_BU[=?@=_$
M_=9+DB;A<UZ6B"%^_V9^]>\O]7,5R;&HR!ADA^WS()M<MHS1/CC%ZJ!Y'E8O
M&1A?7<`(8R!U[7.!D2@_="Z6N5+F6!@2(&Z@ZUF1Y*>VB^1<[>\1L`[;Y]7^
M9]WA./[\)SNJ_\G.L&N12.)_GM"6].>&L!]FSO4HSR5QA]/4,A/X^SD8]>_?
M;@B1,#)V_FUL@7#U$*HW1,A=]"A?X.>CL>^O%GG\>\8%S>-?Z2Y8'O]2>`'V
M1S^16\@D_H'\`L`6_4QOD2;QSU<761+_#&^1)_$O(A<T2>)?TBTH3>)?ERXH
M2^(?T2]@I1?_'@\D\HD9I2*+?[2XH%)%'`JP^>[?]W?W=_\'!>_#:PT*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HQ-3$@,"!O8FH-"CP\#0HO0V]N=&5N=',@
M6R`Q-3(@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E
M;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@
M,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&
M86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-
M"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*
M+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-
M"CX^#0IE;F1O8FH-"@T*,34R(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$
M96-O9&4-"B],96YG=&@@-#4U.0T*/CX-"G-T<F5A;0T*>)S57%EOW$B2?A>@
M_Y`/"XQG(=4R+Q[8)]MC#]S8[IEI:2Z@7R@62\7M*K+,0[+FUV]$WB654M,R
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M;G9'IP_$YK$AF]WI",%.,6UVIR-$2%6ZR@M`+$@5.B!1&,54EA),Y.P&,DG>
M1#1DDAZ='4\3Z9W0:G[#3]-0-:D$"&%4$PZ66H/<#&0P`(8<ZG[?*-M+0!V;
M\8&,'=G7Y3#U-=DXPSCW3I59AD?-1CFX3^<N06^UNVR'L9_02FC74-7]6#8M
MZ0"6]:0!`P*?CZ0>QF8/YF1--NAF[M#-K,B/W:#,#4*X0]_=-0.XG0$_L4)%
M2J"PWM75V-S5_TVVW7U]5_<:])7.8@$WE,5:@`%%P;5@2'"=Z"Y1,+P]7``7
MY&[-!5$!R)Q=!;Q#)IGS#@Q?X\D&2!J!P$=SL%_:.SA,?>#P]@_US:@._M/7
M"07SJJZF7OGF^=%;X4\#U#3),GT:%_,[)7;B#.;W2<P?]1(NB09'3*4W,HG0
M!UP>#CO$4*`]Y6ZG+8MZOP6%[>Y;,O:E00=K4MZ5S:Z\V=5S[S-+1'BLWG->
MSK^2YS?P(9%H@_%P0;QG7XOQMZ(*J`C.N3`QS;NAW-6+&$0T@GJMA#JSP5-J
MS,;@#,"*8%CA[3WI=%A1];7R!#</WLQ'/5R]:VX;$#WO3H))2^4OAD-=-9L&
M9M7.`I99PR+A'I;@!>S<\$+PPBN8-`#[B&Q$@B5""G0=^_*!W-9MW8/F/9`;
M($,IXYIX?XK\\>\NU/,W]GE`!TW?UW==A3I)IG97#\`9TM;WQQP@707G,5PH
M)<8I*K>%"9QOL#(P?`D6`58U+$K3S+&(F<`3_3@>.)QR0#GNM>V47^]:X$])
M#EVO2#)@P8]=>1D"GM2;C88*1BQP[$U]V[0MVC'SP:;I@?)-,U2`F1[JLM<6
M3XT#'F[&>AEA8=)R@@JO.)D-<'_J[NK]3=V'V:T5^53VR("U$2*@4:L**E"$
MQ@/(1M--PQ&9"F*M\:B17LMZT#64B\:+YJ_6"53;KJF0VVKP$CP!D^P4*`\\
ME#$F^J@H2W!CZ_+!$`Q;0X*T3C1NYUM@"(K-0ST2D\;QX'BPT>R@X$S9HG;!
M43=[Y&C3K949F:JMF=KJ2^/G5XJE_27HS,,)V+H`BW*,LPP`9UYL"I.N4KB7
MRDP;NH_=_H"4K;M:L^(&;"<@9G_B3I)"D'W?@/_?EJ@V(&(P104``%X!L150
MUNV:M;+8?3U,NU%1V@'32IP(3,NB$4B>V=05S8/4%;4P%3:X;C1%/:G*84LV
MN^Y^F#]NPR>YRU&)S$/F(K.0>2!KT+=I&%`[;SK%4+3IY*<.3/'K0N18E@=K
M"3P[`8EGIYX!@/'D)RGSJ5.7HKL:N^I7DSP<=(QF!5*)'3!%B:L-GQA'!?M9
MY7J]Y?ZA;%V27UG!E$P#FK8E;%":"T?6@IF4M$C\066KHD"TA`>U[]8:MBPA
MK2QQ`5ZA,ZKOP%PA5$)&SPY$I5MQP:`IIVZ5^6,F%`;'-"KRP-SF1L7W];CM
MUL?6MJ^K[K9M_E4C:FEGUSR4';.K94,)5H3T\]S'C"F7)FA4%G;8EOWL\H-F
MY&WHY%*&RB&H*S>(@AI;=E.B#:_@A.MV4(Z.U-_P=:W@`[K&1;@@P82_#1=D
MH$K`A<(77=+$UH4T%P9EUPUN*.]5274AL)/80!;,OG/V#"-WF[+HNV\JDPCX
MZS^R/+](DH2L(>(T#B+$NW6+8/</=:5P->'6G=QO&X!Y]X`686@U[12VF6!P
M_VPF,G!5KT<6Z;.)B<Q1/K]1@R>S-'59#P6Y-5\!^C%;"2(_0D0*W)&S9]-`
MS.SZL'PN?9R<)B:)K&OXBV1P(2SWJPMJ0E!;Y9U].=!>OQREQK*\\Z6TV6TV
MYV[%0H(!R[@MT;`DXS:T7`'.%Z]$A1$`"L`BH!?PI[,A4F;T21[YX[9L;VM=
M*/C4]YA5[OI>9RM>ER^.%;YI[CGS_98TMA)C`1=8RCP7!#='4,*4AUU9U;;$
M^O[/'P`J-RW:5#P?L,3(EM=K0;R^GHG"67KF:\&8@S;8/2CVDMD!<)&[':`1
MHL(;]]26DE2X;6)2H2TM!@&J%.:W9]@XG&#@_/(MJ`@XQ]/"9;!2BJ]/R_?L
MGIKEP2Y`CMTN.+69$IVPL%TKA,_/BY3)D!?2ZWK&;=GRYUHEZH`5)[1^":GF
MS(4XJ2]AI;8V2;Z8%(_O'G&2-/LQ40@?_(9HD?N2BPJ7_3%5AB/H]OKZZ]3T
M069*96F.:V_X3.]8"\:C-%-@:B$8>P`85#6'G4X[U,K"+@$GJ,MD%JFK"0M9
MI#8EXXSZ215^5'BZZW:P?PCY'5^>H4I/]@4FV`U=.(M]SO!2E1;*HSD6X$):
MV-PE\]!94FG,`J#(%E8W!M^D4*=V&B800LQ?@SP&>;GCX2Y_UZ@6G=K6-RJL
MR;6#SG=YG*H9\_=MW6*J_-'":H)7:M\+',A=:C+S/D]P8>0@OFE,$'7#$=P>
MMMVT6V-18M/M=MU]O=:46:=PG.)7FN&/N`K`12"!J"Y*$P:R+]=*8Y9@1>JZ
M"O/$62*.15B3R'9AR1!DZW6QP44H)NTO-=68^F_@4R7HE8Y!,6CQ!8#7<4!5
MA%3`M!`OA$L3%KE/$Z*E>)$55_5A-+P(67%](I4X'K7(`&],XM`\F2[0N0,D
M>.)HYG.@0O*@D_)$CEV0=:-K6CK-O@C?N4M=9=XJ,\/VH;EM41E+-`K?D>(_
M=,.)=/OLW0O@2RP]1YGMU0*,DZY\GM#"V3&>)-Q%QUXN4;0N?,!JI?$8/X,7
MF!^`<5H$6V5,^H)99BO.01/OC[IZO@C4`5\?<JW(O<G+4O$4SF<:SMMWMA()
MUKS=HA]<D]L)!!`](MHTG>]?XJ1=\P+CPK,O%X9]05]!T']0^L[GG>\]UCE@
M9X`4)@'M.73M6H&21C5*@=6=G_G"$2)<IIW-OTSNEEF@/2FEP6G0-/>G(1/C
M-!'.`0LU+*Z_@?5?JPX)>+O7[K"\Z293R?XVFDY`G=U;0GA\MP?SW1X\]Y5(
M=%`(2>."<]S`<F$:&CQ1TZ"[,5R#9S`6IU+D*A2$5CH0V7V@\6C<E^"!;^<H
MA&_GD*DY,G#JZ,V?*(?!ZO<`4;&!T[2'#NZ&CD'NRF;`86N(HPJ#AH?P8<A"
M8,^-(WA]S-%':SLLO00[7$]'D@:PC]DJ@A9:#?T!ZAX?%T8Y@&>P9:=J^FK:
MZYA@".SD$[P;!4^V@X3XRU&Z_!RV.2P2"4C?Q\&]`RVH<07W#8"UUN#]D(1H
M?\MWM#1DL9:&!>@7ODDC%QY[I388_&T0ZRU;&M"9N(9(G]YB-H?R#/:Y^O31
MMMA<O?<5_21?H/,@\[M<L".:9;E;!N@'\^:+@C:]]1$."F"+*S9]4KJI3O+/
MH%L]^2>6G7X$QOAF(S1YY"\3P.YF\X`/'G\-:O$1HK%7EP;B^3'A.C98'B0I
M7,>&VN^;Y,9DZC:S8'<`33W-"U32(/X3_(TN^="T.,&QV1/S&"HZFE+,S+OZ
M$66)B1U1Q4&W9]=L1M]"*!C+PF,[OM^S@+WB6:!WB5K-X@);$],8->[=ZW;]
MU+4'S:'IBIAS\>&4BZ*ZQ5HVA6^0H4+XL"]+O:M#&UF&_;JU-Y0'92A5?;[9
M8R&_1\NS?VP4OP86LS(&4CUT/-(FS`]3?^@TPBJ)G15;6Y?@@&M2H&EP=XOE
MMM0'B'48=)VO)3<`=76/;KE31S-LZWHTP`Q"AMIWIOH#O5=Y4`N*`3"X[,(Q
M!Y]M;SUBV0(\X+FOZ.<>\8G<"/CQ*0%<`^BU,?4.F^W%JUV!"`"DMPEA2Q^@
M(O.43V<:WB#Z/WJR/J+9L[+$1+(7E"5XD;JXD(<WRE,+_J8]]IB@DONP30=]
M@/)@_V&"UP0VF*=5+RW"[VN\?87W&XXBK"/L:R@^SC2^`?KEDOT_1;^<^O@M
M:*X66>'0[P]36S].^AGDJXJ+!SR9T12AT3R+)3!PP=U>E\3`11&PA/$\@(SY
MTW8.U*F_MN;&YXC]],`29=*NRV\+%'REH&Y["W=T@!@'C$A]5EBF]MXSJM8C
M"7AZ<WX!3,]\W3&EYK*7B[_FOX4MW8(+0K24NE7FA^W@H^WDBZ/V-`_.)RFH
M=P<H4CI%_^4G(G*=$->O\;;.4/7-#>8&;3>Q]@9;^&;;@;]#O!#D]T@YCO#`
M-%K@^`0'',WS^&D%D\;RVQ(VE?FJ<)$$%3)FTJ2N@#26O];*R&-C;37JI"<X
M/_TY9L?4%D&[IK[5J2R59#^)=@%Q>GHO2+4#%*;*7?J]RH$!C%*S'.JVW&$:
M\6+A%@'FJ\(>*'(FW=WYQ[FY"W5_9-?A09EDKRN=.VGY;4E!6UP^CARBF;4E
M..'+IM++!)727@,\D<LSY,YV.6EV8/%</V\**-`2_$ISEL6Y:7Z4X5+%EYZ?
MW/:D\16<+FA&.QH^+/+;$)F+@Y(LB`23H!1N9.QW`][Z!>Z3OAE^U0?7@#8"
MU-^7?;-[P%.;`#OLL!F[A]`-+U,8Y<3J0%4W=^JFZZ;O]H#TAQ%@1C_8OIJQ
M_C8VINW)_/)$NX9!O:O366%?@@_2E[&"=BC7%`?"B,6=P2AY4UE>U%@'*%V/
MAI)H2]GO3@JNLE[6_*G(1E4,E!58=]/-N)EVGFVE[XA:H&F=9H[RU_OLYV9'
MMO*3DZNNOQS[CHN$<#6K?US]9AT,8%+H`>R9`6"%\N@`]>L`D0%I(0H1'9"+
M++I$FN'O^,0&I/A3#;$!0`2/#A`BB5/!^0M4,$'CFZ3X8W&Q`0G&QY$!LL#+
MK+$!.4^3Z(",BR@5$N0ONDDI45MC`P1/X@,X>V&3C,GX`,I8?$#"6)0*4=`\
MNDF18]=R;$"J;C!$!DBP<=$!@F;Q`1P,0W0`HWE\`,6&R]B`A,4EBA<OG`7/
ML80;&Y#1(DHF"%P6E4DNF8R2R06+,XISQN)D,OH"'RB#(#<V(*%Y5'E90>-D
MLIQG\1DRO(X7&Y#R%_8@\79B;(!XP8`P_H*=!$8747E@8`;C`Y(7!L!1I=$]
MT)S'A1;P6!+U.#256935@,=%5&#P5]_B2Z@K5K$!G,8/"T0RKEF4\B1.18)7
M9J,#DKC/*O!7SR+?YTF<T1FV#D9=7O:"(7_!CB=Q],(3'M<82J/?`YY_?OZO
M9HBQ7I2?SF!1A^SH$V0'08N+!JE.NZHN0M.%=ZV0/B!BB&'&)]5H/<W/?\0I
M[Q%I_H`;6N'O.\H<_N@TCWN[.S^[<ILV9)_<<QKN^5&S&@@<9>ZJB;2),/$D
M?Z3%3R^2_;9(@A>XY]3]V**0YM?F/L^XB/YEWW_G4MQW+9*&B_CF79H^AO)Q
M_W19Q-W3)1C-J")<,OP]K-@`5::)#1!%$=752U#F^":S%ZS%99[$U?&R2.+H
M]+(HXKCNDL)9QLD`W8A;S4O*\KAEOJ0\IU'C#D&AC+`39.+3/\[/SL_^#^GO
ML7(-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,34S(#`@;V)J#0H\/`T*+T-O
M;G1E;G1S(%L@,34T(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=
M#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO
M1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@
M,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q
M.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*
M+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E
M("]086=E#0H^/@T*96YD;V)J#0H-"C$U-"`P(&]B:@T*/#P-"B]&:6QT97(@
M+T9L871E1&5C;V1E#0HO3&5N9W1H(#4P.#`-"CX^#0IS=')E86T-"GB<Q5U+
MD]M(<KYW1/\'''20'>PVZ@G4WC2S&GOM\<9ZU>M=.^:")M%J[))$#T&VU//K
MG5DO`$2A2$"D'!,S@A*)JLRLK"\?!6)^^-OMS:^W-^F]5"))\1]]E=\+;OZS
MW-S>$'V')%0F1&H*322]5XKF29["G33-DUUY>_/79*O'RKC`@42>XQ_)[O/M
MS?/MS=,_XU#X3X>0WG/.8()[S@2#/YBBM']?<8'W%<OP?IY+%AZ0)G<$>+(D
M)VD";%QJF9ZT@N8F]3>9;`7^X>'VYE]^*AZ7H!Y+'N`!;0@]J%.=4-"2\^1A
M@R(1&"MY6-[>W('`&4ST\.7VYOT?M@E-4[E(]L_EKDR^%$U2;\MD>6CV]:;<
M`;G8)\5R61^V^W*5/-6[I'AYV=5?JTVQ+]=O,,,O*5BN?DJVY3YIBG79)%^>
MJW695'IHX4;&_^R_U'[H)C3V/R4/?[^]^0C*_=?E3`"/6Q.D(O<FD%EF3!#4
MIRR6SSVE[I.',3V,HA+4KANXMRM6)4BY+*O7XA'L\%BLB^T2S%+^>H"15@GH
M67Y=EN4*KH6SWK[>%^OKZ`^/6OTY^*G5GZ?<ZM^*VBQ@])==V93;?;7]?+S2
MF9:UV*X2B5?(W+R4RWWU"K<7K1)V29N.$;3UDG7=-,CV>&BJ;0G73[MZH_T-
MW2I9UIO':EOLJWJ+7%>PA5+,F4*(K#6%L*8`5TU^K#<OQ?;MTK/GS,_.]<3O
M?Z&47GR6K*,C3:7P.@J\1AV;I*D^;ZNG:EEL]QTOAC5;KY)B]0I_P>4NGIY@
M;9,*UK%^*7=Z69K[N0++$8$Y/.8D?G^5)1?2F8/DW)LC)Q8`']HE!Q-L5X=E
M3V'<W/]6PU[X#_C/(MD4U7:-.^#'9_#41?*G6O\-_\6!_E@BV"$)T6U7'SX_
M:P,"M)5@]*0Y/#;5JBIVE044C2]%TY3`=`WEF;+*IYGRR`=;W^C^2RK2=54\
M5NMJ#Q+!7XG>Q1V3%'K#_AXV\N81P@$C"X-U&KN?B]?2Z[8\[';E=OF&V/9<
M;#^7</%2-P>`2S0/#KHKUX5%^NXC,'52(!L::KVNOS2_NXHQ$/S`&$K>ISF#
MZ]^T.2@7/!0(WBG!%RED"A<7!>*PEX4"^J1$R_+^[N(S<=+.E-TK0KS2-+/^
MWWIW\GLP?K%;@.:27$5SJN1WTIR!]!W-,Y6WZ\UP*VC5<1-#L$O^YU!L06UR
MG?7F5'PGK3E5?B;0-!4(K&;34X$>K[4&S*J:Y^1_U_7^36_-=X@#3"^YAH!+
MBR4@"?X^!A!9N[40\SJ`+YC=Y<G'PZ[NYR[WLU4>"VLR;_%F?E@;&QW!++6#
M_T)Y>@6PS'/APR8NE[5BEJIAV/Q<;C%<(HHG`""`_"_USF5Q&/Y,5;`?YOX[
MS`F7.B;4ASV$QE+'B;]L*R1]VN.@]\DG]WCY=5_NMI!AMN,4^_VN>CP@.S!<
MPQ`R=^ZDLD[UD#)C"!_+,.7%N+Y(5N43X,H*X]G^V6IHK8%_7]8[L`^H!@3(
MPDI#Q]+!J[4PF32,\8ZP19:E"R*HV:L`4ERH!96I+IAPP+>R`$N46ZPGKF$!
M@`2'*%F;45+*;$8YS`Y04JS]+K7-8M(17^!*G^)`=2Z&?KJJP8VV]3ZIOVS!
M7+^];4I(Z+:'IV*Y/^RPX($KFPLMH$B!Y'?;[,MB!8D.V'?SLJ[?T,^P^*MA
ML>&QSO/HC5`!FJ0($@G()-$'UFNW"ZZ@?*9\:4M(ZYO$Z&Z$V-M,\Q_E6UCL
MI&HP)CP5R4.Q6S[7FPJ"X:</BP3#PL4#L^1>:NGK(';Q:;+43X-^"T.8R;2B
M%Y\-9AHJQ2\>W@%SW#001P&#A(FC&+47E\];".LYF#4A>IA2-@PX](8JZ:\`
M0L475Q(ML`FT?-8[Y[$LMW9'X":#,A\P;EE=I]V1Y:[;D9+,E_C4=WO,OL<B
M>`O02S$7.0!R8O^!7#Z09MP+=.54'V)3JSJ@`>O`@0U5&"<\!+@%@LV_Q/84
MI/[8K#*V6):[/52ZR;+:+0^;9J_[5_!$M7].FO(5HOWZ"M82N(V^B[4DC-RQ
M5IIYU^8T)1UK07E:?@%EZQ?3#2B_HN<VVE20P%S#?^7_9XO*S7[=%E5'1][Z
MJ6*N0;6JFN6N1(N;T-64V)D)1Z]%\I_%;E_^(_FAJC\MJ])X*GCUH<&L<@N5
M/*1>D)A6&YU4/A9-92/BIOA[O:N@".KW/"ZM<)9EW\.N64XZAE76L.^ODW=P
MUU0C5+9A(5=Y+_/`I'=7_GJH=N6FQ(8P)OP-),/-4X5+\:;-#DC\>3V2B;W9
M5ISAUL%[D:S+XA5YNGVJU\,:BQ#<EU`'%/!\M<;6TW7ZR!GU?36EVNJ(45MC
M@LR0G&\0-HV6X(]=I[U\P8E"I>K;2\+1\64[_CSALZA%I?)5.R?^D((J8KL6
M_#[YJ?H*;O!!-TLOK9[B7H*K=*&E<.5T*MHS&)92J]Z'_;#'NDB>M,:V/0SH
M!\BE2V4#5Z97"AOA=U<0&(*O3YXI\845>)9T1=_+KH0D3F]RW0/?8-'_FR&4
M7U_*;:.W7T^)4,DZ7CXBC!\U9:E(=9-.U\*""?S+Y5-?,`#+F3<`27G;1W.5
MY>#PR^131_(2JEIY<RTN:@7)Y_JP,HGSLF[V^/SGNEY!7EJOS7G"8"#2#L2M
M%8Y&NH89I#\^"9XFF=[/VDB\@M(17!2/3EY+K5=S?$@(4N+ZXQ&A!FY3$&Q!
MZVJE8;[!IH^)%F"3;SUYBH,.LS!^AQFS\'&,,&YQ7-PG'Y;+W0'D^F@\^N+(
M0R!F.#FN`CU4=?JA;;9%<Q:#GL*J;3?RY>$GOC*$,7]JH6.`Z=V3W!U:R_OD
MTS,`3O)0[C;)'VOL/OZI>,,$X`JA59=3P="JDZ%<-S72A.F!VQ'TNQ[`P+#Y
MC`QTA($*RJ(,1.ANSSA#RC,58Y"*R^@4,N<TBS)DD-]%&<"R>91!,!750G)V
M0@MF6BWC#)3E<0;"1'0M9,JRJ!9",2ZB##GNYQA#QGA42"$91,$8@Z!YG('3
M$T(R;-_&&"A-XPR$IG$M4B*C0G)%\J@_\(S(.(.$C1%E$$3&&3AA\2D8R>(,
ME+*XFH3&/8JG)]:"*:*B4["<Y%$U`?]$U">9I#RJ)@.(BC-PFD;59(S$[<#`
MY=(H`]$-M0A#2N)J4L5D=`0(BSPJ`\U87`:*(!5E$"<`A/(3.$D9RZ+^`"X9
MQP=*3C&DL.`Q!J)8W&EA;ZMHQ"&9D%%3$PDP%V40*HU/(<@)+6#[1Q>+L!,[
MBU"JXEK`]H\;*E7QF*64B@Z0J[BA,Y7'X[(2<2!7<1P7:3Q[`7R+[UJLKZ*^
M&$]=2!K!E5\MBU61L$#RIQ(\/;/)'QF^0"E]IUC8W@0V?G+;['K072?(BG^L
MMWLL7'H)HAGFS_^*0W[!9/3?4:![@2+E\(?I=?N_KF]O/MUV7A#F,+=0FDVO
MA.;05QE>F=OZ\KFK+](XSV&73LYUL3<^DNNV4F7,2>4$[`MC&([D<O=A#2#5
MG/::(#PJ1_M;+;_@R@MF9>Q+8QB.!;/W`50A49]4J_"<0TYI7A%0'+S"G5E\
M;/:Z=A\>R7_3;,2OCSZ.SWPO";(4ZX]_:<JGPSKYN7HJ1Y9/2.JLY`S6-XUA
M.+*2NP_2374K?'3<KUI^R7(OF/3NWI'&,!P+9N^#04G(KR(&%8`<3C!8/I$*
M>Z3Z88/O<XS83W+NQ'02]V4S#$=BNOMRLOGPR8CY[G/]4P,HF2UV88DAN_O_
MR>."HX_LOTA)+CJGBYT^@G1]A)^+1]T%ZO?QL?O_@NV<N,@:&C+9\:VG%C)Z
M]$F0X60^PVAZ5\),\DB`8_+Y\^.34^97>J(L/1:@I4]<-)&V$N#[`BF>@:-S
M#UZW^*9)5'>2R*'MMTQ"1C09'D*?,<LH2E'1KE@27RX-A@&''=(G@>0$A]&H
M-W38#GFJD24-&_G=*4'RH.=VZ5-%46E8%+H@3"RHS.,B::@=VF9`GH3`XVO3
M1@;=F\G"T.OH,Z!7$G]Z)'E[>B1MF_JGPVY;[=V;]D_55[QNQG(WQ$61A:%6
MS`KO^E%Y9MHHLB#&BCF!43]YUL1*SQ`$5TN?C'O23WT&N,Z<I+/X9X#KW$E&
M-,EF3#*.K:TF1]C:R4NY"KKFD#X-5,_P$`U^0]<<D,^?6-(S)\Z#KMFE3T9/
M->*:F5Q`,3Z6U;(\9((!>1IHCIH@F+;"$T'L=/09V,G=\5?G%)>YG_S\7!9-
M^8Q'KM7F95>_FI/',W)5$"@(H#WZ-`#E8V_TAW-5K`D".-HE3\/1*?,K/5$0
M3BU],@@1+T'/9\49>5A@,8;T:9!QOC'T1A\NQH`\#3FFS)\'%Z-+GP,@H<6@
M*21@V3G)U]`@`_(T'!DU2#_Y@K&#`.+H,P"$NG?JTLR^50NU[G852Z]@MB`Z
M].C3T(&.GD#WTRL8/`0+7?(T6#AK8J5G".*!I4\T/,_SKN6Y?3OC_1^V^M<U
MU7ZTM\55T/Y#^C1`.,,,>N,.[3\@3T."LR;.@_;OTN=48';J?L6]2%.VX"*/
M91%#(PS(TW;_J!&"T9DK:1OF>&4;YFGJ>]3FTG^L(Y"'`$<01AQ]!HRDW+=M
M=2<;O?F_R^=JN2Y/)1RP#:U*3KN^)GJ?QI5RW$%8ZM&GP9+5ZLRDP6EA%>J+
MKM'BA!:6.X1P7?(TA#M?!T0"KX-J=?"":Z@XI8-A"8*EI<^I1:T6O<TZ^`G2
MMTS2<>(S:M&YDXQH(F9,$JU%W:*?ZO-)ZE;<+7Y_F35&QU?<<0=#TKR]9QX=
M]5O/CQ'`B2\]')K+W%SF[G)4?,LM$TJ.PIHASPIKH[]?;OD1^;WP>2N\E]@P
MG!#>L(";'$GOZ;.RXS20'1/*%I2I$]DQYTXIIY\[.S)>I,^.X@[EN$,Q=A8,
MFB?'W*F78?,LW-X\HD\Y<<93S9,I)@:^+-RU[-,GQ:^SIL9HE06[ECWRI*!S
MWL1*SQ"*%'WZ^5OO3'-KK`N8>TB?!%EG32UIR-P#\B2X.6_B/&CN+GU&%NVF
M[G?B%CE/%X*+2!8=,,*`/&F'CQLAG$4+GT4+ET4CW>:>]C*216NN-EMNH4+.
MSJ*Y;#]G1T5["$V%Z^<U#;Z[?M@<S*>&5K&?J9R1=HLV[18^[8;JQ^6N]C*6
M=B-+$+;$[%XAEY-ZA2CZ4?1NR;/02YY_3(G;7K0IL_`ILS6=88A;T7('@;!'
MGX!&8HH5-8:(-@T4\DATPQ!/12QW$%/G^8)^=%R+?AHHVC10R".9#</I-%`$
M^YP]\C1</D-X#5VB30.%/)+8,)Q.`P,>U*5/Q?9<>O$1VPD@FOL:0TH7*<T6
M`/=G)(.B30:%/-+',$15<]RA4&'($Q733\K`YYKP,Q.Q]`Q$LO$"KFR\8/XU
M17LY^`2JY0KFE(XNI@<*[M]6DGG[71B2N^\7X?=UT.GT%_BZOU&,98%&0Z>L
M5\R_9&@O!SHZ-GSSD1R'`4M/9X0!?OJ-!"<WX#\[QG]-GH7_+#LOA;0&RY0W
MF+[T[QN.&LRR'9=M'?HLQ&=CKY`>Y9]&;J="7UC#$);;L1TO=(<^"^-'Y3["
M>"NW]'NP(ZQAZ,I]_'`;(%@;(%C6/AS>P8XM%!D,><:;2)P'TN9WL1#A=,];
MW;W"AB&LN[G7QA<FCQ0V#&.ZFWO!P,+F%PTA[<DB)VS!Y6CK'8.%L8(S2%]Z
MPQ!6Q+&%P@B;77'PL8K#`#R5>$J;S6D:T&SL2,!N-QQ[YG:+CRV-W-F\C"<Z
M-MH,QYYG[?&A0]49%6G7]C[H>OKTZHP*5YW1G/N@*QBW0=?]EOI+\1D_%@C5
MV&.Y+9^J4V]<Z#41X09JGSYMF<7YC7]I#!.`.$N>`7%N_JDO6^*,(;QQ]!G]
MS*`HF<P67)UX`4,[WM`R`_(T3QY=F5[>2!D)N["CSW!AYK][F:=9Z\)IUG=A
M_[MX_4UC_36:.GDMMZMZ9SR[QB]!CR63VOL8"3MTCS[-H:WPI](;G"+DR5WR
M-%`[:^)<SQ#T7$N?X[EVZOYID1(+EJI(<RU@@@%YFLN.FB`(OOJEMH#G.OH,
MSR7MESK:CT%R?+%*>^Z?RZ;$[SMJ[UR5K^6Z/N.'&=JM].\@`Y[:HT_S5"OL
MN="+OTL+.&R7/,UAI\R?ZXF"?FOI<_S62M`_KV79@N1GO%\5,,B`/,U]1PW2
M1RTLH$V1CU>FR"?*ETCV,E3DXZV0RWOZ=)<G_NN4X/*LX_*L#];[XBL@]4O@
M\R!]7+3*.3W[.FF&$?4<6VB7].F3=HG3[U39Y^26?E6,L,05,O8R6+GAO<#1
MKB'/V5M$C2)AK^;R4N>MU%Y4S3`JM;D7.M.U]#D[TLE]]`,CB"1J;$=@0675
M<!IYV9FKN,:<QK$%]G&//&D?1UPF!.WXA0Z[G:4[XR&9?Y7%7D;.>)`CN*O[
M]$D?V\DFI>56!:>-DUSZMKR]C+7ED274LG'TB;TY8[K18JR_=Z7ONCCQ6YD-
M0QYL6YA[[<:7[<:W"X@,\05TW('8:LDSRAJW?F=W;KP)\M8$7F_#$#:!N=>B
MB%1'>FN&4R8P+*'P[N@S&CA!(Y"%0CC)Z8D`CZ`A_:F`M4E'%\T05\MQA\`E
MFUN6C>],L^GM1VJ"WUB0W6\L''644Y$H]T%->ZH[-H7]/M34)6'X_X>S;[/*
M^UR_3HPK\M/EIN`I]5-$7X_[EBED9XJ.7_6/F4Q2&OE@QIT2T0]JW!$5_U+/
M'57Q+S?=@?[1;XK<<17_;,J=//%5D;LLC7]5[2Y/XQ]FNE,IB6M!TI3%U2`D
MC7\F"SCP_[L3Y:!Y_(-A=X3)B#EAR3_^[?;F]N;_`&*G87`-"F5N9'-T<F5A
M;0T*#0IE;F1O8FH-"@T*,34U(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,34V
M(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X
M-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P
M(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@
M,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B
M8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G
M94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*
M96YD;V)J#0H-"C$U-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E
M#0HO3&5N9W1H(#,U.3@-"CX^#0IS=')E86T-"GB<S5M;;]M&%GXWX/\P#P&:
M74C:N5_V+4V3Q19)T]T::!_R0DFTS9:B7%*RX_[Z/6>&'%*W<>V(Q<)(3(MS
M.??SG3.C;W^YO/C]\H+.M%.$XH]_LC,EPW^+U>4%\V\8X9HP[3_A1)J9<]P2
M2^$-Y8+4^>7%SZ3R:QFI<"%E+?XB]<WEQ>WEQ?7?<2G\&7Q`9U(*V&`FA1+P
M2SC.=]\[J?"]$P;?6ZO%\04YF3)NN".640+#I/8T77L&PTL67PK=$_SMU>7%
M/]YG\P6P)\@53/""\(MVK#,.7$I)KE9($C7<D*O%Y<44"!:2D:N'RXO7;S;D
MNWR1K^9Y302;$$ZIGI#-;4[>KE=W6?5(;K,ER>[NZO678I5M\O*1O&*.31A7
M9'U-FMMUO2&;O%Z1:KW)&W*7/6;S,I\`J24,7Y+-FLRSZC>RR)I;DBWOLVH!
MPZ[K]8HLMLUFO8*=/^0;6*+!!?]&KGZ]O'@'[/WG?$)`SD$(SLR,=,#Y'UX*
MS&@;I/"VSI?%AGRFBIY[?["#N+_V\G_]F7-Q]FW,@$T^$]08S^;K#Y_>GGLO
M.V!)1I;XV;=1_3;H42)LU9Q['W=40_+LV^QI2%,5-`16QV;GMWMJ=@Q?F-[N
M,<QXN[\"/Q_!0)A2?XF%,.6&)D*M%3'"*0C)GL>&/.1U3AH(,26$HZ(BWV?5
M-JL?258MR?M\7OL_(/1`[#,S<C6(?46UV-80&\CB-JMO<A^@]F(AGRC()H-@
M![&SR<<)8S`U<,J4=!VGDN(S<AJ#*S(622\J"*UYLR'YE[N\`M*R#<E(#>0B
M-V;&U6<*J>\.PG!65=O5[$6DFR3I#M(@4H[&1RWO2&>2M0$8Y/YA7=V<>VO(
MSMW6X'*2TN`#KZ=GW\@,>82D&U,MIT!$<#9,DA^*;%Z4Q:;(7QS']"DY@U=W
M1+Q^L0&>7!VTJ-K%/W/YLCSITE8"<X)]<ZELM&^G6B-!"R%>BC\`U"`_!J0Q
M@J=9Y[J0XH2,(45S/2`D8IX.\J#S`YY9_':[+I?@38MUU10-1@7P,T14U^NR
M7#\4,#<[@KK^.8;*K'&CJLP`O&E5!@MTDE+"MI+ZMBZ6-Y!CUEDU@IX,B^"6
MJQ@0N36MQWVJR,?LD7#G)2QV<>UZOLF*"K23D5=B1LFJ*,MB70$1]^OR'K7D
ME>N!:D9NZO7VS@/>7L/-!*-LN5WB8+_T;9%?DW=?\L5V4]SGY-/U=;'(ZPEY
MN%V/D1&TBZE/N\B_8*Y-"&"!F[J8;]$&(5$QJR:4THG/#P.6UD![3;Y[S);%
MXMQ4@C(BF6<(P:F=`,<-!<)[QQ6BQ0+ORS489+:C1*^<'4E9ULIIGF<UZC:F
M4/!;NYLM0;?%!NJ:LAQ%P;;+^)0-##S6+=OJ+BN6Y`ZH7!1W6=EF_I9:X/6F
MJ("T1[+<0K;OD0_W#B&#)>1?-GFU#."E&Q!BDL(Y$2$Q$6;-R)M=".3`M4!>
M79@;0PY:='(0+H89@11Z.0`YBSQ?MF4E$O%IL5EC=$6"T0]SKTB/!+=-X!7"
M-I`<:.YTCCSL2G,/[EG;#<L6BWH[Q%?7Z]JO=0<5,0:2,>0@8X;DID>`QK0.
MWVI@'J)N"5%WQ[+GC_[U7^+X@KM([KB.#^X]$`QC@D4#L5R<=OP`];V0B@;D
M5"*$K[.R^".("D9#(*^+S6.O8Z@>T-5'M'3>00]0<`3*QC_[3D7(7M\`R&^@
MI&E&*!PY4;A;6U*9OJ0275Y%N7W,ZM_(FQEYM\K*ZZR>DZMZBQ$27&;4?*)T
M)&_D?*+I0!`,-^X$X80Z;583;TKY`A%`^3@),2<KFS7X75:A&SYD-3XU/@AM
M:Z@MH2H#CX0_V4Q%(-)`S9F/U1-31O6<]?[2-08&0.D;](W5"@E"+C$'XMLR
M!_NKD;I7<J:HSXB>8M*&P9\@Y`+Y;\B/=0[AUU?1Z^H>)(3,09!=Y!.L20L?
MF2$%D4=(MX,0OFQ+5"\VWYL;R><4%AAMC]3U/5))V0&()3\'W86>S;\KJ$3N
M`XP/^10IS+_D]:(`E7H>NUAQ9!$PA`:(76X7(2$!#(50AAZ$$R#CA.#CY8!#
MAXEZ##'(#LL#<[U-,-XFEUUL8#`6@D(KM'10J(=!2/?'O+X!>:"^FCP/I1H+
M\GK38.<A;[;E9K*?6(44`735^1T,R:M-AZHA&]?Y"CZ`C'R=%36YS\IM/F(,
M5CR6%5KVR:2K_E;K97%=]'X,D1@]Y"ZK8P/H")T=&(NSBM4J7Q:!^WD.X"$/
M:O>K+S(4ZL2K?9[[DG&%L.*/L,5!3V<,*=`.2S,G8R925)LN1`",N`DZK_*'
M77L=)2U)TZ-A/0##L=A[`QY7$D&'QQCPK]KSI2,>N>->/@+M6_L!.+8!/_CU
MP3ZAED0U;:M>46.(0$4@[&1?X"C=9N8.>V)8-GIBI>VXG>=5#G95@`4.PO!U
MCI+)]_J7))KXD:C5(%HZL,E3QC"&#&*;B%+'>COH&K[!_O9J%.T\;L?@^HJU
M6!^5GG:KY;;NHE!(3L%`#GHW?ETLF#!\-7==\A_'"UAL3AG=1R?1EH3_WN<!
MM+QO[?F78=>B%4'6&<Z3UA+"TL&9H/1"Q2HHSQ:WW4I!;F/(@?+8;^4\HE0>
M4>I3NIH1WQ\"_$5XZ^63(YGW!='"'D8+]W);.-7>,]9%(;RPWYMN[@G=843!
M6<1%RC#3U2)H&9L">Y\_^,/?\5JR@D>,9ONZ2,BN+FI;?3LGV"=*E!HL`MP3
MC$"Q"7=V`+1W@.[VKG6=@0<`YKG>A@*PV#3MFR`!WRU\N"W`G/#(?`P9,-9[
M?A_\)>^Z?:NY;VCN-3#V^Q28&ZR`Y``P)VN"?0.H#V'SF!S?0]@'0+LX/^I4
M4$@-N3*#9GN+.O=UQOE$"7-*9R-(G;L.#3+=AQG)64O@UYG)<Y1F))M0R.@'
M2AO@ZA%A,3?F6,F(EM@VFUOVH03.(`(B7C\\+V4S'2M<>+MS:63O!*4YWH'5
MNQW8MHHJBQSL(V"R>5:&@]!Q:F?L#'2%4E\N4M.7SAV<2J;1]F`:#>6QR];^
M?#K`6)^K@E*#!(!=DBU_!7?`8NB8:`WS*?@(DGG9H6XJ^3@5Y?#RP\:4D'E$
MNISU*,^VR?V[@,P.D<;3"&W_`%_I/XD&]T#R0+EC\$]C1Q.GQ[#3">"(/6%#
M(DWR?B!JS@,%Q[CL8%U$=TKWI^FLJ\+WVP>LQ_=.123Z?X7<F8K=1&FB24OJ
M_E17M<_"[6<U(M5?@<F=TZQ6:]TIIT\FV%K`.?ZLJQFHU'?HLK;ST/?[QN!=
MJ%BT]2=SO,OR/X+PBR6$M<FI0U3/R=O;K*A7636)7;*'XCKW?RQNBW)9Y]YL
M]Z5X%MT^<7>A@Z>"J<B>]<_(WPX\/OO^@%#:_<_0$D_M8P=\TL%YO^K.^\G'
MHEK[VNDG!&BM49X[^7#`'RTA>[G'7TFP!OYWE(3[O?UT?_467DDEPP!^8H!0
M@B4'<,5I<@"3UB0'4(P`B0':2?"8U``K7'(+;831R0$:3"4Y0(DT%UI*FB92
M")<>P(5.ZD(SO$N2&D#Q#G9B@')")+E05J@DD<H()I,#-!8)J0&*/T&DY#(]
M`$KP]`#.69H+QDR:2,I<TAZD928]P.`MA=0`S71Z@&(RO85D-CU`<)ED4W*>
MMBC)GM"%I)PFMQ`.X4MJ@.4Z:9,"0DR237";M*"$XBS)I@!)I@<(3FUR`&<V
MZ;Q0VC_!)A4FN0)W0B9I`#R<IH$;(9,T</U$`.'JB3@)YF*3]L`A#*8'\*<&
M,*'3-%"1-EKF!$UF'&:53HJ:&262!@.^S=);@/LGN6#@_DEEX8WAI&<Q@1V]
MU`".)51J`'/IG,48I>D5*$V+VCJ7%*1Q.ITU73J20TY,[J^H2/J,9"SMUS0-
M7CA-1Q9&S6D=_=X.4<$0V.!;6D.,RB(V9(<7Y75_49Z%9C$>F-GVB.3*@W"H
M$]ZNH5ZN-KOX-"SSWW_AD@^(5;]'@F;XC09E\7J&1]GQS_+RXJ?+P3>Z\&:^
M!?M8!4W#4]D^&7P*K_WC[9!?_`S[FN""S[ZMK.-M'2K%H+1RW6WEK(H=MG!;
M,5[_#[<90T/QL#;>K$\5I/N(_BLXP&_*=2Q,?1-XT.W@;?V$MPD&)S!XG6!R
M3B)PJHPW8H9W#*UK2QM_&:R]&5:6[?6KO7(;+P3OGO;'MNZQ"]A?03!V_3N*
M46J6QPOSG+NV%9FMUMO0*7P5+E?X"Q:[G>8S"[$_IG&F/Z;QSYZB_;XV7DQ]
M\J3L*VCB6&'V1,G^'$OP[F++FV/-=LC($R=9>\,[-&9[R;4=YAGY(3^K,^#4
M_CR$#>Y=L.Z8!XA+73+XBLT!@@PVI[T?`A!LKT*E;Q'XRV!ZP@YT.`B/FG?A
ML8N4,2KZ8!H&J-T`V;T'TL'FG]4K\%/;YM/AMR#Z\0A^.L)T#-P#:L*`(6'[
MDW4_6?>333]Y+^QW[X%Z\\QS,]W;R<ZW/5^=X$Z+`7>VYRZR%`8<YRZ\T_UD
MO<=2&'#`7?@02L9GLP=Y_RA[?"*,G5C!3UB7AM*O9;/C>)>\,&"/TNX]4.2>
M9UQ^9DOHT:_8((Z"V@"]\;EK^ZGV]-)HV+@V2/&Y2X>IJ;5UH/OY$@DSDTM;
MOS2:Q;.E+=-KHSI>1G:8F5C:!^;3@%0/`>D>O@&OLMT1<GMP>FH+'6#]<_T%
MFVRZ;0#K&<`"'=SE_?FVP(LF^L_TF+]F"SW8HG=Z9O=;O.EVW=2ENU13]D3Y
M-.7.)8O,J7#IIL-4T70S;JHI3Y9(4T-YLHZ=6IIN0DT=Y6DN@,MDL3V%1)ZN
M=*>,69XL!:>,JX0P09_O?KF\N+SX'YS,J+\-"F5N9'-T<F5A;0T*#0IE;F1O
M8FH-"@T*,34W(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,34X(#`@4B!=#0HO
M365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]2
M97-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C
M,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*
M+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@
M4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G
M94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-
M"C$U."`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H
M(#0T-C0-"CX^#0IS=')E86T-"GB<Q5Q;D]NV%7[?F?T/>/!TW(Y6(0`"!"9/
M=F)WTIG$;KQM\Y`7BJ(D)A2ID-2NU[^^Y^!&:E<+IXZ8CA/O6H2(<\,YW[F0
MKW^ZOOKM^BI92BU(@G_,;VHI4OM7L;^^HN8*)4P2*LTGC*1BJ3531"5P)6&"
M=.7UU7](8^Z5I0)O))3"'Z3;7E_MKJ\V?\-;X9_)!\DR33ELL$RYX/"#:\9.
MK^M4X'7-,[RNE.3G;\C(#:59(HFB"8%EJ30T;0R#YJ+4X2*7(\&O;Z^OOGJ;
MKPI@CY-;^((1A+FI9YTRX#)-R>T>2:(L8^2VN+ZZ`8*5HN3V_OKJY;N&O#IT
M54V86A"6)')!AEU)OFGWA[QY((=C5^SROER;3[MRGU=-U6P)S9;BYP0DUFY(
MO\N[LB>[LEZ3U8-9"/\W9+AOR;YJVJX:'NRB75NORZ['+U5#3U[U5=Z0_KCJ
MJW65=P\+LJWN\.Y_);>_7%^]`1;_>3E!L,P+(N5I$(3&WU$04ZYIDECF[AL@
M=U<=D.)AEP\38LG/B4CZLB0_M$-)0'@?D,-+4\ZS9"1=LV6:)*"X3T#OS>6W
M2D^DA*;KI)12):V47AM;0#F539\/5=LLR'=]?\R;HC1ZA4O[MB$?AK;X%21$
ME^06!'O>#&91,WS5,0"V']2<,6X9Z,JBK.Z`AQ<\$XL$'$'5D"+O=R1OUH11
MMA`@86?2P,^QZ<IMU0]E!]_Y]B%?5P4I+(\]\FB^WC9@%&5GY$$V;;<@.2S8
MDA:,J@/#`9ON[;DJ4%!U;5<:HRKG$(/6W$DA42H+4A#,J1',N.W659,/P%4#
M!MP#H\`!N=]5Q>[$`[3W[O"?UV%^.'3MQVH/=ZH?R`N:,2-48`V\2E-4A[PV
MDGV1)?Y"7A3=$6Y:-2C5?OAZ%@EDTDN`2NDEP*24W@[JJMQX%3AF+T^'#(18
M6WSY,V/LXMOPY(1?&OP\RX1V&A_UY^5.ZBI?535^A%IYI$B:H;Z^-LK+@9ZZ
MA*/_2%YHZW#Q``;4#!5H^D6:V$,%1V(`JX>/9U$N<F4/N=#AD*>)=KZ\7=75
MUIZQH;7&FS?Y%D/+N@(/,`#9:)QKI,^MF,D$..>!W!E-@/-L(A4X],%W<ZZX
M-P$?S7T`AEANU+;/?WED&N#54"@V0G\8@QY\3K56RR^E7SY#?T9'^E]^L<D\
M=W<T&>YN_C-+DSE,$A"@AQ<`_8))9L[??.<E6W[$T`DJL!(^XXD/^4.^JLM@
MNL'O8KR90*A101-4<I\_\<E\`:C!.F&:+#C\CL=V#ADDPAL@5R+X((6_>XCU
M4.9`?0G!!L(IQ.+]"J(.IQ9[VAB<@`^!O?L#'%0(U?7#EUE;%J552>7UE61T
MC)"9P\5J^0<`761KH<+6%X!SD8WDR*/.EDF"H?^389(&&/`4S5W\Y&4BD/&%
MY_HS>H0\#&]^@UY/!*A#9>J\WK/H=`8GHRB=U<EDVB=SB9QZ^(2%9.[['%P\
M8>Q<,E>!*$#?E"ZT3B88]P3/6AR(7W-HUWBNQEA'7@/:;XHEWIN2-[\=T2U-
MS8>\K\$=868T$[#-,IN?R!!*^<5W46$7D#.CHR/+J'-DCG-D]M*[9_H,C^FE
M=P&/['<!+\0E.F[T0IBQ+2ZN-SWNAL>4I2J(E`EGNA#L_EZ734/>+,D/Y?J^
M@L3R_6[Y[7(Q*SI+1G'/B<[@RM2FDN"GF*8^)2/?[#`C^5!4"*8W</+>;>#O
M$K+)-Q_+XHBQD/P;/B#OX=P:[+H8?_6`X'75OH>#O<_)ZV-?-67?FZ`ZQU&4
M(=/FDTQ;)0Z$YP%K0SH,5)"^VIK:T:IMCH!RP,OL*H`"^T/=/NR1A7S;E27^
M9HL&SD'=`VXB=WF-KBL?R`MA$\F5B5T.16WRJ@,4V_U:#G;IS(E=!C#!\S^C
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M7_9+"#"HKN_SX$P>IV5XG$T5:#NVGC9G"W"79DGPD:<9%2W@"Z/H&,\"`!;F
M=ZOH]F!Z*"`%.)G'VA0HC110JD96,S4'):..-)-*.\I\:E*TD!(WO7&<3=_6
MU=H4Z_H!?J#!&>TZVF'!%]=&(P0*E8;T*1G;N"R=X*#G[.OBY&0C/7/"@4R&
M;0SZ&^&`$B,>`"A0Y]T6*ZO3^JB5P/?@,<FK)7FSS^M-WJW(;7>$A1@B\?);
M@*U%U1>M^_Q?7[WZZEORMEQU)O*CAZ$:.)BQGB'DGU'/\+N`Q5`1K">5WL(?
M">+RR.X<HQ<O:B"`]-O\"54->B)8BD[;&ZCT5?^J*;K2CT]`"'<Q+(P5./_F
M(\$*C`Y(98!W#8QC`.-X]DRE[K1&[G)LZSAQZ1S&*I)0PI"3^GX6_.1=V1G_
M#7QMCG7MN/87L*D!:&=?]7T+Y\MV.]8`9DZQ=K8PP*@AY<>R`[/$+V'9`YAZ
MP0$9F]*!D0F$5C*T0UZ?:V`N)20)=8U)VQRRX"%=IFQL06:^[`P$6?Y,"NJ;
M/Y/6SJFW6I5Y9P7G5H($I`$"R&S>-,>]:>TX499K"]17>1UJVW9`IS:Q:54V
MY:8JL+=GO]'/)08:VLYHM:%2ZC.V39D/QX"ST28>?`<,Q>*Q'/9^K.DZZP'M
MY^M?P!?M76WKR9P!-2@9!%D]ZJS-$7_3++16)1NGJ/Q0R>V98++#\]B;?#-H
MHZM*D\*2^VI3&LLH=E6][LK&`L33:.6BN*D*CA7`4!0<2W]XHV]VD")`YCOC
M4$DJ0Z;*4AN-7X:T<8[]F,\,``L$P)AR/XL$F.<=I/?80&3R'+`^J>,8-`V:
MV+8Y^0#"A)P:M?'>UW)>G=9RW-(%UG_&RA`(-]QC^6H)_J?N6S+/T4H3%3"?
MIJ$B1X7WMT^9MQV;B].2IH&8>4?0:*K"3MC#RT*024,^^+9N.T#@CXMTS9?W
M+I^CABGQ)_'-E)[RK;,QH$CE,%KYL:B//7H`./>EZ?+AN5^7$/W;PVG]_,2$
M,8(,;FS3G0/,:(Z%]:MSF"[7-/`REI)]:'R6?L39%Z=&Z$#.G"`;\)#?1HNE
M2B&O-K;RXU^^O?A>FIUAZ?)P&F)X8&EJ_@BG+VXU+!$3LX%_C6E*2,0!`6R[
M?(]6O$(CWA_J$M%.>U>:,;2RJ]JUJ78>K*7#<?"UW\M7-.AYZ5S<.0@^E0QE
M+)0S>>8'.7:`&.QHS>)DD'.>@)`!\/IS>,^2=-PI6THS]?#)U5(I/XT(]X#V
M25^6O\[BTC)?BF#I:)IZ[%X#0`5@BG`/S!10;3D@8!C*8M>T=;LUR,]ZWZG+
M,SG=Y3-N+D:*9YX:%W(B&\K32<@6#JB,K96R^?2PQY&VCS8KP,/I<Q80&V0R
M/88I_!BP[!&;;D>3%YW(<0[UBM"=Q\:)/V!&;B:/:3N3?&-"BA/-H.RJL",O
MF,782'MQGTBS0-B,E3;&Z(1_1L=*FTA8J+2MJK8<=CDHP<1IG&(_UFU?%<1]
M;,("*!&1!<K%Z7.VZIF`],"3/6-D-XY^M(Y$C%FN\'5("/)C_G!I`B1+SO!Y
M\7`O(9;X;9Y4S[X\OWMN6@Z_X+?[\H'?V(EFH5BEQX@I_"SJO\*8&Z01^W&>
M]O=DB(L16N?5^B3EQ`G;)+'_FQZ4C</58*HW;@"/+2B7BPQ\M*OLS<%^XNM3
MF+Z%1GH:JE,S=@AT%K:?=5Z`3KA,]`07":[/-@]Q?"A=2C56$(-W*M"70:"Q
MG[J"XZ3`('R.G6.W[M!VP]B=?05A`:*!FRLE;SZ"O33;<GS\:0;],C4.QDR>
M\-%^;,`;Y(B2!YRV&KJ\Z=TH"_SW`T!G,X&M_)2#/1>%31E)477%<=\/ILAH
M>%^7?=%5*U-CK-M[7W.`</U`=OF=*6T:,R?Y>EW9H=%9^)=A4B293)])[MO&
MXP$&BMQY]:W8)X/GB)J/O0<AY;H_4W+4"ZUM:QXMQ'9LL8>/,MF4'=8BGLUL
MYQ"`"`\<*"[')%MF3YZ!.==%/6EE;JH&BY>@J4E3$WDPD'IEN=TVU2?+;P><
M-4<S*(/W=757+'?V+=P%[QCFH3`TSL$]#[5!I<9JB?`3NCY5',TU7[4XVP.J
MJQHPC<Z7T!%^]^$S]SA?4]HC$MCX?95#=_?ZN+9WLH-&<[!/QZ<7]-AW$MJQ
M#YHH487#,\]8>+WF>W!D1JU`K0'BDV>FO)HGRA^'PS]O\Z,!7OYIH4P$$<SR
MM!#6/N8<Y*<JY/-9.AY>GOJGA3;&]$`I??610``;=CW`B1H\KLF&)K.7/G!-
M40CV'IIV>#+(>"B+:E-A+'@XV!&B23BHFKNVOO.WZO,ZS,M-?.D<LI`A>TS5
M!*HH_V`V-OA,5C@0?`@18C@+(`OM=MNU?1\\]\+."/H#BQ/&S5`--7+=^KDY
M6QNZ^#A3I@(W\V;=J3J1&QV?MN):NP"`Y2!`G1W.YIH@&,964Y8MN`CC@8^:
MK7.H.`WYDYP\;,6D\M[:]W?%4HDE^6YS8H,GL3QJ#)89!]_@L!AG!<P]0GV+
MY\S#()AY@0L^K.LS;:4G=7X/6:U27*I@7?&>]*U]_X!MJ,-1+5UKU+)LI;5W
MP#4F0!>>^F`9B[FJ%S)-`K,SI@$2TIM1IG3,]42BP@@A.`?2Y4/NN888?U=V
M^78>:Z?C:(`>'P5UMF[JT087>%IL`HK8P1:V@S(-OFK[T@.XZ3F8.&Y@;.<-
MW3273^Z[KOKBV/<>`2W)6QR(GM7$=4A-)@T\YI2!]$#(.AH,O<WMU./CW&1!
MPILU`+:\Z[8YX(\\#."_"\-VEWZB$`?J'/F7?UP1WQGC;C[OLY\IH.,_QH6.
MW5R-&N9)&GR8$*E//O-#A5,Y/^:5P2:OL/IK#/?B4%`H]@RKYA$EA<^>Z81P
M<]?QZ^8M/+!`"&D7L&<6I,!5=`$7*8\N8`(XBRV@J8YOD:1"Q19(G;+H%E(!
M+(@NR%(6Y4+*-,Z%%'AT8@O2E,87<'QH/+8`L'B<"\HS&5V0<!GE0FB>18D4
M"M^T$%N0<1I?(%F<2"&8C"\`7<47<,;C7$!@BA-)&8W:0ZJQLQ];H*ABT049
M]K%C"R25\2T$2^(+4B:C;*:<QRTJ99_114H9BV^1,!IEDVNFHS;)%<NB;&(;
M.+Y`,AYEDX,DXPO`Y&AT`<<&?FP!F%R<3<IU_`X)SZ(T,)W&:6`*7Z<56Y!]
MQH$P^1D_R42:1.V!@1N,+^"?6\#PC2ZQ!93'C1:.#8M&'*J%CHH:$DX1-1B:
MX8O5H@MHG`LJ:5Q95'SF9-$4C"ZZ`(Y_5%"05\1C%F7X7HW8`II\1M0)/A\6
M6:"TBI*0Z;@KSY(X@)&)B!X:07GTNGGK4O1<QUT+PSY.5$"1B/R;6R*L""@_
M#V5I`(_T2;*6C(^Q"_?B+.PF*9>NW9IY;?/JD`;?<G6:<=C;_/AWO.4]@ME_
M($%+@20I^&&1?OAG?7WUP1.=Z>=)EE.2'Z%O<'$J/-LH?%[]M$II`)/=(OL?
M1SK`#TN7ILBE2H5]<\S+MY?;`J)BV"*:"?V1+>1D"Y[@8V:X!=6/LP01]4,W
M6D3M\X;J>,RX83KN*V\`G$<=V8U(XD#G1B;QR'<CM8ISH9*X*[Q1.)4:E9-2
M47]]`R=91UT99((B(DO0UIN?KJ^NK_X+QZP'DPT*96YD<W1R96%M#0H-"F5N
M9&]B:@T*#0HQ-3D@,"!O8FH-"CP\#0HO0V]N=&5N=',@6R`Q-C`@,"!2(%T-
M"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E;G0@,3@T(#`@4@T*
M+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@,3DV(#`@4@T*+T9A
M8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&86)C-B`Q.3(@,"!2
M#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-"B]&86)C.2`Q.34@
M,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*+TEM86=E0@T*+TEM
M86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-"CX^#0IE;F1O8FH-
M"@T*,38P(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$96-O9&4-"B],96YG
M=&@@-30V,PT*/CX-"G-T<F5A;0T*>)S-74N/XT:2OA=0_X&'QJ)WH=+FF\S9
M4X_=,YC%S-H[;L!S\(6M8E5I1B65]:CJ]J_?B'R24C(ELD5C8=@M)X/,>&7$
M%Y%)]A__<7OSZ^T-F2LM"X+_F%_57`K[G\7S[0TU5VC!5$&5&6&%4G.M6554
M!*X0(HIM<WOS<[$VSRJ%Q`?)JL(_BNWC[<W3[<W#?^"C\)_6`)D+P6&"N>"2
MPQ]<,]:]KH7$ZYJ7>+VJ%$\_D!5WE*B*%A4E!9`)97AZ,`+:BV6XR%5D^(^?
M;F_^\T_UYP6(QXM/<(-1A'FH%YTRD%*(XM,SLD09:.;3XO;F#ABN2EU\>KN]
M>?_#NOB?S6OS_+G9%K2<%8P0-2OV3TWQW>;YI5Y_+9KUOMDV]\5RO=^8"S\U
MB\-VN5\VN^+'PW;Q5.^:XL/CMFF>@;1X6^Z?BD6SW=?+-=SSVNSVF^VN@'M?
M/#%<J(N7[?*UWC?%RZI>V#O_O?CTS]N;CR#8_UY/?%8Z\8GF/(@OP2N,^&Q6
M5N6,@#_LGNHM2+1Y*);[7;'8/#]OU@7POOA74>\MOXL&+[\3<U45+Z`O<TM1
MK^^+MWJ[K=?[KIB'%_Q?*<N9./_\==%\:;:+)=PWB1[@5J<'XQ%6#PR\W>HA
M2J?FH*<HW<-F6SQN-[L=*&"S:)I[(\([RF=$\!E59%Y\`I\XM>9;;:1\635[
M<!Z0]?MFX=S,>MD</.RM61O].5^;%7_]ZW=3R*\U]ZM`4>G%%Q1_H_CU`ID$
MCM&_FR^+U6&W?&U+4S_B?U$9^Z2T>.7M:;EXPNM?@;]%`P_(.D;%9XJV_:*U
MZ*ZM@K+200?6^N]_88Q=?1J8(JI:"[O@WN\F,6FIO$>7/`8VSIU''Z^P=W+.
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M+;2<"34DO\=<RSLA9&:GMG-/H(\*D*U+@ISJH`]-G3]<)&Y)]$PI,4I<.9?D
M5%PKK[UU\X*AY82#*92!"\(ZAY!1&02`ND4$;:%9*69:YFP\`Y`$NH-U<8!5
M9%$"P]CU\=?#<O^U^'%5KV<6&W<5`]&Y7C^B$YJU\8[-287B`\KL*@OSU11Z
MD+X^()4.,8(+_(UZ,#9Z/6^BCKZ4/(+4:56!`A!0;7+:2GN24<X4VN"^7*!1
M&<KKHI7LIYB;!(A>8=7B+2&2T7K7%ZZ-H\`/V8W;R]WNT.`%.5.2&:)R)AGO
M-1(,OC20]5\AG,_0U+L#6`VM54\A?5D%A"Y:")UP+WX#C&Q>#-@^*C9K$'2Y
M!7>JM^`[B,1WS?;5KBU4TC9"'Z\-)`(!08^+)Z.+^];C(5O]$R3?64BWV2YA
M>0+:@2KX><)L5:J`9RL9X:S,BF_@&5-79P<PO.=G6A!&=1EF0A#&8F)BPB<F
M\$HP,ZR^Y>8>W1[7P4_-R]XY/O'UY%]:12:,"+L"C-U04\V7O5TSX`SI9;.<
M)-64PN-T0F/I;4:M:2/+JI_C#Q#]5E[8LEMN>!\%X&5`_3W0D1GO#<$H:+-;
M;#=OKFA=[HK/#:IU"O$Y"S%5Q94M2Y=I761R*[2]E%$#]78-%^]C\%N`,VRA
M7C]@`6)<8H:(PQ7?R^?&5N!8Q=SC,C%/_@SK^+#?[6OC///B1Y>BD\MJ-HD6
MJ`>CC/,R%AI.":XN@_1VV%F6%_5J<<"ZS3"Z/A@7`3LZBSJMH9?LFKTI2'FB
M(`61,=.^UJM#XX/7:71<FL;'NKA?OB[1W3Y_G2K**1TPJ"`QS!FHCGJPM?D1
M0@9MW#>X*);K'FU8-^DN"D`F6*UL'M?+WT"F]69]]0J2R2#0Q+4JTV$F#),R
M0E;&?0]O4>^>BK__V_<0-EZ:]2Y5E4%%IKC!9A/!26QE^Y)3AIX$JZ3K2;QC
M%AKZ3MJE4*:+1C[7.]M3Q$<\U,MM\5QO_P7+H./G$_72%(]B3MA+PQNB-ID(
MS0DIA5\LW:#N]#&%55781""M2MI4U29!-_7NL+68Y!Y<S4&GDV7ZU*SN6[FG
M-HGIU.P0CJIR1F%UH0,<%Q>,\ADM97AF_=I`?(?HY7(%1(LI5"#*T&RKG-E1
MU$E*`>6Z]7?=ZI2%UMX/Z^)O!KM:E96FE)[$^#QRHX*S\^M/4W6$ID*VXIMS
M]X\/#S8$%-^#XJ_-`KA50E)Q_6ETF`9R!E>8^7ZSA3:]/O)@+$X'JY?*6%A6
M3$3LT5]?!`R*(7NS=KU"ZV_;S>'QJ?A3\WE[J+=?"Z:--U96%%^^VX;!1,M2
MAMT&HC$/^OT]GQ,M]R:&Q+[U_JU9@1>9LL*%JOUF#Q>P`>ZS1Q#5/&*'(D!<
M@@RJ))DI@-<.<KXM5RO$EY_AS]-"<X-;G68B2+^0MI:[2="E#)LAM(S;G")`
M`YLP#R\N13CX7#]O#FLK,.+FL&GAX%\+BL^+CS7(Z@5Q-X(^7NJO]>=54U3J
M%XA4A6F7`PJ9*API5@59)PQ'BHN62AFOXNY*5;D0_!W*^<$HXNK;:"0EY=5#
M44FCE!WX.DD#NF2TI=,V.A3P7-=TA:5*A?>D*=9)W#+CL<<F3+\-&3BL`6<L
M=_;`P^^R,\L@_GNN)D23C.B6\+04H;LI22F2<'*J-<Q9M,.$:YACJ(@2"];:
M\6"N]>+:S=.L8G#KA)Q77\6"JC#-":"X/CH53+75JN*9(L$KUR<WC0>[>$PU
M[W($+.G]V\9LMM6KE=EM^R];P2VWD'=;XZYE,T4`$`$+D:J%%RJ7*.^;%0#,
M;:PNN1S+!>GC`O@S)9R#9-8U]D_7EY:VQ16QZ\0U=_$.JC5LAOM]4-,=6GZQ
M>1Y`TQIUL4-HYX)@%X*;\LQVE!8;TSX]MN#OH,X2%O/OH<X2=!;5*8@.,$L3
MW\4SZIS":UF0CW/6,J,ZWLDVN*T%;\\;L:=4]["V^161HD.UG7AYW"U<K#8[
M9,$V[Z;0`HF]PWC@1XMPVF7"-*W+,/V$69H"`HM20H!J;015H>G3Z?8<K4A,
MVN_D7%,;_=O]T&?P3=M$]4WE6.B9RD`1]-^=VY9]VR[W4/@4Z\T>[#F_]N$7
M`SZ=J.,/O_0]';Q%5-_T\#+KBL*='C"]"FT#Z_N?W?F)"5Q?\+!+KQQPIG-@
MPN&8#_ML\U3-!/S!*V'&U$Q+-BL!BO=L#L6.&FZ1;E]=[8\[#O4:=RC,"8?6
M?DHX*#-);2MH.,);.A!G8I\5O=T8GA<?(&BY0!!.LYA3K`?<&\.SR.;DTKV5
ML?GRLMS6ICMANI;=HQ@_+/8;LRUGNQH:@^#?:M_EH!SW&T$OS_8!D``7S78]
MT1Z:"&<#J(PM'+!J&5LX$T6^BH?9)XQ\5=F6D=*(510M?>!S)L7V!:2>/1YJ
MP!ZRS7Z[/UP[B#"H@CU3DX0H6LGI#O]1%?.(CDA7:(=TCS;+5?*XR%7/M?>>
M,??G4Z?0@O0[*%3'2J4*ZV;3>D6AY[4$3*F[YOJ(!FK>P-ZWUL$ZWP&.6F"\
M8JU>ECL)^1<7VHT9O[,F_`E->&UF>!F9*;^Q)LY-4ZDPS?47%Z_:&J6$1Y16
MAN.#GS>OC<5@/6\Y#'CE8(IU$0`%Q(G6"Q$>95[PEL-QK,"UM/__\L*#PL7E
M9)QRDY:5+542+F+>,K\3;;7.JPA36#;`)49:/5;I=^#'O?TPH:EX&9F>T%2P
M-ENZ(66KA%2*]IKJ^"V/J[\$`!'#LW44JO#44*D9*4I-"FX>&^\WKQ'BJ4&I
M+0'K(8`\K;,$0@)2R!%P"1$N1P!`*3\%%8`B<P1$B.P42@M8,3F"2HBL%*H4
M>2F4$C++I))"Y`D$MGQS!!SKN!P!$X1F"2CV`7($1)`LDU)SQ;($%1=Y@I+G
MF92*Z3R!9"I/()C*2\$A0F0)`$EE_4$21K,$`E9>F26H&,T3E+3*3Z$8RQ-(
MIK-B@D?F/4KP,[80C,G\%)3QO)B$TZQ/XGY+5DS`I'E%08I063'!I_-ZX))!
M`LP1",:SBY=S=D9,)EC^"93K/`]$Y'E@FNLL#ZPZ$T!8>29.@J)YUA\8A,$\
M@3A'P`7)\\!XWFD98*YLQF%$T:RJJ995UF%HA:_F90E87@I:TKRQJ#JSLJCD
M(B\%+/^LHJ@@^9Q%.>[UYP@8R:N:FD\,Y`@(H5D>-,G'\HJ<03"DRJ==JK+7
M)<W#%T'/Q!;*LE9B-)^2*2G['>E71R*MIU">KH1I@)?TI"`@*C8/*7,-5*+]
MEN<GLSEK"O_UOCGN7]O'_/W/^,@WA+O_C0S-);)4P1]VUSG\[^KVYJ?;]O<M
M`/CA-S*>713F2&%^E?C+7C8_G]KRXA@K\?60P4TUKES=_PN`J2Z>CES!PG1<
M>08#,T8&2R"[?/GK)KX,;"7BK<X,IXQ%>GR1U#/F>.QR8PF.&7/7J8)_RV&;
M&5RA4'X_WW8"WF,_L$=UH@P&]<QVV;($1QSZZ\#&4)/:6_59U2G`>YZQ,MBT
MQ8TE.&;,71^C.BEH4G6R1W50'W@./;-=MBS!$8?^NAJL.7MGG^;<0H.'CEUH
MC/<_VC@\/-1`CA%KA?<M8N_N&+*'J\3<FN,;WY,W?`]W5'-K]MF`.!S?7`Q<
MI<BWB.>CI3MV\_[G9OGXE.J=?]-D.@BBRSG7>-X=3Q1]>&VV]>-I)]PLT7%*
M,[?FE&86Z#ACFUMSSY:`;$;R;6[-/ENQL?K'-^.&&?N;)BN'&=M$%3S$/BX>
M]>JLBQGPWV=7TGC,P*J`&=S/#F;`L9&A#&OD2S"#X\HS&)@)F,'][&(&'!P9
M!YDNSR8^C#N>,<=CEQM+D,`,.(CK:BAD(`INC1].R1^`B!K$D.08]3QWN;,$
M1XSZZR,CLF?T'.KRC#D>N]Q8@F/&W/51$;8R6O1?Y'(G$=]_[/L$V#?,)4@9
ME$#FS'\$[OV/N!N;`7E.(5XW72U8@@3(&VDI>^MY2V'8]8R581&VN+$$"9`W
MTM>%4?QP7\>([!CU/'>YLP1'C/KK(Q/2)1K$(.P94R&ZMKBQ!,>,N>NC$HP:
MYNO?,E<E!_LZ@FZG$*^;KA8L00*5X^"X+)@QU+PRGXWDW!?RIB773FP/(>'Y
M\9[$DMDD9.%P"!.T]=DKZ@X$_!`/=YFWZW'[[W/SN%R;`TZ;!_-F5)YQD[Z`
M0]-L:S%^.CXL(SK.+U"=27$PDSIBX'AX4/4P8'[<)C%]:])EH#T^T'0(GSP'
M>-B?`'HS:"T<ZCO#4FFGC@'F(2;9SOBP)#M`*1A03XW2&AZJ$G-G0B7OSC""
M#;>4=5KC`UD17*=9$?.JRG-C$F#",*?CPW+JY88Q2?+4,"?#@\JO0?/KI#W:
MXP/M(0E-VX/.)"'X'8(\2R:G)HQR.CXL35^N%),+3XW2&AZJ$L5&K18\(Y"R
M3GM\("MXL#/)"G[S(\^-R:&G:CD9'I:4>\T2P8+9WI+I;.S'1V1C]X$@J+^E
MP.^7_M;"1_>Y*EG(='[MC`_+KZ(/FAR5PD(F$ZL8@XGLG><G-ID33XJD,JH;
M'YH^L`$JXNMS5%3A]3E"9_B]-'IT0+'%3VGG3:93-SZ4'W-KXONG>)@P5UB?
MVN-D^/*<;NZ\P!Z8*U/V:(V/R:$M>[1RJ.J3WV2ZA!E.QX<ESPLT8)+<J>I/
MAH=ES8LFUDG5M\>'Y@;1XWIW)]\SNF"6;`;T`A9]Y;/028N>CH^;-Z-8DR%/
M+7HR/."$'[MPXBIIT?;XT!3+R:46O6"6;/(\9U%+=*+6D^%QLUY0#&)N8\(W
ME>&7:RJS*O1Q[<_P=S@D*G&@:.7XF/N[XX-R?_@Z'J&5>WGUS_;[J!=4MU8@
M+UN00X4.L/W9)Y*G3F*(SO@P#,'/[W2;E.W8=Y)T>;8$>?8==0J'M(>'X9!+
MF"\#\UZ.+L>6(,N\ITYB&3<^%#MP%MCO=@=D.2LYNZ`R=T*54:@HB27("^6H
MDX"H,SZLOW")31!S./:=)%V>+4&>?4>=`E*C',K<>0'S!FXXYIT<78XM09YY
M1YT$8^,<RH"QI$/-J;Z@G6`E\L)UQ;`$68D\=1+7C?,F<^LE!D&`X]@O0W1M
M\6P)\NP[ZA0V'.5-YLX+F#=0QS.O(_.!8TMPAGF=]*;V^)AV3,J;Y$Q<TKPT
M0,J*Y27LRF()LF)YZB2P'.=2YM9+K(((R[&O`@1I\6P)\NP[ZA0X'>52YLX+
MF#=HRS-?1>8#QY;@#/-5TJ7:XV-Z2$F7@M]G>D@BI#LO7%<,2Y"5R%.G0.TH
M<Y@[>\UQU/R!Y>30+/QR:);(@`))>\NJV\(B/2TL,KZ%1<*NFRKCITIIF=E0
MP@_SI;:2CAI-5DPO<9`NGG*P/T__:C5'9D[@'H-;-S[B&"<CO=W;+KAU?#L1
MNLQ:@C;?QS='9$PB,K8FM01IZWJR%"0FHUMSY/R^LH%I5F0O?5=.2]`C<AE$
M]M)WY;0$:9$]61)(DW%-0=QF(XDF5/B21JX3Y[101BU$[BU!CR".+`F>R?@3
M,)=8#S&BX]N)$)CE`8KV6<]<B\B;B"-)+4&/T(XL!;GM\)C]P)3MWN6PMY/=
MJ:$KL"5(RVZO1>!.Q)'`EJ!'=D>61.SC/-<@]I3T<IX]TNT4X'719=P2I&7P
M9$F,/LYI[:T7'-M"*.KX+D-VL#]Y0+Q]AC/7(L`GXDA22]`CM"-+(?M14=;>
M>>'Y)R^RCB('.2U!6F1[+98%1!S):0GZ1-9)7VV/CZD'TE$V=9CAJ$5KM>`5
MTN7>$J0%\63)"F"<P]I;+[`>`EW'MPJPS?[D`4_W6<]<B^4#$4>26H(>H1U9
MJFX8%67MG0.BK$&V7O8JRAX$M@1IV>VU6'T0<22P)>B3O4IZ;GM\3-F1DO[D
MH,?1.3.K`*^++N.6("V#)TL5&J,"CKTS_VX():3_G3/5?N?L^,0IO@[FO\O-
MI/^F0W(2]V&`P5D>_[YG>S9:JWDE\.L6:(`_76\*05B8(ON7>WS+%*HU170C
M=E3WX5<:<F\0WNG\2YQW5.=?8;QC6F5?1;WC.O.2(A((G7\+\T[J_!O8=TI7
M>2E*G7\5]:ZJ9/:-VSM=EME7,>\HD1E5@BT^_N/VYO;F_P"Y)IAD#0IE;F1S
M=')E86T-"@T*96YD;V)J#0H-"C$V,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;
M(#$V,B`P(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N
M="`Q.#0@,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q
M.38@,"!2#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A
M8F,V(#$Y,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*
M+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO
M26UA9V5"#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*
M/CX-"F5N9&]B:@T*#0HQ-C(@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E
M8V]D90T*+TQE;F=T:"`T-#0S#0H^/@T*<W1R96%M#0IXG+U<2W/<R)&^,X+_
MH0Z*L':CV8MZ`CA*'HUWO+%K>22'??`%1!=)C-%`#X`FA_[USJQ"/;K9+,YJ
M`(<BJ"91C<K,ROSR"7S\V_75S]=7V5:5DF3XSWPJME+8'_7^^HJ:*Y0P1:@R
M?V%$R&U9LH(4&5S)F"2#OK[Z*^G,O7(A\4:R*/`_,MQ?7SU<7]W])]X*_T5_
MR+9"<-A@*[CD\!\O&3N]7@J)UTN>X_6B4/SR#1FY*56>DX)F!%8)94BZ,_R9
M:\I?XRJ0^_'K]=5_?5_=UL`<)U]AO1&#N:5CG#+@40CR=8\$49Y1\K6^OKH!
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M^7LFLP9^T)A:<M</I.`;!22,#Q4>WH,QA/A<$3'Z._).;D&G#B!/LY(,%0(,
MWKPC[]26\^@::H#9T._X##=^A`ODKGG42V,,+;PH5K6QG`69@Z#!@3&O>;DH
MK-`1?`F`[GZ-`\^5TWI&H[WQ,^X=GTEEG<'21&2EIV)=/(,K@5V`,QGA&3T7
M=5"X2.,`DA[!3HV2'[N?CU7;W#5O@5<LPE^#=MMO/6;UFI(!TX[Q]TO?''5(
MSO?^.Q/9TK=7X?;?1'J>5G]>.KS+($J<]8%AQ&CTH=R2+\:3_>F`OFU<P0`S
MYBB@>$:S1F9\=CL_=.2/57>LAF>,R]3&@.WO^_VAZIXA[.H/J$Y?OO_P!6[&
M46%_1'7]-M]0ODXI*U5$*N?"8L7[+XC."^_%(9YW>_UV1$AMQ&/Y,U;X""<W
MGU'^'ZL1!/RY>C;.>^'S%_053O$@E]Z+!6:MGH&],K[X+A%'<IOS3!B.0*:4
M.J?R0EV7)B)2UL"J6'@7F;'X\+C*I#^\;S3`U&ZG6)&5$5;0.1EY>FCJ!P@7
MP5,/^K$9,1J'.,N)>W%04$4,"BSW`)KG,WY^J.O^"&%M=V]\YL+[@TB*0OY;
M,`GR3;?5JI`$,5_$$E.E$ZG,\;-)1`PBH0O0W5BA6UK:*ZE8KIGQO[.J"?R,
M1&Q?^AS(9R!>!]H@YHG._?/0='5S@&B'?.RK80>NM.E0,U?`.&F^)E?&.`E!
MB=OEQ@C(;O7A\\>E=Q+T`C^+`YG(+RNW.=6E-Y.1):EM5H`/GAT$1.2ST_V_
M?DN87!RO9"EBZZ+,*[9BDEY$+!O]_>`S\!403!4N)2ER6]![_VE_:/MG#2:S
M=+[)_7[@G0L%N9?WSB['1[L$588#^%;7G&28!@K`:69Y;G5MLWAH+2+19C("
M,>E`S-:5(+#;C1;.4._*Y?6.`1V!%B:EK]O*S.G=EZF:;($(//;O(3TDW[?]
MT]()A\ABA<M8L`!6.N/;DC_H3@]8E++91G6`Y+3"R**[@/H0;KC:WERA\NN7
MSY8*%-<,NS30[I(E<#WUT-R"J4:D;LE_]T_Z$8O6+ZD?],_'QI08V]:6FA8F
M&ML)CNI5RQM<YGXC!+?2)S-2^1JF"1T.-ID9\;RT1QJTA6[Q6$(J^>]A'YB,
MV*>A5B^D+U[.O)(=G'AM2Z@0F[3'':+]O2VV@O6MH+;<-VU*%6K+TB69GC);
M-N]ML6&#!W2K8;>ZO^^:?UJU1@NKX6K?-KL*D__1(8<AOH<8S`2%([&GW9NO
M-`.YJ^#'8]4>L<3T>>C1O^TK$,98M_UX'/2&V`0""[8KR("Z3@*CW(>UHBCF
ML/:`*4M_'-MGX%EWY(C$WS[']8X-@DW7D[;O[O6`1>6JG?30`;^/^IO+9@F:
M\R+S"A7:'R)S&O7U0BT&Z0VB=H?GFB0V*QOCM"PJVAQ'U$2\P[[?V=(B?&<\
M8&?E49,)5'2TM]KKZ:'?;<E?3#]B>@#!1%=7D(1RC0%F4GIW>MFLP98>;.N$
MM`1;B/!9ST8&&#,K-L$.AHNP5@%=)3S%ZX(N^-(@&EJ4>63<Y470-3AC#K;I
MT65NR.UQ`JV>C%3@0F6TXSM=Z_TMG.W<D86HQ-YHA;,5OBB.-0VOY=E<KK$(
M8@DGB#FQ?N-)[@T.`395$#P/.^R&D:=F>C!?ZX?FONFJ]A7MM\W!%71`RM)S
MMK+GX;$(!0TZ8#XG=,#TTD^/>H7C964`L0"\F6MAQ\KUVX[Z#7S;DH^ZK@#7
M7^"510_R!*H_ZA;03N]6D03UM2I)?8`@^7Q($`8>6^M%K7&"*VWZW6@;C6BA
MQC'!,O2XN\7[-$"=*MEO;J4D!*#R4-4)Q6XN7!SR><8DWW*PV'/>=;`I,NC!
M:O@-6:*C=5W\9C(2"@0F*K@V=1(T^Q#MQ,,=6M#AR&TWW30TH-7U;#*S8H-&
M5:&NT*SAH)7T9019A."797,E]MQ>;89OT!='-`;=SI8-B`2AV&1CR!!@G%NW
M_?X&P[&+/A]M.0I<GQ[`<FQTNP+OPL?]BD:\SVF^BSJ>]*`]]!HAG,XDC$1C
M2Q?U'_3Z?M#5Y/JV^VKXAY[F0YU!TL`C2,+<<8WH4V4^:Y`\L$7%[)?_U`77
M0:6+$I`T6VC%*,)E.OC+B0UCCOXXAZN@&X"Z-FW`A7%XAM>/W1R:'/K!K<%\
MN3]..,!BTJ>USE86/FV0A0QUDT*>'F[U!"S;&ITWU7526@8`[JA:%9P8R_Q&
M6/#(1*AX*$9?2VK/C]K,8^%L'T-*03XOE&:>:L(OF36??CXVT_,:AYG[?$J&
M\HTP]HO,Q$T-\AFPU4S3F0J=MN,82./BYTD]8>LU#1B$@FZ7,M\6.-[J2J^%
M`^E8^LC^TMX.COHEITNW$W@DSQ=]T<5Q$D.%H%:0G(;HNRQF!_#7AZ;5)S8Q
M/1]PU`['[K"T'S)3,]F&:&=]`2P`E!P`"8^#'8*U&DELK+B&B4B?37+AHW5>
MB#F;-,;=A!0ZQN[-:?T(;?UP'.H'"&`LX/]BXO<6XSI0M4V6^2&]4\Q8/!63
MGB_A]8ZMD/`%Z66<^G8T-Y]1>B,&*_M^#D4VR+:M>9V*9X5CY2Y!S$28LV.E
M&XE0\W&8&&7"8.E!M^?UK\7]"_=TK7<LC.41]S2/XC/N#@7BL/IH2ES]W1U$
M8L-:Y6B>*T_,NHE%D<5GSD++AV>L?+T>?0L9\A[RB/U>[QJKC-&4OATQ/H]:
M9]M=06FIKQQDRN,JEVI.F*N[.Y.KG\$.Q,/WF!QBW/&.;LL,@>B=W):VV&,*
MV&UO<B8_"[R>EHM<>$;6TW*1%WX7C-54&"&G!9.7T`?SB`OQ.R9.(+5<;I<>
M`Q7A1+]Y##2A+:((DT!YZ'"R/'HR!=S1H1_]B7OG!>KB'!KRCXYK'K6MUD`!
M+CVUZZ(`+V.QL#R4W_)\1@$<!0:S[_1=,[D.ZDJ64(9#6M$22A7Q3!4+%67)
MO1L^[3MBTH:CT9VI.![Q09K3JL(*VJID.);@D\K,/^E@ZQAQU/C4'\$G]SC.
M_83XZ^L;6-+!*LJOZ\N9T@,$7=C6F4]\/+4%AZ3'PUQK6(%_X>M%>50O$G2N
M>IEVUMD`853)-7[(UX,O'9D38#6.?=U4ON;R.K<F]K8R-A77N=H:-S]7D`/W
MM2,I0^Z0R=G'K6>.('6W^7K66.01AYDJ0D;!N0I>Z=>HK5'&!NS67*U>50XS
M@'H23K^C&V[CVRWY@'4CJUESQWU?[4Q-;86SI<('W2P*NMD<=)OQ'].".:MW
MF\>S3LO<%UH>+\UB^88`+\6:SU;XVZ\@?9Z'1P=9R,5R5KQHGB^O]&[S]2RK
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MC,W8IH3(,)2"3\H4IB0)%_3PZ&*A<3QB&+0%*R!?-%B*J6&`.H@-EBR?AF::
M('9'/P6AX@F._"ZRMQ5TADIO[&'(D"LY.Z?(PKNY;/70MSM3<'0=4;#<IJL'
M79G)-5NG.$X/_6"2D.YH>`7J7Q'7Y5Z:`013$0OR_L;'"=YXCT$99MZ9S^NX
M]XQR0R7;")';4-SGX2?OK=B;`SWO"OSN,E2"(/]'/Y,/N\=F-#5,Q#VXR4[?
M-5V868VE`>")+SL`7X-R6>5Y.11%X5.[+(N4P8?_&$^US7V#;Y3`DE,U3$W=
M'+`(\?HIQB,1Y]=.YV3VU=Q>0GV:^3VME,Y%[O`@^0I"4,+7.53(\PL7F[S>
M,;JLWQLR#P6\Y/+R%[;DRQ%@QE[<D.9N?I_%QGSSUKP&XZ>Y$K("^R(*T:/6
M`PTS7]/0U/.\-6JM'8>^K+?V_`'TJMW.3JX!T2^/U/[%IK>;RU!0M?ATAY^P
M<(BZ#BI2[MON7`9#*)T.?-:#F05'`O[2-?;)`'QEAVM0`)61B6_))\Q"SK\%
M9!W039@G"X"GH;E_,*<*2*%1]Y'M/:;4.'9O7H%`;&)]BC$K\$]]ML!H<(>%
MRT1/]=M`%[X#PJ`7N+/*Z#.ZM/-6Q45$/)NEG&>&[/?.96;L`3."V[89'U8!
M@-(WH?!I0L][/H<"AXBB^[YJ1Y-F[O7Y1).9AB^9('F9$6ZH"-N9-V#!@AR?
ML,,%[)4%"F?34@NDS%ER@9#@UU,+.+J]U`(FBCRY@`J1WB+#I]P3"U0I9)(+
M58@T%_CJLB212H$+3RZ06/U*+1"8^J46<`&91FH!XT6:"RJR-)$95RJU0)9<
MI!<4/$TDZ%.97J"82B^03"6YD`*?HTLMX$PD]4%2R'V3"S*<4DHL$"5CZ04%
M+9-;B!R3AM0"A2\!22V0/*U10KQQ%H(SF=X",K,TFY33I$Z*#,+OU`)>LK2@
MP&^H))L<))E>`"J7)1=(?*0QM0`BF"2;^#:$]!T8)*')!52\00-D6$D:6/D&
M@+#B#9QDN>!)?6"`8ND%\JT%`N=Q4@LX3RLM8_B,9VH!52PI:I;A"X<2"VA9
MJN068-MI+B`72A\6S=^P+*JX3'*!0\I)05&9I7T6-4_6I18`V*?EP#*1EB3-
M:)J&+$N#>9FE0Y@B*](Q$&9D2:>9CE\D?0-D,=I/VG7:)[.L2&M2EK^^_\_S
MDCEXH?Q"N%K"(?APE;Z(U3,5S0C;.K5Y7,5UC>S;2N\@!.\FS#5.HE1[FQ__
M@+=\PNCYCTC05B))!?QGRV_^U_;ZZHLC.B]?)UG%))\5VP#BPH2'=`7$E\TZ
M$S#9+?+_9X$2\$<I]\:,PKR#!6N'WR^W!;X70/V:L;C?LH6*M@@O?F#T/,](
MF_A-F=;O&_H&5MZP,D]:X`W'M^6E%H@R[;=N9)DGC>P&4X3D@AP?9D\M*/"%
M0$DYR03:@J0__>WZZOKJ7Y5QJ`D-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*
M,38S(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,38T(#`@4B!=#0HO365D:6%"
M;W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C
M97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P
M(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W
M(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-
M"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B])
M;6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C$V-"`P
M(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0W.34-
M"CX^#0IS=')E86T-"GB<O5Q9<^-&DGY7A/X#'OS@W:"TJ!.H>6M?$^N(B9GM
MUEP1?H%(4,0T",@`*;7\ZS>S3I`$BR*;Z'#8AH!"5=[Y95:!/_SK]N;WVYOT
M7BJ1I/B/OLKO!3?_F:]O;XA^0A(J$R+U'9KDV;U2-$_R-$U4SI*NO+WY9]+H
MJ3(N<!Z1Y_B_I'NZO5G=WBS_&V?"?P8WTGO.&<Q_SYE@\#^F*-U]KKC`YXIE
M^#S/)1N?D"9WN11`&$D3&,6E)FFIV=//N'_&9"#WAX?;F__YI7B<`V\L>8#Q
M6@IZ2L<WH0E).4\>UD@029E*'N:W-W=`KL#KU]N;[Q]694+3E"0__[ZM-F_)
MW^JB25Z+/BG69;,H%TG1+&#5?E-LX(]RN2SGF^JE3&!$NTQ^+9IMT;TE9(:3
MB.3Q+=G`A#^VZ^>B>?NOY.$_MS<_`Z7_=PUV!"6!'ZY9^?XW2NG5EQ%#L:4P
MA1>;!"UJL?7)#VW1+5`&/U4=R*3M0"!-\N&YJVHK#JEE5SP_=^T+R.[*9&KE
MTLQ220E8HZ622[Q&*B=5!P$/\A1,IPY0Q9!1(G+J&:4I<>KH-^W\\ZJM%R4H
MHMAHOK4./C1@HG7RE[+<5,T3*NS3<&C5)+]N&SMVTR:_I2(MX#_@G.5B.R_U
M1,UV_5AV^&Z_*L`9\&K>KM>@<+WN)+J%5ZT%*I$'QY72L%R\%%5=/-9ELFR[
MI.K[;=$`N5MPVDX3_8R>#!SQ&<]R^%<XXI==NT[$C`@ZXSQS=Y'Q1\TXO#-O
M&YAUG<S+;E.`B-"$J[YJ&\WZ<':\[DJ('5T)`6.CGU]?&DJQ,7?DN17&)XQ*
MH`V>J@^.PO]M-F77@.H_EB]ELT4W6)3XD*A<SI(0XF;:3Y'_N>._:N9=6?1&
M^^OB2[7>KI.Z6E<0!G&=8`F;%1C;NGA+'LNDWS[^!PC!"8I7B`[]%)+(I#>+
MX`E,9#:>/W5%@Y'ZT`X@`D"$*H&W1?52+=`IT'+P]K+JY_#G6UETR6+;H9_@
MFR"_];Z^R0P\99:"[P^MB>S<NT\^:#OXJ9R7VG$F$(-0/JWE(L1G9<7`;`B>
M(?%=F;SB?^A,"3E3A%BO;9\WQJ2W&\AO(!;@&TV!S$0*8WF:[#J9ENV>9.^3
M!RLI[QICTYJ7)I`#O&TS`!T$Q@RO40Y>=4#Z4PE&NGDMRP84CBD<6-W`'ZCV
M_OX2VO(X;0`(+&V9]!%,4+Q&VG3(U<$X^:L6F08?UY=1C@L:EQ$A2S+&68!`
M/[T5BVKN8@824]0S^'-^GXR3J>,%2O?*]#+*/<'2)U5V[558ZE>YPZ":94XN
M1%(VT,]TFH'L/<(IO_HJTJ^BZ#U'J/OP!ZZ%H?[:BS$VL#::$V]M8'@6JFAL
MO8`8`4%Z6KBL@NE/B):5'#H834-V3B6/@.7*@66/E"?P?%"QU46J`CX6RNK"
M8W-0Q%<"R`F(9[YR$\*G.$XR'MS39)_G;??<]J7+/_M^"^`0,W=7:BBG:Y+-
MIBL`J'PNWP"[-,63QFZSI%P_U^U;6?:SI`&H8/]*%EYI^#)@PWY;0V(#L`=R
MT]!0Y[@)1$`\["=YP,!YFKGLAFP_@QHPW[Y6FU52($%@5\`LU*45QG,H7E%+
M`T\S8@,$_UPVO4%T".>KS0:X?:WJ&CQT7355O[&9_D"D*`A$?0823%4$8)/"
M\I^ID-UY:F&O11JSY'55S5<.A@)X!6UBAM^#.1UJ]7<PYFI9@='O/M5`=M'"
MD(V63/UF!.JA-:519'T_`?]9[F$_YR&N<`OR_NZ1V+Y^`/S-LEV<NE^RK8H7
MQ$.`?^!IV6$4&!92!QAV%%$*L\)$ZL^DP_I$%T!._8KMJ/\`O]*95(:R<_#K
M:?CJP20&E*\"CKHA-\YW!K#`,?[]%$*ERA=0?-`0R_.`!C\,>E\?7>_KH$NF
M\?-H<`#+Z-LUY(LU&-Z\K6O3-`.7ZLIEV74P&Q9D?3(!@)0`>!R/TP%(R8:2
M)(RR$)T=?K2R^G$89E$^_95IR:#V/>3XVD`R@S+3K0)`DJ4(F1%(3A+XB"OK
M2#[P?.8\_P.D*.>GAQ7_4<$;RX1@5\VO#5@@*7NJ=W#VW=47XD/Q,)\7>,JM
M"S\6O77>S=MS-2]J<+P71`&`]3I`",MVVYEF!T"'JETDY9=Y^;S1,5+*;"8`
MQCOI7E^WN$]A`Q`3'I12C55U@:!S.6H*J,,N'*:C:Y/!`AV3:HO`"X%ADM+0
MJ\$^^YZZM)+,G]OGUD"V8KZJ`&8@0-4YW'8D'\MFOEH7W>?#;M-HIF9LQL!C
MIQ-IIN0W$BFH+O,%5RY"#F-"#26Z@^RT$,HO93>O>@T(3*.+"C43$%4F"@J0
MY1VMTP8%``U!*"2388M`OELDUT8R8J"IBY',L<EQ;F'G_HWR]-K3RS#]%#&0
MN\*<R#0+M:TK[!Y"K09SS]NGIOH#U`?ER[5IR0(QTWHMV&3@FN7"YRW)A*WH
MYT6_,N7*E1>GD-"^"9>490,N*0\-,*Y<`\QXXD[Q77[!:[N3M>DGD0&'X/A-
M9,!E$#;V5K$IZ)(\VT4H9I,(<I=N1'VIUE!H`%;Y+LMS4[Y!C/XNR_0URF:"
M<@&=D?I&$Y$!Q_N];EWF):8B.DBRIN!,4S'#.OK9%3JZK`2-SD&33U`$K0KT
MWJ0"EYYODK:9LN\I`DL3]CV%'`@.%.O;4SQWI60/4SZW'8)S[=K+NGT%N/+0
M;HIZ@EB6T=R3-*F%9VQH--\XEF6Y^C9<HF>DOO^8#4(9S]7)4*;;_'7=SG7O
MH%BW=D]UV<+-5^RIN)$XXJGMJK+_TP0@0>395X.$B(2XW^,C5(36?YZ)_1;=
MNEV8MB-$.A<GDG6Y6;5Z8V`#56Q?:1&:0O;3+Q\^P0H,]]D^XF;-;!@SL`6%
MG4I[]&!A&MRZ4Z,SR#/4=;Z\6U8-`/X*G$X/,.<4KB\+'0.,+'@>VI4JMRZA
M25QB+\CJWFXG3.$E1`9ZIO42*8>,ZPUXUZW@V5$W"<V*IGQ-=)\1<J'.&B"C
MMBMG]F0);C7T/OGIHOUH)@(XCS8Q@68S!VE2%30+<-7&`62MZ'1998_$&/M#
M<J=H#[&P-:0".9P?@N<5A*%%B>W=J@&AH6M</_%00CQ)T\)+(@:\?VL0G=%O
MQ"64"H'+5`XP&>/T9.8Y$C[?Z4.]S5#73T9Y&JQDBG*8$3YE.>RGOXCT^$D9
MJOPYSD$6%<+AC'\4]=8?/!L>1;DXC47D2+.O1PP1.?KI)XB+5/HSDYDR@/S[
M3U/4DF&IB4O)`4N4I2&WYNEQ"-J5M0:=D(IVMWBKG5RP[=TY/[RHW<:?J46+
M^6J0HW^HB_GGJ^]3\6\C1`EE49`B&1Z3D\2='YVOVAK*U!?O:`!7R]ILCDY@
MI]SM:Q/&0T=<N?[MLJ@Z38L^T^'4-]3=D1A?X:%6J#AUMPST[W*"WOA`36*'
M'=5ND+$_LJCGJ]\T('5G"I[*INSTWHG?+^DO!C.Q>$/9I/'&33^%'E._09_Q
M`>X-.&Q7DT-W=-V?=Z5EK"91<VOMV+9]LL!B!V:UV_K>G8N^WZZ=RS<3-8U(
M'@[@!GPB;,LH5+D;W5G7?H3&.$?Z7UH(4%6->Y2:/K!:[6YHOK9/;\B&)QNH
MC/%L\N`=:[,3=8\`;3G>)NP>R6PHP<%!0>X/"MIO&HSLNJJ_>@`&Q.QHF#8`
MBWS`+$TS;R^"*-LJ6W9E&4YK=;J,=\8P@?%F-'0M0J6>NQK"FM_?[S^!]/%#
M@&WWEKQ590V9=MN](*7V4RAW4A"/>CB/QCK4;LK/@CV#ZVZ[:E-!EK$[O*'G
MJZ?P[E%7RW+O,,Y4B8@(W[Z101"<9M:/8S3Y@P?5,#:%,#1P7KO)AN>M5L4+
M5L8PE3]LN!<=]-<))7YUIB53?"XQC.%YF?F\W393U/>$^0:&"ONIG+M\K*/J
M8U_B!S;8K<?".G#W7+R9EI([$'1PVO7:NYWH4&SJD[U,[@A&2#&P#W^R%WVV
MT?EL<,2T!I4770.6`#BBT@*;Z42WW((3H`4!LC!&A#(#U6/SKVVN#B_PNP/'
MPQX`P%,V"D^`92I-S'>@X7W]B2:>/Y3$#*!'!F0RS:,#I(#:+C9`",FC`[C@
M\268T+P<'T!Y%E^"<$C<L0$ISZ)<2,7C7,B<YU$B9<:S^`#)6507$,!DE`O)
M.4NC`Q@G<2X`N,>))$R1Z(`4>XF1`4*Q.)$BQ\,.L0$95?$!DJHH%T)0$2>2
M4QFU!T'!YJ(#H&R1T0$IY=$!7%$270(,3L0'9(Q&V01[BEL4N$U<%YS3/+X$
MHS+.)F4\:I.<,!IG,V5Q03%%591-EM.X'%A&\71D9("D(NJ\3-`XFR`%'I^!
M<1JG@?(3-!!.XS2D)P((52?B),VYC-H#9-9X?*#RU`#!69P&SN-&2QG+HAF'
M`A%145,"@3`Z(%5Y?(F4QKD@BL:51?(3GD4RED6Y(.#^44'AV:5H("4BS>,S
M\#0N:L*P7(H-H"F/TT#2>##'+\VC-"C<YXH\S[&XB\.+Z/R2Q*.+P"KE1`2,
M^W4:=PCL8$0%%-'1[W:(335D\(LB'J"J!&MZ"U#)0?&1AN8D(CD$V7JCT7V0
MH/<5H9KXL=58>_?XO)GFXY]QRE?$R[\B0??X$Q8BA_^9XM[_6=_>?')$(_#D
MH!J`N&>?*I"1HX<<^,&Y01;G3FU>C<T-WJ#GAFH$LMKAY%FDFYYG?G(E[H4^
M6?^'^>@UE7:O^M_8AOMYOPVW3X:$F@+)D&=S:-X\QF'X61@M"4Y0?QIP$52=
MOM)*-(_UY6IHB'CO4IUR=9HJ%+^ARA'HB6'Z4@]@NW2YYZ`9R#SG&P0_)JXP
M'HEWA%D:=ZDQ`_8)L\\S>;XQ05DGN-NV,Z6Q_B3SB.0`=#L"':V[5)D!>P2Z
MYQ>XDGGUV%9>&*\-TA(FO:4-J#$#]@FSSR^0G,CEJ.3$$<E!V>8(=+3N4F4&
M[!'HGE_HH<<%=Y_K7W5BS$5R7>T,G6[IG='='Y-0O",EJ/^9#^H;4M3]R,>?
MS=:,^9;7?JF*#967,DZK]B9*!^:T#`ZZ<_\\![7$OD-:VN-@);E'0+A]IJS,
MF_+PLZSO3A&B](I9ND])N'\F*8*DXZ0(1?$(;YP@[:\CNCF\?UX(>+]NM$\?
MZF9P^UR!2'J1;C`_CNEF>/],4F0JCN@F/ZT:'1$.!7-P^[P0<U0Q(?3I/@@;
MCRWN_@6QQ9]JI>E@XTFXC:>/90\@"'<H(+PLRI>R;I^QP1U#*BD;#RKI1;G+
MO'HL!._!D92-1I/TDMAOWGS/PDJO,!H][/VSHX?T2^]8:*[T^?]CN(*K4>D?
MWC\O;+Q#"-J]#Z5_</O]"TOZSH7S4>D/[U\2'\:D3]1!?!A`$Y:/2>#@]GF!
MX:@$QK`'GC0>BP_^_OGQ@?OCO"P+G]=*ZLXU_-CV^E/,IQ9/D/1MO3B-.I"<
ML0"Q>_^L`.'(?"?JP)5&XL3.[;/BQ%GK*[W06+AP]R\(%SP<\`X&R]Z)-<8T
M<GC_K*!QAD30U4<T<G#[K-AQUOKYJ$:&]\\-(2P=:F1PGN+@0,4[5HE%",]G
M<AJWC`CYX/9EBY]H7F"C>VVW45SS@DO?O+"7!S^':T>-AC1W_X*0)I7_'H^$
M\R<4MT[L#TC6M?OY%/RJ7/_64P1U6.X<H[M,F0'C_+EAH\%PY_YYP5`>:]Z$
M\3K:2-\C<73K2]N\4>[RD&X[3":4[(=0>2G4XO)T?T('%D>U"E1[4LV`8U2;
M9^!H>V3[^Q<%7CF"%#(100HZ/$G?_K%<F$OA&B[';,8-&PW7E]F,>?6TS>A(
M)7UWR-&M+VW;*C\J?3=LSV;"[8N"_#ML1L<I1W4>J/:DF@''J,Y';69P_Z+4
M$&SF9&J(KQ*-SG+T=/UN-\V*QDG)RT.X;MHQ0W3#QA+*\/:9)!\UPU$D":_8
MO`)7-J]PZD.PN?0_PSZ"F/EXMV[O_CFM<\[/:H!9%APWGO+4QV-S>8P)-QK[
MZ60_A]C[%_39.1?ORR&6?,O)+LUZP"[YNR^')CT/37JG0#T@JD`W>@S*\TL;
MB$Y_L2;5;D)R(E!!!)YO/>"(",RSD,TXV>/;##@A`C-DM)K@%[<N1X5@?XG@
M'6#>2,0)9Y<3/2#.E!L]FN/XQ>W/B&?NYCA+OO1AQ="<^L1Q3*'Z64B08?O$
M\YZ?Y-V.'BN&+K)I\^89-JWCL!-!'D3@^=8#CHC`/`O9EI,]OLV`$R+(1VUZ
M>/^"ELZX36?O:/EB%C0"<;+9940/B//D1H]E2WYIV_BX0=N3"/9(V^A!!#D\
MB+`7!D%:)/R>A7#'BL<72<W1FW-5PA0>1+`ELKS/.7[LB"KYY8J+\)2&1:+?
M-7S5(G*X2#"NO6/8>'PF>GCE3K'HX9@[XLXH'QM`5?Q\SQU3\0."=UR)Z`&:
M.Z'B)\;N9$ZC9ZWNLBQ^O.\NUQL[1P:`('_^U^W-[<W_`\S]DO0-"F5N9'-T
M<F5A;0T*#0IE;F1O8FH-"@T*,38U(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@
M,38V(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y
M-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B
M8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO
M1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B])
M;6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^
M/@T*96YD;V)J#0H-"C$V-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C
M;V1E#0HO3&5N9W1H(#<P,C<-"CX^#0IS=')E86T-"GB<O5U+D^2VD;Y/Q/P'
M'G30;O34XD6`V)LL2PYO;(2U\H0?$;Z4NCDSM>[I'E75:"3_^DT\"9()D$!W
M;SADE1))YA.9'T"0_;N_O7[U\^M7Y"!UWQ'S/_MK./3"_=_MQ]>OJ!VA'9,=
ME9;".JX.6K.A&PB,$,Z[\_CZU5^[!WLO)7ISHWX8S+^Z\_O7KSZ\?O7NW\VM
MS/\2`CD(P4'`0?">P[^X9FP^KD5OQC579GP8),=OR+HW2DK=#91TP"6D5>F=
MM<^.]7&,RTG=W[U]_>H_OC_^=&N->PO\U@WVEL%PRKI!D^XM6/[U/Y@@_]:]
M_=_7K[Z#*__G66XOI]MW+?<>.LH+JH/CS+W)@<JA[][>OG[UAAQZ0H?N[1<0
M^?WC^=UXNGX^C]V/Q^O8O7L\=W_Z=#T]/ER:M)%E;>`:KXW60]!&2,*<-F\_
MC-VWCQ\_'1]^ZTX7N/W/GT_G\:Z[/G;CY7KZZ#7T&E^ZX[6[PB4P,G:/[[KW
MY^/#M3L^W,&5OYPN,/#A$?X_7'KI3@_=Y?-/%[CM"(R?QO/I\>[2/3YTQ^[V
M\\?/]\?KZ9>Q^^EX.5E><^\7<`+5P0F"J.`$KLUOXP2GEA4>-+]+K.[.Q@NW
M'XX/[\$B$Z_C_7UW^7`\C\^L*R=#5%:S@R"$=F__!1J^>6Y!<Z_`/`Z9P;5V
M3H&8@!>.7X[GN\NA2_/D%E+U=#>:-#E=+]V'T^7Z>#[='N^[\5?CRO'AUB;'
MH\WJ>?I<7BK$)J&=,83$/.>2JF@-9!AD]?%\-AD'>6QTG\)]_&4\']^/:Z5=
M],&<_A]$]*8>@8W=;^/Q;%/!F&/_8WRX@]O\?KP=/_XTG@T?IS<=(T1.*7-]
MO/UGD!`\^\S539E+O3/:RENY,JN!/:TREZLG7.[CR(2(6=GW2K@X?@?UZ?J;
M3<7QX7*TGOSA_@BU\QOKS^Z;6Z@HAN4%3!?]2S:E>/L7F!X*L(.?'FQJ`UQI
MWY3^^``Y^M&Y\\OI^@$$7#Z-MU<S8Z[3U']FQ1@G43-AE0+7,O;L4D1JOS*,
MOM@Q\]O8?^GRB66ZF^US%U,%9']#`(0]^HX-_GEX?!@_?KI__&V$`O<).LGY
M9;VF^O[_P6NFCDQ>T\(Y[>N7P"B*TMB>U=2)&/.=Z'CG2R:X'VKR!RB_\,LX
M.!^TD^TU[Q[O[Q^_7/[S!8J!U/0EBT&\_0OX6Q`1BP%GL1A8J!@PX9?Q]/Y#
MVA<=TKNS>/!X.G>_'.\_)UW^XAC@@KO/Y]/#^UQ?[&)3_`+Q^8H=%#.HT*$I
M!S.NCU>`$J>'*]SG<KKUDI[?#7Q0W@TD@0RL)[XF)K:-OX[GV]-ET[I9U[<&
M#HS<<#'<=%`5P%I!$VM?P*2>!),4+!]#9+GI+,:D;X\74]IO1X!`@'#/CQ\#
M&@D67JHMI-8^0=@<)'Z`L6/W,%Y!`F30U=SS_O%RZ6X!@?T&W<:T:S-'7\`+
M/*[`R%1/>*]T#"QJCBGTIKJ,H-UX`W4=O'([@LK7XZ_=3^/#^,Y`1@OZ@`!>
M^7SKTN,\WEL,Z<M^"O,N,),,AAQO']\_G/XUWK5&/5<KI"31X)<H%DS'!20?
M8DI!"?$+R&^Z=Y_/MB;?C=?CZ3Z4YF#^X^?KY0J>-?$_V@ZZ+@50K"^0*.!9
M0![9LFU1OH:"I6#U[G9`)HWMYH09,BM;P\`R#$,/E;7$H/J!%!ED+U21H>]Y
M600@V[[(`!.V+(()"&6)@<(2O\A`1-D*J84L*BD'T9<9%+3P(H,4HF@%>!I2
ML\0`R]6R%5S0LI*,P]*BQ$!Y7V:``E)4LM><E!D&ILH,BJFB%;VT(+?`T$-?
M*S)P"\8+#(Q1762@!K"5&`A,]A*#T%"-BPP#)T4S!<R<8D8)N1$+T3-9%B&8
M*)HI.&?%G!2,T[*9E&\XBC!5-).#)\L,`Y-#D0%*3''R<LG*9L*TX>4["$'*
M.@!'^0[,;.>5&.A&`8%\*M=)IH4HY@.#,EAF4%L,4K"R#KTH)ZWI!L6.PR!:
M15<SUNMBPL#D5V41,/W+5L#T+P:+ZHV910?>%ZV@,/V+CJ**E'L6E426[]"3
MLJNI('W1DS"Y65D'1LK%G%)2QC"4$%V<.)JJXOA`-Q`,W6C<@!7+O:+<E071
MQ5SB9"AGZU:0B,KK][-G\1",)@_;(F;6G=FS\)B9+C$S)3*LPRBT10N:84FF
M![^R?'O\Z=ZNG;]]A"7SP_4RP[GN-C_^P=SRBX'P_V44.O1&I0'^Y9X-Q/^\
M?_WJSY/2=(`>-\!<JM[0H(05=G;%0-S==?6]W:7EFVMW<T"<5"%W5_DEBH"I
M$.^N*:S?I;+/3,#A/"Q2_FX6LM^9A>Q2=`^UV8J&>-8:YJ[-&C8]*S4>T`,S
MD3.3#W[=^U_2_'+#]N>'-`4-K3&8.OO\--5*!ZV"@E$9X7[J\'/2*XQK:&SU
M>:#]:G*MU\1OW!KUTI->41G'L-++C4,*0?6L3"$31^)VW[4ZR*%W*?1U7*IB
M&=LL376V$MCZ`$@M[E``#O`[%&%EG(E<#V*]AX*SYFYQ#`L/A?'&3`\Z(Z$[
M#/;$`.>A%$("0AM-<O==S.E`SR1/82="2Q6W=5@_;>LPO[GUC=^I_/%T^><R
M7D^0;'+=2RX_DGV*C"&UCI-D4S8\J/_^/([='Z%=G,?+U9X<:)"?K1C#Y-[%
M)M(JN'8:@QP]C^V*7%<7@O#MY+)3#P3U2_D+<H5\725?"RL(6OQ<@81>&?X>
M;I[D&"?*UQ]Q4+2LC9V9('6:U.^FR>[IM=KT(LU&@/WN&1,1?:8>F<R#51(Z
MWP.]8;X+5W#>&.BDX@8][9F?$K\__7*Z&Q_NNK^?QON[4N\5`DW7E%R7KB)7
M"Q?M%21@>9J2Z_)TCV"3B"`!35!/KTT)$!M$SQ(TIX/-(2'PM/3TEK04PV9:
MHMT(>@2:G8'>D)TLG)XA9@\R/#T:M)IWH[\\FC-.]^8QY??'V^OC>4=U!:VP
M=$W)=>GJ==U;74$0EK4IN2YK*^2;)`5!:/)Z>G7R3M&:):_B.VHKR$23V--;
MDCAFSM[:2B2>O8'>D+UT>E!(1$0;C(AY]KJ#B=U_G]Z-I?H*BF`)FY+K$I;N
M7+Z`!"Q34W)=INX1;%(1)*`IZNFU:0%KJ2!:BX.6$%63HJ;U#=+'I._^?KZ4
MZBW(1E-U1J_#_#O<P2&)S2.SC_Y9!O&+V]ZM/]RP6"UN#8WW]>EA+]UN@AQN
M[[4*"D9E[&K),;"Y7F$<`M6S.KW,I9)FZUSD-_O-03&OXUP;Q[!4S(\K6;]!
M0HS'PD-<4,PMG;[^LSF#D,LGH7C0,B@\5\TQ++0,XZ!+]>2SE^[8'!`Z*N9U
MG&OC&):*^7%PW]!7N@\DR%Y,2%1,Q\?,%J&=FD9A\T_WUW!L9K5A\!0-ADYR
M%78GN%G#V_X5BO2SRE*=9+$WD,'![J^_\\=#GE66-K4R'-5@K/>'V7XXGVZ?
MV2B>S`#*Y'0R1DE_YNF'\=S]>76B.]UR82'O0@K.D\TQ+/(NC#=,"'?I]H20
M?(B*R5A_$VT<PU(Q/P[>[&F=-WM3Z&**4(NF3-B^>?_^/+Y']B6>)$LD*4+"
M:1[KCS_&`V+/*=#661EFNX=G?S$GT#*)(45L-"$4<Z<[AH7_P[BLS@MW938O
MD,5/+VG::2-\C/1Z^-C'4]J$\KA_R23W^Y=_2@_]7%<G?C86;+8+@W+3K'DW
M=><9O:H[!Z5W>,VV6Y`D%PHLR?OEVROWR]?$"E(+B)G2*Z,FDK#-5D'T1DIV
M`Z';6)A)@@9E3:_K^?N=8CO`.B@)N=8E]DK$)5]M*:+1Z*3TZ@7`@*O"#W)K
M!U!H-#!K>EWOV1\86V_7@4G(M=Z0F5S="$PO!S0P*;U2%<E)JDJR_;_:_]\A
MI5C4)?KZQ\I(Q[OR]HK<)KRPI#(%1#"\E01Z0RL1,K:2P??;/[BCY*4%IV!X
M>Q!-8,M=FFNJBU6E8&A?$"W=W%VY0[`I_.8P%-80/+VE(7C1BX:@*/RS>*,D
M61M*@OI_3:_K!#O<8"OVVO\K\G[!]LH]@C7J_Y3>4O(Q_XMER4]6(4*CKE_3
MZVK]#@_8FKQV_8J\7[!D.P4/J.M3>DM1GUR_6=3+4HIU-1C8Y98/?,#<NB*W
M2=VW/F`<+^J!WE#46=RNZ`5W>YEQ#^%N!_H'T6AYG]'KRCO;_837%F60A%7Y
ME%Q7Y2ODFZ(.@M!B[^G5Q5Y-08%B0R5W0?D'Z0GG^D;W9.NYOR1H7-;TNK(?
MM)(',7`5M:([%P3K.*W(==U@?YQL\4?BE-);F@)#3P(0MF,=@,1G3:_K#?O]
M82OZ.AXK<EV+J)$_H/%(Z2V=@F&G?_!.T2IEBOKZ':X=-\XV`T%S-\;7%>OH
MK<AUG2@;O?FZ@@B\!05Z0PLB0WB<IGH96]`G\W63TL(")**=9T:OZSQDY^,J
M$(&UG)1<UW+V"#8]Q;Q4@_4:3Z_M-9`MT?NFUZBIJA/*;GJ21=F2H`%(Z;7*
MV$N']00V+::TRE@'8T6NZRL[@F$;!Q*,E-[24`AR<D<<^BSB%AH-PYI>UTEV
M>,!6_+7K5^2Z%K)+\("Z/J6W]`XL]3*]HU7*%.!,[RC?N-@[\!LOEB_K>*W(
M=4TC&R]TL6`>[[G#!^;7O?^EPO-^_S-^X&R]`#(<29>)W6=!K_K$@@Z?M("H
M^^>:WQX?;L?[^\WU#U1N;U*P+EK2A[,"_F?.J,"-=;(YO:J3F1,R6\\C3>,(
MZGM+YCH[AK+ZGAOIAC-R53?<H[SI%D%Y;\=<8\=05MYS8QTUT!LZ:E!_U5$E
M,1^DV5XI>;N"B7-C'$/1KL"-->=`;VC.B5V%YIR$"'IA,,5;-=??,91-\=Q(
M@V_++W?E=GZ9-AB5UY/R46/'L*&\1O,KI3>`A#2_4I`@MM=\WJ)@W-P,QU"T
M*'!C>*.Q6KE+=P1$#E%]&1M(HK-C**OON1',TI9-[LIMY4VOC,H/D_)18\>P
MH?R`9E-*;\`]Z*S&<<^&E!)0B$[:6MJ*V%*#S^;><0Q%1P5N!.FT17EFP,;Y
M2E,H/<21X7RED/%\I?^Y^D:KY\)6UI'>@&UD.(3?=/@C]U*;[=$RGMCTAKJ?
M\<2F_[FR-+"!WHPN`8^GDP;`DW\M:`YX9#S0&?2>E'4,J=[+BR>T)">TY,-K
M&?#P!C8,)LG638,0W4V8Y$WVUL_M=`RXR6YLPEB2+^QT#!F3/1L*KF3;=D62
MTK/FQVZTI#>:EK8)O!>"0^;:.P;<D,"&HBG9M,9VE^Z(G@$*,AZA#7K;GRSB
MD5ST[-@$OR1?6.H8,D9[-@QW.7+#"1XT=E^5`%BP74^V1X,=`VZ[&YO0F^0+
M@QU#SG:-9FY*;X%MF/7B0',/[RVVD/$<JW=`HKACP&T(;"A0:TM:=^EVTEJD
M(.,QUZ"W_<DB[,D%SHY-*$_RA:6.(6.T9\/@75/2NBLKDM8BA6#[,-D>#78,
MN.UN;`*)DB\,=@PYVP<T:5-ZK?6:X-;W-X/N;X3(E5N+T60\:.N]D&CO&'!#
M`AN&WII:I;NR;I^*JP#BN`H@3M"(<MS/TCZ5P`_R1GH#EA/QJP=4"A5>.J+Q
M6XG^H;W]8,DFF,,W<IS9P0/!6D"+`>FXG\6]+&!!H9VGMT`[(?9!.Z^^MV2N
MLV/0Z,2S8V+"A6+"A3[HEJ$8],"-(3S1>@Y99#]CO0!IWG+OA+FYC@&WW(Z)
M"1X*LC#7,90M]]PHT!/-)Z!COL\/O#$-8$_MV41S/@GNF=MB&<IF!6X4]LWH
M=;!O3T@-T/#J>TN"SCZDEB$34C,F)LPHR,)@QU"VW7-CZ$^TGM]&`UI$?\$%
M>G)!M-LQX"ZP8V*"CH(L['8,&R[0:%:G]!80B#F!'^3&>Q86B#AW!,_,S;`,
M98L"-PH)VQ+:7;J=T!:$>/5E;*KNIXX@)Q=-,R8F/"G(PF#'4+;=<V/(L"FA
MW945"6U12'#!,+D@VNT8<!?8,3'!2D$6=CN&#1<,:$*G]!:`B";T#1WT#1,;
M;^U;&.A\$MPSM\4RE,T*W!A<;.J[[LKMG&8#J##T'B=2MR5I?UDKW'#Z///G
M.,S,49/:[_Z`2HSE4.PSW#O[)'?'O0NOZ2D#@N,35A$_8,"T?U?^1_.W>LP7
M]N*+J_:MTMSKSDSWP>TA`G-O.X:%X\.X/?!:YQQS*6,[$*B,^1!TG&OC&):*
M^7'SB5?LZV0E@,@@(L6_<_+$>[,GW+N0$5`F8K:94\>*N:*1_<M:[:+LI3[[
MWB1_0R'=^,[M<9NO=;APALC.8^@8%N$,X_6?M+!79O]010+O.)WT&B:]HC*.
M8:67&P<AM:]DFQ48ZW5\J[X/+W^'%^B7\7J"+`'S+,@J?\'M20:9></VOZ3_
M%%E2QWEDG*>$>Z']ZQ_'C\?3@WGN\IS2!AIGEI'&D[\BYS_$93X/8_YZV[-*
MY>DD(UKY!#&?\LQ^M0)ZO4_CD-'SW'4,BS0.XPV/_<V5.Z97;_YJ8]!+37I%
M91S#2B_5G/*`Y:JFUU-D:;YS>CW)(%DWO9XDJX_3:]\W,)XBB\7)!?"%Q,]:
M*N*_:NF^AO$#]@W2)XCM60*@:/)!F-QC`_,-(9?!(9GG:>L8%AD<QAN.0)@K
M]\PL*(51+SGI%95Q#"N]9/!<+8;I>5_&1T^]=PD?;=V[]&$+D%J#CYXBRER:
MX"/:R]D$,GO)N313$8>'R,YCZ!B6X?3C+2=M]*XT,\NWH)>*,#Q1QC$L]?+C
M#1.T5T-=`7^"+,GIS@+^%(.@8%<5\"?)XG4%_$FR2',!?XI83>H*N-GT\!D<
MDGF>MHYAD<%AO&W#HS"SD*=;5$J[%[!\NA7IM4^WJ/F8/$$VT^@!$@3;C6B5
M)&:2RI^(;A>B<7/,GY73Z.;*AJ3LQHV:)&V=K+-;("#'_OF.)&YK>M762!2_
MG3EV-0Z2U$*!)7F_?-W7R#<?ZS:"Y")S4WIEJ#DL6-%0<RUNA%0;"DGG^L5W
M,5?DNDV$"H>819\Q?"E_0:Z0/U3)![QB#5UD1$JO?G)(,@$YR*W/)IDEXMH;
M*W+=FG._-^PB`9,?R;6^,%>B975#$<'1L*3TZN=_F9((-7CC8()=7ZS=LB+7
M+5CVA\5B9$R^;)8OJ^3[_K",1DJO_HA]9I(P*6_H]GL$&G7(DEP'[2L<HGI4
M_D2N=8?*P8\-10:*1R:AUQ[(IYDI"_-DHYE8&+=VRXI<APNS89D=7:="X8`P
MT*N/.\$_/<7<H"6*!UL%&3PX"=K`@\U"-&Y-QP\#"@<W!.7A((^"LN^!6M`F
M%(X#9_0Z'-CG5A"+9W?F;YDB`#`EUP'`'8(MP@,)*/+S]%KD1WL\J/2&#N1&
M9,^B6XPF%`KZ1/.3HSU.,.!,*!3MB9:%H[URCV`#YXQI&,SS]!:8AWF?'[*?
MY[=P;&W_BER'[W;8;W$8)E@U"U;[!`N..CZEMP`YW/&,9]2P@&MM_XI<A^!V
MV&^1%B98-@N6^P3[(HYBMC;'6\R&.5X1>2,6GX1-CX5KU`5+<AU8V^,"U:."
ME^3]@M6^6F_1%^;[A-Z"RO"DSSK>HJ>U_2MR'1S+VH]NT[$!1V6!WH+*.,->
M8N$:166M@@PJFP1MH+)F(1JWIA,'*1L$%5&9%[1KDP[DH.!L1J\#9SSWER_Q
M33KS%X@1C):2ZS#:?OD6DH$@%*IY>LLF'19I2<3J$T?X)IWY-`^"UU)R'5ZK
M<(A!6<9P!+:EY#K85B'?H#1C*(;>/+T%O:$!.0P;1T8MYEI[8T6N`W'[O6&A
M%R9?-<M75?(%1Z.1TEL@'5[6^XT]!PO$UMY8D>N0W7YO6#R&R9?-\F65?-\6
M4)S7%@V+\[!HT(%M?SW&HC/$(4MR'=RK<(CJ4?E+<AWJJY`_4#P@";T%_&6F
MQ\;W_BUD6WMC1:[#@%EO+/9X2'B'T?SR9],IC:>E:7JL?KZ;!T,)T)EPXYQ>
MAQLI\II`?]`,Q8VM@@QNI-A?`'A6(1JWIE,'RAL$%7$C1?_2P&)+S44Z!#T$
MF.AX`)UH--:!#46;,WH=VJ1\^[0\85%O;\)<6<>0T=NS81@U)==AU#U:RSBO
M@@%S51T#KG5@0Y&MI[<@6Z_W?%,`FD7/<QLR%@%Z,V1,FD1WQY`QP[-A>#@E
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M8L_`DOCJL+<A4=PQX#8$-FQ=UN1Y>V7>\]@N[R#\ZLS]P67S8PC0W?TJ?%YF
MP#?VY^3]"PWS1]=K]H>=[MZ*H+,,`-[]RFGO>4'F[!,Q"9G4KSAVO!=@4+;7
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ML$1Q/O#>F!E@1XNF>%YDH=>4L>;"'1G;4Q:UEE%K&2)'LT#`#L7EX?0NK3>7
M;@$!SXNL$!O-E;O,A:6,-S>"S<E(.YHQUPS%=>6@YD;:T;*YCA=;6K8E:L\H
MFJ@[OPEG5D?>$<XE,ROL:-D>QXNL,=O")_6N\`VA,WK]@ZXRK-ERX1M"9[3L
M:FZD'2V;ZWB1Q6E3?347UM17LZ+R=@^A&T[6VE'<;CL4U[:#FEMK1\MV.UYL
M>=N6MF9UBUF^_=$WLX1U/O#>F!E@1XNF>%YDE=N4L>;";,:Z!:@RWWLRSZ_Q
M.]-<"R*]>77=OYCKWLO-B>B%$U&[BH!E4^_?J9>'09@7W4T4OG\^$0*6.#WV
M-Z2>4X1,1"1KH<63'M:)W@IPW[J:;F3W05CW1IOW+0OC5)NO+148F!:BR,`U
M%+@2@]``N4H,_0"8IL0@E:1%!M7SO`[@I^_^]OK5ZU?_!U/:$?,-"F5N9'-T
M<F5A;0T*#0IE;F1O8FH-"@T*,38W(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@
M,38X(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT
M(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y
M-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B
M8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO
M1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B])
M;6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^
M/@T*96YD;V)J#0H-"C$V."`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C
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MG_KIUK;,/_P?3"13/U\-GO]6YJ/`3+0W5*(%"\!D>(V&^M"2>DW^6N3%[J%H
M"*<+PI)$+<AA4S0%><I:DNWW3?U;N<L.Q?:9O&.+A/)%`IX-7SS4AVQ+CD-T
MYT.C%][H3;&%KZ^`GE1U];5H\1_M6_T@(K.FIA?ZV_T@MI+UN*!>H4UJU?O^
MP6)_>EL:DW0Q)H5HZ$UI(Z,UY8GBLZ;)JL=B5U2'ECS"-2K\6*W`QF!9\NG7
M8WEX)M]7.1"47PORXS:KVB6YWY1M,)J_S+WA'M",P<SU5WA41IZ*\G$#!%,K
M%^#5R3NO%1,Q5*PR0;$24H]3;`:B9H\%V1=-6:\0]C,8%_*7]U.1ZN"G*:..
M![8TY+G(&G#'EJSK[;9^:O\R0[0SDG];L--1,;5QL0YD2XPRG9Q4<B\G39:8
M-G;EP4$WJS"-`$8!S%5>%NT,/$D?+10XDT@MSI`G+CQ/GW;[;?V,_)`/CTWA
MG&IZU6NNOSG/Q,1D'<H3!)53/$L[(;^O,/!3&_AMXLZJ9P*"0A98D;("_\\@
MG/>:R#I-D*?RL"$_9,TOY,.2?-IEVW76/)P\YT\M^;$IVG)EOX@6W93%&BJ"
M(C_:Z//?ZW69%\UR!L?227"L5*3!L8323NY[8+.7!6(H_,TQOE7DP[XIM\1E
M1/@_,@[JV)65365``$+G&\(32R$6Y.%X`/ZJX@D^7M<-:BQ;K4H,R)`E#T^U
M=^&'(L^.$&"KHL0T.X/4*E5!:B8'4@LG]3YK(/P_0F0C3TUY.!05Y.4#V("H
MA*RRYY:`["`!F/U$2+Z$G.%OA3IAB`6L%^!J!1KX1R(3_'1BZ:0V03Q7>8+#
M,#[U*JD<*E'QD!<XY3XO?"Z;%D("BHO"3\R!TGI$3C'U*BD/JYPD6K`>G=IT
M"A)MKU0(^@&9REZC4@%QQ6^`QSDJ*(49QV4?J+I#VT*%]FZ!<$47QQS_0]-'
MLZE9$4G@1033LLE7$6$5@+`<1#^J/83;84A_>(:@5M@8M2#KIMZ=^KYZ$0VT
M#XHUACD;[8Z'&OJ$,G=A$((>M`Y?RQ8K4@R(,YA4LJX1E3K`22;:PZD]YGE1
MK*!\"+)9"[=0#&^+%N1W(=@'1$A&K0UIM;V;=5$1\`!]R\3L"];S/VN1*^"K
MO:*H-+KO'IB'?F<P$)A8Q1PV8%!SG@U0-]`4E(UK,[`%G#[$HUTQ'CAVF>IC
MKU8\>&IE#8D]RS`#!0AF6^A6NVQ\ELT1N&U(O\[V%JF8MWKSNP_F!8&"A-L)
M.RL(%.3^@5:I#D6@,%V7T8$@0PQDD-QF,"Q-0U*E@Z1*O6%?(.XTXCASGV5>
MLLM^`;^M:F^W?(.];VN_/5\4EU0':>:+XA)L,]"942%MB<30D2@>7.'<,V:P
M)6+5!5]!:1]\J0^^WJ7:4`Q7U1'0A0,2TF;;K'E&GWK'D\3.DVPN`9;WF9,$
M/AM\J:Z.K:TIW7P%//JQSK:N0ZP?_EGD!Q>\[:#"2KTBQSV005J;7G29AH$O
M,WV[CC.@KI#X6&?-RK(W!*&MJU`?10:P7I<M!"J7EN#>OFZZL)H-/UM`!Y9O
MCS:-89-A@W0)3;*;S$!O55@OL;JP+O!P;,L*P_@,HJMNYD6Y&:"1>=EW)>2/
M`V3;=H%6QC\`A'5YR![*+4Z=0-`\:T'X;?WDC.B@VG6=UGC6DJY-0F6>#+=R
M.R`X%`72V.'6B8I)O4>R6627851DM`BR2R-"]8K<MM`#N3+V@(G&"^!YM@Q;
M\9RIVJ+"4%=TW7#;9=6@C\K"/3S8U2]X-Z\KUUZV;VZ=+PTDE%9!VCDFTY+R
M,'3K\X!@G(WUY8"1FIR$$Q<HP%WR<N]044*LV$*@@!P&8"-[G&@B]+(<LS=>
MUML21TA6=?`P,,2N[?,^Q(FAUJ%RW*#Q,.0$[UO,H`EA0IMI>,`45]1K`N<K
M]=$[O!5U`6N4NX=CTQ9=H`S^WDW:_1`7Q/Z:Y?Y;.RB$(:2@4HHV;\J]NXUC
M&;R[*EOOHKC`H6SLTQ==J,[M&.Z857DQBQJT"05J'U(%H,.IP:4X\)]MN2[`
MV.VQ<:P\-O5Q_^(NVCC+\]()!S)F!Q<?#TWVM=B&S_KO.,2<@,,&ZT<`5&.K
MR>QK5FZSAVW1.^\,>E"A4!="]H[!NI;ME7#A1$<7<1P&O7G'F#Y4(-."S3F[
M%$SV+C+87I5^N_'[-:#WV&!ZM`U*7PVYF?WI5#,,\=J3M/&G81FU\-JS7=#:
M9BQ,17#1>PG^ZP%[C*QU.?N'62:8(DE#T9[T6P,JT=UX.O#O4'[.%LJ^!N0>
MF^(\M=CB`6K^,[5-+P0W-`PBTMZ"+/&E8@CU"V2_/!V_#"TVL"V:Y;&N5U[4
M4R.W&TP&/KB?/LT.K$=J41LRX$LS2*_%2`'/<<AHI>]<$S?8"O!IFXQ.>,Z"
MFZ]`#?;:ZZ2;K62#_:DPZK!3G`O?FB,.</GM>^4Q/?*^]!Q,9$VWFSV<3<O(
M5L98N]0Z7*#J0$]HC!!BX8;=G_#-1D_Q2_$<XFOK`F^)Y6E583L"AIE!!?TV
MCDQI[TBT'XPT!4IBJ^Y=?7`3C9W=>@='=Z*T?['P^B_4P`]+\@5(,W`]P-&N
M:"#3_2_..\*>S0*T6AW74$C9&+NP8_[^Z?5@)^?\BS,HH-_0D;3?VF#*^]*G
MZG>P+/G8%41=`_93=H!_;VP]]U/V;%/[=Q#=5TT6%;SYI<#=QZDE$3H)HLP[
M_(/8,]`9&VP'):GW&_*QK'_<9,TN>VG;+Z[>F-^P+%7G2?[];.H'[;.Q;8_)
MSQ>(@5R4#HH7?%10_J'(-U6]K1^?R9?G]E#LH$I#T#K'=-MJO@4*AK%S2NO-
M&(XNN>!9QI]\DZJWVWPS,.Q%>RTR(<-!)L42ULW`:LA_F<5*>WP`X4O(Z;/@
MM-]3$7TIPTSJ[?G7YPS:+/(])AR7::'.P*CS\Y</&'46>.QF"=F"?-[63;G*
M(&$T^]I/U)%P8I[!SP/3\^V8<BJ&JO&G`KTVIEY+]F:8U7TY=!BLWS5,M!]X
MO?>FFWHYPT<L-?6>+S=FJ#WH)&2_YSMY!R,2,\2%4?TVI$Y];__=L8$VY+`%
M?QU$O;9HL+V%V'>YOC@I3.9P]K!MENC^T!UGW:$[K"Z^[(N\!!__L:EQ#.VG
MF<,&XV1ZZ1M%+V17GOA2!`_=O:-&+K0?B+^C6BZX3'`DT^[=E'O[/,P.,YQK
M[*2>+Z1KI@>Z9:9O;)62N@OIG7)FL&N_$\9]1_;>FV#R\RIAL1DS)!U*-.BP
M!>M.JXQO$K5^9Z'H=^KMUN^![/!@)[9-Y6%;A!;"G<W`P[L%GHK$L5EH7MVQ
MQ&X(4^>Y]6I7GF23%W"R-^)\24W+=*!81OT1:@N5QSGVO5F_U4?[LZC,GDM%
M*X(J\3AD4V\7DQ_."8O/EWJT#(M,OJF@TX'VJ!T5=/.!;DZ8X8AL#7WA:H&@
M]/O_PS$!#I\`RJ$?"GTD;L&YC1P,Z#Z&A_[1C5S_E?`'MWYIKLGAS\U0IVE?
M=W>=HW>$6<Y$L["]G/#4>,=SX)]\DSTL-A_V,93X12;'/L;_H"TJI!E@WX3(
M<1GO;FC2QM'NRHTE^=F^1O!0XQ0UY)&%VVS/3N:2OO<,@[2IX:E[N\U8JF#W
M&91KA(O*[^?87J;A5`&CM-\#4]0,]\"ZPWHC=K3'W=JV;B;FC4D9F)NUX6(`
MUVXA;+BDB^+ORZG/76%+\J^12/.A737K@ZC0/HJ6=CC='H:;3E,W?5H$-F8<
M`J3)0-C$]*>"N#TAA,+B9L5WN)LV=04C^)B(4X=Q(7H1)X_C^,[10']I'\<5
M]5V1W>HY"[+VK:T7L:'?OWC:E/D&6\O)ZQ`,6OX\T'RH@@J$AD-'P_>&N%`^
M,D)=T!Z:HVV/R?VI=@;O[_S-GZ68!7]XEO:E,B:?WO`DK#(Y_G!7;:!JW4]:
M>7@;;E!#XSX3%`H`@AW499O76L"^6.QZ&`)43^4L>ZZT/ZJE9-\/TZX7>"CR
M&D]IN0;7G6)_V=4BLU:V[3.>%#EDVVW7-KM77W;UT0W9Z9\IP_U#YXWV?/+%
M$1"&0`"U4]IRXFU8+440?I87HGDRW_O0\'AZZ?'P84J-DD2;A'#[X/X)]G5_
M($CPC#,2L'$";12X:8P@Q?-H,0(M(<O%"`!O\26D9&F40`@37\)&OA@!$R8N
M!16O2)$($V52&9'&"5(AH[90&@]]Q0B4$"I*(`6/2@$/$'$FN4ATE(#Q-$Y`
M^2M,)IQ'":3A29P@Q3V<&(%F*LJD5"R-XD$*?,\B1L!Q7ALC8$S%"2@.(V,$
M"1;+$0+`-(^**5(>1Y30K]A"*/Q%B1@!^&Y43*CA5!23@F,RC1$P'E>4@!@<
M%Q,T&27@`#D:)4B9CCHO!\A%Q>1*J/@3I!!Q'H1XA0>.U7B,@+T20#A])4[R
M1.@H'I@1\?C`TM<(M)!1'I@2<=`RR4TTXS"A5%35C`/NXP1)$E^"L5>DH"QN
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M0]VO@TVZ^_KJ)M=0_^:H7!J-K/K?+J'=JX&?W4MD_X>'@?']R3B3UA3`36_%
M=6_=D_O76==S^0?49`T&*ZDS!OK;5RK)?3.\7\L3R.9VSOON-492NZ).SCGI
M[U_+BC'CK*C4_J!6G"&+MY>:>7'[.@!?M$S_TWD8[0T;16ZX?SUR4__6TQ]%
M;GJ!.\07LC$&V=/[5T&V8R^F&(06+C&"U9/;5T6K/[9P:E<8PV9W_PW8#"8Y
MP:9B+[#9<X(8&E'!B]M7@?*R"L:B:@HMXR@VN_MOP*;65V'3O!Y5D9M1B)[<
MOPZB^M+O18U&55QI#*G#V]<A]9KU4[O0*&#]_;<`5NN7@)6&_K%@.J*0%[>O
MP^U%A9R%*YE@B89`@ZNMOQ)XY3ZVER]^PM13C6*]N_\&K,OT&JS3:#!T@G4R
MGLKC",9%Z\A&/>3D_G4>XF4;06B@MQ#T?*M@$7?)W&7:7;[DVY,IZ"?._4J^
M.0/(B^$OT%NX=5RG/=>!54=PB6OW&;X#0<^]4;XI?>`1XH[O$V_4.I8]A.BD
MZ`0*K%N@.()QS'1D8RX\O'V="U]&S&A49[KS9+CRGLQI0+Z[##]6/)*\^'A+
M<';_FC8MY5<5VUZ$3IJ.<V:"&[C+2T)TU)2?@6EP/WF#ZU[NK$Y=U[.O@@D&
M/#N"$_9/O\Q[O^>]WWL#6H*H`3OJL;3*W]JLI/SU9N4T#G0J2'L5!+D=P;@*
M[&>\#R(\.9/;$;RB`D<RFMGY&]ND9%P)X9>'7\GM&#2<3CKUG,IB">)B==1C
MP86_M=FZ[)G=;.;R.$D-QTEG9T8@]H:?D/!O]UU:PD]'KS4)QU]]3[I?24V%
M='7"^\_3+2$2%I:('L?ZEB748(D!KDZ/:-B-R=AL\,[$MYCOJ(D/%^^8B<_S
M[[B)#]OO!&ZPQPBDCF\QWRD9V7,$-7SZ^^W-[<W_`SJR58T-"F5N9'-T<F5A
M;0T*#0IE;F1O8FH-"@T*,38Y(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3<P
M(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X
M-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P
M(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@
M,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B
M8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G
M94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*
M96YD;V)J#0H-"C$W,"`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E
M#0HO3&5N9W1H(#0T-#4-"CX^#0IS=')E86T-"GB<S5Q)<^3&E;XS@O\A#XJP
M/%%=S@V;;^IN2M$*>R2KZ1D?=`%162RX44`)"]F<7S_OY8KBD@RU@`Z'0A)9
M2`)OS^]]+U%O_W5Y\=OE!=VF14(H_J-_RK>)-/^ICI<73%]AA*>$I?H33M)\
M6Q0\)SF%*Y1RTJO+B_\EK;Y7)A.\49+G^#_2WUY>'"XO]O^%M\)_9A_0K90"
M'K"5(A'P/U%P?GZ]D`E>+T2&U_,\%<_?D),W2<I!=D8)K)*I%FFO]=/7F+\F
MTB#NV^O+B[]\7]Y4H)P@U[!>FT'?TBG...@H);D^HD`TY^2ZNKQX`])*T/3Z
M_O+BVP\M*7>[>JR[=D/&@R+ONN.I;!^(:D?5JQVIV[$C^V[J20>7>Z*.IZ9[
M.,)E4M[V2N%/`[FOQP/I]ONZ4OU`RG9'/JD'NU:I@>RFOFYO":<TV9)K>$S=
MPC/+AL!#CO"'Y,_D^M^7%U>@U#\6TYQG3G.>%DYUGN'/J/I,DZG=@6IETY"A
M_OR"BJK=#:1KR7M5J>,-+!=L@PIE&Z-].8W=L1SK"A:IA=5)>!'T*?A64LK(
M]?^!$F^6?I(0<\MQSIBS7,(@;[3E'E39PVU;=5\V`QBO40/8I];Q<2K[\8'L
MI[ZMAP-X'F-J#>?"GUH1$TA\)R(M;%R;8"U)VX%'%$98V[6+RR&"(*MZA8%#
M9BJS)//Q+%G&C<K6(:@RT1X9#V5+"DIVY<-`3GW=]01R&1VB/I_JOL2D1\O@
M)_!OJY-Q2Z[*ZF`_/I(:'-O4M_5-H_"/P?%0,,A-UTYP`1?J6(#5TPFO+^_I
MHA#.T4+Z6)3.SY+^2J&6@0"'&@M/.X$%;LI!D0H*F6H'HR5^L@,9NR#]J0'K
M@,@W"BI@=QKA.M:M8PD5#_Z%7V\>M&G.;@2_'.MQ5,H9[FU7]KMU*EB1I<[A
M/$F]ZB)G1O?W=:^JL8.":V5QM?M7FM`U\@[D<3(9<;[]E7.Q]%/RN>:4RMR7
M[D3:`O1N[I)WSB4+"R)8_HRZ<NFG<.F?<E9#P(EL:0\*@"RSJ`(DY"MG)FT9
MV4.9&":;V=NE)9`T\Q)\NT;.)(6+G"*;X1U7)'5Q>VZ#QTJ']:]N2ZQU6"BJ
MJIO@@DTN]5E5TUC?+1YFN?122Q]F?/&GY#/;<(T*;3W)"FEL`S!-E8CC>K*K
MA_*F;NKQ88._VDKHZ@OBG6X:255.4&CA^L+"ID7JA5VOT&3T/%P"TI'<P6-,
MAG>HY99\V*^$90K,/(M3J8V`M8(M#8];+];2=*832WT60L?$7:3-4C`DWA@V
M71=J!L=I)+-T1D!#YL1<+\@$=!LS!\^"#-`,>Q1DFZ6++7].Q:5W,,F#BHN7
M=`R963!ET$R[:$JHM9^&=0:IM::5Q8`9"7QB^Y`GU0M0X'Z"=N\6,',/B'&%
MK(:6W@E-0PH(FCJTWB@`I1N4$D%V.]9C`_$/B!10G8+4!QD'=0?BM=#`W("@
M^UIO1L>N'0_-`[30PP@MJ^E.:V.!\NBV+/87QG5/KH&QAO<OHF,,P'(-&]#<
M!7XJ?),&($08&YP4-"4:/*=&J\&*`M+=:`A^ZD:T#$C]K"E,TU&>3GWWN8;F
M6X%9ODD2L:&4+@Y=0*$\8TXAD?D=E.>9]&S*W\L>$`:G-(WP*5#-`O#0\?@>
MH-8/C6I;<K4E_ZUV][5M3L`42@/Z6@/"V2V7[OP!(3C]UML;DB)8L<BV25H4
M&NZB&6GBMX=WAUKMR<>J1N_OZXK\9+BEC3&%L<7R>P*Z.`E\69:'F,ULZW'E
M=F;R/T@L_-RKH=ZI`!.=O[&7-+(&QSU9_+;N?CZ4_1%ZTFF`@!\>MW)+6S\K
MO((K^C@7,S,REOM,$6GNL>;]H6N:I15,D=JUCUZ5D4G%/%18GOK^'.YJ2WQW
MCR5LF&[`Z779`Y1^_U#N()A7B%IA&#MX/I74R\)IX2L3E)]6EWLHIAB8__SX
M'0;FAGQHJ^T&BN[W3=?7N_)Y?A;KDRE+2P.D)//2K]C^I,P_!7$V9X$/YNP9
M4*K9WL=4;_X5J-XT"]Y<-X*A"P\FX2P/1&\A6(3H72%ZN2=SL4]U6"G/;<V-
M4,M?@^?E*?4BKNH2GLJ9+6A1S)J%@L587L9_-\V[6D:G1>:U6"^C,W!"L)7(
MJ=]DLB3QF\P<\JX0M]1STP!>9H2*JRAE`V4?X?TW@E($I1N-"RSD_QV\.D_F
M-/<3-&\?]!++/>>WE[="EGM"<<;0BT):*SQEU)^G;Y\PZB_RVX\HRA#)Y%`.
M@)G!.M!=5:-II\(]X>(:;8Z>*)J4368S5CUOU6QU4T*>?OCP@>RL1D3M]_`#
MHDC;NE[Y#]Y#&[.Q?9#>?>\/-7*6F,M0]*"OQ?4X>'0A,(Q=]0G0U`YGKT>E
MQKJ]W7ZAFFE$36G4A&R6=.G;I^'V:WA(>`8F$P'4<V$W&$0\OYL47@\203PY
MB5>$1)F8VZ5@F;=+EL4984CC6<[MER>`,8V<;.MQ<]CQ!@M`FS*C:=PTY(>N
MVY%?5#DLCBI20!5/=5R:G$NA,7%/63RSTEF@`C`2-,L,,-HL_J0LF;F*RU!F
MDQ0*H795B=&ZQWUF/K-8H9@PS^S-Z-R$2QF&DU]C2L*2W,NRXC@6,.E,8S$K
MG[DKGY[`7AH/PY\^U7#I%,%FT#UEW2CF/)O9$G9P3V;S)!./HUB/G%;LNPLO
MRYI]MYA'SW_J+$C7XM532=?BX/ZO.PO*^',J+IU+&0\J+K[=9+R8V4]*Z0]!
M%?KGLUG0\G4_+=PT@\DL='LTLX_^\NG3JK.@%0R1NRD(2XIP+DD/KS7O^>KT
MR?:K&.R:IZAO#R-V;<A+LESSY5HS8B=$^ZYINGL\0:I-ZTJ$/K1ZZKN[>H?6
M.MC>*`S!\.'!;BM8(O4,<!:B47(7C=93T+7U"FZ^FRJ04W?G.]"H[!<_H%5X
MD=8]CY@+_R"DG!-NF@<L7TL_"K+NJ^C$Z9D_4YD%?^:6T3=>PQB&P+*[4X@V
M3.]>'2=,:ET'X.JQ?##DCCT!C7\1(M*'M\D#^!5^/.I+JYPHU$I9PFIV]HM1
M>]QE4/U=72'+@-29/[^M\73=[M1)M7I\!:5N[$O-9"!/`75L_+)Q:Q87UYVM
M3;=9@CXP@T(FI87\5U9`\M:6Q)^;\DN!4H3Y2`KZAYF/B)H:^]F1(TL#)N"!
MG'"[QT%36)(RK)2?=*&T:-'XI+Z9=.1IV@_V`<,=X<'V<!8?:]&<>T1:O:[J
M$T"N+?G9_8(;B0Y>)-)P&3P'T)>A(W-_ZG8%:R2>3I2S(UG4F>/LY((]``"2
M?JZ/T]$EXTZ9+4)SGKCMP!9YFOIA`K7P#^PTK('._DZUDR(?3>"#L+=3HV\]
MF#F8']];/A%I=[29V7364%]X,E$6,ZK*G1O!6G$LQ^J`U<0ZM3]S_N#K"=*C
M^L4%$/SQ+"O5;+!Y(6.%C&%_D"N,%X:$<K_WY,)W42Q-;6'X>]E.>RA0INA^
MY]_B6%Y3346L5QMDZILG/B/7\_QI;7CQA,G&E@'8LRK<6V`/P]0W+[U4JD=R
MGE1U7TU'0)$MUG]W@OP%.^K"`W_T$VP!&%.L*(J-O>$*-I`>>./0,ARELCV3
M+7(8]H`D6T@/)[3)#(!=4,S<GH6YBY_8J9C3WWX:DL<?Y("N%#\N*V0_:_6H
M,-A*8*:13H(5;"`\YL[2T'Q(*MR09::SZ3$:G-Y7A[:NH-!ALNO?NJ:[Q7Y!
M`PV#H+%YZ(U%S+M;H!,`U4F/&^[*VH2+G:3,S[>T4%.&88[D@VT7)T_0",S!
M,\.76/CBN9-367W".#7*#C@'<:,C*]@:M4X4<LT*(++,>SYP]%*(IQ7@6.ZP
M4^S5;Q-HCZICY%K5S],"9XZ?3];9+AVJ$BQ8CQ@>@.MV9IFYKJ"7ND7ZY:YK
MIJ/2(SGUN38V-K%POX+'1>K?>:+<-U@B=1->E[7G.0FI7C733N_^\V'.[.4]
MV/BDR9-1H_1ST[CMO0QO1T(.)914TTU=D2/""VT"@$1X:P-&5E!?.F3(BOG)
MU\*6?^\P]$`Y#%U5:^*L5U4'/<9#\.A,U7]W/7YB$P-6U".>)WB4R\A#8(`,
MFM#0KTGY3MMV/F=66T%Y_OQ;,8OG6.H?M1[WQX,^2)MX5QH_?A>"[,H;_5TW
M?#%@>9DA8,\HNS0+R*!DS;P'29R$=YJ6/Y>;9S/;TB*;'3?T1?(LG/TI`>PE
M&N6.1MRHJCPJ3<U!>IQL%P\^F2$=1,Y;=XY/UULSTX<NRC#8*TQ#,1>H[PHR
M%NJ@L'V[`S&].G9W>K>&+:`^>8$>I3-R%>=GIIFP9Z8_'KJIV9WM]+B=@([S
M2CC?*#3NF;`(F,,MZY"OFJYP1\0"<T$=!JRFOI\S$X]`('2!T+AU-]I*1N)V
MAUM7*'NSLH\+6J6PU+GR"%</78LT".RHW0VTSZ;F/T)%!@*O9(+,MP)L/JQ/
MTFC/LS'>OZ\;+/(H]AVZO-0'3N;"_PG0GIGPHU9XCF0.'U!9&PF&9;:^[A6"
M7E+#+2J+E.L6FHAZE;<J>))[`DL$PC5/[(9XZ@;[708`7J=FU)NT3V4C=%4.
M![)ONGM`#1]:<Y`(R:X[:ZP95Z]SX5#>:?3;=!5DR[-I8`!W:P94/@174%_Z
M]P]F[\4FU+T7>SP+`=NR/*SQ)H0F^]T0/``31WQ?O]P[NB@R'9,KF[-91G4H
M^UNX;$ZSS6'I-)2W4&7`KWVYK_&_]IULV"@W>$(%W(]N,;_WY3TR):I?)Q1Q
MVW$OMX2YIN!9ZGBJP68)](3'FZD?E-,4V3FH4-T.7VV8Z:#C\<<);`#;##N/
M10UC=X:O>\"C81V6I6<J^38E1\AUO&G=VD>MH'U&PX'S/,RQ&;=;TE/M4)QG
MYU6@Q#<\W]`\WX"\TT#^]N'M3[]H#D)L4\TT0A/^A,`RI]?1P'!C\\+-(R.=
MH7>P#/666<$@22!QGWMO!&0,&_#K]F!LD\AT9HX-N>EPH@:P7@\0ECX/().@
MPZIS%@G[53`6$UDH'TS.OV#$#$<>M7;!P\?R$S:[IU[-:L@*?A6I#_39-^CP
MQ,;Y-YPG")U</W469N#A'Z$*(KS``YM;\AULPE9<0\3O5-NYXPZP^FKJ.]#X
M%X6'9K%LPC5-;/L_"@CCO+ZNH#D+QUK#UT\([BBG4-$=['NYC4&2"5MRE+36
M/.4PNJ.L3YEID_^]/@B+1BH'.P$>_GJNIWYW`+].("LH$5K#H(K^FB58P/`[
ME7`!?V&!?CDQLB`K4BZC"_($-L'8@BS)XH](D?>/+4CP==?8`BES&ET@`"=$
M%W#YBA8LH7$AJ2RB"])"IE%?I+DLHEK@=W1ET06IE%$MTD0F<2'A!GET@1!%
M?`$7KPC)A(POH()%%^`[.E$MDIQG42&3C!?1>$@2GL472(['NR(+``W%%W`\
M-1E;P'@>7T"%C*HI"Q&/*$`O<5_(3-#X(U)>1-64">YRL052)%$UI1!Q0TDN
M>%Q-QE^Q`X0<CRT0!9Z#B"V`D(NJ*3*9Q>^0(@R)+4CD*S)(_-J]V`+Q2@$1
M_)4Z*0"F1.-!Z,EM9`$DWBL+<IE&98#,C`<M3R6-[C@\P3<-8PM`A&C`<$E9
M_!&"OZ(%8*>HLZ"=B&<6M*$TJ@4K1!XU%"MH?,]B@*#B=\A8W-0L931J2=A7
MT[@,DL:+.1,LCF$81R`;6P`KX@LHBV.8@L4+3([?[!6'%_%]&3;-^%XA7JF`
M<3=!^8LG!,WC3HKYZ#>[Q-8>)IZ!XP7!\RX6CK,G<)R&61ALBQJ/(]WMCP*8
M5Y3V`+C;\<E9!W.;7W[`6]YC=_`C"K1-4*0<_F>Z/O]K<WGQ,0C-7Y8YG<O\
MJ-&C^G9^8NO&#4^'I!@<QC4`>GY7FR+P2U\+=T@LQ]Y2-ZW?+_<(+##N$=&^
M^(\\(IT](KR`P)/'W4Y\^WQ3Q.O,&X;?2A-;P/-XO7TCLGBU?".S.'!]D^!W
M-[ZT`+2\^M?EQ>7%_P,[A)L.#0IE;F1S=')E86T-"@T*96YD;V)J#0H-"C$W
M,2`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$W,B`P(%(@70T*+TUE9&EA0F]X
M(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@,"!2#0HO4F5S;W5R8V5S
M(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2#0HO1F%B8S$T(#(P,"`P
M(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y,B`P(%(-"B]&86)C-R`Q
M.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y(#$Y-2`P(%(-"CX^#0HO
M4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"#0HO26UA9V5##0HO26UA
M9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N9&]B:@T*#0HQ-S(@,"!O
M8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*+TQE;F=T:"`T-S4T#0H^
M/@T*<W1R96%M#0IXG+5<W8_CN)%_;Z#_!SX,D+F#Q\</D9*0I]G);)!%DKLD
M$UP.V!>UK>Y6(EL>R9Z>SE]_5?R2Y*9HRV-CL=M>NL3ZY*^J2,H__>/^[NO]
M'5VJ7!**_^A/V5(FYC^KS?T=T]\PPA5A2H]PDB?+/.<9R2@E>:I(6][?_2_9
MZJG21.(\,LOP#VF?[N^>[^\>_Q-GPG\&`W29)`+F7R9""O@C<L['W^>)Q.]S
MD>+W6:9$>$)./B2*"Y(Q2H`J,2(]:O7T=\Q_)P;B_O3E_NZ_?BX>5J";(%^`
M7EM!3^GT9IQD@I,O&Y2',_RXNK_[`$*G,B5?7N[OWG]Y+LF?BNWAL5CM#VVU
M?2(?G]JRW)3;/:DZ\E#B4+%:-8?MOER3QZ8E14>ZLOU6K4I2>-IBNR9[F.OC
M>EWMJV9;U.3S]UVQ[>`S^=1T^ZZ?;M^6!4X&$Q5;TNS*MMCC^'^0+_^\O_L,
MBOWE6MHSZ;6GK->>&>7KLNC*)?D(ZK5KD*!^78!$VP,(ORM>42^0L"V![6-=
MKIS(9-5L=LT6M6X>X7\Z_?>I:=9@F*9>DVJK3>%F*MNJT8,OS]7JF90%_,=.
MCS99'T"$"U57$ZJG4GG=WU][<K!KFMNY?^4)O63Z-.JV-,WT]+E:*IY`U/Y;
M^XTE5!C']3&Z;R"ZMNO#:D_^6G9ET8)Q,19_5WXKZV:G:3ZN]M4WB,JR(Q",
M/Y7/1?V(+D,G?0)?%MO7&YA(9C]FHGADIPGSD<T'D0WPX=>UU8T\0]2"'<JV
MQ#`$BW5@G!9"TR_?CKQ4^V?X<EWN2O@/&O:Y:M<0IZVV&SRTLF9NAV9>#\Q<
MC,S\,#+S#0S`$VL`QFGN#"`R9H'-*K\$&%J5NSVNW'79K=KJ`:SP`$*_+,@6
M5K&5L"N'UL!%CU"WJ;;5YK"Q:[C#15S"=%V'3^'#KV"*A;8$/O)4;M&N]2M9
M%=M561</=4D>7F]E`9IZ"V`DVA`0"1M9P+BV6']#D<A+6^WWY194WP.`7QUX
M0"R5I;<,?)52IW7"^L"GW"C]WUORRP$<(.B"<$J3Q7"5CU=!,08)#RG&7H,%
M\(KA7W1=U>U'LT$T?"L@,`[=]**X@0&@WK`&4*D/_(3A9[3`KFW^"<D*0A06
MN9:7JVM+`8O,B9%S,#[F5L#H]Q^NKBX;Z$LIU&U67ZZDU7?3;,%?-LL">&$E
M\3=8\>7F`?2W<:"6Y`];\/?*C/:1`?$`B[S`DH6LH2HA+PB6W_>(@FOTNW]&
M,#.3=C&X_@:>A6>LIK*O5@2SZWDHO?+"OQ'XXZZM:J=WNB1_AR],'`3#?;Q`
M*@SEKX>J-7,=]E5=_;M<^/)NN"AN8`"6N]`62>(-D&<V[6,B@^)K@Q"FY8-8
M_U:M0;[II*27K8:^;T5]P!(.!G?PX/=J`_X&J'C'EEP"U-<U!,&28.:$7-?!
MO*V)"\P$)D78NA<3P:H^0#ZYA1&HJ]AI(GV\"YI:A!.4+N!?TCU#RNF.ZIC?
M&`.!T-V^6?UK,5`:U*1.2^/05=$]+\@[+NF"PH0PDZE0,:)V1;4F!RAS(;;*
MU4';P;+ZW4WA36:N9&=2)CV\J>RH]%N2_SFTW:$P1>")^'YKM*&9R`MD!;*K
MBY7.#03KA.;%IW73M51==S!1UR^$&ZBO,E?74=$G=>74-TL/EWS1;D&<M6G:
M]B9H]RVV<;[I6*#?C4_WU0:%+E^U1BZ^88+FL,?U@;!I8C^<%"MH>3JP',8,
MS`[]G2[T;F``Z0M;2ON&57&+@CHFCZ'(=EP@N6G*H+`#"\"ZW>B5?S@%@0_E
M:V,1#AYZ+"OHA75EB)@X$3,W4%WXDE:'@0O]S*[\XP`U_AI6^39&H:LNGD"[
M)TQH(#>T_@N6RBE-=D?KZ&U7[S%"N_\&FC-7RE+!O--YG@A7TY2N8T8U'TJH
M8&UNTO9X/-2UL<;VH%,DJ&B5?2[KT9K6ZK]-ZI#XLG3!N+RX)(ZHEV2F9OV@
M,3WO:QBE?-7Z)YV^C#@I^14J@%MT#:(7QH`+5.E<7)U+-E*9)=*K+*0T*G]^
M?"RQ880U"5%Z90D@X`-Z)E?GDGLN4`8+1:4I@\%[X,AK<^,]-T`(ACMXKNG%
M7AB-.@EQXRH1"QK7O=I0:YO#TS/YN7QH#T7[2GBN`S$SFIB."+?J=!T`,'&#
M-:)\F9\/RAXI;>(SPFMHZ[<8]R]E#1&D6X#.`,"^V<,7;E<.#>(UU5/H#4E8
M[>_80@&H*2@,7-D#M1%`"WF`OWVB=_`*3Q6&$92,#P54E5?W,%HA<2T`2X7H
M>WIG!6!<VKI,([7)]L4&MV>UOICFH3@]M)C;[=;#(%,NR6?<?G1ZV`<KK/=>
M]6Y%IGX%B$+`U%!_(QQ2T,@Y56^'0PKR:6]0+K*^GLHRB[R?4,N/V@Q7YI[2
MD([7QJ"4]3J.6G%<N==V6PI%6&]0*F1O4$:M0;%D8(D+HANL$)Y[A_*T=RBW
M^WZ'+=0]T/+IXC;8(UT;EP'UG5")]S._.I=\H#K3V[]&=4E3B_[CWN]6:U?P
MW@FW6[L"$:+75W]TVP'<[OQ\_GJHH/B_R>J%@`YH>>W5"VVMY_*F@KAZ)9IP
M-;2I&K37(F/]N8%=-=@HNK2`#=9+`W^@5ZQKO4G^6],N52UDVL$XYLV'6VQW
MHT>LY#0;%`B938WKLH9J4K>T)CD*>:$0='+;$ZI*?Z)H-Y^AYKK!IN=`V43T
MA5XN+,J1=?$*95Q=-R^N_>^J[R:OX\$C6J+#0LY"W[C:]GU=5^*I3L!]MS=F
MBN7L[8V9@L5Z8R8T]T55KC][8UX_8$7NM1/]T3OXT&;*L?N&I>QI#TXTNZZ$
M+;]B66@KV!%,DG6%.Z:^-ES538<B[%H\S[^!$=+,!_)@1]=FK)LFYCSUW&^7
ME_%:0:\C`)-O=87(I,O+)B';I72T%C%-OY/+G!G,'V[I;"`NW0%%::Y7^(9.
M]P"*8NQVZ#UHZ8[.]JY]IP`J3:?I97<*XH?^PI]H4YKW&P8RMU;\(S1]3WI#
M?D$^U46UZ32,?>RZLNMT1KK^6:;@[)9GF8+Z#3^E^EJ6NV3\!Q,PS:[:VOWW
M3;$MGOI];<C0F*6W#?G7MGG9XL:L/O_2!Q;ZE@WN$=?E$VX)M\VJ+/'K#K[$
MC>'F4*_)<P&!")TMT+85D)4Z.EVL]L<*U]>>9_[\&GLEI[U4UN&/$/;;%<JT
M`XPRC@>0.]1[<_R^L^<S':JKN]5'P-/N%F?:7/W@F78\]+GTV3Z7)E.\_R/>
M3;J)V9D_/^;]>:I(>?;FYLB5F8._'?/;`7+.1AJ*'H]=RX]M4KMK6L34Y[)8
M0ZYL(?A-P5LW*WTWK<)[!+L*QA?DY[IIJW6QP,'QT6&VD'BHA#-`*5R6>@^F
MVQ602IO5"I['S1I]^%`0?=G,72ZXOEM9[OORC/=*NQUTM^/3`G3`BFKMR<#Q
M2:A<2(A%#0_E]UW5FKL\Q]OEJ4E31J-G<XVO[%9%;<Y+5W5QZ$R1.=HTM%MX
M>__H#:R0NO:&)GYS0E#I2ZY6]S&X'=B-<VUMUEM!Q,BG3;,G=?%`'HM555?F
MJ.EM8%BO3ACY'=-3'EOUE\.VU.?T-S"#\F?(:=J773I]HQUZ'SKUB[IKAC9@
M,F(#[5DL:EI(1N3A4-4ZZX!I?@_ER;9[:-IF0?[<M&"53T7;U(#DIXQT`R,D
MIO[.TR7'UM?=(E345I_O^(("/MAKF;%P'PFG;]7F8,HTIT1HL7K^^FXO$'"5
M&`(^0<`4="8Q`JI`Y@A!FDMH8&($F4RC+-)40LT5(U"2QEG().-1@D32N!8B
M.:$%ERPN),/+,C$"@(*H+U2>Y%$M5(:G=C&"-$FB6B@%P1PED`FG48(DH7$"
M(4X(R<'640(F6)R`8D$<(9`YSZ)"RHSGT7B0BJ=Q`LFA0(P1)#R-$PB>Q%E`
M710G8$+&U:0B'E$0]'%?))E@419)RO.HFHG"-P]B!!(W\&,$B8@;*A&X&1PC
MX/R$'2#DDB@!Y5ET\8*AXVJ*+$GC,P!(1640@.7Q&238,DJ0G``06+MQG(28
MS:/Q()B,XP-407$"GB<J*@//DGC0\C2AT8S#H<V-FII+E40#!EHE%F<!J3ZN
MA>!Q9T%/$E]9G"4TK@456=Q0E,5S%LL9C<[`H"Z*VH&EC$8M"750&I=!TCB8
M,UB]<1D$7@6)$7#.X@2,Q6L8L&,<87*617T%A=B)\D)$PTGAG9IHKHC[*6$\
M#CXTC\K'3SF)1M#OJR611D0F`D5V3G!SWA;9[$V1397?NY#VZA9>X7"G,E_T
M\1'4]Y^@['^S26>F^>OO<<H7K/E_08&6$D7*X(\Y%O/_6]_?_>U^\.H<@BJC
ML!8W5@_X6+N/&7ZT%/KS\UAG?3R/6\2S=X-@8>73VT$G)X_O!4%`<W=S:OA>
M!P/T-2;]/WV7Q6ST#5N5<9/2&RFEWDC>8+UIE/YL:-383)X"`@#ZI%EF,L]R
M-6&G_@&HYWKQG*A'(EF:8_$<188)=IZAS;,\=0TB3:`,T2>OXY<ACYW[0SPS
M?)8-K@*:33"_IS_A0$B)WD+>6D=6L31'%O(4.J/,<Z!YUDH;<Z`2_2+THAZ)
M9&F.Q7,44*]+-L^8$HH^1A.S?YXG2\ES>_%E\`;JL?=^C&$RB!BQS%-\+P49
M]N^Y7I5?IGK[ZQ<B[,:P?IEV(E2@2?2^\'XYLK^E.?*%IY"S(\4\.ATIRTR_
M!BV$RQZ0E#.I\=&R>G3`Z<<G0'GZ;J2`9_M[%!2*!NT;W+V)2X-`A6P!XT;2
MO!V?A7U.FC/L@9B"G([,,1B>:0WS9,`:[TX)DAJ.\EB2?GRF*-`IAT41(EU0
MR>("(09I'_"Q0&_'9\':#-_@"D9.ZDB`?GBN0?23\WTC;32H_$B2P?A,412=
M"!.AQ`+L%!<(5STR/HJ5-\.S8&3:,SW&(4Q`AQ>$#S=^"7RD-`@?V519A8M<
MJ3!NC,;GX48ZA:/CB@Y9A`!C.'P^8WSR+,:IX1`""#M^"4"$3,\87R243]5$
MTG@[B`SJXH+G'"/H%0PL0I`P'#Z?,3YY#F/KWR`$V/%+("!H?9$!!+"I,D.8
M&`^M?75I"3%M@F`%`<L\"`%N_!((L*^>'4-`?D8%@2Q#2#`:GX<$<NKN2;B"
M`$XA0!@.SP.$.?Q3PRB$"W9\+BY`E3KPQ^`5\S?OF)_!);KFG9[DC&($W1F"
MG-'X9>S/+$:`4PAYAL/SD&<&?QM/00"RXY<`4&C9A0`H7(,`XQ`.#8?GX="D
M0<8U",_"`.3&+P$@^V--1P#$)O,QP@3P"R+/:'P>\E@Q3M8@P"($.</A>9!S
M%N/4<`AAC1V_!&MZTY_$FCB7Z&)W"I)878.>"X',:/PROJ?J&F`10I?A\#QT
M.8>QC9D@K-CQ2V`EM)C.J&N`8PA/AL/S\&32!,&Z!M_S"<&*&[\$5I@(PLH)
M=-500/,PNHS&YZ&+E>;<N@;/P0(@,QR>!S)S^*>&40AK[/@E6-/[XR36Q+E$
MU[S3\YRZ!MT9@IS1^&7LSZQK@%,(>8;#\Y!G!G\;3T$`LN.7`%!HV1D`.F=O
M!1B'<&@X/`^')@TR+BBR++/G:?C)'*=E.7='1O;CFY^QM%0#C/+8=30^"[NR
M7`6Q:VIC`%>XU<`IXP6G[ES)?GRC@R,+(=YX?!;B97ER\A0%%[N3VZHP%E83
M3,EMR0(X.1J>A9/G2(T+W4N=]E)[437!I-2&+(2N;OP"='5RGX&N)[C$X,U;
M9[*2`PRRIG%6&MM#$TR8QI&%,'D\?IG0,9?V"\BI,!961A:0(PL@^6AX%I*?
M(S4"G).Z7SX#437!E-26+(3_;GPV_JMA(`[P/UTD2D[5GXF/&:?06'1-,*&%
M(PLDC='PK*01L7VH7,R4=+E#29<[P'P.@LU'_Q/);\M?I`B5OT?C<VYK9.FL
M>M.JX+3QDJ<>C\W'*24<-</W4(YSB!VG%^20=+*+&.<0*[[59"RS(1B)?_1P
MGX!4GX"L`S5!U(&..I2'S/`%)YG.?['3LG%"<B9(>Q-XO0U!V`3FNSZ;J>Q(
M;T-PP@2&.IC4U&4M`[X%$3)"DN2+A(K3Q;6UB#/.6!-#$%7*40?3D;JX18BL
MS'$ZLN);3;S,J<?X*8?:0/8/9T<*RSZ\)W6WU*&49H8O.`&>%=,:AZT)^F4]
MT-L0A$U@ONL3H\J.]#8$<1-8ZF!^5!?W1T$CY$(NCE\*?-L?)3ZFG7'&FAB"
MJ%*..I0NU:4]UG1$FS3&>#9]T5(-+UH>X2"5>)G6_?"-=&]/AIG8]V7F^@1_
MKX#97V3(U3)+I'EGZOW/5V2"/]3LF41_.OB'F*@ADT'C./XE9'.7,W9[]D/.
MHW?%/[`L?CWW`T_SZ/W?#R)ET=OF'Y+8&U*@Q>=_W-_=W_T_NPAL(0T*96YD
M<W1R96%M#0H-"F5N9&]B:@T*#0HQ-S,@,"!O8FH-"CP\#0HO0V]N=&5N=',@
M6R`Q-S0@,"!2(%T-"B]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T-"B]087)E
M;G0@,3@T(#`@4@T*+U)E<V]U<F-E<R`\/`T*+T9O;G0@/#P-"B]&86)C,3`@
M,3DV(#`@4@T*+T9A8F,Q-"`R,#`@,"!2#0HO1F%B8S$X(#(P-"`P(%(-"B]&
M86)C-B`Q.3(@,"!2#0HO1F%B8S<@,3DS(#`@4@T*+T9A8F,X(#$Y-"`P(%(-
M"B]&86)C.2`Q.34@,"!2#0H^/@T*+U!R;V-3970@6R`O4$1&#0HO5&5X=`T*
M+TEM86=E0@T*+TEM86=E0PT*+TEM86=E22!=#0H^/@T*+U1Y<&4@+U!A9V4-
M"CX^#0IE;F1O8FH-"@T*,3<T(#`@;V)J#0H\/`T*+T9I;'1E<B`O1FQA=&5$
M96-O9&4-"B],96YG=&@@-#`Y,0T*/CX-"G-T<F5A;0T*>)RU7$ESX\85OJM*
M_P$'5V62XC"]`6CD%CMVG*4<QU&60RX0V!01@P`-@-+(OS[O]0:`!)M#62@[
M'D[CL?LMWUL;S)?_N;_[Z?Z.K),LC@C^HS_)=2S,?XK]_1W53VC$DH@F>H5%
M(EYG&9.1)/"$L#AJU?W=OZ-:[Y6*&#>*I<0_HO;I_FYW?[?]#6Z%_XP6R%H(
M#@>L!8\Y_,$SQJ;/,Q'C\XRG^%S*A,]OR**//!%I)"F)@$HDFJ6MED\_X_X9
M3P9VOWRXO_OM-_EC`<+QZ`'HM1KTEDYPRD!&(:*'/3)$4P:$Q?W=1^1:L.CA
MY?[NP\-.1;_ORKR.NN-C5V[*O'V-*I5WJHO*OHN:[;8L5'1HU;[$M;S>1%V?
M;[=17A3-?M]L\KYLZBXZUAO51G59JZ@YJ!96ZR>S492W;5X_J;VJ8<-MTT:]
M:O==A(M(M&V;?=2_-%$/_ZHZ^G7T\+_[NZ]!P+^_FQ98:K4`9D(=?'A5>=NM
MW_^H+"-.WSP37M\$O^/T_56S/^3UZZ^ZBYK/HVU>E%79OT9E'7W;@);^TCA5
MY:C#/2A[7]9-BS1=WQ0_[IH*+=!LHQ[.&/9<1S^`XB/UZ:!J,(:Q4[\KNP44
MG0'847H0F3!P2"L^XRDUXH^@$+WD(.CAT#:?RGW>J^HU^H*EJQ0\$T'V!8M7
M!#YKO(!`VF"1`NXWT1]4H?:/(`:GJX@1DNAOP(=X!2QW!U7TY3-LN%Y"1/B.
M,3"A$%FLA%1FJ9'P#Z_YIBRB[Q2HN4*VOES_:^WL:KT)EZO\,>H..?SMI>QW
M8-1]4_<[4$(+NLDK\(Y>H3%/-"10*:OH95<6.[1IV>*V]9E*4GU(`>AZ5$MH
M@69."R+S885EF84Y"*%>P%)HO1SX,_:+(#"4S0;LV3;'I]T9T_*M#IE<X)0S
MXEG]L(0:"'-J@+2AU4#7DLG,:.&;8W]L%?IIN3_N;33$J%GV)AANCDJKR'I[
M:0.L^NE8'K2/6-S8X-K48-!"58"=ZBS,PE?[.<\`!O(E?%W*V/MZFJ0FK&Z;
MJFI>NM^]];Q+AHQ3?]X2=DQ2;T<J!CBGB32&G(F@>56=6^"V8`4)#SP=2$Y\
MG)-4ASX=!CE-C,N/`]MJ"1W$@SU),B@!EU$'$(M,U#GA5M*!6?L9<DM9%]41
MQ8?\531=CZ'LJ6DV7=1!GM+4I[&?)<-&C,=S.SU!6&DA."+-`AK@TE4)@&B?
MNV/\K)/7!CVYZ]'FSTJ+U9W:!9A$`.CB"),\@J.`^JBI2JB4E"Z>>EL*@4HL
M@H#@O4,?RD/E+_"8-*PK0@?OQPAK\V`J;:;_OFUZ5`OD)I`3_G9H2]5CC?.@
MBEW=5,T3A+OW%SJ6AK$/_V6"O#]&XD3X2I)YL844L_5==RP*U74(XXTZ8#R`
M.`(0.>1MCUD;*^S\T11Z4/TVCWVNG_8:'XCR/2SHQ7P#60%K@L-$L0V@K84M
MP8<J6#V"<P`!H`IV=-%H`2T(7T\+FCHMQ+H@0BT,&NA'QM8"`7>;8]%WSE/^
M69?H%O]`MS`41J2B.=8]0*9;1W_:+B4&]\6ZE&QP>%>L6S&B30.LU4WOC0#Q
MRII!FW!6_2O,]`?5EWT#N6"?OV(EIA,W6/K0YF!"*/[PZV<Z4J`C\\AM@?%F
M`?DI]P$/W<;*G\C8!;SG'-#WI-81XKK*7W30ZIJ]+EM4^50/=@(M:1TYQ1Q&
M+M^63SL4M#&]20[?5Y\0Y%B:]*.MSQ"QLEX`5GA_^47F:GF:C>R?4&'D-S$<
M9=OE8`!5:V%5BV$<9"^AF`?]H*1@UKV&M/-."/L@2]G.J<$@OYO1H=9SIX8=
M;0%?Y,<.#GU<)/&+U-?R4OJ6E<>9'1%@&%&?\OVA4F`-,%7Q(YJJ/586KGO5
M[S"S(^%&;2',H?CS,<FHX,V-62#PBSA;,O`+P7S(&^8HV7G8C[`11V4<(2YW
MW1'L-HUQX_".8X\<2V:UL7^'1Z_OS+V(A6<_8VM!,'?_#%Q_?/>#Y$A/5/)X
M\"F')H4`<(I!C+2U+H`0)$8Q*UORZ=*IRLL]A@CH;8KF&?+"`I9EL>-8R(%C
M2FU'CS'I*XHE#"8NS+N^@GF-_DMBDH/)L<)MGR!8='O#+<`=QS2=B0C@\M`^
M0*G8X??1TJVJ3#VHVF=(!,9[H+%KH!YL,%9`',C;8@=II(*JLP#]0(C(JVZA
MXE<0.;2R/@C0V$?"O6J+TKBRU0/(3C4W<?3]5P_1]\?'"O@TU6PT\0B(\MMR
M^^[`YMG`]Z+`YI`H!@51.30'NF?0*`%//J]EY@".C8]7%.@%.D"C+OOX_6W+
M,^I83\B`<)98GSPT76FX@;C^6#:'7=[N\T(=>XT[%`16^P'U/C&.?;6?E+Y6
M&+>UGD/8]@VJIV-=0#K0=:W6TG-3Z8X*D\RG)320^C%X,AK+LLQ:KU)/5M!M
M;C+63T?5S4#YI82^?U+(#67@3*K7`]MCG1\A0[;ESP`.2.20QW$`VVYT'U#J
M`5[UZJHC6QCI(+*`(N+4ESQ\Z%]T6X.*.)5C6INVRD1A78M$SSDTM:9@K2%Z
M%4HKQ:4WG/P!O=IN77?LFQE,=A#46RBG(?X5K>I/M(QN4V]TP;B`"H2K^AD5
M0]6;)J[-!_<TS9,31<N,$'^$WF2^9/=M38[W)E`&8?6F)QR@2MAF'7T+21ZV
M68&!RTX7B!IN9D0X%QELR["``I@O^SF70RTC;,(K=N"CJGZR-0GR@84]9*1C
MI=M7F[VM>B:F`\_W\HT+';3J1%:M)M/P=OZ(1[RXP!EY"11@A,>VR3<+H8#X
MVA\OW?S%F.O](%D_HTET-VH=V79MY\%N`@><YR+U!C:HFH.9`.DV#G5B<;*.
MOCFVN/4>>H"5.P7U4-9^5%`MT?3HZ;2]$:2#]75@0,$MV]#A[,LJ;[4?5S:+
M08P^%76CL!4"5X<>9C.;`P`IXR]!/X_3C(U."Q/)/>YP7\@)N9F9+:$#/^^=
M1,&$)*.2[T0,R'7(5C\4\,CS-B\KFP>>2PAG_217X,5._3KIXGU/O4@3Q&*V
M9!/$>#P4$H/3,%<$C6,X%+@(D>,!DO\XU(\'6%NKT:*IMR4BOK19>)R"2DPN
M>QT4S\O*/O]1U;CS4=^$[E7>'?%*;)&8P>A0`HJACA)2N)@Q7PR<2@`E@&?4
MA3X'H+DYGQODC0+..'<B+LW0;'SH`N(37T9R[L<E/$OM===%0W5*_=B%JJ71
M-[&PP*#1VAE",P$'VCA_:I6=H&L/4U`T-J\*B]&BJ7P+M52C1.502L;Q*'%0
MURK5F"=SG1F_PY0/IJF@\UM=YK1IH]'7-"8@A4*EN2F[HFHZ=1I8YW5GAF7C
M$(0[+:""Q!>1Z9!!!+4XL)G<E<@`]1J,N3U6)V/3DP+P4EJ8)D2?GHZ/'6JK
MU/T$WIA"OE!U?Q%7"Z@A]H5D3+P>8A;;:*C?=('$5V(OX9WTI01S/NG6QUP.
MV+K_@G,OD26HG7LOE"6H'RM3&:>C,#EZYZBLW;V'G?HZQ((V+DS9+[8E17.L
M-F9$FT=XG=CJ-+(!UP-5E[!OH6];IEI^/';0B:!;+O!>P%!;)H,"4C<#&^Z-
M34UM0M46=%+K$0O$`N,')\;'6W>1Q2)*,Q)QS=5PO'ZM#`AXP@P!NT#`$F`]
M1`"YG04)2)QD(8(TB^/@$:F,:1HD2'$J'2)(<-@8(H@1;R$"(:Y(P84,,\E$
M&B:@0@1MD1*1!*5(,BC,@P02PVZ((!4\R&22X'0K1!#S-$P@^!4FH5P($S!\
M6RQ$0%D6EH*P.,ADG&'1'R)(L7@.$8!CT2`!A/XP@6`L?`3'F5R(@`%%D(#R
M,*)B<L46(F,R>`3X51H44X#G!#$I$!!!`E!$F$"/[D($H*<P`4".!`DH2X+.
M*P@+B\DS$0=WX%+P(`\\%6$>>`**"!+$5P((%U?B).<B">*!0Q@,$]!K!`1O
MC0($+!-AT#+)93#CL#2)@ZIF";XN$R*(\>W&(`&[(@5B+DC`KW@6@TX[+`6X
M?UA1E(1S%KZ&&=R!9B2L:BI)&M0DA;07Y`%O*8*`H3$-US!44!IT',II%B9@
M-%S#4$K#$882D"-$D-%P9I:4ABL82L+%PQ5#Q92$(R!)@OSQ*U9B)!S^:`@G
M/UF2V+!`^4P1GD78=-LBG)ZU(23QK_?$U,PKR)IDT@VKS%NT6^@):CW0F]3:
M9IL?_HA;OF!/\&=D:!TC2Q+^,%>._J_5_=T_[D<_ZX@A-4BFR73-K2GTIPP_
MF<?ZXVXL+ZY!N05.=G-3)SF_T-2-N$J8X\HQZ)E)]4=-D$[Y<L_!!O#?V][;
MQ:_R2R]F#/1XC>H82[R^1MP8@E/&['/(+ES<]@HC5'O02TGW#B.EJ;D5_/`W
MWYN=MH6_Y#1)00U^>I;%]E<H?]6O#5\P5@*]@]6)4\]4$8;@1"?N>7(SAO0W
M^:6W)\E:ZI\S`<JLIV$CF(S1NO4H=NL7T!)ZJYP2=YW/,5/IZWS\/4.8&8TS
MHK>>,'.^?AMTZ:5!R3D'B9$[.6%@6+Y1&?J;<]KXXAHC4I^8DE-.AO5;6<FR
M>5:@@%T!"L,,:5R=:^9L^3:@7K3,X$!ZT)#.(M2OWX[0U+Y,<8I0>2GF8I,@
MTUEH3M=O@J9CXUJXQR-F,#E9_OR#$_:9!TM]PAP&W?J-FL<75V95+\D*^JQ+
M,93+.0V<+=^$O<L:F`N2^".260BZ]3=`,&6S$,RBZU$2CYV%XF3]-BBFERX=
M9Z,DGC2'R/'R;8B\Y7RI#YH%IEU_"S#G#)+&*R:O\*/A=*Z/L^7;\'E1']/8
M*+)Y8+KU-P`SYG/`A%@="H[POUE$3M9O0V3\>;4P'C$'Q?'R;5#\K(.E/F$6
M@W;]+1B<TWV2K"AAH>!XKH&SY=O`=U$#\^&(2=LCX:?*#MZ9:TOL1_^K^IGP
MRMD8K0.*I^LWH7CXB2\;?L.<VE=A`<[4W;.V*M_VJOV,F&?$=!)[Z8AK<^S'
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M[%Y@0S`ONWDVA!DB3P0V!)=D-\]FXPMY4SV@X\N<])+$JT32P,3)ZL"I8\J[
M(9@7PY'-113RYFJ"7JHFK-]GEZ?#R7@Z/-U:@&32_Y[+Y/A+1]@+V5M-P+,X
M2DP=D25K*>+$6.";]SM"$.:/"/[ZY9<<D8R.&-7TTWF<OKH.C?H_9C1XJ?21
M2A:\^?K(4AZ\._O(0Z^4`(]?_^?^[O[N_SV?/XP-"F5N9'-T<F5A;0T*#0IE
M;F1O8FH-"@T*,3<U(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3<V(#`@4B!=
M#0HO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-
M"B]297-O=7)C97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&
M86)C,30@,C`P(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@
M4@T*+T9A8F,W(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU
M(#`@4@T*/CX-"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B])
M;6%G94,-"B]);6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J
M#0H-"C$W-B`P(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N
M9W1H(#0R-#$-"CX^#0IS=')E86T-"GB<O5M9D^.V$7Z?JOD/J#S$FY16(0Y>
MC_;:FZS+3IQXJI*'O%`D-,(N1<H\9BS_^G0W0)":F<4DMICR,9((`>CKZZ\;
MT%?_NKWYZ?8FVB9YS"+\AUYEVUC9_Y7'VQM.3S@3">,)?2(8C\0VST7&LBAB
M>9*Q3M_>_),U-%>J8IPHSC+\P[K[VYO#[<W^CS@5_K/X(-HJ)6&!K9*QA#\R
M%^+R>:YB?)[+%)]G62)?GE"PMR*!+V<\8C!*);2E/<E'S[A_)I-YNU_=W=[\
MZ7VQ*U/&);N#\:0&FG(2G*.\2K$[$/UMM.51"J]+^SI)$W;W>'OSYCLSF/MB
M,&VS87\;#KIC/W1MJ75EFON>M1V[.YBN8C\4W7!F[^K"'.'3/?O0#+JN=3F,
M18W?.&E\_J'9=_`]?=3-P/[`[C[>WGP#&_W[?RT-F2H@C;#2O/FW4-&OG#^H
MK2BE^4%!F<@G92D%'D7*NCMH]JX]GHKF_$7/RO9XU%UI0`/]6):Z[YGI6:5/
MNJE0`:9A)U`;:QO6:$.Z-59!\"\\&F!0SXJF8B=08&?T4'1GUIG[PT`Z'DCS
M.(71_88U8(Q=IXOR@%^'+?Q:#0<TD.>15T`:SPK`UZB`VI2ZZ74/>RL&^)]7
M!SL4/0-Y=*<KD')HV2-(#.O?%R`#O#4@TZ#+0]/6[3W(,\E=C>70;ZWK]3#+
M@V9[4^MJ0P-`A;C(?AS&3K,"_JO-)UV?<48<MG%J7$,5$+A.%;',O"IXFEI5
M%*<3:(,B!UWA0:-AV;UN-(4-OF#[KK@_DI6?Z>M8G$%%_0$E&0=3FU^T51D.
M^OI<5*9D/]3%L&^[([N;%'=&QX?9)\6M(7><.+F%``B;Y,Z<V&V'6^C/_:"/
M/;XDR=`RO3F:NNA0(+^]9Z,K_:!K0(MJ%G;L-7J[&;;L`SJ]AO?.JA<Z[G0_
MUA15IN]'75U$T%*U*^A$YCXL^.P+*G%A@8;$H&A)&-Q+B4@)>_0N?]Y<[/&Q
M'>L*8$%3<+2[H0"Y"N;B"QRG/=+X&0/.VQ40->?YFH":1V+2F\IF7^+PR.'I
M`N$H)(J^ATSR/%P`6/7Q5+=G##)X8+H+T)S53'[5CN`[(_SMS"_D/>!:H-ZJ
M,C;1#<_6=1:XO@JR+/;AE,XI)<LSJX+)B9\@';@TN=`S37SQ!$9=1M$7@0.`
MNDA5@$[H;*8IQPXRU:X?BF;`K%6VO0N?R@!^]:`;C,05E`!,R_E!FHLY?K@#
ME6/1%(XU4#"C@!#W-0-:T;=-HVO43Z7WD%G1`2"9Z'K/BGNP63]0+FPGZ"@=
M1^D@'0%XEFZ\1PMXT+I<O*`PIXG"N/2[@@X03*T.N/(ZD&DRY1,G#&T.#/A^
M[/#5L>THRTVN^@GE<3).7WF:5W;@0+M:+Y#%-!_'IAS`RK/\^J?1##2NT[71
M>_9X,.7!.<L*\DLUR2^0?#KY\XA;^?5^KVF'D-UW=5M^>N+UQ0Z2Y&`SOU4-
M<\EDLV!BF$;1A<`_:I^&+)>P@LU9!*<O'I&>@.\LPZ(JCN"-J_@`]_PRQH0Z
MX6'.+WU@(3DEQ<*!`:;))<5^R0$`*1T;W8_UYB7?Z-#RG<T\)_AHDA>5Y/RE
M;<A15M!`Y`EF(F:"*833`+H[\RS3I<$%6%\"&PK4M,,+#F^QP$^$%`7V6@"8
MT$!$O@TS>WI0UY0>"&G!HYIALS*=2#-/+66BYE#(<JL$ZZFZ@;_(J,'/Z^),
M*<)Y](7#4X+#X`6Y#(@S`-<Z#<1&7("`B#!-4U#\'S7DQ8IP<*;?7R.T6AZ&
M(M?%8P_@@&/VA:DQ(ZV@A23Q@)`OM>`JTP4O6N*[MZG5TJDCDUU8C-QFJ2(J
MF!Y`$C+^+/;U"56JDC4)52HF(AIE4GJ=27R-.G-)PSKP4/S<-NT1"@E`C[XW
M>T>EG2XG=5UYER*?MVFM"KH0XNJK)`ME\&C61>J(5<_><7#@^Z(Q_9$]%EB9
M0Q0<30/(-_8NC8):D&<`[)P.1*GHG0V1+=J0?8^(=&PK"*`U@H![ALRS.2MF
MB>LX?-:&4Q@;8$3PD;;P!2(_&LA\A/+3-T!>D+X`D@<IML-@@>)TM'C?GW1)
ML'IET>)8+6030GJLCWGLV/\_IPH0MD,B]I"8`/6TK^@(],$@U]<[M@NG/)3(
M.0\E+I"*!O+*9;1PNT_*,A5H?/,T[3I.<<+^64\=G,GCT-FHWCT`NP1`+X%J
M`K`AFSF@<T$*=WV-9Y;!:=[QJ]L'59!FWCQ)_*S0_Q%%=;*?6G`DA,YI4Y.S
M60Q^P=O\`_PZD*N/P.UP-E?83TVN1PS&W7DBO11PRP2_0V;Z@-VO7='K-6AI
MDDRT7$@??RI/7"H&^V/QH!^*>KQP!^#,\"&(`A+7ED*"9B;GQ>]4IB_'OJ?>
M!1D?/RSA'?!/:@!V[5[3\Z)V&D61@;P=GJCI<5*F:6`?IMJLH0?EZ?FB\2?C
M*1PJ]JB)FDWM8H8M+U(%M6,P*B`OCT_"8C*@E0\H17_P:1ORL;7XAXM\!(JK
MB-6Y,1N<NM?#4.M908M]K*`+D<ZEFL?D"9*)..DKKZJD7S476Q5A5?0++/;V
MVNND2^G$LA!58NKQ>M7:.G.#=EM$^EP]4,/7MGNA1.D`):Z\7:FR_X]>9+PT
M>Y3G<RY.A5PVOXE+=EWA:K`-E5!=>P:.;6SK%Y2$C0>KHGX`_OV<KB->(,"N
MX+S<5UA1//<JL\CQ(FJU0HK!6ML,OR7W!VAP[,X15J+!\=R;3]6<O>5T3+%,
M(54+5D$X@7(8$NRQ;<S06N`ZC3NP*0%UW?90Y5"VM=V1DKY.%CWIKB#$-C89
M`.4:^P&/:NAT8^Y(SHTY9)&N^/HM9V$A%?@V/9^+)Z64;Z:T'58X+T"KRV4Z
MH`+72?,J`,%+;,.5Z+LKR#*WU^/%D0//I^ZZY8E!#3N);3=S)OI3^_3,'DQ;
M@]071P5?])_I`OHFF<W`:S<$8N&K@$3-"A"I@V1+`+`]59H3F<[V`8N3;8+C
M1T5I>]O++IYIRGJLEEE[R_[2/H+:N@WE4ONE"^E@:E]<S\VRYVWC%;00>4Z>
MJ467.$YF$G+1J'Z];?RDC8IRMN-0.FJ[U`!(W2`3O5`%G60-2%TQ[AT;FYI.
MUU>`RGR;/!9S4'.'W)1\^[9^T/Y@=/;C??&`3MLM>V)^-(0&'B[IYGXXG%$[
MIB7*.IBC7@/^E>OW_VKX#]]J4*Z5CA<9>.+CA4OI$.,?&IS@&W!8B(L?QJX\
M0/$`NFJ&#LR]@KB2KYGM%/?47/(Y+J+(9;L/#?L>C"[@@TN@.CG1$3K8V,QG
MKQQF`L_OJ,(N=8V^4&,(_3N*(YSAVJPS5EZ*Q/>$Y+5722*_"B@HBFV'_<V/
M9K@Z7<^B%P125U\E\:M<L%\P$[^ZC7*Y\#0ALKEC$^6N)P`.U8]8]!+A[S#*
MM(VRR=60)U"4V9+W_>_?K8"3,G<50;I-)7+<7VS\IU.)]I>VIOM+&_;==^_(
MJ:^\"2@/IDVLY\\\FD6E/I5%.B_=M9<#GWHNU+5]FD-4>ONM[=/`IOQBB`A<
M^4,WD4^-XHI8X;<C%`>2;Q!&U5HX*/*75'QMOP'1%GX3J2B;A9ZJP'?SW;7O
M$/A]EOP2WOQ8U/#BOM/$K5;H#*_O9C'D@I?<#+T@<O4\>=P*X!"G?*G_)%OT
MD-S9A-;LKT`L68Y[N#S3Q`M?X(_N"M@*X)DM^@/YO+-4/N=.,XY^:,HME`SL
M?=UVIBH`YKM3V]E>!C4'#RU6U[:AB\6"J0Q>S#$7W*1UU8D9Z+X@-HSOF[DD
M>]DC5U!!XML'*ID[8'DBYD+C,@;\B01RB>WU&:14=D=OUI!6^$Z!G-M:*A+9
MW"Q!L:;2T9YD%.P$C!"-@\VKL<&K%Y\:L"]V]W_WY:XHV^)W.+9N2P)05Y'<
MX1"@D]^.)Y@3RLS)8U:"U!@AU4FX'J3&"*FS'NGH!)="::^\5`)V>2[0M?$Q
MD<JO`O@H$RPFIC1\]=,F/%R8U2?4W..(TY=Z=@@.]NQ_E3,?&<VGZ#[ZE731
MOS<-8!"U5A[@A;^*^<2S$<WP-&?H\$(&#?_9'"$4``8+IJ)-%$6L_VG$J['[
MMEW>V8!9]J;4;&>PN8"WI'L-==C!-:_6;!OBZ?S$"V+;.7VS&PW!_*_%M=!R
M\=32B=)\H>NII7X7`OX78+C=U=C(TOV4'\D(\'T\>%MJSIW2(:Y1)8+H]-@2
M"`G*^V?0>`^&J>OVT75PUU"WG#HZ43PWXR4UYNFF3]W2@0)R4-J<N^"X9*.I
M#<FOQ\[N$S`71+DV9P22,FUVU8,6D65+K2313$%XY-HW:!O7I=I,A@:I(<(.
M9F<PV5!07OT0#GSC_Z.$.$H62A#T(YWIG$8X&((JNNGWNNLF[R1?QL*[<>?E
MKLWIW@R'HB$7,JM44J`9P6=*ZXTFIA\279P1V.J_8#V&+\2B->+&[L]ND"1A
M!2!A3?WKMG-/[6/_\P`/Q'Z:+WKV5>ON;7YM.EBQA5#&+Q?L6'P$NC&<F3OF
M,LW\>YQJ&HL+K'&&#H;T!XAS^T3&T[T^$!DE>@^6+4U?MNRN&WMWV_#[HOO$
MOMRR;XY%O2^ZG7V&&/@G;-Z"S4$$NO]*!^F];;0`?.%/9:QD-9U;X(4@^VZ#
M_>QG\[H9$4;VQ='4:YQG\&P^25WX"K6%Z9:G/N[HDO,'$@7;U>M=2.-0\$P;
M6N]"&@<`G<46,?>X%O/I5,Z>-C7VP,'^5L386S!L/S;5Q95-PGE+RS&\]1ZO
MH3VY<(3TPU3VAT=T*Z(]V9_*T'6OCZU9A4+P-/+`)>=?-"2QR^EX'1-OC/HS
MM,5I.45]B0>+-?WVZ?#9K$U%,<Q2`DCL-+@(5HLC1@YHY#"=8?E;,U;89TNO
M('T\U8[1\L(>]NIL[3@+V]N[>&V)O[N82`A=$--]V9D=%K[FJ/==\>P4AGXO
MD*<Y2_.(2=KDO!OZ`2D,4(FR`\1G!D"=FP4'"+SR$!K`XUP%!T1Q&EPBS6,E
M@@.R.`HND:8JD\$!21P%I4AC%98B53$/;U(B-0@-$"H)VB+EV%\/#8CP^"(P
M(,GQ=#\T(,-F1FA`JB"%AP8D*@H/B.4KFU2@J>``*45X@)`B+`4767B3$39`
M`P/B3*3A`:E(DN"`!&E/:$`L5'@));+P`"GCH)BQD&&/BODKMH@CR8-+J)RN
M60<&9#(-^J2"R`F*J1(95A14J2(HIE(BK`<E)8^#`X3(@L&KN'A%S$BEP1ED
MKN+@'F2FPGL`1<?!/<CD%0"1\2LX*97*@_X`+AG&!RE>&\!5$MY#I,).*W(\
MSP@-R)(TJ&H(715T&)%":@\.2$18"A&+L+&$>B6RA%116`H(_["B!`_G+,$Y
M#\\0\;"J>8X_O`@-R*(TN`?@DF$PYPD/<Q@.,!<,'`Y)+SQ`\C"'X3!!6$S.
MLZ"Q>,3#J3GG\A4B)L/LX15+0=(,;C".\N#^U"MFDE$8_\1KCA(%3/"3&^(R
M"9<OD/8<C.!).W]&VJ/$'WHAU4/63D7Z=`1"OPO#7UJT5*!='JW;:?[Q9YSR
M$6N(;W%#VQBWE,$?VRWR;^O;FQ_]IF7R^3TGRST_N8P!P<_]K4CW0\D7KQ>1
M^UG=\_1_JV9D#HL(6\[DR3:CBW;8[GI_Q454).9%@CVUW[1(LEP$O#&UBXCL
M:5GU"N:]3<.X_)8#DP\.$"H02K"';_YU>W-[\Q]8:*FI#0IE;F1S=')E86T-
M"@T*96YD;V)J#0H-"C$W-R`P(&]B:@T*/#P-"B]#;VYT96YT<R!;(#$W."`P
M(%(@70T*+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@70T*+U!A<F5N="`Q.#0@
M,"!2#0HO4F5S;W5R8V5S(#P\#0HO1F]N="`\/`T*+T9A8F,Q,"`Q.38@,"!2
M#0HO1F%B8S$T(#(P,"`P(%(-"B]&86)C,3@@,C`T(#`@4@T*+T9A8F,V(#$Y
M,B`P(%(-"B]&86)C-R`Q.3,@,"!2#0HO1F%B8S@@,3DT(#`@4@T*+T9A8F,Y
M(#$Y-2`P(%(-"CX^#0HO4')O8U-E="!;("]01$8-"B]497AT#0HO26UA9V5"
M#0HO26UA9V5##0HO26UA9V5)(%T-"CX^#0HO5'EP92`O4&%G90T*/CX-"F5N
M9&]B:@T*#0HQ-S@@,"!O8FH-"CP\#0HO1FEL=&5R("]&;&%T941E8V]D90T*
M+TQE;F=T:"`V,S@T#0H^/@T*<W1R96%M#0IXG+5=68_D1G)^;Z#_`R$LX+%!
MM?/@J3>OI/5JX6.],[+7@%[85>QN6M55K3KFT*]W1&;RS&`6@],-`9KJCTG&
MF9%?!LFJ/_[]]N:WVQMQEY5I)/`_\ZFX2Q/[O\WS[8TT1V2DLDAF!E'P(;DK
M2U5$A1!1*;+H6-_>_$^T-]?*DQ0OE!8%_A,='V]OGFYO'OX)+X7_#0!QER0:
M!-PE.M7PCRZ5&A\ODQ2/ESK'XT61:?J"*OI69JBV%!&,2JQ*#\8^<RSICNF!
MNG_\<'OSSW^J[C=@G(X^P'CC!G/)UG`)]@HX_<,S*B0%G/]A<WOS+:B+U_KP
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M_KTZ_EJ?H_^N=A>XO+O2Z:DZUB?\ZRV<`J>ZW,AEVGHET8EU"LK__O#\4NV_
M_,/)9``H?CH?-K_&$:3%MGYH]ABQ;0VF/^-GA)WB6_!'^WD49<@F\%_T<#P\
M=ZEQ%WV`80%WOX'U9:E;XXM<=L8GJ;-^4^VC^QJ2HMEBXE:[7;2I3D\QANY8
MGR]'D]P(C^,T[[4V6=S1Z'2(=H?](SH-X6'\_?#C7V_@A#QKG:"%ZN9%*:T/
M9NQH3EW"GV$VHT>ZV3#,<N.K^R]X\GVSK]J"L,A7U7[K_`WN>0/#T[*+?C9(
M??R,E@]R&H)O0G'8U4:KZAX^7B"[M\UI`YDP*7,VE]L8@ZLVE^,1BB54U^IT
MJD\G&`1%[@2I`R+0*Q_!&5@.VU)ZM]+<;,;<+"LZ>]^M\F4>]B4L?7CM,K^3
M*4Z?WXTS99H[9TIY%[VO'\V2\4-UKJ*?]F#OLTF(5[95@LQ6GW6VAO.F*-(V
M;TK9+21)FCI3__.E/H)=$.*3-1CB?*S;6HFY#%G^<MB;(U@_8$G<0QZ\'!NH
M=?7^L7HT^0&UYP*9`ND25;"2?FS.#61)=7^XG*-/3\WF":[_4AVQR,*5H6(V
M,/V:WJV8>&]@/612-VOROF86;AFM/E;-KKJ'B0)UX8PZU!^AG(&66Y#U>-E5
M1Y@&4!$PU3=/3?T0'3J';>M-<T+5GZM?<2D]0I$Y7%[0%W@()U?T=/B$10:J
M[F&#MD,=.<!"@:[9VS+=3;$WL!Y6ZK98)H-BF;L5`RPQ_H?EZR[Z^=SLFM]1
M$;`50KLYPLP^-E4\6@*07C5;R(#FH<%2`TEQK%\.Q[-Q8I="][`0;J.#+42/
M]>'Q6+U`$D#(G\VB81806%#JXT<@8C8_WB8!=,LFE11]V2QEX1;-P_[4G,XX
MT3\UYR<;KX&]-MHN7-92<,#>%,+=[LO=6I5GRP&H+*W*[WY1B7A]C^1EWA6$
MOAQHYX\/DUB?GXYU387XN^CGN_=W[6P`+\;1OYP:7%L[Q/CL/VIPYW$''T^#
M0W;-,5?PKPW^W>PN6W3Z&V1$7G0<LBB2OB0@NT(/G"[W)YB[U?$+3L^_'E#U
MKCJ8=-G61ZR,E\\P87"8G<GG&I*\X]<3YUA[J\WF<-F;VO%RV#6;9K".CJJO
M`:KGVC*MP^DMF%2>=70RSWH_Z+QH"060A>9^P"<NS\]H+A*BYG$/!0`8YYDR
M:LPHW`!KJIDZ;9Q/U0Z##!/*D4?S]Z<:/8!N;(Y;H+-'7$EB&X(W<$/2$<I4
MZ\X-,E76#0V(!L&.$[GR%;T@Q^^R..ICW:^CF"Y5N_FLCS&<NK\\P-IX.<)B
M@3D#=.P,'KZ<#V8?5N]__P(A?SD>MI?-&<3"IW/=X,QZJ5_.S=95H3?P@6JY
MI1+%H"C@9_3!`:=P=-\<7EET)CK1I;I+A)"&BKW[]K7E)`,39=(GNRARMYT&
MKKRY8/;!Y`9^N[7;O<=ZCZEG2#3,_1U0A</1$.`(,KW>G]K(0?DR$^!X@,RH
MSSA-SO7F:7_8'1Z_='-\V(G`:_89@2>_R98YEZI;_]+>\+QP]`^""BJ:E;E-
M/*/:!6H.S'N@*W4%^UJ;K[WZ-O-'!7^<^888]K5C;.DH^=UNY/5-Q_Y:6^#Z
M\B9=3F^>ZF=C-BHSF7IM$3_7GX$4V4W4RV7W8C]48"_8M;V@`6T1():Y22G8
MP>YY4`\&,_X-3,];VJL,F[#&IUJVQ.]:C7FK&:_@A%:Y-YWR0)T&7I"E&)2U
M=I<7FO3&"Y`&IBMD2.\>=KVX+<!M]>Y+:'(,-D!WL'-\B_AF';%7:6>9-EL<
MM$P)D<5`OX'%0Y8>GDW"FI2>F[)ND48?8)_S!?+B<P,[,S15BE]$DF+"[FNW
M:!N[0$I*"OGY/2'A#;S0=XH+W3?$M';-()/(K^N#NH)PCQSQ^F:E1=?YS?O8
MIMF`H7?MVL@19T/-FM_KTZ1#U9D&KAAMPP8[[^_>8`^39OE7[V$"EU<RG;F\
MV?.720[;'!%I<^'^"N8^!FZ+,VD'J)D!22:RX`"=PN(2&J#23`4'P&H<%B%2
M<$]@0`Y6!D7D!=[0"0W(DSQH!>P+PE;D:5*$E4R2/#Q`PXXC.$`E6=@*F:@B
M.$`D,F@%Y(L.*ID5&JAP:$"NL_"`3(>5S&!Q#@\`*\,#M"K#5BB5A)64*@OF
M0UJJ)#R@4#H)#H!PA@=D.+=#`U*5A@<8CA<:H'4XHU)U)1:I5'E8A%!9T,RD
MQ(9<:$"A5=#,)-=A1\'4+8-F)JD*^R&!E-/!`:!C</(FD')A,V$W%KZ"2%10
M!UTF81UT`5H$!^17"HC.KM1)G29I,!]TDH3K@];7!JA$AW6023AIM=!Y<,51
M998$7:V*3`83!F9%$1:1J[`5"HI4,%@JO3*SP$]YV`JMTZ"CE!;A-4LID8>O
M(,455PN1!ST)&Y8DJ(,L1+B8RUR&.8S,0,O@@%06X0$P>\,BM`Q7&`G%/A@L
M*65X:<9'`H(95<*(,,\*ARH795!#8(I!!=,K<8("%RY?5S)%B2LQ".7J;VZ(
MJZ!2$TR\A"!T3%SZCV1D73L]E?8>$SZR4K2[%;,_@1W3]X<]WF4YC=BZO<S?
M_A4O^0DW!G]!A>Y25*F`?VR7H/MS=WOS?O0D4H'+O<!ATG[:N4\)?K*'S<>G
MH;V(*9CB0!/8^YJDF-MX]%I!PCBM6@4[993Y:`:HL5[M<7"V$CR][*ES&ZY^
M?*;+3C&GXU@;.V"JF#L.*Q04%=Z]=EW(*'4-]C*_2S+4TMULSW)W#_9_Z^H8
M_;C?PK[[AWI3/]_#3MT]UI7-N!AWC\Z2UJBQ^G;`Q)+V>,J.O#TSNQ[Z`IF;
M=`F)GW;N4]KF@/LX2DC$5B9D4I2+$M)IU2K8*:/;%'`?QPF)H,0PKDA(,>>N
M?KR&NM,JYG0<:V,'3!5SQX$'P/Z6EX\2SE&V=U:F=[B(VO:CN5WG]2G6"U)E
MCI7?",)DE[GMP@X>MWA%:1J6N*3O&B7N'LX[]PC+3%KHK$O6-A!CE]L!$^^W
MQ_F3R)YYO4PE*NGTRKIT'2AC!TSU<L<SQ7=?GG=9@>ZS=P'?V3;A-$Q?(P=V
MU\RD^"IIY8JD2%39.K^-P]CC=L#$^>UQ?E+8,Q<D19GU>I6]7ITR=H"GESV>
MY6SWX:EM4D"P1.&>'GDWO-,S#=?7R-,)-SF^2EJQ(CE24V=L$%P\QIZW`Z9!
M<,=7)(<Y\WIRI+!V.KU:%<?*V`$3O=KC,$]2BM<$%,,G!5(5>$SG:Z\MON+:
M@;"G@X7"\+%V_?MQUSR[!UY/<\'/T\[)SM]CS]H!4R>[X_S@VS.7L=I.K[37
MJU/&#O#T2KO5EAF@#"I!./A?>>U@\*]<.Q3\LG>HJ3#X#!Q.^@^'<[6;"SLR
M:>?>UM-CG]H!$_>VQ]=1[4#8[PKSB@K,$;<5-8W.(7M^Z%AUB\_$('`++LG:
MAX)$_Y"<RMRC`[`"1._QYM]W8=T,@\[,EFZDFX^SF'6KW`+O&$X)DK*)`E-X
MN7QS)D-^:02EQ52!*<Y@D2P-#.G,!GN^AY[%9FNV@O;,Y?(S147`@Y?+SU@9
MH+/"&NHI,,49E$UP-#`,SX^`!_,H(T>^S;5\*G\",^27+/DZLZ&>5"@?9_`B
M5@X8&D5$8`KS>-ER^89U^!'PX.74P)S)D&]S'4ON6($IOER#C.<!Y#)^!#R8
M1XXX\E.J"GDP0W[*DE](<AWP<09/8&E@:(4?`0_F\919^3U_,O=1-4U06GP%
M04FZO9OLW^Q06>*>6O[QLWU#H7OV:8[>&4*1:)JCC'`>1YEM1T_:DB""(B<6
M9OK%GIFW#Q=JD=MN\[L_S&I0&E$D/7$X4P<M2EJ',M9:Q&52S'7CD%<DFB0J
MR>IVVX(P&$+AAV$`<UV0*5X8#!=!&RF.XG"N#GE&ZY#%(E5Q,7MGP9`+/PP>
MS&,K"\)@6`7>?R=HBH69+K!G,L)@"`E&G"(J#N?J4!1#'0:/^WK/^RZ0$J0C
MK8NC.>O*C`SL%%XG-1!80U;\P`Y@IE/MF8S`&IZ3:)K_.)RKPWB.AP*[0$J0
MY5P+K!WD!=:#UTD-!18YD%\X!S#7J>9,3F`+2:Y?0YRK0S&C@TQC7>@X3Y.Y
M1I$NJ3AX,(]AS=_6)KLM2K7W7I5J[[VJK+O=:3]VWWA"]))@Q("2]51MC+.H
MFNZ_LR)WMY9^&KP%MZ"#8ZUJ#>R,2;J[I2H)V=6.)CG>".=Q/#7W+$0_WC`I
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M=I0;3>T?UJ7HT(#0S6W15;S6CK'&=D!0^78TM0=9E:+VS`7*(Y=NE2]ZY3N-
M[8`KRMO1Y/;%X5R6*T<IJB4^UHDIBE]Q)N,DE;$LKM0]P]:=:<[*L3UV0-@T
M-YK:NUB8O840]-S#;VV;BU$A>T/2WI!.>SO@BB$IM:1Z,*_!O"#!S";!*5_T
MLZ/7V`X(*^]&D]NH=1PMTY*.`[$_OBXEN$-:6`/-;7KKJ-9G8^_8`4%'M:.I
M+=ZJ&C@RX$H37<PTT<7Z)KIHF^@JZ[]-,)72O1]NGHOH7_4-==#%3`==K.^@
MBX4==$%WT(<P;V>T2'!I))"[&K&R<=Z+'N]J1*R+(B[28.=<T)USL;ISOL`+
MAO;[[O=@WCYBD>#"FD;M`<3ZACGE_BQ.DBP6Q7S?.J&\[\$\ZK[`"88E"[IA
M/H1YM'N)8"2M8J9/+M;WR<7R/GE82I!QBB5]<B*>4WB=U&M]<C^>'LSCJ(L$
MVUE#\DNQKCTN1_%<PB\G#6T_`@-X#2FDLLLCA9/FME_;/)A'Z)9$HY#DTC+$
MU_2TR:5E44_;#X4'\PC/K!>HCK0N$I+W3'#..T.ZF.755.L8)5'D9HRSR`U'
M`Z`D*(G@.".8Q7%8\DLCB*(Z8YSU""-#`Z0C1I+/;T8PB]]PY&>*BH`'LV@.
M2WYA#278SAAG/<+(T``I"1$!#V9Q')9\FVL$U1G!+*K#D0^<PX2:8#QCG/4(
M(T>#,B,C,(59K(0A'[D$$0$/9I$3EGR;ZQ1'&>.L1Q@Y&N2"BH`'LVZSL^2G
M5!7R8!8AX<@O)+D.^#CK$4:&!L@=B`AX,(N,S,L?=5_PU462A;0XO_N"[R>Z
M1QA+V7U[FTZD^_8VI,K_=CB=S.]-_+3?')[=;S#TWZH;Z,B@8B1I&>$\TI(M
M>]4:15!L90CSV,HBP:5]OY2B*0YG/TY9=J+M)D8.-C$BEBJ-2ZD"71DCF&`M
M%N9V*,R9Q+?%!G8QAFGXX?!@'G59$`[#3=!,BK,X?,5=VF$X!KL8&>?EW!;&
M4`T_#A[,XRX+7&`X!GZ?&$%:AC"/M"P1C*P$HTNQ%8=S^S.I'D\%_.[L=BKD
M.H&Y,*M-F9'^[V&N+N9,WCPP;,./A0?SZ,N"6!A^@CZG>(O#N;MY/8E%.P\P
M%BJ#DA1JK!"A&,`K&BOL4"#M\$N2!_-XS))0%))<(88XN[$BH]`*D>LTENG<
M"F'HAQ^.`<R^Z58N#`?9:$DRFN(DJQ_]TVGWZ)]2W7?+ZURYGQKXR7RG</N3
M!T!P%C1C\%MX*%XSPGF\QFFYM!D#DBAZ,X1Y](8COS2"2);C<.ZR*HM.@]&R
MFF8JSD6^H#>#@@F6,X1YO9GE#C%\Q`^(!_,(#D=^80VE>([#N0$I<SH@*A;Z
M2C@,-_'#X<$\LK/<'8:BX/>Q$9QG"/,X#T,^4AR,.T5]',Z^-97,S(]T0<N&
MB,44YK5LEOO"4!0_%A[,XSP<^78*D-3'X6NHSR`6(^J3EG$IKL3$$!8_)@-X
M#0/J->(LN8:W^*7+@WE$B!&?0I)KR1#G$A`A9N:*2.*BO/)`F:$O?G`\F-??
MF77(N+^C<IK\M/@*\J/;;]12^!6:COR8K]-TY.=<'X'^1/7GEWH__8FC23<'
MU"!9SPCGL1ZGWM5N#HB@Z,X0YM&=18)+(X'D.0YG\YRD$^UM8=-"Q&4VVT5!
M3H)2"9)CX36MG%Z7Y:T</Q8>S&,Z"V)AJ`R:25$<A[-;.?DX%L,ZGNM83FCG
MI)OCAV(`L]\23=BA,*0$I%$L9PCS6,Z"4!@:@\&FZ(W#5SQY0]I//WES14J0
MNK0&AIZ\H6([A==)O?+D#1%/#^8QI46"[10B*9+#V11I/+7Z)=BG1Y/.D.]Z
M#^;=W%KB`>0L?E7S8!X)6B*XD.0*,\2YKA^DF[_"E$D,0*@5Y/M_`*]I!2TJ
M:V0K"/*/9$,MOH(-R?9WV+#$=ZT@(=PO-OU0OQSK36-_"M?\WMSSX7AN?O=_
M<IAN"X%F)$$:X3R"Y#1>VA8"211/&L(\GL217QI!)%UR^)JVD--@?+<E47&F
MLK!"AN"@8((Q#6%>6VBY0PRW\0/BP3RRQ)%?6$,ISN3P-;>_R(`(':>3A\/I
MQI`?$`_F-8:6.\0P'!!$4:8AS*-,#/G(73#R%'-R.)<Y924=$!V7Y;4^79F1
MX9C"/*JSW!V&H/CA\&`>X^'(M_.`)#X.7_&-'(-P7/M&CBM2@KQ&DK]63S>;
M_"![\#KA"Y\8\HN@!_.X%4-^(<E5:8BO:3!1<TZE(I;%%69C2)$?$`_F-9AF
M'3)J,*FB)"E5A_,I%9*$EE+UO]RLA78-IN^KEP9?X#+]I6V#O[L<>F((-:$H
MU!AG4:A6PVL])A1!<*<1S.).RP271@)%FEI\!6EJ14^^2$#&L@P]*F0D^FQI
M!+/8TA(7(*LA?._!+)JT3'!A32/X48NS;YM)VO=9%L.4"/23"-=[,(L7+?$`
M\A>40!"B$<PB1(L$`^,QP2684(NSF9"><;V*53+[37-E1KI^"K,XT!(/(%<A
M7._!+/*S3+#-;HKUM/@*UC-P_376<T5*B'AT!H:^AXR(IP>ODWJEAT14,0]F
M\9Q%@@M)KB!#?`7!(:=2*LLXR><ZTDA$"-][,(O9S+N`ZADAB2$)3HNO(#AY
M^_O68O`=KZ4:OIU>G4[U^115YRN_G45VC8Q>%.49X3S*D\_]>`'9-4))%/,9
MPCSFPY%OJ2=)@!R^XB7V5H-1^B8I+L)Q6I;7&T=&-D&%AC"/"BWWB7:_F4`Q
MHE4QL6<RY-L.*TF,'+[BS78R)FFL\>O2<A56R3`:/R0>S*-(RUUBB`W^("G!
ME(8PCRDQY&O[_"-)F!R^AC!1(2E%7.AKK;PR(^,QA7F\:;D_#-OQX^'!//K$
MD6^G`LFB'+[B=?5A/$:OJ\,TP>JEKE2NU*US%/VQ\(I'BP9*<1\M(JJ8!_,8
M$2-$A217EB&^XAWVN95%ZCS6Q16=#*/QX^/!/(HTZY-Q\R>5-#<:XYQWV/%'
MX*]V.`HK@J0X(YQ'<9:(1BH"(BAN,X1YW&:1X-)(($G-"&>]KKY$M*$:*(+@
M+D.8QUV6",X4Y6P/YI&618(+:QK%5D8XZ\WT):(-B?"=[<$\5K)(L$TDBHX,
M81X=62(8^0:&D^(A(YSU$OHBT65&.GL*\RC'`L&&&OC.]F`>UU@DV&8P23)&
M..M]\T6B<=WWG>W!O#[*(L$I548\F,<:E@@N)%FS?9SU:OD2T681]YWMP3Q6
M,"O8+ONR+.9_;CX;_MS\9-8(,$IT3Q6[WV.=$P+.,T+8?70PNK`&E-E=D4`1
M-T3K3Z\H)!&J%S)J6[ZJD&PH9'"S<$SE442NC`AE)/27PF^!A,/?YOC"1."X
MQ-_#G!L`(G[\^^W-[<W_`RA\HC4-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*
M,3<Y(#`@;V)J#0H\/`T*+T-O;G1E;G1S(%L@,3@P(#`@4B!=#0HO365D:6%"
M;W@@6R`P(#`@-C$R(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C
M97,@/#P-"B]&;VYT(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P
M(#`@4@T*+T9A8F,Q."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W
M(#$Y,R`P(%(-"B]&86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-
M"B]0<F]C4V5T(%L@+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B])
M;6%G94D@70T*/CX-"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C$X,"`P
M(&]B:@T*/#P-"B]&:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#8U-C4-
M"CX^#0IS=')E86T-"GB<M5U;D^,V=G[OJOX/?-BJ3%)RA[@0`/V6]=K9S:9V
MD\RXLJGRBZ9'/=96MS26U+[LKP\.+B1!'H(X&+M<,R-_.N2Y`OAP>-'O_W9_
M]\/]7?N@^JYIX3_WR3QTTO_U^')_Q]PWK.&J8<HAO&$=?^A[;AK3MDW/3',Y
MW-_];W-RY]*R@Q-UQL`_S>7C_=WW]W=/_P*G@O\F0/L@I;`*'J3HA/U'])RG
MW_>R@^][H>%[8Y3`3\B;+[2T]K"VL4)2.8N>G'OPE1B^$FHT]O?O[N_^]9O]
M^T?KFFC>67$7!'?"Z#;CC;8FOGL!:ZRG[Q[O[[X`NWG7O/OI_N[-=VW7[NU?
MK/G3Z7:X'*ZWYO#SI\/I>K"*GO>WX^EC<SLWM^\/S:?7R^/W>_O%^U_<_W_[
M\/:A.7\Z7+S4]?#QY7"Z->>GYF5_>GW:/]Y>+_#%X8?7XR?WU?':[)^?SX_[
MV^%#/.M?#O;OR_/^].$Z.=D_-^_^?G_WM?7POW^%*-C0:B9C%+16+@YO@L4/
M-=IT-N9*:Z>MUP]&:QOV?[BP,\-\U!E_L/%^/+\<FG?[GP_7.G=5QH#.&_#F
M.R[;7S>8<';9QF`*+F-1B=Z>U+GWEW/SZ7+^\7@]GD_-T_G2?'LZ0LK?WFSF
MK\W1>WX#SQM;4<W[P^%DC7@\?SP=_V'EX!"HC5\.^TMS.'VPT!\.CX>7]X=+
M(]BNX6VK&GL<R'QU?OFT/_WBSF-/_'JY6.G?JI#`=RZ"[[QE_3"@5/3]^7R]
M6K=L/3N3[(#:OW\^7K^W5NV;I]?GY^;'_?.K-<Z&!@;#3_O3X^&A>3>Z\D_#
M0#B?P*?FO\XP/';-'\_6H3_#7W#V=[/!L[\<FNOK^[\?'F\PMD*0?WW_;>B]
M_ZWIA@E%=&V84'Q6K=76,CM7_-W.`=</QT?GC'=S*(VK2W12#8\6/5[=)`+)
M?3I#A""/-I066U3!EY4.9H9.9]3G#IW,V:5=(MS9?_W,2$B!'Y5,Z"$S"CY#
M9B#VZ4"$,K(I.!P_GFSD7SZ=3W8Z=(&&*FZ>+N>7:2F^/X!PFC"HNOTU).I:
M-'*__'6#JKMN<+TVJIF$<2U_JX3Q,$G;A'%8CT/"#._'A'VZ'%_VEU^:#\>G
M)[L\V[G"IN'V$TR8MV3*&+-B!4Z'I^/-I?05TKV_C0NVG8]NK[>S/:5-ZP%R
M+>1WK24]4`P@=;"*['#]T9_KX@IEFM;K;Q"(<3UAA@^!T'U8+E>7`&NR_=`!
ML0#S+#TY?3R$R0>;9^-7EN=\"D[:\CZ>/\#Q-DH6?WV^A<J?KBXP<?]B@_5T
M/=Q^FW6%#^L*Z_IA]$JAX[QJK?EPL#4`ZQN2;)O(H[7\=+A-5C^_&%41G(U1
MT0IL5-AOC#:6#.N^;80[ZWBXH[Q60'7<"_`5@:X#VIH1D%W+L@)"*I,5X+++
MJV#2NI\3:(7.JM"]L,,[)V"$R7JAM<A[H2WIR!JI.Z'S`E+(;"ZT$"KO!1="
M9@688'DO6JLC)Z!Z;K=U.0'#=5[`6IDU4BG.\P(=Z_,"DO5Y+P3K\D9RIK/U
MH%K6906ZGMF)-"=@6)<7T(SG52BF\@(=+&4Y`<GS%=6)C5QTG)F\"L9TWLV6
MRVQ-RIZ+K)O2\'R@I&9]UDUI(YD7Z)CILP)VBLH.7BG8AIM<=/DSV/U=WH96
MY&VPFT*>M4&8C0E$Z(UYTEJ@LO5@G<S/#T)N"5@;\S9PD2]:P;C)KCBB[60V
MU'829-F"X<;T614<5K6L@!W^V61QM3&R>,=UW@L[_+.!XJ+/KUF<]R9_!M;G
M0\W;7F<CR?I>9FVP(S,_F3/3YCF,C2/+#ARFVCXO8+?<>16RS<\PS-9<-EG,
MTKQ\'%C+LA7%VK;-VF`V<J7[/FNBZE76PFXC4;+/SX!BHU3LJ,PG8:-869NA
MD3\$D4`DF4!X>F^3,/!T-N?IK%7#U@I8-6PKVH>V-Z%;]6[__MEM`K\ZGVZP
M^4_HO#_-__P[G/(GV#7\!QCTT(%)QOX#'<[)_S[?W[U-NMI&V*_L[/X2_+`?
MG^-'`Q^#A/O\?>JS!>UT9.-'WINP5O*5#L[$MKX;;!OL'"U2[K.74:EU@X2;
M26C6^6,E6S%O/`#:B8-YT=2924%F;EZ4`&9O%PQ2ZQI66FM?&YO74DD]-*\5
M],VA:/X/FCM?HWOR;B7<2LK!G\&WF0]!9N;/(*'(M>`/#=YDB\&FI===J%/X
M]!P^];$FPL>D2`&KK-'>B*(2#59%`P=C="R&\#$M3P`=M:JISG8M7N,!L+.-
ME@4C4W.\P-RR\+T"ADZL2P9%S7R3K^\>[/(J75V^<3VM17NC7I,E%TUO_X`B
M*'JF_?6--W]=OZ3P&7ZU4`KQ^EPKC;^@\.:MOS*U4AA"\1C^F(DTYEY@%O[X
M?4>N5W>DV9ZTI*7`T2XUC*.),5Y@;E?XOB9\4.>Q+"!^PH?OWZ['_6F1I\]1
M9#<8Q*KX+&U]155(NU,+T8^)2$/N!6;1C]_3J\(=65(5O1KMZD>[!F.\P,(N
M_[UEL-3PP:%#57P!UZE:WUQ_,[U<-L_7YRBT:QFQ.CY+FZFH#NB8QBR$A*2A
M]P+S+(3O*ZH#CBRHCL[N)X-=T<34&"\PLRM^;P=*AU&<C&&=@$6.F?5K?)]Y
M\E@)5>?.Y-T=&B+JJ%E<`K]^/KX<3_X:W5KV]4`E8L#3T'J!>93#]_3LNR,+
ML@\,;;"K&^T:C/$""[O"@BO("8*@;63_\TZ>S_[&N7/9-^.:X.:8<#//FW?G
MV_YY+>]`J4-\8ZC3H'J!67SC]W6,.Y/W!^-NAH(1Z`^S2V2GIASZ:>#6$5_)
M0>9*6C]L>2<W:'`5+JK:-:!YNW\^7+_,V^9X=.=V>8EM2YS$KZ-Q!=%QO+*;
M;'R>1KK9U>R'W)'E^@5,.%91-S-@B1.8)"D"CGB"IID!<YC&9`GZ%<<RL(#+
M]2M.TV_P#"QP`FMK*18XDK?,P`*FL4:*_MXITG/],YB@OR?I%\JGNIT9L,`)
MS(A4`XY((1F8PS1F5JZ_"Z-]EH$%7,X-X$B*?E_KBL\-F./E%BA:!(#,+#.P
M@&GLB*(?70<6,$$_:1WH3)COYR6PP`D\@30+.%JQC,`"IO&45?TC?P(V(31.
M4")>05#DL'MCDH\,!3X#1?GZY]OA<MH_-X^OU]OYY7!9HW>.4`B-<Y0$IW&4
MU0;UK#DI-$I./$R,BSLR*.[Y@VBU[SR_^=U:%PSF$:L*I2<!)]H@VAZWH=^I
M7N\ZIM=L`5XA-$I41'7+K2`-CE`LTS"!J2%0G)@&X")8&B8XU0:M<!O4CIEN
M)SN^V@*36!H6,(VM%*3!L0JK`:,I'B:&P!U)28,C))!QC*@$G&J#,5,;9&L'
MEK/ABR\6[:QM+5DZ$D/<K'G7*S2Q<[A.:R:Q79A,,/93E5AW)"6QCN<(C?.?
M@%-M2,=X+K$%6K(L9RNQ3FB9V`5<IS676(VN7Q.8&E1-7+\<?0(?,5H5<*H-
M1N(VL&YG#-_UJE]K%`F#A6,!TQC6^H5NM-MB3Q:NP#(5K\#:[6J\Z.D_#L_6
M(;TD*S&A9"-52W$25>.3Q\;"U27WH-P5Z;;C'1SO570P.L/,<,F4F9Q?41KE
M>`E.XWA\[1Z)4=XQJ6!^\"2UV0ODS0_2&$^<PK0F5HGQP*"\\=&/U&(OD#4^
M2J,4,^!4;F,/B^8G0]08L6L[6="0"DX%_U)/O$#>J2"-<=4I3..J)1D!1AB,
M5\,@GUCL!?+&!VF,[U:5DSNRP'C'!*/Q9C1^L-@+;!AO\'*:X%2.9NV8E%-N
M*2_0DJ7!^(-K>,?.!RK&+(V.%\@&*DIC/+ZJ1!,'<ED&'AN-[T?C!XN]P(;Q
M7AK;"TQA6LNRQ/A^-#[XD5KL!?+&!VET&Q'PFFU$68D6:,D2^L(2[<9U+<8L
MC4ZWO:Y%:6Q'4E>B4P=R%\S;81;MQG5M8K$7R!H?I;%=356)NB-+C`=V'HTW
MH_&#Q5Y@PW@OC6Z(`D[ES5PGBS(\5^%*%-Z.4+0P._8?'`L^IMYX@;QC01K;
M"WF8O"5I\9$'[WM8RY!AHR/=Z,A@O1?8<`3E?`N8UK`N*"^WZ0C&FW%LC!9[
M@;SQ01K=E@6<F`<E5O*`[+>WM61W7(4SH+OL[P,58Y9&QPMD`Q6EL2UC5983
M!_)->=/C3?D!K]CIM;$ISQ4;'L;N&`O/W[K[+-SCM5>X>R#3D0<CL-U:BM-V
M:VU91QY4(#NM!*;MM`H4PVX(-&"[I(B3&_&CSVDCH]UUQO[1;,T8.W*<TN7N
M)H%INYN2*"B.A7\!TW8F18H-'OX)7M.`Q\)?TH!'HK^`:<2](`C`D4$#0KH3
MF$:Z2Q1;RNKRBQ#FB-<0YK:X[[ZA)<LWVX*^.Y;/.5RG=:/OCN1S`=,8:I%B
M/VHP=AGQ&G8Y&4V;[#)MCR/QG\`UE!"KK04E3%OER,RV@&ETKB07)BP@"!6+
M>$V''%U82CKD2!06,(WNK$8!ZV\;;7#6HZN?E3-FE55CC6C0A%(;7=V(IE@`
M5$:CO>0$)C$<@GY':#3>#DYQT@V1%`N`QFBT=YO`)'9#T:\XEH$%3"(Y)/T&
MS\`")]T02;#`49EE!A8PB>&0]/=.$49T=&UWD:(?&(?&&X0I3KHADF)!K]`,
MS&$2)R'H[\)HQZA)50;<D13]OM91AI+@I!LB*18`_5AF8`&3+MJ3]*/KP`(F
M$1**?A/F>XR7)#CIADB"!8YU+".P@$ED9%U_VGOI>IR%1)S>>X'WXH8;(GMX
MFT%X_YMD;'Q)[7^>K]?PGEKW[K/9RPES_1AK&$I:$IQ&6E39X]N@`F,K4YC&
M5@H4.SIB-:`T)>#D?LRHVFUAI!FW,/V.*;WKY5I3P'$,T(N0%@]3K8$C1VN*
M-C&.:"RSL8!IS*4D&T!-L&Q,<*K_)LW&N(F1;&>4RC5GEGE8P#3J4A`"1S'@
M33,(9YG"-,Y2HAA("607(RL!IS9GI%P?"6S7"KT3K<FU4Y`,C##5&CB2.!*Z
M,`U@_*4J&^[(@FPX@@)1QXA+P*G;>:'QD:#U3IJUK;RC&\LT+&`:?RF)@$:7
MA`5,(RXEBDV8^C'&$G!R)T7EEH3>=#O3K[X.1A@L$!.8?(G-%`X$M+$B6YS2
MR.H;!XT<;AQT;W:-K[2%SS^YFPA_/%QO_JWXCM`4-%^L-2B/27`:CPE6EC9?
MK":,SDQA&ITIU^_8BU6$LIJ`5]R+%RU(9@_>LYUL]89!P$)`,4)KIC"M%T,(
MB.)80A8PC=%0]!L\(1.<NIRU"D^(GI%+O"VS3,8"IG&;\F`X1@(O7T4HSA2F
M41R"?F`TD'6,Z02<?!E*KHR.D@8-DHLY3&O0E,>B"S,"1G"J<N&/).CW`P#E
M.0$G\QR1Y(+%7,!B*_G.S+@.WK)9YF0"5UQ(FEA$67`=:5E.7`N8QH((^3%A
MQ<#(4,"IT>C[E;$B^QTW)=V<94`6,*V;LQJ0M)O#&4Y](EY!??CP.Q1=JX8W
MV<,+^P/UF?W0T/`;1+DF#F<X^4EP&OD)=FXV<:P*C/5,81KK*5#L:`UG.-T)
M.)GNR$'UXCITQ]A.]R+7P@&M"-?Q<$T+9[2EO(6SS,4"IA&>DEP`H\%R,<')
M+1R=YF(ZH:MNI]JU5#ABLDS%!"8_:BK)J7#L!%Z`CM"=*4RC.P6I<'P&DHWQ
MG(!3_>_$^K!@6NU:L6I-K]!<C'!-/X>8BR[,"!C=J<J%/W([%X[/0,PQGA/P
MFG[.)!?#.HIPG%D_9YF&!4SKYY1$0*.KPP*F,9D2Q2:L`AB%"3B9PG3KPT##
M?9=B[>T'CFXLPS"!:[HY1<,`[>:T'*<T$:^@-../GME@#-T<>+>YHS1_.'RZ
M'!Z/X=>&3A^:_<OY<CO^PP$%G9V6X^0FP6GDIEW[%3.\LV,U81QG"M,X3KE^
M1VE:CE.=@-=T=H(%L]N\Y,ZNM06='5",L)TI3.OL$`*B.):0!4PC.A3]!D_(
M!*<FI&=X0A3;]6PC'XZA+/.Q@&G-G?)X.')B%6%L9PK3V`Y!/Y`;2#Q&>@).
M)CT:SX<P:J>$VC"H5VA"YC"MPU,>D"[,#!CEJ4J(/Y*@WP\$E/D$O.*=').$
M;+V38T-+EMA$/[>>DG2RBR0OX#KEA7?Y+&?!!4PC5P3])BP_&,<*>$V;")T%
M6[[3HJ1-M`S(`J:UB58#DK2)M*44&*<:<#JGTD8/G$J,5\A:$:Z0?;7_=(1'
MKER7Z,/Q]GK)/G4%EF`<*L5)'"I:N-4@`A4(>4I@$GDJ40SL"#1@K"GB%:PI
MJDZ[F`P>_,F]_,QI7-*E!";1I:(0*([%?@&3>%*98H/'?H)7W-.#QA[NK6+M
M>B-&8K%?P"1J5!("H#"@`>%$"4SB1$6*X1>I(+L(&8HXE0PIL5+W>M>M/^O6
M*S3T<YA$@DHBT(41CK"?NM#[(TL4^_+&:$_$*VC/)/1;M&=#2XYY#`[F7D6&
MY',!UVG=Z"(AT]@")A&=(L4F+!4(PXEX!<-!AY)D[<ZL6@),!`G!`B91F_40
M8%TCK23.<")>P7"4B0QG\IK7GD\?*-]?KX?;%7ZA._]36FC?"&Q#.4^"TSB/
M6OO]`K1O!)HPZC.%:=2G7+]C.E81RH`"7O'<>;0@70F@_ZQVK=[8&3OJ`KH1
M+C2%:5R($!/%L9PL8!HEHN@W>$XF>,7#Z&A.Q$ZV:M<KD3?),9IE2A8PC2*5
MA\01&_C-4X0I36$:4R+H!V($N<<(4\!K"!.6$BUV%M]N'F'YF,,TWE0>CRY,
M#QA]JLJ'/Y*@WP\%E$4%G+KJPL9MDH_D7ER^4\RF16X,$\=6EFF9P!5W"$V,
MHMXAA,QB"YC&B`@I,F$%P8A1P"L>/,=7%IN;3NQ:M?&&*<=HEC%9P#2*M!H3
M3WXZ^*4B0??6'>K9%_P`FPP/=;WYZO5R.9QN7RZXO>R=+GM"<FK=H6M,#\ZM
MO!^ZHFP4SY\;8@CGKHO^^JDQ@MI)-<W%0%!G."E'7?BEU_DO:FX,#PBY=*=.
MC)GBBC@\X-!HS71X%`Q6Y6.@9L;,8=*>%+7E=UN&&*=1MW-+YCCA0G@[-26[
M/=[6DJW%H&7SS6'"8-&>P!W]6C]D?SOS24.ZLR0('0TI3AH-8G@*5??^OL4W
MWYPOA^/'T]H&&JH6?FT2&P@!KQD(`GFB*;>/5]YO;`1XF)@3=Z1`7E*<-<(X
M;6CU)WAY:;0='@LE=HRM]>5<02VC,8%K*K0H&NBTS:0OR&Y6J"E.*E2&-%@*
M)DHH+:L5JK*;5VN"TZJUTAKE8Z!FQLQA6M'6VF*<4JC1;EZ["4XHFJ[6&E=O
MR\@L8%H!%]F23+$27K&$3+$SG%2Y[?`+EJWI?4_LS1\.3P=+"S]\F9EE02<V
MRT:\9I;%7@.U,<O*7F.S;(!K"K8MX3SI+`O:L%DVXC652C0#*@J)Q02N*=$B
M([`Y5IH6K]04IU0J//U428U!*UJK`:^HU<$:^AP+6K&2]7!%R4I3PD[0.1:4
MHI6;X"1V/(G,%CO>T))CQU%+"3M&`CZ!*\9%6<!G\V77A]]2@4_^MU2@:_<<
MOO8?PZM]TUD_W?*/8ZF^%2"5IA)KQ:,+T9O!<N8^@H#_N'`BBHW-A,D8##AU
M2^@.16[<R;WK'$HN^*"&/$P,=P)K/@2Q>0=LA&M&KBJ:189C7?%%#\SHP6"V
M$UCUP'^GV[D+(UXSWA5R6_C*>,]KR8[WH&7U8C&\'SN$)D8IC8<36`E-%$-:
M>77)]4?6+1%0V?;P,%D($R<+R8<AYS]F?G@))-`Y(^+T/8Z4R%,@A2N>=R=Z
M-GC1#N-/9G])*DJC\X=LJ^>/,H_2^2.XHH;43.QW`JDKZ<&2#0?+<=8,B74"
MV<1&:8P]3&':'"216?1WN0DHAL",(1C\=@(K(?#?L>%@R69^>X&-$'@1E+0D
M.*FI@08!:6J@[^T/`8FQ21UQ`GF?HC3&43Q<,_L4%;>?%812M;."4"6-PC!6
M04]E3Z-<C_+^Z+H5N5@/Q!CTU&6G3`TVLPN)MUEG."F'76RS<B:&E_U9>AE>
M]O?MZ7@[?&C>WO:WV0V_Z$P-EF"[K8A7[+:BA15K#VA%YLL$IE4(9DO!A0C0
MB,U:*4ZX?-DFIC`Y7LQM6;MC6NZZK>>J7"DN`[2`:;4]6E7TN"Q4H,#IR@PG
M%;6(#PAR;<9?#^$F_'K('\^GC\V?[5^9/1NH1RLYX#65+$KV+.FV`]1A)2QJ
MU@9_9,G:D.X<0!M:OJ)ZT45C8?J=-3'3Y4*B,8%KYN*B:.!3'6.!I\.GY_"I
MBPPW?,SP=)!`"S_%287/^F%OS\:G.#@+3W'\]?;]X=(\(;M]?/[T+D9O!\]$
MI*_A8XZ[@PC&W2->P=WAR0@J=X^NJ"%=$_N]0-Z5((VT``)<,Q89K8GA*I8-
M)'IP9+#>"VPXXD6P3D#$*QY6%Y,K&NG#ZD+N6K5Q^RP0Y>!8]#'UQ@MD'8O2
MR#X^P#7KV>A6V>L?;'GRO@T3`WQZ#I]D'#[A(];M@Z^P&6'`Z1R=][0K35"6
MP8'HRV`WC\,F?$1[??`=-MXC7C'>RWQ(QWOT00U9F!CN!3BZ4?7?B?%@,1XL
MQX/Q'$8Q9,5.8-(LP7MDNLMMT@??S>C[X+`7P'WWWXGQ8#%SV`NL^>Z_PXA"
MBI-X[M3[.<\UK-^U9O6RF)TS0BAB5%(7O`#N311#V$9=)OV1)3=@^C'/C-W'
M]JZ_A>IA:_??6G+%3*0!W+/?M<T_LUM1IX3\`@&X`S50??5@9*>\,]_\BDHD
MO&]#(_N)17_YLY2HJ9+)_>RSL@(5K5/!G8;Q5*YP>/.%@OM^5[ZW9_CZ;_=W
M]W?_#ZHA\=D-"F5N9'-T<F5A;0T*#0IE;F1O8FH-"@T*,3@Q(#`@;V)J#0H\
M/`T*+T-O;G1E;G1S(%L@,3@R(#`@4B!=#0HO365D:6%";W@@6R`P(#`@-C$R
M(#<Y,B!=#0HO4&%R96YT(#$X-"`P(%(-"B]297-O=7)C97,@/#P-"B]&;VYT
M(#P\#0HO1F%B8S$P(#$Y-B`P(%(-"B]&86)C,30@,C`P(#`@4@T*+T9A8F,Q
M."`R,#0@,"!2#0HO1F%B8S8@,3DR(#`@4@T*+T9A8F,W(#$Y,R`P(%(-"B]&
M86)C."`Q.30@,"!2#0HO1F%B8SD@,3DU(#`@4@T*/CX-"B]0<F]C4V5T(%L@
M+U!$1@T*+U1E>'0-"B]);6%G94(-"B]);6%G94,-"B]);6%G94D@70T*/CX-
M"B]4>7!E("]086=E#0H^/@T*96YD;V)J#0H-"C$X,B`P(&]B:@T*/#P-"B]&
M:6QT97(@+T9L871E1&5C;V1E#0HO3&5N9W1H(#0T.#8-"CX^#0IS=')E86T-
M"GB<M5Q+<^2V$;ZK2O^!!Q\VJ<D$+P)@;HX3IY)#4O%N'@=?J!$E33SBR//8
MM?SKTXT77R!$PG*I=D4!#?;7C>Y&HPGRC_^]O?GQ]H9L9546!'_,E=Z6POZW
M>[Z]H::'%DP65)H65K"*;:N*Z4(34BBEBU-S>_.?HC7W4J+$&Y5:XZ_B]'A[
M\W1[\_!;O!7^]!K(5@@.#+:"EQQ^\8JQ87\E2NRON,)^K26/WY`55)%"4_BG
MI9`&T(.1#GITZ.&R@_K'3[<WO_^VOMN!8+SX!-1&!>9V7F@*HXD0Q:=G!$,U
MR/1I=WOS.T2,UU]N;SY\>FJ*\_ZQW3_L=W5[*7;'YY=CV[27<W%\*"[0^PVT
MU.WK;XI/_[N]^3.P_><O1\9$U4$3!M6'[QEC[\L$9J4G/U%@'4Y^SO`:Y3\7
M;7,I[IN'YG1J[HM+_5-1G\\-B%^W]\5A7]_M#_O+OCF#9MKS_GP!(J>8A^/A
M</RR;Q^+^E+\J=DUSW?-J>!T4S!"Y!^R9)$SLBC:D^5#\:YZ`C-1I/)6(C@+
M5D*8LY*/WW[]$?A7<.,?K_L3:*,N/M>':WW9']NB1CW4[:XI+D>@N+_B%2@H
MIM53\W(\H1+W#YOBKCZC.EM#_:79/SY=O'*;S_O[!FZY*?:78G\NGH^G!J;C
MA^;P"OUU6[3'R[NK05;,JZ$D*JB!XK2@&H#QI3@?GYL"A4#1CR>4WH.."?QE
M#_T(]JX!//5A_W-SORV^?KB`K1B3NF].5HUP$[S74/J[X^4)N)W!!C\WQB;;
MYK'&/S;O+[XJO:](VKD*XU;ZY[JM'YMGB`W%4WT&84&$YWV+XJ)>ZN+A"O!C
M9@&2?47+#==B0\#SZ\=ZWYYA6B]3[P/3VF/KKCF?Z],K:!%'3[QK6V#@>G<%
ME-HH`,0F5(9HR3CZ!*I@!Y;WV!3[-BKF`U@#SMYK4Y_.1=/>@T@3Y&8.X:)$
M.;]"A8B-A&B,S?`G4]6&ZG(#V,\OS0XG^O"Z?7=!&0V"<L`4!*65%?3K2$3;
M])<#,('[HGYY.1U_VC_7%W3+KUBYJ4JY$1`G8,[^M?VX-=-[?#$6#G'R<#Q#
M'*U/IU=0U9?Z=(_QX!F,`3HWQ9>G_>[)^DOSTPM$&7"9QWV+G:CQ=]<!"2NC
M8'H:\QAA%!P50QW,Q?5@0M.N.5T`;W'\TC:G\]/^I;`F<1XJY[E^17\_7^_^
M!W.(81$B5MVVU_H`0>QY?W$>;R/?]0)KS,\A"*!;S"GOO950:N64`.+RH`09
M#'XP62_7T_F*60((]!&-$P!SS7SX^VL+$:$%$;]K/C?M%=5QWX`*B_/E>O^*
M@T+,L%'NX0%NXA(-\`:K2HCX$`C;UXV),C9R-N\__25D7#XQLL'NPQ4\%J;W
MAZ;-<[BYQ1NYE>176KI+SKT<I`QK%B_QVG@RW!'6F1V86+"P7RNM@\`5\/Q:
M61W555_F4O;2%<E\4K=O=[A,VP4%W>_Y>,6<=E<?=M=#C0D(+%DFBVMP`3Z`
MC=:7Z^4(2P[X6X/!&:S/IGCGMR+[.^=ZNIO5D;W`?&NM%-!4I.#FMMUXLZ<`
M`B6$)6`S!%)PDB0H!:P#*0+8/\@D`><JS0+65)$DH*Q*LR`,TI4$@:I8E90"
M])R60BE.DB"59%6:H&0R.1<*EIZT%)R5+$D`^5E:"LK*-$A8Z'B*0%:T2A-H
MF@8I%:RQ20)):9J@I#0IA11$I4%RHI/V("F1:0+(VG2*H*R(3!-HPI,L8%52
M:0().[0D04G3%@7.G9Z+DE.29L&(3HL).Z:D39:$BJ28HJ)I10E-:5),H4A:
M#P+F6R4)2J*3SBM@Q4F*"7MIE;X#8R*-@;(W,!`FDAAX]48`@00N'2>Y8CII
M#QS"8)J@?(M`L#*-@;.TT<(VE217'$Z%3*H:8CU/&@RK<$%/$I"T%$R3]&0Q
M]89GP7)2):5@X/Y)13&ATVL6XQ5)WP'D3.L!<K2T)@GD("D"6NET,`<.Z1R&
MJHHG'8<J0M,$997.82"$I2,,A#"5G"S(<=)+,Z60Q"0)"+AWBJ!Z8ZYT19,0
ME=;I9?>-B8(-9CI^O6$J7*<G@;UAK+1*IY&P!LP[W(^.I+0JHCR2R%<P22&1
MI]/ZNPS;S)+:K0K9DBJ4W^N[@ZF/?7.$S3/L4`;IOKW-=W_!6W[!7<7?$-"V
M1$@:?L%]J]Z?A]N;CQUH0F$E5V#G&0\-2"@$*M[M*1EW>\IOKJ<3E@'GJ^63
M'5%I*OZ`"0O9U;H-D1MK,<&.4I#)W:636,GU=Y?LC;M+KNW=U]_<#9V[.=EJ
M\WP(=GO.=,!CS?9/>58/?D9#^\H)A=U!!?L<7^J2H<K#*^DJNW_R!=A3<X8=
M[N[)3.=]\[DY'%],P?=X=]@_FOI!&C].%0+M9ODA3/^P?=7L>P$6:!"G$SG)
M$8"N>:7^[$C+'[R-$XCIGWX&+%^]!40;CA"_1DBZ]K50(`A%H?`-;$4WM))I
M2&B-$=U,FE>9]_S<=`\XT7S!V*)F[=LSS%J&XJ6L@EDK<VU*7[O=Z0I6W?ST
MTK3G9E0][=`9"P,84:,=M*\S6@<OI1AC7,`B9JW]YE71;!EC;3A$K=.UK[;.
M3N:!=3(A-A57,TB,#4U5,&E>9Y2S*HB&7"'BMNG;,VQ3:&^;F.LZVRPY7J-M
M_K7]#''5E!LAYIX^-^<%@17@1&UTT+[.1AW,I8$5.,5,M=^\SE37\->&4=1B
M77N.Q3H$0XNE>B.E6!!-IPJ9-*\SW%F%#*,I*^,6Z]LS+)95(>G37<[G$M5_
M7)Z:4[&_-,_G#3Z82H52P!`UTT'[.C-UV-X,I<`B9I_]YG7VN8BQ-ARBANG:
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M[)8@+H8GB_ASGO+-R'GE1Q8C+>.+T:A]S3D.K98'6#1Q&5]BANWKO&8%`FEE
MC=F_;<XHA7C^:TLAR#%JTC)KK<%22!2*V)2PW12C4R?1Y2:BFTGS.O.<G9OA
MFB%4W"Z'[:OLLIQSC%$8%S-A7.2'\26LI94N9HDB.Q(O8JP-AZCE#=I73+18
MQ-H8Q%3F2?,Z"YME'`V`L'N+&IIOSTA.N#\BS8BPR<F'OX_2CE_&A)>!"3BV
MP+J[<>S?O2>/JB<():QW;HZY+&NW_AG'`D!S<\N(#HA&9[[B"POPB?KQH'V=
M'WOV"Q<6X!1SYW[S.G=>PU\;1E&O'K2O\^KE"(PO3C4P:5[GW+/\1T$<=@)N
MMT*4WZU0&C)Z>QG=K5`:WZW0O(>%L#W7U#\KI+P*VW.N*[<]__OT$#/Z$;K5
M[M3<[R_#`^&I!<2*[37@I255V!*0^#;-DT4=9M"^SF$H7[9_<;AEF*\>6$LP
M@]N1Q=RLW[S.S1:@-L;H4>L.=8!J">90V[ZH<[KVM<F>%@'WI!S&JXU,;V&L
M)%ZH(7Q+$)?$D\6</$O_9N2\_F.!7FGI?!VOK*_C601G_>XRO'$XS0&0(N;R
MH_95;XM5_LT)5JKPHE!)\-H<:CA>:GSG*985Y+(UYX7$LJP@FX?NB49EY5X+
M<)E`!J/9A!WK:U7T9;[H6NN,P-N#GWNM?3!QEW-FX*EC`7#8OBH`JFIVO1P$
M0`]?!B/N8;8$:?B..A('!\VKXN`2\.BO`;SNP`?$EN`-\)8D%@Y]>T8X]/"7
MA,-I]H*/RZQ<7L2A,)8@*9>GC@3'O$DQ(V<G9;B:*^GKM7CEHJ(,]5IW&<N`
ML"L:#F5VO5:I4*\E-#SJ925UCWK_/7U5,)'E.-&\E$&BD#BXRVB6@WU1)Y?9
MVWM\VV21D\M0I?6X.["68+Y*BWTQ[Y:YM8$EJ(W!R5"E#:@#5$LP7Z7%OJA;
MR[PJK28!-[HU%6Z-^YZ4I'M]-I'I.&F\8$,1+,%\L38R![WFM4LICNQDZ=9K
MD(4NR'H$\_X-5\Z_1;?RV<M4UB/BI=_0GN'F9??"8%EV7U(HRVZC$WD!?,'J
M;H7U<@<917`B>YE<W>T1$$;'CN_:28;CB]D'OT/'=_!EF*P>9DLP@#\:W$4-
MT44-T2VTZ:GVU+'@(7)+W'ZF4R7N813Q*M"="H+<EB"N`MO7A2!1CN2V!&^H
MP))$(Y'(>Y"+[^9U2IC+MN-YA=6%5\M0!DN0%,=3QT*1R"W,>V&2>06$*P$)
MO8T[PFZLS)6U9-/=G\8?0W=95@4M5T<4444.RZ400I[F$'JP`9BU.D/`AAA]
M/P"DL3=15<(9S-#(>=/4JJJJ`-+A'2*S!&.0KK_B<6--@)14!Y"P"[5[-OQ>
MP=Q""1/F`'JL0U268`30]Z,68S.=`FB&EJNTJ+0*(!W>(3)+,`;I^C.TJ)B,
M:G'NK)$FS`/T6(>H+,$(H._/T*(=ND2+SB\A*S=^N7ZE%TJ%E;X[<23"B:-O
M)Z^,F_?,)R\EH/<`BCG'2ZU"9NB2Z.!]!]_"61V#[,@E_HULP*J0C<[(!H4>
MB$/1T'QFRP7LFR:O7*#/.-VM96:&JO!]$U6Y+Q%`YOD]$>6$%3I-EOKLR(7J
M4X3FJD^5<J7ZC+/DJ<\.7:X^\Z*LS':U\'H4B")[9YW<%Y<^7LS'&'I?<]C8
MSZ(\A`\W8*I]U[3-PWY2HC-N!.!R/5!&\L!9#P0^F1Y81@YZSGH@L,GQP%(,
MQ&&L[)G05O*H`SK5Y3B@C&2/D[V?][XLU=F1"U5GO"]/=4JR=:HS'I2G.C-T
MJ>K,"^95MN>)\`T5)KOG=E@'L]O9(W[EY+J[[/$-17/P.^I>O,IV+Q%YHC/K
M7O@Y@#SW$I%*Z:Q[X<F`'/?2<7'8=I2'>M=R:EMK\SATJ3S&0;+49D8N96-<
M*T]M2K&XVK;3CP89U\C3FAFZ5!S[589LKV+A34NJN_5,:K>>?9/Z@%S4O]C\
MSNTM_V)+,SOT$N"3Z5]L85)N_(NQ//]B<7&X@H`<=3`VO\MXR\&6"F3<)$MO
M=N1"-L;!\O2F8"V)ZDW@\]JHB^7IS0Y=(M"HX`*RN8(+H;[@0LI0U["7PX(+
MM.5Z9_>9TTIW&SNAW9KWW=SKS_:DRNSA%/0"*XB7*>#GH?IA+T=U&9*5H]NA
MD??64J5:]#X'TN$=(K,$8Y"N/S,TD(S:D</HX`Z!68(Q1M>?FQ83%<_MZ%;-
MOFF%_FN!>LQ#=):`1VI(>3-NAZH%B6&OAD2"?WF\0V268`S2]6<&M94S;N*&
MQ>CA#H%9@A%&WY^;S<_-.-^2N<=KIISE@#K,0W268`S4]>=N!1;-^#"B<J5=
M1,4K&U'Q&YTN(KG+043%-A-1UY\[YPM>_L=(X%!Y@`%,*`Z[RV%XQ$94G5X?
M'CVP->'1@W1XA\@,P0#D:+`.L14OPV#6#8[4O+$Q+[9RO:ZBC!'$"^AD'4IE
M"&8$M'TA,'L!.ZDLP5A`UZ_E^E@B=5_"WA.HR8&O7\)%+=7C,/0[/7J5#N4W
M!&-5^/[,E-2#--]K=I^Q-R`G%;EA^/=`'>:`CO@H.S?AMB^L'6[">Z)9@LCS
MASR+MB/7/R-Q`GI9AU(9@CD!35]8>)R`/:DLP?CYA>O/VNM6_:"4LNA?PL6@
MEK&3A<MN//M16OS@;/S&PT72SXB;G*$F#<%$J:X_<Y'TJ""I=X=1/\S4J3FS
MGS*C(LZ%SG#!'0=GX5LS/?>+,2'V5.Y:#T"WYM05*>168P71V,>W[\A$H/[I
MPI=K\IG(/I/>9GV4MR"+^8^[`<6?_WM[<WOS?]K@C=P-"F5N9'-T<F5A;0T*
M#0IE;F1O8FH-"@T*,3@S(#`@;V)J#0H\/`T*+U1Y<&4@+T]U=&QI;F5S#0H^
M/@T*96YD;V)J#0H-"C$X-"`P(&]B:@T*/#P-"B]#;W5N="`Y,0T*+TMI9',@
M6R`Q.3$@,"!2#0HQ(#`@4@T*,R`P(%(-"C4@,"!2#0HW(#`@4@T*,3`@,"!2
M#0HQ,R`P(%(-"C$U(#`@4@T*,3<@,"!2#0HQ.2`P(%(-"C(Q(#`@4@T*,C,@
M,"!2#0HR-2`P(%(-"C(W(#`@4@T*,CD@,"!2#0HS,2`P(%(-"C,S(#`@4@T*
M,S4@,"!2#0HS-R`P(%(-"C,Y(#`@4@T*-#$@,"!2#0HT,R`P(%(-"C0U(#`@
M4@T*-#<@,"!2#0HT.2`P(%(-"C4Q(#`@4@T*-3,@,"!2#0HU-2`P(%(-"C4W
M(#`@4@T*-3D@,"!2#0HV,2`P(%(-"C8S(#`@4@T*-C4@,"!2#0HV-R`P(%(-
M"C8Y(#`@4@T*-S$@,"!2#0HW,R`P(%(-"C<U(#`@4@T*-S<@,"!2#0HW.2`P
M(%(-"C@Q(#`@4@T*.#,@,"!2#0HX-2`P(%(-"C@W(#`@4@T*.#D@,"!2#0HY
M,2`P(%(-"CDS(#`@4@T*.34@,"!2#0HY-R`P(%(-"CDY(#`@4@T*,3`Q(#`@
M4@T*,3`S(#`@4@T*,3`U(#`@4@T*,3`W(#`@4@T*,3`Y(#`@4@T*,3$Q(#`@
M4@T*,3$S(#`@4@T*,3$U(#`@4@T*,3$W(#`@4@T*,3$Y(#`@4@T*,3(Q(#`@
M4@T*,3(S(#`@4@T*,3(U(#`@4@T*,3(W(#`@4@T*,3(Y(#`@4@T*,3,Q(#`@
M4@T*,3,S(#`@4@T*,3,U(#`@4@T*,3,W(#`@4@T*,3,Y(#`@4@T*,30Q(#`@
M4@T*,30S(#`@4@T*,30U(#`@4@T*,30W(#`@4@T*,30Y(#`@4@T*,34Q(#`@
M4@T*,34S(#`@4@T*,34U(#`@4@T*,34W(#`@4@T*,34Y(#`@4@T*,38Q(#`@
M4@T*,38S(#`@4@T*,38U(#`@4@T*,38W(#`@4@T*,38Y(#`@4@T*,3<Q(#`@
M4@T*,3<S(#`@4@T*,3<U(#`@4@T*,3<W(#`@4@T*,3<Y(#`@4@T*,3@Q(#`@
M4B!=#0HO5'EP92`O4&%G97,-"CX^#0IE;F1O8FH-"@T*,3@U(#`@;V)J#0HO
M1&5V:6-E4D="#0IE;F1O8FH-"@T*,3@V(#`@;V)J#0HO1&5V:6-E4D="#0IE
M;F1O8FH-"@T*,3@W(#`@;V)J#0HO1&5V:6-E4D="#0IE;F1O8FH-"@T*>')E
M9@T*,"`Q.#@-"C`P,#`P,#`P,#`@-C4U,S4@9@T*,#`P,#`T-C<Q."`P,#`P
M,"!N#0HP,#`P,#0W,#(T(#`P,#`P(&X-"C`P,#`P-#@W.#,@,#`P,#`@;@T*
M,#`P,#`T.3`X.2`P,#`P,"!N#0HP,#`P,#4S-3,P(#`P,#`P(&X-"C`P,#`P
M-3,X,S8@,#`P,#`@;@T*,#`P,#`U.#8Q,B`P,#`P,"!N#0HP,#`P,#4X.34P
M(#`P,#`P(&X-"C`P,#`R,#(T-3(@,#`P,#`@;@T*,#`P,#(P-C8T-"`P,#`P
M,"!N#0HP,#`P,C`V.3@U(#`P,#`P(&X-"C`P,#`R-CDT,S8@,#`P,#`@;@T*
M,#`P,#(W,C0P,"`P,#`P,"!N#0HP,#`P,C<R-S`X(#`P,#`P(&X-"C`P,#`R
M-S<V-3D@,#`P,#`@;@T*,#`P,#(W-SDV-R`P,#`P,"!N#0HP,#`P,C@Q.3`R
M(#`P,#`P(&X-"C`P,#`R.#(R,3`@,#`P,#`@;@T*,#`P,#(X-S`Q-2`P,#`P
M,"!N#0HP,#`P,C@W,S(S(#`P,#`P(&X-"C`P,#`R.3$U.#<@,#`P,#`@;@T*
M,#`P,#(Y,3@Y-2`P,#`P,"!N#0HP,#`P,CDV,3(Y(#`P,#`P(&X-"C`P,#`R
M.38T,S<@,#`P,#`@;@T*,#`P,#,P,#`S,"`P,#`P,"!N#0HP,#`P,S`P,S,X
M(#`P,#`P(&X-"C`P,#`S,#0U-3@@,#`P,#`@;@T*,#`P,#,P-#@V-B`P,#`P
M,"!N#0HP,#`P,S`X.#DV(#`P,#`P(&X-"C`P,#`S,#DR,#0@,#`P,#`@;@T*
M,#`P,#,Q,S4Q,"`P,#`P,"!N#0HP,#`P,S$S.#$X(#`P,#`P(&X-"C`P,#`S
M,3@U.#8@,#`P,#`@;@T*,#`P,#,Q.#@Y-"`P,#`P,"!N#0HP,#`P,S(S,#,V
M(#`P,#`P(&X-"C`P,#`S,C,S-#0@,#`P,#`@;@T*,#`P,#,R-S$S."`P,#`P
M,"!N#0HP,#`P,S(W-#0V(#`P,#`P(&X-"C`P,#`S,S$Y,S0@,#`P,#`@;@T*
M,#`P,#,S,C(T,B`P,#`P,"!N#0HP,#`P,S,V,#DT(#`P,#`P(&X-"C`P,#`S
M,S8T,#(@,#`P,#`@;@T*,#`P,#,T,#<P,"`P,#`P,"!N#0HP,#`P,S0Q,#`X
M(#`P,#`P(&X-"C`P,#`S-#4P,#4@,#`P,#`@;@T*,#`P,#,T-3,Q,R`P,#`P
M,"!N#0HP,#`P,S0X.#8Y(#`P,#`P(&X-"C`P,#`S-#DQ-S<@,#`P,#`@;@T*
M,#`P,#,U,S`W-"`P,#`P,"!N#0HP,#`P,S4S,S@R(#`P,#`P(&X-"C`P,#`S
M-3<V,S(@,#`P,#`@;@T*,#`P,#,U-SDT,"`P,#`P,"!N#0HP,#`P,S8R,#(R
M(#`P,#`P(&X-"C`P,#`S-C(S,S`@,#`P,#`@;@T*,#`P,#,V-C,S,R`P,#`P
M,"!N#0HP,#`P,S8V-C0Q(#`P,#`P(&X-"C`P,#`S-CDX.#`@,#`P,#`@;@T*
M,#`P,#,W,#$X."`P,#`P,"!N#0HP,#`P,S<T,#`Q(#`P,#`P(&X-"C`P,#`S
M-S0S,#D@,#`P,#`@;@T*,#`P,#,W.#(T,"`P,#`P,"!N#0HP,#`P,S<X-30X
M(#`P,#`P(&X-"C`P,#`S.#,Y-S$@,#`P,#`@;@T*,#`P,#,X-#(W.2`P,#`P
M,"!N#0HP,#`P,S@X.3DT(#`P,#`P(&X-"C`P,#`S.#DS,#(@,#`P,#`@;@T*
M,#`P,#,Y-C<Y,2`P,#`P,"!N#0HP,#`P,SDW,#DY(#`P,#`P(&X-"C`P,#`T
M,#0R-SD@,#`P,#`@;@T*,#`P,#0P-#4X-R`P,#`P,"!N#0HP,#`P-#`X-#@W
M(#`P,#`P(&X-"C`P,#`T,#@W.34@,#`P,#`@;@T*,#`P,#0Q,C4Y-R`P,#`P
M,"!N#0HP,#`P-#$R.3`U(#`P,#`P(&X-"C`P,#`T,3<V,S8@,#`P,#`@;@T*
M,#`P,#0Q-SDT-"`P,#`P,"!N#0HP,#`P-#(Q-C,V(#`P,#`P(&X-"C`P,#`T
M,C$Y-#0@,#`P,#`@;@T*,#`P,#0R-SDU,"`P,#`P,"!N#0HP,#`P-#(X,C4X
M(#`P,#`P(&X-"C`P,#`T,S(W.#4@,#`P,#`@;@T*,#`P,#0S,S`Y,R`P,#`P
M,"!N#0HP,#`P-#,W,SDS(#`P,#`P(&X-"C`P,#`T,S<W,#$@,#`P,#`@;@T*
M,#`P,#0T,C$Y,R`P,#`P,"!N#0HP,#`P-#0R-3`Q(#`P,#`P(&X-"C`P,#`T
M-#<Y-C$@,#`P,#`@;@T*,#`P,#0T.#(V.2`P,#`P,"!N#0HP,#`P-#4S-#8Y
M(#`P,#`P(&X-"C`P,#`T-3,W-S<@,#`P,#`@;@T*,#`P,#0U.#4U-"`P,#`P
M,"!N#0HP,#`P-#4X.#8R(#`P,#`P(&X-"C`P,#`T-C(Q,30@,#`P,#`@;@T*
M,#`P,#0V,C0R,B`P,#`P,"!N#0HP,#`P-#<P-S0Y(#`P,#`P(&X-"C`P,#`T
M-S$P-3<@,#`P,#`@;@T*,#`P,#0W-C@U."`P,#`P,"!N#0HP,#`P-#<W,38V
M(#`P,#`P(&X-"C`P,#`T.#8P-C4@,#`P,#`@;@T*,#`P,#0X-C,W-"`P,#`P
M,"!N#0HP,#`P-#DP,C0W(#`P,#`P(&X-"C`P,#`T.3`U-3<@,#`P,#`@;@T*
M,#`P,#0Y-#DR."`P,#`P,"!N#0HP,#`P-#DU,C,X(#`P,#`P(&X-"C`P,#`T
M.3DV-SD@,#`P,#`@;@T*,#`P,#0Y.3DX.2`P,#`P,"!N#0HP,#`P-3`S-3$W
M(#`P,#`P(&X-"C`P,#`U,#,X,C<@,#`P,#`@;@T*,#`P,#4P-C8T."`P,#`P
M,"!N#0HP,#`P-3`V.34X(#`P,#`P(&X-"C`P,#`U,#DV.34@,#`P,#`@;@T*
M,#`P,#4Q,#`P-2`P,#`P,"!N#0HP,#`P-3$S,S<S(#`P,#`P(&X-"C`P,#`U
M,3,V.#,@,#`P,#`@;@T*,#`P,#4Q-S$W-2`P,#`P,"!N#0HP,#`P-3$W-#@U
M(#`P,#`P(&X-"C`P,#`U,3DY-C0@,#`P,#`@;@T*,#`P,#4R,#(W-"`P,#`P
M,"!N#0HP,#`P-3(S,#DV(#`P,#`P(&X-"C`P,#`U,C,T,#8@,#`P,#`@;@T*
M,#`P,#4R-30V-2`P,#`P,"!N#0HP,#`P-3(U-S<U(#`P,#`P(&X-"C`P,#`U
M,C@R-3D@,#`P,#`@;@T*,#`P,#4R.#4V.2`P,#`P,"!N#0HP,#`P-3,T,S0S
M(#`P,#`P(&X-"C`P,#`U,S0V-3,@,#`P,#`@;@T*,#`P,#4T,3DT-R`P,#`P
M,"!N#0HP,#`P-30R,C4W(#`P,#`P(&X-"C`P,#`U-3`X.#<@,#`P,#`@;@T*
M,#`P,#4U,3$Y-R`P,#`P,"!N#0HP,#`P-34X-S@X(#`P,#`P(&X-"C`P,#`U
M-3DP.3@@,#`P,#`@;@T*,#`P,#4V,C$U-2`P,#`P,"!N#0HP,#`P-38R-#8U
M(#`P,#`P(&X-"C`P,#`U-C8Q,3(@,#`P,#`@;@T*,#`P,#4V-C0R,B`P,#`P
M,"!N#0HP,#`P-3<Q,3`S(#`P,#`P(&X-"C`P,#`U-S$T,3,@,#`P,#`@;@T*
M,#`P,#4W-3@W."`P,#`P,"!N#0HP,#`P-3<V,3@X(#`P,#`P(&X-"C`P,#`U
M.#`R,#4@,#`P,#`@;@T*,#`P,#4X,#4Q-2`P,#`P,"!N#0HP,#`P-3@T-C`W
M(#`P,#`P(&X-"C`P,#`U.#0Y,3<@,#`P,#`@;@T*,#`P,#4X.3(Q."`P,#`P
M,"!N#0HP,#`P-3@Y-3(X(#`P,#`P(&X-"C`P,#`U.30X-#<@,#`P,#`@;@T*
M,#`P,#4Y-3$U-R`P,#`P,"!N#0HP,#`P-3DY-#8W(#`P,#`P(&X-"C`P,#`U
M.3DW-S<@,#`P,#`@;@T*,#`P,#8P-#$T-2`P,#`P,"!N#0HP,#`P-C`T-#4U
M(#`P,#`P(&X-"C`P,#`V,#DQ,#(@,#`P,#`@;@T*,#`P,#8P.30Q,B`P,#`P
M,"!N#0HP,#`P-C$T-3@P(#`P,#`P(&X-"C`P,#`V,30X.3`@,#`P,#`@;@T*
M,#`P,#8Q.#4W-B`P,#`P,"!N#0HP,#`P-C$X.#@V(#`P,#`P(&X-"C`P,#`V
M,C,T,S@@,#`P,#`@;@T*,#`P,#8R,S<T."`P,#`P,"!N#0HP,#`P-C(Y,CDY
M(#`P,#`P(&X-"C`P,#`V,CDV,#D@,#`P,#`@;@T*,#`P,#8S-#$T,"`P,#`P
M,"!N#0HP,#`P-C,T-#4P(#`P,#`P(&X-"C`P,#`V,SDS,S,@,#`P,#`@;@T*
M,#`P,#8S.38T,R`P,#`P,"!N#0HP,#`P-C0V-S4X(#`P,#`P(&X-"C`P,#`V
M-#<P-C@@,#`P,#`@;@T*,#`P,#8U,3<U,"`P,#`P,"!N#0HP,#`P-C4R,#8P
M(#`P,#`P(&X-"C`P,#`V-38U.3,@,#`P,#`@;@T*,#`P,#8U-CDP,R`P,#`P
M,"!N#0HP,#`P-C8Q-S0U(#`P,#`P(&X-"C`P,#`V-C(P-34@,#`P,#`@;@T*
M,#`P,#8V-C(S-"`P,#`P,"!N#0HP,#`P-C8V-30T(#`P,#`P(&X-"C`P,#`V
M-S`X-S,@,#`P,#`@;@T*,#`P,#8W,3$X,R`P,#`P,"!N#0HP,#`P-C<W-C4U
M(#`P,#`P(&X-"C`P,#`V-S<Y-C4@,#`P,#`@;@T*,#`P,#8X-#8Q."`P,#`P
M,"!N#0HP,#`P-C@T.3(X(#`P,#`P(&X-"C`P,#`V.#DU,#(@,#`P,#`@;@T*
M,#`P,#8X.34T."`P,#`P,"!N#0HP,#`P-CDP,S<X(#`P,#`P(&X-"C`P,#`V
M.3`T,3$@,#`P,#`@;@T*,#`P,#8Y,#0T-"`P,#`P,"!N#0IT<F%I;&5R#0H\
I/`T*+U-I>F4@,3@X#0H^/@T*<W1A<G1X<F5F#0HQ.#4-"B4E14]&#0H_
`
end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>dyadiclogo2.jpg
<DESCRIPTION>DYADIC LOGO
<TEXT>
begin 644 dyadiclogo2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"C`,(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**S-1\1:'
MI%PMOJ>LZ=93,N]8[FZ2-BN2,@,0<9!Y]C5^">&ZMX[BWE26&50\<D;!E=2,
M@@C@@CO5.,DKM`24445(!7D7Q3^*>N>!_$]MIFF6NG2PRV:W#-<QNS;B[K@;
M7`QA1V]:]=KYJ_:%_P"1^L?^P7'_`.C9:]'*Z4*N(49JZLR)NRT#_AH7Q9_T
M#M%_[\R__'*T]&_:)U%+C;KFB6LT+,HWV+-&T:Y^8[7+!SC&!E>G7GCTKP?X
M/\,77@G0+BX\.:1+-+IUN\DDEC$S.QC4DDE<DD]ZY;XH_"71)]`O=<T.W@TR
M]LHGN)8X@5AFC1<D;!PC`+D%0`3G/7<.Z-;+YU/92IVZ7)M)*]SU;2]4LM:T
MRWU'3KE+FSN%WQRIT(_F"#D$'D$$'D5X]\0OBMXO\$^+9]*6RTB6U95GM99(
M9-SQ-G&<2]00R]L[<X`(K-_9WU^X&H:IX=9=ULT7VZ,Y`V."J-VR=P9._&SI
MR:[OXP>"7\7^%1/9C.I:9OG@4*S&5-OSQJ!_$VU2.#RH'&2:YH4:6%QGLJRO
M%]_/9_HQW<HW1V'A_7;+Q-H-IK&G,YM;I2R>8NUE()5E(]001QD<<$CFCQ!K
MMEX9T&[UC46<6MJH9_+7<S$D*J@>I)`YP.>2!S7AG[/_`(K^R:M=>%[AOW5[
MFXM>.DJK\XX'\2+G)(`\OCEJ/V@/%?VO5K7PO;M^ZLL7%UQUE9?D'(_A1LY!
M(/F<\K1_9K^N^P^SO\OZT]1\_NW-KX>_%;Q?XV\6P:4UEI$5JJM/=2QPR;DB
M7&<9EZDE5[XW9P0#7ME>>?!_P2_A#PJ9[P8U+4]D\ZE64Q)M^2-@?XEW,3P.
M6(YP#7>7U[;Z;I]S?7<GEVUM$TTKX)VHH))P.3P#TKFQTJ4J[C05DM-.HXWM
MJ>1?$OXP:IX1\6G1]&@TZX2&!&N/M,,A9)6RVT$,H(V%#QGJ>>P[?X<>+G\:
M^#H=4N/(6]662&YC@1E1'!R`-Q.?D*'J>OX#YCM[?5OB'XLU&Y99YKV>*XO9
M!#$\NW9&S*@&20I(2->3C<HYX![S]G_Q(]EXFNO#\T^+:_B,L,;;C^_09.W'
M"Y3<22.=BC/`!];%Y?3AA;07OQ2;_7^O(B,WS'T;7A_Q`^,GB'PIXWU'1;&S
MTN2VMO+V-/%(7.Z-7.2'`ZL>U>X5\F?&;_DK&M_]L/\`T1'7#E%&G6KN-175
MOU151M+0WO\`AH7Q9_T#M%_[\R__`!RM[PW^T*\EW#;^)-*@CBDEP]Y9LP$2
M$<$QG<6P>I#=#P"1@^L_\(1X3_Z%?1?_``7Q?_$UY%\8/A9I6E:--XGT)$LD
M@8?:[0$['WN`&C'\)!8#;PN.F,8;II5<OQ$E2=/EOL_,EJ2UN>[P3PW5O'<6
M\J2PRJ'CDC8,KJ1D$$<$$=Z\3^('QD\0^%/&^HZ+8V>ER6UMY>QIXI"YW1JY
MR0X'5CVJ_P#L^:_<7_AG4-%F7,>F2JT+Y'W)2Q*X`[,K'))^_CC`KRWXS?\`
M)6-;_P"V'_HB.IP."A'&3HU5=)?Y6_!CE+W;H^LZ\X^(_P`6;+P2XTZRA2_U
MAE):(OA+<$?*9,<DDX.P8)'.5RN>\U748=(TB]U.X5VALX)+B18P"Q5%+$#)
M`S@>M?*_P[\/?\+$^(K_`-L2>;$?,O[[#>6TWS#(&T<9=USC'&<$'%<N7X:G
M44JU;X8_B.;:T1)/\:O'LMQ)(FLI"CL66*.TA*H"?NC<I.!TY)/J37?^`_CM
M]MN[?2_%<<$#/\BZE&=B;L`#S%Z+D[B7!`&1\H&2/98=*TZWTPZ9!86L5@59
M#:I"JQ%6SN&P#&#DY&.<FO`/B9\([U?%ML_A'27EM=15W:"+B.WE7EN2`L:$
M$%06Z[@,#`KMI5\%BFZ4J:AV>G_`_4EJ4=;G8SP:K<:[C3)=434$EU.6Y6,W
M"QRR+<;K5'8,(DD,(PK2AUV>6&1E*"NX\*S+<2Z[/;AQ92:COM@R,@`,$)DP
MI`VGSO-W#`(??GYLU3T+PNE_X9TD^,M'TN^UN&U6&:6:%;AL`G:"[Y);!RV#
MC<6(X-=3!!#:V\=O;Q)%#$H2..-0JHH&``!P`!VKS,16BUR+II^/]6\BTB2B
MBBN,H*^:OVA?^1^L?^P7'_Z-EKZ5KYJ_:%_Y'ZQ_[!<?_HV6O5R;_>EZ,BI\
M)[OX(_Y$'PY_V"[;_P!%+6]6#X(_Y$'PY_V"[;_T4M:>JZC#I&D7NIW"NT-G
M!)<2+&`6*HI8@9(&<#UKSZJ;JR2[E+8^5_@S_P`E8T3_`+;_`/HB2OK.OECX
M':=->_$ZTN(V0)8P37$@8G)4H8\#CKF1>N.`:^IZ]3/&GB5Z+\V13V/E3XF^
M';CP#\15OM,7R+::47]@ZQC;$X;)0#:%^5QPHSA2F>M'PR\.W'C[XBM?:FOG
MVT,IO[]VC&V5RV0A&TK\SGE3C*A\=*]._:&@A;P3IUPT2&9-15$D*C<JM'(6
M`/4`E5R.^T>E'[/,$*^"=1N%B03/J+(\@4;F58XRH)ZD`LV!VW'UKL^N2_L_
MVOVOAO\`U_5R>7W['KM>:_''Q!_8_P`/Y+**7;<ZG*MNH6;8XC'S.0.K+@!"
M.G[SGT/I5?,_Q\UUM1\<1:2K/Y.EP*I5E4#S9`'9@1R05\L<]U.!W/E971]K
MB8WV6OW?\$N;LCI?V=M"46^K^(9%0NS"QA(9MR@`/)D=,',6#R?E/3OYQK,;
M_#GXMSFT7$>FWZSQ10S,,P-AQ&7//,;!6SGJ>O>_X9^,GB'PIX>M=%L;/2Y+
M:VW[&GBD+G<Y<Y(<#JQ[5SOC+QEJ/CC5XM3U.&UBFB@%NJVRLJ[0S-D[F)SE
MCW]*^@I4*_UJI.HO<EIO]W]>9DVN56/LF">&ZMX[BWE26&50\<D;!E=2,@@C
M@@CO7RA\9O\`DK&M_P#;#_T1'7NGP9UUM<^&]DLK.TVGLUB[,JJ"$P4QCJ!&
MR#)YR#UZGPOXS?\`)6-;_P"V'_HB.O-RFDZ6,G3?1/\`-%S=XIGUG6#XW_Y$
M'Q'_`-@NY_\`135O5RWQ)U&'2_AOX@N)U=D>S>W`0`G=+^[4\D<9<9]L]:\:
M@FZL4NZ-'L>)_L]?\C]??]@N3_T;%6#\9O\`DK&M_P#;#_T1'74_L[:=-+XG
MU?4U9/)M[,6[J2=Q:1PRD<8QB)L\]Q^'+?&;_DK&M_\`;#_T1'7U--IYG/\`
MP_Y&+^`][^,$\UO\*M<>"5XG*Q(61BI*M,BL..Q!(([@D5P'[-__`#,W_;K_
M`.UJ]'^*FG3:I\,=>MX&172`7!+D@;8G61AP#SA#CWQTKRW]G/488M7UW3&5
M_.N((KA&`&T+&S*P/.<YE7''8_CY6'URRJEO?_(M_&CZ"HHKEO%'Q"\/^#]3
ML+'6+EXGO%=]\:;Q"J]"ZCY@&.0"%.2#TP:\FG3G4ERP5V:-V.IHJII>J66M
M:9;ZCIURES9W"[XY4Z$?S!!R"#R""#R*MU+33LP"BBBD`5\U?M"_\C]8_P#8
M+C_]&RU]*UR?B?P9X.\1:E'=^(;6&6[2$1(SW;Q'8"Q`PK@=2W-=N`Q,,-6]
MI/;R)E%R5D>2Z'\?O[&T#3M+_P"$9\[[%:Q6_F_;]N_8H7./+.,XSC)K!\=_
M&34_&6DOI$.G0:?I\NPS+O\`-DD*MN`W$`!<A3@#.5ZX)%>O?\*M^&'_`$#[
M7_P92_\`QRM;0/"?@3PQ=F[TBTT^"Y/29[CS73@CY6=B5R&(.,9[UW+&Y?"7
MM(4WS;Z]_O?Y"]G4>C.=^"W@.X\+Z)/JFJVODZIJ&-L;@;X8!R%/&59CRRY[
M)D`@BO4JJ?VII_\`S_VO_?Y?\:/[4T__`)_[7_O\O^->37KRKU'4GNRU!I6L
M>8_M"_\`(@V/_84C_P#14M'[/7_(@WW_`&%)/_145=QXATWPOXKT^.QUI[6Z
MMHY1,J?:BF'`(!RK`]&/YT>'M-\+^%-/DL=%>UM;:24S,GVHOER`"<LQ/11^
M5=7UNG]3^K];W\A>SES7L;5]>V^FZ?<WUW)Y=M;1--*^"=J*"2<#D\`]*^4_
M`FE7'Q`^*B7%S%`8WNGU.^38&CV!]S+M8\JS,J8YP&R<X-?3NJ-HNL:9<:=?
M7D+VMPNR5$NS&67N-RL#@]",\C(/!K)\.>&?!7A.XGN-$ALK6:90CR&Z,C;0
M<X!=B0,XR!C.!GH*>#QD,/2J)?'+1=D$J<FUH7O^$(\)_P#0KZ+_`."^+_XF
ML+QI\-]&U7P=J=GHVAZ7::DT6ZWE@LXD<NI#!0W&W=MVYSQN_"NP_M33_P#G
M_M?^_P`O^-']J:?_`,_]K_W^7_&N6&)J0DI*6WF/D?8^>?V?M=6P\6WNCRLB
MIJ4`:/*L6:6++!01P!L:0G/]T<]CSOQF_P"2L:W_`-L/_1$=>^67@?P!INMI
MK%C;VMK?1RF5)(+^1`K'J`H?:%Y(VXQ@XQCBC6?`_@#Q#JT^J:I;VMQ>S[?,
ME^WR)NVJ%'"N`.`!TKUXYGAXXMXA)V:L]M]//LB/93Y;'G__``TA_P!2I_Y4
M?_M5</XY^)>L_$9[;2X]/2WLQ.KP6D`,LLDI&T9;&6.2V`H'WL')`->T_P#"
MK?AA_P!`^U_\&4O_`,<K=\/>'_!GA3S#HL&GVLDF=TOG;Y"#C*[V);;\H.W.
M,C.*F.-R^B^>C3?,MK_\.P]G4>C*'PL\%-X+\))!>1(NJW;>=>%2K;3T5-P'
M(4=LD;F?!P:\$^,W_)6-;_[8?^B(Z^J/[4T__G_M?^_R_P"-<GK/@?P!XAU:
M?5-4M[6XO9]OF2_;Y$W;5"CA7`'``Z5SX/,(TL1*O6UNNGJARIR:LD=G/!#=
M6\EO<1)+#*I22.10RNI&""#P01VKY0UW2-;^$?Q`AO+5,1Q2O)I]Q*!(D\1R
MI5C@?-M;:P&",Y&,J:^J/[4T_P#Y_P"U_P"_R_XUFZ[9^&?$VF-IVL-97=J6
M#[&G"E6'0A@05/49!'!(Z$UE@<:L/)J2O&6Z'*FV><0_M$Z&VF&2?1-12_VL
M1`C(T6[G:/,)!P>,G9QD\''/D6K:EJWQ1^(".D6VYOY4@MX-SNEO&.!S@D*!
MEF(&/O-@=*]AG^"7@"6XDD36;V%'8LL4=[$50$_=&Y"<#IR2?4FNT\+^&_!W
M@^W":0+*.8KMDNI)E>:3A<Y<G(!*@[1A<\@"N^&-P.&3GAXOF??H3[.;W-W1
M=(M-`T2STFQ3;;6D0C3(`+8ZLV``6)R2<<DDU?JJFI6+NJ)>V[,QP%$JDD_G
M5JO#<G)W9=K!1112`*^=OC+_`,C\_P#UZQ_UKZ)KA?%GPPL/%FM?VG/J%S!(
M8EC*1JI'&>>?K433:T/1RS$4\/7YZFUCYOHKW/\`X45I7_08O?\`OA:/^%%:
M5_T&+W_OA:SY)'T/]LX3N_N9X917N?\`PHK2O^@Q>_\`?"T?\**TK_H,7O\`
MWPM')(/[9PG=_<SPRBO<_P#A16E?]!B]_P"^%H_X45I7_08O?^^%HY)!_;.$
M[O[F>&45[G_PHK2O^@Q>_P#?"UXIJ%NMIJ5U;(Q989GC!/4@$BI<6MSJPV.H
MXEM4GL5Z*[KX<^!;3QK_`&E]JO)K?[)Y6WRE!W;]^<Y_W:[G_A16E?\`08O?
M^^%IJ+>IE7S/#T*CIS>J\CPRBO<_^%%:5_T&+W_OA:X/XB^![7P7-IZ6MY-<
M"Z60MYJ@;=NWIC_>H<6MQT,SP]>:IP>K\CB**N:39KJ.L6-B[E%N;B.$L!R`
MS`9_6O9_^%%:5_T&+W_OA:2BWL:8G'4<,TJCW/#**]S_`.%%:5_T&+W_`+X6
MC_A16E?]!B]_[X6JY)'+_;.$[O[F>&45[G_PHK2O^@Q>_P#?"T?\**TK_H,7
MO_?"T<D@_MG"=W]S/#**]S_X45I7_08O?^^%H_X45I7_`$&+W_OA:.20?VSA
M.[^YGBVF_P#(5L_^NZ?^A"OL"O+;;X(:3;W<,_\`:UZWENK[=J#.#G'2O4JN
M$6MSQ<VQE+$N'LGM?]`HHHK0\<****`"BBB@`HHHH`****`"OD/6_P#D/:C_
M`-?4O_H1KZ\KY#UO_D/:C_U]2_\`H1K*IT/H,@^.?HCU?X"_\S!_V[?^U:]E
MKQKX"_\`,P?]NW_M6O9:N'PG#F_^^3^7Y(*\6^/'_'SH7^Y/_-*]IKQ;X\?\
M?.A?[D_\TI5-AY1_OD/G^3/,_#'_`"-FC?\`7]!_Z&*^M:^2O#'_`"-FC?\`
M7]!_Z&*^M:FGU.W/_P")#T84445J?/A1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%?(>M_\A[4?^OJ7_P!"-?7E?(>M_P#(>U'_`*^I?_0C653H
M?09!\<_1'J_P%_YF#_MV_P#:M>RUXU\!?^9@_P"W;_VK7LM7#X3AS?\`WR?R
M_)!7BWQX_P"/G0O]R?\`FE>TUXM\>/\`CYT+_<G_`)I2J;#RC_?(?/\`)GF?
MAC_D;-&_Z_H/_0Q7UK7R5X8_Y&S1O^OZ#_T,5]:U-/J=N?\`\2'HPHHHK4^?
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*^0];_P"0]J/_`%]2
M_P#H1KZ\KY#UO_D/:C_U]2_^A&LJG0^@R#XY^B/5_@+_`,S!_P!NW_M6O9:\
M:^`O_,P?]NW_`+5KV6KA\)PYO_OD_E^2"O%OCQ_Q\Z%_N3_S2O::\6^/'_'S
MH7^Y/_-*538>4?[Y#Y_DSS/PQ_R-FC?]?T'_`*&*^M:^2O#'_(V:-_U_0?\`
MH8KZUJ:?4[<__B0]&%%%%:GSX4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!7R'K?_(>U'_KZE_]"-?7E?(>M_\`(>U'_KZE_P#0C653H?09!\<_
M1'J_P%_YF#_MV_\`:M>RUXU\!?\`F8/^W;_VK7LM7#X3AS?_`'R?R_)!7BWQ
MX_X^="_W)_YI7M->+?'C_CYT+_<G_FE*IL/*/]\A\_R9YGX8_P"1LT;_`*_H
M/_0Q7UK7R5X8_P"1LT;_`*_H/_0Q7UK4T^IVY_\`Q(>C"BBBM3Y\****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KEY_ASX2N;B6XFT6%I97+N=[C
M))R>`U=110:4ZM2GK"37H[&3HGAG1_#HG&DV*6OG[?,VLQW;<XZD],G\ZUJ*
M*"9SE-\TG=A63K7AC1O$7D_VM81W1ASY98L"N<9Z$>@K6HH"$Y0?-%V9S%K\
M//"=E=PW5OHT*30N)(VWN=K`Y!P3CK73T446*J5:E1WG)OU=PHHHH,PHHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
5HHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>propagule4x31.jpg
<DESCRIPTION>DYADIC C1 FUNGUS
<TEXT>
begin 644 propagule4x31.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_X1E`17AI9@``24DJ``@````&`!H!!0`!
M````5@```!L!!0`!````7@```"@!`P`!`````@```#(!`@`5````9@```!,"
M`P`!`````@```&F'!``!````>P```/@```!@`````0```&`````!````,C`P
M-SHP-#HP,2`Q-3HT,SHT-P``!P``D`<`!````#`R,C`!D0<`!`````$"`P``
MH`<`!````#`Q,#`!H`,``0````$````"H`0``0```'X!```#H`0``0```&(!
M```%H`0``0```-4``````````@`!``(`!0```/,````"``<`!`````,`````
M`````0$!`0`'``,!`P`!````!@```!H!!0`!````4@$``!L!!0`!````6@$`
M`"@!`P`!`````@````$"!``!````8@$```("!``!````QA<``!,"`P`!````
M`@``````````I@X`$"<```"F#@`0)P``_]C_P``1"`"4`*`#`1$``A$!`Q$!
M_]L`A``&!`4&!00&!@4&!P<&"`H1"PH)"0H5#Q`,$1D6&AH8%A@7&Q\H(1L=
M)1X7&"(O(R4I*BPM+!LA,30P*S0H*RPK`0<'!PH)"A0+"Q0K'!@<'"LK*RLK
M*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RO_
MQ`&B```!!0$!`0$!`0```````````0(#!`4&!P@)"@L0``(!`P,"!`,%!00$
M```!?0$"`P`$$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87
M&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^@$``P$!`0$!`0$!`0``
M``````$"`P0%!@<("0H+$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1
M!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ
M0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3E
MYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/'_`&H`7T]*`!\<8&/6@!&;
M<Q9B22<DDYS0`UOTH`;N_*@!,XH`:6H`0MP:`&,W7-`$3R>M`$#R`4`1&7GB
M@#O/A[\,]=\8S))%']BTW(W74X(!'^P/XJ`/H'0_@=X3TVW1+V.;4[AEP9)9
M2H)]E7&/SH`\,^-7A6R\'>,19:6S?8YX%GCC9MQCR2",^F1Q]:`.'C<&@"PA
MR*`)%XYH`>?>@"*@`/:@`/W3CM0`T],9H`8S#!H`B9\4`1F7B@!IEH`#)0`Q
MY*`*\DF*`*LLN.]`'IGP(\/Z3K>K7UYK48N$L51HK<]&8DX+>H&.E`'T8^KW
M,($J"-[=,*J^6`%XZ#'M0!N>%=5BNK@1(Q"D?=/\-`'AGB/X6^,O'GBC6-<O
M&MK&.21Q:Q7+G>R*2J#:!P"!G)]:`/&]9TZ[T+6;K2]201W=LY210<@'ZT`$
M!W'&.M`&[J&A:IID$,NHZ?=6J3#*-+$5W#VS]10!GGZ4`1'UH`,\4`--`#"1
MS0!"Y%`%663%`':_#3P1'XL:6YOK\6EA#)Y;!!F1SC.!G@=N:`/2+SX':#<6
M;R:;K]Y"Y^ZT\:N@/H<8-`'EGQ#^'VM>!GB?41'<6,IPEW`24)]#GD&@#BFE
M&,YH`K2R]>:`*I9I)51.68@`>IH`]_\`A!\-_&_AW5TN[S1=MA?08D/FKNC(
M;*Y&>/\``T`>QWT=_$&LIHX0"H&/EXP.O!X.#0!1ABN-/NXY@J1V@<)+-OVG
M:?3CG)P*`.ULKY_-&Y\QXP`>N/\`)H`\W\8^%?"FC^*;_7O$-L^I#5NL)4;8
MOE`!]0<J>:`.HT3X9^"9I[+4[?1EB,<8*QF0E3QD%AGDB@#N=0L]-UNTDL]1
MMH;B$C&V1,C\/RH`^,/&^C?\(]XHU'2Q*)1;R$!PA4$'D<&@#GCTH`0G(H`:
M3B@"-SWH`K2GB@"A<.!GF@#L?A%XM?1M>739(S+!J$BJN!DI)T!Q[YP:`/H;
M3KXQI<1#&)#\R'D<>E`&WK36&N>'YM.U"*"ZL98]I5_O#IT]".N:`/CK7O#]
MYIWC&70(%-Q<&8)!M_Y:!ON_H:`.LTOX*>,=0#F6"UL0I(Q<3C)]QMS0!L:-
M\!_$-OJ&F7-S/:R.-1C1H8@SCRP06<L!P.W.*`/H_P`2ZQJT6JPVUK.MC8(%
M`?RR6F8]5'IQB@#B]834]"G>[U>YBU")I<0[&^=BQ&>#ZCWH`O\`C#5;F/P_
M&UI'AIWV()%`8+C(.#^F>:`.N\'SV>JZ3%<12[G8#<A."C`<@B@#F?B/IUR_
MB[2KN>Z7^S8K1@UMC/F2!NI]L$4`=)HU[<_V1)+);R(BKE.V[CM0`[1M9;+*
M\QDE/.UAC:<]J`/%/VFC:?\`"8Z=)#@7DEF#<`=>IVY_"@#Q\$>N!0`TD8XH
M`8Q-`$;GC!H`JS'CWH`S;IN#0!D3R,L@96*L.A!QB@#UKX"W.N:MK4T=U>S2
M:):INF$C;OF_A52>1GG\!0!]&Z9;Z??6TMK$B0ON^25.&5L<$>M`'#:)I1TW
MQ9J6HZE8QKJ\(\E+AN@B[,/0G)'KQB@#9_X26YLI(R)2J$@R+"H&1GGF@#N9
M=5M[+26N-.NY0+@@Q)(P+-DCYL]<=J`/&==U_58/$^I:AKEU+;Z-<70A"C/[
MWY>D?^UD?SH`]"M[V.[MX-2U*SBG2"(+90S,,N3C&%(^]_2@#'\=>&4\:RPS
MR7D]CJL&"%CE+*,?['3\L'B@!?#^AZWX>M%@TR.,NSG?="3=-M.,X#=^/>@#
M/O=2U"]U>Y749[AY%?:%E7;M'H!0!K?$?XAW7ACX?PW%M!";R218(S(>.A)(
M`]`*`/,=/^.>HQ11O_8UBUZ`,S%VVD^NW_Z]`'":YKM_XAU>?4M5G:>[F.68
M]AV`'8#TH`@Z<4`,S0`QC0!#(>*`*DS8!H`S+I^*`,J7#2`%L`G&?2@#Z'^'
MFC1>%;+5K*UN#>,[12R,T>S`*C`Q^=`';Z+>3G4"N]2NT[02<'`S0!E?$'4S
M&FE:DQ8!YA:2KU!W$8)^A_G0!V=CX,ANM/$]U>QPJ$X`<-C!ZG.!0!Q?CWQ+
MI7AB1IY;^"X(C'EI!W/90*`.)\`ZB;G3YM;OV>>\O9V=$=B4@4$@;0>AZ\T`
M=I::K<;1Y3",JVY3N/7^E`%FYU:[>7<[QSQY&T/R1]#UH`O:;KK1R(`TB$<J
M5D/Y$'K0!U4KVVOV#O,BB^@C8Q2CC.!T/M0!YM\0?#FK^/=!T>S\.V@F:&X9
MI7:0*J#8`,D_A0!Y5XM\`^(/!C1'6[54AD8K'-$X=&(`/4?7O0!C0YH`N$\9
MH`:QH`B=N*`*TKXS0!0N)@,\T`-LM(U76?,_LK3[J["?>,,98+]30!EZKI6H
MZ;,R:C8W-LXZB6,K_.@#V/P%XVDU^^NK66/88[1-JYR7"X#?IB@#N=+N@DT,
MPQYL;E6`/WAC_P"O0!!XVF\OP=J<L3,IBC\R)F&2K!<T`>`WGCG7KS1+C3+J
M]>2&>596<GYQMSA0>PYSB@#GG$DH#NY8G^\<F@#OOAIX@\M5TB:VGE&XM$T*
M[B,]01Z>]`'J]TMXEJJV%F&F;H;J38OX`<F@"DJ:VBDWBV`[[8MP(_.@"_ID
MZ7%RUJY\NXC^8JXQD>H/<4`=!'K=O:R+I45TC7]TI4+&=QC4\%CZ<&@#IDU.
M.QM(;"P'EP1K@#^I]Z`-W3[.W\3:'>Z3JB^;;7494[AG8<<,/<=:`/D"]M38
MZA<VKL28)6C)QC.#C^E`#F-`$;MB@"O*_7F@#/N)L#K0!J>%O"^I:UJMB\NF
M7[Z2\RB>=(6VA._S8]*`/HF"\&EHMM;I%9V\:A8H40@*,<9`_K0`DFH6]ZK1
M70@D9N#&Q5D;\&'%`&9:>$_"L%^'T_2TL[P*<SQ2-D$CGC.,>V*`,/2UFO[J
MX@LH)KBYBD;S$B0L01U/';I0!L:9X=NO&UK/I=V;FRTQ2#<R^4=S#/W5XZF@
M#0U?X&^#(+/R8+:X67!R[3-N/TSQF@#Q_P#X5>(O&,]HTS_V/``[.6&\@]%S
MZ^]`'H.G:=8:3`(-'L+2)!U+-EC[DGK0!;=YVCRB(#CYB#_6@"O<W<-K:SM/
ML/R_>)^Z?:@"UH<4D$R7[JHO'PNW:,J@Z*??G)H`ZN673Q#;ZA/96T>H!L1O
MLY<=\CN/K0!0"R/.S.`7))..E`'<^&I4TRPGU"\(2"WC:60GT49H`^0]1O&U
M'4[N\D)WW$SRG/\`M$F@")CU]*`('?%`%2XDP.M`&7-(9)513\S$`4`?6.FZ
ME-HUM86RS?NK.%(5*C`&U1Z4`<Q\1[YK>VFUO3F!=!OG@(^_ZD>A[T`<SX6C
M\5>,Q')IEBMM99^>YOI,1+]!C)_"@#UO3/",<-D([W599[HK@FW0*@/T.21^
M5`&3:>(HOA7I-^+PVSW$MRLC2IR[(W'3VZXH`[?PUX_TGQ1HOVG3+HF2&<K*
MJ186=OZ=<YH`KZG>"XN#*1)AE.[/\)'<&@#RV6]-[+>);.6G:7+Y&&QC@X].
MM`%1('*J)2`'&<D=J`&>)-=LO#VE"2Z269V_U<**<$^I/2@#C/"U]JWC7Q3;
MO*H@TNPD68Q1J?F/\()[G(H`]EL+!C,W4O$3D`=&/K[4`<KI_C.V\2>*]0LD
M$*0Z?(8H2A_UB`X+?F.W;%`'I6A6BSAWE/F#@*/N[1ZD]J`.3_:'\37.FZ7:
M:!IQ'V/4$\R6X0\.JG[B^W0F@#P*(>M`!(P]:`*DLF*`*UM;W6IWT-G80O/=
M3,$CC09+$]J`-WQ+\+_%N@Z:NHWMBODJ`SB*0.\?^\!0!ZZ)V6WB+-EFB1C[
MG`']:`+F@:<NK`RZD-^FQ91D/24_W?IZ_E0!VDEW;"SA\J/8@PD4&S8J*/8=
M:`-+1O\`29",$R$YW]"`.U`'S?\`&>QU'7M>O]0M))I;9'PMOG/RKQD?EF@#
MS[PSXNUKPU*@TR\DAB60.T6!ACWZB@#UOP=K>O>)M-N)9KZ>)9'+!$4,JACU
M/L._:@#@-4T_6+37))[75Y99T)19XR1N'M[4`>E_#^SU2.WDU#Q)=/>R,,00
MN/E4#JQ'>@#U+29+?Q383:3JD"2VLR%"K+]WC@CW%`'+^$O#$7A[21!"W[UY
M69F4_,Q!X_2@#6\92QV?AN2T3?'J&I6[1JRG!12,,WU/3\Z`/F^[L];^'>K0
M7MA,=LH(60QY1O\`98'@_2@#WOX8^-+KQMH\<>JV=K=P082^C$0`W$_*VT=<
M_EUXH`]=\2:?X5N]"CEUG3K.XL-+B:1XBG,2X_A';ITH`^1?%4^CW>O7,WAR
MTFM--9OW<4K;B/4^P]J`.=<DG'4F@#.O6,;,C\,#@@]10![7^SAH\4=C?:],
MG^D22?9X'VY*J!EL>F<CGVH`]5U56GL"H?=%M._/!QW)H`\BCNUNKI[.VE#R
M12&'TQR`!^HH`]"F=]+@BLK1498>K8S]6_/-`!#=W%Z1O?>[@@MCD4`:7B?4
M4T+0)!%)MO[S"18ZJN.6_P`^M`'%Z7`)XPF!D]/K0!P'QZ\/Z7X?F\/W.F:8
MMN\V]YRI#)(<@X;_`&NO'O0!B:3\1H-*LI-,LK"XBTI^659OF)/)R.F,]J`+
MEEXGT"]E4-<O:YZB>/`'XC-`'J_AWR[VPA%G-%/#@AC&XP0>P_2@"WXC\2V/
M@7PY=7-Q+$NI21G[':>9EF;ID@=O>@#A%^,.CV>B"X@M[B?5V08MV7$:/ZEN
MX^E`%[PYKZ^-(S?-/YEZ`-\1/*>P'84`'QFB^R^"(+662W2ZGE61HY&`<HH_
MA'<Y(Z4`>:>$/%&M>&+2^@T:[-NEX`)"%&01T(/8]1^-`$;7U[</(]Q=SR-+
MG>6D)W9.3G\2:`'1C@8H`IV]U#;7<,ES#Y\*N"\>_9N&>1GM0!VWQ/U72=3L
M?(TJWT]I;J>.))8U!,9Z\.,YZ\\T`>X?"ZPTCP1X<CT&[<7\NXO-.%X#-U`'
MH*`+7Q,OK/3?![7&E)YDUR?(B9F`WL3P/;_ZU`'DWAGP:ND3G5;W6)+J]DD$
MTD<2`)N!R0">3Z=J`.YE@-\C-;R,T;MN!'.[V/IWH`BU/5;3P[H.H7ME$NJ7
M]A'NN((Y5Q#[,<\8ZD4`>*#XJW.MZXT_B2-1`QQ&8!Q"O88[CWZT`>DZ!JVE
MW4'VBTU2S:%"`S-*%VD]`<]*`.-^.?B?3-;ATK2],G2[:T9I)IXSE=QP-H/?
MI0!Y/]F![4`--I[4`:NAZAJ6CLW]FWT]J),!PC<'\*`(M4>XO[N2>[N);J4G
M'FRL22.W6@"G]ESVH`M6"W%G-YMI-+!+C&Z-RIQ]10!H3/<7LWG7T\UQ+_?E
M<L?UH`ECB`'2@"S&G-`%F-?:@#F[LY4B@#K_`(*>%[+Q+XID356NC9V*?:?*
MB.`S`C&[T'TH`]UO7VWL5[&/W;GY@M`%_6M"3Q7X6;38;GR;F.59H'QP)5SC
M/L02*`.!M&O;.XDTS6(##?0<21D]?<'N*`-BUME5#+Y#/'W4G&/KB@#1EM=-
MU3PI=Z%);K;6]WM$\T+[)&P<@$XY_'-`'DGCKX+-HN@76M:'J?V^TM1NFADC
MVNB^H(X./PH`\LA1@I4$[2<D9X-`%N.+B@"PL=`$HA%`"B$4`*(10`ODY.<4
M`2)"`1Q0!81.E`$RJ,T`2JHS@4`2#IUH`Y:Y/6@#I?A)K*Z+XL>>6YD@A:W8
M/M&0X&#@B@#V=-0M=1L8I]/N#-!EB2.H!/?TZ_I0!T/A.Z:WU!`[`QN-NSKD
M>OM0!:^(?A>[\2Z67T=_)UNQ99;>8$'SHSP5;U__`%4`<?ITFHQ0JMW;1BX3
MY68$J<CU%`#-+\4:9J6NSZ-MDM]4B^Z2N%DXR<'Z4`=OH]C#K&AZOHUQ,T:W
MT#0[_P"Z2.#0!\FZCILVF:G=6-TNV>VE:*0>ZG!H`(TH`L*GX4`2JHH`<$YZ
M4`*$]:`'!`*`'!:`)%3B@"0#'UH`>O>@!]`%KX;^`KSQ[KLVGVC&*.*!Y7F*
MY52!\H/U.!^=`'MMM\,-*\)>%+`3V3G4;U@MVS,&9?55;'`ZT`8^I?\`",^$
M9UM(;GRVNG"G<<DDG&3Z"@"Q;^9:W"!"'"ON16%`';^%KU_M'WW9@=T8)Y!_
MB4^V*`.$\7^,M-M/B1J'ANXADAF>52EQN!5MR!AGTZT`+J/A>SU2:.1C]GU"
M)@\5PAPRL.A)[CVH`['2;6ZMKF-I$^=ADD#C/J/:@#P7XWP6Z?$[6#:@8=D>
M0`_QE`6_6@#BHT[4`6%48%`$BKP*`'!:`'`4`*!0`Y1DT`.`XH`>!Q0`X<4`
M*.IH`]H^"GQ$\+^#?`,MK?3"/5&>2X=`.90"`%SC`..@H`31_$TWQ*34M9D$
MD<-E='R;4RX$,>WC&/XC@Y)]3S0!YCK5E/XI\6SQW3^<F_`9%^0*I^;!'?F@
M#TO1[I`J65\N9%(6*5!G(Z#/^-`'22:SH_A/=>:WJ%O;H%\Q4W@R2`?W5').
M>*`/E?QYKS>*/&FJ:VBM$MS-NB4GE%``4?7`%`'L_P`,_&5KK>FVUC?7"PZM
M`FP^8<"8#H0?7U%`'KJ1W>J^'[O3K&=K;4#$WV6=2<QR`<?@>E`'R->"X:]N
M&O6=KKS&\UG.6+9YS^-`"QK0!,B^U`$BCVH`?&A=E5%W,QP`.]`$]Y9R6<OE
MS;0^,X5@<?E0!"%.*`%"^M`#@!G%`"@4`.QCK0`M`&',F5-`&WH_BQO"FA+#
MI[++=W#EI0J;0J=-K'^(\?AF@#8^"M_=7,NN)/*Y=E5@I'`SN+'VS@4`>OZ7
M#;+'+=NBPP(,'+?="@$D$^IP/QH`^>OB3)J=[XPNYM8@-O,RJ8X"P;RXR/E&
M1[4`<VL'M0!8BC*D$9!'<4`>U_#7XK'1UBAUUIF,0PEQ&NXLOHP[_6@#SSQ)
M?1:KXBU+4+>+RH;FX>5$/50230!21:`)E6@!ZC/7'`H`!P:`'=>O:@!0.M`"
MXH``.U`#L4`+W/%`"XH`RY$[4`/TQ[2TN)9[RS^U'RR(ER!L?LWX4`=5>^*)
M=.L+'7=,BMXOM#^5-;@`D;2-V[@$YZC'3-`'K^C>(=*N/!D_B*X\N70HQ^]M
M$M\NY#`8.[KSSVH`^=/$ERFJ>(]1OH6=XIIF:,N,'9GY1C)QQB@"BL/M0`]8
ML'I0!.B8Y%`$RK0!*JGK0`\`YS0`\#CF@!5'>@`H`4?2@!>AH`7O@B@!?H*`
M`=30`O;B@"BX%`#&48H`KW2AXE1B2H)('8$]?Y4`:(\3ZRV@)H/V^1=)3C[.
MH"AAD'!(&3R!UH`SE4#M0!(H&!Q0`Y0.#ZT`2*,=*`'B@!XZ4`/[@4`.Z-B@
M`Q\I-`"9H`4?>Q[4`.(&<4`*1TH`7N:`$!SUH`<1VH`__]D`````````````
M````````_^(<;4E#0U]04D]&24Q%``$!```<74QI;F\"$```;6YT<E)'0B!8
M65H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`````````````
M`````/;6``$`````TRU(4"`@````````````````````````````````````
M```````````````````````````18W!R=````5`````S9&5S8P```8,```!L
M=W1P=````>\````48FMP=````@,````4<EA96@```A<````49UA96@```BL`
M```48EA96@```C\````49&UN9````E,```!P9&UD9````L,```"(=G5E9```
M`TL```"&=FEE=P```]$````D;'5M:0```_4````4;65A<P``!`D````D=&5C
M:```!"T````,<E120P``!#D```@,9U120P``#$4```@,8E120P``%%$```@,
M=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O
M;7!A;GD`9&5S8P`````````2<U)'0B!)14,V,3DV-BTR+C$`````````````
M`!)S4D="($E%0S8Q.38V+3(N,0``````````````````````````````````
M````````````````````````````````6%E:(````````/-1``$````!%LQ8
M65H@`````````````````````%A96B````````!OH@``./4```.06%E:(```
M`````&*9``"WA0``&-I865H@````````)*````^$``"VSV1E<V,`````````
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O
M=W=W+FEE8RYC:```````````````````````````````````````````````
M``````````````!D97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````
M````````````````9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````
M``````````````!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@``
M``%865H@``````!,"58`4````%<?YVUE87,``````````0````````*/````
M`@```````````````'-I9R``````0U)4(&-U<G8````````$``````4`"@`/
M`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`
M@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P
M`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!
M@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X
M`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#
M(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M
M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%
M=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C
M!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((
ME@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ
M"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,
MC@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2
M#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1
M;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G
M%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT7
M01=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW
M&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>
M%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.
M(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E
M]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU
M*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N
M[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X
M,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y
M!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@
M/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$
M1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW
M2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0
MNU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$
M5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>
M;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/662
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M-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,
MF+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B
M)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OI
MK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V
M>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#L
MP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,
M-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<
MU^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC
M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`
M[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\
M!_R8_2G]NOY+_MS_;?__8W5R=@````````0`````!0`*``\`%``9`!X`(P`H
M`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`
MF@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-
M`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!
MJ0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G
M`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#
M6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-
M#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV
M*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B
M/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M__]C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____M`"10
M:&]T;W-H;W`@,RXP`#A"24T$!```````!QP"```"``(`_\``$0@!8@%^`P$1
M``(1`0,1`?_;`(0`!@0%!@4$!@8%!@<'!@@*$0L*"0D*%0\0#!$9%AH:&!88
M%QL?*"$;'24>%Q@B+R,E*2HL+2P;(3$T,"LT*"LL*P$'!P<*"0H4"PL4*QP8
M'!PK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK
M*RLK*RLK_\0!H@```04!`0$!`0$```````````$"`P0%!@<("0H+$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H!``,!`0$!
M`0$!`0$````````!`@,$!08'"`D*"Q$``@$"!`0#!`<%!`0``0)W``$"`Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#R'@<8')H`"3T`
M.>U`"8X.`*`'$E>W!Z"@!%+8('`QTH`781C(*YY!/<4`,8[ACMZ"@":>[N;B
M&UBGD9X[>+RH5/\`"N2<#\S0!"V['?'3@=*`#'`.<>N.]``S!N1C/K0`U@,9
MQWQUQS0`#'!)P1Z4`*2<G.<'KB@!K#`Z#@8XH`!@$].10`IR<XZCI0`$\\]?
MY4`-&.,8SZT`(6R!@Y)/-`"KC&T'!SGGUH`:6(QG\Z`&DDN03VH`:Q!(.>GK
M0`I/&!TQS0!&3SG/XT`1L<KMP,'K0`W.,`]1Q0`A/&!^-`#-V0<'IS0`I?&?
M3UH`:&.0,]*`%#$MD`=:`)8E,CA5&YF/`')-`'HW@_X1>*O$<:S"T6PM6&1-
M>93=]%ZG\J`.TN/V==66U#V^N:>\X&?+>-E!]@?_`*U`'D?BCP[J?A?5I--U
MJT>WN4&1SE6'JI[B@#(#]!U'I0!(&YST_I0`JD\G'M0`]1^M`#P3WR<^M`#E
M]0,?I0`9/R@\?UH`<`!SU^IH`?D#D<?6@!`201GMVH`0QASC!(Z\4`-"C()Z
M]QF@!N`^0%_'%`"D\'T'3TH`"1MR#C%`"C@#C!QQ0`YY&E*^:SOL7:N3T'I0
M!&V58X/%`".#P`>G4F@!0<9&`2>N>U`!NZ\`F@!I;G.0<\9[4`(",8&*``MD
MG/4]J`&J3P3CGMZT`*<<J>![<T`-).T``''2@`+?+GVXYZT`'.`,=>>>U`#6
MZYST_6@!2>0V??Z4`(3P<\YZ4`-).../QZT`(21R?QQ0`UCA>!T_2@!K$XXH
M`86'.3P>F:`&LQ!Z9.*`&%LG'I0!$7P>I(H`:9!D\?3-`"!SCK@>E`#WRK$$
M@X-`'JWPU^#6K^*/+N]49],TUOF&Y,R2C_9'8>YH`^E/!GP\\,^&K>(:?ID+
MSQ9/VB4"23/^\?Z4`=3*)&*DMM0^K8/M0!'Y6YE`;>2<Y)SB@#RC]I73(=0^
M'B:HR#[187*['QR48X(^F<4`?*0?#4`.4@#/\Z`)0X.!@XS0`\8)'7%`$GW0
M.>#V-`#QT`'X4`*N.X//I0`]<\XXH`4@@#KUH`4X'.><^E`#60X`QDT`1D\%
MCT[B@!>F<%<F@!1@M@]0<XH`1B..W]:``Y!R1ENX]J``J6)'\/\`*@!.F0"#
MG`H`0$8R.G\J`%[EL9]P*`&!>#CJ1F@!23GH<?2@!O4G!`/8T`-[$$C<*`!C
MNYS0`A.!Q][/0]Z`!@Q0$`X!QGMF@!H89QUS0`$D#GC\:`&[C@@,2*`!B."W
M&.:`$)&SKQB@!`<9R>#Z4`(20V1GVH`:>1CT[XH`86((_K0!'N!ZXR.:`&.Q
M!/S<>F:`(RY&?I^=`#&;CVZ4`,+9[D&@#<\)>%M6\5Z@+/1K5I77F1V.$C'J
MS=J`/IGX??!S1/#=NE[JTL&I:H"#NF'[F(_[*]R/4T`>E%[N>1(+(>7:GF2X
M./F_PH`EN-1N+"\2);>(H5`)1CAO<>E`$T=Y;7>`<QN&*X)R#0!H11LD+`$;
MFX!'84`>$?M3>*H+;1+'PS:ONN+AA/./[J`_+^)/\J`/F=&(P<]^]`$@8-UH
M`F#9/!'6@"4,,\#F@"12-V.,]O:@"121CC)^M`$G9>*`'8)[<T`*@/)S\OI0
M`%3GI@>U`!G8>"N>_-`$0YZ_KUH``".>00?6@!<#Y>,J3^5``W3G.,=<4`'`
MSD=1QSUH`!GGJ.V#0`C`@#"[3U_&@!H#'([,.E``QX()Y[T`(/EX_+VH`0'`
M!.<9Y%`#7(#`@=:`&@D=<`=00*`$S\OOGMVH`9PP^]U]Z`$$K!2@9MI.=I.`
M3ZT`(7X&.30`@DQN_F:`#=TZX^M``7QUQ@\<<T`&><@GGB@!&(R>*`&[N`,Y
M-`#6/7/X`4`,8@A2.M`$3'DF@"-FP!ZT`1LY&*`(F8[J`+NAZ?<:SK%GIUF`
M;B[F6),]B3C-`'V9X4T6Q\&>&TT_3+1(E0#S[I_^6S]V/<\]!0`NI)]JB:3[
M=_JB"PQRQ_V1]*`*-M-+$BRPS/O(YC9B/QH`V--U=[N+#D&4/DQ2-S^!H`TK
M.0I,Z2)M#,6C/<&@#J1(#IQD+<JOS'&..]`'P%XWU^;Q%XLU35+AB3<3-L!.
M=J`X4#VQ0!?T?P-XGU71Y]4L=&NGT^&,RM.4VJRCKMSU_"@#GF5HR%D1E;T8
M$4`2(Q`)'/I0!,C9ZF@"56&WKDT`3KT''?L:`)HNK$?_`%J`'8PHP0".HH`!
MTSCMQ0`#&W"@8_G0`Z,G)VH30!"#D9<\]S0`@`P0,<'\Z``=SU.:``YP0<XZ
M\4``!`R0,>M``6S@X(R?6@!652J@.,G.Y>XH`:,*>GXCO0`PGYAP>G%`",WZ
M]Z`&@@J#V/1OPH`:6Y'/6@!K'!]J`&$YW=OK0!&#A\?F:`$+E>"3TX-`",^1
MZT`('(!';Z4`(&/7L*`%+D@9.2*`#=@$9H`"W4X)]J`&ELDYH`:S``>M`#';
MH.@H`A9N<4`1,V1D=*`(V<8//'\J`(BW3.:`-SP/J:Z5XPT>]D<(D5PI9O09
MQF@#ZXGD$LR@2^8?*W!CR"S'C'X4`);RRR64<D<3AHPP=QR'.?TH`O>(+*."
MSL+B(MF:/+C^$'T%`'-3,-P"J5?J3T%`&EI^IE'5;AF<`XRK4`>C0O#<:2]F
MTDB"Y@8;F'*@C']:`.2\%?#CPIX,TV=K>T&I?:'&^6ZC$NW''''`S_.@#NX_
M,$!@$<$<6-H0+\JKZ`>F*`/#_P!IKP_HJ^%TUZ&P+:B)4@^U1$*J*.S#OZ#B
M@#Y@#<DC.!^E`$\;=LT`65.2!T]Z`-'3;6:^NX+6W0M-,XC10.22:`/H_2_V
M>]/6)3J.M74C%1E8HPH#=^N<^E`'E/B_X>ZMHEUK,J6NW3K"8+N=QDHQ^0@=
M2/>@#B64YQR10`GH.`?6@!K`'[V1]*`&\Y()^4=0*`&8Y[X[4`.YSGM_.@!"
MV#DGKT/3-``0%49/OB@!&."0>2/>@!O&"57'>@!2,8`[]O2@!N1G`.5H`:RX
M7UH`:Q!/3!/ITH`C)R`>/2@",G.<GGN#TH`C=L\YZF@!A(P03Q0`A.1V/H/6
M@#M]!^%GC'7+)+NSTEX[>0;HWN9%B##VW'-`%EO@YXY$C*-'!`&=PN$P?H<T
M`<UXA\&^)?#F#K.BWMLAZ.8]R?\`?0R*`.?#;AR!CTH`7<".G-`"@[5.>AH`
M:S<^]`".V,^E`$3O@Y_.@",MU'0>U`$3.,8%`$#,<\'\:`&,<MDXH`0G()[X
MH`^N?!&L6FN:)H^H0N?+$"),IZAD&"/S%`'96FL+!I;6/V<C:Q8M&<;\^OO0
M`H\1V]UI4EC=QL67Y8@J;BON3ZT`8*JTS_)"D<0.-\I/2@!KK;+V8(#R[_*/
MRH`Z/0[J]UB2.6PN(C#9@(PD)^8#T^@H`Z"?5)X5,GR*[X.T=`O0`#UH`NV%
MT)8F,GRLX8GGG'<4`<5\?-)FUGX7ZE"MG+=3Q2Q-:I`<MG<!N(_$\4`>6_"3
MX37VEZS'<^*X+:6QNK=XVB.'5#VW'M^%`'H.K?`OPMJ>JV=Y;@V-LB@2VT#_
M`"3>AR?N_A0!G^*_@'HMY%&^@32:;<*0'1F,L;#/)YY!QF@#?^''P@L/"J/-
M?3B]U!9UD@ND7:80O8`],]Z`/5!(/,\OG<1G../SH`CO+&UO8C%=P1S(2K$.
MN<D<@_A0!\K?'?PU;>'?%42Z=9_9K*>$.&!)#OD[C[=J`/,,E1VQG-`#'8<9
M*J/5N]`#"<`9)Z]*``8"@G@]*`$`.[DCGOB@!Q`!.#R>G/2@!K<?0\T`&2"1
MC`H`3L0QQV)]*`$R>W!SQSUH`:`-OS#Z4`-(`ZD^YH`C+8)QG)%`#'SCCKVH
M`A;`7(H`B<X`XR:`(F:@#W+X)^%M%71X/$>JVXO;QI&6"&8#RH\'[V/XC]:`
M/9T\021[F>43DGE&4$#Z4`:T.KS7%JEQ:QQN1_K$"#@>XZT`3'5X4A1)]Z12
M'&S`D3\0>E`'&^*/@_X-\0QSM%:-IE])RMS;?*`QZ$KT(H`^8/B-X)U3P)K8
ML=4"2QN-T-Q&#MD'X]_:@#E@X)([?6@!Q<8.3Q]*`(RW)-`#6?J._O0!"S#U
MXH`B=LKGB@"%FYQF@#=\(>$M8\7SWEOH%N+FYM8?.>+<`S+D#Y1W/-`'NUQ^
MS!</H$$MAK@_M<QYFAN$Q'N(Y4$<C'2@#L?AK\(=:\+Z:^GW]Y:.DH\PR*Y(
M#G^$#&<=\T`=S<>$;Z*U25=1@BN``-I&$'XT`87V&[6[6W"QF5SAYD(`49QN
M.:`+<>E+I\A-\HO9U8G/F8QD?*/2@##3P[;ZC9NE]J%Y!=R9PD2;LD]=I_QH
M`M^$TT[PXCZ+97,S26Z-/)]HDW.^X\EL="3V]*`.DC121YF65>-I!X;M]>M`
M%R%VMXB?^6ZL6PG(49Y_&@#<LIUO(Y86QEDYQZ$4`>9_$?Q!/HMHMYHSJ8(7
M$,T&/O>C#\>*`,+PMXTO=<\0V,!+"2;Y6C<$`+U/'L.E`'M-M)(TI\[&PXVD
M&@#0)\E"QSM]AF@"C/J'ED\$MVXQQ0!?@G+VZ22+M9OX:`.0^+4NDP^"[V37
M+%[J!$8Q!$+!9,';G'3GOTH`^-&)YS0`C()>"V,>]`#"HR0`>/6@!&P3SU'/
M/0T`')4@G)]#0`;0!TX_G0`SL#U([T`(22P;-`"G!'H:`$89!X'T]:`&=AD#
M`[>U`#6/0+VH`C)P3SQW]*`(F;'/]:`(7/MP:`(';N<`T`1.W/6@#VCX%:NM
M_HM]HDK@36[>?".Y4\''X_SH`]5ABS:%5=?-!X[9H`BT[4);&_#+N4_Q#M0!
MUNOI#.;>19/*DGC#L>JL>X]C0!>\/W1%L;>]=GB#;5E';V(H`A\<^$+/Q;I$
MNGZM'#=6Y&Z.3=B2%L<,IH`^*/''AJ]\'^)+O2;]6/EL?*EQ@2IV84`88DZC
MVH`3/)&:`(RW7^M`#&;(H`A9N:`(F/'>@#Z`_9`TS[5XCUC4/LV9+6)%BN6)
MPA8G*@="2!0!]=3S0VELTLC*B#EF-`'/'QCI;R;!*2RGIZGT'J:`.$\2^-[;
M4-;CAGBDALK9L[7^5F/J10!GP7<E]K<FI6$H6W8^7+YC?*Z_W1[\4`='I,:P
M[9'8,P(;>%R",]`.QH`VVDD$BS6DA6W"E61EVJO?.?7F@#AKR/2[/Q3%=V]Q
M:F_U%6C,2]9V&,N1GD+C\:`.N\V'S+*8/=3RW)\O]W'D*>Y)'04`7X;61)_(
MM(D,0!?S1D`D?XT`;.F`F-2W+J=IH`^>O&WBBR'B74=(#)*PG8O'SQ@\`#US
M0!U/@O1+;3RFI[-ESY/EQ)D_NPQYSGN:`/3]+GCBMC^\#LJY*B@">:[D4%L$
MJ%!.3P2:`,LZW:QN4:.1PQ^9F;^5`&U;&&YM(Y8$..P<X('M0!?*Q7MH\-Q&
MDL,BE)(W&0P/!!%`'QI\5O#)\)^-+_3XU*VC-YMN3WC;D#\#D?A0!R(P3R`1
M[T`-;:!B@`8XP`.OZ4``((P>HH`0<@DYSCB@!K';T`R#QS0`I.<XX/;VH`9U
M)P!DC\C0`A8D9!X]J`&L>",Y'KB@!C=<X]S0!&Q&#]>GK0!$^,'.:`(9&[=Z
M`*[-P>^!^=`%:1CC/KZ=*`+.@ZY>:!JL.H6$FR>(\@]&'H?:@#Z5\.>(+;Q%
MI-MJ-E(H9U_>JK9,3^AH`W+*Z+2%WCVW$9P%(X(]10!=+NENQR2">6)Y6@#H
MK)UNK%$@D4R+AB`<DX[B@!;=Y3]J\V21I!&0B#C:3TS[T`><_%WPS_PF?AUD
MA*_VC:1FYM'/5ACYX_QQQ[T`?*1D96*N/F4X(/8T`6+*VN;V<0V4$MQ,1D1P
MH6.!WP*`)K'2M2U&[^R6-C<SW.[;Y:1$D'T/I^-`';VGP4\=W40D&CK%&1G,
MDRC],T`5M:^#OC72]/:\?2Q<1)G>MM('9<>W^%`':0?`16^&HU5]6A&KSJ)X
M@^4C1<<QMGG/O[4`>C?LK^&+W1/!]YJ&IZA!]CNKG=!!$X8*P^4DGIDG`Q[4
M`;'Q4O\`4;W4+#3HW5H1(%G\ESA>><]NGY4`2:9X9M-'U=K^XE,R)@PQR/\`
MZK(&"/4]:`,OQ5\-M3MI(KCP_P"?J:,I:9IW!8,3T`[]:`,^+3M9\.V4L6J6
M\?ER1LZP%N6('.W'0^]`&IX(\6:=J7AYKJ6=;4I*86MI&&\8'4>OITH`Z#4Y
M([GPI<ZA!=&RB>-I8I+AB%D?H,H.W3\Z`/(;+5+RX\3V6IZG"BM;+Y2R6Z9C
M`[\GH#WH`]_\)-:ZEH]I<P[WMYP6WJV`?0'OF@#H@F857:0NW`0]1Z4`,BB=
M+DN"0"<C%`'SOJ7P]2R^,FO:_=0NL;S^;9Q,V0[,,M(?;.<"@#L;BZ6)5C$A
MED)WN0.!0!O:!JK-J*Q^5N+\$*>0*`-O7KQ[>RVQ_-)(^%`Z8[T`8VCI:2QL
MUW-+YX;*HI`#"@#>M;EEM+F61]LFX!#_`'1Z4`:>C3LQ`?EL=:`/`_VJ9(SX
MIT501Y@LR2._WSC^M`'B(P1A@30`N<KSG'O0`IZ'/UY-`##R!S^`%``IR,X.
M0.E`!N!8D=2<<=*`$&,DCKCG'>@!/0CH?;%`#0>/4=SVH`1L]../:@"(CIUS
MZ>E`$;X((QVS0!$Y&<XQD4`5Y&Y]?K0!6<GGD4`5G;GV[4`593]>:`/2_A-X
M]T'PCI=]:ZG974MW>2C-PA!2)`,#Y>YY.:`/5-"\4Z3K;(MIJ,4C`9V!\,!]
M#S0!T-KJ,<:2(R94=%)XQ]:`)-.U"<3+)9V4[YZ-""V*`-S6-2OM.ACGO+29
M89`JL\JD#Z'\:`,Z_NU5(Y8)599B9(3G[C?Q+^-`'RG\1=,>P\=:C:P0,!/+
MYD**OWMW.!^)H`]U^"7PZE\'D>(?$MXUK?2Q[8K&/DA>OS_X4`>KVUQ#,SBW
MTORX9&+/,5*%CUR0*`.@M+>5D1GN(X%9<QH,=.Q.:`,[5;I(&B6ZOHX[D-EX
MVR04]O0]:`-'4-&A\56D#7Z*=/<9"+CIC@\T`:6F:-I^EZ/#H>FP);V=N@\J
M-!@#G.?Q-`'!ZEX@\.R^(=3L+J#_`$@2["T:%=Y'!'OUH`P;T6.G3VL^L7AO
M-+^TEE\R(Y'HN/0=*`/0M*N)=4TBTNX+B2"X?=(@49WJ/NX'IB@#R?XB:Q)J
MVH3Z7ID4U[>0RCSV>;RT7L<X]"1P*`.K^'O@1T>VU#5;*&R=")&!`=I#C'4]
M!TYH`R/'GQ!T?2M,FM;AX[]7N)E5$(WJ`<#CMCUH`\PL?&&FZOI5S'=6K6D4
M+$_NG^\OOZ>]`'7?#_QK]DU633T8OI,4:LBO(H`/;;W.>E`'M/A?6QKMA-.(
M9K8!\#=&<NN./_UT`;MS<0V\'FSRB*-4W-(3PM`'EGBS5[?5=<:[M+I9K58P
M%7!&2/YB@#/T2"34]2BA",REMTASVS^E`'JFDZ-9:8KM;Q"*63[Q#;B?:@#.
MUFV>6.6V(RZG<C8Y_"@#D;JS>(Q,&S)SD[NG-`%W358*1(TCNS@C)_.@#N+9
M8=,LWO;Z9(;>*,N[D_*BCG)-`'QW\2_%#>+O&>H:FK'[.6V6ZL?NQKP/SZ_C
M0!S"_,/EX]\T`/STXZG)`ZT``'`'3/.*``YY)_"@!,#GM^/)H`:=N,,!S0`C
M'Y0.`/7'6@!"=I`[=N:`&#!!`Y(Z4`(>3C./QH`CD'S%@<YXQ0!&V,G'\Z`(
M&;`(YH`A?.,T`5I3G(S0!3D.">>/:@"I*<\Y'YT`0.:`"WN)K6=)K>1XI4.5
M=#@B@#Z)^!=QK7B[S;K6(PVF6>$\YC@32=E([XX)H`]O@"02*BS8VG)7.W/T
MQ0!N6MQ%<(]E.(I8I1CRGY5_;!Z4`>2>.[0^&;JXA:&:32IU,EL^?FA<<E#[
M_P`Z`.?\&1:9XEUJPUJ\5I)])<LC,.&)Z;CWQZ4`>GW&MW'F3.AQ*`6R0"0*
M`,\^(+Z^MY%DN)&C(.Y0>M`&7+=RL\3WLHWKA40-_JUS0!Z@OA;3+G389I+J
M>=V4%[A7!XQ_*@"UIVG:E::N<7,$&AI"%CM@,L1_>S[T`<U'K,EGJ%]-'<2$
MF8Q2PR'_`%2KGYE/3GB@#YDOM6G\1>-=3@5KN&?[8S*2V6`SPN?6@#T3P$UY
MXS_M'2]3O%>UTUQ"DLYP_F=P!T)H`]&&NIX=TJ6U:><QVS);)M52X88Z=L&@
M#2\%V]GIU\T%NS2W%W*UQ+-,.2"<MC'3GCK0!HZGXJLHK]X[6]6>2!\/%'E@
M.>06Z#Z4`<)X\\">%O%.HW-_<0/:3WJ[DNXG*@-CJR],YZT`>*W?PQUO1-9,
M-U;2W^D-G;/:G(D';('(H`[WP'+X;\/7MLLDC12SJRK;E"S(,_QYZ4`=!J_C
M34]68Z+IS?V;;R95KB*7#!1Z'L/>@"MXHGU?^R[:R@UA[L0_-<=>0>1@]"><
M4`9^G[U@57W*PP,$\_C0!T&AW4]C?)-`ZAD&&+="">]`'K%GJ=F]DO\`I`E+
MG=E?7^@H`\.^,_Q?&E:K>Z!I%NXO(5`-\),;&.#P._O0!0\)?&O3+FUBA\4V
MT\-THP;BW7<C^Y7J*`.AO_C+X1L4S8B\OY0>%2+8#]6/:@#S;XC?%C5O&L*6
M*H-/TI#_`,>T3$F3T+GOCTZ4`>?JV./2@"10QX!(/M0!,"=Q()('Y"@!8V97
M#*Q#*<Y]*`&ER3D@\C.*`%'4AOO=:`&J,Y(H`;Z<\=J`&D@G!ZCUH`3!Y/>@
M"-B5&#G`YXH`8Q((]S0!&YQ_6@"%L$,>U`$#<`?KS0!5D/H*`*DO0\C-`%23
MJ2>E`$#'(Z4`6=(L)=5U6TL+;'G7,JQ+GU)Q0!]EZ-I^G>&M"M=(TPI%:V2_
M.S`YEDQ\S'WH`)[QI(4V1)L)P&`-`'1Z?J,<FEQM(@2:-\M*#V]!0!L:[I\6
MNZ5-:7*+/;2H0^,;B,=5_P!H=10!XMHOA>]\.7\^@?:XV227S$FQCS4/(R.Q
MQ^M`'8:K<VEJ)H>MRX`F;?P/84`9,]U<"U6.T\@*.3MZD?6@#(N&+!2!@$'.
M>IH`ZOX=W!O+>YT)KF:+[4#)$1R8RO)(/:@#N]3\3Z?86DEE)*UU,$\GR@<]
MNI:@#B(F62UF$@&!DX/I0!POASX=7M_XEO=96=(0\N4#/\N!V..]`''>(/&5
MY<>))M'\/Z.DUY;7#B66,[59@<9..F/6@#U7P/I\VHV5[>Z]Y<@!58;:'/,Q
MQSG\N:`.SOM=L?#.FR03&%;^>-TB\E"Q+=\'V-`&+X:T5;/3&N]1MF^Q,"\T
MN3D'TXZDF@"_8ZU%;%K*:%XK;:&"R*6&#TR#TH`O0VL<X=M.2S=6ZQI.R'\B
M:`)ETRW>4M<6(5^,B1-_/LU`%)_"&CW=Q-)9!8KS/F-'L^5B/]GI0!R/CCPW
MK]K"KVDSW>G(2TDD?#)[%>H&?2@#"L6'EH2<'IGWH`WK0?NFY_UN`HQUH`[3
M2XXDM;AR<"WC`?VZDT`?&/B?4CJWB74K_M/.S+[#/'Z4`5HCG`SS0!:C/(`/
M04`6%/3)H`E5NG&!WH`E&''()';!Q0!87H.I&.]`"G)))&!TH`1F(YZC^5`#
M206R#D4`!Z9[Y[4`(W7J<>U`##R!D')[4`,)(``)]J`&L?FZGG@^U`#"2#TH
M`B9@,@#VH`AD(Z9-`$$G.,B@"K*<DD4`5)3Z"@"HYQ0!"U`';_!2P>_^)&DA
M`I$#-,V[IA5/_P!:@#Z9O9XI[*.`JL<CS$N6ZLP/\L8H`I"^^S.RL1*,Y&T<
M"@"YH^I`32Q2*&B?J`.GO0!TD%P8%3]YYL*X9)`>5H`Y+XN23+8V^LV;@2P,
M`[8YQ0!RUM>V^I()2P5Y%R#V/M0!T-M8W,=B]RD4:JBX4D\MQV%`%*ZL)TTV
MWO[F,Q6D[;8Y'(^;Z4`;&C^1I^D2W2N$U/?LB`R&V$<F@#-7(N`Q.3_.@"35
M]3BTK1KF>:3:J(2Q)XH`\1\':QXF\5Z_%:65]+;V<$K322KGY8S_``D=#TP!
M0![9IME8Z4'>VMX5>1R\\NT%F;U/J:``RR/>Q7RZD8'C.%41Y`'T%`%NYUH*
M(5/DRM"2_F.@RH)R?I0!J0^)KAH$DE;S;)5.R('Y1[CWH`S)_$=KJ"^5J,3;
MB>)4.&Q[^M`#(H;*5F-IJ10GH)%Z?B*`-'3&N%<PIJ?[W&5VN=OTH`UH-5UF
MTE5KJ/S57JWM]>]`'1Z/K=I<KN69HYNFZ3(/T/8T`8?BOP>M_-)?Z(BQ72_-
M-;8P)/5D]_:@#FB2;N(1J$6,#('8XYZT`=3)N&C^(FDX5[-V1O4A":`/B&(Y
M`[]Z`+</48H`LH1QB@"=3D`]:`)E)P/FXH`E5ACIS^E`%M_E^Z<CG-`"`^_/
M8>M`"-D<@<$]<\T`(I(&0`<T`(5.._/M0`UL\#(SZ4`(3P<'IVH`83\PP?RH
M`8QH`B<\]#0!&Q."3TH`@D)YR>O:@""1L\#O0!4E..U`%25LGDT`5W(Z4`=?
M\([+2;_QK:Q:V@FA"EXH'^[*XZ!O;V[T`>QW<6C:3XNBEL--M[&]NK>6/,`V
M#&`<[1],4`;FN)(3:R$D%]A)_NMT-`":DB,P$3A3G'/>@"?2"MKJ%JTK`ACA
M@.1@T`:^JQMI6H%XF9XBW)SP`>G%`!K)@U#PY*KKNA=@KX[#D']:`/&OAAJ`
MNO&"Z#<,2(Y'"X."=H)'Z@4`?1/ASPFU]$)=5N%(R'%M&=WS@YQD]L<8]Z`.
MQ31;2&&XC:VM[F%V5Q;%=RQGN0#_`$H`R%T+2IIQ<ZA#!!(K86!VRQ49`!'3
M\J`/*M1GC@>9FVQ1HY`!/;/>@#PCXF>.CK1DTS3SBR1\/+G_`%N/3VH`[7X2
MQQZ7X&%Q&JF>[E+.PZXS@#/^>M`'0W%X99553PHX]*`&DR22_*5X[D\4`7TV
MM$JL`5/=1S0!=L8([>.Y"L5CFCVA73)S['M0!1-HQ5A,Z(<<?*3^M`$21+')
MCS/,(ZX&`*`+?FJ8V>(.DJ^AZB@#5T[4;HVRJ)F\Q#D9;/'I0!L6VH9PSJ&+
M$=/ZB@#KM"U)E,:[^5Z?_6H`Y7XB01V&OBZCPJ72!U0=GZ'_`!H`A2XN;S1-
M5@AW/Y-H\0P.3\A_K0!X)X,^#WBSQ)ITMY!9&TB508OM(*>=]/\`Z]`&]XP^
M!OB;0%LFL(FU=)L*[6R?ZIR<`'/4>_2@#SS4]-NM)U.YL+^(Q7=NYCE0D':P
MZC(H`C0''2@"5#Z#B@"1AD`'@COC-`%PY'&<@#TH`3H>_P"5`"-@CL3Z4`-)
MQP>#UZ4`(<#H?K0`8`R%(S0`TC!/.,^M`$1(!SVH`:QYZ_A0!$Q[8X^M`$#L
M.10!"[YR?\F@""0\8_.@"G(W&:`*LK=<&@"!CSUH`Z3X8726GCW19)8//1KA
M4*#K\W&1],YH`][\4:9ITGC+3KL1O#+S##N<G((.?K]:`-J]E%SH<<@'[X'Y
MN.X(']*`,R+>]H[(-R&0E#CGGM0`D=TZ7<(FCVN'&>*`.IU^0_VN<,?+GB1@
MOKQT_"@"&VF\W3KRV.3`@!V;ONC/)'XT`>5+IUEX;\;7.L[A]JDD(16;"Q`\
M,Q/N*`.]M?BUIFF7(MWNR2S%8FCD#ACC@>H_^O0!-\8/BEK/@*#1K2*.-M1O
M8O/EZ#8N>`>OS4`>'WWQ@UVZN)9S%#YTC%M[L6(S0!Q^N>*-6UHXO;IO+_YY
MI\J__7H`Q*`/;/AQ>K<^#K>-,;K9RCJ#[Y!_6@#=R<D*I(ZT`7K>,G`8;AVR
M<4`7-ZDKLCPJ\?*:`%Q*<R+;2JN<`A\9_.@!\INQ$3YBVPZG?+N('TH`@69Q
M\OVR"9B/]T_@:`'VP,097.$)^5U.X'V-`#E)A=3&Y)!]:`-JSG/EX7@GVH`Z
MC2IODCD!X'`'KSVH`Y_XKWK3Z[I%K;YDF6+)51DY)XXH`[?PAHT&BV+2WTGF
MW<Y#F+/RH?3_`&C0!L7&O.I")P`>%Z`?A0`^UUYFD&XG'N*`..^*WPJTWQGI
M]SJVBQK:Z^J%_DX6Y(YPP_O>]`'R=+%)!-)#*K)+&Q5E88*D=10`]#CKD^U`
M$JDY.W'XT`6%;).!]>*``\,..!Z4`)@@+SR:`$)&T$D\\=*`&L.```3U/O0`
MTG@^O\Z`(W;"'CWQ0`UFP<'D]J`(G8@CG%`$+L?7OTQ0!#(_'O0!`[_+R>*`
M*TCGI0!6E?GG.:`*SGKB@"%C0!=T*Y6SUFRN9'=$BE5BR'!`!]J`.S\3>.VU
M">![2:>-XY@Q*G`P#V[\T`>UO.D5I;R*2;68[@V>FX`B@"C'*]EJ9#$K!(0&
M'8'L10!HZM&4N;1PVY6&?QZ4`;$=W;7$UL9R5EB3:0>?Q]Z`&6(-GJ,I617M
MF4[N/O*?Y4`>-_'VU2'^SY(V+!G8$CIT%`'D$;M'(KQL5=2"K`\@T`6]7U2^
MUF^DO=4NI;JZ?&Z25LDX&!_*@"F!DX%`#Q#)@?*:`&$$'!&#0!T/@OQ&_AZ_
M=F4R6LP"RH.OL1[B@#VG1KZQU.W%SI]PDT;#D=P?0CL:`-N&*TA*-<S"-,<Y
M8#\J`,C7_%T4"&#0;5I(UX:98]Y)]NU`'&R:SXUU)S_9]N\<(/!F8,3_`(4`
M7[#_`(3&$AKFWTZ1SV9B#]/2@#76]U$,/[0TJW4`<B)LYH`U--DMKIF%G<F&
M4<-#+P:`-:&WN&8/)&K*,\H,@T`7[6.195)4*.^.A-`&U;W"V5MYD[+$B`L2
M3T'K0!!X.W:EJ=YX@NHP&D'EPY7_`%<8X!^IQG\:`.@O]1C9P896VX^9B.?P
M]*`,M;MYW.YBP'04`:.F2J\B#!`SSWH`[SP_.#&<<`8(`[4`?,7[1?A1/#WC
MMKVU'^AZLIN%']U\_./S(/XT`>7*.?2@"5`5Z`Y[T`3GDX.<?K0`K-P,$^]`
M#"0.#G/K0`C<@=\<T`(Q(P`06[4`,)Z9XSTH`8WH3U%`$;MP<<?7M0!"Y[XH
M`@D?@\\4`59']_PH`KRR<GG)H`Z+P?X&\0>,"[:-9DVR'Y[F9MD2^VX]3[4`
M>IZ3\`K$:=OU?6KB>[;.8["+*+_P(T`)<_`O09/W4.K:G!<[<`21JP+?0<XH
M`XG5O@GK=H\PM[VTN-I^5<,K-^F/UH`\]USP_JNA3F+5;&:W;L67Y3]#TH`R
MJ`/H+X=ZQ%K?@.UMKE\26C>0V.N!T/Y$4`:>I&2#8DA5I(OD)/\`$O;]*`-/
M4+@&Y,;#(!^4^E`%NWDCEO1*&!?;T]:`+EF`EKJ,F2%:(X3/3F@#QKX[7*DZ
M3;[\N5,I4=`.G]#0!Y+0`4`2VP!F&:`+#$GIUH`CF&]0<?,*`':;IUYJ=R+>
MPMI9YC_"BYQ]?2@#U7PC\.UL`+K6KQQ(1_JK:0@+[$CJ:`._CT#15@66>*;`
M&?F.XD?C0!>M_+,>-/L4-LO\<X``^E`$T@B**)9P#T\N!?E%`%265`<(N`#@
MG&3^=`%2>-/,60)QGH30!SOC6QAL98=5+SQHI^8PG&?K0!UO@*6]U?2)IT17
M*R#[/*>!,G?\J`-R]EU6RMII(]&,TL8SM20#/TS0!Y==:WK_`(GUU(-1MY-/
MTN-SB$QE2^/7/6@#UW1%E738[=?E7:7<XZ#M0!!<7'F*BH-L*@[?]LYZT`.A
MDP@`!YZ9[_6@#7TYM@P5.&/&:`.VT20(T<[$[(UV,F.3F@#S/]J;1YY]$T/4
MD>,PVCO$^3AB&QMP/PH`^;P.<G.?I0`J\DX7=0!9S@X*\#@$T`-).-W![\=Z
M`&\X..F>?K0`A(Y_6@!I_6@"-L%CTQUSB@!CD`CF@"%FY)R,'O0!!(QY]*`*
M\CGGT]J`*DK]?6@#?^'/AD^+_%4&GR2^5:HIFN7[B-2,X]SG%`'T_?:I96%E
M;Z?:01QV$"[8[>,84`?3OWS0!'::C9;6:WEN[!QR<-E3^!H`L#6X;J-89-4E
MB9AA9I(P0P_F*`&1P:K9A6L2EY"#D&)@X_(\B@"*]6?4[-[35K%(XI?E99F0
M!OJ&YH`R4^$'@""VEDU")&=8]X2&X89)/`!H`K0_#K0])AO9O"INX+ETXADF
MWI)CG'/(-`'-7+KJ5K%(21*G[N4'@J0<<T`69<RQ0F7/G*,$]<X_^M0!.DN)
MA@@=MV.10!I+J@MXY594PR8/N*`/,KKP/KWQ*\27%WI\:V^D6K?9A=39Q\O)
MP.K=>U`'H.E?LYZ4L4?VVZO)I`GS'<$#M[+U`_&@#'UGX*Z(%FALGGBF7(!+
MECGZ4`>8>)_ACKGAVV^U2&&>(-MQ&2&`]2#0!QBL=^TCYAP10!ZCX&^%T^L6
MR:CKDRVMB`&\H,!(P[9ST%`'J^GZ?H6C6H@M,P6X&"D*#+>Y8]:`'2WVDVV/
MLMJ6<?QS_,3]!0`U+FUN6:1R^[J-W"C\*`(;N_+'!?<!VV\"@"N'!9MN&1NI
M]Z`+.G-#%J%HEV!]E9P)<YX7N>*`(M=%NES*ED[M&7/E,W4+GC-`&-JTH\1W
M5OHMG!LC!#SL.<`8SG\J`.KL[B6UO8+73EVP0#"@#`/K0!VEAJUO-*$NT"3#
MY2V.?_KT`+KFA:-=N+^Z:1409=H1@\>M`%#5-;B_L@VL4"0),V[<!RR]@?>@
M#GSRGF9^7&%XH`FM@HC=V``7@`'J?2@#9T]&G>&-%&7;`&:`.XTG`NW@B.X)
MM4GMF@#R+]J[5(?M&@:1$Q\V%7FD&>@.`O\`(T`>``'&,\'D4`/7'\?;IS0!
M,V=V<@C/3%`"%N.HH`;C@'/`ZT`-)QG&/PH`9V8$G-`$;MD\]*`(F;'.03[4
M`0R-SSCB@"M(V.`<4`59&^4<9^AH`T-%\+Z[K\%Q-HFE7=['`560PH3C)P*`
M/2_A5X=U?PAK&IGQ#IES8W,L"+$LJXW*6R2#WZ#-`'ITL!N(5NI(9(DCX.5Z
M?6@"!M85"Q6W655P`Q3=Q^-`$,]QIMR?-O&N#G^!#C^G%`#8[[3<+Y4EU;^H
M\S./TH`T+6SM[MA<PZGYZ#[T<@Y_.@`O]2_TD!2I`X`'2@"[H]R=WFN`#Z4`
M>;>-KN#1O%!N,X@O7V,`,C<?84`7+*.[U"]%MIMK+<W`/$4:%F_*@!GB6SU/
M0+E(M8M9K:1AO7>.H/T_E0`O@FPGU_Q%#:W5G<O9`&1QY;!7`X`S]30!]%PR
M)I*Q6-CIDOEQ*!B-0B_A0!-=&8.S[3&0NXH?O4`85S<"<3X)2;'7`!/XT`</
MXITV.]L)8YV8DC.[OF@#QGPOX$M[SQ3/JEX4;3+,Y9%_Y:2=AC]30!Z==.DC
MKO50B<[<XR?>@"C^YFRKL"Y/`["@!ITR-OFGG6-L_*JC-`"P6JP$['\Q@>./
MYT`!L%.?-F))Y*IU%`"+:Q6QW,3&#V)R3]!0!&TH,OE0Q_,.F:`,+6]5:"XC
MLK5O/OIF"*J\EG/110!U6@:>GAVU>T#":]E.^ZGQR2?X1Z`4`69A+<Y6`H$Z
M=,''>@"S;V\S:C#:VW.X#_Z_-`'1:KJ=MI>G2V\$IG<J4:5AW/7`]!0!AZ=*
MMU:S1RJ&54W*3U%`#(HW\LK$02.<=*`)[>(-!OG;8">?_P!5`'0Z)#Y5]`_&
MYB`HST&.M`'<:':!;G#@*8Y-V/KQS0!\B_&373X@^(^L7:L#%%+]GAP>-J<<
M?CDT`<>@.,#I0!(KA><@9[F@"4N<Y;'/4XZT`-)`!P>W6@!I)Q@'%`$;-G&<
M]Z`&OCH#^-`$;D8XP.QYZT`0LP!SQ0!6>3CCK0!4D?+?6@#IOA790:G\0='@
MNIEB@6<.^Y<[@.<8]Z`/K*\URTM[@Q:,!;QE\-%$@0`X%`%S3]922$)J,:7*
M*X*EURT;#TH`Y/XDV]W^]UG[1+?::IW&"-2&@^JCJ/>@#@K;7+6Y^;S)U1A@
M($Z4`237\*$$P7,V!D*V%'XD4`59]6B92LFG11GLR-DC\^M`$5G?Q6LXE^V&
M(L0"NP\CWH`VX+V"?#EA\O)..M`%A-<C(=(QM49P??ZT`<IJEK<:]KVFV-FZ
M"[>=2DCC*Q_[1^E`'TGX,\*Z;X2@?^S8@][.`MQ<N?FD[X]A["@#=OEL-4MY
MHYTCRP(1Y$#,K8Z@'TH`B3[+H&C)<7<[2"),/,R]??':@"C:W\>JV8U&UG6:
M$'>=[XV@=B!0!D^(;]OM<3*1YDB9RIP"F./SH`Q-TDZ.T#Y<D`*3UH`YKQ5J
M(BLW!^_&2A.>3Q0!S6@006'AZ$`'?.S3-GG<2>I_"@"C/?%YV"`!O[Q-`$4<
MOFRJ)3@*>W6@`N?,Y*2$8Z`]30!?TY97578XB_B9O\\T`7)99?EBLTP6ZL.3
M0!`UD(KD&YF,D^,[!U`]3Z4`<GXT\6V&BVLT,#JURW&U6R[?E]T4`9OP<G?5
M-8U#6;M$\VWC,<&1GR\]2/?IS[T`>C:6&=I))0Q$I*(>N30!<TU7>\;)+HJX
M8#T'>@#K-!M$6:VEC#$W#,`?1%'./J>*`.1\1F0:T()E`"QC:H]#SD^_M0!8
MTQ4A"G<5C(*L:`+Y,-TVT)@J?E*G!_&@#6CTV<K;DQC:Q^7<>2*`.HBMX[&)
M-D8>9R-A)R?<^PH`S?BMXUM_`GAJ9D_>ZG>(T<"D_P`9&"Q]E!_.@#XY!9LM
M(2S$Y8YY)H`D'(S^0H`D`)&/F_"@"1CR0#VZ8H`9VY'TH`:YXQSGI0`PGCD?
M6@"-R,8SGWH`AD(#<]QTH`AE8YX["@"J[\$^M`%25_3\J`/3?V=-.CO?',UY
M,H,5A;--R,X;(`_K0!Z_-(#(\JD@[MV:`+-E>KL?S),.3NR>]`&NFHI+"Z1G
M#@<QGD'_`/70!X]\3M'^P0-KFB%EB4YFMUXQZD"@#SFV\=W>"@MRX/4;J`'R
M:UJVK2+:Z5I\LMW(?E"`NWX"@#TCP7\%?&FJ2)=>)=570[8_\LSB29A[*.!^
M)H`]JT+P/X8T>WC2*RGU25!\US<L0I/<[>!0!MS_`-G2636+V5I'`>!'$@_H
M*`/+->\`S6.HR3Z>6GMW;<!_%%Z#/I0!T7B36-5C\*>2MRLDT!SYT[[-BA>I
M8=>:`,?PSXMTC6-+AUR'S+BZLL*QE)42..K`9SC/K0!ZYX9\5:7XDL%BFDAE
M21,/$<$&@#+U)M.\/R7R^&+6".X=0'*MP,],#VH`@FU&SN[;[->0L]\$#%PN
M0I/;/I[4`8=E=F.]2V;#2#+;EX"B@#CO&K:>IE579Y)5("DXQ[_6@#,:4/H]
MJT;\+&`/;'!_6@#**;AE>1U)H`E6"2&"*1L`$G"]_K]*`+,-FMP\DDSLJ`<^
MK>U`%^WBCN'$>YPG<XH`;KGB#3?#MDW[Y+=EX(!W2'\>U`'B_B?QY?ZCYD6F
M[K:W8G<X^^_XT`<=I]A<:IJ,-M"=TT[XRQ_,F@#Z,\&:#'H'A<VL`WR2\!P.
M9&[GZ9Z?2@#I9H`KBW)*>2H1"#C-`&E;PQ6]I=0$XD=.7_I0!P?QO\6WGAWP
MIIFG:9<_9[Z_1E=H^'2$'G![;CQGT%`&1\.M5?5-"M9WE::XC.R8NVYB1W/X
M4`>DV?V1H628'![8^;-`&EI>F%KM)4=8H<X&\\M]*`.K>=KG4X[:-MXP$!C7
M[@`H`W=8(T72;G5;E-QMH"RPK@LY`S^?M0!\5>,O%&H>+M<FU+5)&8DD119X
MB7.0HH`R%Y!]*`)D!R-V,>]`$H*\[@".W-`"-@8`'&.GI0`TMU[C^=`$;-\N
M5/>@"-R<\9/]*`&.1^'M0!!(W)]^E`%61SG.:`*LS''7VH`JNQS0!ZO^SS?B
MVU+6HLC,MNH/KC./ZT`>IV=PLB74$@&X+G..30!1?FUE>-CA2"<]:`+<4SRI
M]KMV),8&\9Z=J`,3Q#-]KT^X`DW>8!E"/?F@#B/AM\++[Q/>WTY9;#18IF!N
M91DL`>B#^(_I0!]$Z!I.E>"M-2WTRQ$#R#&6P9Y_]IV[#V%`$XU:>\<P[A!%
M']YX!CGTSWH`9?74J8VO-*Q'RL_2@"]#+&WE2.@\T#G/:@#.\<7YT[PI>S-)
MY>[$:ONQC)Z@T`?-_C?Q@/L@BEG>>8+B)&;(`]30!Y.)I!NVNRANH4X%`'NO
MP#U2&STR999+=9F?Y1N+.0,\[>V*`/<?#P\QS+A?W:??5L@8).#Z'F@"GIVJ
M6,VJ7%D+MI"6)`88R?2@!!>V=G]JCAD#W?\`=D(R!Z`T`>8^+K^PNIYFNO-M
M9,'DD8%`'":%\0+;3+K^S[S=/II8XE0<Q$^GJ/6@#TS[;9ZY8VRZ9?6UQ!$F
MU6CP#CT(Z_G0!/JQL0EN8/-C$401VDER&8=>>P]J`*6GF6]F$6G0-<G.&<'*
MC\:`.RL?!\]Y;NMWJ?V9B"-D"8`^IZDT`<'XV^!U]+:27^DZK+J$Z@NT4HZC
MT4^M`'A<MA+!*\4T3))&Q5E88(-`'IOP9\-13S3:I=(2!F*(C_QX_P`A0![%
MI8M4U)Y;AR(X(R(%3J6QQ0!#<V+O=J&)#%0_S<`=Z`.CTY+&XMY[F\(M[2S7
MS)Y3P"`.30!\A_$[Q=-XS\5SZB\:16Z#R;:-.BQJ3C\3G)^M`&G\&Y9%\1R1
M?:TM[9X_W@=P-Q[8SW%`'TCI&@:C)+(TA4JJ@QN3PWO0!T^E:!?R/&DCQ("`
MS9R>/3V%`&?XC\;OH=Q+I_A_P]<7NI)^[$<*8&1_$3_AF@#I?`XU'6;))/$E
MOLD#\0N""IZ_SH`^5_B)X.U30?%VK6TEK)+$LAG$D,;;`C'(/MZ4`<LT+PMM
MFC*,/X2I!_6@!0/E.#@D4`2+]T8Z?G0`T]<`=..30!&V/;-`$;9[8R/6@"-B
M1DYH`A9P,D=:`*\CG&#TH`K2-@=>*`*DC$'KS0!6D)S0!WWP/F>+Q?,5"[3;
M,&+'IR*`/9+B18-5MY.FYVC8?7B@"!R8I+E!S@D$'T-`%"WF"LZEN#QQVH`U
M?!V@-X@N&><F+3;9]URY/+>BCW/Z"@#T[[=#9V:)8%%BC79#%&G`QWH`@;2Y
M([=M2U61F63I&`2Y^OH*`,Y]22=#!;PM%`A^55')/^-`%JRED6\C=X]\"D?N
MGR,CWH`V!';7&I&2W;$``8I_<]J`///CRD=QX1L=&:0B>YF\\@<$!<X_G0!\
MJZYI=SIL^)]SQG[KGO['WH`S*`+-A>W6GW'GV-Q);S8*[XVVG!Z\T`=;X"\=
M7^A:U#)?ZA>R:;O:2>%7W>8Q7'.?PH`T;#Q7/KNOR1RW-[&6F)M;Q2`\(+9`
M<=&'04`=Y)IFIR)"^H7J/<_QRYVY)]J`//\`QOHFOB[8:K-*\*MMB<C`([4`
M<5/IL\38(H`9%%>6LRO")4D'(9"?Z4`=5X1T?5_%&I06=_<79T]&WR;W/3N!
MGN:`/H_319Z%8Q6FG1F*)$^[T!'8T`6[377212'Y[`]!0!UFBZB&="P&[T!Z
M^U`'D/QY\&;/$UEJ5D@\J^PDH/&'['\OY4`;V@:;%HN@VUC:J"0"&<]"W>@"
MY]B6,;O-+R<9)X&3Z"@#ITA6[BMI%&VY9`%;.<=J`.<^*NH6]GX9F\,PN1<Z
M@NV9E/*IZGW/\J`/EC6_".H:=<JD:>?#)]QU_D:`,":*6VG:.5"DJ'!4]0:`
M/0-.^,7C:QBCBM]6_=1\*C1*1CTZ=*`/?$^(M_JGAVQO9I98/-A1V^S+M*CZ
M]^:`.]\(>*)M869)++R3;*FR>3[TVX9)]NU`'HFGR>=$&D!Y]?6@#.N6C'B`
M0WZ2I%)%^[?@Q2GNI'J.O-`'-_$KPWX1U.RD;Q%]CLH90H>]&U)5*\J`<=.M
M`'QO>K!'?7"VCE[<2L(G8\LF>#^5`#4.W)!'/O0!`7(XP,4`1,W)X%`$3D<C
MM0!$Y`')Y/?UH`KR-@<9H`K2/WS0!TOPU\(7/C7Q3!IT4<WV0<W,T>!Y*>N3
MQ0!]&Z#\&?!>BP[9K,ZM<G[TMX_RCZ*.*`,;Q9\(?"NIV;RV&G&P8_*LUFYV
MJ?<'@T`>8>`_"UWX4\?76GZD`\<]LP@G3[LF&'Z^U`'=:YD/<*<[D?>IS0!6
MN9?,OHI&^[*F[([C'>@"+1+&76-<ALK4[6F/)8<*!U)]L4`>F?9;33K+[#9Y
MBTR%OWKD_-=..M`%"$:K=7L5U9QB-$)\HG@+0!=U*\:WL@!</+-.OSY8_,:`
M*EDUQ&%#DHSCY4'6@#0L)'#O%.SESD`DXQ0!T^AVR_9`P``9L`D?>H`\=^(,
MXUKQC>);DLEIB*,YX?;UQ^.:`.2O-&@U&*:WN80=P^4L.M`'DWBWPU<^'[E?
M,^:VE)\M^_T-`'/T`%`':^";19;!Y%4O(TH&!UXZ"@#WF#P_J5WI<3I9M9B+
M;(AF`;*D_,&S0!SOC_6!?*--MY(;N$8+7`3!R#TH`X&:S;D%<M]:`)+'1UEE
M4S,JDM@#')H`]3\-Z,FFZ>\\6)%'RC''U-`%JX,TUE'=2@HC.5!/J*`*UN[(
M1@\Y_"@#NO#22>9$KG`;Y@6'ZB@"[X_6&\_L8S!2<%N?]DD`@>N30!EW,ULE
MG!`J\HN-^>N:`(8X/M,?FQ_?7ALCCZ?E0!T[R0>'_#DNK73#*+^Z3N['H`/K
M0!XO<7LVJW,T]^!)-(Y;Z>@'M0!9M]/B:()(H:)_X2.]`'E?Q4\%3Z3<OJUL
M3)92D>9ZQ,>GX&@#S]$[T`>I_!W65GUVQT+58GN;.XE"([2']T,=,>F<4`?2
M<.AP:3KEK;:+>SDAB'+,6$;?W2>V?2@#J[CQ'%I37JW%]`TEM$)YT)X@3^]@
M<GF@#2T[4]+UC0K?4%O(YH1`9T=F`;:5.>O3C-`'QGXU\5ZIXDU"9=0OIKBT
MBF;[.C8PJ]!T]@*`,!?NY_G0!+'&"2">!W!Q0!4D8&1B@8)GY<G)`]S0`PG'
M4G/8T`0.>3UH`KR-\O6@"K(V._ZT`%C;2ZA?P6=OCSKB01IGIDG'Y4`?8OP_
M\-P>"?#T&DVR1M>F/S;RY7G?(1TSZ#H/:@"Y%+.]UN>=F13\V.<_6@"#4KK=
M-<);JR6X'W2W!;N<4`<%XO3R6MKT9:,$%&4]#WQ0!CSWGVFVMY"V4+[&)^M`
M%:XF*)$,X\B4QGZ9H`[OP;IDFEV<ER[!;F[X&[C8G7'MQR?PH`U+F[TL3"2<
M-,D(Q%#G`^IH`5/$DX&U9%.2"<#``]/I0!6%[$3YNQ=V>689V^PH`'DD75(B
MBJR2'*[>>,T`;$=D'U1;4*=S.,D=<=\4`6_&^J-HVC37.0MP1Y-O$#_J^/YX
M[T`>06L;2;95+";&?]Z@#7C_`'L:S2(,@[6XH`KR^#?^$NM+C2Y5VVY)9+@G
M_5XYR*`.#^+GPMM/"'@K3[_3S)/+'.8[J=C]X,,J<?I0!YQX+2QGU8VVHVXF
M69"J?[)]O>@#TSX?Z-<^$KR6[EEM6@?YXO/8*!CZ]\4`>A:UK^K:II0M6>-[
M=CYA$#[N_`&.U`'%W-HX8"6*4?[R]:`*C1@DH8SU[T`6--M]LY>0%@@R/04`
M=WI1D?2)IX(RZ$[`H/YF@":/%[!';2*6())"\`?A0!+#I\D#-YR=.`,Y_.@#
ML-%MYKNV-Q-*QBB(C$C]<`=!_*@#`\0:M!?Z_+8QO$T^F0JDBQGYE#<Y(]>:
M`(=-1W?)X;&`V,_I0!KM=Z=X<@CGUVX55G)\JWR!).P[`=:`.(U_7]0\2S)/
M-)FRB;Y+8#'DCT]_K0!F);XFW<D'E30!O:9B6(Q2X++]P@=:`(_'\T&G?#G5
M[B\@,\3Q^2HQGYFX4_@>?PH`^7H4!`SUQ0!V'PY\3S^#/%%OJT-O'<^6"'A?
M@./KVH`]O^(/QN"0Z>/"B6:WUPHFU!U3<N<`JF>Y'.30!XIJFNZIJ]_>7E[>
M2O/>?Z[#8##.0N/0>E`%:*>=%*K+(JGC"L<8H`<@YZ4`2`$#V_E0!)R`.OX#
M-`%-R,GIDT`1-G&.WTH`CD4[,@';WH`J2D8Y_G0!3E8]<T`=W\"=-&H?$&VF
MD0M!8Q/.Y'08&!^IH`^HY;J."6&&7=)<2J&9`.@//-`##<0/>B**(1#ZY+4`
M5;VU+0W@;&[&Y%!H`X_Q/#%9Z(UO.1YSC*CMDB@#S:RU**Y\.A(),O'*0X'8
MCB@#>T^S-_KD6GEL&Y,)(S^=`'J'B`12ZD+*S<A84"2GV[\T`<M?@WE[(EL@
M)!YP>,>OTH`1@(WR[CIZ?RH`O7)\Y8U0E8]H^7'4^M`&MIT8,\$S<+$`,^N*
M`.QT:`Q/+?2+B0JS*S#[JYH`\?\`B!KZZ[K[I&?]#@;:F.C'NU`&99##J@88
M)XS0!NVQ$4X,BL(I!\P%`&[HEC=_;EAM+Z&&"=6V,R[MIQW';/K0!SW[2UQJ
MNC_#RSLDE@N+>[F$=U*HY&.5QZ`XH`^5X))()TFA8I(AW*P[&@#4\1>(]3\0
M"W&IS!U@7:BJH4?7CO0!#I6NZGI+`V%Y+$/[H.5_(T`=98?%'5X=JWEO:W,?
M<%-I-`&K%\0=)NR?M-K-9D\G;\ZD_P`Q0!V.C:AH>I1JVEWZ23`?.F"#CW!Y
MH`[*`QM):+9AXE@/!/W6SV__`%T`:=MIEU;2331F*220G9DC*?6@"?3-'N9+
MA=SVQD+<LQW$F@"?QYXPTSP7H,D5]=1M=1HQCA0<R2]@!Z9ZF@#Y/T'QEJFE
M>*9-<\YIIIY-URK\B92>0?Z4`>LM\=M)M4EET[0;@W)SY:RR#8A[$XY-`'C_
M`(Q\8:QXMUTZMJ]R6N%XB5/E6%1T"CM0!Z+X!\3PZNL4$\@CU-/O)T$P]1[^
MU`'HJ0131!;<ECG&S'(-`&QH.F374F%`15/S-TVB@"I\7_#Z>)/#=G8:=?1P
M*KYC$DFP3,.ORY^;VH`^8I85AN9(P6PK8YQF@"Q''Q[T`31IS[GH0*`+"``C
M/X"@"5%Q],T`3`$'MB@"4@%L9`'N>M`#]N20H'XB@#.8Y/`[]O2@!N%//1J`
M.X\(^$GUWPGJDL]C=1JK(UK=Q)NRVX`C;U(Y[4`:5U\$KF749H+77;3RXAM<
MRJ0Y?'0#N,XH`\8U2WFT_4+BRND9)X',;JPP<@T`>S_LN6DMU?>(C&NY/)A1
MAZ_,3B@#Z0DT*_:*:6VM\7$QRQ(P0@X"@F@#)329Q.P>()*OS2'(X]!0`W3[
M>0WDEQ*KB.,X,;K][/8YH`\I^(NNPPG4;NZ(&W)1?[N.`*`/#O!6I;9KFUD/
M,WSK]:`/9_A[-'<>++"8',D=NQ92><@8S0!VMS<%VC6,D?:Y"SMG!(Z=:`*5
MY<6]C`;:RE6<N,R2[,<^@S0!3MH2\X=V^3&6)/-`&E81M<3EE1EMTP6]6]A0
M!UFGV8D6":^Q%$TF$B!SZ?G0!F?$W7CIMD]A#.JZC<\.H/\`J8^P]C0!Y-$&
M'R,N"1U]:`-6U`P%8Y(].QH`UK=F*#YLJ#R":`.HTRXV*T0CB,;)@,5Y7\:`
M,SXQP_:/A)JX)+BW1""PR1\PH`^1MAR>*`%,?X4`-*'F@!I0XZ4`-*4`.A>6
M"19(7>.13D,IP10!V_ACXD:SI$\0NF%[;+P5<8?'LW^-`'KNG_$[PX(HY8K]
M+1#@^7)`TDBMW-`&+X@^-Q2TN8/#EL_VEQM2]F0*4]U6@#Q34KJ[U*Z>YO[B
M6YN'.6DD8L30!4*=J`$,?'`H`3RSCI^M`#HM\4JR1,R.ARK*<$'VH`].\)_%
M.ZTZ#RM:LO[19%Q',K[']MWK]:`.J/QT:+0UM[#1A%<L2&5FR@'8@]2?7-`'
MFGB_Q/J7B_5(;[45CBDB0*JP951[XSUH`S((0HR1DD^M`%E4QCU/I0!(J\$X
MX[T`3`#TPU`$B+GJ10!(%Z^A%`$@7.20?QH`E1"2>F.V:`,AN@`XH`5+I+=_
M,>'S@.0C-@'V/M0![OX'\>P^(?#S6^D*VESV:`3VJ(74+@`%3V%`&=?WAMTN
M-1LGF:ZG0;XG?Y48`Y;COP*`/"HK75_&GBYH+2`W.HW,F-J<`8XR2>@'K0!]
M<?"?P?I7PSTTEI&N=4GV_:968A2X[*/09ZT`>G6.OPWLAC^U!&)X0\;AZ9-`
M#T@TFWO%N2`MR>@9R<GZ4`<_XVU&..&XN`Q!51_P)CT`^M`'RAXM@U7QUXDF
MT?0(O-BMWW7,[/MC#'U/M0!TGAWX)V-E+%<:IKTDDT>"T=F@QGTW'_"@#L-.
MT;P_H&O6][:OJ"SJ#&QFY7##'I0!NWBQPW]OF!91;Y*@MA6ST)_.@"C=6)NY
M)KHK#``Q7R4;]1WQ0`:;I[W,BQ1ARS'&!U/M0!V-\EAI,3))+'^Y3?(J-A5X
MYW/T`^E`'BWCSXYK;S/!X:\NYN$&U+C9B&+_`'!U;'J>/K0!XM:^+-7BU:?4
M+BZ>[GN&W3^>=WF'WH`]1\)>*],UA%C,HMKO_GA(>"?8]Z`.TCM=L@.X%L<`
M#I0!:@@<$J1[T`;NCPR><!@X!P3_`/6H`Q_CSKEOH_@"32C*IO\`4V""+/*Q
M@Y+$?@!^-`'R\$YH`<4SUH`01C/%`#?*&[F@`,//K0`>4!QB@!ZPY/`Q0`_R
MSN557YF(`%`%W5-/.GWT]J9%E\MMN].AH`IL@R<`\"@!OEY//6@`,9H`00D\
M\4`.$7MB@"18<'IF@"=(N,$4`68XQW%`$RKTSR:`'HHSSQQ0!(!Q@]S0!)M.
M.1SB@!Z@9Y]<4`2`8QQP/2@!T:GJ`2?I0`\M\H^7/;&:`,5N<GG'O0!5G;Y>
M:`-?P[X]U#P[HMUI=M:6TD$Y9M[`APQ&,Y'7%`%J\U+^T?`>J:@)%M)9+B*-
MK>-^'<#[X'49&<T`7OV<KF6U^(FZ)`S-9R@Y&<=#0![SJ^K7-S=9N7!`.1@8
M%`!9R?:G`1L,2?FSTH`W-&UBX@O(HKAA);!\#/./I0!6^.5^-,\!ZIJR\2(X
M2+;T))PI_6@#R/X<SBQ\/V\4"?O9OWLT@_B8\G-`':"_#H!Y94`\[#WH`JW=
MP71E`)!ZJ[<"@";3]>&Q;;5(2Z(,+-&,D#T/K0!J6^J:/'-%.FHVZN#P)4.1
M[8H`9J7CB#2+*Z3PY8G5=4E&W:HVC'HN>M`&?\)=:UGQU=7C:GI7DS63_O8'
MB/E3*3@KM/\`$!W-`'B_[04&C67Q!N;+0+.PMX(5'F-9N2"YZAAT!!XP*`/,
MZ`'+D$$<'MB@#K/#_C_Q!HA00WAN(5X\JX&\8],]:`/3K?XKVT7AV"^FTZ"2
M_EE*F".4@*`.I]!0!0O_`(VZHUJT.DZ7:63%=OFLQ<K[CM0!YEJ5_>ZM>R7>
MI74MS<R'+22MDF@"!5[4`."9SZT`/VY!.*``1YYP>:`#RQG&.W>@`"8!&V@!
MRI@\]NU`#MF#SQF@!Q4D9;\:`$*#%`#?+XZ9`H``A(&1S0`HC`_.@!VP`<<T
M`2*N![T`2HGIVH`F5<__`*J`'J.`,4`2*`#T.:`'!>,XXSZT`/`]^!^E`$@'
MH`#UH`=@'`_+B@!V.PR*`)8MX_U0&>^30!SKX/.3S0!5E;@C%`%&9<^]`$=G
M93WU[!:6L;23S.$C1>K,3@4`?4WPJ^$L'@^V?6-7N)#JWD,A2-OW:[CP??C'
M6@#4UY!-%#<H`"R8=<=\T`5-#G,5Y"KM\H.#^-`'1V&#?M978`20XCD!Z'MF
M@"YXLT27Q9X`U?0)"BW)0HC2'A77E#],_P`Z`/FK0Y;WP_>'1M:@DMKRU;8P
M;H?0^X/K0!Z'97P>)68?B*`+Z1)<88-L/<MR/K0`C6NPG]^"!V"]:`+-K:V8
MB$VH-YO)`@2/K[EC0!=M-+TXZI:W$4B6<2`,[$\J>X%`'IMKK.E0J[07\:$Q
MD"&/G<<<'B@#YEU_X)7%\UQ?:#J0=G<L8+SALGG[W3\Z`/,->\&^(-`9QJNE
M74"*<&3863_OH<4`82K0!*BT`3*O%`$RJ<<=*`)$7YLF@"0+\W..:`)%!)X'
M_P"J@!P3.?ZT`.6,$=./8T`*$)X'2@!Q3GC\Z`#8<>U`"A1WZ]J``H>@%``$
MX!Q^M`#@@`/!_"@!"F<GTH``O8CF@!Y0\GMCI0`]4`!STH`D`P<?G0`\J2,]
M1CUH`D"G(YXH`4@AL\^_O0`]`21GH/6@!ZC).,9]*`'`'./;)]J`'9R&]N]`
M"C.,#!'J*`$(SP21_NT`8+X[=*`*LIR.^:`*DF>V<T`=%\+8+B?XA:*MG,D,
MRSAE9VP..WX^E`'UKK-Q?VOAV&#4[B)KLDF7R1\N,D@?E0!CQXOHHHHD#&0$
MJO?(Y_J:`,&>-X9P%7#`G!'<=Z`-F._Q8+-@O(",,.HP>]`'86]Y^[&H)$9(
M)@J7"?Q(>AS]:`,CXA?#NQ\8:?'<Q[3<1*3%<Q_?`]&]?I0!XA:)>Z'J#Z9J
M`_>1?=/9U[$4`=-#^\12I8$CIGB@#1L8Y68?+N3N&'6@"W/ITB+OB!*==F.1
M0!6B9HGS'@D]0:`-2UDMG^8QLK]]M`&K8ZA'$W[HMN'5&Z&@#H].U5+QQ'Y*
MLG1HW&5/M0!XY^T9\.M,M=&/B?1K6.RFCE5+N&$81@QP&`['-`'SLJC/TH`D
M6/VH`E4<#(X[4`3@$`#J*`)`HS[>]`#N0:`'A<_2@!X`P#V[<4`."\XQUH`,
M8/-`"A><_A0`H7`.,'B@`"_+W%`"!1SGIWH`4@G&>!_.@`"<\=?6@!0G/3!H
M`>%'4@XSS0`Y5RV0*`'!><8Z<4`/"?@:`'@>F>*`'=,#\N*`%'TR.V:`),@Y
M&/RH`%ZD8Q0`Y@>G)Q0`O'&#SZT`*AR,[@N>Y[T`<T^<X(H`@D'S#DYH`K2<
M$T`6O#&J/HWB73M0BB65X)E8(3UY_G0!];+KD>O:(+N)'+*QC="V2A'KZT`9
M>G3M_9EQ.W!@G^7L54XS0!F23%9+B/=ED8[2/0T`/L))4V[)/F_NY_E0!TGA
MS48K@WMIJ$LZK-AF=#F0D<D#_"@#MS<R:=#%?:=%+':2("(9!U7U([4`<A\1
M_!5OXDTT75GA)9@7@E'6*7KM/L>!0!X)H'CBWL[QM.U^!K2ZA<QN6R0&!P>>
MHH`]-L1%J5LKV4QN%;D*L@/\J`+\4&H693C='T\IFS_^J@"5EM[IL.1;R$XP
MXQ^M`$4^G3VI\R,$C^%E.0?QH`8+HH%XQ+GYCUH`U-!GD^VI)O(.>F>U`&I\
M;HI+GX+:W*JL[#RN`/X?,7)-`'QF%!Z8Q0!*JX'^>:`)%'MQ]:`)0.1D9-`$
MBKQSTS0`\+QCI0`[CU&??O0`Y0=OM0`_G:0<8[4`.V_G0`T#@9_EUH`<%&,@
MCCJ:``<#!%`"@988X]:`#;CIT'MQ0`JC(':@!=N#G/'K0`Y4&<$?6@`50!GM
M0`X`EMIQ0`\*<@&@!1G'X4`.QN.0.30`HZA>GK[4`.QZ@4`2*><@9/\`.@`7
M.1P:`%&>PS0`,._)]L9Q0!S4ISD^E`%:3_/-`%:7H>M`$,4A@NH90N\QN&VG
MO@]*`/J'3]8TRW$9#_9FDA22>.1@`/E'3Z9H`TK6>&3[='L4"YA)#!N.G%`&
M.\@1K:Y8?))'Y<ASW'&:`)&MV1&,1_>)SQW]Z`->RA$,D%V[N&1<L`O+-Z#_
M`!H`[G3KZTGBM[V1)451]GD"'*J#SEL_TH`L>&)7L->ETN[P\$F0JOR"/X30
M!XE\9?AH]WXHE\16RA3NQ>6X7[I'`<>V.M`&'I.CF-(FMV='4=0<9H`Z2V_M
M%5V_;)CV&6R10`76M7.DVDL]Y.TL,*EG#C/`ZT`5_`/Q*TS7+@V3(UG-(3M@
M9LAO]T_TH`["[ME#>8B@J>CD<CZCM0!+I4JQW,(8!4SS@4`>C68MM6T:YTF^
MY@N8F@;/HP_GS0!\4>-_#5SX2\4W^C78.^VDPC$??3^%OQ%`&(JX/4XH`E51
M@4`2`9.WL/UH`D&/^`T`/51T(YQUH`>$&.F3ZT`.P-O/(H`<!U`(`[\4`*>H
M(/Y>E``1D@].^:`#UX_2@`"DY&./3O0`Y5R.W3IF@!=O;!H`=@XSS0`G)')_
M"@!2/F(&<"@!2H(Y_*@!^TD9/3H*`%P<>PZ^U`"]\\$?SH`=DY/&..F*``<<
M@C.>OI0`\$8`]_I0`H')!P0:`%4\GH?K0``<C/RY/`H`&8@<[1SU-`'-OD@=
M3F@"M*,]N]`%:4$CKP*`-3PYX1U?Q/=K!I=N3N5F\R0[4^7KSW/M0!VNN^&4
MMEMH!<M.T=MY4LB#`+'"\9Z]*`+?@_5M:L;F'3II$D@MYO+#$;FE3I@#L>:`
M/3;BT46L]L$S)')O0EOX30!3LKEK=FB<?+G"Y/##TH`O%9+=!/:L98&/W3R5
MQ0!UFF:O+#91S_(D.-LB;0!(/_K4`:4UTE[:1WMC(S2VC@@-PVP]%]\&@#J[
M2>TUBU%Q)"K3(`)4Z\8Y!'<4`>3>(M%@TOQ!<060S;/B2('L#VS[&@"M<6A$
M,9"X(//&*`,;6M-M]5LIX7=@LZ%'&/UH`\0U#PA>Z`MW<7BS)]G&Z&:(@ACG
MCZ4`>X?#?Q6OBSPT/.D`U*T4+,,?>'J?4&@#H+=##=1EBI4'K0!U^BW4@)9B
M"C-NP#R*`/+_`-K#25-UX?UJ.,[IHFMYG`ZE<%<_@30!\_H`,4`/`Y]*`)47
M/YT`/4'C&/2@"11DXP*`%QD'J?PH`<!EA@Y`_6@"3:,=J`%4=CTH```>>]`"
MC/1LX%`"@<>A/3VH`0+A1ZXYH`<5P>Y)H`3'8]>OUH`<,8/7'7@4`!0^H]Z`
M%`.2#GIR?2@!1WSCIP:`'`@'=0`X9+9XH```0"3QCIB@!<+G.,F@`P3C).,\
M^E`#L'JI!&:`'#V(^@-``,;ATQWH`&R#D9Y]Z`.;?H..OO0!J^#?#-[XM\1V
MFCZ9M%Q.W+O]V-1U8^PH`Z7PU\.%N?B!J'A3Q%<36=W"C>285#>:XZ8SV(YH
M`^FT\&67A3P]!;:3'LAB7)78"5)&&;/7GJ>:`.*L-`T_Q#-?B[FGEN4W"-4P
M"J_WA[T`2CP?IND6SO9PQF\^4S,1DD#H?_U4`5C&8;2*2*6*X,3-%,J\,$)X
MX]AWH`Q=8LC!,@4EHV`(;_/>@!=TT,1W??'`]Z`-K3;A;FS^PW#%&0<'/KVH
M`T_#5P-,O]EVI>VF!0C/;U_"@#L;`1Z3JT(M)"$FXE5CD8/0T`<K\6=8T?PW
MJ&G2ZK/]F6X#+$60E3@YP2.G6@#!_M>QU9HY;*]BGA8;<QN"!0!&("DCHP)P
M<?6@!9=/CN8&CE421,/F0C-`'*V?A4>$?$L6K:4&;3;G,=U".0%/<>XZXH`[
M@0F(@'YT'*$?Q#M0!M:3)Y<&`/F<G;0!4_:`MX[KX/R22X+6UU"T9[@G(/\`
M.@#Y.*<#WH`>HQSC/K[T`2)CF@!ZC+9H`E``'&.?>@`V#J3TH`>HW9&`"*`'
M`8X/<=:`%VA@>/SH`0+P#Q[4`/V[L8SF@!"I*T`*N,'/3O0`IYX!R10`@]`?
MI0`[;D]3D>E``<%O_K=:`'!2<\<>F:`#&!D=#UH`<<<'/L/>@`48)R,$]#F@
M!RC&.>/>@!3C:<]^`10`I&!M!_+O0`N>6['/-`"Y4J3R?6@!%P<C@-0`]>"=
M@#'^GXT`<Y(.!GD4`?3W[+_P^ET^TE\4ZK$4FN(]ED-W_+,_>8CWXQ0!['J6
M@:;=:W:ZP8T6YMXS&K[!G&?7K0!%XTBWZ4]P9_*2-#GYPH(([D\"@#R'PXMK
M;7SZDDG^E!3\L,F[(QR/2@"CXN\4KI5L+R2-KJ2Y`$?E@DD@<;L<8H`\8O?B
M!=6OB6SU&2U$,8)CFA5R=R'&<CU]/I0!['#>17=I'<VTPFL+P`Q2`Y"\=?I0
M!5F,L/R3H"J_Q=_:@"Z+<-']H`)QZ?SH`T[-OMMJ0X'F1C]W@B@#L=*8:II<
M<CAQ+:KC!X+^E`'E?[8GEOX<\-R+C?)<N1]-@S^M`'SKX-UM]`UV"ZY,!^69
M!W4]?RZT`?46FW$6J:7%=VT@<``@K_$IZ&@":.9D?*XV^U`&O92V[ADD0&)^
M'0]#[^U`%^71S;P))!F2T;@8Y*&@!]C8/O4J0RCG@\4`<U^T+?06'PRBTYV4
M7=_=(R1Y^;:N23CTZ?G0!\OJN>".E`$B@=,X/:@!PY'3D>E`$H'J.U`#D'!/
M>@!R].1P?>@!R]1QGVQ0`H&1@#CUH`<.0,'B@`&0>^?:@`'.T'KGC-``!DDY
M.<T`.Z`-R3VH`".>`.:`%*YYP?K0`=Q\O-``N.,]10`_J0"`>:``KG(Z_6@!
M>Y)&*`$[CI0`\CN.10`'[H..>WM0`HZ'KG'K0`HY.,@?6@`7KDT`"]\')%`#
ME*@_,IZ>E`&M\'?#1\3^/]-L9&VVT3B>9L`_*O.,'KD\?C0!]PRR-:1_N8,P
M*N%2,`;<=L=J`,_Q%J%KHNAZAK-W'\EM;M,^YNI`X7^5`'SM!XB\1?$;PS-/
MK$OV;3KQ7(LU0%&C7I[D_4XXH`NZ'87.CW,MXTXAL8;<0V]I-&'<C',GMTH`
M\K^(OBQ;ZY$-FDBV\TOR18V@'.,^U`'%ZEI+3*5<R&\E8)&I7YF.?NF@#U[P
M5<P^&[6WT*^1I[3'S-W5CR2/:@#O9K&)X;>4,LEA(N%E4YX[<T`0P0F"5H@[
M,A7"$CMZ4`6;*W\B81[FP>2<4`=KHP831O$#M*D%!T`'`H`^??VMM<6Z\3:/
MH<4J.NFVVZ4#JKOS@_@!^=`'@P'M0!ZM\$?%+V6JII%VY,,QQ#D\`]U_&@#V
MZ\C:&Y92H"YRON*`'VA.X1N=KGI[T`=GX>NI$5760)@;70_Q8Z4`8'Q<GOO"
MWAR[\5>'[TKY[1Q_99$#QQN3@L/?MCI0!\M^(M>U3Q)J;7VM7DEU<L,;FZ*!
MV`["@#.4>^1WH`D4'Y1SQW(H`D'ZT`2#!'3\C0`H'RX/7T!H`>HSC`H`4`#*
MXP/UH`<!Q[_RH`4=".?SH``N&ZD^]`#B%YP?QH`0K@$]_6@`XQR>W.>U`"C[
MV,_2@`X&><4`*1@\9'I0`H`)Y/ZT`+M`P21P*`#'!YR,>M`!@<C/L<F@`Z`@
M@D9H`?P."0>,T`(/N_**`%P,8;I_6@!<?>QMX]:`%`/12/3%``.H.>G'TH`5
M2P'&&/>@#9^$.K66B^.K2\U&X^S6HC<-(>@.WC/XT`?0'AGXY>&]6CO;+4)Y
M--=28XI9N1*,'YAZ=,\T`?-GQ*^(6O>)(TTJ_P!2%S8V3ND<L)*_:%SPS]FX
MQ0!ZM\`I[_4?!B174"RV<(DMD._)*MUSZ`4`;FMZ3;::NGV%M=9L`Q.9)LD@
M`\9/;/O0!X7XD\E=:DR(KBW\[]PD`R-R]23Z4`;'@F$:U,^IWEKY36DHC&XY
M^?N10!VFJV2F9),*L\Q(;U5>O\J`)=*UFXTR-;>V^:U7Y3"_(/O[4`=IH]S;
MZI%NMI$BZ!X)^`#_`+)H`UH=.-@OVF6:W@1@0)))`%/YT`8'CCXJZ%X(T4Q6
M-Q#J>NLI,,,)RB9Z,[#C'M0!\DZQJ%YK.J7.HZE,\][<N9)9&/+$T`50O!XX
MH`DB+QR*\;%'!RK`X(-`'O'PV^)$.HPQ:7XCD5;L#;%<R<A_0'T-`'J)@20;
M60QR$9"D\'W4T`7-,<*H`<@Y(!/.*`.HL[6WU_0M1T'48UDMKF,J-W\)/0CW
M!P:`/BS6M.DTK6;W3YU82VTS1-GK\IQ0!6`P1QQ0`]`3^-`#ESD_,!0!(.2<
M]".*`'+P!ZCK[T`.`P`"<>U`#CUR>!]:``*>![^M`#F')_R:`%3!)('4T`.C
M1WD5(U+.QVJHZD]J`-V7PQ?6UA]LNC%%&HVN"WS1MG[C#J#_`(T`8;@9..?Z
MT`-&1P!TH`4)TX&/<T`(HQDC-`#]HW#C..O-```<9*YQ^E`"]<]QB@!`3G.:
M`'@\9SP.M`"+@*,=#S0`I`)&3@'I0`H'RJ*``<$D]`<4`!P0V<]*``@\9/XB
M@!T>2<-&&('?I0!AD#IWH`KR*".>AZT`4;E#R.A%`'M/PAFN/`VB7FI&]AO[
M2]=(GLE;Y4D)`Z_WN10!V'CG7[.^TNZFB,/DV:E7RQ)C<CIM'7TH`\%\.^)K
M+3+O%Y;0F`L25C.2,GG-`'NNC:58:5X?B-MA1,_G+&1S\W(-`%>"UNIA<7[Q
M/)`,H7V\`F@"72M)^WW:1J2H0%I"!]U0,DT`=)I"I)+*EM"4M0NTGV^OJ:`/
M!OCGXJ.N>(AIELY^Q:<2FT'@R=_RZ4`>;!<CB@!0O&.<CK0`\)@\4`/5/R%`
M$J`_B#0!WO@WXB:KHDD,%W*;[35(#0RG+*O?:>U`'OF@ZK:ZK8_:M,D2:UF&
M>?O*1V/H:`.Y\*7EFRK]H=(YRVU<-\P^HH`\$_:9T.'3_'46HVRCR]2A\QMO
M]]>&/\J`/(0-QP#QGGO0`]1VQUZYH`D`(;I^)%`#L$,0>?7(H`4<G!'!YR!0
M!)R,`9''6@!W!'/:@`:,@@\A2.#0`<G!(P?:@!2,D9R,'%`%FQNY;*ZBFA*D
MHP)#KE3@YY%`%B;5;RY>1[NX>5FW91C\HW')P.W-`%`C=SS0`<Y`()(YZ4`(
M,Y^4'B@!Q&[.?O9H`"0IZX/N>M`"D`G+9X[4`(#@!<A3V'>@!0.1@\>]`"J"
M#@'`]AF@`R#@9]\4`.7(/3\Z`%.<<`4`(,D@$KN]J`!1\Q4#@G.?6@!3@MG(
MYH`/+9QD+D]^XH`QR,],DGUH`B=>N<?A0!`EG+>74-M!L$LS!5WMM&3ZF@#T
MIH(?A[X5EL]7NX+B]$ADCMXFRR.P!!P>V0.:`/-=3\6WVI:7=VMZJ&6>57$D
M8VXQG.<=<T`<Y:A?M<(D&4WC</49H`^M=2$#S)]E5EBBA78A/3Y1S0`6FLW5
MKX?GTT,C6LG)5AR#[&@#0MH6T_1`$_X_+\;1CLG_`->@#(^+7B-O`WA:PM;&
M(2:A=#:O'\9&2WOC(%`'RZ=[R.TQ8R$DL3U)[YH`D5>/6@!P7#>E`#]@!QB@
M!RCI0!(JC-`$L:#.,<B@#KO`OB^Z\+7NY09K*0@RPD]?<>AH`]_\+>)M$U-D
MO+74K51@%DG<1LGU!H`\P^//BJQ\1:_96NE2I<6VGQ%&G3H[L<D#U`P*`/,5
MZ`Y'7TH`D*X.>QH`<H&_`P6/K0`\GG=SCIF@!PS_`'>:`'@G&,G@=*`$'&0O
M3O0`Y2V3D`X'%`#GY/(Y]Z`$QDC'WA0`N<+G.,=:`%P-P!/2@`&<9!)H`,Y`
M]3F@!4Z$G&`<<T`(>3D'B@!V`5(Q^E``#]T#KT&:`$`QSCYO4T`+SC;QSTH`
M7!8`\T`(2<@=,=Z`%/+'G@4`#G`SN_QH`4#L0/?CK0`X@@^Q-`"'[^`>:`$(
MSU;:/K0!E,IR<@@CKF@"-E(`]_6@"!PV=PZ@Y&.U`%+4WENKE[BYE:6=_O.Y
MR30`S1-#OM>OOLFG1%I`AD)/`"CO0!)<>%M3A$3Q0&Y5P6`CY.`<'B@#Z4TM
MEGT:.Y`VI<6R(%/5&`&X'Z$4`1BVDD5`5).?3C&>M`';6EJUQ=Q3HC>7:0HJ
MJW//0'\^:`.)TS5E\0^)KZXUZTBM;32W:.![T?+L!Y89[GKGTH`\4^*=WIFH
M>/M4GT)8A8;PD;1?=?`Y-`'-*F.30`NTXR.?TH`<%RHY^O%`#BO3`ZT`.`QC
M@].E`#P#@$XY_2@"7;D"@"0`G&,?6@"0#`!SS["@!P!Z]\<9%`#U!/'0']:`
M'`8!QCITH`>%.!ZCL>E`#F&!T[T`*N`.,XH`7&6SDXH`50!@CC'Z4`+(QD<O
M(YW$Y+'N:`$.-V%'%`"J#UYQVSWH`7U(Z9_.@!5'RYW'(_2@!,\'OQGI0`[C
MKS^-`"DK_"#D=:`&ACDG;]?:@!1U&!0`$8'4\]AWH`4<G=Q],4`!((//Z4`.
M))&<<4`-SG')%`"NWS'!ZT`+_$<'J>F.E``"-N`>GZT`+_#T&>E`"DL/]6I9
MN^#TH`RV7YCSUZ<T`1NI&<GD=Z`(F4\#).?:@!EG9I<:G9Q3E%A>90[.<*%R
M.I]*`/3M=NM.T+4="^PZI#I^)!YJ^5@&,>A'!4C'6@"[XJUNWCFT]='DMG2\
MA=TEBC_=J"<`EAR#G/%`'.Q>.+OPI=1K>6\-S;3$++$I(R`,;USW-`'L-KKN
MDMI*:K90SWMN&5%6#!4$^IS_`#H`U=/U?6[VZ6*TTQ+/3_,`DE5MTC'/<>E`
M%CXNVIL_AM=W=SI]I>_9U(="N%*GC/J"*`/CJ.,9.!@9X%`$P4\X&*`'!0,C
M'-`#@@(X_.@!?+/I^5`"X&?3`]*`)`I(!_+TH`?CJ/7CI0`Y,CD\@]*`)$7@
M\4`."DMGMGO0`Y0<\^W([4`*?O9!Y'6@!XZ]/KS0`X]^3Q0`#GCN*`'`X.>/
MI0`N<YXY[&@`(XX!P.<4`&!G`Z^W:@!P(!SUQWQ0`@S@@@8-`"`'(.3[T`.7
M:`3Z'UH`5AN(P,'H1Z4`&T!CSS0`G"N>?SH`<,9P?PH`49Y[#%``.3GMVH`.
M..@)H`/ESG`R.]``2`030`K`9_3I0`#()/4=C0`O!SSQG]*`$.#R`/<YH`1B
M=H(7/;AL4`4F3DB@")A@9)//48H`:ZDX.:`&,HQ\R]?6@"K>0_:$`=F<+PH8
MYQ]*`/2_A'JFG'0[C0[NR5YDW,T[<A(R<[@O?GB@#S3QI8I!KMPT&H0WL$KL
MT;1,3L7/`(/0T`=5X`^(6JZ3K6D6L%I"=*A3R9K.%=JS;N#(Y[MG'/M0!]9Q
M7EI;P27RV@>^6'<883Q(3]U?<F@#Y-U/X@^)YY=:L7U"=+&\EE62SEPX0,W(
MYZ'C%`')QJ`#ZT`2!<KQT]N*`'*G3/6@!0N!Q0`H49[C/;%`"A1QGCZT`.`(
M.#0`]1N&"<'M[T`/VX7GIGTH`50`!SSZT`.&0<?G0`X`Y'(QVH`<O"Y_0T`+
M@9P.@'K0`Y5_`?7I0`O`&,$B@`(RV!T[4`.&0,;0?3VH`#G'!P0>XH``OR98
M<_UH`=CC/^30`F,$@'CWH`.1CMS0`8)<\C!H``#G&?\`&@!RY##'7N,]:`$.
M2O`QZ4`&<+R<COQ0`H7:`<''M0`GH<GD<>U`#LC`P/88H`#VRV<=A0`;3TR?
MZB@`.."/I0`H#`<\@#`]:`#KS_%WXH`#QCJ!GDCTH`0],D,3_LF@"FR8&,C`
MX%`",#N&#GUQWH`8W7MTH`0KR.Y'3B@!I3/?F@";3[N;3YI9K7`>2)XFS_=8
M8/XT`8SVR@$#D_SH`Z#X?:OIOAW7S/K=@;[3IDV31J/F'.01Z\B@#V/Q5\>;
M:&YDM_"]C]IM7MMHDGCV&*3'RE?4"@#P3]Y-+)-,VZ61B[D]R3DT`2(F>>XH
M`<%R/F'`%`#@O!]:`%5"!P.OZT`.Q@`'@T`)M&,8Q0`_9GUY[^M`"J..U`$D
M9VJPP,D8Y&<?2@`(Z#`)QTH`4GG.>#0`X`<'C'2@!1D9H`%/3/.*`'X`4G`R
M*``]N1Z4``SA=P_^O0`JX#$D_3WH`<<@Y&<`<X[T`(%VDYZ'M0`,0#SP/?M0
M`'.?84`*#U((RQY&*`#!Z=3W/:@!#C/`Z<$9H`=DDCI@"@!<<`=<4`-P0&SU
M/'TH`<AQ\I.30`F#WYQZT`.7')!(([4``R".,<T`"8#`J1Q^M`"C##`/2@!`
M3CKR>V*```8`P<^_]*`%);:0>!F@`#8YR5/L:`*K_?E]CQ0`S^-?I0`V,#8/
MK0`)R8\\\T`(W^L3ZT`1CD#/H*`(9?O_`(T`1L!0``#8IP,T`3(!CI0`DO&,
M?WJ`)!]V3ZT`-Z,<4`.ZL,^HH`5O]8?]Z@`;_6"@"2/[U`!V;Z4`*?\`5Y[[
M10`Y^GX4`2H!E.!T%`$8_B^M`#HOO2^Q&*`'OPPQZT`/4`[LB@"./_7`=J`)
M?^634`,/W)/H/Z4`$G"<4`*O1?>@!T@^=AVV_P!*`&-]T?2@`<G*^V*`)(NI
M^G]*`(2>_>@"=?O#Z?TH`9)]\_2@!T/+'//%`$V!EQCC`H`B`&&_&@!W<T`1
M*3L'/]W^8H`EF`!<`<8-`$9_U0/?`H`=D[3_`)[4`/'^K_X#_2@!K?=7Z#^=
*`$J`$\CM0!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>dptchart1.jpg
<DESCRIPTION>DYADIC PLATFORM TECHNOLOGY
<TEXT>
begin 644 dptchart1.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_P``1"`%@`=4#`1$``A$!`Q$!_]L`A``&
M!`4&!00&!@4&!P<&"`H1"PH)"0H5#Q`,$1D6&AH8%A@7&Q\H(1L=)1X7&"(O
M(R4I*BPM+!LA,30P*S0H*RPK`0<'!PH)"A0+"Q0K'!@<'"LK*RLK*RLK*RLK
M*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RLK*RO_Q`&B```!
M!0$!`0$!`0```````````0(#!`4&!P@)"@L0``(!`P,"!`,%!00$```!?0$"
M`P`$$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G
M*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%
MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35
MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^@$``P$!`0$!`0$!`0````````$"
M`P0%!@<("0H+$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@`,`P$``A$#$0`_`/$Z_13Y@*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@#7\'Z%)XG\5Z9HD5VEFUZ[KY[1>:$VQ._W=RYSLQU[U\Y
MQ3G<\ERZ6-A!2::5GIN[;G9@<-'$5>23MH>L_P##/=U_T-D'_@J/_P`>K\N_
MXB_B/^@5?^!/_(]C^Q*?\S#_`(9[NO\`H;(/_!4?_CU'_$7\1_T"K_P)_P"0
M?V)3_F8?\,]W7_0V0?\`@J/_`,>H_P"(OXC_`*!5_P"!/_(/[$I_S,/^&>[K
M_H;(/_!4?_CU'_$7\1_T"K_P)_Y!_8E/^9A_PSW=?]#9!_X*C_\`'J/^(OXC
M_H%7_@3_`,@_L2G_`#,/^&>[K_H;(/\`P5'_`./4?\1?Q'_0*O\`P)_Y!_8E
M/^9A_P`,]W7_`$-D'_@J/_QZC_B+^(_Z!5_X$_\`(/[$I_S,/^&>[K_H;(/_
M``5'_P"/4?\`$7\1_P!`J_\``G_D']B4_P"9A_PSW=?]#9!_X*C_`/'J/^(O
MXC_H%7_@3_R#^Q*?\S#_`(9[NO\`H;(/_!4?_CU'_$7\1_T"K_P)_P"0?V)3
M_F8?\,]W7_0V0?\`@J/_`,>H_P"(OXC_`*!5_P"!/_(/[$I_S,/^&>[K_H;(
M/_!4?_CU'_$7\1_T"K_P)_Y!_8E/^9A_PSW=?]#9!_X*C_\`'J/^(OXC_H%7
M_@3_`,@_L2G_`#,/^&>[K_H;(/\`P5'_`./4?\1?Q'_0*O\`P)_Y!_8E/^9A
M_P`,]W7_`$-D'_@J/_QZC_B+^(_Z!5_X$_\`(/[$I_S,/^&>[K_H;(/_``5'
M_P"/4?\`$7\1_P!`J_\``G_D']B4_P"9A_PSW=?]#9!_X*C_`/'J/^(OXC_H
M%7_@3_R#^Q*?\S#_`(9[NO\`H;(/_!4?_CU'_$7\1_T"K_P)_P"0?V)3_F8?
M\,]W7_0V0?\`@J/_`,>H_P"(OXC_`*!5_P"!/_(/[$I_S,/^&>[K_H;(/_!4
M?_CU'_$7\1_T"K_P)_Y!_8E/^9A_PSW=?]#9!_X*C_\`'J/^(OXC_H%7_@3_
M`,@_L2G_`#,/^&>[K_H;(/\`P5'_`./4?\1?Q'_0*O\`P)_Y!_8E/^9A_P`,
M]W7_`$-D'_@J/_QZC_B+^(_Z!5_X$_\`(/[$I_S,/^&>[K_H;(/_``5'_P"/
M4?\`$7\1_P!`J_\``G_D']B4_P"9A_PSW=?]#9!_X*C_`/'J/^(OXC_H%7_@
M3_R#^Q*?\S#_`(9[NO\`H;(/_!4?_CU'_$7\1_T"K_P)_P"0?V)3_F8?\,]W
M7_0V0?\`@J/_`,>H_P"(OXC_`*!5_P"!/_(/[$I_S,/^&>[K_H;(/_!4?_CU
M'_$7\1_T"K_P)_Y!_8E/^9A_PSW=?]#9!_X*C_\`'J/^(OXC_H%7_@3_`,@_
ML2G_`#,/^&>[K_H;(/\`P5'_`./4?\1?Q'_0*O\`P)_Y!_8E/^9A_P`,]W7_
M`$-D'_@J/_QZC_B+^(_Z!5_X$_\`(/[$I_S,S/$_P/NM#\-:MJW_``DT$_V"
MTEN?*_LTKYFQ"VW/G'&<8S@UTX+Q7Q&)Q%.A]62YI)7YGI=V["EDM-)OF9Y%
M7[6?.!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0!VGP5_P"2L^&?^NL__I--7P'B9_R(*G^*/_I2/5R?_>/DSZ[K^9SZH*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`YGXG?\DU\6?\`8(NO_1+5Z63?\C'#_P#7V/\`Z4B*GP/T/C:O[%/@
MPH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`[
M3X*_\E9\,_\`76?_`-)IJ^`\3/\`D05/\4?_`$I'JY/_`+Q\F?7=?S.?5$%]
M=VUA:2W5]<0VUK$NZ2:9PB(/4D\`5=.E.K-0IIMO9+5@8MIXV\*WEU%;6GB;
M0Y[B5@D<45_$S.QZ``-DFNRIE..IQ<YT9I+=N+M^1#JP75'0UP%A0`4`9MWK
MND6>IP:;>:I80:C<8\FUEN$663)P-J$Y.2".!713P>(J4W5A!N*W:3LO5["E
M)1MS.URU!>VMQ=7-M!<P2W%L5$\22`M$2,C<!R,CD9K.5*I&*G*+2>SZ/T[A
M=7MU+%9C,75?%?AW2+LVNK:]I-C=!0QAN;R.-\'H<,0<5V4,NQ=>'/1I2DNZ
MBVOP0I24=V/3Q-H+Z1)JJ:WI;:7&^Q[P7<9A5L@8+YP#DCC/<4G@,4JJHNE+
MG:VL[_=:XE.+3:>VYI6EQ!>6L-S:31SV\R!XY8F#*ZD9!!'!!'>N:<)4Y.$U
M9IZI[H:::NB6I&9VLZYI.AQQ/K6J6&G)*2(VN[A(@Y'4#<1FNC#X3$8EM4(.
M5NR;_(3:2NS0!!`(.0:YP335T+0,*`"@#/UC6M+T2!)M9U*RT^&1MJ/=SK$K
M-C.`6(R:WP^%KXB3C0@Y-=DW^0FTE=E"Q\9^%[^[BM;#Q)HMS=2G;'##?1.[
MGT"ALFNBKE6.I0<ZE&22W;BTOR)]I#NC?K@+"@#/M];TJXU:;2[?4[&74X%W
M2VB7"M+&..60'('(ZCN*WEA*\*2K2@U![.SL_1["<DGRMZFA6`PH`AN[F"SM
M9;F\GB@MH5+R2RN%5%')))X`]ZJG3E4DH05V]DMP(],U"RU6RCO-,O+>\M),
M[)[>59$;!P<,"0<$$?A55J%2C-TZL7&2Z-6?W,2DI;,M5F,*`"@`H`YGXG?\
MDU\6?]@BZ_\`1+5Z63?\C'#_`/7V/_I2(J?`_0^-J_L4^#"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#M/@K_R5GPS_`-=9
M_P#TFFKX#Q,_Y$%3_%'_`-*1ZN3_`.\?)GUW7\SGU04`?.'PFT^RU/\`9[\9
M6^I(C6XGNY,NN=C+&K*P]P0#7Z+GM>I1S[#2I/6T5ZW;37S,Z,5+%UHO9U#5
M\+^+O&-A^SYI?B+3ELKN>P$@N%OX9)'DMU<J'4JZ\J!SGJ!G(QSRXW+<NJY]
M/"U+Q4K6Y6DE)J]G=/?RV?X<^%<G1ER[J]O1:V_KM8[Z;Q3JTWAZ_P!>T-M,
MU/3X[&*6WC8?9R9&`9V:5Y-H15.[!`]-W&:\&.74(UX8:OS0DYM/[6BT224;
MW;TOKWL;T9NHDU_+KZ]O+[G:]SG_``[\4;I]1\7P:LEK>6NAV"WT=S:6TEMY
MRE-Q&QW?(]'#;2.1D$&N_%\/4U3P\J+<75FXV;4K:VW27S35UL[-$TZC=11;
MT<;^EGKU:?JOQ.1\0ZMK&O\`B+X/:QK(L$6_OFN((K6-U,*L8R%8LQWG&.1M
M[\=Z]?"8;#X7#YA0HW]R%FW;5J^JLE;TU]3"O4E4PZDUI[6/X2=O6_RMY]-2
M/QPOA+7_`(KZG=:58/<:=+:#S+19$>Z+[EC$FYV`P"H)4#^(XYKE>4/'4,!1
MA4=IJ6]FHVLW:R3UUW;Z(Z)-1KR;Z1_RLOQM>WY'IO@^\\43WEY'XDM].:S$
M4,MI?62F-9BRY=3&SNPVGOD`@]*^:S"E@8PB\,Y<UVI1EK:ST=TDM>W0*4YR
M49/9QOZ/MYG$?&F>2V^(?PQFAM9KN1+VX*P0E`[_`"Q\`NRK^9%>UP[!3P&-
MC*2BN2.KO9:OLF_N0\3_``%_U\C^IS^M^%-6L]*^*_BC4K--*L]8LF$.F^8C
MOE1_K)-F4#'D\,>7;/J?0PV8X>I5P&#I2YY4YZRLTM>BOK;IJELA.,I5I5=E
MR-?^2K_(U8?%^L>&OASX573X["&W7PY'=)/<1FX>>5(E_<K"DBR``88R`,J@
M\X`)KEEEF'QF85W4;;]NU9>ZDFW[SDXN/DHZ-O:^Q.'_`(<%WDU^/;K?RUTV
M[4_&WC37]7\,?#6]T^>VTY==U&V6XC$329<2*0,[@=F0"5&">F[&<[9=E6$H
M8G&TZB<O90E;6VEGY/6VSV6]NV<JTI87GZWL_P`=NVWGV[W3Q5I5WJ_Q_P!-
MTS7+BTN;*XT%UF1;>2-6B)82*,2Y#$@X8'@8&#C),%B*=#(IUJ":DJRMJGKI
M9_#LNUM>ZO8TKJ?-25]V^GEKUZK;MIN7H?B=J5MX*?Q?;6NG)X5M;X6:6!BD
M^TM`&$8D$I?;G/.W8>!C=WK"7#]&>,6!E*7MI0YN:ZY>;>W+:]NE^;?6W07,
MXQFJ:TAIZ[?=OYFOHGC'Q;K7BG7=/TVSTB>RTK5((7D*NCM;/RQ`+XWJO.?;
M&TYXY,3E>`P^&I5:LI*4Z<GT:YEMTV;_`.'TU3K2E4E&GTC%KY_U\K;.Y#XA
M\<^)[7XBZ]X=TT:+]GLM';4XI;BWE+#;M^1L2`-GD9&W&<\XPUX3*,%/+Z6+
MJ\UY55!I-=;ZKW=/Q[=;K:3E[:%-;2_#?[]O(I^'_BAKMY=_#^2_L],6S\3"
M6-XX`_F1.G&\,6Q@D_<VG`'WC6V*X>PM..+5.4N:C9W=K-/I:W1=;Z]D<\<1
M*5*-7HY\OXM7\M?7\=/79[.VN+FVN)H4>:V+-"[#F,D8)'O@D?B:^2C5G&,H
M1>CW\SK:3M?H[_U]YXC^RQ9V]YX&U874*R>3KKS1Y_@=8X\,/>OM>-JLZ>-I
M\KM>BD_1MF32>(JI_P`WZMFO#\4=6O\`Q+?Q:3I$MUIMAJHTZ6WBTZXEE=0=
MLDWGK^[0*2#L8$D`\C(QR2X>H4L/!UJEIRI\Z;E%)=5'E?O._=.R?1V%5JN,
MI1CKRK[WU7E^IHZ9XU\2>(M:U)O#.GV$^E:9K"Z;<V\V5G9!_K9@Y<*`#C"[
M6)`//:N>ME.#PE&"Q4VISI<Z:^&_2-K-N_5W20YSESSA#>-OF[ZKR_$Y#Q3?
MZEI7QZ\2ZAHWV/[5:>%FN#]K1G3:A5B-JD$DX`ZC&<\XP?6P5&C7R.C2K7M+
M$):63UNMW?;?;RTO=.I%SQ%**ZK]9&UJ_P`3->C\._#W5-.M=+W^(KB*VN()
MTDPK,0"4<-\HZ]5;MUQ@\=#(,*\1BZ-24OW,6TU;9=U;7[T8^WE]7]K;6]OS
M^[;S+&G_`!1O;+PUXYO_`!!:VD\_AJ^:T0V:M$MR<[5X8N5RW4Y/!]N<ZO#U
M.IB,+2P\FE6AS:V;75[)7T\D;IR52<)?9BG]ZN3S>,M8LM3TC1?$XTV<>(=-
MEF@>RMWB-O(L>YD<,[[P0>&^7D=/2(Y7AZE.IB,+S+V51)\S3NF[)JR5O37U
M%1K2O2FUI)_=M;UWML<C\*?%ESH?PM\`:+I,<#:KK=W<PQ2W",\<"+,Y=RJD
M%C@@`;EZYSQ7K9YEL,3F>+Q%9ODIQBVE9-MQ5E=WMZV?H<U&?LZ3E;>:7WV_
M(V-;^+6JZ1<:CH4MKI\NOVNK6VG_`&P1NMKLF!9963<6&`I!7?UYSVKCPW#5
M"O&&)4FJ<J<I6TYKQT:3M;SOR^5NIM4K.ESJ2O9)_>NN^B[^:19TWQCXZU.+
MQM%IXT&>^\/7!AB7^SYA'=[<D@-YYP^!]W!P<#/.1G6RO*Z+PSJ<ZC5C=^]&
M\;_]N:KS_`TCSNNZ7]U=.KVZ_+\>EGT_P\\57WC#3=$U*WNM.:TELS)?QI:L
M'2;)4*I\P[1D-U#?=Z_,,>9FV74L!4JT91ES*5HZJUM[OW=>FS6_D94:LJD4
M^MW?^OUZ^1W5>&=)S/Q._P"2:^+/^P1=?^B6KTLF_P"1CA_^OL?_`$I$5/@?
MH?&U?V*?!A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0!VGP5_P"2L^&?^NL__I--7P'B9_R(*G^*/_I2/5R?_>/DSZ[K^9SZ
MH@OH9+BTEAANIK21UPL\(0NGN`ZLN?J#5TYJ$U*45)=G>S^YI_<P//-)^$.E
MZ9H-QH<6NZ^^B7,WG7-DTL*K.3C<&=8A(%.T`A6'%?0U^)J]:NL2Z4/:)64K
M2T]$Y.-UTNF9>RUD[N\GKM_E^1T&OW$?AG2M)TS3?#L]_I<T@LI(+2,L+>(H
MV"5`.5R`IS@?-DFO/PL'C*M2M5K*,TN:[>[NNMUKUZ[:(M6HQ3@MFO\`@OSM
M][*<OP[TFZ^&<7@R;SK?3A$BNUJX5PP<.2"01RP.<@]:V6>8B&8O,(V<KO?;
M:WET)IP48.*5KW_'_+^M!NE?#?3+'6=2U*?4-3U"74[,65['=O&4GC"A1D*B
MD'`Q\I`]J=?/:]2C"E&$8J$N:-KW3O?JWU[W%"ER2C)-WBK?+M_7SNV[U+3X
M3Z-%)H7VG4=:O+?0V9M/@EN518,X.`T:JYP0,98GC'(XK6?$F)DJO+",75MS
M-)N_R;:UZV7XDO#Q<>37EO>WW_/=W6NEE:VMYA\+M%DO?$\]]=:A?)XB`%[!
M.T>P%3E"FU`RE<\<_7)YJ/\`6'$J%"-.,8^Q^%J]]=[W;3OUT]+&G(O:.IW5
MK=+&_P"$_#O_``CEA%9KJ^J:C!#&L4`OGC)B0=`-B+GMRV3QUK@QV.^MS=3V
M<8MN[Y;ZOYM_A9$TZ2II)/1+1?U_2Z6U,SQ=X$@\3:]I>K7&M:O:7&EN9+-+
M4P!(G.,M\T3$YP."2..E=.`SB6#H3H1IQDIJTK\UVOE)6^6I52'M(J+>ET_F
MMC8\5:!%XD\-7>BWEW=PP74?E2S0%!(R\9'*D#/0\=^,5R8+&RPF(CB(13<7
M=)WM^:>GJ4D^6U^ECDC\)-)+V;#5];4V^E'1SMEB'FVW/RM^[ZX.,K@\#ODG
MUO\`67$6DO9QUJ<^STEW7O?@[F<:2CRV;]UZ?/\`K??ST5K$WPOTJ7PQH&BG
M4=4"Z'<K<V-T&B\Z-E)*@_N]I`)[KV%9QXAKK$U<1R1_>QM):V=_^WKK[Q*A
M%4W3Z-_U^OW^A=G\!VTOCBU\4_VQJZW]M"+>.+="8A%W0YC+')R22V[DX(XK
M".<3C@I8+V<>63NW[U[]])6T[6MY%3I\_+=OW=OR?W_\,57^&.C/YEL;G4!H
MDE[]N?1PZ?9FEZY^YYFW=\VW?MSVQQ6JX@Q*M/E7M%#EY]>:WW\M[:7Y;^=]
M13I1ES?WM_/^O*QI^&O!MIX?\2:YK-K?ZA--K#B2X@F:,Q*PSM*A4!&`2.IX
MZY/-<V,S2IBL/2P\X)*FK)J]_.]V_7;T'[->T]HM[6^[;[OU9G:I\.+*_P#%
M6I>(#K&KP7U_9M8R+$8-BPD#*J&B)[9R23711SVI2PL,+[.+C&?,K\U[]])(
M<HWG&=]5M_7SO_P"C9_"73+0^&O*UK6]OAYF:Q4M!A=S;FW?NLMGI]/?FMZG
M$M>?MKTX_O?B^+HK*WO:&2P\53]FGIS7^>_YZ_/L>@W<3SVLL45Q+;2.I59H
M@I:,_P!X;@5R/<$>U?/TY*,E)JZ71WL_N:?W,Z#E?ASX!L?`5I>6NDZAJ5Q:
MW,OG-%=M$P60@`L"J*>0`,$D<=*]7-LYJYG*,ZT(IQ5KJ^W;5M&:A:;G?5[B
MV7@.ST[Q)J.KZ3J>J6`U*59;RS@DC\B9QU.&0LI.3DJRFBIG%2KAX4*T(RY%
M:+=[I?)I.W2Z83I\TN>]FU9^?]??VUU$L_`5CIWB;4=9TG4=3T]M1=9+VTMY
M$\B=AGDAD+*3DY*LIHJ9S5JX:&'K0C+D5HMWNON:3MYIA.DI3Y[V;5GY_P!?
M>NFNI4UCX:V&J>)M4UR35]7AN]1L6T^9(C!L$#``JH:(D=,YR3[UKA\^JT<-
M##*G%QA-25^:_,NNDE_D4XWJ1J)ZQV_K\?\`@%27X3Z9)H_AS3?[9UL0:!/Y
M]D0\!8.&W*6)BYQT`].N:UCQ)756M5]G&]56E\6UK.WO=3'ZO'V7LDW:]_Z^
M]_?Z%_2?AOI%C#XD@N;F_P!2MO$$C2WT-VT>TN2<E2B*5//KQ@8YK"OGN(J.
MC*,5!TE:+5]O.[:9KR_O'.^K5OEM^0MK\.[**6.>ZU;5[V[M[)K&RN+AH=]G
M&PVDQ[8P"Q&!N<,>/KDGGE1IQC3C&+GS22YK2:UUO)NWDFA1I*+C;[.WE_7G
M<KZ;\+='T[PSI>C6]]J>-*NC=:?>%X_/M7)R=I";6!).0RMU]AC2MQ#B*N)G
MB)1C[\;26MI+SUNGYIK\R8T(J+@]4W?YHYWXD^#[O2O!UZGAJ:[N=6U74(Y=
M0O;JR%X9U`.!+''&?D'R@!(B.!D8+,/0R?,Z=?%Q>)24(0:C%2Y;?X6Y+7?>
M2\G=)#E"T9RWDTE]S7X6W[WZHR_AM?>./"FAZC)JFG1:OI4+1+;VVG:5)9/&
MS2`2%8?L\;,`K%SA#DC`/WL=6<4<LQU:"I3Y)N]W*:FG9:7ESR2U5E=KTVOA
M356-VM5;;;73R6ZO]QZGX(T"R\/Z5.EA:"T%[=2WDD>W!5I&R`?<+M'MBOE\
MRQM3%54ZDN;EBHW]%^KU.F*7-*:ZO^OOWMTN=#7GEG,_$[_DFOBS_L$77_HE
MJ]+)O^1CA_\`K['_`-*1%3X'Z'QM7]BGP84`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`=I\%?^2L^&?^NL__`*335\!XF?\`
M(@J?XH_^E(]7)_\`>/DSZ[K^9SZH*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`YGXG?\DU\6?]@BZ_\`1+5Z
M63?\C'#_`/7V/_I2(J?`_0^-J_L4^#"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@#I/AKK%CX?\`B#H6JZM*\-C;22F618GD
M*[H)%'RJ">K`=.]?&\>9?B<PR:>'PL'*;E&R7D[GHY74A3K\TW96/H?_`(7/
MX$_Z#,__`(+KG_XW7X/_`*B9_P#]`S^^/^9]']>P_P#.@_X7/X$_Z#,__@NN
M?_C='^HF?_\`0,_OC_F'U[#_`,Z#_A<_@3_H,S_^"ZY_^-T?ZB9__P!`S^^/
M^8?7L/\`SH/^%S^!/^@S/_X+KG_XW1_J)G__`$#/[X_YA]>P_P#.@_X7/X$_
MZ#,__@NN?_C='^HF?_\`0,_OC_F'U[#_`,Z#_A<_@3_H,S_^"ZY_^-T?ZB9_
M_P!`S^^/^8?7L/\`SH/^%S^!/^@S/_X+KG_XW1_J)G__`$#/[X_YA]>P_P#.
M@_X7/X$_Z#,__@NN?_C='^HF?_\`0,_OC_F'U[#_`,Z#_A<_@3_H,S_^"ZY_
M^-T?ZB9__P!`S^^/^8?7L/\`SH/^%S^!/^@S/_X+KG_XW1_J)G__`$#/[X_Y
MA]>P_P#.@_X7/X$_Z#,__@NN?_C='^HF?_\`0,_OC_F'U[#_`,Z#_A<_@3_H
M,S_^"ZY_^-T?ZB9__P!`S^^/^8?7L/\`SH/^%S^!/^@S/_X+KG_XW1_J)G__
M`$#/[X_YA]>P_P#.@_X7/X$_Z#,__@NN?_C='^HF?_\`0,_OC_F'U[#_`,Z.
MA'C31FF>"-M0DO417DLH],N7N8U8L`6A$?F*/EZE1@,A/#INR?!F=J*FZ#L^
MMXV_,OZU1;Y>;4Y[_A<_@3_H,S_^"ZY_^-UK_J)G_P#T#/[X_P"9'U[#_P`Z
M#_A<_@3_`*#,_P#X+KG_`.-T?ZB9_P#]`S^^/^8?7L/_`#H/^%S^!/\`H,S_
M`/@NN?\`XW1_J)G_`/T#/[X_YA]>P_\`.@_X7/X$_P"@S/\`^"ZY_P#C='^H
MF?\`_0,_OC_F'U[#_P`Z#_A<_@3_`*#,_P#X+KG_`.-T?ZB9_P#]`S^^/^8?
M7L/_`#H/^%S^!/\`H,S_`/@NN?\`XW1_J)G_`/T#/[X_YA]>P_\`.@_X7/X$
M_P"@S/\`^"ZY_P#C='^HF?\`_0,_OC_F'U[#_P`Z#_A<_@3_`*#,_P#X+KG_
M`.-T?ZB9_P#]`S^^/^8?7L/_`#H/^%S^!/\`H,S_`/@NN?\`XW1_J)G_`/T#
M/[X_YA]>P_\`.@_X7/X$_P"@S/\`^"ZY_P#C='^HF?\`_0,_OC_F'U[#_P`Z
M#_A<_@3_`*#,_P#X+KG_`.-T?ZB9_P#]`S^^/^8?7L/_`#H/^%S^!/\`H,S_
M`/@NN?\`XW1_J)G_`/T#/[X_YA]>P_\`.@_X7/X$_P"@S/\`^"ZY_P#C='^H
MF?\`_0,_OC_F'U[#_P`Z#_A<_@3_`*#,_P#X+KG_`.-T?ZB9_P#]`S^^/^8?
M7L/_`#H/^%S^!/\`H,S_`/@NN?\`XW1_J)G_`/T#/[X_YA]>P_\`.@_X7/X$
M_P"@S/\`^"ZY_P#C='^HF?\`_0,_OC_F'U[#_P`Z,/QW\6/!FJ>"/$.GV.JS
MRW=WIUQ!#'_9]PN]VC95&3&`,DCKQ7=EG!6>T<;1JU,,U&,XM[;)IOJ3/&X=
MQ:4UL?.%?TX?&A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!);0375S%;VT4DT\KA(XX
MU+,[$X``'))/&*3:BKO8:3;LC?\`^$?M-.X\3:I]AF/'V.TB%U<H?^FB[U2/
M!#`JSB0$#*8.:Y_;RG_"C?S>B^6C;];6\S3V:C\;M^+_`*_'R#_A)O[.^7PM
M:?V1C_E[\SS;P_\`;;`V=6'[I8\J<-NZT?5^?^*^;RZ?=U^=]=K![3E^!6_/
M[_\`*QSE=)D='_PEU_=<>((H/$"C[IU,R/(GIB9667:.?DW[,L3MSS7-]6A'
M^'[OI;\M5\[7\S7VK?Q:^O\`5P^S^&-0XM;R_P!&F/"I?@74)QR6:6)5=<C@
M*(FY`RV"=IS5X;I2]-']ST_%?YEJ;V=O77^ON*VH^&=3L[.2_C@^VZ4F,ZA9
M_O8!D@+N8?ZMCE?D?:XW#*C-5#$0D^6]I=GH_P#@^JNO,4J<DK[KN8M;F84`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`6=.L;O4K
MR.TTZUGN[N3.R&",N[8!)PHY/`)_"HG.,%S2=D.,7)V2-K^R](TGG7;[[9<C
M_EQTJ9'Q_OW&&C7@AAL$N<%6V&L?:5*G\-67=_Y;_?;NKFG+&/Q._I_G_P`.
M17/B>Y^S2VVD6MIHMM,A29+`.&F4C#*TCLTA0C&4W;.`=N>::P\;WFW)KO\`
MY*ROYVOYB=5VM%6]/ZN8-=!F%`!0`4`%`%G3KZ[TV\CN].NI[2[CSLF@D*.N
M00<,.1P2/QJ)PC-<LE=#C)Q=TS:_X2?[;\NOZ78:GG@W'E^1<C/WF\V/&^0]
M=THDY&<'+9Q^K\O\.37XK[GLO)6_(T]K?XE?\_Z];A_96B:ASI.M?99FZ6NJ
MQ&/+'[J),FY&P>"\@B7H>`3M/:58?'&_FO\`)Z_)<W^9RP?PO[_\_P#.Q2U;
MP[JVE6RW5[92"Q=]B7D1$MO(V"<+,A*,>#P"<$$=0:NG7IS=HO7ML_N>I,J<
MHJ[6ADUL0%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!HZ/HFH:O
MYS6-ONAAQYUQ(ZQ0PYSMWRN0B9((&XC)X&3652K"G;F>_P!_R6[+C"4MC2^S
M^'])^>XO/[>N>J0V@DAMAZ>8[JLC<C!157(8$2`\5GS5JFRY5YV;^26GS;?H
M5:$=W?\`+^OZN5M1\3:G>6<EA'/]BTI\9T^S_=0'!!7<H_UC#"_.^YSM&6.*
MJ&'A%\UKR[O5_P#`]%9>0I5)-6V78Q:W,PH`*`"@`H`*`"@`H`*`"@"[I.JW
MVD7+3Z=<R0.Z>7(%.5E0D$HZGAT.!E6!![@UG4IQJ*TE?^OP?F5&3B[HUO[=
MTR^_Y#F@0/)U:XTR3[%(YZ`%=K0A<=EC4D@'.=V[+V,X_P`.?WZ_Y/[VR^>+
M^*/W:?\``_`/["TR^_Y`>OP/)T6WU./[%(YZDAMS0A<=VD4D@C&=NX]M./\`
M$A]VO^3^Y,.2+^&7WZ?\#\3)U;2=1T>Y6WU>PN["=DWK'=0M$Q7)&0&`.,@C
M/L:UIU(5%>#37D1*$HNTE8I5H2%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`:VD
MZ!?:E;-=JL=MIJ/LDOKIO+A1@`2H8_?<`[MB!G(SA36-2M&#Y=WV6_\`PWF]
M/,N--R5^A=\[PYI?RQ6T^N7:=99Y&@M2>A`C7$KKU*MOC)R,H,$&+5I[OE7W
MO[]EZ6?J5>G'S_+_`#_+T,W6-;U#5_)6^N-T,.?)MXT6*&'.-VR)`$3)`)V@
M9/)R:TITH4[\JW^_YO=DRG*6YG5J0%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0!K:3XBU;2K9K6RO9!8N^][.4"6WD;`&6A<%&/`Y(."`>H%8U*%.;O):]]G]
MZU+C4E%63T+O]I:)JGRZMIG]G3'DWNE*3ENK%X';8<D<"-HE7)X(`41[.K#X
M)7\G_FM?OO?\2N:$OB5O3_+_`"L'_",?;?FT#5+#4\\BW\SR+D9^ZOE28WR'
MIMB,G(QDY7)]8Y?XD6OQ7WK9>;M^8>RO\+O^?]>ES%U&QN]-O)+34;6>TNX\
M;X9XRCKD`C*GD<$'\:VA.,US1=T9RBXNS16JQ!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!O6W
MA743;17>IB/1]/E0/'=:CNC652.#&H!>4<KDQJV-P)P#FN=XF%^6'O/LOUZ+
MYM&BI2M=Z+S_`*U^1+_:FD:3QH5C]LN1_P`OVJPH^/\`<M\M&O!*G>9<X#+L
M-+V=2I_$=EV7^>_W6[.X^:,?A5_7_+_AS)U;5;[5[E9]1N9)W1/+C#'"Q("2
M$11PB#)PJ@`=@*UITXTU:*M_7XOS(E)R=V4JT)"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@#:T[Q+J%G9QV4I@OM.3(6UOH5F2-226$98;HMV
M>3&58\'.0",)X>$GS+1]UI]_?YW-(U))6W7]?=\BS]H\,:AS=6=_HTQY9[`B
MZA..`JQ2LKKD<EC*W(.%P1MGEKPV:EZZ/[UI^"_S=Z;W5O37^OO#_A#]3N?F
MT/R-=C/W?[,?S9".[&#`F50>-S(!G')#*2?6H+^)[OKI^.WW,/8R?PZ^G^6Y
MSE=)D%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`,FD$4,DC`E44L
M<=>*SJ5%3@YO9*Y4(N4E%=3M_P#A5?CO_H69_P#P,MO_`([7PG_$3,@_Y^/_
M`,!E_D>G_8^(\OO#_A5?CO\`Z%F?_P`#+;_X[1_Q$S(/^?C_`/`9?Y!_8^(\
MOO#_`(57X[_Z%F?_`,#+;_X[1_Q$S(/^?C_\!E_D']CXCR^\/^%5^._^A9G_
M`/`RV_\`CM'_`!$S(/\`GX__``&7^0?V/B/+[P_X57X[_P"A9G_\#+;_`..T
M?\1,R#_GX_\`P&7^0?V/B/+[P_X57X[_`.A9G_\``RV_^.T?\1,R#_GX_P#P
M&7^0?V/B/+[P_P"%5^._^A9G_P#`RV_^.T?\1,R#_GX__`9?Y!_8^(\OO#_A
M5?CO_H69_P#P,MO_`([1_P`1,R#_`)^/_P`!E_D']CXCR^\/^%5^._\`H69_
M_`RV_P#CM'_$3,@_Y^/_`,!E_D']CXCR^\/^%5^._P#H69__``,MO_CM'_$3
M,@_Y^/\`\!E_D']CXCR^\/\`A5?CO_H69_\`P,MO_CM'_$3,@_Y^/_P&7^0?
MV/B/+[R_HWP?\87ES(NH:6=/@CC,A=YX9&DP1\B*KD%R"<;BB\<LM)^)F0VT
MJ._^&7^0+)\1?6QI_P#"$>,-*^3PSX-GAF7C^TKN[M)+DG^]&/,V0\A6&T&1
M#G$I%8?\1&R&?\6J_11E;YZ7?Y/L:_V57C\"7K?7_@?GYF#<_#+X@W5S+<7/
MAZZFGE<O)))?6S,[$Y)),N22><UNO$KA^*LJCM_A?^1D\HQ+=W;[R/\`X57X
M[_Z%F?\`\#+;_P".T_\`B)F0?\_'_P"`R_R#^Q\1Y?>'_"J_'?\`T+,__@9;
M?_':/^(F9!_S\?\`X#+_`"#^Q\1Y?>'_``JOQW_T+,__`(&6W_QVC_B)F0?\
M_'_X#+_(/['Q'E]X?\*K\=_]"S/_`.!EM_\`':/^(F9!_P`_'_X#+_(/['Q'
ME]X?\*K\=_\`0LS_`/@9;?\`QVC_`(B9D'_/Q_\`@,O\@_L?$>7WA_PJOQW_
M`-"S/_X&6W_QVC_B)F0?\_'_`.`R_P`@_L?$>7WA_P`*K\=_]"S/_P"!EM_\
M=H_XB9D'_/Q_^`R_R#^Q\1Y?>'_"J_'?_0LS_P#@9;?_`!VC_B)F0?\`/Q_^
M`R_R#^Q\1Y?>'_"J_'?_`$+,_P#X&6W_`,=H_P"(F9!_S\?_`(#+_(/['Q'E
M]Y5U3X<^,]+TR[U"^\.SQ6EI"\\TGVJW;8B@LQP)"3@`].:UH^(V15JD:5.H
MW*327NO=Z(3RC$)7=OO.5K[H\L*`"@`H`W?#?@[Q)XFM9[K0-'EO;:";R'D6
M>%`'VJQ&'<'HZ]L<U\IG'&>593B/JV+FU*R>S>C]#OH9=6KPYX6L:_\`PJOQ
MW_T+,_\`X&6W_P`=KR_^(F9!_P`_'_X#+_(V_L?$>7WA_P`*K\=_]"S/_P"!
MEM_\=H_XB9D'_/Q_^`R_R#^Q\1Y?>'_"J_'?_0LS_P#@9;?_`!VC_B)F0?\`
M/Q_^`R_R#^Q\1Y?>'_"J_'?_`$+,_P#X&6W_`,=H_P"(F9!_S\?_`(#+_(/[
M'Q'E]X?\*K\=_P#0LS_^!EM_\=H_XB9D'_/Q_P#@,O\`(/['Q'E]X?\`"J_'
M?_0LS_\`@9;?_':/^(F9!_S\?_@,O\@_L?$>7WA_PJOQW_T+,_\`X&6W_P`=
MH_XB9D'_`#\?_@,O\@_L?$>7WA_PJOQW_P!"S/\`^!EM_P#':/\`B)F0?\_'
M_P"`R_R#^Q\1Y?>'_"J_'?\`T+,__@9;?_':/^(F9!_S\?\`X#+_`"#^Q\1Y
M?>'_``JOQW_T+,__`(&6W_QVC_B)F0?\_'_X#+_(/['Q'E]YT7_"-_$^Y^77
M/#(UV,_>_M.YMI9".RB?S1,J@\[5<#.>"&8'G_XB%PXOX=24?2+7X6M]Z-?[
M-Q3^*S]?\]QT?PAU34W"VVD:IH<IX4:A=6MU!QSN:6)@ZYZ!1"W(&6P3MJ'B
M9DJ=I5+KORR7X6?YDRR>JUII\_UT_(YO_A5?CO\`Z%F?_P`#+;_X[6W_`!$S
M(/\`GX__``&7^1']CXCR^\/^%5^._P#H69__``,MO_CM'_$3,@_Y^/\`\!E_
MD']CXCR^\/\`A5?CO_H69_\`P,MO_CM'_$3,@_Y^/_P&7^0?V/B/+[P_X57X
M[_Z%F?\`\#+;_P".T?\`$3,@_P"?C_\``9?Y!_8^(\OO#_A5?CO_`*%F?_P,
MMO\`X[1_Q$S(/^?C_P#`9?Y!_8^(\OO#_A5?CO\`Z%F?_P`#+;_X[1_Q$S(/
M^?C_`/`9?Y!_8^(\OO#_`(57X[_Z%F?_`,#+;_X[1_Q$S(/^?C_\!E_D']CX
MCR^\/^%5^._^A9G_`/`RV_\`CM'_`!$S(/\`GX__``&7^0?V/B/+[P_X57X[
M_P"A9G_\#+;_`..T?\1,R#_GX_\`P&7^0?V/B/+[P_X57X[_`.A9G_\``RV_
M^.T?\1,R#_GX_P#P&7^0?V/B/+[P_P"%5^._^A9G_P#`RV_^.T?\1,R#_GX_
M_`9?Y!_8^(\OO,CQ)X.\2>&;6"ZU_1Y;*VGF\A)&GA<%]K,!A')Z(W;'%>ID
M_&>59MB/JV$FW*S>S6B]3&OEU:A#GG:QA5]6<`4`%`!0`4`5]0_X\+G_`*Y-
M_(US8S_=ZG^%_D:T/XD?5'WO7\8GW04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`<S\3O\`DFOBS_L$77_HEJ]+)O\`D8X?_K['_P!*
M1%3X'Z'QM7]BGP84`%`!0!]&_LP?\B7K/_87?_T1!7\X>*?_`"//^X4?S9]9
ME/\`NR]6>Q5^;GIA0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0!X[^T__P`B7HW_`&%T_P#1$]?I'A9_R//^X4OS1YF;?[L_5'SE7]'G
MR84`%`!0`4`5]0_X\+G_`*Y-_(US8S_=ZG^%_D:T/XD?5'WO7\8GW04`%`!0
M`4`%`!0!D>+==@\->'KS5KJ.25+=1MBC&6D=B%51[EB!^-=>!P<\9B(T(.U^
MKZ):M_)`VDG)[)-_<9(G\96T%O=7$>C70FFB66R@BDC>V1G4.1*782E5)_@3
M.,\8VGKY,NG)PBY*R=I-IIM)VTLN6[\Y6V\UDG-Q<MM'I_P>_P`MRSH6L:G=
M^+O$&EZA!9Q6]DD$EJ8'9V='W\N2``?DZ`<9ZGK66)PM&&%I5J;;<FT[V2NK
M;;]]WOV0W-^UY.G*G^+7Z?UL4_&^JZYIVL>';71KG3(HM3NC:N;NS>8H1'))
MN&V5./DQCWSGM6V6X;"U:5:=>,FX1OI)*^J5M8OO>_X#JR<8*2_F2^\NZ3K#
M6LBVOB'6]%EO+B5TM%@0VK2[.'`C>1RQ5@<D'I6-?"J:Y\-2DHI*]_>M?;51
M5KKN@3:>KWV]?ZL6U\4>'VL4O5UW2C9NKLLXNX_+8*0&(;.,`D`^F163R_%J
M?L_92YM-.5WUVTMUZ#4DU=/^M_RU)M1U[1],L8+W4M5T^TLY\>5/<7*1QR9&
M1M8G!R.>.U11P>(K3=.E3<I+=)-M>J!3BX\R>G<K0^+?#DZEH/$&D2*(6N,I
M>QD>4I(9^#]T$$$]!@UI++<9%VE2DM;?"]WLMMWV#GB^I+>>)-"LM.MM0O-:
MTRWL+G_47,MTBQR\9^5B<'CTJ*>`Q52HZ4*<G);I)W7JN@<\;<U]#5!!`(.0
M:Y1IIJZ%H&%`!0`4`%`!0!S/Q._Y)KXL_P"P1=?^B6KTLF_Y&.'_`.OL?_2D
M14^!^A\;5_8I\&%`!0`4`?1O[,'_`")>L_\`87?_`-$05_.'BG_R//\`N%'\
MV?693_NR]6>E^+==@\->'KS5KJ.25+=1MBC&6D=B%51[EB!^-?!8'!SQF(C0
M@[7ZOHEJW\D>FVDG)[)-_<<]K.M>)?#>E-KNMC2KC3(</=V=I!(LUM&2,LLI
M<B79GD;$R`2,=#Z&'PF"Q=7ZM0YE-[-M6;[-67+?I[TK>>YG>;CS)=+V_/7O
M\O*_4K>)?B18VXOK7P_<:?=ZG8WEM!<12SC(21T5F15.6VF0*<[0">3Q@Z8/
M(JLN6>(3C"49--+JDVDV]%>U^MUZW1.HE"36_)=?C_P_I;O<[.SU?3;ZSFN[
M+4+.XM(2RRS13JZ(5^\"P.!COGI7C5,-6IS5.<&I/9---WVT\RTU)N*W3M\R
MO%XET*73TOXM:TQ[%V9%N%ND,;,H+,`V<$@`DCT!K1X#%1J.DZ<N9=+.^NFP
M1DI?"[ZV,KQ]K]WIG@*^\0>'+G3YOLUN;I'EC,\4\87.%*.O7@ALD8['-=>5
MX.G6QT<+B8M7E;1V:?G=/;MIZ@FG%M=G^!G:IK_B+PO=Z7<:^VEZCHM[.EK+
M-96SVTMK)(<(Q5I'#H20#@J1G/-=%'!8/&QG'#\T:D4VE)J2DENKJ,;.VJW3
MVT,'4FJ:JO:VOSMKOT.FA\2:'/"LT.M:9)$UR+0.ETA4SGI%G/W_`/9Z^U>9
M+`8J+Y94Y)\O-L]N_IY[&_,E?RW\O4?'K^C2ZPVDQZMI[ZJF=UFMRAF&!DY3
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MM/EB>5&C1RRL9V"D"3I@YV^]>KBJ&`IT(3C&:<X-J\DTFFU:W(KWMW6Y,N=2
MY4ULG][UZ]D=79ZQIE[?W-C9ZC97%[:_Z^WBG5I(O]Y0<K^->54PM>G3C4G!
MJ,MFT[/T?4OF7-RWU.;\4>-;>WT*2]\,WFDZI)!>V]M<A+D2"$22JAR$S\W/
M`)'<]L'T<%E4YUU3Q4903A)K2U[)OKT\]?QNIG-*,[/6,6[?Y_UTMYG16^MZ
M3<V3WEOJ=C+9QR^2\Z7",BOD#:6!P&R0,=<D5Y\L)7A-4Y0:DU>UG>V][=BN
M9.^NV_EZC[/5]-OK.:[LM0L[BTA+++-%.KHA7[P+`X&.^>E34PU:G-4YP:D]
MDTTW?;3S!-2;BMT[?,YS4_&,3W?AP^';G2]3T_4-1-G<7,-P)?+/ELX"[.,_
M+SD\<<'.1Z-'*Y*%;ZS&4)0AS)-6OJEK?7KVU[JVLRJ1Y'*+O9I?>_Z_K?H+
M[6]*L+^VL;[4[&VO;D@06\UPB22Y.!M4G+<\<5P4\)7JPE4IP;BMVDVEZOH5
M*2BKR=BOJ_BCP_HUT+;6-=TJPN2H<175Y'$Q4Y`.&(..#S[5I0R_%XB//1I2
MDNZBVOP02DH[LETF_>2SO;B_N].>."XF7S+63*1QJQP')Z.`/F[`YJ:]%*<8
MTXRNXK1K5MKIY/IY#6LFEY?DOZ7E88/$V@G2#JHUO3#I8;8;S[6GDALXQOSM
MSGMFG]0Q7M?8>RES]K._W;DJ<6FT]C2M+B"\M8;FTFCGMYD#QRQ,&5U(R"".
M"".]<TX2IR<)JS3U3W0TTU='D7[3_P#R)>C?]A=/_1$]?HWA9_R//^X4OS1Y
MN;?[L_5'SE7]'GR84`%`!0`4`5]0_P"/"Y_ZY-_(US8S_=ZG^%_D:T/XD?5'
MWO7\8GW04`%`!0`4`%`!0!SWC[P^WB?PK>:9%,L%PY26"5AE5D1PZ9'<949]
MJ]#*\:L'BHUFKK5->35G^#)G!3A*$MFK?UZ;D>G:OK]YY=O<^&YM/N?^6MS-
M<0R6PP>2FQ_,;/8,B^^*JMAL)3O*-9271)24OG=<J\[-^5R5*=K-:_AZ]_E\
MO,JZ''J0^(6OW5SH]W;Z?<001073RPE)#$7R=JN7&=X(RO8YQTK7$RH_4*4(
MU$Y)MM6E=7MW26EM=?2XI1?MN;IRI?BW^I1^)FE7.LZGX9A_X1R76M-M+TW-
MVI-N8ROE2(%*RNNX[G4],8'7/%;Y-B88>G6E[;V<Y0LOBO>Z>\4[:)K?\`KW
M=.T5?WD_N]>__#DOB;P])86/AP>'-,,]OI6J?:C96QCC/ELLH(3<508,G`R.
M!48/&JK.M]9G9SI\O,[O5..]DWK;>SU&X)4G"*ZI_P#DR;_4XS0?#>LV_C"U
MU2_\'3L;>74Y//$MHY(F??$%)ESG&\<@8+^A)KV<5C\-/"2HT\0M535K37PJ
MTK^[;L_.W>R!WE44FOMW^7*E]]TONZDEO9>(-.T7P38VVE2)KUCIUQ!-;M]G
MN-D7[M#^[-Q&I!^4A@^1C!4[CB9U<)5K8FI*I^[E.+3]Y:ZO?DD]-=''7=/3
M68MQBK:/G;2\M?RNC9L[6Y'_``AVI:#I.H7EEIUE<Z=)!+)"D\9^1`S$N%89
MB.2A/4$9%<=2I#_:*.(J1C*<XSNE)I[NRLKKXM$TNSL%-<L(JWPSUV[-/RWZ
M=-M+%&VT#7[7P+X8MX-+U:U\06-G);^9:SVKI$3@%9DDDV21-@-\N6&T?=-;
MSQN%GC:\I3BZ4I)ZJ:;\XM1NI+;737JA6DH/>_,VK;ZWU5]'OL^OWKU>V\T6
MT0N!&)M@WB/.T-CG&>V:^4GR\SY=KFL$U%)[VZ$M24%`!0`4`%`!0!S/Q._Y
M)KXL_P"P1=?^B6KTLF_Y&.'_`.OL?_2D14^!^A\;5_8I\&%`!0`4`?1O[,'_
M`")>L_\`87?_`-$05_.'BG_R//\`N%'\V?693_NR]6>A^._#Y\3^%KW2XYQ;
MSR;)(9BNX)(C!T)'<;E&?;-?#99C?J>)C6:NE=-=TU9_@STI14XRA+9IK^O3
M<P/$4?B#Q;X>N/#UQH4NEF\3R;R^EN(9(5CSAS"%8NS$9V[T3KDX(VGOPDL)
M@:ZQ4:O/RN\8I23OTYKI))=;.7E?<SYIJ+C;6UK].U^_R^6FYSOBWPYK!'B?
M3K3PY<ZE9:E>V4\3QRVXB,40A#HPDD4YQ&PQM(.1S7H8#'8?]Q5G64)0A-/2
M5[RYK-6BUU76XIQ<4XPZT^5>NO\`F7+[P]K6H1>-(X])N;2.ZO[6\M$-U'%]
MK6)8@T8>*0M&6\K`)QC<I]<8T\;AJ3PS=12<82B]&^5RYK.TE9VYM4KWL_(<
MHN3DHZ7@E?T_2VGI?RO4O/""OJ_A_4K+P7J`FBU9+FZEU"_BNKA56,KN+23/
MQGRR`K$_N^0"%SM3S-JE5I3Q,;.FTE&+C'5WV4%YWNEON[NT2CS0?NZZ;N_6
M[MKM;3I?M;4[/XJ6=_J?@'6=-TC3YK^]OK=K>..)XTVE@?F8NRC:/;)YZ5XV
M25:5''4ZU::C&,D];O;HK)Z_AYG1]E^C_'0R-?L]<\9G2]*FT2?1]'AN8KF]
MGOIX6DE$;!ECC2)W'+!<EB,#H":Z\+5PN7\]:-53FXM145*RNK-MR4=ELE?7
ML<SC.5'V5MTD_33;S9IV>F3+XZO$CDB;24"WYB&[='=.&0^VTJ"V.NXYQR">
M:IB(O!1;7OZQOWBK/UO?3TT-9I\^G5:_+1??_P"V^;.3N-"\0OXCTZYDT2]S
M9ZS//YEK/;1VRPR+*@D2/>I9_F1G,@+9W;3@XKUH8S"+#S@JJ]ZE%:J3E=.+
MLW9I+1J*B[6M?7451-R;M?WDU\K?C;373M;KS_BWPGXDU3X>Z-X;;PA+<7^F
M/()+M;BU:&X/E2)YJEY`^6=E<[E!!SU(&>_`9E@Z./J8OZQ:,TM+3NM8NSM%
MK1)Q5FP4>5.+5_>O?376[^>Z_6QZ'=V>JV]UX9U=-'N+U;6QDM;G3EEB$T3.
MJ'>-T@C./+*GYLX?C/-?/4ZM"4:]!U%'FFFI6E9VOII%RZW6G34F$)JG3[Q_
MRMIYKIY-]=#K-%A2WTJVBBL(].C1`$M(PH$([+A?E&!V&1GH3UKRL1)RJRDY
M\SOOKKYZZ_?KZ&D%:.UCF_"=OJ2^(/%KWFEW=A!?72RVT\DD+!P(4CX".S`Y
M0GD#@COP/1QTZ+H8=0FI.,;-)2_F;ZI+K;U\BN;]]S6TLOP;_.YR>D>!;M]!
METR;2]1M-9ATZ>Q35KG5Y)K=MR[=\4?FLRAR%8J43`[D@9];$9O35=5HSC*F
MYQER*"4M'>TGRI.VJO=W^9C"$HM1=WOK?NGK;^;7M:]]=KV_%VGZCKWA-[>/
MP++#?.;2*=&DM,R1QRJY0'S,-&`K@!B.6'R\L1E@*]'#8I2>*O'WFM)Z-IJ_
MPZ2>FU]GKM<C&2IN%M5"R?\`EUMUUM]YF^)_#>K:I;>*H#X2GN(;O5[.ZM8W
M>T(9(UC61@#+QE8V&#@D.!W;'1@L?AZ,J$OK"3C2FG\>[;:7P]VGZKTO4TVI
MJ*WII?/_`(&GW>AH7GA_7KY?&*VNE/9B?4;6^LX[B6(1WBPB(-&=C,5#>5CY
M@.&&>X'/3QN%I_5W.IS6A*,K)WCS<UGJE>W-T[/R"<.=RBE9."5_Z\M/2_S@
MU?1M=U+X@Z-XB@\/7UK;+<0"YMVGMMX\M9@97Q*0>)E`P6.%;('R@Z8?%86C
M@*F$E63?+*SM*VKB^57C?[+;NDKM;ZVFIS3C\-FK?/5/[E9V\WMU-'7]#UEI
MO&.FKI1U*U\0A6MKT31JMHWE+'ME#,&VH5#J4#'D\`]>?"XS#)8>JZG(Z6\;
M/WM6]+*UVG9\S6W8TE>-1SMS)I*WIT]'?7YZ/KC:I'>66OZO));7EYH5K=VD
M]]<6R02R/-!%$VX,TZNG(0%!&Y(!VG+8'91E3J4*:4E&I*,E%/F2M)R5K*#3
MZV?-%+JK+7&<6H\M[V@D]NC;ZM6TUO\`/1ZEW3O#&JO\.=6TN/2)M.F&JO>6
M]E]I2'SH?/$HC5X7/EDJ-N<C!]N:PK9A0684ZSJ*2]FHN5F[/EY;M26MGKUN
MO,UE%S=1+3F>C^[YZVUTO9]]"S+X=,>EO<Z=X>\365\]ZEP)$U6*>\614*^8
M3-,\;+MPFTL<@GY1@&LXXZ]10J5J<HJ#7P-0LW>WNQ4D[ZW25GUU)4;W<HOI
MUUTUT]//?6ZMOW7AB._B\/:?'K`B&H+"HG\I0J[L>@X!]0"0#G!(KP\:Z4J\
MW1^&^E_ZO]^O<JES<BY]_P"M[:7[VTOL>8?M/_\`(EZ-_P!A=/\`T1/7W_A9
M_P`CS_N%+\T<&;?[L_5'SE7]'GR84`%`!0`4`5]0_P"/"Y_ZY-_(US8S_=ZG
M^%_D:T/XD?5'WO7\8GW04`%`!0`4`%`!0`4`%`!0`4`%`!0!G:SH>DZY'$FM
M:78:BD1)C6[MTE"$]2-P.*Z,/B\1AFW0FXW[-K\A-)JS+T4:11)'$BI&@"JJ
MC`4#H`*PE)R=WN"22LA](84`%`!0`4`%`!0`4`<S\3O^2:^+/^P1=?\`HEJ]
M+)O^1CA_^OL?_2D14^!^A\;5_8I\&%`!0`4`?1O[,'_(EZS_`-A=_P#T1!7\
MX>*?_(\_[A1_-GUF4_[LO5GL5?FYZ84`%`!0`4`%`!0!5L-/L].CDCT^TM[5
M))&E=8(P@=SU8@#DGN:TJUJE5IU)-M*VKOIV]!**3;2W>I:K,84`%`!0`4`%
M`!0`4`%`!0`4`9<WA_1I]7359](TZ35$QLO'MD,RXX&'(R,?6NF.-Q,:3HQJ
M24'TN[?=L3**E:ZO8U*YB@H`*`/'?VG_`/D2]&_["Z?^B)Z_2/"S_D>?]PI?
MFCS,V_W9^J/G*OZ//DPH`*`"@`H`BNHS+:S1J0&="HSTY%8UZ;J4I06[31=.
M2C-2?1GNO_#0EU_T*<'_`(-3_P#&:_$?^(08C_H*7_@+_P`SZ'^VZ?\`*P_X
M:$NO^A3@_P#!J?\`XS1_Q"#$?]!2_P#`7_F']MT_Y6'_``T)=?\`0IP?^#4_
M_&:/^(08C_H*7_@+_P`P_MNG_*P_X:$NO^A3@_\`!J?_`(S1_P`0@Q'_`$%+
M_P`!?^8?VW3_`)6'_#0EU_T*<'_@U/\`\9H_XA!B/^@I?^`O_,/[;I_RL/\`
MAH2Z_P"A3@_\&I_^,T?\0@Q'_04O_`7_`)A_;=/^5A_PT)=?]"G!_P"#4_\`
MQFC_`(A!B/\`H*7_`("_\P_MNG_*P_X:$NO^A3@_\&I_^,T?\0@Q'_04O_`7
M_F']MT_Y6'_#0EU_T*<'_@U/_P`9H_XA!B/^@I?^`O\`S#^VZ?\`*P_X:$NO
M^A3@_P#!J?\`XS1_Q"#$?]!2_P#`7_F']MT_Y66-.^.^I:C>1VMGX/@DF?.`
M=6V@``EF9C"`J@`DL2``"20!43\(ZT%S2Q2_\!?^94<ZIR=E%_@=1!\4&O-#
M_M'3XO#\S1LT<]O)JLT;HXD*H1FVP(F!BQ+)L4-)M8J1SSR\*L1&:@Z_3^7_
M`.VU:[*[[7-5FM)QNC$U;XQ>(-*MENKWP,@L7?8EY%JWFV\C8)PLR0E&/!X!
M."".H-:T_">I-VCBXW[<K3^YNYG+-XQ5W!V^1E?\-"77_0IP?^#4_P#QFMO^
M(08C_H*7_@+_`,R/[;I_RL/^&A+K_H4X/_!J?_C-'_$(,1_T%+_P%_YA_;=/
M^5A_PT)=?]"G!_X-3_\`&:/^(08C_H*7_@+_`,P_MNG_`"L/^&A+K_H4X/\`
MP:G_`.,T?\0@Q'_04O\`P%_YA_;=/^5A_P`-"77_`$*<'_@U/_QFC_B$&(_Z
M"E_X"_\`,/[;I_RL/^&A+K_H4X/_``:G_P",T?\`$(,1_P!!2_\``7_F']MT
M_P"5A_PT)=?]"G!_X-3_`/&:/^(08C_H*7_@+_S#^VZ?\K#_`(:$NO\`H4X/
M_!J?_C-'_$(,1_T%+_P%_P"8?VW3_E8?\-"77_0IP?\`@U/_`,9H_P"(08C_
M`*"E_P"`O_,/[;I_RL/^&A+K_H4X/_!J?_C-'_$(,1_T%+_P%_YA_;=/^5F9
MXG^.%UKGAK5M)_X1F"#[?:2VWF_VD6\O>A7=CR1G&<XR*Z<%X48C#8BG7^LI
M\LD[<KUL[]Q2SJFTURL\BK]K/G`H`*`"@#T'X9_$^X\"Z1?:?'HD6H+<79N1
M*UZ82N8T3;M\MO[F<Y[U^8\6<`5L]Q_UN-907*E:S>U_-=SVL%F<,/25-ILZ
M_P#X:$NO^A3@_P#!J?\`XS7S/_$(,1_T%+_P%_YG5_;=/^5A_P`-"77_`$*<
M'_@U/_QFC_B$&(_Z"E_X"_\`,/[;I_RL/^&A+K_H4X/_``:G_P",T?\`$(,1
M_P!!2_\``7_F']MT_P"5A_PT)=?]"G!_X-3_`/&:/^(08C_H*7_@+_S#^VZ?
M\K#_`(:$NO\`H4X/_!J?_C-'_$(,1_T%+_P%_P"8?VW3_E8?\-"77_0IP?\`
M@U/_`,9H_P"(08C_`*"E_P"`O_,/[;I_RL/^&A+K_H4X/_!J?_C-'_$(,1_T
M%+_P%_YA_;=/^5A_PT)=?]"G!_X-3_\`&:/^(08C_H*7_@+_`,P_MNG_`"L/
M^&A+K_H4X/\`P:G_`.,T?\0@Q'_04O\`P%_YA_;=/^5A_P`-"77_`$*<'_@U
M/_QFC_B$&(_Z"E_X"_\`,/[;I_RL/^&A+K_H4X/_``:G_P",T?\`$(,1_P!!
M2_\``7_F']MT_P"5A_PT)=?]"G!_X-3_`/&:/^(08C_H*7_@+_S#^VZ?\K#_
M`(:$NO\`H4X/_!J?_C-'_$(,1_T%+_P%_P"8?VW3_E8?\-"77_0IP?\`@U/_
M`,9H_P"(08C_`*"E_P"`O_,/[;I_RL/^&A+K_H4X/_!J?_C-'_$(,1_T%+_P
M%_YA_;=/^5A_PT)=?]"G!_X-3_\`&:/^(08C_H*7_@+_`,P_MNG_`"L/^&A+
MK_H4X/\`P:G_`.,T?\0@Q'_04O\`P%_YA_;=/^5A_P`-"77_`$*<'_@U/_QF
MC_B$&(_Z"E_X"_\`,/[;I_RL/^&A+K_H4X/_``:G_P",T?\`$(,1_P!!2_\`
M`7_F']MT_P"5A_PT)=?]"G!_X-3_`/&:/^(08C_H*7_@+_S#^VZ?\K#_`(:$
MNO\`H4X/_!J?_C-'_$(,1_T%+_P%_P"8?VW3_E8?\-"77_0IP?\`@U/_`,9H
M_P"(08C_`*"E_P"`O_,/[;I_RL/^&A+K_H4X/_!J?_C-'_$(,1_T%+_P%_YA
M_;=/^5G(?$SXGW'CK2+'3Y-$BT];>[%R95O3,6Q&Z;=OEK_?SG/:OIN$^`*V
M18_ZW*LIKE:M9K>WF^QRXW,X8BDZ:31Y]7Z<>*%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0!);0375S%;VT4DT\KA(XXU+,[$X``'))/&*3:BKO8:3;LC:U.>
M'2]*.CV4L<ES(Y;4+F!@4D^Z4@5A]Y$*EBP.UF(^\(T<X03G+VDMNB_7U?WI
M=KM%R:BN5?/_`"_K]$96G7MQIUY'=6<GES)G!*A@000RLIR&4@D%2"""000:
MUG!37+(B,G%W1T^DO<W%RUUX"?4]-U@IMFT^SN7,DJD@DP%<,R`CF,[F4*&W
M.`Y3FJ**7+B+./=K\^E_/1=++2^T;MWI:/M_E_E^92_X2I[GG6M(TG5I!TEN
M(6BD)/WF=X&C:1CP2TA8YYR"3F_JR7P2<?Q_.]OE8GVM_B2?]>5OQ#R?"M[_
M`*FYU;2)#\BQW$:7<>>SO*OELJ\\A8W(`R-Q.T%Z\=TI?A^&OYKY;A:F^Z_'
M_+\@_P"$/U.Y^;0_(UV,_=_LQ_-D([L8,"95!XW,@&<<D,I)]:@OXGN^NGX[
M?<P]C)_#KZ?Y;F!<P36MS+;W,4D,\3E)(Y%*LC`X((/((/&*Z$U)76QFTT[,
MCIB"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@"2V
M@FNKF*WMHI)IY7"1QQJ69V)P``.22>,4FU%7>PTFW9&U<SPZ';2V6GRQS:C*
MACN[R)@RQJ1AH8F'!!&0\@^]RJ_)N,N"3JOFEMT7ZO\`1=-WKM;:@K+?^OZ_
MX&^#709A0`4`='YUIXDYO[G[)KS?*+AP!#>MV,SDCRY.QDP58D%]A#R-S6E1
M^%7C^*].Z\NG2^B6MU/??\_7^O7N8%S!-:W,MO<Q20SQ.4DCD4JR,#@@@\@@
M\8KH34E=;&;33LR.F(WK;Q=K4-M%;RW<=[!"@2"/4;>.\6!0,8C$RL(Q@`$+
MC.!GH,<[PU)NZ5F^S:OZVM?YFBJS2M>_KK^9+]N\.:A\M[I4^DR'@3:9*TL:
M@<Y,,S%F8\C(E4`8."0=RY*T/AES>NGXK_)_Y/FIO=6]/\G_`)A_PCUI??-H
M6N6%QGGR+]Q8S*O0EC(?*Z]`LK,00<#Y@I[>4?XD6O35?AK]Z0>S3^%_?I_P
M/Q,W6-#U/1O).IV,]O'/GR)63]W.!C+1N/E=>0=RD@@@@X(K2G6A4OR.]OP]
M>Q,H2CNC.K4@*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`.
MC/\`Q2\4T1YUZ>)X)4/2QC=2CHP[RLK,I!XC!(/[P_NN;^,T_LI_?;]/S]-]
M?X?K^7_!_+UVYRNDR"@`H`*`"@#>MM3AU2VBT_77C01H$MM0$0\R#`PHD*C=
M)'@!<'+(%79P"C\[IN#YZ?S7?T[/\'U[K124E:7W_P!?TNG8SM6TZ;3+E8Y6
MCEBD3S()XB3'/&20'4D`XR",$`@@JP#`@:4ZBFKK_AOZ_P""M"91<64JT)"@
M`H`T='UW5]%\[^QM4O\`3_.QYGV6X>+?C.,[2,XR?S-95*-.I;GBGZHN,Y1^
M%V-+_A(;2^^77=#L+C/'GV""QF5>H"B,>5UZEHF8@D9'RE<_82C_``Y->NJ_
M'7[FBO:)_$ONT_X'X!]A\.:A\UEJL^DR'DPZG$TL:@<8$T*EF8\'!B4`9&20
M-QSUH?%'F]-/P?\`F_\`(Y:;V=O7_-?Y!_PAFMS_`#:3:?VS">1)I3"ZPI^Z
M75,O%D=!(JMP>,@@'UNDOC?+ZZ?GH_E</8S?PJ_IK_7S.<KI,@H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@#HQ_Q2\4,HYUZ>))XG'2QC=0Z.I[RLK*P
M(XC!!'[P_NN;^,VOLI_?;]/S]-]?X?K^7_!_+UVYRNDR"@`H`*`"@`H`*`-;
M2=76UMFLM0LX]0TUWW^2[LC0L0`7B<?<<@`<AE.%+*VU<8U*7,^:+L_ZT?E^
M/9J[+C.RLU=!JVC-:6RWUG/'>:7(^V.X0KN4D$A98P28GX;AN#M8J74;J*=7
MF?+)6?\`6SZK^G9Z!*%E=:HR:V("@`H`*`"@`H`Z/_A,-3N?EUSR-=C/WO[3
M3S9".RB?(F50>=JN!G/!#,#S?58+^'[OII^&WWHU]M)_%KZ_Y[A]H\,:AS=6
M=_HTQY9[`BZA..`JQ2LKKD<EC*W(.%P1M.6O#9J7KH_O6GX+_,O3>ZMZ:_U]
MX?\`",?;?FT#5+#4\\BW\SR+D9^ZOE28WR'IMB,G(QDY7)]8Y?XD6OQ7WK9>
M;M^8>RO\+O\`G_7I<R=6TG4='N5M]7L+NPG9-ZQW4+1,5R1D!@#C((S[&M:=
M2%17@TUY$2A*+M)6*5:$A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!O6T$.AVT5[J$4
M<VHRH)+2SE4,L:D96:53P01@I&?O<,WR;1+SMNJ^6.W5_HOU?39:[:)*"N]_
MZ_K_`(&^+<SS75S+<7,LDT\KEY))&+,[$Y))/))/.:W2459;$-MN[(Z8@H`*
M`"@`H`*`"@`H`NZ3J,VF7+21+'+%(GESP2@F.>,D$HP!!QD`Y!!!`92&`(SJ
M4U-6?_#?U_P'H5&3BR[J.GVES9R:CH(G%I%@7-K/())K;)`#%@JAXV)`W!1M
M8[6`RC/$)R3Y*F_1]'_D_+MJNMJE%-<T?Z_K^O/%K<S"@`H`*`"@`H`*`"@#
M6TGQ%JVE6S6ME>R"Q=][V<H$MO(V`,M"X*,>!R0<$`]0*QJ4*<W>2U[[/[UJ
M7&I**LGH7?[=TR^_Y#F@0/)U:XTR3[%(YZ`%=K0A<=EC4D@'.=VZ/8SC_#G]
M^O\`D_O;*YXOXH_=I_P/P#^RM$U#G2=:^RS-TM=5B,>6/W429-R-@\%Y!$O0
M\`G:>TJP^.-_-?Y/7Y+F_P`SE@_A?W_Y_P"=BMJ/A?6+"SDO)+/S["/'F7EG
M*ES!&20`K2Q%D5LD?*3GYAQR,U#$4Y/E3L^ST?W/44J4DKVT^\Q:W,PH`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@#>TR"'2]*&L7L4<ES(X73[:=04D^\'G93]Y$*A0I&UF)^\(W0
M\\VYR]G';J_T]7]Z7:Z9I%**YG\O\_Z_1F+<SS75S+<7,LDT\KEY))&+,[$Y
M))/))/.:W2459;$-MN[(Z8@H`*`"@`H`*`"@`H`*`"@"SIU]=Z;>1W>G74]I
M=QYV302%'7((.&'(X)'XU$X1FN62NAQDXNZ9M?9K3Q'\U@OV;7GZV*1!8;IN
MYA(/RR-VBV[20=A!9(JQYI4?BUCWZKU\O/[^K-+*>V_];?Y?=V.<KI,@H`*`
M"@`H`*`"@`H`*`"@"SIU]=Z;>1W>G74]I=QYV302%'7((.&'(X)'XU$X1FN6
M2NAQDXNZ9M?\);=W7&NVEAKG?S+^(^<S=BT\925\#@!G*XQQPN,?JT8_PVX^
MFWW.Z^Y&GM6_B5_7_/<-GA6^^2%]6T>3HK7#)>QN3T+E5C:-1W*K(2#P,C#%
MZ\=[2_#_`#O]Z#]V^Z_'_+]0_P"$2N[KG0KNPUSMY=A*?.9NX6"0)*^!R2J%
M<9YX;!]9C'^(G'UV^]77WL/9-_"[^G^6YBZC8W>FWDEIJ-K/:7<>-\,\91UR
M`1E3R."#^-;0G&:YHNZ,Y1<79HK58@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`BNI#%:S2*`61"PSTX%8UZCITI36Z39=.*E-1?5G
MNO\`PSW=?]#9!_X*C_\`'J_$?^(OXC_H%7_@3_R/H?[$I_S,/^&>[K_H;(/_
M``5'_P"/4?\`$7\1_P!`J_\``G_D']B4_P"9A_PSW=?]#9!_X*C_`/'J/^(O
MXC_H%7_@3_R#^Q*?\S#_`(9[NO\`H;(/_!4?_CU'_$7\1_T"K_P)_P"0?V)3
M_F8?\,]W7_0V0?\`@J/_`,>H_P"(OXC_`*!5_P"!/_(/[$I_S,LZ9\`3;WL<
MM]XBANX$!)@_L]HP[8.T,1-G;NQD#!(R`RDA@GXO8AJRPR7_`&\_\AK)*2?Q
M,34?@1J6HWDEU>>,())GQDC2=H```5543`*H``"@``````5,/%RM!<L<*O\`
MP)_Y#EDM.3NY/\"O_P`,]W7_`$-D'_@J/_QZK_XB_B/^@5?^!/\`R)_L2G_,
MP_X9[NO^AL@_\%1_^/4?\1?Q'_0*O_`G_D']B4_YF'_#/=U_T-D'_@J/_P`>
MH_XB_B/^@5?^!/\`R#^Q*?\`,P_X9[NO^AL@_P#!4?\`X]1_Q%_$?]`J_P#`
MG_D']B4_YF<A\3/AA<>!=(L=0DUN+4%N+L6QB6R,)7,;ONW>8W]S&,=Z^FX3
MX_K9[C_JDJ*@N5N]V]K>2[G+C<LAAZ3J)MGGU?IQXH4`:_@_0I/$_BO3-$BN
MTLVO7=?/:+S0FV)W^[N7.=F.O>OG.*<[GDN72QL(*332L]-W;<[,#AHXBKR2
M=M#UG_AGNZ_Z&R#_`,%1_P#CU?EW_$7\1_T"K_P)_P"1[']B4_YF'_#/=U_T
M-D'_`(*C_P#'J/\`B+^(_P"@5?\`@3_R#^Q*?\S#_AGNZ_Z&R#_P5'_X]1_Q
M%_$?]`J_\"?^0?V)3_F8?\,]W7_0V0?^"H__`!ZC_B+^(_Z!5_X$_P#(/[$I
M_P`S#_AGNZ_Z&R#_`,%1_P#CU'_$7\1_T"K_`,"?^0?V)3_F9K:K\%+O5[0-
MJ'B6UDU17&+U-*"-*F#N$H$O[QRV#YA.[EMQ?*[,J?BU6IW4<,K=N9Z>FFGI
MMV1<LGIRWD_P,G_AGNZ_Z&R#_P`%1_\`CU:_\1?Q'_0*O_`G_D1_8E/^9A_P
MSW=?]#9!_P""H_\`QZC_`(B_B/\`H%7_`($_\@_L2G_,P_X9[NO^AL@_\%1_
M^/4?\1?Q'_0*O_`G_D']B4_YF'_#/=U_T-D'_@J/_P`>H_XB_B/^@5?^!/\`
MR#^Q*?\`,P_X9[NO^AL@_P#!4?\`X]1_Q%_$?]`J_P#`G_D']B4_YF<]X^^$
M%SX0\*7>MMXAAO5MGB4P#3S&6WRHGWO-.,;\]#TKU\@\2Z^:9C2P3H**F[7N
MW;1O:R[&.(RFG2I2FI/1'F%?KIX(4`6=+LGU+5]-T^.586O;N&V$K)O">9(J
M;MN1G&[.,BO+SK'RR_`5<7%7<(MV[V.C"TE6JQIOJ>S_`/#/=U_T-D'_`(*C
M_P#'J_'_`/B+^(_Z!5_X$_\`(]S^Q*?\S#_AGNZ_Z&R#_P`%1_\`CU'_`!%_
M$?\`0*O_``)_Y!_8E/\`F8?\,]W7_0V0?^"H_P#QZC_B+^(_Z!5_X$_\@_L2
MG_,P_P"&>[K_`*&R#_P5'_X]1_Q%_$?]`J_\"?\`D']B4_YF;6G?"/Q%86<=
MG'XX@GL(\^79WFC+<P1DDDLL4LK(K9)^8#/S'GDYPGXKU)/F>$2?=2:?WI7-
M(Y3%*W.[?)CK_P"!]E>V$R"\L["]&/(EL;681CGYO,26>0OP,#:R8)).[@"J
M?BYB8WOAT_67^44*634GL[&'_P`,]W7_`$-D'_@J/_QZM?\`B+^(_P"@5?\`
M@3_R(_L2G_,P_P"&>[K_`*&R#_P5'_X]1_Q%_$?]`J_\"?\`D']B4_YF'_#/
M=U_T-D'_`(*C_P#'J/\`B+^(_P"@5?\`@3_R#^Q*?\S#_AGNZ_Z&R#_P5'_X
M]1_Q%_$?]`J_\"?^0?V)3_F8?\,]W7_0V0?^"H__`!ZC_B+^(_Z!5_X$_P#(
M/[$I_P`S,SQ/\#[K0_#6K:M_PDT$_P!@M);GRO[-*^9L0MMSYQQG&,X-=."\
M5\1B<13H?5DN:25^9Z7=NPI9+32;YF>15^UGS@4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0!7U#_CPN?^N3?R-<V,_W>I_A?Y&M#^)'U1][U_&)]T%`!0`4
M`%`!0`4`%`!0`4`%`'CO[3__`")>C?\`873_`-$3U^D>%G_(\_[A2_-'F9M_
MNS]4?.5?T>?)A0!VGP5_Y*SX9_ZZS_\`I--7P'B9_P`B"I_BC_Z4CU<G_P!X
M^3/KNOYG/J@H`*`"@`H`*`"@`H`*`"@`H`\[_:!_Y)-K/_76U_\`2F*OK>!/
M^1_AO\3_`/26<F._W>?H?*E?U4?%A0!K>#_^1T\-?]A>S_\`1Z5\WQ?_`,B/
M%?\`7I_D=N7?[S#U/MFOY,/L@H`*`"@`H`*`"@`H`*`"@`H`YGXG?\DU\6?]
M@BZ_]$M7I9-_R,</_P!?8_\`I2(J?`_0^-J_L4^#"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`*^H?\>%S_`-<F_D:YL9_N]3_"_P`C6A_$CZH^]Z_C$^Z"
M@`H`*`"@`H`*`"@`H`*`"@#QW]I__D2]&_["Z?\`HB>OTCPL_P"1Y_W"E^:/
M,S;_`'9^J/G*OZ//DPH`[3X*_P#)6?#/_76?_P!)IJ^`\3/^1!4_Q1_]*1ZN
M3_[Q\F?7=?S.?5!0`4`%`!0`4`%`!0`4`%`!0!YW^T#_`,DFUG_KK:_^E,5?
M6\"?\C_#?XG_`.DLY,=_N\_0^5*_JH^+"@#6\'_\CIX:_P"PO9_^CTKYOB__
M`)$>*_Z]/\CMR[_>8>I]LU_)A]D%`!0`4`%`!0`4`%`!0`4`%`',_$[_`))K
MXL_[!%U_Z):O2R;_`)&.'_Z^Q_\`2D14^!^A\;5_8I\&%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`5]0_X\+G_`*Y-_(US8S_=ZG^%_D:T/XD?5'WO7\8G
MW04`%`!0!A>*/$*:*UC:P6[7FJZC(8K*T5]OF,!EF9N=J*.6;!P.@)(![L%@
M7B.:<GRP@KR?;M9=6^BT]4M29R4(\S]/5]$,TW6-5.LP:;K&C):O+!),MS:W
M7GP?*4&S<41@YWYP5Q@<$\@.MA:'L76HU+V:5FK/6^NCDK:=[]TM+J\E:ZW=
MOPO^@OA+7YM>75/M.FRZ=+8WK6IAEE5V("JP8["5&0XX!/UHQ^"CAG#EGS*4
M+W2:ZM6UUZ=EZ`IWG*'9KYW2?ZF_7`6%`!0`4`>._M/_`/(EZ-_V%T_]$3U^
MD>%G_(\_[A2_-'F9M_NS]4?.5?T>?)A0!VGP5_Y*SX9_ZZS_`/I--7P'B9_R
M(*G^*/\`Z4CU<G_WCY,^NZ_F<^J"@`H`*`,+Q1XA316L;6"W:\U749#%96BO
MM\Q@,LS-SM11RS8.!T!)`/=@L"\1S3D^6$%>3[=K+JWT6GJEJ3.2A'F?IZOH
MB"UUO6(]16QU70-DSVTMPDEC=B>)]A0",,ZQD.=W\0"\?>/.+GA,.Z?M*573
MF2]Y6>M];)RT5NC;\MKBYM.;J[?AU^[I<L^#=;D\1>'X-2FLFL99))8WMVD$
MAC*2,A!8<'[O;]>M9YAA%A*[I1ES)).]K7ND]OF33GSWTM9M?<[&W7$:!0`4
M`%`'G?[0/_))M9_ZZVO_`*4Q5];P)_R/\-_B?_I+.3'?[O/T/E2OZJ/BPH`U
MO!__`".GAK_L+V?_`*/2OF^+_P#D1XK_`*]/\CMR[_>8>I]LU_)A]D%`!0!A
M^)?$$>C26%I%`UWJFHR-%9VJL%\Q@NYF9C]U%'+-@D=@20#VX/!/$*4V^6$%
M>3[=%9=6^BT\VEJ*4E%<S[V^9FGQ=)I6H+9^+[.WTMY8)9[>>WNC<0R+&NZ1
M=Q1&#A<MC;@@<$D$#I_LQ5Z?M,')SLTFFN5J[LGO)6;TO??==1)RYDFMW;Y]
MOGT_X:][3O$BWWBR[T:.SD2*&RAO$NF<8F60L!M4<@#;U.#G/&,$X5<`Z>%C
MB'+5S<;=K6Z_/I?UZ)<Z?+;:2;_+_/\`KIT%<!84`%`!0`4`<S\3O^2:^+/^
MP1=?^B6KTLF_Y&.'_P"OL?\`TI$5/@?H?&U?V*?!A0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`%?4/^/"Y_ZY-_(US8S_=ZG^%_D:T/XD?5'WO7\8GW04`%
M`!0!Q7C:RO+7Q/X>\36EK<7UOIJSPW=M;C=+Y<JK^\1/XBI094<D'@$\5[66
MU:<\-6P<Y*+GRM-[7C?1OI>^^U]S.K%N,6MXN]N^C3^?;YKJ;NDZVNK3XLK*
M_2V4'S)KRUEM<'L%2559OJ!CWSQ7!7PCH1]^2OT2:E][BVE^?D-3N[)?U_7_
M``>E\+X=W?VC4?%3&TU&W6;4C/$;NQFMQ(ABC4%3(HSRC<#D=^HKNS:GR4Z"
MYHNU.SM*+L[M]&^Z(2:K3\[?@DOS.UKQC8*`"@`H`\=_:?\`^1+T;_L+I_Z(
MGK](\+/^1Y_W"E^:/,S;_=GZH^<J_H\^3"@#M/@K_P`E9\,_]=9__2::O@/$
MS_D05/\`%'_TI'JY/_O'R9]=U_,Y]4%`!0`4`<5XVLKRU\3^'O$UI:W%];Z:
ML\-W;6XW2^7*J_O$3^(J4&5')!X!/%>UEM6G/#5L'.2BY\K3>UXWT;Z7OOM?
M<SJQ;C%K>+O;OHT_GV^:ZFS8^(8[X2S6MCJ0LX$9I9;BQF@;(&=J1.@=S]%Q
MV!)XKBJ8)TK1E*/,WHE*+^]IV7S?X:E1ES-)?Y?G_7>VE\KX52L_A39+:WUK
M*EW<LT=W:20-AYG=2`ZC(VL.1D=NH-=6>12Q5U)-<L=FGM%)[-]49TMY^<F_
MDV['8UY!L%`!0`4`>=_M`_\`))M9_P"NMK_Z4Q5];P)_R/\`#?XG_P"DLY,=
M_N\_0^5*_JH^+"@#6\'_`/(Z>&O^PO9_^CTKYOB__D1XK_KT_P`CMR[_`'F'
MJ?;-?R8?9!0`4`<9XTL;N#Q+X>\2VEO+=PZ8)XKNWA4M)Y4JK\Z+_$5*#*C)
M()P"<`^QEU:G+#UL)-\KGRM-[7BWHWTO??9/?34BJFXIK>+OZZ-/Y]O^"<I\
M4M.G^(FFK'INE7S6.FP7-P6O;.2!IYS"R11QQR!7)RP;=MQP`"3G'JY+7CE5
M2]6HN:<HK22=H\R;;<6ULK6O?NK;O2HXPZ7N_ET^?Y;]+\YJNDZ==PZVMEX;
MU5((O#206<*Z+=1(+L/(3M3RP-X9U(;&1EB#]XUZ-#$UH.DYUHW>(;D^>#?+
M9;OF>EDU;T36QC2C!QA":TY7?3TW[[??;K8Z+Q;I1\0:E8R^(#XA32[C38OL
MILM+$[0W`+>9N5X'D@D(9,/\OW3D@J*\_`XCZK3DL/R<ZJ._-.UXZ6LU.,9+
M1W6N^VI/O.G#GVY==+Z^:U;TVT?7OKH_#K0[.+QIXGNKK3=2:ZCN8WM;K5(9
M78?N520QR2`KDMN4E#@@`#Y0M<V;8RI+!T(1G&SB[J+2^TVKI:[6:YEO?K<T
M4??L[_"M^^ORNK_+6W4].KYHV"@`H`YGXG?\DU\6?]@BZ_\`1+5Z63?\C'#_
M`/7V/_I2(J?`_0^-J_L4^#"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`*^H
M?\>%S_UR;^1KFQG^[U/\+_(UH?Q(^J/O>OXQ/NCG=9\8Z/H^K+IMZ=0^VM&9
M5C@TRYGW(,;F!CC((&X9P>,C->AA\KQ&(I>VAR\M[:RBM?FT]>G<4I*+2?78
MUM'U.RUG3+?4-+N8KJRN%WQ31G(8?X]B.H/%<N(P]7#U'2JQM)/5,FG4C4CS
M1>A<K$LS==UW3-!MX9]7O(K6.>9((M^29)&.%50.2?IT&3T!KIPV#K8J3C1C
M=I-OR2ZL4I*,7*6R-*N884`5)]1M8-2M-/EEVW=TDCPQ[2=RIMW'.,#&Y>OK
M6L:%25.55+W8M7^=[?DP>BOYV_-_HRW60!0`4`>._M/_`/(EZ-_V%T_]$3U^
MD>%G_(\_[A2_-'F9M_NS]4?.5?T>?)A0!VGP5_Y*SX9_ZZS_`/I--7P'B9_R
M(*G^*/\`Z4CU<G_WCY,^NZ_F<^J"@`H`S/$6MV'AW2IM2U:26*RAYDDC@DEV
M#U(120/?&!73A,)5Q=54:*O)[:I?FU]P/1-]BEJ/B_2=.33&O#J"?VD=MLHT
MVX9G;&=I`0E6P"<-@X!/8UM2RS$57-0M[F_O1^_?5>:NC-U8J'/T]'_7IWZ%
M.;X@:!%=BV+:JTS!RHCT>[<.$(#LI$1#*"1DC(Y'K6T<EQ<H\_NVT^W!6OM>
M\M&^SU*<TG;SM\^QI7WB?2;(6?FSRNUW'YT206TLS>7Q\[*BDJO(RS``9Y-<
MU/+Z]3FLOA=G=I:]DVU=^2NQ*I%Q4EUV[OY;FEI][;:C917=A/'<6LHW1RQM
ME7'J#W'O7/5I3I3<*BLUNBHR4E=%BLQA0`4`>=_M`_\`))M9_P"NMK_Z4Q5]
M;P)_R/\`#?XG_P"DLY,=_N\_0^5*_JH^+"@#6\'_`/(Z>&O^PO9_^CTKYOB_
M_D1XK_KT_P`CMR[_`'F'J?;-?R8?9!0!D:UXBTW1IX8+V69KJ8%H[>UMI+B5
ME'5O+C5FVC@%L8R0,\BNO#8&MB(N4$K+JVHKTO)I7\KW%*2BKLB3Q9H3:1?:
MH=3MTL+%MEU+(2GD/@'8P/(;YE&TC.3C&>*IY;BE5C1Y'S2V7==UY:;[6UV"
M+4G9?UZ]C3T^]M]0T^VOK23S+6XB66)\%=R,,@X/(X/>N:K2G2J.G-6:=GZH
M5.:J14H[,KZ%K>G:_8M>:/=QW=H)7B\V/.TLIPV#W&1U'![5IBL)6PL_9UH\
MLK)V]1J2;:71FC7.,*`"@#-TC7=,UBXU"#2[R*ZDL)O(N?+R1')@$KGH2,\X
MS@\'D5TU\'6P\82JQLI*ZOU7<7,N9QZHTJYAG,_$[_DFOBS_`+!%U_Z):O2R
M;_D8X?\`Z^Q_]*1%3X'Z'QM7]BGP84`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0!7U#_`(\+G_KDW\C7-C/]WJ?X7^1K0_B1]4?>]?QB?='GOBZ34HOBEX;;
M1[6SNKG^R[T;+JY:!`N^#)W*CG/3C'XU]!@(T7EE95I-+VD-DF]I=&X_F95M
MZ?\`B?Y(QM&T;Q%X=UKP_P"&X_$$=M;:A#>WEV;.S0LLWF*Y$;2;@%!DP,KT
M#9Y(V]F(Q6#Q=&KBW2NX.$5>3VLUJHVUTN[/>UM$[JTX^\]Y3=_N?^7WZ[:%
ML^)=7DL+G7H-2D\RTUG^SI=$,46PKYXB`SM\SS"K+(#NQR/EQ67U##J<<-*&
MDJ7,IW=_AYN_+RIIQVOYW%-M<^MN7\?7_%LK6UMOUQ_%U[J'B3PQ?ZE_;4UO
M%::]%9OI444)5!'=H@WDJ7#GA^&`P5&.YZ\!2I83$PH^S3<J+ES-RN[P;TUM
M9?#M>]]1UKN-57M:+^>GY/I:VA>L/$6N1'0Q-K5Q<R'Q#=Z;-$\,`-S$@E*[
MML8(8>6O*[>IR#Q6%7`X67M>6FDO81FG>6C?+>UWMJ][E233DN;:<5TV?+_F
MPU:YUC4_A?J.O2>)I$CU#1IY&L%MX@(9=FXI$VT.-H5T8-N)Y(*D4Z%/#T<R
MAAE1UA5BN:[U5[7:O;6Z:M9>J8\-*4YQG>VK5OZZJVO3?0V-/OM6TK7/"FF?
MVA)?6-QI5Q-(DL,8EDD3RRN64`8`?:`%'3DMGCCJT</7HUZW)RR52*T;LD[W
MT;;Z7=V_)(SH+]U2UW:7RY?Z_P`^^?I/B/6[C3?#&M6^K"Z;77:&73Y+>,Q6
M;^6[$IM"R'RVC*L&8YY^Z<5T5\#AH5*^'E3M[)74DW>2NEK>\?>3NK)6\T.$
MG+WWI[UK?.UN][:_)Z6V/A]X@UZ[N_"3ZSJOVU=:TN>>6(6T<:1O&T>UEVC.
M2'(.203T"TLUP6%A#$*C3Y?9U(I.[;:=[WOINM-+]VPO*ZE?[4E;[_GT^[SU
M/4J^8-CQW]I__D2]&_["Z?\`HB>OTCPL_P"1Y_W"E^:/,S;_`'9^J/G*OZ//
MDPH`[3X*_P#)6?#/_76?_P!)IJ^`\3/^1!4_Q1_]*1ZN3_[Q\F?7=?S.?5!0
M`4`<=\8O^26>*?\`L'R_^@U['#__`",Z'^-#Z2_PO\F8_B&#7HM5\&G5]4TJ
MZMSJZ;8[73I('W>1-@[FF<$8SQC\:Z\)/"RI8GV,))^R>KDFOBCT4(_F<T.;
MV&^GN_\`I4?,VM318_B9X:2-55%TV]`51@#Y[>N.BV\NK-_\_(?E,WJ?#'_'
M^C*/BK3)YO%5O+X3UBWTSQ-:V'RVES&'M[VVW'",@(8!7`^=>5#XYW5M@<1&
M.%:Q=-SI2GNM)1E;=/;5='O;R)J*ZBKV>MOPNOR_/H;W@766U_PQ:ZA)9K9R
MNTB20HP9`Z2,C%6'WE)4D'N#7#F>%6%Q,J2ES)6L^MFDU==&D[-"IR;NGNFT
M[;73U_KN;]<!H%`!0!YW^T#_`,DFUG_KK:_^E,5?6\"?\C_#?XG_`.DLY,=_
MN\_0^5*_JH^+"@#6\'_\CIX:_P"PO9_^CTKYOB__`)$>*_Z]/\CMR[_>8>I]
MLU_)A]D%`'`>&&2V^*_C"+42J7]VEM)8[SS+;+'@A,]0K[L@="03UKWL:G/*
M\.Z?PQ<E+RDWU]5:US*?\=-[<J2^]W7KU]+'2W3V!LM=>S,?F[6-TZ#@R",+
MR>A(55!],#->;!5>>DI[:6]+W^Z[9T4VG52ZJWYW_6_S]#&\*ZC=:?X`\+&T
MT;4-4+Z=!N%H\"^7B->OFR)U]L].U=F-H0JXZOSU%"TWOS:ZO^6,OQL<6#TP
MT'Y(X_1;K5M)T>^U2RU-@/\`A)IX$TL01E;D2711E+$%]^"S`JR@;>0<$GV,
M13H5ZT:,X?\`,.GS7>EH73MM;9---N^C6AI4;YJLKVM^=E9?/1*W5[LOQ>(]
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MD`A%5>!QP!TKGSBI"IAL+*$%%<CT5[?$^[;_`!+LU6=W?W8_J=]7@FAS/Q._
MY)KXL_[!%U_Z):O2R;_D8X?_`*^Q_P#2D14^!^A\;5_8I\&%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`5]0_X\+G_KDW\C7-C/]WJ?X7^1K0_B1]4?>]?Q
MB?=&5<>'=$N=6CU2XT?3I=3C(*7<EJC2J1TPY&1CMS75#'8F%)T8U)*#Z7=O
MNV)E",K<RO8FN=&TNZU2WU*YTVRFU&W&V&ZD@5I8QSPKD9'4]#W-1#%5X4W1
MC-J+W5W9^JV&TI63Z#6T32FU@:LVF6)U55VB\-NGG`8QC?C=C''6G];KJE[#
MG?)VN[?=L#BI--K8J:GX1\-ZK>O>:IX?T>]NWP'GN+*.1VP,#+,"3@`"M:.9
MXRA!4Z5:48KHI-+[DPE%2W5QQ\*^'C>_;#H.D_:_,67S_L<>_>OW6W8SD=CV
MI?VCB^3V?M9<MFK<SM9[JU^O47)'MTL2P>'=$@O+N[@T?3HKJ\5EN9DM4#SA
MCE@[`98$]<]:F6.Q,H1A*I)J.RN[*VUNUAV7-S]>XRT\+^'[.>TGM-"TJ":S
M4K;216D:M`"22$('R@EF/'J?6G4S#%U(RC.K)J6]Y/7UUUV7W"Y(VM8>GAW1
M$N[RZ31].6YO4:.ZF%J@>=6^\KG&6![@YS2>.Q+C&#J2M%W2N[*W;M\AV7-S
M]>_4BL_"OAZQN;6XLM!TFWN+4$02Q6<:-""22%(&5SN;IZGUJJF8XNI&49U9
M-2W3DW?UUUV0N2/8VJXRCQW]I_\`Y$O1O^PNG_HB>OTCPL_Y'G_<*7YH\S-O
M]V?JCYRK^CSY,*`.T^"O_)6?#/\`UUG_`/2::O@/$S_D05/\4?\`TI'JY/\`
M[Q\F?7=?S.?5!0`4`4M6TO3]8M/LNK6-I?6VX-Y-U"LB9'0X8$9K:AB*M"7/
M1DXONFT_P!ZJQ3N?"OAZZBLXKK0=)FCLUVVR26<;"`>B`CY1P.E;0S'%P<G"
MK).6_O/7UUU(=.#CRM:=O4GN-!TBYU:+5+C2K"74X@!'=R6Z-*F.F'(R.I[]
MZSAC,1"DZ,:C4'NKNWW;#E%2M=7'ZMHVEZQ#Y.KZ;97\60VRZ@65<C.#A@>F
MYOS/K2H8JOAWS49N+\FU^7H5T:+<$4=O!'#!&D4,:A41%`55`P``.@K&4I2D
MY2=VQ1BHI)*R1)2&%`!0!YW^T#_R2;6?^NMK_P"E,5?6\"?\C_#?XG_Z2SDQ
MW^[S]#Y4K^JCXL*`-;P?_P`CIX:_["]G_P"CTKYOB_\`Y$>*_P"O3_([<N_W
MF'J?;-?R8?9!0!GZQHNEZW`D.LZ;9:A#&VY$NX%E56QC(#`X-;X?%5\/)RH3
M<6^S:_(32:LQ9-&TN72!I4FFV3Z6%""S:!3#M!R!LQMP"!QBA8JNJOMU-\_>
M[O\`?N$4HJRT)-,TZQTJS2TTNSMK*T0DK#;1+&BY.3A5`'6IK5ZM>;G5DY2[
MMW?WL%%1V1!%H.D0ZO)JL.E6$>J2##WBVZ"9N,<OC<>`.]7+&8B5)4'4;@NE
MW;[MA.*;YFM2O-X3\.SWDEW/H&DR74D@E>9[.,NSCHQ8C)(]>M:1S+&1@H1J
MR22M;F=K=M]AN*;NT2Z?X<T33K6ZMM/T;3;2WNQMN(H+5$688(PX`PW!(Y]:
MFKCL36E&=2I*3CLVVVO3L$4HRYUOW$B\-Z'#I$NE1:-IJ:7*VZ2S6U00N<@Y
M*8P3D#MV%$L=BI557=23FNMW?[]Q1C&-^56O_P`-^0NC>'=$T-Y7T71]-TYY
M0!(UI:I$7`Z`[0,T8C'8G$I*O4E*W=M_F"A%.Z1JURE',_$[_DFOBS_L$77_
M`*):O2R;_D8X?_K['_TI$5/@?H?&U?V*?!A0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`%`%?4/^/"Y_ZY-_(US8S_`'>I_A?Y&M#^)'U1][U_&)]T>=>,M#5/
M$&@2-J>M@ZEJICG2'5;F%/+\B5@BHD@"@%%.0`3@^M?0Y?BVZ%5<D?<IW5X1
M;OS15VW%M[O<BI'W7+SC^B?W_J:NM^)=*\`Z796FI7LMS-(7\A+B\C661`V3
MF2>10VT,HY;)]^:Y<-@*^:5)3I1LE:]HNR?I"+:O9O160:4XZOK_`,'KV\QN
MF_$'3M6BMKC1+'5-4L9&B2:ZM(5=;9I,$*Z[@Y(#`MM5MH.3BG6R6M0;C7E&
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M?"KDJ@PJD_PJ`#TKMS#!1JUX^R2A%4H2>]E=+5[O=^;;"3M.;>RDOQ2LOZ]7
MU9K'QO9_8\C3]1.IB\%B=+VQBX$Q4OMR7\O&P%]V_:1T.>*Y/[)J<_QQY.7F
MYM>6U[=N;?2W+>_2VH<^CNK6M^+LOZ]>PRS\<1W-A9WAT+5X8;G4#I^93;CR
MG#["SXE.%W@KQDY'3E<U4RAPG*G[6+:AS:<VJM?3W=[:]K=='9.I92;6SM^G
M^7WWV-_2-2&IK=LEK<0);W,EN&E*8E*'!9=K'Y<@CG!X/%>?B,/['E3DG>*>
ME]+]'=+7TNO,N_O-=O\`ASRW]I__`)$O1O\`L+I_Z(GK]!\+/^1Y_P!PI?FC
MS<V_W9^J/G*OZ//DPH`[3X*_\E9\,_\`76?_`-)IJ^`\3/\`D05/\4?_`$I'
MJY/_`+Q\F?7=?S.?5'FNH>'(T\<Z-82:KK[17=G>3W&S6;J,-(KQ;2`LF%`W
MM@#`_*OI*6.;P52JJ<+QE!+W(/1J5]XZWLM7J1.*5I=YO[K-V-3Q-X\T7P2E
MKI^KW9N+N*W5Y?W\*2;!D>85DD4N25;A-S>W(SRX/)\3F+E5HQM%RTTDU?M[
MJ:5K[NR\Q75**3=W;YO[[?U\S0E\86IO1#I^GZEJ4"R11SW5E$KQV[2!2H8;
M@Y^5U8[5;:#DXKGCE<^3FJ3C!V;2DVF[7O;2VZ:5VKO83JKEO'71/3L]G^MM
M[=-CEO!'C`V$5Q9:T=9OF?5[ZV2_DAWJ61I'"87#$[$.`B%<C;P>*]3,LK]J
MU4H<L?W4'RWMNDKZZ;O7FE?KMJ5)M59+IS)>ETK?CI^+WN=#X8\>:?XAGL$M
M[+4K6*^M'N[::[A5%D5"H<?>)!!=>H`(Y!->?C<GK86,G*46XR46D[M-WMTM
MK;O==4@4[R22W;7S73OY_P#!T"+QC:Z@;>".#4K&VU-'73M49(O*N&VE@4^9
MB"0"R^8@!QWZ$EE<Z5Y-QDX-<T=;K6VNBZZ/E;MY#C47,M+J]K]/\_*^WGJK
MYG@CQ-)!X#\++<1W^LZS>V7FB&)T::55QOD9I&5<`LH)+=6`&:Z<RR]2QU?E
M:ITXSM=WLK[)))OH]ET(C*R=W]IKUU?Z?+\#4?QU926EC)I^GZEJ%U=";_0H
M$C6:+RB!*'$CJH*L0I&223QD<US+)ZJG)5)QBHV]YWL^;X;63>JUV];%J5UM
MK>UO/?T^>VQ)I7C&+43X?9=)U*"'6HFDMYIC!M0!2P#;9"<LHW`*#P><8;$5
M\KE2]K^\BW3=FES=[:7BMGH[V_%7A55RJ5MW;^ON?W>ALZ#J0UC2+;4%M;BU
M2==R1SE-^W/!^1F&",$<]"*X\5A_J]5TG).W57M^*3TVV-+ZM=G8XO\`:!_Y
M)-K/_76U_P#2F*OIN!/^1_AO\3_])9RX[_=Y^A\J5_51\6%`&MX/_P"1T\-?
M]A>S_P#1Z5\WQ?\`\B/%?]>G^1VY=_O,/4^R=;TQ=6M%MI+FZMXO,5G-K.\+
ML!_"'0A@"<9P:_E/#8AT)\ZBF[=4FON::/L6KQ:_K?\`I'#>![6WT_2[[7M0
MUC55BT^^ODF:[U*XGC\B.210"CN1\H"G.,\>]>YF52=6K'#4Z<;SA"UHQ3YF
MD]TD]==+V(]G^\DD]GW_`+OY:W-#2/B?X>U1+\PR,)+01GRTEAF,WF-LC"&*
M1QN9L+M8AN1D`'-<]?A_%T7#F6DK])*UE=WYDG9+6Z379B5:#;UTM>_E^?;=
M7UTU,[Q5XFO6O?#4Z6>OZ68]9%M<:>\2YN@T#LN"A977..C[0<[L;<CIP.`I
M*%:+E"=Z5U*[]VTDGO9I^L;O3EWU<IODEI:SC]UUVO\`Y].NNP_Q!TU+#2[A
MK#5O.U"]DL8[9+;>Z31E@RN5)0<H1G<0>O0,1QK):SG.*E&T(*3=[)IVLU?7
MKV\MVDWS^ZW)6L[?U:_K_P`'0FMO&]I=V=J]EINI7&H7#SH--01+.GDOLE+%
MG$8"M@9WX.X8S43RFI3G)3G%127O:V]Y75K)RU7ETU#G[JSO:W]>6O\`P=#*
MM_$!UCQ[X9GT^]O$L+BRO5GL9,((YHVC!#KUWJ25Y)`QQU)/5/!?5\#7C4BN
M93A:6]TT]GV>^R??LE*=U'H^>S^Y_P!::/?70V)O&MC#=#=:7W]E_:OL;:J!
M&;99MVS:?GW_`'_DW;-N>]<D<IJRCI)<_+S<NO-:U[[6VUM>]N@Y3Y6]+VW\
MOZZVO;KL[5=,\?6VH7UM%%HNLK:W5M+=P7A2)HY8$QEU59#(<[EPNS=\PXZX
MTK9-.E"4G4C>,E%K6Z;Z-N*CT=WS6T>H^9\_*EU:\KHH6_CW0M!\&:!=37EY
M<+?6^^V74+J".YF08RSO*Z)D9&?FSSP#S6\\FQ6)QE6"BERRUY5)Q3[)13?X
M"YXV<N\G^;VOT7GLK+<U;'QWI^IS:;'HUI>ZB+VWCNB8/*'D1.VT.ZNZL0"#
MG8&QCW&>:ID]:BINM)1Y9-:WU:5[)I->EVK_`'DJLFDUU3_#?UU[7_%$_P`3
MO^2:^+/^P1=?^B6K/)O^1CA_^OL?_2D54^!^A\;5_8I\&%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`5]0_X\+G_KDW\C7-C/\`=ZG^%_D:T/XD?5'WO7\8
MGW1SGBG0M0U?4M$N;'4;6TCTVY^TE)K-IC*VQDQD2+M&UV['G'I@^C@L92H4
MZL*D')SC;225M4_Y7?5(FHG*'*M/^!JB3Q#HEY>:G8:IH^H16.I6B20[I[<S
MQ2Q/@LK('0YW(A!#`C!'()J<)BZ=.G.C6AS1DT]'9IK9IV?1M-6_()Q4K=UM
M\]_E_DOG2LO#FL:?JEU<V.NPB&_=);U)K+>QE"A6:$B0",%54897QMSSDYVJ
M8[#U:483I.\4U&TK:7NE+1MZMZIQWZ$<DK\U_>>^FGR7IIJWHEUNWD6?@/5H
M#IV_7;%Q:ZS+JK8TUQO,F[*#]\<#]X_//\/'!SUU,YP\N>U)^]24/B72VOP>
M2_'OI52+ES6>[3^ZW^2"S\!ZM`=.WZ[8N+769=5;&FN-YDW90?OC@?O'YY_A
MXX.2IG.'ESVI/WJ2A\2Z6U^#R7X]]"I%RYK/=I_=;_)%M?`TJBYTX:HA\-7%
M]]N:Q:VS*K^8)2BR[\",R#=@H3R1NZ8R>;Q?+5Y/WJAR\U]+6Y;N-M^73XK;
M.PIP;<K.W-O\][=KKU\K=(+3P%>1::BOK4/]J6^JRZI:7<5D52-Y"V]'C,AW
MJ0[KPRG!'.1FKGG-.52ZIOD=-0DG+5I6LT^56:LGL]?+0<X<SE?J[^C6B]?^
M'^6?XQ\.7-MIHGGNIYK^_P!2CN+Z\LM-GD5-D3+&%B@D$R`;4Y1R<YR=I(KH
MR_'0G4Y8Q2C&FU%2E%7O)-W<H\CZZ.-K;*ZN*2?+)RU;LO1)W^>OSUNM%I:M
M(9V\`3Z3>V4S?:F:"P>TLKB%W)`999`Y=X6\S<2\C9)&X\G%93E%8Y5X27NZ
MRO*+2Z-*W*I*VB45Y+17)@U&+YE=-]G=WW\]>^GR6K[K2K-=/TVVM%=Y!#&$
M,CG+.0.6)[DG)/N:\.O5=6I*HU:[^[R^1=.+C%)N[Z^;ZO[SRC]I_P#Y$O1O
M^PNG_HB>OT/PL_Y'G_<*7YH\_-O]V?JCYRK^CSY,*`.T^"O_`"5GPS_UUG_]
M)IJ^`\3/^1!4_P`4?_2D>KD_^\?)GUW7\SGU1SFH:%J%SXSTS6HM1M8[6S@D
M@-JUFS.XD*ECYGF``_(N/E..>N>/1I8RE#!SP[@VY-._,K:7MIR^;OK]Q,TY
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M8\/^`K_2Y_#8N-9L[FUT>RFLS&-/9&G23&3N\T[3A4['^+U&,\5G-*M&MRTV
MG4FI7YD[->7*K[OKV[:RHR5K/:3E]]_\V2Z?X&O+2ST[3WUF*XTS2&:33(I+
M,^9$P5EC\UQ)^\5`Y``"$X&3ZQ5S>G.<ZJIVG4TF^;1JZ;Y5;1MKJY):V01I
M\KLOAO>WSO:_:^O?SMNS2_`=]I6F>'?L.M0)J^C026J7+61,,\#XRCQ>9GJJ
M'(<<KZ'%57SBE7J5O:4WR5&G;FU4EU3Y;=6K.+T?S%[-VU>JDVOGO_7]/$\7
M^&WT\:3`ES?`%[NZN;VVTVZG\RXE92W%I(DL8(+X!)7&`<D`UVX#'JK[232V
MBDG*"M&*?_/R+B^FMKWVLFT$E)1N]W*]UTLK+3?;\M7KKMWMG<:KX4TG1;ZU
MFL]1>16@DTZWDACMHXWP'W898B8O^6;,3\Q49ZCBIU84,54Q%.2E%)WYFFVV
MMK:.7O?:2MI?R)C[M/E77167;5/RMH]=[6W?*=Y&BQ1K'&H5%`"J.@`[5X3;
M;NS:,5%)+9'GO[0/_))M9_ZZVO\`Z4Q5]9P)_P`C_#?XG_Z2SEQW^[S]#Y4K
M^JCXL*`-;P?_`,CIX:_["]G_`.CTKYOB_P#Y$>*_Z]/\CMR[_>8>I]KON*,$
M(#8X)&0#]*_DQ6OJ?9+S.2T3PC/#X8U?1-<U"&]M]1DN'9[6V:V9/.9F<#,C
M]"QP>W'6O6Q.9QEB:>(H0<7!1W:E\*272/;7]"4GS2<M;_Y6?X"S^&=8U+0I
M+#6]?BGG3RVM;FULO(*2QL'21P7;>=RC(&U2,C'(P1Q^'HUU5H4K)WNG*]TU
M9I:*VCW=WMKWCV5XN$G[MK>?K?NK*VBUW3V4>I^&M>U2YT6XO==TXRZ=?"ZV
MQ:8RHX"LH4`S$@X=LDD_PX`P=U4<?A:,:D84I6G#EUFKK5._P)/9:677756;
MC*47%OJOPU_KR^\SK3P'JT`T[?KMBYM=9EU5L::XWF3=E!^^.`/,?GG^'C@Y
MZ*F<X>7/:D_>I*'Q+I;7X/)?CWT<XN7-KNT_N_X9?C\DTOP!J>FW$6H6VO6J
MZQ%=74JS?V>WDO'<,'DB>/S<D!P&!#J1@9SSEULYHUHNE*D^1QBK<RO>*LFG
MRVVT::?R%*#E)R;UO=>6B7SND7=,\$7&G^(]+U2+4X66W%T]U&UH=UQ+<,&D
M8,'P@RJX7:V`#DG.1A6S:%7#SHN#UY;:[*"LE:VN[N[K7H@<9-)MZ\UW]UK?
M)>O3YM/@>:..[T]=2#^&Y[W[>VGFVS,'\P2F-9MX`0R#=@J3R1N'&'_:\6XU
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M+WUO<^)W_)-?%G_8(NO_`$2U8Y-_R,</_P!?8_\`I2+J?`_0^-J_L4^#"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`*^H?\>%S_`-<F_D:YL9_N]3_"_P`C
M6A_$CZH^]Z_C$^Z"@`H`*`"@`H`*`"@`H`*`"@#QW]I__D2]&_["Z?\`HB>O
MTCPL_P"1Y_W"E^:/,S;_`'9^J/G*OZ//DPH`[3X*_P#)6?#/_76?_P!)IJ^`
M\3/^1!4_Q1_]*1ZN3_[Q\F?7=?S.?5!0`4`%`!0`4`%`!0`4`%`!0!YW^T#_
M`,DFUG_KK:_^E,5?6\"?\C_#?XG_`.DLY,=_N\_0^5*_JH^+"@#6\'_\CIX:
M_P"PO9_^CTKYOB__`)$>*_Z]/\CMR[_>8>I]LU_)A]D%`!0`4`%`!0`4`%`!
M0`4`%`',_$[_`))KXL_[!%U_Z):O2R;_`)&.'_Z^Q_\`2D14^!^A\;5_8I\&
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`5]0_X\+G_`*Y-_(US8S_=ZG^%
M_D:T/XD?5'WO7\8GW04`%`!0`4`%`!0`4`%`!0`4`>._M/\`_(EZ-_V%T_\`
M1$]?I'A9_P`CS_N%+\T>9FW^[/U1\Y5_1Y\F%`':?!7_`)*SX9_ZZS_^DTU?
M`>)G_(@J?XH_^E(]7)_]X^3/KNOYG/J@H`*`"@`H`*`"@`H`*`"@`H`\[_:!
M_P"23:S_`-=;7_TIBKZW@3_D?X;_`!/_`-)9R8[_`'>?H?*E?U4?%A0!K>#_
M`/D=/#7_`&%[/_T>E?-\7_\`(CQ7_7I_D=N7?[S#U/MFOY,/L@H`*`"@`H`*
M`"@`H`*`"@`H`YGXG?\`)-?%G_8(NO\`T2U>EDW_`",</_U]C_Z4B*GP/T/C
M:O[%/@PH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@"&\1I+.=$&6:-@!ZG%8
M8F#G1G&.[B_R-*4E&<6^Y])_\+_\.?\`0&\0?]^K?_X]7\[_`/$+,\_N?^!/
M_(^H_M;#=_P#_A?_`(<_Z`WB#_OU;_\`QZC_`(A9GG]S_P`"?^0?VMAN_P"`
M?\+_`/#G_0&\0?\`?JW_`/CU'_$+,\_N?^!/_(/[6PW?\`_X7_X<_P"@-X@_
M[]6__P`>H_XA9GG]S_P)_P"0?VMAN_X!_P`+_P##G_0&\0?]^K?_`./4?\0L
MSS^Y_P"!/_(/[6PW?\`_X7_X<_Z`WB#_`+]6_P#\>H_XA9GG]S_P)_Y!_:V&
M[_@'_"__``Y_T!O$'_?JW_\`CU'_`!"S//[G_@3_`,@_M;#=_P``_P"%_P#A
MS_H#>(/^_5O_`/'J/^(69Y_<_P#`G_D']K8;O^`?\+_\.?\`0&\0?]^K?_X]
M1_Q"S//[G_@3_P`@_M;#=_P#_A?_`(<_Z`WB#_OU;_\`QZC_`(A9GG]S_P`"
M?^0?VMAN_P"`?\+_`/#G_0&\0?\`?JW_`/CU'_$+,\_N?^!/_(/[6PW?\#A/
MC!\3-+\<:#IVGZ9IVJ6\L%\+EWNTB"[1%(N!MD8YRX[>M?7\$<$9GDV9_6L5
MR\O(UH[[V\EV.+,,PHUJ+A!ZGEM?L!X`4`;O@+78/#/C;1]:O(+BXMK.20R1
MVX4N0T,B#`9@.KCOTKY3C/)\1FV53PF&MS.2W=EH[G?EU>%"MSSVL>X?\+_\
M.?\`0&\0?]^K?_X]7XW_`,0LSS^Y_P"!/_(]W^UL-W_`/^%_^'/^@-X@_P"_
M5O\`_'J/^(69Y_<_\"?^0?VMAN_X!_PO_P`.?]`;Q!_WZM__`(]1_P`0LSS^
MY_X$_P#(/[6PW?\``/\`A?\`X<_Z`WB#_OU;_P#QZC_B%F>?W/\`P)_Y!_:V
M&[_@'_"__#G_`$!O$'_?JW_^/4?\0LSS^Y_X$_\`(/[6PW?\`_X7_P"'/^@-
MX@_[]6__`,>H_P"(69Y_<_\``G_D']K8;O\`@'_"_P#PY_T!O$'_`'ZM_P#X
M]1_Q"S//[G_@3_R#^UL-W_`/^%_^'/\`H#>(/^_5O_\`'J/^(69Y_<_\"?\`
MD']K8;O^`?\`"_\`PY_T!O$'_?JW_P#CU'_$+,\_N?\`@3_R#^UL-W_`/^%_
M^'/^@-X@_P"_5O\`_'J/^(69Y_<_\"?^0?VMAN_X!_PO_P`.?]`;Q!_WZM__
M`(]1_P`0LSS^Y_X$_P#(/[6PW?\``Y;XG?%S1_%G@F^T73]+UB&YN)("LEPD
M(10DR.<E9">BGH.M>[PSX?9MEN:T<77Y>6$M;/79KLNYABLRP]2C*$7JUV/&
MZ_<CYH*`+FB7J:9KVDZA+')+%9WUO<ND>-S*DJL0,D#.`>I%>-Q!@JN.RROA
M:/Q3@TK^9TX.I&G6C.6R/H'_`(7_`.'/^@-X@_[]6_\`\>K\)_XA9GG]S_P)
M_P"1]'_:V&[_`(!_PO\`\.?]`;Q!_P!^K?\`^/4?\0LSS^Y_X$_\@_M;#=_P
M#_A?_AS_`*`WB#_OU;__`!ZC_B%F>?W/_`G_`)!_:V&[_@'_``O_`,.?]`;Q
M!_WZM_\`X]1_Q"S//[G_`($_\@_M;#=_P#_A?_AS_H#>(/\`OU;_`/QZC_B%
MF>?W/_`G_D']K8;O^`?\+_\`#G_0&\0?]^K?_P"/4?\`$+,\_N?^!/\`R#^U
ML-W_``#_`(7_`.'/^@-X@_[]6_\`\>H_XA9GG]S_`,"?^0?VMAN_X!_PO_PY
M_P!`;Q!_WZM__CU'_$+,\_N?^!/_`"#^UL-W_`/^%_\`AS_H#>(/^_5O_P#'
MJ/\`B%F>?W/_``)_Y!_:V&[_`(!_PO\`\.?]`;Q!_P!^K?\`^/4?\0LSS^Y_
MX$_\@_M;#=_P#_A?_AS_`*`WB#_OU;__`!ZC_B%F>?W/_`G_`)!_:V&[_@9'
MC'XV:%K7A'7-*M=(UQ+B^L9[:-I(X`H9T9021*3C)]#77E_AGG6'Q5*M/DM&
M:;M+LT^Q,\UPSBU?\#PFOZ$/E0H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
G*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
